drug_name,disease_term,side_effect,type,groups,synonyms,targets,ATC
carnitine,Cardiomyopathy;Carnitine deficiency;Encephalopathy;Failure to thrive;Hypoglycaemia;Hypotonia;Inborn error of metabolism;Muscle relaxant therapy;Muscular weakness;Renal failure chronic,Abdominal cramps;Abdominal pain;Accidental injury;Amblyopia;Anaemia;Angiopathy;Anorexia;Anxiety;Arrhythmia;Asthenia;Atrial fibrillation;Back pain;Body odor;Body temperature increased;Bronchitis;Cardiovascular disorder;Chest pain;Constipation;Convulsion;Cough;Cramps of lower extremities;Decreased appetite;Depression;Dermatitis;Diarrhoea;Dizziness;Drug dependence;Dysgeusia;Dyspepsia;Dyspnoea;Electrocardiogram abnormal;Eye disorder;Fluid overload;Gastric atony;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Haemoglobin;Haemorrhage;Headache;Hypercalcaemia;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertonia;Hypotension;Impaired gastric emptying;Infection;Influenza;Injection site reaction;Injury;Insomnia;Melaena;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Nausea;Oedema peripheral;Pain;Palpitations;Paraesthesia;Parathyroid disorder;Pharyngitis;Pruritus;Rash;Renal failure;Rhinitis;Sinusitis;Skin odour abnormal;Tachycardia;Urinary tract infection;Vertigo;Vomiting;Weight decreased;Weight increased,small molecule,investigational,ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1,Estrogen receptor,A16AA01
gamma-aminobutyric,Agammaglobulinemia;Bruton's agammaglobulinaemia;Foetal damage;Hepatitis;Hepatitis A;Hepatitis B;Hepatitis viral;Herpes zoster;Hypogammaglobulinaemia;Immunocompromised;Immunodeficiency;Immunodeficiency common variable;Infection;Insomnia;Measles;Rubella;Thymoma;Varicella;Varicella zoster,Anaphylactic shock;Angioedema;Injection site pain;Injection site tenderness;Pain;Urticaria,small molecule,approved; investigational,4-aminobutanoic acid; 4-aminobutyric acid; 4Abu; GABA; gamma-Aminobutyric acid; piperidic acid; piperidinic acid; γ-amino-n-butyric acid; γ-aminobutanoic acid; γ-Aminobuttersäure; γ-aminobutyric acid; ω-aminobutyric acid; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABT3; GAT-3; GAT3; Solute carrier family 6 member 11; CD49 antigen-like family member D; CD49D; Integrin alpha-IV; VLA-4 subunit alpha; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABATR; GABT1; GAT-1; GAT1; Solute carrier family 6 member 1; GABA-B receptor 1; GABA-B-R1; GABA-BR1; GABABR1; Gb1; GPRC3A; G-protein coupled receptor 51; GABA-B receptor 2; GABA-B-R2; GABA-BR2; GABABR2; Gb2; GPR51; GPRC3B; HG20; 2.1.4.1; AGAT; L-arginine:glycine amidinotransferase; Transamidinase; hPAT1; PAT1; Proton/amino acid transporter 1; Solute carrier family 36 member 1,"Gamma-aminobutyric acid receptor subunit gamma-2; Sodium- and chloride-dependent GABA transporter 3; Integrin alpha-4; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-5; Sodium- and chloride-dependent GABA transporter 1; Gamma-aminobutyric acid type B receptor subunit 1; Gamma-aminobutyric acid type B receptor subunit 2; Glycine amidinotransferase, mitochondrial",L03AA03
5-aminolevulinic,Actinic keratosis;Erythropoietic protoporphyria;Malignant glioma;Porphyria non-acute;Seborrhoeic keratosis,Accidental exposure to product;Accidental ingestion;Acne;Alanine aminotransferase increased;Amylase increased;Anaemia;Angiopathy;Aphasia;Application site irritation;Application site reaction;Aspartate aminotransferase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Body temperature increased;Brain neoplasm;Brain oedema;Cardiac disorder;Chills;Convulsion;Dermatitis;Diarrhoea;Discomfort;Dry skin;Dysaesthesia;Embolism;Embolism venous;Erythema;Excoriation;Eye disorder;Eyelid oedema;Feeling hot;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Glioma;Haemoglobin;Haemorrhage;Headache;Hemianopia;Hemiparesis;Hepatobiliary disease;Herpes simplex;Hyperaesthesia;Hyperkeratosis;Hyperpathia;Hypoaesthesia;Hypotension;Induration;Infection;Infestation;Infestation NOS;Leukocytosis;Leukoderma;Mental disorder;Nausea;Neoplasm;Nervous system disorder;Nervousness;Oedema;Pain;Paraesthesia;Petechiae;Photodamaged skin;Photodermatosis;Photosensitivity;Photosensitivity reaction;Pruritus;Pustule;Rash;Rash maculo-papular;Rash pustular;Respiratory failure;Respiratory insufficiency;Scab;Seborrhoeic dermatitis;Skin cancer;Skin carcinoma;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin hypertrophy;Skin tightness;Stinging;Sunburn;Tenderness;Tension;Thrombocytopenia;Thromboembolism;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vomiting;Warmth;Welts;Wound secretion,small molecule,approved,"5-ALA; 5-Aminolevulinic acid; ácido 5-aminolevulínico; Aminolevulinic acid; dALA; δ-ALA; δ-aminolevulinic acid; 1.3.3.4; PPO; 4.2.1.24; ALADH; Porphobilinogen synthase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase,L01XD04
leucovorin,Anaemia;Anaemia megaloblastic;Colon cancer;Colorectal cancer;Colorectal cancer metastatic;Colorectal carcinoma;Foetor hepaticus;Folate deficiency;Hepatocellular injury;Liver disorder;Malabsorption;Malnutrition;Neoplasm malignant;Osteosarcoma;Pernicious anaemia;Sprue,Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Acute kidney injury;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Anorexia;Asthenia;Blood creatinine increased;Body temperature increased;Caecitis;Chills;Confusional state;Constipation;Convulsion;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Disease progression;Dizziness;Dysgeusia;Dyspepsia;Dyspnoea;Erythema;Extravasation;Fatigue;Febrile neutropenia;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Hypersensitivity;Ill-defined disorder;Infection;Kidney function abnormal;Lethargy;Leukopenia;Loss of consciousness;Malaise;Nausea;Neuropathy;Neuropathy peripheral;Pruritus;Rash;Renal failure acute;Renal impairment;Rigors;Sensitisation;Serum creatinine increased;Shock;Skin disorder;Stomatitis;Syncope;Thrombocytopenia;Urticaria;Vomiting;Wheezing,small molecule,approved,"(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate; 10-Formyl-7,8-dihydrofolic acid; 5-Formyl-5,6,7,8-tetrahydrofolic acid; 5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid; 5-Formyltetrahydrofolate; 5-formyltetrahydrofolic acid; Acide folinique; Acido folinico; Folinate; Folinic acid; L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid; Leucovorinum; N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid; N5-Formyl-5,6,7,8-tetrahydrofolic acid; N5-Formyltetrahydrofolic acid; G21; HCP1; Heme carrier protein 1; hPCFT; HsPCFT; PCFT; PCFT/HCP1; Solute carrier family 46 member 1; 1.5.1.3; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Proton-coupled folate transporter; Dihydrofolate reductase, V03AF03;V03AF03;V03AF06
acetate,Hyponatraemia;Infection,Acidosis;Haematuria;Hypernatraemia;Pain;Stinging,small molecule,experimental,"Acetate; Acetate anion; Acetate ion; Acetate ion (1-); Acetic acid anion; Acetic acid, ion(1-); Acetoxy ion; Azetat; 3.4.24.65; HME; Macrophage elastase; Matrix metalloproteinase-12; ME; MME; MMP-12; CALM; CAM; CAM1; 1.15.1.1; hSod1; Superoxide dismutase 1; (S)-3-amino-2-methylpropionate transaminase; 2.6.1.19; GABA aminotransferase; GABA transaminase; GABA-AT; GABA-T; GABAT; Gamma-amino-N-butyrate transaminase; L-AIBAT; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; 2.6.1.16; D-fructose-6-phosphate amidotransferase; GFAT; Glucosamine-6-phosphate synthase; Hexosephosphate aminotransferase; L-glutamine--D-fructose-6-phosphate amidotransferase; 3.1.3.48; Protein-tyrosine phosphatase 1B; PTP-1B; PTP1B; 1.14.13.39; bNOS; Constitutive NOS; N-NOS; NC-NOS; Neuronal NOS; Nitric oxide synthase, brain; nNOS; NOS type I; Peptidyl-cysteine S-nitrosylase NOS1; 1.3.5.2; DHOdehase; Dihydroorotate oxidase; 3.4.21.36; ELA1; Elastase-1; Pancreatic elastase 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; 2.4.2.22; HGPRT; 1.13.11.27; 4-hydroxyphenylpyruvic acid oxidase; 4HPPD; HPD; HPPDase; PPD; 1.14.13.39; cNOS; Constitutive NOS; EC-NOS; Endothelial NOS; eNOS; Nitric oxide synthase, endothelial; NOS type III; NOSIII; ADF; ATL-derived factor; SASP; Surface-associated sulphydryl protein; TRDX; TRX; TRX1; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 3.3.2.6; Leukotriene A(4) hydrolase; LTA-4 hydrolase; LTA4; Tripeptide aminopeptidase LTA4H; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1.1.1.-; 1.1.1.210; 1.1.1.53; 1.1.1.62; 17-beta-HSD 5; 17-beta-hydroxysteroid dehydrogenase type 5; 3-alpha-HSD type 2; 3-alpha-HSD type II, brain; 3-alpha-hydroxysteroid dehydrogenase type 2; Chlordecone reductase homolog HAKRb; DD-3; DD3; DDH1; Dihydrodiol dehydrogenase 3; Dihydrodiol dehydrogenase type I; HA1753; HSD17B5; KIAA0119; PGFS; Prostaglandin F synthase; Testosterone 17-beta-dehydrogenase 5; 3.1.1.4; Group IB phospholipase A2; Phosphatidylcholine 2-acylhydrolase 1B; PLA2; PLA2A; PPLA2; 3.5.2.6; Penicillinase","Macrophage metalloelastase; Calmodulin-1; Superoxide dismutase [Cu-Zn]; 4-aminobutyrate aminotransferase, mitochondrial; Angiotensin-converting enzyme; Glutamine--fructose-6-phosphate aminotransferase [isomerizing]; Tyrosine-protein phosphatase non-receptor type 1; Nitric oxide synthase 1; Dihydroorotate dehydrogenase (quinone), mitochondrial; Chymotrypsin-like elastase family member 1; Estrogen receptor beta; Hypoxanthine-guanine-xanthine phosphoribosyltransferase; 4-hydroxyphenylpyruvate dioxygenase; Nitric oxide synthase 3; Thioredoxin; Carbonic anhydrase 2; Leukotriene A-4 hydrolase; Calmodulin-2; Calmodulin-3; Aldo-keto reductase family 1 member C3; Phospholipase A2; Beta-lactamase",G01AD02
acetylcholine,Miosis,Bradycardia;Corneal decompensation;Corneal oedema;Corneal opacity;Dyspnoea;Flushing;Hyperhidrosis;Hypotension;Sweating,small molecule,approved; investigational,Acetylcholine; ACh; Choline acetate; O-Acetylcholine; NACHRA7; 3.1.1.7; AChE; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; hOCT1; OCT1; Organic cation transporter 1,Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Neuronal acetylcholine receptor subunit alpha-7,S01EB09
adenosine,Atrial fibrillation;Atrial flutter;Atrioventricular block;Cardiac disorder;Convulsion;Coronary artery disease;Electrocardiogram QRS complex;Myocardial ischaemia;Nodal block;Paroxysmal supraventricular tachycardia;QRS complex;Sinus rhythm;Supraventricular tachycardia;Vascular resistance systemic;Ventricular tachycardia;Wolff-Parkinson-White syndrome,Abdominal discomfort;Acute coronary syndrome;Affect lability;Agitation;Anaphylactic shock;Angioedema;Anxiety;Apnoea;Apprehension;Arrhythmia;Asthenia;Atrial fibrillation;Atrioventricular block;Atrioventricular block complete;Atrioventricular block first degree;Atrioventricular block second degree;Back distress;Back pain;Blood pressure increased;Bradycardia;Bronchoconstriction;Bronchospasm;Burning sensation;Cardiac arrest;Cardiac disorder;Cardiac failure;Cerebrovascular accident;Chest discomfort;Chest pain;Chest pressure;Convulsion;Coronary artery disease;Cough;Dermatitis;Device capturing issue;Discomfort;Dizziness;Drowsiness;Dry mouth;Dysgeusia;Dyspnoea;Ear discomfort;Electrocardiogram ST segment depression;Electrocardiogram ST segment elevation;Excitability;Extrasystoles;Fatal outcomes;Flushing;Gastrointestinal discomfort;General discomfort;Grand mal convulsion;Haemorrhage intracranial;Head pressure;Headache;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperventilation;Hypoaesthesia;Hypotension;Injection site reaction;Intracranial pressure increased;Lightheadedness;Limb discomfort;Loss of consciousness;Mediastinal disorder;Micturition urgency;Mood swings;Musculoskeletal discomfort;Myocardial infarction;Myocardial ischaemia;Nasal congestion;Nausea;Nervousness;Nodal block;Non-sustained ventricular tachycardia;Numbness;Pain;Palpitations;Paraesthesia;Pollakiuria;Rash;Respiratory arrest;Respiratory failure;Scotoma;Sensory loss;Shock;Sinoatrial block;Sinus arrest;Sinus tachycardia;Skipped beats;Somnolence;Supraventricular extrasystoles;Sweating;Syncope;Tachycardia;Taste metallic;Tension;Throat tightness;Tingling sensation;Tinnitus;Tonic-clonic seizures;Torsade de pointes;Tremor;Urticaria;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vision blurred;Vomiting,small molecule,approved; investigational,"(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9-β-D-ribofuranosyl-9H-purin-6-amine; Ade-Rib; Adenin riboside; Adenine Deoxyribonucleoside; Adenogesic; Adenosin; Adenosina; Adénosine; Adenosine; Adenosinum; Ado; beta-D-Adenosine; ADORA2; 2.7.4.3; 2.7.4.4; 2.7.4.6; Adenylate monophosphate kinase; AK 1; ATP-AMP transphosphorylase 1; ATP:AMP phosphotransferase; Myokinase; 2.7.4.6; GAAD; Granzyme A-activated DNase; Metastasis inhibition factor nm23; NDK A; NDP kinase A; NDPKA; NM23; NM23-H1; Tumor metastatic process-associated protein; 2.7.4.6; C-myc purine-binding transcription factor PUF; Histidine protein kinase NDKB; NDK B; NDP kinase B; nm23-H2; NM23B; 2.4.2.1; Inosine phosphorylase; Inosine-guanosine phosphorylase; NP; PNP; XDHA; 3.5.4.4; ADA1; Adenosine aminohydrolase; 2.7.1.20; Adenosine 5'-phosphotransferase; AK; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1; 36 kDa nucleolar protein HNP36; Delayed-early response protein 12; DER12; ENT2; Equilibrative NBMPR-insensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter; hENT2; HNP36; Hydrophobic nucleolar protein, 36 kDa; Nucleoside transporter, ei-type; Solute carrier family 29 member 2; ENT3; hENT3; Solute carrier family 29 member 3; ENT4; hENT4; Plasma membrane monoamine transporter; PMAT; Solute carrier family 29 member 4; CNT 1; CNT1; Concentrative nucleoside transporter 1; hCNT1; Na(+)/nucleoside cotransporter 1; Sodium-coupled nucleoside transporter 1; Solute carrier family 28 member 1; CNT 2; CNT2; Concentrative nucleoside transporter 2; hCNT2; Na(+)/nucleoside cotransporter 2; Sodium-coupled nucleoside transporter 2; Sodium/purine nucleoside co-transporter; Solute carrier family 28 member 2; SPNT; Connexin-43; Cx43; Gap junction 43 kDa heart protein; GJAL; CNT 3; CNT3; Concentrative Na(+)-nucleoside cotransporter 3; hCNT3",Adenosine receptor A1; Adenosine receptor A2a; Adenosine receptor A2b; Adenosine receptor A3,C01EB10
arginine,Acrocyanosis;Acromegaly;Adenoma benign;Craniopharyngioma;Cyanosis;Dwarfism;Gigantism;Hypoglycaemia;Hypopituitarism;Injury;Insulin hypoglycemia;Panhypopituitarism;Pituitary dwarfism;Trauma,Anaphylactic shock;Anorexia;Brain oedema;Choking;Decreased appetite;Dermatitis;Edema cerebral;Extravasation;Flushing;Haematuria;Headache;Hyperhidrosis;Hypersensitivity;Hypoaesthesia;Injection site reaction;Lethargy;Nasal obstruction;Nausea;Necrosis;Numbness;Paraesthesia oral;Perioral tingling;Phlebitis superficial;Platelet count decreased;Rash;Rash macular;Sensory loss;Sickle cell anaemia;Skin exfoliation;Skin necrosis;Surgery;Surgical intervention;Sweating;Swelling;Tachycardia;Vomiting,small molecule,investigational; nutraceutical,"(2S)-2-amino-5-(carbamimidamido)pentanoic acid; (2S)-2-amino-5-guanidinopentanoic acid; (S)-2-amino-5-guanidinopentanoic acid; (S)-2-Amino-5-guanidinovaleric acid; Arg; Arginina; Arginine; L-(+)-Arginine; L-Arg; L-Arginin; L-arginine; R; ATRC3; CAT-3; CAT3; Cationic amino acid transporter y+; Solute carrier family 7 member 3; ADC; ARGDC; Arginine decarboxylase; AzI2; KIAA1945; ODC-like protein; ODC-p; ODCP; ornithine decarboxylase paralog; Ornithine decarboxylase-like protein; 4.3.2.1; Arginosuccinase; ASAL; 1.14.13.39; HEP-NOS; Hepatocyte NOS; Inducible NO synthase; Inducible NOS; iNOS; NOS type II; NOS2A; Peptidyl-cysteine S-nitrosylase NOS2; ATRC1; CAT-1; CAT1; Ecotropic retroviral leukemia receptor homolog; Ecotropic retrovirus receptor homolog; ERR; REC1L; Solute carrier family 7 member 1; System Y+ basic amino acid transporter; 3.5.3.1; Arginase II; Kidney-type arginase; Non-hepatic arginase; Type II arginase; CAT-4; CAT4; Solute carrier family 7 member 4; 6.3.4.5; ASS; Citrulline--aspartate ligase; 1.14.13.39; cNOS; Constitutive NOS; EC-NOS; Endothelial NOS; eNOS; Nitric oxide synthase, endothelial; NOS type III; NOSIII; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Aromatic amino acid transporter 1; MCT 10; MCT10; Solute carrier family 16 member 10; T-type amino acid transporter 1; TAT1; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H","Cationic amino acid transporter 3; Antizyme inhibitor 2; Argininosuccinate lyase; Nitric oxide synthase, inducible; High affinity cationic amino acid transporter 1; Arginase-2, mitochondrial; Cationic amino acid transporter 4; Argininosuccinate synthase; Nitric oxide synthase 3", B05XB01;B05XB01;V03AF11
betaine,Homocystinuria;Hypermethioninaemia,Abdominal discomfort;Agitation;Alopecia;Anorexia;Aspiration;Bad taste;Brain oedema;Decreased appetite;Diarrhoea;Distress gastrointestinal;Dysgeusia;Edema cerebral;Gastrointestinal disorder;Glossitis;Headache;Homocystinuria;Hypermethioninaemia;Irritability;Malnutrition;Mental disorder;Nausea;Nervous system disorder;Personality disorder;Skin disorder;Skin odour abnormal;Sleep disorder;Sleep disturbance;Tooth disorder;Unspecified disorder of skin and subcutaneous tissue;Upset stomach;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urticaria;Vomiting,small molecule,approved; investigational; nutraceutical,"2-(Trimethylammonio)Acetate; 2-N,N,N-trimethylammonio acetate; 2-trimethylammonioacetate; Abromine; Acidol; Betaína anhidra; Betaine; Betaine, anhydrous; Glycine betaine; Glycinebetaine; Glykokollbetain; N,N,N-trimethylammonioacetate; N,N,N-Trimethylglycine; TMG; Trimethylaminoacetate; Trimethylammonioacetate; Trimethylglycine; Trimethylglycocoll; 2.1.1.5; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 1.5.5.2; p53-induced gene 6 protein; PIG6; POX2; PRODH2; Proline oxidase; Proline oxidase 2; BGT-1; BGT1; Na(+)/Cl(-) betaine/GABA transporter; Solute carrier family 6 member 12",Betaine--homocysteine S-methyltransferase 1, A09AB02;A09AB02;A16AA06
calcium,Abdominal colic;Abdominal pain;Alkalosis;Allergic conditions;Arthropod bite;Calcium deficiency;Capillary permeability;Cardiotoxicity;Cramp muscle;Dermatitis herpetiformis;Eruption;Hyperkalaemia;Hyperphosphataemia;Hypocalcaemia;Hypocalcemic tetany;Hypoparathyroidism;Intoxication;Muscle spasms;Neonatal tetany;Osteomalacia;Poisoning;Pruritus;Purpura non-thrombocytopenic;Rash;Renal failure chronic;Rickets;Skin disorder;Spider bite;Tetany;Vitamin D deficiency,Abscess;Anorexia;Arrhythmia;Asthenia;Bradycardia;Calcinosis;Cardiac arrest;Chalky taste;Coma;Confusional state;Constipation;Decreased appetite;Delirium;Depressed level of consciousness;Diarrhoea;Dizziness;Dysgeusia;Feeling abnormal;Hypercalcaemia;Hypersensitivity;Hypotension;Loss of consciousness;Nausea;Necrosis;Oedema;Paraesthesia;Peripheral vasodilatation;Pruritus;Sense of oppression;Shock;Stupor;Syncope;Tingling sensation;Vasodilatation;Vasodilation;Vasodilation procedure;Vasospasm;Venospasm;Vomiting,small molecule,nutraceutical,"Calcio; Calcium, elemental; Elemental calcium; Kalzium; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; 7.2.2.10; ATP-dependent Ca(2+) pump PMR1; ATPase 2C1; Ca(2+)/Mn(2+)-ATPase 2C1; KIAA1347; PMR1L; Secretory pathway Ca(2+)-transporting ATPase type 1; SPCA1; TN-C; TNNC; Beta-II spectrin; Fodrin beta chain; Spectrin, non-erythroid beta chain 1; SPTB2; S-100 protein beta chain; S-100 protein subunit beta; S100 calcium-binding protein B; Calpain inhibitor; Sperm BS-17 component; COMP; Thrombospondin-5; TSP5; 1.4.3.22; ABP; ABP1; Amiloride-binding protein; Amiloride-binding protein 1; Amine oxidase copper domain-containing protein 1; DAO; Diamine oxidase; Histaminase; KAO; KDAO; Kidney amine oxidase; S100 calcium-binding protein A13; 3.1.3.1; Alkaline phosphatase Regan isozyme; Placental alkaline phosphatase 1; PLAP; PLAP-1; CAGA; Calgranulin-A; Calprotectin L1L subunit; CFAG; Cystic fibrosis antigen; Leukocyte L1 complex light chain; Migration inhibitory factor-related protein 8; MRP-8; MRP8; p8; S100 calcium-binding protein A8; Urinary stone protein band A; CAGB; Calgranulin-B; Calprotectin L1H subunit; CFAG; Leukocyte L1 complex heavy chain; Migration inhibitory factor-related protein 14; MRP-14; MRP14; p14; S100 calcium-binding protein A9; CAN19; Protein S-100L; S100 calcium-binding protein A2; S100L; Cuproxidase ceruloplasmin; Ferroxidase ceruloplasmin; Glutathione peroxidase ceruloplasmin; Glutathione-dependent peroxiredoxin ceruloplasmin; BMP-2B; BMP-4; BMP2B; Bone morphogenetic protein 2B; DVR4; Cell growth-inhibiting gene 36 protein; MGLAP; MGP; KIAA1313; ALG-2; ALG2; Apoptosis-linked gene 2 protein homolog; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII","Voltage-dependent L-type calcium channel subunit alpha-1C; Calcium-transporting ATPase type 2C member 1; Troponin C, skeletal muscle; Troponin C, slow skeletal and cardiac muscles; Spectrin beta chain, non-erythrocytic 1; Protein S100-B; Calpastatin; Cartilage oligomeric matrix protein; Diamine oxidase [copper-containing]; Protein S100-A13; Alkaline phosphatase, placental type; Protein S100-A8; Protein S100-A9; Protein S100-A2; Ceruloplasmin; Bone morphogenetic protein 4; Matrix Gla protein; Protocadherin-19; Programmed cell death protein 6; Calmodulin", A11AA02; A11GB01; M05BB02; M05BB04; M05BB05; M05BB08;A07XA03;M05BB01
chloramphenicol,Bacteraemia;Chronic suppurative otitis media;Conjunctivitis bacterial;Conjunctivitis infective;Cystic fibrosis;Eye infection;Infection;Meningitis;Otitis externa;Otitis media chronic;Pneumonia chlamydial;Psittacosis;Typhoid fever,Abdominal distension;Agranulocytosis;Anaphylactic shock;Angioedema;Aplastic anaemia;Blood and lymphatic system disorders;Blood disorder;Body temperature increased;Bone marrow aplastic;Bone marrow depression;Burning sensation;Confusional state;Conjunctival hyperaemia;Cyanosis;Delirium;Dermatitis;Diarrhoea;Drug interaction;Endophthalmitis;Enterocolitis;Eye disorder;Eye irritation;Eye swelling;Feeling abnormal;Gastrointestinal disorder;Glossitis;Grey syndrome neonatal;Headache;Hypersensitivity;Hypoplastic anaemia;Immune system disorder;Jarisch-Herxheimer reaction;Leukaemia;Leukopenia;Nausea;Nervous system disorder;Neuritis;Neuropathy peripheral;Ocular hyperaemia;Pain;Pancytopenia;Paroxysmal nocturnal haemoglobinuria;Pruritus;Rash;Rash maculo-papular;Rash vesicular;Reaction gastrointestinal;Reaction to drug excipients;Respiration irregularity;Respiratory disorder;Shock;Skin disorder;Stinging;Stomatitis;Thrombocytopenia;Typhoid fever;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vasomotor collapse;Vomiting,small molecule,approved; vet_approved; withdrawn,"Chloramphénicol; Chloramphenicol; Chloramphenicolum; Chlornitromycin; Cloramfenicol; Cloranfenicol; D-(−)-2,2-dichloro-N-(β-hydroxy-α-(hydroxymethyl)-p-nitrophenylethyl)acetamide; D-(−)-threo-1-p-nitrophenyl-2-dichloroacetylamino-1,3-propanediol; Laevomycetinum; Levomicetina; Levomycetin; Dr hemagglutinin structural subunit precursor; CR; DAF; 2.3.1.28; CAT-III; Chloramphenicol acetyltransferase III; 2.3.1.28; catB7; XAT; Xenobiotic acetyltransferase; 2.7.1.-; CPT; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",50S ribosomal protein L16; Dr hemagglutinin structural subunit; Complement decay-accelerating factor, D10AF03; G01AA05; J01BA01; S01AA01; S02AA01; S03AA08;D06AX02
bupropion,"Agitation;Asthenia;Bradyphrenia;Bradypsychic response;Bronchial hyperreactivity;Cerebration impaired;Chronic obstructive pulmonary disease;Convulsion;Convulsions generalised;Decreased interest;Depressed mood;Depression;Depressive disorder;Disturbance in attention;Dysphoria;Dysthymic disorder;Fatigability;Fatigue;Feeling guilty;Hypersomnia;Insomnia;Major depression;Major depressive disorder, single episode;Mental disability;Mental disorder;Nicotine dependence;Seasonal affective disorder;Sexual dysfunction;Suicidal ideation;Suicide attempt","Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abnormal dreams;Abnormal ejaculation;Accidental injury;Acne;Acute coronary syndrome;Affect lability;Aggression;Agitation;Akathisia;Akinesia;Alopecia;Altered state of consciousness;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anger;Angioedema;Angiopathy;Angle closure glaucoma;Animal scratch;Anorexia;Anxiety;Apathy;Aphasia;Appetite absent;Application site reaction;Arrhythmia;Arthralgia;Arthritis;Arthropod bite;Asthenia;Asthma;Ataxia;Atrioventricular block complete;Auditory disorder NOS;Back injury;Back pain;Basal cell carcinoma;Bipolar I disorder;Bipolar disorder;Bladder pain;Blood pressure increased;Body odor;Body temperature increased;Bradykinesia;Breast calcifications;Breast cancer;Breast disorder;Breast enlargement;Breast microcalcification;Breast tenderness;Breath odour;Bronchitis;Bronchospasm;Bruxism;Bursitis;Cardiac disorder;Cardiac flutter;Cardiovascular disorder;Carpal tunnel syndrome;Cerebration impaired;Cerebrovascular accident;Chest discomfort;Chest pain;Chest wall pain;Chills;Circumoral oedema;Cold sweat;Colitis;Coma;Completed suicide;Concussion;Confusional state;Conjunctivitis;Conjunctivitis infective;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Cyst;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Defaecation urgency;Dehydration;Delirium;Delusion;Dental caries;Depersonalisation;Depressed level of consciousness;Depressed mood;Depressive symptom;Derealisation;Dermal cyst;Dermatitis;Dermatitis atopic;Dermatitis exfoliative;Diarrhoea;Difficulty sleeping;Digestion impaired;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug abuse;Drug hypersensitivity;Drug withdrawal syndrome;Dry eye;Dry mouth;Dry skin;Duodenal ulcer haemorrhage;Dysarthria;Dysgeusia;Dyskinesia;Dyslexia;Dysmenorrhoea;Dyspareunia;Dyspepsia;Dysphagia;Dysphoria;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear infection;Ear pain;Ecchymosis;Eczema;Ejaculation disorder;Electroencephalogram abnormal;Energy increased;Enuresis;Epicondylitis;Epigastric discomfort;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Euphoric mood;Excoriation;Extrapyramidal disorder;Extrasystoles;Eye disorder;Eye pain;Face oedema;Facial bones fracture;Fatigue;Feeling abnormal;Feeling hot;Feeling jittery;Feeling of despair;Feelings of worthlessness;Female sexual arousal disorder;Flank pain;Flat affect;Flatulence;Flushing;Folliculitis;Food allergy;Food poisoning;Frequent bowel movements;Frigidity;Fungal infection;Gastric irritation;Gastric pH decreased;Gastric ulcer;Gastritis;Gastritis viral;Gastroenteritis;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Genital rash;Gingival bleeding;Gingival pain;Gingivitis;Glossitis;Glycosuria;Gynaecomastia;Haemoglobin;Haemorrhage;Hair colour changes;Hallucination;Hallucination, auditory;Headache;Hearing impaired;Heart rate irregular;Hepatic enzyme increased;Hepatic function abnormal;Hepatitis;Hepatitis C;Hepatocellular injury;Hepatotoxicity;Herpes virus infection;Herpes zoster;Hirsutism;Hordeolum;Hostility;Hot flush;Hunger;Hyperacusis;Hyperaesthesia;Hyperchlorhydria;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypersomnia;Hypertension;Hypertonia;Hypertonic bladder;Hypertrophy of breast;Hyperventilation;Hypoaesthesia;Hypoaesthesia oral;Hypoglycaemia;Hypokinesia;Hypomania;Hypotension;Hypotonia;Hypotrichosis;Ill-defined disorder;Immune system disorder;Impaired healing;Impairment of attention;Inappropriate antidiuretic hormone secretion;Increased appetite;Increased tendency to bruise;Increased upper airway secretion;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Influenza-like symptoms;Infrequent bowel movements;Inguinal hernia;Initial insomnia;Injection site joint pain;Injury;Insomnia;Intestinal perforation;Intraocular pressure increased;Irritability;Irritation gum;Jaundice;Joint injury;Joint sprain;Joint stiffness;Joint swelling;Keratoconjunctivitis sicca;Laceration;Lacrimation decreased;Lacrimation increased;Laryngeal pain;Laryngitis;Latex allergy;Lethargy;Leukocytosis;Leukopenia;Libido decreased;Libido increased;Ligament sprain;Limb injury;Lip dry;Liver injury;Localised infection;Loose stools;Loss of consciousness;Lower limb fracture;Lymphadenopathy;Malaise;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Memory impairment;Menopausal symptoms;Menopause;Menstrual disorder;Menstruation irregular;Mental disability;Mental disorder;Metrorrhagia;Micturition disorder;Micturition urgency;Middle insomnia;Migraine;Mood swings;Motion sickness;Mouth injury;Mouth ulceration;Muscle contractions involuntary;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle strain;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Mydriasis;Myocardial infarction;Myoclonus;Nasal congestion;Nasal dryness;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Nerve compression;Nerve injury;Nervous system disorder;Nervousness;Neuralgia;Neurological examination abnormal;Neuropathy;Neuropathy peripheral;Night sweats;Nightmare;Nipple pain;Nocturia;Oedema;Oedema peripheral;Oesophagitis;Oral pain;Orgasm abnormal;Orthostatic hypotension;Osteoarthritis;Osteoporosis;Ovarian cyst;Ovarian disorder;Pain;Pain in extremity;Pain in jaw;Painful ejaculation;Painful erection;Pallor;Palpitations;Pancreatitis;Pancytopenia;Panic attack;Panic reaction;Paraesthesia;Paraesthesia oral;Paranoia;Paranoid reaction;Parkinsonism;Parosmia;Pelvic infection;Peripheral coldness;Perseveration;Pharyngitis;Pharyngitis streptococcal;Pharyngolaryngeal pain;Phlebitis;Photophobia;Photosensitivity;Photosensitivity reaction;Pleuritic pain;Pneumonia;Pollakiuria;Polyp;Polyuria;Poor quality sleep;Post procedural pain;Pregnancy;Premenstrual syndrome;Procedural pain;Prostate infection;Prostatic disorder;Prurigo;Pruritus;Pruritus generalised;Pseudoparkinsonism;Psychotic disorder;Pulmonary congestion;Pulmonary embolism;Rash;Rash erythematous;Rash maculo-papular;Renal pain;Respiration abnormal;Respiratory sighs;Respiratory tract congestion;Respiratory tract infection;Rhabdomyolysis;Rhinitis;Rhinitis seasonal;Rhinorrhoea;Rigors;Rubber sensitivity;Salivary hypersecretion;Salpingitis;Sciatica;Seasonal allergy;Sebaceous gland disorder;Self-injurious ideation;Sensation of heaviness;Sensory disturbance;Serum sickness;Sexual dysfunction;Shakiness;Shock;Sinus congestion;Sinus disorder;Sinus headache;Sinus pain;Sinusitis;Skin disorder;Skin irritation;Skin laceration;Skin odour abnormal;Sleep disorder;Sleep disturbance;Sneezing;Snoring;Social avoidant behaviour;Soft tissue injury;Somnambulism;Somnolence;Sore eye;Sore mouth;Stevens-Johnson syndrome;Stomatitis;Stress;Stress symptoms;Suicidal ideation;Suicide;Suicide attempt;Sunburn;Supraventricular tachycardia;Sweating;Sweating increased;Swelling face;Swollen tongue;Syncope;Tachycardia;Tardive dyskinesia;Taste disorders;Tendon disorder;Tendonitis;Tension;Tension headache;Terminal insomnia;Testicular pain;Testicular swelling;Thinking abnormal;Thirst;Throat irritation;Thrombocytopenia;Tinea pedis;Tinnitus;Tongue disorder;Tongue oedema;Tonsillitis;Tooth abscess;Tooth disorder;Tooth infection;Toothache;Tremor;Trichotillomania;Type IV hypersensitivity reaction;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urethral pain;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal irritation;Vaginal mycosis;Vaginitis bacterial;Vasodilation;Vasodilation procedure;Vertigo;Viral diarrhoea;Viral upper respiratory tract infection;Vision blurred;Visual disturbance;Visual impairment;Vitreous floaters;Vocal cord disorder;Vomiting;Vulvovaginal discomfort;Vulvovaginal mycotic infection;Weight decreased;Weight increased;Wheezing;Withdrawal symptom;Wound infection;Wrist fracture;Yawning",small molecule,approved,"Amfebutamone; Bupropion; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; NACHRA3; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; hOCT2; OCT2; Organic cation transporter 2",Sodium-dependent dopamine transporter; Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; Neuronal acetylcholine receptor subunit alpha-3; 5-hydroxytryptamine receptor 3A, A08AA62; N06AX12;N06AX12;N06AX62
estradiol,Acute coronary syndrome;Alcohol abuse;Angiopathy;Artificial menopause;Atrophic vulvovaginitis;Atrophy;Blindness;Bone density decreased;Bone mass decreased;Breast cancer;Breast feeding;Carcinoma;Cerebrovascular accident;Clotting;Coagulopathy;Coronary artery disease;Coronary heart disease;Cushing's syndrome;Deep vein thrombosis;Dyspareunia;Dysuria;Endometrial hyperplasia;Endometriosis;Feeling hot;Foetor hepaticus;Fracture;Haemoglobin;Haemorrhage;Headache;Hepatocellular injury;Hot flush;Hyperhidrosis;Hyperparathyroidism;Hyperprolactinaemia;Hypersensitivity;Hyperthyroidism;Hypogonadism;Hypogonadism female;Inflammation;Liver disorder;Menopausal symptoms;Menopause;Metastatic disease;Metastatic neoplasm;Micturition burning;Micturition urgency;Migraine;Multiple fractures;Myocardial infarction;Natural menopause;Neoplasm malignant;Oestrogen deficiency;Osteopenia;Osteoporosis;Osteoporosis postmenopausal;Osteoporotic fracture;Ovarian failure;Phlebitis;Pollakiuria;Porphyrin metabolism disorder;Postmenopausal syndrome;Postmenopause;Premature menopause;Primary ovarian failure;Prostate cancer;Prostate carcinoma;Pruritus;Pruritus vulvae;Pulmonary embolism;Skin irritation;Sleep disorder;Sleep disturbance;Surgical menopause;Sweating;Thrombophlebitis;Thyrotoxicosis;Type 1 diabetes mellitus;Unspecified visual loss;Vaginal haemorrhage;Vaginitis atrophic;Varicose vein;Vulvovaginal pruritus;Warmth,Abdominal bloating;Abdominal cramps;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abnormal vision;Abnormal withdrawal bleeding;Accidental injury;Ache;Acne;Acute coronary syndrome;Affect lability;Agitation;Alanine aminotransferase increased;Allergic contact dermatitis;Alopecia;Amenorrhoea;Amnesia;Anal pruritus;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorectal discomfort;Anxiety;Anxiety NEC;Aphasia;Application site erythema;Application site irritation;Application site rash;Application site reaction;Arthralgia;Arthritis;Arthritis aggravated;Arthropathy;Arthropod bite;Asthenia;Asthma;Back pain;Bacterial infection;Basal cell carcinoma;Benign vaginal neoplasm;Bladder infection;Bladder pain;Bleeding breakthrough;Blepharitis;Blindness;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood oestrogen increased;Blood pressure fluctuation;Blood pressure increased;Body temperature increased;Bone disorder;Bone pain;Bradyphrenia;Breast cancer;Breast cancer invasive NOS;Breast discharge;Breast discomfort;Breast disorder;Breast engorgement;Breast enlargement;Breast malformation;Breast mass;Breast neoplasm;Breast oedema;Breast pain;Breast pain female;Breast swelling;Breast tenderness;Bronchitis;Bronchospasm;Candida infection;Carbohydrate tolerance decreased;Cardiac disorder;Cardiovascular disorder;Carpal tunnel syndrome;Cerebrovascular accident;Cerebrovascular disorder;Cervical discharge;Cervical polyp;Change in blood pressure;Chest discomfort;Chest pain;Chills;Chloasma;Cholecystitis;Cholelithiasis;Chorea;Clotting;Coagulopathy;Common cold;Confusional state;Congenital anomaly;Conjunctivitis;Connective tissue disorder;Constipation;Contact lens intolerance;Contusion;Coronary artery thrombosis;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Cyst;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Deep vein thrombosis;Dementia;Depression;Dermatitis;Dermatitis contact;Dermatitis hemorrhagic;Developmental delay;Diarrhoea;Discomfort;Disorder sight;Disturbance in sexual arousal;Diverticulitis;Dizziness;Drug effect decreased;Drug ineffective;Drug interaction;Dry eye;Dry mouth;Dry skin;Dry throat;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Ear disorder;Ear infection;Ear pain;Ectropion of cervix;Eczema;Embolism;Embolism venous;Emotional disorder;Emotional disturbance NOS;Endocrine disorder;Endometrial cancer;Endometrial disorder;Endometrial hyperplasia;Endometriosis;Endophthalmitis;Enlargement abdomen;Epilepsy;Epistaxis;Eruption;Erythema;Erythema multiforme;Erythema nodosum;Exacerbation of asthma;Eye disorder;Eye infection;Eye irritation;Eyelid oedema;Face oedema;Facial rash;Family stress;Fatigue;Feeling abnormal;Fibrocystic breast disease;Flatulence;Fluid retention;Flushing;Foetal disorder;Fungal infection;Gait disturbance;Galactorrhoea;Gallbladder disorder;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrooesophageal reflux disease;Generalised erythema;Genital candidiasis;Glucose tolerance decreased;Glucose tolerance impaired;Goitre;Gynaecomastia;Haemangioma;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhoids;Headache;Hearing impaired;Heart rate irregular;Hemiparesis;Hepatic function abnormal;Hepatic neoplasm;Hepatitis;Hepatitis acute;Hepatobiliary disease;Hereditary angioedema;Herpes simplex;Herpes zoster;Hirsutism;Hot flush;Hyperaesthesia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypocalcaemia;Ill-defined disorder;Immune system disorder;Incontinence;Increased appetite;Increased tendency to bruise;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Intestinal obstruction;Irritability;Jaundice;Jaundice cholestatic;Jerky movement NOS;Joint sprain;Laryngeal pain;Laryngitis;Leg edema;Leg pain;Lethargy;Leukorrhea;Libido decreased;Libido increased;Ligament sprain;Liver function test abnormal;Local swelling;Localized exfoliation;Loss of consciousness;Loss of libido;Lymphadenopathy;Malaise;Malignant mesenchymoma;Malnutrition;Mass;Mediastinal disorder;Medical device complication;Meningioma;Menopausal symptoms;Menorrhagia;Menstrual disorder;Menstruation irregular;Mental disorder;Metrorrhagia;Migraine;Migraine aggravated;Mood alteration NOS;Mood swings;Muscle contractions involuntary;Muscle spasms;Muscle strain;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Myoclonus;Nail disorder;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Neoplasm;Neoplasm malignant;Nervous system disorder;Nervousness;Neuritis;Neuropathy peripheral;Night sweats;Nipple pain;Nuchal rigidity;Numbness;Ocular hyperaemia;Oedema;Oedema genital;Oedema peripheral;Optic neuritis;Osteoarthritis;Otitis media;Ovarian cancer;Ovarian cyst;Pain;Pain in extremity;Pain of skin;Palpitations;Pancreatitis;Papule;Paraesthesia;Pelvic pain;Pelvic venous thrombosis;Perineal pain;Peripheral swelling;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Pleural infection;Pneumonia;Pollakiuria;Polyp;Polyuria;Porphyria cutanea tarda;Porphyria non-acute;Porphyrin metabolism disorder;Pre-existing disease;Prurigo;Pruritus;Pruritus generalised;Pruritus genital;Pulmonary embolism;Pulse irregular;Purpura;Raised liver function tests;Rash;Rash erythematous;Rash generalised;Redness;Reproductive tract disorder;Respiratory tract infection;Retinal vascular thrombosis;Retinal vein occlusion;Rhinitis;Rigors;Sensory loss;Shock;Sinus congestion;Sinus headache;Sinusitis;Skin discolouration;Skin disorder;Skin exfoliation;Skin hypertrophy;Skin tenderness;Skin ulcer;Slurred speech;Somnolence;Speech loss;Sunburn;Superficial phlebothrombosis;Superficial thrombophlebitis of leg;Sweating increased;Swelling;Syncope;Tachycardia;Tenderness;Tension;Tension headache;Thromboembolism;Thrombophlebitis;Thrombophlebitis superficial;Thrombosis;Tinnitus;Tooth abscess;Tooth disorder;Toothache;Toxic reaction (NOS);Toxic shock syndrome;Toxicity to various agents;Transient ischaemic attack;Tremor;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Uterine cancer;Uterine cervical erosion;Uterine enlargement;Uterine haemorrhage;Uterine leiomyoma;Uterine pain;Vaginal discharge;Vaginal discomfort;Vaginal disorder;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal irritation;Vaginal itching;Vaginal moniliasis;Vaginal mycosis;Vaginal pain;Vaginal ulceration;Vaginismus;Vaginitis ulcerative;Varicose vein;Vascular pain;Vascular purpura;Vasodilation;Vasodilation procedure;Vein pain;Ventricular extrasystoles;Vertigo;Viral infection;Visual disturbance;Visual impairment;Vomiting;Vulva discomfort;Vulval disorder;Vulvovaginal candidiasis;Vulvovaginal discomfort;Vulvovaginal mycotic infection;Vulvovaginal pain;Vulvovaginal pruritus;Vulvovaginitis;Weight decreased;Weight fluctuation;Weight increased;Withdrawal bleed,small molecule,approved; investigational; vet_approved,"(17β)-estra-1,3,5(10)-triene-3,17-diol; 17beta oestradiol; 17β-estra-1,3,5(10)-triene-3,17-diol; 17β-estradiol; 17β-oestradiol; beta-Estradiol; cis-Estradiol; Estradiol; Estradiol-17beta; Estradiolum; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; NACRA4; CEPR; Chemoattractant receptor-like 2; CMKRL2; DRY12; FEG-1; Flow-induced endothelial G-protein coupled receptor 1; G protein-coupled estrogen receptor 1; G-protein coupled receptor 30; GPCR-Br; GPER; GPR30; IL8-related receptor DRY12; LYGPR; Lymphocyte-derived G-protein coupled receptor; Membrane estrogen receptor; mER; ATP6; ATPASE6; F-ATPase protein 6; MTATP6; Coiled-coil myosin-like BCL2-interacting protein; GT197; Protein GT197; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.1.1.6; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; FABPI; Fatty acid-binding protein 2; I-FABP; Intestinal-type fatty acid-binding protein; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; OAT-RP-5; OATP-14; OATP-F; OATP-RP5; OATP14; OATP1C1; OATPF; Organic anion transporter 1C1; Organic anion transporter F; Organic anion transporter polypeptide-related protein 5; Organic anion-transporting polypeptide 14; SLC21A14; Solute carrier family 21 member 14; Thyroxine transporter",Estrogen receptor; Estrogen receptor beta; Nuclear receptor subfamily 1 group I member 2; Neuronal acetylcholine receptor subunit alpha-4; G-protein coupled estrogen receptor 1; ATP synthase subunit a; Beclin-1, G02BB01; G03AA14; G03AA17; G03AB08; G03CA03; G03CA53; G03EA01; G03EA02; G03EA03; G03FA01; G03FA02; G03FA03; G03FA04; G03FA05; G03FA06; G03FA07; G03FA08; G03FA09; G03FA10; G03FA11; G03FA12; G03FA13; G03FA14; G03FA15; G03FA17; G03FB01; G03FB02; G03FB03; G03FB04; G03FB05; G03FB06; G03FB07; G03FB08; G03FB09; G03FB10; G03FB11; G03FB12; G03HB01; H01CC53; H01CC54;G03CA03;G03FA16
N-acetylcysteine,Aspartate aminotransferase increased;Asthma;Atelectasis;Bronchiectasis;Bronchitis;Bronchitis asthmatic;Bronchopulmonary disease;Bronchospasm;Cystic fibrosis;Emphysema;Eruption;Hepatotoxicity;Liver injury;Pneumonia;Pneumothorax;Primary amyloidosis;Rash;Tracheobronchitis;Traumatic liver injury;Tuberculosis,Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Asthma;Body temperature increased;Bronchoconstriction;Bronchospasm;Cardiac disorder;Chest discomfort;Chest tightness;Cold sweat;Cough;Dermatitis;Dizziness;Drowsiness;Dyspepsia;Dysphoria;Dyspnoea;Ear and labyrinth disorders;Ear pain;Erythema;Erythema facial;Eye pain;Face oedema;Feeling hot;Flushing;Gait disturbance;Gastrointestinal disorder;Gastrointestinal symptom NOS;Haemoptysis;Hyperhidrosis;Hypersensitivity;Hypotension;Immune system disorder;Loss of consciousness;Mediastinal disorder;Mental disability;Nasopharyngitis;Nausea;Oedema;Palmar erythema;Pharyngitis;Pruritus;Rash;Respiratory distress;Rhinorrhoea;Rhonchi;Sensitisation;Shock;Skin disorder;Somnolence;Sticky skin;Stomatitis;Stridor;Sweating;Syncope;Tachycardia;Thinking abnormal;Throat tightness;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vomiting;Wheezing,small molecule,approved; investigational,(2R)-2-acetylamino-3-sulfanylpropanoic acid; (R)-2-acetylamino-3-mercaptopropanoic acid; (R)-mercapturic acid; Acetilcisteina; Acetylcysteine; Acetylcysteinum; L-acetylcysteine; L-α-acetamido-β-mercaptopropionic acid; Mercapturic acid; N-acetyl-L-(+)-cysteine; N-acetyl-L-cysteine; N-acetylcysteine; NAC; 6.3.2.3; Glutathione synthase; GSH synthetase; GSH-S; Amino acid transport system xc-; Calcium channel blocker resistance protein CCBR1; Solute carrier family 7 member 11; xCT; 3.5.1.14; ACY-1; N-acyl-L-amino-acid amidohydrolase; 2.7.11.10; I-kappa-B kinase 2; I-kappa-B-kinase beta; IkBKB; IKK-2; IKK-B; IKK-beta; IKK2; IKKB; NFKBIKB; Nuclear factor NF-kappa-B inhibitor kinase beta; Serine/threonine protein kinase IKBKB; 2.7.11.10; Conserved helix-loop-helix ubiquitous kinase; I-kappa-B kinase 1; I-kappa-B kinase alpha; IkappaB kinase; IkBKA; IKK-1; IKK-A; IKK-alpha; IKK1; IKKA; NFKBIKA; Nuclear factor NF-kappa-B inhibitor kinase alpha; TCF-16; TCF16; Transcription factor 16; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; 3.5.1.14; ACY-1; N-acyl-L-amino-acid amidohydrolase; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1,"Glutathione synthetase; Cystine/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A", S01XA08; V03AB23;R05CB01
cytarabine,Acute leukaemia;Acute lymphocytic leukaemia;Acute myeloid leukaemia;Blast cell crisis;Chronic myeloid leukaemia;Erythroleukaemia;Leptomeningeal metastases;Leukaemia;Leukaemic infiltration brain;Lymphoma;Malignant transformation;Meningeal leukemia;Meningeal neoplasm;Metastases to meninges;Myelodysplastic syndrome;Neoplasm;Neoplasm malignant;Non-Hodgkin's lymphoma;Solid tumour;Tetanus;Type IV hypersensitivity reaction,Abdominal pain;Acute respiratory distress syndrome;Agitation;Allergic oedema;Alopecia;Altered state of consciousness;Amnesia;Amylase increased;Anaemia;Anaemia megaloblastic;Anal inflammation;Anaphylactic shock;Angiopathy;Anorexia;Anxiety;Arachnoiditis;Arthralgia;Asthenia;Back pain;Blindness;Blood and lymphatic system disorders;Blood bilirubin increased;Blood disorder;Blood uric acid increased;Body temperature increased;Bone pain;CNS toxicity;Capillary leak syndrome;Cardiac disorder;Cardio-respiratory arrest;Cardiomegaly;Cardiomyopathy;Cardiotoxicity;Cauda equina syndrome;Cellulitis;Cerebellar syndrome;Cerebral dysfunction;Chest pain;Cognitive disorder;Cognitive impairment;Coma;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Cough;Cranial nerve paralysis;Cyst;Cytarabine syndrome;Deafness;Decreased appetite;Dehydration;Depression;Dermatitis;Diarrhoea;Diffuse large B-cell lymphoma;Diplegia;Discomfort;Disease progression;Dizziness;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Ephelides;Extravasation;Eye disorder;Eye pain;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Gait disturbance;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal necrosis;Gastrointestinal pain;Guillain-Barre syndrome;Haemoglobin;Haemorrhage;Haemorrhoids;Headache;Hearing impaired;Hemiplegia;Hepatic function abnormal;Hepatobiliary disease;Hepatocellular injury;Hydrocephalus;Hydrocephalus acquired;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperuricaemia;Hypoaesthesia;Hypoalgesia;Hypocalcaemia;Hypokalaemia;Hyponatraemia;Hypotension;Hypoxemia;Hypoxia;Ileus;Ill-defined disorder;Immune status;Immune system disorder;Immunology test;Incontinence;Infection;Infectious meningitis;Infestation;Infestation NOS;Inflammation;Injection site reaction;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal infections;Intestinal necrosis;Jaundice;Keratitis;Lacrimation;Lacrimation increased;Lethargy;Leukoencephalopathy;Leukopenia;Lipase increased;Liver abscess;Liver injury;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Memory loss;Meningism;Meningitis;Mental disorder;Monoplegia;Mucosal inflammation;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myelosuppression;Nausea;Neck pain;Neck stiffness;Necrotising colitis;Nervous system disorder;Neuritis;Neurological impairment;Neurological symptom;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Non-cardiogenic pulmonary oedema;Nuchal rigidity;Numbness;Ocular toxicity;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pain in extremity;Pancreatitis;Pancytopenia;Paraesthesia;Paraparesis;Paraplegia;Pericarditis;Peripheral sensory neuropathy;Peritonitis;Personality change;Photophobia;Platelet count decreased;Pneumatosis cystoides intestinalis;Pneumatosis intestinalis;Pneumonia;Polyp;Pruritus;Psychotic disorder;Pulmonary oedema;Pulmonary toxicity;Rash;Rash maculo-papular;Reflexes abnormal;Renal failure acute;Respiratory distress;Rhabdomyolysis;Sensation of foreign body;Sensory loss;Sepsis;Shock;Skin disorder;Skin exfoliation;Skin ulcer;Solar lentigo;Somnolence;Spastic paraparesis;Spinal cord disorder;Sweating increased;Syncope;Tachycardia;Tachypnoea;Throat sore;Thrombocytopenia;Thrombophlebitis;Transaminases increased;Traumatic liver injury;Tremor;Tumour lysis syndrome;Ulcer;Unspecified disorder of intestine;Unspecified disorder of skin and subcutaneous tissue;Ureteric obstruction;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output;Urticaria;Vasculitis necrotising;Venoocclusive disease;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight increased,small molecule,approved; investigational,"1-beta-D-Arabinofuranosylcytosine; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; Citarabina; Cytarabine; Cytarabine liposome; Cytarabinum; Cytosine arabinoside; Cytosine-1-beta-D-arabinofuranoside; cytosine-β-D-arabinofuranoside; 2.7.7.7; 5'-deoxyribose-phosphate lyase; 5'-dRP lyase; AP lyase; 2.7.7.7; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; 3.1.3.35; 3.1.3.5; 3.1.3.89; 3.1.3.91; 3.1.3.99; 5'-deoxynucleotidase; 5'-NT; Ecto-5'-nucleotidase; IMP-specific 5'-nucleotidase; NT5; NTE; Thymidylate 5'-phosphatase; 3.5.4.12; dCMP deaminase; 3.5.4.5; CDD; Cytidine aminohydrolase; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1",DNA polymerase beta; DNA polymerase catalytic subunit; DNA, L01XY01;L01BC01
lactate,Dry skin;Ichthyosis;Ichthyosis vulgaris;Pruritus;Skin exfoliation;Skin irritation;Skin scaly;Xerosis,Dermatitis;Eczema;Erythema;Ichthyosis;Ichthyosis acquired;Localized exfoliation;Pain;Petechiae;Rash;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Stinging,small molecule,experimental,"Acetate; Acetate anion; Acetate ion; Acetate ion (1-); Acetic acid anion; Acetic acid, ion(1-); Acetoxy ion; Azetat; 3.4.24.65; HME; Macrophage elastase; Matrix metalloproteinase-12; ME; MME; MMP-12; CALM; CAM; CAM1; 1.15.1.1; hSod1; Superoxide dismutase 1; (S)-3-amino-2-methylpropionate transaminase; 2.6.1.19; GABA aminotransferase; GABA transaminase; GABA-AT; GABA-T; GABAT; Gamma-amino-N-butyrate transaminase; L-AIBAT; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; 2.6.1.16; D-fructose-6-phosphate amidotransferase; GFAT; Glucosamine-6-phosphate synthase; Hexosephosphate aminotransferase; L-glutamine--D-fructose-6-phosphate amidotransferase; 3.1.3.48; Protein-tyrosine phosphatase 1B; PTP-1B; PTP1B; 1.14.13.39; bNOS; Constitutive NOS; N-NOS; NC-NOS; Neuronal NOS; Nitric oxide synthase, brain; nNOS; NOS type I; Peptidyl-cysteine S-nitrosylase NOS1; 1.3.5.2; DHOdehase; Dihydroorotate oxidase; 3.4.21.36; ELA1; Elastase-1; Pancreatic elastase 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; 2.4.2.22; HGPRT; 1.13.11.27; 4-hydroxyphenylpyruvic acid oxidase; 4HPPD; HPD; HPPDase; PPD; 1.14.13.39; cNOS; Constitutive NOS; EC-NOS; Endothelial NOS; eNOS; Nitric oxide synthase, endothelial; NOS type III; NOSIII; ADF; ATL-derived factor; SASP; Surface-associated sulphydryl protein; TRDX; TRX; TRX1; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 3.3.2.6; Leukotriene A(4) hydrolase; LTA-4 hydrolase; LTA4; Tripeptide aminopeptidase LTA4H; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1.1.1.-; 1.1.1.210; 1.1.1.53; 1.1.1.62; 17-beta-HSD 5; 17-beta-hydroxysteroid dehydrogenase type 5; 3-alpha-HSD type 2; 3-alpha-HSD type II, brain; 3-alpha-hydroxysteroid dehydrogenase type 2; Chlordecone reductase homolog HAKRb; DD-3; DD3; DDH1; Dihydrodiol dehydrogenase 3; Dihydrodiol dehydrogenase type I; HA1753; HSD17B5; KIAA0119; PGFS; Prostaglandin F synthase; Testosterone 17-beta-dehydrogenase 5; 3.1.1.4; Group IB phospholipase A2; Phosphatidylcholine 2-acylhydrolase 1B; PLA2; PLA2A; PPLA2; 3.5.2.6; Penicillinase","Macrophage metalloelastase; Calmodulin-1; Superoxide dismutase [Cu-Zn]; 4-aminobutyrate aminotransferase, mitochondrial; Angiotensin-converting enzyme; Glutamine--fructose-6-phosphate aminotransferase [isomerizing]; Tyrosine-protein phosphatase non-receptor type 1; Nitric oxide synthase 1; Dihydroorotate dehydrogenase (quinone), mitochondrial; Chymotrypsin-like elastase family member 1; Estrogen receptor beta; Hypoxanthine-guanine-xanthine phosphoribosyltransferase; 4-hydroxyphenylpyruvate dioxygenase; Nitric oxide synthase 3; Thioredoxin; Carbonic anhydrase 2; Leukotriene A-4 hydrolase; Calmodulin-2; Calmodulin-3; Aldo-keto reductase family 1 member C3; Phospholipase A2; Beta-lactamase",G01AD01
dopamine,Acute coronary syndrome;Acute hypotension;Angiopathy;Blood pressure increased;Cardiac failure;Cardiac failure high output;Cardiac output decreased;Cardiac output increased;Cerebrovascular accident;Coma;Confusional state;Decompensation cardiac;Diuresis;Feeling abnormal;Hypotension;Hypovolaemia;Injury;Myocardial infarction;Pallor;Polyuria;Renal failure;Sepsis;Septicemia;Shock;Tachyarrhythmia;Trauma;Urine output;Vascular resistance systemic;Vascular resistance systemic decreased;Vasoconstriction;Vasoconstriction peripheral,Angina pectoris;Anxiety;Atrial fibrillation;Azotaemia;Bradycardia;Cyanosis;Cyanosis peripheral;Dyspnoea;Electrocardiogram QRS complex;Extrasystoles;Extravasation;Gangrene;Headache;Hypertension;Menorrhagia;Nausea;Necrosis;Palpitations;Piloerection;Prolonged menses;QRS complex;Tachycardia;Ventricular arrhythmia;Vomiting,small molecule,approved,"2-(3,4-dihydroxyphenyl)ethylamine; 3-Hydroxytyramine; 3,4-Dihydroxyphenethylamine; 4-(2-aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-aminoethyl)catechol; 4-(2-aminoethyl)pyrocatechol; Dopamina; Dopamine; Dopaminum; Oxytyramine; Dopamine D2 receptor; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 1.14.17.1; Dopamine beta-monooxygenase; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT3-B; 5-HT3B; Serotonin receptor 3B; 1.15.1.1; hSod1; Superoxide dismutase 1; Solute carrier family 18 member 2; SVMT; VAT2; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT2; 1.14.17.1; Dopamine beta-monooxygenase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 2.1.1.6; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Oct-3; Oct-4; OCT3; OCT4; Octamer-binding protein 3; Octamer-binding protein 4; Octamer-binding transcription factor 3; OTF-3; OTF3",D(2) dopamine receptor; D(1A) dopamine receptor; D(1B) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; Sodium-dependent dopamine transporter; Dopamine beta-hydroxylase; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 7; D(1) dopamine receptor; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 3B; Superoxide dismutase [Cu-Zn]; Synaptic vesicular amine transporter,C01CA04
estrone,Atrophy;Hypogonadism;Menopause;Osteoporosis postmenopausal;Ovarian failure;Primary ovarian failure,Abdominal bloating;Abdominal cramps;Abdominal distension;Abdominal pain;Abnormal withdrawal bleeding;Acute coronary syndrome;Anaphylactic shock;Angioedema;Arthralgia;Asthma;Bleeding breakthrough;Blood pressure increased;Breast cancer;Breast discharge;Cerebrovascular accident;Chloasma;Chorea;Cramps of lower extremities;Dementia;Depression;Dermatitis;Dermatitis hemorrhagic;Dizziness;Dysmenorrhoea;Ectropion of cervix;Endometrial cancer;Endometrial hyperplasia;Epilepsy;Erythema multiforme;Erythema nodosum;Exacerbation of asthma;Fibrocystic breast disease;Flatulence;Galactorrhoea;Gallbladder disorder;Haemangioma;Headache;Hirsutism;Hypocalcaemia;Irritability;Jaundice cholestatic;Metrorrhagia;Migraine;Mood alteration NOS;Mood swings;Muscle spasms;Musculoskeletal discomfort;Myocardial infarction;Nausea;Nervousness;Oedema;Ovarian cancer;Pain;Pancreatitis;Porphyrin metabolism disorder;Pruritus;Pulmonary embolism;Purpura;Rash;Retinal vascular thrombosis;Superficial phlebothrombosis;Tenderness;Tension;Thrombophlebitis;Thrombophlebitis superficial;Urticaria;Uterine leiomyoma;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved,"3-Hydroxy-1,3,5(10)-estratrien-17-one; Estrona; Estrone; Estronum; Follicular hormone; Folliculin; Oestrone; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Estrogen receptor; Estrogen receptor beta; Androgen receptor; Aromatase; Sex hormone-binding globulin, G03CA07;G03CA07;G03CC04
lindane,Acarodermatitis;Infestation;Infestation NOS;Lice infestation;Scabies,Alopecia;Convulsion;Dermatitis;Dermatitis contact;Dermatitis irritant contact;Dizziness;Headache;Pain;Paraesthesia;Pruritus;Urticaria,small molecule,approved; withdrawn,"(1r,2c,3t,4c,5c,6t)-1,2,3,4,5,6-hexachlorocyclohexane; (1α,2α,3β,4α,5α,6β)-1,2,3,4,5,6-hexachlorocyclohexane; 1,2,3,4,5,6-hexachlorocyclohexane; Benzene hexachloride; gamma-1,2,3,4,5,6-hexachlorocyclohexane; gamma-benzene hexachloride; gamma-BHC; gamma-HCH; gamma-Hexachlorocyclohexane; gamma-Lindane; Gammallin; Gammaxene; Lindan; Lindane; Lindano; Lindanum; γ-hexachlorocyclohexane; γ-Hexachlorzyklohexan; γ-lindane; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; Glycine receptor 48 kDa subunit; Glycine receptor strychnine-binding subunit; Glycine receptor 58 kDa subunit; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit rho-1; GABA(C) receptor; GABAAR subunit rho-1; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR",Gamma-aminobutyric acid receptor subunit beta-1; Glycine receptor subunit alpha-1; Glycine receptor subunit alpha-2; Glycine receptor subunit alpha-3; Glycine receptor subunit beta; Gamma-aminobutyric acid receptor subunit beta-3; Gamma-aminobutyric acid receptor subunit rho-1; Progesterone receptor; Estrogen receptor; Nuclear receptor subfamily 1 group I member 2,P03AB02
histamine,Acute leukaemia;Acute myeloid leukaemia;Cutaneous hypersensitivity;Dermatitis atopic;Skin test positive;Type I hypersensitivity;Urticaria;Welts,Abdominal cramps;Abdominal distension;Abdominal pain;Abdominal pain upper;Anaemia;Anaphylactic shock;Angiopathy;Anorexia;Anxiety;Arthralgia;Asthenia;Asthma;Back pain;Blood and lymphatic system disorders;Body temperature increased;Bronchoconstriction;Bronchospasm;Cardiac disorder;Chest pain;Chills;Connective tissue disorder;Constipation;Cough;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Endocrine disorder;Eosinophilia;Erythema;Fatigue;Feeling abnormal;Feeling hot;Flushing;Gastritis;Gastrointestinal disorder;Headache;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Hypothyroidism;Ill-defined disorder;Infection;Infestation;Infestation NOS;Influenza like illness;Injection site bruising;Injection site dermatitis;Injection site erythema;Injection site fibrosis;Injection site granuloma;Injection site haemorrhage;Injection site inflammation;Injection site pain;Injection site pruritus;Injection site reaction;Injection site swelling;Injection site urticaria;Insomnia;Leukopenia;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nausea;Neoplasm;Nervous system disorder;Neutropenia;Night sweats;Oedema peripheral;Pain;Pain in extremity;Palpitations;Paraesthesia;Pneumonia;Pruritus;Rash;Shock;Skin disorder;Stomatitis;Tachycardia;Taste metallic;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Vasomotor collapse;Vertigo;Vomiting;Weight decreased;Welts;Wheezing,small molecule,approved; investigational,1H-Imidazole-4-ethanamine; 2-(4-imidazolyl)ethylamine; 4-imidazoleethylamine; 5-imidazoleethylamine; beta-aminoethylglyoxaline; beta-aminoethylimidazole; H1-R; H1R; HH1R; Gastric receptor I; H2R; HH2R; G-protein coupled receptor 97; GPCR97; H3R; HH3R; AXOR35; G-protein coupled receptor 105; GPCR105; GPRv53; H4R; HH4R; Pfi-013; SP9144; Solute carrier family 18 member 2; SVMT; VAT2; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT2; 2.1.1.8; HMT; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5,Histamine H1 receptor; Histamine H2 receptor; Histamine H3 receptor; Histamine H4 receptor; Synaptic vesicular amine transporter, V04CG03;L03AX14
potassium,Arrhythmia;Ascites;Blood potassium decreased;Cardiac failure congestive;Digitalis intoxication (NOS);Essential hypertension;Familial periodic paralysis;Gastric ulcer;Haemoglobin;Haemorrhage;Hepatic cirrhosis;Hyperkalaemia;Hypokalaemia;Intoxication;Metabolic alkalosis;Nephrolithiasis;Nephropathy;Paralysis;Poisoning;Potassium deficiency;Renal tubular acidosis;Road traffic accident;Toxicity to various agents,Abdominal discomfort;Abdominal pain;Apathy;Areflexia;Arrhythmia;Asthenia;Atrioventricular block;Block heart;Body temperature increased;Cardiac arrest;Confusional state;Dermatitis;Diarrhoea;Discomfort;Dysarthria;Electrocardiogram QRS complex;Electrocardiogram abnormal;Extravasation;Feeling abnormal;Flat affect;Flatulence;Fluid overload;Gastrointestinal pain;Gastrointestinal tract irritation;Gastrointestinal ulcer haemorrhage;Haemoglobin;Haemorrhage;Hyperkalaemia;Hypotension;Ileus;Infection;Intoxication;Loose stools;Nausea;Pain;Paraesthesia;Paralysis flaccid;Paresthesia of limbs;Phlebitis;Poisoning;Pregnancy;QRS complex;Rash;Respiratory paralysis;Slurred speech;Ulcer;Venous thrombosis;Vomiting,small molecule,approved; experimental,"K; Kalium; Potasio; Potassium metal; Potassium, elemental; Potassium, metal; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1; BSC1; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; Kidney-specific Na-K-Cl symporter; Na-K-2Cl cotransporter 2; NKCC2",Sodium/potassium-transporting ATPase subunit alpha-1, C03AB01; C03AB02; C03AB04; C03AB05; C03AB06; C03AB07; C03AB08; C03AB09; C03BB02; C03BB03; C03BB04; C03BB05; C03BB07; C03CB01; C03CB02;C03AB03
kanamycin,Infection;Renal failure;Renal impairment;Staphylococcal infection,Albuminuria;Apnoea;Azotaemia;Body temperature increased;Deafness;Dermatitis;Diarrhoea;Drug fever;Headache;Hearing impaired;Malabsorption;Meniere's disease;Nausea;Nephropathy toxic;Nephrotoxicity;Neurotoxicity;Nystagmus;Oliguria;Ototoxicity;Pain;Paraesthesia;Paralysis;Rash;Tinnitus;Vertigo;Vestibular toxicity;Vomiting,small molecule,approved; investigational; vet_approved,"4,6-diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-α-D-glucoside; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside; Kanamycin A; strA; 2.3.1.-; AAC(2')-Ic; 2.7.7.-; kan; Neo(R); 2.7.1.95; APH(3')-I; APH(3')I; Kanamycin kinase, type I; Neomycin-kanamycin phosphotransferase type I; nptI",30S ribosomal protein S12; 16S ribosomal RNA, A07AA08; J01GB04;A07AA08;S01AA24
epinephrine,Acute sinusitis;Adams-Stokes syndrome;Agitation;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anxiety;Arthropod sting;Asthenia;Asthma;Atrioventricular block;Atrioventricular block complete;Bite;Block heart;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiovascular disorder;Carotid sinus hypersensitivity;Carotid sinus syndrome;Convulsion;Coronary artery disease;Dermatitis;Diabetes mellitus;Diabetic;Dizziness;Dyspnoea;Exercise-induced anaphylaxis;Glaucoma;Headache;Hypersensitivity;Hypertension;Hyperthyroidism;Hypotension;Laryngospasm;Loss of consciousness;Pain;Pallor;Parkinson's disease;Parkinsonism;Pruritus;Rash;Respiratory distress;Rhinitis;Rhinitis seasonal;Seasonal allergy;Serum sickness;Shock;Shock hypoglycaemic;Shock insulin;Sting;Stinging;Syncope;Throbbing headache;Tremor;Urticaria;Uterine contractions;Uterine contractions during pregnancy,Acute coronary syndrome;Agitation;Arrhythmia;Blanching of skin;Blood pressure increased;Central nervous system haemorrhage;Cerebral haemorrhage;Cerebrovascular accident;Chest pain;Coldness;Contusion;Disorientation;Dizziness;Drowsiness;Drug interaction;Erythema;Excitability;Extravasation;Feeling cold;Flushing;Gas gangrene;Gastrointestinal disorder;Haemoglobin;Haemorrhage;Hallucination;Hemiplegia;Hyperglycaemia;Hyperhidrosis;Hypertension;Hypertensive;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Injection site injury;Injection site pallor;Insomnia;Ischaemia;Lactic acidosis;Lightheadedness;Local reaction;Memory impairment;Mental disorder;Mydriasis;Myocardial infarction;Myocardial ischaemia;Nausea;Necrosis;Nephropathy;Nervous system disorder;Nervousness;Pallor;Palpitations;Panic reaction;Paraesthesia;Peripheral coldness;Piloerection;Psychotic disorder;Pulmonary oedema;Rales;Redness of face;Renal failure;Renal impairment;Skeletal injury;Skin disorder;Skin exfoliation;Skin necrosis;Somnolence;Subarachnoid haemorrhage;Supraventricular tachycardia;Sweating;Sweating increased;Tachyarrhythmia;Tachycardia;Tension;Tingling sensation;Unspecified disorder of skin and subcutaneous tissue;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular fibrillation;Vomiting,small molecule,approved; vet_approved,"(−)-(R)-epinephrine; (−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol; (−)-adrenaline; (R)-(-)-Adnephrine; (R)-(-)-Adrenaline; (R)-(-)-Epinephrine; (R)-(-)-Epirenamine; (R)-(−)-adrenaline; 1,2-BENZENEDIOL, 4-(1-HYDROXY-2-(METHYLAMINO)ETHYL)-, (R)-; 4-((1R)-1-HYDROXY-2-(METHYLAMINO)ETHYL)-1,2-BENZENEDIOL; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; Adrénaline; Adrenaline; BENZYL ALCOHOL, 3,4-DIHYDROXY-.ALPHA.-((METHYLAMINO)METHYL)-, (-)-; Epinefrin; Epinefrina; Epinephrin; Epinephrine; Epinephrinum; L-Adrenaline; Levoepinephrine; RACEPINEFRINE, (R)-; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; Cachectin; TNF-a; TNF-alpha; TNFA; TNFSF2; Tumor necrosis factor ligand superfamily member 2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.1.1.6; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1",Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-1D adrenergic receptor; Tumor necrosis factor, B02BC09; C01CA24; R01AA14; R03AA01; R03AK01; S01EA01; S01EA51;A01AD01
thyroxine,Absence congenital;Acute myocardial infarction;Adrenal insufficiency;Atrophy;Autoimmune thyroiditis;Congenital anomaly;Dysfunction thyroid;Follicular thyroid cancer;Goitre;Hashimoto's disease;Hypersensitivity;Hyperthyroidism;Hypothyroidism;Myxoedema coma;Neoplasm malignant;Primary hypothyroidism;Subclinical hypothyroidism;Thyroid disorder;Thyroid neoplasm;Thyroid nodule;Thyroiditis;Thyroiditis subacute;Thyrotoxicosis;Tri-iodothyronine normal,Abdominal cramps;Abdominal pain;Acute coronary syndrome;Affect lability;Agitation;Alopecia;Angina pectoris;Angioedema;Anxiety;Arrhythmia;Arthralgia;Asthenia;Basedow's disease;Benign intracranial hypertension;Body temperature increased;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Cerebral artery embolism;Choking;Coma;Confusional state;Convulsion;Craniosynostosis;Dehydration;Dermatitis;Diarrhoea;Disorientation;Dysphagia;Dyspnoea;Epiphysiolysis;Fatigue;Feeling abnormal;Fluid loss;Flushing;Gagging;Gastrointestinal pain;Headache;Heat intolerance;Hyperhidrosis;Hyperkinesia;Hyperthyroidism;Hypoglycaemia;Increased appetite;Infertility;Insomnia;Irritability;Menstruation irregular;Mood swings;Muscular weakness;Musculoskeletal discomfort;Myocardial infarction;Nausea;Nervousness;Palpitations;Pruritus;Rash;Retching;Serum sickness;Shock;Slipped femoral capital epiphysis;Sweating;Sweating increased;Tachycardia;Temperature intolerance;Tension;Tremor;Urticaria;Vomiting;Weight decreased;Wheezing,small molecule,approved; investigational; nutraceutical,(−)-α-amino-p-hydroxyhydrocinnamic acid; (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid; (S)-(-)-Tyrosine; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; (S)-3-(p-Hydroxyphenyl)alanine; (S)-alpha-amino-4-Hydroxybenzenepropanoic acid; (S)-Tyrosine; (S)-α-amino-4-hydroxybenzenepropanoic acid; 4-hydroxy-L-phenylalanine; L-Tyrosin; L-tyrosine; Tirosina; Tyr; Tyrosine; Tyrosinum; Y; 1.14.16.2; TH; TYH; Tyrosine 3-hydroxylase; 6.1.1.1; Tyrosyl-tRNA synthetase; TyrRS; 6.1.1.1; Tyrosyl-tRNA synthetase; TyrRS; YARS; 2.6.1.5; L-tyrosine:2-oxoglutarate aminotransferase; TAT; MCT 7; MCT 8; MCT7; MCT8; Monocarboxylate transporter 7; Solute carrier family 16 member 2; X-linked PEST-containing transporter; XPCT; Aromatic amino acid transporter 1; MCT 10; MCT10; Solute carrier family 16 member 10; T-type amino acid transporter 1; TAT1,"Tyrosine 3-monooxygenase; Tyrosine--tRNA ligase, mitochondrial; Tyrosine--tRNA ligase, cytoplasmic; Tyrosine aminotransferase",C10AX01
melatonin,Insomnia;Poor quality sleep;Primary insomnia,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abnormal bowel sounds;Abnormal dreams;Affect lability;Aggression;Agitation;Angina pectoris;Angioedema;Angiopathy;Anxiety;Arthralgia;Arthritis;Asthenia;Back pain;Blood and lymphatic system disorders;Blood triglycerides increased;Breast disorder;Breath odour;Cardiac disorder;Chest pain;Connective tissue disorder;Depressed mood;Dermatitis;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dreamy state;Dry mouth;Dry skin;Dyspepsia;Ear and labyrinth disorders;Eczema;Erythema;Eye disorder;Fatigue;Flatulence;Galactorrhoea;Gastric disorder;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal sounds abnormal;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;Glycosuria;Haematuria;Hand dermatitis;Headache;Hepatic enzyme increased;Hepatobiliary disease;Herpes zoster;Hot flush;Hyperbilirubinaemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypocalcaemia;Hyponatraemia;Immune system disorder;Infection;Infestation;Infestation NOS;Insomnia;Irritability;Laboratory test abnormal;Lacrimation increased;Lethargy;Leukopenia;Libido increased;Liver function test abnormal;Loss of consciousness;Malnutrition;Memory impairment;Menopausal symptoms;Mental disorder;Migraine;Mood swings;Mouth ulceration;Muscle spasms;Musculoskeletal discomfort;Nail disorder;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Nervousness;Night cramps;Night sweats;Nightmare;Nocturia;Oedema mouth;Oral mucosal blistering;Pain;Pain in extremity;Palpitations;Paraesthesia;Polyuria;Priapism;Prostatitis;Protein urine present;Proteinuria;Prurigo;Pruritus;Pruritus generalised;Psoriasis;Rash;Rash generalised;Restless legs syndrome;Salivary hypersecretion;Shock;Skin disorder;Somnolence;Stomatitis;Stress;Stress symptoms;Syncope;Tension;Terminal insomnia;Thirst;Thrombocytopenia;Tongue disorder;Tongue oedema;Tongue ulceration;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine output increased;Vertigo;Vertigo positional;Vision blurred;Visual acuity reduced;Vomiting;Weight increased,small molecule,approved; nutraceutical; vet_approved,"5-methoxy-N-acetyltryptamine; Melatonin; Melatonina; Mélatonine; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; N-Acetyl-5-methoxytryptamine; Mel-1A-R; Mel1a receptor; Mel-1B-R; Mel1b receptor; 1.10.5.1; NMOR2; NRH dehydrogenase [quinone] 2; NRH:quinone oxidoreductase 2; QR2; Quinone reductase 2; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; NR1F2; Nuclear receptor RZR-beta; Nuclear receptor subfamily 1 group F member 2; Retinoid-related orphan receptor-beta; RZRB; 1.11.2.2; MPO; 1.11.1.7; EPER; EPO; EPP; Calregulin; CRP55; CRTC; Endoplasmic reticulum resident protein 60; ERp60; grp60; HACBP; 2.1.1.4; HIOMT; Hydroxyindole O-methyltransferase; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.1.1.4; HIOMT; Hydroxyindole O-methyltransferase; 1.13.11.52; IDO; IDO-1; INDO; Indoleamine-pyrrole 2,3-dioxygenase; 1.11.2.2; MPO; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Melatonin receptor type 1A; Melatonin receptor type 1B; Ribosyldihydronicotinamide dehydrogenase [quinone]; Estrogen receptor; Nuclear receptor ROR-beta; Myeloperoxidase; Eosinophil peroxidase; Calreticulin; Acetylserotonin O-methyltransferase; Calmodulin,N05CH01
niacin,Abdominal pain;Acute coronary syndrome;Blood triglycerides increased;Cardiovascular disorder;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Diabetic;Dyslipidaemia;Flushing;Gastrointestinal pain;Gout;High density lipoprotein increased;Hypercholesterolaemia;Hyperlipidaemia;Hyperlipoproteinemia;Hypertriglyceridaemia;Myocardial infarction;Nicotinic acid deficiency;Pancreatitis;Peptic ulcer;Type 2 diabetes mellitus;Type V hyperlipidaemia;Vasodilation;Vasodilation procedure,Abdominal distension;Abdominal pain;Abnormal vision;Acanthosis nigricans;Alopecia;Amblyopia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Application site reaction;Arrhythmia;Arterial thrombosis;Arthralgia;Arthritis;Ascites;Asthenia;Atherothrombosis;Atrial fibrillation;Blood glucose increased;Blood insulin increased;Blood uric acid increased;Body temperature increased;Bone disorder;Breast pain;Bronchitis;Burning sensation;Bursitis;Chills;Cholelithiasis;Cholestasis;Cough;Cough increased;Cramps of lower extremities;Cystoid macular oedema;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatitis contact;Diabetes mellitus;Diarrhoea;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Dyspepsia;Dysphagia;Dyspnoea;Eczema;Enlargement abdomen;Erectile dysfunction;Eructation;Erythema;Eye disorder;Face oedema;Faecal incontinence;Feeling hot;Fibrosis;Flatulence;Fluid retention;Flushing;Fungal skin infection;Furuncle;Furunculosis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal symptom NOS;Generalised oedema;Generalized flushing;Glaucoma;Glucose tolerance decreased;Gout;Haemoglobin;Haemoptysis;Haemorrhage;Headache;Heartburn;Hepatic function abnormal;Hepatitis;Hepatomegaly;Hepatotoxicity;Hernia;Herpes zoster;High density lipoprotein decreased;Hyperbilirubinaemia;Hyperhidrosis;Hyperinsulinism;Hyperkeratosis;Hypersensitivity;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypokinesia;Hypotension;Hypothyroidism;Influenza;Insomnia;Jaundice;Jaundice cholestatic;Keratosis;Laryngeal oedema;Laryngitis;Laryngospasm;Leukopenia;Libido increased;Liver function test abnormal;Loss of consciousness;Lung disorder;Macular oedema;Malnutrition;Metabolic syndrome;Migraine;Mucous membrane disorder;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myopathy;Nausea;Necrosis;Neoplasm skin;Nervousness;Oedema;Oedema peripheral;Oesophagitis;Orthostatic hypotension;Pain;Palpitations;Paraesthesia;Peptic ulcer;Polyuria;Prostatic disorder;Pruritus;Raised liver function tests;Rash;Rash maculo-papular;Rash pustular;Redness;Rhabdomyolysis;Rhinitis;Sensation of heat;Sensation of warmth;Shock;Skin burning sensation;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin ulcer;Somnolence;Stomatitis;Sweating;Syncope;Tachycardia;Tension;Tingling sensation;Tinnitus;Tongue disorder;Tongue oedema;Unspecified disorder of skin and subcutaneous tissue;Urinary retention;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vertigo;Vesiculobullous rash;Vision blurred;Visual impairment;Vomiting;Warmth;Xanthoma,small molecule,approved; investigational; nutraceutical,"3-carboxypyridine; 3-Pyridinecarboxylic acid; 3-Pyridylcarboxylic acid; Acide nicotinique; ácido nicotínico; Acidum Nicotinicum; anti-pellagra vitamin; m-pyridinecarboxylic acid; Niacin; Niacina; Nicotinic acid; Nikotinsäure; pyridine-β-carboxylic acid; β-pyridinecarboxylic acid; G-protein coupled receptor 109B; G-protein coupled receptor HM74; G-protein coupled receptor HM74B; GPR109B; HCA3; HM74B; Niacin receptor 2; NIACR2; Nicotinic acid receptor 2; 2.3.1.20; Acyl-CoA retinol O-fatty-acyltransferase; ARAT; Diglyceride acyltransferase 2; Retinol O-fatty-acyltransferase; G-protein coupled receptor 109A; G-protein coupled receptor HM74A; GPR109A; HCA2; HM74A; Niacin receptor 1; NIACR1; Nicotinic acid receptor; 2.4.2.19; QAPRTase; QPRTase; Quinolinate phosphoribosyltransferase [decarboxylating]; 2.1.1.1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; Serpin A7; T4-binding globulin; TBG; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; MCT 1; MCT1; Solute carrier family 16 member 1; AIT; Apical iodide transporter; Electrogenic sodium monocarboxylate cotransporter; SMCT; SMCT1; Sodium iodide-related cotransporter; Solute carrier family 5 member 8; MCT 4; MCT3; MCT4; Solute carrier family 16 member 3",Hydroxycarboxylic acid receptor 3; Diacylglycerol O-acyltransferase 2; Hydroxycarboxylic acid receptor 2; Nicotinate-nucleotide pyrophosphorylase [carboxylating]; Nicotinamide N-methyltransferase, C04AC01; C10AD52; C10BA01;C04AC01;C10AD02
nicotine,Acute coronary syndrome;Angina pectoris;Arrhythmia;Coronary artery disease;Coronary heart disease;Drug withdrawal syndrome;Eczema;Endocrine disorder;Gangrene;Hepatic failure;Hepatic impairment;Hepatic insufficiency;Hypersensitivity;Liver disorder;Local reaction;Malignant hypertension;Myocardial infarction;Nicotine dependence;Non-smoker;Non-tobacco user;Palpitations;Peptic ulcer;Peripheral vascular disorder;Pregnancy;Prinzmetal angina;Rash generalised;Renal failure;Renal impairment;Sensitisation;Skin disorder;Sleep disorder;Sleep disturbance;Thromboangiitis obliterans;Urticaria;Vasodilation;Vasodilation procedure;Withdrawal symptom,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal faeces;Abnormal vision;Acne;Affect lability;Agitation;Amnesia;Anaphylactic shock;Angioedema;Anxiety;Apathy;Aphasia;Aphthous stomatitis;Application site reaction;Arrhythmia;Arthralgia;Arthritis;Asthenia;Atrial fibrillation;Back pain;Bladder pain;Blister;Blood pressure fluctuation;Blood pressure increased;Body temperature increased;Bronchitis;Bronchospasm;Burning sensation;Cardiac disorder;Cardiac failure;Cerebration impaired;Change in blood pressure;Chest discomfort;Chest pain;Chest tightness;Cold sweat;Completed suicide;Confusional state;Constipation;Convulsion;Coordination abnormal;Cough;Cramps of lower extremities;Cystitis;Cystitis noninfective;Dependence;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Disturbance in attention;Dizziness;Dreaming excessive;Drug abuse;Dry mouth;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Ear pain;Epistaxis;Eructation;Erythema;Extrasystoles;Eye irritation;Fatigue;Feeling abnormal;Flat affect;Flatulence;Fluid retention;Flushing;Gastric ulcer;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal pain;Gingivitis;Headache;Heartburn;Herpes labialis;Hiccups;Hoarseness;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Ill-defined disorder;Immune system disorder;Increased appetite;Influenza;Influenza like illness;Influenza-like symptoms;Insomnia;Irritability;Lacrimation increased;Laryngeal pain;Local reaction;Local swelling;Loss of consciousness;Malaise;Mediastinal disorder;Memory impairment;Menopausal symptoms;Menstrual disorder;Mental disability;Mental disorder;Migraine;Mood swings;Motor dysfunction;Mouth ulceration;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasal discomfort;Nasal irritation;Nasal ulcer;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Nicotine dependence;Nicotine poisoning;Numbness;Oedema;Oedema peripheral;Oral discomfort;Oral herpes;Pain;Pain in jaw;Pallor;Palpitations;Paraesthesia;Pharyngitis;Pharyngolaryngeal pain;Prostration;Pruritus;Rash;Redness;Respiratory failure;Respiratory paralysis;Rhinitis;Rhinorrhoea;Salivary hypersecretion;Salivation;Sensory loss;Shock;Sickness;Sinusitis;Sleep disorder;Sleep disturbance;Sneezing;Somnolence;Stomatitis;Suicide;Sweating increased;Syncope;Tachycardia;Tearing eyes;Tenderness;Tension;Throat irritation;Thyroid disorder;Tingling sensation;Tobacco poisoning;Tobacco withdrawal symptoms;Tongue disorder;Tooth disorder;Toothache;Tremor;Ulcerative stomatitis;Urticaria;Vertigo;Visual impairment;Vomiting;Water retention;Weight increased;Withdrawal syndrome,small molecule,approved,"(−)-nicotine; (S)-(−)-nicotine; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; (S)-Nicotine; 3-(2-(N-methylpyrrolidinyl))pyridine; 3-(N-methylpyrollidino)pyridine; L(−)-nicotine; Nicotina; Nicotine; Nicotine betadex; Nicotine polacrilex; Nikotin; Nikotyna; NACRA4; NACHRA7; NACHRA3; NACHRA5; NACHR alpha-9; NACHRA9; Nicotinic acetylcholine receptor subunit alpha-9; NACHR alpha-10; NACHRA10; Nicotinic acetylcholine receptor subunit alpha-10; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 2.3.1.6; ChAT; CHOACTase; Choline acetylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIIA13; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H",Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit alpha-7; Neuronal acetylcholine receptor subunit beta-2; Neuronal acetylcholine receptor subunit alpha-2; Neuronal acetylcholine receptor subunit alpha-3; Neuronal acetylcholine receptor subunit alpha-5; Neuronal acetylcholine receptor subunit alpha-6; Neuronal acetylcholine receptor subunit alpha-9; Neuronal acetylcholine receptor subunit alpha-10; Neuronal acetylcholine receptor subunit beta-3; Neuronal acetylcholine receptor subunit beta-4; Aromatase; Choline O-acetyltransferase,N07BA01
norepinephrine,Acute coronary syndrome;Cardiac arrest;Hyperthyroidism;Hypotension;Hypotensive;Myocardial infarction;Poliomyelitis;Sepsis;Septicemia,Aggression;Anxiety;Arrhythmia;Blood pressure increased;Bradycardia;Chest pain;Dyspnoea;Extravasation;Gangrene;Headache;Hyperhidrosis;Hypertension;Hypovolaemia;Injection site necrosis;Intermittent headache;Lactic acidosis;Pallor;Photophobia;Retrosternal pain;Sweating;Violent;Vomiting,small molecule,approved,"(−)-arterenol; (−)-noradrenaline; (−)-norepinephrine; (R)-(−)-norepinephrine; (R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol; (R)-noradrenaline; (R)-norepinephrine; 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Arterenol; L-noradrenaline; L-Norepinephrine; Nor-adrenaline; Noradrenaline; Norepinefrina; Norépinéphrine; Norepinephrine; Norepinephrinum; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; 1.14.16.1; PAH; Phe-4-monooxygenase; Solute carrier family 18 member 2; SVMT; VAT2; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT2; Solute carrier family 18 member 1; VAT1; Vesicular amine transporter 1; VMAT1; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; hOCT1; OCT1; Organic cation transporter 1; Oct-3; Oct-4; OCT3; OCT4; Octamer-binding protein 3; Octamer-binding protein 4; Octamer-binding transcription factor 3; OTF-3; OTF3",Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Beta-3 adrenergic receptor; Phenylalanine-4-hydroxylase; Synaptic vesicular amine transporter; Chromaffin granule amine transporter,C01CA03
pyrazinamide,Active tuberculosis;Jaundice;Tuberculosis,Acute yellow liver atrophy;Anorexia;Arthralgia;Blood iron increased;Blood uric acid increased;Body temperature increased;Clotting;Coagulopathy;Decreased appetite;Dermatitis;Digestion impaired;Discomfort;Dyspepsia;Dysuria;Feeling abnormal;Gastrointestinal disorder;Gout;Gout acute;Gouty arthritis;Hepatitis;Hepatomegaly;Hepatotoxicity;Hyperplasia erythroid;Hypersensitivity;Hyperuricaemia;Ill-defined disorder;Liver tenderness;Malaise;Marrow hyperplasia;Musculoskeletal discomfort;Myalgia;Nausea;Nephritis interstitial;Peptic ulcer;Photosensitivity;Photosensitivity reaction;Polyarthralgia;Porphyrin metabolism disorder;Pruritus;Rash;Rash maculo-papular;Serum iron increased;Sideroblastic anaemia;Splenomegaly;Thrombocytopenia;Tubulointerstitial nephritis;Urticaria;Vomiting,small molecule,approved; investigational,2-carbamylpyrazine; 2-pyrazinecarboxamide; Aldinamide; Pirazinamida; Pirazinamide; Pyrazinamid; Pyrazinamida; Pyrazinamide; Pyrazinamidum; Pyrazine carboxamide; pyrazine-2-carboxamide; Pyrazineamide; Pyrazinecarboxamide; Pyrazinoic acid amide; Pyrizinamide; 1.3.1.9; ENR; FAS-II enoyl-ACP reductase; NADH-dependent 2-trans-enoyl-ACP reductase; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase; XDHA,Probable fatty acid synthase Fas (Fatty acid synthetase); Enoyl-[acyl-carrier-protein] reductase [NADH], J04AM05; J04AM06;J04AK01
pyridoxine,Anaemia;Anorexia;Cheilosis;Convulsion;Decreased appetite;Dermatitis;Homocystinuria;Hyperoxaluria;Inborn error of metabolism;Nausea;Neuritis;Neurological symptom;Neuropathy peripheral;Pyridoxine deficiency;Sideroblastic anaemia;Vitamin B6 deficiency;Vomiting,Headache;Nausea;Neuropathy peripheral;Paraesthesia;Somnolence,small molecule,approved; investigational; nutraceutical; vet_approved,"2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine; 3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine; 3-hydroxy-4,5-dimethylol-α-picoline; 5-hydroxy-6-methyl-3,4-pyridinedimethanol; Piridoxina; Pyridoxine; Pyridoxinum; Pyridoxol; Vitamin B6; 4.1.1.28; AADC; DDC; DOPA decarboxylase; 2.7.1.35; C21orf124; C21orf97; PKH; PNK; Pyridoxine kinase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 2.7.1.35; C21orf124; C21orf97; PKH; PNK; Pyridoxine kinase; 3.1.3.16; 3.1.3.74; CIN; PLP; PLP phosphatase; PLPP; Pyridoxal phosphate phosphatase; 3.1.3.1; Alkaline phosphatase liver/bone/kidney isozyme; AP-TNAP; Phosphoamidase; Phosphocreatine phosphatase; TNS-ALP; TNSALP; 3.1.3.1; Alkaline phosphatase liver/bone/kidney isozyme; AP-TNAP; Phosphoamidase; Phosphocreatine phosphatase; TNS-ALP; TNSALP",Aromatic-L-amino-acid decarboxylase; Pyridoxal kinase, A11HA02;A11HA02;J04AM08
quinidine,Atrial fibrillation;Babesiosis;Cardiac flutter;Cramps of lower extremities;Falciparum malaria;Malaria;Muscle spasms;Myotonia;Plasmodium falciparum infection;Sinus rhythm;Sustained ventricular tachycardia;Tachyarrhythmia;Ventricular arrhythmia;Ventricular tachycardia,"Abdominal discomfort;Abdominal pain;Abdominal pain upper;Acute interstitial nephritis;Agitation;Agranulocytosis;Allergic contact dermatitis;Angina pectoris;Angina symptom;Angioedema;Anorexia;Anuria;Anxiety;Aphasia;Aplastic anaemia;Apprehension;Arrhythmia;Arthralgia;Asthenia;Asthma;Ataxia;Atrioventricular block;Azotaemia;Blackwater fever;Blindness;Blindness, both eyes;Body temperature increased;Bone disorder;Bradycardia;Breast disorder;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiotoxicity;Cerebral hypoperfusion;Cerebral ischaemia;Chest pain;Chills;Cinchonism;Coagulopathy;Coma;Completed suicide;Confusional state;Convulsion;Cutaneous vasculitis;Deafness;Decreased appetite;Delirium;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatitis psoriasiform;Diarrhoea;Diplopia;Disorder sight;Disorientation;Disseminated intravascular coagulation;Distress gastrointestinal;Dizziness;Drug eruption;Dyspepsia;Dyspnoea;Dystonia;Dystonic reaction;Ear and labyrinth disorders;Ecchymosis;Eczema;Electrocardiogram QRS complex;Electrocardiogram U wave present;Electrocardiogram U-wave abnormality;Electrocardiogram abnormal;Epigastric discomfort;Epigastric pain;Erythema;Erythema multiforme;Excitement;Exfoliative rash;Eye disorder;Factor II deficiency;Fatigue;Feeling abnormal;Fixed drug eruption;Flushing;Gastric irritation;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Granulomatous liver disease;Haemoglobin;Haemoglobinuria;Haemolysis;Haemolytic anaemia;Haemolytic uraemic syndrome;Haemorrhage;Headache;Hearing impaired;Heartburn;Hepatitis;Hepatitis granulomatous;Hepatotoxicity;High frequency deafness;Hyperhidrosis;Hypersensitivity;Hypoglycaemia;Hypoprothrombinaemia;Hypotension;Idiopathic thrombocytopenic purpura;Immune system disorder;Jaundice;Leukopenia;Lichen planus;Lightheadedness;Liver function test abnormal;Loss of consciousness;Lupus erythematosus;Lupus-like syndrome;Lymphadenopathy;Malnutrition;Mediastinal disorder;Mental disorder;Mental state abnormal;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myasthenia gravis;Mydriasis;Nausea;Necrosis;Nervous system disorder;Nervousness;Neutropenia;Night blindness;Nodule;Oedema;Oesophagitis;Oliguria;Optic atrophy;Optic neuritis;Orthostatic hypotension;Pain;Palpitations;Pancytopenia;Partial hearing loss;Petechiae;Photophobia;Photosensitivity;Photosensitivity reaction;Plasmodium falciparum infection;Pneumonia;Pruritus;Psychotic disorder;Pulmonary oedema;Purpura;QRS complex;Rash;Renal failure;Renal failure acute;Renal impairment;Scotoma;Shock;Sjogren's syndrome;Skin disorder;Stevens-Johnson syndrome;Sudden visual loss;Suicide;Sweating;Syncope;Syndrome sicca;Systemic lupus erythematosus;Tachycardia;Tension;Thrombocytopenia;Thrombocytopenic purpura;Thrombotic thrombocytopenic purpura;Tinnitus;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Uraemic syndrome;Uremia;Urethral disorder;Urinary tract disorder;Urticaria;Uveitis;Vasculitis;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual field constriction;Visual impairment;Vomiting",small molecule,approved; investigational,"(+)-quinidine; (8R,9S)-Quinidine; (R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol; (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol; 6-methoxy-α-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol; beta-Quinine; Chinidin; Chinidinum; CIN-QUIN; Conchinin; Conquinine; Pitayine; Quinidina; α-(6-methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol; β-quinine; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; HOHO1; Inward rectifying potassium channel protein TWIK-1; KCNO1; Potassium channel K2P1; Potassium channel KCNO1; TWIK1; Inward rectifying potassium channel protein TWIK-2; TOSS; TWIK-originated similarity sequence; TWIK2; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Sodium channel protein type 5 subunit alpha; Potassium channel subfamily K member 1; Potassium channel subfamily K member 6; Voltage-gated inwardly rectifying potassium channel KCNH2; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor, C01BA51; C01BA71;C01BA01
thiamine,Anorexia;Ataxia;Beriberi;Body temperature increased;Cardiac failure;Cardiovascular disorder;Chronic fever;Coma;Decreased appetite;Encephalopathy;Foetor hepaticus;Gastrointestinal disorder;Hepatocellular injury;Hyperthyroidism;IIIrd nerve paralysis;Liver disorder;Malabsorption;Mental deterioration;Mental disability;Nausea;Neuritis;Neuropathy peripheral;Nystagmus;Oedema;Ophthalmoplegia;Unspecified disorder of intestine;Vitamin B1 deficiency;Vomiting;Wernicke's encephalopathy,Agitation;Anaphylactic shock;Angioedema;Asthenia;Collapse;Cyanosis;Feeling hot;Haemoglobin;Haemorrhage;Hyperhidrosis;Hypersensitivity;Induration;Nausea;Pruritus;Pulmonary oedema;Sensation of warmth;Shock;Sweating;Tenderness;Throat tightness;Urticaria,small molecule,approved; investigational; nutraceutical; vet_approved,Aneurin; Antiberiberi factor; Thiamin; Thiamine; thiamine(1+); thiamine(1+) ion; thiaminium; Thiaminum; Tiamina; Vitamin B1; hTPK1; Placental protein 20; PP20; Thiamin pyrophosphokinase 1; 1.2.4.1; PDH E1 component; 1.14.14.1; CYPIVB1; Cytochrome P450-HP; hTPK1; Placental protein 20; PP20; Thiamin pyrophosphokinase 1; 3.6.1.6; CD39 antigen-like 4; CD39L4; Ectonucleoside triphosphate diphosphohydrolase 5; ER-UDPase; GDPase ENTPD5; Guanosine-diphosphatase ENTPD5; Inosine diphosphate phosphatase ENTPD5; NTPDase 5; Nucleoside diphosphatase; PCPH; UDPase ENTPD5; Uridine-diphosphatase ENTPD5; 3.6.1.28; ThTPase; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Solute carrier family 19 member 2; TC1; Thiamine carrier 1; THT1; ThTr-1; ThTr1; TRMA; Solute carrier family 19 member 3; ThTr-2; ThTr2,Thiamine pyrophosphokinase 1; Pyruvate dehydrogenase E1 component,A11DA01
thymidine,Alanine aminotransferase increased;Chronic hepatitis B;Fibrosis;Foetor hepaticus;Hepatitis B;Hepatitis B e antigen positive;Hepatitis C;Hepatocellular injury;Infection;Inflammation;Liver disorder;Viral infection,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Alanine aminotransferase increased;Amylase increased;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blood amylase increased;Blood creatine phosphokinase increased;Body temperature increased;Chest discomfort;Chest pain;Chest wall pain;Connective tissue disorder;Cough;Cramp muscle;Creatine phosphokinase increased;Dermatitis;Diarrhoea;Discomfort;Disease progression;Dizziness;Dysgeusia;Dyspepsia;Fatigue;Feeling abnormal;Fibromyalgia;Flank pain;Frequent bowel movements;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hepatic pain;Hepatitis;Hepatitis B;Hepatitis acute;Hepatobiliary disease;Hepatomegaly;Hypoaesthesia;Ill-defined disorder;Influenza;Influenza like illness;Influenza-like symptoms;Insomnia;Lactic acidosis;Laryngeal pain;Lipase increased;Loose stools;Malaise;Malnutrition;Mediastinal disorder;Migraine;Multi-organ failure;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myofascial pain syndrome;Myopathy;Myositis;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Neuropathy peripheral;Neutropenia;Non-cardiac chest pain;Pain;Pain in extremity;Paraesthesia;Pharyngitis;Pharyngolaryngeal pain;Pneumonia due to Streptococcus, group b;Pneumonia streptococcal;Post procedural pain;Procedural pain;Productive cough;Pruritus;Rash;Renal failure;Renal impairment;Rhabdomyolysis;Rhinorrhoea;Right upper quadrant pain;Sciatica;Sepsis;Sinus headache;Skin disorder;Stiffness;Tenderness;Tension headache;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Vomiting",small molecule,experimental; investigational,2'-deoxy-5-methyluridine; 2'-deoxythymidine; 2'-thymidine; Deoxyribosylthymine; Deoxythymidine; dThd; Thymidine; Thymine 2'-deoxyriboside; Thymine deoxyriboside; 2.7.4.9; dTMP kinase; Thymidine monophosphate kinase; TMPK; 2.4.2.3; UPase; 2.7.1.21; 2.7.1.21; 2'-deoxyuridine kinase TK2; Deoxycytidine kinase TK2; Mt-TK; nupA; 2.7.7.24; 2.7.1.21; CNT 3; CNT3; Concentrative Na(+)-nucleoside cotransporter 3; hCNT3,"Thymidylate kinase; Uridine phosphorylase; Thymidine kinase; Thymidine kinase 2, mitochondrial; Nucleoside-specific channel-forming protein tsx; Glucose-1-phosphate thymidylyltransferase; Thymidine kinase, cytosolic",J05AF11
methamphetamine,Affect lability;Agitation;Attention deficit disorder;Attention deficit/hyperactivity disorder;Distractibility;Electroencephalogram abnormal;Hyperkinesia;Learning disability;Mood swings;Obesity,Agitation;Cardio-respiratory arrest;Constipation;Diarrhoea;Digestion impaired;Dizziness;Dyspepsia;Dysphoria;Erectile dysfunction;Euphoric mood;Gastrointestinal disorder;Headache;Hypersensitivity;Insomnia;Palpitations;Psychotic disorder;Psychotic episode;Tachycardia;Tourette's disorder;Tremor;Urticaria,small molecule,experimental; illicit,"(2RS)-1-(4-methoxyphenyl)propan-2-amine; 4-methoxyamfetamine; D,L-p-methoxyamphetamine; Formoterol fumarate related compound G; P-methoxyamfetamine; P-methoxyamphetamine; Paramethoxyamphetamine; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; Solute carrier family 18 member 2; SVMT; VAT2; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT2; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Sodium-dependent dopamine transporter; Alpha-1D adrenergic receptor; Sodium-dependent serotonin transporter; Synaptic vesicular amine transporter; Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; Amine oxidase [flavin-containing] A; Amine oxidase [flavin-containing] B,N06BA03
naproxen,Abdominal discomfort;Ache;Acute migraine;Ankylosing spondylitis;Arthritis;Back pain;Body temperature increased;Bursitis;Chronic pain;Common cold;Cramp muscle;Dysmenorrhoea;Fibromyalgia;Gastrointestinal haemorrhage;Gout;Gout acute;Gouty arthritis;Headache;Inflammation;Injury;Joint swelling;Juvenile idiopathic arthritis;Ligament sprain;Lumbo-sacral pain;Migraine;Muscle spasms;Musculoskeletal disorder;Musculoskeletal stiffness;Nasopharyngitis;Nephropathy;Osteoarthritis;Osteoarthritis of cervical spine;Pain;Postoperative pain;Primary dysmenorrhea;Procedural pain;Rheumatic disorder;Rheumatism;Rheumatoid arthritis;Rhinitis;Rotator cuff syndrome;Spinal osteoarthritis;Spondylitis;Sprain;Stiffness;Subacromial bursitis;Supraspinatus tendonitis;Tendonitis;Toothache;Trauma;Ulcer;Upset stomach;Uterine pain;Vasculitis,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abscess;Abscess periodontal;Acne;Acute coronary syndrome;Affect lability;Agranulocytosis;Albuminuria;Alcohol abuse;Alkalosis;Alopecia;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angiodermatitis;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Aortic valve stenosis;Aphthous stomatitis;Aplastic anaemia;Apnoea;Appetite absent;Arrhythmia;Arthralgia;Arthropathy;Asthenia;Asthma;Bladder pain;Bleeding time prolonged;Blister;Blood and lymphatic system disorders;Blood creatinine increased;Blood disorder;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Breast cancer;Breast disorder;Breast feeding;Breast neoplasm;Bronchitis;Bundle branch block;Calculus of kidney;Carcinoma;Carcinoma breast;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cataract;Cellulitis;Cerebration impaired;Chest pain;Chills;Cholecystitis;Cholelithiasis;Cholestasis;Chronic sinusitis;Cognitive disorder;Cognitive impairment;Colitis;Colitis ulcerative;Coma;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Corneal opacity;Coronary artery disease;Cough;Cough increased;Cramp muscle;Crohn's disease;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Depression;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Diverticulitis;Dizziness;Drowsiness;Drug eruption;Dry mouth;Dry skin;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ecchymosis;Eczema;Electrocardiogram abnormal;Enlargement abdomen;Eosinophilia;Epidermolysis bullosa;Epigastric pain;Epistaxis;Eructation;Eruption;Erythema;Erythema multiforme;Erythema nodosum;Eye disorder;Eye pain;Fatigue;Feeling abnormal;Fixed drug eruption;Flatulence;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glossitis;Glycosuria;Haematemesis;Haematochezia;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hearing impaired;Heartburn;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatosplenomegaly;Herpes simplex;Herpes zoster;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hypoglycaemia;Hypokalaemia;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infertility;Infertility female;Inflammation;Inflammatory bowel disease;Influenza;Influenza like illness;Influenza-like symptoms;Insomnia;Jaundice;Keratitis;Keratoconjunctivitis;Kidney function abnormal;Lacrimal disorder;Lacrimal structural disorder;Laryngitis;Leukopenia;Lichen planus;Lightheadedness;Liver function test abnormal;Loss of consciousness;Lung disorder;Lupus erythematosus;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melaena;Meningitis aseptic;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Metabolic acidosis;Metrorrhagia;Migraine;Mood swings;Mouth ulceration;Mucous membrane disorder;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Nail disorder;Nasal polyps;Nausea;Neck pain;Neck stiffness;Necrolysis epidermal;Necrosis;Neoplasm malignant;Neoplasm skin;Nephritic syndrome;Nephritis;Nephritis interstitial;Nephrolithiasis;Nephropathy;Nephrosclerosis;Nephrotic syndrome;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuritis retrobulbar;Neuropathy peripheral;Nocturia;Nuchal rigidity;Oedema;Oedema peripheral;Oesophageal achalasia;Oesophageal ulcer;Oesophagitis;Oliguria;Optic neuritis;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Otitis media;Pain;Palpitations;Pancreatitis;Pancytopenia;Papilloedema;Paraesthesia;Paralysis;Peptic ulcer;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Porphyria cutanea tarda;Porphyria non-acute;Porphyrin metabolism disorder;Proctocolitis;Prostatic disorder;Protein urine present;Proteinuria;Pruritus;Pseudoporphyria;Pulmonary eosinophilia;Pulmonary function test decreased;Pulmonary oedema;Purpura;Pyelonephritis;Pyuria;Rash;Reaction gastrointestinal;Rectal disorder;Rectal haemorrhage;Red blood cell abnormality;Redness;Renal failure;Renal impairment;Renal pain;Renal papillary necrosis;Renal tubular necrosis;Respiratory depression;Respiratory distress;Rhinitis;Scleritis;Sepsis;Serum creatinine increased;Shock;Sinusitis;Skin disorder;Skin exfoliation;Skin fragility;Skin mass;Skin necrosis;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Subcutaneous nodule;Subdural haematoma;Sunburn;Sweating;Swelling;Syncope;Systemic lupus erythematosus;Tachycardia;Tenderness;Tendon disorder;Tension;Thirst;Throat sore;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tooth abscess;Tooth disorder;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Ulcer;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Urticaria chronic;Uterine spasm;Vaginal infection;Vaginal inflammation;Vascular anomaly;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;WBC abnormal NOS;Weight decreased;Wheezing;White blood cell disorder,small molecule,approved; vet_approved,"(+)-(S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid; (+)-(S)-Naproxen; (+)-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-2-(Methoxy-2-naphthyl)-propionic acid; (+)-2-(Methoxy-2-naphthyl)-propionsäure; (+)-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; (S)-2-(6-Methoxy-2-naphthyl)propanoic acid; (S)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; (S)-Naproxen; Naprolag; Naproxen; Naproxène; Naproxeno; Naproxenum; 3.1.1.3; Pancreatic lipase; PL; PTL; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Pancreatic triacylglycerol lipase; Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2; Peptostreptococcal albumin-binding protein, G02CC02; M01AE52; M01AE56; M01AE57; M02AA12; N02CC51;G02CC02;M01AE02
cladribine,B-cell chronic lymphocytic leukemia;Body temperature increased;Chronic lymphocytic leukaemia;Hairy cell leukaemia;Leukaemia;Lymphoma;Nausea;Neoplasm malignant;Non-Hodgkin's lymphoma,Abdominal discomfort;Abdominal pain;Abnormal chest sounds NOS;Administration site reaction;Alopecia;Altered state of consciousness;Amyloidosis;Anaemia;Angiopathy;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Arthralgia;Arthritis;Asthenia;Ataxia;Atrial fibrillation;Autoimmune haemolytic anaemia;Back pain;Bacteraemia;Bacterial infection;Blepharitis;Blood and lymphatic system disorders;Blood bilirubin increased;Blood disorder;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Breath sounds abnormal;Cachexia;Candida infection;Cardiac disorder;Cardiac failure;Cardiac murmur;Catheter site cellulitis;Cellulitis;Cerebrovascular accident;Chest pain;Chills;Cholecystitis;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Cough;Culture negative;Cyst;Death;Decompensation cardiac;Decreased appetite;Depressed level of consciousness;Dermatitis;Diarrhoea;Discomfort;Disorientation;Dizziness;Dyspnoea;Dyspnoea exertional;Ecchymosis;Eosinophilia;Epilepsy;Epistaxis;Erythema;Erythema multiforme;Extravasation;Eye disorder;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Flatulence;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Graft versus host disease;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic failure;Hepatobiliary disease;Herpes NOS;Herpes virus infection;Herpes zoster;Hypereosinophilia;Hyperhidrosis;Hypersensitivity;Hyperuricaemia;Hypotension;Ileus;Ill-defined disorder;Immune system disorder;Infarction;Infection;Infestation;Infestation NOS;Inflammation;Infusion site reaction;Injection site reaction;Insomnia;Interstitial lung disease;Intestinal infections;Lethargy;Localised infection;Localised oedema;Lung infiltration;Lymphopenia;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Metabolic acidosis;Mucosal inflammation;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myelodysplastic syndrome;Myelosuppression;Myocardial ischaemia;Nausea;Neoplasm;Neoplasm malignant;Nervous system disorder;Neuritis;Neurotoxicity;Neutropenia;Oedema;Oedema peripheral;Opportunistic infection;Oral candidiasis;Pain;Pain in extremity;Pain of skin;Pancytopenia;Paraesthesia;Paralysis;Paraparesis;Peripheral motor neuropathy;Peripheral sensory neuropathy;Petechiae;Pharyngitis;Phlebitis;Pneumonia;Polyneuropathy;Polyp;Pruritus;Pulmonary embolism;Pulmonary fibrosis;Purpura;Quadriparesis;Rales;Rash;Rash erythematous;Rash macular;Redness;Renal failure;Renal failure acute;Renal impairment;Respiratory tract infection;Sepsis;Septic shock;Septicemia;Skin disorder;Skin infection;Somnolence;Stevens-Johnson syndrome;Sweating increased;Swelling;Tachycardia;Thrombocytopenia;Thrombosis;Toxic epidermal necrolysis;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Ureteric obstruction;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output;Urticaria;Vascular purpura;Viral skin infection;Vomiting;Wheezing,small molecule,approved; investigational,"(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-chloro-2′-deoxy-adenosine; 2-chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine; 2-Chlorodeoxyadenosine; 2ClAdo; Cladribina; Cladribine; Cladribinum; CldAdo; 1.17.4.1; Ribonucleoside-diphosphate reductase subunit M1; Ribonucleotide reductase large subunit; RR1; 3.5.4.4; ADA1; Adenosine aminohydrolase; 1.17.4.1; Ribonucleotide reductase small chain; Ribonucleotide reductase small subunit; RR2; 1.17.4.1; p53-inducible ribonucleotide reductase small subunit 2-like protein; P53R2; TP53-inducible ribonucleotide reductase M2 B; 2.7.7.7; DNA polymerase alpha catalytic subunit p180; POLA; 2.7.7.7; 3'-5' exodeoxyribonuclease; DNA polymerase II subunit A; POLE1; DNA polymerase epsilon subunit B; DNA polymerase II subunit 2; DPE2; Arsenic-transactivated protein; AsTP; CHRAC-17; CHRAC17; Chromatin accessibility complex 17 kDa protein; DNA polymerase epsilon subunit p17; DNA polymerase II subunit 3; HuCHRAC17; DNA polymerase epsilon subunit p12; DNA polymerase II subunit 4; 2.4.2.1; Inosine phosphorylase; Inosine-guanosine phosphorylase; NP; PNP; 2.4.2.30; ADP-ribosyltransferase diphtheria toxin-like 1; ADPRT; ADPRT 1; ARTD1; DNA ADP-ribosyltransferase PARP1; NAD(+) ADP-ribosyltransferase 1; PARP-1; Poly[ADP-ribose] synthase 1; PPOL; Protein poly-ADP-ribosyltransferase PARP1; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; 2.7.1.113; Deoxyadenosine kinase, mitochondrial; DGK; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; CNT 3; CNT3; Concentrative Na(+)-nucleoside cotransporter 3; hCNT3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1",Ribonucleoside-diphosphate reductase large subunit; Adenosine deaminase; Ribonucleoside-diphosphate reductase subunit M2; Ribonucleoside-diphosphate reductase subunit M2 B; DNA; DNA polymerase alpha catalytic subunit; DNA polymerase epsilon catalytic subunit A; DNA polymerase epsilon subunit 2; DNA polymerase epsilon subunit 3; DNA polymerase epsilon subunit 4; Purine nucleoside phosphorylase; Poly [ADP-ribose] polymerase 1, L01BB04;L01BB04;L04AA40
doxorubicin,Acquired immunodeficiency syndrome;Acute leukaemia;Acute lymphocytic leukaemia;Acute myeloid leukaemia;Adenocarcinoma gastric;Advanced breast cancer;Autoimmune disorder;Bladder cancer;Bladder cancer stage IV;Bladder carcinoma;Bladder neoplasm;Bladder transitional cell carcinoma;Bladder transitional cell carcinoma metastatic;Bone sarcoma;Brain neoplasm;Breast cancer;Breast cancer stage IV;Bronchial carcinoma;Carcinoma;Carcinoma breast;Carcinoma of lung;Carcinoma stomach;Carcinoma testes;Cardiac disorder;Cardiotoxicity;Drug interaction;Endometrial cancer;Ewing's sarcoma;Gastric cancer;Generalized illness;Hepatic cancer;Hepatic cancer metastatic;Hepatic function abnormal;Hepatocellular carcinoma;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hypersensitivity;Immunodeficiency;Kaposi's sarcoma;Kaposi's sarcoma AIDS related;Leukaemia;Lung neoplasm malignant;Lymphoma;Malaise;Malignant melanoma;Menopause;Metastases to liver;Metastasis;Metastatic carcinoma;Metastatic gastric adenocarcinoma;Metastatic neoplasm;Neoplasm;Neoplasm malignant;Nephroblastoma;Neuroblastoma;Node-positive breast cancer;Non-Hodgkin's lymphoma;Non-small cell lung cancer;Osteosarcoma;Ovarian cancer;Ovarian carcinoma;Ovarian epithelial cancer;Ovarian epithelial cancer stage IV;Pancreatic carcinoma;Plasma cell myeloma;Plasmacytoma;Prostate cancer;Prostate carcinoma;Renal cancer;Renal carcinoma;Rhabdomyosarcoma;Sarcoma;Small cell lung cancer;Solid tumour;Squamous cell carcinoma;Testis cancer;Thymoma;Thyroid cancer;Thyroid carcinoma,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal pigmentation;Abnormal vision;Abscess;Abscess periodontal;Acral erythema;Acute cardiac toxicity;Acute leukaemia;Acute lymphocytic leukaemia;Acute myeloid leukaemia;Affect lability;Ageusia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Alopecia reversible;Amblyopia;Amenorrhoea;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anuria;Anxiety;Aphthous stomatitis;Aplastic anaemia;Arrhythmia;Arthralgia;Arthropathy;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrioventricular block;Azoospermia;Back pain;Balanitis;Bilirubin total increased;Bladder constriction;Bladder pain;Bladder stenosis;Blindness;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood disorder;Blood lactate dehydrogenase increased;Blood thromboplastin decreased;Blood urea increased;Blood uric acid increased;Body temperature decreased;Body temperature increased;Bone disorder;Bone marrow depression;Bone pain;Bradycardia;Breast disorder;Breast pain;Bronchitis;Bullous eruption;Bundle branch block;Burning sensation;Cachexia;Caecitis;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiogenic shock;Cardiomegaly;Cardiomyopathy;Cardiotoxicity;Cardiovascular disorder;Cellulitis;Cerebrovascular accident;Chemical cystitis;Chest pain;Chills;Cholangitis sclerosing;Colitis;Coma;Confusional state;Congestive cardiomyopathy;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cramps of lower extremities;Creatinine increased;Cryptococcosis;Cyst;Cystitis;Cystitis haemorrhagic;Cystitis noninfective;Decreased appetite;Dehydration;Delirium;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diarrhoea haemorrhagic;Diplopia;Discomfort;Dizziness;Drowsiness;Drug eruption;Drug hypersensitivity;Drug interaction;Dry eye;Dry mouth;Dry skin;Dysaesthesia;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dyspnoea exertional;Dysuria;Ecchymosis;Eczema;Effusion;Ejection fraction decreased;Electrocardiogram QRS complex abnormal;Electrocardiogram ST segment depression;Embolism;Embolism arterial;Embolism venous;Enlargement abdomen;Eosinophilia;Epistaxis;Eructation;Eruption;Erythema;Erythema multiforme;Erythema nodosum;Extravasation;Eye disorder;Eye pain;Face oedema;Faecalith;Faecaloma;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Feeling hot;Flatulence;Fluid retention;Flushing;Folliculitis;Fungal infection;Fungal skin infection;Furuncle;Furunculosis;Gait disturbance;Gallop rhythm;Gastric erosions;Gastric ulcer;Gastritis;Gastritis erosive;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal toxicity;Generalised oedema;Gingival bleeding;Gingivitis;Glossitis;Glycosuria;Gravitational oedema;Haematemesis;Haematochezia;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Hand and foot syndrome secondary to sickle cell anaemia;Headache;Heart disease congenital;Heart malformation;Heart sounds abnormal;Hemiplegia;Hepatic cancer metastatic;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hepatosplenomegaly;Herpes labialis;Herpes simplex;Herpes zoster;Hiccups;Hot flush;Hydronephrosis;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hypermagnesaemia;Hypernatraemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypochloraemia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hypolipidaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hyporeflexia;Hypotension;Hypothermia;Hypotonia;Ileus;Ill-defined disorder;Immune status;Immune system disorder;Immunodeficiency;Immunology test;Increased appetite;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Injection site haemorrhage;Injection site infection;Injection site inflammation;Injection site pain;Injection site reaction;Insomnia;Jaundice;Jaundice cholestatic;Keratitis;Ketosis;Kidney function abnormal;Laboratory test abnormal;Lacrimation;Lacrimation increased;Lactic acidosis;Lactic dehydrogenase activity increased;Laryngitis;Left ventricular ejection fraction decreased;Leg edema;Lethargy;Leukaemia;Leukemia secondary;Leukoderma;Leukopenia;Leukoplakia oral;Leukorrhea;Liver function test abnormal;Liver injury;Local reaction;Loss of consciousness;Lung disorder;Lymphadenopathy;Lymphangitis;Lymphoedema;Lymphopenia;Malaise;Malnutrition;Mastitis;Mediastinal disorder;Melaena;Menopausal symptoms;Mental disability;Mental disorder;Metastases to liver;Metastatic disease;Metastatic neoplasm;Migraine;Mood swings;Mouth ulceration;Mucosal inflammation;Mucous membrane disorder;Multi-organ failure;Muscle relaxant therapy;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myasthenia;Myelodysplasia;Myelodysplastic syndrome;Myeloid leukaemia;Myelosuppression;Myocarditis;Myositis;Nail disorder;Nasopharyngitis;Nausea;Neck pain;Necrosis;Necrotising colitis;Neoplasm;Neoplasm malignant;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutropenic sepsis;Nocturia;Nystagmus;Ocular toxicity;Oedema;Oedema genital;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Oligospermia;Oliguria;Onycholysis;Opportunistic infection;Optic neuritis;Oral candidiasis;Oral herpes;Oral neoplasm;Oral pain;Orthostatic hypotension;Osteoarthritis;Other conjunctivitis;Otitis media;Ovarian cancer;Pain;Pain in extremity;Palmar-plantar erythrodysaesthesia syndrome;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paralysis;Parosmia;Pelvic pain;Penicillin allergy;Pericardial effusion;Pericarditis;Peripheral motor neuropathy;Peripheral sensory neuropathy;Peripheral vascular disorder;Petechiae;Pharyngitis;Phlebitis;Phlebosclerosis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pleural effusion;Pneumocystis jirovecii pneumonia;Pneumonia;Pneumothorax;Pollakiuria;Polyneuropathy;Polyp;Premature menopause;Proctalgia;Proctitis;Proctitis ulcerative;Prostatic disorder;Prothrombin level increased;Pruritus;Pseudolymphoma;Psoriasis;Pulmonary embolism;Pulmonary oedema;Purpura;QRS voltage decreased;Radiation injury;Radiation recall reaction (dermatologic);Rash;Rash erythematous;Rash maculo-papular;Rash papular;Rash pustular;Recall phenomenon;Rectal disorder;Rectal haemorrhage;Rectal tenesmus;Red blood cell abnormality;Red blood cell disorders;Redness;Renal failure;Renal failure acute;Renal impairment;Retinitis;Retrosternal pain;Rhinitis;Rigors;Salivary hypersecretion;Scotoma;Scrotal erythema;Seborrhoeic dermatitis;Secondary infection;Sensitisation;Sepsis;Septic shock;Septicemia;Serum bilirubin increased;Serum creatinine increased;Shock;Sinus tachycardia;Sinusitis;Skin candida;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin mass;Skin necrosis;Skin nodule;Skin scaly;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Stinging;Stomatitis;Supraventricular extrasystoles;Sweating;Syncope;Tachyarrhythmia;Tachycardia;Tension;Testicular disorder;Thinking abnormal;Thrombocytopenia;Thrombocytosis;Thromboembolism;Thrombophlebitis;Thromboplastin decreased;Thrombosis;Tinnitus;Tooth abscess;Toxic epidermal necrolysis;Toxoplasmosis;Transaminases increased;Tumour lysis syndrome;Tumour necrosis;Ulcer;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Ureteric obstruction;Urethral disorder;Urethral obstruction;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output;Urticaria;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vascular purpura;Vasodilation;Vasodilation procedure;Venous thromboembolism;Venous thrombosis;Ventricular arrhythmia;Ventricular dysfunction;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Viral infection;Vision blurred;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Warmth;Weight decreased;Weight increased,small molecule,approved; investigational,"(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside; (8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione; 14-hydroxydaunomycin; 14-hydroxydaunorubicine; Doxorubicin; Doxorubicin nanoparticles; Doxorubicina; Doxorubicine; Doxorubicinum; Hydroxydaunorubicin; MTC-DOX; MTC-DOX for Injection; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 2.7.7.49; EST2; HEST2; TCS1; Telomerase catalytic subunit; Telomerase-associated protein 2; TP2; TRT; 5.6.2.1; DNA topoisomerase I; 5.6.2.2; DNA topoisomerase II, beta isozyme; 140 kDa nucleolar phosphoprotein; HCV NS5A-transactivated protein 13; Hepatitis C virus NS5A-transactivated protein 13; KIAA0035; Nopp140; NS5ATP13; Nucleolar 130 kDa protein; Nucleolar phosphoprotein p130; 1.1.1.2; 1.1.1.372; 1.1.1.54; Alcohol dehydrogenase [NADP(+)]; Aldehyde reductase; ALDR1; ALR; Glucuronate reductase; Glucuronolactone reductase; S-nitroso-CoA reductase; ScorR; 1.1.1.21; 1.1.1.300; 1.1.1.372; 1.1.1.54; Aldehyde reductase; Aldose reductase; ALDR1; ALR2; AR; 1.1.1.-; 1.1.1.210; 1.1.1.53; 1.1.1.62; 17-beta-HSD 5; 17-beta-hydroxysteroid dehydrogenase type 5; 3-alpha-HSD type 2; 3-alpha-HSD type II, brain; 3-alpha-hydroxysteroid dehydrogenase type 2; Chlordecone reductase homolog HAKRb; DD-3; DD3; DDH1; Dihydrodiol dehydrogenase 3; Dihydrodiol dehydrogenase type I; HA1753; HSD17B5; KIAA0119; PGFS; Prostaglandin F synthase; Testosterone 17-beta-dehydrogenase 5; 1.1.1.-; 1.1.1.209; 1.1.1.210; 1.1.1.51; 1.1.1.53; 1.1.1.62; 3-alpha-HSD1; 3-alpha-hydroxysteroid dehydrogenase type I; 3alpha-hydroxysteroid 3-dehydrogenase; CDR; CHDR; Chlordecone reductase; DD-4; DD4; Dihydrodiol dehydrogenase 4; HAKRA; 1.1.1.300; 1.1.1.54; AKR1B11; Aldose reductase-like; Aldose reductase-related protein; ARL-1; ARP; hARP; SI reductase; Small intestine reductase; 1.1.1.184; 15-hydroxyprostaglandin dehydrogenase [NADP(+)]; 20-beta-hydroxysteroid dehydrogenase; Alcohol dehydrogenase [NAD(P)+] CBR1; CBR; CRN; NADPH-dependent carbonyl reductase 1; PG-9-KR; Prostaglandin 9-ketoreductase; Prostaglandin-E(2) 9-reductase; SDR21C1; Short chain dehydrogenase/reductase family 21C member 1; 1.1.1.184; NADPH-dependent carbonyl reductase 3; Quinone reductase CBR3; SDR21C2; Short chain dehydrogenase/reductase family 21C member 2; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.6.2.4; CPR; CYPOR; P450R; 1.6.5.2; Azoreductase; DIA4; DT-diaphorase; DTD; Menadione reductase; NAD(P)H:quinone oxidoreductase 1; NMOR1; Phylloquinone reductase; QR1; Quinone reductase 1; 7.1.1.2; CI-49kD; Complex I-49kD; NADH-ubiquinone oxidoreductase 49 kDa subunit; 7.1.1.2; CI-30kD; Complex I-30kD; NADH-ubiquinone oxidoreductase 30 kDa subunit; 7.1.1.2; CI-20kD; Complex I-20kD; NADH-ubiquinone oxidoreductase 20 kDa subunit; PSST subunit; 1.14.13.39; bNOS; Constitutive NOS; N-NOS; NC-NOS; Neuronal NOS; Nitric oxide synthase, brain; nNOS; NOS type I; Peptidyl-cysteine S-nitrosylase NOS1; 1.14.13.39; cNOS; Constitutive NOS; EC-NOS; Endothelial NOS; eNOS; Nitric oxide synthase, endothelial; NOS type III; NOSIII; 1.14.13.39; HEP-NOS; Hepatocyte NOS; Inducible NO synthase; Inducible NOS; iNOS; NOS type II; NOS2A; Peptidyl-cysteine S-nitrosylase NOS2; XDHA; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; 7.6.2.3; Anthracycline resistance-associated protein; ARA; MOAT-E; MRP6; Multi-specific organic anion transporter E; Multidrug resistance-associated protein 6; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Carnitine transporter 2; CT2; Flipt 2; FLIPT2; Fly-like putative transporter 2; OCT6; Organic cation transporter OKB1; Organic cation/carnitine transporter 6; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; ABCB8; ATP-binding cassette sub-family B member 8, mitochondrial; M-ABC1; MABC1; Mitochondrial ATP-binding cassette 1; Mitochondrial sulfonylurea-receptor; MITOSUR; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 76 kDa Ral-interacting protein; Dinitrophenyl S-glutathione ATPase; DNP-SG ATPase; Ral-interacting protein 1; RalBP1; RLIP; RLIP1; RLIP76; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",DNA topoisomerase 2-alpha; Telomerase reverse transcriptase; DNA; DNA topoisomerase 1; DNA topoisomerase 2-beta; Nucleolar and coiled-body phosphoprotein 1,L01DB01
phenytoin,Arrhythmia;Convulsion;Convulsive seizure;Drug interaction;Epilepsy;Foetor hepaticus;Hepatocellular injury;Hypoalbuminaemia;Intoxication;Liver disorder;Poisoning;Renal failure;Status epilepticus;Status epilepticus grand mal;Temporal lobe epilepsy,Abdominal pain upper;Accidental injury;Acidosis;Acute hepatic failure;Affect lability;Ageusia;Agitation;Agranulocytosis;Akathisia;Albuminuria;Alkalosis;Amblyopia;Amnesia;Anaemia;Anaemia megaloblastic;Anaphylactic shock;Anaphylactoid reaction;Anorectal discomfort;Anorexia;Aphasia;Apnoea;Appetite absent;Arthralgia;Asterixis;Asthenia;Asthma;Ataxia;Atelectasis;Atrial flutter;Back pain;Blood and lymphatic system disorders;Body temperature increased;Bradycardia;Brain oedema;Breast disorder;Bronchitis;Bundle branch block;CNS depression NOS;Cachexia;Cardiac arrest;Cardiac failure congestive;Cardiomegaly;Cerebral haemorrhage;Cerebral infarction;Chest discomfort;Chest pain;Chills;Chorea;Circumoral paresthesia;Cognitive disorder;Cognitive impairment;Coma;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cramps of lower extremities;Cryptococcosis;Cyanosis;Deafness;Decreased appetite;Dehydration;Delirium;Depersonalisation;Depressed level of consciousness;Dermatitis;Dermatitis contact;Diabetes insipidus;Diarrhoea;Diplopia;Discomfort;Dizziness;Drowsiness;Drug eruption;Drug reaction with eosinophilia and systemic symptoms;Dry mouth;Dupuytren's contracture;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphemia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Encephalitis;Encephalopathy;Eosinophilia;Epigastric discomfort;Epigastric pain;Epistaxis;Erythema multiforme;Excitement;Extensor plantar response;Extrapyramidal disorder;Extravasation;Eye pain;Face oedema;Fatigue;Feeling abnormal;Fibrosis;Flatulence;Fluid retention;Fracture;Gastric irritation;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Generalised oedema;Gingival hyperplasia;Gingivitis;Gynaecomastia;Haemoglobin;Haemoptysis;Haemorrhage;Headache;Hemiplegia;Hepatic function abnormal;Hepatitis toxic;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hirsutism;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hostility;Hyperacusis;Hyperaesthesia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperplasia;Hyperreflexia;Hypersensitive syndrome;Hypersensitivity;Hypertension;Hypertrichosis;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypochromic anaemia;Hypokalaemia;Hypokinesia;Hypophosphataemia;Hypopnoea;Hyporeflexia;Hypotension;Hypotonia;Ileus;Ill-defined disorder;Immune system disorder;Increased bronchial secretion;Infection;Inflammation;Influenza;Injection site haemorrhage;Injection site inflammation;Injection site pain;Injection site reaction;Injection site swelling;Injury;Insomnia;Intracranial pressure increased;Irritability;Ketosis;Leukocytosis;Leukopenia;Liver function test abnormal;Liver injury;Loss of consciousness;Lung infiltration;Lupus erythematosus;Lymphadenopathy;Lymphoma;Malaise;Measles;Meningitis;Mental disability;Migraine;Mood swings;Multiple fractures;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Mydriasis;Myoclonus;Myopathy;Nausea;Necrosis;Nephritis interstitial;Nervous system disorder;Nervousness;Neurosis;Non-Hodgkin's lymphoma;Nystagmus;Oedema genital;Oliguria;Orthostatic hypotension;Osteoarthritis;Osteomalacia;Osteoporosis;Palpitations;Pancytopenia;Paraesthesia;Paraesthesia oral;Paralysis;Parosmia;Pelvic pain;Personality disorder;Petechiae;Peyronie's disease;Pharyngitis;Photophobia;Photosensitivity reaction;Pneumonia;Pneumonia aspiration;Pneumothorax;Polyarteritis nodosa;Polyneuropathy;Polyuria;Proctalgia;Pruritus;Pseudolymphoma;Psychotic disorder;Pulmonary embolism;Purple glove syndrome;Purpura;Purpuric rash;Rash;Rash maculo-papular;Rash morbilliform;Rash pustular;Rectal tenesmus;Renal failure;Rhinitis;Salivary hypersecretion;Scotoma;Sepsis;Shallow breathing;Shock;Sinus bradycardia;Sinusitis;Skin discolouration;Skin mass;Skin nodule;Slurred speech;Somnolence;Speech disorder;Sputum increased;Stevens-Johnson syndrome;Stupor;Stuttering;Subdural haematoma;Sweating;Syncope;Systemic lupus erythematosus;Tachycardia;Taste altered;Taste metallic;Tenderness;Tension;Thinking abnormal;Thrombocytopenia;Thrombophlebitis;Tingling sensation;Tinnitus;Tongue disorder;Tongue oedema;Tonic convulsion;Toxic epidermal necrolysis;Traumatic liver injury;Trembling;Tremor;Tubulointerstitial nephritis;Urethral pain;Urinary incontinence;Urinary retention;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Ventricular extrasystoles;Ventricular fibrillation;Vertigo;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased,small molecule,approved; vet_approved,"5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-diphenylimidazolidine-2,4-dione; 5,5-diphenyltetrahydro-1H-2,4-imidazoledione	; 5,5-Diphenyltetrahydro-1H-2,4-imidazoledione; Diphenylhydantoin; Fenitoina; Phentytoin; Phenytoin; Phenytoine; Phenytoinum; PR-122 (redox-phenytoin); Redox-phenytoin; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; NAC1; SCN1; Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; BI; Brain calcium channel I; CACH4; CACN3; CACNL1A4; Calcium channel, L type, alpha-1 polypeptide isoform 4; Voltage-gated calcium channel subunit alpha Cav2.1; HBA; HBSC II; NAC2; SCN2A1; SCN2A2; Sodium channel protein brain II subunit alpha; Sodium channel protein type II subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.2; MED; Sodium channel protein type VIII subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.6; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; KIAA1356; NAC3; Sodium channel protein brain III subunit alpha; Sodium channel protein type III subunit alpha; Voltage-gated sodium channel subtype III; Voltage-gated sodium channel subunit alpha Nav1.3; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 3.3.2.9; EPHX; EPOX; Epoxide hydratase; mEH; Microsomal epoxide hydrolase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.1.1.6; 1.6.5.2; Azoreductase; DIA4; DT-diaphorase; DTD; Menadione reductase; NAD(P)H:quinone oxidoreductase 1; NMOR1; Phylloquinone reductase; QR1; Quinone reductase 1; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; Serpin A7; T4-binding globulin; TBG; OAT-RP-5; OATP-14; OATP-F; OATP-RP5; OATP14; OATP1C1; OATPF; Organic anion transporter 1C1; Organic anion transporter F; Organic anion transporter polypeptide-related protein 5; Organic anion-transporting polypeptide 14; SLC21A14; Solute carrier family 21 member 14; Thyroxine transporter; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",Sodium channel protein type 5 subunit alpha; Sodium channel protein type 1 subunit alpha; Voltage-gated inwardly rectifying potassium channel KCNH2; Voltage-dependent L-type calcium channel; Sodium channel protein type 2 subunit alpha; Sodium channel protein type 8 subunit alpha; Nuclear receptor subfamily 1 group I member 2; Sodium channel regulatory subunit beta-1; Sodium channel protein type 3 subunit alpha; GABA(A) Receptor, N03AB52;N03AB02
methazolamide,Acute angle-closure glaucoma;Angle closure glaucoma;Chronic open angle glaucoma;Glaucoma;Open angle glaucoma;Primary open angle glaucoma;Secondary glaucoma,Agranulocytosis;Anaphylactic shock;Anorexia;Aplastic anaemia;Appetite absent;Asthenia;Blood disorder;Body temperature increased;Bone marrow depression;Calculus of kidney;Confusional state;Convulsion;Crystalluria;Decreased appetite;Dermatitis;Diarrhoea;Digestion impaired;Discomfort;Drowsiness;Dysgeusia;Dyspepsia;Electrolyte imbalance;Erythema multiforme;Fatigue;Feeling abnormal;Gastrointestinal disorder;Glycosuria;Haematuria;Haemolytic anaemia;Headache;Hepatic failure;Hepatic insufficiency;Hepatic necrosis;Ill-defined disorder;Leukopenia;Malaise;Melaena;Metabolic acidosis;Myopia;Myopia transient;Nausea;Nephrolithiasis;Pancytopenia;Paraesthesia;Paralysis flaccid;Photosensitivity;Photosensitivity reaction;Polyuria;Rash;Somnolence;Stevens-Johnson syndrome;Thrombocytopenic purpura;Tingling sensation;Tinnitus;Toxic epidermal necrolysis;Urine output increased;Urticaria;Vertigo;Vomiting,small molecule,approved,Metazolamida; Methazolamid; Methazolamide; Méthazolamide; Methazolamidum; Methenamide; Neptazaneat; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 4.2.1.1; CA-IV; Carbonate dehydratase IV; Carbonic anhydrase IV; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-VII; Carbonate dehydratase VII; Carbonic anhydrase VII; 4.2.1.1; CA-III; Carbonate dehydratase III; Carbonic anhydrase III; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1,Carbonic anhydrase 1; Carbonic anhydrase 4; Carbonic anhydrase 2; Carbonic anhydrase 7; Carbonic anhydrase 3, S01EC05;G01AE10;S01EC05
5-azacytidine,Acute leukaemia;Acute myeloid leukaemia;Chronic myelomonocytic leukaemia;Dysplasia;Lung disorder;Myelodysplastic syndrome;Myelodysplastic syndrome transformation;Myeloproliferative disorder;Neutropenia;Refractory anaemia with an excess of blasts;Refractory anemia;Refractory anemia with excess blasts in transformation;Refractory cytopenia with unilineage dysplasia;Thrombocytopenia,Abdominal distension;Abdominal pain;Abdominal pain upper;Abdominal tenderness;Abscess limb;Acute febrile neutrophilic dermatosis;Agranulocytosis;Alopecia;Anaemia;Anaemia NOS aggravated;Anaphylactic shock;Angiopathy;Anorexia;Anxiety;Arthralgia;Asthenia;Atelectasis;Atrial fibrillation;Back pain;Bacterial infection;Blastomycosis;Blood and lymphatic system disorders;Body temperature increased;Bone marrow depression;Bone pain;Bone pain aggravated;Breath sounds abnormal;Bronchitis;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac murmur;Cardio-respiratory arrest;Catheter site erythema;Catheter site haemorrhage;Cellulitis;Cerebral haemorrhage;Chest pain;Chest wall pain;Chills;Cholecystitis;Coma;Coma hepatic;Confusional state;Congestive cardiomyopathy;Conjunctival haemorrhage;Connective tissue disorder;Constipation;Contusion;Convulsion;Cough;Cramp muscle;Cyst;Decreased appetite;Dehydration;Depression;Dermatitis;Diarrhoea;Discomfort;Diverticulitis;Dizziness;Dry skin;Dyspepsia;Dysphagia;Dyspnoea;Dyspnoea exacerbated;Dyspnoea exertional;Dysuria;Ecchymosis;Epistaxis;Erythema;Eye disorder;Eye haemorrhage;Fatal outcomes;Fatigue;Fatigue aggravated;Febrile neutropenia;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;General physical health deterioration;Gingival bleeding;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhoidal haemorrhage;Haemorrhoids;Headache;Hepatic failure;Hepatobiliary disease;Herpes simplex;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypokalaemia;Hypotension;Ill-defined disorder;Immune system disorder;Induration;Infection;Infestation;Infestation NOS;Inflammation;Infusion site reactions;Injection site bruising;Injection site dermatitis;Injection site discolouration;Injection site erythema;Injection site granuloma;Injection site haematoma;Injection site haemorrhage;Injection site induration;Injection site infection;Injection site necrosis;Injection site pain;Injection site pigmentation changes;Injection site pruritus;Injection site reaction;Injection site swelling;Insomnia;Interstitial lung disease;Klebsiella sepsis;Laryngeal pain;Lethargy;Leukaemia cutis;Leukopenia;Local swelling;Loin pain;Loose stools;Loss of consciousness;Lung infiltration;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melaena;Mental disorder;Metastatic disease;Metastatic neoplasm;Mouth haemorrhage;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myelodysplastic syndrome transformation;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Nervous system disorder;Neutropenia;Neutropenic sepsis;Night sweats;Nodule;Oedema;Oedema peripheral;Oral mucosal petechiae;Orthostatic hypotension;Pain;Pain in extremity;Pallor;Pancytopenia;Peripheral swelling;Perirectal abscess;Petechiae;Pharyngitis;Pharyngitis streptococcal;Pharyngolaryngeal pain;Pitting edema;Pleural effusion;Pneumonia;Pneumonia klebsiella;Pneumothorax;Polyp;Post procedural haemorrhage;Post procedural pain;Postnasal drip;Procedural pain;Productive cough;Prurigo;Pruritus;Purpura;Pyoderma gangrenosum;Rales;Rash;Rash macular;Refractory anaemia with an excess of blasts;Refractory anemia with excess blasts in transformation;Renal failure;Renal tubular acidosis;Respiratory distress;Respiratory sounds decreased;Rhinitis;Rhinorrhoea;Rhonchi;Rigors;Road traffic accident;Sepsis;Septic shock;Shock;Sinusitis;Skin disorder;Skin induration;Skin lesion;Skin mass;Skin nodule;Splenomegaly;Staphylococcal bacteraemia;Staphylococcal infection;Stomatitis;Sweating increased;Syncope;Systemic inflammatory response syndrome;Tachycardia;Thrombocytopenia;Tongue ulceration;Toxoplasmosis;Transfusion reaction;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upper-airway cough syndrome;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular purpura;Vomiting;Weight decreased;Wheezing,small molecule,experimental,3.5.4.5; CDA; Cytidine aminohydrolase,Cytidine deaminase,L01BC07
methylprednisolone,Acquired immunodeficiency syndrome;Acute leukaemia;Adrenal insufficiency;Adrenocortical insufficiency acute;Allergic conditions;Anaemia;Ankylosing spondylitis;Aplasia pure red cell;Arthritis;Aspiration pneumonitis;Asthma;Autoimmune disorder;Azotaemia;Berylliosis;Bursitis;Chorioretinitis;Choroiditis;Colitis ulcerative;Collagen disorder;Conjunctivitis allergic;Corneal ulcer marginal;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatomyositis;Diuresis;Drug hypersensitivity;Endocrine disorder;Enteritis;Epicondylitis;Erythema multiforme;Erythema multiforme severe;Erythroblastopenia;Gastrointestinal disorder;Gout;Gouty arthritis;Haemolytic anaemia;Hypercalcaemia;Hypoplastic anaemia;Idiopathic thrombocytopenic purpura;Inflammation;Injury;Iridocyclitis;Iritis;Juvenile idiopathic arthritis;Keratitis;Laryngeal oedema;Leukaemia;Loeffler's syndrome;Lupus erythematosus;Lymphoma;Meningitis tuberculous;Multiple sclerosis;Mycosis fungoides;Neoplasm malignant;Nephrotic syndrome;Non-Hodgkin's lymphoma;Oedema;Ophthalmic herpes zoster;Optic neuritis;Osteoarthritis;Pemphigus;Perennial allergic rhinitis;Pneumocystis jirovecii pneumonia;Pneumonia aspiration;Polymyositis;Polyuria;Posterior uveitis;Proctocolitis;Protein urine present;Proteinuria;Psoriasis;Psoriatic arthropathy;Pulmonary eosinophilia;Pulmonary tuberculosis;Purpura;Rheumatic heart disease;Rheumatoid arthritis;Rhinitis perennial;Sarcoidosis;Seborrhoeic dermatitis;Secondary adrenocortical insufficiency;Secondary thrombocytopenia;Serum sickness;Skin disorder;Stevens-Johnson syndrome;Sympathetic ophthalmia;Synovitis;Systemic lupus erythematosus;Tenosynovitis;Thrombocytopenia;Transfusion reaction;Trauma;Trichiniasis;Ulcerative keratitis;Uremia;Urticaria,Abdominal distension;Abdominal pain;Abnormal behaviour;Abscess;Acne;Acute coronary syndrome;Affect lability;Affective disorder;Alanine aminotransferase increased;Alkalosis hypokalaemic;Amnesia;Anaphylactic shock;Angioedema;Anxiety;Arachnoiditis;Arrhythmia;Arthralgia;Aseptic necrosis;Atrophy;Benign intracranial hypertension;Bladder dysfunction;Blood potassium decreased;Blood urea increased;Bronchospasm;Carbohydrate tolerance decreased;Cardiac arrest;Cardiac failure congestive;Cataract subcapsular;Central serous retinopathy;Chorioretinopathy;Cognitive disorder;Confusional state;Convulsion;Delusion;Dependence psychological;Depressed mood;Dermatitis;Diabetes mellitus;Diabetic;Diarrhoea;Diplegia;Dizziness;Drug dependence;Dyslipidaemia;Dyspepsia;Ecchymosis;Epidural lipomatosis;Erythema;Erythema facial;Euphoric mood;Exophthalmos;Feeling abnormal;Fluid retention;Functional gastrointestinal disorder;Gastric haemorrhage;Gastrointestinal pain;Glaucoma;Glucose tolerance impaired;Hallucination;Headache;Hiccups;Hirsutism;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hypotension;Impaired healing;Increased appetite;Increased insulin requirement;Infection;Injection site reaction;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Irritability;Leukoderma;Lipomatosis;Malaise;Malaise and fatigue;Mania;Meningitis;Menstruation irregular;Mental disorder;Monoplegia;Mood swings;Muscle mass;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial rupture;Myopathy;Nausea;Neuropathic arthropathy;Nitrogen balance negative;Oedema peripheral;Oesophagitis;Opportunistic infection;Optic neuritis;Osteonecrosis;Osteoporosis;Pancreatitis;Papilloedema;Paraplegia;Peptic ulcer;Peptic ulcer haemorrhage;Peritonitis;Personality change;Petechiae;Pruritus;Psychotic disorder;Rash;Schizophrenia;Shock;Skin atrophy;Skin hyperpigmentation;Skin striae;Spinal compression fracture;Steroid myopathy;Steroid withdrawal syndrome;Suicidal ideation;Sweating increased;Tendon rupture;Ulcer;Urine calcium increased;Vertigo;Vomiting;Weight increased,small molecule,approved; vet_approved,"(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione; 1-dehydro-6α-methylhydrocortisone; 6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione; delta(1)-6alpha-Methylhydrocortisone; Methylprednisolon; Methylprednisolone; Methylprednisolonum; Metilprednisolona; GR; GRL; Nuclear receptor subfamily 3 group C member 1; Annexin I; Annexin-1; ANX1; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; LPC1; p35; Phospholipase A2 inhibitory protein; 1.1.1.-; 1.1.1.112; 1.1.1.209; 1.1.1.210; 1.1.1.357; 1.1.1.51; 1.1.1.53; 1.1.1.62; 1.3.1.20; 20-alpha-HSD; 20-alpha-hydroxysteroid dehydrogenase; Chlordecone reductase homolog HAKRC; DD1; DDH; DDH1; Dihydrodiol dehydrogenase 1; HBAB; High-affinity hepatic bile acid-binding protein; 1.-.-.-; 1.1.1.112; 1.1.1.209; 1.1.1.53; 1.1.1.62; 1.3.1.20; 3-alpha-HSD3; Chlordecone reductase homolog HAKRD; DD-2; DD/BABP; DD2; DDH2; Dihydrodiol dehydrogenase 2; Dihydrodiol dehydrogenase/bile acid-binding protein; Type III 3-alpha-hydroxysteroid dehydrogenase; 1.1.1.-; 1.1.1.210; 1.1.1.53; 1.1.1.62; 17-beta-HSD 5; 17-beta-hydroxysteroid dehydrogenase type 5; 3-alpha-HSD type 2; 3-alpha-HSD type II, brain; 3-alpha-hydroxysteroid dehydrogenase type 2; Chlordecone reductase homolog HAKRb; DD-3; DD3; DDH1; Dihydrodiol dehydrogenase 3; Dihydrodiol dehydrogenase type I; HA1753; HSD17B5; KIAA0119; PGFS; Prostaglandin F synthase; Testosterone 17-beta-dehydrogenase 5; 1.1.1.-; 1.1.1.209; 1.1.1.210; 1.1.1.51; 1.1.1.53; 1.1.1.62; 3-alpha-HSD1; 3-alpha-hydroxysteroid dehydrogenase type I; 3alpha-hydroxysteroid 3-dehydrogenase; CDR; CHDR; Chlordecone reductase; DD-4; DD4; Dihydrodiol dehydrogenase 4; HAKRA; 1.1.1.146; 11-beta-HSD1; 11-DH; 7-oxosteroid reductase; Corticosteroid 11-beta-dehydrogenase isozyme 1; HSD11; HSD11L; SDR26C1; Short chain dehydrogenase/reductase family 26C member 1; 1.1.1.-; 11-beta-HSD type II; 11-beta-HSD2; 11-beta-hydroxysteroid dehydrogenase type II; 11-DH2; 11-HSD type II; Corticosteroid 11-beta-dehydrogenase isozyme 2; HSD11K; NAD-dependent 11-beta-hydroxysteroid dehydrogenase; SDR9C3; Short chain dehydrogenase/reductase family 9C member 3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Glucocorticoid receptor; Annexin A1, D07CA02; D10AA02; H02AB04; H02BX01; S01CA08; S03CA07;D07AA01
abacavir,Cross resistance;Disease progression;Drug interaction;Epilepsy;Hypersensitivity;Immunodeficiency;Infection;Pathogen resistance,AIDS dementia complex;Abdominal discomfort;Abdominal pain;Abnormal dreams;Acute coronary syndrome;Acute respiratory distress syndrome;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Anorexia;Anxiety;Aplasia pure red cell;Aplastic anaemia;Appetite absent;Arthralgia;Aspartate aminotransferase increased;Asthenia;Autoimmune disorder;Basedow's disease;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood triglycerides increased;Body temperature increased;Breast enlargement;Breath sounds abnormal;Bronchitis;Buffalo hump;Chills;Conjunctivitis;Convulsion;Cough;Creatine phosphokinase increased;Creatinine increased;Decreased appetite;Depressed mood;Depression;Depressive disorder;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drug hypersensitivity;Dyspnoea;Dysthymic disorder;Erythema multiforme;Fat redistribution;Fatal outcomes;Fatigue;Feeling abnormal;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal signs and symptoms;Gastrointestinal symptom NOS;Headache;Hepatic failure;Hepatic steatosis;Hepatitis;Hepatitis B;Hepatomegaly;Hyperamylasaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperlactacidaemia;Hypersensitivity;Hypertriglyceridaemia;Hypertrophy of breast;Hypotension;Ill-defined disorder;Infection;Inflammation;Influenza like illness;Insomnia;Insulin resistance;Lactic acidosis;Lethargy;Leukopenia;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Liver function test abnormal;Lymphadenopathy;Lymphopenia;Malaise;Malnutrition;Migraine;Mouth ulceration;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Nausea;Nervous system disorder;Neuropathy;Neuropathy peripheral;Neutropenia;Oedema;Opportunistic infection;Oropharyngeal discomfort;Oropharyngeal pain;Other sleep disturbances;Pain;Pancreatitis;Paraesthesia;Pharyngitis;Pneumonia;Pruritus;Raised liver function tests;Rash;Renal failure;Respiratory failure;Respiratory tract infection;Rhabdomyolysis;Sensitisation;Skin disorder;Sleep disorder;Splenomegaly;Stevens-Johnson syndrome;Stomatitis;Throat sore;Thrombocytopenia;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vertigo;Vomiting;Wheezing,small molecule,approved; investigational,{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; Abacavir; ABC ; Pr160Gag-Pol; 2.7.1.20; Adenosine 5'-phosphotransferase; AK; 1.1.1.1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1,Reverse transcriptase/RNaseH; Gag-Pol polyprotein, J05AF06; J05AR02; J05AR04;J05AF06;J05AR13
amphotericin,Acquired immunodeficiency syndrome;Aspergillosis;Aspergillus infection;Autoimmune disorder;Blastomycosis;Blood creatinine increased;Body temperature increased;Candida infection;Cell death;Chills;Coccidioidomycosis;Creatinine increased;Cryptococcosis;Extravasation;Fungal infection;Histoplasmosis;Immunocompromised;Immunodeficiency;Infection;Kidney function abnormal;Meningitis cryptococcal;Menorrhagia;Mucocutaneous leishmaniasis;Mucormycosis;Nausea;Nephropathy toxic;Nephrotoxicity;Oesophageal candidiasis;Oral candidiasis;Prolonged menses;Renal failure;Renal impairment;Rigors;Sporotrichosis;Systemic candida;Vaginal moniliasis;Visceral leishmaniasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Zygomycosis,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Accidental injury;Acidosis;Acne;Acute coronary syndrome;Acute hepatic failure;Acute urticaria;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Alveolitis allergic;Amblyopia;Amylase increased;Anaemia;Anal pruritus;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anuria;Anxiety;Apnoea;Application site pain;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Asthma;Atelectasis;Atrial fibrillation;Azotaemia;Back pain;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood fibrinogen increased;Blood lactate dehydrogenase increased;Blood potassium decreased;Blood thromboplastin decreased;Blood urea increased;Blood uric acid increased;Body temperature decreased;Body temperature increased;Bone pain;Bradycardia;Bronchospasm;Burning sensation;Candida infection;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Cardiac valve disease;Cardiomegaly;Cardiovascular disorder;Cellulitis;Chest discomfort;Chest pain;Chest tightness;Chills;Cholestasis;Coagulopathy;Coma;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine increased;Cyanosis;Cystitis haemorrhagic;Deafness;Decreased appetite;Dehydration;Depressed level of consciousness;Dermatitis;Dermatitis bullous;Diarrhoea;Diarrhoea haemorrhagic;Diplopia;Discomfort;Distress gastrointestinal;Dizziness;Drug interaction;Dry eye;Dry mouth;Dry skin;Dysaesthesia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear disorder;Ecchymosis;Encephalopathy;Enlargement abdomen;Eosinophilia;Epigastric pain;Epilepsy;Epistaxis;Eructation;Erythema;Erythema multiforme;Extrasystoles;Extravasation;Eye haemorrhage;Face oedema;Faecal incontinence;Feeling abnormal;Flatulence;Fluid overload;Fluid retention;Flushing;Folliculitis;Function kidney decreased;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Generalized aching;Gingivitis;Glossitis;Glycosuria;Graft versus host disease;Haematemesis;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhoids;Hallucination;Headache;Hearing impaired;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis cholestatic;Hepatocellular injury;Hepatomegaly;Hepatotoxicity;Herpes simplex;Hiccups;Hyperbilirubinaemia;Hyperchloraemia;Hyperfibrinogenaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hypermagnesaemia;Hypernatraemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoalbuminaemia;Hypocalcaemia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hyposthenuria;Hypotension;Hypothermia;Hypoventilation;Hypoxia;Ileus;Ill-defined disorder;Immune system disorder;Infection;Inflammation;Influenza like illness;Influenza-like symptoms;Infusion related reaction;Injection site inflammation;Injection site pain;Injection site reaction;Injury;Insomnia;Instillation site pain;Jaundice;Lactic dehydrogenase activity increased;Leg edema;Leg pain;Leukocytosis;Leukopenia;Liver function test abnormal;Liver injury;Loss of consciousness;Low back pain;Lung disorder;Malaise;Malnutrition;Melaena;Meningitis cryptococcal;Mental disability;Mouth haemorrhage;Mouth ulceration;Mucosal inflammation;Mucous membrane disorder;Multi-organ failure;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Nausea;Neck pain;Nephrocalcinosis;Nephrogenic diabetes insipidus;Nephropathy toxic;Nephrosis;Nephrotic syndrome;Nephrotoxicity;Nervousness;Neurological symptom;Neuropathy;Neuropathy peripheral;Neurosis;Nodule;Normochromic normocytic anaemia;Normocytic anemia;Oedema;Oedema peripheral;Oliguria;Oral candidiasis;Orthostatic hypotension;Pain;Pain in extremity;Pancreatitis;Paraesthesia;Pelvic haemorrhage;Petechiae;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Pleural effusion;Pneumonia;Pneumothorax;Procedural complication;Prothrombin level decreased;Prothrombin level increased;Pruritus;Pruritus genital;Psychotic disorder;Pulmonary haemorrhage;Pulmonary oedema;Purpura;Rash;Rash erythematous;Rash follicular;Rash maculo-papular;Rash pustular;Reaction febrile;Rectal disorder;Renal abscess;Renal failure;Renal failure acute;Renal impairment;Renal tubular acidosis;Respiratory alkalosis;Respiratory failure;Respiratory insufficiency;Retrosternal pain;Rhabdomyolysis;Rhinitis;Rigors;Road traffic accident;Sensory disturbance;Sepsis;Septic arthritis streptobacillus;Serum creatinine increased;Serum potassium decreased;Serum urea increased;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin exfoliation;Skin mass;Skin nodule;Skin ulcer;Somnolence;Speech disorder;Splenomegaly;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Streptobacillary fever;Stupor;Supraventricular tachycardia;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Tachypnoea;Tendon disorder;Tension;Thinking abnormal;Thrombocytopenia;Thrombophlebitis;Thromboplastin decreased;Tinnitus;Toxic epidermal necrolysis;Transfusion reaction;Tremor;Type IV hypersensitivity reaction;Ulcerative stomatitis;Uremia;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urticaria;Vaginal haemorrhage;Vascular purpura;Venoocclusive liver disease;Ventricular extrasystoles;Ventricular fibrillation;Vertigo;Vesiculobullous rash;Visual impairment;Vomiting;Weight decreased;Weight increased;Wheezing,small molecule,approved; investigational,Amfotericina B; AMPH-b; Amphotericin B; Amphotéricine B; Amphotericinum B; Liposomal amphotericin B,Ergosterol, A01AB04; A07AA07; J02AA01;A01AB04;G01AA03
acebutolol,Angina pectoris;Arrhythmia;Extrasystoles;Hypertension;Hypertensive;Myocardial ischaemia;Ventricular arrhythmia;Ventricular extrasystoles,Abdominal pain;Abnormal dreams;Abnormal vision;Ache;Affect lability;Agranulocytosis;Alopecia;Alopecia reversible;Amnesia;Angiopathy;Anorexia;Anxiety;Appetite absent;Arterial thrombosis;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrioventricular block;Atrioventricular block complete;Atrioventricular block second degree;Back pain;Blood bilirubin increased;Body temperature increased;Bradycardia;Bronchospasm;Cardiac failure;Cardiac failure congestive;Cardiac output decreased;Catatonia;Chest pain;Chills;Claudication;Colitis ischaemic;Confusional state;Conjunctival xerosis;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Decreased appetite;Depression;Dermatitis;Dermatitis exfoliative;Dermatitis psoriasiform;Diarrhoea;Discomfort;Disorientation;Dizziness;Drowsiness;Dry eye;Dyspepsia;Dyspnoea;Dysuria;Erectile dysfunction;Eye pain;Eye pruritus;Fatigue;Feeling abnormal;Flatulence;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Heartburn;Hot flush;Hyperhidrosis;Hypoaesthesia;Hypotension;Ill-defined disorder;Insomnia;Intermittent claudication;Laryngospasm;Lethargy;Lightheadedness;Loss of consciousness;Loss of libido;Lung infiltration;Lupus-like syndrome;Malaise;Mediastinal disorder;Menopausal symptoms;Mood swings;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Nocturia;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Pain;Pain in extremity;Palpitations;Paraesthesia;Peripheral coldness;Peyronie's disease;Pharyngitis;Pleuritic pain;Pneumonia;Pruritus;Psychotic disorder;Rash;Rash erythematous;Respiratory distress;Rhinitis;Shivering;Shock;Short-term memory loss;Sinus arrest;Skin disorder;Somnolence;Sweating;Syncope;Systemic lupus erythematosus;Throat sore;Thrombocytopenic purpura;Tinnitus;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vivid dreams;Vomiting;Weight increased;Wheezing;Xerosis,small molecule,approved; investigational,(±)-acebutolol; 3'-acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 5'-butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone; Acebutolol; Acebutololum; Acetobutolol; N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1,Beta-1 adrenergic receptor; Beta-2 adrenergic receptor, C07BB04;C07AB04
acetaminophen,Ache;Acute pain;Arthritis;Back pain;Body temperature increased;Common cold;Cough;Difficulty sleeping;Discomfort;Dry cough;Dysmenorrhoea;Dyspepsia;Flu symptoms;Glucose-6-phosphate dehydrogenase deficiency;Gout;Headache;Influenza;Insomnia;Migraine;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasopharyngitis;Neuralgia;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Pain;Poor quality sleep;Renal failure;Rheumatic disorder;Rheumatism;Rhinitis;Rhinorrhoea;Sinus headache;Sinus pain;Sinusitis;Tension headache;Throat sore;Toothache;Ulcer,Abdominal discomfort;Abdominal distension;Abdominal pain;Acute angle-closure glaucoma;Acute generalised exanthematous pustulosis;Acute hepatic failure;Administration site reaction;Agitation;Agranulocytosis;Alveolitis;Anaemia;Anaemia postoperative;Anaphylactic shock;Angioedema;Angiopathy;Angle closure glaucoma;Anorexia;Anxiety;Aspartate aminotransferase increased;Asthenia;Asthma;Atelectasis;Azotaemia;Balance disorder;Benign prostatic hyperplasia;Bladder neck obstruction;Blood and lymphatic system disorders;Blood disorder;Blood pressure increased;Body temperature increased;Breath sounds abnormal;Bronchospasm;Cardiac disorder;Chest discomfort;Chest pain;Chest tightness;Chills;Coma;Confusional state;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cutaneous hypersensitivity;Cytolytic hepatitis;Decreased appetite;Dermatitis;Dermatitis atopic;Dermatitis exfoliative;Diarrhoea;Digestion impaired;Discomfort;Disturbance in attention;Dizziness;Drowsiness;Drug eruption;Drug interaction;Dry mouth;Dyskinesia;Dyspepsia;Dysphoria;Dyspnoea;Dystonia;Dystonic reaction;Dysuria;Energy increased;Enlargement abdomen;Eructation;Erythema;Erythema multiforme;Euphoric mood;Eye disorder;Fatigue;Feeling abnormal;Fixed drug eruption;Fluid overload;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis fulminant;Hepatobiliary disease;Hepatocellular injury;Hyperglycaemia;Hyperhidrosis;Hyperreflexia;Hypersensitivity;Hypertension;Hypoalbuminaemia;Hypokalaemia;Hypomagnesaemia;Hypophosphataemia;Hypotension;Hypotonia;Ill-defined disorder;Immune system disorder;Infusion site pain;Injection site pain;Injection site reaction;Insomnia;Irritability;Kounis syndrome;Leukopenia;Lightheadedness;Liver injury;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Mental status changes;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Mydriasis;Myoclonus;Nausea;Nephrosis lower nephron;Nervous system disorder;Nervousness;Neutropenia;Nightmare;Oedema;Oedema peripheral;Oliguria;Pain in extremity;Palpitations;Pancreatitis acute;Pancytopenia;Pemphigoid;Pemphigoid reaction;Periorbital oedema;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pneumothorax;Post procedural haemorrhage;Postoperative hemorrhage;Prostatic hypertrophy;Pruritus;Pulmonary function test decreased;Pulmonary oedema;Rash;Rash macular;Rash maculo-papular;Rash pustular;Renal failure acute;Renal tubular necrosis;Respiratory depression;Serotonin syndrome;Shivering;Shock;Skin disorder;Somnolence;Stevens-Johnson syndrome;Strangury;Stridor;Sweating;Sweating increased;Tachycardia;Tension;Thrombocytopenia;Toxic epidermal necrolysis;Traumatic liver injury;Tremor;Trismus;Unspecified disorder of skin and subcutaneous tissue;Unsteadiness;Uremia;Urethral disorder;Urinary hesitation;Urinary retention;Urinary tract disorder;Urticaria;Vision blurred;Vomiting;Wheezing,small molecule,approved,"4-(Acetylamino)phenol; 4-acetamidophenol; 4'-hydroxyacetanilide; Acenol; Acetaminofén; Acetaminophen; Acétaminophène; APAP; N-acetyl-p-aminophenol; p-acetamidophenol; p-acetaminophenol; p-Acetylaminophenol; p-hydroxy-acetanilid; p-hydroxyacetanilide; p-hydroxyphenolacetamide; Paracétamol; Paracetamol; Paracetamolum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 5.3.99.3; cPGES; Cytosolic prostaglandin E2 synthase; Hsp90 co-chaperone; P23; Progesterone receptor complex p23; TEBP; Telomerase-binding protein p23; Capsaicin receptor; Osm-9-like TRP channel 1; OTRPC1; TrpV1; Vanilloid receptor 1; VR1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.8.2.1; Aryl sulfotransferase 1; HAST1/HAST2; P-PST 1; Phenol sulfotransferase 1; Phenol-sulfating phenol sulfotransferase 1; ST1A1; ST1A3; STP; STP1; Thermostable phenol sulfotransferase; Ts-PST; 2.8.2.1; Aryl sulfotransferase 1A3/1A4; Catecholamine-sulfating phenol sulfotransferase; HAST3; M-PST; Monoamine-sulfating phenol sulfotransferase; Placental estrogen sulfotransferase; ST1A3; STM; Sulfotransferase 1A3/1A4; Sulfotransferase, monoamine-preferring; Thermolabile phenol sulfotransferase; TL-PST; 2.3.1.5; AAC2; Arylamide acetylase 2; N-acetyltransferase type 2; N-hydroxyarylamine O-acetyltransferase; NAT-2; PNAT; Polymorphic arylamine N-acetyltransferase; 3.5.1.99; Anandamide amidohydrolase 1; FAAH1; Fatty acid ester hydrolase; Oleamide hydrolase 1; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 2.5.1.18; GST class-mu 1; GST HB subunit 4; GST1; GSTM1-1; GSTM1a-1a; GSTM1b-1b; GTH4; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Prostaglandin G/H synthase 2; Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; Prostaglandin G/H synthase 1; Prostaglandin E synthase 3; Transient receptor potential cation channel subfamily V member 1, N02AJ01; N02AJ06; N02AJ13; N02AJ17; N02AJ22; N02BE01; N02BE51;N02BE01;N02BE71
acetazolamide,Acute angle-closure glaucoma;Angle closure glaucoma;Cardiac failure congestive;Convulsion;Epilepsy;Glaucoma;Mountain sickness acute;Oedema;Petit mal epilepsy;Secondary glaucoma,Agitation;Agranulocytosis;Anaphylactic shock;Anaphylactoid reaction;Aplastic anaemia;Appetite absent;Asthenia;Ataxia;Blood disorder;Body temperature increased;Confusional state;Convulsion;Decreased appetite;Diarrhoea;Digestion impaired;Discomfort;Dizziness;Drowsiness;Dysgeusia;Dyspepsia;Electrolyte imbalance;Erythema multiforme;Excitement;Fatigue;Feeling abnormal;Flushing;Gastrointestinal disorder;Glycosuria;Growth retardation;Haematuria;Headache;Hepatic failure;Hepatic function abnormal;Hepatic insufficiency;Hepatic necrosis;Hepatobiliary disease;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hyponatraemia;Ill-defined disorder;Injection site pain;Irritability;Jaundice cholestatic;Leukopenia;Malaise;Melaena;Metabolic acidosis;Myopia;Myopia transient;Nausea;Numbness;Osteomalacia;Paraesthesia;Paralysis flaccid;Photosensitivity;Photosensitivity reaction;Polydipsia;Polyuria;Reaction gastrointestinal;Sensory loss;Shock;Somnolence;Stevens-Johnson syndrome;Thirst;Thrombocytopenia;Thrombocytopenic purpura;Tingling of extremity;Tingling sensation;Tinnitus;Toxic epidermal necrolysis;Urine output increased;Urticaria;Vomiting,small molecule,approved; vet_approved,"2-acetylamino-1,3,4-thiadiazole-5-sulfonamide; 5-acetamido-1,3,4-thiadiazole-2-sulfonamide; 5-acetylamino-1,3,4-thiadiazole-2-sulfonamide; Acetazolamid; Acetazolamida; Acétazolamide; Acetazolamide; Acetazolamidum; N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide; N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-IV; Carbonate dehydratase IV; Carbonic anhydrase IV; 4.2.1.1; CA-XII; Carbonate dehydratase XII; Carbonic anhydrase XII; Tumor antigen HOM-RCC-3.1.3; 4.2.1.1; CA-XIV; Carbonate dehydratase XIV; Carbonic anhydrase XIV; 4.2.1.1; CA-III; Carbonate dehydratase III; Carbonic anhydrase III; 4.2.1.1; CA-VII; Carbonate dehydratase VII; Carbonic anhydrase VII; AQP-1; Aquaporin-CHIP; Channel-like integral membrane protein of 28 kDa; CHIP28; Urine water channel; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",Carbonic anhydrase 1; Carbonic anhydrase 2; Carbonic anhydrase 4; Carbonic anhydrase 12; Carbonic anhydrase 14; Carbonic anhydrase 3; Carbonic anhydrase 7; Aquaporin-1, S01EC01;G01AE10;S01EC01
acetohydroxamic,Infection;Phlebitis;Renal failure;Urinary tract infection;Venous thrombosis,Abdominal discomfort;Alopecia;Anaemia;Anorexia;Anxiety;Asthenia;Decreased appetite;Deep vein thrombosis;Depression;Dermatitis;Discomfort;Fatigue;Feeling abnormal;Feeling hot;Gastrointestinal disorder;Gastrointestinal symptom NOS;Gastrointestinal tract irritation;Haemolytic anaemia;Headache;Ill-defined disorder;Injury;Lethargy;Malaise;Nausea;Nervousness;Palpitations;Phlebitis superficial;Rash;Renal failure;Renal impairment;Reticulocytosis;Sensation of warmth;Tension;Thrombophlebitis;Tremor;Tremulousness;Vomiting,small molecule,approved,"Acethydroxamsaeure; Acetic acid, oxime; Acetohydroxamate; Acetohydroxamic acid; Acetohydroximic acid; Acetyl hydroxyamino; Acetylhydroxamic acid; Acide acetohydroxamique; Acido acetohidroxamico; Acidum acetohydroxamicum; AHA; Cetohyroxamic acid; Methylhydroxamic acid; N-Acetyl hydroxyacetamide; N-Acetylhydroxylamine; N-Hydroxyacetamide; 3.5.1.5; Urea amidohydrolase subunit alpha; 3.4.24.65; HME; Macrophage elastase; Matrix metalloproteinase-12; ME; MME; MMP-12",Urease subunit alpha; Macrophage metalloelastase,G04BX03
methacholine,Asthma;Bronchoconstriction;Bronchospasm;Cardiovascular disorder;Epilepsy;Occupational asthma;Peptic ulcer;Thyroid disorder;Urinary tract obstruction,Atrioventricular block complete;Bradycardia;Bronchoconstriction;Bronchospasm;Cardiac arrest;Chest discomfort;Chest pain;Chest tightness;Cholinergic syndrome;Cough;Dizziness;Headache;Hypotension;Lightheadedness;Loss of consciousness;Nausea;Pregnancy;Pruritus;Respiratory distress;Retrosternal pain;Rhinitis seasonal;Seasonal allergy;Shock;Syncope;Teratogenicity;Throat irritation;Vagotonia;Vomiting;Wheezing,small molecule,approved; investigational,Acetyl-beta-methylcholine; Acetylmethylcholine; beta-Methylacetylcholine; MCh; Methacholine; Methacholinum; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5,Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5,V04CX03
actinomycin,Ewing's sarcoma;Gestational trophoblastic tumour;Neoplasm;Neoplasm malignant;Nephroblastoma;Rhabdomyosarcoma;Testis cancer,Abdominal pain;Agranulocytosis;Alopecia;Anaemia;Anorexia;Aplastic anaemia;Ascites;Aspartate aminotransferase increased;Asthenia;Body temperature increased;Cheilitis;Chills;Coagulopathy;Decreased appetite;Diarrhoea;Discomfort;Dysphagia;Epidermolysis;Eruption;Erythema;Erythema multiforme;Extravasation;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Flushing;Folliculitis;Gastrointestinal pain;Growth retardation;Hepatic failure;Hepatitis;Hepatomegaly;Hepatotoxicity;Hypersensitivity;Hypocalcaemia;Ill-defined disorder;Infection;Lethargy;Leukopenia;Liver function test abnormal;Malaise;Mouth ulceration;Multi-organ failure;Muscle contracture;Musculoskeletal discomfort;Myalgia;Myelosuppression;Nausea;Necrosis;Neutropenia;Neutropenic sepsis;Oedema;Oesophagitis;Pain;Pancytopenia;Pharyngitis;Phlebitis;Pneumonia;Proctitis;Radiation injury;Radiation recall reaction (dermatologic);Raised liver function tests;Rash;Recall phenomenon;Reticulocytopenia;Sepsis;Stevens-Johnson syndrome;Stomatitis;Thrombocytopenia;Toxic epidermal necrolysis;Ulcer;Ulcerative stomatitis;Venoocclusive disease;Venoocclusive liver disease;Vomiting,small molecule,approved; investigational,"2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; 3H-PHENOXAZINE-1,9-DICARBOXAMIDE, 2-AMINO-N,N'-BIS(HEXADECAHYDRO-6,13-DIISOPROPYL-2,5,9-TRIMETHYL-1,4,7,11,14-PENTAOXO-1H-PYRROLO(2,1-I)(1,4,7,10,13)OXATETRAAZACYCLOHEXADECIN-10-YL)-4,6-DIMETHYL-3-OXO-; ActD; Actinomycin C1; Actinomycin D; ACTINOMYCIN I1; Actinomycin IV; ACTINOMYCIN X1; ACTINOMYCIN-D; ANA-conjugated dactinomycin nanoemulsion; Dactinomicina; Dactinomycin; Dactinomycine; Dactinomycinum; DILACTONE ACTINOMYCIN D ACID; Meractinomycin; N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINE) DILACTONE; ONCOSTATIN K; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 5.6.2.2; DNA topoisomerase II, beta isozyme; 5.6.2.1; DNA topoisomerase I; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.3; Anthracycline resistance-associated protein; ARA; MOAT-E; MRP6; Multi-specific organic anion transporter E; Multidrug resistance-associated protein 6; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",DNA; DNA topoisomerase 2; DNA topoisomerase 1,L01DA01
spectinomycin,Cervicitis;Gonorrhoea;Infection;Proctitis;Urethritis;Urethritis noninfective,Anaphylactic shock;Anaphylactoid reaction;Body temperature increased;Chills;Dizziness;Hypersensitivity;Insomnia;Nausea;Nephropathy toxic;Tenderness;Urine output;Urticaria,small molecule,approved; investigational; vet_approved,Actinospectacina; Espectinomicina; SCM; Spectinomicina; Spectinomycin; Spectinomycine; Spectinomycinum; strA,30S ribosomal protein S12,J01XX04
acyclovir,Acquired immunodeficiency syndrome;Acute pain;Anterior uveitis;Autoimmune disorder;Body temperature increased;Congenital herpes simplex infection;Cytomegalovirus infection;Dermatitis;Drug interaction;Eczema;Fatigue;Genital herpes;Herpes NOS;Herpes labialis;Herpes simplex;Herpes simplex encephalitis;Herpes virus infection;Herpes zoster;Herpes zoster disseminated;Hypersensitivity;Immunocompromised;Immunodeficiency;Infection;Iridocyclitis;Keratitis;Meningoencephalitis herpetic;Mucocutaneous herpes simplex;Ophthalmic herpes simplex;Ophthalmic herpes zoster;Oral herpes;Pain;Papule;Post herpetic neuralgia;Pregnancy;Prostration;Rash;Renal failure;Renal failure chronic;Renal impairment;Scab;Sexually transmitted disease;Ulcer;Varicella;Varicella zoster;Viraemia;Viral infection,"Abdominal discomfort;Abdominal pain;Accelerated hair loss;Ache;Aggression;Agitation;Alanine aminotransferase increased;Alopecia;Altered state of consciousness;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Anuria;Aphthous stomatitis;Aplastic anaemia;Application site irritation;Application site pain;Application site reaction;Arthralgia;Aspartate aminotransferase increased;Asthenia;Ataxia;Auditory and visual hallucinations;Blepharitis;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood urea increased;Body temperature increased;Cardiac tamponade;Chapped lips;Chest pain;Chills;Coma;Confusional state;Conjunctivitis;Constipation;Convulsion;Cramp muscle;Creatinine increased;Decreased appetite;Dehydration;Delirium;Depressed level of consciousness;Dermatitis;Dermatitis contact;Diarrhoea;Digestion impaired;Discomfort;Disseminated intravascular coagulation;Distress gastrointestinal;Dizziness;Dysarthria;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Eczema;Encephalopathy;Erythema;Erythema multiforme;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gingival pain;Haematuria;Haemoglobinaemia;Haemolytic uraemic syndrome;Hallucination;Hallucinations, mixed;Headache;Hepatitis;Hepatobiliary disease;Herpes NOS;Herpes simplex;Herpes virus infection;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypokalaemia;Hypotension;Ill-defined disorder;Immune system disorder;Inflammation;Injection site phlebitis;Insomnia;Instillation site pain;Irritability;Ischaemia;Jaundice;Leg pain;Lethargy;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Lightheadedness;Lip dry;Liver function test abnormal;Lymphadenopathy;Malaise;Mania;Mediastinal disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Necrosis;Nervous system disorder;Neurologic reaction;Neurological symptom;Neutropenia;Neutrophilia;Oedema;Oedema peripheral;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Pain;Pain in extremity;Palpitations;Paraesthesia;Pars planitis;Phlebitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Platelet count decreased;Pruritus;Psychotic disorder;Pulmonary oedema;Punctate keratitis;Purpura fulminans;Raised liver function tests;Rash;Renal failure;Renal failure acute;Renal impairment;Renal pain;Rhinorrhoea;Rigors;Sensitisation;Skin burning sensation;Skin disorder;Skin exfoliation;Somnolence;Stevens-Johnson syndrome;Stinging;Stupor;Superficial punctate keratopathy;Sweating increased;Tachycardia;Thirst;Throat sore;Thrombocytopenia;Thrombocytopenic purpura;Thrombocytosis;Thrombophlebitis superficial;Thrombotic thrombocytopenic purpura;Toxic epidermal necrolysis;Tremor;Type I hypersensitivity;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urine analysis abnormal;Urticaria;Uveitis;Vasculitis;Vertigo;Vomiting",small molecule,approved,"Aciclovir; Aciclovirum; Acycloguanosine; Acyclovir; 2.7.7.7; 2.7.7.7; 2.7.1.21; UL23; 2.7.4.8; GMK; GMP kinase; GMPK; Guanylate kinase 1; 2.7.4.6; GAAD; Granzyme A-activated DNase; Metastasis inhibition factor nm23; NDK A; NDP kinase A; NDPKA; NM23; NM23-H1; Tumor metastatic process-associated protein; 2.7.4.6; C-myc purine-binding transcription factor PUF; Histidine protein kinase NDKB; NDK B; NDP kinase B; nm23-H2; NM23B; 2.7.1.40; PK1; PKL; Pyruvate kinase 1; Pyruvate kinase isozymes L/R; R-type/L-type pyruvate kinase; Red cell/liver pyruvate kinase; 2.7.1.40; CTHBP; Cytosolic thyroid hormone-binding protein; OIP-3; OIP3; Opa-interacting protein 3; p58; PK2; PK3; PKM2; Pyruvate kinase 2/3; Pyruvate kinase muscle isozyme; THBP1; Threonine-protein kinase PKM2; Thyroid hormone-binding protein 1; Tumor M2-PK; Tyrosine-protein kinase PKM2; 2.7.3.2; B-CK; Brain creatine kinase; CKBB; CPK-B; Creatine kinase B chain; Creatine phosphokinase B-type; 2.7.3.2; CKMM; CPK-M; Creatine kinase M chain; Creatine phosphokinase M-type; M-CK; 2.7.3.2; Basic-type mitochondrial creatine kinase; Mib-CK; S-MtCK; Sarcomeric mitochondrial creatine kinase; 2.7.3.2; Acidic-type mitochondrial creatine kinase; CKMT; Mia-CK; U-MtCK; Ubiquitous mitochondrial creatine kinase; 2.7.2.3; Cell migration-inducing gene 10 protein; PGKA; Primer recognition protein 2; PRP 2; 2.7.2.3; PGKB; Phosphoglycerate kinase, testis specific; 6.2.1.5; A-SCS; ATP-specific succinyl-CoA synthetase subunit beta; SCS-betaA; Succinyl-CoA synthetase beta-A chain; 6.2.1.4; 6.2.1.5; SCS-alpha; Succinyl-CoA synthetase subunit alpha; 6.2.1.4; G-SCS; GTP-specific succinyl-CoA synthetase subunit beta; GTPSCS; SCS-betaG; Succinyl-CoA synthetase beta-G chain; 4.1.1.32; mtPCK2; PEPCK-M; PEPCK2; Phosphoenolpyruvate carboxykinase 2, mitochondrial; 4.1.1.32; PEPCK-C; PEPCK1; Serine-protein kinase PCK1; 6.3.4.4; Adenylosuccinate synthetase-like 1; Adenylosuccinate synthetase, basic isozyme; Adenylosuccinate synthetase, muscle isozyme; AdSS 1; ADSSL1; AMPSase 1; IMP--aspartate ligase 1; M-type adenylosuccinate synthetase; 6.3.4.4; Adenylosuccinate synthetase, acidic isozyme; Adenylosuccinate synthetase, liver isozyme; ADSS; AdSS 2; AMPSase 2; IMP--aspartate ligase 2; L-type adenylosuccinate synthetase; hOCT1; OCT1; Organic cation transporter 1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Apical sodium-dependent bile acid transporter; ASBT; IBAT; Ileal Na(+)/bile acid cotransporter; Ileal sodium-dependent bile acid transporter; ISBT; Na(+)-dependent ileal bile acid transporter; NTCP2; Sodium/taurocholate cotransporting polypeptide, ileal; Solute carrier family 10 member 2; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2",DNA polymerase catalytic subunit; DNA polymerase catalytic subunit, D06BB03; D06BB53; S01AD03;D06BB03;J05AB01
albendazole,Cyst;Echinococciasis;Foetor hepaticus;Hepatocellular injury;Infection;Liver disorder;Neurocysticercosis;Oedema,Abdominal pain;Acute hepatic failure;Agranulocytosis;Alopecia;Alopecia reversible;Aplastic anaemia;Blood and lymphatic system disorders;Body temperature increased;Dermatitis;Dizziness;Erythema multiforme;Gastrointestinal pain;Headache;Hepatitis;Hepatobiliary disease;Hypersensitivity;Immune system disorder;Intracranial pressure increased;Leukopenia;Liver function test abnormal;Nausea;Neutropenia;Pancytopenia;Rash;Renal failure acute;Skin disorder;Stevens-Johnson syndrome;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vertigo;Vomiting,small molecule,approved; vet_approved,"(5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; 5-(propylthio)-2-carbomethoxyaminobenzimidazole; Albendazol; Albendazole; Albendazolum; Eskazole; O-methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Proftril; 3.6.5.-; Alpha-tubulin 3; TUBA3; Tubulin alpha-3 chain; Tubulin B-alpha-1; TUBB2C; Tubulin beta-2 chain; Tubulin beta-2C chain; 1.3.5.4; FL cyt; Flavocytochrome c; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Tubulin beta-2 chain; Tubulin alpha-1A chain; Tubulin beta-4B chain; Fumarate reductase flavoprotein subunit,P02CA03
salbutamol,Asthma;Asthma exercise induced;Bronchial hyperreactivity;Bronchitis chronic;Bronchospasm;Chronic obstructive pulmonary disease;Coordination abnormal;Diabetes mellitus;Diabetic;Emphysema;Exacerbation of asthma;Exercise-induced bronchospasm;Heart rate normal;Inflammation;Obstructive airways disorder;Pregnancy;Premature labour;Reversible airways obstruction;Sinus tachycardia;Status asthmaticus,Abdominal bloating;Abdominal distension;Abdominal pain;Abdominal pain upper;Accidental injury;Affect lability;Aggression;Agitation;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Appetite absent;Application site reaction;Arrhythmia;Arthralgia;Asthenia;Asthma;Ataxia;Atrial fibrillation;Autonomic neuropathy;Back pain;Blood pressure increased;Body temperature increased;Breast pain;Bronchitis;Bronchospasm;Bronchospasm aggravated;Bronchospasm paradoxical;Cardiac disorder;Cardiac failure high output;Cardiac fibrillation;Cardiac murmur;Cardiac output increased;Chest discomfort;Chest pain;Chills;Coagulopathy;Cold symptoms;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Decreased appetite;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dry throat;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphonia;Dyspnoea;Dysuria;Ear disorder;Ear pain;Eczema;Electrocardiogram ST segment depression;Electrocardiogram abnormal;Electrocardiogram change;Emotional distress;Epigastric distress;Epigastric pain;Epistaxis;Eructation;Euphoric mood;Exacerbation of asthma;Excitement;Extrasystoles;Eye pruritus;Fatigue;Feeling abnormal;Feeling hot;Feeling tense;Flatulence;Fluid overload;Flushing;Gagging;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrooesophageal reflux disease;Glossitis;Glycosuria;Haematuria;Haemoglobin;Haemorrhage;Headache;Heartburn;Herpes simplex;Hoarseness;Hyperaesthesia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hypotension;Ileus;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Inflammation;Influenza;Injury;Insomnia;Irritability;Jaundice;Ketosis;Lactic acidosis;Laryngitis;Lightheadedness;Loss of consciousness;Lung disorder;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Mental disability;Mental disorder;Metabolic acidosis;Migraine;Mood swings;Multiple pregnancy;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Myalgia;Mydriasis;Myocardial ischaemia;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Nightmare;Oedema;Oropharyngeal swelling;Otitis media;Pain;Pallor;Palpitations;Paraesthesia;Peripheral vasodilatation;Pharyngitis;Pre-eclampsia;Pruritus;Pulmonary oedema;Rash;Respiratory tract infection;Retching;Rhinitis;Rigors;Saliva altered;Sensation of warmth;Shakiness;Shock;Sinusitis;Skin disorder;Somnolence;Stomach ache;Stomatitis;Strangury;Supraventricular tachycardia;Sweating;Sweating increased;Syncope;Tachycardia;Tachycardia foetal;Taste altered;Tension;Thinking abnormal;Throat irritation;Tinnitus;Tongue discolouration;Tongue ulceration;Tracheitis;Tremor;Tremor fine;Tremor muscle;Tremor of hands;Type I hypersensitivity;Unspecified disorder of autonomic nervous system;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal moniliasis;Vascular resistance systemic;Vasodilatation;Vasodilation;Vasodilation procedure;Vertigo;Viral infection;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Wheezing,small molecule,approved; investigational,(-)-Albuterol; (-)-Salbutamol; (R)-salbutamol; Levalbuterol; Levosalbutamol; R-salbutamol; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8,Beta-2 adrenergic receptor,R03AC02
alendronate,Bone density decreased;Bone disorder;Bone mass decreased;Fracture;Gastrointestinal disorder;Multiple fractures;Neoplasm malignant;Osteitis deformans;Osteopenia;Osteoporosis;Osteoporosis postmenopausal;Osteoporotic fracture;Peptic ulcer;Renal failure;Renal impairment;Spinal compression fracture;Spinal fracture,Abdominal discomfort;Abdominal distension;Abdominal pain;Acute phase reaction;Alopecia;Anaemia;Anastomotic ulcer;Angioedema;Asthenia;Asthma;Atypical fracture;Atypical stress fracture;Body temperature increased;Chest pain;Constipation;Cramp muscle;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drug interaction;Dry skin;Duodenal ulcer;Dysgeusia;Dyspepsia;Dysphagia;Episcleritis;Erosive oesophagitis;Erythema;Erythema multiforme;Esophageal erosions;Exacerbation of asthma;Feeling abnormal;Femur fracture;Femur fracture subtrochanteric;Femur shaft fracture;Flatulence;Gastric ulcer;Gastritis;Gastrointestinal pain;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Headache;Heartburn;Hypercalcaemia;Hypercalciuria;Hypersensitivity;Hypocalcaemia;Ill-defined disorder;Impaired healing;Infection;Influenza like illness;Influenza-like symptoms;Joint swelling;Leukaemia;Lymphopenia;Malaise;Melaena;Menopause;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nausea;Nephrolithiasis;Oedema peripheral;Oesophageal disorder;Oesophageal irritation;Oesophageal stenosis;Oesophageal ulcer;Oesophagitis;Oral disorder;Osteogenesis imperfecta;Osteomyelitis;Osteonecrosis of jaw;Pain;Photosensitivity;Photosensitivity reaction;Pruritus;Rash;Regurgitation;Retrosternal pain;Scleritis;Stevens-Johnson syndrome;Stomatitis;Toxic epidermal necrolysis;Transaminases increased;Ulcer;Urticaria;Uveitis;Vertigo;Vomiting,small molecule,approved; investigational,"ácido ibandrónico; Ibandronic acid; (2E,6E)-farnesyl diphosphate synthase; 2.5.1.-; Dimethylallyltranstransferase; Farnesyl diphosphate synthase; Farnesyltranstransferase; Geranylgeranyl diphosphate synthase; Geranyltranstransferase; GGPP synthase; GGPPSase; (2E,6E)-farnesyl diphosphate synthase; 2.5.1.10; Dimethylallyltranstransferase; Farnesyl diphosphate synthase; FPP synthase; FPS; Geranyltranstransferase; KIAA1293",Hydroxylapatite; Geranylgeranyl pyrophosphate synthase; Farnesyl pyrophosphate synthase, M05BB09;M05BA04;M05BA06
alfuzosin,Acute retention of urine;Benign prostatic hyperplasia;Blood pressure systolic decreased;Coronary artery disease;Urinary retention,Abdominal pain;Abdominal pain upper;Angina pectoris;Angioedema;Angiopathy;Arthralgia;Arthritis;Arthritis aggravated;Arthropathy;Asthenia;Atrial fibrillation;Back pain;Blood and lymphatic system disorders;Blood pressure diastolic decreased;Blood pressure fluctuation;Blood pressure systolic decreased;Breast disorder;Bronchitis;Bursitis;Calculus of kidney;Cardiac disorder;Cardiac fibrillation;Cardiovascular disorder;Change in blood pressure;Chest pain;Cholestasis;Cholestatic liver disease;Cholestatic liver injury;Connective tissue disorder;Constipation;Coronary artery disease;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Ear and labyrinth disorders;Erectile dysfunction;Eye disorder;Fatigue;Feeling abnormal;Floppy iris syndrome;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hepatobiliary disease;Hepatocellular injury;Hyperhidrosis;Hypotension;Ill-defined disorder;Infection;Infestation;Infestation NOS;Inflicted injury;Influenza like illness;Influenza-like symptoms;Injury;Intervertebral disc disorder;Intraoperative floppy iris syndrome;Ischial neuralgia;Jaundice;Laryngitis;Liver injury;Loss of consciousness;Lumbar disc lesion;Malaise;Mediastinal disorder;Mental disorder;Miosis;Musculoskeletal discomfort;Nausea;Nephrolithiasis;Nervous system disorder;Neuralgia;Neuropathy;Neuropathy peripheral;Oedema;Oedema due to cardiac disease;Orthostatic hypotension;Osteoarthritis;Pain;Palpitations;Pharyngitis;Priapism;Pruritus;Rash;Rhinitis;Sciatica;Shock;Sinusitis;Skin disorder;Somnolence;Stomach ache;Sweating;Syncope;Tachycardia;Thrombocytopenia;Torsade de pointes;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Ventricular arrhythmia;Ventricular tachycardia;Vertigo;Vomiting,small molecule,approved; investigational,"(±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide; Alfuzosin; Alfuzosina; Alfuzosine; Alfuzosinum; N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Alpha-1 adrenergic receptors; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor, G04CA51;G04CA01
allopurinol,Blood disorder;Blood uric acid increased;Calculus of kidney;Glycogen storage disorder;Gout;Gout acute;Gouty arthritis;Gouty tophus;Haemolytic anaemia;Hyperuricaemia;Hyperuricosuria;Inflammation;Joint destruction;Leukaemia;Lymphoma;Myeloid metaplasia;Myeloproliferative disorder;Neoplasm;Neoplasm malignant;Nephrolithiasis;Nephropathy;Non-Hodgkin's lymphoma;Polycythaemia vera;Renal failure;Renal impairment;Secondary gout;Solid tumour;Total hypoxanthine-guanine phosphoribosyl transferase deficiency;Urate nephropathy;Uric acid level increased,Abdominal distension;Abdominal pain;Abdominal pain upper;Ageusia;Agitation;Agranulocytosis;Albuminuria;Allergic cutaneous angiitis;Alopecia;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Angiitis necrotising;Angina pectoris;Angioedema;Angioimmunoblastic T-cell lymphoma;Anorexia;Aplasia;Aplastic anaemia;Apnoea;Arthralgia;Asthenia;Asthma;Ataxia;Azotaemia;Blast cell crisis;Blood and lymphatic system disorders;Blood creatinine increased;Blood electrolytes abnormal;Body temperature increased;Bone marrow depression;Bradycardia;Breast disorder;Bronchospasm;Cardiac disorder;Cardiac failure;Cardio-respiratory arrest;Cardiovascular disorder;Cataract;Cellulitis;Cerebral infarction;Cerebrovascular accident;Chest discomfort;Chest tightness;Chills;Coma;Confusional state;Conjunctivitis;Constipation;Contusion;Convulsion;Convulsions generalised;Creatinine increased;Crystalluria;Decreased appetite;Depression;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Digestion impaired;Discomfort;Disorder sight;Disseminated intravascular coagulation;Dizziness;Drowsiness;Dysgeusia;Dyspepsia;Dysuria;Ecchymosis;Eczema;Electrolyte abnormality;Electrolyte imbalance;Enlargement abdomen;Eosinophilia;Epilepsy;Epistaxis;Erectile dysfunction;Erythema multiforme;Eye disorder;Face oedema;Feeling abnormal;Flatulence;Fluid overload;Flushing;Foetor hepaticus;Footdrop;Function kidney decreased;Furuncle;Furunculosis;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalized lymphadenopathy;Glycosuria;Gout;Gout attack;Granulomatous liver disease;Gynaecomastia;Haematemesis;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis granulomatous;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hepatotoxicity;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hypernatraemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypotension;Hypotonia;Ill-defined disorder;Immune system disorder;Infection;Infertility;Infertility male;Injection site reaction;Insomnia;Intestinal obstruction;Iritis;Jaundice;Jaundice cholestatic;Lactic acidosis;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Lichen planus;Liver disorder;Liver injury;Loss of libido;Lymphadenopathy;Lymphocytosis;Malaise;Malnutrition;Mental disorder;Mental status changes;Metabolic acidosis;Mucosal inflammation;Muscle relaxant therapy;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myoclonus;Myopathy;Nausea;Nephritis;Nephritis interstitial;Nervous system disorder;Neuritis;Neuropathy;Neuropathy peripheral;Neutropenia;Nocturnal emission;Numbness;Oedema;Oliguria;Onycholysis;Optic neuritis;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pancreatitis haemorrhagic;Pancytopenia;Paraesthesia;Paralysis;Pericarditis;Peripheral vascular disorder;Peroneal nerve palsy;Pharyngitis;Proctitis;Pruritus;Pulmonary embolism;Purpura;Rash;Rash maculo-papular;Renal failure acute;Renal impairment;Respiratory failure;Reticulocytosis;Retinitis;Rhinitis;Salivary gland enlargement;Salivary gland swelling;Sensory loss;Sepsis;Septic shock;Skin disorder;Skin exfoliation;Skin oedema;Skin scaly;Somnolence;Splenomegaly;Status epilepticus;Steatorrhoea;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Sweating;Sweating increased;Swelling;Swelling face;Throat sore;Thrombocytopenia;Thrombophlebitis;Tingling sensation;Tinnitus;Tongue disorder;Tongue oedema;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Tumour lysis syndrome;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Uremia;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular purpura;Vasculitis;Vasculitis gastrointestinal;Vasculitis necrotising;Vasodilation;Vasodilation procedure;Ventricular fibrillation;Vertigo;Visual impairment;Vomiting;Water intoxication;Weight increased;Wheezing,small molecule,approved,"1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one; 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one; 1H-Pyrazolo(3,4-d)pyrimidin-4-ol; 4-HPP; 4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine; 4-Hydroxy-3,4-pyrazolopyrimidine; 4-Hydroxypyrazolo(3,4-d)pyrimidine; 4-Hydroxypyrazolopyrimidine; 4-Hydroxypyrazolyl(3,4-d)pyrimidine; 4'-Hydroxypyrazolol(3,4-d)pyrimidine; 4H-Pyrazolo(3,4-d)pyrimidin-4-one; Allopurinol; Allopurinolum; Alopurinol; XDHA; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase; XDHA; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; hOCT2; OCT2; Organic cation transporter 2",Xanthine dehydrogenase/oxidase, M04AA51;M04AA01
alosetron,Abdominal pain;Diarrhoea;Diarrhoea predominant irritable bowel syndrome;Disability;Discomfort;Faecal incontinence;Functional gastrointestinal disorder;Gastrointestinal pain;Irritable bowel syndrome,Abdominal discomfort;Abdominal distension;Abdominal pain upper;Abnormal dreams;Acne;Alanine aminotransferase increased;Allergic skin reaction;Alopecia;Anxiety;Arrhythmia;Asthenia;Balance disorder;Bilirubin abnormal;Bladder pain;Blood bilirubin abnormal;Blood pressure increased;Bone pain;Burning sensation;Cholecystitis;Cognitive disorder;Colitis;Colitis ischaemic;Colitis ulcerative;Confusional state;Constipation;Contusion;Cough;Cramp muscle;Cystitis;Cystitis noninfective;Depression;Depressive disorder;Dermatitis;Dermatitis atopic;Discomfort;Diuresis;Diverticulitis;Drug interaction;Dry mouth;Dysequilibrium;Dyspeptic signs and symptoms;Dysthymic disorder;Eczema;Extrasystoles;Faecal occult blood positive;Fatigue;Feeling abnormal;Feeling cold;Feeling hot and cold;Feeling of body temperature change;Flatulence;Folliculitis;Fungal infection;Gastric pH decreased;Gastritis;Gastroduodenitis;Gastroenteritis;Gastrointestinal discomfort;Gastrointestinal infection;Gastrointestinal obstruction;Gastrointestinal signs and symptoms;Haematoma;Haemoglobin;Haemorrhage;Haemorrhage urinary tract;Haemorrhoidal haemorrhage;Haemorrhoids;Headache;Hepatitis;Hyperchlorhydria;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoglycaemia;Hypopituitarism;Ileus;Ill-defined disorder;Infection;Injury;Intestinal ischaemia;Intussusception;Jaundice;Laryngitis;Malaise;Menstrual disorder;Mesenteric ischemia;Muscle rigidity;Muscle spasms;Muscle stiffness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Nail disorder;Nasopharyngitis;Nausea;Occult blood positive;Pain;Photophobia;Pollakiuria;Polyuria;Proctitis;Proctocolitis;Rash;Regurgitation;Reproductive system haemorrhages;Respiration abnormal;Respiratory disorder;Respiratory tract infection;Rhinitis allergic;Sinusitis;Skin disorder;Skin infection;Sleep disorder;Sweating;Tachyarrhythmia;Tenderness;Trauma;Tremor;Ulcer;Upper respiratory tract infection;Urinary tract infection;Urine output increased;Urticaria;Viral diarrhoea;Vomiting,small molecule,approved; withdrawn,"2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; Alosetron; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J",5-hydroxytryptamine receptor 3A,A03AE01
alprazolam,Abdominal discomfort;Abdominal distress;Ache;Aggression;Agitation;Agoraphobia;Anxiety;Anxiety depression;Anxiety disorder;Anxiety neurosis;Anxiety state;Apprehension;Asthenia;Borderline personality disorder;Cerebration impaired;Chest pain;Chills;Choking;Choking sensation;Completed suicide;Decreased interest;Depersonalisation;Depressed mood;Depression;Depressive symptom;Derealisation;Diarrhoea;Disability;Discomfort;Disturbance in attention;Dizziness;Dry mouth;Dyspnoea;Dysthymic disorder;Exaggerated startle response;Fatigability;Fatigue;Fear of death;Flushing;Generalised anxiety disorder;Heart pounding;Hot flush;Hyperhidrosis;Hyperkinesia;Hyperthyroidism;Hypoaesthesia;Insomnia;Intoxication;Irritability;Lightheadedness;Loss of consciousness;Malaise;Mass;Menopausal symptoms;Mental disability;Mental disorder;Muscle twitching;Nausea;Nervousness;Neurotic depression;Numbness;Pain;Palpitations;Panic attack;Panic disorder;Paraesthesia;Phobia;Phobic avoidance;Poisoning;Pollakiuria;Post-traumatic stress disorder;Reactive depression;Sensory loss;Shaky feelings;Shock;Sickness;Social phobia;Substance abuse;Suicide;Sweating;Syncope;Tachycardia;Tenderness;Tension;Tingling sensation;Trembling;Tremor;Violent,Abdominal discomfort;Abdominal distress;Abdominal pain;Abnormal dreams;Abnormal involuntary movements;Affect lability;Aggression;Agitation;Akathisia;Altered state of consciousness;Amnesia;Amnesia transient;Anger;Angioedema;Angiopathy;Anorexia;Anxiety;Apathy;Arthralgia;Asthenia;Ataxia;Back pain;Balance disorder;Blood bilirubin increased;Body temperature increased;Bradyphrenia;Breast disorder;Cardiac disorder;Cerebration impaired;Chest discomfort;Chest pain;Chest tightness;Chills;Choking sensation;Clumsiness;Cognitive disorder;Cold sweat;Completed suicide;Confusional state;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cramp muscle;Decreased appetite;Depersonalisation;Depressed level of consciousness;Depressed mood;Depression;Derealisation;Dermatitis;Diarrhoea;Diplopia;Discomfort;Disinhibition;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug withdrawal convulsions;Dry mouth;Dysarthria;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Energy increased;Epistaxis;Erythema multiforme;Euphoric mood;Eye disorder;Fatigue;Fear;Feeling abnormal;Feeling drunk;Feeling hot;Feeling jittery;Feeling of relaxation;Flat affect;Galactorrhoea;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Gynaecomastia;Hallucination;Hangover;Headache;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Homicidal ideation;Hostility;Hot flush;Hyperaesthesia;Hyperhidrosis;Hyperprolactinaemia;Hypersensitivity;Hypersomnia;Hyperventilation;Hypoaesthesia;Hypomania;Hypotension;Hypotonia;Ill-defined disorder;Incontinence;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Intraocular pressure increased;Irritability;Jaundice;Laryngeal pain;Lethargy;Libido decreased;Libido increased;Lightheadedness;Liver function test abnormal;Logorrhoea;Loss of consciousness;Loss of control of legs;Major depression;Malaise;Malnutrition;Mania;Mediastinal disorder;Memory impairment;Menopausal symptoms;Menstrual disorder;Menstruation irregular;Mental disability;Mental disorder;Mental retardation;Mood swings;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle spasticity;Muscle stiffness;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Mydriasis;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Nightmare;Oedema;Oedema peripheral;Osteoarthritis;Pain in extremity;Palpitations;Panic disorder;Panic reaction;Paraesthesia;Pharyngolaryngeal pain;Photophobia;Photosensitivity reaction;Pollakiuria;Premenstrual syndrome;Pruritus;Psychomotor retardation;Rash;Rhinitis allergic;Rhinorrhoea;Rigors;Road traffic accident;Salivary hypersecretion;Salivation;Sexual dysfunction;Shock;Sinus tachycardia;Skin disorder;Sleep apnoea syndrome;Sleep disorder;Sleep disturbance;Sleep talking;Sluggishness;Slurred speech;Somnolence;Stevens-Johnson syndrome;Sticky skin;Strangury;Stupor;Substance abuse;Suicidal ideation;Suicide;Sweating;Sweating increased;Syncope;Tachycardia;Talkativeness;Tension;Thirst;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urticaria;Vertigo;Vision blurred;Vomiting;Weight decreased;Weight increased;Withdrawal seizures;Withdrawal syndrome,small molecule,approved; illicit; investigational,"8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; Alprazolam; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2",GABA(A) Receptor; Translocator protein; GABA(A) Receptor Benzodiazepine Binding Site,N05BA12
amantadine,Carbon monoxide poisoning;Cerebral arteriosclerosis;Chronic respiratory disease;Cor pulmonale;Diabetes mellitus;Disease progression;Immunocompromised;Immunodeficiency;Infection;Influenza;Influenza A virus infection;Intoxication;Malaise;Neuromyopathy;Parkinson's disease;Parkinsonism;Parkinsonism post encephalitic;Pneumonia;Poisoning;Renal failure;Renal impairment;Respiratory tract infection;Secondary parkinsonism;Sickness;Viral infection,Acute respiratory failure;Aggression;Agitation;Agranulocytosis;Alopecia;Amnesia;Anaphylactic shock;Angiopathy;Anorexia;Anxiety;Arrhythmia;Asthenia;Ataxia;Blood and lymphatic system disorders;Body temperature decreased;Body temperature increased;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cerebration impaired;Coma;Completed suicide;Confusional state;Constipation;Convulsion;Corneal oedema;Corneal opacity;Decreased appetite;Delirium;Delusion;Depressed level of consciousness;Dermatitis;Diarrhoea;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry mouth;Dysarthria;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Eczema;Elevated mood;Euphoric mood;Excitement;Eye disorder;Fatigue;Feeling abnormal;Gait disturbance;Gastrointestinal disorder;Hallucination;Headache;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypersexuality;Hypertension;Hypertonia;Hypokinesia;Hypotension;Hypothermia;Insomnia;Irritability;Keratitis;Lethargy;Leukocytosis;Leukopenia;Libido decreased;Libido increased;Lightheadedness;Livedo reticularis;Liver function test abnormal;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Mental disability;Mental disorder;Muscle contractions involuntary;Mydriasis;Nasal dryness;Nausea;Nerve paralysis;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Neutropenia;Nightmare;Oculogyric crisis;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Palpitations;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Pathological gambling;Photosensitivity;Photosensitivity reaction;Pruritus;Psychotic disorder;Pulmonary oedema;Punctate keratitis;Rash;Renal failure acute;Skin disorder;Slurred speech;Somnolence;Stupor;Subepithelial opacities;Sudden visual loss;Suicidal ideation;Suicide;Sweating increased;Tachycardia;Tachypnoea;Tension;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting,small molecule,approved,1-adamantanamine; 1-adamantylamine; 1-aminoadamantane; Amantadina; Amantadine; Amantadinum; Amantidine; Aminoadamantane; Proton channel protein M2; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; Dopamine D2 receptor; NACHRA7; NACRA4; NACHRA3; 4.1.1.28; AADC; DDC; DOPA decarboxylase; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1,"Matrix protein 2; Glutamate receptor ionotropic, NMDA 3A; D(2) dopamine receptor; Neuronal acetylcholine receptor subunit alpha-7; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit alpha-3",N04BB01
amcinonide,Dermatitis atopic;Neurodermatitis;Psoriasis;Skin disorder,Acneiform eruption;Allergic contact dermatitis;Atrophy;Cataract subcapsular;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis infected;Dermatitis perioral;Folliculitis;Hypertrichosis;Infection;Leukoderma;Miliaria;Pain;Pruritus;Pustule;Pyoderma;Rash pustular;Secondary adrenocortical insufficiency;Secondary infection;Skin atrophy;Skin striae;Stinging;Telangiectasia;Tenderness,small molecule,approved,"Amcinónida; Amcinonide; Amcinonidum; Triamcinolonacetatcyclopentanonid; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; GR; GRL; Nuclear receptor subfamily 3 group C member 1; Annexin I; Annexin-1; ANX1; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; LPC1; p35; Phospholipase A2 inhibitory protein; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3",Steroid hormone receptor ERR1; Steroid hormone receptor ERR2; Estrogen-related receptor gamma; Glucocorticoid receptor; Annexin A1,D07AC11
amifostine,Body temperature increased;Dry mouth;Infection;Infection induced;Neoplasm malignant;Nephropathy toxic;Nephrotoxicity;Neutropenia;Non-small cell lung cancer;Ovarian cancer,Acute coronary syndrome;Anaphylactic shock;Anaphylactoid reaction;Apnoea;Arrhythmia;Atrial fibrillation;Blood calcium decreased;Blood pressure diastolic decreased;Body temperature increased;Bradycardia;Cardiac arrest;Cardiac flutter;Chest discomfort;Chest pain;Chest tightness;Chills;Coldness;Convulsion;Dermatitis;Dermatitis exfoliative;Discomfort;Dizziness;Dyspnoea;Erythema multiforme;Extrasystoles;Feeling abnormal;Feeling cold;Feeling hot;Flushing;Hiccups;Hypersensitivity;Hypertension;Hypocalcaemia;Hypoparathyroidism;Hypotension;Ill-defined disorder;Laryngeal oedema;Loss of consciousness;Malaise;Myocardial infarction;Myocardial ischaemia;Nausea;Pruritus;Rash;Renal failure;Respiratory arrest;Rigors;Sensation of warmth;Serum calcium decreased;Shock;Sneezing;Somnolence;Stevens-Johnson syndrome;Supraventricular tachycardia;Syncope;Tachycardia;Toxic epidermal necrolysis;Toxic skin eruption;Urticaria;Vomiting,small molecule,approved; investigational,"Amifostina; Amifostine; Amifostine anhydrous; Amifostinum; Aminopropylaminoethyl thiophosphate; Ethiofos; 3.1.3.1; Alkaline phosphatase Nagao isozyme; Alkaline phosphatase, placental-like; ALP-1; ALPPL; ALPPL2; GCAP; Germ cell alkaline phosphatase; Placental alkaline phosphatase-like; PLAP-like; 3.1.3.1; Alkaline phosphatase liver/bone/kidney isozyme; AP-TNAP; Phosphoamidase; Phosphocreatine phosphatase; TNS-ALP; TNSALP","Alkaline phosphatase, germ cell type",V03AF05
amikacin,Abdominal infection;Bacterial sepsis;Infection;Meningitis;Peritonitis;Recurrent urinary tract infection;Renal failure;Renal impairment;Sepsis neonatal;Staphylococcal infection;Urinary tract infection,Albuminuria;Anaemia;Apnoea;Arthralgia;Azotaemia;Blindness;Body temperature increased;Deafness;Dermatitis;Drug fever;Eosinophilia;Headache;Hearing impaired;High frequency deafness;Hypomagnesaemia;Hypotension;Infarction;Musculoskeletal discomfort;Nausea;Nephropathy toxic;Nephrotoxicity;Neurotoxicity;Oliguria;Ototoxicity;Paraesthesia;Paralysis;Rash;Renal failure acute;Tremor;Unspecified visual loss;Vomiting,small molecule,approved; investigational; vet_approved,"1-N-(L(−)-γ-amino-α-hydroxybutyryl)kanamycin A; Amikacin; Amikacina; Amikacine; Amikacinum; D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-N(SUP 1)-(4-AMINO-2-HYDROXY-1-OXOBUTYL)-2-DEOXY-, (S)-; encochleated amikacin; O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6))-N(SUP 3)-(4-AMINO-L-2-HYDROXYBUTYRYL)-2-DEOXY-L-STREPTAMINE; strA",30S ribosomal protein S12, D06AX12; J01GB06; J01RA06;D06AX12;S01AA21
aminoglutethimide,Adrenal adenoma;Adrenal carcinoma;Adrenal gland cancer;Cushing's syndrome;Hyperadrenocorticism;Hyperplasia adrenal;Neoplasm;Neoplasm malignant;Pituitary-dependent Cushing's syndrome,Adrenal insufficiency;Agranulocytosis;Alveolitis allergic;Anaemia;Anorexia;Body temperature increased;Decreased appetite;Dermatitis;Dizziness;Drowsiness;Goitre;Haematocrit decreased;Haemolytic anaemia;Headache;Hepatotoxicity;Hirsutism;Hypersensitivity;Hypotension;Hypothyroidism;Leukopenia;Musculoskeletal discomfort;Myalgia;Nausea;Neutropenia;Pancytopenia;Precocious puberty;Pruritus;Rash;Somnolence;Tachycardia;Urticaria;Vascular resistance;Vascular resistance systemic;Virilism;Vomiting,small molecule,approved; investigational,"2-(p-Aminophenyl)-2-ethylglutarimide; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine; Aminoglutethimid; Aminoglutéthimide; Aminoglutethimide; Aminoglutethimidum; Aminoglutetimida; Aminoglutetimide; DL-Aminoglutethimide; p-Aminoglutethimide; α-(p-Aminophenyl)-α-ethylglutarimide; 1.14.15.6; Cholesterol desmolase; CYP11A; CYPXIA1; Cytochrome P450 11A1; Cytochrome P450(scc); 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase","Cholesterol side-chain cleavage enzyme, mitochondrial; Aromatase",L02BG01
theophylline,Asthma;Asthma chronic;Bronchial hyperreactivity;Bronchitis chronic;Bronchospasm;Chronic obstructive pulmonary disease;Emphysema;Hyperthyroidism;Lung disorder,Abdominal pain;Abdominal pain upper;Acute overdose;Agitation;Albuminuria;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Anorexia;Anxiety;Arrhythmia;Atrial fibrillation;Atrial tachycardia;Blood uric acid increased;Body temperature increased;Brain injury;Cardiac flutter;Cardio-respiratory arrest;Coma;Convulsion;Convulsions generalised;Decreased appetite;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Disorientation;Diuresis;Dizziness;Epigastric discomfort;Epigastric pain;Extrasystoles;Extravasation;Fluid overload;Flushing;Gastric irritation;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematemesis;Haematuria;Haemodynamic instability;Headache;Hypercalcaemia;Hyperglycaemia;Hypersensitivity;Hyperuricaemia;Hypokalaemia;Hypotension;Hypoxic-ischaemic encephalopathy;Inappropriate antidiuretic hormone secretion;Infection;Insomnia;Intoxication;Irritability;Multifocal atrial tachycardia;Nausea;Nervous system disorder;Nervousness;Overdose;Palpitations;Peptic ulcer;Persistent vomiting;Phlebitis;Poisoning;Polyuria;Pruritus;Pulmonary function test decreased;Rash;Respiratory arrest;Respiratory depression;Rhabdomyolysis;Shock;Sinus tachycardia;Status epilepticus;Supraventricular tachycardia;Tachycardia;Tachypnoea;Tension;Tremor;Tremor muscle;Urinary retention;Urticaria;Venous thrombosis;Ventricular arrhythmia;Ventricular extrasystoles;Vomiting,small molecule,approved,"1,3-dimethyl-7H-purine-2,6-dione; 1,3-dimethylxanthine; Teofilina; Theophyllin; Theophylline anhydrous; Theophylline, anhydrous; 3.1.3.35; 3.1.3.5; 3.1.3.89; 3.1.3.91; 3.1.3.99; 5'-deoxynucleotidase; 5'-NT; Ecto-5'-nucleotidase; IMP-specific 5'-nucleotidase; NT5; NTE; Thymidylate 5'-phosphatase; ADORA2; 3.1.4.53; cAMP-specific phosphodiesterase 4B; DPDE4; PDE32; 3.1.4.35; CGB-PDE; cGMP-binding cGMP-specific phosphodiesterase; PDE5; 3.1.4.53; cAMP-specific phosphodiesterase 4A; DPDE2; PDE46; 3.1.4.17; cGI-PDE; CGI-PDE A; cGMP-inhibited cAMP phosphodiesterase; Cyclic GMP-inhibited phosphodiesterase A; 3.5.1.98; HD2; Protein deacylase HDAC2; Chromobindin 17; Copine I; CPN1; 3.4.23.-; H13; hIMP1; IMP-1; IMP1; IMPAS-1; Intramembrane protease 1; Presenilin-like protein 3; PSL3; Signal peptide peptidase; SPP; Nodal modulator 1; PM5; pM5 protein; 2.4.2.30; ADP-ribosyltransferase diphtheria toxin-like 1; ADPRT; ADPRT 1; ARTD1; DNA ADP-ribosyltransferase PARP1; NAD(+) ADP-ribosyltransferase 1; PARP-1; Poly[ADP-ribose] synthase 1; PPOL; Protein poly-ADP-ribosyltransferase PARP1; Resistant to inhibitor of cholinesterase 3; 6.3.2.-; HOTTL; Tubulin--tyrosine ligase-like protein 3; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 3.5.4.4; ADA1; Adenosine aminohydrolase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2","Adenosine receptor A1; 5'-nucleotidase; Adenosine receptor A2a; Adenosine receptor A2b; 3',5'-cyclic-AMP phosphodiesterase 4B; cGMP-specific 3',5'-cyclic phosphodiesterase; 3',5'-cyclic-AMP phosphodiesterase 4A; cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A; Histone deacetylase 2; Copine-1; Minor histocompatibility antigen H13; BOS complex subunit NOMO1; Poly [ADP-ribose] polymerase 1; Protein RIC-3; Tubulin monoglycylase TTLL3", R03DA04; R03DA20; R03DA74; R03DB04;R03DA04;R03DA54
amiodarone,Agitation;Arrhythmia;Asthma;Atrial fibrillation;Atrial fibrillation and flutter;Drug interaction;Hyperkinesia;Pulmonary fibrosis;Recurrent ventricular fibrillation;Respiratory failure;Sinoatrial node dysfunction;Sinus arrhythmia;Sudden death;Tachyarrhythmia;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Wolff-Parkinson-White syndrome,Abdominal pain;Abnormal dreams;Abnormal involuntary movements;Acquired keratoderma;Acute interstitial pneumonitis;Acute respiratory distress syndrome;Agitation;Agranulocytosis;Akinesia;Alanine aminotransferase increased;Alopecia;Alveolitis;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Apnoea;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrial fibrillation;Atrioventricular block;Atrioventricular block second degree;Back pain;Bad taste;Benign intracranial hypertension;Blindness;Blood thyroid stimulating hormone increased;Body temperature increased;Bone marrow depression;Bone marrow granuloma;Bradycardia;Bradykinesia;Bronchiolitis obliterans with organizing pneumonia;Bronchospasm;Bundle branch block left;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Cardiogenic shock;Cellulitis;Cerebellar ataxia;Chronic anxiety;Chronic liver disease;Cognitive disorder;Confusional state;Constipation;Coordination abnormal;Corneal degeneration;Corneal deposits;Cough;Decreased appetite;Delirium;Demyelinating polyneuropathy;Dermatitis;Dermatitis exfoliative;Device capturing issue;Diarrhoea;Discomfort;Disorientation;Distress;Disturbance in sexual arousal;Dizziness;Drug eruption;Drug interaction;Dry eye;Dry mouth;Dysfunction thyroid;Dysgeusia;Dyskinesia;Dyspepsia;Dyspnoea;Ecchymosis;Eczema;Electrocardiogram QT prolonged;Emotional distress;Eosinophilia;Eosinophilic pneumonia;Epididymitis;Epididymo-orchitis;Erectile dysfunction;Eruption;Erythema;Erythema multiforme;Extrapyramidal disorder;Extrapyramidal symptoms;Extravasation;Fatigue;Feeling abnormal;Fibrosis;Flushing;Foetor hepaticus;Foreign body sensation in eyes;Gait disturbance;Gastrointestinal disorder;Gastrointestinal pain;Goitre;Granuloma;Granulomatous liver disease;Gritty feeling in eyes;Haemolytic anaemia;Haemoptysis;Hallucination;Hamman-Rich syndrome;Headache;Hepatic failure;Hepatic function abnormal;Hepatic granuloma;Hepatitis;Hepatitis alcoholic;Hepatitis cholestatic;Hepatocellular injury;Hepatomegaly;Hot flush;Hypercalcaemia;Hyperhidrosis;Hyperkeratosis;Hypersensitivity;Hyperthyroidism;Hypokinesia;Hypotension;Hypothyroidism;Idiopathic pulmonary fibrosis;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Incessant ventricular tachycardia;Increased tendency to bruise;Induration;Infection;Inflammation;Injection site reaction;Insomnia;Interstitial lung disease;Interstitial pneumonia;Jaundice;Keratopathy;Kidney function abnormal;Lenticular opacities;Libido decreased;Liver disorder;Liver function test abnormal;Liver injury;Lung disorder;Lung infiltration;Macular degeneration;Malaise;Menopausal symptoms;Movements involuntary;Multifocal ventricular tachycardia;Muscular weakness;Myocardial ischaemia;Myopathy;Nausea;Necrosis;Neoplasm malignant;Neuromyopathy;Neuropathy;Neuropathy peripheral;Neutropenia;Nightmare;Nodal arrhythmia;Obliterative bronchiolitis;Ocular discomfort;Oedema;Onycholysis;Optic nerve disorder;Optic neuritis;Orchitis;Organising pneumonia;Pain;Pancreatitis;Pancytopenia;Papilloedema;Paraesthesia;Paroxysmal ventricular tachycardia;Peripheral sensorimotor neuropathy;Phlebitis;Photophobia;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Pleural effusion;Pleurisy;Pneumonia;Polyserositis;Pruritus;Pulmonary alveolar haemorrhage;Pulmonary haemorrhage;Pulmonary oedema;Pulmonary toxicity;Pulseless electrical activity;Pustular psoriasis;Rash;Reaction gastrointestinal;Renal failure;Renal failure acute;Renal failure chronic;Renal impairment;Rhabdomyolysis;Salivary hypersecretion;Salivation;Scotoma;Shock;Sinoatrial block;Sinus arrest;Sinus bradycardia;Skin cancer;Skin discolouration;Skin disorder;Skin exfoliation;Skin necrosis;Sleep disorder;Sleep disturbance;Solar dermatitis;Spontaneous bruising;Stevens-Johnson syndrome;Sweating;Tachycardia;Thrombocytopenia;Thrombophlebitis;Thyroid disorder;Thyroid function abnormal;Thyroid function test abnormal;Thyroid neoplasm;Thyroid nodule;Thyrotropin high;Tinnitus;Torsade de pointes;Toxic epidermal necrolysis;Traumatic liver injury;Tremor;Urticaria;Vasculitis;Venous thrombosis;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vivid dreams;Vomiting;Weight decreased;Weight increased;Wheezing,small molecule,approved; investigational,"2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran; Amiodarona; Amiodarone; Amiodaronum; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; Eag-related protein 2; ERG-2; ERG2; Ether-a-go-go-related gene potassium channel 2; Ether-a-go-go-related protein 2; hERG-2; hERG2; Potassium voltage-gated channel subfamily H member 6; Voltage-gated potassium channel subunit Kv11.2; Eag-related protein 3; ERG-3; ERG3; Ether-a-go-go-related gene potassium channel 3; Ether-a-go-go-related protein 3; hERG-3; Potassium voltage-gated channel subfamily H member 7; Voltage-gated potassium channel subunit Kv11.3; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; Ca(v)3.3; KIAA1120; Voltage-gated calcium channel subunit alpha Cav3.3; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; c-erbA-1; c-erbA-alpha; EAR-7; EAR7; ERBA1; NR1A1; Nuclear receptor subfamily 1 group A member 1; THRA1; THRA2; V-erbA-related protein 7; c-erbA-2; c-erbA-beta; ERBA2; NR1A2; Nuclear receptor subfamily 1 group A member 2; THR1; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; NR1C1; Nuclear receptor subfamily 1 group C member 1; PPAR; PPAR-alpha; PERC; PGC-1-beta; PGC-1-related estrogen receptor alpha coactivator; PGC1; PGC1B; PPAR-gamma coactivator 1-beta; PPARGC-1-beta; PPARGC1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.-; Albendazole monooxygenase (hydroxylating); Albendazole monooxygenase (sulfoxide-forming); Arachidonic acid epoxygenase; CYPIIJ2; Hydroperoxy icosatetraenoate isomerase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; hOCT2; OCT2; Organic cation transporter 2",HERG human cardiac K+ channel; Beta adrenergic receptor; Voltage-dependent T-type calcium channel subunit alpha-1I; Voltage gated L-type calcium channel; Thyroid hormone receptor; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma coactivator 1-beta,C01BD01
amisulpride,Blunted affect;Chronic schizophrenia;Delusion;Hallucination;Schizophrenia;Social avoidant behaviour;Social withdrawal,Abdominal pain;Acute dystonia;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Akathisia;Amenorrhoea;Angioedema;Angiopathy;Anxiety;Asthenia;Blood and lymphatic system disorders;Bradycardia;Breast pain;Cardiac arrest;Cardiac disorder;Cardiovascular disorder;Central nervous system disorder;Constipation;Convulsion;Deep vein thrombosis;Depression;Diarrhoea;Dizziness;Drug withdrawal syndrome;Dry mouth;Dyskinesia;Dyspepsia;Dystonia;Embolism venous;Endocrine disorder;Erectile dysfunction;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Galactorrhoea;Gastrointestinal disorder;Gastrointestinal pain;Gynaecomastia;Headache;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypokinesia;Hypotension;Immune system disorder;Insomnia;Leukopenia;Malnutrition;Menstrual disorder;Mental disorder;Movements involuntary;Muscle rigidity;Muscle spasms;Nausea;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Neuropathy peripheral;Neutropenia;Oculogyric crisis;Orthostatic hypotension;Pregnancy;Pruritus;Pulmonary embolism;Salivary hypersecretion;Skin disorder;Somnolence;Sudden death;Suicide attempt;Sweating increased;Tardive dyskinesia;Tension;Torsade de pointes;Tremor;Trismus;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vaginal infection;Vaginal inflammation;Venous thromboembolism;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide; Aminosultopride; Amisulprida; Amisulpride; Amisulpridum; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; Dopamine D2 receptor; Dopamine D3 receptor; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; K-OR-1; KOR-1; OPRK; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; hOCT1; OCT1; Organic cation transporter 1,5-hydroxytryptamine receptor 7; 5-hydroxytryptamine receptor 2A; D(2) dopamine receptor; D(3) dopamine receptor; Mu-type opioid receptor; Delta-type opioid receptor; Kappa-type opioid receptor,N05AL05
amitriptyline,Depressive symptom;Endogenous depression;Enuresis;Major depression;Nocturnal enuresis,Abnormal involuntary movements;Accommodation disorder;Acute coronary syndrome;Ageusia;Agitation;Agranulocytosis;Alopecia;Anorexia;Antinuclear antibody positive;Anxiety;Arrhythmia;Arthritis;Asthenia;Ataxia;Atrioventricular block;Black hairy tongue;Block heart;Body temperature increased;Bone marrow depression;Breast enlargement;Bundle branch block;Cardiomyopathy;Cerebration impaired;Cerebrovascular accident;Coma;Conduction disorder;Confusional state;Constipation;Convulsion;Coordination abnormal;Decreased appetite;Delusion;Dermatitis;Diarrhoea;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug withdrawal syndrome;Dry mouth;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Electrocardiogram QRS complex;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Eosinophilia;Epigastric distress;Erectile dysfunction;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Feeling abnormal;Galactorrhoea;Gynaecomastia;Hallucination;Headache;Hepatic failure;Hepatitis;Hyperhidrosis;Hyperpyrexia;Hypertension;Hypoaesthesia;Hypomania;Hypotension;Ileus paralytic;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Insomnia;Intraocular pressure increased;Irritability;Jaundice;Leukopenia;Libido decreased;Loss of consciousness;Lupus-like syndrome;Malaise;Mania;Mental disability;Mental status changes;Muscle rigidity;Mydriasis;Myocardial infarction;Nausea;Neuroleptic malignant syndrome;Neuropathy peripheral;Nightmare;Numbness;Oedema;Orthostatic hypotension;Osteoarthritis;Palpitations;Pancytopenia;Paraesthesia;Paresthesia of limbs;Parotid gland enlargement;Parotid swelling;Pollakiuria;Pruritus;Purpura;QRS complex;Rash;Sensory loss;Serotonin syndrome;Shock;Sleep disorder;Sleep disturbance;Somnolence;Stomatitis;Sweating increased;Syncope;Tachycardia;Tardive dyskinesia;Taste peculiar;Testicular swelling;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue discolouration;Torsade de pointes;Tremor;Urinary retention;Urticaria;Vascular purpura;Ventricular fibrillation;Ventricular tachycardia;Vision blurred;Vomiting;Weight increased;Withdrawal symptom,small molecule,approved,"10,11-dihydro-5-(γ-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Δ5,γ-propylamine; 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(γ-dimethylaminopropylidene)-5H-dibenzo[a,d][1,4]cycloheptadiene; Amitriptilina; Amitriptylin; Amitriptyline; Amitriptylinum; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; D-OR-1; DOR-1; OPRD; K-OR-1; KOR-1; OPRK; 2.7.10.1; gp140trk; MTC; Neurotrophic tyrosine kinase receptor type 1; p140-TrkA; TRK; Trk-A; TRK1-transforming tyrosine kinase protein; TRKA; Tropomyosin-related kinase A; Tyrosine kinase receptor; Tyrosine kinase receptor A; 2.7.10.1; GP145-TrkB; Neurotrophic tyrosine kinase receptor type 2; Trk-B; TRKB; TrkB tyrosine kinase; Tropomyosin-related kinase B; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; H1-R; H1R; HH1R; KQT-like 2; Neuroblastoma-specific potassium channel subunit alpha KvLQT2; Voltage-gated potassium channel subunit Kv7.2; Voltage-gated K(+) channel HuKI; Voltage-gated potassium channel HBK1; Voltage-gated potassium channel subunit Kv1.1; Gastric receptor I; H2R; HH2R; AXOR35; G-protein coupled receptor 105; GPCR105; GPRv53; H4R; HH4R; Pfi-013; SP9144; Aging-associated gene 8 protein; hSigmaR1; OPRS1; SIG-1R; Sigma 1-type opioid receptor; Sigma1-receptor; Sigma1R; SR-BP; SR31747-binding protein; SRBP; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-6; 5-HT6; Serotonin receptor 6; KQT-like 3; Potassium channel subunit alpha KvLQT3; Voltage-gated potassium channel subunit Kv7.3; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-hydroxytryptamine receptor 1C; 5ht1c; Htr1c; Serotonin receptor 2C; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; Eag-related protein 2; ERG-2; ERG2; Ether-a-go-go-related gene potassium channel 2; Ether-a-go-go-related protein 2; hERG-2; hERG2; Potassium voltage-gated channel subfamily H member 6; Voltage-gated potassium channel subunit Kv11.2; Eag-related protein 3; ERG-3; ERG3; Ether-a-go-go-related gene potassium channel 3; Ether-a-go-go-related protein 3; hERG-3; Potassium voltage-gated channel subfamily H member 7; Voltage-gated potassium channel subunit Kv11.3; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 2.4.1.17; UDPGT 2B10; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 13-hydroperoxyoctadecadienoate peroxidase; 2.5.1.18; Androst-5-ene-3,17-dione isomerase; GST class-alpha member 1; GST HA subunit 1; GST-epsilon; GSTA1-1; GTH1; 2.5.1.18; GST class-alpha member 2; GST HA subunit 2; GST-gamma; GST2; GSTA2-2; GTH2; 2.5.1.18; GST class-mu 1; GST HB subunit 4; GST1; GSTM1-1; GSTM1a-1a; GSTM1b-1b; GTH4; 2.5.1.18; GST class-mu 2; GST4; GSTM2-2; 2.5.1.18; GST class-mu 3; GST5; GSTM3-3; hGSTM3-3; 2.5.1.18; GST class-mu 4; GST-Mu2; GSTM4-4; Leukotriene C4 synthase GSTM4; 2.5.1.18; GST class-mu 5; GSTM5-5; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 2.5.1.18; Glutathione transferase T1-1; GST class-theta-1; 2.5.1.18; GST class-theta-2; 2.5.1.18; Glutathione S-transferase theta-2; GST class-theta-2; GSTT2; 5.3.99.2; Glutathione S-transferase; Glutathione-dependent PGD synthase; Glutathione-requiring prostaglandin D synthase; GST class-sigma; GSTS; H-PGDS; PGDS; Prostaglandin-H2 D-isomerase; PTGDS2; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 1A; Delta-type opioid receptor; Kappa-type opioid receptor; High affinity nerve growth factor receptor; BDNF/NT-3 growth factors receptor; Alpha-1A adrenergic receptor; Alpha-1D adrenergic receptor; Alpha-2A adrenergic receptor; Histamine H1 receptor; Potassium voltage-gated channel subfamily KQT member 2; Potassium voltage-gated channel subfamily A member 1; Histamine H2 receptor; Histamine H4 receptor; Sigma non-opioid intracellular receptor 1; 5-hydroxytryptamine receptor 2C; Alpha-1B adrenergic receptor; 5-hydroxytryptamine receptor 7; 5-hydroxytryptamine receptor 1D; Mu-type opioid receptor; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 6; Potassium voltage-gated channel subfamily KQT member 3; 5-hydroxytryptamine receptor 2C; Muscarinic acetylcholine receptor; HERG human cardiac K+ channel, N06CA01;N06AA09
amlexanox,Aphthous stomatitis,Aphthous stomatitis;Gastrointestinal disorder;Headache;Liver function test abnormal;Mouth ulceration;Nausea;Nervous system disorder;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Paraesthesia;Stomatitis;Throat sore,small molecule,approved; investigational; withdrawn,"2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; Amlexanox; Amlexanoxo; Amlexanoxum; Amoxanox; 3.6.4.10; Heat shock 86 kDa; Heat shock protein family C member 1; HSP 86; HSP86; HSP90A; HSPC1; HSPCA; LAP-2; Lipopolysaccharide-associated protein 2; LPS-associated protein 2; Renal carcinoma antigen NY-REN-38; CAAF1; CAGC; Calcium-binding protein in amniotic fluid 1; Calgranulin-C; CGRP; EN-RAGE; Extracellular newly identified RAGE-binding protein; Migration inhibitory factor-related protein 6; MRP-6; Neutrophil S100 protein; p6; S100 calcium-binding protein A12; S100 calcium-binding protein A13; Hematopoietic growth factor; IL-3; Mast cell growth factor; MCGF; Multipotential colony-stimulating factor; P-cell-stimulating factor; Acidic fibroblast growth factor; aFGF; ECGF; Endothelial cell growth factor; FGF-1; FGFA; HBGF-1; Heparin-binding growth factor 1",Heat shock protein HSP 90-alpha; Protein S100-A12; Protein S100-A13; Interleukin-3; Fibroblast growth factor 1, R03DX01;A01AD07
amlodipine,Acute coronary syndrome;Acute hypotension;Angina pectoris;Anginal attack;Arteriospasm coronary;Bronchial hyperreactivity;Cardiac failure;Cardiac failure congestive;Chronic obstructive pulmonary disease;Coronary artery disease;Diabetes mellitus;Diabetic nephropathy;Electrocardiogram ST segment depression;Hyperlipidaemia;Hypertension;Hypotension;Myocardial infarction;Myocardial ischaemia;Peripheral vascular disorder;Prinzmetal angina;Pulmonary oedema;Stable angina pectoris;Vascular resistance systemic;Vasospasm,Abdominal pain;Abnormal dreams;Abnormal vision;Accommodation disorder;Affect lability;Agitation;Alopecia;Amnesia;Angioedema;Angiopathy;Anorexia;Anxiety;Apathy;Arrhythmia;Arthralgia;Arthropathy;Asthenia;Ataxia;Atrial fibrillation;Back pain;Blood and lymphatic system disorders;Bradycardia;Breast disorder;Bronchial hyperreactivity;Cardiac disorder;Cardiac failure congestive;Chest pain;Chills;Cholestasis;Chronic obstructive pulmonary disease;Clotting;Coagulopathy;Cold sweat;Conjunctivitis;Connective tissue disorder;Constipation;Coronary artery disease;Cough;Cramp muscle;Decreased appetite;Depersonalisation;Dermatitis;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Dizziness;Dizziness postural;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Epistaxis;Erectile dysfunction;Erythema multiforme;Extrasystoles;Eye disorder;Eye pain;Fatigue;Feeling abnormal;Flat affect;Flatulence;Flushing;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gingival hyperplasia;Gynaecomastia;Haemoglobin;Haemorrhage;Headache;Hepatitis;Hot flush;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertonia;Hypoaesthesia;Ill-defined disorder;Immune system disorder;Increased appetite;Insomnia;Jaundice;Leukopenia;Loose stools;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Micturition disorder;Migraine;Mood swings;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Nocturia;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Pain;Palpitations;Pancreatitis;Paraesthesia;Parosmia;Peripheral ischaemia;Peripheral vascular disorder;Pollakiuria;Polyuria;Pruritus;Purpura;Rash;Rash erythematous;Rash maculo-papular;Rhinitis;Rigors;Sexual dysfunction;Shock;Skin cold clammy;Skin discolouration;Skin disorder;Somnolence;Sweating increased;Syncope;Tachycardia;Tension;Thirst;Thrombocytopenia;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;Vascular purpura;Vasculitis;Ventricular tachycardia;Vertigo;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;Xerophthalmia,small molecule,approved,"(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; Amlodipine; Amlodipine free base; Amlodipino; Amlodipinum; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; Ca(v)3.3; KIAA1120; Voltage-gated calcium channel subunit alpha Cav3.3; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; Voltage-gated calcium channel subunit alpha-2/delta-3; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 3.1.4.12; 3.1.4.3; Acid sphingomyelinase; ASM; aSMase; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent calcium channel subunit alpha-2/delta-1; Voltage-dependent T-type calcium channel subunit alpha-1I; Voltage-dependent N-type calcium channel subunit alpha-1B; Voltage-dependent L-type calcium channel subunit beta-1; Voltage-dependent calcium channel subunit alpha-2/delta-3; Carbonic anhydrase 1; Sphingomyelin phosphodiesterase; Voltage-dependent N-type calcium channel, C07FB07; C07FB12; C07FB13; C08CA01; C08CA51; C08GA02; C09BB03; C09BB04; C09BB07; C09BX01; C09BX03; C09BX04; C09BX06; C09DB01; C09DB02; C09DB04; C09DB05; C09DB06; C09DB07; C09DB09; C09DX01; C09DX03; C09DX06; C09DX07; C09DX08; C09XA53; C09XA54; C10BX03; C10BX07; C10BX09; C10BX11; C10BX14; C10BX18; C10BX19;C08CA01;C09BB13
amobarbital,Insomnia,Agitation;Anaemia megaloblastic;Angioedema;Anxiety;Apnoea;Ataxia;Atelectasis;Body temperature increased;Bradycardia;CNS depression NOS;Confusional state;Constipation;Depressed level of consciousness;Dermatitis;Dermatitis exfoliative;Dizziness;Feeling abnormal;Hallucination;Headache;Hepatocellular injury;Hyperkinesia;Hypersensitivity;Hypotension;Hypoventilation;Hypoxia;Injection site reaction;Liver injury;Loss of consciousness;Mental disability;Nausea;Nervousness;Nightmare;Pneumothorax;Rash;Respiratory failure;Shock;Somnolence;Syncope;Tension;Thinking abnormal;Vomiting,small molecule,approved; illicit,"5-ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-ethyl-5-(3-methylbutyl)barbituric acid; 5-ethyl-5-isoamylbarbituric acid; 5-ethyl-5-isopentylbarbituric acid; Amobarbital; Amobarbitale; Amylobarbitone; Barbamil; Barbamyl; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; NACRA4; NACHRA7; AMPA-selective glutamate receptor 2; GluA2; GluR-2; GluR-B; GluR-K2; GLUR2; Glutamate receptor ionotropic, AMPA 2; EAA4; Excitatory amino acid receptor 4; GluK2; GluR-6; GLUR6; Glutamate receptor 6","Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit alpha-4; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-6; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit alpha-7; Glutamate receptor 2; Glutamate receptor ionotropic, kainate 2", N05CB01;N05CA02
amoxapine,Agitation;Anxiety;Depression;Depressive disorder;Depressive symptom;Dysthymic disorder;Psychotic disorder,Abdominal pain;Accommodation disorder;Acute coronary syndrome;Adenitis;Agitation;Agranulocytosis;Alopecia;Anorexia;Appetite exaggerated;Arrhythmia supraventricular;Asthenia;Ataxia;Atrial arrhythmia;Atrial fibrillation;Atrioventricular block;Black hairy tongue;Block heart;Body temperature increased;Breast enlargement;Cerebration impaired;Cerebrovascular accident;Confusional state;Constipation;Convulsion;Coordination abnormal;Decreased appetite;Delusion;Dermatitis;Diarrhoea;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug fever;Dry mouth;Dysgeusia;Dyspepsia;Eosinophilia;Epigastric distress;Erectile dysfunction;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Feeling abnormal;Flatulence;Galactorrhoea;Gastrointestinal pain;Gynaecomastia;Hallucination;Headache;Hepatitis;Hypertension;Hypoaesthesia;Hypomania;Hypotension;Ileus paralytic;Inappropriate antidiuretic hormone secretion;Increased appetite;Insomnia;Jaundice;Lacrimation;Lacrimation increased;Leukopenia;Libido decreased;Loss of consciousness;Lymphadenitis;Menstruation irregular;Mental disability;Mydriasis;Myocardial infarction;Nasal congestion;Nausea;Nervousness;Neuroleptic malignant syndrome;Nightmare;Numbness;Oedema;Painful ejaculation;Palpitations;Pancreatitis;Paraesthesia;Paresthesia of limbs;Parotid gland enlargement;Parotid swelling;Petechiae;Pollakiuria;Pruritus;Purpura;Rash;Sensory loss;Shock;Somnolence;Stomatitis;Syncope;Tachycardia;Tardive dyskinesia;Taste peculiar;Tension;Testicular swelling;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue discolouration;Tremor;Urinary retention;Urticaria;Vascular purpura;Vasculitis;Vision blurred;Vomiting;Weight increased,small molecule,approved,"2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; Amoxapin; Amoxapina; Amoxapine; Amoxapinum; Amoxepine; Desmethylloxapin; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; Dopamine D2 receptor; Dopamine D1 receptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-6; 5-HT6; Serotonin receptor 6; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; AXOR35; G-protein coupled receptor 105; GPCR105; GPRv53; H4R; HH4R; Pfi-013; SP9144; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1",Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; D(2) dopamine receptor; D(1A) dopamine receptor; Alpha-2A adrenergic receptor; Alpha-1A adrenergic receptor; Muscarinic acetylcholine receptor M1; Gamma-aminobutyric acid receptor subunit alpha-1; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; D(3) dopamine receptor; D(4) dopamine receptor; Histamine H1 receptor; Alpha-1 adrenergic receptors; Muscarinic acetylcholine receptor; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B; Alpha-2 adrenergic receptors; Histamine H4 receptor; GABA(A) Receptor; Sodium-dependent dopamine transporter,N06AA17
amoxicillin,Asthma;Bacteraemia;Duodenal ulcer;Endocarditis;Endocarditis bacterial;Escherichia coli infection;Escherichia infection;Function kidney decreased;Gonorrhoea;Hypersensitivity;Hypertrophic cardiomyopathy;Infection;Infectious mononucleosis;Inflammation;Mitral valve prolapse;Pharyngitis;Regurgitation;Renal failure;Renal impairment;Rhinitis seasonal;Seasonal allergy;Tonsillitis;Urticaria,Abdominal pain;Acute cytolytic hepatitis;Acute generalised exanthematous pustulosis;Agitation;Agranulocytosis;Allergic cutaneous angiitis;Anaemia;Anaphylactic shock;Angioedema;Antibiotic associated colitis;Anxiety;Appetite absent;Black hairy tongue;Blood and lymphatic system disorders;Body temperature increased;Candida infection;Cholestasis;Clostridium difficile colitis;Colitis;Coma;Confusional state;Convulsion;Convulsive seizure;Crystalluria;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Dizziness;Drug fever;Dry mouth;Dysgeusia;Enterocolitis haemorrhagic;Eosinophilia;Epilepsy;Erythema multiforme;Feeling abnormal;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Glossitis;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hemorrhagic colitis;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hyperkinesia;Hypersensitivity;Immune system disorder;Infection;Infestation;Infestation NOS;Insomnia;Jaundice cholestatic;Leukocytoclastic vasculitis;Leukopenia;Meningitis;Mucocutaneous candidiasis;Nausea;Nephritis;Nephritis interstitial;Nervous system disorder;Neutropenia;Pruritus;Pseudomembranous colitis;Rash;Rash erythematous;Rash maculo-papular;Renal failure;Renal impairment;Serum sickness;Skin disorder;Soft stools;Stevens-Johnson syndrome;Stomatitis;Superinfection;Thrombocytopenia;Thrombocytopenic purpura;Tongue discolouration;Tooth discolouration;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved; vet_approved,"(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid; Amox; Amoxicilina; Amoxicillin; Amoxicillin (anhydrous); Amoxicillin anhydrous; Amoxicilline; Amoxicillinum; Amoxycillin; AX; p-Hydroxyampicillin; α-amino-p-hydroxybenzylpenicillin; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 3.5.2.6; Beta-lactamase II; Cephalosporinase; Penicillinase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",Penicillin binding protein, A02BD01; A02BD03; A02BD04; A02BD05; A02BD06; A02BD07; A02BD10; A02BD11; A02BD13; A02BD14; A02BD15; A02BD16; A02BD17; J01CA04; J01CR50;A02BD12;J01CA04
ampicillin,"Asthma;Bacterial sepsis;Dysentery;Endocarditis;Gastrointestinal infection;Gonorrhoea;Hypersensitivity;Infection;Meningitis;Meningitis bacterial;Pneumonia due to Streptococcus, group b;Pneumonia streptococcal;Respiratory tract infection;Rhinitis seasonal;Seasonal allergy;Sepsis;Septicaemia due to gram-negative organism, unspecified;Septicemia;Streptococcal endocarditis;Typhoid fever;Urinary tract infection;Urticaria",Agranulocytosis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Black hairy tongue;Body temperature increased;Dermatitis;Dermatitis exfoliative;Diarrhoea;Enterocolitis;Eosinophilia;Eruption;Erythema multiforme;Glossitis;Laryngospasm;Leukopenia;Nausea;Oral pain;Pruritus;Pseudomembranous colitis;Purpura;Rash;Serum sickness;Sore mouth;Stomatitis;Thrombocytopenia;Thrombocytopenic purpura;Tongue discolouration;Vascular purpura;Vomiting,small molecule,approved; vet_approved,"ABPC; Aminobenzylpenicillin; Ampicilina; Ampicillin; Ampicillin (anhydrous); Ampicillin acid; Ampicillin anhydrous; Ampicillin, anhydrous; Ampicilline; Ampicillinum; Anhydrous ampicillin; AP; D-(−)-6-(α-aminophenylacetamido)penicillanic acid; D-(−)-ampicillin; Putative D-alanyl-D-alanine carboxypeptidase; exp2; Exported protein 2; PBP-1A; pbp2b; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; 2.7.10.1; Endothelial tyrosine kinase; hTIE2; p140 TEK; TIE2; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains-2; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; VMCM; VMCM1; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; MCT 1; MCT1; Solute carrier family 16 member 1",Penicillin-binding protein 2a; Penicillin-binding protein 1b; Penicillin-binding protein 3; Penicillin-binding protein 1A; Penicillin-binding protein 2B; Solute carrier family 15 member 1; Solute carrier family 15 member 2; Angiopoietin-1 receptor, J01CA01; J01CA51; S01AA19;J01CA01;J01CR50
amprenavir,Dermatitis;Disease progression;Immunodeficiency;Infection;Rash,Abdominal discomfort;Abdominal pain;Abdominal symptom;Acute coronary syndrome;Affective disorder;Alanine aminotransferase increased;Amylase increased;Angioedema;Anorexia;Aspartate aminotransferase increased;Asthenia;Blood creatine phosphokinase increased;Blood triglycerides increased;Breast enlargement;Buffalo hump;Cardiac disorder;Connective tissue disorder;Creatine phosphokinase increased;Decreased appetite;Depression;Depressive disorder;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Dyspeptic signs and symptoms;Dysthymic disorder;Erythema multiforme;Fat redistribution;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Headache;Hepatitis B;Hepatobiliary disease;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperlactacidaemia;Hypertriglyceridaemia;Hypertrophy of breast;Inflammation;Insulin resistance;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Liver function test abnormal;Loose stools;Malnutrition;Mental disorder;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myositis;Nausea;Nephrolithiasis;Nervous system disorder;Neutropenia;Opportunistic infection;Paraesthesia;Paraesthesia oral;Perioral paraesthesia;Pruritus;Rash;Rhabdomyolysis;Skin disorder;Sleep disorder;Stevens-Johnson syndrome;Taste disorders;Transaminases increased;Tremor;Unspecified disorder of skin and subcutaneous tissue;Vomiting,small molecule,approved; investigational,"(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; Amprenavir; Amprénavir; Amprenavirum; Pr160Gag-Pol; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Pol polyprotein; Gag-Pol polyprotein,J05AE05
amsacrine,Hypokalaemia;Leukaemia,Abdominal pain;Affect lability;Agranulocytosis;Alopecia;Anaemia;Angiopathy;Anorexia;Aplasia;Aplastic anaemia;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bradycardia;Cardiac disorder;Cardiac failure congestive;Cardiomyopathy;Chromaturia;Confusional state;Connective tissue disorder;Convulsion;Creatinine increased;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dysphagia;Dyspnoea;Ejection fraction decreased;Extravasation;Fatigue;Febrile neutropenia;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Gingival bleeding;Gingivitis;Haematemesis;Haematuria;Haemoglobin;Haemorrhage;Headache;Hepatic failure;Hepatic insufficiency;Hepatitis;Hepatobiliary disease;Hepatotoxicity;Hypersensitivity;Hyperuricaemia;Hypoaesthesia;Hypomagnesaemia;Hypotension;Infection;Infestation;Infestation NOS;Inflammation;Injection site inflammation;Injection site reaction;Jaundice;Lethargy;Leukopenia;Malnutrition;Mediastinal disorder;Mental disorder;Mood swings;Mucosal inflammation;Musculoskeletal pain;Myelosuppression;Nausea;Necrosis;Pain;Pancytopenia;Paraesthesia;Perirectal abscess;Phlebitis;Phosphatase alkaline increased;Protein urine present;Proteinuria;Purpura;Rash;Renal failure;Sepsis;Sinus tachycardia;Skin disorder;Stomatitis;Tachycardia;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Ureteric obstruction;Urethral disorder;Urinary tract disorder;Urine color abnormal;Urine output;Urticaria;Vascular purpura;Ventricular arrhythmia;Ventricular fibrillation;Vision blurred;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; 4'-(9-Acridinylamino)methanesulphon-m-anisidide; Acridinyl anisidide; Amsacrina; Amsacrine; Amsacrinum; m-AMSA; mAMSA; 5.6.2.2; DNA topoisomerase II, beta isozyme; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",DNA; DNA topoisomerase 2-beta; DNA topoisomerase 2-alpha; Voltage-gated inwardly rectifying potassium channel KCNH2; Alpha-1-acid glycoprotein 1; Albumin,L01XX01
anagrelide,Essential thrombocythaemia;Myeloproliferative disorder;Thrombocytosis;Thrombosis,Abdominal discomfort;Abdominal pain;Abnormal vision;Accidental injury;Acute coronary syndrome;Alopecia;Alveolitis allergic;Amblyopia;Amnesia;Anaemia;Angina pectoris;Anorexia;Aphthous stomatitis;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Asthenia;Asthma;Atrial arrhythmia;Atrial fibrillation;Atrioventricular block complete;Back pain;Blood and lymphatic system disorders;Blood creatinine increased;Body temperature increased;Bone pain;Bronchitis;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac fibrillation;Cardiomegaly;Cardiomyopathy;Cardiovascular disorder;Cellulitis;Cerebrovascular accident;Chest pain;Chills;Chronic myeloid leukaemia;Colitis;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cramps of lower extremities;Decreased appetite;Dehydration;Depression;Dermatitis;Diarrhoea;Diplopia;Discomfort;Distress gastrointestinal;Dizziness;Dry mouth;Dry skin;Duodenal ulcer;Dysarthria;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ecchymosis;Eosinophilic pneumonia;Epistaxis;Erectile dysfunction;Eructation;Essential thrombocythaemia;Eye disorder;Fatigue;Feeling abnormal;Fibrosis;Flatulence;Flu symptoms;Fluid retention;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingival bleeding;Haematuria;Haemoglobin;Haemorrhage;Headache;Headache occurring;Hepatic enzyme increased;Hepatitis;Hepatobiliary disease;Hepatotoxicity;Hyperhidrosis;Hypertension;Hypoaesthesia;Hypotension;Ill-defined disorder;Incontinence;Infection;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Interstitial lung disease;Interstitial pneumonia;Laboratory test abnormal;Liver function test abnormal;Loss of consciousness;Lung infiltration;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melaena;Migraine;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Neck pain;Nervous system disorder;Nervousness;Nocturia;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Pericardial effusion;Pericarditis;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pneumonia;Pollakiuria;Polycythaemia vera;Pruritus;Pulmonary fibrosis;Pulmonary hypertension;Raised liver function tests;Rash;Renal failure;Renal impairment;Rhinitis;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin ulcer;Somnolence;Supraventricular tachycardia;Sweating;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Torsade de pointes;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urticaria;Ventricular tachycardia;Vision blurred;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved,Anagrelida; Anagrelide; Anagrelidum; 3.1.4.17; cGI-PDE; CGI-PDE A; cGMP-inhibited cAMP phosphodiesterase; Cyclic GMP-inhibited phosphodiesterase A; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase,"cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A",L01XX35
anastrozole,Advanced breast cancer;Angioedema;Breast cancer;Breast cancer stage IV;Disease progression;Erythema multiforme;Menopause;Myocardial ischaemia,Abdominal pain;Accidental injury;Acute coronary syndrome;Ageusia;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anxiety;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Back pain;Blister;Blood alkaline phosphatase increased;Blood cholesterol increased;Body temperature increased;Bone pain;Breast neoplasm;Breast pain;Breast tenderness;Bronchitis;Cardiovascular disorder;Carpal tunnel syndrome;Cataract;Cataract specified;Cerebral infarction;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Cholesterol serum elevated;Confusional state;Constipation;Coronary artery disease;Cough;Cough increased;Cutaneous vasculitis;Cyst;Decreased appetite;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Digestion impaired;Discomfort;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Embolism;Embolism venous;Emotional distress;Endometrial cancer;Erythema;Erythema multiforme;Fatigue;Feeling abnormal;Fracture;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Henoch-Schonlein purpura;Hepatic pain;Hepatitis;Hepatitis acute;Hepatitis toxic;Hepatobiliary disease;Hepatotoxicity;High cholesterol;High density lipoprotein decreased;Hip fracture;Hot flush;Hypercalcaemia;Hypercholesterolaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Ill-defined disorder;Increased appetite;Infection;Inflammation;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Jaundice;Joint stiffness;Lethargy;Leukopenia;Leukorrhea;Lipid metabolism disorder;Liver function test abnormal;Low density lipoprotein increased;Lymphoedema;Malaise;Menopausal symptoms;Menopause;Mood alteration NOS;Mood swings;Multiple fractures;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Neck pain;Neoplasm;Neoplasm malignant;Nervousness;Neuropathy;Neuropathy peripheral;Oedema;Oedema peripheral;Oestrogenic effect;Osteoarthritis;Osteoporosis;Osteoporotic fracture;Pain;Paraesthesia;Pelvic pain;Pharyngitis;Phosphatase alkaline increased;Pruritus;Pulmonary embolism;Raised liver function tests;Rash;Retinal vein thrombosis;Rhinitis;Sinusitis;Somnolence;Stevens-Johnson syndrome;Stiffness;Sweating;Sweating increased;Swelling;Tension;Thromboembolic event;Thromboembolism;Thrombophlebitis;Thrombosis;Trigger finger;Tumour flare;Ulcer;Urinary tract infection;Urticaria;Vaginal discharge;Vaginal dryness;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vasodilation;Vasodilation procedure;Vomiting;Vulvovaginal dryness;Vulvovaginitis;Weight decreased;Weight increased,small molecule,approved; investigational,"Anastrozol; Anastrozole; α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Aromatase,L02BG03
apomorphine,Parkinson's disease;Parkinsonism,Angina pectoris;Anxiety;Arthralgia;Asthenia;Back pain;Cardiac failure congestive;Chest pain;Confusional state;Constipation;Contusion;Dehydration;Diarrhoea;Disturbance in sexual arousal;Dizziness;Drowsiness;Dyskinesia;Dyspnoea;Ecchymosis;Fatigue;Feeling abnormal;Flushing;Granuloma;Hallucination;Headache;Hyperhidrosis;Hypersexuality;Hypotension;Injection site reaction;Insomnia;Libido increased;Loss of consciousness;Mental disorder;Musculoskeletal discomfort;Nasopharyngitis;Nausea;Oedema;Orthostatic hypotension;Pain in extremity;Pallor;Parkinson's disease;Parkinson's disease aggravated;Pathological gambling;Pneumonia;Priapism;Pruritus;Psychotic disorder;Rhinorrhoea;Shock;Somnolence;Sweating increased;Swelling;Syncope;Urinary tract infection;Vomiting;Yawning,small molecule,approved; investigational,"(−)-10,11-dihydroxyaporphine; (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol; Apomorfina; Apomorphin; Apomorphine; R-(−)-apomorphine; D(2C) dopamine receptor; Dopamine D4 receptor; Dopamine D2 receptor; Dopamine D3 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D1 receptor; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 2.1.1.6; 2.8.2.1; Aryl sulfotransferase 1; HAST1/HAST2; P-PST 1; Phenol sulfotransferase 1; Phenol-sulfating phenol sulfotransferase 1; ST1A1; ST1A3; STP; STP1; Thermostable phenol sulfotransferase; Ts-PST; 2.8.2.1; Aryl sulfotransferase 2; P-PST 2; Phenol sulfotransferase 2; Phenol-sulfating phenol sulfotransferase 2; ST1A2; STP2; 2.8.2.1; Aryl sulfotransferase 1A3/1A4; Catecholamine-sulfating phenol sulfotransferase; HAST3; M-PST; Monoamine-sulfating phenol sulfotransferase; Placental estrogen sulfotransferase; ST1A3; STM; Sulfotransferase 1A3/1A4; Sulfotransferase, monoamine-preferring; Thermolabile phenol sulfotransferase; TL-PST; 2.8.2.4; EST-1; Estrogen sulfotransferase; ST1E1; STE; Sulfotransferase, estrogen-preferring; 2.8.2.1; ST1B1; ST1B2; Sulfotransferase 1B2; Sulfotransferase family cytosolic 1B member 1; SULT1B2; Thyroid hormone sulfotransferase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; Solute carrier family 18 member 2; SVMT; VAT2; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT2",D(4) dopamine receptor; D(2) dopamine receptor; D(3) dopamine receptor; D(1B) dopamine receptor; D(1A) dopamine receptor; Alpha-2C adrenergic receptor; Alpha-2B adrenergic receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; Alpha-2A adrenergic receptor; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1B, N04BC07;G04BE07
apraclonidine,Tachyphylaxis,Abdominal discomfort;Abdominal pain;Abnormal vision;Angiopathy;Arrhythmia;Asthenia;Asthma;Blanching;Blepharitis;Blepharoconjunctivitis;Blepharospasm;Bradycardia;Chest pain;Conjunctival follicles;Conjunctival oedema;Conjunctivitis;Constipation;Coordination abnormal;Corneal erosion;Corneal infiltrates;Corneal staining;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dysgeusia;Dyspnoea;Endophthalmitis;Erythema;Erythema of eyelid;Eye discharge;Eye disorder;Eye irritation;Eye oedema;Eye pain;Eye pruritus;Eyelid disorder;Eyelid margin crusting;Eyelid oedema;Eyelid ptosis;Eyelid retraction;Face oedema;Fatigue;Feeling abnormal;Foreign body sensation in eyes;Gastrointestinal disorder;Gastrointestinal pain;Haemorrhage;Headache;Heart rate irregular;Hyperaemia;Hypersensitivity;Ill-defined disorder;Infection;Infestation;Infestation NOS;Inflammation;Insomnia;Irritability;Keratitis;Keratopathy;Lacrimation;Lacrimation increased;Libido decreased;Malaise;Mediastinal disorder;Mental disorder;Microhemorrhage;Musculoskeletal discomfort;Myalgia;Mydriasis;Nasal dryness;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Ocular discomfort;Ocular hyperaemia;Oedema;Oedema peripheral;Pain;Pallor;Palpitations;Paraesthesia;Parosmia;Pharyngitis;Photophobia;Presyncope;Pruritus;Rhinitis;Rhinorrhoea;Scab;Sensation of foreign body;Skin disorder;Somnolence;Syncope;Syncope vasovagal;Tension;Throat irritation;Unspecified disorder of skin and subcutaneous tissue;Upset stomach;Vasodilation;Vasodilation procedure;Vision blurred;Visual acuity reduced;Visual impairment;Vital dye staining cornea present;Vomiting,small molecule,approved,4-Aminoclonidine; Apraclonidina; Apraclonidine; Apraclonidinum; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR,Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor,S01EA03
argatroban,Acute myocardial infarction;Heparin-induced thrombocytopenia;Thrombosis,Abdominal pain;Acute coronary syndrome;Angina pectoris;Angina unstable;Angiopathy;Aortic valve stenosis;Apnoea;Arterial thrombosis;Atrial fibrillation;Back pain;Body temperature increased;Bradycardia;Bullous eruption;Cardiac arrest;Cardiac failure;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Confusional state;Constipation;Coronary artery occlusion;Coronary artery thrombosis;Cough;Dermatitis;Dermatitis bullous;Diarrhoea;Digestion impaired;Disseminated intravascular coagulation;Dizziness;Dyspepsia;Dyspnoea;Feeling abnormal;Gangrene;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Headache;Hypersensitivity;Hypotension;Infection;Kidney function abnormal;Major bleed;Minor bleed;Myocardial infarction;Myocardial ischaemia;Nausea;Pain;Peripheral gangrene;Peripheral ischaemia;Pleural effusion;Pneumonia;Pulmonary embolism;Pulmonary oedema;Rash;Renal failure acute;Renal impairment;Respiratory failure;Respiratory insufficiency;Retroperitoneal haemorrhage;Sepsis;Tachycardia;Thrombophlebitis;Thrombosis;Urinary tract infection;Vasodilation;Vasodilation procedure;Ventricular tachycardia;Vomiting,small molecule,approved; investigational,"Argatroban; Argatroban anhydrous; 3.4.21.5; Coagulation factor II; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2",Prothrombin,B01AE03
atenolol,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Arrhythmia;Arteriosclerosis coronary artery;Asthma;Bradycardia;Cardiac failure;Chest pain;Diabetes mellitus;Diabetic nephropathy;Foetor hepaticus;Hepatocellular injury;Hyperlipidaemia;Hypertension;Hypertensive;Hypotension;Liver disorder;Myocardial infarction;Myocardial ischaemia;Renal failure;Renal impairment;Systolic hypertension;Tachycardia;Ventricular arrhythmia,ANA increased;Abdominal discomfort;Abnormal dreams;Ache;Affect lability;Aggression;Agranulocytosis;Alopecia;Alopecia reversible;Amnesia;Anorexia;Antinuclear antibody increased;Anxiety;Arrhythmia;Arterial thrombosis;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrial fibrillation;Atrial flutter;Atrioventricular block;Block heart;Body temperature increased;Bradycardia;Bronchospasm;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Cardiac septal defect;Cardiogenic shock;Cardiomegaly;Catatonia;Chest pain;Cholestasis;Cholestasis intrahepatic;Colitis ischaemic;Confusional state;Constipation;Cough;Decreased appetite;Depression;Dermatitis;Dermatitis exfoliative;Dermatitis psoriasiform;Diarrhoea;Digestion impaired;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry eye;Dry mouth;Dyspepsia;Dyspnoea;Epistaxis;Erectile dysfunction;Fatigue;Feeling abnormal;Flushing;Gastrointestinal disorder;Hallucination;Headache;Hepatic enzyme increased;Hot flush;Hyperhidrosis;Hypotension;Ill-defined disorder;Infarction;Insomnia;Intermittent claudication;Laryngospasm;Left ventricular failure;Leg pain;Lethargy;Libido decreased;Lightheadedness;Loss of consciousness;Malaise;Menopausal symptoms;Mitral valve incompetence;Mood swings;Myocardial infarction;Myocardial reinfarction;Nasal congestion;Nausea;Nervousness;Nightmare;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Pain;Pain in extremity;Palpitations;Paraesthesia;Peripheral coldness;Peyronie's disease;Pruritus;Psoriasis;Psoriasis flare-up;Psychotic disorder;Pulmonary oedema;Purpura;Rash;Rash erythematous;Regurgitation;Renal failure;Respiratory distress;Shock;Short-term memory loss;Sick sinus syndrome;Sinus arrest;Somnolence;Status asthmaticus;Supraventricular tachycardia;Sweating;Syncope;Systemic lupus erythematosus;Systolic hypertension;Tachycardia;Tension;Throat sore;Thrombocytopenia;Thrombocytopenic purpura;Tinnitus;Vascular purpura;Ventricular septal defect;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vivid dreams;Wheezing,small molecule,approved,1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; Atenolol; Atenololum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP,Beta-1 adrenergic receptor; Beta-2 adrenergic receptor, C07AB03; C07BB03; C07CB03; C07DB01; C07FB03;C07AB03;C07CB53
atorvastatin,Acute coronary syndrome;Agitation;Albuminuria;Alcohol abuse;Alcoholism;Angina pectoris;Arteriosclerosis;Atherosclerosis;Blood pressure increased;Blood triglycerides increased;Cardiovascular disorder;Carotid artery disease;Central obesity;Cerebrovascular accident;Combined hyperlipidaemia;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Dyslipidaemia;Foetor hepaticus;Glucose tolerance impaired;Hepatocellular injury;Heterozygous familial hypercholesterolemia;High density lipoprotein decreased;High density lipoprotein increased;Homozygous familial hypercholesterolaemia;Hypercholesterolaemia;Hyperlipidaemia;Hypertension;Hypertensive;Hypertriglyceridaemia;Hypothyroidism;Increased activity;Insulin resistance;Lipids abnormal;Liver disorder;Metabolic syndrome;Myocardial infarction;Nephrotic syndrome;Peripheral vascular disorder;Premature menopause;Retinal disorder;Type 2 diabetes mellitus;Type II hyperlipidaemia;Type III hyperlipidaemia;Type IIa hyperlipidaemia;Weight decreased,Abdominal discomfort;Abdominal pain;Abnormal dreams;Abnormal ejaculation;Accidental injury;Affect lability;Ageusia;Agitation;Alanine aminotransferase increased;Alopecia;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Anorectal discomfort;Anorexia;Arrhythmia;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthma;Back pain;Biliary colic;Bladder pain;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood magnesium decreased;Body temperature increased;Breast disorder;Breast enlargement;Bronchitis;Bursitis;Calculus of kidney;Cerebral haemorrhage;Cheilitis;Chest pain;Cholestasis;Cognitive disorder;Cognitive impairment;Colitis;Confusional state;Connective tissue disorder;Constipation;Coordination abnormal;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drug interaction;Dry eye;Dry mouth;Dry skin;Duodenal ulcer;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ecchymosis;Eczema;Ejaculation disorder;Enteritis;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Eye disorder;Eye haemorrhage;Face oedema;Facial paralysis;Fatigue;Feeling abnormal;Fibrocystic breast disease;Flatulence;Fluid retention;Forgetfulness;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gingival bleeding;Glaucoma;Glossitis;Gout;Gynaecomastia;Haematuria;Haemorrhagic stroke;Headache;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatobiliary disease;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertonia;Hypoaesthesia;Hypoglycaemia;Ill-defined disorder;Immune system disorder;Immune-mediated necrotising myopathy;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Interstitial lung disease;Ischaemic stroke;Jaundice cholestatic;Joint swelling;Laryngeal pain;Libido decreased;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melaena;Memory impairment;Memory loss;Mental disorder;Metrorrhagia;Mg reduced;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Muscle fatigue;Muscle spasms;Muscle swelling;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myasthenia;Myoglobin urine present;Myoglobinuria;Myopathy;Myositis;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Nephritis;Nephrolithiasis;Nervous system disorder;Neuropathy peripheral;Nightmare;Nocturia;Nuchal rigidity;Oedema peripheral;Oesophagitis;Orthostatic hypotension;Pain;Pain in extremity;Palpitations;Pancreatitis;Paraesthesia;Parosmia;Petechiae;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Photosensitivity reaction;Pneumonia;Pollakiuria;Proctalgia;Pruritus;Rash;Rectal haemorrhage;Rectal tenesmus;Refraction disorder;Renal failure;Renal failure acute;Renal impairment;Rhabdomyolysis;Rhinitis;Seborrhoeic dermatitis;Shock;Sinusitis;Skin disorder;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating;Syncope;Tendinous contracture;Tendon rupture;Tenosynovitis;Thrombocytopenia;Tinnitus;Torticollis;Toxic epidermal necrolysis;Transaminases increased;Transient ischaemic attack;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urinary incontinence;Urinary retention;Urinary tract infection;Urticaria;Uterine haemorrhage;VIIth nerve paralysis;Vaginal haemorrhage;Vision blurred;Vomiting;Weight increased;White blood cells urine positive,small molecule,approved,"Atorvastatin; atorvastatina; atorvastatine; atorvastatinum; 1.1.1.34; HMG-CoA reductase; 3.4.14.5; ADABP; ADCP-2; ADCP2; Adenosine deaminase complexing protein 2; CD26; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103; Ah receptor; AhR; BHLHE76; Class E basic helix-loop-helix protein 76; 3.5.1.98; HD2; Protein deacylase HDAC2; CAR; Constitutive activator of retinoid response; Constitutive active response; Constitutive androstane receptor; Orphan nuclear receptor MB67; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.-; 7.6.2.2; MOAT-C; MRP5; Multi-specific organic anion transporter C; Multidrug resistance-associated protein 5; pABC11; SMRP; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",3-hydroxy-3-methylglutaryl-coenzyme A reductase; Dipeptidyl peptidase 4; Aryl hydrocarbon receptor; Histone deacetylase 2; Nuclear receptor subfamily 1 group I member 3, C10AA05; C10BX03; C10BX06; C10BX08; C10BX11; C10BX12; C10BX15; C10BX18; C10BX19;C10AA05;C10BA05
azathioprine,Arthritis;Autoimmune haemolytic anaemia;Colitis ulcerative;Crohn's disease;Dermatomyositis;Hepatitis chronic active;Idiopathic thrombocytopenic purpura;Inflammatory bowel disease;Pemphigus;Pemphigus vulgaris;Polyarteritis nodosa;Polymyositis;Proctocolitis;Purpura;Rheumatic disorder;Rheumatism;Rheumatoid arthritis;Systemic lupus erythematosus;Venoocclusive liver disease,Abdominal discomfort;Abdominal pain;Acute febrile neutrophilic dermatosis;Acute leukaemia;Acute myeloid leukaemia;Agranulocytosis;Alopecia;Anaemia;Anaemia macrocytic;Anaemia megaloblastic;Aplastic anaemia;Arrhythmia;Arthralgia;Bacterial infection;Blood and lymphatic system disorders;Body temperature increased;Bone marrow depression;Cervical dysplasia;Cervix carcinoma stage 0;Chills;Cholestasis;Colitis;Cyst;Dermatitis;Diarrhoea;Discomfort;Diverticulitis;Dizziness;Erythema multiforme;Feeling abnormal;Formication;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Hepatic failure;Hepatic function abnormal;Hepatic insufficiency;Hepatitis B;Hepatitis toxic;Hepatobiliary disease;Hepatocellular injury;Hepatosplenic T-cell lymphoma;Hepatotoxicity;Herpes zoster;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hypersensitivity;Hypoplasia erythroid;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Inflammatory bowel disease;Interstitial lung disease;Interstitial pneumonia;Intestinal perforation;Jaundice cholestatic;Leukopenia;Liver injury;Lymphoma;Lymphoproliferative disorder;Malaise;Malignant melanoma;Mediastinal disorder;Meningitis;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Myelosuppression;Nausea;Neoplasm;Neoplasm malignant;Nitrogen balance negative;Nodular regenerative hyperplasia;Non-Hodgkin's lymphoma;Pancreatitis;Pancytopenia;Panuveitis;Peliosis hepatis;Pneumonia;Polyp;Rash;Reaction gastrointestinal;Rigors;Sarcoma;Secondary infection;Skin cancer;Skin disorder;Steatorrhoea;Stevens-Johnson syndrome;Thrombocytopenia;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Uveitis;Varicella;Vasculitis;Venoocclusive disease;Vomiting;X-linked lymphoproliferative syndrome,small molecule,approved,"6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; Azamun; Azathioprine; Azathioprinum; Azatioprina; 2.4.2.14; ATase; Glutamine phosphoribosylpyrophosphate amidotransferase; GPAT; 3.6.5.2; Cell migration-inducing gene 5 protein; p21-Rac1; Ras-like protein TC25; TC25; 2.4.2.8; HGPRT; HGPRTase; HPRT; 3.6.1.9; MTH2; MutT homolog 2; Nucleoside diphosphate-linked moiety X motif 15; Nucleoside diphosphate-linked to another moiety X hydrolase 15; Nudix hydrolase 15; Nudix motif 15; XDHA; 2.1.1.67; Thiopurine methyltransferase; 13-hydroperoxyoctadecadienoate peroxidase; 2.5.1.18; Androst-5-ene-3,17-dione isomerase; GST class-alpha member 1; GST HA subunit 1; GST-epsilon; GSTA1-1; GTH1; 2.5.1.18; GST class-alpha member 2; GST HA subunit 2; GST-gamma; GST2; GSTA2-2; GTH2; 2.5.1.18; GST class-mu 1; GST HB subunit 4; GST1; GSTM1-1; GSTM1a-1a; GSTM1b-1b; GTH4; 1.1.1.205; IMP dehydrogenase 1; IMPD 1; IMPD1; IMPDH 1; IMPDH-I; 1.1.1.205; IMP dehydrogenase 2; IMP dehydrogenase II; IMPD 2; IMPD2; IMPDH 2; IMPDH-II; Inosine-5'-monophosphate dehydrogenase type II; 6.3.5.2; Glutamine amidotransferase; GMP synthetase; 3.6.1.9; C20orf37; Inosine triphosphatase; ITPase; Non-canonical purine NTP pyrophosphatase; Non-standard purine NTP pyrophosphatase; NTPase; Nucleoside-triphosphate diphosphatase; Nucleoside-triphosphate pyrophosphatase; Putative oncogene protein hlc14-06-p; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 36 kDa nucleolar protein HNP36; Delayed-early response protein 12; DER12; ENT2; Equilibrative NBMPR-insensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter; hENT2; HNP36; Hydrophobic nucleolar protein, 36 kDa; Nucleoside transporter, ei-type; Solute carrier family 29 member 2; CNT 3; CNT3; Concentrative Na(+)-nucleoside cotransporter 3; hCNT3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; ENBT1; Protein FOAP-13; Solute carrier family 43 member 3",Amidophosphoribosyltransferase; Ras-related C3 botulinum toxin substrate 1,L04AX01
azelastine,Conjunctivitis allergic;Nasal congestion;Nasopharyngitis;Perennial allergic rhinitis;Postnasal drip;Pruritus;Rhinitis allergic;Rhinitis perennial;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Sneezing;Upper-airway cough syndrome;Vasomotor rhinitis,Abdominal pain;Abnormal vision;Ageusia;Agitation;Alanine aminotransferase increased;Albuminuria;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Anosmia;Anxiety;Aphthous stomatitis;Application site irritation;Arthritis;Asthenia;Asthma;Atrial fibrillation;Back pain;Body temperature increased;Breast pain;Bronchitis;Bronchospasm;Burning in throat;Chest pain;Cold symptoms;Confusional state;Congenital eye disorder;Conjunctivitis;Constipation;Cough;Depersonalisation;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dry throat;Dysaesthesia;Dysgeusia;Dyspnoea;Eczema;Epistaxis;Eye burns;Eye disorder;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flushing;Furuncle;Furunculosis;Gastroenteritis;Gastrointestinal pain;Glossitis;Haematuria;Headache;Herpes simplex;Hyperkinesia;Hypersensitivity;Hypertension;Hypoaesthesia;Ill-defined disorder;Increased appetite;Infection;Influenza like illness;Influenza-like symptoms;Joint dislocation;Laceration;Lacrimation increased;Laryngeal pain;Laryngitis;Malaise;Mental disability;Mouth ulceration;Mucosal inflammation;Mucosal ulceration;Muscle contractions involuntary;Musculoskeletal discomfort;Myalgia;Nasal burning;Nasal discomfort;Nasal dryness;Nasal septum perforation;Nasopharyngitis;Nausea;Nervousness;Nocturnal dyspnoea;Pain;Palpitations;Paraesthesia;Paranasal sinus hypersecretion;Parosmia;Pharyngitis;Pharyngolaryngeal pain;Pollakiuria;Pruritus;Rash;Rheumatoid arthritis;Rhinitis;Sinusitis;Skin laceration;Sleep disorder;Sneezing;Somnolence;Stinging;Tachycardia;Taste bitter;Taste sweet;Tearing eyes;Tension;Thinking abnormal;Throat irritation;Toothache;Ulcer;Ulcerative stomatitis;Upper respiratory tract infection;Urinary retention;Vertigo;Viral infection;Vision blurred;Visual impairment;Vomiting;Weight increased;Xerophthalmia,small molecule,approved,"4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; Azelastina; Azelastine; Azélastine; Azelastinum; H1-R; H1R; HH1R; Gastric receptor I; H2R; HH2R; 3.1.1.4; Group IB phospholipase A2; Phosphatidylcholine 2-acylhydrolase 1B; PLA2; PLA2A; PPLA2; 4.4.1.20; Glutathione S-transferase LTC4; Leukotriene-C(4) synthase; Leukotriene-C4 synthase; LTC4 synthase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Histamine H1 receptor; Histamine H2 receptor; Phospholipase A2; Leukotriene C4 synthase, R01AC03; S01GX07;R01AC03;R06AX19
azithromycin,Abscess;Acne;Acute pharyngitis;Acute sinusitis;Asplenia;Atypical pneumonia;Bacteraemia;Blood culture negative;Bronchial hyperreactivity;Bronchitis;Bronchitis bacterial;Bronchitis chronic;Cervicitis;Chancroid;Chronic obstructive pulmonary disease;Community acquired pneumonia;Conjunctivitis;Conjunctivitis bacterial;Conjunctivitis infective;Cross resistance;Cystic fibrosis;Drug interaction;Fasting;Genital ulceration;Gonorrhoea;Hepatic failure;Hepatic function abnormal;Hepatic impairment;Hepatic insufficiency;Immunodeficiency;Infection;Liver disorder;Lower respiratory tract infection;Lyme disease;Malaise;Mycobacterial infection;Mycobacterium avium complex infection;Mycobacterium test;Nosocomial infection;Obstructive airways disorder;Otitis media acute;Pathogen resistance;Pelvic inflammatory disease;Pertussis;Pharyngitis;Pharyngitis streptococcal;Pneumonia;Pneumonia chlamydial;Pneumonia mycoplasmal;Renal failure;Renal impairment;Respiratory tract infection;Rheumatic disorder;Rheumatic fever;Sexually transmitted disease;Sickness;Sinusitis bacterial;Streptococcus pyogenes pharyngitis;Syphilis;Tonsillitis;Trachoma;Unspecified non-gonococcal urethritis (NGU);Upper respiratory tract infection;Urethritis;Urethritis noninfective,Abdominal pain;Abdominal pain upper;Abnormal faeces;Abnormal vision;Acne;Acquired immunodeficiency syndrome;Aggression;Aggressive reaction;Agitation;Alanine aminotransferase increased;Alkaline phosphatase serum increased;Allergic rash;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Application site pain;Application site reaction;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Asthma;Autoimmune disorder;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood lactate dehydrogenase increased;Blood potassium decreased;Body temperature increased;Breast feeding;Bronchospasm;Candida infection;Chest pain;Chills;Common cold;Congenital anomaly;Constipation;Convulsion;Corneal erosion;Cough;Cough increased;Cross resistance;Deafness;Decreased appetite;Dehydration;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Developmental delay;Diarrhoea;Discomfort;Dizziness;Drug interaction;Drug-induced hepatitis;Drug-induced liver injury;Dry eye;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear infection;Eczema;Enteritis;Eosinophilia;Erythema multiforme;Extravasation;Eye irritation;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flatulence;Fungal infection;Fungal skin infection;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Genetic polymorphism;Haemoglobin decreased;Headache;Hearing impaired;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatotoxicity;Hostility;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypoaesthesia;Hyponatraemia;Hypotension;Ill-defined disorder;Immunocompromised;Immunodeficiency;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Infusion site reaction;Injection site pain;Insomnia;Instillation site pain;Irritability;Jaundice;Jaundice cholestatic;Lactic dehydrogenase activity increased;Leukopenia;Liver function test abnormal;Loose stools;Loss of consciousness;Malaise;Melaena;Menorrhagia;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Nephritis;Nephritis interstitial;Nephrotic syndrome;Nervousness;Neutropenia;Oedema;Oesophagitis;Oral candidiasis;Otitis media;Pain;Palpitations;Pancreatitis;Paraesthesia;Parosmia;Pathogen resistance;Pertussis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Platelet count decreased;Pleural effusion;Pneumonia;Pollakiuria;Potassium low;Prolonged menses;Pruritus;Pseudomembranous colitis;Punctate keratitis;Pyloric stenosis;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Renal failure acute;Rhinitis;Serum sickness;Shock;Sinusitis;Sinusitis bacterial;Skin discolouration;Skin infection;Sodium decreased;Somnolence;Stevens-Johnson syndrome;Stinging;Stomach ache;Stomatitis;Sweating;Swelling;Swelling face;Syncope;Tension;Thrombocytopenia;Tinnitus;Tongue discolouration;Torsade de pointes;Toxic epidermal necrolysis;Transaminases increased;Tubulointerstitial nephritis;Unspecified non-gonococcal urethritis (NGU);Urethritis;Urticaria;Vaginal infection;Vaginal inflammation;Vasculitis;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Viral infection;Vision blurred;Visual impairment;Vomiting,small molecule,approved,"Azithromycin; Azithromycine; Azithromycinum; Azitromicina; 3.5.3.15; HL-60 PAD; PAD4; PADI5; PDI5; Peptidylarginine deiminase IV; Protein-arginine deiminase type IV; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",23S ribosomal RNA; Protein-arginine deiminase type-4, J01FA10; J01RA16; S01AA26;J01FA10;J01RA07
aztreonam,Abdominal infection;Abscess;Asymptomatic bacteriuria;Bacteraemia;Bladder pain;Bone and joint infections;Bronchitis;Cystic fibrosis;Cystitis;Cystitis noninfective;Endometritis;Genital infection female;Gonorrhoea;Gynecological infection;Infection;Lower respiratory tract infection;Meningitis;Nephropathy toxic;Nephrotoxicity;Ototoxicity;Parametritis;Pelvic inflammatory disease;Peritonitis;Pneumonia;Pseudomonas infection;Pyelonephritis;Sepsis;Septicemia;Ulcer;Urinary tract infection;Wound,Abdominal cramps;Abdominal distension;Abdominal pain;Ache;Alanine aminotransferase increased;Anaemia;Anaphylactic shock;Angioedema;Aspartate aminotransferase increased;Asthenia;Blood creatinine increased;Body temperature increased;Breast tenderness;Breath odour;Bronchospasm;Candida infection;Chest discomfort;Chest pain;Confusional state;Convulsion;Coombs test positive;Cough;Dermatitis;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Dizziness;Dysgeusia;Dyspnoea;Eosinophilia;Erythema;Erythema multiforme;Extrasystoles;Feeling abnormal;Flushing;Gastrointestinal haemorrhage;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Hepatitis;Hyperhidrosis;Hypersensitivity;Hypotension;Ill-defined disorder;Induration;Injection site swelling;Insomnia;Jaundice;Joint swelling;Laryngeal pain;Leukocytosis;Local reaction;Malaise;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nausea;Neutropenia;Pain;Pancytopenia;Paraesthesia;Petechiae;Pharyngolaryngeal pain;Phlebitis;Pruritus;Pseudomembranous colitis;Purpura;Rash;Serum creatinine increased;Sneezing;Stomatitis;Sweating increased;Swelling;Taste altered;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Tinnitus;Toxic epidermal necrolysis;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vascular purpura;Ventricular bigeminy;Ventricular extrasystoles;Vertigo;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Wheezing,small molecule,approved,"(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid; 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl) -2- {[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino} -2- oxoethylidene]amino}oxy)-2-methylpropanoic acid; Aztreonam; Aztréonam; Aztreonamum; PBP 3; Penicillin-binding protein C; PSPB20; ycsM; yzsA; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; 3.5.2.6; blaC; Cephalosporinase; 3.5.2.6",Penicillin-binding protein 3; Peptidoglycan synthase FtsI; Beta-lactamase; Beta-lactamase Toho-1,J01DF01
baclofen,Bladder dysfunction;Brain disorder NOS;Brain injury;Cerebral palsy;Cerebrovascular disorder;Clonus;Epilepsy;Head injury;Hypertonia;Multiple sclerosis;Muscle rigidity;Muscle spasms;Muscle spasticity;Nervous system disorder;Pain;Pulmonary function test decreased;Respiratory depression;Spinal cord disorder;Spinal cord injury;Traumatic brain injury,Abdominal colic;Abdominal pain;Abnormal ejaculation;Abnormal vision;Accidental injury;Accommodation disorder;Affect lability;Ageusia;Agitation;Akathisia;Albuminuria;Alopecia;Amnesia;Anaemia;Angiopathy;Ankle edema;Anorexia;Anxiety;Apnoea;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Ataxia;Autonomic nervous system imbalance;Back pain;Bladder pain;Bladder spasm;Blood alkaline phosphatase increased;Blood in stool;Body temperature decreased;Body temperature increased;Bradycardia;Breast disorder;Calculus of kidney;Carcinoma;Cardiac disorder;Cardiac output decreased;Cerebral ischaemia;Cerebrovascular accident;Cerebrovascular disorder;Chest discomfort;Chest pain;Chest tightness;Chills;Coma;Completed suicide;Confusional state;Connective tissue disorder;Constipation;Conversion disorder;Convulsion;Coordination abnormal;Decreased appetite;Deep vein thrombosis;Dehydration;Depression;Dermatitis;Dermatitis contact;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disorientation;Dizziness;Drowsiness;Drug ineffective;Drug withdrawal syndrome;Dry mouth;Dysarthria;Dysautonomia;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphoria;Dyspnoea;Dysuria;Ejaculation disorder;Enuresis;Erectile dysfunction;Euphoric mood;Excitement;Exhaustion;Eye disorder;Face oedema;Faecal incontinence;Fatigue;Feeling abnormal;Flatulence;Flushing;Gait disturbance;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Haematochezia;Haematuria;Hallucination;Headache;Hepatic function abnormal;Hepatobiliary disease;Hyperglycaemia;Hyperhidrosis;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypogeusia;Hyporeflexia;Hypotension;Hypothermia;Hypotonia;Hypoventilation;Hypoxia;Hysteria;Ileus;Ill-defined disorder;Infection;Influenza;Injury;Insomnia;Joint swelling;Lack of drug effect;Lassitude;Lethargy;Leukocytosis;Lightheadedness;Loss of consciousness;Major depression;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Memory loss;Meningitis;Mental disability;Mental disorder;Miosis;Mood swings;Muscle relaxant therapy;Muscle spasticity;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Mydriasis;Nasal congestion;Nausea;Neck stiffness;Neoplasm malignant;Nephrolithiasis;Nervous system disorder;Nightmare;Nocturia;Nuchal rigidity;Numbness;Nystagmus;Oedema;Oedema peripheral;Oliguria;Opisthotonus;Orthostatic hypotension;Osteoarthritis;Pain;Pallor;Palpitations;Paraesthesia;Paranoia;Paranoid reaction;Personality change;Personality disorder;Petechiae;Phosphatase alkaline increased;Photophobia;Pneumonia;Pneumonia aspiration;Pollakiuria;Pruritus;Psychotic depression;Psychotic disorder;Pulmonary embolism;Pulmonary function test decreased;Rash;Renal failure;Respiratory depression;Respiratory failure;Respiratory rate decreased;Retching;Rhinitis;Salivary hypersecretion;Sensory loss;Sepsis;Septicemia;Sexual dysfunction;Shock;Skin disorder;Skin ulcer;Slurred speech;Somnolence;Speech disorder;Subdural haematoma;Suicidal ideation;Suicide;Suicide attempt;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Taste disorders;Thinking abnormal;Thrombophlebitis;Tingling sensation;Tinnitus;Tongue disorder;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urination impaired;Urticaria;Vaginal infection;Vaginal inflammation;Ventricular arrhythmia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;Withdrawal symptom;Wound dehiscence,small molecule,approved,(+-)-Baclofen; 4-Amino-3-(4-chlorophenyl)butyric acid; Baclofen; Baclofène; Baclofeno; Baclofenum; beta-(4-Chlorophenyl)gaba; beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; beta-(Aminomethyl)-p-chlorohydrocinnamic acid; beta-(p-Chlorophenyl)-gamma-aminobutyric acid; DL-4-Amino-3-p-chlorophenylbutanoic acid; DL-Baclofen; gamma-Amino-beta-(p-chlorophenyl)butyric acid; G-protein coupled receptor 51; GABA-B receptor 2; GABA-B-R2; GABA-BR2; GABABR2; Gb2; GPR51; GPRC3B; HG20; CXC-R4; CXCR-4; FB22; Fusin; HM89; LAP-3; LCR1; LESTR; Leukocyte-derived seven transmembrane domain receptor; Lipopolysaccharide-associated protein 3; LPS-associated protein 3; NPYRL; SDF-1 receptor; Stromal cell-derived factor 1 receptor; GABA-B receptor 1; GABA-B-R1; GABA-BR1; GABABR1; Gb1; GPRC3A,Gamma-aminobutyric acid type B receptor subunit 2; C-X-C chemokine receptor type 4; Gamma-aminobutyric acid type B receptor subunit 1,M03BX01
beclomethasone,Asthma;Cutaneous lupus erythematosus;Discoid lupus erythematosus;Eczema;Intertrigo;Lichen planus;Lichen simplex chronicus;Localised infection;Nasal polyps;Neurodermatitis;Polyp;Pruritus;Psoriasis;Rhinitis;Rhinitis perennial;Seborrhoeic dermatitis;Skin disorder,Ageusia;Anaphylactic shock;Angioedema;Back pain;Bronchospasm;Cataract;Cataract subcapsular;Cough;Cushing's syndrome;Dermatitis;Dizziness;Dysmenorrhoea;Dysphonia;Epistaxis;Glaucoma;Growth retardation;Headache;Hyperadrenocorticism;Hypertrichosis;Infection;Intraocular pressure increased;Lacrimation increased;Lightheadedness;Nasal congestion;Nasal discomfort;Nasal irritation;Nasal septum perforation;Nasopharyngitis;Nausea;Oropharyngeal candidiasis;Pain;Pharyngitis;Rash;Rhinorrhoea;Secondary adrenocortical insufficiency;Sinusitis;Skin atrophy;Skin striae;Sneezing;Type IV hypersensitivity reaction;Ulcer;Urticaria;Wheezing,small molecule,approved,"(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 7α-Chloro-16α-methylprednisolone; Alclometasone; CBG; Serpin A6; Transcortin; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin",Corticosteroid-binding globulin; Glucocorticoid receptor, S01BA10;A07EA07;D07AB10
beclomethasone,Asthma;Localised infection;Nasal polyps;Polyp;Rhinitis,Ageusia;Aggression;Agitation;Anaphylactic shock;Angioedema;Asthma;Back pain;Bronchospasm;Candida albicans infection;Candida infection;Cataract;Cough;Dermatitis;Dizziness;Dysmenorrhoea;Dysphonia;Epistaxis;Glaucoma;Growth retardation;Headache;Hyperadrenocorticism;Hypersensitivity;Impaired healing;Infection;Intraocular pressure increased;Lacrimation increased;Lightheadedness;Nasal congestion;Nasal discomfort;Nasal irritation;Nasal septum perforation;Nasal septum ulceration;Nasopharyngitis;Nausea;Oropharyngeal candidiasis;Pain;Perennial allergic rhinitis;Pharyngitis;Rash;Rhinitis;Rhinitis perennial;Rhinorrhoea;Secondary adrenocortical insufficiency;Sinusitis;Sleep disorder;Sneezing;Suicidal ideation;Type IV hypersensitivity reaction;Ulcer;Upper respiratory tract infection;Urticaria;Wheezing,small molecule,approved,"(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 7α-Chloro-16α-methylprednisolone; Alclometasone; CBG; Serpin A6; Transcortin; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin",Corticosteroid-binding globulin; Glucocorticoid receptor, S01BA10;D07AB10
benazepril,Angioedema;Essential hypertension;Hypertension;Hypertensive;Nephropathy;Renal artery stenosis;Renal failure;Renal impairment,Abdominal pain;Acute coronary syndrome;Agranulocytosis;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anxiety;Arrhythmia;Arthralgia;Arthritis;Asthenia;Asthma;Back pain;Blood creatinine increased;Blood urea increased;Bronchitis;Cerebrovascular accident;Chest pain;Constipation;Coordination abnormal;Cough;Cough increased;Dermatitis;Diarrhoea;Disturbance in sexual arousal;Dizziness;Dizziness postural;Dyspepsia;Dyspnoea;Electrocardiogram change;Eosinophilia;Erectile dysfunction;Erythema multiforme;Face oedema;Fatigue;Flatulence;Flu symptoms;Flushing;Gastritis;Gastrointestinal pain;Haemolytic anaemia;Headache;Hepatitis;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertonia;Hyponatraemia;Hypotension;Hypotension symptomatic;Infection;Influenza;Insomnia;Jaundice cholestatic;Laryngeal oedema;Leukopenia;Libido decreased;Lip oedema;Lipoedema;Loss of consciousness;Melaena;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Nausea;Nervousness;Neutropenia;Oedema;Oedema peripheral;Orthostatic hypotension;Palpitations;Pancreatitis;Paraesthesia;Pemphigus;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pollakiuria;Protein urine present;Proteinuria;Pruritus;Pulmonary eosinophilia;Rash;Rhinitis;Serum creatinine increased;Shock;Sinusitis;Small bowel angioedema;Somnolence;Stevens-Johnson syndrome;Sweating;Syncope;Taste disorders;Tension;Thrombocytopenia;Tinnitus;Upper respiratory tract signs and symptoms;Urinary tract infection;Vertigo;Vomiting,small molecule,approved; investigational,"Bénazépril; Benazepril; Benazeprilum; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; 1.5.1.53; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Angiotensin-converting enzyme, C09AA07; C09BA07;C09AA07;C09BB13
bendrofluazide,Cardiac failure congestive;Essential hypertension;Nephrotic syndrome;Oedema,Allergic cutaneous angiitis;Anorexia;Asthenia;Blood disorder;Constipation;Cramp muscle;Decreased appetite;Dermatitis;Diabetes mellitus;Diarrhoea;Dizziness;Drug interaction;Epigastric discomfort;Erectile dysfunction;Gastric irritation;Gout;Hepatic encephalopathy;Hypocalciuria;Hypokalaemia;Hypotension;Hypotensive;Leukocytoclastic vasculitis;Muscle spasms;Nausea;Orthostatic hypotension;Pancreatitis;Polyuria;Potassium imbalance;Purpura;Rash;Thirst;Thrombocytopenia;Urine output increased;Vascular purpura;Vomiting,small molecule,approved,"±-3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; Bendrofluazide; Bendroflumethiazid; Bendrofluméthiazide; Bendroflumethiazide; Bendroflumethiazidum; Bendroflumetiazida; Benzhydroflumethiazide; Na-Cl cotransporter; Na-Cl symporter; NCC; Thiazide-sensitive sodium-chloride cotransporter; TSC; BSC1; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; Kidney-specific Na-K-Cl symporter; Na-K-2Cl cotransporter 2; NKCC2; BK channel; BKCA alpha; Calcium-activated potassium channel, subfamily M subunit alpha-1; hSlo; K(VCA)alpha; KCa1.1; KCNMA; Maxi K channel; MaxiK; SLO; Slo homolog; Slo-alpha; Slo1; Slowpoke homolog; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-IV; Carbonate dehydratase IV; Carbonic anhydrase IV; 2.1.1.67; Thiopurine methyltransferase",Solute carrier family 12 member 3; Solute carrier family 12 member 1; Calcium-activated potassium channel subunit alpha-1; Carbonic anhydrase 1; Carbonic anhydrase 2; Carbonic anhydrase 4, C03AA01; C03EA13; G01AE10;C03AA01;C03AB01
benzocaine,Acute swimmers' ear;Aphthous stomatitis;Discomfort;Ear pain;Otitis externa;Otitis media acute;Pain,Burning mouth;Cyanosis;Dermatitis;Dermatitis contact;Dyspnoea;Erythema;Hypersensitivity;Methaemoglobinaemia;Oedema;Oral discomfort;Pruritus;Rash;Redness;Respiratory distress;Swelling;Tenderness;Urticaria,small molecule,approved; investigational,"4-aminobenzoic acid ethyl ester; Amben ethyl ester; Benzocaina; Benzocaine; Benzocainum; Ethyl aminobenzoate; Ethyl p-aminobenzoate; Ethyl p-aminophenylcarboxylate; p-(Ethoxycarbonyl)aniline; p-Carbethoxyaniline; p-Ethoxycarboxylic aniline; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium channel protein type 10 subunit alpha, D04AB04; N01BA05; R02AD01;C05AD03
benztropine,Extrapyramidal disorder;Parkinson's disease;Parkinsonism;Tardive dyskinesia,"Apathy;Appetite absent;Body temperature increased;Cerebrovascular accident;Confusional state;Constipation;Decreased appetite;Dermatitis;Disorientation;Dry mouth;Dysphagia;Dysuria;Feeling abnormal;Flat affect;Hallucination, visual;Heat stroke;Hypersensitivity;Hypoaesthesia;Ileus;Ileus paralytic;Memory impairment;Mydriasis;Nausea;Nervousness;Numbness in fingers;Psychotic disorder;Rash;Tachycardia;Tension;Urinary retention;Vision blurred;Vomiting",small molecule,approved,"3-alpha-(diphenylmethoxy)tropane; 3endo-benzhydryloxytropane; 3α-(diphenylmethoxy)-1αH,5αH-tropane; 3α-(diphenylmethoxy)tropane; 3α-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; Benzatropina; Benzatropine; Benzatropinum; benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether; Benztropine; Tropine benzohydryl ether; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; H1-R; H1R; HH1R; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2",Muscarinic acetylcholine receptor M1; Sodium-dependent dopamine transporter; Histamine H1 receptor; Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter,N04AC01
penicillin,Actinomycosis;Anthrax;Arthritis;Asthma;Bacillary infections;Bacteraemia;Bacterial sepsis;Botulism;Cardiac valve disease;Chorea;Clostridial infection;Congenital syphilis;Corynebacterium infection;Diphtheria;Empyema;Endocarditis;Endocarditis bacterial;Erysipelas;Erysipeloid;Gas gangrene;Gingivitis ulcerative;Glomerulonephritis acute;Gonorrhoea;Heart disease congenital;Hypersensitivity;Infection;Listeriosis;Meningitis;Meningitis meningococcal;Necrotising ulcerative gingivostomatitis;Neurosyphilis;Otitis media;Pasteurella infection;Pericarditis;Peritonitis;Pharyngitis;Pharyngitis streptococcal;Pinta;Pneumococcal infection;Pneumonia;Pneumonia anthrax;Pneumonia staphylococcal;Rat-bite fever;Renal failure;Renal impairment;Rheumatic disorder;Rheumatic fever;Rheumatic heart disease;Rhinitis seasonal;Scarlet fever;Seasonal allergy;Sepsis;Septic arthritis streptobacillus;Septicemia;Sexually transmitted disease;Soft tissue infection;Staphylococcal infection;Streptobacillary fever;Streptococcal infection;Streptococcus pyogenes pharyngitis;Subacute bacterial endocarditis;Subacute endocarditis;Syphilis;Tetanus;Tonsillitis;Trench mouth;Urticaria;Wound infection;Yaws;Zoonotic bacterial infection,"Abdominal discomfort;Abdominal pain;Abscess;Aggravation of existing disorder;Agitation;Allergic cutaneous angiitis;Anaphylactic shock;Angioedema;Anxiety;Apnoea;Application site pain;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Atrophy;Auditory and visual hallucinations;Blindness;Blood disorder;Blood in stool;Blood sodium increased;Blood urea increased;Body temperature increased;Bronchospasm;Cardiac arrest;Cardiac failure congestive;Cellulitis;Cerebrovascular accident;Chills;Coagulopathy;Coma;Condition aggravated;Confusional state;Convulsion;Coombs positive haemolytic anaemia;Cyanosis;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Discomfort;Dizziness;Dyspnoea;Ecchymosis;Eosinophilia;Eosinophiluria;Erectile dysfunction;Eruption;Euphoric mood;Fatigue;Feeling abnormal;Feeling hot;Flushing;Gangrene;Gastrointestinal necrosis;Gastrointestinal pain;Gastrointestinal tract irritation;Haematochezia;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucinations, mixed;Headache;Hoigne's syndrome;Hyperhidrosis;Hyperkalaemia;Hyperreflexia;Hyperventilation;Hypoaesthesia;Hypotension;Hypoxia;Ill-defined disorder;Inflammation;Injection site pain;Injection site reaction;Instillation site pain;Intestinal necrosis;Jarisch-Herxheimer reaction;Laryngeal oedema;Laryngospasm;Leukocytoclastic vasculitis;Leukopenia;Local reaction;Loss of consciousness;Lyme disease;Lymphadenopathy;Malaise;Mass;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myelitis transverse;Myoglobin urine present;Myoglobinuria;Nausea;Necrosis;Nephritis interstitial;Nephropathy;Nervousness;Neurogenic bladder;Neuropathy;Neuropathy peripheral;Neutropenia;Numbness of limbs;Oedema;Osteoarthritis;Pain;Pallor;Palpitations;Periostitis;Phlebitis;Platelet dysfunction;Priapism;Prostration;Protein urine present;Proteinuria;Pruritus;Pseudomembranous colitis;Psychotic disorder;Pulmonary embolism;Pulmonary hypertension;Rash;Relapsing fever;Renal failure;Rhabdomyolysis;Sensitisation;Serum sickness;Shock;Skin ulcer;Sodium high;Somnolence;Stomatitis;Sweating increased;Syncope;Tachycardia;Tension;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tongue discolouration;Tongue hairy;Tremor;Tubulointerstitial nephritis;Vasodilation;Vasodilation procedure;Vasospasm;Vision blurred;Vomiting;Warmth;White blood cells urine positive",small molecule,approved,"(−)-penicillamine; (S)-2-amino-3-mercapto-3-methylbutanoic acid; (S)-3,3-dimethylcysteine; 3-mercapto-D-valine; D-(−)-penicillamine; D-penicillamine; D-β,β-dimethylcysteine; penicilamina; Penicillamine; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Copper,J01CE01;M01CC01
bepridil,Angina pectoris;Stable angina pectoris,Abdominal discomfort;Abdominal pain;Acute myocardial infarction;Akathisia;Angina pectoris;Anorexia;Anxiety;Arrhythmia;Arthritis;Asthenia;Atrioventricular block first degree;Body temperature increased;Bradycardia;Cardiac disorder;Cardiac failure;Constipation;Cough;Decreased appetite;Depression;Dermatitis;Diarrhoea;Distress;Distress gastrointestinal;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Dyspnoea;Electrocardiogram QT prolonged;Emotional distress;Erectile dysfunction;Flatulence;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Headache;Hyperhidrosis;Hypertension;Increased appetite;Influenza;Insomnia;Liver function test abnormal;Loss of consciousness;Loss of libido;Musculoskeletal discomfort;Myalgia;Nausea;Nervousness;Oedema;Pain;Palpitations;Paraesthesia;Pharyngitis;Rash;Respiratory tract infection;Rhinitis;Shock;Sinus bradycardia;Sinus tachycardia;Skin irritation;Somnolence;Sudden death;Superinfection;Sweating;Syncope;Tension;Tinnitus;Torsade de pointes;Tremor;Vasodilation;Vasodilation procedure;Ventricular arrhythmia;Ventricular tachycardia;Vertigo;Vision blurred,small molecule,approved; withdrawn,"1-(2-(N-BENZYLANILINO)-1-(ISOBUTOXYMETHYL)ETHYL)-PYRROLIDINE; 1-PYRROLIDENEETHANAMINE, .BETA.-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-; Bepadin; Bepridil; BI; Brain calcium channel I; CACH4; CACN3; CACNL1A4; Calcium channel, L type, alpha-1 polypeptide isoform 4; Voltage-gated calcium channel subunit alpha Cav2.1; Low-voltage-activated calcium channel alpha1 3.2 subunit; Voltage-gated calcium channel subunit alpha Cav3.2; KIAA0558; Voltage-gated calcium channel subunit alpha-2/delta-2; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1; KCNA8; KCNA9; KQT-like 1; KVLQT1; Voltage-gated potassium channel subunit Kv7.1; TN-C; TNNC; 3.1.4.17; 63 kDa Cam-PDE; Cam-PDE 1B; PDES1B; 3.1.4.17; 61 kDa Cam-PDE; Cam-PDE 1A; hCam-1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","Voltage-dependent P/Q-type calcium channel subunit alpha-1A; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent calcium channel subunit alpha-2/delta-2; Sodium/potassium-transporting ATPase subunit alpha-1; Potassium voltage-gated channel subfamily KQT member 1; Troponin C, slow skeletal and cardiac muscles; Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A; Voltage-gated inwardly rectifying potassium channel KCNH2; Calmodulin",C08EA02
betahistine,Deafness;Hearing impaired;Meniere's disease;Nausea;Tinnitus;Vertigo;Vomiting,Abdominal bloating;Abdominal distension;Abdominal pain upper;Anaphylactic shock;Angioedema;Asthenia;Asthma;Bronchospasm;Confusional state;Convulsion;Cutaneous hypersensitivity;Dermatitis;Dermatitis atopic;Diarrhoea;Digestion impaired;Discomfort;Dizziness;Dyspepsia;Dyspnoea;Epigastric pain;Erythema multiforme;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal disorder;Hallucination;Headache;Hypersensitivity;Ill-defined disorder;Immune system disorder;Malaise;Nausea;Nervous system disorder;Orthostatic hypotension;Pruritus;Rash;Skin disorder;Somnolence;Stevens-Johnson syndrome;Tachycardia;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Vomiting,small molecule,approved; investigational,[2-(2-pyridyl)ethyl]methylamine; 2-(β-methylaminoethyl)pyridine; 2-[2-(methylamino)ethyl]pyridine; Betahistina; Bétahistine; Betahistine; Betahistinum; N-methyl-2-(2-pyridinyl)ethanamine; N-methyl-2-pyridineethanamine; H1-R; H1R; HH1R; G-protein coupled receptor 97; GPCR97; H3R; HH3R; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B,Histamine H1 receptor; Histamine H3 receptor,N07CA01
dexamethasone,Acute leukaemia;Addison's disease;Adrenal insufficiency;Adrenocortical insufficiency acute;Anterior ischemic optic neuropathy;Arthritis;Asthma;Asthma chronic;Blood disorder;Brain neoplasm;Brain oedema;Cerebrovascular accident;Chorioretinitis;Colitis ulcerative;Collagen disorder;Conjunctivitis allergic;Corneal ulcer marginal;Cutaneous sarcoidosis;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Dermatomyositis;Edema cerebral;Endocrine disorder;Enteritis;Erythema multiforme;Eye disorder;Gastrointestinal disorder;Giant cell arteritis;Haemolytic anaemia;Hypercalcaemia;Infection;Injury;Keratitis;Laryngitis;Laryngospasm;Leukaemia;Lichen simplex chronicus;Lung disorder;Lymphoma;Neoplasm;Neoplasm malignant;Neurodermatitis;Non-Hodgkin's lymphoma;Oedema;Optic ischaemic neuropathy;Optic neuritis;Osteoarthritis;Pemphigus;Polyarteritis nodosa;Proctocolitis;Psoriasis;Respiratory failure;Respiratory insufficiency;Rheumatic disorder;Rheumatic heart disease;Rheumatism;Rheumatoid arthritis;Sarcoidosis;Seborrhoeic dermatitis;Secondary adrenocortical insufficiency;Shock;Skin disorder;Status asthmaticus;Systemic lupus erythematosus;Temporal arteritis;Thrombocytopenic purpura;Trauma;Ulcer;Ulcerative keratitis,Abdominal distension;Abdominal pain;Abscess;Acute coronary syndrome;Alkalosis hypokalaemic;Amenorrhoea;Angioedema;Angiopathy;Anorexia;Anxiety;Arthralgia;Arthropathy;Aseptic necrosis;Asthenia;Atrophy;Birth weight low;Blister;Body temperature increased;Carbohydrate tolerance decreased;Cardiac failure congestive;Cataract;Cataract subcapsular;Cognitive disorder;Cognitive impairment;Convulsion;Decreased appetite;Delusion;Dependence psychological;Dermatitis atopic;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Drug dependence;Dyspepsia;Ecchymosis;Electrolyte imbalance;Embolism;Embolism venous;Epilepsy;Erythema;Euphoric mood;Exophthalmos;Eye infection;Eye infection viral;Fatigue;Feeling abnormal;Gastrointestinal pain;Glaucoma;Growth retardation;Haemoglobin;Haemorrhage;Hallucination;Headache;Herpes simplex;Hiccups;Hirsutism;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertrophic cardiomyopathy;Hypocalcaemia;Hypotension;Ill-defined disorder;Impaired healing;Increased appetite;Increased insulin requirement;Increased tendency to bruise;Inflammatory bowel disease;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Irritability;Lethargy;Leukocytosis;Leukoderma;Low birth weight baby;Malaise;Mania;Menstruation irregular;Muscle atrophy;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial rupture;Myopathy;Nausea;Necrosis ischaemic;Nerve injury;Neuropathy;Neuropathy peripheral;Oesophageal candidiasis;Oesophagitis;Opportunistic infection;Optic neuritis;Osteoarthritis;Osteonecrosis;Osteoporosis;Pain;Pancreatitis;Pancreatitis acute;Papilloedema;Paraesthesia;Peptic ulcer;Petechiae;Polymorphonuclear leukocytosis;Posterior subcapsular cataract;Proximal myopathy;Retinopathy of prematurity;Schizophrenia;Scleral thinning;Skin atrophy;Skin exfoliation;Skin hyperpigmentation;Skin striae;Spinal compression fracture;Steroid myopathy;Steroid withdrawal syndrome;Stinging;Suicidal ideation;Sweating increased;Telangiectasia;Tendon rupture;Thromboembolism;Tingling sensation;Tuberculosis;Urticaria;Vasculitis;Vertigo;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational; vet_approved,"1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 1-Dehydro-16α-methyl-9α-fluorohydrocortisone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16α-Methyl-9α-fluoro-1-dehydrocortisol; 9alpha-Fluoro-16alpha-methylprednisolone; 9α-Fluoro-16α-methylprednisolone; Dexametasona; Dexaméthasone; Dexamethasone; Dexamethasonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; AHC; DAX1; DSS-AHC critical region on the X chromosome protein 1; Nuclear receptor DAX-1; Annexin I; Annexin-1; ANX1; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; LPC1; p35; Phospholipase A2 inhibitory protein; 1.14.13.39; HEP-NOS; Hepatocyte NOS; Inducible NO synthase; Inducible NOS; iNOS; NOS type II; NOS2A; Peptidyl-cysteine S-nitrosylase NOS2; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1.1.1.-; 11-beta-HSD type II; 11-beta-HSD2; 11-beta-hydroxysteroid dehydrogenase type II; 11-DH2; 11-HSD type II; Corticosteroid 11-beta-dehydrogenase isozyme 2; HSD11K; NAD-dependent 11-beta-hydroxysteroid dehydrogenase; SDR9C3; Short chain dehydrogenase/reductase family 9C member 3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.1.1.146; 11-beta-HSD1; 11-DH; 7-oxosteroid reductase; Corticosteroid 11-beta-dehydrogenase isozyme 1; HSD11; HSD11L; SDR26C1; Short chain dehydrogenase/reductase family 26C member 1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.19; 17-alpha-hydroxyprogesterone aldolase; CYP17; CYPXVII; Cytochrome P450 17A1; Cytochrome P450-C17; Cytochrome P450c17; S17AH; Steroid 17-alpha-monooxygenase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; 1.14.14.1; 20-HETE synthase; 20-hydroxyeicosatetraenoic acid synthase; CYP4A2; CYP4AII; CYPIVA11; Cytochrome P-450HK-omega; Cytochrome P450HL-omega; Fatty acid omega-hydroxylase; Lauric acid omega-hydroxylase; Long-chain fatty acid omega-monooxygenase; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3","Glucocorticoid receptor; Nuclear receptor subfamily 0 group B member 1; Annexin A1; Nitric oxide synthase, inducible; Nuclear receptor subfamily 1 group I member 2", A01AC02; C05AA09; D07AB19; D07CB04; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CA01; S01CB01; S02BA06; S02CA06; S03BA01; S03CA01;R01AD53
betaxolol,Asthma;Bronchial hyperreactivity;Chronic obstructive pulmonary disease;Chronic open angle glaucoma;Glaucoma;Hypertension;Ocular hypertension;Open angle glaucoma;Primary open angle glaucoma,Abnormal dreams;Abnormal sensation in eye;Abnormal vision;Accidental injury;Ache;Acidosis;Acute coronary syndrome;Affect lability;Ageusia;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Amnesia;Anaemia;Angina pectoris;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Arrhythmia;Arterial thrombosis;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthenopia;Asthma;Ataxia;Atrioventricular block;Bizarre dreams;Bladder pain;Blepharitis;Blepharospasm;Block heart;Blood lactate dehydrogenase increased;Blood uric acid increased;Body temperature increased;Bradycardia;Breast abscess;Breast disorder;Breast pain;Bronchitis;Bronchospasm;Cardiac disorder;Cardiac failure;Cardiac failure acute;Cataract;Catatonia;Cerebration impaired;Cerebrovascular disorder;Chest pain;Chills;Colitis ischaemic;Confusional state;Conjunctival disorder;Conjunctival oedema;Conjunctivitis;Constipation;Corneal sensitivity decreased;Cough;Cramp muscle;Cramps of lower extremities;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Depressed level of consciousness;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Disorientation;Distress;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Eczema;Emotional distress;Endophthalmitis;Epistaxis;Erectile dysfunction;Erythema;Erythema of eyelid;Eye discharge;Eye disorder;Eye haemorrhage;Eye irritation;Eye pain;Eye pruritus;Eyelid margin crusting;Fatigue;Feeling abnormal;Fibroadenoma of breast;Fibroadenosis of breast;Flushing;Foreign body sensation in eyes;Gastrointestinal disorder;Glossitis;Gout;Hallucination;Headache;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hypersensitivity;Hyperthyroidism;Hypertonia;Hypertrichosis;Hyperuricaemia;Hypoaesthesia;Hypoaesthesia eye;Hypoglycaemia;Hypokalaemia;Hypotension;Hypothyroidism;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Injury;Insomnia;Intermittent claudication;Iritis;Keratitis;Kidney function abnormal;Lacrimal disorder;Lacrimation;Lacrimation abnormal NOS;Lacrimation increased;Lactic dehydrogenase activity increased;Laryngospasm;Lethargy;Leukocytosis;Libido decreased;Loss of consciousness;Lupus erythematosus;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Menstrual disorder;Mental disability;Mental disorder;Micturition disorder;Mood swings;Mouth ulceration;Muscle spasms;Muscle twitching;Musculoskeletal chest pain;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Myocardial infarction;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Nightmare;Numbness;Ocular discomfort;Ocular hyperaemia;Oedema;Oliguria;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Otitis media;Pain;Palpitations;Panophthalmitis;Paraesthesia;Periorbital oedema;Peripheral coldness;Peripheral ischaemia;Peyronie's disease;Pharyngitis;Photophobia;Pneumonia;Prostatitis;Protein urine present;Proteinuria;Pruritus;Psoriasis;Psychotic disorder;Punctate keratitis;Pupils unequal;Purpura;Purpura non-thrombocytopenic;Rash;Rash erythematous;Rectal disorder;Refraction disorder;Renal impairment;Renal pain;Respiratory distress;Respiratory failure;Rhinitis;Rhinorrhoea;Rigors;Salivary hypersecretion;Salivation;Scotoma;Sensation of foreign body;Sensory loss;Shock;Short-term memory loss;Sinusitis;Skin disorder;Sleep disorder;Sleep disturbance;Speech disorder;Stomatitis;Stupor;Sweating;Syncope;Systemic lupus erythematosus;Tachycardia;Tendonitis;Tension;Thinking abnormal;Thirst;Throat sore;Thrombocytopenia;Thrombocytopenic purpura;Thrombophlebitis;Thrombosis;Thyrotoxicosis;Tinnitus;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Vascular anomaly;Vascular purpura;Vertigo;Vision blurred;Visual acuity reduced;Visual impairment;Vitreous disorder;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; Betaxolol; Bétaxolol; Betaxololum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase,Beta-1 adrenergic receptor; Beta-2 adrenergic receptor, C07AB05; S01ED52;C07AB05;S01ED02
bethanechol,Urinary retention,Abdominal colic;Abdominal cramps;Abdominal pain;Asthma;Borborygmi;Bronchoconstriction;Bronchospasm;Convulsion;Diarrhoea;Discomfort;Eructation;Feeling abnormal;Feeling hot;Flushing;Gastrointestinal sounds abnormal;Headache;Hyperhidrosis;Hypotension;Ill-defined disorder;Lacrimation;Lacrimation increased;Malaise;Micturition urgency;Miosis;Nausea;Pollakiuria;Reflex tachycardia;Salivary hypersecretion;Salivation;Sensation of heat;Sensation of warmth;Sweating;Tachycardia,small molecule,approved,"(2-hydroxypropyl)trimethylammonium carbamate; 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium; 2-carbamoyloxypropyl-trimethylazanium; Amidopropyldimethylbetaine; Bethanechol; Carbamoyl-beta-methylcholine; carbamoyl-β-methylcholine; Carbamyl-beta-methylcholine; carbamyl-β-methylcholine",Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M5; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M4,N07AB02
bicalutamide,Adenocarcinoma of the prostate metastatic;Prostate cancer;Prostate cancer metastatic,Abdominal pain;Abnormal vision;Abscess periodontal;Acute coronary syndrome;Alanine aminotransferase increased;Alopecia;Anaemia;Angina pectoris;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Arrhythmia;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthma;Atrial fibrillation;Back pain;Balanitis;Bladder stenosis;Blood alkaline phosphatase increased;Blood bilirubin increased;Blood creatinine increased;Blood disorder;Blood urea increased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Breast disorder;Breast pain;Breast tenderness;Bronchitis;Calculus of kidney;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cataract;Cataract specified;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Chills;Confusional state;Conjunctivitis;Constipation;Coronary artery disease;Cough;Cough increased;Cramps of lower extremities;Creatinine increased;Cyst;Decreased appetite;Dehydration;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ecchymosis;Eosinophilia;Epistaxis;Erectile dysfunction;Face oedema;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Flatulence;Fracture;Gastritis;Gastrointestinal carcinoma;Gastrointestinal disorder;Gastrointestinal pain;Gout;Gynaecomastia;Haematuria;Haemoglobin;Haemoglobin decreased;Haemorrhage;Headache;Hepatic failure;Hepatobiliary disease;Hepatotoxicity;Hernia;Herpes zoster;Hirsutism;Hot flush;Hydronephrosis;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hypertransaminasaemia;Hypochromic anaemia;Hypoglycaemia;Immune system disorder;Incontinence;Infection;Influenza;Influenza like illness;Influenza-like symptoms;Injection site reaction;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal obstruction;Iron deficiency anaemia;Jaundice;Laboratory test abnormal;Libido decreased;Liver function test abnormal;Loss of consciousness;Lung disorder;Lung infiltration;Malnutrition;Mediastinal disorder;Melaena;Menopausal symptoms;Mental disorder;Micturition urgency;Multiple fractures;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Nausea;Neck pain;Neck stiffness;Neoplasm;Neoplasm malignant;Nephrolithiasis;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Nocturia;Nuchal rigidity;Oedema;Oedema peripheral;Osteoporotic fracture;Pain;Paraesthesia;Pelvic pain;Pharyngitis;Phosphatase alkaline increased;Pleural effusion;Pneumonia;Pollakiuria;Prostatic disorder;Pruritus;Pulmonary fibrosis;Rash;Rectal disorder;Rectal haemorrhage;Rhinitis;Sepsis;Shock;Sinusitis;Skin cancer;Skin carcinoma;Skin disorder;Skin hypertrophy;Skin ulcer;Somnolence;Sweating;Syncope;Tenderness;Tension;Thrombocytopenia;Thrombophlebitis;Tooth abscess;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urticaria;Visual impairment;Vomiting;Weight decreased;Weight increased;Yellow skin,small molecule,approved,"Bicalutamida; Bicalutamide; Bicalutamidum; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Androgen receptor, L02AE51;L02BB03
bisacodyl,Constipation,Abdominal cramps;Abdominal discomfort;Abdominal pain;Abdominal rigidity;Abdominal spasm;Anaphylactic shock;Angioedema;Anorectal discomfort;Blood in stool;Colitis;Cramp muscle;Dehydration;Diarrhoea;Dizziness;Gastrointestinal disorder;Gastrointestinal pain;Haematochezia;Headache;Hypersensitivity;Immune system disorder;Loss of consciousness;Malnutrition;Muscle spasms;Nausea;Nervous system disorder;Shock;Syncope;Vomiting,small molecule,approved,"Bisacodilo; Bisacodyl; Bisacodyle; Bisacodylum; Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester); AQP-3; Aquaglyceroporin-3; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1; 7.2.2.13; KIAA0778; Na(+)/K(+) ATPase alpha-2 subunit; Sodium pump subunit alpha-2; 7.2.2.13; Na(+)/K(+) ATPase alpha-3 subunit; Na(+)/K(+) ATPase alpha(III) subunit; Sodium pump subunit alpha-3; 7.2.2.13; ATP1AL2; Na(+)/K(+) ATPase alpha-4 subunit; Sodium pump subunit alpha-4; ATP1B; Sodium/potassium-dependent ATPase subunit beta-1; Adhesion molecule in glia; AMOG; Sodium/potassium-dependent ATPase subunit beta-2; ATPB-3; Sodium/potassium-dependent ATPase subunit beta-3; ATP1C; ATP1G1; FXYD domain-containing ion transport regulator 2; Na(+)/K(+) ATPase subunit gamma; Sodium pump gamma chain",Aquaporin-3; Sodium/Potassium Transporting ATPase, A06AB02; A06AG02;A06AB02;A06AB52
bisoprolol,Asthma;Cardiac failure;Hypertension;Hypertensive,Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal vision;Ache;Acute coronary syndrome;Affect lability;Ageusia;Agitation;Agranulocytosis;Alopecia;Angioedema;Angiopathy;Anosmia;Anxiety;Aphasia;Arrhythmia;Arterial thrombosis;Arthralgia;Arthropathy;Asthenia;Asthma;Atrial fibrillation;Atrioventricular block;Auditory disorder NOS;Back pain;Balance disorder;Bladder pain;Blood triglycerides increased;Body temperature increased;Bradycardia;Breast disorder;Breast pain;Bronchitis;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiomyopathy;Catatonia;Cerebrovascular disorder;Chest pain;Claudication;Coldness;Colitis ischaemic;Coma;Conduction disorder;Confusional state;Congenital anomaly;Congenital eye disorder;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cramp muscle;Cutaneous vasculitis;Cystitis;Cystitis noninfective;Depression;Dermatitis;Dermatitis exfoliative;Developmental delay;Diarrhoea;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dyspnoea exertional;Ear and labyrinth disorders;Ear pain;Eczema;Embolism;Encephalopathy;Epigastric pain not food-related;Erectile dysfunction;Erythema;Extrasystoles;Eye disorder;Eye pain;Fatigue;Feeling abnormal;Feeling cold;Fluid retention;Flushing;Fracture;Galactorrhoea;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gout;Hallucination;Headache;Hearing impaired;Hepatitis;Hepatobiliary disease;Hepatomegaly;Hot flush;Hyperaesthesia;Hyperhidrosis;Hypersensitivity;Hypoaesthesia;Hypoglycaemia;Hypotension;Ill-defined disorder;Infection;Injury;Insomnia;Intermittent claudication;Ischaemia;Lacrimal disorder;Lacrimation abnormal NOS;Laryngospasm;Left ventricular failure;Libido decreased;Loss of consciousness;Loss of libido;Malaise;Mediastinal disorder;Menopausal symptoms;Mental disorder;Mood swings;Multiple fractures;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Neck pain;Necrolysis epidermal;Nervous system disorder;Neuralgia;Nightmare;Numbness of limbs;Oedema;Oedema peripheral;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Osteoarthritis;Overdose effect;Pain;Palpitations;Paraesthesia;Paresis;Partial hearing loss;Peptic ulcer;Peripheral coldness;Peripheral ischaemia;Peyronie's disease;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pneumonia;Polyuria;Pruritus;Psoriasis;Pulmonary oedema;Purine metabolism disorder;Purpura;Rash;Raynaud's phenomenon;Raynaud-like disorder;Renal colic;Respiratory distress;Respiratory failure;Respiratory insufficiency;Respiratory tract haemorrhage;Respiratory tract oedema;Rhinitis;Rhinitis allergic;Scleroderma;Serum triglycerides increased;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin hyperpigmentation;Skin irritation;Sleep disorder;Sleep disturbance;Somnolence;Speech disorder;Stillbirth;Stridor;Sweating;Sweating increased;Syncope;Tachycardia;Throat sore;Thrombocytopenia;Thrombocytopenic purpura;Tingling sensation;Tinnitus;Toxic epidermal necrolysis;Toxicity to various agents;Tremor;Unspecified disorder of skin and subcutaneous tissue;Unsteadiness;Urinary tract infection;Urine output increased;Urticaria;Vascular purpura;Vasculitis;Vein disorder;Ventricular fibrillation;Vertigo;Viral infection;Visual disturbance;Visual impairment;Vivid dreams;Vomiting;Weight increased,small molecule,approved,"(+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol; (RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol; Bisoprolol; Bisoprololum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Beta-1 adrenergic receptor; Beta-2 adrenergic receptor, C07AB07; C07BB07; C07FB07; C09BX02; C09BX04; C09BX05; C09BX06;C07AB07;C07FX04
bretylium,Arrhythmia;Cardiac fibrillation;Sinus rhythm;Ventricular arrhythmia;Ventricular tachycardia,Abdominal pain;Affect lability;Angina pectoris;Anginal attack;Anxiety;Body temperature increased;Bradycardia;Confusional state;Conjunctivitis;Diarrhoea;Dizziness;Dyspnoea;Feeling abnormal;Flushing;Gastrointestinal pain;Hiccups;Hyperhidrosis;Hypertension;Inferior vena cava syndrome;Lethargy;Lightheadedness;Loss of consciousness;Mood swings;Nasal congestion;Nausea;Orthostatic hypotension;Paranoia;Psychotic disorder;Rash macular;Shock;Supine hypotension;Sweating increased;Syncope;Tenderness;Ventricular extrasystoles;Vertigo;Vomiting,small molecule,approved,"(2-bromobenzyl)ethyldimethylaminium; 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium; Bretylium; N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor",Sodium/potassium-transporting ATPase subunit alpha-1; Beta-1 adrenergic receptor,C01BD02
brimonidine,Chronic open angle glaucoma;Developmental glaucoma;Erythema;Erythema facial;Glaucoma;Ocular hypertension;Open angle glaucoma;Primary open angle glaucoma;Rosacea,Abnormal vision;Accidental exposure to product;Accidental ingestion;Acne;Allergic contact dermatitis;Angiopathy;Anterior uveitis;Anxiety;Apnoea;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Blanching;Blepharitis;Blepharoconjunctivitis;Blindness;Body temperature decreased;Bradycardia;Bronchitis;Burning sensation;Burning sensation in eye;Cardiac disorder;Cataract;Chest pain;Coma;Common cold;Conjunctival discharge;Conjunctival follicles;Conjunctival haemorrhage;Conjunctival hyperaemia;Conjunctival oedema;Conjunctivitis;Conjunctivitis allergic;Corneal erosion;Corneal oedema;Corneal staining;Cough;Cyanosis;Depression;Dermatitis;Dermatitis contact;Developmental glaucoma;Diabetes mellitus;Discomfort;Dizziness;Drowsiness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Endophthalmitis;Erythema;Erythema facial;Erythema of eyelid;Eye discharge;Eye disorder;Eye infection;Eye irritation;Eye oedema;Eye pain;Eye pruritus;Eye redness;Eyelid oedema;Eyelid retraction;Eyelids pruritus;Face oedema;Fatigue;Feeling hot;Flushing;Follicular conjunctivitis;Gastrointestinal disorder;Gastrointestinal symptom NOS;Glaucoma;Headache;Hordeolum;Hyperaemia;Hypercholesterolaemia;Hypersensitivity;Hypertension;Hypertrophy;Hypotension;Hypothermia;Hypotonia;Hypoventilation;Hypoxia;Immune system disorder;Infection;Influenza;Insomnia;Intraocular pressure increased;Iridocyclitis;Iritis;Keratitis;Keratoconjunctivitis sicca;Lacrimation;Lacrimation increased;Lethargy;Loss of consciousness;Mediastinal disorder;Mental disorder;Miosis;Muscle relaxant therapy;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasal dryness;Nasopharyngitis;Nausea;Nervous system disorder;Ocular hyperaemia;Ocular stinging;Oedema;Osteoarthritis;Osteoporosis;Pain;Pain of skin;Pallor;Palpitations;Paraesthesia;Peripheral coldness;Pharyngitis;Photophobia;Pruritus;Pulmonary function test decreased;Punctate keratitis;Rash;Rash papular;Respiratory depression;Respiratory failure;Respiratory tract infection;Rhinitis;Rosacea;Scab;Scotoma;Sensation of foreign body;Shock;Sinusitis;Skin burning sensation;Skin discomfort;Skin disorder;Skin irritation;Skin warm;Somnolence;Stinging;Superficial punctate keratopathy;Swelling;Syncope;Systemic allergic reaction;Tachycardia;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Vasodilation;Vasodilation procedure;Vision blurred;Visual disturbance;Visual impairment;Vital dye staining cornea present;Vitreous detachment;Vitreous disorder;Vitreous floaters,small molecule,approved,5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; Brimonidina; Brimonidine; Brimonidinum; Bromoxidine; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase,Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor, S01EA05; S01GA07;D11AX21;S01EA05
bromazepam,Agitation;Anxiety;Anxiety disorder;Anxiety neurosis;Distress;Emotional distress;Tension,Aggression;Agitation;Alertness decreased;Anaphylactic shock;Anger;Anorexia;Anterograde amnesia;Asthenia;Ataxia;Blood glucose decreased;Cardiac arrest;Cardiac disorder;Cardiac failure;Confusional state;Connective tissue disorder;Convulsion;Decreased appetite;Delusion;Depressed level of consciousness;Dermatitis;Digestion impaired;Diplopia;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Emotional disorder;Emotional disturbance NOS;Euphoric mood;Excitability;Eye disorder;Fatigue;Feeling abnormal;Fracture;Gastrointestinal disorder;Haemoglobin decreased;Hallucination;Headache;Hostility;Hypersensitivity;Hypotension;Incontinence;Irritability;Malnutrition;Mental disorder;Multiple fractures;Muscle spasms;Muscular weakness;Nausea;Nervous system disorder;Nervousness;Nightmare;Palpitations;Pruritus;Psychotic disorder;Pulmonary function test decreased;Rash;Respiratory depression;Skin disorder;Sleep disorder;Somnolence;Speech disorder;Tachycardia;Tension;Tremor;Unspecified disorder of skin and subcutaneous tissue;Vision blurred;Vomiting;White blood cell count decreased,small molecule,approved; illicit; investigational,Bromacepam; Bromazepam; Bromazepamum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J,GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site,N05BA08
bromhexine,Common cold;Cough;Infection;Influenza;Nasopharyngitis;Rhinitis,Abdominal pain upper;Anaphylactic shock;Angioedema;Bronchospasm;Dermatitis;Diarrhoea;Gastrointestinal disorder;Hypersensitivity;Immune system disorder;Nausea;Pruritus;Rash;Skin disorder;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vomiting,small molecule,approved,"3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine; Bromexina; Bromhexina; Bromhexine; Bromhexinum; N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine; 3.4.21.122; PRSS10; Serine protease 10; 3.4.17.23; ACE-related carboxypeptidase; ACEH; Angiotensin-converting enzyme homolog; Angiotensin-converting enzyme-related carboxypeptidase; Metalloprotease MPROT15; 3.4.17.23; ACE-related carboxypeptidase; ACEH; Angiotensin-converting enzyme homolog; Angiotensin-converting enzyme-related carboxypeptidase; Metalloprotease MPROT15",Transmembrane protease serine 2; Angiotensin-converting enzyme 2,R05CB02
bromocriptine,Abdominal bloating;Abdominal distension;Abnormal involuntary movements;Acromegaly;Acute coronary syndrome;Adenoma benign;Amenorrhoea;Angina pectoris;Azoospermia;Breast pain;Breast tenderness;Cerebrovascular accident;Confusional state;Dyskinesia;Endocrine disorder;Erectile dysfunction;Feeling abnormal;Fibrocystic breast disease;Flatulence;Galactorrhoea;Glucose tolerance impaired;Hallucination;Hypercholesterolaemia;Hyperprolactinaemia;Hypertension;Hypogonadism;Hypotension;Hypothyroidism;Infertility;Infertility female;Loss of libido;Luteal phase deficiency;Mood alteration NOS;Mood swings;Myocardial infarction;Nausea;Neoplasm;Oedema;Oligomenorrhoea;Oligospermia;Ovarian failure;Parkinson's disease;Parkinsonism;Premenstrual syndrome;Primary hypothyroidism;Prolactinoma;Stillbirth;Type 2 diabetes mellitus,"Abdominal cramps;Abdominal discomfort;Abdominal pain;Abdominal pain upper;Acromegaly;Acute coronary syndrome;Agitation;Alopecia;Amblyopia;Angiopathy;Anorexia;Anxiety;Arrhythmia;Asthenia;Ataxia;Binge eating;Blepharospasm;Body temperature increased;Bradycardia;Burning sensation;CNS toxicity;Cardiac disorder;Cardiac failure congestive;Cardiac valve disease;Cerebrospinal fluid leakage;Cerebrospinal fluid rhinorrhea;Cerebrovascular accident;Cold feet;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cramp muscle;Cramps of lower extremities;Decreased appetite;Delirium;Delusion;Dermatitis;Dermatitis atopic;Diabetes mellitus;Diabetic;Diarrhoea;Diplopia;Disseminated intravascular coagulation;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry mouth;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Epigastric pain;Ergot poisoning;Erythromelalgia;Excessive daytime sleepiness;Eye disorder;Fatigue;Feeling abnormal;Fibrosis;Gastric haemorrhage;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal ulcer;Hallucination;Hallucination, visual;Headache;Hyperprolactinaemia;Hypersexuality;Hypertension;Hypoaesthesia;Hypoglycaemia;Hypotension;Hypotensive;Impulse-control disorder;Infection;Influenza;Insomnia;Laboratory test abnormal;Lassitude;Lethargy;Libido increased;Lightheadedness;Loss of consciousness;Lung infiltration;Malignant syndrome NOS;Mania;Mediastinal disorder;Mental disorder;Muscle spasms;Myocardial infarction;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm recurrence;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Neurological symptom;Neurotoxicity;Nightmare;Numbness;Ocular discomfort;Oedema;Oedema peripheral;Orthostatic hypotension;Pallor;Pallor facial;Paraesthesia;Paranoia;Parkinson's disease;Parkinsonism;Pathological gambling;Peptic ulcer;Pericardial effusion;Pericarditis;Pericarditis constrictive;Peripheral coldness;Pleural effusion;Pleural fibrosis;Pleural thickening;Pleurisy;Pollakiuria;Presyncope;Psychotic disorder;Psychotic episode;Pulmonary fibrosis;Rash;Retroperitoneal fibrosis;Rhinitis;Rhinorrhoea;Secondary parkinsonism;Sensory loss;Shock;Sinusitis;Skin disorder;Sluggishness;Somnolence;Status epilepticus;Sudden onset of sleep;Superior sagittal sinus thrombosis;Syncope;Syncope vasovagal;Tachycardia;Taste metallic;Tension;Tingling sensation;Tinnitus;Type 2 diabetes mellitus;Unspecified disorder of skin and subcutaneous tissue;Urinary incontinence;Urinary retention;Urticaria;Vasculitis;Vasospasm;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting",small molecule,approved; investigational; withdrawn,"2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-bromo-α-ergocryptine; 2-bromo-α-ergokryptin; 2-bromo-α-ergokryptine; Bromocriptina; Bromocriptine; Bromocriptinum; Bromocryptine; Bromoergocriptine; Bromoergocryptine; Dopamine D2 receptor; Dopamine D3 receptor; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; D(2C) dopamine receptor; Dopamine D4 receptor; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D1 receptor; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",D(2) dopamine receptor; D(3) dopamine receptor; 5-hydroxytryptamine receptor 1D; Alpha-2A adrenergic receptor; 5-hydroxytryptamine receptor 1A; Alpha-2C adrenergic receptor; Alpha-2B adrenergic receptor; 5-hydroxytryptamine receptor 2B; D(4) dopamine receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 2C; D(1B) dopamine receptor; D(1A) dopamine receptor; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; 5-hydroxytryptamine receptor 7, G02CB01;G02CB01;N04BC01
budesonide,Asthma;Colitis ulcerative;Crohn's disease;Croup;Croup infectious;Inflammation;Nasal polyps;Perennial allergic rhinitis;Proctocolitis;Rhinitis;Rhinitis perennial;Rhinitis seasonal;Seasonal allergy;Vasomotor rhinitis,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal vision;Abscess;Ache;Acne;Adrenal insufficiency;Affect lability;Agitation;Allergic conditions;Allergic granulomatous angiitis;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Ankle edema;Anorectal disorder;Anorexia;Anosmia;Anus disorder;Anxiety;Appetite absent;Arthralgia;Arthritis;Arthritis aggravated;Asthenia;Back pain;Bad taste;Benign intracranial hypertension;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood cortisol decreased;Body temperature increased;Bone disorder;Breast disorder;Bronchitis;Bronchoconstriction;Bronchospasm;Bronchospasm paradoxical;Buffalo hump;Burning in throat;C-reactive protein increased;Candida albicans infection;Candida infection;Cardiac disorder;Cataract;Chest pain;Clotting;Coagulopathy;Confusional state;Congenital eye disorder;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Cough;Cough increased;Cramp muscle;Crohn's disease;Crohns disease aggravated;Cushing's syndrome;Cushingoid;Decreased appetite;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Disorder sight;Dizziness;Drug withdrawal syndrome;Dry mouth;Dysgeusia;Dyspepsia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear infection;Ear pain;Ear pruritus;Ecchymosis;Eczema;Endocrine disorder;Enteritis;Epigastric pain;Epistaxis;Eye disorder;Eye infection;Face oedema;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Flushing;Fracture;Gastric disorder;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal fistula;Gastrointestinal pain;Glaucoma;Glossitis;Gravitational oedema;Growth retardation;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoids;Hair growth abnormal;Hair growth increased;Headache;Herpes simplex;Hirsutism;Hoarseness;Hyperadrenocorticism;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hypokalaemia;Ill-defined disorder;Immune system disorder;Impaired healing;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Intestinal obstruction;Intraocular pressure increased;Irritability;Joint swelling;Leukocytoclastic vasculitis;Leukocytosis;Lightheadedness;Lipohypertrophy;Local reaction;Loss of consciousness;Lymphadenopathy;Lymphadenopathy cervical;Malaise;Malnutrition;Mediastinal disorder;Menstrual disorder;Mental disorder;Metrorrhagia;Migraine;Mood swings;Multiple fractures;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasal discomfort;Nasal irritation;Nasal septum perforation;Nasopharyngitis;Nausea;Neck pain;Necrosis ischaemic;Nervous system disorder;Nervousness;Nocturia;Oedema peripheral;Oral candidiasis;Oropharyngeal candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Osteonecrosis;Osteoporosis;Otitis media;Pain;Palpitations;Paraesthesia;Pharyngeal disorder;Pharyngitis;Phosphatase alkaline increased;Pollakiuria;Procedural complication;Pruritus;Psychiatric symptom;Psychotic disorder;Purpura;Pyuria;Rash;Rash pustular;Red blood cell sedimentation rate increased;Respiratory tract infection;Rhinitis;Rhinitis allergic;Scab;Secondary adrenocortical insufficiency;Sexual dysfunction;Shock;Sinusitis;Skin disorder;Skin irritation;Skin striae;Sleep disorder;Sneezing;Somnolence;Stridor;Sweating increased;Swelling;Syncope;Tachycardia;Tenderness;Tension;Thirst;Throat irritation;Throat sore;Tongue disorder;Tongue oedema;Tooth disorder;Tremor;Type IV hypersensitivity reaction;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular purpura;Vertigo;Viral diarrhoea;Viral infection;Viral upper respiratory tract infection;Vision blurred;Visual impairment;Vomiting;Weight increased;Wheezing;Withdrawal symptom,small molecule,approved,"(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; Budesónida; Budesonide; GR; GRL; Nuclear receptor subfamily 3 group C member 1; Annexin I; Annexin-1; ANX1; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; LPC1; p35; Phospholipase A2 inhibitory protein; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Glucocorticoid receptor; Annexin A1, A07EA06; D07AC09; R01AD05; R03AK07; R03AK12; R03AL11; R03BA02;A07EA06;R03AK15
bumetanide,Acute pulmonary oedema;Cardiac failure congestive;Foetor hepaticus;Hepatocellular injury;Hypersensitivity;Liver disorder;Nephropathy;Nephrotic syndrome;Oedema,Abdominal discomfort;Abdominal pain;Amylase increased;Arthralgia;Arthritic pains;Asterixis;Asthenia;Azotaemia;Blood creatinine increased;Blood disorder;Blood uric acid increased;Chest pain;Cholestasis;Cholestasis extrahepatic;Cramp muscle;Dehydration;Dermatitis;Diarrhoea;Diuresis;Dizziness;Dry mouth;Ear discomfort;Electrolyte imbalance;Encephalopathy;Erythema multiforme;Fatigue;Fluid and electrolyte imbalance;Gastrointestinal pain;Glucose urine increased;Glycosuria;Gynaecomastia;Headache;Hearing impaired;Hepatocellular injury;Hyperglycaemia;Hyperhidrosis;Hyperuricaemia;Hyperventilation;Hypochloraemia;Hypokalaemia;Hyponatraemia;Hypotension;Leukopenia;Liver injury;Muscle spasms;Musculoskeletal pain;Nausea;Nipple pain;Nipple tenderness;Pancreatitis;Partial hearing loss;Polyuria;Premature ejaculation;Pruritus;Rash;Renal failure;Serum amylase increased;Serum creatinine increased;Stevens-Johnson syndrome;Sweating;Thrombocytopenia;Toxic epidermal necrolysis;Upset stomach;Urticaria;Vertigo;Vomiting,small molecule,approved,3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid; 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid; 3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid; Bumetanida; Bumetanide; Bumetanidum; BSC1; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; Kidney-specific Na-K-Cl symporter; Na-K-2Cl cotransporter 2; NKCC2; Basolateral Na-K-Cl symporter; BSC2; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2; hNKCC1; Na-K-2Cl cotransporter 1; NKCC1; Electroneutral potassium-chloride cotransporter 1; Erythroid K-Cl cotransporter 1; hKCC1; KCC1; Electroneutral potassium-chloride cotransporter 2; hKCC2; K-Cl cotransporter 2; KCC2; KIAA1176; Neuronal K-Cl cotransporter; ABCC7; ATP-binding cassette sub-family C member 7; cAMP-dependent chloride channel; CFTR; Channel conductance-controlling ATPase; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3,Solute carrier family 12 member 1; Solute carrier family 12 member 2; Solute carrier family 12 member 4; Solute carrier family 12 member 5; Cystic fibrosis transmembrane conductance regulator, C03CA02; C03CB02; C03EB02;C03CA02;G01AE10
bupivacaine,Agitation;Atrioventricular block;Cardiac arrest;Cardiac output decreased;Chills;Chronic pain;Coma;Convulsion;Excitability;Foetor hepaticus;Hepatocellular injury;Hypotonia;Labour pain;Liver disorder;Muscle relaxation;Pain;Postoperative pain;Procedural pain;Respiratory arrest;Shivering;Tremor;Vascular resistance systemic;Vasodilation;Vasodilation procedure;Ventricular arrhythmia;Wound,Abdominal distension;Abdominal pain;Acidosis;Agitation;Alanine aminotransferase increased;Anaemia;Anaemia postoperative;Anal haemorrhage;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anterior spinal artery syndrome;Anxiety;Apnoea;Apprehension;Arachnoiditis;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrioventricular block;Back pain;Block heart;Blood bilirubin increased;Blood creatinine increased;Blood pressure increased;Body temperature decreased;Body temperature increased;Bone disorder;Bradycardia;Breast pain;Bronchospasm;CNS depression NOS;CNS toxicity;Carbon dioxide increased;Cardiac arrest;Cardiac disorder;Cardiac fibrillation;Cardiac output decreased;Cardiovascular disorder;Cauda equina syndrome;Chills;Chondrolysis;Circumoral paresthesia;Cold sweat;Confusional state;Constipation;Convulsion;Cough;Cranial nerve paralysis;Decreased appetite;Delayed delivery;Depressed level of consciousness;Depressed mood;Diarrhoea;Diplegia;Diplopia;Dizziness;Dizziness postural;Drowsiness;Drug hypersensitivity;Drug toxicity;Dysaesthesia;Dysarthria;Dyschezia;Dyspepsia;Dysphagia;Dyspnoea;Electrocardiogram abnormal;Enlargement abdomen;Erythema;Euphoric mood;Excitement;Extradural abscess;Extrasystoles;Extravasation;Feeling abnormal;Feeling hot;Flatulence;Flushing;Foetal distress syndrome;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Haematuria;Haemorrhage in pregnancy;Haemorrhagic anaemia;Headache;Horner's syndrome;Hyperacusis;Hypercapnia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoaesthesia oral;Hypocalcaemia;Hypoesthesia tongue;Hypokinesia;Hypotension;Hypotensive;Hypothermia;Ileus;Incision site oedema;Infection;Infestation;Infestation NOS;Injury;Injury associated with device;Insomnia;Laryngeal oedema;Laryngospasm;Lethargy;Leukocytosis;Lightheadedness;Loss of consciousness;Malnutrition;Meningism;Meningitis;Meningitis aseptic;Mental disorder;Miosis;Monoplegia;Muscle contractions involuntary;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Nausea;Neck pain;Neck stiffness;Needle injury;Nervous system disorder;Nervousness;Neurologic reaction;Neurological symptom;Neuropathy;Neuropathy peripheral;Neurotoxicity;Nuchal rigidity;Numbness;Numbness of tongue;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Oxygen saturation decreased;Pain;Pallor;Palpitations;Paraesthesia;Paraesthesia oral;Paralysis;Paraplegia;Paresis;Peripheral nerve injury;Post procedural swelling;Postoperative pain;Priapism;Procedural hypertension;Procedural hypotension;Procedural nausea;Procedural pain;Prurigo;Pruritus;Pruritus generalised;Pulmonary function test decreased;Pulmonary oedema;Purpura;Rectal discharge;Respiratory arrest;Respiratory depression;Respiratory failure;Respiratory insufficiency;Respiratory paralysis;Rigors;Sensation of heat;Sensory disturbance;Sensory loss;Shivering;Shock;Sinus bradycardia;Skin discolouration;Skin disorder;Slurred speech;Sneezing;Somnolence;Spinal anaesthesia;Stiffness;Supraventricular extrasystoles;Sweating;Sweating increased;Swelling face;Syncope;Tachycardia;Tension;Tinnitus;Total spinal block;Toxicity to various agents;Trauma;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urinary incontinence;Urinary retention;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine flow decreased;Urticaria;Vascular purpura;Vasoconstriction;Vasoconstriction peripheral;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vision blurred;Vomiting;Wound discharge increased;Wound secretion,small molecule,approved; investigational,"(±)-bupivacaine; (RS)-bupivacaine; 1-Butyl-2',6'-pipecoloxylidide; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; Bupivacaina; Bupivacaine; Bupivacainum; dl-1-Butyl-2',6'-pipecoloxylidide; DL-Bupivacaine; Racemic bupivacaine; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; PGE receptor EP1 subtype; PGE2 receptor EP1 subtype; Prostanoid EP1 receptor; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Sodium channel protein type 10 subunit alpha; Prostaglandin E2 receptor EP1 subtype, N01BB51; N01BB59;N01BB01
buprenorphine,Acute pain;Chronic pain;Dependence on opiates;Drug dependence;Opioid naive;Pain;Postoperative pain;Procedural pain;Therapy naive,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abscess;Accidental injury;Affect lability;Agitation;Alanine aminotransferase increased;Altered state of consciousness;Amblyopia;Anaphylactic responses;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Apathy;Apnoea;Appetite absent;Application site erythema;Application site irritation;Application site pruritus;Application site rash;Application site reaction;Arthralgia;Asthenia;Asthenic conditions;Asthma;Asthma aggravated;Atrioventricular block second degree;Back pain;Balance disorder;Biliary colic;Blood pressure increased;Body temperature increased;Bradycardia;Breast disorder;Bronchitis;Bronchospasm;CNS depression NOS;Cardiac disorder;Cardiovascular disorder;Cerebration impaired;Chest pain;Chills;Coma;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cramp muscle;Cyanosis;Decreased appetite;Dehydration;Depersonalisation;Depressed level of consciousness;Depressed mood;Depression;Dermatitis;Dermatitis contact;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Dizziness;Drug hypersensitivity;Drug interaction;Drug withdrawal syndrome;Dry eye;Dry mouth;Dry skin;Dysarthria;Dysequilibrium;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphoria;Dyspnoea;Ear and labyrinth disorders;Ear pain;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Erythema;Euphoric mood;Eye disorder;Eyelid oedema;Face oedema;Fasciculation;Fatigue;Feeling abnormal;Feeling hot;Flat affect;Flatulence;Flushing;Gait disturbance;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Heartburn;Hepatobiliary disease;Hiccups;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperventilation;Hypoaesthesia;Hypotension;Hypotensive;Hypoventilation;Hypoxia;Ileus;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Injection site reaction;Injury;Insomnia;Joint swelling;Laryngeal pain;Lethargy;Libido decreased;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Mental disability;Mental disorder;Mental retardation;Mental status changes;Migraine;Miosis;Mood swings;Muscle contractions involuntary;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Nervousness;Nightmare;Numbness;Oedema;Oedema peripheral;Oropharyngeal swelling;Orthostatic hypotension;Osteoarthritis;Pain;Pain in extremity;Pallor;Palpitations;Paraesthesia;Pharyngitis;Pharyngolaryngeal pain;Poor quality sleep;Pruritus;Pruritus generalised;Psychotic disorder;Pulmonary function test decreased;Pustule;Rash;Rash pustular;Respiration abnormal;Respiratory depression;Respiratory disorder;Respiratory distress;Respiratory failure;Retching;Rhinitis;Rigors;Sedation;Sensory loss;Sexual dysfunction;Shock;Sinusitis;Skin disorder;Sleep disorder;Slurred speech;Somnolence;Sweating;Swollen tongue;Syncope;Tachycardia;Tension;Tinnitus;Tremor;Unspecified circulatory system disorder;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vasodilation;Vasodilation procedure;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Wakefulness;Warmth;Weight decreased;Wenckebach phenomenon;Wheezing;Withdrawal syndrome,small molecule,approved; illicit; investigational; vet_approved,"(−)-buprenorphine; 17-cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol; 2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol; 21-cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; Buprenophine; Buprenorfina; Buprenorphine; Buprenorphinum; K-OR-1; KOR-1; OPRK; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; Kappa-type 3 opioid receptor; KOR-3; OOR; ORL1; Orphanin FQ receptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Kappa-type opioid receptor; Mu-type opioid receptor; Delta-type opioid receptor; Nociceptin receptor, N02AE01; N07BC51;N02AE01;N07BC01
buspirone,Abdominal discomfort;Agitation;Anxiety;Anxiety disorder;Blepharospasm;Depression;Depressive disorder;Depressive symptom;Diarrhoea;Discomfort;Distractibility;Dizziness;Dry mouth;Dysthymic disorder;Fatigability;Fatigue;Feeling jittery;Flushing;Generalised anxiety disorder;Heart pounding;Hepatic impairment;Hyperhidrosis;Hyperkinesia;Impatience;Insomnia;Irritability;Lightheadedness;Liver disorder;Mass;Mental disorder;Muscle strain;Musculoskeletal discomfort;Myalgia;Nervousness;Pallor;Palpitations;Paraesthesia;Pollakiuria;Psychotic disorder;Renal failure;Renal impairment;Schizophrenia;Shakiness;Sweating;Tension;Tingling feet/hands;Trembling;Tremor;Upset stomach,Abnormal dreams;Ache;Acne;Acute coronary syndrome;Affect lability;Agitation;Akathisia;Alcohol abuse;Alopecia;Amenorrhoea;Anger;Angioedema;Anorexia;Aphonia;Arthralgia;Asthenia;Ataxia;Bleeding breakthrough;Blister;Body temperature increased;Bradycardia;Burning tongue;Cardiac failure congestive;Cardiomyopathy;Cerebrovascular accident;Chest pain;Chills;Claustrophobia;Cogwheel rigidity;Cold intolerance;Cold sweat;Confusional state;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cramp muscle;Decreased appetite;Decreased interest;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Difficulty thinking;Digestion impaired;Discomfort;Dissociative disorder;Distress;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyskinesia;Dysosmia;Dyspepsia;Dysphoria;Dyspnoea;Dystonia;Dystonic reaction;Dysuria;Ecchymosis;Ejaculation delayed;Electrocardiogram change;Emotional distress;Enuresis;Eosinophilia;Epistaxis;Erectile dysfunction;Erythema;Euphoric mood;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Eye pain;Face oedema;Fatigue;Fear;Feeling abnormal;Flatulence;Flushing;Functional gastrointestinal disorder;Galactorrhoea;Gastrointestinal disorder;Glossodynia;Haemoglobin;Haemorrhage;Hallucination;Headache;Hiccups;Hostility;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperventilation;Hypoaesthesia;Hypotension;Ill-defined disorder;Increased appetite;Increased tendency to bruise;Influenza like illness;Influenza-like symptoms;Insomnia;Irritable bowel syndrome;Leukopenia;Libido increased;Lightheadedness;Loss of consciousness;Malaise;Menstruation irregular;Mental disability;Metrorrhagia;Miosis;Mood swings;Movements involuntary;Muscle rigidity;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nail disorder;Nail thinning;Nasal congestion;Nausea;Neck stiffness;Nervousness;Nightmare;Nocturia;Nuchal rigidity;Numbness;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Palpitations;Paraesthesia;Parkinsonism;Parosmia;Pelvic inflammatory disease;Photophobia;Pollakiuria;Pruritus;Psychotic disorder;Pulmonary congestion;Rash;Rectal haemorrhage;Redness;Respiratory tract congestion;Restless legs syndrome;Salivary hypersecretion;Salivation;Sensory loss;Serotonin syndrome;Shock;Slurred speech;Somnolence;Sore eye;Sticky skin;Stupor;Suicidal ideation;Sweating;Syncope;Tachycardia;Taste altered;Temperature intolerance;Tension;Thinking abnormal;Throat sore;Thrombocytopenia;Tingling sensation;Tinnitus;Tremor;Tunnel vision;Urinary hesitation;Urinary retention;Urticaria;Vertigo;Vision blurred;Vivid dreams;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; Buspiron; Buspirona; Buspirone; Buspironum; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; Dopamine D2 receptor; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 1A; D(2) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; Alpha-1 adrenergic receptors,N05BE01
busulfan,Acute leukaemia;Acute lymphocytic leukaemia;Acute myeloid leukaemia;Breast cancer;Chronic myeloid leukaemia;Disease recurrence;Hepatotoxicity;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Leukaemia;Myelodysplastic syndrome;Non-Hodgkin's lymphoma;Ovarian cancer;Plasma cell myeloma;Plasmacytoma;Thalassaemia;Venoocclusive liver disease,Abdominal distension;Abdominal pain;Acute graft versus host disease;Acute leukaemia;Acute respiratory distress syndrome;Addison's disease;Adrenal insufficiency;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Amenorrhoea;Anaemia;Anal discomfort;Angiopathy;Anhidrosis;Anorectal discomfort;Anorectal disorder;Anorexia;Anxiety;Anxiety depression;Aplasia;Aplastic anaemia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Atelectasis;Atrial arrhythmia;Atrial fibrillation;Atrioventricular block complete;Atrophy;Back pain;Bladder pain;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bradycardia;Breath sounds abnormal;Capillary leak syndrome;Cardiac disorder;Cardiac fibrillation;Cardiac tamponade;Cardiomegaly;Cataract;Cerebral haemorrhage;Cheilosis;Chest pain;Chills;Chronic graft versus host disease;Chronic myeloid leukaemia;Chronic phase chronic myeloid leukemia;Coma;Confusional state;Connective tissue disorder;Constipation;Convulsion;Corneal thinning;Cough;Creatinine increased;Cystitis;Cystitis haemorrhagic;Cystitis noninfective;Cytomegalovirus viraemia;Cytopenia;Death;Decreased appetite;Delayed puberty;Delirium;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Discomfort rectal;Dizziness;Drug interaction;Dry cough;Dry mouth;Dyspepsia;Dysplasia;Dyspnoea;Dystrophic calcification;Dysuria;Ear disorder;Ejection fraction decreased;Encephalopathy;Endocardial fibrosis;Endocrine disorder;Enlargement abdomen;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Erythema nodosum;Extravasation;Eye disorder;Fatigue;Febrile neutropenia;Feeling abnormal;Femoral artery thrombosis;Fever chills;Fibrosis;Fluid overload;Flushing;Fungal infection;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glossitis;Graft versus host disease;Gynaecomastia;Haematemesis;Haematological malignancy;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Hallucination;Headache;Hepatic necrosis;Hepatitis cholestatic;Hepatobiliary disease;Hepatomegaly;Hiccups;Hot flush;Hyperbilirubinaemia;Hyperglycaemia;Hypersensitivity;Hypertension;Hyperuricaemia;Hyperuricosuria;Hyperventilation;Hypocalcaemia;Hypogonadism;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Hypoxia;Ileus;Immune system disorder;Infection;Infertility;Infestation;Infestation NOS;Inflammation;Injection site inflammation;Injection site pain;Insomnia;Interstitial lung disease;Interstitial pneumonia;Jaundice;Jaundice cholestatic;Left ventricular failure;Lethargy;Leukopenia;Lung disorder;Lung fibrosis interstitial;Lymphoma;Malnutrition;Mediastinal disorder;Melanoderma;Menopausal symptoms;Menopause;Mental disorder;Mucosal inflammation;Multi-organ failure;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Myelosuppression;Nausea;Necrosis;Neoplasm;Neoplasm malignant;Nervous system disorder;Nervousness;Neurological symptom;Neutropenia;Non-Hodgkin's lymphoma;Oedema;Oesophagitis;Oliguria;Opportunistic infection;Organ failure;Pain;Pancreatitis;Pancytopenia;Pericardial effusion;Pericarditis;Peripheral artery thrombosis;Pharyngitis;Pigmentation disorder;Pleural effusion;Pneumonia;Pneumothorax;Porphyria cutanea tarda;Porphyria non-acute;Prothrombin level increased;Pruritus;Pulmonary fibrosis;Pulmonary oedema;Pulmonary ossification;Pulmonary toxicity;Pulmonary valve incompetence;Rales;Rash;Rash maculo-papular;Rash pustular;Rash vesicular;Rectal disorder;Renal failure;Renal impairment;Respiratory failure;Restrictive cardiomyopathy;Rhinitis;Sepsis;Serum sickness;Sinusitis;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Somnolence;Stomatitis;Tachycardia;Tension;Thrombocytopenia;Thrombosis;Thrombotic microangiopathy;Transaminases increased;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Varices oesophageal;Vasodilation;Vasodilation procedure;Venoocclusive disease;Ventricular extrasystoles;Vesiculobullous rash;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"1,4-Bis(methanesulfonoxy)butane; 1,4-Butanediol dimethanesulfonate; 1,4-Dimesyloxybutane; 1,4-Dimethanesulfonoxybutane; Busulfan; Busulfano; Busulfanum; Busulphan; Tetramethylene bis(methanesulfonate); 2.5.1.18; GST class-mu 1; GST HB subunit 4; GST1; GSTM1-1; GSTM1a-1a; GSTM1b-1b; GTH4; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 2.5.1.18; Glutathione peroxidase MGST2; GST2; Leukotriene C4 synthase MGST2; Microsomal glutathione S-transferase II; Microsomal GST-2; Microsomal GST-II; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.5.1.18; GST class-alpha member 2; GST HA subunit 2; GST-gamma; GST2; GSTA2-2; GTH2; 13-hydroperoxyoctadecadienoate peroxidase; 2.5.1.18; Androst-5-ene-3,17-dione isomerase; GST class-alpha member 1; GST HA subunit 1; GST-epsilon; GSTA1-1; GTH1",DNA,L01AB01
butabarbital,Insomnia,Agitation;Angioedema;Anxiety;Apnoea;Ataxia;Body temperature increased;Bradycardia;CNS depression NOS;Confusional state;Constipation;Depressed level of consciousness;Dermatitis;Dermatitis exfoliative;Dizziness;Feeling abnormal;Hallucination;Headache;Hepatocellular injury;Hyperkinesia;Hypersensitivity;Hypotension;Hypoventilation;Hypoxia;Liver injury;Loss of consciousness;Nausea;Nervousness;Nightmare;Rash;Respiratory failure;Shock;Somnolence;Syncope;Tension;Vomiting,small molecule,approved; illicit,"5-ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-ethyl-5-(1-methylpropyl)barbituric acid; 5-sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-sec-butyl-5-ethylbarbituric acid; 5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione; Butabarbital; Secbutabarbital; Secbutabarbitale; Secbutabarbitalum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; NACHR alpha-10; NACHRA10; Nicotinic acetylcholine receptor subunit alpha-10; NACHRA3; NACRA4; NACHRA5; NACHRA7; NACHR alpha-9; NACHRA9; Nicotinic acetylcholine receptor subunit alpha-9; AMPA-selective glutamate receptor 1; GLUA1; GLUH1; GluR-1; GluR-A; GluR-K1; GLUR1; Glutamate receptor ionotropic, AMPA 1; AMPA-selective glutamate receptor 2; GluA2; GluR-2; GluR-B; GluR-K2; GLUR2; Glutamate receptor ionotropic, AMPA 2; AMPA-selective glutamate receptor 3; GluA3; GluR-3; GluR-C; GluR-K3; GLUR3; GLURC; Glutamate receptor ionotropic, AMPA 3; AMPA-selective glutamate receptor 4; GluA4; GluR-4; GluR-D; GLUR4; Glutamate receptor ionotropic, AMPA 4; EAA3; Excitatory amino acid receptor 3; GluK1; GluR-5; GLUR5; Glutamate receptor 5; EAA4; Excitatory amino acid receptor 4; GluK2; GluR-6; GLUR6; Glutamate receptor 6; EAA5; Excitatory amino acid receptor 5; GluK3; GluR-7; GLUR7; Glutamate receptor 7; EAA1; Excitatory amino acid receptor 1; GluK4; Glutamate receptor KA-1; GRIK; KA1; EAA2; Excitatory amino acid receptor 2; GluK5; Glutamate receptor KA-2; GRIK2; KA2; Glucose transporter type 1, erythrocyte/brain; GLUT-1; GLUT1; HepG2 glucose transporter","GABA(A) Receptor; Gamma-aminobutyric acid receptor subunit alpha-1; Neuronal Acetylcholine (nACh) Receptor Subunits; Glutamate receptor 1; Glutamate receptor 2; Glutamate receptor 3; Glutamate receptor 4; Glutamate receptor ionotropic, kainate 1; Glutamate receptor ionotropic, kainate 2; Glutamate receptor ionotropic, kainate 3; Glutamate receptor ionotropic, kainate 4; Glutamate receptor ionotropic, kainate 5",N05CB01
butenafine,Body tinea;Immunocompromised;Immunodeficiency;Infection;Photosensitivity reaction;Phototoxicity;Pityriasis;Tinea cruris;Tinea infection;Tinea pedis,Dermatitis contact;Dysgeusia;Erythema;Pain;Pruritus;Stinging,small molecule,approved,(4-tert-Butyl-benzyl)-methyl-naphthalen-1-ylmethyl-amine; (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine; 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine; Butenafina; Butenafine; Butenafinum; N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine; 1.14.14.17; ERG1; SE; Squalene epoxidase; 1.14.14.17; SE; Squalene epoxidase,Squalene monooxygenase; Squalene monooxygenase,D01AE23
butorphanol,Acute pain;Migraine;Pain;Postoperative pain;Procedural pain,Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal involuntary movements;Accidental injury;Ageusia;Agitation;Anorexia;Anxiety;Apnoea;Arrhythmia;Asthenia;Ataxia;Back pain;Blood pressure increased;Body temperature increased;Bronchitis;Chest pain;Chills;Cold sweat;Confusional state;Constipation;Convulsion;Coordination abnormal;Cough;Deafness;Decreased appetite;Delusion;Depressed level of consciousness;Depression;Derealisation;Dermatitis;Diplopia;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug effect increased;Drug effect prolonged;Drug withdrawal syndrome;Dry mouth;Dysarthria;Dyskinesia;Dysphagia;Dysphoria;Dyspnoea;Ear disorder;Ear pain;Epistaxis;Erythema;Euphoric mood;Eye disorder;Eye pain;Fatal outcomes;Feeling abnormal;Feeling cold;Feeling hot;Flatulence;Floating feeling;Gait disturbance;Gastrointestinal pain;Hallucination;Headache;Hearing impaired;Hostility;Hyperacusis;Hyperaesthesia;Hyperhidrosis;Hypertension;Hypopnoea;Hypotension;Hypotonia;Hypoventilation;Hypoxia;Increased appetite;Injury;Insomnia;Intoxication;Leg pain;Lethargy;Libido increased;Loss of consciousness;Mental disability;Muscle relaxation;Muscle spasms;Nasal congestion;Nasal discomfort;Nasal irritation;Nasal pain;Nausea;Nervousness;Oedema;Osteoarthritis;Pain in extremity;Pallor;Palpitations;Paraesthesia;Paresis;Petechiae;Pharyngitis;Photophobia;Poisoning;Pruritus;Psychomotor retardation;Rash;Respiratory failure;Rhinalgia;Rhinitis;Sensation of heat;Shallow breathing;Shock;Sinus congestion;Sinusitis;Somnolence;Sticky skin;Stomach ache;Stupor;Sweating;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Tinnitus;Tremor;Upper respiratory tract infection;Urticaria;Vasodilation;Vasodilation procedure;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Withdrawal symptom,small molecule,approved; illicit; vet_approved,"(−)-17-(cyclobutylmethyl)morphinan-3,14-diol; (−)-butorphanol; (−)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; Butorfanol; Butorphanol; Butorphanolum; K-OR-1; KOR-1; OPRK; D-OR-1; DOR-1; OPRD; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor",Kappa-type opioid receptor; Delta-type opioid receptor; Mu-type opioid receptor,N02AF01
cabergoline,Amenorrhoea;Anovulation;Anovulatory cycle;Breast feeding;Cleft lip;Death neonatal;Empty sella syndrome;Galactorrhoea;Hyperprolactinaemia;Mental disorder;Oligomenorrhoea;Parkinson's disease;Parkinsonism;Pituitary adenoma;Pituitary tumour;Pituitary tumour benign;Prolactinoma;Stillbirth,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abnormal vision;Acne;Aggression;Alopecia;Anorexia;Anxiety;Arrhythmia;Arthralgia;Arthropathy;Asthenia;Back pain;Blood creatinine increased;Breast pain;Breast pain female;Bronchitis;Cardiac disorder;Cardiac failure;Cardiac valve disease;Cerebration impaired;Confusional state;Congenital anomaly;Congenital genitourinary abnormality;Constipation;Cramps of lower extremities;Decreased appetite;Delusion;Depression;Dermatitis;Developmental delay;Diarrhoea;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry mouth;Duodenal ulcer;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Epigastric pain;Epistaxis;Euphoric mood;Excessive daytime sleepiness;Face oedema;Fatigue;Feeling abnormal;Fibrosis;Flatulence;Gastritis;Gastrointestinal pain;Gravitational oedema;Hallucination;Headache;Hemianopia;Hepatic function abnormal;Hot flush;Hyperhidrosis;Hypersensitivity;Hypersexuality;Hypertension;Hypokinesia;Hypotension;Hypotension symptomatic;Hypotensive;Ill-defined disorder;Impulse-control disorder;Influenza;Influenza like illness;Influenza-like symptoms;Insomnia;Leg edema;Libido increased;Lightheadedness;Liver function test abnormal;Loss of consciousness;Malaise;Menopausal symptoms;Mental disability;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Nasal congestion;Nausea;Neoplasm malignant;Nervousness;Nightmare;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Pain;Palpitations;Paraesthesia;Pathological gambling;Pericardial effusion;Pericarditis;Pericarditis constrictive;Periorbital oedema;Pleural effusion;Pleural fibrosis;Pleurisy;Pneumonia;Prostatic disorder;Pruritus;Psychotic disorder;Pulmonary fibrosis;Rash;Regurgitation;Respiratory failure;Retroperitoneal fibrosis;Rhinitis;Shock;Sleep disorder;Somnolence;Sudden onset of sleep;Sweating increased;Syncope;Tension;Throat irritation;Toothache;Upper respiratory tract infection;Upset stomach;Urinary tract infection;Vasospasm;Vertigo;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved,"(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; 1-((6-allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'β-carbonyl)urea; Cabergolina; Cabergoline; Cabergolinum; Dopamine D2 receptor; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; Dopamine D3 receptor; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; D(2C) dopamine receptor; Dopamine D4 receptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D1 receptor; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",D(2) dopamine receptor; 5-hydroxytryptamine receptor 2B; D(3) dopamine receptor; 5-hydroxytryptamine receptor 2A; Alpha-2B adrenergic receptor; 5-hydroxytryptamine receptor 1D; D(4) dopamine receptor; Alpha-2A adrenergic receptor; 5-hydroxytryptamine receptor 1A; Alpha-2C adrenergic receptor; D(1B) dopamine receptor; D(1A) dopamine receptor; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 7; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; D(1) dopamine receptor, G02CB03;G02CB03;N04BC06
caffeine,Apnoea;Apnoea neonatal;Primary apnea of premature newborns;Pulmonary function test decreased;Respiratory depression,Accidental injury;Acidosis;Agitation;Blood creatinine increased;Blood sodium increased;Brain hypoxia;Brain injury;Ca++ increased;Cardiac disorder;Cerebral haemorrhage;Convulsion;Creatinine increased;Deafness;Dermatitis;Disseminated intravascular coagulation;Dry skin;Dyspnoea;Ear and labyrinth disorders;Failure to thrive;Feeling jittery;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Haemoglobin;Haemoglobin decreased;Haemorrhage;Hypercalcaemia;Hyperglycaemia;Hypersensitivity;Hypertension;Hypoglycaemia;Immune system disorder;Impaired healing;Infection;Infestation;Infestation NOS;Infusion site inflammation;Infusion site phlebitis;Injury;Irritability;Malnutrition;Necrotising colitis;Necrotising enterocolitis neonatal;Necrotizing enterocolitis;Nervous system disorder;Nervousness;Pulmonary oedema;Rash;Regurgitation;Renal failure;Retinopathy of prematurity;Sepsis;Skin breakdown;Skin disorder;Sodium high;Stroke volume increased;Tachycardia;Thyroxine decreased;Urine output increased,small molecule,approved,"1-methyltheobromine; 1,3,7-trimethyl-2,6-dioxopurine; 1,3,7-trimethylpurine-2,6-dione; 1,3,7-trimethylxanthine; 3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion; 7-methyltheophylline; Anhydrous caffeine; Cafeína; Caféine; Caffeine; Caffeinum; Coffein; Coffeinum; Guaranine; Koffein; Mateína; Methyltheobromine; Teína; Thein; Theine; 3.1.3.35; 3.1.3.5; 3.1.3.89; 3.1.3.91; 3.1.3.99; 5'-deoxynucleotidase; 5'-NT; Ecto-5'-nucleotidase; IMP-specific 5'-nucleotidase; NT5; NTE; Thymidylate 5'-phosphatase; ADORA2; 3.1.4.53; cAMP-specific phosphodiesterase 4D; DPDE3; PDE43; 3.1.4.17; CGI-PDE B; CGIP1; CGIPDE1; Cyclic GMP-inhibited phosphodiesterase B; 3.1.4.35; CGB-PDE; cGMP-binding cGMP-specific phosphodiesterase; PDE5; 3.1.4.17; 63 kDa Cam-PDE; Cam-PDE 1B; PDES1B; 3.1.4.53; cAMP-specific phosphodiesterase 4B; DPDE4; PDE32; RYDR; RYR-1; RyR1; Skeletal muscle calcium release channel; Skeletal muscle ryanodine receptor; Skeletal muscle-type ryanodine receptor; Type 1 ryanodine receptor; 3.1.4.53; cAMP-specific phosphodiesterase 4A; DPDE2; PDE46; 3.1.4.53; cAMP-specific phosphodiesterase 4B; DPDE4; PDE32; 3.1.4.53; cAMP-specific phosphodiesterase 4C; DPDE1; PDE21; 3.1.4.53; cAMP-specific phosphodiesterase 4D; DPDE3; PDE43; 3.1.4.53; cAMP-specific phosphodiesterase 7B; 3.1.4.17; 3.1.4.17; CGS-PDE; cGSPDE; Cyclic GMP-stimulated phosphodiesterase; 3.1.4.17; cGI-PDE; CGI-PDE A; cGMP-inhibited cAMP phosphodiesterase; Cyclic GMP-inhibited phosphodiesterase A; 3.1.4.17; CGI-PDE B; CGIP1; CGIPDE1; Cyclic GMP-inhibited phosphodiesterase B; 3.1.4.35; CGB-PDE; cGMP-binding cGMP-specific phosphodiesterase; PDE5; 3.1.4.35; cGMP phosphodiesterase 6C; PDEA2; 3.1.4.35; 3.1.4.53; cAMP and cGMP phosphodiesterase 11A; 3.1.4.17; 61 kDa Cam-PDE; Cam-PDE 1A; hCam-1; 3.1.4.17; 63 kDa Cam-PDE; Cam-PDE 1B; PDES1B; 3.1.4.17; Cam-PDE 1C; Hcam3; 3.1.4.53; cAMP-specific phosphodiesterase 7A; HCP1; TM22; 3.1.4.53; 3.1.4.53; Cell proliferation-inducing gene 22 protein; HsPDE8B; 3.1.4.35; 3.1.4.35; GMP-PDE alpha; PDE V-B1; PDEA; 3.1.4.35; GMP-PDE beta; PDEB; 2.7.11.1; DNA-PK catalytic subunit; DNA-PKcs; DNPK1; HYRC; HYRC1; p460; 2.7.1.137; 2.7.1.153; p110delta; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PI3-kinase subunit delta; PI3K-delta; PI3Kdelta; PtdIns-3-kinase subunit delta; PtdIns-3-kinase subunit p110-delta; 2.7.1.137; 2.7.1.153; p110alpha; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; Phosphoinositide 3-kinase alpha; Phosphoinositide-3-kinase catalytic alpha polypeptide; PI3-kinase subunit alpha; PI3K-alpha; PI3Kalpha; PtdIns-3-kinase subunit alpha; PtdIns-3-kinase subunit p110-alpha; Serine/threonine protein kinase PIK3CA; 2.7.1.153; p110beta; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; PI3-kinase subunit beta; PI3K-beta; PI3Kbeta; PIK3C1; PtdIns-3-kinase subunit beta; PtdIns-3-kinase subunit p110-beta; Serine/threonine protein kinase PIK3CB; Inositol 1,4,5 trisphosphate receptor; Inositol 1,4,5-trisphosphate receptor type 1; INSP3R1; IP3 receptor isoform 1; IP3R 1; Type 1 inositol 1,4,5-trisphosphate receptor; Type 1 InsP3 receptor; Inositol 1,4,5-trisphosphate receptor type 2; InsP3R2; IP3 receptor isoform 2; IP3R 2; Type 2 inositol 1,4,5-trisphosphate receptor; Type 2 InsP3 receptor; InsP3R3; IP3 receptor isoform 3; IP3R-3; Type 3 inositol 1,4,5-trisphosphate receptor; Type 3 InsP3 receptor; 2.7.11.1; A-T mutated; Ataxia telangiectasia mutated; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter","Adenosine receptor A1; 5'-nucleotidase; Adenosine receptor A2a; Adenosine receptor A2b; Adenosine receptor A3; Phosphodiesterase enzymes; 3',5'-cyclic-AMP phosphodiesterase 4B; Ryanodine receptor 1; Cyclic nucleotide phosphodiesterase; DNA-dependent protein kinase catalytic subunit; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform; Inositol 1,4,5-trisphosphate receptor; Serine-protein kinase ATM", N06BC01; R03DA20; V04CG30;D11AX26;N06BC01
verapamil,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Angina unstable;Arrhythmia;Asthma;Atrial fibrillation;Atrial flutter;Cardiac disorder;Cardiac failure;Cardiac fibrillation;Cardiac flutter;Cardiac index;Cardiomyopathy;Chronic atrial fibrillation;Coronary artery insufficiency;Diabetes mellitus;Diabetic nephropathy;Essential hypertension;Exercise induced angina;Fasting;Hyperlipidaemia;Hypertension;Hypertensive;Hypertrophic cardiomyopathy;Hypotension;Hypotensive;Infarction;Intermittent claudication;Myocardial infarction;Paroxysmal supraventricular tachycardia;Peripheral vascular disorder;Prinzmetal angina;Reflex tachycardia;Sinus rhythm;Stable angina pectoris;Supraventricular tachycardia;Tachyarrhythmia;Tachycardia;Vascular resistance systemic;Vasodilation;Vasodilation procedure,Abdominal discomfort;Accidental injury;Acute coronary syndrome;Agitation;Allergy aggravated;Alopecia;Anaphylactic shock;Angina pectoris;Angioedema;Ankle edema;Arthralgia;Asthenia;Atrioventricular block;Atrioventricular block complete;Atrioventricular dissociation;Blood prolactin increased;Bradycardia;Bronchospasm;Cardiac arrest;Cardiac failure;Cardiac flutter;Cerebrovascular accident;Chest pain;Cholestasis;Claudication;Coldness;Confusional state;Constipation;Contusion;Convulsion;Cramp muscle;Depressive symptom;Dermatitis;Diarrhoea;Diplopia;Discomfort;Distress;Distress gastrointestinal;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Ecchymosis;Electrocardiogram abnormal;Emotional distress;Erectile dysfunction;Erythema multiforme;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Feeling abnormal;Feeling cold;Flushing;Galactorrhoea;Gingival hyperplasia;Gynaecomastia;Headache;Hepatic enzyme increased;Hepatitis;Hepatitis symptom;Hepatotoxicity;Hyperhidrosis;Hyperkeratosis;Hyperkinesia;Hyperprolactinaemia;Hypersensitivity;Hypertension;Hypertrophic cardiomyopathy;Hypoaesthesia;Hypotension;Hypotension asymptomatic;Hypotension symptomatic;Idiopathic hypertrophic subaortic stenosis;Ileus;Ileus paralytic;Infection;Influenza;Injury;Insomnia;Intermittent claudication;Jaundice;Joint swelling;Laryngospasm;Lethargy;Loss of consciousness;Macule;Muscle fatigue;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Numbness of limbs;Nystagmus;Oedema;Oedema peripheral;Oligomenorrhoea;Orthostatic hypotension;Pain;Palpitations;Paraesthesia;Paralysis;Petechiae;Pharyngitis;Pollakiuria;Pruritus;Psychotic disorder;Pulmonary oedema;Purpura;Quadriparesis;Rash;Rash maculo-papular;Respiratory failure;Rhinitis;Shakiness;Shock;Sinus arrest;Sinusitis;Sleep disorder;Sleep disturbance;Somnolence;Stevens-Johnson syndrome;Sweating;Sweating increased;Syncope;Tachycardia;Tinnitus;Tremor;Upper respiratory tract infection;Urticaria;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Visual impairment;Vomiting,small molecule,approved,"Iproveratril; Vérapamil; Verapamil; Verapamilo; Verapamilum; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; BI; Brain calcium channel I; CACH4; CACN3; CACNL1A4; Calcium channel, L type, alpha-1 polypeptide isoform 4; Voltage-gated calcium channel subunit alpha Cav2.1; IKATP; Inward rectifier K(+) channel Kir6.2; Potassium channel, inwardly rectifying subfamily J member 11; Cav3.1c; KIAA1123; NBR13; Voltage-gated calcium channel subunit alpha Cav3.1; Low-voltage-activated calcium channel alpha1 3.2 subunit; Voltage-gated calcium channel subunit alpha Cav3.2; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; CACNLG; Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma; Neuronal voltage-gated calcium channel gamma-2 subunit; TARP gamma-2; Transmembrane AMPAR regulatory protein gamma-2; Neuronal voltage-gated calcium channel gamma-3 subunit; TARP gamma-3; Transmembrane AMPAR regulatory protein gamma-3; Neuronal voltage-gated calcium channel gamma-4 subunit; TARP gamma-4; Transmembrane AMPAR regulatory protein gamma-4; Neuronal voltage-gated calcium channel gamma-5 subunit; TARP gamma-5; Transmembrane AMPAR regulatory protein gamma-5; Neuronal voltage-gated calcium channel gamma-6 subunit; Neuronal voltage-gated calcium channel gamma-7 subunit; TARP gamma-7; Transmembrane AMPAR regulatory protein gamma-7; CACNG6; Neuronal voltage-gated calcium channel gamma-8 subunit; TARP gamma-8; Transmembrane AMPAR regulatory protein gamma-8; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; KIAA0558; Voltage-gated calcium channel subunit alpha-2/delta-2; Voltage-gated calcium channel subunit alpha-2/delta-3; Voltage-gated calcium channel subunit alpha-2/delta-4; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; BI; Brain calcium channel I; CACH4; CACN3; CACNL1A4; Calcium channel, L type, alpha-1 polypeptide isoform 4; Voltage-gated calcium channel subunit alpha Cav2.1; BII; Brain calcium channel II; CACH6; CACNL1A6; Calcium channel, L type, alpha-1 polypeptide, isoform 6; Voltage-gated calcium channel subunit alpha Cav2.3; Cav3.1c; KIAA1123; NBR13; Voltage-gated calcium channel subunit alpha Cav3.1; Low-voltage-activated calcium channel alpha1 3.2 subunit; Voltage-gated calcium channel subunit alpha Cav3.2; Ca(v)3.3; KIAA1120; Voltage-gated calcium channel subunit alpha Cav3.3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2",Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent N-type calcium channel subunit alpha-1B; Voltage-dependent P/Q-type calcium channel subunit alpha-1A; ATP-sensitive inward rectifier potassium channel 11; Voltage-dependent T-type calcium channel subunit alpha-1G; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-gated inwardly rectifying potassium channel KCNH2; Sodium-dependent serotonin transporter; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Voltage-dependent calcium channel; ATP-dependent translocase ABCB1, C08DA01; C08DA51;C08DA01;C09BB10
calcipotriol,Plaque psoriasis;Psoriasis;Psoriasis of scalp;Skin disorder,Application site erythema;Application site pain;Dermatitis;Dry skin;Erythema;Folliculitis;Hypercalcaemia;Hypersensitivity;Instillation site pain;Koebner phenomenon;Localized exfoliation;Pain;Paraesthesia;Pruritus;Rash;Skin atrophy;Skin exfoliation;Skin hyperpigmentation;Skin irritation;Stinging;Tingling sensation,small molecule,approved,"Calcipotriene; Calcipotriol; 1,25-dihydroxyvitamin D3 receptor; NR1I1; Nuclear receptor subfamily 1 group I member 1; VDR; 1.11.2.2; MPO; 1.14.15.16; 24-OHase; CYP24; Cytochrome P450 24A1; Cytochrome P450-CC24; Vitamin D(3) 24-hydroxylase",Vitamin D3 receptor, D05AX02;D05AX02;D05AX52
candesartan,Cardiac failure;Cardiac failure congestive;Essential hypertension;Hypertension;Hypertensive;Left ventricular dysfunction;Left ventricular systolic dysfunction;Renal failure;Renal impairment,Abdominal pain;Acute angle-closure glaucoma;Acute coronary syndrome;Agitation;Agranulocytosis;Albuminuria;Anaemia;Anaphylactic shock;Angiitis necrotising;Angina pectoris;Angioedema;Angiopathy;Angle closure glaucoma;Anorexia;Anxiety;Aplastic anaemia;Appetite absent;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Atrioventricular block;Azotaemia;Back pain;Bilirubin total increased;Bladder pain;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood disorder;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone marrow depression;Bone pain;Bronchitis;Brown urine;Cardiac arrest;Cardiovascular disorder;Chest pain;Cholelithiasis;Chromaturia;Coagulopathy;Cold symptoms;Conjunctivitis;Connective tissue disorder;Constipation;Coronary artery disease;Cough;Creatine phosphokinase increased;Creatinine increased;Cutaneous lupus erythematosus;Cutaneous vasculitis;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Dermatitis;Diabetes mellitus;Diarrhoea;Dizziness;Dry mouth;Dyslipidaemia;Dyspepsia;Dyspnoea;Ear infection;Eczema;Electrolyte imbalance;Epigastric discomfort;Epistaxis;Erectile dysfunction;Fatigue;Flushing;Gastric irritation;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Glycosuria;Haematuria;Haemoglobin;Haemorrhage;Headache;Hepatic function abnormal;Hepatitis;Hepatitis A;Hepatobiliary disease;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertonia;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypokalaemia;Hyponatraemia;Hypotension;Infection;Infestation;Infestation NOS;Inflammation;Inflicted injury;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Jaundice;Jaundice cholestatic;Kidney function abnormal;Laryngitis;Leukopenia;Lightheadedness;Loss of consciousness;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Muscle atrophy;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myocardial infarction;Myopathy;Myopia;Myositis;NPN increased;Nasopharyngitis;Nausea;Nephritis interstitial;Nervous system disorder;Nervousness;Neurosis;Neutropenia;Nightmare;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Otitis;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Peripheral ischaemia;Pharyngitis;Photosensitivity reaction;Pneumonia;Pruritus;Pulmonary oedema;Rash;Renal failure;Renal failure acute;Renal impairment;Respiratory distress;Respiratory tract infection;Rhabdomyolysis;Rhinitis;Serum creatinine increased;Shock;Sinusitis;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Tenderness;Tendon disorder;Tension;Thrombocytopenia;Thrombophlebitis;Tinnitus;Toothache;Toxic epidermal necrolysis;Transaminases increased;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Uremia;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urticaria;Vasculitis;Vasculitis necrotising;Vertigo;Vision blurred;Vomiting;Yellow skin,small molecule,experimental,2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid; Candesartan; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6,Type-1 angiotensin II receptor, C09CA06; C09DB07; C09DX06; C10BX19;C09DA06
candesartan,Cardiac failure;Cardiac failure congestive;Hypertension;Left ventricular dysfunction;Left ventricular systolic dysfunction,Abdominal pain;Acute coronary syndrome;Agranulocytosis;Albuminuria;Anaemia;Angina pectoris;Angioedema;Anxiety;Arthralgia;Asthenia;Back pain;Bilirubin total increased;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bronchitis;Cardiac failure;Cardiac failure congestive;Chest pain;Coagulopathy;Cough;Creatine phosphokinase increased;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Dyspnoea;Epistaxis;Fatigue;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Haematuria;Haemoglobin;Haemorrhage;Headache;Hepatitis;Hepatitis A;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypertension;Hypertriglyceridaemia;Hyperuricaemia;Hyponatraemia;Hypotension;Kidney function abnormal;Leukopenia;Malnutrition;Mental disorder;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Nephropathy;Neutropenia;Oedema peripheral;Palpitations;Paraesthesia;Pharyngitis;Pruritus;Rash;Renal failure;Renal impairment;Rhabdomyolysis;Rhinitis;Serum creatinine increased;Sinusitis;Somnolence;Sweating increased;Tachycardia;Thrombocytopenia;Transaminases increased;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Vertigo;Vomiting,small molecule,experimental,2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid; Candesartan; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6,Type-1 angiotensin II receptor, C09CA06; C09DB07; C09DX06; C10BX19;C09CA06;C09DA06
capreomycin,Cirrhosis alcoholic;Laennec's cirrhosis;Lung infection;Tuberculosis,Abscess;Body temperature increased;Deafness;Dermatitis;Eosinophilia;Foetor hepaticus;Hearing impaired;Hepatocellular injury;Hypersensitivity;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Induration;Injection site haemorrhage;Leukocytosis;Leukopenia;Liver disorder;Nephritis;Nephropathy toxic;Nephrosis lower nephron;Nephrotoxicity;Oliguria;Ototoxicity;Pain;Rash;Reaction febrile;Renal failure;Renal impairment;Renal tubular necrosis;Thrombocytopenia;Tinnitus;Urine abnormality;Urine analysis abnormal;Urticaria;Vertigo,small molecule,approved,Capreomicina; Capreomycin; 16S rRNA (cytidine1409-2'-O)-methyltransferase; 2.1.1.226; 23S rRNA (cytidine1920-2'-O)-methyltransferase; Hemolysin TlyA,16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA,J04AB30
capsaicin,Diabetes mellitus;Diabetic;Neuralgia;Pain;Post herpetic neuralgia,Angiopathy;Application site anaesthesia;Application site burn;Application site dryness;Application site erosion;Application site erythema;Application site excoriation;Application site exfoliation;Application site haematoma;Application site hyperaesthesia;Application site inflammation;Application site irritation;Application site oedema;Application site pain;Application site papules;Application site paraesthesia;Application site pruritus;Application site rash;Application site reaction;Application site swelling;Application site urticaria;Application site vesicles;Application site warmth;Blood pressure increased;Bronchitis;Burning sensation;Burns second degree;Cardiac disorder;Connective tissue disorder;Cough;Dizziness;Dysgeusia;Erythema;Eye disorder;Eye irritation;Eye pain;Gastrointestinal disorder;HIV associated nephropathy;Headache;Herpes zoster;Hyperaesthesia;Hypertension;Hypoaesthesia;Infection;Infestation;Infestation NOS;Instillation site pain;Mediastinal disorder;Muscle spasms;Nasopharyngitis;Nausea;Nervous system disorder;Neuropathy;Neuropathy peripheral;Oedema peripheral;Pain in extremity;Palpitations;Peripheral sensory neuropathy;Pruritus;Sinusitis;Skin disorder;Skin odour abnormal;Tachycardia;Throat irritation;Unspecified disorder of skin and subcutaneous tissue;Vomiting,small molecule,approved,"(E)-8-Methyl-N-vanillyl-6-nonenamide; Capsaicin; Capsaicina; Isodecenoic acid vanillylamide; trans-8-Methyl-N-vanillyl-6-nonenamide; Capsaicin receptor; Osm-9-like TRP channel 1; OTRPC1; TrpV1; Vanilloid receptor 1; VR1; B-cell receptor-associated protein BAP37; BAP; D-prohibitin; REA; Repressor of estrogen receptor activity; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.11.2.2; MPO; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.14.17.1; Dopamine beta-monooxygenase; 6.3.1.2; GLNS; Glutamate--ammonia ligase; GS; Palmitoyltransferase GLUL; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase",Transient receptor potential cation channel subfamily V member 1; Prohibitin-2, N01BX04;M02AB01
captopril,Acute coronary syndrome;Aldosterone low;Angioedema;Blood aldosterone decreased;Blood potassium increased;Cardiac failure;Cardiac failure congestive;Cardiac failure high output;Cardiac output increased;Cerebrovascular accident;Collagen-vascular disease;Dehydration;Dermatitis;Diabetes mellitus;Diabetic nephropathy;Fluid loss;Hypertension;Hypertensive;Hypotension;Hypotensive;Infarction;Left ventricular dysfunction;Malignant hypertension;Microalbuminuria;Myocardial infarction;Nephropathy;Postinfarction;Protein urine present;Proteinuria;Rash;Renal failure;Renal impairment;Renin decreased;Retinal disorder;Serum potassium increased;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Vascular resistance;Vascular resistance systemic,Abdominal pain;Acidosis;Ageusia;Agranulocytosis;Airway obstruction NOS;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Antinuclear antibody positive;Anuria;Aphthous stomatitis;Arthralgia;Asthenia;Ataxia;Blister;Blood potassium increased;Blood pressure increased;Blood pressure normal;Body temperature increased;Bronchospasm;Cardiac arrest;Cerebrovascular accident;Chest pain;Cholestasis;Confusional state;Constipation;Cough;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diabetic;Diarrhoea;Discomfort;Dizziness;Drug interaction;Dry eye;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Eosinophilia;Epigastric discomfort;Erectile dysfunction;Erythema multiforme;Fatigue;Feeling abnormal;Flushing;Gastric irritation;Gastrointestinal pain;Glossitis;Gynaecomastia;Haemolytic anaemia;Hallucination;Headache;Hepatic necrosis;Hepatitis;Hepatocellular injury;Hyperkalaemia;Hyponatraemia;Hyponatraemic;Hypotension;Hypotensive;Hypovolaemia;Ill-defined disorder;Insomnia;Irreversible renal failure;Jaundice;Jaundice cholestatic;Laryngeal oedema;Liver injury;Loss of consciousness;Loss of libido;Lymphadenopathy;Malaise;Microcephaly;Microsomia;Muscle contracture;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Nausea;Necrosis;Nephritis;Nephritis interstitial;Nephrotic syndrome;Nervousness;Neutropenia;Obstructive airways disorder;Oligohydramnios;Oliguria;Orthostatic hypotension;Pallor;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Patent ductus arteriosus;Pemphigoid;Pemphigus;Peptic ulcer;Persistent dry cough;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyuria;Pregnancy;Protein urine present;Proteinuria;Pruritus;Pulmonary eosinophilia;Rales;Rash;Red blood cell sedimentation rate increased;Renal failure;Renal failure acute;Renal failure chronic;Renovascular hypertension;Rhinitis;Scald;Serum potassium increased;Serum sickness;Shock;Skull hypoplasia;Somnolence;Stevens-Johnson syndrome;Stomatitis;Syncope;Tachycardia;Tension;Thermal burn;Thrombocytopenia;Tongue ulceration;Traumatic liver injury;Tubulointerstitial nephritis;Ulcer;Urine output increased;Vasculitis;Vision blurred;Vomiting;Weight decreased,small molecule,approved,"(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; Captopril; Captoprilum; Captopryl; CP; D-2-methyl-3-mercaptopropanoyl-L-proline; D-3-mercapto-2-methylpropanoyl-L-proline; L-Captopril; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; 3.4.24.24; 72 kDa gelatinase; CLG4A; Gelatinase A; Matrix metalloproteinase-2; MMP-2; TBE-1; 3.4.24.35; 92 kDa gelatinase; 92 kDa type IV collagenase; CLG4B; Gelatinase B; GELB; MMP-9; 3.3.2.6; Leukotriene A(4) hydrolase; LTA-4 hydrolase; LTA4; Tripeptide aminopeptidase LTA4H; B1R; BK-1 receptor; BRADYB1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",Angiotensin-converting enzyme; 72 kDa type IV collagenase; Matrix metalloproteinase-9; Leukotriene A-4 hydrolase; B1 bradykinin receptor, C09BA01;C09AA01
carbamazepine,"Ache;Affective disorder;Alcohol withdrawal syndrome;Atonic seizures;Atrioventricular block;Bipolar I disorder;Bipolar disorder;Convulsion;Convulsions generalised;Decreased interest;Depressed mood;Diabetes insipidus;Diabetic neuropathy;Electroencephalogram abnormal;Epilepsy;Facial pain;Fasting;Glossopharyngeal neuralgia;Grand mal convulsion;Headache;Irritability;Loss of consciousness;Major depression;Major depressive disorder, single episode;Mania;Mania acute;Manic episode;Multiple sclerosis;Myoclonic epilepsy;Pain;Partial epilepsy;Partial seizures;Petit mal epilepsy;Polydipsia;Polyuria;Simple partial seizures;Status epilepticus;Thrombophlebitis;Tonic-clonic seizures;Trigeminal neuralgia;Urine output increased","Abdominal discomfort;Abdominal pain;Abnormal involuntary movements;Accidental injury;Accommodation disorder;Acute generalised exanthematous pustulosis;Acute retention of urine;Adams-Stokes syndrome;Aggression;Agitation;Agranulocytosis;Albuminuria;Alopecia;Amblyopia;Amnesia;Anaemia;Anaemia macrocytic;Anaemia megaloblastic;Anaphylactic shock;Anger;Angioedema;Angiopathy;Anorexia;Anuria;Anxiety;Aplasia pure red cell;Aplastic anaemia;Appetite absent;Arrhythmia;Arterial insufficiency;Arthralgia;Asterixis;Asthenia;Ataxia;Atrioventricular block;Auditory disorder NOS;Azotaemia;Back pain;Balance disorder;Bipolar I disorder;Bipolar disorder;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood calcium decreased;Blood cholesterol increased;Blood disorder;Blood osmolarity decreased;Blood pressure increased;Blood prolactin increased;Blood thyroid stimulating hormone increased;Blood triglycerides increased;Blood urea increased;Body temperature decreased;Body temperature increased;Bone density decreased;Bone disorder;Bone marrow depression;Bone metabolism disorder;Bradycardia;Brain injury;Breast feeding;Bronchitis;CNS depression NOS;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Chest pain;Chills;Choreoathetosis;Colitis;Coma;Completed suicide;Conduction disorder;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Convulsive seizure;Coordination abnormal;Coordination disturbance;Coronary artery disease;Coronary artery disease aggravated;Coronary artery insufficiency;Cramp muscle;Cramps of lower extremities;Cyanosis;Deafness;Decreased appetite;Delayed gastric emptying;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Digestion impaired;Diplopia;Disorientation;Distress;Diuresis;Dizziness;Drowsiness;Drug eruption;Drug interaction;Dry mouth;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Ear pain;Electrocardiogram QRS complex;Embolism;Embolism venous;Emotional distress;Endocrine disorder;Enzyme induction;Eosinophilia;Epigastric discomfort;Erectile dysfunction;Eruption;Erythema;Erythema multiforme;Erythema nodosum;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye movement disorder;Fatal outcomes;Fatigue;Feeling abnormal;Fluid retention;Flushing;Folate deficiency;Forgetfulness;Fracture;Galactorrhoea;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Glossitis;Glossodynia;Glycosuria;Granulomatous liver disease;Gynaecomastia;Haematuria;Haemolytic anaemia;Hallucination;Hallucination, visual;Headache;Hearing impaired;Hepatic failure;Hepatitis;Hepatitis cholestatic;Hepatitis granulomatous;Hepatobiliary disease;Hepatosplenomegaly;High density lipoprotein increased;Hirsutism;Human herpesvirus 6 infection;Hyperacusis;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hypogammaglobulinaemia;Hypokalaemia;Hyponatraemia;Hypotension;Hypothermia;Immune system disorder;Impaired gastric emptying;Infection;Infertility male;Infestation;Infestation NOS;Injury;Insomnia;Intoxication;Intraocular pressure increased;Irritability;Jaundice;Jaundice hepatocellular;Ketonuria;Lenticular opacities;Lethargy;Leukocytosis;Leukopenia;Lichenoid keratosis;Liver function test abnormal;Logorrhoea;Loss of consciousness;Low back pain;Lupus erythematosus;Lymphadenopathy;Lymphoma;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Memory impairment;Meningitis;Meningitis aseptic;Mental disability;Mental disorder;Metabolic acidosis;Multiple fractures;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Mydriasis;Myoclonus;Nausea;Nephritis interstitial;Nephropathy;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neurodermatitis;Neuroleptic malignant syndrome;Neuropathy peripheral;Non-Hodgkin's lymphoma;Nystagmus;Oedema;Oedema peripheral;Oliguria;Onychomadesis;Orofacial dyskinesia;Orthostatic hypotension;Osteoarthritis;Osteomalacia;Osteopenia;Osteoporosis;Pain;Pancreatitis;Pancytopenia;Paraesthesia;Paralysis;Paresis;Pharyngitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Plasma calcium decreased;Plasma osmolality decreased;Pneumonia;Poisoning;Pollakiuria;Polyuria;Porphyria acute;Porphyria cutanea tarda;Porphyria hepatic;Porphyria non-acute;Porphyrin metabolism disorder;Pregnancy;Pruritus;Pseudolymphoma;Psychotic disorder;Pulmonary embolism;Pulmonary function test decreased;Pulmonary oedema;Purpura;QRS complex;Rage;Rash;Reflexes abnormal;Renal failure;Renal impairment;Respiratory depression;Reticulocytosis;Rhinitis;Sexual dysfunction;Shock;Sinusitis;Skin discolouration;Skin disorder;Slurred speech;Somnolence;Speech disorder;Speech impairment NOS;Sperm concentration decreased;Sperm count decreased;Spermatogenesis abnormal;Stevens-Johnson syndrome;Stomatitis;Suicidal behaviour;Suicidal ideation;Suicide attempt;Sweating increased;Swelling;Syncope;Systemic lupus erythematosus;Tachycardia;Talkativeness;Tension;Testicular atrophy;Thinking abnormal;Thrombocytopenia;Thrombocytopenic purpura;Thromboembolism;Thrombophlebitis;Thyroid function abnormal;Thyroid function test abnormal;Thyrotropin high;Tinnitus;Toxic epidermal necrolysis;Transaminases increased;Trembling;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Unsteadiness;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vanishing bile duct syndrome;Variegate porphyria;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Vomiting;Water intoxication;Weight increased",small molecule,approved; investigational,"5-Carbamoyl-5H-dibenz(b,f)azepine; 5-carbamoyl-5H-dibenz[b,f]azepine; 5-Carbamoyl-5H-dibenzo(b,f)azepine; 5-Carbamyl-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine-5-carboxamide; Carbamazepen; Carbamazepin; Carbamazepina; Carbamazépine; Carbamazepine; Carbamazepinum; CBZ; Molecusol-Carbamazepine; NAC1; SCN1; Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; HBA; HBSC II; NAC2; SCN2A1; SCN2A2; Sodium channel protein brain II subunit alpha; Sodium channel protein type II subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.2; KIAA1356; NAC3; Sodium channel protein brain III subunit alpha; Sodium channel protein type III subunit alpha; Voltage-gated sodium channel subtype III; Voltage-gated sodium channel subunit alpha Nav1.3; SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Atypical sodium channel Nav2.1; Nax channel; SCN6A; Sodium channel protein type VII subunit alpha; MED; Sodium channel protein type VIII subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.6; hNE-Na; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Sodium channel protein type IX subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.7; NACRA4; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 76 kDa Ral-interacting protein; Dinitrophenyl S-glutathione ATPase; DNP-SG ATPase; Ral-interacting protein 1; RalBP1; RLIP; RLIP1; RLIP76; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",Voltage-gated sodium channel alpha subunit; Neuronal acetylcholine receptor subunit alpha-4; Nuclear receptor subfamily 1 group I member 2,N03AF01
carbenicillin,Asymptomatic bacteriuria;Infection;Prostatitis,Abdominal cramps;Abdominal pain;Anaemia;Anorexia;Bad taste;Body temperature increased;Decreased appetite;Dermatitis;Diarrhoea;Dry mouth;Dysgeusia;Dyspepsia;Eosinophilia;Epigastric distress;Eye pruritus;Flatulence;Glossitis;Headache;Hypersensitivity;Leukopenia;Loose stools;Nausea;Neutropenia;Pruritus;Rash;Rectal haemorrhage;Thrombocytopenia;Urticaria;Vaginal infection;Vaginal inflammation;Vomiting,small molecule,approved; investigational,"(2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Carbenicilina; Carbenicillin; Carbenicilline; Carbenicillinum; Carboxybenzylpenicillin; CBPC; N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid; α-carboxybenzylpencillin; α-phenyl(carboxymethylpenicillin); 3.4.16.4; Beta-lactamase; DD-carboxypeptidase; PBP-5; Penicillin-binding protein 5; pfv; 3.4.16.4; D-alanyl-D-alanine endopeptidase; DD-carboxypeptidase; DD-endopeptidase; PBP-4; Penicillin-binding protein 4; 3.4.16.4; DD-carboxypeptidase; PBP-6; Penicillin-binding protein 6; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; PBP-2; pbpA; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; 3.5.2.6; CPLA2; Phospholipase A2 group IVA; PLA2G4; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",Penicillin-binding protein; Beta-lactamase Toho-1, J01CA03;J01CA03;J01CR50
carbinoxamine,Anaphylactic shock;Angioedema;Conjunctivitis allergic;Hypersensitivity;Mechanical urticaria;Perennial allergic rhinitis;Rhinitis perennial;Urticaria;Urticaria physical;Vasomotor rhinitis,Agitation;Agranulocytosis;Anorexia;Asthenia;Chest discomfort;Chest tightness;Chills;Confusional state;Constipation;Conversion disorder;Convulsion;Decreased appetite;Diarrhoea;Diplopia;Dizziness;Drowsiness;Drug eruption;Dyspepsia;Epigastric distress;Euphoric mood;Extrasystoles;Fatigue;Feeling abnormal;Haemolytic anaemia;Headache;Hyperhidrosis;Hypotension;Hysteria;Insomnia;Irritability;Labyrinthitis;Nasal congestion;Nausea;Nervousness;Neuritis;Neuropathy peripheral;Palpitations;Paraesthesia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Somnolence;Sweating increased;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Tremor;Urinary retention;Urticaria;Vertigo;Vision blurred;Vomiting;Wheezing,small molecule,approved,(±)-carbinoxamine; {2-[(4-Chloro-phenyl)-pyridin-2-yl-methoxy]-ethyl}-dimethyl-amine; 2-(p-chloro-α-(2-(dimethylamino)ethoxy)benzyl)pyridine; Carbinoxamin; Carbinoxamina; Carbinoxamine; Carbinoxamine base; Carbinoxaminum; Paracarbinoxamine; H1-R; H1R; HH1R; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2,Histamine H1 receptor,R06AA08
carisoprodol,Discomfort,Agitation;Ataxia;Back pain;Blood disorder;Convulsion;Dizziness;Drowsiness;Dyspepsia;Epigastric discomfort;Epigastric distress;Flushing;Headache;Hiccups;Insomnia;Irritability;Leukopenia;Loss of consciousness;Low back pain;Nausea;Orthostatic hypotension;Pancytopenia;Shock;Somnolence;Syncope;Tachycardia;Tremor;Vertigo;Viral infection;Vomiting,small molecule,approved,"(±)-2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate; (1-methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester; (RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate; 2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate; 2-methyl-2-propyltrimethylene carbamate isopropylcarbamate; carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester; Carisoprodol; Carisoprodolo; Carisoprodolum; Isobamate; Isomeprobamate; Isopropyl meprobamate; Isopropylmeprobamate; N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit gamma-2; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-3, M03BA52; M03BA72;M03BA02
carteolol,Chronic open angle glaucoma;Hypertension;Open angle glaucoma;Primary open angle glaucoma,Arrhythmia;Asthenia;Atrioventricular block;Blepharoconjunctivitis;Block heart;Bradycardia;Bronchospasm;Cardiac failure congestive;Cerebral ischaemia;Cerebrovascular accident;Conjunctival hyperaemia;Conjunctivitis;Corneal staining;Decreased night vision;Depression;Diabetes mellitus;Diabetic;Diplopia;Dizziness;Dysgeusia;Dyspnoea;Eye irritation;Eyelid ptosis;Headache;Hypersensitivity;Hypoglycaemia;Hypotension;Insomnia;Keratitis;Lacrimation;Lacrimation increased;Loss of consciousness;Nausea;Night blindness;Oedema;Palpitations;Photophobia;Rash generalised;Respiratory failure;Shock;Sinusitis;Syncope;Vision blurred;Visual disturbance;Visual impairment;Vital dye staining cornea present,small molecule,approved,Carteolol; Cartéolol; Carteololum; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase,Beta-2 adrenergic receptor; Beta-1 adrenergic receptor, C07AA15; S01ED05;C07AA15;S01ED55
carvedilol,Acute coronary syndrome;Angina pectoris;Angina unstable;Arrhythmia;Asthma;Atrial pressure;Cardiac failure;Cardiac failure chronic;Cardiac failure congestive;Cardiomyopathy;Cerebrovascular accident;Drug interaction;Dyspnoea;Essential hypertension;Foetor hepaticus;Hepatic impairment;Hepatocellular injury;Hypertension;Hypertensive;Ischaemic cardiomyopathy;Left ventricular dysfunction;Liver disorder;Myocardial infarction;Non-ischemic cardiomyopathy;Prostatism;Reflex tachycardia;Renal failure;Renal impairment;Renal vessel disorder;Tachycardia;Vascular resistance systemic;Vasodilation;Vasodilation procedure;Ventricular dysfunction,Abdominal pain;Abnormal vision;Accidental injury;Acute coronary syndrome;Acute myocardial infarction;Affect lability;Alanine aminotransferase increased;Albuminuria;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angina pectoris aggravated;Angina unstable;Angioedema;Angiopathy;Ankle edema;Anorexia;Aplastic anaemia;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Atrioventricular block;Atrioventricular block complete;Atrioventricular block first degree;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bradycardia;Breast feeding;Bronchitis;Bronchospasm;Bundle branch block;Cardiac arrest;Cardiac failure;Cardioactive drug level increased;Cardiogenic shock;Cardiovascular disorder;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Clotting;Coagulopathy;Cold hands;Coldness;Confusional state;Constipation;Convulsion;Convulsions generalised;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatinine increased;Decreased appetite;Dehydration;Depressed mood;Depression;Depression aggravated;Dermatitis;Dermatitis exfoliative;Dermatitis psoriasiform;Diabetes mellitus;Diabetic;Diarrhoea;Digoxin level increased;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug level increased;Dry mouth;Dyspepsia;Dyspnoea;Erectile dysfunction;Erythema multiforme;Extrasystoles;Fatigue;Feeling abnormal;Feeling cold;Flatulence;Fluid overload;Fluid retention;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Glucose tolerance impaired;Glycosuria;Gout;Gravitational oedema;Haematuria;Haemoglobin;Haemorrhage;Headache;Hearing impaired;Heart failure signs and symptoms;Hepatic congestion;High density lipoprotein decreased;Hyperaesthesia;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypocholesterolaemia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hypotension;Hypotension symptomatic;Hypotonia;Hypovolaemia;Ill-defined disorder;Immune system disorder;Infection;Influenza;Injury;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intoxication;Ischaemic cardiomyopathy;Joint swelling;Kidney function abnormal;Leg edema;Leukopenia;Libido decreased;Lightheadedness;Liver injury;Loss of consciousness;Lung disorder;Malaise;Malnutrition;Mediastinal disorder;Melaena;Mental disability;Migraine;Mood swings;Muscle relaxant therapy;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;NPN increased;Nasal congestion;Nasopharyngitis;Nausea;Nervousness;Neuralgia;Nightmare;Oedema;Oedema peripheral;Orthostatic hypotension;Pain;Pain in extremity;Palpitations;Pancytopenia;Paraesthesia;Paranoia;Paresis;Partial hearing loss;Periodontitis;Peripheral coldness;Peripheral ischaemia;Peripheral vascular disorder;Pharyngitis;Phosphatase alkaline increased;Photosensitivity reaction;Pneumonia;Poisoning;Pollakiuria;Presyncope;Prothrombin level decreased;Pruritus;Psoriasis;Psychotic disorder;Pulmonary oedema;Purpura;Rales;Rash;Rash erythematous;Rash maculo-papular;Rash psoriaform;Renal artery stenosis;Renal failure;Renal failure acute;Renal impairment;Respiration abnormal;Respiratory alkalosis;Respiratory disorder;Respiratory distress;Retrosternal pain;Rhinitis;Shock;Sinus bradycardia;Sinus congestion;Sinusitis;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Stevens-Johnson syndrome;Sudden death;Sweating increased;Swelling;Syncope;Tachycardia;Tension;Thinking abnormal;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Traumatic liver injury;Unspecified disorder of skin and subcutaneous tissue;Unwell;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular purpura;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Viral infection;Vision blurred;Visual impairment;Vomiting;Weight decreased;Weight increased;Wheezing,small molecule,approved; investigational,"(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; Carvédilol; Carvedilol; Carvedilolum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; CI-B14.5b; Complex I-B14.5b; HLC-1; Human lung cancer oncogene 1 protein; NADH-ubiquinone oxidoreductase subunit B14.5b; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; L-VEGF; Vascular permeability factor; VEGF; VPF; Brain natriuretic factor prohormone; Gamma-brain natriuretic peptide; Iso-ANP; preproBNP; proBNP; Connexin-43; Cx43; Gap junction 43 kDa heart protein; GJAL; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; INCAM-100; V-CAM 1; VCAM-1; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; CD62 antigen-like family member E; ELAM-1; ELAM1; Endothelial leukocyte adhesion molecule 1; LECAM2; Leukocyte-endothelial cell adhesion molecule 2; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; BHLHE78; Class E basic helix-loop-helix protein 78; HIF-1-alpha; HIF1-alpha; Member of PAS protein 1; MOP1; PAS domain-containing protein 8; PASD8; Hippocampal inward rectifier; HIR; HIRK2; HRK1; Inward rectifier K(+) channel Kir2.3; IRK-3; IRK3; Potassium channel, inwardly rectifying subfamily J member 4; Cardiac inward rectifier potassium channel; hIRK1; Inward rectifier K(+) channel Kir2.1; IRK-1; IRK1; Potassium channel, inwardly rectifying subfamily J member 2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; XDHA; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","Beta-1 adrenergic receptor; Alpha-1A adrenergic receptor; Alpha-1 adrenergic receptors; NADH dehydrogenase [ubiquinone] 1 subunit C2; Beta-2 adrenergic receptor; Vascular endothelial growth factor A, long form; Natriuretic peptides B; Gap junction alpha-1 protein; Voltage-gated inwardly rectifying potassium channel KCNH2; Vascular cell adhesion protein 1; Alpha-1D adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-2C adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2A adrenergic receptor; E-selectin; Hypoxia-inducible factor 1-alpha; Inward rectifier potassium channel 4; Inward rectifier potassium channel 2", C07FX06;C07AG02
cefaclor,Acute bronchitis;Atypical pneumonia;Bacterial infection;Bladder pain;Bronchitis;Bronchitis chronic;Community acquired pneumonia;Cystitis;Cystitis noninfective;Drug hypersensitivity;Infection;Lower respiratory tract infection;Otitis media;Penicillin allergy;Pharyngitis;Pneumonia;Pyelonephritis;Renal failure;Renal impairment;Respiratory tract infection;Rheumatic disorder;Rheumatic fever;Sinusitis bacterial;Skin infection;Streptococcal infection;Tonsillitis;Tracheobronchitis;Upper respiratory tract infection;Urinary tract infection,Abdominal pain;Accidental injury;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albumin low;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Arthralgia;Asthenia;Asthma;Back pain;Bilirubin total increased;Blood albumin decreased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood calcium decreased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood potassium increased;Blood sodium increased;Blood urea increased;Body temperature increased;Calcium low;Candida infection;Cardiac failure congestive;Chest pain;Chills;Cholestasis;Colitis;Confusional state;Conjunctivitis;Constipation;Convulsion;Cough;Cough increased;Creatine phosphokinase increased;Creatinine increased;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drug hypersensitivity;Dysmenorrhoea;Dyspepsia;Dyspnoea;Dysuria;Ear pain;Eosinophilia;Epistaxis;Eruption;Erythema multiforme;Face oedema;Feeling abnormal;Flatulence;Gamma-glutamyltransferase increased;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertonia;Hyponatraemia;Hypotension;Ill-defined disorder;Immune system disorder;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Jaundice cholestatic;Lactic dehydrogenase activity increased;Leukopenia;Leukorrhea;Loss of consciousness;Lung disorder;Lymphocyte count decreased;Lymphocytosis;Malaise;Menstrual disorder;Musculoskeletal discomfort;Myalgia;Nausea;Neck pain;Nephritis interstitial;Nephropathy;Nephropathy toxic;Nervous system disorder;Nervousness;Neutropenia;Nocturia;Oedema;Oedema peripheral;Otitis media;Pain;Palpitations;Pancytopenia;Paraesthesia;Penicillin allergy;Phosphatase alkaline increased;Platelet count decreased;Potassium increased;Prothrombin level increased;Pruritus;Pruritus genital;Pseudomembranous colitis;Pyuria;Rash;Rash maculo-papular;Rhinitis;Serum sickness;Serum sickness-like reaction;Serum urea increased;Shock;Sinusitis;Sodium decreased;Sodium high;Somnolence;Stevens-Johnson syndrome;Superinfection;Sweating;Syncope;Tension;Thrombocytopenia;Thrombocytosis;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Urethral disorder;Urinary tract disorder;Urine analysis abnormal;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vertigo;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved,"3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; CCL; Céfaclor; Cefaclor; Cefaclor anhydrous; Cefaclorum; Céfeaclor; Cephaclor; Putative D-alanyl-D-alanine carboxypeptidase; PBP1; 1.11.2.2; MPO; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Penicillin-binding protein 3; Penicillin-binding protein 1A,J01DC04
cefadroxil,Acute pharyngitis;Infection;Lower respiratory tract infection;Pharyngitis;Pneumonia;Renal failure;Renal impairment;Rheumatic disorder;Rheumatic fever;Tonsillitis;Urinary tract infection,Abdominal pain;Agranulocytosis;Alanine aminotransferase increased;Anaphylactic shock;Angioedema;Aplastic anaemia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Blood alkaline phosphatase increased;Blood bilirubin increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Cholestasis;Convulsion;Cramp muscle;Creatinine increased;Dermatitis;Diarrhoea;Digestion impaired;Dizziness;Drowsiness;Dyspepsia;Eosinophilia;Erythema multiforme;Gastrointestinal disorder;Gastrointestinal pain;Genital candidiasis;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic failure;Hepatic function abnormal;Hypersensitivity;Infertility;Lactic dehydrogenase activity increased;Muscle spasms;Musculoskeletal discomfort;Nausea;Nephropathy toxic;Nervousness;Neutropenia;Pancytopenia;Phosphatase alkaline increased;Prothrombin level increased;Pruritus;Pruritus genital;Pseudomembranous colitis;Rash;Serum sickness;Somnolence;Stevens-Johnson syndrome;Superinfection;Swelling;Tension;Thrombocytopenia;Toxic epidermal necrolysis;Urticaria;Vaginal infection;Vaginal inflammation;Vertigo;Vomiting,small molecule,approved; vet_approved; withdrawn,"CDX; Cefadroxil; Cefadroxil anhydrous; Cefadroxilo; Cefadroxilum; Cephadroxil; D-Cefadroxil; Putative D-alanyl-D-alanine carboxypeptidase; exp2; Exported protein 2; PBP-1A; pbp2b; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Penicillin-binding protein 3; Penicillin-binding protein 1A; Penicillin-binding protein 1b; Penicillin-binding protein 2B,J01DB05
cefazolin,Bone and joint infections;Cholecystitis acute;Endocarditis;Epididymitis;Function kidney decreased;Genital infection;Infection;Jaundice cholestatic;Prostatitis;Renal failure;Renal impairment;Respiratory tract infection;Rheumatic disorder;Rheumatic fever;Sepsis;Septicemia;Soft tissue infection;Streptococcal infection;Urinary tract infection,Abdominal pain;Abdominal pain upper;Agitation;Agranulocytosis;Anaemia;Anal pruritus;Anaphylactic shock;Anorectal discomfort;Anorexia;Aplastic anaemia;Aspartate aminotransferase increased;Asthenia;Blood bilirubin increased;Blood creatinine increased;Blood disorder;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Candida infection;Cheilitis;Cholestasis;Colitis;Confusional state;Convulsion;Creatinine increased;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Drug fever;Dyspepsia;Eosinophilia;Epigastric pain;Erythema multiforme;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal pain;Genital candidiasis;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Heartburn;Hepatic function abnormal;Hepatic impairment;Hepatitis;Hyperkinesia;Hypersensitivity;Hypertonia;Hypotension;Induration;Jaundice cholestatic;Lactic dehydrogenase activity increased;Leukopenia;Lightheadedness;Liver disorder;Local reaction;Loss of consciousness;Mouth ulceration;Nausea;Nephritis interstitial;Nephropathy;Nephropathy toxic;Neutropenia;Oral candidiasis;Pain;Pancytopenia;Phlebitis;Pneumonia streptococcal;Post procedural infection;Postoperative infection;Prothrombin level increased;Pruritus;Pruritus genital;Pruritus vulvae;Pseudomembranous colitis;Rash;Renal failure;Serum sickness-like reaction;Shock;Somnolence;Stevens-Johnson syndrome;Stomach cramps;Stomatitis;Superinfection;Syncope;Thrombocytopenia;Thrombocytosis;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Urticaria;Vaginal infection;Vaginal inflammation;Vomiting;Vulvovaginal pruritus,small molecule,approved,"(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefamezin; Cefazolin; Cefazolina; Cefazoline; Cefazolinum; Cephamezine; Cephazolidin; Cephazolin; Cephazoline; CEZ; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; PBP-1c; yfgN; PBP-2; pbpA; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; 3.1.1.2; 3.1.1.81; 3.1.8.1; A-esterase 1; Aromatic esterase 1; K-45; PON; PON 1; Serum aryldialkylphosphatase 1; IL-15; IL-2; T-cell growth factor; TCGF; 2.1.1.67; Thiopurine methyltransferase; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4",Penicillin-binding protein 1A; Penicillin-binding protein 1B; Penicillin-binding protein 1C; Penicillin-binding protein 2; Peptidoglycan synthase FtsI; Serum paraoxonase/arylesterase 1; Interleukin-15; Interleukin-2,J01DB04
cefepime,"Abdominal infection;Bacteraemia;Blister;Body temperature increased;Bronchitis;Cystic fibrosis;Dermatitis bullous;Febrile neutropenia;Haematological malignancy;Hepatic function abnormal;Hypotension;Infection;Lower respiratory tract infection;Neutropenia;Peritonitis;Pneumonia;Pneumonia due to Streptococcus, group b;Pneumonia streptococcal;Pyelonephritis;Renal failure;Renal impairment;Sepsis;Septicemia;Urinary tract infection","Abdominal infection;Abdominal pain;Agitation;Agranulocytosis;Alanine aminotransferase increased;Altered state of consciousness;Anaemia;Anaphylactic shock;Aplastic anaemia;Blood alkaline phosphatase increased;Blood calcium decreased;Blood phosphorus decreased;Blood potassium increased;Body temperature increased;Bronchitis;Ca++ increased;Calcium low;Candida infection;Chills;Cholestasis;Colitis;Coma;Confusional state;Consciousness abnormal;Constipation;Convulsion;Depressed level of consciousness;Dermatitis;Diarrhoea;Disability;Dizziness;Dysgeusia;Dyspnoea;Encephalopathy;Eosinophilia;Erythema;Erythema multiforme;Excitability;Extravasation;Fatal outcomes;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Haemoglobin;Haemolysis;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hepatic failure;Hepatic function abnormal;Hepatic impairment;Hypercalcaemia;Hypersensitivity;Hypocalcaemia;Infection;Inflammation;Injection site inflammation;Leukopenia;Liver disorder;Local reaction;Muscle mass;Myoclonus;Nausea;Nephropathy toxic;Neurotoxicity;Neutropenia;Nonconvulsive status epilepticus;Oral candidiasis;Pain;Pancytopenia;Paraesthesia;Phlebitis;Phosphatase alkaline increased;Phosphorus low;Pneumonia;Pneumonia due to Streptococcus, group b;Pneumonia streptococcal;Potassium increased;Prothrombin level increased;Pruritus;Pruritus genital;Pseudomembranous colitis;Pyelonephritis;Rash;Renal failure;Renal impairment;Sepsis;Septicemia;Shock;Status epilepticus;Stevens-Johnson syndrome;Stupor;Thrombocytopenia;Toxic epidermal necrolysis;Urinary tract infection;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vasodilation;Vasodilation procedure;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection",small molecule,approved; investigational,"(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Cefepima; Cefepime; Cefepimum; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; PBP-2; pbpA; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; mrcB; Murein polymerase; PBP-1b; ftsI; ftsI_1; ftsI_2; Penicillin-binding protein 3; Peptidoglycan synthase FtsI; penA; Sporulation-specific penicillin-binding protein; spoVD; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Penicillin-binding protein 1A; Penicillin-binding protein 1B; Penicillin-binding protein 2; Peptidoglycan synthase FtsI; Penicillin-binding protein 1B; Cell division protein; Penicillin-binding protein 2, J01RA06;J01DE01
cefotaxime,"Abdominal infection;Arthritis bacterial;Asymptomatic bacteriuria;Bacteraemia;Bacterial infection;Bacterial sepsis;Bladder pain;Bone and joint infections;Borrelia infection;Bronchiectasis;Bronchitis chronic;CNS ventriculitis;Cellulitis;Central nervous system infection;Cystitis;Cystitis noninfective;Endometritis;Enterococcal infection;Genital infection female;Gonorrhoea;Gynecological infection;Infection;Lower respiratory tract infection;Lung abscess;Meningitis;Nephropathy toxic;Nephrotoxicity;Osteomyelitis;Other bacterial diseases;Ototoxicity;Parametritis;Pelvic inflammatory disease;Peritonitis;Pneumonia;Pneumonia bacterial;Pyelonephritis chronic;Renal failure;Renal impairment;Respiratory tract infection;Sepsis;Septicaemia due to gram-negative organism, unspecified;Septicemia;Skin infection;Soft tissue infection;Urinary tract infection;Ventriculitis;Wound infection",Abdominal pain;Agranulocytosis;Anaphylactic shock;Angioedema;Aplastic anaemia;Arrhythmia;Body temperature increased;Bronchospasm;Bullous eruption;Candida infection;Cholestasis;Colitis;Convulsion;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Encephalopathy;Enterocolitis;Eosinophilia;Erythema multiforme;Feeling abnormal;Function kidney decreased;Gastrointestinal pain;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic function abnormal;Hepatitis;Hypersensitivity;Ill-defined disorder;Induration;Injection site inflammation;Jaundice;Leukopenia;Liver injury;Local reaction;Malaise;Nausea;Nephritis interstitial;Nephropathy toxic;Neutropenia;Pain;Pruritus;Pseudomembranous colitis;Rash;Renal failure;Renal impairment;Shock;Stevens-Johnson syndrome;Superinfection;Tenderness;Thrombocytopenia;Toxic epidermal necrolysis;Traumatic liver injury;Tubulointerstitial nephritis;Urticaria;Vaginal infection;Vaginal inflammation;Vomiting,small molecule,approved,"(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefotaxim; Cefotaxima; Cefotaxime; Céfotaxime; Cefotaximum; Cephotaxime; PBP 3; Penicillin-binding protein C; PSPB20; ycsM; yzsA; exp2; Exported protein 2; PBP-1A; pbp2b; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; 3.5.2.6; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2",Penicillin-binding protein 1b; Penicillin-binding protein 2a; Penicillin-binding protein 3; Penicillin-binding protein 1A; Penicillin-binding protein 2B; Solute carrier family 22 member 6; Organic anion transporter 3; Solute carrier family 22 member 11; Solute carrier family 22 member 7; Solute carrier family 15 member 1; Albumin; Beta-lactamase; Solute carrier family 15 member 2,J01DD01
cefoxitin,Abdominal abscess;Abdominal infection;Abscess;Bone and joint infections;Endocarditis;Endometritis;Genital infection female;Gynecological infection;Infection;Infection mixed;Lower respiratory tract infection;Lung abscess;Parametritis;Pelvic infection;Pelvic inflammatory disease;Peritonitis;Pneumonia;Renal failure;Renal impairment;Respiratory tract infection;Sepsis;Septicemia;Urinary tract infection,Abdominal pain;Acute prerenal failure;Agranulocytosis;Anaemia;Anaphylactic shock;Angioedema;Aplastic anaemia;Azotaemia;Azotemia prerenal;Blood bilirubin increased;Body temperature increased;Bone marrow depression;Candida infection;Cholestasis;Colitis;Convulsion;Dermatitis;Dermatitis exfoliative;Diarrhoea;Dyspnoea;Eosinophilia;Erythema;Erythema multiforme;Flushing;Gastrointestinal pain;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hepatic function abnormal;Hypersensitivity;Hypotension;Induration;Jaundice;Leukopenia;Local reaction;Myasthenia gravis;Nausea;Nephritis interstitial;Nephropathy toxic;Neutropenia;Pain;Pancytopenia;Phlebitis;Prothrombin level increased;Pruritus;Pseudomembranous colitis;Rash;Rash maculo-papular;Renal failure acute;Serum sickness;Stevens-Johnson syndrome;Superinfection;Tenderness;Thrombocytopenia;Thrombophlebitis;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Urethral disorder;Urinary tract disorder;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved,"(6R,7S)-4-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(thiophen-2-enyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefoxitin; Cefoxitina; Cefoxitine; Cefoxitinum; Ceftoxitin; Cephoxitin; CFX; Rephoxitin; 3.4.16.4; DD-carboxypeptidase; PBP-6; Penicillin-binding protein 6; 3.4.16.4; Beta-lactamase; DD-carboxypeptidase; PBP-5; Penicillin-binding protein 5; pfv; 3.4.21.-; DD-endopeptidase; PBP-7; Penicillin-binding protein 7; yohB; 3.4.16.4; D-alanyl-D-alanine endopeptidase; DD-carboxypeptidase; DD-endopeptidase; PBP-4; Penicillin-binding protein 4; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; Putative D-alanyl-D-alanine carboxypeptidase; exp2; Exported protein 2; PBP-1A; pbp2b; 3.5.2.6; blaP; Penicillinase",D-alanyl-D-alanine carboxypeptidase DacC; D-alanyl-D-alanine carboxypeptidase DacA; D-alanyl-D-alanine endopeptidase; D-alanyl-D-alanine carboxypeptidase DacB; Penicillin-binding protein 1A; Penicillin-binding protein 1B; Peptidoglycan synthase FtsI; Penicillin-binding protein 3; Penicillin-binding protein 1b; Penicillin-binding protein 2a; Penicillin-binding protein 1A; Penicillin-binding protein 2B,J01DC01
cefprozil,Abscess;Acute bronchitis;Acute cystitis;Acute sinusitis;Bacterial infection;Bladder pain;Bronchitis;Bronchitis chronic;Cystitis;Cystitis noninfective;Infection;Influenza;Otitis media;Pharyngitis;Renal failure;Renal impairment;Rheumatic disorder;Rheumatic fever;Streptococcal infection;Tonsillitis;Tracheobronchitis;Urinary tract infection,"Abdominal pain;Acute sinusitis;Agitation;Agranulocytosis;Anaphylactic shock;Angioedema;Aplastic anaemia;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Colitis;Confusional state;Congenital anomaly;Convulsion;Dermatitis;Dermatitis diaper;Dermatitis exfoliative;Developmental delay;Diarrhoea;Dizziness;Drowsiness;Eosinophilia;Erythema;Erythema multiforme;Feeling abnormal;Gastrointestinal pain;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hyperkinesia;Hypersensitivity;Insomnia;Jaundice cholestatic;Lactic dehydrogenase activity increased;Nausea;Nephropathy toxic;Nervousness;Neutropenia;Pain;Pancytopenia;Pharyngitis;Pneumonia due to Streptococcus, group b;Pneumonia streptococcal;Prothrombin level increased;Pruritus;Pruritus genital;Pseudomembranous colitis;Rash;Serum sickness;Somnolence;Stevens-Johnson syndrome;Superinfection;Tension;Thrombocytopenia;Tonsillitis;Tooth discolouration;Toxic epidermal necrolysis;Urticaria;Vaginal infection;Vaginal inflammation;Vomiting",small molecule,approved,Cefprozil; Cefprozil anhydrous; Cefprozilo; Cefprozilum; PBP-1A; PBP-2x; pbp2b,Penicillin-binding protein 1A; Penicillin-binding protein 2x; Penicillin-binding protein 2B,J01DC10
ceftazidime,Abdominal abscess;Abdominal infection;Abscess;Arthritis bacterial;Bacteraemia;Bacterial sepsis;Bladder pain;Bone and joint infections;Bronchiectasis;Bronchitis;Bronchopneumonia;Bursitis;Calculus of kidney;Cellulitis;Central nervous system infection;Cystic fibrosis;Cystitis;Cystitis noninfective;Endometritis;Enterocolitis;Erysipelas;Genital infection female;Gynecological infection;Immunocompromised;Immunodeficiency;Infection;Infection mixed;Lower respiratory tract infection;Mastitis;Mastoiditis;Meningitis;Nephrolithiasis;Osteitis;Osteomyelitis;Otitis media;Parametritis;Peritonitis;Pleurisy;Pneumonia;Pseudomonas infection;Pyelitis;Pyelonephritis;Pyelonephritis chronic;Renal failure;Renal impairment;Respiratory tract infection;Sepsis;Sepsis neonatal;Septicemia;Soft tissue infection;Urethritis;Urethritis noninfective;Urinary tract infection;Wound,Abdominal pain;Agitation;Agranulocytosis;Alcohol intolerance;Allergic exanthema;Anaphylactic shock;Angioedema;Angiopathy;Aplastic anaemia;Application site pain;Asterixis;Bad taste;Blood and lymphatic system disorders;Body temperature increased;Bronchospasm;Candida infection;Cardio-respiratory arrest;Cholestasis;Colitis;Coma;Convulsion;Coombs test positive;Dermatitis;Dermatitis atopic;Diarrhoea;Disulfiram like reaction;Dizziness;Dysgeusia;Encephalopathy;Eosinophilia;Erythema multiforme;Excitability;Flushing;Foetal damage;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hepatic function abnormal;Hepatobiliary disease;Hot flush;Hyperbilirubinaemia;Hypersensitivity;Hypotension;Immune system disorder;Infestation;Infestation NOS;Inflammation;Injection site pain;Instillation site pain;Jaundice;Lethargy;Leukopenia;Local reaction;Lymphocytosis;Menopausal symptoms;Myoclonus;Nausea;Nephropathy;Nephropathy toxic;Nervous system disorder;Neutropenia;Oral candidiasis;Pain;Pancytopenia;Paraesthesia;Phlebitis;Prothrombin level increased;Pruritus;Pseudomembranous colitis;Rash;Reaction gastrointestinal;Renal failure;Renal impairment;Skin disorder;Skin exfoliation;Stevens-Johnson syndrome;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vaginal infection;Vaginal inflammation;Vision blurred;Vomiting,small molecule,approved,CAZ; Ceftazidim; Ceftazidima; Ceftazidime; Ceftazidime anhydrous; Ceftazidimum; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; PBP-2; pbpA; 3.5.2.6; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1,Peptidoglycan synthase FtsI; Penicillin-binding protein 1A; Penicillin-binding protein 1B; Penicillin-binding protein 2; Beta-lactamase Toho-1,J01DD02
ceftizoxime,Abdominal infection;Bone and joint infections;Gonorrhoea;Infection;Lower respiratory tract infection;Meningitis;Pelvic inflammatory disease;Renal failure;Renal impairment;Sepsis;Septicemia;Urinary tract infection,Agranulocytosis;Anaemia;Anaphylactic shock;Aplastic anaemia;Blood lactate dehydrogenase increased;Body temperature increased;Cellulitis;Convulsion;Coombs test positive;Dermatitis;Diarrhoea;Eosinophilia;Erythema multiforme;Fatal outcomes;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hypersensitivity;Hypoaesthesia;Induration;Injection site burning;Injection site pain;Lactic dehydrogenase activity increased;Leukopenia;Nausea;Nephropathy toxic;Neutropenia;Numbness;Pain;Pancytopenia;Paraesthesia;Phlebitis;Prothrombin level increased;Pruritus;Pseudomembranous colitis;Rash;Sensory loss;Serum sickness-like reaction;Stevens-Johnson syndrome;Tenderness;Thrombocytopenia;Thrombocytosis;Toxic epidermal necrolysis;Vaginal infection;Vaginal inflammation;Vomiting,small molecule,approved; withdrawn,"7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Ceftizoxima; Ceftizoxime; Ceftizoximum; syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; 3.4.16.4; DD-carboxypeptidase; PBP-6; Penicillin-binding protein 6; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Penicillin-binding protein 1A; Penicillin-binding protein 1B; Peptidoglycan transpeptidase; D-alanyl-D-alanine carboxypeptidase DacC,J01DD07
ceftriaxone,"Abdominal infection;Bacterial sepsis;Bone and joint infections;Cholecystitis acute;Cholecystitis chronic;Genital infection;Gonorrhoea;Infection;Jaundice cholestatic;Lower respiratory tract infection;Meningitis;Otitis media bacterial;Pelvic inflammatory disease;Peritonitis;Pneumonia;Pneumonia due to Streptococcus, group b;Pneumonia streptococcal;Renal failure;Renal impairment;Respiratory tract infection;Sepsis;Shunt infection;Urinary tract infection;Wound",Abdominal pain;Abdominal pain upper;Agitation;Agranulocytosis;Alveolitis allergic;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Aplastic anaemia;Aspartate aminotransferase increased;Ataxia;Autoimmune haemolytic anaemia;Basophilia;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urine;Blood urine present;Body temperature increased;Bronchospasm;Burning tongue;Candida infection;Chills;Cholelithiasis;Cholestasis;Coagulopathy;Colitis;Convulsion;Crystalluria;Dermatitis;Dermatitis atopic;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Drug fever;Drug interaction;Dysgeusia;Dyspepsia;Enterocolitis;Eosinophilia;Epistaxis;Erythema multiforme;Fatal outcomes;Feeling abnormal;Feeling hot;Flatulence;Flushing;Fungal infection;Gallbladder sludge;Gastrointestinal pain;Glossitis;Glossodynia;Glycosuria;Haematocrit decreased;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic function abnormal;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertonia;Ill-defined disorder;Induration;Infection;Jaundice;Lactic dehydrogenase activity increased;Laryngeal oedema;Leukocytosis;Leukopenia;Local reaction;Loose stools;Lymphocytosis;Lymphopenia;Malaise;Monocytosis;Nausea;Nephrolithiasis;Nephropathy toxic;Neutropenia;Oedema;Oliguria;Pain;Palpitations;Pancreatitis;Paraesthesia;Phlebitis;Protein urine present;Proteinuria;Prothrombin time shortened;Pruritus;Pseudomembranous colitis;Rash;Renal failure;Renal impairment;Secondary infection;Serum creatinine increased;Serum sickness;Serum sickness-like reaction;Shivering;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Superinfection;Sweating increased;Tenderness;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Toxic epidermal necrolysis;Urticaria;Vaginal infection;Vaginal inflammation;Vomiting;Warmth,small molecule,approved,"Ceftriaxona; Ceftriaxone; Ceftriaxonum; Rocephin; pbp2b; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; 6.3.1.2; GLNS; Glutamate--ammonia ligase; GS; Palmitoyltransferase GLUL; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Penicillin-binding protein 2B; Solute carrier family 22 member 11; Solute carrier family 22 member 6; Organic anion transporter 3; Solute carrier family 15 member 1, J01DD54;J01DD04
cefuroxime,"Acute bronchitis;Arthritis bacterial;Asymptomatic bacteriuria;Bacterial infection;Bacterial sepsis;Bladder pain;Bone and joint infections;Bronchiectasis;Bronchitis;Bronchitis chronic;Cellulitis;Cystitis;Cystitis noninfective;Erysipelas;Erythema migrans;Foetor hepaticus;Gonorrhoea;Hepatocellular injury;Hypersensitivity;Impetigo;Infection;Infection mixed;Liver disorder;Lower respiratory tract infection;Lung abscess;Lyme disease;Maxillary sinusitis;Meningitis;Osteomyelitis;Otitis media;Otitis media bacterial;Overgrowth bacterial;Pathogen resistance;Pelvic inflammatory disease;Peritonitis;Pharyngitis;Pneumonia;Pneumonia bacterial;Pyelonephritis chronic;Renal failure;Renal impairment;Respiratory tract infection;Rheumatic disorder;Rheumatic fever;Sepsis;Septicaemia due to gram-negative organism, unspecified;Septicemia;Sinusitis;Soft tissue infection;Streptococcal infection;Tonsillitis;Tracheobronchitis;Urinary tract infection;Wound infection",Abdominal cramps;Abdominal pain;Acute bronchitis;Agitation;Agranulocytosis;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Aplastic anaemia;Arthralgia;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine decreased;Blood creatinine increased;Blood urea increased;Body temperature increased;Bronchitis;Candida infection;Chest pain;Chills;Cholestasis;Colitis;Convulsion;Coombs test positive;Cough;Cramp muscle;Creatinine increased;Creatinine low;Cutaneous vasculitis;Decreased appetite;Dermatitis;Dermatitis diaper;Diarrhoea;Digestion impaired;Disability;Dizziness;Drowsiness;Drug fever;Dyspepsia;Dyspnoea;Dysuria;Eosinophilia;Erythema;Erythema multiforme;Felt faint;Flatulence;Gastrointestinal disorder;Gastrointestinal infection;Gastrointestinal pain;Gastrointestinal symptom NOS;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemorrhage;Headache;Hepatic enzyme increased;Hepatic function abnormal;Hepatic impairment;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Immune system disorder;Infestation;Infestation NOS;Injection site pain;Intertrigo candida;Irritability;Jarisch-Herxheimer reaction;Jaundice;Joint swelling;Leukopenia;Liver disorder;Local reaction;Lockjaw;Loose stools;Mouth ulceration;Muscle spasms;Muscle stiffness;Muscle tightness;Musculoskeletal discomfort;Musculoskeletal stiffness;Nausea;Neck tightness;Nephritis interstitial;Nephropathy toxic;Neutropenia;Pain;Palpitations;Pancytopenia;Phosphatase alkaline increased;Prothrombin level increased;Pruritus;Pruritus vulvae;Pseudomembranous colitis;Rash;Red blood cell sedimentation rate increased;Renal failure;Renal impairment;Renal pain;Salivary hypersecretion;Serum sickness-like reaction;Sinusitis;Skin disorder;Somnolence;Stevens-Johnson syndrome;Stiffness;Stomatitis;Sweating;Swollen tongue;Tachycardia;Thirst;Thrombocytopenia;Thrombophlebitis;Toxic epidermal necrolysis;Tracheobronchitis;Trismus;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urethral pain;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginal irritation;Vaginal itching;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal discomfort;Vulvovaginal mycotic infection;Vulvovaginal pruritus,small molecule,approved,"(6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefuroxim; Cefuroxima; Cefuroxime; Cefuroximo; Cefuroximum; Cephuroxime; PBP1; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Penicillin-binding protein 1A, J01DC02; J01RA03;J01DC02;S01AA27
celecoxib,Acute pain;Adenomatous polyposis coli;Ankylosing spondylitis;Arthritis;Colon adenoma;Dysmenorrhoea;Hypertension;Inflammation;Injury;Intestinal polyp;Juvenile idiopathic arthritis;Large intestine polyp;Ligament sprain;Osteoarthritis;Pain;Polyp;Primary dysmenorrhea;Rheumatoid arthritis;Soft tissue injury;Spondylitis;Spondyloarthropathy;Sprain;Trauma,Abdominal pain;Abdominal pain upper;Activated partial thromboplastin time prolonged;Acute coronary syndrome;Acute generalised exanthematous pustulosis;Adenoma benign;Ageusia;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Allergy aggravated;Alopecia;Alveolar osteitis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angina unstable;Angioedema;Angiopathy;Anorectal discomfort;Anorexia;Anosmia;Anxiety;Aortic valve incompetence;Aplastic anaemia;Arrhythmia;Arteriosclerosis coronary artery;Arthralgia;Arthropathy;Aspartate aminotransferase increased;Asthenia;Ataxia;Back pain;Bacterial infection;Bacteriuria;Bacteriuria NOS present;Benign prostatic hyperplasia;Bladder pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood culture positive;Blood glucose increased;Blood potassium increased;Blood pressure increased;Blood sodium increased;Blood testosterone decreased;Blood urea increased;Blood uric acid increased;Blood urine;Blood urine present;Body temperature increased;Bone disorder;Breast disorder;Breast neoplasm;Breast pain;Breast tenderness;Bronchitis;Bronchospasm;Bronchospasm aggravated;Bullous eruption;Calculus of kidney;Candida infection;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cataract;Cellulitis;Cerebral haemorrhage;Cerebral infarction;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Cholelithiasis;Cholestasis;Clotting;Coagulopathy;Colitis;Completed suicide;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Connective tissue disorder;Constipation;Coronary artery disease;Cough;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine increased;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Deep vein thrombosis;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diverticulitis;Diverticulum;Dizziness;Drug eruption;Drug interaction;Drug reaction with eosinophilia and systemic symptoms;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear infection;Ear pain;Ecchymosis;Enterocolitis haemorrhagic;Eosinophilia;Epicondylitis;Epilepsy;Epilepsy aggravated;Epistaxis;Eructation;Erysipelas;Erythema multiforme;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Fatigue;Feeling abnormal;Fibroadenoma of breast;Fibroadenosis of breast;Flatulence;Fluid retention;Flushing;Foot fracture;Fracture;Frequent bowel movements;Functional gastrointestinal disorder;Fungal infection;Gangrene;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Genital candidiasis;Gingival infection;Glaucoma;Glomerulonephritis minimal lesion;Haematocrit decreased;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoglobin increased;Haemorrhage;Haemorrhage intracranial;Haemorrhoidal haemorrhage;Haemorrhoids;Hallucination;Headache;Hearing impaired;Helicobacter infection;Hemorrhagic colitis;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis cholestatic;Hepatitis fulminant;Hepatobiliary disease;Herpes simplex;Herpes zoster;Hiatus hernia;Hot flush;Hyperchloraemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitive syndrome;Hypersensitivity;Hypertension;Hypertension worsened;Hypertonia;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hyponatraemia;Hypophosphataemia;Ileus;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza like illness;Influenza-like symptoms;Injection site reaction;Insomnia;Intestinal obstruction;Intestinal perforation;Irritable bowel syndrome;Ischaemic stroke;Jaundice;Labyrinthitis;Large intestine polyp;Laryngitis;Leukopenia;Lipoid nephrosis;Lipoma;Liver function test abnormal;Loss of consciousness;Lower limb fracture;Mediastinal disorder;Melaena;Meningitis aseptic;Menopausal symptoms;Menstrual disorder;Mental disorder;Migraine;Mouth ulceration;Multiple fractures;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myositis;NPN increased;Nail disorder;Nasopharyngitis;Nausea;Neck stiffness;Necrolysis epidermal;Neoplasm;Nephritis interstitial;Nephrolithiasis;Nephrotic syndrome;Nervous system disorder;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Nocturia;Nuchal rigidity;Oedema;Oedema peripheral;Oesophageal perforation;Oesophagitis;Osteoarthritis;Otitis media;Ovarian cyst;Palpitations;Pancreatitis;Pancreatitis acute;Pancytopenia;Paraesthesia;Partial hearing loss;Peripheral gangrene;Pharyngitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Proctalgia;Prostatic disorder;Prostatic specific antigen increased;Prostatitis;Protein urine present;Proteinuria;Pruritus;Pulmonary embolism;Rash;Rash erythematous;Rash maculo-papular;Rectal tenesmus;Renal failure acute;Rhinitis;Sepsis;Shock;Sinus bradycardia;Sinusitis;Skin disorder;Skin exfoliation;Skin mass;Skin nodule;Sleep disorder;Soft tissue infection;Somnolence;Stevens-Johnson syndrome;Stiffness;Stomatitis;Sudden death;Suicide;Sweating increased;Syncope;Synovitis;Tachycardia;Tendon rupture;Tendonitis;Tension;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Tinnitus;Tooth disorder;Toxic epidermal necrolysis;Transaminases increased;Transient ischaemic attack;Tubulointerstitial nephritis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urea increased;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urine analysis abnormal;Urticaria;Uveitis;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vasculitis;Venous occlusion;Ventricular fibrillation;Ventricular hypertrophy;Vertigo;Vertigo CNS origin;Viral infection;Vision blurred;Vitreous floaters;Vomiting;Weight increased;Wound infection,small molecule,approved; investigational,"Celecoxib; Célécoxib; Celecoxibum; p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; Acute-phase response factor; APRF; 3.2.1.18; Acetylneuraminyl hydrolase; G9 sialidase; Lysosomal sialidase; N-acetyl-alpha-neuraminidase 1; NANH; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-III; Carbonate dehydratase III; Carbonic anhydrase III; OB-cadherin; OSF-4; Osteoblast cadherin; 2.7.11.1; hPDK1; PDK1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Prostaglandin G/H synthase 2; Signal transducer and activator of transcription 3; Sialidase-1; Carbonic anhydrase 2; Carbonic anhydrase 3; Cadherin-11; 3-phosphoinositide-dependent protein kinase 1, C08CA51; G01AE10; L01XX33; M01AH01;L01XX33;N02AJ16
celiprolol,Angina pectoris;Asthma;Hypertension,ANA increased;Abdominal pain;Abdominal pain upper;Alveolitis allergic;Antinuclear antibody increased;Arrhythmia;Asthenia;Atrioventricular block;Bradycardia;Bronchospasm;Cardiac failure;Confusional state;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Dizziness;Dry eye;Dyspnoea;Fatigue;Feeling abnormal;Hallucination;Headache;Hot flush;Hyperthyroidism;Hypoglycaemia;Hypotension;Insomnia;Intermittent claudication;Menopausal symptoms;Nausea;Nightmare;Palpitations;Paraesthesia;Psychotic disorder;Rash;Raynaud's disease;Raynaud's phenomenon;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Stomach ache;Tachycardia;Thyrotoxicosis;Tremor;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,"Celiprolol; Celiprololum; RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Beta-3 adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor,C07AB08
cephalexin,Acute prostatitis;Bacterial infection;Endocarditis;Endocarditis bacterial;Hypersensitivity;Infection;Otitis media;Prostatitis;Renal failure;Renal impairment;Respiratory tract infection;Rheumatic disorder;Rheumatic fever;Sinusitis bacterial;Soft tissue infection;Streptococcal infection;Tooth infection,Abdominal pain;Agitation;Agranulocytosis;Alanine aminotransferase increased;Anal pruritus;Anaphylactic shock;Angioedema;Anorectal discomfort;Aplastic anaemia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Breast disorder;Cholestasis;Colitis;Confusional state;Connective tissue disorder;Convulsion;Creatinine increased;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Eosinophilia;Erythema multiforme;Fatigue;Feeling abnormal;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Genital candidiasis;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hypersensitivity;Immune system disorder;Infestation;Infestation NOS;Jaundice cholestatic;Lactic dehydrogenase activity increased;Leukopenia;Mental disorder;Musculoskeletal discomfort;Nausea;Nephritis interstitial;Nephropathy toxic;Nervous system disorder;Neutropenia;Osteoarthritis;Pancytopenia;Phosphatase alkaline increased;Prothrombin level increased;Pruritus;Pruritus genital;Pseudomembranous colitis;Rash;Skin disorder;Stevens-Johnson syndrome;Thrombocytopenia;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vomiting,small molecule,approved; investigational; vet_approved,"(6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid; 7-beta-(D-alpha-Amino-alpha-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid; Anhydrous cefalexin; Anhydrous cephalexin; Cefalexin; Cefalexin anhydrous; Cefalexina; Céfalexine; Cefalexinum; Cephalexin anhydrous; Putative D-alanyl-D-alanine carboxypeptidase; pbp2b; exp2; Exported protein 2; PBP-1A; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Penicillin-binding protein 3; Penicillin-binding protein 2a; Penicillin-binding protein 1b; Penicillin-binding protein 2B; Penicillin-binding protein 1A,J01DB01
cefixime,Acute bronchitis;Bladder pain;Bronchitis;Bronchitis chronic;Cystitis;Cystitis noninfective;Gonorrhoea;Infection;Otitis media;Pharyngitis;Renal failure;Renal impairment;Rheumatic disorder;Rheumatic fever;Sinusitis;Tonsillitis;Tracheobronchitis;Urethritis;Urethritis noninfective;Urinary tract infection,"Abdominal pain;Agranulocytosis;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Aplastic anaemia;Blister;Blood bilirubin increased;Blood lactate dehydrogenase increased;Body temperature increased;Candida infection;Cholestasis;Colitis;Convulsion;Coombs test positive;Dermatitis;Dermatitis bullous;Diarrhoea;Dizziness;Drug fever;Dyspepsia;Eosinophilia;Erythema multiforme;Face oedema;Flatulence;Gastrointestinal pain;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic function abnormal;Hepatitis;Hyperbilirubinaemia;Hypersensitivity;Jaundice;Lactic dehydrogenase activity increased;Leukopenia;Loose stools;Meningitis;Nausea;Nephropathy toxic;Neutropenia;Pancytopenia;Pneumonia due to Streptococcus, group b;Pneumonia streptococcal;Pruritus;Pruritus genital;Pseudomembranous colitis;Rash;Renal failure;Renal failure acute;Renal impairment;Serum sickness;Shock;Stevens-Johnson syndrome;Superinfection;Thrombocytopenia;Thrombocytosis;Toxic epidermal necrolysis;Urinary tract infection;Urticaria;Vaginal infection;Vaginal inflammation;Vomiting",small molecule,approved; investigational,"(−)-cefixim; Cefixim; Cefixima; Céfixime; Cefixime; Cefixime anhydrous; Cefiximum; 3.4.16.4; Beta-lactamase; DD-carboxypeptidase; PBP-5; Penicillin-binding protein 5; pfv; 3.4.16.4; D-alanyl-D-alanine endopeptidase; DD-carboxypeptidase; DD-endopeptidase; PBP-4; Penicillin-binding protein 4; 3.4.16.4; DD-carboxypeptidase; PBP-6; Penicillin-binding protein 6; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; PBP-2; pbpA; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; PBP-2; pbpA; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Penicillin-binding protein; Penicillin-binding protein 2, J01RA15; J01RA16;J01DD08
cerivastatin,Blood triglycerides increased;Carotid artery disease;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Dyslipidaemia;High density lipoprotein decreased;Hypercholesterolaemia;Hyperlipidaemia;Hyperlipoproteinemia;Hypertension;Hypertriglyceridaemia;Low density lipoprotein increased;Peripheral vascular disorder;Premature menopause;Type IIb hyperlipidaemia;Type IIb hyperlipoproteinemia,Abdominal pain;Accidental injury;Agitation;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Antinuclear antibody positive;Anxiety;Arthralgia;Arthritis;Asthenia;Back pain;Body temperature increased;Bronchitis;Cataract;Cataract specified;Chest pain;Chills;Colitis;Constipation;Cough;Cramp muscle;Decreased appetite;Dermatitis;Dermatomyositis;Diarrhoea;Discomfort;Dizziness;Drug reaction with eosinophilia and systemic symptoms;Duodenal ulcer;Dysgeusia;Dyspepsia;Dyspnoea;Eosinophilia;Epistaxis;Erectile dysfunction;Erythema multiforme;Facial paresis;Feeling abnormal;Flatulence;Flushing;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gynaecomastia;Haemolytic anaemia;Headache;Hepatic cancer;Hepatic necrosis;Hepatitis;Hepatitis chronic active;Hepatocellular carcinoma;Hyperkinesia;Hypersensitive syndrome;Hypersensitivity;Hypertonia;IIIrd nerve paralysis;Ill-defined disorder;Influenza;Injury;Insomnia;Jaundice cholestatic;Kidney function abnormal;Leg pain;Lenticular opacities;Leukopenia;Loss of libido;Lupus erythematosus;Malaise;Memory loss;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myoglobin urine present;Myoglobinuria;Myopathy;Myositis;Nausea;Neuropathy peripheral;Nodule;Oedema;Ophthalmoplegia;Pain in extremity;Pancreatitis;Paraesthesia;Paralysis;Peripheral nerve palsy;Pharyngitis;Photosensitivity;Photosensitivity reaction;Polymyalgia rheumatica;Pruritus;Purpura;Rash;Renal failure acute;Renal impairment;Rhabdomyolysis;Rhinitis;Sinusitis;Somnolence;Stevens-Johnson syndrome;Systemic lupus erythematosus;Thrombocytopenia;Toxic epidermal necrolysis;Transaminases increased;Tremor;Urticaria;VIIth nerve paralysis;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; withdrawn,"Cerivastatin; 1.1.1.34; HMG-CoA reductase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",3-hydroxy-3-methylglutaryl-coenzyme A reductase,C10AA06
cetirizine,Arthropod bite;Asthma;Chronic spontaneous urticaria;Conjunctivitis;Conjunctivitis allergic;Erythema;Hypersensitivity;Insect bite NOS;Lacrimation;Lacrimation increased;Nasal congestion;Nasopharyngitis;Perennial allergic rhinitis;Postnasal drip;Pruritus;Redness;Rhinitis allergic;Rhinitis perennial;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Sneezing;Tearing eyes;Upper-airway cough syndrome;Urticaria;Urticaria chronic,Abdominal distension;Abdominal pain;Abnormal vision;Accidental injury;Accommodation disorder;Affect lability;Ageusia;Aggression;Aggressive reaction;Agitation;Alopecia;Amnesia;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Application site reaction;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Ataxia;Back pain;Bladder pain;Blindness;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Body temperature increased;Bone disorder;Breast pain;Breast pain female;Bronchitis;Bronchospasm;Bullous eruption;Cardiac disorder;Cardiac failure;Cerebration impaired;Chest pain;Chills;Cholestasis;Completed suicide;Confusional state;Congenital eye disorder;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cough;Cramps of lower extremities;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Dental caries;Depersonalisation;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug eruption;Dry mouth;Dry skin;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphonia;Dyspnoea;Dysuria;Ear pain;Eczema;Enlargement abdomen;Enuresis;Epistaxis;Eructation;Euphoric mood;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Fatigue;Feeling abnormal;Fixed drug eruption;Flatulence;Fluid retention;Flushing;Fracture;Fungal infection;Furuncle;Furunculosis;Gamma-glutamyltransferase increased;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Glaucoma;Glomerulonephritis;Haematuria;Haemolytic anaemia;Haemorrhoids;Hallucination;Headache;Hepatic function abnormal;Hepatitis;Herpes simplex;Hot flush;Hyperaesthesia;Hyperhidrosis;Hyperkeratosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hypertrichosis;Hyperventilation;Hypoaesthesia;Hypotension;Ill-defined disorder;Immune system disorder;Impaired healing;Increased appetite;Increased bronchial secretion;Infection;Injection site inflammation;Injury;Insomnia;Irritability;Jaundice;Leg edema;Leukorrhea;Libido decreased;Loss of consciousness;Lymphadenopathy;Malaise;Melaena;Memory impairment;Menopausal symptoms;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Metrorrhagia;Migraine;Mood swings;Mouth ulceration;Movement disorder;Multiple fractures;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myelitis;Myoclonus;Nasal polyps;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Nightmare;Oculogyration;Oculogyric crisis;Oedema;Oedema peripheral;Orofacial dyskinesia;Osteoarthritis;Otitis media;Ototoxicity;Pain;Pallor;Palpitations;Paraesthesia;Paralysis;Parosmia;Periorbital oedema;Pharyngitis;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Pruritus;Purpura;Rash;Rash erythematous;Rash maculo-papular;Rectal haemorrhage;Rhinitis;Rhinitis seasonal;Rigors;Salivary hypersecretion;Scotoma;Seborrhoeic dermatitis;Shock;Sinusitis;Skin disorder;Skin mass;Skin nodule;Sleep disorder;Somnolence;Speech disorder;Sputum increased;Stillbirth;Stomatitis;Suicidal ideation;Suicide;Sweating increased;Syncope;Tachycardia;Tendon disorder;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thyroid disorder;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Tooth caries aggravated NOS;Transaminases increased;Tremor;Ulcerative stomatitis;Unintended pregnancy;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Urticaria chronic;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vascular purpura;Vertigo;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight increased;Xerophthalmia,small molecule,approved,Cetirizin; Cetirizina; Cetirizine; Cetirizinum; H1-R; H1R; HH1R; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1,Histamine H1 receptor, R06AE07;R06AE07;S01GX12
cevimeline,Dry mouth;Sjogren's syndrome,Abdominal distension;Abdominal pain;Abnormal platelets;Abnormal vision;Abscess;Acute coronary syndrome;Affect lability;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Allergy aggravated;Alopecia;Amenorrhoea;Amnesia;Amylase increased;Anaemia;Angina pectoris;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anxiety;Apathy;Aphasia;Apnoea;Appendicitis;Arrhythmia;Arthralgia;Arthritis;Arthritis aggravated;Arthropathy;Asthenia;Asthma;Atelectasis;Atrophic vulvovaginitis;Avascular necrosis femoral head;Back pain;Bacterial infection;Basal cell carcinoma;Bladder discomfort;Bladder pain;Blepharitis;Blood alkaline phosphatase increased;Blood disorder;Blood electrolytes abnormal;Blood pressure fluctuation;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Breast neoplasm;Breast pain;Breast pain female;Bronchial hyperreactivity;Bronchitis;Bronchoconstriction;Bronchospasm;Bullous eruption;Bundle branch block;Bursitis;Calculus of kidney;Candida infection;Cardiac disorder;Cardiac murmur;Cardiomegaly;Cardiovascular disorder;Carpal tunnel syndrome;Cataract;Cellulitis;Change of bowel habit;Chest pain;Chills;Choking;Cholecystitis;Cholelithiasis;Cholinergic syndrome;Chronic obstructive pulmonary disease;Cold sweat;Colitis ulcerative;Coma;Common wart;Confusional state;Congenital eye disorder;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Corneal opacity;Costochondritis;Cough;Cramps of lower extremities;Crying;Crying abnormal;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Delirium;Delusion;Dementia;Dental caries;Depersonalisation;Depression;Depression aggravated;Dermatitis;Dermatitis bullous;Dermatitis contact;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Diverticulitis;Dizziness;Dry skin;Duodenitis;Dysaesthesia;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear pain;Eczema;Electrocardiogram T wave inversion;Electrocardiogram abnormal;Electrolyte abnormality;Electrolyte imbalance;Endocrine disorder;Endometrial disorder;Enlargement abdomen;Enterocolitis;Eosinophilia;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Eruption lichenoid;Extrasystoles;Eye disorder;Eye haemorrhage;Eye infection;Eye pain;Face oedema;Failure to thrive;Fatigue;Feeling abnormal;Flat affect;Flatulence;Flushing;Food poisoning;Functional gastrointestinal disorder;Fungal infection;Furuncle;Furunculosis;Gait disturbance;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Genital candidiasis;Gingival hyperplasia;Gingivitis;Glaucoma;Glossitis;Glycosuria;Goitre;Gout;Haematoma;Haematuria;Haemoglobin;Haemoglobinaemia;Haemoptysis;Haemorrhage;Haemorrhoids;Hallucination;Headache;Hearing impaired;Heat stroke;Hepatitis viral;Herpes simplex;Herpes zoster;Hiccups;Hot flush;Hyperaesthesia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhemoglobinemia;Hyperhidrosis;Hyperkalaemia;Hyperkeratosis;Hyperkinesia;Hyperlipidaemia;Hyperproteinaemia;Hypersensitivity;Hypertension;Hypertension worsened;Hypertonia;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hyponatraemia;Hyporeflexia;Hypotension;Hypothyroidism;Ileus;Ill-defined disorder;Illusion;Increased appetite;Infection;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Intestinal obstruction;Irritable bowel syndrome;Joint dislocation;Keratitis;Keratoconjunctivitis;Kidney function abnormal;Laryngitis;Leg pain;Leukocytosis;Leukopenia;Leukorrhea;Lichen planus;Lichenoid keratosis;Loss of consciousness;Lupus erythematosus;Lymphadenopathy;Lymphadenopathy cervical;Lymphocytosis;Malaise;Malnutrition;Mania;Manic psychosis;Melaena;Menopausal symptoms;Menorrhagia;Menstrual disorder;Mental disability;Metrorrhagia;Micturition disorder;Migraine;Mood swings;Motion sickness;Mouth haemorrhage;Mouth ulceration;Mucosal inflammation;Multiple sclerosis;Muscle contractions involuntary;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Mydriasis;Myocardial infarction;Myopia;Nail discolouration;Nail disorder;Nasal ulcer;Nausea;Neoplasm;Nephrolithiasis;Nephrosis;Nephrotic syndrome;Nervous system disorder;Neuralgia;Neuropathy;Neuropathy peripheral;Neurosis;Nightmare;Nocturia;Oedema;Oedema mouth;Oedema peripheral;Oesophageal stenosis;Oesophagitis;Oliguria;Onychia;Onychomycosis;Orthostatic hypotension;Osteoarthritis;Osteomyelitis;Osteonecrosis;Osteoporosis;Otitis media;Ovarian cyst;Ovarian disorder;Pain;Pain in extremity;Pallor;Palpitations;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Paronychia;Parosmia;Partial hearing loss;Peptic ulcer;Pericarditis;Periodontal destruction;Periorbital oedema;Peripheral ischaemia;Personality disorder;Pharyngitis;Phlebitis superficial;Phosphatase alkaline increased;Photopsia;Photosensitivity reaction;Plantar fasciitis;Platelet disorder;Pleural effusion;Pleurisy;Pneumonia;Pneumothorax;Pollakiuria;Polyuria;Post procedural haemorrhage;Postoperative hemorrhage;Postoperative pain;Precordial pain;Procedural pain;Proctalgia;Proctocolitis;Prostatic disorder;Pruritus;Pruritus genital;Pulmonary congestion;Pulmonary embolism;Pulmonary fibrosis;Purpura;Pyelonephritis;Pyuria;Rash;Rash erythematous;Rectal disorder;Rectal tenesmus;Renal impairment;Renal pain;Respiratory tract congestion;Retinal deposits;Retinal disorder;Retrosternal pain;Rheumatoid arthritis;Rheumatoid arthritis aggravated;Rhinitis;Rigors;Rosacea;Salivary gland enlargement;Salivary gland pain;Salivary hypersecretion;Scleritis;Scleroderma;Seborrhoeic dermatitis;Sepsis;Sexual dysfunction;Shock;Sialoadenitis;Sinusitis;Skin cold clammy;Skin discolouration;Skin disorder;Skin exfoliation;Skin hypertrophy;Skin papilloma;Skin ulcer;Somnolence;Speech disorder;Squamous cell carcinoma;Stomatitis;Strangury;Supraventricular tachycardia;Surgery;Surgical intervention;Sweating increased;Syncope;Synovitis;Systemic lupus erythematosus;Tachycardia;Tendonitis;Tenosynovitis;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytopenic purpura;Thrombocytosis;Thrombophlebitis;Tinnitus;Tongue discolouration;Tongue disorder;Tongue geographic;Tongue ulceration;Tooth disorder;Toothache;Toxicity to various agents;Trauma;Tremor;Ulcerative keratitis;Ulcerative stomatitis;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine flow decreased;Urine output increased;Urogenital disorder;Urticaria;Uterine haemorrhage;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginitis atrophic;Vascular purpura;Vasculitis;Vertigo;Viral infection;Visual impairment;Vitreous detachment;Vomiting;Weight decreased;Weight increased;Xerophthalmia;Yawning,small molecule,approved,"2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine; Cevimelina; Cévimèline; Cevimeline; Cevimelinum; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.13.148; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 1; Dimethylaniline oxidase 1; Fetal hepatic flavin-containing monooxygenase 1; FMO 1; Trimethylamine monooxygenase",Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1,N07AX03
chlorambucil,B-cell lymphoma;Breast cancer;Chronic lymphocytic leukaemia;Dermatitis;Epilepsy;Extranodal marginal zone B-cell lymphoma (MALT type);Gestational trophoblastic tumour;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Leukaemia;Lymphocytic leukaemia;Lymphoma;MALT lymphoma;Mantle cell lymphoma;Nodular lymphoma;Non-Hodgkin's lymphoma;Ovarian adenocarcinoma;Ovarian cancer;Ovarian epithelial cancer;Rash;Waldenstrom's macroglobulinaemia,Abdominal pain;Acute overdose;Agitation;Alopecia;Amenorrhoea;Anaemia;Angioedema;Anorexia;Asthenia;Ataxia;Bladder pain;Blood uric acid increased;Body temperature increased;Confusional state;Convulsion;Convulsions generalised;Cutaneous hypersensitivity;Cystitis;Cystitis noninfective;Decreased appetite;Dermatitis atopic;Diarrhoea;Digestion impaired;Drug fever;Dyskinesia;Dyspepsia;Erythema multiforme;Fatigue;Febrile neutropenia;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Haematological malignancy;Haemolytic anaemia;Hallucination;Hepatotoxicity;Hypersensitivity;Hyperuricaemia;Inappropriate antidiuretic hormone secretion;Infection;Infertility;Interstitial lung disease;Interstitial pneumonia;Jaundice;Leukopenia;Lung fibrosis interstitial;Lymphadenopathy;Lymphopenia;Metastatic neoplasm;Mouth ulceration;Movement disorder;Mucosal inflammation;Muscle twitching;Myelodysplastic syndrome;Nausea;Neoplasm;Neoplasm malignant;Nephrotic syndrome;Neuritis;Neuropathy peripheral;Neutropenia;Optic atrophy;Overdose;Pain;Pancytopenia;Paralysis flaccid;Paresis;Peripheral motor neuropathy;Pneumonia;Pruritus;Puberty;Pulmonary fibrosis;Renal failure acute;Stevens-Johnson syndrome;Stomatitis;Testicular atrophy;Thrombocytopenia;Toxic epidermal necrolysis;Tremor;Ureteric obstruction;Urine output;Urticaria;Vomiting,small molecule,approved,"4-(p-bis(beta-chloroethyl)aminophenyl)butyric acid; 4-(p-bis(β-chloroethyl)aminophenyl)butyric acid; 4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid; Ambochlorin; Chlorambucil; Chloraminophen; Clorambucilo; gamma-[p-di(2-chloroethyl)aminophenyl]butyric acid; N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid; N,N-di-2-chloroethyl-γ-p-aminophenylbutyric acid; Phenylbutyric acid nitrogen mustard; γ-[p-di(2-chloroethyl)aminophenyl]butyric acid; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 13-hydroperoxyoctadecadienoate peroxidase; 2.5.1.18; Androst-5-ene-3,17-dione isomerase; GST class-alpha member 1; GST HA subunit 1; GST-epsilon; GSTA1-1; GTH1; 2.5.1.18; GST class-alpha member 2; GST HA subunit 2; GST-gamma; GST2; GSTA2-2; GTH2; 2.5.1.18; GST class-mu 1; GST HB subunit 4; GST1; GSTM1-1; GSTM1a-1a; GSTM1b-1b; GTH4; 2.5.1.18; GST class-mu 2; GST4; GSTM2-2; 2.5.1.18; GST class-mu 3; GST5; GSTM3-3; hGSTM3-3; 2.5.1.18; GST class-mu 4; GST-Mu2; GSTM4-4; Leukotriene C4 synthase GSTM4; 2.5.1.18; GST class-mu 5; GSTM5-5; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 2.5.1.18; Glutathione transferase T1-1; GST class-theta-1; 2.5.1.18; GST class-theta-2; 2.5.1.18; Glutathione S-transferase theta-2; GST class-theta-2; GSTT2; 5.3.99.2; Glutathione S-transferase; Glutathione-dependent PGD synthase; Glutathione-requiring prostaglandin D synthase; GST class-sigma; GSTS; H-PGDS; PGDS; Prostaglandin-H2 D-isomerase; PTGDS2; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3",DNA,L01AA02
chlordiazepoxide,Alcohol abuse;Alcoholism;Anxiety;Anxiety disorder;Apprehension;Drug withdrawal syndrome;Tension;Withdrawal symptom,Agranulocytosis;Ataxia;Blood disorder;Confusional state;Constipation;Disturbance in sexual arousal;Dizziness;Drowsiness;Eruption;Extrapyramidal disorder;Extrapyramidal symptoms;Feeling abnormal;Hepatic function abnormal;Jaundice;Libido decreased;Loss of consciousness;Menstruation irregular;Nausea;Oedema;Rash;Shock;Somnolence;Syncope,small molecule,approved; illicit; investigational,"7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide; CDP; Chloradiazepoxide; Chlordiazepoxide; Chlordiazepoxidum; Clopoxide; Clordiazepóxido; Methaminodiazepoxide; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Translocator protein; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site,N05BA02
chlorhexidine,Chronic periodontitis;Dental caries;Erythema;Gingival bleeding;Gingivitis;Gingivitis ulcerative;Necrotising ulcerative gingivostomatitis;Periodontitis;Redness;Skin wound;Swelling;Trench mouth,Abscess;Ache;Anaphylactic shock;Aphthous stomatitis;Arthralgia;Arthropathy;Back pain;Bronchitis;Burning sensation;Cough;Discomfort;Dry mouth;Dysgeusia;Dysmenorrhoea;Dyspepsia;Erythema;Fracture;Gingival bleeding;Gingival hyperplasia;Glossitis;Headache;Hypersensitivity;Hypertension;Hypoaesthesia;Influenza like illness;Influenza-like symptoms;Injury;Mouth irritation;Mouth ulceration;Multiple fractures;Musculoskeletal discomfort;Myalgia;Oral mucosal exfoliation;Oral pain;Osteoarthritis;Pain;Paraesthesia;Pharyngitis;Redness;Rhinitis;Sialoadenitis;Sinusitis;Skin exfoliation;Stomatitis;Swelling;Tenderness;Tendonitis;Tongue coated;Tongue disorder;Tongue geographic;Tongue oedema;Tooth disorder;Toothache;Trauma;Type I hypersensitivity;Ulcer;Ulcerative stomatitis;Upper respiratory tract infection;Urticaria,small molecule,approved; vet_approved; withdrawn,"1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); Chlorhexidin; Chlorhexidine; Chlorhexidinum; Cloresidina; Clorhexidina; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide",Bacterial outer membrane, A01AB03; A01AB53; B05CA02; D08AC02; D08AC52; D09AA12; S01AX09; S02AA09; S03AA04;A01AB03;R02AA05
chloroquine,Amoebiasis;Falciparum malaria;Infection;Plasmodium falciparum infection;Plasmodium malariae infection;Plasmodium ovale infection;Plasmodium vivax infection;Quartan malaria,Abdominal cramps;Abdominal pain;Agitation;Agranulocytosis;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Asthenia;Atrophy;Cardiomyopathy;Confusional state;Convulsion;Convulsive seizure;Corneal opacity;Deafness neurosensory;Decreased appetite;Delirium;Dermatitis exfoliative;Diarrhoea;Drug eruption;Dyskinesia;Electrocardiogram QRS complex;Electrocardiogram change;Eosinophilia;Eruption;Erythema multiforme;Extrapyramidal disorder;Feeling abnormal;Gastrointestinal disorder;Hallucination;Headache;Hearing impaired;Hepatitis;Hypotension;Insomnia;Intermittent headache;Lichen planus;Macular degeneration;Maculopathy;Myopathy;Nausea;Neural hearing loss;Neuromyopathy;Neutropenia;Night blindness;Pancytopenia;Partial hearing loss;Personality change;Photosensitivity;Photosensitivity reaction;Polyneuritis;Polyneuropathy;Protrusion tongue;Pruritus;Psychotic disorder;QRS complex;Rash;Reaction gastrointestinal;Retinal damage;Retinal injury;Scotoma;Skin exfoliation;Stevens-Johnson syndrome;Thrombocytopenia;Tinnitus;Torticollis;Toxic epidermal necrolysis;Urticaria;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational; vet_approved,"Chloraquine; Chlorochin; Chloroquina; Chloroquine; Chloroquinium; Chloroquinum; Cloroquina; N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine; DARC; Duffy antigen/chemokine receptor; FY; Fy glycoprotein; Glycoprotein D; GPD; GpFy; Plasmodium vivax receptor; 2.5.1.18; GST class-alpha member 2; GST HA subunit 2; GST-gamma; GST2; GSTA2-2; GTH2; Cachectin; TNF-a; TNF-alpha; TNFA; TNFSF2; Tumor necrosis factor ligand superfamily member 2; 2.5.1.18; PfGST; High mobility group protein 1; HMG-1; HMG1; 2.5.1.18; GST class-mu 1; GST HB subunit 4; GST1; GSTM1-1; GSTM1a-1a; GSTM1b-1b; GTH4; 3.4.17.23; ACE-related carboxypeptidase; ACEH; Angiotensin-converting enzyme homolog; Angiotensin-converting enzyme-related carboxypeptidase; Metalloprotease MPROT15; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Atypical chemokine receptor 1; Glutathione S-transferase A2; Tumor necrosis factor; Toll-like receptor 9; Glutathione S-transferase; High mobility group protein B1; Glutathione S-transferase Mu 1; Angiotensin-converting enzyme 2, P01BA01;N06DX02;P01BB52
chlorpheniramine,Anal pruritus;Anaphylactic shock;Angioedema;Anorectal discomfort;Arthropod bite;Conjunctivitis;Conjunctivitis allergic;Dermatitis atopic;Dermatitis contact;Hypersensitivity;Insect bite NOS;Mechanical urticaria;Pruritus;Pruritus genital;Pruritus vulvae;Rhinitis allergic;Rhinitis seasonal;Seasonal allergy;Serum sickness;Skin disorder;Urticaria;Urticaria physical;Vasomotor rhinitis;Vulvovaginal pruritus,Agitation;Agranulocytosis;Anorexia;Anxiety;Asthenia;Cerebration impaired;Chest discomfort;Chest tightness;Chills;Confusional state;Constipation;Conversion disorder;Convulsion;Decreased appetite;Diarrhoea;Diplopia;Disturbance in attention;Dizziness;Drowsiness;Drug eruption;Dry mouth;Dyskinesia;Dyspepsia;Epigastric distress;Euphoric mood;Extrasystoles;Fatigue;Feeling abnormal;Haemolytic anaemia;Hallucination;Headache;Hyperhidrosis;Hypertension;Hypoplastic anaemia;Hyporeflexia;Hypotension;Hysteria;Insomnia;Irritability;Labyrinthitis;Lassitude;Mental disability;Mydriasis;Nasal congestion;Nausea;Nervousness;Neuritis;Neuropathy peripheral;Palpitations;Paraesthesia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Somnolence;Sweating increased;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Tremor;Urinary hesitation;Urinary retention;Vertigo;Vision blurred;Vomiting;Wheezing,small molecule,approved,"1-(p-chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 1-(p-chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 2-[p-chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine; 3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; Chlorophenylpyridamine; Chlorphenamin; Chlorphenamine; Chlorphenaminum; Chlorpheniramine; Chlorpheniramine polistirex; Chlorpheniraminum; Clorfenamina; Clorfeniramina; γ-(4-chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; γ-(4-chlorophenyl)-γ-(2-pyridyl)propyldimethylamine; H1-R; H1R; HH1R; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1",Histamine H1 receptor; Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent dopamine transporter, R06AB04;R06AB02;R06AB54
chlorpromazine,Affect lability;Agitation;Anxiety;Apprehension;Bipolar I disorder;Bipolar disorder;Conduct disorder;Disturbance in social behaviour;Electroencephalogram abnormal;Foetor hepaticus;Frustration;Hepatocellular injury;Hiccups;Hyperkinesia;Increased activity;Intractable hiccups;Liver disorder;Mitral valve incompetence;Mood swings;Nausea;Porphyria acute;Psychotic disorder;Schizophrenia;Tetanus;Vomiting,Agranulocytosis;Akathisia;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Aplastic anaemia;Asphyxia;Asthma;Blood disorder;Body temperature increased;Brain oedema;Breast engorgement;Cardiac arrest;Catatonia;Cogwheel rigidity;Colon atonic;Constipation;Convulsion;Convulsive seizure;Cough;Dermatitis contact;Dermatitis exfoliative;Dizziness;Drooling;Drowsiness;Dry mouth;Dyskinesia;Dysphagia;Dyspnoea;Edema cerebral;Endocrine disorder;Eosinophilia;Erectile dysfunction;Extrapyramidal disorder;Extrapyramidal symptoms;Feeling jittery;Gait disturbance;Gait shuffling;Glycosuria;Gynaecomastia;Haemolytic anaemia;Hepatitis A;Hyperglycaemia;Hyperpyrexia;Hypersensitivity;Hypoglycaemia;Hypotension;Hypotensive;Ileus paralytic;Infection;Influenza;Insomnia;Jaundice;Jaundice cholestatic;Keratopathy;Laryngeal oedema;Leukopenia;Loss of consciousness;Masked facies;Megacolon;Menorrhagia;Miosis;Motor restlessness;Movements involuntary;Muscle spasms;Mydriasis;Nasal congestion;Nervousness;Neuroleptic malignant syndrome;Obstipation;Oedema peripheral;Orofacial dyskinesia;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Pancytopenia;Parkinsonian rest tremor;Parkinsonism;Petit mal epilepsy;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Pill rolling;Pregnancy test false positive;Priapism;Prolonged menses;Protrusion tongue;Pseudoparkinsonism;Retinal disorder;Shock;Somnolence;Sudden death;Syncope;Systemic lupus erythematosus;Tachycardia;Tardive dyskinesia;Throat sore;Throat tightness;Thrombocytopenic purpura;Tremor;Urinary retention;Visual impairment,small molecule,approved; investigational; vet_approved,"3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine; 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine; Chlorpromazine; Chlorpromazinum; Clorpromazina; CPZ; N-(3-dimethylaminopropyl)-3-chlorophenothiazine; Dopamine D2 receptor; Dopamine D1 receptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; H1-R; H1R; HH1R; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 3.1.4.12; 3.1.4.3; Acid sphingomyelinase; ASM; aSMase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; 5-HT-6; 5-HT6; Serotonin receptor 6; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; AXOR35; G-protein coupled receptor 105; GPCR105; GPRv53; H4R; HH4R; Pfi-013; SP9144; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",D(2) dopamine receptor; D(1A) dopamine receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Histamine H1 receptor; Voltage-gated inwardly rectifying potassium channel KCNH2; D(1) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; D(1B) dopamine receptor; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine 2 receptor; Alpha-1 adrenergic receptors; Alpha-2 adrenergic receptors; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M3; Sphingomyelin phosphodiesterase; alpha1-acid glycoprotein; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; Histamine H4 receptor; Calmodulin,N05AA01
chlorpropamide,Type 2 diabetes mellitus,Agranulocytosis;Alcohol intolerance;Anorexia;Aplastic anaemia;Decreased appetite;Dermatitis exfoliative;Diarrhoea;Digestion impaired;Disulfiram like reaction;Dizziness;Drug interaction;Dyspepsia;Eosinophilia;Eruption;Erythema multiforme;Fluid retention;Gastrointestinal disorder;Haemolytic anaemia;Headache;Hunger;Hypoglycaemia;Hyponatraemia;Inappropriate antidiuretic hormone secretion;Jaundice cholestatic;Leukopenia;Nausea;Pancytopenia;Photosensitivity reaction;Porphyria cutanea tarda;Porphyria hepatic;Porphyria non-acute;Proctocolitis;Pruritus;Rash;Thrombocytopenia;Urticaria;Vomiting;Water retention,small molecule,approved; investigational,"1-(p-chlorobenzenesulfonyl)-3-propylurea; 1-(p-chlorophenylsulfonyl)-3-propylurea; 1-propyl-3-(p-chlorobenzenesulfonyl)urea; 4-chloro-N-((propylamino)carbonyl)benzenesulfonamide; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide; Chlorpropamid; Chlorpropamide; Chlorpropamidum; Clorpropamida; N-(4-chlorophenylsulfonyl)-N'-propylurea; N-(p-chlorobenzenesulfonyl)-N'-propylurea; n-propyl-N'-(p-chlorobenzenesulfonyl)urea; n-propyl-N'-p-chlorophenylsulfonylcarbamide; HRINS; Sulfonylurea receptor 1; SUR; SUR1; ATP-dependent inwardly rectifying potassium channel Kir4.1; Inward rectifier K(+) channel Kir1.2; Potassium channel, inwardly rectifying subfamily J member 10; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",ATP-binding cassette sub-family C member 8; ATP-sensitive inward rectifier potassium channel 10, A10BB02;A10BB02;G01AE10
chlorthalidone,Ascites;Cardiac failure chronic;Cardiac failure congestive;Discomfort;Fluid retention;Glomerulonephritis acute;Gravitational oedema;Hepatic cirrhosis;Hypercalciuria;Hypertension;Nephrotic syndrome;Oedema;Pre-eclampsia;Pregnancy;Premenstrual syndrome;Renal failure chronic;Venous insufficiency,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Agitation;Agranulocytosis;Alkalosis hypochloraemic;Angiitis necrotising;Anorexia;Aplastic anaemia;Appetite absent;Arrhythmia;Asthenia;Blood uric acid increased;Cholestasis;Cholestasis intrahepatic;Constipation;Cramp muscle;Cutaneous vasculitis;Decreased appetite;Dermatitis;Diabetes mellitus;Diarrhoea;Distress gastrointestinal;Dizziness;Eosinophilia;Epigastric discomfort;Erectile dysfunction;Gastric irritation;Glycosuria;Gout;Headache;Hypercalcaemia;Hyperglycaemia;Hypersensitivity;Hyperuricaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Jaundice;Jaundice cholestatic;Leukopenia;Metabolic disorder;Muscle spasms;Nausea;Nephritis interstitial;Orthostatic hypotension;Pancreatitis;Paraesthesia;Photosensitivity;Photosensitivity reaction;Pulmonary oedema;Purpura;Rash;Stomach ache;Thrombocytopenia;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Urticaria;Vascular purpura;Vasculitis;Vasculitis necrotising;Vertigo;Vomiting;Worsening of diabetes;Xanthopsia,small molecule,approved,"1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline; 1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide; 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide; 3-(4'-chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine; 3-hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine; Chlorphthalidolone; Chlortalidone; Chlortalidonum; Chlorthalidone; Clortalidona; Phthalamodine; Phthalamudine; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; BSC1; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; Kidney-specific Na-K-Cl symporter; Na-K-2Cl cotransporter 2; NKCC2",Carbonic anhydrase 1; Solute carrier family 12 member 1, C03BA04; C03BB04; C03EA06;C03BA04;G01AE10
chlorzoxazone,Discomfort,Anaphylactic shock;Angioedema;Chromaturia;Dermatitis;Digestion impaired;Discomfort;Dizziness;Drowsiness;Dyspepsia;Ecchymosis;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal haemorrhage;Ill-defined disorder;Lightheadedness;Malaise;Petechiae;Rash;Somnolence;Urine color abnormal,small molecule,approved,"2-hydroxy-5-chlorobenzoxazole; 5-chloro-2-benzoxazolinone; 5-chloro-2-benzoxazolol; 5-chloro-2-benzoxazolone; 5-chloro-2-hydroxybenzoxazole; 5-chloro-2(3H)-benzoxazolone; 5-chloro-3H-benzooxazol-2-one; 5-chlorobenzoxazolidone; 5-chlorobenzoxazolin-2-one; Chlorzoxane; Chlorzoxazon; Chlorzoxazona; Chlorzoxazone; Chlorzoxazonum; Clorzoxazona; Clorzoxazone; BK channel; BKCA alpha; Calcium-activated potassium channel, subfamily M subunit alpha-1; hSlo; K(VCA)alpha; KCa1.1; KCNMA; Maxi K channel; MaxiK; SLO; Slo homolog; Slo-alpha; Slo1; Slowpoke homolog; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Calcium-activated potassium channel subunit alpha-1, M03BB53; M03BB73;M03BB03
ciclopirox,Body tinea;Candida infection;Dandruff;Diabetes mellitus;Diabetic;Diabetic neuropathy;Epilepsy;Fungal infection;Fungal skin infection;Herpes simplex;Herpes zoster;Hypersensitivity;Infection;Nail disorder;Onychomycosis;Pityriasis;Seborrhoeic dermatitis;Skin candida;Tinea cruris;Tinea infection;Tinea pedis,Alopecia;Application site hypersensitivity;Application site irritation;Application site rash;Application site reaction;Burning sensation;Dermatitis;Dermatitis contact;Dry skin;Eczema;Erythema;Eye pain;Face oedema;Hair colour changes;Hair discoloration;Hair texture abnormal;Headache;Immune system disorder;Ingrowing nail;Nail disorder;Pain;Periungual erythema;Pruritus;Rash;Skin burning sensation;Skin disorder;Skin exfoliation;Unspecified disorder of skin and subcutaneous tissue;Ventricular tachycardia,small molecule,approved; investigational,6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; Ciclopirox; Ciclopiroxum; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1,Sodium/potassium-transporting ATPase subunit alpha-1, G01AX12;D01AE14
cilazapril,Cardiac failure;Cardiac failure congestive;Cerebrovascular disorder;Essential hypertension;Hepatic function abnormal;Hypertension;Hypertensive;Myocardial ischaemia;Nephropathy;Renal artery stenosis;Renal failure;Renovascular hypertension,Abdominal pain;Abnormal vision;Acute coronary syndrome;Agranulocytosis;Alopecia;Anaemia;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Arrhythmia;Arthralgia;Asthenia;Ataxia;Atrial fibrillation;Atrioventricular block;Azotaemia;Blood and lymphatic system disorders;Blood creatinine abnormal;Blood disorder;Bradycardia;Bronchitis;Bronchospasm;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiogenic shock;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Chills;Confusional state;Conjunctivitis;Constipation;Cough;Cramps of lower extremities;Decompensation cardiac;Decreased appetite;Dermatitis;Diarrhoea;Digestion impaired;Discomfort;Disturbance in sexual arousal;Dizziness;Dry cough;Dry mouth;Dysgeusia;Dyspepsia;Dysphonia;Dyspnoea;Dysuria;Epistaxis;Erectile dysfunction;Erythema multiforme;Extrasystoles;Face oedema;Fatigue;Feeling abnormal;Flatulence;Flushing;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gout;Haemolytic anaemia;Headache;Hepatic function abnormal;Hepatitis cholestatic;Hepatobiliary disease;Hot flush;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Hypotension symptomatic;Ill-defined disorder;Immune system disorder;Insomnia;Laryngeal oedema;Leukopenia;Libido decreased;Liver function test abnormal;Loss of consciousness;Malaise;Menopausal symptoms;Migraine;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Necrosis;Nephropathy;Nervousness;Neutropenia;Oedema;Orthostatic hypotension;Pain;Palpitations;Pancreatitis;Paraesthesia;Pemphigus;Pharyngitis;Photophobia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyuria;Protein urine present;Proteinuria;Pruritus;Purpura;Raised liver function tests;Rash;Rash erythematous;Rash maculo-papular;Rectal haemorrhage;Renal artery stenosis;Renal failure;Renal failure acute;Renal impairment;Renal pain;Respiratory tract infection;Rhinitis;Rigors;Scleroderma;Serum creatinine abnormal;Shock;Sinusitis;Skin disorder;Somnolence;Stevens-Johnson syndrome;Sweating increased;Syncope;Systemic lupus erythematosus;Tachycardia;Tension;Thrombocytopenia;Thrombocytopenic purpura;Tinnitus;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Uremia;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;Vascular purpura;Vertigo;Visual impairment;Vomiting,small molecule,approved,"Cilazapril; Cilazapril anhydrous; Cilazaprilum; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Angiotensin-converting enzyme, C09AA08;C09AA08;C09BA08
cilostazol,Intermittent claudication,Abdominal pain;Abnormal faeces;Abscess periodontal;Acute coronary syndrome;Agranulocytosis;Albuminuria;Amblyopia;Anaemia;Angina pectoris;Angiopathy;Anorexia;Anxiety;Aplastic anaemia;Arthralgia;Arthritis;Asthenia;Asthma;Atrial fibrillation;Atrial flutter;Atrioventricular block complete;Back pain;Bladder pain;Bleeding tendency;Blindness;Blood and lymphatic system disorders;Blood creatinine increased;Blood glucose increased;Blood pressure increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone pain;Bradyarrhythmia;Bronchitis;Bursitis;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cerebral haemorrhage;Cerebral infarction;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Chills;Cholelithiasis;Colitis;Conjunctivitis;Cough;Cough increased;Cramps of lower extremities;Creatinine increased;Cystitis;Cystitis noninfective;Decreased appetite;Dermatitis;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Dizziness;Drug eruption;Dry skin;Duodenal ulcer;Duodenitis;Dyspepsia;Dyspnoea;Ear pain;Ecchymosis;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Epidural haemorrhage;Epistaxis;Eruption;Erythema multiforme;Eye haemorrhage;Face oedema;Feeling abnormal;Flatulence;Fluid retention;Furuncle;Furunculosis;Gamma-glutamyltransferase increased;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Gingival bleeding;Gout;Haematemesis;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhage subcutaneous;Haemorrhagic disorder;Headache;Hepatic function abnormal;Hepatobiliary disease;Hot flush;Hyperaesthesia;Hyperlipidaemia;Hypertension;Hyperuricaemia;Hypoaesthesia;Hypotension;Ill-defined disorder;Infection;Influenza;Insomnia;Interstitial lung disease;Interstitial pneumonia;Iron deficiency anaemia;Jaundice;Leukopenia;Liver function test abnormal;Loss of consciousness;Malaise;Mediastinal disorder;Melaena;Menopausal symptoms;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Neck stiffness;Nervous system disorder;Neuralgia;Nodal arrhythmia;Nuchal rigidity;Oedema;Oedema peripheral;Oesophageal haemorrhage;Oesophagitis;Orthostatic hypotension;Pain;Palpitations;Pancytopenia;Paraesthesia;Pelvic pain;Peptic ulcer;Pharyngitis;Platelet count decreased;Pneumonia;Pollakiuria;Polycythaemia;Pruritus;Pulmonary haemorrhage;Purpura;Rash;Rectal haemorrhage;Retinal haemorrhage;Retroperitoneal haemorrhage;Rhinitis;Shock;Sinusitis;Skin disorder;Skin hypertrophy;Stevens-Johnson syndrome;Subdural haematoma;Supraventricular tachycardia;Syncope;Tachycardia;Thrombocytopenia;Thrombosis;Tinnitus;Tongue disorder;Tongue oedema;Tooth abscess;Torsade de pointes;Unspecified disorder of skin and subcutaneous tissue;Urinary tract infection;Urticaria;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Varicose vein;Vascular purpura;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vomiting;White blood cell count decreased,small molecule,approved; investigational,"3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one; Cilostazol; Cilostazole; Cilostazolum; 3.1.4.17; cGI-PDE; CGI-PDE A; cGMP-inhibited cAMP phosphodiesterase; Cyclic GMP-inhibited phosphodiesterase A; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2","cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A",B01AC23
cimetidine,Acid indigestion;Adenoma benign;Anaphylactic shock;Arthritis;Duodenal ulcer;Dyspepsia;Erosive oesophagitis;Functional dyspepsia;Gastric pH decreased;Gastric ulcer;Gastrinoma;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Heartburn;Hyperchlorhydria;Pain;Peptic ulcer;Scleroderma;Sour stomach;Stress ulcer;Systemic mastocytosis;Ulcer;Upper gastrointestinal haemorrhage;Zollinger-Ellison syndrome,Agitation;Agranulocytosis;Allergic cutaneous angiitis;Alopecia;Alopecia reversible;Anaemias haemolytic immune;Anaphylactic shock;Anxiety;Aplastic anaemia;Arthralgia;Asthenia;Atrioventricular block;Block heart;Blood creatinine increased;Body temperature increased;Bone marrow depression;Bradycardia;Confusional state;Constipation;Dermatitis;Dermatitis exfoliative;Diarrhoea;Disorientation;Dizziness;Drowsiness;Erectile dysfunction;Erythema multiforme;Fatal outcomes;Fatigue;Feeling abnormal;Flatulence;Galactorrhoea;Gynaecomastia;Hallucination;Headache;Hepatic failure;Hepatic fibrosis;Hepatic insufficiency;Hepatitis;Hepatotoxicity;Hypersensitivity;Immunocompromised;Immunodeficiency;Leukocytoclastic vasculitis;Leukopenia;Liver injury;Malaise;Mental disorder due to a general medical condition;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nausea;Necrolysis epidermal;Nephritis interstitial;Neutropenia;Organic brain syndrome;Pancreatitis;Pancytopenia;Plasma creatinine increased;Pneumonia;Polymyositis;Psychotic disorder;Rash;Renal failure;Renal impairment;Sickness;Sinus bradycardia;Somnolence;Stevens-Johnson syndrome;Strongyloidiasis;Tachycardia;Thrombocytopenia;Toxic epidermal necrolysis;Traumatic liver injury;Tubulointerstitial nephritis;Urinary retention;Vomiting;White blood cell count decreased;White blood cell count low,small molecule,approved; investigational,"1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 2-cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; Cimetidin; Cimetidina; Cimétidine; Cimetidine; Cimetidinum; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; Gastric receptor I; H2R; HH2R; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase; 1.14.13.148; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 1; Dimethylaniline oxidase 1; Fetal hepatic flavin-containing monooxygenase 1; FMO 1; Trimethylamine monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2",Histamine H2 receptor, A02BA01;A02BA01;A02BA51
cinoxacin,Recurrent urinary tract infection;Urinary tract infection,Abdominal cramps;Abdominal pain;Anaphylactic shock;Angioedema;Anorexia;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Drowsiness;Eosinophilia;Erythema multiforme;Gastrointestinal pain;Headache;Hypersensitivity;Insomnia;Nausea;Oedema;Pain;Paraesthesia;Photophobia;Pruritus;Rash;Somnolence;Stevens-Johnson syndrome;Thrombocytopenia;Tingling sensation;Tinnitus;Toxic epidermal necrolysis;Urticaria;Vomiting,small molecule,approved; investigational; withdrawn,"1-ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; 5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid; Cinoxacin; Cinoxacine; Cinoxacino; Cinoxacinum; 5.99.1.3; 5.6.2.2; DNA topoisomerase II, beta isozyme; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",DNA gyrase subunit A; DNA topoisomerase 2-beta; DNA topoisomerase 2-alpha; DNA,J01MB06
ciprofloxacin,Abdominal infection;Acute cystitis;Acute exacerbation of chronic bronchitis;Acute pneumonia;Acute sinusitis;Adnexitis;Anthrax;Arthropathy;Back pain;Bacteraemia;Bacterial prostatitis;Bladder pain;Blepharitis;Body temperature increased;Bone and joint infections;Bronchial infection;Bronchitis;Bronchitis chronic;Cervicitis;Conjunctivitis;Conjunctivitis bacterial;Conjunctivitis infective;Convulsion;Cross resistance;Cystic fibrosis;Cystitis;Cystitis noninfective;Drug interaction;Dysentery;Fasting;Function kidney decreased;Gastroenteritis;Gastrointestinal infection;Glucose-galactose malabsorption;Gonorrhoea;Hepatic failure;Hepatic impairment;Hepatic insufficiency;Infection;Infection mixed;Influenza;Liver disorder;Lower respiratory tract infection;Nosocomial pneumonia;Osteoarthritis;Osteomyelitis;Overgrowth bacterial;Paratyphoid fever;Pathogen resistance;Peritonitis;Pneumonia;Pneumonia anthrax;Pneumonia streptococcal;Prostatitis;Pseudomonas infection;Pyelitis;Pyelonephritis;Renal clearances low;Renal failure;Renal function test abnormal;Renal impairment;Respiratory tract infection;Salpingo-oophoritis;Sepsis;Septicemia;Soft tissue infection;Tuberculosis;Typhoid fever;Ulcerative keratitis;Urethritis;Urethritis noninfective;Urinary tract infection,AGEP;Abdominal aortic bruit;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abnormal dreams;Abnormal vision;Accidental injury;Ache wrists;Acidosis;Acute coronary syndrome;Acute cystitis;Acute generalised exanthematous pustulosis;Ageusia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Allergic oedema;Alopecia;Amylase increased;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorectal discomfort;Anorexia;Anosmia;Anthrax;Antibiotic associated colitis;Anxiety;Aortic bruit;Apathy;Aphasia;Application site pain;Arrhythmia;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthenopia;Asthma;Ataxia;Atrial fibrillation;Atrial flutter;Back pain;Bad taste;Benign intracranial hypertension;Bladder infection;Bladder pain;Blister;Blood albumin decreased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood cholesterol increased;Blood creatinine decreased;Blood creatinine increased;Blood electrolytes abnormal;Blood glucose decreased;Blood lactate dehydrogenase increased;Blood monocytes increased;Blood potassium decreased;Blood potassium increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone and joint infections;Bone disorder;Bone marrow depression;Bone pain;Bradycardia;Breast disorder;Breast pain;Bronchospasm;Calculus of kidney;Candida infection;Candiduria;Cardiac arrest;Cardiac disorder;Cardiac murmur;Cardio-respiratory arrest;Cerebral thrombosis;Cerebrovascular disorder;Chemosis;Chest pain;Chills;Cholesterol serum elevated;Chromatopsia;Chromosomal mutation;Clostridium difficile colitis;Coagulopathy;Colitis;Colour blindness;Completed suicide;Confusional state;Conjunctival hyperaemia;Conjunctival oedema;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Convulsive seizure;Coordination abnormal;Corneal deposits;Corneal disorder;Corneal epithelium defect;Corneal infiltrates;Corneal opacity;Corneal staining;Cough;Cough increased;Cramp muscle;Creatinine increased;Creatinine low;Creatinine renal clearance decreased;Cross resistance;Crystalluria;Cystitis;Cystitis haemorrhagic;Cystitis noninfective;Deafness;Deafness transitory;Decreased appetite;Delirium;Dementia;Depersonalisation;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Diplopia;Disability;Discomfort;Disorientation;Disturbance in attention;Dizziness;Drowsiness;Drug fever;Drug interaction;Drug intolerance;Dry eye;Dry mouth;Dry skin;Dysaesthesia;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphasia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Ear pruritus;Electrolyte abnormality;Electrolyte imbalance;Endophthalmitis;Enlargement abdomen;Eosinophilia;Epidermolysis;Epigastric pain;Epistaxis;Eruption;Erythema;Erythema multiforme;Erythema multiforme minor;Erythema nodosum;Erythema of eyelid;Extrasystoles;Extravasation;Eye discharge;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Eye swelling;Eyelid exfoliation;Eyelid margin crusting;Eyelid oedema;Face oedema;Fatal outcomes;Fatigue;Feeling abnormal;Fixed eruption;Flat affect;Flatulence;Flushing;Foetor hepaticus;Foot pain;Foreign body sensation in eyes;Functional gastrointestinal disorder;Fungal infection;Fungal skin infection;Gait disturbance;Gamma-glutamyltransferase increased;Gastritis;Gastrointestinal candidiasis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glossitis;Gout;Gout flare;Grand mal convulsion;Gynaecomastia;Haematuria;Haemoglobin;Haemolytic anaemia;Haemoptysis;Haemorrhage;Hallucination;Headache;Hearing impaired;Hemiplegia;Hepatic failure;Hepatic function abnormal;Hepatic impairment;Hepatic necrosis;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hiccups;Hordeolum;Hot flush;Hyperaemia;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypoaesthesia eye;Hypocalcaemia;Hypoglycaemia;Hypotension;Ileus;Ill-defined disorder;Immune system disorder;Impaired healing;Increased appetite;Infestation;Infestation NOS;Inflammation;Infusion site reactions;Injection site pain;Injection site reaction;Injury;Insomnia;Instillation site pain;Intentional self-injury;International normalised ratio decreased;Intestinal perforation;Intracranial pressure increased;Irritability;Irritable bowel syndrome;Jaundice;Jaundice cholestatic;Joint sprain;Joint stiffness;Joint swelling;Keratitis;Keratoconjunctivitis;Keratopathy;Kidney function abnormal;Kidney infection;Laboratory test abnormal;Lacrimation;Lacrimation increased;Lactic dehydrogenase activity increased;Laryngeal oedema;Leg pain;Lethargy;Leukocytosis;Leukopenia;Leukorrhea;Ligament sprain;Lightheadedness;Lipase increased;Liver disorder;Liver function test abnormal;Liver injury;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Medication residue;Medication residue present;Megacolon;Megacolon toxic;Melaena;Meningism;Menopausal symptoms;Mental disorder;Metabolic disorder;Methaemoglobinaemia;Micturition urgency;Migraine;Monocyte count increased;Mouth ulceration;Muscle spasms;Muscle spasticity;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myasthenia gravis;Myocardial infarction;Myoclonus;NPN increased;Nasopharyngitis;Nausea;Necrolysis epidermal;Necrosis;Nephritis;Nephritis interstitial;Nephrolithiasis;Nephropathy toxic;Nervous system disorder;Nervousness;Neuritis;Neuropathy peripheral;Neutropenia;Night cramps;Nightmare;Nodule;Nosocomial pneumonia;Nystagmus;Ocular discomfort;Ocular hyperaemia;Ocular toxicity;Oedema;Oedema peripheral;Oesophagitis;Oral candidiasis;Orthostatic hypotension;Otitis externa;Pain;Pain in arm;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Panophthalmitis;Papule;Paraesthesia;Paranasal sinus hypersecretion;Paranoia;Parosmia;Pathogen resistance;Pericarditis;Petechiae;Pharyngitis;Phlebitis;Phobia;Phosphatase alkaline increased;Photophobia;Photopsia;Photosensitivity;Photosensitivity reaction;Phototoxicity;Platelet count decreased;Pleural effusion;Pneumonia;Pneumonia anthrax;Pneumonia klebsiella;Pollakiuria;Polyneuritis;Polyneuropathy;Polyuria;Proctalgia;Protein total decreased;Prothrombin level abnormal;Prothrombin level decreased;Prothrombin level increased;Prothrombin time shortened;Prurigo;Pruritus;Pruritus genital;Pseudomembranous colitis;Psychotic disorder;Pulmonary embolism;Pulmonary haemorrhage;Pulmonary oedema;Punctate epithelial erosion;Punctate keratitis;Purpura;Rash;Rash maculo-papular;Rash pustular;Rectal tenesmus;Red blood cell sedimentation rate increased;Redness;Renal failure;Renal failure acute;Renal failure chronic;Renal impairment;Renal neoplasm;Renal vasculitis;Repetitive strain injury;Respiratory acidosis;Respiratory arrest;Respiratory distress;Retrosternal pain;Rhabdomyolysis;Rhinitis;Rigors;Scab;Self injurious behaviour;Sensation of foreign body;Sepsis;Septicemia;Serum albumin decreased;Serum calcium increased;Serum potassium decreased;Serum potassium increased;Serum sickness-like reaction;Serum total protein decreased;Shock;Skin candida;Skin disorder;Skin haemorrhage;Skin hyperpigmentation;Sleep disorder;Somnolence;Status epilepticus;Stevens-Johnson syndrome;Stinging;Stomatitis;Stridor;Suicidal ideation;Superinfection;Suprapubic pain;Surgery;Surgical intervention;Sweating;Sweating increased;Swelling;Swollen tongue;Syncope;Tachycardia;Taste disorders;Tenderness;Tendon rupture;Tendonitis;Tension;Thirst;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Tingling sensation;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Tooth discolouration;Torsade de pointes;Toxic epidermal necrolysis;Transaminases increased;Trembling;Tremor;Tubulointerstitial nephritis;Typhoid fever;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urethral haemorrhage;Uric acid level increased;Urinary incontinence;Urinary retention;Urinary tract disorder;Urine odour abnormal;Urine output increased;Urticaria;Uveitis;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginal itching;Vaginal moniliasis;Vaginitis bacterial;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Ventricular arrhythmia;Ventricular bigeminy;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Vision blurred;Visual acuity reduced;Visual colour distortions;Visual disturbance;Visual impairment;Vital dye staining cornea present;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginal pruritus,small molecule,approved; investigational,"1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; Ciprofloxacin; Ciprofloxacine; Ciprofloxacino; Ciprofloxacinum; 5.99.1.3; Topoisomerase IV subunit A; 5.99.1.3; 2.1.1.45; CDC21; TS; TSA1; 5.99.1.3; 5.99.1.3; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 5.99.1.3; hisW; nalA; parD; 5.99.1.3; grlA; Topoisomerase IV subunit A; 5.99.1.3; grlB; Topoisomerase IV subunit B; 5.99.1.3; cafB; nalA; Multidrug-efflux transporter; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2",DNA topoisomerase 4 subunit A; DNA gyrase subunit B; Thymidylate synthase; DNA gyrase subunit A; DNA gyrase subunit A; DNA topoisomerase 2-alpha; Voltage-gated inwardly rectifying potassium channel KCNH2; DNA gyrase subunit A; DNA topoisomerase 4 subunit A; DNA topoisomerase 4 subunit B; DNA gyrase subunit A; Multidrug resistance protein MdtK; Gyrase A, J01MA02; J01RA10; J01RA12; S01AE03; S02AA15; S03AA07;J01MA02;J01RA11
cisplatin,Adrenal carcinoma;Adrenal gland cancer;Anal cancer;Bladder cancer;Bladder carcinoma;Bladder transitional cell carcinoma;Brain neoplasm malignant;Breast cancer;Carcinoma;Carcinoma of lung;Cervix carcinoma;Choriocarcinoma;Endometrial cancer;Gestational trophoblastic tumour;Hepatic cancer;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hypocalcaemia;Hypomagnesaemia;Lung neoplasm malignant;Lymphoma;Malignant melanoma;Malignant neoplasm of esophagus;Mesothelioma;Neoplasm;Neoplasm malignant;Neutropenia;Non-Hodgkin's lymphoma;Oesophageal carcinoma;Osteosarcoma;Ovarian cancer;Ovarian carcinoma;Ovarian neoplasm;Penile cancer;Prostate cancer;Renal cancer;Renal failure;Renal impairment;Sarcoma;Squamous cell carcinoma;Testicular neoplasm,Acute coronary syndrome;Acute leukaemia;Ageusia;Alopecia;Amnesia;Amylase increased;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Anorexia;Anxiety;Apprehension;Areflexia;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Autonomic neuropathy;Azoospermia;Blindness;Blindness cortical;Blood and lymphatic system disorders;Blood creatinine increased;Blood uric acid increased;Body temperature increased;Bone marrow toxicity;Bradycardia;Breast disorder;Cardiac disorder;Cardiac failure congestive;Carpo-pedal spasm;Cellulitis;Cerebral arteritis;Cerebrovascular accident;Clonus;Conjunctivitis;Connective tissue disorder;Convulsion;Coronary artery disease;Coronary heart disease;Cramp muscle;Deafness;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Discomfort;Diuresis;Dysarthria;Dyspnoea;Ear and labyrinth disorders;Electric shock;Erythema;Extravasation;Eye disorder;Face oedema;Febrile neutropenia;Feeling abnormal;Fibrosis;Fluid retention;Flushing;Gastrointestinal disorder;Generalised erythema;Generalised oedema;Glucose tolerance impaired;Haemolysis;Haemolytic anaemia;Haemolytic uraemic syndrome;Hearing impaired;Heart disease congenital;Heart malformation;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hiccups;High frequency deafness;Hyperhidrosis;Hypersensitivity;Hyperuricaemia;Hypokalaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Infection;Irreversible renal failure;Irritability;Leukoencephalopathy;Leukopenia;Lhermitte's sign;Liver injury;Loss of proprioception;Malaise;Malnutrition;Mediastinal disorder;Memory loss;Metastatic neoplasm;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myelosuppression;Myocardial infarction;Nasal congestion;Nasopharyngitis;Nausea;Necrosis;Nephropathy toxic;Nephrotoxicity;Nervous system disorder;Neurological symptom;Neuropathy;Neuropathy peripheral;Neurotoxicity;Ocular toxicity;Oedema;Optic neuritis;Orthostatic hypotension;Ototoxicity;Pain;Pancreatitis;Pancytopenia;Papilloedema;Paraesthesia;Phlebitis;Polyuria;Posterior reversible encephalopathy syndrome;Pulmonary toxicity;Rash;Renal failure;Renal failure acute;Renal failure chronic;Renal tubular disorder;Retinal pigmentation;Retinal toxicity;Rhinorrhoea;Secondary anemia;Serum amylase increased;Serum creatinine increased;Skin disorder;Skin exfoliation;Skin necrosis;Slurred speech;Spinal cord disorder;Stomatitis;Sweating increased;Tachycardia;Tetany;Thrombocytopenia;Thrombotic microangiopathy;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine output;Vestibular toxicity;Vision blurred;Visual impairment;Vomiting;Wheezing,small molecule,approved,"(SP-4-2)-DIAMMINEDICHLOROPLATINUM; CDDP; Cis-DDP; CIS-DIAMMINEDICHLOROPLATINUM; CIS-DIAMMINEDICHLOROPLATINUM II; cis-diamminedichloroplatinum(II); Cisplatin; cisplatino; INT-230-6 COMPONENT CISPLATIN; INT230-6 COMPONENT CISPLATIN; PLATINUM, DIAMMINEDICHLORO-, (SP-4-2)-; 3-alkyladenine DNA glycosylase; 3-methyladenine DNA glycosidase; 3.2.2.21; AAG; ADPG; ANPG; MID1; N-methylpurine-DNA glycosylase; Alpha-2-M; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5; CPAMD5; Beta-1 metal-binding globulin; Siderophilin; Transferrin; HAH1; Metal transport protein ATX1; 1.11.2.2; MPO; XDHA; 1.14.14.1; 20-HETE synthase; 20-hydroxyeicosatetraenoic acid synthase; CYP4A2; CYP4AII; CYPIVA11; Cytochrome P-450HK-omega; Cytochrome P450HL-omega; Fatty acid omega-hydroxylase; Lauric acid omega-hydroxylase; Long-chain fatty acid omega-monooxygenase; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 2.3.1.5; NAT; nhoA; tbnat; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 2.5.1.18; Glutathione transferase T1-1; GST class-theta-1; Metallothionein-IA; MT-1A; MT-IA; MT1S; CES1; Metallothionein-2A; Metallothionein-II; MT-2; MT-II; MT2; 1.15.1.1; hSod1; Superoxide dismutase 1; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 1.6.5.2; Azoreductase; DIA4; DT-diaphorase; DTD; Menadione reductase; NAD(P)H:quinone oxidoreductase 1; NMOR1; Phylloquinone reductase; QR1; Quinone reductase 1; 2.5.1.18; GST class-mu 1; GST HB subunit 4; GST1; GSTM1-1; GSTM1a-1a; GSTM1b-1b; GTH4; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; 7.6.2.2; MOAT-C; MRP5; Multi-specific organic anion transporter C; Multidrug resistance-associated protein 5; pABC11; SMRP; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; hOCT2; OCT2; Organic cation transporter 2; Copper transporter 1; COPT1; CTR1; hCTR1; Solute carrier family 31 member 1; Copper transporter 2; COPT2; CTR2; hCTR2; Solute carrier family 31 member 2; 7.6.2.-; 7.6.2.3; Anthracycline resistance-associated protein; ARA; MOAT-E; MRP6; Multi-specific organic anion transporter E; Multidrug resistance-associated protein 6; 7.2.2.8; Copper pump 2; PWD; WC1; Wilson disease-associated protein; WND; 7.2.2.8; Copper pump 1; MC1; Menkes disease-associated protein; MNK; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",DNA; DNA-3-methyladenine glycosylase; Alpha-2-macroglobulin; Serotransferrin; Copper transport protein ATOX1,L01XA01
citalopram,"Affect lability;Aggression;Agitation;Akathisia;Amnesia;Anxiety;Anxiety disorder;Asthenia;Bradyphrenia;Bradypsychic response;Cardiac disorder;Cardiotoxicity;Cerebral arteriosclerosis;Cerebral artery embolism;Cerebral haemorrhage;Cerebral infarction;Cerebral thrombosis;Cerebration impaired;Cerebrovascular disorder;Cognitive disorder;Compulsions;Compulsive personality disorder;Decreased interest;Dementia;Dementia Alzheimer's type;Depersonalisation;Depressed mood;Depression;Depressive disorder;Disinhibition;Distress;Disturbance in attention;Drug abuse;Dry mouth;Dysphoria;Dysthymic disorder;Electroencephalogram abnormal;Emotional distress;Fasting;Fatigue;Feeling guilty;Function kidney decreased;Function liver decreased;Generalised anxiety disorder;Hepatic function abnormal;Hostility;Hypersomnia;Insomnia;Irritability;Ischaemia;Major depression;Major depressive disorder, single episode;Melancholia;Mental disability;Mood swings;Multi-infarct dementia;Obsessive rumination;Obsessive thoughts;Obsessive-compulsive disorder;Obsessive-compulsive personality disorder;Orthostatic hypotension;Renal failure;Renal impairment;Sleep disorder;Sleep disturbance;Social phobia;Subarachnoid haemorrhage;Suicidal behaviour;Suicidal ideation;Suicide attempt;Tension;Vascular dementia;Vision blurred;Wave slowing","Abdominal bloating;Abdominal cramps;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal ejaculation;Abnormal vision;Abortion spontaneous;Abscess;Accidental injury;Accommodation disorder;Acne;Acute bronchitis;Acute coronary syndrome;Acute psychosis;Acute sinusitis;Affect lability;Ageusia;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Akathisia;Alanine aminotransferase increased;Alcohol intolerance;Alcohol problem;Allergic oedema;Allergic sinusitis;Allergy aggravated;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anal fissure;Anal pruritus;Anaphylactic shock;Aneurysm;Anger;Angina pectoris;Angioedema;Angiopathy;Angle closure glaucoma;Animal bite;Ankle fracture;Anorectal discomfort;Anorexia;Anorgasmia;Anxiety;Anxiety aggravated;Anxiety attack;Apathy;Aphasia;Aplastic anaemia;Appendicitis;Arrhythmia;Arteriosclerosis;Arthralgia;Arthritis;Arthropathy;Arthropod bite;Arthropod sting;Aspartate aminotransferase increased;Asthenia;Asthenopia;Asthma;Ataxia;Atrial fibrillation;Atrophic vulvovaginitis;Autonomic nervous system imbalance;Autonomic neuropathy;Back distress;Back injury;Back pain;Bacterial infection;Balance disorder;Benign breast neoplasm;Black hairy tongue;Bladder dilatation;Bladder discomfort;Bladder pain;Blepharospasm;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood cholesterol increased;Blood glucose increased;Blood pressure fluctuation;Blood pressure increased;Blood uric acid increased;Blood urine present;Blunted affect;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Breast cancer female;Breast discharge;Breast disorder;Breast enlargement;Breast neoplasm;Breast pain;Breast tenderness;Bronchitis;Bronchitis viral;Bronchospasm;Bruxism;Bundle branch block;Burning sensation;Bursitis;Calculus of kidney;Candida infection;Carbohydrate craving;Carbuncle;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiovascular disorder;Carpal tunnel syndrome;Cataract;Catatonia;Catatonic reaction;Cellulitis;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Cerumen impaction;Change in blood pressure;Change of bowel habit;Chest discomfort;Chest pain;Chest tightness;Chest wall pain;Chills;Choking;Cholecystitis;Cholelithiasis;Choreoathetosis;Chromatopsia;Chromaturia;Clonic convulsion;Coagulopathy;Cold sweat;Colitis;Colitis ulcerative;Collagen disorder;Colonic polyp;Coma;Common wart;Completed suicide;Concussion;Confusional state;Congenital eye disorder;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Conversion disorder;Convulsion;Coordination abnormal;Coronary artery disease;Costochondritis;Cough;Cramp muscle;Cramps of lower extremities;Crohn's disease;Crying;Crying abnormal;Cyanosis;Cyst;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Delusion;Dental caries;Dependence;Dependence physiological;Dependence psychological;Depersonalisation;Depressed level of consciousness;Depressed mood;Depression;Depression aggravated;Derealisation;Dermal cyst;Dermatitis;Dermatitis acneiform;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disinhibition;Disorder sight;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Diuresis;Diverticulitis;Dizziness;Dizziness postural;Drug abuse;Drug dependence;Drug interaction;Drug level decreased;Drug level increased;Drug seeking behavior;Drug tolerance;Dry eye;Dry mouth;Dry skin;Duodenal ulcer;Dysaesthesia;Dysarthria;Dysequilibrium;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphasia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear infection;Ear pain;Early satiety;Ecchymosis;Eczema;Ejaculation delayed;Ejaculation disorder;Ejaculation failure;Electric shock;Electrocardiogram PR shortened;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Embolism;Emotional disorder;Emotional distress;Endocrine disorder;Enteritis;Eosinophilia;Epidermal naevus;Epigastric discomfort;Epistaxis;Erectile dysfunction;Eructation;Eruption lichenoid;Erysipelas;Erythema;Erythema multiforme;Euphoric mood;Excitability;Excoriation;Exostosis;Extrapyramidal disorder;Extrasystoles;Eye disorder;Eye haemorrhage;Eye infection;Eye injury;Eye irritation;Eye pain;Eye pruritus;Eye swelling;Eyelid oedema;Face oedema;Facial bones fracture;Facial paralysis;Facial paresis;Facial spasm;Family stress;Fatigue;Feeling abnormal;Feeling hot;Feeling jittery;Female sexual dysfunction;Femoral neck fracture;Fibromyalgia;Finger deformity;Flat affect;Flatulence;Fluid retention;Flushing;Foetal death;Folliculitis;Food craving;Food poisoning;Foot fracture;Forgetfulness;Frequent bowel movements;Functional gastrointestinal disorder;Fungal infection;Fungal skin infection;Furuncle;Furunculosis;Gagging;Gait disturbance;Galactorrhoea;Gamma-glutamyltransferase increased;Gastric polyps;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal infection;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised anxiety disorder;Genital candidiasis;Genital infection;Genital pain;Genitourinary chlamydia infection;Gilbert's syndrome;Gingival bleeding;Gingival infection;Gingival pain;Gingivitis;Glaucoma;Glossitis;Glucose tolerance abnormal;Glucose tolerance impaired;Goitre;Gout;Grand mal convulsion;Gravitational oedema;Gynaecomastia;Haematemesis;Haematochezia;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemorrhage;Haemorrhagic disorder;Haemorrhoids;Hallucination;Hallucination, auditory;Hallucination, visual;Hand dermatitis;Head discomfort;Headache;Heartburn;Hemorrhage abnormal;Hepatic enzyme increased;Hepatic failure;Hepatic necrosis;Hepatitis;Hepatitis cholestatic;Hepatitis fulminant;Hepatobiliary disease;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hostility;Hot flush;House dust allergy;Hunger;Hyperaesthesia;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hypermagnesaemia;Hyperphagia;Hyperprolactinaemia;Hyperreflexia;Hypersensitivity;Hypersomnia;Hypertension;Hypertension worsened;Hypertensive crisis;Hyperthyroidism;Hypertonia;Hypertrichosis;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypochromic anaemia;Hypogeusia;Hypoglycaemia;Hypohidrosis;Hypokalaemia;Hypokinesia;Hypomania;Hyponatraemia;Hypotension;Hypothyroidism;Hysteria;Idiopathic thrombocytopenia;Idiopathic thrombocytopenic purpura;Ileitis;Ill-defined disorder;Immune system disorder;Impetigo;Inappropriate antidiuretic hormone secretion;Increased appetite;Increased bronchial secretion;Increased tendency to bruise;Infection;Infection parasitic;Infestation;Infestation NOS;Inflicted injury;Influenza;Influenza like illness;Influenza-like symptoms;Ingrowing nail;Initial insomnia;Injury;Insomnia;International normalised ratio increased;Intervertebral disc disorder;Intervertebral disc protrusion;Iritis;Irritability;Irritable bowel syndrome;Ischial neuralgia;Jaundice;Jaw stiffness;Joint dislocation;Joint injury;Joint sprain;Joint stiffness;Keratitis;Keratoconus;Laceration;Lacrimal disorder;Lacrimation abnormal NOS;Large intestine polyp;Laryngeal pain;Laryngitis;Latent tetany;Leg edema;Leg pain;Lethargy;Leukocytosis;Leukopenia;Libido decreased;Libido increased;Lichenoid keratosis;Ligament injury;Ligament sprain;Lightheadedness;Limb injury;Lip dry;Lipoma;Liver function test abnormal;Local swelling;Loss of consciousness;Loss of libido;Lumbar disc lesion;Lung infection;Lymphadenitis;Lymphadenopathy;Lymphadenopathy cervical;Lymphatic disorder;Lymphocytosis;Lymphopenia;Major depression;Malaise;Malnutrition;Mania;Manic psychosis;Marrow hyperplasia;Mastitis;Mediastinal disorder;Melaena;Melancholia;Melanosis;Memory impairment;Meniere's disease;Menometrorrhagia;Menopausal symptoms;Menorrhagia;Menstrual disorder;Menstruation irregular;Mental disability;Mental disorder;Mental status changes;Metrorrhagia;Micturition disorder;Micturition urgency;Middle insomnia;Migraine;Migraine aggravated;Mood swings;Motion sickness;Mouth injury;Mouth ulceration;Movement disorder;Muscle contractions involuntary;Muscle contracture;Muscle rigidity;Muscle rupture;Muscle spasms;Muscle stiffness;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Mydriasis;Myocardial infarction;Myocardial ischaemia;Myocarditis;Myoclonus;Myopathy;Myopia;Nasal congestion;Nasal polyps;Nasal septum deviation;Nasopharyngitis;Nausea;Neck injury;Neck pain;Necrolysis epidermal;Neoplasm;Nephrolithiasis;Nerve root lesion;Nervous system disorder;Nervous tremulousness;Nervousness;Neuralgia;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Neurosis;Neurotransmitter level altered;Night blindness;Night sweats;Nightmare;Nocturia;Nodal rhythm;Nystagmus;Obesity;Obsessive-compulsive disorder;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Onychomycosis;Oral pain;Orchitis noninfective;Orgasm abnormal;Orthostatic hypotension;Osteoarthritis;Osteoporosis;Otitis externa;Otitis media;Otosalpingitis;Ovarian cyst;Pain;Pain in extremity;Pain in jaw;Painful erection;Pallor;Palpitations;Pancreatitis;Pancytopenia;Panic attack;Panic reaction;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Parkinsonism;Pelvic inflammatory disease;Pelvic pain;Penis disorder;Performance status decreased;Pericardial disease;Periodontal destruction;Peripheral coldness;Peripheral ischaemia;Personality disorder;Petit mal epilepsy;Pharyngitis;Pharyngitis streptococcal;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Photophobia;Photopsia;Photosensitivity reaction;Plantar fasciitis;Platelet count decreased;Pneumonia;Pollakiuria;Polyp;Polyuria;Post-traumatic neck syndrome;Post-traumatic pain;Postnasal drip;Pregnancy;Pregnancy test positive;Premenstrual syndrome;Premenstrual tension;Presyncope;Priapism;Procedural pain;Proctocolitis;Prolonged menses;Prostatic disorder;Prothrombin level decreased;Prothrombin level increased;Prothrombin time shortened;Pruritus;Pruritus genital;Psoriasis;Psoriasis flare-up;Psychomotor retardation;Psychotic depression;Psychotic disorder;Pulmonary embolism;Pulmonary hypertension;Purpura;Pyelonephritis;Pyelonephritis acute;Radiculopathy;Radius fracture;Rash;Rash erythematous;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Red blood cell disorders;Reflux gastritis;Renal failure acute;Renal pain;Respiration abnormal;Respiratory sighs;Respiratory tract infection;Restless legs syndrome;Restlessness aggravated;Retching;Retinal detachment;Rhabdomyolysis;Rheumatoid arthritis;Rhinitis;Rhinitis perennial;Rhinitis seasonal;Rhinorrhoea;Rib fracture;Rigors;Road traffic accident;Sacroiliitis;Salivary hypersecretion;Salmonellosis;Salpingitis;Sciatica;Scoliosis;Scotoma;Seasonal allergy;Self-injurious ideation;Sensation of blood flow;Sensation of heaviness;Sensory disturbance;Sepsis;Serotonin syndrome;Sexual dysfunction;Shivering;Shock;Shoulder pain;Sinus bradycardia;Sinus congestion;Sinus headache;Sinus tachycardia;Sinusitis;Skin discolouration;Skin disorder;Skin infection;Skin irritation;Skin laceration;Skin mass;Skin nodule;Skin odour abnormal;Skin papilloma;Skin warm;Sleep apnoea syndrome;Sleep disorder;Sleep talking;Sluggishness;Snoring;Somnolence;Speech disorder;Sports injury;Sputum increased;Staphylococcal infection;Stevens-Johnson syndrome;Stomatitis;Streptococcal infection;Stress at work;Stupor;Sudden death;Suicidal ideation;Suicidal tendency;Suicide;Suicide attempt;Sunburn;Supraventricular extrasystoles;Surgery;Surgical intervention;Sweating;Sweating decreased;Sweating increased;Syncope;Syncope vasovagal;Tachycardia;Tardive dyskinesia;Taste metallic;Tendon disorder;Tendonitis;Tenosynovitis;Tension;Tension headache;Terminal insomnia;Testicular disorder;Testicular pain;Tetany;Thermal burn;Thinking abnormal;Thirst;Throat irritation;Throat tightness;Thrombocytopenia;Thrombosis;Thyroiditis;Tinnitus;Tolerance development;Tongue discolouration;Tongue disorder;Tonic-clonic seizures;Tonsillitis;Tooth abscess;Tooth disorder;Tooth erosion;Tooth infection;Tooth injury;Toothache;Torsade de pointes;Torticollis;Toxic epidermal necrolysis;Tracheal disorder;Tracheitis;Tracheobronchitis;Transient ischaemic attack;Trauma;Traumatic haematoma;Tremor;Trismus;Tuberculosis;Tympanic membrane perforation;Ulcerative stomatitis;Ulna fracture;Unintended pregnancy;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upper-airway cough syndrome;Upset stomach;Urethral disorder;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Uterine leiomyoma;Uterine spasm;VIIth nerve paralysis;Vaginal discharge;Vaginal dryness;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vaginitis atrophic;Varicella;Varicose vein;Vascular purpura;Vasodilatation;Vein disorder;Vein distended;Ventricular arrhythmia;Ventricular tachycardia;Vertigo;Viral infection;Viral upper respiratory tract infection;Vision blurred;Visual disturbance;Visual impairment;Vitreous detachment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal dryness;Vulvovaginal mycotic infection;Weight decreased;Weight increased;Wheezing;Whiplash injury;Withdrawal syndrome;Wound infection;Xerophthalmia;Yawning",small molecule,approved,"Citalopram; Citalopramum; Nitalapram ; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; H1-R; H1R; HH1R; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent serotonin transporter; Histamine H1 receptor,N06AB04
clemastine,Angioedema;Lacrimation;Lacrimation increased;Nasopharyngitis;Pruritus;Rhinitis allergic;Rhinorrhoea;Sneezing;Urticaria,Agitation;Agranulocytosis;Anaphylactic shock;Anorexia;Asthenia;Chest discomfort;Chest tightness;Chills;Confusional state;Constipation;Conversion disorder;Convulsion;Decreased appetite;Diarrhoea;Diplopia;Dizziness;Drowsiness;Drug eruption;Dyspepsia;Epigastric distress;Euphoric mood;Extrasystoles;Fatigue;Feeling abnormal;Haemolytic anaemia;Headache;Hyperhidrosis;Hypotension;Hysteria;Insomnia;Irritability;Labyrinthitis;Nasal congestion;Nausea;Nervousness;Neuritis;Neuropathy peripheral;Palpitations;Paraesthesia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Somnolence;Sweating increased;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Tremor;Urinary retention;Vertigo;Vision blurred;Vomiting;Wheezing,small molecule,approved; investigational,(+)-(2R)-2-(2-(((R)-p-chloro-α-methyl-α-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; Clemastina; Clemastine; Clemastinum; H1-R; H1R; HH1R; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase,Histamine H1 receptor, R06AA04; R06AA54;D04AA14
clindamycin,Abdominal abscess;Abdominal infection;Abscess;Abscess periodontal;Acne;Acne vulgaris;Acquired immunodeficiency syndrome;Arthritis bacterial;Autoimmune disorder;Bone and joint infections;Bronchitis;Cellulitis;Cervicitis;Comedone;Diarrhoea;Diarrhoea haemorrhagic;Empyema;Endocarditis;Endometritis;Erysipelas;Furuncle;Genital infection female;Gonorrhoea;Gynecological infection;Herpes simplex;Impetigo;Infection;Lower respiratory tract infection;Lung abscess;Myocarditis;Osteomyelitis;Otitis media;Panaritium;Parametritis;Paronychia;Pelvic infection;Pelvic inflammatory disease;Periodontitis;Peritonitis;Pharyngitis;Plasmodium falciparum infection;Pneumocystis jirovecii pneumonia;Pneumonia;Pseudomembranous colitis;Respiratory tract infection;Salpingitis;Scarlet fever;Sensitisation;Sepsis;Septicemia;Sinusitis;Soft tissue infection;Tonsillitis;Tooth abscess;Tooth infection;Tubo-ovarian abscess;Upper respiratory tract infection;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginitis bacterial;Vaginitis gardnerella;Vulvovaginitis;Wound infection,Abdominal bloating;Abdominal cramps;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain generalised;Abdominal pain localised;Abdominal pain upper;Abnormal labour;Abscess;Acne;Acute generalised exanthematous pustulosis;Agranulocytosis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Antibiotic associated colitis;Application site burn;Application site dryness;Application site erythema;Application site pain;Application site pruritus;Application site rash;Application site reaction;Asthenia;Azotaemia;Back pain;Bacterial infection;Body temperature increased;Breath odour;Burning feeling vagina;Candida infection;Cardiac arrest;Cardio-respiratory arrest;Clostridium difficile colitis;Colitis;Constipation;Cramp muscle;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Diarrhoea haemorrhagic;Digestion impaired;Discomfort;Dizziness;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Endometriosis;Eosinophilia;Epistaxis;Erythema;Erythema multiforme;Exacerbation of acne;Fatal outcomes;Fatigue;Flank pain;Flatulence;Flushing;Folliculitis;Fungal infection;Fungal skin infection;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Generalized aching;Haematochezia;Headache;Hypersensitivity;Hypertension;Hyperthyroidism;Hypotension;Induration;Inflammation;Inflammatory swelling;Injection site irritation;Instillation site pain;Jaundice;Leukocytosis;Leukopenia;Local reaction;Localised oedema;Localized erythema;Localized exfoliation;Measles;Menstrual disorder;Metrorrhagia;Muscle spasms;Nausea;Neutropenia;Oesophageal ulcer;Oesophagitis;Oily skin;Oliguria;Other acne;Pain;Pain of skin;Pelvic pain;Photosensitivity reaction;Pimples;Polyarthritis;Protein urine present;Proteinuria;Prurigo;Pruritus;Pseudomembranous colitis;Pyelonephritis;Rash;Rash erythematous;Rash maculo-papular;Rash pustular;Redness;Seborrhoeic dermatitis;Skin exfoliation;Skin irritation;Skin scaly;Stevens-Johnson syndrome;Stinging;Stomach cramps;Sunburn;Superinfection;Swelling;Taste bitter;Taste metallic;Tenderness;Thrombocytopenia;Thrombophlebitis;Thrombophlebitis superficial;Toxic epidermal necrolysis;Trichomonal vaginitis;Ulcer;Upper respiratory tract infection;Urinary tract infection;Urticaria;Vaginal discharge;Vaginal erythema;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal irritation;Vaginal moniliasis;Vaginal pain;Vaginal swelling;Vertigo;Vesiculobullous rash;Vomiting;Vulval erythema;Vulvitis;Vulvovaginal burning sensation;Vulvovaginal candidiasis;Vulvovaginal discomfort;Vulvovaginal disorder;Vulvovaginal dryness;Vulvovaginal erythema;Vulvovaginal mycotic infection;Vulvovaginal pain;Vulvovaginal swelling;Vulvovaginitis;Vulvovaginitis trichomonal;Watery diarrhoea,small molecule,approved; vet_approved,"7-CDL; 7(S)-Chloro-7-deoxylincomycin; Clindamicina; Clindamycin; Clindamycine; Clindamycinum; Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",50S ribosomal protein L1, D10AF51; G01AA10; J01FF01;D10AF01
clobazam,Anxiety;Brain injury;Convulsion;Epilepsy;Lennox-Gastaut syndrome;Sleep disorder;Sleep disturbance,Abdominal distension;Abnormal behaviour;Aggression;Agitation;Amnesia;Anaemia;Anorexia;Anterograde amnesia;Anxiety;Apathy;Appetite absent;Asthenia;Asthma;Ataxia;Balance disorder;Behavior disorder;Blood disorder;Body temperature increased;Bronchitis;Confusional state;Constipation;Cough;Decreased appetite;Delirium;Delusion;Dependence;Dependence psychological;Depression;Dermatitis;Diarrhoea;Diplopia;Disorder sight;Disorientation;Disturbance in sexual arousal;Dizziness;Drooling;Drowsiness;Drug dependence;Drug withdrawal syndrome;Dry mouth;Dysarthria;Dysphagia;Eosinophilia;Erythema multiforme;Euphoric mood;Eye disorder;Fatigue;Feeling abnormal;Flat affect;Gastrointestinal disorder;Hallucination;Hangover;Headache;Hepatic enzyme increased;Hostility;Hyperhidrosis;Hypotension;Increased appetite;Infection;Infestation;Infestation NOS;Insomnia;Irritability;Lethargy;Leukopenia;Libido decreased;Liver function test abnormal;Loss of libido;Malnutrition;Mental disorder;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Nausea;Nervous system disorder;Nervousness;Nightmare;Nystagmus;Osteoarthritis;Pneumonia;Pruritus;Psychotic disorder;Pulmonary function test decreased;Rash;Respiratory depression;Respiratory failure;Respiratory insufficiency;Skin disorder;Slurred speech;Somnolence;Stevens-Johnson syndrome;Stiffness;Suicidal behaviour;Sweating;Tension;Thrombocytopenia;Toxic epidermal necrolysis;Tremor;Tremor fine;Unspecified disorder of skin and subcutaneous tissue;Unsteadiness;Upper respiratory tract infection;Urinary tract infection;Urticaria;Vision blurred;Visual impairment;Vomiting;Weight increased;Withdrawal symptom,small molecule,approved; illicit,"1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; 7-Chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione; Clobazam; Clobazamum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",GABA(A) Receptor; Gamma-aminobutyric acid receptor subunit gamma-3; Gamma-aminobutyric acid receptor subunit alpha-1; GABA(A) Receptor Benzodiazepine Binding Site,N05BA09
clobetasol,Dermatitis atopic;Eczema;Erythema;Excoriation;Induration;Lichenification;Non-scalp psoriasis;Plaque psoriasis;Pruritus;Psoriasis;Psoriasis of scalp;Seborrhoeic dermatitis;Skin disorder,Acneiform eruption;Allergic contact dermatitis;Alopecia;Application site atrophy;Application site burn;Application site discolouration;Application site dryness;Application site irritation;Application site pain;Application site pigmentation changes;Application site pruritus;Application site reaction;Asteatosis;Atrophy;Connective tissue disorder;Cushing's syndrome;Delusion;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis infected;Dermatitis perioral;Dry skin;Eruption;Erythema;Eye irritation;Folliculitis;Glycosuria;Headache;Hyperadrenocorticism;Hyperglycaemia;Hypersensitivity;Hypertrichosis;Hypoaesthesia;Infection;Instillation site pain;Leukoderma;Miliaria;Numbness in fingers;Oedema peripheral;Pain;Pain in extremity;Paraesthesia;Paranoid delusions;Pruritus;Psoriasis;Psoriasis flare-up;Purpura;Pustule;Pyoderma;Rash;Rash pustular;Rosacea;Secondary adrenocortical insufficiency;Secondary infection;Sensation of pressure;Skin atrophy;Skin discomfort;Skin disorder;Skin hyperpigmentation;Skin hypertrophy;Skin striae;Stinging;Telangiectasia;Tenderness;Tingling sensation;Unspecified disorder of skin and subcutaneous tissue;Vascular purpura,small molecule,approved; experimental; investigational,"Clobetasol; 3.1.1.4; Group IB phospholipase A2; Phosphatidylcholine 2-acylhydrolase 1B; PLA2; PLA2A; PPLA2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3",Phospholipase A2, D07CD01;D07AD01
clobetasone,Allergic contact dermatitis;Dermatitis;Dermatitis atopic;Dermatitis contact;Eczema;Neurodermatitis;Otitis externa;Prurigo nodularis;Pruritus;Scratch;Seborrhoeic dermatitis;Skin disorder,Allergic contact dermatitis;Atrophy;Cataract;Central obesity;Contusion;Cushingoid;Dermatitis;Dermatitis contact;Endocrine disorder;Erythema;Glaucoma;Glycosuria;Growth retardation;Hair disorder;Hyperglycaemia;Hypersensitivity;Hypertension;Hypertrichosis;Immune system disorder;Infection;Infestation;Infestation NOS;Obesity;Opportunistic infection;Osteoporosis;Pruritus;Rash;Rosacea;Secondary adrenocortical insufficiency;Secondary infection;Skin atrophy;Skin disorder;Skin striae;Telangiectasia;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Weight increased,small molecule,approved,"Clobetasona; Clobetasone; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Glucocorticoid receptor, S01BA09; S01CA11;D07AB01
clofazimine,Erythema nodosum leprosum;Lepromatous leprosy;Leprosy;Type 2 lepra reaction,Abdominal pain upper;Acneiform eruption;Anaemia;Anorexia;Asthenia;Bladder pain;Body temperature increased;Bone pain;Cheilosis;Completed suicide;Constipation;Corneal pigmentation;Cystitis;Cystitis noninfective;Decreased appetite;Depression;Dermatitis;Dermatitis acneiform;Dermatitis exfoliative;Diarrhoea;Dizziness;Drowsiness;Embolism;Embolism venous;Enteritis;Eosinophilia;Epigastric pain;Fatigue;Gastrointestinal haemorrhage;Headache;Hepatitis;Hepatomegaly;Hyperglycaemia;Hypokalaemia;Ichthyosis;Ichthyosis acquired;Intestinal obstruction;Jaundice;Lymphadenopathy;Nausea;Neuralgia;Oedema;Photosensitivity reaction;Phototoxicity;Pruritus;Rash;Skin discolouration;Somnolence;Splenic infarction;Suicide;Taste disorders;Thromboembolism;Vascular pain;Vision decreased;Visual acuity reduced;Visual impairment;Vomiting;Weight decreased,small molecule,approved; investigational,"Clofazimin; Clofazimina; Clofazimine; Clofaziminum; Riminophenazine; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; HGK5; HLK3; HPCN3; Voltage-gated K(+) channel HuKIII; Voltage-gated potassium channel subunit Kv1.3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1",Peroxisome proliferator-activated receptor gamma; Potassium voltage-gated channel subfamily A member 3, J04BA51;J04BA01
clomiphene,Adrenal disorder;Amenorrhea secondary;Amenorrhoea;Anovulatory cycle;Assisted fertilisation;Endometrial cancer;Endometriosis;Fertilization;Gynaecomastia;Haemoglobin;Haemorrhage;Hyperprolactinaemia;Infertility;Infertility male;Ovarian cyst;Ovarian enlargement;Ovarian failure;Polycystic ovaries;Pregnancy;Testicular neoplasm;Thyroid disorder;Uterine haemorrhage;Uterine leiomyoma;Vaginal haemorrhage,"Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal symptom;Accommodation disorder;Acne;Acute abdomen;Adnexa uteri pain;Adnexal torsion;Affect lability;Alopecia;Amaurosis;Amelia;Anal atresia;Anencephaly;Anxiety;Arrhythmia;Arterial occlusion;Arterial occlusive disease;Arteriovenous fistula;Arthralgia;Ascites;Asthenia;Astrocytoma;Back pain;Bladder cancer;Bladder carcinoma;Blindness;Blood triglycerides increased;Body temperature increased;Bone development abnormal;Brain abscess;Breast cancer;Breast discomfort;Breast tenderness;Carcinoma breast;Carcinoma of tongue;Cataract;Cerebrovascular accident;Chest pain;Cholestasis;Choriocarcinoma;Cleft lip;Cleft palate;Cloacal exstrophy;Coarctation of the aorta;Congenital anomaly;Congenital central nervous system anomaly;Congenital clubfoot;Conjoined twins;Constipation;Convulsion;Corpus luteum cyst;Cryptorchism;Cyst;Cytogenetic abnormality;Deafness;Death neonatal;Dependence;Dermatitis;Dermatitis atopic;Dermoid cyst;Dermoid cyst of ovary;Developmental delay;Diaphragmatic hernia;Diarrhoea;Diplopia;Disorder sight;Distention;Dizziness;Drug abuse;Dry hair;Dwarfism;Dyspnoea;Ectopic pregnancy;Ectromelia;Embolism;Endometrial cancer;Endometriosis;Erythema;Erythema multiforme;Erythema nodosum;Exomphalos;Eye pain;Fallot's tetralogy;Fatigue;Fibrocystic breast disease;Fibrocystic disease;Flatulence;Flushing;Foetor hepaticus;Gastrointestinal malformation;Glioblastoma multiforme;Haemangioma;Hair texture abnormal;Headache;Heart disease congenital;Heart malformation;Hemimelia;Hepatic adenoma;Hepatic angiosarcoma;Hepatic cancer;Hepatitis;Hepatoblastoma;Hepatocellular adenoma;Hepatocellular carcinoma;Hepatocellular injury;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hot flush;Hydrocephalus;Hydrothorax;Hypersensitivity;Hypertension;Hypertrichosis;Hypertriglyceridaemia;Hypovolaemia;Ichthyosis;Ichthyosis acquired;Increased appetite;Inguinal hernia;Insomnia;Irritability;Jaundice;Leukaemia;Leukocytosis;Lightheadedness;Limb reduction defect;Liver disorder;Loss of consciousness;Lymphocytic leukaemia;Macular oedema;Malignant melanoma;Meningomyelocele;Menopausal symptoms;Menorrhagia;Mental disability;Mental retardation;Microcephaly;Migraine;Mood swings;Multiple pregnancy;Muscular ventricular septal defect;Musculoskeletal discomfort;Myalgia;Myopathy;Nausea;Neoplasm;Nervousness;Neural tube defect;Neuroectodermal neoplasm;Neurofibromatosis;Oedema;Omphalocele;Optic neuritis;Ovarian cancer;Ovarian carcinoma;Ovarian cyst;Ovarian enlargement;Ovarian germ cell teratoma benign;Ovarian haemorrhage;Ovarian hyperstimulation syndrome;Ovarian pain;Ovulation pain;Pain;Palpitations;Pancreatitis;Paraesthesia;Patent ductus arteriosus;Pectus excavatum;Pelvic discomfort;Peritoneal haemorrhage;Phlebitis;Phocomelia;Photophobia;Photopsia;Pituitary tumour;Plasma cell myeloma;Plasmacytoma;Pollakiuria;Polydactyly;Posterior vitreous detachment;Prolactinoma;Prolonged menses;Pruritus;Psychotic disorder;Pulmonary embolism;Rash;Renal agenesis;Renal aplasia;Renal cell carcinoma;Renal dysgenesis;Renal failure;Retinal haemorrhage;Scotoma;Shock;Skull malformation;Spina bifida occulta;Stillbirth;Syncope;Syndactyly;Tachycardia;Talipes;Tenderness;Tension;Thromboembolic event;Thrombophlebitis;Thrombosis;Thyroid disorder;Thyroid neoplasm;Tibial torsion;Tinnitus;Tongue neoplasm malignant stage unspecified;Tracheo-oesophageal fistula;Transaminases increased;Trisomy 21;Tubal pregnancy;Umbilical hernia;Unspecified congenital anomaly of brain, spinal cord, and nervous system;Unspecified visual loss;Urticaria;Uterine haemorrhage;Vaginal dryness;Vasospasm;Ventricular septal defect;Vertigo;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vitreous detachment;Vitreous floaters;Vomiting;Vulvovaginal dryness;Weight increased",small molecule,investigational,Enclomifene; Enclomifeno; Enclomifenum; Enclomiphene; trans-Clomifene; trans-Clomiphene; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase,Estrogen receptor,G03GB02
clomipramine,Affective disorder;Anxiety;Cataplexy;Compulsions;Distress;Emotional distress;Major depression;Narcolepsy;Obsessive rumination;Obsessive thoughts;Obsessive-compulsive disorder;Panic attack;Parkinson's disease;Parkinsonism;Personality disorder;Phobia;Schizophrenia;Senile dementia;Senility,Abdominal disorder;Abdominal pain;Abnormal vision;Accommodation disorder;Acne;Acute coronary syndrome;Affect lability;Ageusia;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Akathisia;Albuminuria;Alopecia;Alveolitis allergic;Amenorrhoea;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Aneurysm;Angiopathy;Angle closure glaucoma;Anorexia;Anticholinergic syndrome;Anxiety;Anxiety state;Apathy;Aphasia;Apraxia;Arrhythmia;Arthralgia;Arthropathy;Asthenia;Ataxia;Atrial flutter;Atrioventricular block;Back pain;Bladder pain;Blepharitis;Blepharospasm;Block heart;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood in stool;Blood pressure increased;Blood prolactin increased;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bradycardia;Breast disorder;Breast engorgement;Breast enlargement;Breast pain;Breath odour;Bronchitis;Bronchospasm;Bruxism;Bundle branch block;Calculus of kidney;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiomyopathy;Catalepsy;Cellulitis;Cerebral haemorrhage;Cerebration impaired;Cerebrovascular accident;Cervical dysplasia;Cheilitis;Chest pain;Chills;Chloasma;Cholinergic syndrome;Choreoathetosis;Chromatopsia;Colitis;Coma;Completed suicide;Conduction disorder;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Cough;Cramps of lower extremities;Cyanosis;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Delirium;Delusion;Dental caries;Depersonalisation;Depressed level of consciousness;Depression;Depression aggravated;Depressive symptom;Dermatitis;Dermatitis atopic;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Dizziness;Drowsiness;Drug withdrawal syndrome;Dry mouth;Dry skin;Duodenitis;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Eczema;Ejaculation failure;Electrocardiogram QRS complex;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Electroencephalogram abnormal;Encephalopathy;Endocrine disorder;Endometrial hyperplasia;Endometriosis;Enteritis;Eosinophilia;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Euphoric mood;Exophthalmos;Exostosis;Extrapyramidal disorder;Extrapyramidal symptoms;Extrasystoles;Eye disorder;Eye pain;Faeces discoloured;Fat intolerance;Fatigue;Feeling abnormal;Fibroadenoma of breast;Fibroadenosis of breast;Flat affect;Flatulence;Flushing;Folliculitis;Fracture;Functional gastrointestinal disorder;Gait disturbance;Galactorrhoea;Gastric dilatation;Gastric ulcer;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised spasm;Gingival bleeding;Gingivitis;Glaucoma;Glossitis;Glycosuria;Goitre;Gout;Gravitational oedema;Gynaecomastia;Haematochezia;Haematuria;Haemoptysis;Haemorrhoids;Hallucination;Headache;Hemiparesis;Hepatic necrosis;Hepatitis;Hepatitis acute;Hepatobiliary disease;Hiccups;Hostility;Hot flush;Hyperacusis;Hyperaesthesia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hypertrichosis;Hyperuricaemia;Hyperventilation;Hypnagogic hallucination;Hypoaesthesia;Hypokalaemia;Hypokinesia;Hypomania;Hypotension;Hypothyroidism;Hypoventilation;Hypoxia;IIIrd nerve paralysis;Ileus paralytic;Ill-defined disorder;Illusion;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection susceptibility increased;Inner ear disorder;Insomnia;Intestinal obstruction;Irritability;Irritable bowel syndrome;Jaundice;Keratitis;Labyrinthine disorder;Lacrimal disorder;Lacrimation abnormal NOS;Laryngitis;Laryngospasm;Leukaemoid reaction;Leukopenia;Leukorrhea;Libido disorder;Local swelling;Loss of consciousness;Lupus erythematosus;Lymphadenopathy;Malaise;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Memory impairment;Menopausal symptoms;Menstrual disorder;Mental disability;Mental disorder;Micturition disorder;Migraine;Mood swings;Mouth ulceration;Multiple fractures;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Mutism;Myalgia;Mydriasis;Myocardial infarction;Myocardial ischaemia;Myoclonus;Myopathy;Myositis;Nausea;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Night blindness;Nightmare;Nocturia;Nystagmus;Oculogyric crisis;Oedema;Oesophagitis;Oliguria;Orthostatic hypotension;Osteoarthritis;Otitis media;Ovarian cyst;Pain;Pallor;Palpitations;Pancytopenia;Panic reaction;Paraesthesia;Paranoia;Paresis;Parkinson's disease;Parkinsonism;Parosmia;Parotid gland enlargement;Parotid swelling;Peptic ulcer;Perineal pain;Peripheral ischaemia;Pharyngeal oedema;Pharyngitis;Phobia;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Piloerection;Pneumonia;Pollakiuria;Polyarteritis nodosa;Polyuria;Premature ejaculation;Prostatic disorder;Pruritus;Pruritus genital;Pseudolymphoma;Psoriasis;Psychosomatic disease;Psychotic disorder;Pupils unequal;Purpura;Pyelonephritis;Pyuria;QRS complex;Rash;Rash erythematous;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Renal cyst;Renal pain;Respiratory failure;Retinal disorder;Rhabdomyolysis;Rhinitis;Salivary gland enlargement;Salivary hypersecretion;Schizophrenic reaction;Schizophreniform disorder;Scleritis;Scotoma;Seborrhoeic dermatitis;Sensation of foreign body;Sensory disturbance;Serotonin syndrome;Shock;Sinus tachycardia;Sinusitis;Skin discolouration;Skin disorder;Skin hypertrophy;Skin odour abnormal;Skin ulcer;Sleep disorder;Sleep disturbance;Somnambulism;Somnolence;Speech disorder;Stomach dilation procedure;Stupor;Sudden death;Suicidal ideation;Suicide;Suicide attempt;Sweating;Sweating increased;Syncope;Systemic lupus erythematosus;Tachycardia;Tardive dyskinesia;Tension;Testicular swelling;Thinking abnormal;Thirst;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tongue ulceration;Tooth disorder;Torsade de pointes;Torticollis;Toxicity to various agents;Transaminases increased;Tremor;Ulcerative stomatitis;Unrest;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Uterine haemorrhage;Uterine inflammation;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasospasm;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vestibular disorder;Vision blurred;Visual impairment;Vomiting;Vulval disorder;Waxy flexibility;Weight decreased;Weight increased;Withdrawal symptom;Withdrawal syndrome;Yawning,small molecule,approved; investigational; vet_approved,"3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-5H-dibenzo[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloroimipramine; Chlorimipramine; Clomipramina; Clomipramine; Clomipraminum; Monochlorimipramine; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; Sodium-dependent noradrenaline transporter; Glutathione S-transferase P,N06AA04
clonazepam,Abdominal discomfort;Abdominal distress;Agoraphobia;Akinetic seizures;Atonic seizures;Chest pain;Chills;Choking sensation;Convulsion;Convulsive seizure;Depersonalisation;Derealisation;Discomfort;Dizziness;Drug tolerance;Dyspnoea;Epilepsy;Fear of death;Grand mal convulsion;Heart pounding;Hot flush;Hyperhidrosis;Hypoaesthesia;Infantile spasms;Lennox-Gastaut syndrome;Lightheadedness;Menopausal symptoms;Myoclonic epilepsy;Nausea;Numbness;Palpitations;Panic attack;Panic disorder;Paraesthesia;Partial epilepsy;Partial seizures;Petit mal epilepsy;Salaam's tic;Sensory loss;Status epilepticus;Sweating;Temporal lobe epilepsy;Tingling sensation;Tolerance development;Tonic-clonic seizures;Trembling;Tremor,Abdominal discomfort;Abdominal pain;Abnormal behaviour;Abnormal dreams;Abnormal eye movements NOS;Affect lability;Ageusia;Aggression;Aggressive reaction;Agitation;Airway obstruction NOS;Akinesia;Alcohol intoxication;Alcohol poisoning;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Anger;Angioedema;Ankle edema;Anorexia;Anterograde amnesia;Anxiety;Apathy;Aphonia;Appetite disorder;Arthralgia;Asthenia;Asthma;Asthmatic attack;Ataxia;Back pain;Bladder dysfunction;Bladder pain;Body temperature increased;Brain injury;Breast disorder;Breast pain;Bronchitis;CNS depression NOS;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiovascular disorder;Cellulitis;Cerebellar syndrome;Cerebration impaired;Chest pain;Chills;Chorea;Chromaturia;Coagulopathy;Coma;Completed suicide;Confusional state;Connective tissue disorder;Constipation;Conversion disorder;Coordination abnormal;Cough;Cramp muscle;Cramps of lower extremities;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Delusion;Dependence;Dependence physiological;Depressed level of consciousness;Depression;Depressive symptom;Dermatitis;Dermatitis contact;Diarrhoea;Diplopia;Discomfort;Disinhibition;Disorder sight;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dreaming excessive;Drowsiness;Drug abuse;Dry mouth;Dysarthria;Dysdiadochokinesis;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dysphoria;Dyspnoea;Dysuria;Ear infection;Ear pain;Ejaculation decreased;Ejaculation delayed;Ejaculation failure;Endocrine disorder;Enuresis;Eosinophilia;Epistaxis;Erectile dysfunction;Euphoric mood;Excitability;Excitement;Eye disorder;Eye irritation;Eye movement disorder;Face oedema;Fatigue;Feeling abnormal;Feeling jittery;Flat affect;Flatulence;Flushing;Forgetfulness;Fracture;Fungal infection;Gait disturbance;Gastritis;Gastrointestinal disorder;Gastrointestinal inflammation;Gastrointestinal pain;Gingival pain;Gout;Gynaecomastia;Haemoglobin;Haemorrhage;Haemorrhage urinary tract;Haemorrhoids;Hallucination;Headache;Headache fullness;Heartburn;Hemiparesis;Hepatomegaly;Herpes simplex;Hirsutism;Hoarseness;Hordeolum;Hostility;Hunger abnormal;Hyperkinesia;Hyperphagia;Hypersensitivity;Hypertonia;Hypoaesthesia;Hypotension;Hypotonia;Hysteria;Ill-defined disorder;Illusion;Immune system disorder;Incomplete precocious puberty;Incontinence;Increased appetite;Infection;Infectious mononucleosis;Inflammation;Inflammation localised;Influenza;Insomnia;Irritability;Joint swelling;Knee pain;Lassitude;Lethargy;Leukopenia;Libido decreased;Libido increased;Ligament sprain;Lightheadedness;Liver function test abnormal;Loss of libido;Low back pain;Lymphadenopathy;Malaise;Malnutrition;Memory impairment;Menorrhagia;Menstruation irregular;Mental disability;Mental disorder;Migraine;Mood swings;Motion sickness;Multiple fractures;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Nightmare;Nocturia;Nystagmus;Obstructive airways disorder;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Otitis;Pain;Pain in jaw;Painful ankle;Palpitations;Panic reaction;Paresis;Periorbital oedema;Pharyngeal oedema;Pharyngitis;Pigmentation disorder;Platelet count decreased;Pleurisy;Pneumonia;Pollakiuria;Polyuria;Prolonged menses;Pruritus;Psychotic disorder;Pulmonary congestion;Pulmonary function test decreased;Rage;Rash;Respiratory depression;Respiratory tract congestion;Rhinitis;Rhinorrhoea;Salivary hypersecretion;Scotoma;Shivering;Sinusitis;Skin burning sensation;Skin discolouration;Skin disorder;Sleep disorder;Sleep disturbance;Slurred speech;Sneezing;Sneezing excessive;Somnolence;Sprain;Suicide;Swelling;Swelling of knees;Tachycardia;Tendonitis;Tension;Thirst;Thrombocytopenia;Thrombophlebitis;Thrombophlebitis of the leg;Tongue coated;Tongue disorder;Tongue oedema;Tooth disorder;Toothache;Tremor;Unspecified disorder of skin and subcutaneous tissue;Unsteady gait;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine color abnormal;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vertigo;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Vivid dreams;Vomiting;Weight decreased;Weight increased;Xeroderma;Xerophthalmia;Yawning,small molecule,approved; illicit,"1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one; 5-(2-chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 5-(2-chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one; 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Clonazepam; Clonazepamum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 2.3.1.5; AAC2; Arylamide acetylase 2; N-acetyltransferase type 2; N-hydroxyarylamine O-acetyltransferase; NAT-2; PNAT; Polymorphic arylamine N-acetyltransferase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site; Nuclear receptor subfamily 1 group I member 2,N03AE01
clonidine,Agitation;Attention deficit/hyperactivity disorder;End stage cancer;Essential hypertension;Flushing;Forgetfulness;Hyperkinesia;Hypertension;Hypertensive;Hypertensive crisis;Hypotension;Hypotensive;Memory impairment;Menopause;Mental disorder;Migraine;Neoplasm malignant;Neuralgia;Pain;Psychotic disorder;Renal hypertension;Vascular headache;Visceral pain,"Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal sleep-related event;Accommodation disorder;Aggression;Agitation;Alopecia;Angioedema;Angiopathy;Anorexia;Anxiety;Application site burn;Application site discolouration;Application site erosion;Application site erythema;Application site pain;Application site papules;Application site rash;Arrhythmia;Arthralgia;Asthenia;Asthma;Atrioventricular block;Auditory and visual hallucinations;Blanching;Blood glucose increased;Body temperature increased;Bradyarrhythmia;Bradycardia;Bradyphrenia;Breast disorder;Breast enlargement;Cardiac disorder;Cardiac failure congestive;Catheter related infection;Cerebrovascular accident;Chest pain;Colonic pseudo-obstruction;Confusional state;Constipation;Coombs test positive;Cough;Cramp muscle;Cramps of lower extremities;Crying;Decreased appetite;Delirium;Delusional perception;Dental caries;Depression;Dermatitis;Dermatitis contact;Device related infection;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry eye;Dry mouth;Dry throat;Dyspnoea;Dysuria;Ear pain;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Emotional disorder;Endocrine disorder;Enuresis;Epistaxis;Erectile dysfunction;Erythema;Excoriation;Eye disorder;Fatigue;Feeling abnormal;Formication;Gastrointestinal disorder;Gastrointestinal pain;Generalized macular rash;Gynaecomastia;Hallucination;Hallucinations, mixed;Headache;Hepatitis;Hyperaesthesia;Hyperhidrosis;Hypersensitivity;Hypoaesthesia;Hypotension;Hypoventilation;Hypoxia;Ileus;Ill-defined disorder;Infection;Influenza like illness;Insomnia;Instillation site pain;Intractable pain;Irritability;Junctional bradycardia;Lacrimation decreased;Lethargy;Libido decreased;Liver function test abnormal;Localised numbness;Loss of consciousness;Loss of libido;Lower respiratory tract infection;Malaise;Malaise and fatigue;Mediastinal disorder;Meningitis;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Nasal congestion;Nasal dryness;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Nightmare;Nocturia;Nodal arrhythmia;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Otitis media acute;Pain;Pain in extremity;Pallor;Palpitations;Papule;Paraesthesia;Paresthesia of limbs;Parotitis;Pollakiuria;Pruritus;Rash;Rash generalised;Rash macular;Rash maculo-papular;Rebound hypertension;Respiratory failure;Rhinitis;Rhinorrhoea;Salivary gland pain;Sensitisation;Sexual dysfunction;Shock;Sick sinus syndrome;Sinus bradycardia;Skin disorder;Skin hyperpigmentation;Skin ulcer;Sleep disorder;Sleep disturbance;Sleep terror;Sneezing;Somnolence;Strangury;Sweating;Syncope;Tachycardia;Tearfulness;Tension;Thirst;Throat sore;Thrombocytopenia;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary retention;Urinary tract infection;Urticaria;Viral diarrhoea;Vision blurred;Vivid dreams;Vomiting;Weight increased;Withdrawal hypertension;Withdrawal syndrome",small molecule,approved,"2-((2,6-Dichlorophenyl)imino)imidazolidine; 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; Chlofazoline; Clonidin; Clonidina; Clonidine; Clonidinum; 1.4.3.21; Amine oxidase copper-containing 3; Copper amine oxidase; HPAO; Semicarbazide-sensitive amine oxidase; SSAO; VAP-1; VAP1; Vascular adhesion protein 1; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H",Amine oxidase [copper-containing] 3; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor, C02AC01; C02LC01; C02LC51; N02CX02;C02AC01;S01EA04
clopidogrel,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Angina unstable;Arteriosclerosis;Atherosclerosis;Atrial fibrillation;Cerebrovascular accident;Cerebrovascular disorder;Coronary artery disease;Electrocardiogram ST segment elevation;Embolism;Haemoglobin;Haemorrhage;Infarction;Ischaemia;Ischaemic stroke;Myocardial infarction;Nephritic syndrome;Neutropenia;Non-Q wave MI;Peripheral arterial disease;Peripheral arterial occlusive disease;Thrombocytopenia;Thromboembolic event,Abdominal distension;Abdominal pain;Abdominal pain upper;Acquired haemophilia;Acute hepatic failure;Agranulocytosis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anxiety;Aplastic anaemia;Arterial thrombosis;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Atherothrombosis;Autonomic neuropathy;Back pain;Bladder pain;Bleeding time prolonged;Blindness;Blood and lymphatic system disorders;Blood creatine increased;Blood creatinine increased;Blood disorder;Blood uric acid increased;Body temperature increased;Bone disorder;Bronchitis;Bronchospasm;Bullous eruption;Cardiac failure;Cardiovascular disorder;Cataract;Cerebral haemorrhage;Chest pain;Claudication;Clotting;Coagulopathy;Colitis;Colitis microscopic;Confusional state;Conjunctivitis;Constipation;Contusion;Cough;Cramps of lower extremities;Creatinine increased;Cross reactive drug hypersensitivity;Cystitis;Cystitis noninfective;Deafness;Decompensation cardiac;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Disorder sight;Dizziness;Drug eruption;Drug hypersensitivity;Drug interaction;Drug reaction with eosinophilia and systemic symptoms;Drug-induced hypersensitivity syndrome;Duodenal ulcer;Duodenitis haemorrhagic;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Ecchymosis;Eczema;Eosinophilia;Eosinophilic pneumonia;Epigastric distress;Epistaxis;Erythema multiforme;Exfoliative rash;Eye bleeding;Eye disorder;Eye haemorrhage;Factor VIII deficiency;Fatal outcomes;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Food allergy;Gastric ulcer;Gastric ulcer perforation;Gastritis;Gastritis haemorrhagic;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal ulcer haemorrhage;Generalised oedema;Glomerulonephritis;Glucose-6-phosphate dehydrogenase deficiency;Gout;Gravitational oedema;Haemarthrosis;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolysis;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhagic stroke;Haemothorax;Hallucination;Headache;Hearing impaired;Henoch-Schonlein purpura;Hepatic enzyme increased;Hepatic function abnormal;Hepatic steatosis;Hepatitis;Hepatitis A;Hepatobiliary disease;Hernia;Hyperbilirubinaemia;Hypercholesterolaemia;Hypersensitivity;Hypertension;Hyperuricaemia;Hypoaesthesia;Hypochromic anaemia;Hypoglycaemia;Hypotension;Immune system disorder;Infection;Inflicted injury;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Intermittent claudication;Interstitial lung disease;Interstitial pneumonia;Intestinal perforation;Intestinal ulcer;Iron deficiency anaemia;Kidney function abnormal;Leukaemia;Leukopenia;Lichen planus;Liver fatty;Liver function test abnormal;Liver injury;Loss of consciousness;Lymphocytic colitis;Malnutrition;Mediastinal disorder;Menorrhagia;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Necrosis ischaemic;Nephritic syndrome;Nervous system disorder;Neuralgia;Neuropathy peripheral;Neutropenia;Neutrophil count decreased;Non-cardiogenic pulmonary oedema;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Osteoarthritis;Osteonecrosis;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Peptic ulcer;Peripheral ischaemia;Peritoneal haemorrhage;Platelet count decreased;Pneumonia;Pruritus;Pruritus generalised;Pulmonary embolism;Pulmonary haemorrhage;Puncture site haemorrhage;Purpura;Rash;Rash erythematous;Rash maculo-papular;Red blood cell disorders;Renal colic;Renal failure;Renal failure acute;Renal impairment;Respiratory tract haemorrhage;Retinal haemorrhage;Retroperitoneal haemorrhage;Rhinitis;Serum sickness;Shock;Sinusitis;Skin bleeding;Skin disorder;Skin haemorrhage;Skin ulcer;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Surgery;Surgical intervention;Syncope;Taste disorders;Thrombotic thrombocytopenic purpura;Tinnitus;Toxic epidermal necrolysis;Traumatic liver injury;Ulcer;Ulcer haemorrhage;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Upper gastrointestinal symptoms;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular purpura;Vasculitis;Vasomotor rhinitis;Vertigo;Visual impairment;Vomiting,small molecule,approved,"(+)-Clopidogrel; Clopidogrel; Clopidogrelum; ADP-glucose receptor; ADPG-R; HORK3; P2T(AC); P2Y(AC); P2Y(ADP); P2Y(cyc); P2Y12; P2Y12 platelet ADP receptor; SP1999; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2",P2Y purinoceptor 12,B01AC04
clorazepate,Alcohol withdrawal syndrome;Anxiety;Anxiety disorder;Epilepsy;Partial seizures;Tension,Asthenia;Ataxia;Blood pressure systolic decreased;Confusional state;Dermatitis;Diplopia;Dizziness;Drowsiness;Dry mouth;Dysarthria;Fatigue;Feeling abnormal;Haematocrit decreased;Headache;Insomnia;Irritability;Nervousness;Rash;Slurred speech;Somnolence;Tension;Tremor;Vision blurred,small molecule,approved,Loracepam; Lorazepam; o-Chlorooxazepam; o-Chloroxazepam; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8,Translocator protein; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site, N05BA06;N05BA56
clotrimazole,Balanitis candida;Body tinea;Candida infection;Erythrasma;Genital candidiasis;Immunocompromised;Immunodeficiency;Infection;Leukaemia;Neoplasm;Oropharyngeal candidiasis;Paronychia;Pruritus;Skin candida;Solid tumour;Tinea cruris;Tinea pedis;Tinea versicolour;Vaginal discharge;Vaginal moniliasis;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,Abdominal bloating;Abdominal cramps;Abdominal distension;Abdominal pain;Aspartate aminotransferase increased;Bladder pain;Blister;Burning feeling vagina;Burning sensation;Cramp muscle;Cystitis;Cystitis noninfective;Dermatitis;Dermatitis bullous;Erythema;Flatulence;Haemoglobin;Haemorrhage;Liver function test abnormal;Localized exfoliation;Muscle spasms;Nausea;Oedema;Pain;Pollakiuria;Rash;Redness;Skin exfoliation;Skin irritation;Stinging;Urticaria;Vomiting;Vulvovaginal burning sensation,small molecule,approved; vet_approved,"1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole; 1-(o-Chloro-α,α-diphenylbenzyl)imidazole; 1-(o-Chlorotrityl)imidazole; 1-(α-(2-Chlorophenyl)benzhydryl)imidazole; Clotrimazol; Clotrimazole; Clotrimazolum; CDw128b; CXC-R2; CXCR-2; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8 receptor type 2; IL-8R B; IL8RB; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase; Gardos channel; hIK1; hKCa4; hSK4; IK1; IKCA1; KCa3.1; KCA4; Putative Gardos channel; SK4; SKCa 4; SKCa4; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; G-protein coupled receptor 109A; G-protein coupled receptor HM74A; GPR109A; HCA2; HM74A; Niacin receptor 1; NIACR1; Nicotinic acid receptor; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",C-X-C chemokine receptor type 2; Lanosterol 14-alpha demethylase; Intermediate conductance calcium-activated potassium channel protein 4; Ergosterol; Nuclear receptor subfamily 1 group I member 2; Hydroxycarboxylic acid receptor 2, A01AB18; G01AF02; G01AF20;A01AB18;D01AC01
clozapine,Agranulocytosis;Cardiac arrest;Cardiovascular disorder;Completed suicide;Convulsion;Convulsions generalised;Diarrhoea;Epilepsy;Headache;Hyperglycaemia;Leukopenia;Myocarditis;Myoclonus;Nausea;Neutropenia;Psychotic disorder;Schizoaffective disorder;Schizophrenia;Suicidal behaviour;Suicide;Tardive dyskinesia;Vomiting,"Abdominal discomfort;Abdominal distension;Abnormal ejaculation;Abnormal faeces;Ache;Acute coronary syndrome;Acute interstitial nephritis;Agitation;Akathisia;Akinesia;Amnesia;Anaemia;Angina pectoris;Angle closure glaucoma;Anorexia;Anxiety;Aphasia;Areflexia;Arrhythmia;Arthralgia;Asthenia;Ataxia;Atrioventricular block;Block heart;Blood and lymphatic system disorders;Blood triglycerides increased;Blood uric acid increased;Bloodshot eye;Body temperature decreased;Body temperature increased;Bone marrow disorder;Bradycardia;Breast pain;Bronchitis;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiomyopathy;Cataplexy;Chest pain;Chills;Cholestasis;Cholinergic syndrome;Coma;Confusional state;Constipation;Contusion;Convulsion;Cough;Cyanosis;Decreased appetite;Deep vein thrombosis;Delirium;Delusion;Dementia;Depression;Dermatitis;Diabetes mellitus;Diabetic hyperosmolar coma;Diarrhoea;Discomfort;Disorder sight;Diuresis;Dizziness;Drowsiness;Drug abuse;Dry mouth;Dry throat;Dysarthria;Dysgeusia;Dyskinesia;Dyslipidaemia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphemia;Dyspnoea;Ear disorder;Eczema;Ejaculation disorder;Electrocardiogram change;Electroencephalogram abnormal;Embolism;Embolism venous;Enuresis;Eosinophilia;Epilepsy;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eyelid disorder;Faecalith;Faecaloma;Fatigue;Feeling abnormal;Foetor hepaticus;Gastric ulcer;Gastroenteritis;Gastrointestinal disorder;Glucose tolerance impaired;Haematemesis;Haemoglobin increased;Hallucination;Headache;Heart disease congenital;Heart malformation;Heartburn;Hepatic cirrhosis;Hepatic enzyme increased;Hepatic failure;Hepatic fibrosis;Hepatic necrosis;Hepatic steatosis;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hot flush;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypokinesia;Hyponatraemia;Hypotension;Hypothermia;Ileus;Ileus paralytic;Ill-defined disorder;Incontinence;Increased appetite;Infection;Insomnia;Insomnia NEC;Intestinal obstruction;Irritability;Jaundice;Jaundice cholestatic;Ketoacidosis;Laryngitis;Lethargy;Leukocytosis;Leukopenia;Liver disorder;Liver injury;Loss of consciousness;Lower respiratory tract infection;Malaise;Malnutrition;Memory loss;Menopausal symptoms;Mental disorder;Micturition urgency;Mitral valve incompetence;Movements involuntary;Muscle rigidity;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenic syndrome;Mydriasis;Myocardial infarction;Myoclonus;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm malignant;Nephritis interstitial;Nervous system disorder;Neuroleptic malignant syndrome;Neutropenia;Nightmare;Nocturnal enuresis;Numbness;Nystagmus;Ocular hyperaemia;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Osteoarthritis;Pain;Pallor;Palpitations;Pancreatitis;Pancreatitis acute;Paraesthesia;Paranoia;Parkinsonism;Parotid gland enlargement;Pericardial effusion;Pericarditis;Periorbital oedema;Petechiae;Phenylketonuria;Phlebitis;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pneumonia;Pneumonia aspiration;Pollakiuria;Polydipsia;Polyuria;Priapism;Pruritus;Psychotic disorder;Pulmonary embolism;Pulmonary function test decreased;Rash;Reaction gastrointestinal;Rectal haemorrhage;Red blood cell sedimentation rate increased;Renal failure;Respiratory arrest;Respiratory depression;Rhabdomyolysis;Rhinorrhoea;Salivary gland enlargement;Salivary gland swelling;Salivary hypersecretion;Salivation;Sensory loss;Sepsis;Shakiness;Shock;Skin disorder;Slurred speech;Sneezing;Somnolence;Speech loss;Status epilepticus;Stevens-Johnson syndrome;Stuttering;Sudden death;Sudden death, cause unknown;Suicidal ideation;Sweating;Syncope;Tachycardia;Tardive dyskinesia;Taste bitter;Tenderness;Throat sore;Throat tightness;Thrombocytopenia;Thrombocytosis;Thromboembolism;Thrombophlebitis;Torsade de pointes;Toxicity to various agents;Traumatic liver injury;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary abnormalities;Urinary incontinence;Urinary retention;Urinary tract disorder;Urticaria;Vaginal itching;Vasculitis;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal pruritus;Weight decreased;Weight increased;Wheezing;White blood cell count decreased",small molecule,approved,"Clozapin; Clozapina; Clozapine; Clozapinum; Dopamine D2 receptor; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; Dopamine D1 receptor; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-6; 5-HT6; Serotonin receptor 6; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; H1-R; H1R; HH1R; AXOR35; G-protein coupled receptor 105; GPCR105; GPRv53; H4R; HH4R; Pfi-013; SP9144; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; DRD1IP; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; GABA-B receptor 1; GABA-B-R1; GABA-BR1; GABABR1; Gb1; GPRC3A; G-protein coupled receptor 51; GABA-B receptor 2; GABA-B-R2; GABA-BR2; GABABR2; Gb2; GPR51; GPRC3B; HG20; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3",D(2) dopamine receptor; 5-hydroxytryptamine receptor 2A; D(1A) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; D(1B) dopamine receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1E; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; Alpha-2C adrenergic receptor; Histamine H1 receptor; Histamine H4 receptor; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; Neuron-specific vesicular protein calcyon; Glutathione S-transferase P; Gamma-aminobutyric acid type B receptor subunit 1; Gamma-aminobutyric acid type B receptor subunit 2; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit beta-1; Gamma-aminobutyric acid receptor subunit gamma-1,N05AH02
codeine,Cough;Diarrhoea;Dry cough;Headache;Pain;Postoperative pain;Procedural pain,Abdominal cramps;Abdominal discomfort;Abdominal pain;Affect lability;Agitation;Angioedema;Anorexia;Anxiety;Asthenia;Biliary colic;Body temperature decreased;Body temperature increased;Bone disorder;Bradycardia;Breast disorder;Cardiac arrest;Cardiac disorder;Cardiovascular insufficiency;Central nervous system stimulation;Circulatory depression;Confusional state;Constipation;Convulsion;Cramp muscle;Decreased appetite;Dehydration;Depression;Dermatitis;Diplopia;Discomfort;Distress gastrointestinal;Diuretic effect;Dizziness;Drowsiness;Drug withdrawal syndrome;Dry mouth;Dysphoria;Dyspnoea;Erythema;Euphoric mood;Excitation cerebral;Excitement;Eye disorder;Fatigue;Feeling abnormal;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Hyperhidrosis;Hypersensitivity;Hypotension;Hypothermia;Ill-defined disorder;Immune system disorder;Insomnia;Intracranial pressure increased;Irritability;Lacrimation;Lacrimation increased;Lightheadedness;Loss of consciousness;Loss of libido;Malaise;Mediastinal disorder;Miosis;Mood swings;Muscle rigidity;Muscle spasms;Mydriasis;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Nightmare;Orthostatic hypotension;Palpitations;Pancreatitis;Piloerection;Polyuria;Pruritus;Pulmonary function test decreased;Rash;Redness;Respiratory arrest;Respiratory depression;Rhinorrhoea;Shakiness;Shock;Sneezing;Somnolence;Spasm biliary;Sweating;Sweating increased;Syncope;Tachycardia;Tension;Tremor;Ureteral spasm;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;Vertigo;Visual disturbance;Visual impairment;Vomiting;Withdrawal symptom;Withdrawal syndrome;Yawning,small molecule,approved; illicit,"(−)-Codeine; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; 7,8-didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol; Codein; Codeína; Codéine; Codeine anhydrous; Codeine polistirex; Codeinum; L-Codeine; Methylmorphine; morphine 3-methyl ether; Morphine monomethyl ether; morphine-3-methyl ether; O3-Methylmorphine; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; K-OR-1; KOR-1; OPRK; D-OR-1; DOR-1; OPRD; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; hOCT1; OCT1; Organic cation transporter 1",Mu-type opioid receptor; Kappa-type opioid receptor; Delta-type opioid receptor, N02AA59; N02AJ06; N02AJ07; N02AJ08; R05DA04;N02AA79;R05DA04
colchicine,Diarrhoea;Gout;Gout acute;Gout flare,Abdominal cramps;Abdominal discomfort;Abdominal pain;Acute respiratory distress syndrome;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Angioedema;Anuria;Aplastic anaemia;Appetite absent;Arthralgia;Aspartate aminotransferase increased;Asthenia;Axonal neuropathy;Azoospermia;Bladder pain;Bladder spasm;Blood creatine phosphokinase increased;Blood creatinine increased;Blood disorder;Cramp muscle;Creatine phosphokinase increased;Creatinine increased;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Disseminated intravascular coagulation;Eye disorder;Fatigue;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal symptom NOS;Gout;Haematuria;Headache;Hepatic function abnormal;Hepatocellular injury;Hypersensitivity;Hypoaesthesia;Hypotension;Hypothyroidism;Ileus paralytic;Lactase deficiency;Lactose intolerance;Laryngeal pain;Leukopenia;Liver injury;Malabsorption;Malnutrition;Mediastinal disorder;Metabolic acidosis;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myelosuppression;Myopathy;Myotonia;Nausea;Nervous system disorder;Neuritis;Neuropathy peripheral;Neutropenia;Numbness in fingers;Oligospermia;Oliguria;Pancytopenia;Peripheral motor neuropathy;Pharyngolaryngeal pain;Prostration;Purpura;Purpura non-thrombocytopenic;Rash;Rash maculo-papular;Rhabdomyolysis;Shock;Skin disorder;Steatorrhoea;Stomatitis;Thrombocytopenia;Ulcerative keratitis;Urticaria;Vascular purpura;Vomiting,small molecule,approved,"Colchicin; Colchicina; Colchicine; Colchicinum; TUBB5; Tubulin beta-5 chain; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Tubulin beta chain, M04AC01;M04AC01;M04AC51
cyanocobalamin,"Acquired immunodeficiency syndrome;Anaemia;Autoimmune disorder;Coeliac disease;Crohn's disease;Diphyllobothriasis;Drug interaction;Endocrine disorder;Folate deficiency;Gastritis atrophic;Gluten free diet;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hyperthyroidism;Ileitis regional;Intestinal parasitism, unspecified;Iron deficiency;Malabsorption;Malnutrition;Multiple sclerosis;Neoplasm;Neoplasm malignant;Nephropathy;Overgrowth bacterial;Parasitic gastroenteritis;Pathogen resistance;Pernicious anaemia;Sprue;Stasis syndrome;Thyrotoxicosis;Tropical sprue;Vegetarian;Vitamin B12 deficiency",Anaphylactic shock;Anxiety;Arthritis;Asthenia;Back pain;Cardiac failure congestive;Coordination abnormal;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Dyspnoea;Gait disturbance;Generalized aching;Glossitis;Headache;Hypoaesthesia;Infection;Musculoskeletal discomfort;Myalgia;Nausea;Nervousness;Pain;Paraesthesia;Peripheral vascular disorder;Polycythaemia vera;Pruritus;Pulmonary oedema;Rash;Rhinitis;Swelling;Tension;Thrombosis;Vomiting,small molecule,approved; nutraceutical,Cianocobalamina; Cyanocob(III)alamin; Cyanocobalamin; Cyanocobalamine; Cyanocobalaminum; Vitamin B12; Vitamin B12 complex; Vitamin B12 NOS; 2.1.1.13; 5-methyltetrahydrofolate--homocysteine methyltransferase; Cobalamin-dependent methionine synthase; MS; Vitamin-B12 dependent methionine synthase; 5.4.99.2; MCM; Methylmalonyl-CoA isomerase; MUT; 1.16.1.8; AqCbl reductase; Aquacobalamin reductase; MSR; 3.6.-.-; Alkylcobalamin:glutathione S-alkyltransferase; CblC; Cyanocobalamin reductase (cyanide-eliminating); Methylmalonic aciduria and homocystinuria type C protein; MMACHC; 1.5.1.53; 2.5.1.-; ATP:co(I)rrinoid adenosyltransferase MMAB; Methylmalonic aciduria type B protein; Adenosylcobinamide kinase; Adenosylcobinamide-phosphate guanylyltransferase; Haptocorrin; HC; Protein R; TC I; TC-1; TC1; TCI; Transcobalamin I; TC II; TC-2; TC2; TCII; Transcobalamin II; Gastric intrinsic factor; GIF; IF; IFMH; INF; Intrinsic factor; 460 kDa receptor; IFCR; Intestinal intrinsic factor receptor; Intrinsic factor-cobalamin receptor; Intrinsic factor-vitamin B12 receptor; Glycoprotein 330; gp330; LRP-2; Megalin; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1,"Methionine synthase; Methylmalonyl-CoA mutase, mitochondrial; Methionine synthase reductase; Methylmalonic aciduria type A protein, mitochondrial; Cyanocobalamin reductase / alkylcobalamin dealkylase; Methylenetetrahydrofolate reductase (NADPH)", B03AE01; B03BA51;B03BA01
cyclobenzaprine,Central nervous system disorder;Cerebral palsy;Muscle spasms;Muscle spasticity;Nervous system disorder;Pain;Spinal cord disorder;Tenderness,Abdominal pain;Accommodation disorder;Acne;Acute coronary syndrome;Ageusia;Aggression;Agitation;Agranulocytosis;Alopecia;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Arrhythmia;Asthenia;Ataxia;Atrioventricular block;Bell's palsy;Black hairy tongue;Block heart;Bone marrow depression;Breast enlargement;Cerebration impaired;Cerebrovascular accident;Chest pain;Cholestasis;Confusional state;Constipation;Convulsion;Coordination abnormal;Decreased appetite;Delusion;Depressed mood;Dermatitis;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug withdrawal syndrome;Dry mouth;Dry throat;Dysarthria;Dysgeusia;Dyspepsia;Dyspnoea;Eosinophilia;Epigastric distress;Erectile dysfunction;Euphoric mood;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Face oedema;Fatigue;Feeling abnormal;Flatulence;Gait disturbance;Galactorrhoea;Gastritis;Gastrointestinal pain;Gynaecomastia;Hallucination;Headache;Hepatic function abnormal;Hepatitis;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypotension;Ileus paralytic;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Insomnia;Irritability;Jaundice;Leukopenia;Libido decreased;Libido increased;Loss of consciousness;Malaise;Mental disability;Muscle twitching;Musculoskeletal discomfort;Myalgia;Mydriasis;Myocardial infarction;Nausea;Nervousness;Neuroleptic malignant syndrome;Neuropathy peripheral;Nightmare;Numbness;Oedema;Osteoarthritis;Palpitations;Pancytopenia;Paraesthesia;Paranoia;Parotid gland enlargement;Parotid swelling;Pharyngitis;Pollakiuria;Pruritus;Psychotic disorder;Purpura;Rash;Regurgitation;Sensory loss;Serotonin syndrome;Shock;Somnolence;Stomatitis;Sweating;Swollen tongue;Syncope;Tachycardia;Tension;Testicular swelling;Thinking abnormal;Thirst;Thrombocytopenia;Tingling of extremity;Tinnitus;Tongue coated;Tongue discolouration;Tongue disorder;Tongue oedema;Tremor;Upper respiratory tract infection;Urinary retention;Urticaria;VIIth nerve paralysis;Vascular purpura;Vertigo;Vision blurred;Vomiting;Weight increased;Withdrawal symptom,small molecule,approved,"(3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine; Ciclobenzaprina; Cyclobenzaprine; Cyclobenzaprinum; N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamine; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-6; 5-HT6; Serotonin receptor 6; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; hToll; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; UDPGT 2B10",Alpha-2C adrenergic receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 6; Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; 5-hydroxytryptamine receptor 7; Toll-like receptor 4; Aldehyde oxidase,M03BX08
cyclopentolate,Accommodation disorder;Cycloplegia;Mydriasis,Abdominal distension;Agitation;Anterior uveitis;Ataxia;Blepharoconjunctivitis;Choroiditis;Coma;Conjunctivitis;Conjunctivitis allergic;Convulsion;Coordination abnormal;Dermatitis;Disorientation;Drowsiness;Dry mouth;Eye redness;Flushing;Gastroenteritis;Hallucination;Hyperaemia;Hyperkinesia;Hyperpyrexia;Incoherent;Intraocular pressure increased;Iridocyclitis;Iris adhesions;Lacrimation;Lacrimation increased;Ocular hyperaemia;Paralysis;Photophobia;Posterior synechiae of iris;Posterior uveitis;Pruritus;Psychotic disorder;Punctate keratitis;Rash;Somnolence;Tachycardia;Tremor;Urinary retention;Vasodilation;Vasodilation procedure;Vertigo;Vision blurred,small molecule,approved,(±)-cyclopentolate; 1-hydroxy-α-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid β-(dimethylamino)ethyl ester; Ciclopentolato; Cyclopentolate; Cyclopentolatum; α-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; β-(dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; β-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase,Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M5, S01FA04;S01FA04;S01FA54
cyclophosphamide,Acute leukaemia;Acute myeloid leukaemia;Acute myelomonocytic leukaemia;Aplastic anaemia;Autoimmune disorder;B-cell lymphoma;Bladder cancer;Brain neoplasm malignant;Breast cancer;Burkitt's lymphoma;Carcinoma breast;Cardiac disorder;Cervix carcinoma;Chronic lymphocytic leukaemia;Chronic myeloid leukaemia;Diffuse large B-cell lymphoma;Endometrial cancer;Ewing's sarcoma;Gestational trophoblastic tumour;Granulomatosis with polyangiitis;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Leukaemia;Leukaemia monocytic;Lung neoplasm malignant;Lymphoblastic lymphoma;Lymphoma;Lymphoproliferative disorder;Mediastinal disorder;Mycosis fungoides;Neoplasm;Neoplasm malignant;Nephrotic syndrome;Neuroblastoma;Neutropenia;Nodular lymphoma;Non-Hodgkin's lymphoma;Osteosarcoma;Ovarian adenocarcinoma;Ovarian epithelial cancer;Plasma cell myeloma;Plasmacytoma;Renal failure;Renal impairment;Retinoblastoma;Rhabdomyosarcoma;Sarcoma;Testis cancer;Thymoma;Transplant rejection;Viral infection;Waldenstrom's macroglobulinaemia;Wegener's granulomatosis;X-linked lymphoproliferative syndrome,Abdominal discomfort;Acute cardiac toxicity;Acute coronary syndrome;Acute leukaemia;Acute respiratory distress syndrome;Agitation;Agranulocytosis;Alopecia;Alveolitis allergic;Amenorrhoea;Anaemia;Anaphylactic shock;Anorexia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Ascites;Asthenia;Atrial fibrillation;Azoospermia;Bacterial colonisation;Bacterial disease carrier;Bacterial infection;Bladder cancer;Bladder carcinoma;Bladder fibrosis;Bladder necrosis;Bladder pain;Bladder spasm;Blister;Blood bilirubin increased;Blood glucose decreased;Blood glucose increased;Blood lactate dehydrogenase increased;Blood uric acid increased;Body temperature increased;Bradycardia;Bronchospasm;C-reactive protein increased;Caecitis;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Cardiac tamponade;Cardiogenic shock;Cardiomyopathy;Cardiomyopathy secondary NOS;Cardiotoxicity;Carditis;Chemical cystitis;Chest pain;Chills;Cholestasis;Colitis;Confusional state;Congenital anomaly;Conjunctivitis;Constipation;Convulsion;Cough;Cystitis;Cystitis haemorrhagic;Cystitis interstitial;Cystitis noninfective;Cytolytic hepatitis;Deafness;Decompensation cardiac;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatomyositis;Developmental delay;Diabetes mellitus;Diarrhoea;Discomfort;Disseminated intravascular coagulation;Diuresis;Dizziness;Drug interaction;Dry cough;Dysaesthesia;Dysgeusia;Dyspnoea;Embolism;Embolism venous;Encephalopathy;Enteritis;Enterocolitis;Enterocolitis haemorrhagic;Erythema;Erythema multiforme;Extravasation;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Fibrosis;Fluid overload;Fluid retention;Flushing;Foetal death;Gastroenteritis;Gastrointestinal haemorrhage;Generalized urticaria;Granulomatosis with polyangiitis;Growth retardation;Haematuria;Haemoglobin;Haemolytic anaemia;Haemolytic uraemic syndrome;Haemorrhage;Headache;Hearing impaired;Heart disease congenital;Heart malformation;Hemorrhagic colitis;Hepatic encephalopathy;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis cholestatic;Hepatitis viral;Hepatomegaly;Hepatotoxicity;Herpes zoster;Hot flush;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hyperuricaemia;Hypoaesthesia;Hypogeusia;Hyponatraemia;Hypotension;Hypothrombinaemia;Hypoxemia;Hypoxia;Ill-defined disorder;Impaired healing;Inappropriate antidiuretic hormone secretion;Infection;Infertility;Inflammation;Influenza like illness;Infusion site reactions;Injection site pain;Interstitial lung disease;Interstitial pneumonia;Jaundice;Lacrimation;Lacrimation increased;Leukopenia;Lung fibrosis interstitial;Lupus erythematosus;Lymphoma;Malaise;Malignant neoplasm of renal pelvis;Menopausal symptoms;Menorrhagia;Menstruation irregular;Metastatic neoplasm;Methaemoglobinaemia;Microscopic hematuria;Microsomia;Mouth ulceration;Mucosal inflammation;Multi-organ failure;Muscle contracture;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myelodysplastic syndrome;Myeloid leukaemia;Myeloproliferative disorder;Myelosuppression;Myocardial haemorrhage;Myocardial infarction;Myocardial necrosis;Myocarditis;Myopericarditis;Myopia;Myxoedema;Nail changes;Nail disorder;Nasal congestion;Nasal discomfort;Nasopharyngitis;Nausea;Necrosis;Neoplasm;Neoplasm malignant;Nephrogenic diabetes insipidus;Nephropathy toxic;Nephrotoxicity;Neuralgia;Neuropathy peripheral;Neurotoxicity;Non-Hodgkin's lymphoma;Obliterative bronchiolitis;Obstipation;Oedema;Oligomenorrhoea;Oligospermia;Oral mucosa sore;Organising pneumonia;Oropharyngeal pain;Ovarian atrophy;Ovarian disorder;Ovarian failure;Pain;Palmar-plantar erythema;Palmar-plantar erythrodysaesthesia syndrome;Palpitations;Pancreatitis acute;Pancytopenia;Paraesthesia;Parosmia;Parotid gland inflammation;Pericardial effusion;Pericardial haemorrhage;Pericarditis;Peripheral ischaemia;Phlebitis;Pigmentation disorder;Pigmentation skin;Platelet count decreased;Pleural effusion;Pneumonia;Polyneuropathy;Polyuria;Posterior reversible encephalopathy syndrome;Pregnancy;Premature labour;Prolonged menses;Prurigo;Pruritus;Pulmonary embolism;Pulmonary haemorrhage;Pulmonary hypertension;Pulmonary oedema;Pulmonary toxicity;Pulmonary veno-occlusive disease;Radiation injury;Radiation recall reaction (dermatologic);Rales;Rash;Recall phenomenon;Redness;Renal cell carcinoma;Renal failure;Renal failure acute;Renal impairment;Renal tubular disorder;Renal tubular necrosis;Respiratory distress;Respiratory failure;Rhabdomyolysis;Rhinitis;Rhinorrhoea;Sarcoma;Scleroderma;Sepsis;Septic shock;Shock;Sinus congestion;Skin hyperpigmentation;Sneezing;Spinal cord disorder;Stevens-Johnson syndrome;Stillbirth;Stomatitis;Sweating;Sweating increased;Swelling;Swelling face;Systemic lupus erythematosus;Tachycardia;Telangiectasia;Tenderness;Testicular atrophy;Thrombocytopenia;Thromboembolism;Thrombosis;Thrombotic microangiopathy;Tinnitus;Toxic epidermal necrolysis;Toxic skin eruption;Tremor;Tuberculosis;Tumour lysis syndrome;Ulcer;Ureteric cancer;Ureteric obstruction;Ureteritis;Urine flow decreased;Urine output;Urticaria;Vasculitis;Venoocclusive disease;Venoocclusive liver disease;Venous thrombosis;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Viral infection;Vision blurred;Visual impairment;Vomiting;Water intoxication;Water retention;Wegener's granulomatosis;Weight increased;Wound;Wound healing normal,small molecule,approved; investigational,"(+-)-Cyclophosphamide; (±)-2-(BIS(2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE MONOHYDRATE; (RS)-Cyclophosphamide; 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide; Anhydrous cyclophosphamide; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; Ciclofosfamida; Ciclofosfamide; Cyclophosphamid; Cyclophosphamide; Cyclophosphamide anhydrous; Cyclophosphamidum; Cytophosphane; N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase",DNA; Nuclear receptor subfamily 1 group I member 2,L01AA01
cyproheptadine,Anaphylactic shock;Angioedema;Cold urticaria;Conjunctivitis;Conjunctivitis allergic;Hypersensitivity;Mechanical urticaria;Rhinitis allergic;Rhinitis seasonal;Seasonal allergy;Urticaria;Urticaria physical;Vasomotor rhinitis,Agitation;Agranulocytosis;Anorexia;Asthenia;Chest discomfort;Chest tightness;Chills;Cholestasis;Confusional state;Constipation;Conversion disorder;Convulsion;Decreased appetite;Dermatitis;Diarrhoea;Diplopia;Dizziness;Drowsiness;Dyspepsia;Epigastric distress;Euphoric mood;Extrasystoles;Fatigue;Feeling abnormal;Haemolytic anaemia;Hallucination;Headache;Hepatic failure;Hepatitis;Hyperhidrosis;Hypotension;Hysteria;Increased appetite;Insomnia;Irritability;Jaundice;Labyrinthitis;Leukopenia;Loss of consciousness;Nasal congestion;Nasal dryness;Nausea;Nervousness;Neuritis;Neuropathy peripheral;Oedema;Palpitations;Paraesthesia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Rash;Shock;Somnolence;Sweating increased;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Tremor;Urinary retention;Urticaria;Vertigo;Vision blurred;Vomiting;Weight increased;Wheezing,small molecule,approved,"1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine; 5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene; Ciproheptadina; Cyproheptadin; Cyproheptadine; Cyproheptadinum; H1-R; H1R; HH1R; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; Gastric receptor I; H2R; HH2R; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; UDPGT 2B10; hOCT1; OCT1; Organic cation transporter 1",Histamine H1 receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2C; Histamine H2 receptor; 5-hydroxytryptamine receptor 2B; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; 5-hydroxytryptamine receptor 7,R06AX02
danazol,Angioedema;Breast disorder;Breast pain;Diabetes mellitus;Diabetic;Endometriosis;Fibrocystic breast disease;Hereditary angioedema;Menorrhagia;Pain;Stress;Tenderness,Abdominal pain upper;Acne;Acute coronary syndrome;Affect lability;Alopecia;Amenorrhoea;Anxiety;Arterial thrombosis;Arthralgia;Asthenia;Back pain;Bartholin's cyst;Benign intracranial hypertension;Blood insulin increased;Body temperature increased;Breast discharge;Carpal tunnel syndrome;Cataract;Chills;Constipation;Convulsion;Cramp muscle;Dermatitis;Dizziness;Dyspepsia;Dysphonia;Eosinophilia;Epigastric pain;Epilepsy;Erythema multiforme;Erythrocytosis;Fatigue;Fluid retention;Flushing;Gastroenteritis;Gingival bleeding;Guillain-Barre syndrome;Haematuria;Haemoglobin;Haemorrhage;Headache;Hepatic adenoma;Hepatic function abnormal;Hepatic neoplasm;Hirsutism;Hoarseness;Hyperhidrosis;Hyperinsulinism;Hypertension;Hypertrophy;Interstitial lung disease;Interstitial pneumonia;Irritability;Jaundice;Jaundice cholestatic;Joint lock;Joint swelling;Laboratory test abnormal;Leukocytosis;Leukopenia;Loss of consciousness;Migraine;Mood swings;Muscle spasms;Musculoskeletal discomfort;Myocardial infarction;Nasal congestion;Nausea;Nervousness;Nodule;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Palpitations;Pancreatitis;Paraesthesia;Peliosis hepatis;Pelvic pain;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Pleuritic pain;Polycythaemia;Pruritus;Rash;Seborrhoeic dermatitis;Shock;Sleep disorder;Splenic peliosis;Stevens-Johnson syndrome;Sweating;Syncope;Tachycardia;Tension;Testicular atrophy;Throat sore;Thrombocytopenia;Thrombosis;Tremor;Tremor muscle;Urticaria;Vaginal dryness;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal dryness;Weight increased,small molecule,approved,"Danazol; Danazolum; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; GnRH receptor; GnRH-R; GRHR; GnRH II receptor; GnRH-II-R; Type II GnRH receptor; HC11; MCAF; MCP-1; MCP1; Monocyte chemoattractant protein 1; Monocyte chemotactic and activating factor; Monocyte chemotactic protein 1; Monocyte secretory protein JE; SCYA2; Small-inducible cytokine A2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin",Estrogen receptor; Androgen receptor; Progesterone receptor; Gonadotropin-releasing hormone receptor; Putative gonadotropin-releasing hormone II receptor; C-C motif chemokine 2,G03XA01
dantrolene,Body temperature increased;Carbon dioxide increased;Cerebral palsy;Cerebrovascular accident;Clonus;Cyanosis;Hypercapnia;Hypermetabolism;Immobile;Metabolic acidosis;Multiple sclerosis;Muscle rigidity;Muscle spasticity;Neuroleptic malignant syndrome;Spinal cord injury;Tachycardia;Tachypnoea,Abdominal cramps;Abdominal pain;Acne;Anaemia;Anaphylactic shock;Anorexia;Aplastic anaemia;Asthenia;Atrioventricular block;Back pain;Body temperature increased;Cardiac failure;Chills;Choking sensation;Chromaturia;Coagulopathy;Confusional state;Constipation;Convulsion;Crystalluria;Decreased appetite;Depression;Dermatitis;Diarrhoea;Diplopia;Discomfort;Dizziness;Drooling;Drowsiness;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Eosinophilia;Epigastric discomfort;Eruption;Erythema;Extravasation;Fatigue;Feeling abnormal;Flushing;Gastric irritation;Gastrointestinal haemorrhage;Gastrointestinal pain;Haematuria;Haemoglobin;Haemorrhage;Hair growth abnormal;Headache;Hepatic failure;Hepatitis;Hepatotoxicity;Hyperhidrosis;Hypersensitivity;Hypertension;Ill-defined disorder;Infusion site pain;Injection site reaction;Insomnia;Intestinal obstruction;Lacrimation increased;Leukopenia;Lightheadedness;Lymphoma;Malaise;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nausea;Necrosis;Nervousness;Nocturia;Non-Hodgkin's lymphoma;Pain;Pain in extremity;Pericarditis;Phlebitis;Pleural effusion;Pollakiuria;Pruritus;Pulmonary function test decreased;Pulmonary oedema;Rash;Renal failure;Respiratory depression;Respiratory failure;Somnolence;Speech disorder;Speech impairment NOS;Sweating;Swelling;Tachycardia;Tension;Thrombocytopenia;Thrombophlebitis;Urinary incontinence;Urinary retention;Urticaria;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin; Dantrolene; Dantroleno; Dantrolenum; RYDR; RYR-1; RyR1; Skeletal muscle calcium release channel; Skeletal muscle ryanodine receptor; Skeletal muscle-type ryanodine receptor; Type 1 ryanodine receptor; Serpin A7; T4-binding globulin; TBG,Ryanodine receptor 1,M03CA01
dapsone,Acne;Acne vulgaris;Dermatitis herpetiformis;Leprosy;Sensitisation,Abdominal pain;Albuminuria;Anoxia;Application site burn;Application site dryness;Application site erythema;Application site pain;Application site pruritus;Application site reaction;Body temperature increased;Cough;Drug-induced lupus erythematosus;Erythema;Gastrointestinal pain;Glucose-6-phosphate dehydrogenase deficiency;Headache;Hypoalbuminaemia;Infectious mononucleosis;Infertility male;Influenza;Insomnia;Joint sprain;Ligament sprain;Localized exfoliation;Lupus-like syndrome;Muscular weakness;Nasopharyngitis;Nausea;Nephrotic syndrome;Nerve injury;Neuropathy peripheral;Pancreatitis;Pharyngitis;Photosensitivity reaction;Phototoxicity;Protein urine present;Proteinuria;Psychotic disorder;Pulmonary eosinophilia;Renal papillary necrosis;Sinusitis;Skin exfoliation;Suicide attempt;Swelling face;Tachycardia;Tinnitus;Tonic clonic movements;Vertigo;Vision blurred;Vomiting,small molecule,approved; investigational,"1,1'-sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 4-(4-amino-benzenesulfonyl)-phenylamine; 4-(4-aminophenylsulfonyl)aniline; 4-(4-aminophenylsulfonyl)benzenamine; 4-aminophenyl sulfone; 4,4'-dapsone; 4,4'-diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl sulphone; 4,4'-Diaminodiphenylsulfone; 4,4'-sulfonylbisaniline; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonylbisbenzeneamine; 4,4'-Sulfonyldianilin; 4,4'-sulfonyldianiline; bis(4-aminophenyl)sulfone; Bis(p-aminophenyl) sulfone; DADPS; Dapsona; Dapsone; Dapsonum; DDS; Diaphenylsulfone; p-aminophenyl sulfone; p,p-sulphonylbisbenzamine; p,p-sulphonylbisbenzenamine; p,p'-diaminodiphenyl sulfone; DHPS 2; Dihydropteroate pyrophosphorylase 2; 2.5.1.15; DHPS; Dihydropteroate pyrophosphorylase; folP; 1.11.2.2; MPO; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.3.1.5; AAC2; Arylamide acetylase 2; N-acetyltransferase type 2; N-hydroxyarylamine O-acetyltransferase; NAT-2; PNAT; Polymorphic arylamine N-acetyltransferase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2",Inactive dihydropteroate synthase 2; Dihydropteroate synthase, D10AX05; J04BA02; J04BA51;D10AX05;J04BA50
anthracycline,Acute leukaemia;Acute lymphocytic leukaemia;Acute myeloid leukaemia;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Kaposi's sarcoma;Leukaemia;Lymphoma;Neoplasm;Neoplasm malignant;Neuroblastoma;Non-Hodgkin's lymphoma;Rhabdomyosarcoma,Abdominal pain;Abnormal vision;Acute cardiac toxicity;Acute coronary syndrome;Affect lability;Agitation;Alopecia;Alopecia reversible;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Anorectal discomfort;Anorexia;Anxiety;Arrhythmia;Arthralgia;Asthenia;Ataxia;Atrial fibrillation;Atrioventricular block;Back pain;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bundle branch block;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac tamponade;Cardiomyopathy;Cardiotoxicity;Cellulitis;Chest discomfort;Chest pain;Chest tightness;Chills;Confusional state;Conjunctivitis;Constipation;Convulsion;Cough;Deafness;Decreased appetite;Dehydration;Dental caries;Depression;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Electrocardiogram abnormal;Electrocardiogram change;Erythema;Extravasation;Eye pain;Fatigue;Febrile neutropenia;Feeling abnormal;Flushing;Folliculitis;Gait disturbance;Gastritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingival bleeding;Haemoptysis;Haemorrhoids;Hallucination;Headache;Hepatic function abnormal;Hepatic impairment;Hepatomegaly;Hiccups;Hot flush;Hyperhidrosis;Hyperkinesia;Hyperpyrexia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Ill-defined disorder;Increased appetite;Induration;Infection;Influenza like illness;Influenza-like symptoms;Injection site inflammation;Insomnia;Leukopenia;Liver disorder;Local reaction;Loss of consciousness;Lung infiltration;Lymphadenopathy;Malaise;Melaena;Meningitis;Menopausal symptoms;Mental disability;Mood swings;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Myelodysplastic syndrome;Myelosuppression;Myocardial infarction;Myocarditis;Nail changes;Nail disorder;Nausea;Necrosis;Neuropathy;Neuropathy peripheral;Neutropenia;Nocturia;Oedema;Oesophagitis;Opportunistic infection;Pain;Palpitations;Pancytopenia;Pericardial effusion;Pericarditis;Polyuria;Proctalgia;Pruritus;Pulmonary hypertension;Radiation recall reaction (dermatologic);Rash;Rash macular;Recall phenomenon;Rectal tenesmus;Red blotches;Renal failure;Renal impairment;Rhinitis;Rigors;Seborrhoeic dermatitis;Secondary infection;Shock;Sickness;Sinus tachycardia;Sinusitis;Skin hyperpigmentation;Somnolence;Splenomegaly;Stomatitis;Supraventricular tachycardia;Sweating increased;Syncope;Tachycardia;Thinking abnormal;Thirst;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tremor;Ulcer;Urine output increased;Urticaria;Ventricular extrasystoles;Viral infection;Visual impairment;Vomiting;Welts,small molecule,approved,Anthralin; Dithranol; Ditranol; CK-2e; Cytokeratin-2e; Epithelial keratin-2e; K2e; Keratin-2 epidermis; Keratin-2e; KRT2A; KRT2E; Type-II keratin Kb2; CK-12; Cytokeratin-12; K12; Keratin-12; IB-1; IB1; Islet-brain 1; JIP-1; JIP1; JNK MAP kinase scaffold protein 1; JNK-interacting protein 1; Mitogen-activated protein kinase 8-interacting protein 1; PRKM8IP,"Keratin, type II cytoskeletal 2 epidermal; Keratin, type I cytoskeletal 12; C-Jun-amino-terminal kinase-interacting protein 1", D05AC51;D05AC01;L01DB02
deferiprone,Anaemia;Cooley's anemia;Iron overload;Thalassaemia;Thalassaemia beta,Abdominal pain;Acute respiratory distress syndrome;Agranulocytosis;Alanine aminotransferase increased;Anaphylactic shock;Angiopathy;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Back pain;Blood and lymphatic system disorders;Blood bilirubin increased;Body temperature increased;Bruxism;Cardiac disorder;Cardiac failure;Cerebellar syndrome;Cerebral haemorrhage;Chills;Chondropathy;Chromaturia;Connective tissue disorder;Convulsion;Cryptococcal cutaneous infection;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Diplopia;Disability;Discomfort;Dyspepsia;Effusion;Encephalitis;Enterocolitis;Epistaxis;Eye disorder;Fatigue;Fibrosis;Furuncle;Gait disturbance;Gastric ulcer;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Glycosuria;Haemoglobinuria;Haemoptysis;Headache;Henoch-Schonlein purpura;Hepatitis;Hepatitis C;Hepatobiliary disease;Hepatomegaly;Hyperhidrosis;Hypersensitivity;Hypersplenism;Hypertension;Hypotension;Hypotonia;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Intracranial pressure increased;Jaundice;Malnutrition;Mediastinal disorder;Mental disorder;Metabolic acidosis;Multi-organ failure;Muscle relaxant therapy;Musculoskeletal discomfort;Myositis;Nausea;Nephropathy;Nervous system disorder;Neutropenia;Neutrophil count decreased;Nystagmus;Obsessive-compulsive disorder;Oedema peripheral;Optic neuritis;Osteoarthritis;Pain;Pain in extremity;Pancreatitis;Pancytopenia;Papilloedema;Parotid gland enlargement;Periorbital oedema;Pharyngitis;Photosensitivity reaction;Pneumonia;Pruritus;Psychomotor skills impaired;Pulmonary embolism;Pyramidal tract syndrome;Rash;Rash pustular;Rectal haemorrhage;Retinal toxicity;Sepsis;Skin disorder;Somnolence;Subcutaneous abscess;Thrombocytosis;Torsade de pointes;Trismus;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine color abnormal;Urticaria;Vomiting;Weight increased,small molecule,approved,"1,2-Dimethyl-3-hydroxypyrid-4-one; 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone; Deferiprona; Deferiprone; Défériprone; Deferipronum; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F",Iron,V03AC02
deferoxamine,Acidosis;Aluminium overload;Anaemia;Autoimmune haemolytic anaemia;Bone disorder;Cardiac disorder;Chronic iron overload;Cooley's anemia;Dialysis dementia;Haemochromatosis;Haemosiderosis;Hepatic fibrosis;Hypoproteinaemia;Intoxication;Iron overload;Poisoning;Porphyria cutanea tarda;Porphyria non-acute;Renal failure;Renal failure chronic;Shock;Sideroblastic anaemia;Thalassaemia;Thalassaemia beta;Toxic encephalopathy,Abdominal discomfort;Abdominal pain;Acute respiratory distress syndrome;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Aphasia;Arrhythmia;Arthralgia;Asthma;Blindness;Blood and lymphatic system disorders;Blood creatinine increased;Blood disorder;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Cataract;Chromatopsia;Chromaturia;Connective tissue disorder;Convulsion;Corneal opacity;Cramps of lower extremities;Cyanosis;Deafness neurosensory;Delusion;Dialysis dementia;Diarrhoea;Dizziness;Drug eruption;Dyschromatopsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Eosinophilia;Erythema;Eschar;Eye disorder;Gastroenteritis yersinia;Gastrointestinal disorder;Gastrointestinal pain;Grand mal convulsion;Growth retardation;Hallucination;Headache;Hepatic function abnormal;Hepatic impairment;Hypersensitivity;Hypotension;Immobile;Immune system disorder;Induration;Infection;Infestation;Infestation NOS;Injection site pain;Injection site reaction;Lenticular opacities;Leukopenia;Liver disorder;Local reaction;Local swelling;Lung infiltration;Mediastinal disorder;Metaphyseal dysplasia;Mucormycosis;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Neuropathy;Neuropathy peripheral;Night blindness;Oedema;Optic neuritis;Pain;Paraesthesia;Paranoid delusions;Pruritus;Pyelonephritis;Rash generalised;Renal failure;Renal failure acute;Renal impairment;Renal tubular disorder;Respiratory distress;Retinal degeneration;Retinal disorder;Scab;Scotoma;Serum creatinine increased;Shock;Skin disorder;Swelling;Tachycardia;Thrombocytopenia;Tinnitus;Tonic-clonic seizures;Toxic encephalopathy;Transaminases increased;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Urethral disorder;Urinary tract disorder;Urine color abnormal;Urticaria;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Welts;Zygomycosis,small molecule,approved; investigational,Deferoxamin; Deferoxamina; Déferoxamine; Deferoxamine; Deferoxaminum; Deferrioxamine; Deferrioxamine B; Desferrioxamine; DFO; DFOA; DFOM; A4; ABPP; AD1; Alzheimer disease amyloid A4 protein homolog; Alzheimer disease amyloid protein; Amyloid precursor protein; Amyloid-beta (A4) precursor protein; Amyloid-beta A4 protein; APP; APPI; Cerebral vascular amyloid peptide; CVAP; PN-II; PreA4; Protease nexin-II; XDHA,Iron; Aluminum; Amyloid-beta precursor protein,V03AC01
desipramine,Bipolar I disorder;Bipolar disorder;Depression;Depressive disorder;Dysthymic disorder;Involutional depression;Major depression;Orthostatic hypotension;Psychotic depression;Psychotic disorder,Abdominal cramps;Abdominal pain;Accommodation disorder;Acute coronary syndrome;Adenitis;Agitation;Agranulocytosis;Alopecia;Anorexia;Anxiety;Arrhythmia;Asthenia;Ataxia;Atrioventricular block;Black hairy tongue;Block heart;Blood alkaline phosphatase increased;Body temperature increased;Breast enlargement;Cerebrovascular accident;Confusional state;Constipation;Convulsion;Coordination abnormal;Decreased appetite;Delusion;Depression;Dermatitis;Diarrhoea;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug fever;Drug withdrawal syndrome;Dry mouth;Dysgeusia;Dyspepsia;Eosinophilia;Epigastric distress;Erectile dysfunction;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Feeling abnormal;Flushing;Galactorrhoea;Gynaecomastia;Hallucination;Headache;Hepatitis;Hyperkinesia;Hypertension;Hypoaesthesia;Hypomania;Hypotension;Ileus paralytic;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Insomnia;Intraocular pressure increased;Jaundice;Libido decreased;Lightheadedness;Liver function test abnormal;Lymphadenitis;Malaise;Mydriasis;Myocardial infarction;Nausea;Neuroleptic malignant syndrome;Neuropathy peripheral;Nightmare;Nocturia;Numbness;Oedema;Painful ejaculation;Palpitations;Pancreatic enzymes increased;Paraesthesia;Paresthesia of limbs;Parotid gland enlargement;Parotid swelling;Petechiae;Phosphatase alkaline increased;Pollakiuria;Pruritus;Psychotic disorder;Purpura;Raised liver function tests;Rash;Sensory loss;Somnolence;Stomatitis;Sudden death;Tachycardia;Taste peculiar;Testicular swelling;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue discolouration;Tremor;Urinary retention;Urticaria;Vascular purpura;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vision blurred;Vomiting;Weight increased;Withdrawal symptom,small molecule,approved; investigational,"5-(gamma-methylaminopropyl)iminodibenzyl; 5-(γ-methylaminopropyl)iminodibenzyl; Déméthylimipramine; Desipramin; Desipramina; Desipramine; Désipramine; Desipraminum; Desmethylimipramine; DMI; Monodemethylimipramine; N-(3-methylaminopropyl)iminobibenzyl; Norimipramine; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; 3.1.4.12; 3.1.4.3; Acid sphingomyelinase; ASM; aSMase; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; Dopamine D2 receptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; hOCT2; OCT2; Organic cation transporter 2; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H",Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2A; Beta-2 adrenergic receptor; Beta-1 adrenergic receptor; Sphingomyelin phosphodiesterase; Histamine H1 receptor; Alpha-1 adrenergic receptors; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2C; D(2) dopamine receptor; Alpha-2 adrenergic receptors,N06AA01
desoximetasone,Skin disorder,Acne;Acneiform eruption;Allergic contact dermatitis;Application site dryness;Application site irritation;Application site pruritus;Burning sensation;Cataract subcapsular;Comedone;Cushing's syndrome;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis infected;Dermatitis perioral;Erythema;Folliculitis;Glycosuria;Hyperglycaemia;Hypertrichosis;Infection;Leukoderma;Miliaria;Pain;Pigmentation disorder;Pigmentation skin;Plaque psoriasis;Pruritus;Psoriasis;Pyoderma;Secondary adrenocortical insufficiency;Secondary infection;Skin atrophy;Skin striae;Stinging;Telangiectasia,small molecule,approved,"(11β,16α)-9-fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone; Deoxymethasone; Desoximetason; Desoximetasona; Désoximétasone; Desoximetasone; Desoximetasonum; Desoxymethasone; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; GR; GRL; Nuclear receptor subfamily 3 group C member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1",Estrogen-related receptor gamma; Glucocorticoid receptor; Steroid hormone receptor ERR2; Steroid hormone receptor ERR1, D07XC02;D07AC03
dexamethasone,Abdominal distension;Acute leukaemia;Acute respiratory distress syndrome;Addison's disease;Adrenal insufficiency;Adrenocortical insufficiency acute;Adrenogenital syndrome;Allergic bronchitis;Allergic conditions;Alopecia areata;Anaemia;Ankylosing spondylitis;Anterior ischemic optic neuropathy;Aplasia pure red cell;Arteritis;Arthritis;Arthropod bite;Aspiration pneumonitis;Asthma;Asthma chronic;Azotaemia;Berylliosis;Blood disorder;Brain cancer metastatic;Brain neoplasm;Brain oedema;Bursitis;Central retinal vein occlusion;Cerebrovascular accident;Chorioretinitis;Choroiditis;Colitis;Colitis ulcerative;Collagen disorder;Congenital adrenal hyperplasia;Congenital aplastic anaemia;Conjunctivitis allergic;Conjunctivitis infective;Connective tissue disorder;Corneal ulcer marginal;Cushing's syndrome;Cutaneous lupus erythematosus;Cutaneous sarcoidosis;Cyclitis;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatomyositis;Diabetic macular edema;Diabetic retinal oedema;Diamond-Blackfan anemia;Discoid lupus erythematosus;Diuresis;Drug hypersensitivity;Eczema infantile;Eczema nummular;Edema cerebral;Endocrine disorder;Endocrine disorders congenital;Enteritis;Enteritis ulcerative;Eosinophilic pneumonia;Epicondylitis;Erythema;Erythema multiforme;Erythema multiforme severe;Erythroblastopenia;Eye disorder;Fibromyalgia;Fungal infection;Gastrointestinal disorder;Giant cell arteritis;Gout;Gouty arthritis;Granuloma annulare;Haemolytic anaemia;Head injury;Herpes zoster keratitis;Hyperadrenocorticism;Hypercalcaemia;Hyperplasia adrenal;Hypersensitivity;Hypoplastic anaemia;Idiopathic thrombocytopenic purpura;Infection;Infective otitis externa;Inflammation;Inflammatory bowel disease;Injury;Injury corneal;Insect bite NOS;Iridocyclitis;Iritis;Juvenile idiopathic arthritis;Keloid scar;Keratitis;Laryngeal oedema;Laryngitis;Laryngospasm;Leukaemia;Lichen planus;Lichen simplex chronicus;Loeffler's syndrome;Lung disorder;Lupus erythematosus;Lymphoma;Macular oedema;Meningitis tuberculous;Metastases to central nervous system;Multiple sclerosis;Mycosis fungoides;Myositis;Nausea;Necrobiosis lipoidica diabeticorum;Neonatal respiratory distress syndrome;Neoplasm;Neoplasm malignant;Nephropathy;Nephrotic syndrome;Nephrotic syndrome with lesion of minimal change glomerulonephritis;Neurodermatitis;Non-Hodgkin's lymphoma;Oedema;Oesophagitis ulcerative;Ophthalmic herpes zoster;Optic ischaemic neuropathy;Optic neuritis;Osteoarthritis;Otitis externa;Pancreatitis;Pemphigus;Perennial allergic rhinitis;Phagocytosis;Pneumonia aspiration;Polyarteritis nodosa;Polymyositis;Polyuria;Posterior uveitis;Pregnancy;Premature baby;Premature delivery;Proctocolitis;Protein urine present;Proteinuria;Psoriasis;Psoriatic arthropathy;Pulmonary eosinophilia;Pulmonary tuberculosis;Punctate keratitis;Purpura;Redness;Respiratory distress syndrome;Respiratory failure;Respiratory insufficiency;Retinal vein branch occlusion;Retinal vein occlusion;Rheumatic disorder;Rheumatic heart disease;Rheumatism;Rheumatoid arthritis;Rhinitis perennial;Rhinitis seasonal;Rosacea;Sarcoidosis;Scleroderma;Seasonal allergy;Seborrhoeic dermatitis;Secondary adrenal insufficiency;Secondary adrenocortical insufficiency;Secondary thrombocytopenia;Senile pruritus;Serum sickness;Shock;Skin disorder;Solar dermatitis;Stasis dermatitis;Status asthmaticus;Stevens-Johnson syndrome;Swelling;Sympathetic ophthalmia;Synovitis;Systemic lupus erythematosus;Temporal arteritis;Tenderness;Tendonitis;Tenosynovitis;Thermal burn;Thrombocytopenia;Thrombocytopenic purpura;Thyroiditis;Transfusion reaction;Trauma;Trichiniasis;Ulcerative keratitis;Uremia;Urticaria;Uveitis;Vomiting,Abdominal pain;Abscess;Acne;Acneiform eruption;Acute coronary syndrome;Adrenocortical insufficiency acute;Affect lability;Alkalosis hypokalaemic;Allergic contact dermatitis;Alopecia;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Anterior chamber cell;Anterior chamber flare;Anterior chamber inflammation;Anxiety;Arachnoiditis;Arrhythmia;Arthropathy;Aseptic necrosis;Asthenia;Atrophy;Benign intracranial hypertension;Birth weight low;Bladder dysfunction;Blepharitis;Blindness;Blister;Body temperature increased;Bradycardia;Calcinosis;Carbohydrate tolerance decreased;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Cardiomegaly;Cataract;Cataract subcapsular;Cognitive disorder;Cognitive impairment;Complication of device insertion;Conjunctival haemorrhage;Conjunctival hyperaemia;Conjunctival oedema;Conjunctivitis;Contusion;Convulsion;Corneal erosion;Corneal oedema;Corneal thinning;Cushing's syndrome;Cushingoid;Decreased appetite;Delusion;Dependence psychological;Dermatitis;Dermatitis acneiform;Dermatitis bullous;Dermatitis contact;Dermatitis perioral;Device dislocation;Diabetes mellitus;Diabetic;Diarrhoea;Diplegia;Discomfort;Dizziness;Drug dependence;Drug withdrawal syndrome;Dry eye;Dry skin;Dyspepsia;Ecchymosis;Electrolyte imbalance;Embolism;Embolism venous;Endophthalmitis;Epilepsy;Erythema;Erythema facial;Euphoric mood;Exophthalmos;Extravasation;Eye disorder;Eye infection;Eye pain;Eyelid ptosis;Fat embolism;Fatigue;Feeling abnormal;Fluid retention;Folliculitis;Fracture;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Glaucoma;Glucose tolerance impaired;Glycosuria;Growth retardation;Haemoglobin;Haemorrhage;Hallucination;Headache;Hepatomegaly;Herpes simplex;Hiccups;Hirsutism;Hyperaemia;Hyperglycaemia;Hyperhidrosis;Hypernatraemia;Hypertension;Hypertrichosis;Hypertrophic cardiomyopathy;Hypokalaemia;Hypotension;Hypotensive;Hypotony of eye;Ill-defined disorder;Impaired healing;Increased appetite;Increased insulin requirement;Infection;Injury;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Irritability;Joint instability;Keratitis;Lethargy;Leukocytosis;Leukoderma;Loss of consciousness;Loss of skin markings;Low birth weight baby;Malaise;Mania;Mass;Meningitis;Menstruation irregular;Migraine;Migration of implant;Miliaria;Monoplegia;Mood swings;Multiple fractures;Muscle atrophy;Muscle mass;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Myocardial infarction;Myocardial rupture;Myopathy;Nausea;Necrosis;Necrosis ischaemic;Nerve injury;Nervous system disorder;Neuritis;Neuropathy;Neuropathy peripheral;Nitrogen balance negative;Ocular hypertension;Oedema;Oesophageal candidiasis;Oesophageal ulcer;Oesophagitis;Opportunistic infection;Optic neuritis;Osteoarthritis;Osteonecrosis;Osteoporosis;Pain;Pancreatitis acute;Panophthalmitis;Papilloedema;Paraesthesia;Paraparesis;Paraplegia;Peptic ulcer;Personality change;Petechiae;Photopsia;Polymorphonuclear leukocytosis;Posterior subcapsular cataract;Proximal myopathy;Pruritus;Pseudotumor;Psychotic disorder;Pulmonary oedema;Rash;Rash erythematous;Rash follicular;Retinal aneurysm;Retinal detachment;Retinal tear;Retinopathy of prematurity;Schizophrenia;Scleral thinning;Secondary infection;Sensation of foreign body;Shock;Skin atrophy;Skin depigmentation;Skin exfoliation;Skin hyperpigmentation;Skin scaly;Skin striae;Spinal compression fracture;Steroid myopathy;Steroid withdrawal syndrome;Stinging;Suicidal ideation;Sweating increased;Syncope;Tachycardia;Telangiectasia;Tendon rupture;Thrombocytopenia;Thromboembolism;Thrombophlebitis;Tingling sensation;Trauma;Tuberculosis;Ulcer;Unspecified disorder of intestine;Urticaria;Vasculitis;Vertigo;Visual acuity reduced;Visual disturbance;Visual impairment;Vitreous detachment;Vitreous floaters;Vitreous haemorrhage;Vitreous opacities;Vomiting;Water retention;Weight decreased;Weight increased;Withdrawal symptom,small molecule,approved; investigational; vet_approved,"1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 1-Dehydro-16α-methyl-9α-fluorohydrocortisone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16α-Methyl-9α-fluoro-1-dehydrocortisol; 9alpha-Fluoro-16alpha-methylprednisolone; 9α-Fluoro-16α-methylprednisolone; Dexametasona; Dexaméthasone; Dexamethasone; Dexamethasonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; AHC; DAX1; DSS-AHC critical region on the X chromosome protein 1; Nuclear receptor DAX-1; Annexin I; Annexin-1; ANX1; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; LPC1; p35; Phospholipase A2 inhibitory protein; 1.14.13.39; HEP-NOS; Hepatocyte NOS; Inducible NO synthase; Inducible NOS; iNOS; NOS type II; NOS2A; Peptidyl-cysteine S-nitrosylase NOS2; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1.1.1.-; 11-beta-HSD type II; 11-beta-HSD2; 11-beta-hydroxysteroid dehydrogenase type II; 11-DH2; 11-HSD type II; Corticosteroid 11-beta-dehydrogenase isozyme 2; HSD11K; NAD-dependent 11-beta-hydroxysteroid dehydrogenase; SDR9C3; Short chain dehydrogenase/reductase family 9C member 3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.1.1.146; 11-beta-HSD1; 11-DH; 7-oxosteroid reductase; Corticosteroid 11-beta-dehydrogenase isozyme 1; HSD11; HSD11L; SDR26C1; Short chain dehydrogenase/reductase family 26C member 1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.19; 17-alpha-hydroxyprogesterone aldolase; CYP17; CYPXVII; Cytochrome P450 17A1; Cytochrome P450-C17; Cytochrome P450c17; S17AH; Steroid 17-alpha-monooxygenase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; 1.14.14.1; 20-HETE synthase; 20-hydroxyeicosatetraenoic acid synthase; CYP4A2; CYP4AII; CYPIVA11; Cytochrome P-450HK-omega; Cytochrome P450HL-omega; Fatty acid omega-hydroxylase; Lauric acid omega-hydroxylase; Long-chain fatty acid omega-monooxygenase; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3","Glucocorticoid receptor; Nuclear receptor subfamily 0 group B member 1; Annexin A1; Nitric oxide synthase, inducible; Nuclear receptor subfamily 1 group I member 2", A01AC02; C05AA09; D07AB19; D07CB04; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CA01; S01CB01; S02BA06; S02CA06; S03BA01; S03CA01;A01AC02;R01AD53
amphetamine,Affect lability;Agitation;Appetite absent;Attention deficit disorder;Attention deficit/hyperactivity disorder;Decreased appetite;Distractibility;Electroencephalogram abnormal;Forgetfulness;Hyperkinesia;Learning disability;Memory impairment;Mental disorder;Mood swings;Narcolepsy;Psychotic disorder,Abdominal cramps;Abdominal pain;Abdominal pain upper;Accidental injury;Acidosis;Acute coronary syndrome;Affect lability;Aggression;Agitation;Allergic urticaria;Alopecia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anhedonia;Anorexia;Anxiety;Arrhythmia;Asthenia;Ataxia;Blood pressure increased;Blood pressure systolic increased;Body temperature increased;Breast disorder;Cardiac death;Cardiac disorder;Cardiomyopathy;Cerebration impaired;Cerebrovascular accident;Chest pain;Chills;Choreoathetoid movements;Choreoathetosis;Colitis ischaemic;Coma;Compulsions;Confusional state;Connective tissue disorder;Constipation;Convulsion;Decreased appetite;Delirium;Depression;Dermatitis;Diarrhoea;Digestion impaired;Disturbance in attention;Disturbance in sexual arousal;Diuresis;Dizziness;Drug craving;Drug dependence;Drug withdrawal syndrome;Dry mouth;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphoria;Dyspnoea;Erectile dysfunction;Erythema multiforme;Euphoric mood;Exhaustion;Extrasystoles;Eye disorder;Fatigue;Feeling abnormal;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Growth retardation;Haemorrhage intracranial;Hallucination;Headache;Hyperhidrosis;Hyperkinesia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypersomnia;Hypertension;Hypotension;Increased appetite;Infection;Injury;Insomnia;Irritability;Lethargy;Libido decreased;Lightheadedness;Loss of consciousness;Malnutrition;Mental disability;Mental disorder;Mood swings;Motor tic;Muscle twitching;Mydriasis;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Pallor;Palpitations;Panic attack;Panic reaction;Paranoia;Photosensitivity reaction;Polyuria;Psychomotor retardation;Psychotic disorder;Psychotic episode;Rash;Rhabdomyolysis;Shock;Skin disorder;Sleep terror;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stomach ache;Sudden death;Sweating;Syncope;Tachycardia;Tension;Tic;Tooth disorder;Tourette's disorder;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vasculitis cerebral;Viral infection;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Withdrawal symptom,small molecule,approved; illicit; investigational,"(+-)-alpha-Methylphenylethylamine; 1-phenyl-2-aminopropane; alpha-Methylbenzeneethaneamine; Amfetamina; Amfetamine; Amfetaminum; Amphetamine; beta-Aminopropylbenzene; beta-Phenylisopropylamin; Desoxynorephedrine; rac-(2R)-1-phenylpropan-2-amine; rac-amphetamine; α-methylbenzeneethaneamine; α-methylphenethylamine; β-aminopropylbenzene; β-phenylisopropylamine; Solute carrier family 18 member 2; SVMT; VAT2; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT2; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; CART; TA1; TaR-1; TAR1; Trace amine receptor 1; TRAR1; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; Dopamine D2 receptor; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5",Synaptic vesicular amine transporter; Sodium-dependent dopamine transporter; Cocaine- and amphetamine-regulated transcript protein; Trace amine-associated receptor 1; Monoamine oxidase; Sodium-dependent noradrenaline transporter; Alpha adrenergic receptor; Beta adrenergic receptor; D(2) dopamine receptor; Amine oxidase [flavin-containing] B; Sodium-dependent serotonin transporter,N06BA01
dextromethorphan,Cough,Abdominal discomfort;Abdominal pain;Agitation;Asthenia;Confusional state;Constipation;Diarrhoea;Digestion impaired;Dizziness;Drowsiness;Dyspepsia;Fatigue;Feeling abnormal;Fructose intolerance;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Hypersensitivity;Hypoglycaemia;Immune system disorder;Irritability;Mental disorder;Nausea;Nervous system disorder;Nervousness;Psychotic disorder;Pulmonary function test decreased;Respiratory depression;Serotonin syndrome;Somnolence;Tension;Upset stomach;Vomiting,small molecule,approved,"(+)-dextromethorphan; D-methorphan; delta-Methorphan; Dex; Dextromethorfan; Dextromethorphan; Dextrométhorphane; Dextromethorphanum; Dextrometorfano; DM; Aging-associated gene 8 protein; hSigmaR1; OPRS1; SIG-1R; Sigma 1-type opioid receptor; Sigma1-receptor; Sigma1R; SR-BP; SR31747-binding protein; SRBP; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; Dap1; HPR6.6; IZA; mPR; PGRMC; NACHRA3; NACRA4; NACHRA7; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; K-OR-1; KOR-1; OPRK; 1.-.-.-; CGD91-phox; Cytochrome b(558) subunit beta; Cytochrome b558 subunit beta; gp91-1; gp91-phox; Heme-binding membrane glycoprotein gp91phox; NADPH oxidase 2; Neutrophil cytochrome b 91 kDa polypeptide; NOX2; p22 phagocyte B-cytochrome; Superoxide-generating NADPH oxidase heavy chain subunit; Cytochrome b(558) alpha chain; Cytochrome b558 subunit alpha; Neutrophil cytochrome b 22 kDa polypeptide; p22 phagocyte B-cytochrome; p22-phox; p22phox; Superoxide-generating NADPH oxidase light chain subunit; 47 kDa autosomal chronic granulomatous disease protein; 47 kDa neutrophil oxidase factor; NCF-1; NCF-47K; Neutrophil NADPH oxidase factor 1; Nox organizer 2; Nox-organizing protein 2; NOXO2; p47-phox; SH3 and PX domain-containing protein 1A; SH3PXD1A; 67 kDa neutrophil oxidase factor; NADPH oxidase activator 2; NCF-2; Neutrophil NADPH oxidase factor 2; NOXA2; p67-phox; P67PHOX; NCF-4; Neutrophil NADPH oxidase factor 4; p40-phox; p40phox; SH3 and PX domain-containing protein 4; SH3PXD4; 3.6.5.2; Cell migration-inducing gene 5 protein; p21-Rac1; Ras-like protein TC25; TC25; GX; p21-Rac2; Small G protein; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; C19-steroid-specific UDP-glucuronosyltransferase; C19-steroid-specific UDPGT; UDPGT 2B17; UGT2B17","Sigma non-opioid intracellular receptor 1; Aromatase; Glutamate receptor ionotropic, NMDA 3A; Neuronal acetylcholine receptor subunit alpha-2; Sodium-dependent serotonin transporter; Membrane-associated progesterone receptor component 1; Neuronal acetylcholine receptor subunit alpha-3; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-4; Neuronal acetylcholine receptor subunit beta-2; Neuronal acetylcholine receptor subunit alpha-7; Mu-type opioid receptor; Delta-type opioid receptor; Kappa-type opioid receptor; NADPH oxidase; Sodium-dependent noradrenaline transporter", N07XX59; R05DA09;N06AX62;R05DA09
diazepam,Agitation;Alcohol withdrawal syndrome;Anxiety;Anxiety disorder;Anxiety neurosis;Anxiety state;Apprehension;Athetosis;Aura;Body temperature increased;Cerebral palsy;Convulsion;Convulsion in childhood;Convulsive disorder;Convulsive seizure;Delirium;Diplegia;Distress;Emotional distress;Epilepsy;Inflammation;Injury;Insomnia;Irritability;Migraine;Monoplegia;Muscle spasms;Muscle spasticity;Myoclonus;Paraplegia;Psychotic disorder;Sleep terror;Somnambulism;Status epilepticus;Stiff person syndrome;Tension;Tension headache;Tetanus;Trauma;Tremor;Unrest,"Abdominal pain;Abnormal behaviour;Abnormal faeces;Abnormal vision;Accidental injury;Acidosis;Acute coronary syndrome;Affect lability;Aggression;Agitation;Agranulocytosis;Alertness decreased;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Anger;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anterograde amnesia;Arrhythmia;Arthralgia;Asthenia;Asthma;Ataxia;Auditory and visual hallucinations;Back pain;Balance disorder;Blood disorder;Blood thromboplastin decreased;Body temperature decreased;Bradycardia;Burning rectal;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiovascular insufficiency;Cerebration impaired;Chills;Circulatory depression;Confusional state;Conjunctivitis;Constipation;Coordination abnormal;Cough;Cough increased;Cramp muscle;Cyanosis;Decreased appetite;Dehydration;Delusion;Dependence;Dependence physiological;Depersonalisation;Depressed level of consciousness;Depression;Derealisation;Dermatitis;Dermatitis exfoliative;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disorder sight;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug withdrawal syndrome;Dry mouth;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ecchymosis;Emotional distress;Emotional poverty;Erectile dysfunction;Erythema;Euphoric mood;Excitability;Excitement;Eye disorder;Faecal incontinence;Fatigue;Feeling abnormal;Floppy infant;Fracture;Gastrointestinal disorder;Gastrointestinal pain;Grand mal convulsion;Gynaecomastia;Hallucination;Hallucinations, mixed;Headache;Heart rate irregular;Hepatic function abnormal;Hepatobiliary disease;Hiccups;Hostility;Hyperacusis;Hyperexcitation;Hyperhidrosis;Hyperkinesia;Hyperpyrexia;Hypersensitivity;Hyperventilation;Hypoaesthesia;Hypokinesia;Hyporeflexia;Hypotension;Hypothermia;Hypotonia;Hypoventilation;Hypoxia;Incontinence;Increased appetite;Increased bronchial secretion;Infection;Injection site reaction;Injury;Insomnia;Jaundice;Laryngospasm;Lethargy;Leukopenia;Libido increased;Lightheadedness;Local reaction;Loss of consciousness;Loss of libido;Lymphadenopathy;Malnutrition;Memory impairment;Memory loss;Mental disability;Mental disorder;Mood swings;Movement disorder;Multiple fractures;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Mydriasis;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Neutropenia;Nightmare;Numbness;Nystagmus;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Otitis media;Pain;Pallor;Palpitations;Panic reaction;Paraesthesia;Phlebitis;Photosensitivity;Photosensitivity reaction;Pneumonia;Proctalgia;Prothrombin level increased;Pruritus;Psychotic disorder;Pulmonary function test decreased;Rage;Rash;Rectal disorder;Rectal haemorrhage;Rectal tenesmus;Renal failure;Respiratory arrest;Respiratory depression;Respiratory failure;Retching reflex decreased;Rhinitis;Salivary hypersecretion;Salivation;Sensory loss;Shock;Sinusitis;Skin discolouration;Skin disorder;Sleep disorder;Sleep disturbance;Slurred speech;Somnolence;Speech disorder;Strangury;Stupor;Suicidal ideation;Sweating;Swelling;Syncope;Tachycardia;Tenderness;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thromboplastin decreased;Tingling of extremity;Transaminases increased;Type I hypersensitivity;Unspecified disorder of skin and subcutaneous tissue;Unsteadiness;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vasodilation;Vasodilation procedure;Venous thrombosis;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Withdrawal symptom",small molecule,approved; illicit; investigational; vet_approved,"7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; Diazepam; Methyl diazepinone; NRL-1; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Translocator protein; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site,N05BA01
diazoxide,Adenoma benign;Blood insulin increased;Blood pressure increased;Carcinoma;Cardiac failure congestive;Cerebral haemorrhage;Diabetes mellitus;Diabetic;Haemoglobin;Haemorrhage;Hyperinsulinism;Hyperplasia;Hypertension;Hypertensive;Hypertensive crisis;Hypertensive encephalopathy;Hypoglycaemia;Hypotension;Hypotensive;Malignant hypertension;Neoplasm malignant;Nephritis;Refractory hypertension;Renal failure;Renal impairment;Vascular resistance systemic,Abdominal discomfort;Abdominal pain;Ageusia;Albuminuria;Anorexia;Anxiety;Aspartate aminotransferase increased;Asthenia;Azotaemia;Blood creatinine decreased;Blood immunoglobulin G decreased;Body temperature increased;Breast mass;Cataract;Cerebral ischaemia;Chest pain;Conjunctival haemorrhage;Creatinine low;Decreased appetite;Dermatitis;Diabetic hyperosmolar coma;Diabetic ketoacidosis;Diarrhoea;Diplopia;Discomfort;Dizziness;Drug interaction;Emotional distress;Eosinophilia;Extrapyramidal disorder;Extrapyramidal symptoms;Feeling abnormal;Feeling hot;Fluid retention;Flushing;Galactorrhoea;Gastrointestinal pain;Glycosuria;Gout;Gout acute;Haematuria;Haemoglobin;Haemoglobin decreased;Haemorrhage;Headache;Herpes NOS;Herpes virus infection;Hirsutism;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypokalaemia;Hypotension;Ileus;Ill-defined disorder;Immunoglobulin G low;Insomnia;Ketoacidosis;Lacrimation;Lacrimation increased;Leukopenia;Lightheadedness;Lymphadenopathy;Malaise;Nausea;Nephrotic syndrome;Oedema;Pain;Palpitations;Pancreatic necrosis;Pancreatitis;Paraesthesia;Polyneuritis;Polyneuropathy;Pruritus;Purpura;Rash;Scotoma;Scotoma annular;Sensation of warmth;Subconjunctival hemorrhage;Sweating;Tachycardia;Thrombocytopenia;Vascular purpura;Vision blurred;Vomiting;Water retention;Weight increased,small molecule,approved,"7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; Diazossido; Diazoxide; Diazoxido; Diazoxidum; IKATP; Inward rectifier K(+) channel Kir6.2; Potassium channel, inwardly rectifying subfamily J member 11; ATP synthase F1 subunit alpha; ATP5A; ATP5A1; ATP5AL2; ATPM; 7.1.2.2; ATP synthase F1 subunit beta; ATP5B; ATPMB; ATPSB; ATP synthase F1 subunit delta; ATP5D; F-ATPase delta subunit; ATP synthase F1 subunit epsilon; ATP5E; ATPase subunit epsilon; ATP synthase F1 subunit gamma; ATP5C; ATP5C1; ATP5CL1; F-ATPase gamma subunit; ATP synthase peripheral stalk subunit OSCP; ATP5O; ATPO; Oligomycin sensitivity conferral protein; OSCP",ATP-sensitive inward rectifier potassium channel 11; Mitochondrial ATP synthase F1 domain, C02DA01; V03AH01;C02DA01;G01AE10
diclofenac,Actinic keratosis;Acute migraine;Acute pain;Adnexitis;Ankylosing spondylitis;Arthritis;Aura;Biliary colic;Body temperature increased;Cataract;Chronic hepatitis;Chronic pain;Cluster headache;Contusion;Convulsion;Decompensated cirrhosis;Diuresis;Dysmenorrhoea;Ear infection;Effusion;Foetor hepaticus;Gastrointestinal disorder;Gout;Gout attack;Hand osteoarthritis;Hepatic cirrhosis;Hepatic function abnormal;Hepatic impairment;Hepatocellular injury;Hypotension;Infection;Inflammation;Injury;Juvenile idiopathic arthritis;Ligament sprain;Liver disorder;Migraine;Osteoarthritis;Otitis;Pain;Pharyngotonsillitis;Photophobia;Polyuria;Post-traumatic pain;Postoperative pain;Primary dysmenorrhea;Procedural pain;Pulmonary function test decreased;Renal colic;Renal failure;Renal impairment;Respiratory depression;Rheumatic disorder;Rheumatism;Rheumatoid arthritis;Salpingo-oophoritis;Seborrhoeic keratosis;Spinal osteoarthritis;Spondylitis;Sprain;Swelling;Trauma;Vomiting;Wound,Abdominal cramps;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal vision;Abrasion NOS;Abscess periodontal;Accidental injury;Acne;Acute coronary syndrome;Agitation;Agranulocytosis;Alanine aminotransferase increased;Allergic conditions;Allergic skin reaction;Alopecia;Amblyopia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Aphasia;Aphthous stomatitis;Aplastic anaemia;Appetite absent;Application site dryness;Application site erythema;Application site induration;Application site irritation;Application site papules;Application site paraesthesia;Application site pruritus;Application site rash;Application site reaction;Application site vesicles;Arrhythmia;Arteriosclerosis;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Atrophy;Azotaemia;Back pain;Bad taste;Bladder pain;Bleeding time prolonged;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine abnormal;Blood creatinine increased;Blood pressure increased;Body odor;Body temperature increased;Bone pain;Bradycardia;Breath odour;Bronchitis;Bronchospasm;Bullous eruption;Burning sensation;Carcinoma;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiovascular disorder;Cataract;Cerebration impaired;Cerebrovascular accident;Chest pain;Chills;Colitis;Colitis ulcerative;Coma;Confusional state;Conjunctival hyperaemia;Conjunctivitis;Conjunctivitis allergic;Constipation;Contusion;Convulsion;Coordination abnormal;Corneal deposits;Corneal disorder;Corneal erosion;Corneal infiltrates;Corneal oedema;Corneal opacity;Corneal perforation;Corneal thinning;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine abnormal NOS;Creatinine increased;Crohn's disease;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dental caries;Depression;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Diarrhoea haemorrhagic;Diplopia;Discomfort;Disorientation;Disturbance in attention;Dizziness;Drowsiness;Drug ineffective;Dry mouth;Dry skin;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Dysthymic disorder;Dysuria;Ear and labyrinth disorders;Ear pain;Ecchymosis;Eczema;Encephalopathy;Endophthalmitis;Enterocolitis haemorrhagic;Eosinophilia;Epidermolysis;Epigastric pain;Epistaxis;Erectile dysfunction;Eructation;Eruption;Erythema;Erythema multiforme;Erythema of eyelid;Exacerbation of asthma;Excoriation;Eye allergy;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Eyelid oedema;Eyelids pruritus;Face oedema;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Flushing;Foetor hepaticus;Furuncle;Furunculosis;Gait disturbance;Gastric pH decreased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrointestinal ulcer;Gingivitis;Glossitis;Gout;Haematemesis;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Haemorrhoids;Hair disorder;Hallucination;Headache;Hearing impaired;Heartburn;Hemorrhagic colitis;Hemorrhoids aggravated;Henoch-Schonlein purpura;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis fulminant;Hepatobiliary disease;Hepatocellular injury;Hepatorenal syndrome;Hernia;Herpes simplex;Hyperaesthesia;Hyperchlorhydria;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypokinesia;Hypotension;Ill-defined disorder;Immune system disorder;Induration;Infection;Infestation;Infestation NOS;Influenza;Injection site abscess;Injection site induration;Injection site necrosis;Injection site pain;Injection site reaction;Injury;Insomnia;Intestinal diaphragm disease;Intestinal perforation;Intestinal ulcer;Iritis;Irritability;Jaundice;Keratitis;Kidney function abnormal;Lack of drug effect;Lacrimal disorder;Lacrimal structural disorder;Lacrimation;Lacrimation increased;Laryngeal oedema;Laryngitis;Laryngospasm;Lethargy;Leukopenia;Lightheadedness;Lip swelling;Liver disorder;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melaena;Memory impairment;Meningitis;Meningitis aseptic;Mental disability;Mental disorder;Migraine;Mouth ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Nail disorder;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Neoplasm malignant;Nephritis interstitial;Nephrotic syndrome;Nervous system disorder;Nervousness;Neuritis;Neuropathy peripheral;Night blindness;Nightmare;Nocturia;Nuchal rigidity;Ocular hyperaemia;Oedema;Oedema peripheral;Oesophageal disorder;Oesophagitis;Oliguria;Osteoarthritis;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Partial hearing loss;Peptic ulcer;Pharyngitis;Phlebitis;Photosensitivity;Photosensitivity reaction;Platelet count decreased;Pneumonia;Pollakiuria;Polyuria;Procedural pain;Proctitis;Proctocolitis;Prostatic specific antigen increased;Protein urine present;Proteinuria;Pruritus;Psychotic disorder;Pulmonary function test decreased;Punctate keratitis;Purpura;Purpuric rash;Rash;Rash maculo-papular;Rash pustular;Rectal disorder;Rectal haemorrhage;Redness;Renal failure;Renal failure acute;Renal impairment;Renal papillary necrosis;Respiratory depression;Rheumatoid arthritis;Rhinitis;Scab;Scotoma;Seborrhoeic dermatitis;Secondary anemia;Sepsis;Shock;Sinus congestion;Sinusitis;Skin burning sensation;Skin cancer;Skin carcinoma;Skin discolouration;Skin disorder;Skin exfoliation;Skin hypertrophy;Skin irritation;Skin mass;Skin nodule;Skin odour abnormal;Skin ulcer;Sleep disorder;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stinging;Stomach ache;Stomatitis;Sweating;Sweating increased;Swelling;Swelling of eyelid;Swollen tongue;Syncope;Tachycardia;Taste disorders;Tension;Testicular disorder;Thinking abnormal;Thirst;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue coated;Tooth abscess;Toothache;Toxic epidermal necrolysis;Toxic shock syndrome;Transaminases increased;Tremor;Tubulointerstitial nephritis;Ulcer;Ulcerative keratitis;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary abnormalities;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vaginal haemorrhage;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Vertigo;Vesiculobullous rash;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Vitreous floaters;Vomiting;Water retention;Weight decreased;Weight increased;Wheezing,small molecule,approved; vet_approved,"[2-(2,6-dichloroanilino)phenyl]acetic acid; 2-((2,6-dichlorophenyl)amino)benzeneacetic acid; Diclofenac; Diclofenac acid; Diclofenaco; Diclofenacum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 1.13.11.-; 5-lipoxygenase; 5-LO; Arachidonate 5-lipoxygenase; LOG5; 3.1.1.4; GIIC sPLA2; Group IIA phospholipase A2; Non-pancreatic secretory phospholipase A2; NPS-PLA2; Phosphatidylcholine 2-acylhydrolase 2A; PLA2B; PLA2L; RASF-A; ATTR; PALB; Prealbumin; TBPA; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; OAT-RP-5; OATP-14; OATP-F; OATP-RP5; OATP14; OATP1C1; OATPF; Organic anion transporter 1C1; Organic anion transporter F; Organic anion transporter polypeptide-related protein 5; Organic anion-transporting polypeptide 14; SLC21A14; Solute carrier family 21 member 14; Thyroxine transporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4; ACCN2; Amiloride-sensitive cation channel 2, neuronal; ASIC1; BNAC2; Brain sodium channel 2; KQT-like 2; Neuroblastoma-specific potassium channel subunit alpha KvLQT2; Voltage-gated potassium channel subunit Kv7.2; KQT-like 3; Potassium channel subunit alpha KvLQT3; Voltage-gated potassium channel subunit Kv7.3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1, D11AX18; M01AB05; M01AB55; M02AA15; S01BC03;D11AX18;S01CC01
dicloxacillin,Cellulitis;Infection;Osteomyelitis;Pneumonia;Pneumonia streptococcal;Renal failure;Renal impairment;Staphylococcal infection;Wound infection,Abdominal discomfort;Abdominal pain;Agranulocytosis;Alanine aminotransferase increased;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Arthralgia;Aspartate aminotransferase increased;Blood alkaline phosphatase increased;Body temperature increased;Bone disorder;Bone marrow depression;Bronchospasm;Confusional state;Convulsion;Dermatitis;Diarrhoea;Digestion impaired;Discomfort;Dyspepsia;Eosinophilia;Epigastric discomfort;Epilepsy;Feeling abnormal;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal tract irritation;Haematuria;Haemolytic anaemia;Hepatitis cholestatic;Hepatotoxicity;Hypersensitivity;Hypotension;Ill-defined disorder;Laryngeal oedema;Laryngospasm;Lethargy;Leukopenia;Liver function test abnormal;Loose stools;Malaise;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myoclonus;Nausea;Nephritis interstitial;Nephropathy;Neurotoxicity;Neutropenia;Oesophageal ulcer;Oesophagitis;Pain;Pancytopenia;Phlebitis;Protein urine present;Proteinuria;Pruritus;Pseudomembranous colitis;Rash;Reaction gastrointestinal;Renal failure;Renal impairment;Renal tubular disorder;Sensitisation;Serum sickness;Shock;Sneezing;Stomatitis;Thrombocytopenia;Thrombophlebitis;Tongue discolouration;Tongue hairy;Tubulointerstitial nephritis;Ulcer;Urticaria;Vomiting;Wheezing,small molecule,approved; investigational; vet_approved,"(2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Dicloxacilina; Dicloxacillin; Dicloxacillina; Dicloxacilline; Dicloxacillinum; Putative D-alanyl-D-alanine carboxypeptidase; exp2; Exported protein 2; PBP-1A; pbp2b; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Penicillin-binding protein 3; Penicillin-binding protein 1b; Penicillin-binding protein 2a; Penicillin-binding protein 3; Penicillin-binding protein 1A; Penicillin-binding protein 2B, J01CF01;J01CF01;J01CR50
dicyclomine,Benign prostatic hyperplasia;Functional gastrointestinal disorder;Irritable bowel syndrome;Prostatic hypertrophy,"Abdominal distension;Abdominal pain;Accommodation disorder;Affect lability;Ageusia;Agitation;Amnesia;Anaphylactic shock;Angioedema;Anorexia;Apnoea;Asphyxia;Asthenia;Benign prostatic hyperplasia;Bloated feeling;Breast disorder;Cardiac disorder;Cervicobrachial syndrome;Coagulation necrosis;Complex regional pain syndrome;Confusional state;Constipation;Cycloplegia;Decreased appetite;Delirium;Delusion;Dermatitis;Dermatitis atopic;Diplopia;Discomfort;Disorientation;Dizziness;Drowsiness;Drug hypersensitivity;Dry mouth;Dyskinesia;Dyspepsia;Dyspnoea;Erectile dysfunction;Erythema;Excitement;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Hallucination, visual;Headache;Hypersensitivity;Hypertension;Hypoaesthesia;Hypohidrosis;Ill-defined disorder;Immune system disorder;Injection site reaction;Insomnia;Lethargy;Lightheadedness;Loss of consciousness;Malaise;Mania;Mediastinal disorder;Mental disorder;Mood swings;Muscular weakness;Mydriasis;Nasal congestion;Nausea;Necrosis;Nervous system disorder;Nervousness;Neurological symptom;Numbness;Oedema;Pain;Palpitations;Paraesthesia;Paralysis;Prostatic hypertrophy;Pruritus;Pseudodementia;Rash;Reflex sympathetic dystrophy;Sensory loss;Shock;Sneezing;Somnolence;Speech disorder;Speech impairment NOS;Suppressed lactation;Sweating decreased;Syncope;Tachyarrhythmia;Tachycardia;Tension;Thrombophlebitis;Thrombosis;Tingling sensation;Transient global amnesia;Urinary hesitation;Urinary retention;Urticaria;Vision blurred;Vomiting",small molecule,approved,2-(diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate; Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester; Dicicloverina; Dicyclomine; Dicycloverin; Dicycloverine; Dicycloverinum,Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2,A03AA07
didanosine,Disease progression;Hepatic impairment;Immunodeficiency;Infection;Liver disorder;Pancreatitis;Renal failure;Renal impairment,Abdominal pain;Abdominal pain upper;Acquired immunodeficiency syndrome;Agranulocytosis;Alkaline phosphatase serum increased;Alopecia;Amylase increased;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Anorexia;Arthralgia;Asthenia;Autoimmune disorder;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood disorder;Blood uric acid increased;Body temperature increased;Breast feeding;Buffalo hump;Chills;Decreased appetite;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Drug interaction;Dry eye;Dry mouth;Dyspepsia;Fat redistribution;Flatulence;Function kidney decreased;Gastrointestinal pain;Headache;Hepatic failure;Hepatic function abnormal;Hepatic steatosis;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hepatotoxicity;Hyperglycaemia;Hyperlactacidaemia;Hypersensitivity;Hyperuricaemia;Hypoaesthesia;Hypoglycaemia;Infection;Inflammation;Lactic acidosis;Leukoderma;Leukopenia;Lipohypertrophy;Liver injury;Malaise;Metabolic disorder;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Myopathy;Nausea;Nephropathy;Neuritis;Neurological symptom;Neuropathy;Neuropathy peripheral;Numbness;Optic neuritis;Pain;Pancreatitis;Paraesthesia;Parotid gland enlargement;Portal hypertension;Pruritus;Rash;Renal failure acute;Renal impairment;Retinal degeneration;Retinal depigmentation;Retinal disorder;Rhabdomyolysis;Sensory loss;Serum amylase increased;Sialoadenitis;Sickness;Stomach ache;Symptomatic hyperlactatemia;Thrombocytopenia;Tingling sensation;Vomiting,small molecule,approved,"2,3-Dideoxyinosine; 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one; 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; ddI; ddIno; Didanosina; Didanosine; Didanosinum; Dideoxyinosine; Pr160Gag-Pol; 2.4.2.1; Inosine phosphorylase; Inosine-guanosine phosphorylase; NP; PNP; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1; 36 kDa nucleolar protein HNP36; Delayed-early response protein 12; DER12; ENT2; Equilibrative NBMPR-insensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter; hENT2; HNP36; Hydrophobic nucleolar protein, 36 kDa; Nucleoside transporter, ei-type; Solute carrier family 29 member 2",Reverse transcriptase/RNaseH; Gag-Pol polyprotein; Purine nucleoside phosphorylase,J05AF02
diflorasone,Skin disorder,Acneiform eruption;Allergic contact dermatitis;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Folliculitis;Hypertrichosis;Infection;Itch burning;Leukoderma;Miliaria;Pruritus;Secondary infection;Skin atrophy;Skin striae,small molecule,approved,"(6α,11β,16β)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Diflorasona; Diflorasone; Diflorasonum; 3.1.1.4; Group IB phospholipase A2; Phosphatidylcholine 2-acylhydrolase 1B; PLA2; PLA2A; PPLA2; GR; GRL; Nuclear receptor subfamily 3 group C member 1",Phospholipase A2; Glucocorticoid receptor,D07AC10
diflunisal,Arthritis;Osteoarthritis;Pain;Rheumatoid arthritis,Acute anaphylaxis;Agranulocytosis;Allergic cutaneous angiitis;Anaphylactic shock;Angioedema;Anorexia;Asthenia;Body temperature increased;Bronchospasm;Cellulitis gangrenous;Chest pain;Cholestasis;Confusional state;Constipation;Cramp muscle;Deafness;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Disorientation;Dizziness;Drug reaction with eosinophilia and systemic symptoms;Dyspepsia;Dyspnoea;Dysuria;Eructation;Erythema multiforme;Fatal outcomes;Fatigue;Feeling abnormal;Flatulence;Flushing;Gastritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Haematuria;Haemolytic anaemia;Hallucination;Headache;Hearing impaired;Hepatitis;Hyperhidrosis;Hypersensitive syndrome;Hypersensitivity;Insomnia;Jaundice;Leukocytoclastic vasculitis;Lightheadedness;Loss of consciousness;Muscle spasms;Nausea;Necrotising fasciitis;Nephritis interstitial;Nephrotic syndrome;Nervousness;Oedema;Palpitations;Paraesthesia;Peptic ulcer;Photosensitivity;Photosensitivity reaction;Protein urine present;Proteinuria;Pruritus;Rash;Renal failure;Renal impairment;Shock;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating;Syncope;Tension;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Urticaria;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,"2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid; 5-(2,4-difluorophenyl)salicylic acid; Diflunisal; Diflunisalum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; ATTR; PALB; Prealbumin; TBPA; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1,N02BA11
digoxin,Atrial fibrillation;Cardiac failure;Cardiac failure congestive;Chronic atrial fibrillation;Tachyarrhythmia,Abdominal pain;Anorexia;Anxiety;Apathy;Arrhythmia;Asthenia;Atrial tachycardia;Atrioventricular block;Atrioventricular block complete;Atrioventricular block first degree;Atrioventricular block second degree;Atrioventricular dissociation;Block heart;Cardiac arrest;Cardiac disorder;Cardiotoxicity;Chorea;Conduction disorder;Confusional state;Decreased appetite;Delirium;Dermatitis;Diarrhoea;Digestion impaired;Digitalis toxicity;Digoxin effect;Digoxin toxicity;Dissociation;Dizziness;Drug interaction;Dyspepsia;Electrocardiogram PR prolongation;Electrocardiogram ST segment depression;Electrocardiogram change;Extrasystoles;Feeling abnormal;Flat affect;Gastrointestinal disorder;Gastrointestinal pain;Gynaecomastia;Hallucination;Headache;Intestinal ischaemia;Mesenteric vascular insufficiency;Nausea;Necrosis;Palpitations;Psychotic disorder;Rash;Rash maculo-papular;Sinus bradycardia;Supraventricular tachyarrhythmia;Tachycardia;Thrombocytopenia;Toxicity to various agents;Ventricular arrhythmia;Ventricular bigeminy;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Wenckebach phenomenon;Xanthopsia,small molecule,approved,12β-hydroxydigitoxin; Digossina; Digoxin; Digoxina; Digoxine; Digoxinum; 7.2.2.13; KIAA0778; Na(+)/K(+) ATPase alpha-2 subunit; Sodium pump subunit alpha-2; 7.2.2.13; Na(+)/K(+) ATPase alpha-3 subunit; Na(+)/K(+) ATPase alpha(III) subunit; Sodium pump subunit alpha-3; ATP1B; Sodium/potassium-dependent ATPase subunit beta-1; Adhesion molecule in glia; AMOG; Sodium/potassium-dependent ATPase subunit beta-2; ATPB-3; Sodium/potassium-dependent ATPase subunit beta-3; OATP-H; OATP-M1; OATP4C1; OATPX; Organic anion transporter M1; Organic anion transporting polypeptide 4C1; SLC21A20; SLCO4C1; Solute carrier family 21 member 20; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1; 1.14.15.6; Cholesterol desmolase; CYP11A; CYPXIA1; Cytochrome P450 11A1; Cytochrome P450(scc); ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP-H; OATP-M1; OATP4C1; OATPX; Organic anion transporter M1; Organic anion transporting polypeptide 4C1; SLC21A20; SLCO4C1; Solute carrier family 21 member 20; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; OST-alpha; OSTA; Solute carrier family 51 subunit alpha; OST-beta; OSTB; Solute carrier family 51 subunit beta; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6,Sodium/potassium-transporting ATPase subunit alpha-2; Sodium/potassium-transporting ATPase subunit alpha-3; Sodium/potassium-transporting ATPase subunit beta-1; Sodium/potassium-transporting ATPase subunit beta-2; Sodium/potassium-transporting ATPase subunit beta-3; Solute carrier organic anion transporter family member 4C1; Sodium/potassium-transporting ATPase subunit alpha-1,C01AA05
dihydrocodeine,Chronic pain;Neoplasm malignant;Pain;Postoperative pain;Procedural pain,Abdominal pain;Affect lability;Angioedema;Angiopathy;Asthenic conditions;Biliary colic;Confusional state;Constipation;Convulsion;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Dysphoria;Dyspnoea;Ear and labyrinth disorders;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Hepatic enzyme increased;Hepatobiliary disease;Hyperhidrosis;Hypotension;Ileus paralytic;Immune system disorder;Mediastinal disorder;Mental disorder;Mood swings;Nausea;Nervous system disorder;Paraesthesia;Pruritus;Pulmonary function test decreased;Rash;Respiratory depression;Skin disorder;Somnolence;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;Vertigo;Vomiting;Withdrawal syndrome,small molecule,approved; illicit,"DHC; Dihydrocodeine; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Mu-type opioid receptor, N02AA08; N02AJ01; N02AJ02;N02AA08;N02AA58
dihydroergotamine,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Arteriospasm coronary;Aura;Basilar migraine;Blood pressure increased;Cardiovascular disorder;Cerebral haemorrhage;Cerebral ischaemia;Cerebrovascular accident;Cluster headache;Coldness;Colitis ischaemic;Coronary artery disease;Cyanosis;Feeling cold;Fibrosis;Gangrene;Hepatic impairment;Hypersensitivity;Hypertension;Hypoaesthesia;Ischaemia;Liver disorder;Microsomia;Migraine;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Numbness;Pallor;Peripheral arterial disease;Peripheral arterial occlusive disease;Prinzmetal angina;Retroperitoneal fibrosis;Sensory loss;Sepsis;Subarachnoid haemorrhage;Uncontrolled hypertension;Vasospasm,Abdominal pain;Abnormal vision;Acute coronary syndrome;Agitation;Angina pectoris;Anorexia;Anxiety;Aphonia;Application site reaction;Arteriospasm coronary;Arthralgia;Asthenia;Bladder pain;Body temperature increased;Bronchitis;Bronchospasm;Cerebration impaired;Cerebrovascular accident;Chills;Cold sweat;Confusional state;Conjunctivitis;Cramp muscle;Cystitis;Cystitis noninfective;Decreased appetite;Depressed level of consciousness;Dermatitis;Diarrhoea;Discomfort;Disturbance in attention;Dizziness;Dry mouth;Dyspepsia;Dysphagia;Dyspnoea;Ear pain;Epistaxis;Euphoric mood;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flushing;Gait disturbance;Gastrointestinal pain;Headache;Herpes simplex;Hiccups;Hot flush;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Ill-defined disorder;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Lacrimal disorder;Lacrimation abnormal NOS;Malaise;Menopausal symptoms;Mental disability;Migraine;Migraine aggravated;Muscle contractions involuntary;Muscle rigidity;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Nervousness;Oedema;Oesophageal spasm;Pain;Palpitations;Paraesthesia;Parosmia;Pelvic inflammatory disease;Periorbital oedema;Peripheral ischaemia;Petechiae;Pharyngitis;Photophobia;Pleuritic pain;Pollakiuria;Pruritus;Rash;Rash papular;Retroperitoneal fibrosis;Rhinitis;Rigors;Salivary hypersecretion;Shock;Sinusitis;Skin cold clammy;Somnolence;Speech disorder;Stiffness;Stupor;Sweating increased;Swelling;Tachycardia;Tension;Tingling sensation;Tinnitus;Trauma;Tremor;Upper respiratory tract infection;Urticaria;Vaginal infection;Vaginal inflammation;Vasospasm;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Visual impairment;Vomiting;Yawning,small molecule,approved; investigational,"(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide; 5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; 9,10-dihydroergotamine; Dihidroergotamina; Dihydroergotamin; Dihydroergotamine; Dihydroergotaminum; Diidroergotamina; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; Dopamine D2 receptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; 5-HT-4; 5-HT4; Serotonin receptor 4; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1F; D(2) dopamine receptor; Alpha-2A adrenergic receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1E; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; Alpha-1 adrenergic receptors; Alpha-2 adrenergic receptors; D(3) dopamine receptor; D(4) dopamine receptor; 5-hydroxytryptamine receptor 4; Beta-3 adrenergic receptor, N02CA01;N02CA01;N02CA51
diltiazem,Agitation;Angina pectoris;Arrhythmia;Arteriospasm coronary;Atrial fibrillation;Atrial flutter;Bradycardia;Coronary artery disease;Diabetes mellitus;Diabetic;Essential hypertension;Excitable;Exercise induced angina;Heart disease congenital;Heart malformation;Hepatic function abnormal;Hypertension;Hypertensive;Hypotension;Nodal arrhythmia;Paroxysmal supraventricular tachycardia;Prinzmetal angina;Reciprocating tachycardia;Sinus rhythm;Stable angina pectoris;Supraventricular tachycardia;Tachycardia;Vascular resistance systemic;Vasospasm;Wolff-Parkinson-White syndrome,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal vision;Accidental injury;Acute coronary syndrome;Acute generalised exanthematous pustulosis;Acute liver damage;Acute liver injury;Affect lability;Agranulocytosis;Albuminuria;Allergic cutaneous angiitis;Alopecia;Amblyopia;Amnesia;Angioedema;Angiopathy;Anorexia;Arrhythmia;Arthralgia;Arthropathy;Aspartate aminotransferase increased;Asthenia;Atrioventricular block;Atrioventricular block complete;Atrioventricular block first degree;Atrioventricular block second degree;Bladder pain;Bleeding time prolonged;Block heart;Blood creatine phosphokinase increased;Blood uric acid increased;Body temperature increased;Bone pain;Bradycardia;Bronchitis;Bundle branch block;Bursitis;Calculus of kidney;Cardiac arrest;Cardiac disorder;Cardiac failure congestive;Cardiac fibrillation;Cardiac flutter;Chest pain;Colitis;Conjunctivitis;Constipation;Cough;Cramp muscle;Creatine phosphokinase increased;Crystalluria;Cystitis;Cystitis noninfective;Decreased appetite;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Device capturing issue;Diarrhoea;Diplopia;Discomfort;Dissociation;Dizziness;Drug-induced parkinsonism;Dry mouth;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Ear pain;Ecchymosis;Edema of lower extremities;Electrocardiogram ST segment elevation;Endophthalmitis;Enlargement abdomen;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Extrapyramidal disorder;Extrapyramidal symptoms;Extrasystoles;Eye disorder;Eye haemorrhage;Eye irritation;Face oedema;Fatigue;Feeling abnormal;Feeling jittery;Flatulence;Flushing;Gait disturbance;Gastric ulcer;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gingival hyperplasia;Gout;Gynaecomastia;Haemolytic anaemia;Hallucination;Headache;Hepatitis;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertonia;Hyperuricaemia;Hypotension;Hypotension asymptomatic;Hypotension symptomatic;Ill-defined disorder;Infection;Influenza;Injection site reaction;Injury;Insomnia;Joint swelling;Left ventricular dysfunction;Lethargy;Leukocytoclastic vasculitis;Leukopenia;Lichenoid keratosis;Lightheadedness;Liver injury;Local swelling;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melanocytic naevus;Mental disability;Mood swings;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Myopathy;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Neck swelling;Necrolysis epidermal;Nephrolithiasis;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Nevus;Nocturia;Nodal rhythm;Nuchal rigidity;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Osteoarticular pain;Otitis media;Pain;Pallor;Palpitations;Panophthalmitis;Paraesthesia;Parkinsonism;Periorbital oedema;Peripheral swelling;Personality change;Petechiae;Pharyngitis;Phlebitis;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyuria;Prostatic disorder;Pruritus;Purpura;Pyelonephritis;Rash;Rash generalised;Rash pustular;Renal failure;Respiratory distress;Retinal disorder;Rhinitis;Shock;Sinoatrial block;Sinoatrial node dysfunction;Sinus arrest;Sinus arrhythmia;Sinus bradycardia;Sinus congestion;Sinus headache;Sinusitis;Skin hyperpigmentation;Skin hypertrophy;Somnolence;Stevens-Johnson syndrome;Stomach ache;Sweating;Swelling;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Tinnitus;Tooth disorder;Toxic epidermal necrolysis;Tremor;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Visual impairment;Vitreous floaters;Vomiting;Weight increased,small molecule,approved; investigational,"(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; d-cis-diltiazem; Diltiazem; Diltiazemum; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; CACNLG; Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent calcium channel subunit alpha-2/delta-1; Voltage-dependent calcium channel gamma-1 subunit, C05AE03;C08DB01
dimercaprol,Lead poisoning;Mercury poisoning;Metal poisoning,Abdominal pain;Abscess;Agitation;Anxiety;Asthenia;Blood pressure increased;Burning sensation;Conjunctivitis;Gastrointestinal pain;Headache;Hyperhidrosis;Lacrimation;Lacrimation increased;Muscle spasms;Nasopharyngitis;Nausea;Pain;Paraesthesia;Rhinorrhoea;Salivary hypersecretion;Salivation;Sweating;Tachycardia;Tingling sensation;Unrest;Vomiting,small molecule,approved,"1,2-dimercapto-3-propanol; 1,2-dithioglycerol; 2,3-dimercapto-1-propanol; 2,3-dimercaptol-1-propanol; 2,3-dimercaptopropanol; 2,3-dithiopropanol; 2,3-mercaptopropan-1-ol; 2,3-Mercaptopropanol; 3-hydroxy-1,2-propanedithiol; BAL; British anti-lewisite; British antilewisite; Dimercaprol; Dimercaprolum; Dimercaptopropanol; Dithioglycerine; Dithioglycerol; Sulfactin; α,β-dithioglycerol; A4; ABPP; AD1; Alzheimer disease amyloid A4 protein homolog; Alzheimer disease amyloid protein; Amyloid precursor protein; Amyloid-beta (A4) precursor protein; Amyloid-beta A4 protein; APP; APPI; Cerebral vascular amyloid peptide; CVAP; PN-II; PreA4; Protease nexin-II",Arsenic; Cadmium; Mercury; Amyloid-beta precursor protein,V03AB09
diphenhydramine,Allergic conditions;Anaphylactic shock;Angioedema;Common cold;Conjunctivitis allergic;Hypersensitivity;Lacrimation increased;Mechanical urticaria;Motion sickness;Nasopharyngitis;Parkinsonism;Pruritus;Rhinitis;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Sneezing;Tearing eyes;Throat irritation;Urticaria;Urticaria physical,Agitation;Agranulocytosis;Anorexia;Asthenia;Chest discomfort;Chest tightness;Chills;Confusional state;Constipation;Convulsion;Decreased appetite;Diarrhoea;Diplopia;Dizziness;Drowsiness;Drug eruption;Dyspepsia;Epigastric distress;Euphoric mood;Extrasystoles;Fatigue;Feeling abnormal;Haemolytic anaemia;Headache;Hyperhidrosis;Hypotension;Insomnia;Irritability;Labyrinthitis;Nasal congestion;Nausea;Nervousness;Neuritis;Neuropathy peripheral;Palpitations;Paraesthesia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Somnolence;Sweating increased;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Tremor;Urinary retention;Urticaria;Vertigo;Vision blurred;Vomiting;Wheezing,small molecule,approved; investigational,"2-(benzhydryloxy)-N,N-dimethylethylamine; 2-diphenylmethoxy-N,N-demthylethanamine; Difenhidramina; Diphenhydramine; Diphenhydraminum; N-(2-(diphenylmethoxy)ethyl)-N,N-dimethylamine; O-benzhydryldimethylaminoethanol; α-(2-dimethylaminoethoxy)diphenylmethane; β-dimethylaminoethanol diphenylmethyl ether; β-dimethylaminoethyl benzhydryl ether; 2.1.1.8; HMT; H1-R; H1R; HH1R; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; hOCT2; OCT2; Organic cation transporter 2; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5",Histamine N-methyltransferase; Histamine H1 receptor; Muscarinic acetylcholine receptor M2, D04AA33; M01AE57; R06AA02; R06AA52;D04AA32
dipivefrin,Accommodation disorder;Cataract;Chronic open angle glaucoma;Glaucoma;Lenticular opacities;Miosis;Night blindness;Open angle glaucoma;Primary open angle glaucoma;Spasm of accommodation;Vision blurred,Arrhythmia;Conjunctivitis;Follicular conjunctivitis;Hypersensitivity;Hypertension;Mydriasis;Pain;Stinging;Tachycardia,small molecule,approved,"(±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; 1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol; 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; Dipivalyl epinephrine; Dipivefrin; Dipivefrina; Dipivefrine; Dipivéfrine; Dipivefrinum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 3.1.1.7; AChE",Beta-1 adrenergic receptor; Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; Beta-2 adrenergic receptor; Cholinesterase; Acetylcholinesterase,S01EA02
dipyridamole,Acute coronary syndrome;Cardiac valve replacement complication;Coronary artery disease;Embolism;Embolism venous;Ischaemic stroke;Myocardial infarction;Thromboembolism;Transient ischaemic attack;Vasodilation;Vasodilation procedure,Abdominal cramps;Abdominal discomfort;Abdominal distress;Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorectal discomfort;Anxiety;Arrhythmia;Arthralgia;Arthritis;Asthenia;Atrial fibrillation;Atrioventricular block;Back pain;Block heart;Blood and lymphatic system disorders;Bone disorder;Bradycardia;Breast pain;Bronchospasm;Cardiac arrest;Cardiac death;Cardiac disorder;Cardiac fibrillation;Cardiomyopathy;Cerebrovascular accident;Chest pain;Chills;Cholelithiasis;Claudication;Convulsion;Coordination abnormal;Coronary artery disease;Coronary heart disease;Cough;Cramp muscle;Depersonalisation;Dermatitis;Diarrhoea;Discomfort;Distress;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Ear pain;Electrocardiogram ST-T change;Electrocardiogram abnormal;Electrocardiogram change;Emotional distress;Epigastric discomfort;Eructation;Extrasystoles;Eye pain;Fatigue;Feeling abnormal;Flatulence;Flushing;Gastric irritation;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Grand mal convulsion;Haemoglobin;Haemorrhage;Headache;Hepatic function abnormal;Hepatitis;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypotension;Ill-defined disorder;Immune system disorder;Increased appetite;Injection site pain;Injection site reaction;Intermittent claudication;Intraoperative hemorrhage;Ischaemia;Laryngeal oedema;Laryngospasm;Loss of consciousness;Malaise;Mediastinal disorder;Menopausal symptoms;Migraine;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Oedema;Orthostatic hypotension;Pain;Palpitations;Paraesthesia;Peptic ulcer;Perineal pain;Pharyngitis;Pleuritic pain;Post procedural haemorrhage;Procedural haemorrhage;Proctalgia;Pruritus;Pulmonary oedema;Rash;Rectal tenesmus;Renal pain;Rhinitis;Rigors;Seizure cerebral;Shock;Shoulder pain;Sinus arrest;Skin disorder;Somnolence;Stomach ache;Supraventricular tachycardia;Sustained ventricular tachycardia;Sweating increased;Syncope;Tachycardia;Tension;Thirst;Thrombocytopenia;Tinnitus;Tonic-clonic seizures;Transient cerebral ischemia;Transient ischaemic attack;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vomiting,small molecule,approved,Dipiridamol; Dipyridamine; Dipyridamole; Dipyridamolum; Dipyudamine; Dypyridamol; 3.1.4.17; 3.1.4.35; CGB-PDE; cGMP-binding cGMP-specific phosphodiesterase; PDE5; 3.1.4.53; cAMP-specific phosphodiesterase 4A; DPDE2; PDE46; 3.5.4.4; ADA1; Adenosine aminohydrolase; ADAPT78; CSP1; Down syndrome critical region protein 1; DSC1; DSCR1; MCIP1; Myocyte-enriched calcineurin-interacting protein 1; Regulator of calcineurin 1; AGP 1; AGP1; OMD 1; Orosomucoid-1; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.-; 7.6.2.2; MOAT-C; MRP5; Multi-specific organic anion transporter C; Multidrug resistance-associated protein 5; pABC11; SMRP; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A; cGMP-specific 3',5'-cyclic phosphodiesterase; 3',5'-cyclic-AMP phosphodiesterase 4A; Adenosine deaminase; Calcipressin-1; Alpha-1-acid glycoprotein 1",B01AC07
disopyramide,Acute coronary syndrome;Agitation;Arrhythmia;Atrioventricular block complete;Atrioventricular block first degree;Bundle branch block;Bundle branch block left;Bundle branch block right;Cardiac disorder;Cardiac failure;Cardiomyopathy;Conduction disorder;Decompensation cardiac;Depressed mood;Electrocardiogram QT prolonged;Excitability;Glaucoma;Hemiblock NOS;Hepatic failure;Hepatic impairment;Hepatic insufficiency;Hypersensitivity;Infarction;Ischaemia;Liver disorder;Myocardial infarction;Proarrhythmia;Renal failure;Renal impairment;Shock;Sinoatrial node dysfunction;Sinus arrhythmia;Sudden death;Sustained ventricular tachycardia;Ventricular arrhythmia;Ventricular tachycardia,Abdominal bloating;Abdominal distension;Abdominal pain upper;Accommodation disorder;Ache;Acute psychosis;Acute retention of urine;Agranulocytosis;Angioedema;Anorexia;Apnoea;Arrhythmia;Asthenia;Atrioventricular block;Bad taste;Block heart;Blood creatinine increased;Blood urea increased;Body temperature increased;Bradycardia;Bundle branch block;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Cardiac fibrillation;Cardiac output decreased;Cardiogenic shock;Chest pain;Coma;Confusional state;Constipation;Creatinine increased;Cyanosis;Decreased appetite;Defect conduction intraventricular;Depression;Dermatitis;Diarrhoea;Diplopia;Discomfort;Dissociation;Dizziness;Drowsiness;Dry eye;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Electrocardiogram QRS complex;Epigastric pain;Erectile dysfunction;Fatigue;Feeling abnormal;Feeling hot;Flatulence;Gynaecomastia;Haemoglobin decreased;Headache;Hepatic enzyme increased;Hepatitis;Hypercholesterolaemia;Hyperhidrosis;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hypotension;Ill-defined disorder;Insomnia;Intoxication;Jaundice cholestatic;Loss of consciousness;Lupus erythematosus;Malaise;Muscular weakness;Mydriasis;Nasal dryness;Nausea;Nervousness;Neutropenia;Nodal rhythm;Numbness;Oedema;Pain;Pallor;Paraesthesia;Poisoning;Pollakiuria;Proarrhythmic effect;Prostatism;Pruritus;Psychotic disorder;QRS complex;Rash;Rash generalised;Rash morbilliform;Sensation of warmth;Sensory loss;Shock;Sinus arrest;Skin disorder;Somnolence;Sweating increased;Syncope;Systemic lupus erythematosus;Tension;Thrombocytopenia;Tingling sensation;Torsade de pointes;Urinary hesitation;Urinary retention;Urticaria;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Vomiting;Weight increased,small molecule,approved,"Disopiramida; Disopyramide; Disopyramidum; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; KIAA1044; Potassium voltage-gated channel subfamily D member 2; Voltage-gated potassium channel subunit Kv4.2; Potassium voltage-gated channel subfamily D member 3; Voltage-gated potassium channel subunit Kv4.3; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; AGP 2; AGP2; OMD 2; Orosomucoid-2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2",Sodium channel protein type 5 subunit alpha; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; A-type voltage-gated potassium channel KCND2; A-type voltage-gated potassium channel KCND3; Voltage-gated inwardly rectifying potassium channel KCNH2; Alpha-1-acid glycoprotein 2,C01BA03
disulfiram,Alcohol abuse;Alcoholism;Flushing;Headache;Lipids increased;Nausea;Palpitations;Throbbing headache;Vomiting,Abdominal discomfort;Acneiform eruption;Asthenia;Breath odour;Dermatitis acneiform;Dermatitis atopic;Dizziness;Drowsiness;Erectile dysfunction;Eruption;Eye pain;Fatigability;Fatigue;Headache;Hepatic failure;Hepatic necrosis;Hepatitis;Hepatitis fulminant;Hypoaesthesia;Jaundice;Lassitude;Neuritis;Neuropathy;Neuropathy peripheral;Numbness;Optic neuritis;Pain;Paraesthesia;Peripheral sensorimotor neuropathy;Polyneuritis;Polyneuropathy;Psychotic disorder;Rash;Sensory loss;Somnolence;Stress;Tenderness;Tingling sensation;Upset stomach,small molecule,approved,"1,1'-dithiobis(N,N-diethylthioformamide); bis(diethylthiocarbamoyl) disulfide; Disulfiram; N,N,N',N'-tetraethylthiuram disulfide; Tetraethylthioperoxydicarbonic diamide; Tetraethylthiuram disulfide; Tetraethylthiuram disulphide; 1.14.17.1; Dopamine beta-monooxygenase; 1.2.1.3; 1.2.1.94; Aldehyde dehydrogenase 10; ALDH10; FALDH; Fatty aldehyde dehydrogenase; Microsomal aldehyde dehydrogenase; 1.2.1.3; ALDH class 2; ALDH-E2; ALDHI; ALDM; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP","Dopamine beta-hydroxylase; Aldehyde dehydrogenase family 3 member A2; Aldehyde dehydrogenase, mitochondrial", N07BB01; P03AA54;N07BB01;P03AA04
docetaxel,Adenocarcinoma gastric;Adenocarcinoma of the gastroesophageal junction;Breast cancer;Breast cancer stage IV;Carcinoma of lung;Foetor hepaticus;Hepatocellular injury;Hormone-refractory prostate cancer;Hypersensitivity;Lacrimation;Lacrimation increased;Liver disorder;Lung neoplasm malignant;Mesothelioma;Metastatic carcinoma;Metastatic disease;Metastatic gastric adenocarcinoma;Metastatic neoplasm;Metastatic squamous cell carcinoma;Nausea;Neoplasm;Neoplasm malignant;Node-negative breast cancer;Node-positive breast cancer;Non-small cell lung cancer;Oedema peripheral;Oesophageal adenocarcinoma;Ovarian cancer;Ovarian carcinoma;Peripheral sensory neuropathy;Prostate cancer;Prostate cancer metastatic;Solid tumour;Squamous cell carcinoma;Squamous cell carcinoma of head and neck;Vomiting,Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Acute leukaemia;Acute myeloid leukaemia;Acute pulmonary oedema;Acute respiratory distress syndrome;Advanced breast cancer;Ageusia;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Amenorrhoea;Anaemia;Anaphylactic shock;Angina pectoris;Angina unstable;Angiopathy;Anorexia;Arrhythmia;Arthralgia;Ascites;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrial fibrillation;Atrial flutter;Auditory disorder NOS;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood pressure increased;Body temperature increased;Bone disorder;Bone pain;Breast cancer;Breast disorder;Bronchopneumonia;Bronchospasm;Bullous eruption;Burning sensation;Cancer pain;Candida infection;Carcinoma breast;Carcinoma of lung;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiotoxicity;Chest discomfort;Chest pain;Chest tightness;Chills;Colitis;Colitis ischaemic;Coma hepatic;Confusional state;Congestive cardiomyopathy;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cramp muscle;Cutaneous hypersensitivity;Cutaneous lupus erythematosus;Cyst;Cystoid macular oedema;Dacryostenosis acquired;Deafness;Death;Decreased appetite;Deep vein thrombosis;Dehydration;Dermatitis;Dermatitis atopic;Dermatitis bullous;Diarrhoea;Diarrhoea haemorrhagic;Disseminated intravascular coagulation;Dizziness;Drug fever;Drug interaction;Dry mouth;Dry skin;Duodenal ulcer;Dysaesthesia;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Edema of lower extremities;Effusion;Embolism;Enteritis;Enterocolitis;Epistaxis;Eruption;Erythema;Erythema multiforme;Exfoliative rash;Extravasation;Eye disorder;Eye irritation;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Fluid imbalance;Fluid retention;Flushing;Foetor hepaticus;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;General disorders and administration site conditions;Haemoglobin;Haemoglobin decreased;Haemorrhage;Haemorrhoids;Hand and foot syndrome secondary to sickle cell anaemia;Headache;Hearing impaired;Heartburn;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hot flush;Hyperbilirubinaemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hyponatraemia;Hypotension;Ileus;Immune system disorder;Infection;Infestation;Infestation NOS;Inflammation;Influenza like illness;Infusion site reaction;Infusion site reactions;Injection site infection;Injection site reaction;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal obstruction;Jaundice;Lacrimal disorder;Lacrimal duct obstruction;Lacrimal structural disorder;Lacrimation;Lacrimation increased;Large intestine perforation;Laryngeal pain;Lethargy;Leukopenia;Lightheadedness;Liver disorder;Liver function test abnormal;Liver function test normal;Localized rash;Loss of consciousness;Lower respiratory tract infection;Lung neoplasm malignant;Lupus erythematosus;Lymphatic disorder;Lymphoedema;Lymphopenia;Malnutrition;Mediastinal disorder;Menopausal symptoms;Menstruation irregular;Mental disorder;Metastatic disease;Metastatic neoplasm;Migraine;Mucosal inflammation;Multi-organ failure;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myelodysplastic syndrome;Myelosuppression;Myocardial infarction;Myocardial ischaemia;Nail changes;Nail discolouration;Nail disorder;Nail toxicity;Nasopharyngitis;Nausea;Necrosis;Necrotising colitis;Necrotising enterocolitis neonatal;Necrotizing enterocolitis;Neoplasm;Nervous system disorder;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutropenic colitis;Neutropenic enterocolitis;Neutropenic infection;Neutropenic sepsis;Non-cardiac chest pain;Odynophagia;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Oliguria;Onycholysis;Onychomadesis;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Otitis media;Ototoxicity;Ovarian cancer;Pain;Pain in extremity;Pain localised;Palmar-plantar erythrodysaesthesia syndrome;Palpitations;Pancytopenia;Paraesthesia;Parosmia;Pericardial effusion;Peripheral motor neuropathy;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Photopsia;Pleural effusion;Pneumonia;Polyneuropathy;Polyp;Prothrombin level decreased;Prurigo;Pruritus;Pulmonary embolism;Pulmonary fibrosis;Pulmonary oedema;Radiation pneumonitis;Radiation recall reaction (dermatologic);Raised liver function tests;Rash;Rash erythematous;Rash generalised;Reaction gastrointestinal;Recall phenomenon;Redness;Renal failure;Renal impairment;Respiratory failure;Rhinitis;Rhinorrhoea;Rigors;Scleroderma;Scotoma;Sepsis;Shock;Sinus tachycardia;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin toxicity;Somnolence;Stevens-Johnson syndrome;Stomatitis;Supraventricular tachycardia;Swelling;Syncope;Systemic lupus erythematosus;Tachycardia;Tearing eyes;Throat sore;Thrombocytopenia;Thromboembolic event;Thrombophlebitis;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"Docetaxel; Docetaxel anhydrous; N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; TXL; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1",Tubulin beta-1 chain; Apoptosis regulator Bcl-2; Nuclear receptor subfamily 1 group I member 2,L01CD02
dolasetron,Cardiovascular disorder;Nausea;Nausea postoperative;Neoplasm malignant;Procedural nausea;Vomiting,Abdominal distension;Abdominal pain;Abnormal vision;Activated partial thromboplastin time prolonged;Acute coronary syndrome;Agitation;Alanine aminotransferase increased;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrial arrhythmia;Atrial flutter;Atrioventricular block;Atrioventricular block first degree;Atrioventricular block second degree;Block heart;Blood alkaline phosphatase increased;Body temperature increased;Bradycardia;Breath sounds abnormal;Bronchospasm;Bundle branch block;Cardiac arrest;Cardiac fibrillation;Chest pain;Chills;Confusional state;Constipation;Convulsion;Cough;Decreased appetite;Dehydration;Depersonalisation;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Electrocardiogram U wave present;Electrocardiogram U-wave abnormality;Electrocardiogram abnormal;Electrocardiogram abnormal specific;Electrocardiogram poor R-wave progression;Epistaxis;Eructation;Extrasystoles;Face oedema;Fatigue;Feeling abnormal;Flatulence;Fluid overload;Flushing;Gamma-glutamyltransferase increased;Gastrointestinal pain;Gravitational oedema;Haematoma;Haematuria;Headache;Hepatic function abnormal;Hiccups;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Ill-defined disorder;Increased appetite;Influenza like illness;Influenza-like symptoms;Injection site pain;Intestinal obstruction;Jaundice;Loss of consciousness;Malaise;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Nasal discomfort;Nasal irritation;Nodal arrhythmia;Oedema;Oedema peripheral;Oliguria;Orthostatic hypotension;Pain;Palpitations;Pancreatitis;Paraesthesia;Peripheral ischaemia;Phlebitis;Phosphatase alkaline increased;Photophobia;Pneumonia;Polyuria;Prothrombin level increased;Pruritus;Pulmonary congestion;Purpura;QRS axis abnormal;Rash;Renal failure acute;Respiratory tract congestion;Sepsis;Serum transaminase increased;Shivering;Shock;Sinus arrhythmia;Sleep disorder;Sneezing;Somnolence;Stomatitis;Sweating increased;Syncope;Tachycardia;Throat irritation;Thrombocytopenia;Thrombophlebitis;Tinnitus;Transaminases increased;Tremor;Urinary retention;Urine output increased;Urticaria;Vascular purpura;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Visual impairment;Wenckebach phenomenon;Wide complex tachycardia,small molecule,approved; investigational,"Dolasetron; Dolasétron; Dolasetronum; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",5-hydroxytryptamine receptor 3A,A04AA04
domperidone,Abdominal bloating;Abdominal distension;Anorexia nervosa;Diabetic gastroparesis;Distention;Early satiety;Flatulence;Gastric atony;Gastritis;Gastrointestinal disorder;Gastrointestinal symptom NOS;Impaired gastric emptying;Migraine;Nausea;Orthostatic hypotension;Parkinson's disease;Parkinsonism;Renal failure;Renal impairment;Vomiting,Abdominal cramps;Abdominal pain;Arrhythmia;Asthenia;Blood prolactin increased;Breast enlargement;Breast pain;Conjunctivitis;Constipation;Cramps of lower extremities;Dermatitis;Diarrhoea;Disorientation;Dizziness;Drowsiness;Drug intolerance;Dry mouth;Dyspepsia;Dystonia;Dystonic reaction;Dysuria;Galactorrhoea;Gynaecomastia;Headache;Heartburn;Hot flush;Hypotension;Insomnia;Irritability;Lethargy;Menopausal symptoms;Menstruation irregular;Migraine;Muscle spasms;Nausea;Nervousness;Oedema;Palpitations;Pollakiuria;Pruritus;Rash;Regurgitation;Serum prolactin increased;Somnolence;Stomatitis;Sudden death;Tension;Thirst;Torsade de pointes;Urticaria;Vomiting,small molecule,approved; investigational; vet_approved,"1-(3-(4-(5-chloro-2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[d]imidazol-2(3H)-one; 5-chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one; Domperidona; Domperidone; Domperidonum; Dopamine D3 receptor; Dopamine D2 receptor; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",D(3) dopamine receptor; D(2) dopamine receptor,A03FA03
donepezil,Cerebrovascular disorder;Dementia;Dementia Alzheimer's type;Vascular dementia,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal vision;Abrasion NOS;Abscess;Abscess periodontal;Accidental injury;Acute coronary syndrome;Affect lability;Aggression;Agitation;Alanine aminotransferase increased;Albuminuria;Alopecia;Anaemia;Anaemia vitamin B12 deficiency;Angina pectoris;Anorexia;Anxiety;Apathy;Aphasia;Arrhythmia;Arteritis;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Assault;Asthenia;Asthma;Ataxia;Atelectasis;Atrial fibrillation;Atrioventricular block;Back pain;Bad taste;Bladder pain;Blepharitis;Block heart;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Bradycardia;Bronchitis;Cachexia;Cardiac failure;Cardiac failure congestive;Cardiomegaly;Cataract;Cellulitis;Cerebral haemorrhage;Cerebral infarction;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Chills;Cholecystitis;Cholelithiasis;Coldness;Common cold;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Constipation;Contusion;Convulsion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine increased;Crying;Crying abnormal;Cyst;Cystitis;Cystitis noninfective;Decreased appetite;Deep vein thrombosis;Deficiency anaemia;Dehydration;Delusion;Dementia;Depression;Dermatitis;Dermatitis bullous;Device capturing issue;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in sexual arousal;Diverticulitis;Dizziness;Drooling;Dry eye;Dry mouth;Dry skin;Duodenal ulcer;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dysphasia;Dysphoria;Dyspnoea;Dysuria;Ear buzzing;Ear disorder;Ear pain;Ecchymosis;Eczema;Electrocardiogram abnormal;Emotional poverty;Enuresis;Eosinophilia;Epigastric distress;Epigastric pain;Epistaxis;Eructation;Erythema;Erythropenia;Euphoric mood;Excoriation;Extrapyramidal disorder;Eye irritation;Face oedema;Faecal incontinence;Fasciculation;Fatigue;Feeling abnormal;Feeling cold;Fibroadenoma of breast;Fibroadenosis of breast;Fibrocystic breast disease;Flat affect;Flatulence;Fracture;Functional gastrointestinal disorder;Fungal infection;Fungal skin infection;Gait disturbance;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingivitis;Glaucoma;Glycosuria;Goitre;Gout;Grand mal convulsion;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Haemorrhage intracranial;Haemorrhoids;Hallucination;Head pressure;Headache;Headache fullness;Hearing impaired;Hemiplegia;Hepatitis;Hernia;Herpes labialis;Herpes zoster;Hiatus hernia;Hirsutism;Hostility;Hot flush;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkeratosis;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertonia;Hypertrophy;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hypoproteinaemia;Hypotension;Ileus;Ill-defined disorder;Increased appetite;Increased thirst;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Iron deficiency anaemia;Irritability;Irritable bowel syndrome;Jaundice;Laceration;Lacrimal disorder;Lacrimal structural disorder;Lactic dehydrogenase activity increased;Leukocytosis;Libido decreased;Libido increased;Liver function test abnormal;Loss of consciousness;Major depression;Malaise;Malnutrition;Mastitis;Melaena;Melancholia;Menopausal symptoms;Mental disorder;Metrorrhagia;Micturition urgency;Mood swings;Motion sickness;Multiple fractures;Muscle contractions involuntary;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuralgia;Neurodermatitis;Neuroleptic malignant syndrome;Night sweats;Nocturia;Numbness;Nystagmus;Oedema;Oedema peripheral;Oesophagitis;Oral herpes;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Osteoarthritis;Osteoporosis;Otitis externa;Otitis media;Pain;Pancreatitis;Paraesthesia;Paranoia;Partial hearing loss;Periodontitis;Periorbital oedema;Peripheral vascular disorder;Personality disorder;Pharyngitis;Phosphatase alkaline increased;Physical assault;Physical wandering;Pleurisy;Pneumonia;Pneumothorax;Pollakiuria;Polydipsia;Postnasal drip;Pruritus;Psoriasis;Psychotic disorder;Pulmonary congestion;Pyelonephritis;Pyuria;Rash;Rash pustular;Rectal haemorrhage;Renal failure;Respiratory tract congestion;Retinal haemorrhage;Rhinitis;Salivary hypersecretion;Sensory loss;Sepsis;Shock;Sickness;Sinoatrial block;Skin discolouration;Skin laceration;Skin striae;Skin ulcer;Sleep apnoea syndrome;Snoring;Somnolence;Spots before eyes;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating;Sweating increased;Syncope;Tension;Thirst;Throat sore;Thrombocytopenia;Thrombocytosis;Tinnitus;Tongue disorder;Tongue oedema;Tooth abscess;Toothache;Transaminases increased;Transient ischaemic attack;Tremor;Upper-airway cough syndrome;Upset stomach;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal infection;Vaginal inflammation;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Vertigo;Vesiculobullous rash;Vision blurred;Visual impairment;Vomiting;Weight decreased;Weight increased;Wheezing;Withdrawal emotional,small molecule,approved,"Domepezil; Donepezil; Donepezilo; Donepezilum; 3.1.1.7; AChE; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 1.14.13.39; bNOS; Constitutive NOS; N-NOS; NC-NOS; Neuronal NOS; Nitric oxide synthase, brain; nNOS; NOS type I; Peptidyl-cysteine S-nitrosylase NOS1; 3.1.1.-; Hyaluronate-binding protein; TNF alpha-induced protein 6; TNF-stimulated gene 6 protein; TSG-6; TSG6; Tumor necrosis factor alpha-induced protein 6; Catabolin; IL-1 beta; IL1F2; DNA-binding factor KBF2; H2TF1; Lymphocyte translocation chromosome 10 protein; LYT10; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2; Oncogene Lyt-10; DNA-binding factor KBF1; EBP-1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Acetylcholinesterase; 5-hydroxytryptamine receptor 2A; Cholinesterase; Nitric oxide synthase 1; Tumor necrosis factor-inducible gene 6 protein; Interleukin-1 beta; Nuclear factor NF-kappa-B; NMDA receptor, N06DA02; N06DA53;N06DA02;N06DA52
dorzolamide,Calculus urinary;Diabetes mellitus;Diabetic;Foetor hepaticus;Glaucoma;Hepatocellular injury;Liver disorder;Ocular hypertension;Open angle glaucoma;Urolithiasis,Abdominal pain;Abnormal dreams;Ache;Acute coronary syndrome;Affect lability;Agranulocytosis;Alopecia;Amnesia;Anaphylactic shock;Angina pectoris;Angioedema;Anorexia;Anxiety;Arrhythmia;Arterial insufficiency;Arterial thrombosis;Arthralgia;Asthenia;Atrioventricular block;Back pain;Blepharitis;Block heart;Blood urea increased;Body temperature increased;Bradycardia;Bronchial obstruction;Bronchitis;Bronchospasm;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Cataract subcapsular;Catatonia;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Choroidal detachment;Claudication;Cold hands & feet;Colitis ischaemic;Confusional state;Conjunctival discharge;Conjunctival follicles;Conjunctival hyperaemia;Conjunctival oedema;Conjunctivitis;Corneal erosion;Corneal oedema;Corneal sensitivity decreased;Corneal staining;Cough;Cystoid macular oedema;Decreased appetite;Depression;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Dermatitis psoriasiform;Device capturing issue;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Dreaming excessive;Dry eye;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Erythema of eyelid;Eye discharge;Eye irritation;Eye pain;Eye pruritus;Eye redness;Eyelid irritation;Eyelid oedema;Eyelid pain;Fatigue;Feeling abnormal;Follicular conjunctivitis;Gastrointestinal pain;Hallucination;Headache;Hepatomegaly;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia eye;Hypoglycaemia;Hypotension;Influenza;Insomnia;Intermittent claudication;Iridocyclitis;Keratitis;Lacrimation;Lacrimation increased;Laryngospasm;Lenticular opacities;Libido decreased;Local reaction;Loss of consciousness;Memory loss;Metabolic acidosis;Mood swings;Musculoskeletal discomfort;Myasthenia gravis;Myocardial infarction;Myopia;Myopia transient;Nasal congestion;Nausea;Nervousness;Nightmare;Ocular hyperaemia;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pain in extremity;Palpitations;Paraesthesia;Peripheral coldness;Peyronie's disease;Pharyngitis;Photophobia;Pruritus;Psoriasis;Psoriasis flare-up;Pulmonary oedema;Punctate keratitis;Purpura non-thrombocytopenic;Rales;Rash;Rash erythematous;Rash generalised;Redness;Respiratory distress;Respiratory failure;Retroperitoneal fibrosis;Scab;Scotoma;Sensation of foreign body;Serum urea increased;Shock;Sinoatrial block;Sinusitis;Skin irritation;Somnolence;Stevens-Johnson syndrome;Stinging;Strangury;Sweating;Syncope;Systemic lupus erythematosus;Taste bitter;Tension;Throat irritation;Throat sore;Thrombocytopenic purpura;Tinnitus;Toxic epidermal necrolysis;Upper respiratory tract infection;Urinary tract infection;Urticaria;Vasodilation;Vasodilation procedure;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vital dye staining cornea present;Vitreous detachment;Vomiting;Weight decreased,small molecule,approved,"(4S,6S)-4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; (4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; 4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide; 4S,6S-dorzolamide; Dorzolamid; Dorzolamida; Dorzolamide; Dorzolamidum; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-IV; Carbonate dehydratase IV; Carbonic anhydrase IV; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 4.2.1.1; CA-III; Carbonate dehydratase III; Carbonic anhydrase III; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cyp2b-1; CYPIIB1; Cytochrome P450-B; Cytochrome P450-LM2; Cytochrome P450-PB1; Cytochrome P450-PB2; Cytochrome P450b; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; Cyp3a-2; Cyp3a11; CYPIIIA2; Cytochrome P450-PCN2; Cytochrome P450/6-beta-A; Testosterone 6-beta-hydroxylase",Carbonic anhydrase 2; Carbonic anhydrase 4; Carbonic anhydrase 1; Carbonic anhydrase 3, S01EC03;G01AE10;S01EC03
doxapram,Acute respiratory failure;Acute respiratory insufficiency;Airway obstruction NOS;Apnoea;Bronchial hyperreactivity;CNS depression NOS;Carbon dioxide increased;Cardiovascular disorder;Chronic obstructive pulmonary disease;Depressed level of consciousness;Depression;Hypercapnia;Lung disorder;Obstructive airways disorder;Pulmonary function test decreased;Respiratory depression;Vomiting,Agitation;Albuminuria;Anxiety;Apprehension;Arrhythmia;Blood pressure increased;Body temperature increased;Bronchospasm;Chest discomfort;Chest pain;Chest tightness;Clonus;Convulsion;Cough;Diarrhoea;Disorientation;Dizziness;Dyskinesia;Dyspnoea;Fasciculation;Feeling hot;Flushing;Hallucination;Headache;Hiccups;Hyperhidrosis;Hyperkinesia;Hyperreflexia;Hyperventilation;Hypoventilation;Hypoxia;Laryngospasm;Leukopenia;Movements involuntary;Muscle contractions involuntary;Muscle spasticity;Mydriasis;Nausea;Paraesthesia;Phlebitis;Pruritus;Respiratory failure;Sensation of warmth;Sweating;Tachypnoea;Urinary retention;Ventricular fibrillation;Ventricular tachycardia,small molecule,approved; vet_approved,"(±)-doxapram; 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone; Doxapram; Doxapramum; Acid-sensitive potassium channel protein TASK-1; TASK; TASK1; TWIK-related acid-sensitive K(+) channel 1; Two pore K(+) channel KT3.1; Two pore potassium channel KT3.1; Acid-sensitive potassium channel protein TASK-3; TASK3; TWIK-related acid-sensitive K(+) channel 3; Two pore K(+) channel KT3.2; Two pore potassium channel KT3.2",Potassium channel subfamily K member 3; Potassium channel subfamily K member 9,R07AB01
doxazosin,Acute coronary syndrome;Angina pectoris;Benign prostatic hyperplasia;Bladder neck contracture;Bladder neck obstruction;Bladder neck stricture;Blood pressure normal;Calculus bladder;Cardiac failure;Diabetes mellitus;Diabetic nephropathy;Diuresis;Dribbling of urine;Essential hypertension;Hyperlipidaemia;Hypertension;Hypertensive;Hypotension;Myocardial infarction;Neurogenic bladder;Nocturia;Parkinsonism;Peak expiratory flow rate;Peak flow;Polyuria;Poor urinary stream;Urinary incontinence;Urine flow decreased,Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal vision;Acute coronary syndrome;Affect lability;Agitation;Alopecia;Amnesia;Aneurysm;Angina pectoris;Anorectal discomfort;Anorexia;Anxiety;Apathy;Arrhythmia;Arthralgia;Arthritis;Asthenia;Ataxia;Atrial fibrillation;Back pain;Bladder pain;Blood pressure normal;Blood uric acid increased;Body temperature increased;Bradycardia;Breast neoplasm;Breast pain;Bronchitis;Bronchospasm;Bronchospasm aggravated;Calculus of kidney;Carcinoma;Carcinoma of lung;Cardiac failure;Cataract;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Chills;Cholelithiasis;Cholestasis;Confusional state;Congenital eye disorder;Conjunctivitis;Constipation;Convulsion;Cough;Cramp muscle;Cramps of lower extremities;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Depersonalisation;Depression;Dermatitis;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Dizziness;Dizziness postural;Drowsiness;Dry mouth;Dry skin;Dysgeusia;Dyskinesia;Dyspepsia;Dyspnoea;Dysuria;Ear pain;Eczema;Ejaculation failure;Electrocardiogram abnormal;Encephalopathy;Enlargement abdomen;Epididymitis;Epilepsy;Epistaxis;Erectile dysfunction;Essential hypertension;Extrasystoles;Eye disorder;Eye pain;Face oedema;Faecal incontinence;Fatigue;Feeling abnormal;Flat affect;Flatulence;Floppy iris syndrome;Flushing;Fungal infection;Gastric ulcer;Gastroenteritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal tract irritation;Gingivitis;Gout;Grand mal convulsion;Gynaecomastia;Haematocrit decreased;Haematuria;Headache;Hepatitis;Hepatitis cholestatic;Hernia;Herpes simplex;Herpes zoster;Hot flush;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertension worsened;Hypertensive;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypokalaemia;Hypokinesia;Hypotension;Ill-defined disorder;Increased appetite;Infection;Influenza like illness;Influenza-like symptoms;Insomnia;Intermittent claudication;Intraoperative floppy iris syndrome;Jaundice;Lacrimal disorder;Lacrimation abnormal NOS;Leukopenia;Libido decreased;Liver function test abnormal;Loss of consciousness;Lung neoplasm malignant;Lymphadenopathy;Malaise;Malnutrition;Melaena;Menopausal symptoms;Mental disability;Mental disorder;Micturition disorder;Migraine;Mood swings;Movement disorder;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Myopia;Nail disorder;Nausea;Neoplasm malignant;Nephrolithiasis;Nervousness;Neutropenia;Nightmare;Nocturia;Oedema;Oesophagitis;Oliguria;Orthostatic hypotension;Otitis media;Pain;Pallor;Palpitations;Paraesthesia;Paresis;Parosmia;Perineal pain;Peripheral ischaemia;Pharyngitis;Photophobia;Photosensitivity reaction;Pneumonia;Pollakiuria;Polymyalgia rheumatica;Polyuria;Priapism;Proctalgia;Prostatic disorder;Pruritus;Pruritus genital;Psoriasis;Psoriasis flare-up;Purpura;Rash;Rash erythematous;Rash maculo-papular;Rectal haemorrhage;Rectal tenesmus;Renal failure chronic;Renal pain;Respiratory tract infection;Retrograde ejaculation;Rhinitis;Rigors;Scotoma;Seborrhoeic dermatitis;Semen abnormal;Semen analysis abnormal;Sepsis;Sexual dysfunction;Shock;Sinusitis;Skin disorder;Skin hypertrophy;Somnolence;Speech disorder;Subarachnoid haemorrhage;Sudden death;Sweating;Sweating increased;Syncope;Tachycardia;Tendon disorder;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Tinnitus;Tongue disorder;Tonic-clonic seizures;Tooth disorder;Tooth hypoplasia;Tremor;Upper respiratory tract infection;Urinary incontinence;Urinary retention;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Vascular purpura;Vertigo;Viral infection;Vision blurred;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved,"1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin; Doxazosin; Doxazosina; Doxazosine; Doxazosinum; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; Eag-related protein 2; ERG-2; ERG2; Ether-a-go-go-related gene potassium channel 2; Ether-a-go-go-related protein 2; hERG-2; hERG2; Potassium voltage-gated channel subfamily H member 6; Voltage-gated potassium channel subunit Kv11.2; Eag-related protein 3; ERG-3; ERG3; Ether-a-go-go-related gene potassium channel 3; Ether-a-go-go-related protein 3; hERG-3; Potassium voltage-gated channel subfamily H member 7; Voltage-gated potassium channel subunit Kv11.3; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1",Alpha-1A adrenergic receptor; Alpha-1D adrenergic receptor; HERG human cardiac K+ channel; Alpha-1B adrenergic receptor, G04CA55;C02CA04
doxepin,Alcohol abuse;Alcoholism;Anxiety;Anxiety depression;Apprehension;Asthenia;Bipolar I disorder;Bipolar disorder;Cardiac failure congestive;Cardiovascular disorder;Chronic anxiety;Coma;Depressed mood;Depression;Depressive disorder;Dermatitis atopic;Drug interaction;Dysthymic disorder;Fatigue;Insomnia;Involutional depression;Lichen simplex chronicus;Major depression;Neurodermatitis;Neurosis;Neurotic depression;Pruritus;Psychotic depression;Psychotic disorder;Sleep disorder;Sleep disturbance;Tension,Abdominal pain;Abnormal dreams;Accommodation disorder;Adenitis;Adjustment disorder;Ageusia;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Alanine aminotransferase increased;Allergic contact dermatitis;Alopecia;Anaemia;Angiopathy;Anorexia;Anxiety;Aphthous stomatitis;Apnoea;Appetite exaggerated;Application site reaction;Arrhythmia;Arthralgia;Aspiration;Asthenia;Asthma;Ataxia;Atrioventricular block;Back injury;Back pain;Blepharospasm;Blood and lymphatic system disorders;Blood glucose increased;Blood pressure inadequately controlled;Blood pressure increased;Body temperature increased;Bone marrow depression;Bradycardia;Breast cyst;Breast disorder;Breast enlargement;Bronchitis;Cardiac death;Cardiac disorder;Cellulitis staphylococcal;Cerebration impaired;Cerebrovascular accident;Chest pain;Chills;Chronic insomnia;Cold sweat;Completed suicide;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cough;Cramp muscle;Cyst;Deafness;Decreased appetite;Delusion;Dermatitis;Dermatitis contact;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug fever;Drug withdrawal syndrome;Dry mouth;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Eczema;Electrocardiogram QRS complex abnormal;Electrocardiogram ST-T segment abnormal;Electrocardiogram change;Elevated mood;Enuresis;Eosinophilia;Epigastric distress;Erectile dysfunction;Erythema;Exacerbation of asthma;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye infection;Eye pain;Eye redness;Fatigue;Feeling abnormal;Flatulence;Flushing;Folliculitis;Fracture;Fungal infection;Gait disturbance;Galactorrhoea;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival recession;Glaucoma;Gynaecomastia;Haematochezia;Haematoma;Haemoglobinuria;Haemolytic anaemia;Hallucination;Headache;Hearing impaired;Hepatitis;Hepatobiliary disease;Herpes zoster;Hot flush;Hyperbilirubinaemia;Hyperhidrosis;Hyperkalaemia;Hypermagnesaemia;Hyperpyrexia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoaesthesia oral;Hypokalaemia;Hypomania;Hypotension;Ileus paralytic;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Infective tenosynovitis;Infestation;Infestation NOS;Influenza;Insomnia;Jaundice;Jaundice cholestatic;Joint range of motion decreased;Joint sprain;Laceration;Lacrimation;Lacrimation decreased;Lacrimation increased;Laryngeal pain;Laryngitis;Lethargy;Leukopenia;Libido decreased;Ligament sprain;Lip blister;Loss of consciousness;Lower respiratory tract infection;Lung adenocarcinoma stage I;Lymphadenitis;Malaise;Malignant melanoma;Malnutrition;Mediastinal disorder;Menopausal symptoms;Menstruation irregular;Mental disability;Mental disorder;Migraine;Motion sickness;Multiple fractures;Muscle spasms;Musculoskeletal discomfort;Myalgia;Mydriasis;Nasal congestion;Nasopharyngeal disorder;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Nervous system disorder;Nervousness;Neuropathy peripheral;Neutrophil count decreased;Nightmare;Nocturia;Numbness;Numbness of tongue;Ocular hyperaemia;Oedema;Oedema peripheral;Onychomycosis;Orofacial dyskinesia;Pain;Pain in extremity;Pallor;Palpitations;Pancytopenia;Paraesthesia;Paresthesia of limbs;Parotid gland enlargement;Parotid swelling;Petechiae;Pharyngeal disorder;Pharyngitis;Pharyngolaryngeal pain;Pneumonia;Pollakiuria;Polyp;Presyncope;Pruritus;Psychotic disorder;Pulmonary function test decreased;Purpura;QRS axis abnormal;Rales;Rash;Respiratory depression;Rhinorrhoea;Rosacea;Sensation of heaviness;Sensory loss;Shock;Sinus congestion;Sinusitis;Skin disorder;Skin irritation;Skin laceration;Sleep paralysis;Somnolence;Stinging;Stomatitis;Suicide;Suicide attempt;Sweating;Syncope;Syncope vasovagal;Tachycardia;Tardive dyskinesia;Taste peculiar;Tension;Testicular swelling;Thinking abnormal;Thrombocytopenia;Thrombocytosis;Tingling sensation;Tinnitus;Tooth infection;Transaminases increased;Transient insomnia;Tremor;Tympanic membrane perforation;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular purpura;Ventricular extrasystoles;Vertigo;Viral diarrhoea;Viral infection;Vision blurred;Vomiting;Weight increased;Wheezing;Withdrawal symptom,small molecule,approved; investigational,"Doxepin; Doxepina; Doxepinum; H1-R; H1R; HH1R; Gastric receptor I; H2R; HH2R; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-6; 5-HT6; Serotonin receptor 6; AXOR35; G-protein coupled receptor 105; GPCR105; GPRv53; H4R; HH4R; Pfi-013; SP9144; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Histamine H1 receptor; Histamine H2 receptor; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 6; Histamine H4 receptor; Voltage-gated inwardly rectifying potassium channel KCNH2, D04AX01;N06AA12
droperidol,Aggression;Agitation;Anxiety;Bipolar I disorder;Bipolar disorder;Delirium;Hyperkinesia;Nausea;Pain;Psychotic disorder;Schizophrenic reaction;Schizophreniform disorder;Shock;Vomiting,Akathisia;Altered state of consciousness;Amenorrhoea;Anaphylactic shock;Angioedema;Anxiety;Autonomic nervous system imbalance;Blood pressure increased;Body temperature increased;Bronchospasm;Cardiac arrest;Chills;Consciousness abnormal;Depression;Dermatitis;Dizziness;Drowsiness;Dysphoria;Extrapyramidal disorder;Extrapyramidal symptoms;Galactorrhoea;Gynaecomastia;Hallucination;Hyperglycaemia;Hyperprolactinaemia;Hypersensitivity;Hypertension;Hypotension;Hypovolaemia;Inappropriate antidiuretic hormone secretion;Laryngospasm;Light anaesthesia;Loss of consciousness;Muscle rigidity;Neuroleptic malignant syndrome;Oculogyric crisis;Palpitations;Rash;Shivering;Shock;Somnolence;Sudden death;Syncope;Tachycardia;Tardive dyskinesia;Torsade de pointes;Ventricular arrhythmia;Ventricular tachycardia,small molecule,approved; vet_approved,"1-(1-(3-(p-fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-(1-(4-(p-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-{1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1H-benzo[d]imidazol-2-one; Droperidol; Dropéridol; Droperidolo; Droperidolum; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Dopamine D2 receptor",Alpha-1A adrenergic receptor; D(2) dopamine receptor,N01AX01;N05AD08
dyphylline,Asthma;Bronchitis chronic;Bronchospasm;Emphysema,Abdominal pain upper;Agitation;Albuminuria;Convulsion;Diarrhoea;Diuresis;Epigastric pain;Extrasystoles;Flushing;Haematemesis;Haematuria;Headache;Hyperglycaemia;Hypotension;Inappropriate antidiuretic hormone secretion;Insomnia;Irritability;Microscopic hematuria;Muscle twitching;Nausea;Palpitations;Polyuria;Shock;Tachycardia;Tachypnoea;Ventricular arrhythmia;Vomiting,small molecule,approved,"(±)-7-(2,3-dihydroxypropyl)theophylline; (±)-diprophylline; (±)-dyphylline; (1,2-dihydroxy-3-propyl)thiophyllin; 1,3-dimethyl-7-(2,3-dihydroxypropyl)xanthine; 7-(2,3-dihydroxypropyl)-1,3-dimethylxanthine; 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 7-(2,3-dihydroxypropyl)theophylline; 7-(β,γ-dihydroxypropyl)theophylline; Dihydroxypropyl theopylin; Diprofilina; Diprophylline; Diprophyllinum; Dyphylline; 3.1.4.53; cAMP-specific phosphodiesterase 4B; DPDE4; PDE32; 3.1.3.35; 3.1.3.5; 3.1.3.89; 3.1.3.91; 3.1.3.99; 5'-deoxynucleotidase; 5'-NT; Ecto-5'-nucleotidase; IMP-specific 5'-nucleotidase; NT5; NTE; Thymidylate 5'-phosphatase; 3.1.4.53; cAMP-specific phosphodiesterase 4A; DPDE2; PDE46; 3.1.4.53; cAMP-specific phosphodiesterase 4C; DPDE1; PDE21; 3.1.4.53; cAMP-specific phosphodiesterase 4D; DPDE3; PDE43; ADORA2","3',5'-cyclic-AMP phosphodiesterase 4B; 5'-nucleotidase; 3',5'-cyclic-AMP phosphodiesterase 4A; 3',5'-cyclic-AMP phosphodiesterase 4C; 3',5'-cyclic-AMP phosphodiesterase 4D; Adenosine receptor A1; Adenosine receptor A2a", R03DA01; R03DA51; R03DB01;R03DA01;R03DA20
econazole,Body tinea;Fungal skin infection;Skin candida;Skin infection;Tinea cruris;Tinea infection;Tinea pedis;Tinea versicolour,Burning sensation;Erythema;Pain;Prurigo;Pruritus;Stinging,small molecule,approved,"(+-)-Econazole; Econazol; Econazole; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Lanosterol 14-alpha demethylase; Nuclear receptor subfamily 1 group I member 2, D01AC03; G01AF20; G01AF55;D01AC03;G01AF05
trabectedin,Leiomyosarcoma;Liposarcoma;Ovarian cancer;Sarcoma,Abdominal pain;Abdominal pain upper;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Anemic;Angiopathy;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Bilirubin conjugated increased;Blood albumin decreased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Body temperature increased;Connective tissue disorder;Constipation;Cough;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Dizziness;Dysgeusia;Dyspepsia;Dyspnoea;Extravasation;Fatal outcomes;Fatigue;Febrile neutropenia;Flushing;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Hepatic failure;Hepatic pain;Hepatobiliary disease;Hepatomegaly;Hepatotoxicity;Hyperbilirubinaemia;Hypersensitivity;Hypokalaemia;Hypotension;Infection;Infestation;Infestation NOS;Injection site reaction;Insomnia;Jaundice;Left ventricular dysfunction;Leukopenia;Liver injury;Loss of consciousness;Malnutrition;Mediastinal disorder;Mental disorder;Mucosal inflammation;Multi-organ failure;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nausea;Necrosis;Nervous system disorder;Neutropenia;Neutropenic infection;Neutropenic sepsis;Oedema;Oedema peripheral;Pancytopenia;Paraesthesia;Peripheral sensory neuropathy;Pulmonary embolism;Pulmonary oedema;Rash;Rhabdomyolysis;Sepsis;Septic shock;Shock;Skin disorder;Skin hyperpigmentation;Stomatitis;Syncope;Thrombocytopenia;Traumatic liver injury;Unspecified disorder of skin and subcutaneous tissue;Vomiting;Weight decreased,small molecule,approved; investigational,"Ecteinascidin 743; Trabectedin; Trabectedina; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",DNA,L01CX01
edrophonium,Cholinergic crisis;Cholinergic syndrome;Myasthenia gravis;Pulmonary function test decreased;Respiratory depression,Abdominal cramps;Abdominal pain;Abnormal behaviour;Accommodation disorder;Arrhythmia;Asthenia;Bradycardia;Cardiac arrest;Conjunctival hyperaemia;Convulsion;Diarrhoea;Diplopia;Dysarthria;Dysphagia;Dysphonia;Fasciculation;Hyperhidrosis;Hypotension;Incontinence;Lacrimation increased;Laryngospasm;Muscle contractions involuntary;Nausea;Osteoarthritis;Paralysis;Pollakiuria;Respiratory paralysis;Spasm of accommodation;Sweating increased;Vermiculation;Vomiting,small molecule,approved,"(3-hydroxyphenyl)dimethylethylammonium; 3-hydroxy-N,N-dimethyl-N-ethylanilinium; Edrophonium cation; Edrophonium ion; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylanilinium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 3.1.1.7; AChE",Cholinesterase; Acetylcholinesterase,V04CX07
efavirenz,Carcinogenicity;Cross resistance;Dermatitis;Drug interaction;Foetor hepaticus;HIV infection;Hepatitis B;Hepatocellular injury;Human immunodeficiency virus type;Immunodeficiency;Infection;Liver disorder;Mental disorder;Pathogen resistance;Rash,Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal vision;Affect lability;Aggression;Agitation;Alcohol intolerance;Alopecia;Amnesia;Amylase increased;Anaemia;Anencephaly;Angioedema;Angiopathy;Anophthalmos;Anorexia;Anxiety;Apathy;Apnoea;Arrhythmia;Arthralgia;Asthenia;Asthma;Ataxia;Autoimmune disorder;Back pain;Basedow's disease;Blister;Blood bilirubin increased;Blood cholesterol increased;Blood creatinine increased;Blood triglycerides increased;Body temperature increased;Bone pain;Breast disorder;Breast enlargement;Buffalo hump;Cachexia;Calculus of kidney;Cardiac disorder;Cardiac failure congestive;Cerebration impaired;Chest pain;Cleft palate;Common wart;Completed suicide;Confusional state;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Creatinine increased;Decreased appetite;Delirium;Delusion;Depersonalisation;Depressed level of consciousness;Depression;Depression aggravated;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Dizziness;Drowsiness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Eczema;Endocrine disorder;Enlargement abdomen;Enzyme induction;Eruption;Erythema;Erythema multiforme;Erythema nodosum;Euphoric mood;Eye disorder;Fanconi syndrome;Fasting;Fat redistribution;Fatigue;Feeling abnormal;Flank pain;Flat affect;Flatulence;Flushing;Folliculitis;Fracture;Gastrointestinal disorder;Gastrointestinal pain;Glaucoma;Glycosuria;Gynaecomastia;Haematuria;Hallucination;Headache;Hepatic enzyme increased;Hepatic failure;Hepatic steatosis;Hepatitis;Hepatitis C antibody positive;Hepatitis acute;Hepatobiliary disease;Hepatomegaly;Hepatotoxicity;High cholesterol;Hot flush;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlactacidaemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypertrophy of breast;Hypoaesthesia;Hypokalaemia;Hypophosphataemia;Ill-defined disorder;Immune system disorder;Infestation;Infestation NOS;Inflammation;Influenza like illness;Influenza-like symptoms;Insomnia;Insulin resistance;Iritis;Jaundice;Lactic acidosis;Lightheadedness;Lipidosis;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Lipoma;Loose stools;Loss of consciousness;Malabsorption;Malaise;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Menopausal symptoms;Mental disability;Migraine;Mood swings;Multiple fractures;Muscle contractions involuntary;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myopathy;Nail disorder;Nasopharyngitis;Nausea;Necrolysis epidermal;Necrosis;Neoplasm malignant;Nephritis interstitial;Nephrogenic diabetes insipidus;Nephrolithiasis;Nephrosis lower nephron;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neurological symptom;Neuropathy;Neuropathy peripheral;Neurosis;Obesity;Oedema peripheral;Opportunistic infection;Osteomalacia;Osteonecrosis;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paranoia;Paranoid reaction;Paresis;Parosmia;Photocontact dermatitis;Photosensitivity reaction;Pneumonia;Polyarthritis;Polyuria;Pregnancy;Protein urine present;Proteinuria;Pruritus;Psychiatric symptom;Psychotic disorder;Rash;Rash generalised;Rash maculo-papular;Rash pustular;Rash recurrent;Renal failure;Renal failure acute;Renal impairment;Renal tubular disorder;Renal tubular necrosis;Rhabdomyolysis;Rhinitis;Serum amylase increased;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin papilloma;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stupor;Suicidal ideation;Suicide;Suicide attempt;Sweating;Sweating increased;Syncope;Tachycardia;Tension;Teratogenicity;Thinking abnormal;Thrombocytopenia;Thrombophlebitis;Tinnitus;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;Vertigo;Vesiculobullous rash;Vision blurred;Visual impairment;Vomiting,small molecule,approved; investigational,"(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one; Efavirenz; Éfavirenz; Efavirenzum; Pr160Gag-Pol; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; hOCT1; OCT1; Organic cation transporter 1",Gag-Pol polyprotein; Reverse transcriptase/RNaseH, J05AG03; J05AR11;J05AG03;J05AR06
emedastine,Conjunctivitis allergic,Abnormal dreams;Asthenia;Asthenopia;Bad taste;Cardiac disorder;Conjunctival hyperaemia;Corneal infiltrates;Corneal staining;Dermatitis;Discomfort;Dry eye;Dysgeusia;Endophthalmitis;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Foreign body sensation in eyes;Headache;Hyperaemia;Keratitis;Lacrimation;Lacrimation increased;Mental disorder;Nervous system disorder;Ocular hyperaemia;Pain;Pruritus;Rash;Rhinitis;Sensation of foreign body;Sinus headache;Sinusitis;Skin disorder;Stinging;Tachycardia;Unspecified disorder of skin and subcutaneous tissue;Vision blurred;Vital dye staining cornea present,small molecule,approved,"1-(2-Ethoxy-ethyl)-2-(4-methyl-[1,4]diazepan-1-yl)-1H-benzoimidazole; 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole; 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole; Emedastina; Emedastine; Emedastinum; H1-R; H1R; HH1R",Histamine H1 receptor,S01GX06
enflurane,Uterine atony;Uterine haemorrhage;Uterine relaxation,Arrhythmia;Body temperature increased;Carbon dioxide decreased;Chills;Convulsion;Hepatic failure;Hepatic necrosis;Hepatotoxicity;Hyperkalaemia;Hypocapnia;Hypotension;Liver injury;Nausea;Pulmonary function test decreased;Respiratory depression;Shivering;Traumatic liver injury;Vomiting,small molecule,approved; investigational; vet_approved,"2-chloro-1,1,2-trifluoroethyl difluoromethyl ether; Alyrane; Efrane; Enflurane; Enflurano; Enfluranum; Methylflurether; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; CACNLG; Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma; Neuronal voltage-gated calcium channel gamma-2 subunit; TARP gamma-2; Transmembrane AMPAR regulatory protein gamma-2; Neuronal voltage-gated calcium channel gamma-3 subunit; TARP gamma-3; Transmembrane AMPAR regulatory protein gamma-3; Neuronal voltage-gated calcium channel gamma-4 subunit; TARP gamma-4; Transmembrane AMPAR regulatory protein gamma-4; Neuronal voltage-gated calcium channel gamma-5 subunit; TARP gamma-5; Transmembrane AMPAR regulatory protein gamma-5; Neuronal voltage-gated calcium channel gamma-6 subunit; Neuronal voltage-gated calcium channel gamma-7 subunit; TARP gamma-7; Transmembrane AMPAR regulatory protein gamma-7; CACNG6; Neuronal voltage-gated calcium channel gamma-8 subunit; TARP gamma-8; Transmembrane AMPAR regulatory protein gamma-8; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; KIAA0558; Voltage-gated calcium channel subunit alpha-2/delta-2; Voltage-gated calcium channel subunit alpha-2/delta-3; Voltage-gated calcium channel subunit alpha-2/delta-4; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; BI; Brain calcium channel I; CACH4; CACN3; CACNL1A4; Calcium channel, L type, alpha-1 polypeptide isoform 4; Voltage-gated calcium channel subunit alpha Cav2.1; BII; Brain calcium channel II; CACH6; CACNL1A6; Calcium channel, L type, alpha-1 polypeptide, isoform 6; Voltage-gated calcium channel subunit alpha Cav2.3; Cav3.1c; KIAA1123; NBR13; Voltage-gated calcium channel subunit alpha Cav3.1; Low-voltage-activated calcium channel alpha1 3.2 subunit; Voltage-gated calcium channel subunit alpha Cav3.2; Ca(v)3.3; KIAA1120; Voltage-gated calcium channel subunit alpha Cav3.3; Glycine receptor 48 kDa subunit; Glycine receptor strychnine-binding subunit; Potassium voltage-gated channel subfamily D member 1; Shal-type potassium channel KCND1; Voltage-gated potassium channel subunit Kv4.1; KIAA1044; Potassium voltage-gated channel subfamily D member 2; Voltage-gated potassium channel subunit Kv4.2; Potassium voltage-gated channel subfamily D member 3; Voltage-gated potassium channel subunit Kv4.3; Delayed-rectifier K(+) channel alpha subunit 1; Delayed-rectifier potassium channel subunit Kv9.1; hKv9.1; Potassium voltage-gated channel modifier subfamily S member 1; Delayed-rectifier K(+) channel alpha subunit 3; Delayed-rectifier potassium channel subunit Kv9.3; Kv9.3; Potassium voltage-gated channel subfamily S member 3; Voltage-gated K(+) channel HuKI; Voltage-gated potassium channel HBK1; Voltage-gated potassium channel subunit Kv1.1; Voltage-gated potassium channel subunit Kv1.8; NGK1; Voltage-gated K(+) channel HuKIV; Voltage-gated potassium channel HBK5; Voltage-gated potassium channel subunit Kv1.2; HGK5; HLK3; HPCN3; Voltage-gated K(+) channel HuKIII; Voltage-gated potassium channel subunit Kv1.3; HPCN2; KCNA4L; Voltage-gated K(+) channel HuKII; Voltage-gated potassium channel HBK4; Voltage-gated potassium channel HK1; Voltage-gated potassium channel subunit Kv1.4; HPCN1; Voltage-gated potassium channel HK2; Voltage-gated potassium channel subunit Kv1.5; Voltage-gated potassium channel HBK2; Voltage-gated potassium channel subunit Kv1.6; Delayed rectifier potassium channel 1; DRK1; h-DRK1; Voltage-gated potassium channel subunit Kv2.1; Voltage-gated potassium channel subunit Kv2.2; Delayed rectifier potassium channel subunit IsK; IKs producing slow voltage-gated potassium channel subunit beta Mink; Minimal potassium channel; MinK; Minimum potassium ion channel-related peptide 1; MinK-related peptide 1; MiRP1; Potassium channel subunit beta MiRP1; Minimum potassium ion channel-related peptide 2; MinK-related peptide 2; MiRP2; Potassium channel subunit beta MiRP2; Minimum potassium ion channel-related peptide 3; MinK-related peptide 3; MiRP3; Potassium channel subunit beta MiRP3; AMME syndrome candidate gene 2 protein; AMMECR2; KCNE1L; Potassium channel subunit beta MiRP4; Potassium voltage-gated channel subfamily E member 1-like protein; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1; KCNA8; KCNA9; KQT-like 1; KVLQT1; Voltage-gated potassium channel subunit Kv7.1; KQT-like 2; Neuroblastoma-specific potassium channel subunit alpha KvLQT2; Voltage-gated potassium channel subunit Kv7.2; KQT-like 3; Potassium channel subunit alpha KvLQT3; Voltage-gated potassium channel subunit Kv7.3; KQT-like 4; Potassium channel subunit alpha KvLQT4; Voltage-gated potassium channel subunit Kv7.4; KQT-like 5; Potassium channel subunit alpha KvLQT5; Voltage-gated potassium channel subunit Kv7.5; Neuronal potassium channel alpha subunit HNKA; Voltage-gated potassium channel subunit Kv8.1; Voltage-gated potassium channel subunit Kv8.2; EAG; EAG channel 1; EAG1; Ether-a-go-go potassium channel 1; h-eag; hEAG1; Potassium voltage-gated channel subfamily H member 1; Voltage-gated potassium channel subunit Kv10.1; BEC2; Brain-specific eag-like channel 2; ELK channel 1; ELK1; Ether-a-go-go-like potassium channel 1; Potassium voltage-gated channel subfamily H member 4; Voltage-gated potassium channel subunit Kv12.3; EAG2; Ether-a-go-go potassium channel 2; hEAG2; Potassium voltage-gated channel subfamily H member 5; Voltage-gated potassium channel subunit Kv10.2; ELK channel 3; ELK1; ELK3; Ether-a-go-go-like potassium channel 3; hElk-1; Potassium voltage-gated channel subfamily H member 8; Voltage-gated potassium channel subunit Kv12.1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; BEC1; Brain-specific eag-like channel 1; ELK channel 2; ELK2; Ether-a-go-go-like potassium channel 2; KIAA1282; Potassium voltage-gated channel subfamily H member 3; Voltage-gated potassium channel subunit Kv12.2; Eag-related protein 2; ERG-2; ERG2; Ether-a-go-go-related gene potassium channel 2; Ether-a-go-go-related protein 2; hERG-2; hERG2; Potassium voltage-gated channel subfamily H member 6; Voltage-gated potassium channel subunit Kv11.2; Eag-related protein 3; ERG-3; ERG3; Ether-a-go-go-related gene potassium channel 3; Ether-a-go-go-related protein 3; hERG-3; Potassium voltage-gated channel subfamily H member 7; Voltage-gated potassium channel subunit Kv11.3; NGK2; Potassium voltage-gated channel subfamily C member 1; Voltage-gated potassium channel subunit Kv3.1; Voltage-gated potassium channel subunit Kv4; Potassium voltage-gated channel subfamily C member 2; Shaw-like potassium channel; Voltage-gated potassium channel Kv3.2; KSHIIID; Potassium voltage-gated channel subfamily C member 3; Voltage-gated potassium channel subunit Kv3.3; C1orf30; KSHIIIC; Potassium voltage-gated channel subfamily C member 4; Voltage-gated potassium channel subunit Kv3.4; kH1; Potassium voltage-gated channel subfamily F member 1; Voltage-gated potassium channel subunit Kv5.1; kH2; Potassium voltage-gated channel subfamily G member 1; Voltage-gated potassium channel subunit Kv6.1; Cardiac potassium channel subunit; KCNF2; Potassium voltage-gated channel subfamily G member 2; Voltage-gated potassium channel subunit Kv6.2; Potassium voltage-gated channel subfamily G member 3; Voltage-gated potassium channel subunit Kv10.1; Voltage-gated potassium channel subunit Kv6.3; KCNG3; Potassium voltage-gated channel subfamily G member 4; Voltage-gated potassium channel subunit Kv6.3; Voltage-gated potassium channel subunit Kv6.4; 1.1.1.-; K(+) channel subunit beta-1; KCNA1B; Kv-beta-1; 1.1.1.-; hKvbeta2; K(+) channel subunit beta-2; KCNA2B; KCNK2; Kv-beta-2; 7.2.2.10; ATP-dependent Ca(2+) pump PMR1; ATPase 2C1; Ca(2+)/Mn(2+)-ATPase 2C1; KIAA1347; PMR1L; Secretory pathway Ca(2+)-transporting ATPase type 1; SPCA1; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; 7.2.2.10; Calcium pump 1; Calcium-transporting ATPase sarcoplasmic reticulum type, fast twitch skeletal muscle isoform; Endoplasmic reticulum class 1/2 Ca(2+) ATPase; SERCA1; SR Ca(2+)-ATPase 1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J",GABA(A) Receptor; Voltage-dependent calcium channel; Glycine receptor subunit alpha-1; Voltage-gated Potassium Channels; Calcium-transporting ATPase type 2C member 1; Glutamate (NMDA) receptor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,N01AB04
epinastine,Conjunctivitis allergic;Pruritus,Burning sensation in eye;Cold symptoms;Cough;Cough increased;Eye irritation;Headache;Hyperaemia;Infection;Lacrimation increased;Nasopharyngitis;Pharyngitis;Pruritus;Rhinitis;Sinusitis;Upper respiratory tract infection,small molecule,approved; investigational,"(±)-epinastine; 3-amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine; Epinastin; Epinastina; Epinastine; épinastine; Epinastinum; H1-R; H1R; HH1R; Gastric receptor I; H2R; HH2R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Histamine H1 receptor; Histamine H2 receptor; Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 7, R06AX24;R06AX24;S01GX10
vitamin,Hypoparathyroidism;Hypophosphataemia;Rickets;Rickets (vitamin D resistant);Rickets familial hypophosphataemic,Ache;Acidosis;Anaemia;Anorexia;Asthenia;Azotaemia;Calcinosis;Constipation;Decreased appetite;Deposit calcium;Dwarfism;Hypercalciuria;Hypertension;Hypervitaminosis D;Irreversible renal failure;Mental disability;Mental retardation;Musculoskeletal stiffness;Nausea;Nephrocalcinosis;Nocturia;Osteoporosis;Pain;Polydipsia;Polyuria;Renal failure chronic;Stiffness;Urine output increased;Vascular calcification;Weight decreased,small molecule,approved; nutraceutical; vet_approved,"(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; all-trans-retinol; all-trans-retinyl alcohol; all-trans-vitamin A alcohol; Retinol; Retinolum; Vitamin A1; NR2B3; Nuclear receptor subfamily 2 group B member 3; Retinoid X receptor gamma; Apo-D; ApoD; 5.3.99.2; Beta-trace protein; Cerebrin-28; Glutathione-independent PGD synthase; L-PGDS; Lipocalin-type prostaglandin-D synthase; PDS; PGD2 synthase; PGDS; PGDS2; Prostaglandin-D2 synthase; 1.1.1.300; All-trans and 9-cis retinol dehydrogenase; SDR7C2; Short chain dehydrogenase/reductase family 7C member 2; 1.1.1.209; 1.1.1.315; 1.1.1.53; 11-cis RDH; 11-cis retinol dehydrogenase; 11-cis RoDH; 9-cis retinol dehydrogenase; 9cRDH; HSD17B9; RDH1; SDR9C5; Short chain dehydrogenase/reductase family 9C member 5; 1.1.1.300; SDR7C3; Short chain dehydrogenase/reductase family 7C member 3; 1.2.1.36; Aldehyde dehydrogenase family 1 member A2; ALDH1A2; RALDH 2; RALDH(II); RALDH2; Retinaldehyde-specific dehydrogenase type 2; 1.2.1.19; 1.2.1.28; 1.2.1.3; 1.2.1.36; 3-deoxyglucosone dehydrogenase; ALDC; Aldehyde dehydrogenase family 1 member A1; Aldehyde dehydrogenase, cytosolic; ALDH-E1; ALDH1; ALHDII; PUMB1; RALDH 1; RalDH1; Retinal dehydrogenase 1; 2.3.1.135; Phosphatidylcholine--retinol O-acyltransferase; 1.1.1.300; DD83.1; RDH17; Retinal short-chain dehydrogenase/reductase 1; Retinol dehydrogenase 17; retSDR1; SDR16C1; Short chain dehydrogenase/reductase family 16C member 1; 1.2.1.36; Aldehyde dehydrogenase 6; Aldehyde dehydrogenase family 1 member A3; ALDH1A3; ALDH6; RALDH-3; RalDH3; 1.3.99.23; All-trans-13,14-dihydroretinol saturase; PPAR-alpha-regulated and starvation-induced gene protein; PPSIG; RetSat; 1.1.1.300; Androgen-regulated short-chain dehydrogenase/reductase 1; ARSDR1; HCV core-binding protein HCBP12; Prostate short-chain dehydrogenase/reductase 1; PSDR1; RalR1; Retinal reductase 1; SDR7C1; Short chain dehydrogenase/reductase family 7C member 1; 1.1.1.184; CR; humNRDR; NADPH-dependent carbonyl reductase; NADPH-dependent retinol dehydrogenase/reductase; NRDR; Peroxisomal short-chain alcohol dehydrogenase; Protein SDR25C2; PSCD; SCAD-SRL; SDR25C2; Short chain dehydrogenase/reductase family 25C member 2; Short-chain dehydrogenase/reductase family member 4; 1.1.1.300; Alcohol dehydrogenase PAN2; PAN2; SDR7C4; Short chain dehydrogenase/reductase family 7C member 4; 1.1.1.300; Photoreceptor outer segment all-trans retinol dehydrogenase; PRRDH; SDR28C2; Short chain dehydrogenase/reductase family 28C member 2; 1.14.13.-; CYP26; CYP26A1; Cytochrome P450 retinoic acid-inactivating 1; Cytochrome P450RAI; hP450RAI; P450RAI1; Retinoic acid 4-hydroxylase; Retinoic acid-metabolizing cytochrome; Cellular retinaldehyde-binding protein; CRALBP; Interphotoreceptor retinoid-binding protein; Interstitial retinol-binding protein; IRBP; Cellular retinol-binding protein; Cellular retinol-binding protein I; CRBP; CRBP-I; CRBP1; Cellular retinol-binding protein III; CRBP-III; HRBPiso; Cellular retinoic acid-binding protein 4; Cellular retinoic acid-binding protein IV; CRABP-IV; CRABP4; CRBP4; Plasma retinol-binding protein; PRBP; RBP; Cellular retinol-binding protein II; CRBP-II; CRBP2; Retinol-binding protein receptor STRA6; Stimulated by retinoic acid gene 6 protein homolog","Retinoic acid receptor RXR-gamma; Apolipoprotein D; Prostaglandin-H2 D-isomerase; Retinol dehydrogenase 12; Retinol dehydrogenase 5; Retinol dehydrogenase 13; Retinal dehydrogenase 2; Aldehyde dehydrogenase 1A1; Lecithin retinol acyltransferase; Short-chain dehydrogenase/reductase 3; Retinaldehyde dehydrogenase 3; All-trans-retinol 13,14-reductase; Retinol dehydrogenase 11; Dehydrogenase/reductase SDR family member 4; Retinol dehydrogenase 14; Retinol dehydrogenase 8", A11CA01; D10AD02; R01AX02; V04CB01;A11CC01;S01XA02
ergotamine,Headache;Migraine;Variants of migraine;Vascular headache,Asthenia;Bradycardia;Cyanosis;Distress;Emotional distress;Gangrene;Hypertension;Hypoaesthesia;Ischaemia;Localised oedema;Musculoskeletal discomfort;Myalgia;Nausea;Numbness;Pain;Paraesthesia;Paresthesia of limbs;Peripheral coldness;Pruritus;Pulse absent;Sensory loss;Tachycardia;Vertigo;Vomiting,small molecule,approved,"(5'α)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione; 12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione; Ergotamin; Ergotamina; Ergotamine; Ergotaminum; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; Dopamine D2 receptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 2A; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; D(2) dopamine receptor; Alpha-2A adrenergic receptor; D(1) dopamine receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1F; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2B; Alpha-2C adrenergic receptor, N02CA52; N02CA72;N02CA02
erythromycin,Acne;Acne vulgaris;Amoebiasis;Amoebic colitis;Birth weight low;Cardiac valve disease;Chlamydia trachomatis infection;Chlamydial infection;Conjunctivitis;Corynebacterium infection;Diphtheria;Endocarditis;Endocarditis bacterial;Endophthalmitis;Erythrasma;Eye infection;Gonorrhoea;Hepatic function abnormal;Hypersensitivity;Hypertrophic cardiomyopathy;Idiopathic hypertrophic subaortic stenosis;Inclusion conjunctivitis;Infection;Legionella infection;Listeriosis;Low birth weight baby;Lower respiratory tract infection;Meningitis;Mitral valve prolapse;Ophthalmia neonatorum;Otitis media;Overgrowth bacterial;Panophthalmitis;Pathogen resistance;Pelvic inflammatory disease;Pertussis;Pharyngitis;Pharyngitis streptococcal;Pneumonia;Pneumonia legionella;Primary syphilis;Renal failure;Renal impairment;Respiratory tract infection;Rheumatic disorder;Rheumatic fever;Rheumatic heart disease;Sexually transmitted disease;Soft tissue infection;Streptococcal infection;Syphilis;Tetanus;Tetany;Tonsillitis;Trachoma;Unspecified non-gonococcal urethritis (NGU);Upper respiratory tract infection;Urethritis;Whooping cough;Wound,Abdominal cramps;Abdominal discomfort;Abdominal pain;Anaphylactic shock;Anorexia;Arrhythmia;Bilious vomiting;Burning sensation;Chest pain;Chlamydial infection;Confusional state;Congenital hypertrophic pyloric stenosis;Convulsion;Deafness;Decreased appetite;Diarrhoea;Discomfort;Dizziness;Dysgeusia;Electrocardiogram QT prolonged;Eruption;Erythema;Erythema multiforme;Eye irritation;Feeling abnormal;Gastrointestinal pain;Generalized urticaria;Hallucination;Hearing impaired;Hepatic function abnormal;Hepatitis;Hepatitis symptom;Hepatotoxicity;Hypersensitivity;Injury;Irritability;Jaundice;Liver function test abnormal;Localized exfoliation;Nausea;Nephritis interstitial;Pain;Pain of skin;Palpitations;Pancreatitis;Pruritus;Pseudomembranous colitis;Pyloric stenosis;Rash;Redness;Sensitisation;Skin exfoliation;Skin irritation;Skin tenderness;Stevens-Johnson syndrome;Streptococcal infection;Superinfection;Taste bitter;Tenderness;Tinnitus;Torsade de pointes;Toxic epidermal necrolysis;Trauma;Tubulointerstitial nephritis;Urticaria;Ventricular arrhythmia;Ventricular tachycardia;Vertigo;Vomiting,small molecule,approved; investigational; vet_approved,"3''-O-demethylerythromycin; Abomacetin; Eritromicina; Erythromycin; Erythromycin A; Erythromycin C; érythromycine; Erythromycinum; G-protein coupled receptor 38; GPR38; MTLR; MTLR1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3",23S ribosomal RNA; Motilin receptor; Voltage-gated inwardly rectifying potassium channel KCNH2, D10AF02; D10AF52; S01AA17;D10AF02;J01FA01
monomycin,Amoebiasis;Amoebic colitis;Conjunctivitis;Corynebacterium infection;Diphtheria;Erythrasma;Gonorrhoea;Infection;Legionella infection;Listeriosis;Lower respiratory tract infection;Pelvic inflammatory disease;Pertussis;Pharyngitis;Pharyngitis streptococcal;Pneumonia;Pneumonia legionella;Primary syphilis;Renal failure;Renal impairment;Respiratory tract infection;Rheumatic disorder;Rheumatic fever;Syphilis;Tonsillitis;Unspecified non-gonococcal urethritis (NGU);Upper respiratory tract infection;Urethritis;Whooping cough,Abdominal pain;Anaphylactic shock;Anorexia;Convulsion;Deafness;Decreased appetite;Diarrhoea;Eruption;Erythema multiforme;Gastrointestinal pain;Hearing impaired;Hepatic function abnormal;Hepatitis;Hepatitis symptom;Hypersensitivity;Liver function test abnormal;Nausea;Pancreatitis;Pseudomembranous colitis;Rash;Stevens-Johnson syndrome;Torsade de pointes;Toxic epidermal necrolysis;Urticaria;Ventricular arrhythmia;Ventricular tachycardia;Vomiting,small molecule,approved; vet_approved,Fradiomycin; Kaomycine; Neomicina; Neomycin; Vonamycin; strA; CaR; CaSR; GPRC2A; hCasR; Parathyroid cell calcium-sensing receptor 1; PCAR1,30S ribosomal protein S12; 16S ribosomal RNA; Extracellular calcium-sensing receptor, A01AB08; A07AA01; B05CA09; D06AX04; J01GB05; R02AB01; S01AA03; S02AA07; S03AA01;A07AA51
estazolam,Insomnia,Abdominal pain;Abnormal vision;Affect lability;Agitation;Agranulocytosis;Amnesia;Anxiety;Apathy;Arrhythmia;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Back pain;Body temperature increased;Breast swelling;Chest pain;Chills;Circumoral paresthesia;Cold symptoms;Confusional state;Constipation;Convulsion;Coordination abnormal;Cough;Decreased appetite;Depressed level of consciousness;Depression;Dermatitis;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Dysmenorrhoea;Dyspepsia;Dyspnoea;Ear pain;Enterocolitis;Epistaxis;Erythema multiforme;Euphoric mood;Eye irritation;Eye pain;Eye swelling;Feeling abnormal;Flat affect;Flatulence;Flushing;Gastritis;Gastrointestinal pain;Haematuria;Hallucination;Hangover;Headache;Hearing impaired;Hostility;Hyperhidrosis;Hypersensitivity;Hyperventilation;Hypokinesia;Hyporeflexia;Ill-defined disorder;Increased appetite;Laryngitis;Leukopenia;Libido decreased;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Melaena;Mental disability;Micturition urgency;Mood swings;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Nasopharyngitis;Nausea;Neck pain;Nervousness;Neuritis;Neuropathy peripheral;Nocturia;Nystagmus;Oedema;Oliguria;Pain;Pain in arm;Pain in extremity;Pain in jaw;Pain of lower extremities;Palpitations;Paraesthesia;Paraesthesia oral;Partial hearing loss;Penile discharge;Pharyngitis;Photophobia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Pruritus;Purpura;Rash;Rhinitis;Scotoma;Shock;Sinusitis;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Stiffness;Stupor;Sweating;Syncope;Tension;Thinking abnormal;Thirst;Thyroid neoplasm;Thyroid nodule;Tinnitus;Tremor;Ulcer;Urinary hesitation;Urinary incontinence;Urticaria;Vaginal discharge;Vascular purpura;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved; illicit,"8-chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; Estazolam; Estazolamum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",GABA(A) Receptor; Translocator protein; GABA(A) Receptor Benzodiazepine Binding Site,N05CD04
estradiol,Hypogonadism;Menopause,Abdominal bloating;Abdominal cramps;Abdominal distension;Abdominal pain;Abnormal withdrawal bleeding;Acute coronary syndrome;Anaphylactic shock;Angioedema;Arthralgia;Asthma;Bleeding breakthrough;Blood pressure increased;Breast cancer;Breast discharge;Breast tenderness;Cerebrovascular accident;Chloasma;Chorea;Cramps of lower extremities;Dementia;Depression;Dermatitis;Dermatitis hemorrhagic;Dizziness;Dysmenorrhoea;Ectropion of cervix;Endometrial cancer;Endometrial hyperplasia;Epilepsy;Erythema multiforme;Erythema nodosum;Exacerbation of asthma;Fibrocystic breast disease;Flatulence;Galactorrhoea;Gallbladder disorder;Haemangioma;Headache;Hirsutism;Hypocalcaemia;Irritability;Jaundice cholestatic;Metrorrhagia;Migraine;Mood alteration NOS;Mood swings;Muscle spasms;Musculoskeletal discomfort;Myocardial infarction;Nausea;Nervousness;Oedema;Ovarian cancer;Pain;Pancreatitis;Porphyrin metabolism disorder;Pruritus;Pulmonary embolism;Purpura;Rash;Retinal vascular thrombosis;Superficial phlebothrombosis;Tension;Thrombophlebitis;Thrombophlebitis superficial;Urticaria;Uterine leiomyoma;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved; investigational; vet_approved,"(17β)-estra-1,3,5(10)-triene-3,17-diol; 17beta oestradiol; 17β-estra-1,3,5(10)-triene-3,17-diol; 17β-estradiol; 17β-oestradiol; beta-Estradiol; cis-Estradiol; Estradiol; Estradiol-17beta; Estradiolum; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; NACRA4; CEPR; Chemoattractant receptor-like 2; CMKRL2; DRY12; FEG-1; Flow-induced endothelial G-protein coupled receptor 1; G protein-coupled estrogen receptor 1; G-protein coupled receptor 30; GPCR-Br; GPER; GPR30; IL8-related receptor DRY12; LYGPR; Lymphocyte-derived G-protein coupled receptor; Membrane estrogen receptor; mER; ATP6; ATPASE6; F-ATPase protein 6; MTATP6; Coiled-coil myosin-like BCL2-interacting protein; GT197; Protein GT197; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.1.1.6; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; FABPI; Fatty acid-binding protein 2; I-FABP; Intestinal-type fatty acid-binding protein; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; OAT-RP-5; OATP-14; OATP-F; OATP-RP5; OATP14; OATP1C1; OATPF; Organic anion transporter 1C1; Organic anion transporter F; Organic anion transporter polypeptide-related protein 5; Organic anion-transporting polypeptide 14; SLC21A14; Solute carrier family 21 member 14; Thyroxine transporter",Estrogen receptor; Estrogen receptor beta; Nuclear receptor subfamily 1 group I member 2; Neuronal acetylcholine receptor subunit alpha-4; G-protein coupled estrogen receptor 1; ATP synthase subunit a; Beclin-1, G02BB01; G03AA14; G03AA17; G03AB08; G03CA03; G03CA53; G03EA01; G03EA02; G03EA03; G03FA01; G03FA02; G03FA03; G03FA04; G03FA05; G03FA06; G03FA07; G03FA08; G03FA09; G03FA10; G03FA11; G03FA12; G03FA13; G03FA14; G03FA15; G03FA17; G03FB01; G03FB02; G03FB03; G03FB04; G03FB05; G03FB06; G03FB07; G03FB08; G03FB09; G03FB10; G03FB11; G03FB12; G03HB01; H01CC53; H01CC54;G03FA16
estradiol,Atrophy;Hypogonadism;Menopause;Oestrogen deficiency;Osteoporosis postmenopausal;Ovarian failure;Primary ovarian failure;Prostate cancer;Prostate carcinoma,Abdominal bloating;Abdominal cramps;Abdominal distension;Abdominal pain;Abnormal withdrawal bleeding;Acne;Acute coronary syndrome;Anaphylactic shock;Angioedema;Anxiety;Asthenia;Asthma;Bleeding breakthrough;Blood pressure increased;Breast cancer;Breast discharge;Breast disorder;Breast enlargement;Breast pain;Breast tenderness;Cardiac disorder;Cerebrovascular accident;Chloasma;Chorea;Connective tissue disorder;Contact lens intolerance;Cramp muscle;Cramps of lower extremities;Dementia;Depressed mood;Depression;Dermatitis;Dermatitis hemorrhagic;Disturbance in sexual arousal;Dizziness;Dysmenorrhoea;Dyspepsia;Ectropion of cervix;Endometrial cancer;Endometrial hyperplasia;Epilepsy;Erythema multiforme;Erythema nodosum;Exacerbation of asthma;Eye disorder;Fatigue;Fibrocystic breast disease;Flatulence;Galactorrhoea;Gallbladder disorder;Gastrointestinal disorder;Gastrointestinal pain;Haemangioma;Headache;Hereditary angioedema;Hirsutism;Hypersensitivity;Hypocalcaemia;Immune system disorder;Irritability;Jaundice cholestatic;Libido decreased;Libido increased;Malnutrition;Mental disorder;Metrorrhagia;Migraine;Mood alteration NOS;Mood swings;Muscle spasms;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Oedema;Ovarian cancer;Pain;Palpitations;Pancreatitis;Porphyrin metabolism disorder;Pruritus;Pulmonary embolism;Purpura;Rash;Retinal vascular thrombosis;Superficial phlebothrombosis;Tenderness;Tension;Thrombophlebitis;Thrombophlebitis superficial;Urticaria;Uterine leiomyoma;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased;Weight increased,small molecule,approved; investigational; vet_approved,"(17β)-estra-1,3,5(10)-triene-3,17-diol; 17beta oestradiol; 17β-estra-1,3,5(10)-triene-3,17-diol; 17β-estradiol; 17β-oestradiol; beta-Estradiol; cis-Estradiol; Estradiol; Estradiol-17beta; Estradiolum; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; NACRA4; CEPR; Chemoattractant receptor-like 2; CMKRL2; DRY12; FEG-1; Flow-induced endothelial G-protein coupled receptor 1; G protein-coupled estrogen receptor 1; G-protein coupled receptor 30; GPCR-Br; GPER; GPR30; IL8-related receptor DRY12; LYGPR; Lymphocyte-derived G-protein coupled receptor; Membrane estrogen receptor; mER; ATP6; ATPASE6; F-ATPase protein 6; MTATP6; Coiled-coil myosin-like BCL2-interacting protein; GT197; Protein GT197; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.1.1.6; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; FABPI; Fatty acid-binding protein 2; I-FABP; Intestinal-type fatty acid-binding protein; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; OAT-RP-5; OATP-14; OATP-F; OATP-RP5; OATP14; OATP1C1; OATPF; Organic anion transporter 1C1; Organic anion transporter F; Organic anion transporter polypeptide-related protein 5; Organic anion-transporting polypeptide 14; SLC21A14; Solute carrier family 21 member 14; Thyroxine transporter",Estrogen receptor; Estrogen receptor beta; Nuclear receptor subfamily 1 group I member 2; Neuronal acetylcholine receptor subunit alpha-4; G-protein coupled estrogen receptor 1; ATP synthase subunit a; Beclin-1, G02BB01; G03AA14; G03AA17; G03AB08; G03CA03; G03CA53; G03EA01; G03EA02; G03EA03; G03FA01; G03FA02; G03FA03; G03FA04; G03FA05; G03FA06; G03FA07; G03FA08; G03FA09; G03FA10; G03FA11; G03FA12; G03FA13; G03FA14; G03FA15; G03FA17; G03FB01; G03FB02; G03FB03; G03FB04; G03FB05; G03FB06; G03FB07; G03FB08; G03FB09; G03FB10; G03FB11; G03FB12; G03HB01; H01CC53; H01CC54;G03FA16
estramustine,Neoplasm;Prostate cancer;Prostate carcinoma,Abdominal discomfort;Acute coronary syndrome;Affect lability;Alopecia;Anaemia;Angioedema;Anorexia;Anxiety;Burning in throat;Cardiac arrest;Cardiac failure congestive;Cerebrovascular accident;Chest pain;Confusional state;Congenital anomaly;Cramps of lower extremities;Decreased appetite;Depression;Dermatitis;Developmental delay;Diarrhoea;Digestion impaired;Disturbance in sexual arousal;Diuresis;Dry skin;Dyspepsia;Dysphonia;Dyspnoea;Embolism;Embolism venous;Eye pain;Feeling abnormal;Flatulence;Fluid retention;Flushing;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal symptom NOS;Gastrointestinal tract irritation;Gynaecomastia;Headache;Hoarseness;Hot flush;Hypercalcaemia;Hypertension;Increased tendency to bruise;Insomnia;Lacrimation;Lacrimation increased;Lethargy;Leukopenia;Libido decreased;Menopausal symptoms;Mood swings;Muscle spasms;Muscular weakness;Myocardial infarction;Myocardial ischaemia;Nausea;Night sweats;Oedema;Polyuria;Pruritus;Rash;Skin exfoliation;Tenderness;Thirst;Throat irritation;Thrombocytopenia;Thromboembolism;Thrombophlebitis;Tinnitus;Transaminases increased;Vomiting,small molecule,approved; investigational,"17β-Estradiol 3-(bis(2-chloroethyl)carbamate); Estradiol 3-(N,N-bis(2-chloroethyl)carbamate); Estramustina; Estramustine; Estramustinum; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; MAP-2; MAP-1A; MAP1L; Proliferation-related protein p80; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Estrogen receptor beta; Estrogen receptor; Microtubule-associated protein 2; Microtubule-associated protein 1A,L01XX11
estriol,Atrophic vulvovaginitis;Atrophy;Breast cancer;Cardiovascular disorder;Climacteric;Convalescence;Convalescent;Dyspareunia;Dysuria;Eyelid ptosis;Hostility;Hot flush;Infection;Infertility;Inflammation;Menopausal disorder;Menopausal symptoms;Menopause;Night sweats;Oestrogen deficiency;Postmenopause;Pruritus;Pruritus vulvae;Ptosis;Recurrent infection;Ulcer;Urinary incontinence;Uterovaginal prolapse;Vaginal haemorrhage;Vaginal infection;Vaginitis atrophic;Vulvovaginal atrophy;Vulvovaginal pruritus,Acute coronary syndrome;Application site irritation;Breast cancer;Breast cancer invasive NOS;Breast discomfort;Breast disorder;Breast tension;Cerebrovascular accident;Cervical discharge;Chloasma;Dementia;Embolism venous;Endometrial cancer;Erythema multiforme;Erythema nodosum;Fluid retention;Gallbladder disorder;Gastrointestinal disorder;Malnutrition;Myocardial infarction;Nausea;Neoplasm;Pain;Pelvic venous thrombosis;Postmenopausal haemorrhage;Postmenopausal spotting;Pruritus;Pulmonary embolism;Vascular purpura;Venous thromboembolism,small molecule,approved; investigational; vet_approved,"(16α,17β)-estra-1,3,5(10)-triene-3,16,17-triol; 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol; 16-alpha-Hydroxyestradiol; 16alpha-hydroxyestradiol; 16α-hydroxyestradiol; 16α,17β-estriol; 3,16alpha,17beta-Trihydroxy-delta(1,3,5)-estratriene; Estriol; Oestriol; Östriol; Trihydroxyestrin; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Estrogen receptor; Estrogen receptor beta; Sex hormone-binding globulin, G03CA04;G03CA04;G03CC06
ethambutol,"Disseminated tuberculosis;Eye disorder;Joint tuberculosis;Meningitis tuberculous;Miliary tuberculosis;Primary tuberculous infection;Pulmonary tuberculosis;Tuberculosis;Tuberculosis of bones and joints, unspecified;Tuberculosis of genitourinary system",Abdominal discomfort;Abdominal pain;Anaphylactic shock;Anaphylactoid reaction;Anorexia;Arthralgia;Blindness;Body temperature increased;Colour blindness;Confusional state;Decreased appetite;Dermatitis;Dermatitis exfoliative;Discomfort;Disorientation;Dizziness;Drug reaction with eosinophilia and systemic symptoms;Eosinophilia;Erythema multiforme;Feeling abnormal;Gastrointestinal pain;Gastrointestinal tract irritation;Gout;Gout acute;Hallucination;Headache;Hepatic function abnormal;Hepatitis;Hypersensitive syndrome;Hypersensitivity;Hypoaesthesia;Ill-defined disorder;Leukopenia;Liver function test abnormal;Lung infiltration;Lymphadenopathy;Malaise;Musculoskeletal discomfort;Myocarditis;Nausea;Nephritis;Neuritis;Neuritis retrobulbar;Neuropathy peripheral;Neutropenia;Numbness;Optic nerve disorder;Optic neuritis;Paraesthesia;Pericarditis;Pneumonia;Pruritus;Rash;Refraction disorder;Scotoma;Sensory loss;Stevens-Johnson syndrome;Thrombocytopenia;Tingling of extremity;Toxic epidermal necrolysis;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting,small molecule,approved,"(+)-2,2'-(ethylenediimino)di-1-butanol; (+)-ethambutol; (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine; (+)-S,S-ethambutol; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; (S,S)-ethambutol; EMB; Etambutol; Etambutolo; Ethambutol; Ethambutolum; S,S-Ethambutol; 2.4.2.-; 2.4.2.-; 2.4.2.-; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Probable arabinosyltransferase C; Probable arabinosyltransferase B; Probable arabinosyltransferase A, J04AM03; J04AM06; J04AM07;J04AK02
ethosuximide,Epilepsy;Petit mal epilepsy,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Aggression;Agitation;Agranulocytosis;Anorexia;Aplastic anaemia;Asthenia;Ataxia;Blood and lymphatic system disorders;Breast disorder;Cerebration impaired;Connective tissue disorder;Cramp muscle;Decreased appetite;Dermatitis;Diarrhoea;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug eruption;Eosinophilia;Erythema multiforme;Euphoric mood;Eye disorder;Fatigue;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Gingival hypertrophy;Haematuria;Headache;Hiccups;Hirsutism;Hyperkinesia;Hypersensitivity;Immune system disorder;Irritability;Lethargy;Leukopenia;Libido increased;Malnutrition;Mediastinal disorder;Mental disability;Mental disorder;Microscopic hematuria;Muscle spasms;Myopia;Nausea;Nervous system disorder;Pancytopenia;Paranoia;Psychotic disorder;Rash;Rash erythematous;Skin disorder;Sleep disorder;Sleep terror;Somnolence;Stevens-Johnson syndrome;Suicidal ideation;Swollen tongue;Systemic lupus erythematosus;Tongue disorder;Tongue oedema;Unspecified disorder of skin and subcutaneous tissue;Upset stomach;Urethral disorder;Urinary tract disorder;Urticaria;Vaginal haemorrhage;Vomiting;Weight decreased,small molecule,approved,"(±)-2-ethyl-2-methylsuccinimide; 2-ethyl-2-methylsuccinimide; 2-methyl-2-ethylsuccinimide; 3-ethyl-3-methyl-2,5-pyrrolidinedione; 3-ethyl-3-methylsuccinimide; 3-methyl-3-ethylpyrrolidine-2,5-dione; 3-methyl-3-ethylsuccinimide; Aethosuximide; Atysmal; Ethosuximid; éthosuximide; Ethosuximide; Ethosuximidum; Etosuximida; Thilopemal; α-ethyl-α-methylsuccinimide; α-methyl-α-ethylsuccinimide; γ-ethyl-γ-methyl-succinimide; γ-methyl-γ-ethyl-succinimide; Cav3.1c; KIAA1123; NBR13; Voltage-gated calcium channel subunit alpha Cav3.1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J",Voltage-dependent T-type calcium channel subunit alpha-1G, N03AD51;N03AD01
ethotoin,Convulsion,Asthenia;Ataxia;Body temperature increased;Chest pain;Dermatitis;Diarrhoea;Diplopia;Distress;Dizziness;Emotional distress;Erythema multiforme;Fatigue;Gingival hypertrophy;Headache;Hypoaesthesia;Insomnia;Lymphadenopathy;Lymphoma;Nausea;Non-Hodgkin's lymphoma;Numbness;Nystagmus;Rash;Sensory loss;Stevens-Johnson syndrome;Systemic lupus erythematosus;Vomiting,small molecule,approved,"(±)-3-ethyl-5-phenylhydantoin; 1-ethyl-2,5-dioxo-4-phenylimidazolidine; 3-ethyl-5-phenyl-2,4-imidazolidinedione; 3-Ethyl-5-phenyl-imidazolidine-2,4-dione; 3-ethyl-5-phenylhydantoin; 3-ethyl-5-phenylimidazolidin-2,4-dione; Ethotoin; Ethotoïne; Ethotoinum; Etotoina; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; Serpin A7; T4-binding globulin; TBG",Sodium channel protein type 5 subunit alpha; Nuclear receptor subfamily 1 group I member 2,N03AB01
etodolac,Acute pain;Arthritis;Diabetes mellitus;Diabetic;Juvenile idiopathic arthritis;Osteoarthritis;Pain;Rheumatoid arthritis,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal faeces;Acute coronary syndrome;Ageusia;Agranulocytosis;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Arthralgia;Asthenia;Asthma;Bladder pain;Bleeding time prolonged;Blood urea increased;Body temperature increased;Bronchitis;Bronchospasm;Burning sensation;Calculus of kidney;Cardiac failure congestive;Cerebrovascular accident;Chills;Colitis;Coma;Confusional state;Conjunctivitis;Constipation;Convulsion;Cutaneous vasculitis;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Dry mouth;Duodenitis;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ecchymosis;Eosinophilia;Epidermal necrosis;Epigastric pain;Eructation;Erythema multiforme;Fatigue;Feeling abnormal;Flatulence;Flushing;Gastric ulcer;Gastritis;Gastrointestinal discomfort;Gastrointestinal haemorrhage;Gastrointestinal pain;Glossitis;Haematemesis;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hearing impaired;Heartburn;Hepatic enzyme increased;Hepatic failure;Hepatic necrosis;Hepatitis;Hepatitis cholestatic;Hepatitis fulminant;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Ill-defined disorder;Infection;Insomnia;Intestinal ulcer;Irritability;Jaundice;Jaundice cholestatic;Kidney function abnormal;Leukocytoclastic vasculitis;Leukopenia;Leukorrhea;Loss of consciousness;Lung infiltration;Lymphadenopathy;Malaise;Melaena;Meningitis;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Nephritis interstitial;Nephrolithiasis;Nervousness;Neutropenia;Oedema;Oesophageal achalasia;Oesophagitis;Oliguria;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Peptic ulcer;Pharyngitis;Photophobia;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Protein urine present;Proteinuria;Pruritus;Pulmonary function test decreased;Purpura;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Renal failure;Renal impairment;Renal papillary necrosis;Respiratory depression;Rhinitis;Sepsis;Shock;Sinusitis;Skin exfoliation;Skin hyperpigmentation;Somnolence;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Sweating;Syncope;Tachycardia;Tension;Thirst;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Ulcer;Ulcerative stomatitis;Upper abdominal discomfort;Urine output increased;Urticaria;Uterine haemorrhage;Vaginal discharge;Vascular purpura;Vasculitis;Vertigo;Vesiculobullous rash;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational; vet_approved,"(±)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; (1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid; 1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid; Étodolac; Etodolac; Etodolaco; Etodolacum; Etodolic acid; Etodolsäure; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; NR2B1; Nuclear receptor subfamily 2 group B member 1; Retinoid X receptor alpha; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1; Retinoic acid receptor RXR-alpha,M01AB08
etoposide,Acquired immunodeficiency syndrome;Autoimmune disorder;Bladder cancer;Bone marrow depression;Brain neoplasm;Cervix carcinoma;Ewing's sarcoma;Gestational trophoblastic tumour;Hepatic cancer;Hepatic function abnormal;Hepatocellular carcinoma;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hypersensitivity;Kaposi's sarcoma;Leukaemia;Lymphocytic leukaemia;Lymphoma;Neoplasm;Neoplasm malignant;Nervous system disorder;Neuroblastoma;Neutropenia;Non-Hodgkin's lymphoma;Ovarian cancer;Pancytopenia;Prostate cancer;Renal failure;Renal impairment;Rhabdomyosarcoma;Small cell carcinoma;Small cell lung cancer;Testicular neoplasm,Abdominal pain;Acute coronary syndrome;Acute leukaemia;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Alopecia reversible;Anaemia;Anal irritation;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Anorectal discomfort;Anorexia;Apnoea;Ascites;Asthenia;Back pain;Blindness cortical;Blood albumin decreased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood uric acid increased;Body temperature increased;Bronchospasm;CNS toxicity;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiotoxicity;Cardiovascular disorder;Cellulitis;Chest discomfort;Chest pain;Chills;Confusional state;Constipation;Convulsion;Cough;Cramp muscle;Cyanosis;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dysgeusia;Dysphagia;Dyspnoea;Erythema multiforme;Extravasation;Eye disorder;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal toxicity;Haematotoxicity;Headache;Hepatobiliary disease;Hepatotoxicity;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperuricaemia;Hypoaesthesia;Hypotension;Ill-defined disorder;Immune system disorder;Induration;Infection;Infestation;Infestation NOS;Inflammation;Interstitial lung disease;Interstitial pneumonia;Jaundice;Laryngospasm;Leukopenia;Loss of consciousness;Lung cancer metastatic;Malaise;Mediastinal disorder;Metabolic acidosis;Mouth ulceration;Mucosal inflammation;Muscle spasms;Myelosuppression;Myocardial infarction;Nail changes;Nail disorder;Nail pigmentation;Nausea;Necrolysis epidermal;Necrosis;Nephropathy;Nephropathy toxic;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutropenic sepsis;Numbness;Oesophagitis;Optic neuritis;Pain;Palmar-plantar erythema;Palmar-plantar erythrodysaesthesia syndrome;Pancytopenia;Paraesthesia;Parotitis;Phlebitis;Phosphatase alkaline increased;Pigmentation disorder;Pneumonia;Pruritus;Pulmonary fibrosis;Radiation recall reaction (dermatologic);Rash;Rash maculo-papular;Recall phenomenon;Renal failure;Rigors;Sensory loss;Sepsis;Septic shock;Septicemia;Serum albumin decreased;Skin discolouration;Skin disorder;Skin exfoliation;Skin necrosis;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Swelling;Swollen tongue;Tachycardia;Throat tightness;Thrombocytopenia;Tingling sensation;Toxic epidermal necrolysis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vertigo;Vomiting,small molecule,approved,"(−)-etoposide; 4-demethylepipodophyllotoxin β-D-ethylideneglucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one; Etoposide; Etoposido; Etoposidum; trans-Etoposide; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 5.6.2.2; DNA topoisomerase II, beta isozyme; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.5.1.18; Glutathione transferase T1-1; GST class-theta-1; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; 7.6.2.3; Anthracycline resistance-associated protein; ARA; MOAT-E; MRP6; Multi-specific organic anion transporter E; Multidrug resistance-associated protein 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",DNA topoisomerase 2-alpha; DNA topoisomerase 2-beta,L01CB01
famciclovir,Dermatitis;Genital herpes;Herpes labialis;Herpes simplex;Herpes zoster;Immunocompromised;Immunodeficiency;Infection;Mucocutaneous herpes simplex;Ophthalmic herpes zoster;Oral herpes;Pain;Post herpetic neuralgia;Pruritus;Rash;Scab;Tenderness,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Anaemia;Angioedema;Anorexia;Anxiety;Arthralgia;Asthenia;Back pain;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Body temperature increased;Cardiac disorder;Chills;Confusional state;Constipation;Creatine phosphokinase increased;Decreased appetite;Delirium;Dermatitis;Diarrhoea;Disorientation;Dizziness;Dry mouth;Dysmenorrhoea;Dyspepsia;Enzyme abnormality;Erythema multiforme;Eyelid oedema;Face oedema;Fatigue;Feeling abnormal;Flatulence;Fungal infection;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Hepatic enzyme increased;Hepatobiliary disease;Herpes zoster;Hyperbilirubinaemia;Hyperhidrosis;Infection;Insomnia;Jaundice;Jaundice cholestatic;Laryngeal pain;Leukocytoclastic vasculitis;Leukopenia;Lipase increased;Liver function test abnormal;Mental disorder;Migraine;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Nasopharyngitis;Nausea;Nervous system disorder;Neutropenia;Palpitations;Paraesthesia;Periorbital oedema;Pharyngeal oedema;Pharyngitis;Pharyngolaryngeal pain;Pruritus;Rash;Renal failure acute;Rigors;Sinusitis;Skin disorder;Somnolence;Stevens-Johnson syndrome;Sweating increased;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urticaria;Vomiting,small molecule,approved; investigational,"2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine; acetic acid 2-acetoxymethyl-4-(2-amino-purin-9-yl)-butyl ester; Famciclovir; Famciclovirum; FCV; 2.7.7.7; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase",DNA polymerase catalytic subunit, S01AD07;J05AB09
famotidine,Abdominal discomfort;Acid indigestion;Acute duodenal ulcer;Adenoma benign;Agitation;Agranulocytosis;Anaphylactic shock;Angioedema;Asthenia;Body temperature increased;Bradycardia;Breast feeding;Carcinogenicity;Chest discomfort;Chest tightness;Confusional state;Congenital anomaly;Constipation;Contusion;Developmental delay;Diarrhoea;Diuretic effect;Dizziness;Drug interaction;Duodenal ulcer;Dyspepsia;Erectile dysfunction;Erosive oesophagitis;Esophageal erosions;Excitement;Fatigue;Feeling abnormal;Foetor hepaticus;Gastric cancer;Gastric erosions;Gastric ulcer;Gastrinoma;Gastritis erosive;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;Grand mal convulsion;Gynaecomastia;Haemoglobin;Haemorrhage;Hallucination;Headache;Heartburn;Hepatocellular injury;Herpes labialis;Hyperchlorhydria;Hyperplasia;Hypersensitivity;Hypertension;Hypertensive;Jaundice cholestatic;Leukopenia;Liver disorder;Neoplasm;Oesophagitis;Oral herpes;Pancytopenia;Peptic ulcer;Polyuria;Renal failure;Renal failure chronic;Renal impairment;Sleep disorder;Sleep disturbance;Sour stomach;Swelling;Teratogenicity;Thrombocytopenia;Tonic-clonic seizures;Toxic epidermal necrolysis;Ulcer;Upset stomach;Urticaria;Vomiting;Zollinger-Ellison syndrome,Abdominal discomfort;Abdominal pain;Acne;Agitation;Agranulocytosis;Alopecia;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Anxiety disorder;Appetite absent;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrioventricular block;Back pain;Benign prostatic hyperplasia;Benign prostatic hypertrophy;Body temperature increased;Bone marrow depression;Bradycardia;Bronchitis;Bronchospasm;Chest pain;Confusional state;Conjunctival hyperaemia;Constipation;Convulsion;Cough;Cramp muscle;Decreased appetite;Depression;Dermatitis;Diarrhoea;Disorientation;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Dry throat;Dysgeusia;Dyspepsia;Dysuria;Ear pain;Electrocardiogram QT prolonged;Erectile dysfunction;Erosive oesophagitis;Erythema multiforme;Eustachian tube disorder;Extravasation;Face oedema;Fatigue;Feeling abnormal;Flushing;Foot pain;Gastrointestinal pain;Gingivitis;Glossodynia;Grand mal convulsion;Gynaecomastia;Haematuria;Hallucination;Headache;Hepatitis;Hypersensitivity;Hypotrichosis;Infection;Influenza;Influenza like illness;Injection site irritation;Insomnia;Interstitial lung disease;Interstitial pneumonia;Irritability;Jaundice;Jaundice cholestatic;Knee pain;Laceration;Leukopenia;Libido decreased;Loss of consciousness;Measles;Menstrual disorder;Mental disorder;Migraine;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasal congestion;Nausea;Neck pain;Neutropenia;Oedema;Orbital oedema;Pain;Pain in extremity;Palpitations;Pancytopenia;Paraesthesia;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pollakiuria;Pruritus;Psychotic disorder;Rash;Rhabdomyolysis;Shock;Sinus disorder;Sinusitis;Sneezing;Somnolence;Stevens-Johnson syndrome;Supraventricular extrasystoles;Swelling;Syncope;Taste disorders;Thrombocytopenia;Tinnitus;Tonic-clonic seizures;Toxic epidermal necrolysis;Upper respiratory tract infection;Urticaria;Ventricular extrasystoles;Viral infection;Vomiting;Wheezing,small molecule,approved,(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide; 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine; Famotidina; Famotidine; Famotidinum; N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide; Gastric receptor I; H2R; HH2R; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hOCT2; OCT2; Organic cation transporter 2; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1,Histamine H2 receptor, A02BA53;A02BA03
felbamate,Convulsion;Convulsions generalised;Epilepsy;Lennox-Gastaut syndrome;Partial seizures,Abdominal pain;Abnormal vision;Acne;Acquired megacolon;Acute leukaemia;Affect lability;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Anencephaly;Anorexia;Antinuclear antibody positive;Anxiety;Apathy;Aplastic anaemia;Arrhythmia supraventricular;Arthralgia;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrial arrhythmia;Atrial fibrillation;Blood alkaline phosphatase increased;Blood lactate dehydrogenase increased;Body odor;Body temperature decreased;Body temperature increased;Bradycardia;Brain oedema;Bullous eruption;Cardiac arrest;Cardiac failure;Cerebration impaired;Cerebrovascular disorder;Chest pain;Chills;Choreoathetosis;Coagulopathy;Coma;Confusional state;Congenital genital malformation;Conjunctivitis;Constipation;Cough;Decreased appetite;Dehydration;Delusion;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Diplopia;Discomfort;Disseminated intravascular coagulation;Disturbance in attention;Dizziness;Drug interaction;Dry mouth;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Edema cerebral;Embolism limb;Encephalocele;Encephalopathy;Enteritis;Eosinophilia;Epistaxis;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Face oedema;Fatigue;Feeling abnormal;Flat affect;Flatulence;Flushing;Foetal death;Foetal disorder;Gait disturbance;Gangrene;Gastric dilatation;Gastric ulcer;Gastritis;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival bleeding;Glossitis;Haematemesis;Haematuria;Haemoglobin;Haemolytic anaemia;Haemolytic uraemic syndrome;Haemorrhage;Haemorrhage urinary tract;Hallucination;Headache;Hearing impaired;Hemianopia;Henoch-Schonlein purpura;Hepatic failure;Hepatitis;Hepatorenal syndrome;Hiccups;Hyperammonaemia;Hyperglycaemia;Hyperhidrosis;Hypernatraemia;Hyperpyrexia;Hypertension;Hypocalcaemia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Hypothermia;Ileus;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Influenza like illness;Influenza-like symptoms;Insomnia;Intestinal obstruction;Jaundice;Kidney function abnormal;Lactic dehydrogenase activity increased;Leukaemia;Leukocytosis;Leukopenia;Lichen planus;Livedo reticularis;Lymphadenopathy;Lymphoma;Lymphoproliferative disorder;Malaise;Mania;Manic psychosis;Mean cell volume increased;Megacolon;Menstrual disorder;Mental disability;Microcephaly;Migraine;Miosis;Mononeuritis;Mood swings;Mouth ulceration;Mucosal swelling;Muscle contractions involuntary;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myeloid leukaemia;Nausea;Necrosis;Neoplasm;Nephrosis;Nephrotic syndrome;Nervousness;Non-Hodgkin's lymphoma;Nystagmus;Oedema;Oedema mucosal;Oesophagitis;Osteoarthritis;Otitis media;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Partial hearing loss;Peripheral embolism;Peripheral ischaemia;Pharyngitis;Phosphatase alkaline increased;Photosensitivity allergic reaction;Photosensitivity reaction;Placental disorder;Platelet disorder;Pleural effusion;Pneumonia;Prothrombin time shortened;Pruritus;Psychotic disorder;Pulmonary function test decreased;Pulmonary haemorrhage;Purpura;Rash;Rectal haemorrhage;Renal failure acute;Renal impairment;Respiratory depression;Respiratory failure;Respiratory insufficiency;Retrosternal pain;Rhabdomyolysis;Rhinitis;Rigors;Sepsis;Sickness;Sinusitis;Skin odour abnormal;Somnolence;Status epilepticus;Stevens-Johnson syndrome;Stomach dilation procedure;Stupor;Sudden death;Sudden infant death syndrome;Suicide attempt;Supraventricular tachycardia;Sweating;Tachycardia;Tension;Thinking abnormal;Thrombocytopenia;Thrombophlebitis;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Ulcerative stomatitis;Upper respiratory tract infection;Urinary incontinence;Urinary retention;Urinary tract infection;Urticaria;Vaginal haemorrhage;Vascular purpura;Vasculitis;Visual impairment;Vomiting;Weight decreased;Weight increased;X-linked lymphoproliferative syndrome,small molecule,approved,"2-phenyl-1,3-propanediol dicarbamate; carbamic acid 2-phenyltrimethylene ester; Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester; Felbamate; Felbamato; Felbamatum; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase","Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 2A",N03AX10
felodipine,Acute coronary syndrome;Angina pectoris;Cardiac failure;Diabetes mellitus;Diabetic nephropathy;Essential hypertension;Gingivitis;Hyperlipidaemia;Hypertension;Hypotension;Myocardial infarction,Abdominal discomfort;Abdominal pain;Allergic cutaneous angiitis;Anaemia;Angina pectoris;Angioedema;Ankle edema;Anxiety disorder;Arrhythmia;Arthralgia;Asthenia;Atrioventricular block second degree;Back pain;Body temperature increased;Bradycardia;Bronchitis;Cerebrovascular accident;Chest pain;Confusional state;Constipation;Contusion;Cough;Coxalgia;Cramp muscle;Dermatitis;Diarrhoea;Disturbance in sexual arousal;Dizziness;Dry mouth;Dyspepsia;Dyspnoea;Dysuria;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Erythema nodosum;Extrasystoles;Face oedema;Fatigue;Feeling abnormal;Feeling cold;Feeling hot;Flatulence;Flushing;Foot pain;Gastrointestinal pain;Gingival hyperplasia;Gynaecomastia;Headache;Hepatitis cholestatic;Hyperplasia;Hypersensitivity;Influenza;Influenza like illness;Insomnia;Irritability;Joint swelling;Knee pain;Leg pain;Leukocytoclastic vasculitis;Libido decreased;Loss of consciousness;Loss of libido;Micturition urgency;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Nervousness;Oedema peripheral;Orthostatic hypotension;Pain in arm;Pain in extremity;Palpitations;Paraesthesia;Pharyngitis;Photosensitivity reaction;Pollakiuria;Polyuria;Pruritus;Rash;Regurgitation;Respiratory tract infection;Rhinorrhoea;Salivary gland enlargement;Sensation of warmth;Sexual dysfunction;Shock;Sinusitis;Sneezing;Somnolence;Swelling;Syncope;Tachycardia;Tenderness;Tension;Tingling sensation;Transaminases decreased;Tremor;Upper respiratory tract infection;Upset stomach;Urine output increased;Urticaria;Vasodilation;Vasodilation procedure;Vertigo;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,"(±)-ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; Felodipina; Felodipine; Felodipino; Felodipinum; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; Low-voltage-activated calcium channel alpha1 3.2 subunit; Voltage-gated calcium channel subunit alpha Cav3.2; KIAA0558; Voltage-gated calcium channel subunit alpha-2/delta-2; 3.1.4.17; 63 kDa Cam-PDE; Cam-PDE 1B; PDES1B; 3.1.4.17; 61 kDa Cam-PDE; Cam-PDE 1A; hCam-1; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; TN-C; TNNC; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP","Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent calcium channel subunit alpha-2/delta-1; Voltage-dependent L-type calcium channel subunit beta-2; Voltage-dependent L-type calcium channel subunit alpha-1D; Voltage-dependent L-type calcium channel subunit alpha-1S; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent calcium channel subunit alpha-2/delta-2; Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A; Mineralocorticoid receptor; Troponin C, skeletal muscle; Troponin C, slow skeletal and cardiac muscles; Calmodulin", C08CA02; C09BB05;C07FB02;C08CA02
fenofibrate,Abdominal aortic aneurysm;Aortic aneurysm;Blood triglycerides increased;Cardiac disorder;Carotid artery disease;Combined hyperlipidaemia;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Diabetic;Diabetic retinopathy;Dyslipidaemia;Dyslipoproteinaemia;High density lipoprotein decreased;Hypercholesterolaemia;Hyperchylomicronaemia;Hyperlipidaemia;Hyperlipoproteinemia;Hypertriglyceridaemia;Hypothyroidism;Low density lipoprotein increased;Obesity;Pancreatitis;Peripheral arterial disease;Peripheral arterial occlusive disease;Peripheral vascular disorder;Renal failure;Renal impairment;Type 2 diabetes mellitus;Type I hyperlipidaemia;Type IV hyperlipidaemia;Weight decreased,Abdominal pain;Abnormal vision;Accidental injury;Acne;Acute coronary syndrome;Alanine aminotransferase increased;Alopecia;Alveolitis;Amblyopia;Anaemia;Angina pectoris;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Arrhythmia;Arteriosclerosis;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Atherosclerosis;Atrial fibrillation;Back pain;Bladder pain;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Breast feeding;Bronchitis;Bursitis;Calculus urinary;Cardiac disorder;Cardiovascular disorder;Cataract;Cataract specified;Chest pain;Cholecystitis;Cholelithiasis;Colitis;Conjunctivitis;Connective tissue disorder;Constipation;Coronary artery disease;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine increased;Cutaneous hypersensitivity;Cystitis;Cystitis noninfective;Decreased appetite;Deep vein thrombosis;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drug interaction;Dry mouth;Duodenal ulcer;Dyspepsia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Eczema;Electrocardiogram abnormal;Embolism;Embolism venous;Eosinophilia;Epigastric distress;Erectile dysfunction;Eructation;Erythema;Extrasystoles;Eye disorder;Fatigue;Feeling abnormal;Flatulence;Fungal skin infection;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gout;Gynaecomastia;Headache;Hepatic enzyme increased;Hepatic steatosis;Hepatitis;Hepatobiliary disease;Hernia;Herpes NOS;Herpes simplex;Herpes virus infection;Herpes zoster;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hypoglycaemia;Hypotension;Ill-defined disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Jaundice;Kidney function abnormal;Laboratory test abnormal;Lactic dehydrogenase activity increased;Laryngeal pain;Laryngitis;Leukopenia;Libido decreased;Liver fatty deposition;Liver function test abnormal;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Migraine;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myasthenia;Myocardial infarction;Myopathy;Myositis;Nail disorder;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuralgia;Oedema;Oedema peripheral;Oesophagitis;Osteoarthritis;Otitis media;Pain;Pain in extremity;Palpitations;Pancreatitis;Paraesthesia;Peptic ulcer;Peripheral vascular disorder;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Plasma creatinine increased;Pneumonia;Pollakiuria;Prostatic disorder;Pruritus;Pulmonary alveolitis;Pulmonary embolism;Raised liver function tests;Rash;Rash maculo-papular;Rectal disorder;Rectal haemorrhage;Refraction disorder;Renal failure;Renal failure acute;Renal impairment;Rhabdomyolysis;Rhinitis;Serum creatinine increased;Sinusitis;Skin disorder;Skin ulcer;Somnolence;Sweating;Tachycardia;Tenosynovitis;Tension;Thrombocytopenia;Thromboembolic event;Thromboembolism;Tooth disorder;Unintended pregnancy;Unspecified disorder of intestine;Unspecified disorder of skin and subcutaneous tissue;Unwell;Upper respiratory tract infection;Urinary tract infection;Urolithiasis;Urticaria;Vaginal moniliasis;Varicose vein;Vasodilation;Vasodilation procedure;Venous thromboembolism;Ventricular extrasystoles;Vertigo;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased;Weight increased,small molecule,approved,"2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester; Fenofibrate; Fenofibrato; Fenofibratum; Finofibrate; FNF; Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Procetofen; NR1C1; Nuclear receptor subfamily 1 group C member 1; PPAR; PPAR-alpha; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 3.4.24.-; Leukolysin; Membrane-type matrix metalloproteinase 6; Membrane-type-6 matrix metalloproteinase; MMP-25; MMP20; MMPL1; MT-MMP 6; MT6-MMP; MT6MMP; MTMMP6; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; 1.1.1.184; 15-hydroxyprostaglandin dehydrogenase [NADP(+)]; 20-beta-hydroxysteroid dehydrogenase; Alcohol dehydrogenase [NAD(P)+] CBR1; CBR; CRN; NADPH-dependent carbonyl reductase 1; PG-9-KR; Prostaglandin 9-ketoreductase; Prostaglandin-E(2) 9-reductase; SDR21C1; Short chain dehydrogenase/reductase family 21C member 1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.1.1.-; 1.1.1.112; 1.1.1.209; 1.1.1.210; 1.1.1.357; 1.1.1.51; 1.1.1.53; 1.1.1.62; 1.3.1.20; 20-alpha-HSD; 20-alpha-hydroxysteroid dehydrogenase; Chlordecone reductase homolog HAKRC; DD1; DDH; DDH1; Dihydrodiol dehydrogenase 1; HBAB; High-affinity hepatic bile acid-binding protein; 1.-.-.-; 1.1.1.112; 1.1.1.209; 1.1.1.53; 1.1.1.62; 1.3.1.20; 3-alpha-HSD3; Chlordecone reductase homolog HAKRD; DD-2; DD/BABP; DD2; DDH2; Dihydrodiol dehydrogenase 2; Dihydrodiol dehydrogenase/bile acid-binding protein; Type III 3-alpha-hydroxysteroid dehydrogenase; 1.1.1.-; 1.1.1.210; 1.1.1.53; 1.1.1.62; 17-beta-HSD 5; 17-beta-hydroxysteroid dehydrogenase type 5; 3-alpha-HSD type 2; 3-alpha-HSD type II, brain; 3-alpha-hydroxysteroid dehydrogenase type 2; Chlordecone reductase homolog HAKRb; DD-3; DD3; DDH1; Dihydrodiol dehydrogenase 3; Dihydrodiol dehydrogenase type I; HA1753; HSD17B5; KIAA0119; PGFS; Prostaglandin F synthase; Testosterone 17-beta-dehydrogenase 5; 1.1.1.21; 1.1.1.300; 1.1.1.372; 1.1.1.54; Aldehyde reductase; Aldose reductase; ALDR1; ALR2; AR; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Peroxisome proliferator-activated receptor alpha; Nuclear receptor subfamily 1 group I member 2; Matrix metalloproteinase-25, C10AB05; C10BA04; C10BA09; C10BA12;C10AB05;C10BA03
fenoldopam,Hypertension;Hypertensive;Malignant hypertension,Abdominal pain;Acute coronary syndrome;Angina pectoris;Anxiety;Back pain;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Bradycardia;Cardiac failure;Chest pain;Constipation;Cramp of limb;Creatinine increased;Diarrhoea;Dizziness;Dyspnoea;Electrocardiogram T wave inversion;Extrasystoles;Flushing;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Hyperhidrosis;Hypokalaemia;Hypotension;Injection site reaction;Insomnia;Lactic dehydrogenase activity increased;Leukocytosis;Muscle spasms;Myocardial infarction;Myocardial ischaemia;Nasal congestion;Nausea;Nervousness;Oliguria;Orthostatic hypotension;Palpitations;Sweating;Tachycardia;Tension;Transaminases increased;Urinary tract infection;Vomiting,small molecule,approved,Fénoldopam; Fenoldopam; Fenoldopamum; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D1 receptor; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR,D(1B) dopamine receptor; D(1A) dopamine receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Alpha-1A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Alpha-2A adrenergic receptor,C01CA19
fenoprofen,Arthritis;Osteoarthritis;Pain;Rheumatoid arthritis,Abdominal pain;Agranulocytosis;Alopecia;Anaphylactic shock;Angioedema;Anorexia;Anuria;Aphthous stomatitis;Aplastic anaemia;Asthenia;Atrial fibrillation;Azotaemia;Bladder pain;Body temperature increased;Breast pain;Burning tongue;Confusional state;Constipation;Contusion;Convulsion;Cystitis;Cystitis noninfective;Decreased appetite;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disorientation;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Electrocardiogram change;Erythema multiforme;Fatigue;Feeling abnormal;Flatulence;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glossodynia;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hearing impaired;Hepatitis cholestatic;Hyperhidrosis;Hypersensitivity;Ill-defined disorder;Insomnia;Jaundice;Lymphadenopathy;Malaise;Nasopharyngitis;Nausea;Nephritis interstitial;Nephrosis;Nephrotic syndrome;Nervousness;Oedema peripheral;Oliguria;Optic neuritis;Palpitations;Pancreatitis;Pancytopenia;Partial hearing loss;Peptic ulcer;Personality change;Pruritus;Pulmonary oedema;Purpura;Rash;Reaction gastrointestinal;Renal failure;Renal papillary necrosis;Somnolence;Stevens-Johnson syndrome;Supraventricular tachycardia;Sweating increased;Tachycardia;Taste metallic;Tension;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tremor;Trigeminal neuralgia;Tubulointerstitial nephritis;Upper respiratory tract infection;Urticaria;Vascular purpura;Vision blurred;Vomiting,small molecule,approved,(+/-)-fenoprofen; (+/-)-m-phenoxyhydratropic acid; (±)-2-(3-phenoxyphenyl)propionic acid; 2-(3-phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 3-phenoxyhydratropic acid; DL-2-(3-phenoxyphenyl)propionic acid; Fenoprofen; Fénoprofène; Fenoprofeno; Fenoprofenum; α-(m-phenoxyphenyl)propionic acid; α-methyl-3-phenoxybenzeneacetic acid; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; NR1C1; Nuclear receptor subfamily 1 group C member 1; PPAR; PPAR-alpha; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma,Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma,M01AE04
fentanyl,Acute pain;Alcohol abuse;Analgesic effect;Analgesic therapy;Apnoea;Bradycardia;Breakthrough cancer pain;Breakthrough pain;Bronchoconstriction;Bronchospasm;Cancer pain;Chronic pain;Coordination abnormal;Cough;Dissociation;Drug abuse;Drug dependence;Drug seeking behavior;Euphoric mood;Headache;Hypotension;Hypotensive;Hypoventilation;Hypoxia;Major depression;Mental disorder;Migraine;Miosis;Mucosal inflammation;Muscle rigidity;Neoplasm malignant;Opioid abuse;Opioid naive;Pain;Pain worsened;Polymenorrhoea;Postoperative pain;Procedural pain;Pulmonary function test decreased;Respiratory depression;Respiratory failure;Short period;Substance abuse;Therapy naive;Toothache;Urticaria;Welts,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal sensation in eye;Abnormal vision;Abscess;Abscess periodontal;Accidental injury;Accidental overdose;Acidosis;Acute pain;Affect lability;Ageusia;Agitation;Akathisia;Alopecia;Altered state of consciousness;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angiopathy;Anorectal disorder;Anorexia;Anorgasmia;Anosmia;Anuria;Anxiety;Anxiety depression;Aphasia;Aphthous stomatitis;Apnoea;Application site eczema;Application site hypersensitivity;Application site irritation;Application site pain;Application site rash;Application site reaction;Application site ulcer;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Attention deficit disorder;Attention deficit/hyperactivity disorder;Back pain;Bacterial infection;Balance disorder;Biliary tract disorder;Bladder pain;Bleeding time prolonged;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood glucose increased;Blood lactate dehydrogenase increased;Blood pressure increased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Bradycardia-tachycardia syndrome;Breast disorder;Breast neoplasm;Breast pain;Breath sounds abnormal;Bronchitis;Bronchospasm;Burning sensation;Cachexia;Cancer pain;Candida infection;Cardiac arrest;Cardiac disorder;Cardio-respiratory arrest;Cardiovascular insufficiency;Cellulitis;Cerebral ischaemia;Cerebration impaired;Chapped lips;Cheilitis;Chest discomfort;Chest pain;Chest wall pain;Chills;Chronic pain;Circulatory depression;Clonic convulsion;Cognitive disorder;Cold sweat;Coma;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Cough;Cough increased;Cramps of lower extremities;Cyanosis;Cyst;Deafness permanent;Deafness transitory;Decreased appetite;Decubitus ulcer;Deep vein thrombosis;Dehydration;Delirium;Dental caries;Dependence;Dependence physiological;Dependence psychological;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug abuse;Drug dependence;Drug hypersensitivity;Drug interaction;Drug withdrawal syndrome;Drug withdrawal syndrome neonatal;Dry eye;Dry mouth;Dysaesthesia;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dysphoria;Dyspnoea;Dyspnoea exertional;Dysuria;Ear and labyrinth disorders;Ear discomfort;Ear disorder;Ear pain;Ecchymosis;Eczema;Endocrine disorder;Endophthalmitis;Enlargement abdomen;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye haemorrhage;Face oedema;Facial paralysis;Faecal incontinence;Faecalith;Faecaloma;Fatigue;Feeling abnormal;Feeling hot;Feeling jittery;Feeling of body temperature change;Flank pain;Flatulence;Fluid retention;Flushing;Footdrop;Fungal infection;Gait disturbance;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Gingival bleeding;Gingival pain;Gingival ulceration;Gingivitis;Glossitis;Glossodynia;Grand mal convulsion;Granuloma;Haematemesis;Haematocrit decreased;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Hallucination;Hallucination, visual;Head injury;Headache;Hemiplegia;Hemorrhage of colon;Hepatic enzyme increased;Hepatic impairment;Hepatobiliary disease;Hepatorenal syndrome;Herpes zoster;Hiccups;Hostility;Hot flush;Hydronephrosis;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperlactacidaemia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypoaesthesia eye;Hypoaesthesia oral;Hypoalbuminaemia;Hypocalcaemia;Hypoglycaemia;Hypogonadism;Hypokalaemia;Hypokinesia;Hypomagnesaemia;Hyponatraemia;Hypoproteinaemia;Hypotension;Hypotensive;Hypotonia;Hypoventilation;Hypoxia;Ileus;Ill-defined disorder;Immune system disorder;Impaired gastric emptying;Increased appetite;Increased bronchial secretion;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Influenza-like symptoms;Injection site pain;Injury;Insomnia;Instillation site pain;Intentional drug misuse;Intestinal obstruction;Intestinal perforation;Intracranial pressure increased;Intranasal hypoaesthesia;Irritability;Jaundice;Joint swelling;Lacrimal disorder;Lacrimal structural disorder;Lactate increased;Lactic dehydrogenase activity increased;Large intestinal haemorrhage;Laryngeal pain;Laryngitis;Laryngospasm;Lethargy;Leukopenia;Libido decreased;Light anaesthesia;Lip dry;Lip pain;Lip ulceration;Liver disorder;Liver tenderness;Localised skin reaction;Loss of consciousness;Lung disorder;Lymphadenopathy;Lymphoedema;Malaise;Malaise and fatigue;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Mental disability;Mental disorder;Mental status changes;Micturition disorder;Micturition urgency;Miosis;Mood swings;Motion sickness;Motor dysfunction;Mouth ulceration;Mucous membrane disorder;Muscle atrophy;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myasthenia;Myoclonus;Myopathy;Nail longitudinal striations;Nail ridging;Nasal congestion;Nasal discomfort;Nasal dryness;Nasal mucosal disorder;Nasal septum perforation;Nasal ulcer;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Neoplasm;Neoplasm malignant;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Night sweats;Nocturia;Non-cardiac chest pain;Nuchal rigidity;Ocular hyperaemia;Oculogyric crisis;Oedema;Oedema peripheral;Oesophageal stenosis;Oesophagitis;Oliguria;Onychoclasis;Opioid naive;Oral candidiasis;Oral discomfort;Oral disorder;Oral herpes;Oral mucosal blistering;Oral mucosal discolouration;Oral pustule;Oral soft tissue disorder NOS;Oropharyngeal pain;Orthostatic hypotension;Osteoarthritis;Pain;Pain in extremity;Pain of skin;Pallor;Palpitations;Pancytopenia;Papule;Paraesthesia;Paraesthesia oral;Paranoia;Paranoid reaction;Parosmia;Partial permanent deafness;Partial transitory deafness;Pelvic pain;Peripheral vascular disorder;Peritonitis;Peroneal nerve palsy;Pharyngitis;Pharyngolaryngeal pain;Photopsia;Platelet count decreased;Pleural effusion;Pneumonia;Pneumothorax;Pollakiuria;Polyp;Polyuria;Postnasal drip;Pregnancy;Proctalgia;Protein urine present;Proteinuria;Pruritus;Pruritus generalised;Psychotic disorder;Pulmonary embolism;Pulmonary function test decreased;Pustule;Pyelonephritis;Rash;Rash erythematous;Rash maculo-papular;Rash pustular;Rectal disorder;Rectal haemorrhage;Renal failure;Renal impairment;Renal pain;Respiratory arrest;Respiratory depression;Respiratory distress;Respiratory failure;Respiratory insufficiency;Respiratory rate decreased;Respiratory sounds decreased;Retching;Rhinalgia;Rhinitis;Rhinorrhoea;Rigors;Scrotal oedema;Sepsis;Sexual dysfunction;Shivering;Shock;Shoulder pain;Sick sinus syndrome;Sinus tachycardia;Sinusitis;Skin discolouration;Skin disorder;Skin lesion;Skin reaction;Skin ulcer;Sleep apnoea syndrome;Sleep disorder;Sluggishness;Sneezing;Somnolence;Speech disorder;Spinal compression fracture;Sputum increased;Stevens-Johnson syndrome;Stomatitis;Stupor;Subdural haematoma;Subileus;Sweating;Sweating increased;Swelling;Swelling face;Syncope;Synovitis;Tachycardia;Tendon disorder;Tension;Therapy naive;Thinking abnormal;Thirst;Throat irritation;Throat tightness;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tongue blistering;Tongue disorder;Tongue ulceration;Tonic-clonic seizures;Tooth abscess;Tooth disorder;Tooth loss;Tremor;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper airway obstruction;Upper respiratory tract congestion;Upper respiratory tract infection;Upper-airway cough syndrome;Upset stomach;Urethral disorder;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urine output increased;Urticaria;VIIth nerve paralysis;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vasodilation;Vasodilation procedure;Vertigo;Vesiculobullous rash;Viral infection;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;Wheezing;Withdrawal symptom;Withdrawal syndrome;Wound",small molecule,approved; illicit; investigational; vet_approved,"1-Phenethyl-4-(N-phenylpropionamido)piperidine; 1-phenethyl-4-N-propionylanilinopiperidine; Fentanil; Fentanila; Fentanilo; Fentanyl; Fentanyl CII; Fentanylum; N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide; N-(1-phenethyl-4-piperidyl)propionanilide; N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide; N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide; N-phenethyl-4-(N-propionylanilino)piperidine; N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide; Phentanyl; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; K-OR-1; KOR-1; OPRK; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Mu-type opioid receptor; Delta-type opioid receptor; Kappa-type opioid receptor; ATP-dependent translocase ABCB1, N01AH51; N02AB03;N01AH01
fexofenadine,Chronic spontaneous urticaria;Eye redness;Hypersensitivity;Lacrimation;Lacrimation increased;Nasopharyngitis;Ocular hyperaemia;Perennial allergic rhinitis;Pruritus;Rhinitis allergic;Rhinitis perennial;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Sedation;Sneezing;Tearing eyes;Urticaria;Welts,Abdominal discomfort;Abdominal pain;Accidental injury;Agitation;Anaphylactic shock;Angioedema;Asthenia;Atrial fibrillation;Back pain;Body temperature increased;Cardiac failure congestive;Chest discomfort;Chest tightness;Cough;Dermatitis;Diarrhoea;Dizziness;Drowsiness;Dry eye;Dry mouth;Dysmenorrhoea;Dyspepsia;Dyspnoea;Ear pain;Epistaxis;Fatigue;Flatulence;Flushing;Gastrointestinal pain;Headache;Hypersensitivity;Increased appetite;Infection;Injury;Insomnia;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Nervousness;Nightmare;Otitis media;Pain;Pain in extremity;Palpitations;Paranoia;Perennial allergic rhinitis;Pollakiuria;Pruritus;Psychotic disorder;Rash;Rhinitis perennial;Rhinorrhoea;Sinusitis;Sleep disorder;Somnolence;Tachycardia;Tension;Thirst;Throat irritation;Upper respiratory tract infection;Upset stomach;Urticaria;Viral infection;Vision blurred;Vomiting,small molecule,approved; investigational,"4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid; Carboxyterfenadine; Fexofenadina; Fexofenadine; Terfenadine acid metabolite; Terfenadine carboxylate; Terfenadine-COOH; H1-R; H1R; HH1R; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Histamine H1 receptor,R06AX26
finasteride,Alopecia;Androgenetic alopecia;Benign prostatic hyperplasia;Diuresis;Polyuria;Prostate cancer;Prostatomegaly,Abnormal ejaculation;Androgenetic alopecia;Angioedema;Asthenia;Breast cancer;Breast cancer male;Breast disorder;Breast enlargement;Breast tenderness;Bronchitis;Dermatitis;Disturbance in sexual arousal;Dizziness;Dyspnoea;Ejaculation disorder;Erectile dysfunction;Gynaecomastia;Headache;Hypersensitivity;Hypotension;Immune system disorder;Infection;Infertility male;Influenza;Injury;Libido decreased;Mental disorder;Musculoskeletal disorder;Neoplasm;Neoplasm malignant;Neoplasm prostate;Oedema peripheral;Orgasm abnormal;Orthostatic hypotension;Pain;Pharyngitis;Prostatic disorder;Prostatic specific antigen increased;Pruritus;Rash;Rhinitis;Sexual dysfunction;Sinusitis;Somnolence;Swelling;Tenderness;Testicular pain;Trauma;Urticaria,small molecule,approved,"(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; Finasterida; Finasteride; Finasteridum; 1.3.1.22; 5 alpha-SR2; S5AR 2; SR type 2; Steroid 5-alpha-reductase 2; Type II 5-alpha reductase; 1.3.1.94; 3-oxo-5-alpha-steroid 4-dehydrogenase 3; S5AR 3; SR type 3; SRD5A2L; Steroid 5-alpha-reductase 2-like; Steroid 5-alpha-reductase 3; 1.3.1.22; S5AR 1; SR type 1; Steroid 5-alpha-reductase 1; 1.3.1.3; 3-oxo-5-beta-steroid 4-dehydrogenase; Delta(4)-3-ketosteroid 5-beta-reductase; Delta(4)-3-oxosteroid 5-beta-reductase; SRD5B1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; Electroneutral potassium-chloride cotransporter 2; K-Cl cotransporter 2; Kcc2; Kiaa1176; mKCC2; Neuronal K-Cl cotransporter",3-oxo-5-alpha-steroid 4-dehydrogenase 2; Polyprenal reductase; 3-oxo-5-alpha-steroid 4-dehydrogenase 1; Aldo-keto reductase family 1 member D1, G04CA51; G04CA55; G04CB01; G04CB51;D11AX10
flavoxate,Abdominal pain lower;Dysuria;Incontinence;Nocturia;Suprapubic pain,Confusional state;Drowsiness;Dry mouth;Eosinophilia;Feeling abnormal;Headache;Hyperpyrexia;Leukopenia;Nausea;Nervousness;Other dermatoses;Palpitations;Skin disorder;Somnolence;Tachycardia;Tension;Urticaria;Vertigo;Vision blurred;Vomiting,small molecule,approved,2-(1-piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-piperidinoethyl 3-methylflavone-8-carboxylate; Flavoxate; Flavoxato; Flavoxatum; β-piperidinoethyl 3-methylflavone-8-carboxylate,Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M5; Muscarinic acetylcholine receptor M2,G04BD02
flecainide,AV nodal reentrant tachycardia;AV reentrant tachycardia;Acute coronary syndrome;Arrhythmia;Arrhythmia supraventricular;Atrial fibrillation;Atrial flutter;Cardiac disorder;Cardiac fibrillation;Cardiac flutter;Myocardial infarction;Myocardial ischaemia;Nodal arrhythmia;Non-sustained ventricular tachycardia;Paroxysmal atrial fibrillation;Paroxysmal atrial flutter;Paroxysmal supraventricular tachycardia;Pre-excitation syndrome;Reciprocating tachycardia;Sudden death;Supraventricular tachycardia;Sustained ventricular tachycardia;Tachyarrhythmia;Ventricular arrhythmia;Ventricular tachycardia;Wolff-Parkinson-White syndrome,Abdominal pain;Abnormal dreams;Ageusia;Agranulocytosis;Alkaline phosphatase serum increased;Alopecia;Amnesia;Angina pectoris;Anorexia;Anxiety;Apathy;Arthralgia;Asthenia;Ataxia;Atrioventricular block;Atrioventricular block complete;Balance disorder;Blood alkaline phosphatase increased;Blood disorder;Body temperature increased;Bradycardia;Bronchospasm;Cardiac arrest;Cardiac failure congestive;Chest pain;Cholestasis;Coma;Confusional state;Constipation;Convulsion;Corneal deposits;Cough;Deafness;Decreased appetite;Depersonalisation;Depressed level of consciousness;Dermatitis;Dermatitis exfoliative;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dysgeusia;Dyskinesia;Dyspepsia;Dysphonia;Dyspnoea;Dysuria;Erectile dysfunction;Euphoric mood;Eye disorder;Eye pain;Fatigue;Feeling abnormal;Flat affect;Flatulence;Flushing;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gynaecomastia;Haematuria;Hallucination;Headache;Hemiparesis;Hepatic failure;Hepatic function abnormal;Hyperglycaemia;Hyperhidrosis;Hypertension;Hypertrichosis;Hypoaesthesia;Hypotension;Ill-defined disorder;Immune system disorder;Insomnia;Interstitial lung disease;Jaundice;Laryngospasm;Leukopenia;Libido decreased;Lightheadedness;Lip swelling;Loss of consciousness;Lung infiltration;Malaise;Micturition disorder;Morbid dreams;Muscle twitching;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Nystagmus;Oedema;Pain;Palpitations;Paraesthesia;Paranoia;Paranoid reaction;Paresis;Parosmia;Peripheral ischaemia;Photophobia;Photosensitivity reaction;Pneumonia;Polyuria;Presyncope;Pruritus;Pulmonary fibrosis;Pulmonary oedema;Rash;Renal failure;Scotoma;Shock;Sinus arrest;Sinus bradycardia;Skin discolouration;Skin disorder;Somnolence;Speech disorder;Spots before eyes;Stupor;Sweating increased;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Unsteadiness;Urinary retention;Urine output increased;Urticaria;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; withdrawn,"(±)-flecainide; Flecaine; Flecainida; Flecainide; Flécaïnide; Flecainidum; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; Cardiac muscle ryanodine receptor; Cardiac muscle ryanodine receptor-calcium release channel; hRYR-2; RYR-2; RyR2; Type 2 ryanodine receptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1",Sodium channel protein type 4 subunit alpha; Sodium channel protein type 5 subunit alpha; Voltage-gated inwardly rectifying potassium channel KCNH2; Ryanodine receptor 2,C01BC04
flucloxacillin,Abscess;Acute tonsillitis;Carbuncle;Cellulitis;Eczema;Empyema;Endocarditis;Enteritis;Furuncle;Furunculosis;Impetigo;Infection;Lung abscess;Meningitis;Osteomyelitis;Otitis media;Peritonsillar abscess;Pharyngitis;Pneumonia;Renal failure;Renal impairment;Respiratory tract infection;Sepsis;Septicemia;Sinusitis;Skin disorder;Soft tissue infection;Tonsillitis;Ulcer;Urinary tract infection;Wound infection,Abdominal pain;Agranulocytosis;Anaemia;Anaphylactic shock;Angioedema;Appetite absent;Arthralgia;Bad taste;Blood and lymphatic system disorders;Body temperature increased;Bronchospasm;Candida infection;Colitis;Connective tissue disorder;Constipation;Convulsion;Decreased appetite;Dermatitis;Diarrhoea;Digestion impaired;Discomfort;Dizziness;Dysgeusia;Dyspepsia;Eosinophilia;Erythema multiforme;Erythema nodosum;Fatal outcomes;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Glossodynia;Haematuria;Haemolytic anaemia;Headache;Heartburn;Hepatitis;Hepatobiliary disease;Hypersensitivity;Ill-defined disorder;Immune system disorder;Jaundice;Jaundice cholestatic;Leukopenia;Malaise;Musculoskeletal discomfort;Myalgia;Nausea;Nephritis;Nephritis interstitial;Nervous system disorder;Neutropenia;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Pruritus vulvae;Pseudomembranous colitis;Purpura;Rash;Reaction gastrointestinal;Renal failure;Serum sickness;Skin disorder;Stevens-Johnson syndrome;Throat sore;Thrombocytopenia;Thrombocytopenic purpura;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vascular purpura;Vomiting;Vulvovaginal pruritus,small molecule,approved; investigational,"(2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin; Floxacillin; Flucloxacilina; Flucloxacillin; Flucloxacilline; Flucloxacillinum; PBP1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Penicillin-binding protein 1A, J01CF05;J01CF05;J01CR50
fluconazole,Acquired immunodeficiency syndrome;Autoimmune disorder;Body tinea;Candida infection;Candidemia;Candiduria;Chronic mucocutaneous candidiasis;Cryptococcosis;Fungal infection;Fungal skin infection;Hepatitis;Immunocompromised;Immunodeficiency;Infection;Meningitis cryptococcal;Mucocutaneous candidiasis;Neoplasm malignant;Neutropenia;Oesophageal candidiasis;Oral pain;Oropharyngeal candidiasis;Peritonitis;Pneumonia;Renal failure;Renal impairment;Sore mouth;Systemic candida;Tinea cruris;Tinea pedis;Tinea versicolour;Urinary tract infection;Vaginal moniliasis;Vaginal yeast;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Yeast infection,Abdominal pain;Abnormal vision;Acne;Acute generalised exanthematous pustulosis;Acute hepatic failure;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alcohol abuse;Alopecia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Aspartate aminotransferase increased;Aspergillosis;Aspergillus infection;Asthenia;Ataxia;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood triglycerides increased;Body temperature increased;Breast disorder;Cardiac disorder;Cardiomyopathy;Cardiovascular disorder;Chills;Cholestasis;Clonic convulsion;Connective tissue disorder;Constipation;Convulsion;Cross resistance;Cryptococcosis;Culture negative;Cyanosis;Deafness;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drug eruption;Drug interaction;Dry mouth;Dry skin;Dysgeusia;Dysmenorrhoea;Dyspepsia;Ear and labyrinth disorders;Erythema multiforme;Eye disorder;Face oedema;Fatal outcomes;Fatigue;Feeling abnormal;Female sexual dysfunction;Flatulence;Flushing;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Hepatic failure;Hepatic necrosis;Hepatobiliary disease;Hepatocellular injury;Herpes simplex;Hot flush;Hypercholesterolaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hypertriglyceridaemia;Hypokalaemia;Hypokinesia;Hypopnoea;Hypoxia;Ileus;Ill-defined disorder;Immune system disorder;Immunodeficiency;Infestation;Infestation NOS;Insomnia;Jaundice;Lacrimation;Lacrimation increased;Leukopenia;Leukorrhea;Liver injury;Loose stools;Lung infection;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Menorrhagia;Mental disorder;Metrorrhagia;Musculoskeletal discomfort;Myalgia;Nausea;Neoplasm malignant;Nervous system disorder;Nervousness;Neutropenia;Opportunistic mycosis;Pain;Paraesthesia;Pathogen resistance;Pharyngitis;Phosphatase alkaline increased;Polyuria;Pregnancy;Pruritus;Pruritus genital;Purpura;Rash;Rash erythematous;Renal pain;Rigors;Salivary hypersecretion;Salivation;Scotoma;Sepsis;Shallow breathing;Skin disorder;Skin odour abnormal;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Tension;Thirst;Thrombocytopenia;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urine output increased;Urticaria;Uterine spasm;Vaginal discharge;Vaginal disorder;Vaginal infection;Vaginal inflammation;Vascular purpura;Vertigo;Visual impairment;Vomiting,small molecule,approved; investigational,"Diflucan; Difluconazole; Fluconazol; Fluconazole; Fluconazolum; Triflucan; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Lanosterol 14-alpha demethylase, D01AC15; J02AC01;D01AC15;J01RA07
5-fluorocytosine,Candida infection;Chromoblastomycosis;Cryptococcosis;Endocarditis;Infection;Lung infection;Meningitis;Sepsis;Septicemia;Systemic candida;Urinary tract infection,Abdominal pain;Acute liver damage;Acute liver injury;Agranulocytosis;Anaemia;Anorexia;Aplastic anaemia;Asthenia;Ataxia;Azotaemia;Body temperature increased;Bone marrow toxicity;Cardiac arrest;Chest pain;Colitis ulcerative;Confusional state;Convulsion;Crystalluria;Deafness;Decreased appetite;Dermatitis;Diarrhoea;Dry mouth;Duodenal ulcer;Dyspnoea;Enterocolitis;Eosinophilia;Fatal outcomes;Fatigue;Feeling abnormal;Gastrointestinal haemorrhage;Gastrointestinal pain;Haemoglobin;Haemorrhage;Hallucination;Headache;Hearing impaired;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hypersensitivity;Hypoglycaemia;Hypokalaemia;Jaundice;Leukopenia;Liver injury;Nausea;Neuropathy peripheral;Pancytopenia;Paraesthesia;Parkinsonism;Photosensitivity;Photosensitivity reaction;Proctocolitis;Pruritus;Psychotic disorder;Rash;Renal failure;Respiratory arrest;Thrombocytopenia;Toxic epidermal necrolysis;Urticaria;Ventricular dysfunction;Vertigo;Vomiting,small molecule,approved; investigational,5-FC; 5-Fluorocystosine; 5-Fluorocytosine; flucytosina; Flucytosine; Flucytosinum; 2.1.1.45; CDC21; TS; TSA1; 2.1.1.37; AIM; CXXC-type zinc finger protein 9; CXXC9; DNA methyltransferase HsaI; DNA MTase HsaI; DNMT; Dnmt1; M.HsaI; MCMT,DNA; Thymidylate synthase; DNA (cytosine-5)-methyltransferase 1, D01AE21;D01AE21;J02AX01
fludarabine,Chronic lymphocytic leukaemia;Chronic lymphocytic leukaemia refractory;Leukaemia;Lymphoma;Neoplasm;Non-Hodgkin's lymphoma;Renal failure;Renal impairment;Solid tumour,Abdominal pain;Absolute neutrophil count decreased;Acquired haemophilia;Acute coronary syndrome;Acute leukaemia;Acute myeloid leukaemia;Acute respiratory distress syndrome;Agitation;Alopecia;Alveolitis allergic;Anaemia;Anaphylactic shock;Aneurysm;Angina pectoris;Anorexia;Aplasia;Arrhythmia;Arthralgia;Asthenia;Autoimmune haemolytic anaemia;Autoimmune thrombocytopenia;Back pain;Blindness;Blood lactate dehydrogenase increased;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bronchitis;Cardiac failure;Cardiac failure congestive;Cerebellar syndrome;Cerebral haemorrhage;Cerebrovascular accident;Chest pain;Chills;Cholelithiasis;Coma;Confusional state;Constipation;Convulsion;Cough;Cough increased;Crystalluria;Cystitis haemorrhagic;Cytopenia;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Dermatitis;Diarrhoea;Digestion impaired;Discomfort;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Epistaxis;Erythema multiforme;Evans syndrome;Fatal outcomes;Fatigue;Feeling abnormal;Fibrosis;Flank pain;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemoptysis;Haemorrhage;Headache;Hearing impaired;Hepatic failure;Hepatobiliary disease;Herpes simplex;Herpes zoster;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperphosphataemia;Hypersensitivity;Hyperuricaemia;Hypocalcaemia;Hypoxia;Ill-defined disorder;Infection;Influenza;Lactic dehydrogenase activity increased;Liver function test abnormal;Lung infection;Lung infiltration;Lymphoproliferative disorder;Malaise;Metabolic acidosis;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Myelodysplastic syndrome;Myelosuppression;Myocardial infarction;Nausea;Neoplasm;Nervous system disorder;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutrophil count decreased;Oedema;Oedema peripheral;Oesophagitis;Opportunistic infection;Optic nerve disorder;Optic neuritis;Osteoporosis;Pain;Pancytopenia;Paraesthesia;Pemphigus;Pericardial effusion;Pharyngitis;Phlebitis;Platelet count decreased;Pneumonia;Progressive multifocal leukoencephalopathy;Protein urine present;Proteinuria;Pruritus;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary toxicity;Radial nerve palsy;Rash;Renal failure;Renal function test abnormal;Respiratory distress;Respiratory failure;Rhinitis;Seborrhoeic dermatitis;Sinusitis;Skin cancer;Skin disorder;Skin toxicity;Sleep disorder;Stevens-Johnson syndrome;Stomatitis;Supraventricular tachycardia;Sweating increased;Thrombocytopenia;Thrombocytopenic purpura;Toxic epidermal necrolysis;Transient ischaemic attack;Tumour lysis syndrome;Upper respiratory tract infection;Urate crystalluria;Urinary hesitation;Urinary tract infection;Viral infection;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Wrist drop;X-linked lymphoproliferative syndrome,small molecule,approved,"2-F-ARAA; 2-fluoro ARA-A; Fludarabina; Fludarabine; Fludarabinum; 3.5.4.4; ADA1; Adenosine aminohydrolase; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; 2.7.7.7; DNA polymerase alpha catalytic subunit p180; POLA; 1.17.4.1; Ribonucleoside-diphosphate reductase subunit M1; Ribonucleotide reductase large subunit; RR1; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1; CNT 3; CNT3; Concentrative Na(+)-nucleoside cotransporter 3; hCNT3",DNA; Adenosine deaminase; Deoxycytidine kinase; DNA polymerase alpha catalytic subunit; Ribonucleoside-diphosphate reductase large subunit,L01BB05
fludrocortisone,Addison's disease;Adrenogenital syndrome;Secondary adrenocortical insufficiency,Abdominal distension;Alkalosis hypokalaemic;Anaphylactic shock;Anaphylactoid reaction;Angiitis necrotising;Anorexia;Aseptic necrosis;Benign intracranial hypertension;Cardiac failure congestive;Cataract subcapsular;Contusion;Convulsion;Decreased appetite;Diabetes mellitus;Diarrhoea;Dysgeusia;Ecchymosis;Eruption;Erythema;Erythema facial;Exophthalmos;Fat atrophy;Fluid retention;Gastric pH decreased;Glaucoma;Glucose tolerance impaired;Glycosuria;Haemoglobin;Haemorrhage;Hallucination;Headache;Hirsutism;Hyperchlorhydria;Hyperglycaemia;Hyperhidrosis;Hypernatraemia;Hypertension;Impaired healing;Increased insulin requirement;Infection;Injury;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Lipoatrophy;Measles;Menstruation irregular;Muscle mass;Muscular weakness;Myopathy;Nitrogen balance negative;Oesophagitis;Optic neuritis;Osteonecrosis;Osteoporosis;Pancreatitis;Papilloedema;Peptic ulcer;Petechiae;Purpura;Rash;Skin hyperpigmentation;Skin striae;Spinal compression fracture;Steroid myopathy;Sweating increased;Thrombophlebitis;Trauma;Ulcer;Varicella;Vascular purpura;Vasculitis necrotising;Vertigo,small molecule,approved; investigational,"9alpha-Fluorocortisol; Fludrocortison; Fludrocortisona; Fludrocortisone; Fludrocortisonum; Fluohydrocortisone; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.1.1.-; 11-beta-HSD type II; 11-beta-HSD2; 11-beta-hydroxysteroid dehydrogenase type II; 11-DH2; 11-HSD type II; Corticosteroid 11-beta-dehydrogenase isozyme 2; HSD11K; NAD-dependent 11-beta-hydroxysteroid dehydrogenase; SDR9C3; Short chain dehydrogenase/reductase family 9C member 3; 1.1.1.146; 11-beta-HSD1; 11-DH; 7-oxosteroid reductase; Corticosteroid 11-beta-dehydrogenase isozyme 1; HSD11; HSD11L; SDR26C1; Short chain dehydrogenase/reductase family 26C member 1; CBG; Serpin A6; Transcortin",Androgen receptor; Mineralocorticoid receptor; Glucocorticoid receptor, H02AA02; S01CA06; S03CA05;S02CA07
fluphenazine,Convulsion;Psychotic disorder;Renal failure;Renal impairment,Abnormal dreams;Agitation;Agranulocytosis;Akathisia;Allergic skin reaction;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Appetite absent;Asthma;Bizarre dreams;Blood creatine phosphokinase increased;Blood disorder;Body temperature increased;Brain injury;Brain oedema;Cardiac arrest;Catatonia;Choreoathetoid movements;Choreoathetosis;Constipation;Corneal opacity;Creatine phosphokinase increased;Decreased appetite;Dermatitis atopic;Dermatitis exfoliative;Disturbance in sexual arousal;Drowsiness;Dry mouth;Dyskinesia;Dysphagia;Dyspnoea;Eczema;Edema cerebral;Eosinophilia;Erythema;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Faecalith;Faecaloma;Glaucoma;Gynaecomastia;Headache;Hepatocellular injury;Hyperreflexia;Hypersensitivity;Hypertension;Hypotension;Hypotensive;Ileus paralytic;Jaundice cholestatic;Laryngeal oedema;Lethargy;Leukocytosis;Leukopenia;Libido increased;Liver injury;Menstruation irregular;Mitral valve incompetence;Muscle rigidity;Muscle spasms;Nasal congestion;Nausea;Neurogenic bladder;Neuroleptic malignant syndrome;Oculogyric crisis;Oedema peripheral;Opisthotonus;Pancytopenia;Paralysis of bladder;Parkinsonism;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Pneumonia;Polyuria;Pruritus;Pseudoparkinsonism;Psychotic behaviour;Purpura non-thrombocytopenic;Renal failure acute;Salivary hypersecretion;Salivation;Seborrhoeic dermatitis;Skin disorder;Somnolence;Systemic lupus erythematosus;Tachycardia;Tardive dyskinesia;Tenderness;Throat tightness;Upper respiratory tract infection;Urine output increased;Urticaria;Vision blurred,small molecule,approved,1-(2-hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine; 10-(3-(2-hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; 10-(3'-(4''-(β-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; 2-(4-(3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol; 2-(trifluoromethyl)-10-(3-(1-(β-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 4-(3-(-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol; 4-(3-(2-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; Flufenazina; Fluorfenazine; Fluorophenazine; Fluorphenazine; Fluphenazin; Fluphénazine; Fluphenazine; Fluphenazinum; Triflumethazine; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; Dopamine D2 receptor; Dopamine D1 receptor; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1,5-hydroxytryptamine receptor 1B; D(2) dopamine receptor; D(1A) dopamine receptor; Androgen receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2C; Calmodulin,N05AB02
flumazenil,Convulsion;Drug withdrawal syndrome;Hepatic impairment;Liver disorder;Panic disorder;Renal clearances low;Renal function test abnormal;Withdrawal symptom,Abnormal vision;Affect lability;Aggression;Agitation;Anger;Anxiety;Anxiety attack;Arrhythmia;Asphyxia;Asthenia;Ataxia;Bradycardia;Chest pain;Chills;Confusional state;Congenital skin disorder;Cough;Crying;Crying abnormal;Deafness;Delirium;Dependence;Depersonalisation;Depressed level of consciousness;Depressed mood;Dermatitis;Diplopia;Discomfort;Dizziness;Drowsiness;Drug abuse;Drug withdrawal syndrome;Dry mouth;Dysphonia;Dysphoria;Dyspnoea;Epilepsy;Erythema;Euphoric mood;Fatigue;Fear;Feeling abnormal;Feeling cold;Flushing;Hallucination;Headache;Hearing impaired;Hiccups;Hot flush;Hyperacusis;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperventilation;Hypoaesthesia;Hypopnoea;Hypotension;Ill-defined disorder;Injection site pain;Injection site reaction;Insomnia;Junctional tachycardia;Malaise;Menopausal symptoms;Mood swings;Nasal congestion;Nausea;Nervousness;Pain;Palpitations;Panic attack;Panic disorder;Paraesthesia;Paranoia;Pruritus;Psychotic disorder;Rash;Redness;Rigors;Salivary hypersecretion;Salivation;Scotoma;Shivering;Somnolence;Speech disorder;Stupor;Supraventricular tachycardia;Sweating;Sweating increased;Tachycardia;Tearfulness;Tension;Tetany;Thrombophlebitis;Tinnitus;Tongue disorder;Tongue oedema;Tremor;Urticaria;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vision blurred;Visual impairment;Vomiting;Withdrawal symptom,small molecule,approved,Flumazenil; Flumazenilo; Flumazenilum; Flumazepil; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1,Translocator protein; Gamma-aminobutyric acid receptor subunit gamma-2; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit gamma-3; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit alpha-5; GABA(A) Receptor; Gamma-aminobutyric acid receptor subunit alpha-1,V03AB25
flumethasone,Skin disorder,Acneiform eruption;Allergic contact dermatitis;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Folliculitis;Hypertrichosis;Infection;Leukoderma;Miliaria;Pruritus;Secondary infection;Skin atrophy;Skin striae,small molecule,approved; vet_approved,"6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; Flumetasona; Flumétasone; Flumetasone; Flumetasonum; Flumethasone; GR; GRL; Nuclear receptor subfamily 3 group C member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin",Glucocorticoid receptor; Steroid hormone receptor ERR2; Estrogen-related receptor gamma; Steroid hormone receptor ERR1, D07BB01; D07CB05; D07XB01; S02CA02;D07AB03
flunisolide,Asthma;Localised infection;Rhinitis perennial;Rhinitis seasonal;Seasonal allergy,Abdominal discomfort;Abdominal distension;Abdominal pain;Accidental injury;Ageusia;Agitation;Anosmia;Anxiety;Asthenia;Back pain;Body temperature increased;Bronchitis;Bronchospasm;Candida albicans infection;Candida infection;Capillary fragility;Cataract;Chest discomfort;Chest pain;Chest tightness;Chills;Cold symptoms;Conjunctivitis;Constipation;Cough;Cough increased;Cushing's syndrome;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry throat;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphonia;Dyspnoea;Ear infection;Ear pain;Eczema;Epistaxis;Erythema multiforme;Eye infection;Fatigue;Feeling abnormal;Fullness abdominal;Gastroenteritis;Gastrointestinal pain;Glaucoma;Glossitis;Growth retardation;Headache;Heartburn;Hoarseness;Hyperadrenocorticism;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypokinesia;Ill-defined disorder;Increased appetite;Infection;Injury;Insomnia;Intraocular pressure increased;Irritability;Lacrimation increased;Laryngitis;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Migraine;Mouth irritation;Musculoskeletal discomfort;Myalgia;Nasal burning;Nasal congestion;Nasal discomfort;Nasal irritation;Nasal septum perforation;Nasopharyngitis;Nausea;Neck pain;Numbness;Ocular discomfort;Oedema;Oedema peripheral;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Palpitations;Pharyngitis;Pleurisy;Pneumonia;Pruritus;Pulmonary congestion;Rash;Respiratory tract congestion;Rhinitis;Rhinorrhoea;Secondary adrenocortical insufficiency;Sensory loss;Shakiness;Shock;Sinus congestion;Sinusitis;Sneezing;Stinging;Stomatitis;Sweating;Syncope;Tachycardia;Tachycardia nervous;Tearing eyes;Throat irritation;Throat sore;Tremor;Upper respiratory tract infection;Upset stomach;Urinary tract infection;Urticaria;Vaginal infection;Vaginal inflammation;Vertigo;Vision blurred;Vomiting;Weight increased;Wheezing,small molecule,approved; investigational,"Flunisolida; Flunisolide; Flunisolide anhydrous; Flunisolidum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin",Glucocorticoid receptor, R03BA03;R01AD04
flunitrazepam,Insomnia,Aggression;Agitation;Amnesia;Angioedema;Anxiety;Asthenia;Ataxia;Balance disorder;Confusional state;Delusion;Dermatitis;Diplopia;Discomfort;Disorientation;Dizziness;Drowsiness;Dry mouth;Dysarthria;Emotional distress;Fatigue;Feeling abnormal;Hallucination;Hangover;Headache;Hiccups;Hyperhidrosis;Hypotension;Ill-defined disorder;Irritability;Malaise;Muscular weakness;Nightmare;Orthostatic hypotension;Psychotic disorder;Rash;Sleep disorder;Sleep disturbance;Slurred speech;Somnolence;Sweating;Tachycardia;Tremor;Unsteadiness,small molecule,approved; illicit,"Flunitrazepam; Flunitrazepamum; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Translocator protein; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site,N05CD03
fluocinonide,Dermatitis atopic;Psoriasis;Skin disorder,Acneiform eruption;Allergic contact dermatitis;Application site burn;Application site pain;Application site reaction;Atrophy;Cataract subcapsular;Condition aggravated;Cushing's syndrome;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Dizziness;Dry skin;Eruption;Erythema;Folliculitis;Glycosuria;Headache;Hyperglycaemia;Hypersensitivity;Hypertrichosis;Immune system disorder;Infection;Itch burning;Leukoderma;Miliaria;Nasal congestion;Nasopharyngitis;Nervous system disorder;Pain;Pruritus;Rash;Secondary adrenocortical insufficiency;Secondary infection;Skin atrophy;Skin disorder;Skin exfoliation;Skin striae;Skin tightness;Swelling;Telangiectasia;Unspecified disorder of skin and subcutaneous tissue,small molecule,approved; investigational,"Fluocinonida; Fluocinonide; Fluocinonido; Fluocinonidum; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; GR; GRL; Nuclear receptor subfamily 3 group C member 1; Protein Gx; SMOH; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; CBG; Serpin A6; Transcortin",Steroid hormone receptor ERR1; Steroid hormone receptor ERR2; Estrogen-related receptor gamma; Glucocorticoid receptor; Protein smoothened, D07AC08; D07CC05;C05AA11
fluorometholone,Inflammation,Acute uveitis;Anterior uveitis;Cataract;Cataract subcapsular;Conjunctival hyperaemia;Conjunctivitis;Dermatitis;Dysgeusia;Endophthalmitis;Erythema of eyelid;Eye discharge;Eye disorder;Eye infection;Eye irritation;Eye pain;Eye pruritus;Eye swelling;Eyelid oedema;Foreign body sensation in eyes;Glaucoma;Hyperadrenocorticism;Hypersensitivity;Impaired healing;Iridocyclitis;Keratitis;Lacrimation increased;Mydriasis;Nerve injury;Ocular discomfort;Ocular hyperaemia;Pain;Posterior subcapsular cataract;Rash;Scotoma;Sensation of foreign body;Stinging;Ulcerative keratitis;Uveitis;Viral infection;Vision blurred;Visual disturbance;Visual impairment,small molecule,approved; investigational,"(1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; Fluorometholon; Fluorométholone; Fluorometholone; Fluorometholonum; Fluorometolona; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin",Glucocorticoid receptor, C05AA06; D07AB06; D07CB03; D10AA01; S01BA07; S01BB03; S01CA07; S01CB05;C05AA06;D07XB04
fluoxetine,"Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal distress;Affect lability;Affective disorder;Agitation;Agoraphobia;Anger;Anxiety;Asthenia;Binge eating;Bipolar I disorder;Bradyphrenia;Bradypsychic response;Breast tenderness;Bulimia;Bulimia nervosa;Cerebration impaired;Chest pain;Chills;Choking sensation;Compulsions;Decreased interest;Depressed mood;Depression;Depressive disorder;Discomfort;Distress;Disturbance in attention;Dizziness;Drug abuse;Drug interaction;Dysphoria;Dyspnoea;Dysthymic disorder;Emotional distress;Fatigue;Fear of death;Feeling guilty;Flatulence;Foetor hepaticus;Headache;Heart pounding;Hepatic impairment;Hepatocellular injury;Hot flush;Hyperhidrosis;Hypersomnia;Hypoaesthesia;Insomnia;Irritability;Lightheadedness;Liver disorder;Major depression;Major depressive disorder, single episode;Malaise;Menopausal symptoms;Mental disability;Mood swings;Musculoskeletal discomfort;Myalgia;Nausea;Nephropathy;Numbness;Obsessive rumination;Obsessive thoughts;Obsessive-compulsive disorder;Palpitations;Panic attack;Panic disorder;Panic reaction;Paraesthesia;Premenstrual dysphoric disorder;Premenstrual syndrome;Purging;Reduced interest in usual activities;Renal failure;Renal impairment;Sensory loss;Sickness;Suicidal ideation;Suicide attempt;Sweating;Swelling;Tension;Tingling sensation;Tourette's disorder;Trembling;Tremor;Vomiting;Weight increased",Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal ejaculation;Abnormal vision;Abortion;Accidental injury;Accommodation disorder;Acne;Acute abdomen;Acute coronary syndrome;Acute overdose;Affect lability;Ageusia;Aggression;Agitation;Akathisia;Alanine aminotransferase increased;Albuminuria;Alcohol intolerance;Alopecia;Alveolitis allergic;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anorgasmia;Antisocial behaviour;Antisocial personality disorder;Anxiety;Apathy;Aphthous stomatitis;Aplastic anaemia;Apnoea;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asocial behaviour;Asthenia;Asthma;Ataxia;Atelectasis;Atrial fibrillation;Atrioventricular block;Atrioventricular block first degree;Attention deficit disorder;Attention deficit/hyperactivity disorder;Azoospermia;Back pain;Balance disorder;Battery;Biliary colic;Blacked-out (not amnesia);Bladder pain;Bleeding time prolonged;Blepharitis;Blister;Block heart;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Blood disorder;Blood pressure increased;Blood urea increased;Blood uric acid increased;Body height decreased;Body temperature decreased;Body temperature increased;Bone pain;Bradycardia;Breast disorder;Breast engorgement;Breast enlargement;Breast feeding;Breast pain;Bronchitis;Bronchospasm;Bruxism;Buccoglossal syndrome;Bundle branch block;Bursitis;CNS depression NOS;Cachexia;Calculus of kidney;Calculus urinary;Candida infection;Carcinogenicity;Cardiac arrest;Cardiac failure congestive;Cardiotoxicity;Cataract;Central nervous system stimulation;Cerebral artery embolism;Cerebral ischaemia;Cerebration impaired;Cerebrovascular accident;Cervix haemorrhage uterine;Chest pain;Chills;Cholecystitis;Cholelithiasis;Chondrodystrophy;Circumoral paresthesia;Clonic convulsion;Colitis;Coma;Completed suicide;Confusional state;Conjunctivitis;Constipation;Conversion disorder;Convulsion;Coordination abnormal;Corneal lesion;Cough;Cough decreased;Cough increased;Cramps of lower extremities;Creatine phosphokinase increased;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Delirium;Delusion;Dependence;Dependence physiological;Dependence psychological;Depersonalisation;Depressed level of consciousness;Depression;Depressive symptom;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diabetic ketoacidosis;Diarrhoea;Diarrhoea haemorrhagic;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Diuresis;Diverticulitis;Dizziness;Drowsiness;Drug dependence;Drug interaction;Drug seeking behavior;Drug tolerance;Dry eye;Dry mouth;Dry skin;Duodenal ulcer;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspareunia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Eczema;Ejaculation disorder;Electroencephalogram abnormal;Emphysema;Enlarged clitoris;Enlargement abdomen;Enteritis;Enterocolitis;Eosinophilia;Eosinophilic pneumonia;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Erythema nodosum;Euphoric mood;Excitation cerebral;Exophthalmos;Extrapyramidal disorder;Extrasystoles;Eye haemorrhage;Eye pain;Face oedema;Faecal incontinence;Fatal outcomes;Fatigue;Feeling abnormal;Feeling jittery;Female sexual dysfunction;Fibrocystic breast disease;Flat affect;Flatulence;Fluid retention;Foetal alcohol syndrome;Footdrop;Fungal skin infection;Furuncle;Furunculosis;Gait disturbance;Galactorrhoea;Gastric pH decreased;Gastric ulcer;Gastric ulcer haemorrhage;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Genital haemorrhage;Gingival bleeding;Gingivitis;Glaucoma;Glossitis;Glycosuria;Goitre;Gout;Grand mal convulsion;Gynaecomastia;Haematemesis;Haematochezia;Haematoma;Haematuria;Haemoglobin;Haemolytic anaemia;Haemoptysis;Haemorrhage;Hallucination;Hangover;Headache;Hemorrhage of colon;Hepatic failure;Hepatic steatosis;Hepatitis;Hepatocellular injury;Hepatomegaly;Herpes simplex;Herpes zoster;Hiccups;Hirsutism;Histiocytosis X of lung;Hostility;Hot flush;Hydrocephalus;Hyperacusis;Hyperaesthesia;Hyperchlorhydria;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hyperplasia;Hyperprolactinaemia;Hyperreflexia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypomania;Hypomenorrhoea;Hyponatraemia;Hyporeflexia;Hypotension;Hypothermia;Hypothyroidism;Hypoventilation;Hypoxia;Hysteria;Ill-defined disorder;Immobile;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Influenza;Injury;Insomnia;Intentional injury;Intestinal obstruction;Iritis;Iron deficiency anaemia;Irritability;Jaundice;Jaundice cholestatic;Lactation female;Langerhans' cell histiocytosis;Large intestinal haemorrhage;Laryngeal oedema;Lethargy;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Lightheadedness;Liver fatty deposition;Liver function test abnormal;Liver injury;Liver tenderness;Loss of consciousness;Lymphadenopathy;Lymphocytosis;Lymphoedema;Lymphoma;Malaise;Malignant syndrome NOS;Malnutrition;Mania;Manic psychosis;Melaena;Memory impairment;Menometrorrhagia;Menopausal symptoms;Menopause;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Mental status changes;Metrorrhagia;Micturition disorder;Micturition urgency;Migraine;Mood swings;Mouth haemorrhage;Mouth ulceration;Movement disorder;Muscle haemorrhage;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Mydriasis;Myocardial infarction;Myoclonus;Myopathy;Myositis;Nausea;Neck pain;Neck stiffness;Necrolysis epidermal;Necrosis;Neoplasm;Nephrolithiasis;Nephropathy;Nervousness;Neuralgia;Neuritis;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Neurosis;Nocturia;Non-Hodgkin's lymphoma;Nuchal rigidity;Numbness;Oculogyric crisis;Oedema peripheral;Oesophageal pain;Oesophageal ulcer;Oesophageal varices haemorrhage;Oesophagitis;Oligospermia;Oliguria;Optic neuritis;Orchitis;Orchitis noninfective;Orthostatic hypotension;Osteoarthritis;Osteomyelitis;Osteonecrosis;Osteoporosis;Ovarian disorder;Overdose;Pain;Pain in jaw;Pallor;Palpitations;Pancreatitis;Pancytopenia;Panic attack;Paraesthesia;Paraesthesia oral;Paralysis;Paranoia;Paranoid reaction;Parosmia;Pelvic pain;Peptic ulcer;Peripheral vascular disorder;Peroneal nerve palsy;Personality disorder;Petechiae;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Photosensitivity reaction;Physical assault;Pleural effusion;Pneumonia;Pneumothorax;Pollakiuria;Polymenorrhoea;Polyuria;Pregnancy;Priapism;Protrusion tongue;Pruritus;Psoriasis;Psychotic disorder;Pulmonary embolism;Pulmonary fibrosis;Pulmonary hypertension;Pulmonary oedema;Purpura;Purpuric rash;Pyelonephritis;Pyuria;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Red blood cell sedimentation rate increased;Renal failure;Renal impairment;Renal pain;Respiratory distress;Respiratory failure;Retinal haemorrhage;Rheumatoid arthritis;Rhinitis;Salivary gland enlargement;Salivary hypersecretion;Salivation;Salpingitis;Scleritis;Scotoma;Seborrhoeic dermatitis;Self-injurious ideation;Sensory loss;Serotonin syndrome;Serum sickness;Sexual dysfunction;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin hypertrophy;Skin ulcer;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Stomatitis;Stridor;Stupor;Suicidal ideation;Suicide;Suicide attempt;Sweating;Sweating increased;Syncope;Systemic lupus erythematosus;Tachycardia;Tardive dyskinesia;Tenosynovitis;Tension;Teratogenicity;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytopenic purpura;Thrombocytosis;Thrombophlebitis;Thrombosis;Tinnitus;Toe walking;Tolerance development;Tongue discolouration;Tongue disorder;Tongue oedema;Tonic-clonic seizures;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Ulcer haemorrhage;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral pain;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary retention;Urinary tract infection;Urination impaired;Urine output increased;Urogenital haemorrhage;Urolithiasis;Urticaria;Uterine fibroids enlarged;Uterine haemorrhage;Uterine leiomyoma;Uterine spasm;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vascular headache;Vascular purpura;Vasculitis;Vasospasm;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Violent;Visual impairment;Vomiting;Weight decreased;Weight increased;Withdrawal syndrome;Yawning,small molecule,approved; vet_approved,"(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Fluoxetin; Fluoxetina; Fluoxetine; Fluoxétine; Fluoxetinum; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; NACHRA3; CKS-1; CKS1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; CYP2B7; Cytochrome P450 2B7 short isoform; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2C; Neuronal acetylcholine receptor subunit alpha-2; Neuronal acetylcholine receptor subunit alpha-3; Neuronal acetylcholine receptor subunit beta-4; Cyclin-dependent kinases regulatory subunit 1; Voltage-gated inwardly rectifying potassium channel KCNH2, N06AB03;N06AB03;N06CA03
fluoxymesterone,Androgen deficiency;Breast cancer;Cryptorchism;Delayed puberty;Hypogonadism male;Injury;Neoplasm;Orchitis;Orchitis noninfective;Primary hypogonadism;Puberty;Secondary hypogonadism;Testosterone deficiency;Trauma,Alopecia;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Androgenetic alopecia;Anxiety;Azoospermia;Blood cholesterol increased;Cholesterol serum elevated;Clotting;Coagulopathy;Coma hepatic;Disturbance in sexual arousal;Enlarged clitoris;Gynaecomastia;Haemoglobin;Haemorrhage;Headache;Hirsutism;Hypersensitivity;Jaundice cholestatic;Libido decreased;Menstruation irregular;Nausea;Oligospermia;Paraesthesia;Paresthesia generalized;Peliosis hepatis;Polycythaemia;Seborrhoeic dermatitis;Virilism,small molecule,approved; illicit,"11β,17β-Dihydroxy-9α-fluoro-17α-methyl-4-androster-3-one; 17α-Methyl-9α-fluoro-11β-hydroxytesterone; 9-Fluoro-11β,17β-dihydroxy-17-methylandrost-4-en-3-one; 9α-Fluoro-11β-hydroxy-17-methyltestosterone; Fluoximesterona; Fluoxymesterone; Fluoxymestérone; Fluoxymesteronum; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1.1.1.-; 11-beta-HSD type II; 11-beta-HSD2; 11-beta-hydroxysteroid dehydrogenase type II; 11-DH2; 11-HSD type II; Corticosteroid 11-beta-dehydrogenase isozyme 2; HSD11K; NAD-dependent 11-beta-hydroxysteroid dehydrogenase; SDR9C3; Short chain dehydrogenase/reductase family 9C member 3; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin",Androgen receptor; Estrogen receptor; Glucocorticoid receptor; 11-beta-hydroxysteroid dehydrogenase type 2,G03BA01
fluphenazine,Angina pectoris;Atherosclerosis cerebral;Blood disorder;Bone marrow depression;Brain injury;Cerebral arteriosclerosis;Coma;Convulsion;Hepatocellular injury;Hypersensitivity;Hypothyroidism;Liver injury;Pancytopenia;Phaeochromocytoma;Psychotic disorder;Renal failure;Renal impairment;Schizophrenia;Sedation,Abnormal dreams;Aggression;Agitation;Agranulocytosis;Akathisia;Akinesia;Altered state of consciousness;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Appetite absent;Arrhythmia;Asphyxia;Asthma;Autonomic nervous system imbalance;Bizarre dreams;Blood creatine phosphokinase increased;Blood disorder;Body temperature decreased;Body temperature increased;Brain oedema;Cardiac arrest;Catatonia;Choreoathetoid movements;Choreoathetosis;Colour blindness;Confusional state;Consciousness abnormal;Constipation;Corneal opacity;Cough;Creatine phosphokinase increased;Decreased appetite;Deep vein thrombosis;Defective colour vision;Depressed level of consciousness;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diabetic;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry mouth;Dyskinesia;Dystonia;Dystonic reaction;Eczema;Edema cerebral;Embolism venous;Eosinophilia;Epigastric discomfort;Erectile dysfunction;Erythema;Erythema multiforme;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Faecalith;Faecaloma;Feeling abnormal;Galactorrhoea;Gastric irritation;Glaucoma;Gynaecomastia;Haemolytic anaemia;Headache;Hepatitis;Hepatocellular injury;Hyperhidrosis;Hyperreflexia;Hypertension;Hyponatraemia;Hypotension;Hypotensive;Hypothermia;Ileus paralytic;Inappropriate antidiuretic hormone secretion;Jaundice cholestatic;Labile blood pressure;Laryngeal dystonia;Laryngeal oedema;Lethargy;Leukocytosis;Leukopenia;Libido increased;Liver injury;Loss of consciousness;Lupus erythematosus;Menorrhagia;Menstruation irregular;Mitral valve incompetence;Movements involuntary;Muscle rigidity;Muscle spasms;Mydriasis;Nasal congestion;Nausea;Neurogenic bladder;Neuroleptic malignant syndrome;Night blindness;Oculogyric crisis;Oedema peripheral;Opisthotonus;Pain;Pancytopenia;Paralysis of bladder;Parkinsonism;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Pneumonia;Polyuria;Priapism;Prolonged menses;Protrusion tongue;Pruritus;Pseudoparkinsonism;Psychotic behaviour;Pulmonary embolism;Purpura non-thrombocytopenic;Renal failure acute;Retinal disorder;Salivary hypersecretion;Salivation;Seborrhoeic dermatitis;Shock;Skin disorder;Somnolence;Spasmodic dysphonia;Stupor;Sweating increased;Syncope;Systemic lupus erythematosus;Tachycardia;Tardive dyskinesia;Tenderness;Torsade de pointes;Tremor;Upper respiratory tract infection;Urine output increased;Urticaria;Venous thromboembolism;Vision blurred;Vomiting,small molecule,approved,1-(2-hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine; 10-(3-(2-hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; 10-(3'-(4''-(β-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; 2-(4-(3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol; 2-(trifluoromethyl)-10-(3-(1-(β-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 4-(3-(-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol; 4-(3-(2-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; Flufenazina; Fluorfenazine; Fluorophenazine; Fluorphenazine; Fluphenazin; Fluphénazine; Fluphenazine; Fluphenazinum; Triflumethazine; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; Dopamine D2 receptor; Dopamine D1 receptor; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1,5-hydroxytryptamine receptor 1B; D(2) dopamine receptor; D(1A) dopamine receptor; Androgen receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2C; Calmodulin,N05AB02
flurandrenolone,Skin disorder,Allergic contact dermatitis;Dermatitis;Dermatitis contact;Dermatitis perioral;Eruption;Folliculitis;Hypersensitivity;Hypertrichosis;Infection;Leukoderma;Miliaria;Pruritus;Rash;Secondary infection;Skin atrophy;Skin discolouration;Skin striae,small molecule,approved,"Fludroxicortida; Fludroxicortide; Fludroxycortid; Fludroxycortide; Fludroxycortidum; Flurandrenolide; Flurandrenolone; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin",Steroid hormone receptor ERR1; Steroid hormone receptor ERR2; Estrogen-related receptor gamma; Glucocorticoid receptor, D07AC07;D07AC07;D07CC03
flurazepam,Insomnia;Terminal insomnia,Abdominal discomfort;Agitation;Agranulocytosis;Anaphylactic shock;Anaphylactoid reaction;Anorexia;Anxiety;Apprehension;Arthralgia;Aspartate aminotransferase increased;Asthenia;Ataxia;Blood alkaline phosphatase increased;Chest pain;Coma;Confusional state;Constipation;Decreased appetite;Dermatitis;Diarrhoea;Disorientation;Dizziness;Drowsiness;Drug intolerance;Dry mouth;Dysarthria;Dysgeusia;Dyspepsia;Dyspnoea;Euphoric mood;Excitement;Feeling abnormal;Flushing;Gait disturbance;Gastrointestinal pain;Hallucination;Headache;Heartburn;Hyperhidrosis;Hyperkinesia;Hypotension;Irritability;Lethargy;Leukopenia;Lightheadedness;Logorrhoea;Loss of consciousness;Mental disability;Musculoskeletal discomfort;Nausea;Nervousness;Palpitations;Phosphatase alkaline increased;Pruritus;Rash;Salivary hypersecretion;Shock;Slurred speech;Somnolence;Staggering gait;Sweating;Syncope;Talkativeness;Taste bitter;Tension;Thinking abnormal;Upset stomach;Vision blurred;Vomiting;Withdrawal syndrome,small molecule,approved; illicit; investigational,"Flurazepam; Flurazépam; Flurazepamum; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT2; OCT2; Organic cation transporter 2",Translocator protein; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site,N05CD01
flurbiprofen,Ankylosing spondylitis;Arthritis;Bursitis;Dysmenorrhoea;Inflammation;Injury;Intraocular pressure increased;Leukocytosis;Miosis;Osteoarthritis;Pain;Rheumatoid arthritis;Tendonitis;Trauma;Vasodilation;Vasodilation procedure,Abdominal discomfort;Abdominal distension;Abdominal pain;Abscess periodontal;Acute coronary syndrome;Affect lability;Agranulocytosis;Albuminuria;Alopecia;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorectal discomfort;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Arthritis;Arthropathy;Asthenia;Asthma;Ataxia;Bladder pain;Bleeding tendency;Bleeding time prolonged;Blepharitis;Blood uric acid increased;Body temperature increased;Breast pain;Bronchitis;Calculus of kidney;Cardiac failure congestive;Cardiac failure right;Cerebral ischaemia;Cerebrovascular accident;Chills;Cholecystitis;Colitis;Coma;Confusional state;Conjunctivitis;Constipation;Convulsion;Corneal opacity;Cough;Cough increased;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Diarrhoea haemorrhagic;Diplopia;Discomfort;Discomfort rectal;Distress;Distress gastrointestinal;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug interaction;Dry mouth;Dry skin;Dyspepsia;Dyspnoea;Dysuria;Ear disorder;Ecchymosis;Eczema;Electroencephalogram abnormal;Emotional distress;Endophthalmitis;Enlargement abdomen;Enteritis;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Euphoric mood;Extrasystoles;Eye irritation;Feeling abnormal;Fever chills;Fibrosis;Flatulence;Gastritis;Gastroenteritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Gastrointestinal ulcer haemorrhage;Gingival bleeding;Gingivitis;Glaucoma;Glossitis;Haematemesis;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Haemorrhagic disorder;Hallucination;Headache;Hearing impaired;Heartburn;Hepatic enzyme increased;Hepatic failure;Hepatitis;Herpes simplex;Herpes zoster;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hyperventilation;Hyphaema;Hypotension;Ill-defined disorder;Incontinence;Increased appetite;Infection;Inflammatory bowel disease;Influenza;Insomnia;Iron deficiency anaemia;Jaundice;Jaundice cholestatic;Keratitis;Keratoconjunctivitis;Kidney function abnormal;Laryngitis;Leukocytosis;Leukopenia;Leukorrhea;Libido decreased;Loss of consciousness;Lung disorder;Lymphadenopathy;Malaise;Melaena;Meningitis;Meningitis aseptic;Migraine;Mood swings;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Mydriasis;Myocardial infarction;Nail discolouration;Nail disorder;Nausea;Nephritis interstitial;Nephrolithiasis;Nervousness;Neuralgia;Neuritis retrobulbar;Neutropenia;Ocular hyperaemia;Oedema;Oesophageal disorder;Oesophagitis;Oliguria;Optic neuritis;Osteoarthritis;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Parosmia;Peptic ulcer;Petechiae;Pharyngitis;Phlebitis;Photophobia;Photosensitivity;Photosensitivity reaction;Pneumonia;Polyuria;Prostatic disorder;Protein urine present;Proteinuria;Pruritus;Pulmonary embolism;Pulmonary function test decreased;Pulmonary infarction;Purpura;Pyuria;Rash;Rectal haemorrhage;Renal failure;Renal impairment;Respiratory depression;Retinal haemorrhage;Rhinitis;Right ventricular failure;Scleritis;Seborrhoeic dermatitis;Sepsis;Shock;Sinusitis;Skin exfoliation;Skin ulcer;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stinging;Stomatitis;Subarachnoid haemorrhage;Sweating;Syncope;Tachycardia;Tenosynovitis;Tension;Thirst;Thrombocytopenia;Tinnitus;Tooth abscess;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Ulcer;Urethritis;Urethritis noninfective;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Uterine haemorrhage;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Vertigo;Visual impairment;Vomiting;Vulvovaginitis;WBC abnormal NOS;White blood cell disorder,small molecule,approved; investigational,"(±)-2-fluoro-α-methyl-4-biphenylacetic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid; 3-fluoro-4-phenylhydratropic acid; Flurbiprofen; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1, M01AE09; R02AX01; S01BC04;M01AE09;M02AA19
flutamide,Adenocarcinoma of the prostate metastatic;Benign prostatic hyperplasia;Benign prostatic hypertrophy;Carcinoma;Metastatic carcinoma;Metastatic neoplasm;Neoplasm malignant;Prostate cancer;Prostate cancer metastatic;Prostate carcinoma,Anaemia;Anaemia macrocytic;Anorexia;Anxiety;Aspartate aminotransferase increased;Asthenia;Bladder pain;Blood urea increased;Breast mass;Breast neoplasm;Breast neoplasm NOS male;Breast tenderness;Bullous eruption;Carcinoma;Chromaturia;Confusional state;Constipation;Cystitis;Cystitis noninfective;Decreased appetite;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diabetes mellitus exacerbated;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drowsiness;Ecchymosis;Erectile dysfunction;Erythema;Fatigue;Feeling abnormal;Galactorrhoea;Gynaecomastia;Haematuria;Haemolytic anaemia;Headache;Hepatic encephalopathy;Hepatic necrosis;Hepatitis;Herpes zoster;Hot flush;Hyperglycaemia;Hypertension;Ill-defined disorder;Increased appetite;Injection site irritation;Insomnia;Interstitial lung disease;Jaundice;Jaundice cholestatic;Laboratory test abnormal;Leukopenia;Libido decreased;Liver injury;Loss of libido;Malaise;Menopausal symptoms;Metastasis;Metastatic carcinoma;Metastatic neoplasm;Methaemoglobinaemia;Nausea;Necrolysis epidermal;Neoplasm;Neoplasm malignant;Nervousness;Nodule;Oedema;Oedema peripheral;Photosensitivity reaction;Proctitis;Pruritus;Pulmonary embolism;Rash;Rectal haemorrhage;Skin disorder;Somnolence;Sulphaemoglobinaemia;Tension;Thrombocytopenia;Toxic epidermal necrolysis;Transaminases increased;Traumatic liver injury;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Urine color abnormal;Vomiting,small molecule,approved; investigational,"4'-nitro-3'-trifluoromethylisobutyranilide; Flutamid; Flutamida; Flutamide; Flutamidum; FTA; NFBA; Niftolid; Niftolide; α,α,α-trifluoro-2-methyl-4'-nitro-m-propionotoluidide; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; Ah receptor; AhR; BHLHE76; Class E basic helix-loop-helix protein 76; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1",Androgen receptor; Aryl hydrocarbon receptor; Nuclear receptor subfamily 1 group I member 2,L02BB01
fluticasone,Asthma;Asthma chronic;Dermatitis atopic;Discomfort;Eczema;Glaucoma;Hypersensitivity;Nasal obstruction;Nasal polyps;Nasopharyngitis;Pruritus;Rhinitis;Rhinitis allergic;Rhinitis perennial;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Sinus headache;Sinus pain;Skin disorder;Sneezing,Abdominal discomfort;Abdominal distension;Abdominal pain;Ache;Acneiform eruption;Ageusia;Agitation;Allergic contact dermatitis;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anxiety;Asthma;Blister;Body temperature increased;Bronchitis;Bronchospasm;Bronchospasm paradoxical;Candida infection;Cataract;Chest pain;Common wart;Conjunctivitis;Contusion;Cough;Cushing's syndrome;Cutaneous hypersensitivity;Dermatitis;Dermatitis acneiform;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis perioral;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dry throat;Dysphonia;Dyspnoea;Eczema;Eczema infected;Endocrine disorder;Epistaxis;Erythema;Excoriation;Eye disorder;Eye irritation;Eyelid oedema;Face oedema;Feeling abnormal;Folliculitis;Fracture;Gastrointestinal pain;Glaucoma;Growth retardation;Headache;Herpes simplex;Hoarseness;Hyperadrenocorticism;Hyperglycaemia;Hyperkinesia;Hypersensitivity;Hypertension;Hypertrichosis;Hypoaesthesia;Hypogeusia;Ill-defined disorder;Immune system disorder;Impetigo;Infection;Infestation;Infestation NOS;Influenza like illness;Influenza-like symptoms;Intraocular pressure increased;Irritability;Lacrimation;Lacrimation increased;Leukoderma;Lightheadedness;Lower respiratory tract infection;Malaise;Malnutrition;Mediastinal disorder;Menopause;Mental disorder;Miliaria;Multiple fractures;Nasal burning;Nasal congestion;Nasal discomfort;Nasal dryness;Nasal irritation;Nasal septum perforation;Nasal soreness;Nasal ulcer;Nasopharyngitis;Nausea;Nervous system disorder;Numbness in fingers;Oedema;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Oropharyngeal swelling;Osteopenia;Osteoporosis;Pain;Perennial allergic rhinitis;Pharyngitis;Plaque psoriasis;Pruritus;Psoriasis;Pustular psoriasis;Rash;Rash erythematous;Rhinalgia;Rhinitis allergic;Rhinitis perennial;Rhinorrhoea;Scab;Secondary adrenocortical insufficiency;Secondary infection;Sinus headache;Sinus pain;Sinusitis;Skin atrophy;Skin disorder;Skin infection;Skin irritation;Skin papilloma;Skin striae;Sleep disorder;Sneezing;Stinging;Stinging of nose;Swelling of eyelid;Telangiectasia;Telangiectasis facial;Throat irritation;Throat sore;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Viral infection;Vision blurred;Vomiting;Wheezing,small molecule,approved; experimental,"Fluticason; Fluticasona; Fluticasone; Fluticasonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; CPLA2; Phospholipase A2 group IVA; PLA2G4; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; CBG; Serpin A6; Transcortin; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Glucocorticoid receptor; Progesterone receptor; Cytosolic phospholipase A2; Mineralocorticoid receptor, D07AC17; R01AD08; R01AD58; R03AK06; R03AK11;R03BA05
fluvastatin,Acute coronary syndrome;Alcohol abuse;Alcoholism;Arteriosclerosis;Arteriosclerosis coronary artery;Atherosclerosis;Cardiac death;Cardiac disorder;Cardiovascular disorder;Carotid artery disease;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Dyslipidaemia;Foetor hepaticus;Hepatocellular injury;Heterozygous familial hypercholesterolemia;Hypercholesterolaemia;Hyperlipidaemia;Hyperlipoproteinemia;Hypertension;Hypothyroidism;Liver disorder;Menarche;Myocardial infarction;Nephrotic syndrome;Peripheral vascular disorder;Premature menopause;Type IIa hyperlipidaemia,Abdominal pain;Abdominal pain upper;Abnormal vision;Alopecia;Amnesia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Antinuclear antibody positive;Anxiety;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Atrial fibrillation;Back pain;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Body temperature increased;Breast disorder;Bronchitis;Cardiac disorder;Cataract;Chest pain;Chills;Cognitive disorder;Cognitive impairment;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cramp muscle;Decreased appetite;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Dizziness;Drug reaction with eosinophilia and systemic symptoms;Dysaesthesia;Dysgeusia;Dyspepsia;Dyspnoea;Dyspnoea exertional;Eczema;Eosinophilia;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Face oedema;Facial paresis;Fatigue;Feeling abnormal;Flatulence;Flushing;Forgetfulness;Gastric disorder;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Gynaecomastia;Haemolytic anaemia;Headache;Heartburn;Hepatic cancer;Hepatic failure;Hepatic necrosis;Hepatitis;Hepatitis chronic active;Hepatobiliary disease;Hepatocellular carcinoma;Hot flush;Hyperhidrosis;Hypersensitive syndrome;Hypersensitivity;Hypertension;Hypoaesthesia;IIIrd nerve paralysis;Ill-defined disorder;Immune system disorder;Immune-mediated necrotising myopathy;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Intermittent claudication;Jaundice cholestatic;Leg pain;Lenticular opacities;Leukopenia;Loss of consciousness;Loss of libido;Lupus erythematosus;Malaise;Memory impairment;Memory loss;Menopausal symptoms;Mental disorder;Muscle spasms;Muscle swelling;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myoglobin urine present;Myoglobinuria;Myopathy;Myositis;Nasopharyngitis;Nausea;Nervous system disorder;Neuropathy peripheral;Nodule;Oedema peripheral;Ophthalmoplegia;Osteoarthritis;Pain;Pain in extremity;Pancreatitis;Pancreatitis acute;Paraesthesia;Peripheral nerve palsy;Pharyngitis;Photosensitivity;Photosensitivity reaction;Polymyalgia rheumatica;Pruritus;Purpura;Rash;Renal failure acute;Rhabdomyolysis;Rhinitis;Shock;Sinusitis;Skin disorder;Stevens-Johnson syndrome;Sweating;Syncope;Systemic lupus erythematosus;Tenderness;Thrombocytopenia;Tooth disorder;Toxic epidermal necrolysis;Transaminases increased;Trauma;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urticaria;VIIth nerve paralysis;Vascular purpura;Vasculitis;Vertigo;Visual impairment;Vomiting,small molecule,approved,"Fluvastatin; fluvastatina; fluvastatine; fluvastatinum; 1.1.1.34; HMG-CoA reductase; 3.5.1.98; HD2; Protein deacylase HDAC2; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",3-hydroxy-3-methylglutaryl-coenzyme A reductase; Histone deacetylase 2,C10AA04
fluvoxamine,Anxiety;Compulsions;Convulsion;Depression;Depressive disorder;Distress;Dysthymic disorder;Emotional distress;Foetor hepaticus;Hepatocellular injury;Liver disorder;Major depression;Obsessive rumination;Obsessive thoughts;Obsessive-compulsive disorder;Panic attack;Performance fear;Phobia;Renal failure;Renal impairment;Social phobia,Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal ejaculation;Abnormal vision;Abscess;Accidental injury;Accommodation disorder;Ache;Acne;Activation syndrome;Acute coronary syndrome;Administration site reaction;Affect lability;Ageusia;Aggression;Agitation;Agoraphobia;Agranulocytosis;Akathisia;Akinesia;Alcohol intolerance;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anger;Angina pectoris;Angioedema;Angiopathy;Anorectal discomfort;Anorexia;Anorgasmia;Anuria;Anxiety;Apathy;Aplastic anaemia;Apnoea;Appetite absent;Application site reaction;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Ataxia;Atrioventricular block;Back pain;Biliary colic;Bladder pain;Blepharitis;Blood and lymphatic system disorders;Blood glucose increased;Blood lactate dehydrogenase increased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Breast disorder;Breast pain;Breath odour;Bronchitis;Bruxism;Bullous eruption;Bursitis;CNS depression NOS;Calculus of kidney;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac fibrillation;Cardio-respiratory arrest;Cardiomyopathy;Cardiovascular disorder;Central nervous system neoplasm;Cerebrovascular accident;Chest pain;Chills;Cholecystitis;Cholelithiasis;Colitis;Coma;Compulsive personality disorder;Confusional state;Conjunctivitis;Constipation;Conversion disorder;Convulsion;Coordination abnormal;Coronary artery disease;Cough;Cough increased;Cramps of lower extremities;Crying;Cutaneous hypersensitivity;Cyanosis;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Delirium;Delusion;Dental caries;Depersonalisation;Depressed level of consciousness;Depression;Depressive symptom;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Diuresis;Dizziness;Drowsiness;Drug interaction;Drug withdrawal syndrome;Drug withdrawal syndrome neonatal;Dry eye;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Eczema;Ejaculation delayed;Ejaculation disorder;Electric shock;Electrocardiogram QT prolonged;Electrocardiogram ST segment;Embolism;Embolus;Endocrine disorder;Enlargement abdomen;Enuresis;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Extrapyramidal symptoms;Extrasystoles;Eye disorder;Eye pain;Face oedema;Faecal incontinence;Fatigue;Feeling abnormal;Feeling drunk;Feeling jittery;Female sexual dysfunction;Flat affect;Flatulence;Fracture;Furuncle;Furunculosis;Gait disturbance;Galactorrhoea;Gastritis;Gastroenteritis;Gastrointestinal carcinoma;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal ulcer;Gastrooesophageal reflux disease;Gingivitis;Glaucoma;Glossitis;Glossodynia;Goitre;Haematemesis;Haematospermia;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhoids;Hallucination;Hangover;Headache;Heart alternation;Heart rate irregular;Hemiplegia;Henoch-Schonlein purpura;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hernia;Herpes NOS;Herpes simplex;Herpes virus infection;Herpes zoster;Hiccups;Hoarseness;Homicidal ideation;Hostility;Hyperacusis;Hyperaesthesia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hyperprolactinaemia;Hypersensitivity;Hypersomnia;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypochondriasis;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hypomenorrhoea;Hyponatraemia;Hyporeflexia;Hypotension;Hypothyroidism;Hypotonia;Hysteria;Ileus;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Influenza;Injury;Insomnia;Intentional self-injury;Interstitial lung disease;Intestinal obstruction;Irritability;Jaundice;Lacrimal disorder;Lacrimal structural disorder;Lactation female;Lactic dehydrogenase activity increased;Laryngitis;Laryngospasm;Lethargy;Leukocytosis;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Ligament sprain;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Major depression;Malaise;Malignant syndrome NOS;Malnutrition;Mania;Manic psychosis;Melaena;Menopause;Menorrhagia;Menstrual disorder;Menstruation delayed;Mental disability;Mental disorder;Metrorrhagia;Micturition disorder;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Multiple fractures;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Mutism;Myalgia;Myasthenia;Mydriasis;Myocardial infarction;Myoclonus;Myopathy;Nausea;Neck pain;Neck stiffness;Neoplasm;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Neurosis;Nocturia;Nuchal rigidity;Obesity;Obsessive rumination;Obsessive thoughts;Obsessive-compulsive personality disorder;Obstructive airways disorder;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Orthostatic hypotension;Osteoarthritis;Otitis media;Pain;Pallor;Palpitations;Pancreatitis;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Parkinsonism;Parosmia;Pelvic pain;Pericarditis;Peripheral coldness;Peripheral vascular disorder;Pharyngitis;Phlebitis;Phobia;Photophobia;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Porphyrin metabolism disorder;Premenstrual syndrome;Priapism;Proctalgia;Prostatic disorder;Pruritus;Psoriasis;Psychotic depression;Psychotic disorder;Pulmonary infarction;Pulse irregular;Purpura;Rash;Rash maculo-papular;Rectal haemorrhage;Rectal tenesmus;Renal failure;Renal failure acute;Renal impairment;Renal pain;Retinal detachment;Rhabdomyolysis;Rheumatoid arthritis;Rhinitis;Salivary hypersecretion;Schizophrenic reaction;Schizophreniform disorder;Scotoma;Screaming;Seborrhoeic dermatitis;Self injurious behaviour;Self-injurious ideation;Serotonin syndrome;Sexual dysfunction;Shock;Sinusitis;Skin discolouration;Sleep disorder;Slurred speech;Somnolence;Somnolence neonatal;Sprain;Stevens-Johnson syndrome;Stomatitis;Stupor;Sudden death;Suicidal behaviour;Suicidal ideation;Suicidal tendency;Suicide attempt;Supraventricular extrasystoles;Sweating;Sweating increased;Syncope;Syndrome screaming;Tachycardia;Tardive dyskinesia;Tendinous contracture;Tenosynovitis;Tension;Tetany;Thinking abnormal;Thirst;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Tooth disorder;Toothache;Torsade de pointes;Torticollis;Toxic epidermal necrolysis;Tremor;Trismus;Ulcerative keratitis;Unintended pregnancy;Unsteady gait;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urine output increased;Urticaria;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasculitis;Ventricular tachycardia;Vertigo;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;White blood cell count decreased;Withdrawal symptom;Withdrawal syndrome;Yawning,small molecule,approved; investigational,"Fluvoxamina; Fluvoxamine; Fluvoxaminum; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Sodium-dependent serotonin transporter; Voltage-gated inwardly rectifying potassium channel KCNH2,N06AB08
folate,Anaemia;Anaemia megaloblastic;Coeliac disease;Epilepsy;Folate deficiency;Pernicious anaemia,Abdominal distension;Agitation;Anaphylactic shock;Anorexia;Bad taste;Bronchospasm;Confusional state;Convulsion;Decreased appetite;Depression;Dermatitis;Digestion impaired;Discomfort;Dysgeusia;Dyspepsia;Dyspnoea;Erythema;Excitement;Feeling abnormal;Flatulence;Gastrointestinal disorder;Ill-defined disorder;Irritability;Judgement impaired;Malaise;Nausea;Overactivity;Pruritus;Rash;Sensitisation;Vitamin B12 deficiency,small molecule,investigational,"Adult folate-binding protein; FBP; Folate receptor 1; Folate receptor, adult; FOLR; FR-alpha; KB cells FBP; Ovarian tumor-associated antigen MOv18; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Folate receptor alpha,B03BB01
formoterol,Asthma;Asthma exercise induced;Bronchial hyperreactivity;Bronchitis chronic;Bronchoconstriction;Bronchospasm;Chronic obstructive pulmonary disease;Emphysema;Exercise-induced bronchospasm;Obstructive airways disorder;Reversible airways obstruction,Abdominal pain;Abnormal vision;Abrasion NOS;Abscess;Abscess periodontal;Acute bronchitis;Acute coronary syndrome;Acute sinusitis;Agitation;Anaphylactic shock;Angina pectoris;Angioedema;Anxiety;Arrhythmia;Arteriosclerosis;Arthralgia;Arthritis;Asthenia;Asthma;Atrial fibrillation;Atrial flutter;Atrioventricular block;Back pain;Bladder pain;Block heart;Blood pressure increased;Body temperature increased;Bone disorder;Breast neoplasm;Bronchitis;Bronchospasm;Bronchospasm paradoxical;COPD exacerbation;Calculus of kidney;Candida infection;Carcinoma of lung;Cardiac disorder;Cardiac failure congestive;Central nervous system disorder;Cerebral infarction;Chest pain;Chronic obstructive pulmonary disease;Circumoral paresthesia;Conjunctival irritation;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cramp muscle;Cramps of lower extremities;Crystalluria calcium;Cystitis;Cystitis noninfective;Dehydration;Dermatitis;Dermatitis contact;Diarrhoea;Digitalis intoxication (NOS);Discomfort;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphonia;Dyspnoea;Electrocardiogram QT prolonged;Electrocardiogram T wave inversion;Exacerbation of asthma;Excoriation;Extrasystoles;Eyelid oedema;Fatigue;Feeling abnormal;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Glaucoma;Glucose tolerance decreased;Glycosuria;Gout;Haematuria;Headache;Hernia;Herpes simplex;Herpes zoster;Hypercalciuria;Hyperglycaemia;Hyperkalaemia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hypotension;Ill-defined disorder;Immune system disorder;Increased bronchial secretion;Infection;Inflammation;Influenza;Injection site pain;Injury;Insomnia;Leukocytosis;Lower respiratory tract infection;Lung disorder;Lung neoplasm malignant;Malaise;Malnutrition;Mediastinal disorder;Melaena;Mental disorder;Metabolic acidosis;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nasal congestion;Nasopharyngitis;Nausea;Neck stiffness;Neoplasm;Nephrolithiasis;Nervous system disorder;Nervousness;Nocturia;Nuchal rigidity;Oedema;Oedema mouth;Oedema peripheral;Oral candidiasis;Pain;Palpitations;Paraesthesia oral;Paralysis;Pelvic pain;Pharyngeal disorder;Pharyngitis;Pharyngitis streptococcal;Pruritus;Pyuria;Rash;Rectal haemorrhage;Respiratory arrest;Respiratory tract infection;Retroperitoneal haemorrhage;Rheumatoid arthritis;Rhinitis;Rhinitis allergic;Sinusitis;Skin discolouration;Skin disorder;Skin hypertrophy;Sleep disorder;Sleep disturbance;Somnolence;Sputum increased;Supraventricular tachycardia;Tachyarrhythmia;Tachycardia;Tendinous contracture;Tension;Throat irritation;Tonsillitis;Tooth abscess;Toxicity to various agents;Tracheobronchitis;Trauma;Tremor;Tremor muscle;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urticaria;Ventricular extrasystoles;Viral diarrhoea;Viral infection;Viral upper respiratory tract infection;Visual impairment;Vomiting,small molecule,approved; investigational,"2'-hydroxy-5'-(1-hydroxy-2-((p-methoxy-α-methylphenethyl)amino)ethyl)formanilide; 2'-hydroxy-5'-{1-hydroxy-2-[(p-methoxy-α-methylphenethyl)amino]ethyl}formanilide; Formoterol; Formoterolum; N-[2-hydroxy-5-(1-hydroxy-2-{[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)phenyl]formamide; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5",Beta-2 adrenergic receptor; Beta-1 adrenergic receptor; Beta-3 adrenergic receptor, R03AC13; R03AK07; R03AK08; R03AK09; R03AK11; R03AL05; R03AL07; R03AL10; R03AL11; R03CC15;R03AC13;R03AL09
foscarnet,Acquired immunodeficiency syndrome;Autoimmune disorder;Cytomegalovirus chorioretinitis;Cytomegalovirus infection;Cytomegalovirus retinitis;Encephalitis;Gastroenteritis;Immunocompromised;Immunodeficiency;Infection;Pneumonia;Retinitis,Abdominal pain;Abnormal platelets;Abscess;Acidosis;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albumin globulin ratio abnormal;Albuminuria;Amnesia;Anaemia;Anorexia;Anxiety;Aphasia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrioventricular block first degree;Back pain;Bacterial infection;Blood alkaline phosphatase increased;Blood creatinine decreased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Bronchospasm;Cachexia;Calculus of kidney;Candida infection;Cardiac arrest;Cerebrovascular disorder;Chest pain;Chills;Coma;Confusional state;Congenital eye disorder;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cough;Cramps of lower extremities;Creatinine low;Decreased appetite;Dehydration;Dementia;Depressed level of consciousness;Dermatitis;Dermatitis bullous;Diabetes insipidus;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Electroencephalogram abnormal;Electrolyte imbalance;Erythema multiforme;Eye disorder;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flatulence;Flushing;Fungal infection;Gamma-glutamyltransferase increased;Gastrointestinal pain;Generalised spasm;Grand mal convulsion;Haematuria;Haemoptysis;Hallucination;Headache;Hyperhidrosis;Hyperphosphataemia;Hypertension;Hypoaesthesia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hypotension;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Infection;Influenza like illness;Influenza-like symptoms;Injection site inflammation;Injection site pain;Insomnia;Kidney function abnormal;Lactic dehydrogenase activity increased;Leukopenia;Lung infiltration;Lymphadenopathy;Malaise;Melaena;Meningitis;Mouth ulceration;Muscle contractions involuntary;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myopathy;Myositis;Nausea;Neoplasm;Nephrolithiasis;Nephropathy toxic;Nephrotoxicity;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Nocturia;Oedema;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Pharyngitis;Phosphatase alkaline increased;Platelet disorder;Pneumothorax;Polyuria;Pruritus;Pseudolymphoma;Rash;Rash erythematous;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Renal failure;Renal failure acute;Renal impairment;Respiratory failure;Respiratory insufficiency;Rhabdomyolysis;Rhinitis;Rigors;Seborrhoeic dermatitis;Sepsis;Serum creatinine increased;Sinus tachycardia;Sinusitis;Skin discolouration;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Stridor;Stupor;Sweating increased;Tension;Thirst;Thrombocytopenia;Thrombosis;Tonic-clonic seizures;Toxic epidermal necrolysis;Tremor;Ulcerative stomatitis;Urethral disorder;Urinary retention;Urinary tract infection;Urine output increased;Ventricular arrhythmia;Vesiculobullous rash;Vomiting;WBC abnormal NOS;Weight decreased;White blood cell disorder,small molecule,approved,Carboxyphosphonic acid; Foscarmet; Phosphonoformate; Phosphonoformic acid; Phosphonomethanoic acid; 2.7.7.7; 2.7.7.7; HFLF2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; MCT 1; MCT1; Solute carrier family 16 member 1,DNA polymerase catalytic subunit; DNA polymerase catalytic subunit,J05AD01
fosfomycin,Bacteriuria;Perinephric abscess;Pyelonephritis;Urinary tract infection,Abdominal pain;Abnormal faeces;Alanine aminotransferase increased;Anaphylactic shock;Angioedema;Anorexia;Aplastic anaemia;Aspartate aminotransferase increased;Asthenia;Asthma;Back pain;Blood alkaline phosphatase increased;Blood bilirubin increased;Body temperature increased;Constipation;Deafness;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Dyspepsia;Dysuria;Ear disorder;Eosinophil count increased;Eosinophilia;Flatulence;Gastrointestinal pain;Haematocrit decreased;Haematuria;Haemoglobin decreased;Headache;Hearing impaired;Hepatic necrosis;Infection;Influenza;Insomnia;Jaundice cholestatic;Lymphadenopathy;Megacolon;Megacolon toxic;Menstrual disorder;Migraine;Musculoskeletal discomfort;Myalgia;Nausea;Nervousness;Optic neuritis;Pain;Paraesthesia;Pharyngitis;Phosphatase alkaline increased;Platelet count decreased;Pruritus;Rash;Rhinitis;Skin disorder;Somnolence;Tension;Vaginal infection;Vaginal inflammation;Vomiting;White blood cell count decreased,small molecule,approved,"(-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid; (1R,2S)-epoxypropylphosphonic acid; (2R-cis)-(3-Methyloxiranyl)phosphonic acid; 1R-cis-(1,2-epoxypropyl)phosphonic acid; cis-(1R,2S)-epoxypropylphosphonic acid; FCM; Fosfocina; Fosfomicina; Fosfomycin; Fosfomycine; Fosfomycinum; L-cis-1,2-epoxypropylphosphonic acid; Phosphomycin; Phosphonemycin; Phosphonomycin; 2.5.1.7; Enoylpyruvate transferase; EPT; murZ; UDP-N-acetylglucosamine enolpyruvyl transferase",UDP-N-acetylglucosamine 1-carboxyvinyltransferase, J01XX01;J01XX01;S02AA17
fosinopril,Aldosterone low;Biliary cirrhosis;Blood aldosterone decreased;Blood potassium increased;Blood pressure fluctuation;Blood pressure increased;Cardiac failure;Cardiac failure congestive;Cardiac failure high output;Cardiac index;Cardiac output increased;Change in blood pressure;Essential hypertension;Function kidney decreased;Hepatic failure;Hepatic impairment;Hepatic insufficiency;Hypertension;Hypertensive;Hypotension;Liver disorder;Microalbuminuria;Pregnancy;Protein urine present;Proteinuria;Reflex tachycardia;Renal failure;Renal failure chronic;Renal impairment;Renin decreased;Renovascular hypertension;Serum potassium increased;Tachycardia;Vascular resistance systemic,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal faeces;Acral erythema;Acute coronary syndrome;Affect lability;Agitation;Agranulocytosis;Albumin urine increased;Albumin urine present;Anaemia;Anaemia megaloblastic;Anaphylactic shock;Anaphylactoid reaction;Angiitis necrotising;Angina pectoris;Angioedema;Anorexia;Antinuclear antibody positive;Anuria;Aplastic anaemia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Asthenia;Asthma;Atrial rhythm;Bad taste;Blister;Blood creatinine increased;Blood pressure increased;Body temperature increased;Bradycardia;Breast disorder;Breath odour;Bronchospasm;Calculus of kidney;Cardiac arrest;Cardiac pain;Cardiac tamponade;Cardio-respiratory arrest;Cerebral infarction;Cerebrovascular accident;Chest pain;Chills;Claudication;Conduction disorder;Confusional state;Constipation;Coronary artery disease;Cough;Cramp muscle;Cranial nerve disorder;Creatinine increased;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug interaction;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Ear infection;Ear pain;Ecchymosis;Edema of lower extremities;Eosinophilia;Epigastric pain;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Eschar;Eye irritation;Fatigue;Feeling abnormal;Feeling cold;Flatulence;Flushing;Gastritis;Gastroenteritis;Gastrointestinal pain;Gout;Haematocrit decreased;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Heartburn;Hepatic failure;Hepatitis;Hepatomegaly;Hoarseness;Hot flush;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertensive crisis;Hypoaesthesia;Hyponatraemia;Hypotension;Hypotension symptomatic;Hypovolaemia;Ill-defined disorder;Increased appetite;Infection;Influenza;Injury;Insomnia;Intermittent claudication;Intestinal obstruction;Irreversible renal failure;Jaundice;Laboratory test abnormal;Laryngitis;Leukocytosis;Leukopenia;Libido decreased;Lightheadedness;Limb paresis;Local swelling;Loss of consciousness;Lymphadenopathy;Malaise;Memory impairment;Menopausal symptoms;Menstrual disorder;Microcephaly;Microsomia;Monoparesis;Mood swings;Muscle contracture;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Nail abnormality NOS;Nail disorder;Nausea;Nephritis interstitial;Nephrolithiasis;Nephropathy;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Numbness;Oedema;Oedema peripheral;Oligohydramnios;Oliguria;Oral disorder;Oral lesion;Orthostatic hypotension;Pain;Palmar-plantar erythrodysaesthesia syndrome;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Patent ductus arteriosus;Pemphigus;Peripheral vascular disorder;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pleurisy;Pleuritic pain;Pneumonia;Pollakiuria;Polydipsia;Polyp;Polyuria;Pregnancy;Prostatic disorder;Protein urine present;Proteinuria;Prurigo;Pruritus;Pulmonary congestion;Pulmonary eosinophilia;Pulmonary oedema;Purpura;Rash;Renal failure;Renal failure acute;Renal failure chronic;Renal pain;Respiration abnormal;Respiratory arrest;Respiratory disorder;Respiratory distress;Respiratory tract congestion;Respiratory tract infection;Rhinitis;Rhythm idioventricular;Sensory loss;Serositis;Serum creatinine increased;Sexual dysfunction;Shock;Sialoadenitis;Sinusitis;Skin bacterial infection;Skin discomfort;Skin induration;Skull hypoplasia;Sleep disorder;Sleep disturbance;Sneezing;Somnolence;Stevens-Johnson syndrome;Sudden death;Sweating increased;Swelling;Swelling of limb;Swollen tongue;Syncope;Tachycardia;Tendonitis;Tension;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tracheobronchitis;Transaminases increased;Transient ischaemic attack;Trauma;Tremor;Tubulointerstitial nephritis;Upper respiratory tract infection;Urinary sediment abnormal;Urine output increased;Urticaria;Vaginal haemorrhage;Vascular purpura;Vasculitis;Vasculitis necrotising;Ventricular arrhythmia;Vertigo;Viral infection;Vision blurred;Visual impairment;Vomiting;Weight decreased;Weight increased;Xanthopsia,small molecule,approved,"Fosenopril; Fosinopril; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Angiotensin-converting enzyme, C09AA09;C09AA09;C09BA09
Romidepsin,Infection;Peripheral T-cell lymphoma unspecified,Abdominal pain;Acute respiratory distress syndrome;Alanine aminotransferase increased;Anaemia;Anorexia;Arrhythmia supraventricular;Aspartate aminotransferase increased;Asthenia;Blood and lymphatic system disorders;Blood uric acid increased;Body temperature increased;Candida sepsis;Cardiac disorder;Cardiogenic shock;Cardiopulmonary failure;Catheter related infection;Cellulitis;Central line infection;Chest pain;Chills;Constipation;Cough;Cutaneous T-cell lymphoma;Death;Decreased appetite;Deep vein thrombosis;Dehydration;Dermatitis;Dermatitis exfoliative;Device related infection;Diarrhoea;Disease progression;Dizziness;Dysgeusia;Dyspnoea;Fatigue;Febrile neutropenia;Found dead (cause undetermined);Gastrointestinal disorder;Gastrointestinal pain;Headache;Hyperbilirubinaemia;Hyperglycaemia;Hypermagnesaemia;Hypersensitivity;Hyperuricaemia;Hypoalbuminaemia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Infection;Leukopenia;Loss of consciousness;Lymphopenia;Malnutrition;Mediastinal disorder;Multi-organ failure;Mycosis fungoides;Myocardial ischaemia;Nausea;Neoplasm malignant;Nervous system disorder;Neutropenia;Oedema;Oedema peripheral;Pneumonia;Pruritus;Pulmonary embolism;Renal failure acute;Sepsis;Septic shock;Shock;Stomatitis;Syncope;Tachycardia;Thrombocytopenia;Ventricular arrhythmia;Vomiting;Weight decreased,small molecule,approved; investigational,"Romidepsin; Romidepsina; Romidepsine; Romidepsinum; 3.5.1.98; HD1; Protein deacetylase HDAC1; Protein deacylase HDAC1; RPD3L1; 3.5.1.98; HD2; Protein deacylase HDAC2; 3.5.1.98; HD4; KIAA0288; 3.5.1.98; HD6; KIAA0901; Protein deacetylase HDAC6; Tubulin-lysine deacetylase HDAC6; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 3.5.1.98; HD1; Protein deacetylase HDAC1; Protein deacylase HDAC1; RPD3L1; 3.5.1.98; HD11; 3.5.1.98; HD2; Protein deacylase HDAC2; 3.5.1.98; HD3; Protein deacetylase HDAC3; Protein deacylase HDAC3; RPD3-2; SMAP45; 3.5.1.98; HD4; KIAA0288; 3.5.1.98; Antigen NY-CO-9; HD5; KIAA0600; 3.5.1.98; HD6; KIAA0901; Protein deacetylase HDAC6; Tubulin-lysine deacetylase HDAC6; 3.5.1.98; HD7; HD7a; HDAC7A; Histone deacetylase 7A; Protein deacetylase HDAC7; 3.5.1.98; HD8; HDACL1; Protein deacetylase HDAC8; Protein decrotonylase HDAC8; 3.5.1.98; HD7; HD7b; HD9; HDAC7; HDAC7B; HDRP; Histone deacetylase 7B; Histone deacetylase-related protein; KIAA0744; MEF2-interacting transcription repressor MITR; MITR; 3.5.1.48; 3.5.1.62; HD10; Histone deacetylase 10; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOCT2; OCT2; Organic cation transporter 2",Histone deacetylase 1; Histone deacetylase 2; Histone deacetylase 4; Histone deacetylase 6; Multidrug resistance-associated protein 1; Histone deacetylase,L01XH02;L01XX39
furosemide,Acute pulmonary oedema;Anuria;Brain oedema;Cardiac failure;Cardiac failure congestive;Chronic nephritis;Diuresis;Diuretic effect;Edema cerebral;Fluid retention;Function kidney decreased;Glomerulonephritis chronic;Hepatic failure;Hepatic insufficiency;Hypersensitivity;Hypertension;Hypertensive;Hypoproteinaemia;Immobile;Infection;Intercapillary glomerulosclerosis;Jaundice;Lupus erythematosus;Nephritic syndrome;Nephritis;Nephropathy;Nephrosis;Nephrotic syndrome;Nodular glomerulosclerosis;Oedema;Oliguria;Polyuria;Renal failure;Renal failure acute;Renal failure chronic;Renal impairment;Systemic lupus erythematosus,AGEP;Abdominal bloating;Abdominal distension;Abdominal pain;Accidental exposure to product;Accidental ingestion;Acute generalised exanthematous pustulosis;Acute retention of urine;Agitation;Agranulocytosis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angiitis necrotising;Angiopathy;Anorexia;Apathy;Aplastic anaemia;Application site pain;Arrhythmia;Asthenia;Auditory disorder NOS;Benign prostatic hyperplasia;Bladder pain;Bladder spasm;Blister;Blood and lymphatic system disorders;Blood cholesterol increased;Blood creatinine increased;Blood triglycerides increased;Blood uric acid increased;Body temperature increased;Bullous eruption;Central nervous system disorder;Cerebration impaired;Cholestasis;Cholestasis intrahepatic;Chronic diarrhea;Confusional state;Constipation;Cramp muscle;Cramps of lower extremities;Deafness;Deafness permanent;Decompensated cirrhosis;Decreased appetite;Dehydration;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Disturbance in attention;Diuresis;Dizziness;Drowsiness;Drug eruption;Drug interaction;Dry mouth;Dysgeusia;Ear and labyrinth disorders;Electrolyte depletion;Eosinophilia;Epidermolysis bullosa;Epigastric discomfort;Eruption;Erythema;Erythema multiforme;Eye disorder;Fatigue;Feeling abnormal;Flat affect;Flatulence;Gastric irritation;Gastrointestinal disorder;Gastrointestinal pain;Glucose tolerance decreased;Glucose tolerance impaired;Glycosuria;Gout;Gout attack;Haemolytic anaemia;Headache;Hearing impaired;Hepatic cirrhosis;Hepatic encephalopathy;Hepatobiliary disease;Hydronephrosis;Hypercoagulation;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hyperuricaemia;Hypocalcaemia;Hypochloraemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypotension;Hypotensive;Hypovolaemia;Immune system disorder;Incontinence;Injection site pain;Instillation site pain;Irritability;Jaundice cholestatic;Lethargy;Leukopenia;Lightheadedness;Local reaction;Malnutrition;Mental disability;Metabolic acidosis;Metabolic alkalosis;Muscle spasms;Muscular weakness;Nausea;Nephritis interstitial;Nephrocalcinosis;Nephrolithiasis;Nervous system disorder;Orthostatic hypotension;Orthostatic intolerance;Ototoxicity;Pain;Pancreatitis;Pancreatitis acute;Paraesthesia;Patent ductus arteriosus;Pemphigoid;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyangiitis;Polydipsia;Polyuria;Prostatic hypertrophy;Pruritus;Pseudo-Bartter syndrome;Purpura;Rash;Renal failure;Shock;Skin disorder;Somnolence;Stevens-Johnson syndrome;Sweating;Swelling;Taste sweet;Tetany;Thirst;Thrombocytopenia;Thrombophilia;Thrombophlebitis;Thrombosis;Tinnitus;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urine output increased;Urticaria;Vascular purpura;Vasculitis;Vasculitis necrotising;Vertigo;Vision blurred;Visual impairment;Vomiting;Xanthopsia,small molecule,approved; vet_approved,2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; Frusemide; Furosemid; Furosemida; Furosemide; Furosemidu; Furosemidum; BSC1; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; Kidney-specific Na-K-Cl symporter; Na-K-2Cl cotransporter 2; NKCC2; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; KYNA receptor; Kynurenic acid receptor; 1.1.1.44; PGDH; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; Serpin A7; T4-binding globulin; TBG; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; OATP2A1; PGT; PHOAR2; Prostaglandin transporter; SLC21A2; SLCO2A1; Solute carrier family 21 member 2; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4,Solute carrier family 12 member 1; Carbonic anhydrase 2; G-protein coupled receptor 35, C03CA01; C03CB01; G01AE10;C03CA01;C03EB01
gabapentin,Asthenia;Ataxia;Convulsion;Diabetes mellitus;Diabetic neuropathy;Diabetic peripheral neuropathy;Dizziness;Epilepsy;Erythema multiforme;Fatigue;Grand mal convulsion;Hypersensitivity;Neuralgia;Pain;Pancreatitis;Partial seizures;Post herpetic neuralgia;Pseudocroup;Renal failure;Renal impairment;Restless legs syndrome;Somnolence;Stevens-Johnson syndrome;Tonic-clonic seizures;Urinary incontinence,Abdominal pain;Abnormal dreams;Abnormal ejaculation;Abnormal faeces;Abnormal vision;Abrasion NOS;Abscess;Abscess periodontal;Accidental injury;Accommodation disorder;Acne;Acute coronary syndrome;Affect lability;Ageusia;Agitation;Alcohol intolerance;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angular cheilitis;Anorectal disorder;Anorexia;Antisocial behaviour;Antisocial personality disorder;Anuria;Anxiety;Apathy;Aphasia;Apnoea;Apraxia;Areflexia;Arthralgia;Arthritis;Arthropathy;Asocial behaviour;Asthenia;Asthma;Ataxia;Atrial fibrillation;Atrioventricular block;Aura;Back pain;Balance disorder;Bladder pain;Bleeding time prolonged;Blindness;Blister;Block heart;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose fluctuation;Blood lactate dehydrogenase increased;Blood pressure increased;Blood urea abnormal;Body odor;Body temperature increased;Bone pain;Bradycardia;Breast cancer;Breast disorder;Breast enlargement;Breast feeding;Breast pain;Bronchitis;Bronchospasm;Bursitis;Calculus of kidney;Candida infection;Capillary fragility increased;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiovascular disorder;Cataract;Cellulitis;Central nervous system neoplasm;Cerebellar syndrome;Cerebrovascular accident;Cheilitis;Chest pain;Chills;Cholecystitis;Cholelithiasis;Choreoathetosis;Chorioretinitis;Circumoral paresthesia;Coagulopathy;Colitis;Completed suicide;Confusional state;Conjunctival hyperaemia;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Conversion disorder;Convulsion;Coordination abnormal;Corneal disorder;Costochondritis;Cough;Cough increased;Cramps of lower extremities;Creatinine increased;Cystitis;Cystitis noninfective;Dandruff;Deafness;Death;Decreased appetite;Dehydration;Delusion;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diabetic ketoacidosis;Diabetic neuropathy;Diabetic peripheral neuropathy;Diabetic retinopathy;Diarrhoea;Difficulty focusing eyes;Diplopia;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug eruption;Drug interaction;Dry eye;Dry mouth;Dry skin;Dry throat;Duodenal ulcer;Dysaesthesia;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear infection;Ear pain;Ecchymosis;Eczema;Ejaculation disorder;Encephalopathy;Eosinophilia;Epididymitis;Epilepsy;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Euphoric mood;Eustachian tube disorder;Excoriation;Extensor plantar response;Eye disorder;Eye haemorrhage;Eye pain;Eye pruritus;Face oedema;Facial paralysis;Faecal incontinence;Fatigue;Feeling abnormal;Feeling drunk;Flat affect;Flatulence;Fluid retention;Found dead (cause undetermined);Fracture;Function kidney decreased;Functional gastrointestinal disorder;Fungal skin infection;Furuncle;Furunculosis;Gait disturbance;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gingival bleeding;Gingivitis;Glaucoma;Glossitis;Glycosuria;Goitre;Gout;Gynaecomastia;Haematemesis;Haematochezia;Haematuria;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhoids;Hair disorder;Hallucination;Hangover;Headache;Hearing impaired;Hemiplegia;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis cholestatic;Hepatitis fulminant;Hepatobiliary disease;Hepatomegaly;Hernia;Herpes NOS;Herpes simplex;Herpes virus infection;Herpes zoster;Hiatus hernia;Hiccups;Hirsutism;Hoarseness;Hordeolum;Hostility;Hyperaesthesia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hyperreflexia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hypertrophy of breast;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypokinesia;Hypomania;Hyponatraemia;Hyporeflexia;Hypotension;Hypothyroidism;Hypotonia;Hypoventilation;Hypoxia;Hysteria;Ill-defined disorder;Immune system disorder;Incontinence;Increased appetite;Infection;Infectious mononucleosis;Infestation;Infestation NOS;Influenza;Injury;Inner ear infection;Insomnia;Intentional self-injury;Intestinal obstruction;Intestinal ulcer;Iritis;Irritability;Irritable bowel syndrome;Jaundice;Joint stiffness;Joint swelling;Labored breathing;Labyrinthitis;Lacrimation increased;Lactic dehydrogenase activity increased;Laryngitis;Lassitude;Leg ulcer;Lethargy;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Lip haemorrhage;Liver function test abnormal;Local swelling;Loss of consciousness;Loss of libido;Lung disorder;Lymphadenopathy;Lymphocytosis;Lymphoma;Malaise;Malnutrition;Mania;Mass;Mediastinal disorder;Melaena;Melanosis;Memory impairment;Meningism;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Microhemorrhage;Micturition urgency;Migraine;Miosis;Mood swings;Mouth ulceration;Movement disorder;Mucosal inflammation;Mucous membrane disorder;Multiple fractures;Muscle contracture;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myocardial infarction;Myoclonus;Nail disorder;Nasal obstruction;Nasopharyngitis;Nausea;Neck pain;Nephrolithiasis;Nephropathy;Nephrosis;Nephrotic syndrome;Nerve paralysis;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neurosis;Nocturia;Nodule;Non-Hodgkin's lymphoma;Nystagmus;Occipital neuralgia;Oedema;Oedema peripheral;Oesophageal spasm;Oesophagitis;Oral candidiasis;Orofacial dyskinesia;Osteoarthritis;Osteoporosis;Otitis;Otitis externa;Otitis media;Ovarian failure;Pain;Pain in extremity;Palpitations;Pancreatitis;Papule;Paraesthesia;Paraesthesia oral;Paralysis;Paranoia;Parasuicide;Paresis;Pelvic pain;Penile swelling;Peptic ulcer;Pericardial effusion;Pericardial rub;Pericarditis;Peripheral sensory neuropathy;Peripheral vascular disorder;Personality disorder;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Photosensitivity reaction;Pneumonia;Pneumonia aspiration;Pollakiuria;Polyuria;Proctitis;Prothrombin level decreased;Pruritus;Pruritus genital;Pseudolymphoma;Psoriasis;Psychotic disorder;Pulmonary embolism;Pulmonary oedema;Pulmonary thrombosis;Purpura;Pyelonephritis;Pyuria;Raised liver function tests;Rash;Rash maculo-papular;Rash pustular;Rectal disorder;Rectal haemorrhage;Renal failure;Renal failure acute;Renal impairment;Renal pain;Respiratory failure;Respiratory tract infection;Retinal degeneration;Retinal disorder;Retinal vein thrombosis;Rhabdomyolysis;Rhinitis;Rhinitis seasonal;Salivary gland enlargement;Salivary hypersecretion;Scotoma;Scrotal swelling;Seasonal allergy;Seborrhoeic dermatitis;Sepsis;Sexual dysfunction;Shock;Sinusitis;Skin cancer;Skin carcinoma;Skin discolouration;Skin disorder;Skin exfoliation;Skin hypertrophy;Skin mass;Skin necrosis;Skin odour abnormal;Skin ulcer;Slurred speech;Snoring;Somnambulism;Somnolence;Speech disorder;Status epilepticus;Stevens-Johnson syndrome;Stomatitis;Stupor;Subcutaneous nodule;Subdural haematoma;Suicidal behaviour;Suicide;Suicide attempt;Supraventricular extrasystoles;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Tearing eyes;Tendon disorder;Tendonitis;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tongue disorder;Tooth abscess;Tooth discolouration;Tooth disorder;Trauma;Tremor;Tympanic membrane perforation;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;VIIth nerve paralysis;Vaginal discharge;Vaginal haemorrhage;Vaginal moniliasis;Vaginal pain;Varicose vein;Vascular purpura;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Vertigo;Vesiculobullous rash;Vestibular disorder;Viral diarrhoea;Viral infection;Vision blurred;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginal pain;Weight decreased;Weight increased;White blood cell count decreased,small molecule,approved; investigational,"1-(Aminomethyl)cyclohexaneacetic acid; Gabapentin; Gabapentina; Gabapentine; Gabapentino; Gabapentinum; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; G-protein coupled receptor 51; GABA-B receptor 2; GABA-B-R2; GABA-BR2; GABABR2; Gb2; GPR51; GPRC3B; HG20; GABA-B receptor 1; GABA-B-R1; GABA-BR1; GABABR1; Gb1; GPRC3A; KIAA0558; Voltage-gated calcium channel subunit alpha-2/delta-2; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; KQT-like 3; Potassium channel subunit alpha KvLQT3; Voltage-gated potassium channel subunit Kv7.3; KQT-like 5; Potassium channel subunit alpha KvLQT5; Voltage-gated potassium channel subunit Kv7.5; 2.6.1.42; BCAT(c); BCT1; ECA39; 4F2 LC; 4F2 light chain; 4F2LC; CD98 light chain; CD98LC; E16; hLAT1; Integral membrane protein E16; L-type amino acid transporter 1; LAT1; MPE16; Solute carrier family 7 member 5; y+ system cationic amino acid transporter",Voltage-dependent calcium channel subunit alpha-2/delta-1; Gamma-aminobutyric acid type B receptor subunit 2; Gamma-aminobutyric acid type B receptor subunit 1; Voltage-dependent calcium channel subunit alpha-2/delta-2; Voltage-dependent N-type calcium channel; Adenosine receptor A1; Potassium voltage-gated channel subfamily KQT member 3; Potassium voltage-gated channel subfamily KQT member 5,N02BF01;N03AX12
galantamine,Dementia Alzheimer's type,"Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abrasion NOS;Aggression;Aggressive reaction;Agitation;Anaemia;Angiopathy;Anorexia;Anxiety;Apathy;Aphasia;Apraxia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Asthenia;Ataxia;Atrial arrhythmia;Atrial fibrillation;Atrioventricular block;Atrioventricular block first degree;Back pain;Bladder pain;Blood alkaline phosphatase increased;Blood urea increased;Body temperature increased;Bone pain;Bradycardia;Bronchitis;Bundle branch block;Calculus of kidney;Cardiac disorder;Cardiac failure;Cataract;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Coagulopathy;Cognitive disorder;Cognitive impairment;Completed suicide;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cough;Cramps of lower extremities;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Delirium;Depression;Depression aggravated;Dermatitis;Diarrhoea;Discomfort;Disorder sight;Disturbance in sexual arousal;Diverticulitis;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Ear and labyrinth disorders;Electrocardiogram QT prolonged;Electrocardiogram T wave inversion;Epistaxis;Excoriation;Eye disorder;Fatigue;Feeling abnormal;Flat affect;Flatulence;Flushing;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gravitational oedema;Haematuria;Haemoglobin;Haemorrhage;Hallucination;Hallucination, auditory;Hallucination, visual;Headache;Hepatic enzyme increased;Hepatitis;Hepatobiliary disease;Hiccups;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypersomnia;Hypertension;Hypertonia;Hypokalaemia;Hypokinesia;Hypotension;Ill-defined disorder;Immune system disorder;Incontinence;Infarction;Injury;Insomnia;Leg pain;Lethargy;Libido increased;Loss of consciousness;Lower gastrointestinal haemorrhage;Malaise;Malnutrition;Melaena;Mental disorder;Muscle contractions involuntary;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial ischaemia;NPN increased;Nausea;Nephrolithiasis;Nervous system disorder;Nervousness;Neuropathy peripheral;Nightmare;Nocturia;Oedema peripheral;Oesophageal perforation;Orthostatic hypotension;Pain in extremity;Palpitations;Paraesthesia;Paranoia;Paranoid reaction;Phosphatase alkaline increased;Pneumonia;Pollakiuria;Purpura;Rash;Rectal haemorrhage;Red blood cell disorders;Renal failure;Renal impairment;Retching;Rhinitis;Salivary hypersecretion;Shock;Sinus bradycardia;Skin disorder;Somnolence;Suicidal ideation;Suicide;Suicide attempt;Supraventricular extrasystoles;Supraventricular tachycardia;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Transient ischaemic attack;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Vascular dementia;Vascular purpura;Ventricular tachycardia;Vertigo;Vision blurred;Visual impairment;Vomiting;Weight decreased",small molecule,approved,"(-)-Galanthamine; Galantamina; Galantamine; Galanthamine; 3.1.1.7; AChE; NACHRA7; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Acetylcholinesterase; Neuronal acetylcholine receptor subunit alpha-7; Muscle nicotinic acetylcholine receptor; Cholinesterase,N06DA04
ganciclovir,Acquired immunodeficiency syndrome;Autoimmune disorder;Candida infection;Carcinogenicity;Congenital cytomegalovirus infection;Cotton wool spots;Cytomegalovirus chorioretinitis;Cytomegalovirus infection;Cytomegalovirus retinitis;Histoplasmosis;Immunocompromised;Immunodeficiency;Neoplasm;Pneumonia cytomegaloviral;Reproductive toxicity;Retinal exudates;Retinal scar;Retinitis;Toxoplasmosis,Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal vision;Abscess;Acidosis;Affect lability;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Angiopathy;Anorexia;Anosmia;Anxiety;Aphasia;Aphthous stomatitis;Aplastic anaemia;Arrhythmia;Arthralgia;Arthritis;Ascites;Aspartate aminotransferase increased;Asthenia;Ataxia;Attention deficit/hyperactivity disorder;Back pain;Blindness;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Blood creatinine decreased;Blood creatinine increased;Blood culture positive;Blood glucose decreased;Blood lactate dehydrogenase increased;Blood magnesium decreased;Blood urea increased;Blood urine;Blood urine present;Body temperature increased;Bone marrow depression;Bone pain;Breast pain;Bronchospasm;Cachexia;Cardiac arrest;Cataract;Catheter infection;Catheter related infection;Catheter sepsis;Cellulitis;Cerebrovascular accident;Chest pain;Chills;Cholelithiasis;Cholestasis;Coma;Confusional state;Congenital anomaly;Conjunctival hyperaemia;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatinine increased;Creatinine low;Creatinine renal clearance decreased;Deafness;Decreased appetite;Dehydration;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Developmental delay;Device related infection;Device related sepsis;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drug level increased;Dry eye;Dry mouth;Dry skin;Dysaesthesia;Dysgeusia;Dyspepsia;Dysphagia;Dysphasia;Dyspnoea;Dysuria;Ear pain;Emotional disorder;Emotional disturbance NOS;Encephalopathy;Enlargement abdomen;Eosinophilia;Erectile dysfunction;Eructation;Erythema multiforme;Euphoric mood;Eye haemorrhage;Eye irritation;Eye pain;Face oedema;Facial paralysis;Faecal incontinence;Fatigue;Feeling abnormal;Fixed eruption;Flatulence;Gait disturbance;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Glaucoma;Haematuria;Haemoglobin;Haemolytic anaemia;Haemolytic uraemic syndrome;Haemorrhage;Hallucination;Headache;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Herpes simplex;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypocalcaemia;Hypochromic anaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;IIIrd nerve paralysis;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Infection;Infertility;Infestation;Infestation NOS;Injection site abscess;Injection site haemorrhage;Injection site infection;Injection site inflammation;Injection site pain;Injection site phlebitis;Injection site reaction;Injection site swelling;Injection site thrombosis;Insomnia;Intestinal ulcer;Intracranial pressure increased;Irritability;Ischaemia;Jaundice;Jaundice cholestatic;Kidney function abnormal;Laboratory test abnormal;Lactic dehydrogenase activity increased;Leukopenia;Libido decreased;Liver function test abnormal;Loose stools;Lower respiratory tract infection;Lymphadenopathy;Malaise;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Melaena;Mental disability;Mental disorder;Migraine;Mood swings;Mouth ulceration;Mucous membrane disorder;Multi-organ failure;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myasthenic syndrome;Myoclonus;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Nephropathy toxic;Nephrotoxicity;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Nuchal rigidity;Oedema;Oedema peripheral;Oesophageal candidiasis;Oesophagitis;Pain;Pain in extremity;Pancreatitis;Pancytopenia;Paraesthesia;Peripheral ischaemia;Pharyngitis;Phlebitis;Photophobia;Photosensitivity reaction;Pleural effusion;Pneumocystis jirovecii pneumonia;Pneumonia;Pollakiuria;Post procedural complication;Postoperative complications NOS;Postoperative pain;Postoperative wound infection;Procedural pain;Productive cough;Pruritus;Psychotic disorder;Pulmonary fibrosis;Punctate keratitis;Rash;Rash maculo-papular;Rash pustular;Renal failure;Renal failure acute;Renal impairment;Renal tubular disorder;Retinal detachment;Rhabdomyolysis;Rhinitis;Rhinorrhoea;Rigors;Sepsis;Sepsis secondary;Serum urea increased;Sinus congestion;Skin discolouration;Skin disorder;Somnolence;Spinal cord disorder;Splenomegaly;Stevens-Johnson syndrome;Stomatitis;Sweating;Tachycardia;Tension;Thinking abnormal;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tongue disorder;Torsade de pointes;Transplant rejection;Tremor;Trismus;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;VIIth nerve paralysis;Vasculitis;Ventricular arrhythmia;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Vision blurred;Visual impairment;Vitreous disorder;Vomiting;Weight decreased;Wound dehiscence,small molecule,approved; investigational,"2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine; GA2; Ganciclovir; Ganciclovirum; Gancyclovir; 2.7.7.7; 2.7.1.21; UL23; hOCT1; OCT1; Organic cation transporter 1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2",DNA polymerase catalytic subunit; DNA; Thymidine kinase, S01AD09;J05AB06
gemcitabine,Adenocarcinoma pancreas;Alcohol abuse;Alcoholism;Apoptosis;Bladder cancer;Breast cancer;Breast cancer stage IV;Carcinoma of lung;Cardiovascular disorder;Cervix carcinoma;Febrile neutropenia;Function kidney decreased;Hepatic failure;Hepatic insufficiency;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hypersensitivity;Lung neoplasm malignant;Lymphoma;Malignant neoplasm of pancreas;Mesothelioma;Myelosuppression;Neoplasm;Neoplasm malignant;Neuropathy;Neuropathy peripheral;Non-Hodgkin's lymphoma;Non-small cell lung cancer;Ovarian cancer;Ovarian epithelial cancer;Pancreatic carcinoma;Pancytopenia;Pneumonia;Renal failure;Renal impairment;Solid tumour;Thrombocytopenia;Transitional cell carcinoma,Acute coronary syndrome;Acute dyspnea;Acute respiratory distress syndrome;Agranulocytosis;Alanine aminotransferase increased;Allergic bronchospasm;Alopecia;Alopecia reversible;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Anorexia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Aspartate aminotransferase increased;Asthenia;Azoospermia;Back pain;Bilirubin normal;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood bilirubin normal;Blood creatinine increased;Blood urea increased;Body temperature increased;Bone disorder;Bone pain;Breast cancer;Bronchospasm;Capillary leak syndrome;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiotoxicity;Cellulitis;Cerebrovascular accident;Chest pain;Chills;Colitis ischaemic;Connective tissue disorder;Constipation;Cough;Creatinine increased;Cutaneous hypersensitivity;Deafness;Decreased appetite;Dermatitis;Dermatitis atopic;Dermatitis bullous;Diarrhoea;Difficulty sleeping;Discomfort;Disease progression;Drug interaction;Dyspnoea;Eruption;Erythema;Erythema multiforme;Extravasation;Face oedema;Fatigue;Febrile neutropenia;Feeling abnormal;Flu symptoms;Fluid retention;Gangrene;Gastrointestinal disorder;Generalised oedema;Haematuria;Haemoglobin;Haemolytic uraemic syndrome;Haemorrhage;Headache;Hearing impaired;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatobiliary disease;Hepatotoxicity;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hypertension;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyporeflexia;Hypotension;Hypoxemia;Hypoxia;Ill-defined disorder;Immune system disorder;Infection;Influenza;Influenza like illness;Influenza-like symptoms;Injection site necrosis;Injection site reaction;Insomnia;Interstitial lung disease;Interstitial pneumonia;Irreversible renal failure;Leukopenia;Liver function test abnormal;Lung infiltration;Lymphoma;Lymphopenia;Malaise;Mediastinal disorder;Metastatic disease;Metastatic neoplasm;Microangiopathic haemolytic anaemia;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Neoplasm malignant;Nephropathy toxic;Nervous system disorder;Neuritis;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Non-Hodgkin's lymphoma;Oedema;Oedema peripheral;Oligospermia;Oral toxicity;Pain;Pancytopenia;Paraesthesia;Peripheral motor neuropathy;Peripheral sensory neuropathy;Petechiae;Pharyngitis;Phosphatase alkaline increased;Pleural effusion;Pneumonia;Poor quality sleep;Posterior reversible encephalopathy syndrome;Progressive renal failure;Protein urine present;Proteinuria;Pruritus;Pulmonary fibrosis;Pulmonary oedema;Pulmonary toxicity;Radiation recall reaction (dermatologic);Raised liver function tests;Rash;Recall phenomenon;Renal failure;Renal failure chronic;Renal impairment;Respiratory distress syndrome;Respiratory failure;Reticulocytosis;Rhinitis;Road traffic accident;Sepsis;Septic arthritis streptobacillus;Shivering;Skin disorder;Skin exfoliation;Somnolence;Stevens-Johnson syndrome;Stomatitis;Streptobacillary fever;Sweating;Tachypnoea;Tenderness;Tendon reflex decreased;Thrombocytopenia;Thrombocytosis;Toxic epidermal necrolysis;Traffic accident;Transaminases increased;Transaminitis;Traumatic lung injury;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vasculitis;Venoocclusive liver disease;Vomiting,small molecule,approved,"2'-Deoxy-2',2'-difluorocytidine; 2',2'-Difluorodeoxycytidine; 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; Gemcitabin; Gemcitabina; Gemcitabine; Gemcitabinum; 1.17.4.1; Ribonucleotide reductase small chain; Ribonucleotide reductase small subunit; RR2; 1.17.4.1; Ribonucleoside-diphosphate reductase subunit M1; Ribonucleotide reductase large subunit; RR1; 2.1.1.45; TS; TSase; 2.7.4.14; CK; CMK; CMPK; dCMP kinase; Deoxycytidylate kinase; Nucleoside-diphosphate kinase; UCK; UMK; UMP/CMP kinase; UMP/CMPK; UMPK; Uridine monophosphate/cytidine monophosphate kinase; 2.7.1.21; 2'-deoxyuridine kinase TK2; Deoxycytidine kinase TK2; Mt-TK; 2.7.4.14; CK; CMK; CMPK; dCMP kinase; Deoxycytidylate kinase; Nucleoside-diphosphate kinase; UCK; UMK; UMP/CMP kinase; UMP/CMPK; UMPK; Uridine monophosphate/cytidine monophosphate kinase; 2.7.4.6; GAAD; Granzyme A-activated DNase; Metastasis inhibition factor nm23; NDK A; NDP kinase A; NDPKA; NM23; NM23-H1; Tumor metastatic process-associated protein; 3.5.4.5; CDD; Cytidine aminohydrolase; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1; CNT 1; CNT1; Concentrative nucleoside transporter 1; hCNT1; Na(+)/nucleoside cotransporter 1; Sodium-coupled nucleoside transporter 1; Solute carrier family 28 member 1; 36 kDa nucleolar protein HNP36; Delayed-early response protein 12; DER12; ENT2; Equilibrative NBMPR-insensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter; hENT2; HNP36; Hydrophobic nucleolar protein, 36 kDa; Nucleoside transporter, ei-type; Solute carrier family 29 member 2; CNT 3; CNT3; Concentrative Na(+)-nucleoside cotransporter 3; hCNT3",DNA; Ribonucleoside-diphosphate reductase subunit M2; Ribonucleoside-diphosphate reductase large subunit; Thymidylate synthase; UMP-CMP kinase,L01BC05
gemeprost,Pregnancy,Abdominal pain lower;Acute coronary syndrome;Anaphylactic shock;Arteriospasm coronary;Back pain;Body temperature increased;Chest pain;Chills;Diarrhoea;Dizziness;Dysmenorrhoea;Dyspnoea;Flushing;Headache;Hypotension;Loose stools;Muscular weakness;Myocardial infarction;Nausea;Palpitations;Surgery;Surgical intervention;Tachycardia;Uterine pain;Vaginal haemorrhage;Vomiting,small molecule,approved; withdrawn,"16,16-Dimethyl-trans-delta-2-PGE1 methyl ester; 16,16-Dimethyl-trans-delta(sup 2)-prostaglandin E1 methyl ester; Gemeprost; SC-37681; PGE receptor EP3 subtype; PGE2 receptor EP3 subtype; PGE2-R; Prostanoid EP3 receptor; PGE receptor EP2 subtype; PGE2 receptor EP2 subtype; Prostanoid EP2 receptor",Prostaglandin E2 receptor EP3 subtype; Prostaglandin E2 receptor EP2 subtype,G02AD03
gemfibrozil,Abdominal pain;Acute coronary syndrome;Blood triglycerides increased;Combined hyperlipidaemia;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Diabetic;Dyslipidaemia;Fasting;Gastrointestinal pain;High density lipoprotein decreased;Hypercholesterolaemia;Hyperlipidaemia;Hyperlipoproteinemia;Hypertriglyceridaemia;Hypothyroidism;Low density lipoprotein increased;Myocardial infarction;Pancreatitis;Type IV hyperlipidaemia;Type V hyperlipidaemia;Weight decreased;Xanthoma,Abdominal pain;Abdominal pain upper;Acute appendicitis;Alopecia;Anaemia;Anaphylactic shock;Angioedema;Angioedema of larynx;Antinuclear antibody increased;Antinuclear antibody positive;Appendicitis;Arthralgia;Asthenia;Atrial fibrillation;Bacterial infection;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Bone marrow depression;Breast disorder;Cataract;Cerebral haemorrhage;Chest pain;Cholecystitis;Cholelithiasis;Colitis;Common cold;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cough;Creatine phosphokinase increased;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Disturbance in sexual arousal;Dizziness;Drug interaction;Dysgeusia;Dyspepsia;Eczema;Eosinophilia;Epigastric pain;Erectile dysfunction;Extrasystoles;Eye disorder;Fatigue;Feeling abnormal;Fertility male decreased;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gout;Headache;Hepatic cancer;Hepatobiliary disease;Hepatocellular carcinoma;Hyperaesthesia;Hypoaesthesia;Infertility male;Jaundice;Jaundice cholestatic;Laryngeal oedema;Leukopenia;Libido decreased;Liver function test abnormal;Loss of consciousness;Lupus-like syndrome;Mediastinal disorder;Mental disorder;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myasthenia;Myopathy;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuritis;Neuropathy peripheral;Oedema;Pain;Pancreatitis;Pancytopenia;Paraesthesia;Peripheral vascular disorder;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pruritus;Rash;Reaction gastrointestinal;Renal failure;Retinal oedema;Rhabdomyolysis;Rhinitis;Shock;Skin disorder;Somnolence;Syncope;Synovitis;Tension;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urinary tract infection;Urogenital disorder;Urticaria;Vasculitis;Vertigo;Vision blurred;Vomiting;Weight decreased,small molecule,approved,"2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansäure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid; Gemfibrozil; Gemfibrozilo; Gemfibrozilum; NR1C1; Nuclear receptor subfamily 1 group C member 1; PPAR; PPAR-alpha; 3.1.1.34; LIPD; LPL; Phospholipase A1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; C19-steroid-specific UDP-glucuronosyltransferase; C19-steroid-specific UDPGT; UDPGT 2B17; UGT2B17",Peroxisome proliferator-activated receptor alpha; Lipoprotein lipase; Solute carrier organic anion transporter family member 1B1; Organic anion transporter 3; Solute carrier organic anion transporter family member 2B1; Solute carrier organic anion transporter family member 1B3,C10AB04
gentamicin,"Abortion infected;Abscesses of skin;Acne pustular;Arthropod bite;Arthropod sting;Bacteraemia;Bacterial infection;Bacterial sepsis;Blepharitis;Blepharoconjunctivitis;Conjunctivitis;Dacryocystitis;Dermal cyst;Dermatitis contact;Ecthyma;Eczema;Endocarditis;Excoriation;Eye infection bacterial;Folliculitis;Furuncle;Furunculosis;Impetigo;Infection;Infection mixed;Influenza;Insect bite NOS;Keratitis;Keratoconjunctivitis;Laceration;Meibomianitis;Meningitis;Paronychia;Peritonitis;Pneumonia klebsiella;Pneumonia staphylococcal;Pseudofolliculitis barbae;Pustular psoriasis;Pyoderma gangrenosum;Renal failure;Renal impairment;Respiratory tract infection;Seborrhoeic dermatitis;Secondary infection;Sepsis;Sepsis neonatal;Septicaemia due to gram-negative organism, unspecified;Septicemia;Skin disorder;Skin infection;Skin ulcer;Soft tissue infection;Staphylococcal infection;Sting;Subcutaneous abscess;Superinfection;Sycosis barbae;Ulcerative keratitis;Urinary tract infection;Viral infection;Wound;Wound infection",Agranulocytosis;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Application site pain;Arthralgia;Atrophy;Benign intracranial hypertension;Blood calcium decreased;Body temperature increased;Confusional state;Conjunctival hyperaemia;Convulsion;Deafness;Decreased appetite;Dermatitis;Dizziness;Ear roaring;Encephalopathy;Eosinophilia;Erythema;Extravasation;Fat necrosis;Feeling abnormal;Fluid overload;Hallucination;Headache;Hearing impaired;Hepatomegaly;Hypersensitivity;Hypertension;Hypoaesthesia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hypotension;Injection site pain;Instillation site pain;Laryngeal oedema;Lethargy;Leukopenia;Mental disorder due to a general medical condition;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myasthenia gravis-like syndrome;Myasthenic syndrome;Nausea;Nephropathy toxic;Nephrotoxicity;Neuropathy peripheral;Neurotoxicity;Numbness;Oliguria;Organic brain syndrome;Paraesthesia;Phlebitis;Pruritus;Pulmonary fibrosis;Pulmonary function test decreased;Purpura;Rash;Respiratory depression;Salivary hypersecretion;Sensory loss;Serum calcium decreased;Splenomegaly;Stomatitis;Tetany;Thrombocytopenia;Thrombocytopenic purpura;Tingling skin;Tinnitus;Urticaria;Vascular purpura;Venous thrombosis;Vertigo;Visual disturbance;Visual impairment;Vomiting;Weight decreased,small molecule,approved; vet_approved,Gentamicin; Gentamicina; strA; 6.3.1.5; General stress protein 38; GSP38; outB; Spore outgrowth factor B; Sporulation protein OutB; 1.5.1.3; hOCT2; OCT2; Organic cation transporter 2; Glycoprotein 330; gp330; LRP-2; Megalin; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2,30S ribosomal protein S12; 16S ribosomal RNA; 23S ribosomal RNA; Bacterial outer membrane; Cytoplasmic membrane; NH(3)-dependent NAD(+) synthetase; Dihydrofolate reductase, D06AX07; J01GB03; S02AA14; S03AA06;D06AX07;S01AA11
gliclazide,Diabetes mellitus;Diabetic;Hyperglycaemia;Ketosis;Platelet adhesiveness;Type 2 diabetes mellitus,Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal vision;Acute coronary syndrome;Aggression;Agitation;Agranulocytosis;Albuminuria;Alcohol abuse;Alcohol intolerance;Alcoholism;Alkaline phosphatase serum increased;Allergic cutaneous angiitis;Anaemia;Anal fissure;Angina pectoris;Angioedema;Anxiety;Aphasia;Arrhythmia;Arteritis;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Back pain;Balanoposthitis;Benign breast neoplasm;Benign gastrointestinal neoplasm;Bladder pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood disorder;Blood pressure increased;Blood triglycerides increased;Blood urea increased;Body temperature increased;Bone pain;Bradycardia;Breast neoplasm benign female;Bronchitis;Bursitis;Calculus of kidney;Carcinoma;Cardiac failure;Carpal tunnel syndrome;Cataract;Central nervous system disorder;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Cerebrovascular insufficiency;Chest pain;Chills;Cholestasis;Cold sweat;Coldness;Colitis;Coma;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Constipation;Convulsion;Coronary artery disease;Coronary heart disease;Cough;Cystitis;Cystitis noninfective;Deafness;Delirium;Depression;Dermatitis;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disorder sight;Disturbance in attention;Disulfiram like reaction;Dizziness;Drowsiness;Dry mouth;Dry skin;Duodenal ulcer;Dyspepsia;Dyspnoea;Eczema;Elevated liver enzyme levels;Epigastric discomfort;Epigastric fullness;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Erythropenia;Eye disorder;Faecal incontinence;Fatigue;Feeling abnormal;Feeling cold;Flatulence;Flushing;Fungal infection;Fungal skin infection;Gastric irritation;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Glaucoma;Glycosuria;Gout;Haemolytic anaemia;Haemorrhoids;Headache;Hearing impaired;Heartburn;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hepatomegaly;Hernia congenital;Hunger;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkeratosis;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypoaesthesia;Hypoglycaemia;Hypoglycaemic coma;Hypoglycaemic episode;Hyponatraemia;Hypopituitarism;Hypopnoea;Hypotension;Hypothyroidism;Ill-defined disorder;Increased appetite;Infection;Inflicted injury;Injury;Insomnia;Jaundice;Jaundice cholestatic;Laboratory test abnormal;Lacrimal disorder;Lacrimation abnormal NOS;Lassitude;Leg edema;Leg pain;Leukocytoclastic vasculitis;Leukopenia;Lipid metabolism disorder;Loss of consciousness;Malaise;Malnutrition;Mastitis;Melaena;Menstrual disorder;Mental disability;Mental disorder;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nail disorder;Nausea;Neoplasm;Neoplasm malignant;Nephrolithiasis;Nephropathy;Nervous system disorder;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Nocturia;Numbness;Oedema peripheral;Oesophagitis;Onychomycosis;Osteoarthritis;Otitis media;Pain;Pain in extremity;Pallor;Pallor of skin;Palpitations;Pancreatitis acute;Pancytopenia;Paraesthesia;Paresis;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pneumonia;Polyuria;Poor concentration;Porphyria cutanea tarda;Porphyria hepatic;Porphyria non-acute;Porphyrin metabolism disorder;Prostatic disorder;Pruritus;Rash;Rash maculo-papular;Reaction gastrointestinal;Renal cyst;Renal failure;Renal failure acute;Renal impairment;Respiratory tract infection;Retinal disorder;Rhinitis;Salivary hypersecretion;Sensory disturbance;Sensory loss;Shakiness;Shallow breathing;Sinusitis;Skin disorder;Skin ulcer;Sleep disorder;Somnolence;Speech disorder;Spine malformation;Stevens-Johnson syndrome;Sticky skin;Sweating;Tachycardia;Tendonitis;Tension;Thirst;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tooth disorder;Toothache;Toxic epidermal necrolysis;Tracheitis;Trembling;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urinary tract infection;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vein disorder;Viral infection;Visual disturbance;Visual impairment;Vitreous disorder;Vomiting;Weight increased;Xerophthalmia,small molecule,approved,1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea; 1-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea; Gliclazida; Gliclazide; Gliclazidum; HRINS; Sulfonylurea receptor 1; SUR; SUR1; L-VEGF; Vascular permeability factor; VEGF; VPF; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase,"ATP-binding cassette sub-family C member 8; Vascular endothelial growth factor A, long form", G01AE10;A10BB09
glimepiride,Blood glucose decreased;Coma;Diabetes mellitus;Diabetic;Diabetic ketoacidosis;Hyperglycaemia;Hypoglycaemia;Nephropathy;Neuropathy;Neuropathy peripheral;Obesity;Retinal disorder;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Weight decreased,Abdominal distension;Abdominal pain;Accidental injury;Aggression;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alcohol intolerance;Allergic cutaneous angiitis;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Anorexia;Anxiety;Aphasia;Aplastic anaemia;Arrhythmia;Asthenia;Bradycardia;Cerebration impaired;Cerebrovascular accident;Cholestasis;Cold sweat;Coma;Confusional state;Convulsion;Decreased appetite;Delirium;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diabetic;Diarrhoea;Disorder sight;Disturbance in attention;Disulfiram like reaction;Dizziness;Drowsiness;Drug eruption;Dry mouth;Dyspepsia;Dyspnoea;Eosinophilia;Eruption;Erythema;Erythema multiforme;Erythropenia;Fatigue;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal fullness;Gastrointestinal pain;Gastrointestinal symptom NOS;Glucose-6-phosphate dehydrogenase deficiency;Granulomatous liver disease;Haemolytic anaemia;Headache;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis cholestatic;Hepatitis granulomatous;Hot flush;Hunger;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoglycaemia;Hypoglycaemic episode;Hypoglycemic reaction;Hyponatraemia;Hypopnoea;Hypotension;Inappropriate antidiuretic hormone secretion;Increased appetite;Influenza;Injury;Insomnia;Jaundice;Laboratory test abnormal;Lassitude;Leukocytoclastic vasculitis;Leukopenia;Loss of consciousness;Malnutrition;Menopausal symptoms;Mental disability;Nausea;Nervousness;Nocturia;Pain in extremity;Palpitations;Pancytopenia;Paraesthesia;Paresis;Photosensitivity reaction;Pollakiuria;Porphyria cutanea tarda;Porphyria hepatic;Porphyria non-acute;Pruritus;Rash;Reaction gastrointestinal;Shallow breathing;Shock;Somnolence;Speech disorder;Stevens-Johnson syndrome;Sticky skin;Sweating;Sweating increased;Tachycardia;Tension;Thrombocytopenia;Thrombocytopenic purpura;Tremor;Urticaria;Vasculitis;Vasodilation;Vasodilation procedure;Vision blurred;Visual impairment;Vomiting;Weight increased,small molecule,approved,"Glimepirida; Glimepiride; Glimépiride; Glimepiridum; Sulfonylurea receptor 2; SUR2; IKATP; Inward rectifier K(+) channel Kir6.2; Potassium channel, inwardly rectifying subfamily J member 11; ATP-regulated potassium channel ROM-K; Inward rectifier K(+) channel Kir1.1; Potassium channel, inwardly rectifying subfamily J member 1; ROMK1; HRINS; Sulfonylurea receptor 1; SUR; SUR1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",ATP-binding cassette sub-family C member 9; ATP-sensitive inward rectifier potassium channel 11; ATP-sensitive inward rectifier potassium channel 1; ATP-binding cassette sub-family C member 8, A10BB12; A10BD06;A10BB12;A10BD04
glipizide,Blood glucose decreased;Diabetes mellitus;Diabetic;Diabetic retinopathy;Glucose-6-phosphate dehydrogenase deficiency;Hyperglycaemia;Ketosis;Nephropathy;Neuropathy;Neuropathy peripheral;Obesity;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Weight decreased,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abnormal vision;Agranulocytosis;Alcohol intolerance;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Arthralgia;Asthenia;Blood in stool;Chills;Confusional state;Conjunctivitis;Constipation;Cramps of lower extremities;Decreased appetite;Dermatitis;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disturbance in sexual arousal;Disulfiram like reaction;Dizziness;Drowsiness;Dyspepsia;Dyspnoea;Dysuria;Eczema;Eruption;Erythema;Eye disorder;Feeling abnormal;Flatulence;Flushing;Foetor hepaticus;Gait disturbance;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal tract irritation;Haematochezia;Haemolytic anaemia;Headache;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypoglycaemia;Hyponatraemia;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Insomnia;Jaundice;Jaundice cholestatic;Leukopenia;Libido decreased;Liver disorder;Liver injury;Loss of consciousness;Malaise;Migraine;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Nervousness;Oedema;Pain;Pancytopenia;Paraesthesia;Pharyngitis;Photosensitivity reaction;Polyuria;Porphyria cutanea tarda;Porphyria hepatic;Porphyria non-acute;Pruritus;Rash;Retinal haemorrhage;Rhinitis;Shock;Somnolence;Stomach ache;Sweating;Syncope;Tension;Thirst;Thrombocytopenia;Traumatic liver injury;Tremor;Urine output increased;Urticaria;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,"1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea; Glipizida; Glipizide; Glipizidum; N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylurea; HRINS; Sulfonylurea receptor 1; SUR; SUR1; ATP-dependent inwardly rectifying potassium channel Kir4.1; Inward rectifier K(+) channel Kir1.2; Potassium channel, inwardly rectifying subfamily J member 10; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",ATP-binding cassette sub-family C member 8; ATP-sensitive inward rectifier potassium channel 10; Peroxisome proliferator-activated receptor gamma,A10BB07
granisetron,Dysphagia;Nausea;Nausea postoperative;Neoplasm malignant;Procedural nausea;Vomiting,Abdominal distension;Abdominal pain;Abnormal vision;Agitation;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Angina pectoris;Angiopathy;Anxiety;Application site erythema;Application site irritation;Application site pain;Application site pruritus;Application site rash;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Atrioventricular block;Body temperature increased;Bradycardia;Chest pain;Chills;Coagulation time prolonged;Coma;Coma hepatic;Connective tissue disorder;Constipation;Cough;Decreased appetite;Depersonalisation;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drug interaction;Dry mouth;Dysgeusia;Dyskinesia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Enlargement abdomen;Eosinophilia;Epistaxis;Extrapyramidal disorder;Extrapyramidal symptoms;Feeling abnormal;Flatulence;Fluid retention;Flushing;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Grand mal convulsion;Headache;Hepatic enzyme increased;Hepatobiliary disease;Hepatocellular injury;Hiccups;Hyperbilirubinaemia;Hyperhidrosis;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypokalaemia;Hyponatraemia;Hypotension;Ileus;Ill-defined disorder;Increased bronchial secretion;Infection;Insomnia;Instillation site pain;Jaundice;Leukocytosis;Leukopenia;Liver function test abnormal;Liver injury;Loss of consciousness;Malaise;Malnutrition;Melaena;Migraine;Musculoskeletal discomfort;Nausea;Nervous system disorder;Nervousness;Oedema;Oliguria;Orthostatic hypotension;Pain;Palpitations;Paraesthesia;Photosensitivity;Photosensitivity reaction;Pruritus;Puncture site pain;Rash;Retching;Rhinitis;Shock;Sinus bradycardia;Sinusitis;Skin disorder;Somnolence;Sputum increased;Sweating;Syncope;Tachycardia;Taste disorders;Tension;Thrombocytopenia;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urinary incontinence;Urinary tract infection;Urticaria;Ventricular arrhythmia;Ventricular extrasystoles;Vertigo;Visual impairment;Vomiting,small molecule,approved; investigational,"Granisétron; Granisetrón; Granisetron; Granisetronum; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase",5-hydroxytryptamine receptor 3A,A04AA02
griseofulvin,Actinomycosis;Bacterial infection;Blastomycosis;Body tinea;Candida infection;Chromoblastomycosis;Coccidioidomycosis;Cryptococcosis;Histoplasmosis;Infection;Nocardiosis;Onychomycosis;Sporotrichosis;Tinea barbae;Tinea capitis;Tinea cruris;Tinea infection;Tinea pedis;Tinea versicolour,Agranulocytosis;Angioedema;Asthenia;Candida infection;Coagulopathy;Confusional state;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Epigastric distress;Erythema;Erythema multiforme;Fatigue;Feeling abnormal;Gastrointestinal haemorrhage;Headache;Hepatic enzyme increased;Hepatitis;Hyperbilirubinaemia;Hypersensitivity;Insomnia;Leukopenia;Nausea;Nephrosis;Nephrotic syndrome;Neuropathy;Neuropathy peripheral;Oral candidiasis;Paraesthesia;Protein urine present;Proteinuria;Rash;Systemic lupus erythematosus;Urticaria;Vomiting,small molecule,approved; investigational; vet_approved,"(+)-griseofulvin; Amudane; Griseofulvin; Griseofulvin, microcrystalline; Griseofulvin, ultramicrosize; Griseofulvina; Griséofulvine; Griseofulvinum; Beta-tubulin; CK-12; Cytokeratin-12; K12; Keratin-12; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase","Tubulin beta chain; Keratin, type I cytoskeletal 12", D01AA08;D01AA08;D01BA01
guaifenesin,Bronchitis chronic;Cough;Productive cough,Calculus of kidney;Dermatitis;Discomfort;Dizziness;Headache;Nausea;Nephrolithiasis;Rash;Urticaria;Vomiting,small molecule,approved; investigational; vet_approved,Glyceryl guaiacolate; Guaifenesin; Guaifenesina; guaiphenesin; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B,NMDA receptor,R05CA03
guanfacine,Attention deficit/hyperactivity disorder;Hypertension,Abdominal discomfort;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Acute coronary syndrome;Affect lability;Agitation;Alanine aminotransferase increased;Alopecia;Amnesia;Anxiety;Arthralgia;Asthenia;Asthma;Atrioventricular block;Block heart;Bradycardia;Cardiac failure congestive;Cardiac fibrillation;Cerebrovascular accident;Chest pain;Confusional state;Conjunctivitis;Constipation;Convulsion;Cramps of lower extremities;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Enuresis;Erectile dysfunction;Eye disorder;Fatigue;Feeling abnormal;Gastrointestinal pain;Hallucination;Headache;Hyperhidrosis;Hypersensitivity;Hypersomnia;Hypertension;Hypertensive;Hypokinesia;Hypotension;Ill-defined disorder;Immune system disorder;Initial insomnia;Insomnia;Iritis;Irritability;Leg pain;Lethargy;Liver function test abnormal;Loss of consciousness;Loss of libido;Malaise;Middle insomnia;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Nervousness;Nightmare;Nocturia;Oedema;Orthostatic hypotension;Pain in extremity;Pallor;Palpitations;Paraesthesia;Paresis;Pollakiuria;Pruritus;Purpura;Rash;Renal failure acute;Retrosternal pain;Rhinitis;Shock;Sinus arrhythmia;Skin exfoliation;Somnolence;Sweating;Syncope;Tachycardia;Tension;Testicular disorder;Tinnitus;Tremor;Upset stomach;Urinary incontinence;Vascular purpura;Vertigo;Vision blurred;Visual impairment;Vomiting;Weight increased,small molecule,approved; investigational,"Guanfacina; Guanfacine; Guanfacinum; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2",Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor,C02AC02
halcinonide,Dermatitis atopic;Dermatitis contact;Eczema;Lichen simplex chronicus;Neurodermatitis;Pruritus;Psoriasis;Skin disorder,Acneiform eruption;Allergic contact dermatitis;Atrophy;Burning sensation;Cataract subcapsular;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis infected;Dermatitis perioral;Ecchymosis;Erythema;Folliculitis;Hirsutism;Hypertension;Hypertrichosis;Infection;Leukoderma;Miliaria;Muscular weakness;Oedema;Peptic ulcer;Pigmentation disorder;Pigmentation skin;Pyoderma;Secondary adrenocortical insufficiency;Secondary infection;Skin atrophy;Skin striae;Swelling,small molecule,approved; investigational; withdrawn,"(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-6b-(chloroacetyl)-4b-fluoro-5-hydroxy-4a,6a,8,8-tetramethyl-3,4,4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-tetradecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; Halcinonid; Halcinonida; Halcinonide; Halcinonidum; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; Protein Gx; SMOH; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Steroid hormone receptor ERR1; Steroid hormone receptor ERR2; Estrogen-related receptor gamma; Protein smoothened,D07AD02
haloperidol,Abnormal behaviour;Affect lability;Agitation;Conduct disorder;Disturbance in social behaviour;Frustration;Hyperkinesia;Increased activity;Mood swings;Psychotic disorder;Schizoaffective disorder;Schizophrenia;Tourette's disorder,"Abnormal behaviour;Acute hepatic failure;Agitation;Agranulocytosis;Akathisia;Akinesia;Alopecia;Amenorrhoea;Anaemia;Anaphylactic shock;Angiopathy;Anorexia;Anxiety;Argininosuccinate synthetase deficiency;Blood and lymphatic system disorders;Body temperature decreased;Body temperature increased;Bradykinesia;Breast discomfort;Breast disorder;Breast engorgement;Breast pain;Bronchospasm;Cardiac arrest;Cardiac disorder;Cataract;Catatonia;Cholestasis;Cogwheel rigidity;Confusional state;Connective tissue disorder;Constipation;Convulsion;Decreased appetite;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug withdrawal syndrome neonatal;Dry mouth;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Electrocardiogram QT prolonged;Endocrine disorder;Erectile dysfunction;Euphoric mood;Extrapyramidal disorder;Extrapyramidal symptoms;Extrasystoles;Eye disorder;Face oedema;Feeling abnormal;Gait disturbance;Galactorrhoea;Gastrointestinal disorder;Grand mal convulsion;Gynaecomastia;Hallucination;Headache;Heat stroke;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hyperammonaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperprolactinaemia;Hyperpyrexia;Hypersensitivity;Hypertension;Hypertonia;Hypoglycaemia;Hypokinesia;Hyponatraemia;Hypotension;Hypothermia;Immune system disorder;Inappropriate antidiuretic hormone secretion;Injection site reaction;Insomnia;Jaundice;Laryngeal oedema;Laryngospasm;Lethargy;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Libido decreased;Libido increased;Liver function test abnormal;Loss of libido;Malnutrition;Masked facies;Mediastinal disorder;Menorrhagia;Menstrual disorder;Menstruation irregular;Mental disorder;Motor dysfunction;Movements involuntary;Muscle contractions involuntary;Muscle rigidity;Muscle spasms;Muscle twitching;Musculoskeletal stiffness;Nausea;Nervous system disorder;Neuroleptic malignant syndrome;Neutropenia;Nystagmus;Oculogyric crisis;Oedema;Opisthotonus;Orofacial dyskinesia;Orthostatic hypotension;Pancytopenia;Parkinsonism;Photosensitivity;Photosensitivity reaction;Pregnancy;Priapism;Protrusion tongue;Pruritus;Psychotic disorder;Rash;Retinal disorder;Salivary hypersecretion;Sexual dysfunction;Skin disorder;Somnolence;Sudden death;Sudden death, cause unknown;Sweating increased;Tachycardia;Tardive dyskinesia;Throat tightness;Thrombocytopenia;Tonic-clonic seizures;Torsade de pointes;Torticollis;Tremor;Trismus;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Vermiculation;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased",small molecule,approved,"1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine; 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one; 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone; 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone; Haloperidol; Haloperidolum; γ-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; Dopamine D2 receptor; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; Dopamine D3 receptor; G-protein coupled receptor 24; GPR24; MCH receptor 1; MCH-1R; MCH-R1; MCH1R; MCHR; MCHR-1; SLC-1; SLC1; Somatostatin receptor-like protein; Solute carrier family 18 member 2; SVMT; VAT2; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT2; Aging-associated gene 8 protein; hSigmaR1; OPRS1; SIG-1R; Sigma 1-type opioid receptor; Sigma1-receptor; Sigma1R; SR-BP; SR31747-binding protein; SRBP; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-6; 5-HT6; Serotonin receptor 6; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; Dopamine D1 receptor; 1.1.1.184; 15-hydroxyprostaglandin dehydrogenase [NADP(+)]; 20-beta-hydroxysteroid dehydrogenase; Alcohol dehydrogenase [NAD(P)+] CBR1; CBR; CRN; NADPH-dependent carbonyl reductase 1; PG-9-KR; Prostaglandin 9-ketoreductase; Prostaglandin-E(2) 9-reductase; SDR21C1; Short chain dehydrogenase/reductase family 21C member 1; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","5-hydroxytryptamine receptor 2C; D(2) dopamine receptor; 5-hydroxytryptamine receptor 2A; D(3) dopamine receptor; Melanin-concentrating hormone receptor 1; Synaptic vesicular amine transporter; Sigma non-opioid intracellular receptor 1; Histamine H1 receptor; Muscarinic acetylcholine receptor M3; Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; Glutamate receptor ionotropic, NMDA 2B; D(1A) dopamine receptor",N05AD01
hexachlorophene,Infection,Dermatitis;Erythema;Photosensitivity;Photosensitivity reaction;Redness,small molecule,approved; withdrawn,"2,2'-dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane; 2,2'-dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane; 2,2'-methanediylbis(3,4,6-trichlorophenol); 2,2'-methylenebis(3,4,6-trichlorophenol); 2,2',3,3',5,5'-hexachloro-6,6'-dihydroxydiphenylmethane; bis(2-hydroxy-3,5,6-trichlorophenyl)methane; bis(3,5,6-trichloro-2-hydroxyphenyl)methane; hexachlorophène; Hexachlorophene; Hexachlorophenum; Hexaclorofeno; 1.1.1.28; Respiratory D-lactate dehydrogenase; CII-4; CybS; Malate dehydrogenase [quinone] cytochrome b small subunit; QPs3; SDH4; Succinate dehydrogenase complex subunit D; Succinate-ubiquinone oxidoreductase cytochrome b small subunit; Succinate-ubiquinone reductase membrane anchor subunit; 1.4.1.3; GDH 1; GLUD; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1","D-lactate dehydrogenase; Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial; Glutamate dehydrogenase 1, mitochondrial; Estrogen receptor",D08AE01
homatropine,Accommodation disorder;Ciliary muscle spasm;Cycloplegia;Iridocyclitis;Iritis;Lenticular opacities;Mydriasis;Paralysis,Abdominal distension;Agitation;Anhidrosis;Ataxia;Ataxic gait;Bladder dilatation;Bladder distension;Body temperature increased;Brain injury;Cardiac disorder;Confusional state;Conjunctivitis;Convulsion;Dermatitis;Disorientation;Drowsiness;Drug effect prolonged;Eczema;Endophthalmitis;Eye discharge;Eye disorder;Eye irritation;Eye oedema;Eye pain;Feeling abnormal;Flushing;Follicular conjunctivitis;Glaucoma;Hallucination;Heart rate irregular;Hyperkinesia;Hyperpyrexia;Hypotension;Incoherent;Intraocular pressure increased;Mental aberration;Mental disorder;Nervous system disorder;Ocular hyperaemia;Oedema;Pain;Photophobia;Psychotic disorder;Pulmonary function test decreased;Pulse irregular;Rash;Respiratory depression;Retrograde amnesia;Somnolence;Spastic paralysis;Stinging;Tachycardia;Thirst;Trisomy 21;Urinary retention;Vasodilation;Vasodilation procedure;Vision blurred,small molecule,approved,Homatropina; Omatropina; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase,Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5,S01FA05
hydralazine,Cardiac failure congestive;Cardiac failure high output;Cardiac output increased;Cerebrovascular accident;Eclampsia;Essential hypertension;Fluid retention;Hypertension;Hypertensive crisis;Hypotension;Oedema;Orthostatic hypotension;Peripheral vasodilatation;Pre-eclampsia;Renal failure;Renal impairment;Tachycardia;Vascular resistance;Vascular resistance systemic;Vasodilatation,Agitation;Agranulocytosis;Anaemia;Angina pectoris;Anorexia;Anxiety;Arthralgia;Blood disorder;Body temperature increased;Cardiac failure;Cardiac failure congestive;Chills;Conjunctivitis;Constipation;Cramp muscle;Decreased appetite;Depression;Dermatitis;Diarrhoea;Digestion impaired;Discomfort;Disorientation;Dizziness;Dyspepsia;Dyspnoea;Dysuria;Eosinophilia;Exophthalmos;Feeling abnormal;Flushing;Gastrointestinal disorder;Glomerulonephritis;Haematuria;Haemolytic anaemia;Hallucination;Headache;Hepatic function abnormal;Hepatitis;Hepatomegaly;Hypersensitivity;Hypoaesthesia;Hypotension;Ileus paralytic;Ill-defined disorder;Jaundice;Joint swelling;Lacrimation;Lacrimation increased;Leukocytosis;Leukopenia;Lymphadenopathy;Malaise;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nausea;Neuritis;Neuropathy peripheral;Neutropenia;Numbness;Oedema;Palpitations;Pancytopenia;Paradoxical pressor response;Paraesthesia;Pleuritic pain;Polyneuritis;Polyneuropathy;Protein urine present;Proteinuria;Pruritus;Psychotic disorder;Purpura;Rash;Renal failure acute;Retroperitoneal fibrosis;Sensory loss;Splenomegaly;Strangury;Tachycardia;Thrombocytopenia;Tingling sensation;Tremor;Urinary retention;Urticaria;Vascular purpura;Vasculitis;Vomiting;Weight decreased,small molecule,approved,"(1Z)-1(2H)-Phthalazinone hydrazone; (2H)-Phthalazinone hydrazone; 1-Hydrazinophthalazine; 1-Phthalazinylhydrazine; 6-Hydralazine; Hidralazina; Hydralazin; Hydralazine; Hydralazinum; Hydrallazine; Hydrazinophthalazine; Hydrazone 1(2H)-phthalazinone; Hypophthalin; Idralazina; Phthalazin-1-ylhydrazine; 1.4.3.21; Amine oxidase copper-containing 3; Copper amine oxidase; HPAO; Semicarbazide-sensitive amine oxidase; SSAO; VAP-1; VAP1; Vascular adhesion protein 1; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; BHLHE78; Class E basic helix-loop-helix protein 78; HIF-1-alpha; HIF1-alpha; Member of PAS protein 1; MOP1; PAS domain-containing protein 8; PASD8; 1.14.11.2; 4-PH alpha-1; P4HA; Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Amine oxidase [copper-containing] 3; Hypoxia-inducible factor 1-alpha; Prolyl 4-hydroxylase subunit alpha-1, C02LG02;C02DB02
hydrochlorothiazide,Cardiac failure congestive;Cardiovascular disorder;Cerebrovascular accident;Chronic kidney disease;Dehydration;Dilatation ventricular;Discomfort;Eclampsia;Essential hypertension;Fluid loss;Fluid overload;Fluid retention;Glomerulonephritis acute;Gravitational oedema;Hepatic cirrhosis;Hyperkalaemia;Hypertension;Hypertensive;Left ventricular hypertrophy;Nephrotic syndrome;Normal pregnancy;Obesity;Oedema;Pre-eclampsia;Pregnancy;Premenstrual syndrome;Premenstrual tension;Renal failure chronic,Abdominal pain;Acute coronary syndrome;Agitation;Agranulocytosis;Airway obstruction NOS;Alopecia;Anaemia;Anaphylactic shock;Angiitis necrotising;Angina pectoris;Angioedema;Anorexia;Anxiety;Anxiety disorder;Aplastic anaemia;Arrhythmia;Arthralgia;Arthritis;Asthenia;Ataxia;Atrial fibrillation;Atrioventricular block second degree;Back pain;Blood creatinine increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Chest pain;Confusional state;Conjunctivitis;Constipation;Cough;Coxalgia;Cramp muscle;Cutaneous vasculitis;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry cough;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Ecchymosis;Electrolyte imbalance;Epigastric discomfort;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Face oedema;Feeling abnormal;Fibromyalgia;Flatulence;Flushing;Gastric irritation;Gastritis;Gastrointestinal pain;Glycosuria;Gout;Haemolytic anaemia;Headache;Henoch-Schonlein purpura;Hepatitis;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hyperuricaemia;Hypoaesthesia;Hyponatraemia;Hypotension;Ill-defined disorder;Insomnia;Jaundice;Jaundice cholestatic;Joint swelling;Knee pain;Leg pain;Leukopenia;Libido decreased;Loss of consciousness;Malaise;Memory impairment;Migraine;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nasal congestion;Nausea;Nephritis interstitial;Nervousness;Neuropathy peripheral;Nocturia;Obstructive airways disorder;Oedema;Orthostatic hypotension;Pain;Pain in arm;Pain in extremity;Palpitations;Pancreatitis;Panic disorder;Paraesthesia;Persistent dry cough;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Pruritus;Pulmonary oedema;Purpura;Rash;Renal failure;Respiratory distress;Rhabdomyolysis;Rhinitis;Serum creatinine increased;Shock;Shoulder pain;Sialoadenitis;Sinus bradycardia;Sinus disorder;Sinusitis;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Stiffness;Stinging;Sweating;Swelling;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Toothache;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Upper respiratory tract infection;Urinary tract infection;Urticaria;Vascular purpura;Vasculitis;Vasculitis necrotising;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Vomiting;Xanthopsia,small molecule,approved; vet_approved,"HCTZ; Hidroclorotiazida; Hydrochlorothiazide; Hydrochlorothiazidum; Na-Cl cotransporter; Na-Cl symporter; NCC; Thiazide-sensitive sodium-chloride cotransporter; TSC; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; BK channel; BKCA alpha; Calcium-activated potassium channel, subfamily M subunit alpha-1; hSlo; K(VCA)alpha; KCa1.1; KCNMA; Maxi K channel; MaxiK; SLO; Slo homolog; Slo-alpha; Slo1; Slowpoke homolog; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4",Solute carrier family 12 member 3; Angiotensin-converting enzyme; Calcium-activated potassium channel subunit alpha-1, C03AA03; C03AB03; C03AX01; C03EA01; C09DX01; C09DX03; C09DX06; C09DX07; C09DX08; C09XA52; C09XA54; G01AE10;C03AA03;C09BX03
hydrocortisone,Dermatitis;Dry skin;Eczema;Lichen simplex chronicus;Neurodermatitis;Psoriasis;Seborrhoeic dermatitis;Skin disorder,Acneiform eruption;Allergic contact dermatitis;Cataract;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Folliculitis;Hypersensitivity;Hypertrichosis;Infection;Intraocular pressure increased;Leukoderma;Miliaria;Pruritus;Purpura;Rebound effect;Rosacea;Secondary infection;Skin atrophy;Skin striae;Telangiectasia;Vascular purpura;Viral infection,small molecule,approved; vet_approved,"(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione; 11beta-hydrocortisone; 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione; 11β-hydrocortisone; 17-Hydroxycorticosterone; 4-pregnen-11β,17α,21-triol-3,20-dione; Cortisol; Hidrocortisona; Hydrocortisone; Hydrocortisonum; Kendall's compound F; Reichstein's substance M; GR; GRL; Nuclear receptor subfamily 3 group C member 1; Annexin I; Annexin-1; ANX1; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; LPC1; p35; Phospholipase A2 inhibitory protein; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; ALDOS; Aldosterone synthase; Aldosterone-synthesizing enzyme; Corticosterone 18-monooxygenase, CYP11B2; CYPXIB2; Cytochrome P-450Aldo; Cytochrome P-450C18; Steroid 11-beta-hydroxylase, CYP11B2; Steroid 18-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.3.1.3; 3-oxo-5-beta-steroid 4-dehydrogenase; Delta(4)-3-ketosteroid 5-beta-reductase; Delta(4)-3-oxosteroid 5-beta-reductase; SRD5B1; 1.3.1.22; 5 alpha-SR2; S5AR 2; SR type 2; Steroid 5-alpha-reductase 2; Type II 5-alpha reductase; 1.1.1.-; 11-beta-HSD type II; 11-beta-HSD2; 11-beta-hydroxysteroid dehydrogenase type II; 11-DH2; 11-HSD type II; Corticosteroid 11-beta-dehydrogenase isozyme 2; HSD11K; NAD-dependent 11-beta-hydroxysteroid dehydrogenase; SDR9C3; Short chain dehydrogenase/reductase family 9C member 3; 1.1.1.146; 11-beta-HSD1; 11-DH; 7-oxosteroid reductase; Corticosteroid 11-beta-dehydrogenase isozyme 1; HSD11; HSD11L; SDR26C1; Short chain dehydrogenase/reductase family 26C member 1; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; CBG; Serpin A6; Transcortin; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Glucocorticoid receptor; Annexin A1, A01AC03; A07EA02; C05AA01; D07AA02; D07BA04; D07CA01; D07XA01; H02AB09; R01AD60; S01BA02; S01BB01; S01CA03; S02BA01; S02CA03; S03CA04;D07AB02;S01CB03
hydroflumethiazide,Cardiac failure congestive;Glomerulonephritis acute;Hepatic cirrhosis;Hypertension;Nephrotic syndrome;Oedema;Renal failure chronic,Agitation;Agranulocytosis;Angiitis necrotising;Anorexia;Aplastic anaemia;Asthenia;Blood uric acid increased;Constipation;Cramp muscle;Cutaneous vasculitis;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Epigastric discomfort;Gastric irritation;Glycosuria;Headache;Hyperglycaemia;Hypersensitivity;Hyperuricaemia;Jaundice;Jaundice cholestatic;Leukopenia;Muscle spasms;Nausea;Orthostatic hypotension;Pancreatitis;Photosensitivity;Photosensitivity reaction;Purpura;Rash;Thrombocytopenia;Urticaria;Vascular purpura;Vasculitis;Vasculitis necrotising;Vertigo;Vomiting;Xanthopsia,small molecule,approved; investigational; withdrawn,"Dihydroflumethazide; Hidroflumetiazid; Hidroflumetiazida; Hydrofluméthiazide; Hydroflumethiazide; Hydroflumethiazidum; Idroflumetiazide; Metforylthiadiazin; BSC1; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; Kidney-specific Na-K-Cl symporter; Na-K-2Cl cotransporter 2; NKCC2; 4.2.1.1; CA-VII; Carbonate dehydratase VII; Carbonic anhydrase VII; 4.2.1.1; CA-IX; CAIX; Carbonate dehydratase IX; Carbonic anhydrase IX; G250; Membrane antigen MN; MN; P54/58N; pMW1; RCC-associated antigen G250; Renal cell carcinoma-associated antigen G250; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1; BK channel; BKCA alpha; Calcium-activated potassium channel, subfamily M subunit alpha-1; hSlo; K(VCA)alpha; KCa1.1; KCNMA; Maxi K channel; MaxiK; SLO; Slo homolog; Slo-alpha; Slo1; Slowpoke homolog; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-IV; Carbonate dehydratase IV; Carbonic anhydrase IV; 4.2.1.1; CA-XII; Carbonate dehydratase XII; Carbonic anhydrase XII; Tumor antigen HOM-RCC-3.1.3; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Solute carrier family 12 member 1; Carbonic anhydrase 7; Carbonic anhydrase 9; Sodium/potassium-transporting ATPase subunit alpha-1; Calcium-activated potassium channel subunit alpha-1; Carbonic anhydrase 1; Carbonic anhydrase 2; Carbonic anhydrase 4; Carbonic anhydrase 12, C03AB02; C03AH02; G01AE10;C03AA02
hydromorphone,Acute coronary syndrome;Acute pain;Acute ulcerative colitis;Advanced cancer;Biliary colic;Burn;Cancer pain;Chronic pain;Colitis ulcerative;Discomfort;Injury;Myocardial infarction;Neoplasm malignant;Pain;Postoperative pain;Procedural pain;Proctocolitis;Renal colic;Thermal burn;Trauma,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal faeces;Accidental injury;Accidental overdose;Ache;Acute pain;Addison's disease;Affect lability;Aggression;Agitation;Alcohol abuse;Alcoholism;Altered state of consciousness;Amnesia;Amylase increased;Anal fissure;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Anxiety;Apathy;Apnoea;Appetite absent;Application site pain;Apprehension;Arrhythmia;Arthralgia;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthenic conditions;Asthma;Azotaemia;Back pain;Balance disorder;Barrett's oesophagus;Bedridden;Bezoar;Biliary colic;Blood amylase increased;Blood potassium decreased;Blood testosterone decreased;Blood uric acid increased;Body temperature decreased;Body temperature increased;Bradycardia;Brain cancer metastatic;Breakthrough pain;Breast disorder;Breast feeding;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiovascular insufficiency;Chest discomfort;Chest pain;Chest tightness;Cheyne-Stokes respiration;Chills;Circulatory depression;Cognitive disorder;Cold sweat;Coma;Completed suicide;Confusional state;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Cough;Cramp muscle;Cramps of lower extremities;Cutis anserina;Cyanosis;Decreased appetite;Dehydration;Delayed gastric emptying;Dependence;Dependence physiological;Dependence psychological;Depressed level of consciousness;Depression;Dermatitis;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Diverticulum;Dizziness;Drowsiness;Drug abuse;Drug dependence;Drug interaction;Drug tolerance;Drug withdrawal syndrome;Dry eye;Dry mouth;Duodenitis;Dysarthria;Dyschezia;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphoria;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Early satiety;Encephalopathy;Endocrine disorder;Erectile dysfunction;Eructation;Erythema;Euphoric mood;Extrasystoles;Eye disorder;Faecalith;Faecaloma;Fatigue;Feeling abnormal;Feeling drunk;Feeling hot;Feeling jittery;Feeling of body temperature change;Flat affect;Flatulence;Fluid retention;Flushing;Fullness abdominal;Gait disturbance;Gastric atony;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal motility disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematochezia;Haemorrhoids;Hallucination;Hangover;Head injury;Headache;Hepatic enzyme increased;Hepatobiliary disease;Hepatomegaly;Hiccups;Hyperaesthesia;Hypercalcaemia;Hyperhidrosis;Hyperpathia;Hyperreflexia;Hypersensitivity;Hypertension;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypogonadism;Hyponatraemia;Hyporeflexia;Hypotension;Hypotensive;Hypothermia;Hypotonia;Ileus;Ileus paralytic;Ill-defined disorder;Immune system disorder;Impaired gastric emptying;Incontinence;Increased appetite;Induration;Infection;Infestation;Infestation NOS;Injection site pain;Injection site reaction;Injection site urticaria;Injury;Insomnia;Instillation site pain;Intestinal obstruction;Intracranial pressure increased;Large intestine perforation;Laryngospasm;Lethargy;Leukopenia;Libido decreased;Lightheadedness;Loss of consciousness;Low back pain;Lung disorder;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Menstrual disorder;Mental disorder;Metastases to central nervous system;Micturition disorder;Migraine;Miosis;Mood swings;Muscle contractions involuntary;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle tone flaccid;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myoclonus;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Nystagmus;Oedema peripheral;Oliguria;Opioid naive;Oropharyngeal swelling;Orthostatic hypotension;Osteoarthritis;Oxygen saturation decreased;Pain;Pain in extremity;Pain worsened;Palpitations;Panic attack;Paraesthesia;Paranoia;Paranoid reaction;Piloerection;Pollakiuria;Polyuria;Post herpetic neuralgia;Presyncope;Pruritus;Psychotic disorder;Pulmonary function test decreased;Pulmonary oedema;Rash;Reflux esophagitis;Respiration abnormal;Respiratory arrest;Respiratory depression;Respiratory disorder;Respiratory distress;Respiratory failure;Rhinitis;Rhinorrhoea;Sedation;Sexual dysfunction;Shivering;Shock;Skin cold clammy;Skin disorder;Sneezing;Somnolence;Stomach cramps;Stomatitis;Stupor;Substance abuse;Suicide;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Tension;Therapy naive;Tinnitus;Tranquillisation excessive;Tremor;Tremor muscle;Tumour invasion;Unspecified disorder of skin and subcutaneous tissue;Unsteadiness;Uremia;Ureteral spasm;Urethral disorder;Urethral stenosis;Urinary hesitation;Urinary retention;Urinary tract disorder;Urine output increased;Urticaria;VT;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Walking disability;Weight decreased;Welts;Wheezing;Withdrawal symptom;Withdrawal syndrome;Yawning,small molecule,approved; illicit,"(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; 6-Deoxy-7,8-dihydro-6-oxomorphine; 7,8-Dihydromorphinone; Dihydromorfinon; Dihydromorphinone; Dimorphone; Hidromorfona; Hydromorfona; Hydromorphone; Hydromorphonum; Idromorfone; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; K-OR-1; KOR-1; OPRK; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Mu-type opioid receptor; Delta-type opioid receptor; Kappa-type opioid receptor, N02AA03; N02AG04;N02AA03;N02AA53
hydroxychloroquine,Arthritis;Cutaneous lupus erythematosus;Discoid lupus erythematosus;Lupus erythematosus;Plasmodium falciparum infection;Plasmodium malariae infection;Plasmodium ovale infection;Rheumatoid arthritis;Systemic lupus erythematosus,Abdominal cramps;Abdominal pain;Abdominal pain upper;Abnormal pigmentation;Accommodation disorder;Acute generalised exanthematous pustulosis;Acute hepatic failure;Affect lability;Agitation;Agranulocytosis;Alopecia;Anaemia;Angioedema;Anorexia;Aplastic anaemia;Appetite absent;Asthenia;Ataxia;Atrophy;Blacked-out (not amnesia);Blood disorder;Body temperature increased;Bone marrow depression;Bronchospasm;Bullous eruption;Cardiac failure;Cardiomyopathy;Cardiovascular disorder;Central nervous system disorder;Central scotoma;Contusion;Convulsion;Corneal deposits;Corneal sensitivity decreased;Deafness;Deafness neurosensory;Decreased appetite;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Dizziness;Drowsiness;Drug eruption;Ear buzzing;Edema transient;Eosinophilia;Eruption;Erythema annulare;Erythema annulare centrifugum;Erythema multiforme;Excitability;Eye disorder;Fatigue;Foetor hepaticus;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemorrhage;Halo vision;Headache;Hearing impaired;Hepatic function abnormal;Hepatitis fulminant;Hepatocellular injury;Hypersensitivity;Hypoaesthesia eye;Hypoglycaemia;Hypokinesia;Intermittent headache;Irritability;Lassitude;Leukoderma;Leukopenia;Lightheadedness;Liver disorder;Liver function test abnormal;Lividity;Loss of consciousness;Macular degeneration;Macular pigmentation;Maculopathy;Malnutrition;Mental disorder;Mood swings;Mucosal pigmentation;Muscular weakness;Myopathy;Nausea;Nervous system disorder;Nervousness;Neural hearing loss;Neuromyopathy;Night blindness;Nightmare;Nystagmus;Oedema;Optic atrophy;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pallor;Pancytopenia;Paralysis;Photophobia;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Porphyrin metabolism disorder;Pruritus;Psoriasis;Psychotic disorder;Rash;Reaction gastrointestinal;Retinal disorder;Scotoma;Skin discolouration;Skin disorder;Somnolence;Stevens-Johnson syndrome;Stomach cramps;Suicidal behaviour;Tension;Throat sore;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vertigo;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Weight decreased,small molecule,approved,"(±)-hydroxychloroquine; 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol; 2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol; 7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline; 7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline; 7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline; 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline; Hidroxicloroquina; Hydroxychloroquine; Hydroxychloroquinum; Oxichlorochine; Oxichloroquine; 3.4.17.23; ACE-related carboxypeptidase; ACEH; Angiotensin-converting enzyme homolog; Angiotensin-converting enzyme-related carboxypeptidase; Metalloprotease MPROT15; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3",Toll-like receptor 7; Toll-like receptor 9; DNA; Angiotensin-converting enzyme 2,P01BA02
hydroxyurea,Acute chest syndrome;Carcinoma;Carcinoma of lung;Cervix carcinoma;Chronic myeloid leukaemia;Hepatic function abnormal;Leukaemia;Lung neoplasm malignant;Malignant melanoma;Myeloproliferative disorder;Neoplasm;Neoplasm malignant;Ovarian cancer;Ovarian epithelial cancer;Renal failure;Renal impairment;Sickle cell anaemia;Teratogenicity;Uterine cancer,Alopecia;Amenorrhoea;Anaemia;Anaemia megaloblastic;Angiopathy;Anorexia;Aphagia;Asthenia;Atrophy;Azoospermia;Blepharitis;Blister;Blood and lymphatic system disorders;Blood creatinine increased;Blood iron decreased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone marrow depression;Breast disorder;Chills;Chronic myeloid leukaemia;Constipation;Convulsion;Creatinine increased;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatitis radiation NOS;Dermatomyositis;Diarrhoea;Digestion impaired;Discomfort;Disorientation;Distress;Dizziness;Drowsiness;Dyspepsia;Dyspnoea;Dysuria;Emotional distress;Epigastric discomfort;Eruption;Erythema;Erythema facial;Erythema infectiosum;Face oedema;Fatigue;Febrile neutropenia;Feeling abnormal;Fibrosis;Folate deficiency;Gangrene;Gastric irritation;Gastrointestinal disorder;Gastrointestinal symptom NOS;Gastrointestinal ulcer;Haemoglobin;Haemorrhage;Hallucination;Headache;Hepatic enzyme increased;Hepatic failure;Hepatic insufficiency;Hepatobiliary disease;Hepatotoxicity;Hypersensitivity;Hypersplenism;Hyperuricaemia;Hypomagnesaemia;Ill-defined disorder;Infection;Infestation;Infestation NOS;Intoxication;Leg ulcer;Leukaemia;Leukemia secondary;Leukopenia;Lung infiltration;Lupus erythematosus;Malaise;Melanonychia;Metastatic disease;Metastatic neoplasm;Mucosal inflammation;Myelosuppression;Nail pigmentation;Nausea;Neoplasm;Nervous system disorder;Neuropathy peripheral;Neutropenia;Oedema;Oligospermia;Pain;Pancreatitis;Pancytopenia;Papule;Platelet count decreased;Poisoning;Pulmonary fibrosis;Pulmonary oedema;Radiation injury;Radiation skin injury;Rash;Rash maculo-papular;Recall phenomenon;Renal failure acute;Reticulocytopenia;Serum iron decreased;Skin atrophy;Skin cancer;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin necrosis;Skin ulcer;Solid tumour;Somnolence;Splenic sequestration;Stomatitis;Systemic lupus erythematosus;Tenderness;Thrombocytopenia;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Ureteric obstruction;Urine output;Vomiting;Weight increased,small molecule,approved,"Carbamohydroxamic acid; Carbamohydroximic acid; Carbamoyl oxime; Carbamyl hydroxamate; Hidroxicarbamida; Hydrea; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxyharnstoff; Hydroxyurea; N-Carbamoylhydroxylamine; N-Hydroxyurea; Oxyurea; 1.17.4.1; Ribonucleoside-diphosphate reductase subunit M1; Ribonucleotide reductase large subunit; RR1; 1.17.4.1; Ribonucleotide reductase small chain; Ribonucleotide reductase small subunit; RR2; 3.5.1.5; Urea amidohydrolase subunit alpha; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; HUT2; Solute carrier family 14 member 2; Urea transporter, kidney; UT2; HUT11; JK; RACH1; Solute carrier family 14 member 1; Urea transporter, erythrocyte; UT1; UTE; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5",Ribonucleoside-diphosphate reductase large subunit; Ribonucleoside-diphosphate reductase subunit M2,L01XX05
hydroxyzine,Agitation;Alcohol abuse;Alcoholism;Allergic conditions;Anxiety;Apprehension;Asthma;Cardiac disorder;Delirium tremens;Drug withdrawal syndrome;Emotional disorder;Emotional problems;Nausea;Neurosis;Pruritus;Psychotic disorder;Skin disorder;Tension;Urticaria chronic;Vomiting;Vomiting in pregnancy;Withdrawal symptom,Convulsion;Depressed level of consciousness;Dermatitis;Drowsiness;Drug eruption;Dry mouth;Fixed drug eruption;Hallucination;Headache;Hypersensitivity;Hypotension;Rash;Somnolence;Stupor;Tremor;Urticaria,small molecule,approved,"Hidroxizina; Hychotine; Hydroksyzyny; Hydroxine; Hydroxizine; Hydroxizinum; Hydroxycine; Hydroxyzin; Hydroxyzine; Hydroxyzinum; Idrossizina; H1-R; H1R; HH1R; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Histamine H1 receptor; Voltage-gated inwardly rectifying potassium channel KCNH2, N05BB51;N05BB01
atropine,Abdominal colic;Abdominal cramps;Abdominal pain;Abdominal pain upper;Accommodation disorder;Acute enterocolitis;Acute myocardial infarction;Angle closure glaucoma;Arrhythmia;Atrioventricular block;Automatic bladder;Biliary colic;Bladder pain;Block heart;Bradycardia;Brain lesion;Bronchospasm;Central nervous system lesion;Cholinergic syndrome;Common cold;Conjunctivitis bacterial;Conjunctivitis infective;Cycloplegia;Cystitis;Cystitis noninfective;Diarrhoea;Diverticulitis;Dysentery;Dyspnoea;Enterocolitis;Eye infection;Fasciculation;Flushing;Functional gastrointestinal disorder;Gastrointestinal disorder;Hyperhidrosis;Hypertonia;Hypertonicity;Hypotension;Infantile colic;Intoxication;Irritability;Irritable bowel syndrome;Lacrimation;Lacrimation increased;Muscarinic effects;Muscle contractions involuntary;Muscle rigidity;Muscle spasms;Mydriasis;Nasopharyngitis;Nausea;Neurogenic bladder;Neurogenic bowel;Open angle glaucoma;Pain;Pancreatitis;Paralysis;Parkinsonism;Peptic ulcer;Poisoning;Pulmonary oedema;Pylorospasm;Renal colic;Rhinitis;Rhinitis seasonal;Rhinorrhoea;Salivary hypersecretion;Salivation;Seasonal allergy;Sinus bradycardia;Splenic flexure syndrome;Sweating increased;Tachycardia;Tremor;Unspecified disorder of intestine;Urethral disorder;Urinary tract disorder;Vomiting;Wheezing,Abdominal distension;Abdominal pain;Accommodation disorder;Acute angle-closure glaucoma;Acute coronary syndrome;Ageusia;Agitation;Amnesia;Anaphylactic shock;Angina pectoris;Angioedema;Angle closure glaucoma;Anhidrosis;Anxiety;Arrhythmia;Arrhythmia supraventricular;Asthenia;Ataxia;Atrial arrhythmia;Atrial fibrillation;Atrioventricular dissociation;Balance disorder;Blepharitis;Blepharoconjunctivitis;Blindness;Bloated feeling;Blood disorder;Blood pressure increased;Blood urea increased;Body temperature increased;Bowel sounds decreased;Bradycardia;Cardiac arrest;Cardiac syncope;Cerebellar syndrome;Chest pain;Clonus;Clumsiness;Coma;Confusional state;Conjunctivitis;Conjunctivitis allergic;Conjunctivitis papillary;Constipation;Convulsion;Cyanosis;Cyclophoria;Cycloplegia;Dehydration;Delayed gastric emptying;Delirium;Depressed level of consciousness;Depression;Dermatitis;Dermatitis contact;Diarrhoea;Disorientation;Dizziness;Drowsiness;Dry eye;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dysmetria;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Eczema;Electrocardiogram QRS complex;Electrocardiogram QT prolonged;Enuresis;Erectile dysfunction;Erythema;Excessive thirst;Excitement;Extensor plantar response;Extrasystoles;Eye pain;Fatigue;Feeling abnormal;Feeling hot;Flushing;Follicular conjunctivitis;Gastrointestinal pain;Gastrointestinal sounds abnormal;Gastrooesophageal reflux disease;Haemoglobin decreased;Haemoglobin increased;Hallucination;Headache;Heart rate irregular;Heartburn;Heat intolerance;Hot dry skin;Hyperaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypertonia;Hypoglycaemia;Hypohidrosis;Hypokalaemia;Hyponatraemia;Hypotension;Ileus paralytic;Impaired gastric emptying;Injection site reaction;Insomnia;Intoxication;Intraocular pressure increased;Irritability;Junctional tachycardia;Keratitis;Keratoconjunctivitis sicca;Labile blood pressure;Labored breathing;Lacrimation decreased;Laryngitis;Laryngospasm;Left ventricular failure;Lethargy;Leukocytosis;Loss of consciousness;Loss of libido;Mania;Mental disorder;Muscle twitching;Mydriasis;Myocardial infarction;Myopia;Nasal congestion;Nasal dryness;Nausea;Nervousness;Nocturnal enuresis;Nodal rhythm;Oedema;Oral disorder;Oral lesion;Osteoarthritis;Pain;Palpitations;Paralysis;Paranoia;Petechiae;Photophobia;Poisoning;Pruritus;Psychotic disorder;Pulmonary function test decreased;Pulmonary oedema;Pulse irregular;QRS complex;Rash;Rash erythematous;Rash macular;Rash maculo-papular;Rash papular;Rash scarlatiniform;Respiratory depression;Respiratory failure;Retrosternal pain;Scab;Shock;Short-term memory loss;Sinus tachycardia;Skin exfoliation;Skin warm;Slurred speech;Somnolence;Speech disorder;Speech impairment NOS;Stinging;Strabismus;Strangury;Stridor;Stridor inspiratory;Stupor;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating;Sweating decreased;Swelling;Syncope;Tachycardia;Tachypnoea;Taste altered;Temperature intolerance;Tension;Thirst;Unsteadiness;Urinary hesitation;Urinary retention;Urticaria;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular fibrillation;Ventricular flutter;Ventricular tachycardia;Vertigo;Vision blurred;Visual acuity reduced;Vomiting,small molecule,approved; vet_approved,(±)-atropine; (±)-hyoscyamine; Atropin; Atropina; Atropine; Atropinum; dl-Hyoscyamine; dl-tropyltropate; Tropine tropate; Glycine receptor 48 kDa subunit; Glycine receptor strychnine-binding subunit; NACRA4; AGP 1; AGP1; OMD 1; Orosomucoid-1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP,Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; Glycine receptor subunit alpha-1; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2, A03BA01; A03CB03; V03AB54;A03BA01;S01FA01
ibuprofen,Ache;Acute pain;Analgesic effect;Analgesic therapy;Ankylosing spondylitis;Arthritis;Arthropathy;Autoimmune disorder;Back pain;Blood pressure increased;Body temperature increased;Bursitis;Capsulitis;Chronic pain;Common cold;Connective tissue disorder;Cramp muscle;Discomfort;Dysmenorrhoea;Ear pain;Flu symptoms;Frozen shoulder;Haemoglobin;Haemorrhage;Headache;Inflammation;Influenza;Juvenile idiopathic arthritis;Ligament sprain;Low back pain;Migraine;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Neuralgia;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Otitis media;Pain;Patent ductus arteriosus;Periarthritis;Postoperative pain;Primary dysmenorrhea;Procedural pain;Renal failure;Renal impairment;Rheumatoid arthritis;Rhinitis;Soft tissue injury;Sprain;Still's disease;Systemic lupus erythematosus;Tendonitis;Tenosynovitis;Tension headache;Throat sore;Toothache;Ulcer;Uterine pain,Abdominal bloating;Abdominal cramps;Abdominal discomfort;Abdominal distension;Abdominal distress;Abdominal pain;Abdominal pain upper;Abnormal dreams;Acidosis;Acute coronary syndrome;Adrenal insufficiency;Affect lability;Agitation;Agranulocytosis;Alopecia;Amblyopia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Apnoea;Appetite absent;Arrhythmia;Arthralgia;Arthritis;Asthenia;Asthma;Asthma aggravated;Atelectasis;Azotaemia;Azotaemia of renal origin;Bacteraemia;Bad taste;Benign intracranial hypertension;Bladder pain;Bleeding time prolonged;Blood and lymphatic system disorders;Blood creatinine decreased;Blood creatinine increased;Blood disorder;Blood lactate dehydrogenase increased;Blood urea increased;Bronchitis;Bronchopulmonary dysplasia;Bronchospasm;Bruxism;Cardiac failure;Cardiac failure congestive;Cataract;Cellulitis gangrenous;Cerebrovascular accident;Chills;Cholestasis;Cognitive disorder;Cognitive impairment;Colitis;Colitis ulcerative;Color vision change;Colour blindness acquired;Coma;Confusional state;Conjunctivitis;Constipation;Contusion;Convulsion;Cough;Cough increased;Cramp muscle;Creatinine increased;Creatinine low;Crohn's disease;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry eye;Dry mouth;Duodenal ulcer;Duodenitis;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ecchymosis;Encephalitis;Eosinophilia;Epidermal necrosis;Epigastric pain;Epistaxis;Erectile dysfunction;Eructation;Eruption;Erythema;Erythema multiforme;Euphoric mood;Exacerbation of asthma;Exhaustion;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Foetor hepaticus;Foot edema;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Gastrooesophageal reflux disease;Glomerular filtration rate decreased;Glomerulitis;Glomerulonephritis;Glossitis;Glycosuria;Gynaecomastia;Haematemesis;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hearing impaired;Heartburn;Henoch-Schonlein purpura;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis toxic;Hepatobiliary disease;Hepatocellular injury;Hepatorenal syndrome;Hiccups;Hoarseness;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypernatraemia;Hypersensitivity;Hypertension;Hypertonia;Hypoalbuminaemia;Hypocalcaemia;Hypoglycaemia;Hypoglycemic reaction;Hypokalaemia;Hyponatraemia;Hypopnoea;Hypoproteinaemia;Hypotension;Hypoxemia;Hypoxia;Ileus;Ill-defined disorder;Immune system disorder;Infection;Influenza;Influenza like illness;Influenza-like symptoms;Inguinal hernia;Injection site reaction;Insomnia;Intestinal perforation;Intraventricular haemorrhage;Jaundice;Kidney function abnormal;Lactic dehydrogenase activity increased;Leukopenia;Libido decreased;Lightheadedness;Liver disorder;Liver function test abnormal;Local swelling;Loss of consciousness;Lupus erythematosus;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melaena;Meningitis aseptic;Meningoencephalitis;Menorrhagia;Mental disorder;Metrorrhagia;Mixed connective tissue disease;Mood swings;Mouth ulceration;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nasal congestion;Nausea;Neck stiffness;Necrolysis epidermal;Necrotising colitis;Necrotising enterocolitis neonatal;Necrotising fasciitis;Necrotizing enterocolitis;Neoplasm;Nephritis;Nephritis interstitial;Nephropathy toxic;Nephrotic syndrome;Nephrotoxicity;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuropathy peripheral;Neutropenia;Nuchal rigidity;Oedema;Oedema peripheral;Oesophageal spasm;Oesophagitis;Oliguria;Optic neuritis;Palpitations;Pancreatitis;Pancreatitis acute;Pancytopenia;Paraesthesia;Peptic ulcer;Periventricular leukomalacia;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pneumonia;Pneumonia bacterial;Pneumothorax;Pollakiuria;Polyuria;Proctocolitis;Protein urine present;Proteinuria;Pruritus;Pulmonary congestion;Pulmonary function test decreased;Pulmonary haemorrhage;Pulmonary hypertension;Purpura;Rash;Rash pustular;Rectal haemorrhage;Renal failure;Renal failure acute;Renal impairment;Renal papillary necrosis;Renal tubular necrosis;Respiratory depression;Respiratory failure;Respiratory tract congestion;Respiratory tract infection;Reye's syndrome;Rhinitis;Scotoma;Sepsis;Serum sickness;Serum urea increased;Shallow breathing;Shock;Sinus bradycardia;Sinus tachycardia;Sinusitis;Skin disorder;Skin lesion;Slurred speech;Somnolence;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Sweating;Swelling;Syncope;Systemic lupus erythematosus;Tachycardia;Teeth clenching;Tension;Thirst;Thrombocytopenia;Thrombocytosis;Tinnitus;Toxic epidermal necrolysis;Toxic neuropathy;Tremor;Tubulointerstitial nephritis;Ulcer;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output;Urine output increased;Urticaria;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Vertigo;Vesiculobullous rash;Vision blurred;Vision decreased;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Wheezing;Wound haemorrhage,small molecule,approved,"(±)-2-(p-isobutylphenyl)propionic acid; (±)-ibuprofen; (±)-p-isobutylhydratropic acid; (±)-α-methyl-4-(2-methylpropyl)benzeneacetic acid; (4-isobutylphenyl)-α-methylacetic acid; (RS)-ibuprofen; 2-(4-isobutylphenyl)propanoic acid; 4-isobutylhydratropic acid; Ibuprofen; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; α-(4-isobutylphenyl)propionic acid; α-(p-isobutylphenyl)propionic acid; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; CDw128b; CXC-R2; CXCR-2; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8 receptor type 2; IL-8R B; IL8RB; C-X-C motif chemokine 8; Chemokine (C-X-C motif) ligand 8; Emoctakin; GCP-1; Granulocyte chemotactic protein 1; IL-8; IL8; MDNCF; MONAP; Monocyte-derived neutrophil chemotactic factor; Monocyte-derived neutrophil-activating peptide; NAP-1; Neutrophil-activating protein 1; Protein 3-10C; T-cell chemotactic factor; CDw128a; CMKAR1; CXC-R1; CXCR-1; High affinity interleukin-8 receptor A; IL-8 receptor type 1; IL-8R A; IL8RA; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; Fetomodulin; THRM; TM; FABPI; Fatty acid-binding protein 2; I-FABP; Intestinal-type fatty acid-binding protein; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; ABCC7; ATP-binding cassette sub-family C member 7; cAMP-dependent chloride channel; CFTR; Channel conductance-controlling ATPase; NR1C1; Nuclear receptor subfamily 1 group C member 1; PPAR; PPAR-alpha; Antigen CD42b-alpha; Glycoprotein Ibalpha; GP-Ib alpha; GPIb-alpha; GPIbA; PSOR1; Psoriasin; S100 calcium-binding protein A7; S100A7C; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4","Prostaglandin G/H synthase 2; C-X-C chemokine receptor type 2; Interleukin-8; C-X-C chemokine receptor type 1; Prostaglandin G/H synthase 1; Apoptosis regulator Bcl-2; Thrombomodulin; Fatty acid-binding protein, intestinal; Peroxisome proliferator-activated receptor gamma; Cystic fibrosis transmembrane conductance regulator; Peroxisome proliferator-activated receptor alpha; Platelet glycoprotein Ib alpha chain; Protein S100-A7", G02CC01; M01AE01; M01AE51; M02AA13; N02AJ08; N02AJ19; N02AJ23; R02AX02;C01EB16
phenelzine,Anxiety depression;Depression,Agitation;Anorgasmia;Anxiety;Asthenia;Ataxia;Blood creatine phosphokinase increased;Body temperature increased;Coma;Constipation;Convulsion;Creatine phosphokinase increased;Delirium;Delirium toxic;Dermatitis;Digestion impaired;Discomfort;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Erectile dysfunction;Euphoric mood;Fatigue;Feeling abnormal;Feeling jittery;Gastrointestinal disorder;Glaucoma;Headache;Hepatocellular injury;Hyperhidrosis;Hypernatraemia;Hyperpyrexia;Hyperreflexia;Hypersomnia;Hypertonia;Ill-defined disorder;Insomnia;Jaundice;Leukopenia;Liver injury;Lupus-like syndrome;Malaise;Mania;Manic psychosis;Metabolic acidosis;Muscle rigidity;Muscle twitching;Nausea;Nervousness;Nightmare;Nystagmus;Oedema;Orthostatic hypotension;Paraesthesia;Pruritus;Psychotic disorder;Rash;Repetitive speech;Schizophrenia;Shock;Sleep disorder;Sleep disturbance;Somnolence;Sweating;Tachycardia;Tachypnoea;Tremor;Urinary retention;Vision blurred;Vomiting;Weight increased;Withdrawal syndrome,small molecule,approved,"Fenelzina; Phenelzin; Phenelzine; Phénelzine; Phenelzinum; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.4.3.21; Amine oxidase copper-containing 3; Copper amine oxidase; HPAO; Semicarbazide-sensitive amine oxidase; SSAO; VAP-1; VAP1; Vascular adhesion protein 1; (S)-3-amino-2-methylpropionate transaminase; 2.6.1.19; GABA aminotransferase; GABA transaminase; GABA-AT; GABA-T; GABAT; Gamma-amino-N-butyrate transaminase; L-AIBAT; 2.6.1.2; AAT1; ALT1; Glutamate pyruvate transaminase 1; Glutamic--alanine transaminase 1; Glutamic--pyruvic transaminase 1; GPT 1; GPT1; 2.6.1.2; AAT2; ALT2; Glutamate pyruvate transaminase 2; Glutamic--alanine transaminase 2; Glutamic--pyruvic transaminase 2; GPT 2; EC 4.1.1.15; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J","Amine oxidase [flavin-containing] A; Amine oxidase [flavin-containing] B; Amine oxidase [copper-containing] 3; 4-aminobutyrate aminotransferase, mitochondrial; Alanine aminotransferase 1; Alanine aminotransferase 2; Glutamic acid decarboxylase",N06AF03
lidocaine,Acute coronary syndrome;Acute myocardial infarction;Agitation;Anal fissure;Anal pruritus;Anorectal discomfort;Arrhythmia;Arthropod bite;Bladder pain;Cardiac arrest;Cardiovascular insufficiency;Circulatory depression;Cystitis;Cystitis noninfective;Digitalis intoxication (NOS);Discomfort;Dumping syndrome;Eczema;Excitability;Gagging;Haemorrhoids;Herpes zoster;Insect bite NOS;Myocardial infarction;Oesophagitis;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Photosensitivity reaction;Post gastric surgery syndrome;Post herpetic neuralgia;Pruritus;Pruritus genital;Pruritus vulvae;Retching;Sunburn;Tenderness;Throat sore;Toxicity to various agents;Urethritis;Urethritis noninfective;Ventricular arrhythmia;Vulvovaginal pruritus,Acidosis;Agitation;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anterior spinal artery syndrome;Anxiety;Aphonia;Apnoea;Application site irritation;Application site reaction;Apprehension;Arachnoiditis;Asthenia;Asthma;Atrioventricular block;Back pain;Blister;Block heart;Bradycardia;Bronchospasm;Burning sensation;CNS depression NOS;CNS toxicity;Cardiac arrest;Cardiac disorder;Cauda equina syndrome;Chest pain;Chills;Circumoral paresthesia;Coma;Confusional state;Conjunctival hyperaemia;Contusion;Convulsion;Cranial nerve paralysis;Depressed level of consciousness;Dermatitis;Dermatitis bullous;Dermatitis contact;Diplopia;Disorientation;Dizziness;Drowsiness;Dysarthria;Dysgeusia;Dysphagia;Dysphonia;Dyspnoea;Electric shock;Endotracheal intubation complication;Endotracheal tube obstruction;Erythema;Euphoric mood;Eye disorder;Feeling abnormal;Feeling hot;Flushing;Gastrointestinal disorder;Gingivitis;Haemoglobin;Haemorrhage;Headache;Hoarseness;Hyperacusis;Hyperaesthesia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoaesthesia oral;Hypoesthesia tongue;Hypotension;Immune system disorder;Laryngospasm;Leukoderma;Lightheadedness;Local reaction;Loss of consciousness;Meningism;Meningitis;Methaemoglobinaemia;Mouth irritation;Muscle twitching;Myocardial depression;Nausea;Nerve injury;Nervous system disorder;Nervousness;Neurologic reaction;Neurological symptom;Neuropathy;Neuropathy peripheral;Neurotoxicity;Numbness;Numbness of tongue;Obstruction;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Pain;Pain worsened;Papule;Paraesthesia;Paraesthesia oral;Paralysis;Peripheral nerve injury;Petechiae;Pregnancy;Psychotic disorder;Pulmonary function test decreased;Rash;Redness;Respiratory arrest;Respiratory depression;Respiratory paralysis;Rhinitis;Sedation;Sensation of heat;Sensory loss;Shivering;Shock;Skin exfoliation;Skin irritation;Slurred speech;Somnolence;Spinal anaesthesia;Stomatitis;Sweating increased;Taste metallic;Tenderness;Tension;Teratogenicity;Throat sore;Tinnitus;Total spinal block;Tremor;Urinary incontinence;Urinary retention;Urticaria;Venipuncture site hemorrhage;Ventricular fibrillation;Ventricular tachycardia;Vessel puncture site haemorrhage;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; vet_approved,"2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; alpha-diethylamino-2,6-dimethylacetanilide; Lidocaína; Lidocaina; Lidocaine; Lidocainum; Lignocaine; α-diethylamino-2,6-dimethylacetanilide; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; hNE-Na; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Sodium channel protein type IX subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.7; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; 2.7.10.1; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium channel protein type 11 subunit alpha; Sodium channel protein type 10 subunit alpha; Sodium channel protein type 9 subunit alpha; Sodium channel protein type 5 subunit alpha; Epidermal growth factor receptor; Sodium channel protein type 4 subunit alpha; Alpha-1-acid glycoprotein 1; Alpha-1-acid glycoprotein 2, C01BB01; C05AD01; D04AB01; N01BB02; N01BB52; R02AD02; S02DA01;C01BB01;S01HA07
idarubicin,Acute coronary syndrome;Acute leukaemia;Acute lymphocytic leukaemia;Acute myeloid leukaemia;Advanced breast cancer;Arrhythmia;Breast cancer;Cardiac disorder;Cardiac failure congestive;Chest pain;Chronic myeloid leukaemia;Gastrointestinal disorder;Myocardial infarction;Non-Hodgkin's lymphoma,Abdominal cramps;Abdominal pain;Acral erythema;Acute coronary syndrome;Alopecia;Alopecia reversible;Anaemia;Anaphylactic shock;Angiopathy;Anorexia;Aplasia;Arrhythmia;Atrial fibrillation;Atrioventricular block;Autonomic nervous system imbalance;Blood and lymphatic system disorders;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bundle branch block;Burning sensation;Cardiac failure congestive;Cardiomyopathy;Cardiotoxicity;Chemical phlebitis;Chest pain;Chills;Colitis;Convulsion;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Embolism;Embolism venous;Enterocolitis;Extravasation;Febrile neutropenia;Fluid overload;Flushing;Gastrointestinal pain;Gastrointestinal toxicity;Haemoglobin;Haemorrhage;Headache;Hepatic function abnormal;Hot flush;Hypersensitivity;Hyperuricaemia;Immune system disorder;Infection;Injection site urticaria;Instability vasomotor;Leukaemia;Leukopenia;Local reaction;Lymphoma;Malnutrition;Menopausal symptoms;Mucosal inflammation;Myelodysplastic syndrome;Myelosuppression;Myocardial infarction;Myocarditis;Nausea;Necrosis;Neoplasm;Neutropenia;Neutropenic colitis;Neutropenic enterocolitis;Non-Hodgkin's lymphoma;Oesophagitis;Palmar-plantar erythrodysaesthesia syndrome;Pancytopenia;Pericarditis;Phlebitis;Radiation injury;Radiation recall reaction (dermatologic);Rash;Rash generalised;Recall phenomenon;Sepsis;Septic shock;Septicemia;Shock;Sinus tachycardia;Skin disorder;Skin hyperpigmentation;Stomatitis;Tachyarrhythmia;Thrombocytopenia;Thromboembolism;Thrombophlebitis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vomiting,small molecule,approved,"(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; Idarubicin; Idarubicina; Idarubicine; Idarubicinum; 5.6.2.2; DNA topoisomerase II, beta isozyme; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1",DNA topoisomerase 2-beta; DNA; DNA topoisomerase 2-alpha,L01DB06
ifosfamide,Acute lymphocytic leukaemia;Cervix carcinoma;Cystitis haemorrhagic;Encephalopathy;Lymphoma;Menorrhagia;Neoplasm malignant;Non-Hodgkin's lymphoma;Pancreatic carcinoma;Prolonged menses;Sarcoma;Testis cancer,"Abdominal pain;Acidosis;Acute coronary syndrome;Acute leukaemia;Acute lymphocytic leukaemia;Acute myeloid leukaemia;Acute promyelocytic leukaemia;Acute respiratory distress syndrome;Agitation;Agranulocytosis;Alopecia;Alveolitis allergic;Amenorrhoea;Aminoaciduria;Amnesia;Anaemia;Anaemia neonatal;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Asterixis;Asthenia;Atrial fibrillation;Atrial flutter;Azoospermia;Bladder irritation;Blood and lymphatic system disorders;Blood creatinine increased;Blood gonadotrophin increased;Blood oestrogen decreased;Body temperature increased;Bradycardia;Bradyphrenia;Brain cancer metastatic;Breast disorder;Bronchospasm;Bundle branch block left;Bundle branch block right;CNS toxicity;Caecitis;Capillary leak syndrome;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiogenic shock;Cardiomyopathy;Cardiotoxicity;Catatonia;Cerebral arteriosclerosis;Chest pain;Chills;Cholestasis;Coagulopathy;Colitis;Coma;Confusional state;Congestive cardiomyopathy;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Convulsions generalised;Cough;Cyst;Cystitis haemorrhagic;Cytolytic hepatitis;Deafness;Decreased appetite;Deep vein thrombosis;Delirium;Delusion;Depressed level of consciousness;Dermatitis;Diarrhoea;Discomfort;Disorientation;Disseminated intravascular coagulation;Dizziness;Drug interaction;Dysaesthesia;Dysarthria;Dyskinesia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Echolalia;Ejection fraction decreased;Electrocardiogram QRS complex abnormal;Electrocardiogram ST segment;Electrocardiogram ST segment abnormal;Electrocardiogram T wave inversion;Encephalitis;Endocrine disorder;Enterocolitis;Enuresis;Erythema;Erythema multiforme;Extrapyramidal disorder;Extravasation;Eye disorder;Eye irritation;Faecal incontinence;Fanconi syndrome;Fatal outcomes;Fatigue;Febrile bone marrow aplasia;Febrile neutropenia;Feeling abnormal;Feeling of residual urine;Fever of unknown origin;Flushing;Frank hematuria;Fungal infection;Gait disturbance;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Growth retardation;Haematemesis;Haematotoxicity;Haematuria;Haemoglobin;Haemolytic anaemia;Haemolytic uraemic syndrome;Haemorrhage;Hallucination;Hallucination, auditory;Hearing impaired;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis fulminant;Hepatitis viral;Hepatobiliary disease;Hepatotoxicity;Herpes zoster;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonic bladder;Hypocalcaemia;Hypokalaemia;Hypophosphataemia;Hypotension;Hypoxia;Ileus;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Incontinence;Infection;Infertility;Infestation;Infestation NOS;Inflammation;Infusion site reactions;Interstitial lung disease;Interstitial pneumonia;Left ventricular failure;Leukoencephalopathy;Leukopenia;Logorrhoea;Lung fibrosis interstitial;Lymphoma;Major depression;Malaise;Malnutrition;Mania;Mediastinal disorder;Mental disorder;Metabolic acidosis;Metastases to central nervous system;Methaemoglobinaemia;Microscopic hematuria;Microsomia;Movement disorder;Mucosal inflammation;Mucosal ulceration;Multi-organ failure;Muscle twitching;Musculoskeletal discomfort;Mutism;Myalgia;Myelodysplastic syndrome;Myelosuppression;Myocardial depression;Myocardial haemorrhage;Myocardial infarction;Myocarditis;Nail disorder;Nausea;Necrosis;Neoplasm;Neoplasm malignant;Nephrogenic diabetes insipidus;Nephropathy;Nephropathy toxic;Nephrotoxicity;Nervous system disorder;Neuralgia;Neuropathy peripheral;Neurotoxicity;Non-Hodgkin's lymphoma;Obstruction;Oedema;Oligospermia;Osteoarthritis;Osteomalacia;Ovarian disorder;Ovarian failure;Ovulation disorder;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Panic attack;Paraesthesia;Paranoia;Pelvic neoplasm;Pericardial effusion;Pericarditis;Perseveration;Petechiae;Phlebitis;Pleural effusion;Pneumonia;Pollakiuria;Polydipsia;Polyneuropathy;Polyp;Polyuria;Portal vein thrombosis;Posterior reversible encephalopathy syndrome;Premature menopause;Progressive multifocal leukoencephalopathy;Protein urine present;Proteinuria;Pruritus;Psychosis depressive;Psychotic disorder;Pulmonary embolism;Pulmonary fibrosis;Pulmonary hypertension;Pulmonary oedema;Pulmonary toxicity;Radiation recall reaction (dermatologic);Rash;Rash macular;Rash papular;Recall phenomenon;Renal cell carcinoma;Renal failure;Renal failure acute;Renal failure chronic;Renal impairment;Renal neoplasm;Renal rickets;Renal tubular acidosis;Renal tubular disorder;Renal tubular necrosis;Respiratory failure;Rhabdomyolysis;Rickets;Road traffic accident;Salivary hypersecretion;Salivation;Sarcoma;Sepsis;Septic shock;Serum creatinine increased;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin necrosis;Somnolence;Status epilepticus;Stevens-Johnson syndrome;Stomatitis;Stupor;Supraventricular extrasystoles;Swelling;Swelling face;Tenderness;Thrombocytopenia;Thrombophlebitis;Tinnitus;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urine output increased;Urine phosphate increased;Urine phosphorus increased;Urticaria;Vasculitis;Venoocclusive liver disease;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Visual impairment;Vomiting",small molecule,approved,"3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; Ifosfamida; Ifosfamide; Ifosfamidum; Iphosphamide; Isofosfamide; Isophosphamide; Isosfamide; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1",DNA; Nuclear receptor subfamily 1 group I member 2,L01AA06
imipramine,Alcohol abuse;Alcoholism;Depression;Depressive symptom;Endogenous depression;Enuresis;Major depression;Personality disorder,Abdominal cramps;Abdominal disorder;Abdominal pain;Accommodation disorder;Acute coronary syndrome;Adenitis;Affect lability;Aggression;Agitation;Agranulocytosis;Alopecia;Alveolitis allergic;Anaphylactic shock;Angiopathy;Angle closure glaucoma;Anorexia;Anxiety;Arrhythmia;Asthenia;Ataxia;Atrioventricular block;Black hairy tongue;Block heart;Blood and lymphatic system disorders;Blood pressure increased;Body temperature increased;Bone marrow depression;Breast disorder;Breast enlargement;Bundle branch block;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cerebrovascular accident;Conduction disorder;Confusional state;Constipation;Convulsion;Coordination abnormal;Decreased appetite;Delirium;Delusion;Dental caries;Dermatitis;Dermatitis atopic;Diarrhoea;Digestion impaired;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug fever;Drug withdrawal syndrome;Dry mouth;Dysgeusia;Dyspepsia;Ear and labyrinth disorders;Electrocardiogram QRS complex;Electroencephalogram abnormal;Endocrine disorder;Eosinophilia;Epigastric distress;Erectile dysfunction;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Fatigue;Feeling abnormal;Flushing;Galactorrhoea;Gastrointestinal disorder;Gastrointestinal pain;Glaucoma;Gynaecomastia;Hallucination;Headache;Hepatitis;Hepatobiliary disease;Hot flush;Hyperhidrosis;Hypertension;Hypertrophy of breast;Hypoaesthesia;Hypomania;Ileus paralytic;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Infection;Infestation;Infestation NOS;Insomnia;Jaundice;Lacrimation decreased;Leukopenia;Libido decreased;Libido disorder;Liver function test abnormal;Loss of consciousness;Lymphadenitis;Malaise;Malnutrition;Mania;Mediastinal disorder;Menopausal symptoms;Mental disorder;Micturition disorder;Mood swings;Mydriasis;Myocardial infarction;Myoclonus;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Nightmare;Numbness;Oedema;Orthostatic hypotension;Palpitations;Pancytopenia;Paraesthesia;Paresthesia of limbs;Parotid gland enlargement;Parotid swelling;Petechiae;Photosensitivity reaction;Pollakiuria;Pruritus;Psychotic disorder;Purpura;QRS complex;Rash;Sensory loss;Shock;Sinus tachycardia;Skin disorder;Skin hyperpigmentation;Sleep disorder;Sleep disturbance;Somnolence;Speech disorder;Stomatitis;Sudden death;Syncope;Tachycardia;Taste peculiar;Tension;Testicular swelling;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue discolouration;Tongue ulceration;Torsade de pointes;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;Vascular purpura;Vasospasm;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Vision blurred;Vomiting;Weight decreased;Weight increased;Withdrawal symptom,small molecule,approved,"10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; Imipramin; Imipramina; Imipramine; Imipraminum; Imizine; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(γ-dimethylaminopropyl)iminodibenzyl; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; KIAA1044; Potassium voltage-gated channel subfamily D member 2; Voltage-gated potassium channel subunit Kv4.2; Potassium voltage-gated channel subfamily D member 3; Voltage-gated potassium channel subunit Kv4.3; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D2 receptor; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-6; 5-HT6; Serotonin receptor 6; EAG; EAG channel 1; EAG1; Ether-a-go-go potassium channel 1; h-eag; hEAG1; Potassium voltage-gated channel subfamily H member 1; Voltage-gated potassium channel subunit Kv10.1; AGP 2; AGP2; OMD 2; Orosomucoid-2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H",Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2A; Histamine H1 receptor; Alpha-1A adrenergic receptor; Alpha-1D adrenergic receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; A-type voltage-gated potassium channel KCND2; A-type voltage-gated potassium channel KCND3; 5-hydroxytryptamine receptor 2C; Alpha-1B adrenergic receptor; 5-hydroxytryptamine receptor 7; D(1) dopamine receptor; D(2) dopamine receptor; Voltage-gated inwardly rectifying potassium channel KCNH2; Sodium-dependent dopamine transporter; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 6; Voltage-gated delayed rectifier potassium channel KCNH1; Alpha-1-acid glycoprotein 2,N06AA02
indapamide,Anuria;Blood potassium increased;Cardiac failure congestive;Diabetes mellitus;Discomfort;Essential hypertension;Fluid retention;Gout;Gravitational oedema;Hyperkaliuria;Hypersensitivity;Hypertension;Hypokalaemia;Kaluresis;Lipids increased;Oedema;Potassium increased;Pre-eclampsia;Pregnancy;Vascular resistance systemic,Abdominal pain;Abdominal pain upper;Agitation;Agranulocytosis;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Angiitis necrotising;Angina pectoris;Angioedema;Anorectal disorder;Anorexia;Anxiety;Aplastic anaemia;Application site reaction;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Ataxia;Atrial fibrillation;Atrial flutter;Back pain;Bladder pain;Blister;Blood glucose increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Bronchitis;Bullous eruption;Bundle branch block;Candida infection;Carcinoma;Cardiac disorder;Cataract;Cerebrovascular accident;Chest pain;Chondrodystrophy;Conjunctivitis;Constipation;Cough;Cramp muscle;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diabetic hyperosmolar coma;Diarrhoea;Digestion impaired;Discomfort;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug interaction;Dry mouth;Duodenitis;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear disorder;Ear infection;Ear pain;Ecchymosis;Electrocardiogram QT prolonged;Electrocardiogram U wave present;Electrocardiogram U-wave abnormality;Electrolyte imbalance;Elevated liver enzyme levels;Epigastric discomfort;Erectile dysfunction;Erythema;Erythema multiforme;Face oedema;Fatigue;Feeling abnormal;Flatulence;Flushing;Fracture;Gastric irritation;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Glycosuria;Gout;Haemolytic anaemia;Headache;Heart rate irregular;Hepatic encephalopathy;Hepatic enzyme increased;Hepatic failure;Hepatic insufficiency;Hepatitis;Hepatobiliary disease;Hernia;Hyperaesthesia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypochloraemia;Hypokalaemia;Hyponatraemia;Hypotension;Hypovolaemia;Ill-defined disorder;Increased appetite;Infection;Influenza;Insomnia;Irritability;Jaundice;Jaundice cholestatic;Laryngitis;Lethargy;Leukopenia;Libido decreased;Lightheadedness;Lithium toxicity;Liver function test abnormal;Loss of consciousness;Lung disorder;Malaise;Malnutrition;Metabolic alkalosis;Migraine;Multiple fractures;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Myasthenia;Myopathy;Myopia;Nail disorder;Nasopharyngitis;Nausea;Necrolysis epidermal;Neoplasm malignant;Nephritis interstitial;Nervous system disorder;Nervousness;Nocturia;Numbness of limbs;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Optic neuritis;Oral candidiasis;Orthostatic hypotension;Osteoarthritis;Otitis;Pain;Palpitations;Pancreatitis;Paraesthesia;Pharyngitis;Photophobia;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Proctitis;Pruritus;Purpura;Rash;Rectal disorder;Renal failure;Renal pain;Respiratory distress;Rhabdomyolysis;Rhinitis;Rhinorrhoea;Serum urea increased;Shock;Sialoadenitis;Sinus bradycardia;Sinusitis;Skin disorder;Skin mass;Skin nodule;Somnolence;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Supraventricular tachycardia;Sweating;Syncope;Systemic lupus erythematosus;Tachycardia;Tension;Thrombocytopenia;Thyroid disorder;Tingling of extremity;Tinnitus;Tooth disorder;Torsade de pointes;Toxic epidermal necrolysis;Toxicity to various agents;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasculitis;Vasculitis necrotising;Vasodilation;Vasodilation procedure;Ventricular arrhythmia;Ventricular extrasystoles;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Xanthopsia,small molecule,approved,"Indapamid; Indapamida; Indapamide; Indapamidum; Metindamide; Na-Cl cotransporter; Na-Cl symporter; NCC; Thiazide-sensitive sodium-chloride cotransporter; TSC; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1; KCNA8; KCNA9; KQT-like 1; KVLQT1; Voltage-gated potassium channel subunit Kv7.1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 3.3.2.9; EPHX; EPOX; Epoxide hydratase; mEH; Microsomal epoxide hydrolase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2",Solute carrier family 12 member 3; Potassium voltage-gated channel subfamily KQT member 1, C09BX01; C09BX06; C10BX13; G01AE10;C03BA11
indinavir,Acquired immunodeficiency syndrome;Autoimmune disorder;Haemophilia;Immunodeficiency;Malaise;Sickness,Abdominal distension;Abdominal pain;Accommodation disorder;Acquired immunodeficiency syndrome;Acute coronary syndrome;Acute haemolytic anaemia;Agitation;Alanine aminotransferase increased;Allergic cutaneous angiitis;Alopecia;Amylase increased;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anxiety;Anxiety disorder;Aphthous stomatitis;Arthralgia;Aspartate aminotransferase increased;Asthenia;Autoimmune disorder;Back pain;Bacteraemia;Basedow's disease;Bilirubin unconjugated increased;Blood and lymphatic system disorders;Blood bilirubin unconjugated increased;Blood cholesterol increased;Blood creatinine increased;Blood glucose increased;Blood triglycerides increased;Body odor;Body temperature increased;Breath odour;Bruxism;Calculus urinary;Cardiovascular disorder;Cerebrovascular disorder;Cheilitis;Chest pain;Chills;Cholecystitis;Cholestasis;Cholesterol serum elevated;Connective tissue disorder;Constipation;Cough;Cramp muscle;Creatinine increased;Crystalluria;Decreased appetite;Dermatitis;Dermatitis contact;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dry skin;Dysaesthesia;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Eructation;Erythema multiforme;Excitement;Eye pain;Eye swelling;Fasciculation;Fat redistribution;Fatigue;Feeling abnormal;Flank pain;Flatulence;Flushing;Folliculitis;Food allergy;Fungal infection;Gastric flu;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gingival bleeding;Gingivitis;Glossodynia;Glucose increased;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemophilia;Haemorrhage;Headache;Hepatic cirrhosis;Hepatic failure;Hepatitis;Hepatobiliary disease;Herpes simplex;Herpes zoster;Hydronephrosis;Hyperaemia;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlactacidaemia;Hypersensitivity;Hypertriglyceridaemia;Hypoaesthesia;Ill-defined disorder;Immune system disorder;Increased appetite;Inflammation;Influenza like illness;Ingrowing nail;Insomnia;Insulin resistance;Jaundice;Leg pain;Leukocytoclastic vasculitis;Lipoatrophy;Lipomatosis;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Microscopic hematuria;Muscle contractions involuntary;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myositis;Nausea;Nephritis;Nephritis interstitial;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neuropathy peripheral;Neurosis;Neutrophil count increased;Night sweats;Nocturia;Oedema;Opportunistic infection;Orbital oedema;Osteonecrosis;Pain;Pain in extremity;Palpitations;Pancreatitis;Paraesthesia;Paraesthesia oral;Paronychia;Periarthritis;Pharyngitis;Platelet count decreased;Pneumonia;Pollakiuria;Premenstrual syndrome;Protein urine present;Proteinuria;Pruritus;Pyelonephritis;Pyuria;Rales;Rash;Regurgitation;Renal colic;Renal failure;Renal failure acute;Renal impairment;Respiratory failure;Rhabdomyolysis;Rhonchi;Seborrhoeic dermatitis;Serum amylase increased;Serum triglycerides increased;Shock;Shoulder pain;Sinus disorder;Sinusitis;Skin disorder;Skin hyperpigmentation;Skin infection;Skin odour abnormal;Sleep disorder;Somnolence;Spleen disorder;Stevens-Johnson syndrome;Stiffness;Sweating;Swelling;Syncope;Taste disorders;Tension;Thrombocytopenia;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urolithiasis;Urticaria;Vasculitis;Vertigo;Viral diarrhoea;Vision blurred;Vomiting;Weight increased;White blood cells urine positive,small molecule,approved,"(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide; Indinavir; Indinavir anhydrous; Pr160Gag-Pol; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Gag-Pol polyprotein; Pol polyprotein,J05AE02
indomethacin,Acute pain;Ankylosing spondylitis;Arthritis;Back pain;Bursitis;Capsulitis;Colitis ulcerative;Drug interaction;Dysmenorrhoea;Fracture;Gout;Gouty arthritis;Inflammation;Joint dislocation;Ligament sprain;Low back pain;Multiple fractures;Musculoskeletal disorder;Oedema;Osteoarthritis;Pain;Patent ductus arteriosus;Periarthritis;Primary dysmenorrhea;Proctocolitis;Rheumatoid arthritis;Sprain;Synovitis;Tendonitis;Tenosynovitis,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal distress;Abdominal pain;Abdominal pain upper;Acidosis;Acute anaphylaxis;Agranulocytosis;Alkalosis;Alopecia;Anaemia;Anaphylactic shock;Angioedema;Ankylosing spondylitis;Anorectal discomfort;Anorexia;Anxiety;Apathy;Aplastic anaemia;Apnoea;Arrhythmia;Asthenia;Asthma;Azotaemia;Blood potassium increased;Body temperature increased;Bone marrow depression;Bradycardia;Carcinoma;Cardiac failure congestive;Cellulitis gangrenous;Chest pain;Coagulopathy;Colitis;Coma;Confusional state;Constipation;Convulsion;Corneal deposits;Crohn's disease;Deafness;Decreased appetite;Depersonalisation;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disseminated intravascular coagulation;Distention;Distress;Diverticulum;Dizziness;Drowsiness;Dysarthria;Dyskinesia;Dyspepsia;Dyspnoea;Ecchymosis;Electrolyte imbalance;Emotional distress;Epigastric distress;Epigastric pain;Epilepsy;Epistaxis;Erythema;Erythema multiforme;Erythema nodosum;Eye pain;Fatal outcomes;Fatigue;Feeling abnormal;Flat affect;Flatulence;Fluid retention;Flushing;Gastric perforation;Gastritis;Gastroenteritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Glycosuria;Gout;Gouty arthritis;Gynaecomastia;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Haemorrhage intracranial;Headache;Heartburn;Hepatitis;Hepatitis toxic;Hot flush;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypoglycaemia;Hyponatraemia;Hypotension;Ileitis regional;Ileus;Ill-defined disorder;Insomnia;Intestinal ulcer;Jaundice;Leukaemia;Leukopenia;Lightheadedness;Loss of consciousness;Lung infection;Malaise;Menopausal symptoms;Mouth ulceration;Muscle movement involuntary;Muscular weakness;Nausea;Necrolysis epidermal;Necrotising colitis;Necrotising enterocolitis neonatal;Necrotising fasciitis;Necrotizing enterocolitis;Neoplasm malignant;Nephritic syndrome;Nephritis;Nephritis interstitial;Nephrotic syndrome;Nervousness;Neuropathy peripheral;Oedema;Oliguria;Osteoarthritis;Pain;Palpitations;Pancytopenia;Paraesthesia;Parkinsonism;Peptic ulcer;Periorbital pain;Petechiae;Platelet count decreased;Pneumothorax;Pollakiuria;Post procedural haemorrhage;Post procedural oedema;Post procedural swelling;Presyncope;Proctalgia;Proctitis;Protein urine present;Proteinuria;Pruritus;Pruritus generalised;Psychotic disorder;Psychotic episode;Pulmonary haemorrhage;Pulmonary hypertension;Pulmonary oedema;Pulmonary vasculitis;Purpura;Rash;Rectal haemorrhage;Rectal tenesmus;Renal failure;Renal impairment;Respiratory distress;Retinopathy of prematurity;Secondary anemia;Serum potassium increased;Shock;Skin exfoliation;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating;Syncope;Tachycardia;Tenderness;Tension;Thrombocytopenia;Thrombocytopenic purpura;Thrombophlebitis;Tinnitus;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Ulcer;Ulcerative stomatitis;Uremia;Urticaria;Vaginal haemorrhage;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Vomiting;Weight increased,small molecule,approved; investigational,"{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid; 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid; Indometacin; Indometacina; Indometacine; Indometacinum; Indomethacin; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 3.1.1.4; GIIC sPLA2; Group IIA phospholipase A2; Non-pancreatic secretory phospholipase A2; NPS-PLA2; Phosphatidylcholine 2-acylhydrolase 2A; PLA2B; PLA2L; RASF-A; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.3.1.48; 15-oxoprostaglandin 13-reductase; PRG-2; ZADH1; Zinc-binding alcohol dehydrogenase domain-containing protein 1; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; 4.4.1.5; Aldoketomutase; Glx I; Glyoxalase I; Ketone-aldehyde mutase; Methylglyoxalase; S-D-lactoylglutathione methylglyoxal lyase; Chemoattractant receptor-homologous molecule expressed on Th2 cells; CRTH2; DL1R; G-protein coupled receptor 44; GPR44; NR1C1; Nuclear receptor subfamily 1 group C member 1; PPAR; PPAR-alpha; 1.1.1.-; 1.1.1.210; 1.1.1.53; 1.1.1.62; 17-beta-HSD 5; 17-beta-hydroxysteroid dehydrogenase type 5; 3-alpha-HSD type 2; 3-alpha-HSD type II, brain; 3-alpha-hydroxysteroid dehydrogenase type 2; Chlordecone reductase homolog HAKRb; DD-3; DD3; DDH1; Dihydrodiol dehydrogenase 3; Dihydrodiol dehydrogenase type I; HA1753; HSD17B5; KIAA0119; PGFS; Prostaglandin F synthase; Testosterone 17-beta-dehydrogenase 5; 2.7.11.1; eIF-2A protein kinase 2; Eukaryotic translation initiation factor 2-alpha kinase 2; Interferon-inducible RNA-dependent protein kinase; P1/eIF-2A protein kinase; p68 kinase; PKR; PRKR; Protein kinase R; Protein kinase RNA-activated; Tyrosine-protein kinase EIF2AK2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.-; 7.6.2.3; Anthracycline resistance-associated protein; ARA; MOAT-E; MRP6; Multi-specific organic anion transporter E; Multidrug resistance-associated protein 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; 7.6.2.3; MRP8; Multidrug resistance-associated protein 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP","Prostaglandin G/H synthase 2; Phospholipase A2, membrane associated; Human Cyclooxygenases; Prostaglandin G/H synthase 1; Prostaglandin reductase 2; Peroxisome proliferator-activated receptor gamma; Lactoylglutathione lyase; Prostaglandin D2 receptor 2; Peroxisome proliferator-activated receptor alpha; Aldo-keto reductase family 1 member C3; Interferon-induced, double-stranded RNA-activated protein kinase", C01EB03; M01AB01; M01AB51; M02AA23; S01BC01;C01EB03;S01CC02
ipratropium,Asthma;Bronchial hyperreactivity;Bronchitis chronic;Bronchospasm;Chronic obstructive pulmonary disease;Common cold;Emphysema;Glaucoma;Hypersensitivity;Nasal congestion;Nasopharyngitis;Obstructive chronic bronchitis;Postnasal drip;Reversible airways obstruction;Rhinitis;Rhinitis perennial;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Sneezing;Upper-airway cough syndrome,Abdominal discomfort;Abdominal pain;Abnormal vision;Accommodation disorder;Acute angle-closure glaucoma;Acute glaucoma;Anaphylactic shock;Angioedema;Angle closure glaucoma;Arthritis;Asthenia;Asthma;Atrial fibrillation;Back pain;Bad taste;Breast feeding;Bronchial hyperreactivity;Bronchitis;Bronchoconstriction;Bronchospasm;Bronchospasm aggravated;Bronchospasm paradoxical;COPD exacerbation;Cardiac disorder;Cardiovascular disorder;Chest pain;Chronic obstructive pulmonary disease;Congenital anomaly;Conjunctival hyperaemia;Conjunctivitis;Constipation;Corneal oedema;Cough;Dermatitis;Developmental delay;Diarrhoea;Disorder sight;Distress gastrointestinal;Dizziness;Dry mouth;Dry throat;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Emotional distress;Epistaxis;Eye disorder;Eye irritation;Eye pain;Fatigue;Flatulence;Flu symptoms;Flushing;Foetal damage;Gastrointestinal disorder;Gastrointestinal motility disorder;Gastrointestinal pain;Generalized urticaria;Glaucoma;Glaucoma both eyes;Haemoglobin;Haemorrhage;Halo vision;Headache;Heart rate irregular;Hoarseness;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertension worsened;Hypoaesthesia;Hypotension;Immune system disorder;Increased bronchial secretion;Infection;Inflammation;Influenza;Influenza like illness;Influenza-like symptoms;Insomnia;Intestinal obstruction;Intraocular pressure increased;Laryngospasm;Local reaction;Lung disorder;Mediastinal disorder;Musculoskeletal discomfort;Myalgia;Mydriasis;Nasal burning;Nasal congestion;Nasal discomfort;Nasal dryness;Nasal irritation;Nasal itching;Nasal mucus blood tinged;Nasal oedema;Nasal polyps;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Numbness in leg;Oedema;Oedema mouth;Oropharyngeal swelling;Pain;Palpitations;Paraesthesia;Pharyngeal oedema;Pharyngitis;Pollakiuria;Pregnancy;Prostatomegaly;Pruritus;Rash;Rhinitis;Salivary hypersecretion;Sinusitis;Skin disorder;Somnolence;Sputum increased;Status asthmaticus;Stomatitis;Supraventricular tachycardia;Sweating;Swelling;Swollen tongue;Tachycardia;Taste bitter;Tension;Thirst;Throat irritation;Tinnitus;Tongue disorder;Tongue oedema;Tremor;Type I hypersensitivity;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vision blurred;Visual impairment;Vomiting;Wheezing,small molecule,approved; experimental,bromuro de ipratropio; Ipratropium cation; Ipratropium ion; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H,Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2, R01AX03; R03AL01; R03AL02;R01AX03;R03BB01
irbesartan,Angina pectoris;Angina unstable;Blood magnesium decreased;Cardiac failure;Chronic renal insufficiency;Diabetes mellitus;Diabetic;Diabetic nephropathy;Essential hypertension;Foetor hepaticus;Hepatic impairment;Hepatocellular injury;Hyperkalaemia;Hypertension;Hypertensive;Liver disorder;Mg reduced;Microalbuminuria;Nephropathy;Protein urine present;Proteinuria;Rebound effect;Renal aplasia;Renal failure;Renal failure chronic;Renal impairment;Renal vessel disorder;Single functional kidney;Type 2 diabetes mellitus;Unilateral renal agenesis,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal faeces;Abnormalities of the hair;Acute coronary syndrome;Affect lability;Agitation;Agranulocytosis;Anaemia;Anaphylactic shock;Angiitis necrotising;Angina pectoris;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Asthenia;Asthma;Atrial rhythm;Bad taste;Blindness;Blood creatine phosphokinase increased;Blood pressure increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone pain;Bradycardia;Breast disorder;Breast feeding;Brown urine;Bursitis;Cardiac disorder;Cardiac murmur;Cardio-respiratory arrest;Cerebrovascular accident;Chest pain;Chills;Chromaturia;Chronic renal insufficiency;Common cold;Conduction disorder;Conjunctivitis;Connective tissue disorder;Constipation;Coordination abnormal;Coordination disturbance;Cough;Cramp muscle;Creatine phosphokinase increased;Cutaneous vasculitis;Decreased appetite;Dermatitis;Diabetes mellitus;Diabetic;Diarrhoea;Discomfort;Distention;Dizziness;Dizziness postural;Drug interaction;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Ear infection;Ear pain;Ecchymosis;Electrolyte imbalance;Emotional disorder;Emotional disturbance NOS;Epigastric discomfort;Epigastric pain;Epistaxis;Erythema;Erythema facial;Essential hypertension;Excitement;Face oedema;Fatigue;Feeling abnormal;Feeling cold;Feeling hot;Flatulence;Flushing;Gastric irritation;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;General disorders and administration site conditions;Glycosuria;Gout;Haemolytic anaemia;Hair disorder;Headache;Heartburn;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hot flush;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertensive crisis;Hyperuricaemia;Hypoaesthesia;Hypokalaemia;Hyponatraemia;Hypotension;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Influenza;Injury;Inner ear disorder;Jaundice;Jaundice cholestatic;Joint stiffness;Labyrinthine disorder;Leukocytoclastic vasculitis;Leukopenia;Lightheadedness;Limb paresis;Liver function test abnormal;Local swelling;Localised oedema;Loss of consciousness;Lymphopenia;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Monoparesis;Mood swings;Muscle atrophy;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Myositis;Nasopharyngitis;Nausea;Neck oedema of;Nephritis interstitial;Nephropathy;Nervous system disorder;Nervousness;Neutropenia;Numbness;Oedema;Oedema peripheral;Oesophagitis;Oral disorder;Oral lesion;Orthostatic hypotension;Pain;Pancreatitis;Paraesthesia;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pneumonia;Prostatic disorder;Protein urine present;Proteinuria;Pruritus;Pulmonary congestion;Pulmonary oedema;Raised liver function tests;Rash;Reflexes abnormal;Renal failure;Renal failure chronic;Renal impairment;Respiratory distress;Respiratory tract congestion;Rhabdomyolysis;Rhinitis;Rhinitis seasonal;Rhythm idioventricular;Seasonal allergy;Sensation of warmth;Sensory loss;Sexual dysfunction;Shock;Sialoadenitis;Skin discomfort;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Stiffness;Stress;Swelling;Swelling of limb;Syncope;Tachycardia;Tenderness;Tension;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tracheobronchitis;Transient ischaemic attack;Trauma;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper limb oedema;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vasculitis;Vasculitis necrotising;Ventricular arrhythmia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight increased;Wheezing;Xanthopsia,small molecule,approved; investigational,"2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; Irbesartan; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; Activator protein 1; AP1; p39; Proto-oncogene c-Jun; Transcription factor AP-1 subunit Jun; V-jun avian sarcoma virus 17 oncogene homolog; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2",Type-1 angiotensin II receptor; Transcription factor Jun, C09DA04; C09DB05; C09DX07;C09CA04
irinotecan,Ascites;Carcinoma of lung;Cardiac disorder;Cervix carcinoma;Colorectal cancer;Colorectal cancer metastatic;Dehydration;Diarrhoea;Dyspnoea;Glioma;Hepatic cancer metastatic;Lung neoplasm malignant;Lymphoma;Malignant neoplasm of esophagus;Malignant neoplasm of pancreas;Mesothelioma;Metastases to liver;Metastatic carcinoma;Metastatic neoplasm;Neoplasm;Neoplasm malignant;Neutropenia;Non-Hodgkin's lymphoma;Oesophageal carcinoma;Pancreatic carcinoma;Pleural effusion;Solid tumour,Abdominal cramps;Abdominal distension;Abdominal pain;Accidental injury;Acute coronary syndrome;Acute leukaemia;Akathisia;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angiopathy;Anorectal disorder;Anorexia;Arrhythmia;Arterial thrombosis;Aspartate aminotransferase increased;Asthenia;Back pain;Bilirubin abnormal;Blacked-out (not amnesia);Blood alkaline phosphatase increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood creatinine increased;Body temperature increased;Bradycardia;Caecitis;Cardiac arrest;Cardiac disorder;Cerebral infarction;Cerebrovascular accident;Chills;Cholinergic syndrome;Colitis;Colitis ischaemic;Colitis ulcerative;Colon cancer;Confusional state;Connective tissue disorder;Constipation;Cough;Cough increased;Cramp muscle;Decreased appetite;Dehydration;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Dysarthria;Dyspepsia;Dyspnoea;Electrolyte imbalance;Embolism;Embolus leg;Enlargement abdomen;Extravasation;Fatigue;Febrile neutropenia;Feeling abnormal;Flatulence;Flushing;Frequent bowel movements;Gait disturbance;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Genetic polymorphism;Haemoglobin;Haemorrhage;Hand and foot syndrome secondary to sickle cell anaemia;Hand rash;Headache;Hepatic cancer metastatic;Hepatomegaly;Hiccups;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypokalaemia;Hypokinesia;Hypomagnesaemia;Hyponatraemia;Hypotension;Hypotension orthostatic symptomatic;Hypovolaemia;Ileus;Ill-defined disorder;Immune system disorder;Infection;Injury;Insomnia;Intestinal obstruction;Intestinal perforation;Ischaemia;Jaundice;Lacrimation;Lacrimation increased;Leukopenia;Lipase increased;Loss of consciousness;Lung cancer metastatic;Lung disorder;Lung infiltration;Lung neoplasm;Lymphopenia;Malaise;Mediastinal disorder;Megacolon;Megacolon toxic;Metastases to liver;Miosis;Mucosal inflammation;Muscle spasms;Myocardial infarction;Myocardial ischaemia;Nausea;Neoplasm;Neoplasm malignant;Nervous system disorder;Neutropenia;Neutropenic colitis;Neutropenic enterocolitis;Neutropenic infection;Neutropenic sepsis;Oedema;Orthostatic hypotension;Osteoarthritis;Pain;Palmar-plantar erythrodysaesthesia syndrome;Pancreatitis;Paraesthesia;Peripheral embolism;Peripheral vascular disorder;Phosphatase alkaline increased;Piloerection;Pneumonia;Proctocolitis;Pulmonary embolism;Rash;Rectal disorder;Renal failure;Renal failure acute;Renal impairment;Rhinitis;Salivary hypersecretion;Salivation;Sepsis;Serum creatinine increased;Shock;Sickness;Somnolence;Speech disorder;Stomatitis;Sudden death;Sweating;Sweating increased;Syncope;Thrombocytopenia;Thromboembolic event;Thrombophlebitis;Thrombosis;Toxicity to various agents;Tumour lysis syndrome;Ulcer;Upper respiratory tract infection;Vasodilation;Vasodilation procedure;Vertigo;Visual disturbance;Visual impairment;Vomiting;Weight decreased,small molecule,approved; investigational,"(+)-Irinotecan; (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-1H-indol-1-yl)ethyl)piperidine-1-carboxylate; Irinotecan; Irinotecan lactone; Irinotecan liposome injection; Irinotecanum; 5.6.2.1; TOP1mt; 5.6.2.1; DNA topoisomerase I; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 3.1.1.84; Carboxylesterase 2; CE-2; hCE-2; ICE; Methylumbelliferyl-acetate deacetylase 2; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2","DNA topoisomerase I, mitochondrial; DNA topoisomerase 1",L01CE02;L01XX19
isocarboxazid,"Agitation;Anxiety;Anxious mood;Asthenia;Bradyphrenia;Bradypsychic response;Cerebration impaired;Decreased interest;Depressed mood;Disturbance in attention;Dysphoria;Fatigue;Feeling guilty;Hypersomnia;Insomnia;Major depression;Major depressive disorder, single episode;Mental disability;Panic reaction;Suicidal ideation;Suicide attempt",Agitation;Akathisia;Amblyopia;Ataxia;Black hairy tongue;Chills;Coma;Constipation;Diarrhoea;Dizziness;Drowsiness;Dry mouth;Dysuria;Erectile dysfunction;Euphoric mood;Forgetfulness;Hallucination;Headache;Hyperhidrosis;Hyperkinesia;Inappropriate antidiuretic hormone secretion;Incontinence;Lethargy;Loss of consciousness;Memory impairment;Myoclonus;Nausea;Neuritis;Neuropathy peripheral;Orthostatic hypotension;Palpitations;Paraesthesia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Sensation of heaviness;Shock;Sleep disorder;Sleep disturbance;Somnolence;Sweating;Syncope;Telangiectasia;Tongue discolouration;Tremor;Urinary hesitation;Urinary retention,small molecule,approved,Isocarboxazid; Isocarboxazida; Isocarboxazide; Isocarboxazidum; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B,Amine oxidase [flavin-containing] A; Amine oxidase [flavin-containing] B,N06AF01
isoflurane,Diabetes mellitus;Diabetic,Agitation;Arrhythmia;Body temperature increased;Breath holding;Breath holding attack;Bronchospasm;Carbon dioxide increased;Cardiac arrest;Cardiac disorder;Chills;Cough;Delirium;Dermatitis;Excitement;Hallucination;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hiccups;Hypercapnia;Hyperglycaemia;Hyperkalaemia;Hypotension;Ileus;Jaundice;Laryngospasm;Liver injury;Muscle rigidity;Nausea;Necrosis;Postoperative ileus;Pulmonary function test decreased;Rash;Respiratory depression;Rhythm idioventricular;Salivary hypersecretion;Salivation;Shivering;Traumatic liver injury;Ventricular arrhythmia;Vomiting,small molecule,approved; vet_approved,"1-chloro-2,2,2-trifluoroethyl difluoromethyl ether; Isoflurane; Isoflurano; Isofluranum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; 7.2.2.10; ATP-dependent Ca(2+) pump PMR1; ATPase 2C1; Ca(2+)/Mn(2+)-ATPase 2C1; KIAA1347; PMR1L; Secretory pathway Ca(2+)-transporting ATPase type 1; SPCA1; Glycine receptor 48 kDa subunit; Glycine receptor strychnine-binding subunit; AMPA-selective glutamate receptor 1; GLUA1; GLUH1; GluR-1; GluR-A; GluR-K1; GLUR1; Glutamate receptor ionotropic, AMPA 1; Voltage-gated K(+) channel HuKI; Voltage-gated potassium channel HBK1; Voltage-gated potassium channel subunit Kv1.1; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; ATP synthase F1 subunit delta; ATP5D; F-ATPase delta subunit; NACRA4; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 7.1.1.2; MTND1; NADH dehydrogenase subunit 1; NADH1; ND1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J","Gamma-aminobutyric acid receptor subunit alpha-1; Calcium-transporting ATPase type 2C member 1; Glycine receptor subunit alpha-1; Glutamate receptor 1; Potassium voltage-gated channel subfamily A member 1; GABA(A) Receptor; ATP synthase subunit delta, mitochondrial; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2; Calmodulin",N01AB06
isoniazid,Active tuberculosis;Carcinoma;Chronic peptic ulcer;Diabetes mellitus;Extrapulmonary tuberculosis;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Immunodeficiency;Induration;Infection;Leukaemia;Low income;Malabsorption;Malnutrition;Neoplasm malignant;Peptic ulcer;Renal failure chronic;Silicosis;Skin test positive;Skin test reaction;Tuberculosis;Ulcer;Weight decreased,Agranulocytosis;Anorexia;Aplastic anaemia;Asthenia;Atrophy;Body temperature increased;Convulsion;Decreased appetite;Diabetes mellitus;Diabetic;Discomfort;Distress;Dyspepsia;Emotional distress;Eosinophilia;Epigastric distress;Eruption;Fatigue;Feeling abnormal;Gastrointestinal disorder;Gynaecomastia;Hepatic function abnormal;Hepatitis;Hepatitis symptom;Hepatocellular injury;Hyperbilirubinaemia;Hyperglycaemia;Hypersensitivity;Ill-defined disorder;Jaundice;Liver injury;Lymphadenopathy;Malaise;Malaise and fatigue;Memory impairment;Metabolic acidosis;Nausea;Neuritis;Neuropathy peripheral;Neurotoxicity;Nicotinic acid deficiency;Optic neuritis;Paraesthesia;Paraesthesia foot;Psychotic disorder;Pyridoxine deficiency;Rash;Reaction gastrointestinal;Systemic lupus erythematosus;Thrombocytopenia;Toxic encephalopathy;Vasculitis;Vitamin B6 deficiency;Vomiting,small molecule,approved; investigational,"4-pyridinecarbohydrazide; INH; Isoniazid; Isoniazida; Isonicotinic acid hydrazide; Isonicotinic hydrazide; Isonicotinohydrazide; Isonicotinoylhydrazide; Isonicotinsäurehydrazid; Isonicotinylhydrazine; Pyridine-4-carboxylic acid hydrazide; 1.11.1.21; CP; Peroxidase/catalase; 1.3.1.9; ENR; FAS-II enoyl-ACP reductase; NADH-dependent 2-trans-enoyl-ACP reductase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.5.1.3; dfrA; 2.3.1.5; AAC2; Arylamide acetylase 2; N-acetyltransferase type 2; N-hydroxyarylamine O-acetyltransferase; NAT-2; PNAT; Polymorphic arylamine N-acetyltransferase; 2.3.1.5; NAT; nhoA; tbnat; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Catalase-peroxidase; Enoyl-[acyl-carrier-protein] reductase [NADH]; Cytochrome P450 2C8; Cytochrome P450 1A2; Cytochrome P450 3A4; Cytochrome P450 2C19; Dihydrofolate reductase, J04AC01; J04AC51; J04AM01; J04AM02; J04AM03; J04AM05; J04AM06; J04AM07; J04AM08;J04AC01;J04AM04
isosorbide,Acute myocardial infarction;Angina decubitus;Angina pectoris;Angina unstable;Arteriosclerosis coronary artery;Cardiac failure congestive;Coronary artery disease;Left ventricular failure;Myocardial ischaemia;Prinzmetal angina;Pulmonary oedema;Stable angina pectoris,Angina pectoris;Angina unstable;Bradycardia;Dermatitis;Dermatitis exfoliative;Dizziness;Flushing;Haemolytic anaemia;Headache;Hypotension;Hypotensive;Lightheadedness;Loss of consciousness;Methaemoglobinaemia;Nausea;Oedema peripheral;Rash;Rebound hypertension;Reflex tachycardia;Shock;Syncope;Tachycardia;Vomiting;Withdrawal hypertension,small molecule,approved; investigational,Isosorbide; 4.6.1.2; GCS-alpha-1; GCS-alpha-3; Guanylate cyclase soluble subunit alpha-3; GUC1A3; GUCSA3; GUCY1A3; Soluble guanylate cyclase large subunit; 4.6.1.2; GCS-alpha-2; GUC1A2; GUCSA2; 4.6.1.2; GCS-beta-1; GCS-beta-3; Guanylate cyclase soluble subunit beta-3; GUC1B3; GUCSB3; GUCY1B3; Soluble guanylate cyclase small subunit; 4.6.1.2; GCS-beta-2,Guanylate cyclase,C01DA08
isradipine,Hypertension;Hypertensive,Abdominal discomfort;Acute coronary syndrome;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anxiety;Arthralgia;Asthenia;Atrial fibrillation;Back pain;Bradycardia;Breast disorder;Cardiac disorder;Cardiac failure;Cerebrovascular accident;Chest pain;Connective tissue disorder;Constipation;Cough;Cramp muscle;Decreased appetite;Depression;Dermatitis;Dermatitis atopic;Diarrhoea;Digestion impaired;Discomfort;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Dyspnoea;Erectile dysfunction;Eye disorder;Fatigue;Feeling abnormal;Fluid retention;Flushing;Gastrointestinal disorder;Gingival hyperplasia;Gynaecomastia;Headache;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hypoaesthesia;Hypotension;Ill-defined disorder;Immune system disorder;Insomnia;Lethargy;Leukopenia;Libido decreased;Liver function test abnormal;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Nocturia;Numbness;Oedema;Oedema peripheral;Oropharyngeal discomfort;Oropharyngeal pain;Pain in extremity;Palpitations;Paraesthesia;Photosensitivity reaction;Pollakiuria;Polyuria;Pruritus;Raised liver function tests;Rash;Sensory loss;Shock;Skin disorder;Somnolence;Syncope;Tachycardia;Tension;Throat sore;Thrombocytopenia;Tingling sensation;Transient ischaemic attack;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;Ventricular arrhythmia;Ventricular fibrillation;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight increased,small molecule,approved; investigational,"Isradipine; Isradipino; Isradipinum; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; Low-voltage-activated calcium channel alpha1 3.2 subunit; Voltage-gated calcium channel subunit alpha Cav3.2; KIAA0558; Voltage-gated calcium channel subunit alpha-2/delta-2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent calcium channel subunit alpha-2/delta-1; Voltage-dependent L-type calcium channel subunit beta-2; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent calcium channel subunit alpha-2/delta-2; Voltage-dependent L-type calcium channel subunit alpha-1D; Voltage-dependent L-type calcium channel subunit alpha-1S,C08CA03
itraconazole,Acquired immunodeficiency syndrome;Aspergillosis;Aspergillus infection;Autoimmune disorder;Azotaemia;Blastomycosis;Body temperature increased;Body tinea;Bronchopulmonary aspergillosis;Candida infection;Chromoblastomycosis;Chronic pulmonary histoplasmosis;Cystic fibrosis;Drug intolerance;Foetor hepaticus;Fungal infection;Fungal skin infection;Hepatic enzyme abnormal;Hepatic impairment;Hepatocellular injury;Histoplasmosis;Immunocompromised;Immunodeficiency;Infection;Invasive bronchopulmonary aspergillosis;Keratitis fungal;Liver disorder;Lung disorder;Oesophageal candidiasis;Onychomycosis;Oral candidiasis;Oropharyngeal candidiasis;Paracoccidioides infection;Renal failure;Renal impairment;Septic arthritis streptobacillus;Skin infection;Sporotrichosis;Streptobacillary fever;Systemic candida;Tinea cruris;Tinea infection;Tinea pedis;Tinea versicolour;Uremia;Vulvovaginal candidiasis,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal vision;Acute generalised exanthematous pustulosis;Acute hepatic failure;Adrenal insufficiency;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Anxiety;Application site reaction;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Bacteriuria;Bladder pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood triglycerides increased;Blood urea increased;Body temperature increased;Breast disorder;Breast pain;Breast pain male;Bronchial hyperreactivity;Bronchitis;Bronchospasm;Bursitis;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiovascular disorder;Chest pain;Chills;Chronic obstructive pulmonary disease;Confusional state;Congenital anomaly;Connective tissue disorder;Constipation;Cough;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Depression;Dermatitis;Dermatitis exfoliative;Developmental delay;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug interaction;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Ear and labyrinth disorders;Electrocardiogram abnormal;Encephalocele;Epigastric pain;Erectile dysfunction;Erythema multiforme;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Flatulence;Fluid overload;Fluid retention;Foetor hepaticus;Fungal infection;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gingivitis;Gynaecomastia;Haematuria;Haemorrhoids;Headache;Hearing impaired;Heartburn;Hepatic enzyme abnormal;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatic impairment;Hepatic insufficiency;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Herpes zoster;Hot flush;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypoaesthesia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hypophosphataemia;Hypotension;Ill-defined disorder;Immune system disorder;Implant site reaction;Implantation complication;Increased appetite;Increased bronchial secretion;Infection;Infestation;Infestation NOS;Injection site inflammation;Inner ear disorder;Insomnia;Jaundice;Kidney function abnormal;Labyrinthine disorder;Lactic dehydrogenase activity increased;Laryngeal pain;Left ventricular failure;Leukocytoclastic vasculitis;Leukopenia;Libido decreased;Liver disorder;Liver function test abnormal;Liver injury;Loss of consciousness;Lung disorder;Lung infiltration;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Menstrual disorder;Mental disorder;Mouth ulceration;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Neuropathy;Neuropathy peripheral;Neutropenia;Oedema;Oedema peripheral;Onychomycosis;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Pain;Pancreatitis;Paraesthesia;Pharyngitis;Pharyngolaryngeal pain;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pneumocystis carinii infection;Pneumocystis jirovecii infection;Pneumonia;Pollakiuria;Pruritus;Pulmonary oedema;Rash;Rash erythematous;Renal failure;Renal impairment;Rhinitis;Rigors;Serum creatinine increased;Serum sickness;Shock;Sinus bradycardia;Sinusitis;Skin disorder;Somnolence;Sputum increased;Stevens-Johnson syndrome;Sweating increased;Syncope;Tachycardia;Teratogenicity;Throat sore;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tremor;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urine analysis abnormal;Urticaria;Vasculitis;Vein disorder;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased,small molecule,approved; investigational,"(±)-1-SEC-BUTYL-4-(P-(4-(P-(((2R*,4S*)-2-(2,4-DICHLOROPHENYL)-2-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)-1-PIPERAZINYL)PHENYL)-.DELTA.(SUP 2)-1,2,4-TRIAZOLIN-5-ONE; 3H-1,2,4-TRIAZOL-3-ONE, 4-(4-(4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)-1-PIPERAZINYL)PHENYL)-2,4-DIHYDRO-2-(1-METHYLPROPYL)-; Itraconazol; Itraconazole; ITRACONAZOLE COMPONENT OF SUBA-ITRACONAZOLE; Itraconazolum; Oriconazole; 1.14.14.154; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; Sterol 14-alpha demethylase; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9",Lanosterol 14-alpha demethylase; Lanosterol 14-alpha demethylase,J02AC02
ketamine,Glaucoma;Hypotonia;Muscle relaxation;Visceral pain,Airway obstruction NOS;Anaphylactic shock;Anorexia;Apnoea;Arrhythmia;Bladder pain;Bradycardia;Clonic movements;Clonus;Convulsion;Cystitis;Cystitis noninfective;Decreased appetite;Dermatitis;Diplopia;Epilepsy;Erythema;Hypotension;Laryngospasm;Muscle twitching;Nausea;Nystagmus;Obstructive airways disorder;Pain;Pulmonary function test decreased;Rash;Rash morbilliform;Respiratory depression;Salivary hypersecretion;Shock;Vision blurred;Vomiting,small molecule,approved; vet_approved,"(+-)-Ketamine; (±)-ketamine; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone; 2-(methylamino)-2-(2-chlorophenyl)cyclohexanone; 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone; DL-ketamine; Ketamina; Ketamine; Kétamine; Ketaminum; NMDA; Special K; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; NACHRA7; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 1.14.13.39; bNOS; Constitutive NOS; N-NOS; NC-NOS; Neuronal NOS; Nitric oxide synthase, brain; nNOS; NOS type I; Peptidyl-cysteine S-nitrosylase NOS1; NK-1 receptor; NK-1R; NK1R; SPR; TAC1R; Tachykinin receptor 1; Dopamine D2 receptor; D-OR-1; DOR-1; OPRD; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; K-OR-1; KOR-1; OPRK; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase","Glutamate receptor ionotropic, NMDA 3A; 5-hydroxytryptamine receptor 3A; Neuronal acetylcholine receptor subunit alpha-7; Cholinesterase; Nitric oxide synthase 1; Substance-P receptor; D(2) dopamine receptor; Delta-type opioid receptor; Sodium-dependent noradrenaline transporter; Kappa-type opioid receptor; Mu-type opioid receptor; Muscarinic acetylcholine receptor; 5-hydroxytryptamine receptor 2; 5-hydroxytryptamine receptor 1",N01AX03
ketoconazole,Blastomycosis;Body tinea;Candida infection;Candiduria;Chromoblastomycosis;Chronic mucocutaneous candidiasis;Coccidioidomycosis;Dandruff;Fungal infection;Histoplasmosis;Infection;Meningitis fungal;Mucocutaneous candidiasis;Oral candidiasis;Paracoccidioides infection;Pityriasis;Seborrhoeic dermatitis;Skin candida;Tinea cruris;Tinea infection;Tinea pedis;Tinea versicolour,Abdominal pain;Abdominal pain upper;Accidental exposure to product;Accidental ingestion;Acute generalised exanthematous pustulosis;Alcohol intolerance;Allergic conditions;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Application site burn;Application site pain;Application site reaction;Arrhythmia;Arthralgia;Asthenia;Azoospermia;Blood and lymphatic system disorders;Blood triglycerides increased;Body temperature increased;Breast disorder;Burning sensation;Chills;Connective tissue disorder;Constipation;Decreased appetite;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Electrocardiogram QT prolonged;Endocrine disorder;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Eye disorder;Eye irritation;Eye swelling;Fatigue;Feeling abnormal;Feeling hot;Flatulence;Fontanelle bulging;Gastrointestinal disorder;Gastrointestinal pain;Gynaecomastia;Haemolytic anaemia;Hair colour changes;Hair discoloration;Hair texture abnormal;Headache;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hepatotoxicity;Hot flush;Hyperlipidaemia;Hypersensitivity;Hypertriglyceridaemia;Ill-defined disorder;Immune system disorder;Impetigo;Increased appetite;Insomnia;Intracranial pressure increased;Jaundice;Keratoconjunctivitis sicca;Leukopenia;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Menstrual disorder;Mental disorder;Musculoskeletal discomfort;Myalgia;Nail discolouration;Nausea;Nervous system disorder;Nervousness;Oedema peripheral;Oily hair;Oligospermia;Optic neuritis;Orthostatic hypotension;Pain;Papilloedema;Paraesthesia;Photophobia;Photosensitivity;Photosensitivity reaction;Platelet count decreased;Pruritus;Pustule;Pyogenic granuloma;Rash;Rash pustular;Seborrhoeic dermatitis;Sensitisation;Skin burning sensation;Skin disorder;Skin irritation;Somnolence;Stinging;Swelling;Swelling face;Tension;Thrombocytopenia;Tongue discolouration;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Ventricular arrhythmia;Vomiting;Warmth;Xeroderma,small molecule,approved; investigational,"Ketoconazol; Ketoconazole; Ketoconazolum; Ketozole; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; Sterol 14-alpha demethylase; 1.14.14.19; 17-alpha-hydroxyprogesterone aldolase; CYP17; CYPXVII; Cytochrome P450 17A1; Cytochrome P450-C17; Cytochrome P450c17; S17AH; Steroid 17-alpha-monooxygenase; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; 1.14.14.16; 21-OHase; CYP21; CYP21B; Cytochrome P-450c21; Cytochrome P450 21; Cytochrome P450 XXI; Cytochrome P450-C21; Cytochrome P450-C21B; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; CAR; Constitutive activator of retinoid response; Constitutive active response; Constitutive androstane receptor; Orphan nuclear receptor MB67; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.14.14.1; CYPIVF12; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.14.14.1; 20-HETE synthase; 20-hydroxyeicosatetraenoic acid synthase; Arachidonic acid omega-hydroxylase; CYPIVF2; Cytochrome P450-LTB-omega; Docosahexaenoic acid omega-hydroxylase; Leukotriene-B(4) 20-monooxygenase 1; Leukotriene-B(4) omega-hydroxylase 1; Phylloquinone omega-hydroxylase CYP4F2; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP","Lanosterol 14-alpha demethylase; Lanosterol 14-alpha demethylase; Steroid 17-alpha-hydroxylase/17,20 lyase; Androgen receptor; Steroid 21-hydroxylase; Voltage-gated inwardly rectifying potassium channel KCNH2; Nuclear receptor subfamily 1 group I member 2; Nuclear receptor subfamily 1 group I member 3", D01AC08; G01AF20; H02CA03; J02AB02;D01AC08;G01AF11
ketoprofen,Ankylosing spondylitis;Arthralgia;Arthritis;Back pain;Bursitis;Capsulitis;Contusion;Dysmenorrhoea;Fibromyalgia;Gout;Inflammation;Ligament sprain;Low back pain;Musculoskeletal discomfort;Osteoarthritis;Osteoarthritis of cervical spine;Pain;Periarthritis;Post-traumatic pain;Postoperative pain;Primary dysmenorrhea;Procedural pain;Rheumatoid arthritis;Sciatica;Spinal osteoarthritis;Spondylitis;Sports injury;Sprain;Swelling;Synovitis;Tendonitis,Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Affective disorder;Agranulocytosis;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Anorectal discomfort;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Asthenia;Asthma;Asthmatic attack;Blood urea increased;Bronchospasm;Cardiac failure;Cardiac failure congestive;Chills;Colitis;Colitis ulcerative;Confusional state;Conjunctivitis;Constipation;Convulsion;Crohn's disease;Deafness;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dysgeusia;Dyspepsia;Dysphoria;Dyspnoea;Eczema;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flatulence;Flushing;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Gastrointestinal symptom NOS;Glossodynia;Gynaecomastia;Haematemesis;Haematuria;Haemolysis;Haemoptysis;Hallucination;Headache;Hearing impaired;Hepatic function abnormal;Hepatitis;Hepatitis cholestatic;Hyperhidrosis;Hypersensitivity;Hypertension;Hyponatraemia;Ill-defined disorder;Increased appetite;Infection;Insomnia;Intestinal ulcer;Jaundice;Kidney function abnormal;Laryngeal oedema;Localized erythema;Malaise;Melaena;Meningitis aseptic;Menometrorrhagia;Migraine;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Necrosis;Nephritis interstitial;Nephrotic syndrome;Nervousness;Nightmare;Oedema;Onycholysis;Palpitations;Pancreatitis;Paraesthesia;Peptic ulcer;Peripheral vascular disorder;Personality disorder;Pharyngitis;Photosensitivity;Photosensitivity reaction;Proctalgia;Proctocolitis;Pruritus;Purpura;Purpuric rash;Rash;Rash bullous;Reaction gastrointestinal;Rectal haemorrhage;Rectal tenesmus;Renal failure;Renal impairment;Retinal haemorrhage;Rhinitis;Salivary hypersecretion;Salivation;Sepsis;Septicemia;Shock;Sjogren's syndrome;Skin discolouration;Somnolence;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Sweating;Syndrome sicca;Tachycardia;Tension;Thirst;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Upper gastrointestinal symptoms;Urticaria;Vascular purpura;Vasodilation;Vasodilation procedure;Vertigo;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved; vet_approved,2-(3-Benzoylphenyl)propionic acid; 3-Benzoyl-alpha-methylbenzeneacetic acid; 3-Benzoyl-α-methylbenzeneacetic acid; 3-Benzoylhydratropic acid; Ketoprofen; Ketoprofeno; L'acide (benzoyl-3-phenyl)-2-propionique; m-Benzoylhydratropic acid; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; CDw128a; CMKAR1; CXC-R1; CXCR-1; High affinity interleukin-8 receptor A; IL-8 receptor type 1; IL-8R A; IL8RA; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2,Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1; C-X-C chemokine receptor type 1, M01AE53; M02AA10;M01AE03
ketorolac,Acute pain;Breakthrough pain;Conjunctivitis allergic;Eye pain;Eye pruritus;Haemoglobin;Haemorrhage;Inflammation;Injury;Pain;Postoperative pain;Procedural pain;Stinging;Trauma;Uterine cramps;Uterine spasm,Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal vision;Acute coronary syndrome;Agitation;Agranulocytosis;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Asthma;Azotaemia;Bladder pain;Bleeding time prolonged;Body temperature increased;Bradycardia;Bronchospasm;Cardiac failure congestive;Cataract;Cerebration impaired;Chest pain;Colitis ulcerative;Coma;Confusional state;Conjunctival hyperaemia;Conjunctivitis;Constipation;Convulsion;Corneal erosion;Corneal infiltrates;Corneal oedema;Corneal perforation;Corneal thinning;Cough;Crohn's disease;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Depressed level of consciousness;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Disturbance in attention;Dizziness;Drowsiness;Dry eye;Dry mouth;Dyspepsia;Dyspnoea;Dysuria;Ecchymosis;Eosinophilia;Epidermal necrosis;Epistaxis;Eructation;Erythema multiforme;Euphoric mood;Exacerbation of asthma;Excessive thirst;Extrapyramidal disorder;Extrapyramidal symptoms;Eye infection;Eye irritation;Feeling abnormal;Flank pain;Flatulence;Flushing;Gastritis;Gastrointestinal fullness;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Glossitis;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemolytic anaemia;Haemolytic uraemic syndrome;Haemorrhage;Hallucination;Headache;Hearing impaired;Heartburn;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hypersensitivity;Hypertension;Hyponatraemia;Hypotension;Ill-defined disorder;Increased appetite;Infection;Infertility;Infertility female;Inflammatory bowel disease;Injection site pain;Insomnia;Intraocular pressure increased;Iritis;Jaundice;Jaundice cholestatic;Keratitis;Kidney function abnormal;Lacrimation;Lacrimation increased;Laryngeal oedema;Leukopenia;Loss of consciousness;Lymphadenopathy;Malaise;Melaena;Meningitis aseptic;Mental disability;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nasal discomfort;Nasal pain;Nausea;Nephritis;Nephritis interstitial;Nervousness;Oedema;Oesophagitis;Oliguria;Pain;Pallor;Palpitations;Pancreatitis acute;Pancytopenia;Paraesthesia;Peptic ulcer;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Post procedural haemorrhage;Postoperative hemorrhage;Proctocolitis;Protein urine present;Proteinuria;Pruritus;Psychotic disorder;Pulmonary function test decreased;Pulmonary oedema;Purpura;Rash;Rash maculo-papular;Rectal haemorrhage;Renal failure;Renal failure acute;Renal impairment;Respiratory depression;Rhinalgia;Rhinitis;Sepsis;Shock;Somnolence;Stevens-Johnson syndrome;Stinging;Stomatitis;Stupor;Sweating;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Throat irritation;Thrombocytopenia;Tinnitus;Tongue disorder;Tongue oedema;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Ulcer;Ulcerative keratitis;Ulcerative stomatitis;Urinary retention;Urine output increased;Urticaria;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight increased;Wound haemorrhage,small molecule,approved,"Ketorolac; Kétorolac; Ketorolaco; Ketorolacum; rac-Ketorolac; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1, S01BC05; S01FB51;M01AB15
ketotifen,Asthma;Asthmatic attack;Conjunctivitis allergic;Inflammation,Abdominal pain;Bladder pain;Blood in stool;Body temperature increased;Conjunctival hyperaemia;Cystitis;Cystitis noninfective;Dermatitis;Diarrhoea;Dizziness;Drowsiness;Dry eye;Dry mouth;Epistaxis;Erythema multiforme;Eyelid disorder;Eyelid oedema;Gastrointestinal pain;Haematochezia;Headache;Hepatic enzyme increased;Hepatitis;Hypertension;Increased appetite;Infection;Insomnia;Irritability;Loss of consciousness;Nausea;Nervousness;Pain;Paraesthesia;Pruritus;Rash;Shock;Sleep disorder;Sleep disturbance;Somnolence;Stevens-Johnson syndrome;Stinging;Swelling of eyelid;Syncope;Tension;Thrombocytopenia;Tingling sensation;Urticaria;Vomiting;Weight increased,small molecule,approved,Ketotifen; Ketotifene; Ketotifeno; Ketotifenum; H1-R; H1R; HH1R; 1.1.1.44; PGDH; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; UDPGT 2B10,"Histamine H1 receptor; 6-phosphogluconate dehydrogenase, decarboxylating", R06AX17;R06AX17;S01GX08
labetalol,Angina pectoris;Asthma;Cardiac failure congestive;Hypertension;Renal failure;Renal impairment,Abdominal pain;Abdominal pain upper;Ache;Acute retention of urine;Affect lability;Agranulocytosis;Alopecia;Alopecia reversible;Amnesia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Ankle edema;Asthenia;Atrioventricular block;Block heart;Blood urea increased;Body temperature increased;Bradycardia;Bronchospasm;Bullous lichen planus;Cardiac failure;Catatonia;Colitis ischaemic;Collagen disorder;Confusional state;Constipation;Cramp muscle;Depressed mood;Depression;Dermatitis;Diarrhoea;Discomfort;Disorientation;Dizziness;Drowsiness;Drug effect increased;Drug eruption;Drug fever;Dry eye;Dyspepsia;Dyspnoea;Dysuria;Ejaculation failure;Epigastric pain;Epistaxis;Erectile dysfunction;Erythema;Erythema facial;Fatigue;Feeling abnormal;Flushing;Foot edema;Gastrointestinal pain;Hallucination;Headache;Hepatic necrosis;Hepatitis;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertensive;Hyperthyroidism;Hypoaesthesia;Hypoglycaemia;Hypotension;Hypotension orthostatic symptomatic;Ill-defined disorder;Increased effect;Intermittent claudication;Jaundice;Jaundice cholestatic;Joint swelling;Laryngospasm;Lethargy;Lichen planus;Liver function test abnormal;Local swelling;Loss of consciousness;Loss of libido;Lupus erythematosus;Malaise;Mental disorder;Mesenteric artery thrombosis;Metabolic disorder;Mood swings;Muscle spasms;Myopathy toxic;Nasal congestion;Nausea;Nightmare;Numbness;Oedema;Oedema peripheral;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Pain;Palpitations;Paraesthesia;Peyronie's disease;Pruritus;Psychotic disorder;Purpura non-thrombocytopenic;Raised liver function tests;Rash;Respiratory distress;Sensory loss;Shock;Short-term memory loss;Skin lesion;Sleep disorder;Sleep disturbance;Somnolence;Strangury;Sweating;Sweating increased;Syncope;Systemic lupus erythematosus;Throat sore;Thyrotoxicosis;Tingling sensation;Tremor;Urinary retention;Urticaria;Ventricular arrhythmia;Vertigo;Vision blurred;Visual impairment;Vomiting;Wheezing;Yawning,small molecule,approved,"3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide; Labétalol; Labetalol; Labetalolum; Labetolol; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ABCB5 P-gp; P-glycoprotein ABCB5",Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Alpha-1 adrenergic receptors, C07AG01; C07CG01;C07AG01;C07BG01
lactulose,Altered state of consciousness;Coma;Coma hepatic;Consciousness abnormal;Constipation;Constipation chronic;Depressed level of consciousness;Diarrhoea;Foetor hepaticus;Haemorrhoids;Hepatic encephalopathy;Hepatocellular injury;Intoxication;Liver disorder;Neuropsychiatric syndrome;Poisoning;Precoma;Soft stools,Abdominal discomfort;Abdominal distension;Anorexia;Cramp muscle;Decreased appetite;Dehydration;Diarrhoea;Distention;Eructation;Flatulence;Fluid loss;Gastrointestinal pain;Hypernatraemia;Hypokalaemia;Hyponatraemia;Increased thirst;Intestinal cramps;Muscle spasms;Nausea;Thirst;Vomiting,small molecule,approved,4-O-beta-D-Galactopyranosyl-D-fructofuranose; 4-O-beta-D-Galactopyranosyl-D-fructose; Lactulosa; Lactulose; Lactulosum; 3.2.1.23; Beta-gal; Lactase,Evolved beta-galactosidase subunit alpha, A06AD11;A06AD11;A06AD61
lamivudine,Alanine aminotransferase increased;Chronic hepatitis B;Cross resistance;Fibrosis;Foetor hepaticus;HBV DNA decreased;Hepatic failure;Hepatic insufficiency;Hepatitis B;Hepatitis B DNA decreased;Hepatitis B e antigen positive;Hepatitis B surface antigen positive;Hepatitis C;Hepatitis D;Hepatitis chronic active;Hepatitis viral;Hepatocellular injury;Immunodeficiency;Infection;Inflammation;Liver disorder;Pancreatitis;Pathogen resistance;Viral infection,Abdominal cramps;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Acidosis;Acne;Affect lability;Affective disorder;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Amblyopia;Amylase increased;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Aplasia pure red cell;Aplastic anaemia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Auricular swelling;Autoimmune disorder;Back pain;Basedow's disease;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood disorder;Blood triglycerides increased;Body odor;Body temperature increased;Bone disorder;Bone marrow depression;Breast enlargement;Breath sounds abnormal;Bronchitis;Buffalo hump;Cardiomyopathy;Chest pain;Chills;Chronic hepatitis;Completed suicide;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cough;Cramp muscle;Creatine phosphokinase increased;Deafness;Decreased appetite;Dehydration;Depression;Depressive disorder;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drug interaction;Dry mouth;Dysgeusia;Dyspepsia;Dyspeptic signs and symptoms;Dysphagia;Dysphonia;Dyspnoea;Dysthymic disorder;Dysuria;Epistaxis;Eructation;Erythema;Erythema multiforme;Fat redistribution;Fatigue;Feeling abnormal;Flatulence;Folliculitis;Fungal skin infection;Gas;Gastroenteritis;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal infection;Gastrointestinal pain;Gingival bleeding;Gynaecomastia;Headache;Hearing impaired;Hepatic steatosis;Hepatitis;Hepatitis B;Hepatitis C;Hepatobiliary disease;Hepatomegaly;Hoarseness;Hyperaesthesia;Hyperamylasaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlactacidaemia;Hyperpathia;Hypersensitivity;Hypertriglyceridaemia;Hypertrophy of breast;Hypoaesthesia;Hypoglycaemia;Hypotension;Hypoxemia;Hypoxia;Ill-defined disorder;Immune system disorder;Infection;Inflammation;Influenza;Injury;Insomnia;Insulin resistance;Jaundice;Lactic acidosis;Leukopenia;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Liver function test abnormal;Localised oedema;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Migraine;Mood swings;Mouth ulceration;Mucosal pigmentation;Muscle atrophy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myopathy;Nail pigmentation;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Oedema;Oedema auricular;Opportunistic infection;Oropharyngeal discomfort;Oropharyngeal pain;Other sleep disturbances;Pain;Pancreatic enzymes abnormal;Pancreatitis;Pancytopenia;Paraesthesia;Pharyngitis;Phlebitis;Photophobia;Pollakiuria;Polyuria;Pregnancy;Pruritus;Raised liver function tests;Rash;Rectal haemorrhage;Renal failure;Renal impairment;Respiration abnormal;Respiratory disorder;Respiratory tract infection;Rhabdomyolysis;Rhinitis;Rhinorrhoea;Sensitisation;Sepsis;Shock;Sickness;Sinusitis;Skin disorder;Skin infection;Skin odour abnormal;Sleep disorder;Somnolence;Splenomegaly;Stevens-Johnson syndrome;Stomatitis;Suicide;Suicide attempt;Sweating;Sweating increased;Syncope;Taste disorders;Tension;Thirst;Throat sore;Thrombocytopenia;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urinary hesitation;Urine output increased;Urticaria;Vasculitis;Vasodilation;Vasodilation procedure;Vertigo;Viral infection;Viral skin infection;Vomiting;Wheezing,small molecule,approved; investigational,"(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-2'-Deoxy-3'-thiacytidine; 2',3'-Dideoxy-3'-thiacytidine; 3'-Thia-2',3'-dideoxycytidine; 3TC; beta-L-2',3'-Dideoxy-3'-thiacytidine; beta-L-3'-Thia-2',3'-dideoxycytidine; Lamivudin; Lamivudina; Lamivudine; Lamivudinum; Pr160Gag-Pol; 2.7.7.7; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; 2.7.4.14; CK; CMK; CMPK; dCMP kinase; Deoxycytidylate kinase; Nucleoside-diphosphate kinase; UCK; UMK; UMP/CMP kinase; UMP/CMPK; UMPK; Uridine monophosphate/cytidine monophosphate kinase; 2.7.2.3; Cell migration-inducing gene 10 protein; PGKA; Primer recognition protein 2; PRP 2; 2.7.4.6; GAAD; Granzyme A-activated DNase; Metastasis inhibition factor nm23; NDK A; NDP kinase A; NDPKA; NM23; NM23-H1; Tumor metastatic process-associated protein; 2.7.4.6; C-myc purine-binding transcription factor PUF; Histidine protein kinase NDKB; NDK B; NDP kinase B; nm23-H2; NM23B; 2.7.7.15; CCT A; CCT-alpha; CT A; CTP:phosphocholine cytidylyltransferase A; CTPCT; PCYT1; Phosphorylcholine transferase A; 2.7.7.14; CTP:phosphoethanolamine cytidylyltransferase; Phosphorylethanolamine transferase; 3.1.3.-; Cytosolic 5',3'-pyrimidine nucleotidase; Deoxy-5'-nucleotidase 1; dNT-1; DNT1; UMPH2; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",Gag-Pol polyprotein; Reverse transcriptase/RNaseH; DNA; Protein P, J05AF05; J05AR01; J05AR02; J05AR04; J05AR05; J05AR07; J05AR11; J05AR12; J05AR13; J05AR16; J05AR24; J05AR25; J05AR28;J05AF05;J05AR27
lamotrigine,Affective disorder;Bipolar I disorder;Bipolar disorder;Convulsion;Convulsions generalised;Dysmenorrhoea;Epilepsy;Grand mal convulsion;Hepatic function abnormal;Hypomania;Lennox-Gastaut syndrome;Mania;Parkinson's disease;Parkinsonism;Partial seizures;Renal failure;Renal impairment;Tonic-clonic seizures,Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal ejaculation;Abscess;Accidental injury;Accommodation disorder;Acne;Action tremor;Acute coronary syndrome;Affect lability;Ageusia;Agitation;Agranulocytosis;Akathisia;Alanine aminotransferase increased;Alcohol intolerance;Alopecia;Altered state of consciousness;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaemia macrocytic;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anorgasmia;Anxiety;Anxiety depression;Apathy;Aphasia;Aphthous stomatitis;Aplasia pure red cell;Aplastic anaemia;Apnoea;Apraxia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrial fibrillation;Back pain;Balance disorder;Balanitis;Bipolar I disorder;Bipolar disorder;Bladder pain;Blepharitis;Blood disorder;Body temperature increased;Breast abscess;Breast feeding;Breast neoplasm;Breast pain;Breath odour;Bronchitis;Bronchospasm;Bursitis;CNS depression NOS;Cardiac arrest;Cardiac failure;Cerebellar syndrome;Cerebrovascular accident;Chest pain;Chills;Choreoathetosis;Clonic convulsion;Coma;Completed suicide;Confusional state;Conjunctivitis;Connective tissue disorder;Consciousness abnormal;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cramps of lower extremities;Cushing's syndrome;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Delirium;Delusion;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disseminated intravascular coagulation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug interaction;Drug reaction with eosinophilia and systemic symptoms;Drug withdrawal convulsions;Drug withdrawal syndrome;Dry eye;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphoria;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear pain;Ecchymosis;Eczema;Ejaculation disorder;Enlargement abdomen;Enterocolitis haemorrhagic;Eosinophilia;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Eye disorder;Eye pain;Face oedema;Facial pain;Fatigue;Feeling abnormal;Flat affect;Flatulence;Flushing;Fungal skin infection;Gait disturbance;Galactorrhoea;Gastric ulcer;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingival bleeding;Gingival hyperplasia;Gingivitis;Glossitis;Goitre;Grand mal convulsion;Haematemesis;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hemiplegia;Hemorrhagic colitis;Hepatic failure;Hepatitis;Herpes zoster;Hiccups;Hirsutism;Hostility;Hot flush;Hyperaesthesia;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperpathia;Hyperreflexia;Hypersensitive syndrome;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypokinesia;Hypomania;Hyporeflexia;Hypothyroidism;Hypotonia;Ill-defined disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Iron deficiency anaemia;Irritability;Keratitis;Laboratory test abnormal;Lacrimal disorder;Lacrimal structural disorder;Lactation female;Laryngeal pain;Leukocytosis;Leukoderma;Leukopenia;Libido decreased;Libido increased;Lip swelling;Liver function test abnormal;Loss of consciousness;Lupus erythematosus;Lymphadenopathy;Lymphocytosis;Malaise;Malnutrition;Mania;Mediastinal disorder;Melaena;Meningitis aseptic;Menopausal symptoms;Menorrhagia;Menstrual disorder;Mental disorder;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Movement disorder;Multi-organ failure;Muscle atrophy;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myocardial infarction;Myoclonus;Nail disorder;Nasal congestion;Nausea;Neck pain;Nephropathy;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuropathy peripheral;Neurosis;Neutropenia;Nocturia;Nystagmus;Oedema;Oedema peripheral;Oesophagitis;Oral pain;Organ failure;Orthostatic hypotension;Oscillopsia;Osteoarthritis;Pain;Palpitations;Pancreatitis;Pancytopenia;Panic attack;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Parkinson's disease;Parkinsonism;Parosmia;Penis disorder;Peptic ulcer;Personality disorder;Petechiae;Pharyngitis;Pharyngolaryngeal pain;Photophobia;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Pruritus;Psychotic disorder;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Red cell aplasia;Renal failure;Renal failure acute;Renal pain;Rhabdomyolysis;Rhinitis;Salivary hypersecretion;Scotoma;Seborrhoeic dermatitis;Shock;Sinusitis;Skin discolouration;Skin ulcer;Sleep disorder;Somnolence;Sore eye;Sore mouth;Speech disorder;Status epilepticus;Stevens-Johnson syndrome;Stomatitis;Stupor;Sudden unexplained death in epilepsy;Suicidal behaviour;Suicidal ideation;Suicide;Suicide attempt;Sweating;Syncope;Systemic lupus erythematosus;Tachycardia;Tendinous contracture;Tension;Thirst;Thrombocytopenia;Thrombophlebitis;Thrombosis;Tinnitus;Tongue disorder;Tongue oedema;Tooth disorder;Toxic epidermal necrolysis;Tremor;Unsteadiness;Urinary incontinence;Urinary retention;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Uveitis;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vasculitis;Vasodilation;Vasodilation procedure;Vertigo;Vesiculobullous rash;Vision blurred;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased;Weight increased;Withdrawal seizures;Yawning,small molecule,approved; investigational,"3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; Lamotrigina; Lamotrigine; Lamotriginum; BII; Brain calcium channel II; CACH6; CACNL1A6; Calcium channel, L type, alpha-1 polypeptide, isoform 6; Voltage-gated calcium channel subunit alpha Cav2.3; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; NAC1; SCN1; Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; HBA; HBSC II; NAC2; SCN2A1; SCN2A2; Sodium channel protein brain II subunit alpha; Sodium channel protein type II subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.2; KIAA1356; NAC3; Sodium channel protein brain III subunit alpha; Sodium channel protein type III subunit alpha; Voltage-gated sodium channel subtype III; Voltage-gated sodium channel subunit alpha Nav1.3; SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Atypical sodium channel Nav2.1; Nax channel; SCN6A; Sodium channel protein type VII subunit alpha; MED; Sodium channel protein type VIII subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.6; hNE-Na; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Sodium channel protein type IX subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.7; ADORA2; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D2 receptor; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; H1-R; H1R; HH1R; K-OR-1; KOR-1; OPRK; ACHRA; CHNRA; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; AMPA-selective glutamate receptor 1; GLUA1; GLUH1; GluR-1; GluR-A; GluR-K1; GLUR1; Glutamate receptor ionotropic, AMPA 1; 1.5.1.3; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1",Voltage-dependent R-type calcium channel subunit alpha-1E; Sodium channel protein type 11 subunit alpha; Voltage-gated sodium channel alpha subunit; Adenosine receptor A1; Adenosine receptor A2a; Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; Beta-1 adrenergic receptor; D(1) dopamine receptor; D(2) dopamine receptor; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site; Histamine H1 receptor; Kappa-type opioid receptor; Acetylcholine receptor subunit alpha; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 3A; Glutamate receptor 1,N03AX09
lansoprazole,Barrett's oesophagus;Chronic gastritis;Duodenal ulcer;Dyspepsia;Erosive oesophagitis;Gastric ulcer;Gastrinoma;Gastritis;Gastrooesophageal reflux disease;Heartburn;Infection;Oesophagitis;Peptic ulcer;Reflux esophagitis;Ulcer;Zollinger-Ellison syndrome,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal tenderness;Abnormal bowel sounds;Abnormal dreams;Abnormal faeces;Abnormal platelets;Abnormal vision;Accidental injury;Acute coronary syndrome;Affect lability;Ageusia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albumin globulin ratio abnormal;Albuminuria;Allergic cutaneous angiitis;Alopecia;Amblyopia;Amnesia;Anaemia;Anal discomfort;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anxiety;Apathy;Aplastic anaemia;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Autoimmune haemolytic anaemia;Avitaminosis;B-cell lymphoma;Back pain;Barrett's oesophagus;Bezoar;Biliary colic;Blepharitis;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood disorder;Blood electrolytes decreased;Blood gastrin increased;Blood glucose increased;Blood lactate dehydrogenase increased;Blood potassium increased;Blood urea increased;Body temperature increased;Bone disorder;Bradycardia;Breast disorder;Breast enlargement;Breast pain;Breast tenderness;Breath odour;Bronchitis;Bursitis;Calculus of kidney;Candida infection;Carcinoma;Cardiac disorder;Cataract;Central obesity;Cerebral infarction;Cerebrovascular accident;Chest pain;Chills;Cholecystitis acute;Cholelithiasis;Colitis;Colitis microscopic;Colitis ulcerative;Colonic polyp;Confusional state;Congenital genitourinary abnormality;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatinine increased;Crystal urine present;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Dementia;Depersonalisation;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disease recurrence;Disturbance in sexual arousal;Dizziness;Drug-induced hepatitis;Drug-induced liver injury;Dry eye;Dry mouth;Dry skin;Duodenitis;Dyschezia;Dysgeusia;Dysmenorrhoea;Dyspareunia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear pain;Electrolytes NOS decreased;Endocrine disorder;Enlargement abdomen;Enteritis;Eosinophilia;Epigastric discomfort;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Eye disorder;Eye irritation;Eye pain;Eye swelling;Face oedema;Faecal occult blood positive;Faeces discoloured;Fatigue;Feeling abnormal;Fixed eruption;Flat affect;Flatulence;Folliculitis;Fracture;Functional gastrointestinal disorder;Fundic gland polyp;Gastric polyps;Gastritis;Gastroenteritis;Gastrointestinal candidiasis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal hypermotility;Gastrointestinal malformation;Gastrointestinal pain;Gastrointestinal sounds abnormal;Gingival bleeding;Glaucoma;Glossitis;Glycosuria;Goitre;Gout;Gynaecomastia;Haematemesis;Haematochezia;Haematuria;Haemoglobin decreased;Haemolytic anaemia;Haemoptysis;Haemorrhoids;Hair disorder;Hallucination;Hallucination, auditory;Headache;Hemiplegia;Hepatitis;Hepatobiliary disease;Hepatomegaly;Hepatotoxicity;Herpes zoster;Hiatus hernia;Hiccups;Hoarseness;Hostility;Hot flush;Hunger;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypotension;Hypothyroidism;Hypovitaminosis;Idiopathic thrombocytopenic purpura;Ill-defined disorder;Immune system disorder;Impaired gastric emptying;Increased appetite;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Injection site pain;Injection site reaction;Injury;Insomnia;Interstitial lung disease;Interstitial pneumonia;Irritable bowel syndrome;Jaundice;Joint sprain;Laboratory test abnormal;Lactic dehydrogenase activity increased;Large intestine polyp;Laryngeal neoplasm;Leukocytoclastic vasculitis;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Ligament sprain;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melaena;Memory impairment;Menopausal symptoms;Menorrhagia;Menstrual disorder;Mental disorder;Metaplasia;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Mucosal inflammation;Mucous stools;Multiple fractures;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Myositis;Nail disorder;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Neoplasm malignant;Nephritis interstitial;Nephrolithiasis;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neurosis;Neutropenia;Neutrophil count increased;Nodule;Nuchal rigidity;Occult blood positive;Oedema;Oedema peripheral;Oesophageal achalasia;Oesophageal candidiasis;Oesophageal disorder;Oesophageal stenosis;Oesophageal ulcer;Oesophagitis;Optic neuritis;Oral candidiasis;Oral disorder;Oral herpes;Oral mucosal blistering;Oral pain;Oral soft tissue disorder NOS;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Otitis media;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paraesthesia oral;Parosmia;Pelvic pain;Penis disorder;Petechiae;Pharyngeal oedema;Pharyngitis;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Platelet count decreased;Platelet disorder;Pleural disorder;Pneumonia;Pollakiuria;Polyp;Polyuria;Procedural pain;Proctalgia;Proctitis;Proctocolitis;Pruritus;Pulmonary fibrosis;Purpura;Rash;Rash generalised;Rash maculo-papular;Rectal disorder;Rectal haemorrhage;Rectal tenesmus;Red blood cell abnormality;Renal failure;Renal failure acute;Renal impairment;Renal pain;Respiratory tract congestion;Restless legs syndrome;Retching;Retinal degeneration;Rhinitis;Salivary hypersecretion;Scotoma;Shock;Sinusitis;Skin cancer;Skin carcinoma;Skin disorder;Skin lesion;Sleep disorder;Somnolence;Sore mouth;Speech disorder;Stevens-Johnson syndrome;Stomatitis;Stridor;Sunburn;Sweating;Syncope;Synovitis;Tachycardia;Taste altered;Tenderness;Tension;Testicular disorder;Thirst;Throat sore;Throat tightness;Thrombocytopenia;Thrombocytosis;Thrombotic thrombocytopenic purpura;Tinnitus;Tongue disorder;Tonsillitis;Tooth disorder;Toxic epidermal necrolysis;Transient ischaemic attack;Tremor;Trigeminal neuralgia;Tubulointerstitial nephritis;Ulcer;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urethral pain;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasodilation;Vasodilation procedure;Vertigo;Viral infection;Vision blurred;Visual impairment;Vomiting;WBC abnormal NOS;Weight increased;Wheezing;White blood cell disorder",small molecule,approved; investigational,"Lansoprazol; Lansoprazole; Lansoprazolum; 7.2.2.19; Gastric H(+)/K(+) ATPase subunit alpha; Proton pump; MAPTL; MTBT1; Neurofibrillary tangle protein; Paired helical filament-tau; PHF-tau; TAU; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3",Potassium-transporting ATPase alpha chain 1; Microtubule-associated protein tau, A02BC53; A02BD02; A02BD03; A02BD07; A02BD09; A02BD10;A02BC03
latanoprost,Angle closure glaucoma;Asthma;Chronic angle-closure glaucoma;Ocular hypertension;Open angle glaucoma,Allergic skin reaction;Angina pectoris;Arthralgia;Asthma;Asthmatic attack;Back pain;Blepharitis;Bronchitis;Chest pain;Conjunctival hyperaemia;Conjunctivitis;Connective tissue disorder;Corneal oedema;Cystoid macular oedema;Dermatitis;Dermatitis atopic;Diabetic retinopathy;Diplopia;Discomfort;Dizziness;Dry eye;Dyspnoea;Eczema;Embolism;Embolus;Erythema;Exacerbation of asthma;Eye irritation;Eye pain;Eyelid oedema;Headache;Hepatic function abnormal;Hyperaemia;Inflammation;Iris hyperpigmentation;Iritis;Keratitis;Keratopathy;Lacrimation increased;Localised skin reaction;Macular oedema;Mediastinal disorder;Musculoskeletal discomfort;Nervous system disorder;Oedema;Ophthalmic herpes simplex;Pain;Periorbital oedema;Photophobia;Pruritus;Rash;Retinal detachment;Scab;Sensation of foreign body;Skin disorder;Skin reaction;Stinging;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Uveitis;Vision blurred;Vitreous haemorrhage,small molecule,approved; investigational,"5-HEPTENOIC ACID, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)-1-METHYLETHYL ESTER, (1R-(1.ALPHA.(Z),2.BETA.(R*),3.ALPHA.,5.ALPHA.))-; isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate; Latanoprost; Latanoprostum; propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate; PGF receptor; PGF2-alpha receptor; Prostanoid FP receptor; OATP2A1; PGT; PHOAR2; Prostaglandin transporter; SLC21A2; SLCO2A1; Solute carrier family 21 member 2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Prostaglandin F2-alpha receptor, S01EE51;S01EE01
leflunomide,Arthralgia;Arthritis;Autoimmune disorder;Chronic renal insufficiency;Disability;Disease progression;Drug interaction;Enzyme inhibition;Graft versus host disease;Inhibition of enzyme activity;Joint destruction;Joint swelling;Joint tenderness;Lung disorder;Musculoskeletal stiffness;Neoplasm;Pain;Psoriatic arthropathy;Renal failure;Renal failure chronic;Renal impairment;Rheumatoid arthritis;Sepsis;Septicemia;Stiffness;Swelling;Tenderness,Abdominal pain;Abscess;Acne;Acquired immunodeficiency syndrome;Acute overdose;Acute yellow liver atrophy;Agranulocytosis;Albuminuria;Alopecia;Amblyopia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anxiety;Aphthous stomatitis;Appetite absent;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Autoimmune disorder;Back pain;Bladder pain;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood disorder;Blood lactate dehydrogenase increased;Blood pressure increased;Body temperature increased;Bone pain;Breast disorder;Bronchitis;Bursitis;Candida infection;Cardiac disorder;Cardiovascular disorder;Cataract;Chest pain;Chills;Cholelithiasis;Cholestasis;Colitis;Congenital anomaly;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Cutaneous lupus erythematosus;Cyst;Cystitis;Cystitis noninfective;Decreased appetite;Dermatitis;Dermatitis contact;Developmental delay;Diabetes mellitus;Diarrhoea;Digestion impaired;Discomfort;Dizziness;Drug abuse;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ecchymosis;Eczema;Endocrine disorder;Eosinophilia;Epistaxis;Erythema multiforme;Eye disorder;Fatal outcomes;Fatigue;Feeling abnormal;Flatulence;Foetor hepaticus;Fungal skin infection;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gingivitis;Haematoma;Haematuria;Haemoglobin;Haemorrhage;Hair colour changes;Hair discoloration;Headache;Hepatic enzyme abnormal;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hernia;Herpes simplex;Herpes zoster;Hyperglycaemia;Hyperhidrosis;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertensive crisis;Hyperthyroidism;Hypokalaemia;Hypophosphataemia;Hypotension;Hypouricaemia;Ill-defined disorder;Immobile;Immune system disorder;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Insomnia;Interstitial lung disease;Interstitial pneumonia;Iron deficiency anaemia;Jaundice;Juvenile idiopathic arthritis;Lactic dehydrogenase activity increased;Leukopenia;Liver disorder;Liver function test abnormal;Liver injury;Lymphadenopathy;Malaise;Malignant hypertension;Malnutrition;Mediastinal disorder;Melaena;Menstrual disorder;Mental disorder;Migraine;Mouth ulceration;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nail disorder;Nausea;Neck pain;Neoplasm;Nervous system disorder;Neuralgia;Neuritis;Neuropathy peripheral;Neutropenia;Oedema peripheral;Oesophagitis;Opportunistic infection;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Osteonecrosis;Overdose;Pain;Pallor;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Pelvic pain;Pharyngitis;Pneumonia;Pollakiuria;Polyp;Pre-existing disease;Prostatic disorder;Pruritus;Psoriasis;Pulmonary fibrosis;Pustular psoriasis;Raised liver function tests;Rash;Rash maculo-papular;Renal failure;Respiratory tract infection;Rhinitis;Salivary gland enlargement;Sepsis;Sinusitis;Skin discolouration;Skin disorder;Skin mass;Skin nodule;Skin ulcer;Sleep disorder;Sperm concentration;Stevens-Johnson syndrome;Stomatitis;Subcutaneous nodule;Sweating increased;Synovitis;Tachycardia;Tendon rupture;Tenosynovitis;Throat sore;Thrombocytopenia;Tingling sensation;Tooth disorder;Toxic epidermal necrolysis;Traumatic liver injury;Tuberculosis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine phosphate increased;Urine phosphorus increased;Urticaria;Vaginal moniliasis;Varicose vein;Vasculitis;Vasculitis necrotising;Vasodilation;Vasodilation procedure;Vertigo;Vision blurred;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased,small molecule,approved; investigational,"4-ISOXAZOLECARBOXAMIDE, 5-METHYL-N-(4-(TRIFLUOROMETHYL)PHENYL)-; 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; Leflunomida; Leflunomide; Léflunomide; Leflunomidum; N-(4-(TRIFLUOROMETHYL)PHENYL) 5 METHYLISOXAZOLE-4-CARBOXAMIDE; N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide; 1.3.5.2; DHOdehase; Dihydroorotate oxidase; 1.3.5.2; DHOdehase; Dihydroorotate oxidase; Ah receptor; AhR; BHLHE76; Class E basic helix-loop-helix protein 76; 2.7.10.2; CADTK; CAK-beta; CAKB; Calcium-dependent tyrosine kinase; Calcium-regulated non-receptor proline-rich tyrosine kinase; Cell adhesion kinase beta; FADK 2; FAK2; Focal adhesion kinase 2; Proline-rich tyrosine kinase 2; PYK2; RAFTK; Related adhesion focal tyrosine kinase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter","Dihydroorotate dehydrogenase (quinone), mitochondrial; Dihydroorotate dehydrogenase (quinone), mitochondrial; Aryl hydrocarbon receptor; Protein-tyrosine kinase 2-beta",L04AA13;L04AK01
letrozole,Advanced breast cancer;Breast cancer;Breast cancer stage IV;Disease progression;Hepatic cirrhosis;Hepatic function abnormal;Hepatic impairment;Liver disorder;Menopause;Neoplasm;Neoplasm malignant;Renal failure;Renal impairment,Abdominal pain;Acute coronary syndrome;Alopecia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety depression;Arterial thrombosis;Arthralgia;Arthritis;Asthenia;Back pain;Body temperature increased;Bone disorder;Bone pain;Breast disorder;Breast pain;Cancer pain;Cardiac disorder;Cardiac failure;Cardiovascular disorder;Carpal tunnel syndrome;Cataract;Cerebral haemorrhage;Cerebral infarction;Cerebrovascular accident;Cerebrovascular infarction;Chest pain;Chest wall pain;Connective tissue disorder;Constipation;Coronary artery disease;Coronary heart disease;Cough;Cyst;Decreased appetite;Depression;Dermatitis;Dermatitis psoriasiform;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dry skin;Dysaesthesia;Dysgeusia;Dyspepsia;Dyspnoea;Edema of lower extremities;Embolism;Embolism venous;Endometrial cancer;Endometrial hyperplasia;Erythema multiforme;Eye disorder;Eye irritation;Fatigue;Feeling abnormal;Flushing;Fracture;Gastrointestinal disorder;Gastrointestinal pain;Gravitational oedema;Haemoglobin;Haemorrhage;Haemorrhagic stroke;Headache;Hemiparesis;Hepatitis;Hepatobiliary disease;Hot flush;Hypercalcaemia;Hypercholesterolaemia;Hyperhidrosis;Hypertension;Hypoaesthesia;Ill-defined disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Irritability;Leg edema;Leg pain;Lethargy;Leukopenia;Lightheadedness;Lymphoedema;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Menopause;Mental disorder;Metabolic disorder;Mucosal dryness;Multiple fractures;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Neoplasm;Neoplasm malignant;Nephropathy;Nervous system disorder;Nervousness;Night sweats;Oedema;Oedema peripheral;Oestrogen deficiency;Oestrogenic effect;Osteopenia;Osteoporosis;Pain;Pain in arm;Pain in extremity;Palpitations;Paraesthesia;Phlebitis;Pleural effusion;Pollakiuria;Polyp;Portal vein thrombosis;Pruritus;Pulmonary embolism;Rash;Rash erythematous;Rash maculo-papular;Rash vesicular;Skin disorder;Somnolence;Stomatitis;Sweating;Sweating increased;Tachycardia;Tension;Thirst;Thromboembolic event;Thromboembolism;Thrombophlebitis;Toxic epidermal necrolysis;Transient ischaemic attack;Trigger finger;Tumour pain;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal discharge;Vaginal dryness;Vaginal haemorrhage;Vaginal irritation;Venous thrombosis;Vertigo;Viral infection;Vision blurred;Vomiting;Vulvovaginal discomfort;Vulvovaginal dryness;Weight decreased;Weight increased,small molecule,approved; investigational,"Letrozol; Letrozole; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Aromatase,L02BG04
levobunolol,Chronic open angle glaucoma;Ocular hypertension;Open angle glaucoma;Primary open angle glaucoma,Alopecia;Arrhythmia;Asthenia;Ataxia;Atrioventricular block;Blepharoconjunctivitis;Block heart;Bradycardia;Bronchospasm;Cardiac arrest;Cardiac failure congestive;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Confusional state;Conjunctivitis;Corneal sensitivity decreased;Depression;Diabetes mellitus;Diabetic;Diarrhoea;Diplopia;Dizziness;Dyspnoea;Erectile dysfunction;Erythema multiforme;Eyelid ptosis;Feeling abnormal;Headache;Hypersensitivity;Hypoaesthesia eye;Hypoglycaemia;Hypotension;Iridocyclitis;Keratitis;Lethargy;Loss of consciousness;Myasthenia gravis;Nasal congestion;Nausea;Pain;Palpitations;Paraesthesia;Pruritus;Rash generalised;Respiratory failure;Shock;Stevens-Johnson syndrome;Stinging;Syncope;Urticaria;Visual disturbance;Visual impairment,small molecule,approved,"(-)-Bunolol; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; Levobunolol; Levobunololum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Beta-1 adrenergic receptor; Beta-2 adrenergic receptor,S01ED03
levocabastine,Conjunctivitis allergic,Asthenia;Cough;Dermatitis;Dry mouth;Dyspnoea;Erythema;Eye pain;Eye redness;Eyelid oedema;Fatigue;Headache;Lacrimation;Lacrimation increased;Nausea;Ocular hyperaemia;Pain;Pharyngitis;Rash;Somnolence;Stinging;Visual disturbance;Visual impairment,small molecule,approved; investigational,Levocabastina; Levocabastine; Levocabastinum; H1-R; H1R; HH1R; Levocabastine-sensitive neurotensin receptor; NT-R-2; NTR2,Histamine H1 receptor; Neurotensin receptor type 2, S01GX02;R01AC02
lincomycin,Abscess;Arthritis bacterial;Bacillary dysentery;Bone and joint infections;Bronchitis chronic;Cellulitis;Corynebacterium infection;Diphtheria;Endocarditis;Erysipelas;Furuncle;Gangrene;Impetigo;Infection;Lymphadenitis;Mastitis;Mastoiditis;Osteomyelitis;Otitis media;Panaritium;Paronychia;Pharyngitis;Pneumonia;Respiratory tract infection;Scarlet fever;Sepsis;Septicemia;Shigella infection;Sinusitis;Staphylococcal infection;Tonsillitis;Upper respiratory tract infection;Wound infection,Abdominal cramps;Abdominal discomfort;Abdominal distress;Abdominal pain;Abscess;Agranulocytosis;Anal pruritus;Anaphylactic shock;Angioedema;Anorectal discomfort;Antibiotic-associated diarrhea;Aplastic anaemia;Azotaemia;Body temperature increased;Cardio-respiratory arrest;Colitis;Dermatitis;Dermatitis bullous;Diarrhoea;Enterocolitis;Erythema multiforme;Glossitis;Hepatic function abnormal;Hypersensitivity;Hypotension;Induration;Jaundice;Leukocytosis;Leukopenia;Liver function test abnormal;Local reaction;Megacolon;Megacolon toxic;Nausea;Neutropenia;Oesophagitis;Oliguria;Pain;Pancytopenia;Peritonitis;Phlebitis;Protein urine present;Proteinuria;Pruritus;Pruritus genital;Pseudomembranous colitis;Rash;Rash pustular;Serum sickness;Shock;Stevens-Johnson syndrome;Stomatitis;Thrombocytopenic purpura;Thrombophlebitis;Tinnitus;Urticaria;Vaginal infection;Vaginal inflammation;Vertigo;Vesiculobullous rash;Vomiting,small molecule,approved; vet_approved,Cillimycin; LCM; Lincomicina; Lincomycin; Lincomycine; Lincomycinum; AGP 1; AGP1; OMD 1; Orosomucoid-1,23S ribosomal RNA,J01FF02
linezolid,Bacteraemia;Cellulitis gangrenous;Community acquired pneumonia;Decubitus ulcer;Diabetes mellitus;Diabetic;Diabetic foot infection;Infection;Necrotising fasciitis;Nosocomial pneumonia;Osteomyelitis;Pneumonia;Urinary tract infection,Abdominal cramps;Abdominal pain;Abdominal pain generalised;Abdominal pain localised;Alanine aminotransferase increased;Amylase increased;Anaemia;Anaphylactic shock;Angioedema;Anorectal disorder;Anorexia;Aplasia;Apnoea;Aspartate aminotransferase increased;Asthenia;Biliary colic;Blindness;Blood creatine phosphokinase increased;Blood lactate dehydrogenase increased;Body temperature increased;Candida infection;Cardiac failure congestive;Catheter site pain;Catheter site phlebitis;Chills;Clostridium difficile colitis;Constipation;Contusion;Convulsion;Cough;Cramp muscle;Creatine phosphokinase serum increased;Decreased appetite;Dermatitis;Diarrhoea;Disorientation;Dizziness;Drug interaction;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Ecchymosis;Eosinophilia;Erythema;Erythema multiforme;Fatigue;Flatulence;Fluid retention;Fungal infection;Fungal skin infection;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Glossitis;Haemoglobin;Haemorrhage;Headache;Hyperglycaemia;Hyperhidrosis;Hypertension;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hyponatraemia;Impaired healing;Increased thirst;Injury;Insomnia;Jaundice cholestatic;Laboratory test abnormal;Lactic acidosis;Lactic dehydrogenase activity increased;Leukopenia;Liver function test abnormal;Loose stools;Muscle spasms;Myelosuppression;Nausea;Neuropathy;Neuropathy peripheral;Neutropenia;Optic nerve disorder;Oral candidiasis;Pain;Pain localised;Pancreatitis;Pancytopenia;Paraesthesia;Peripheral vascular disorder;Pharyngitis;Phlebitis;Platelet count decreased;Pneumonia;Polyuria;Pruritus;Rash;Rectal disorder;Red man syndrome;Renal failure;Sepsis;Serotonin syndrome;Skin candida;Skin disorder;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Thirst;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Tinnitus;Tongue discolouration;Tooth discolouration;Transient ischaemic attack;Trauma;Unspecified visual loss;Upper respiratory tract infection;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vertigo;Vision blurred;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved; investigational,Linezolid; Linezolide; Linezolidum; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8,23S ribosomal RNA,J01XX08
Lisinopril,Acute coronary syndrome;Acute myocardial infarction;Aldosterone low;Angina pectoris;Angioedema;Blood aldosterone decreased;Cardiac failure;Cardiac failure congestive;Cardiac failure high output;Cardiac output increased;Cardiogenic shock;Coronary artery disease;Cough;Diabetes mellitus;Diabetic;Diabetic nephropathy;Essential hypertension;Hepatic function abnormal;Hyperlipidaemia;Hypertension;Hypertensive;Hypotension;Infarction;Left ventricular dysfunction;Myocardial infarction;Pregnancy;Reflex tachycardia;Renal artery stenosis;Renal failure;Renal impairment;Renin decreased;Renovascular hypertension;Tachycardia;Ventricular arrhythmia,Abdominal pain;Abnormal chest sounds NOS;Accidental injury;Acute coronary syndrome;Acute myocardial infarction;Agranulocytosis;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorexia;Antinuclear antibody positive;Anuria;Anxiety;Anxiety depression;Appetite absent;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Ataxia;Atrial fibrillation;Atrial fibrillation and flutter;Atrial flutter;Atrial tachycardia;Atrioventricular block complete;Azotaemia;Back pain;Bladder pain;Blindness;Blood and lymphatic system disorders;Blood creatinine increased;Blood urea increased;Body temperature increased;Bone marrow depression;Bradycardia;Breast disorder;Breast pain;Breath sounds abnormal;Bronchitis;Bronchospasm;Bursitis;Cardiac arrest;Cardiac fibrillation;Cerebral ischaemia;Cerebrovascular accident;Chest discomfort;Chest pain;Chills;Common cold;Confusional state;Constipation;Cough;Cough increased;Coxalgia;Cramp muscle;Creatinine increased;Cystitis;Cystitis noninfective;Cytopenia;Decreased appetite;Dehydration;Depression;Depressive symptom;Dermatitis;Diabetes mellitus;Diabetic;Diabetic complication;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Drug interaction;Dry cough;Dry mouth;Dysaesthesia;Dysgeusia;Dyspepsia;Dyspnoea;Dyspnoea paroxysmal nocturnal;Dysuria;Ear disorder;Eczema;Endocrine disorder;Eosinophilia;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Face oedema;Fatigue;Feeling abnormal;Flank pain;Flatulence;Fluid overload;Fluid retention;Flushing;Gastritis;Gastroenteritis;Gastrointestinal cramps;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gout;Haematuria;Haemolytic anaemia;Haemoptysis;Hallucination;Headache;Heartburn;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Herpes zoster;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hypersensitivity;Hypersomnia;Hypertonia;Hypoglycaemia;Hypoglycemic reaction;Hyponatraemia;Hypotension;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Infarction;Infection;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Irritability;Jaundice;Jaundice cholestatic;Knee pain;Laryngeal oedema;Laryngitis;Leg pain;Leukocytosis;Leukopenia;Libido decreased;Lightheadedness;Loss of consciousness;Low back pain;Lung infiltration;Lung neoplasm;Lymphocytoma cutis;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;NPN increased;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Oedema;Oedema peripheral;Oliguria;Oropharyngeal discomfort;Oropharyngeal pain;Orthopnoea;Orthostatic hypotension;Osteoarthritis;Otitis media;Pain;Pain in arm;Pain in extremity;Painful respiration;Palpitations;Pancreatitis;Pancytopenia;Papillary muscle rupture;Paraesthesia;Pelvic pain;Pemphigus;Persistent foetal circulation;Pharyngitis;Photophobia;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pneumonia;Postinfarction angina;Protein urine present;Proteinuria;Pruritus;Pseudolymphoma;Psoriasis;Pulmonary embolism;Pulmonary eosinophilia;Pulmonary oedema;Pyelonephritis;Rash;Red blood cell sedimentation rate increased;Renal failure;Renal failure acute;Renal impairment;Renal pain;Rhinitis;Rhinorrhoea;Salivary hypersecretion;Serum creatinine increased;Shock;Shoulder pain;Sinusitis;Skin disorder;Skin infection;Sleep disorder;Sleep disturbance;Somnolence;Stevens-Johnson syndrome;Sustained ventricular tachycardia;Sweating;Sweating increased;Syncope;Tachycardia;Taste disorders;Tendon disorder;Tension;Throat sore;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Transient ischaemic attack;Tremor;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Upper respiratory tract infection;Uremia;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vasculitis;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Viral infection;Vision blurred;Vomiting;Weight decreased;Weight increased;Wheezing,small molecule,approved; investigational,"(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; [N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; Lisinopril; Lisinopril anhydrous; Lisinoprilum; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; 3.4.23.15; Angiotensinogenase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Angiotensin-converting enzyme; Renin, C09AA03; C09BB03; C10BX07;C09AA03;C09BA03
lisuride,Acromegaly;Akinesia;Amenorrhoea;Blood growth hormone increased;Blood prolactin increased;Bradykinesia;Chills;Dyskinesia;Galactorrhoea;Growth hormone overproduction;Hypokinesia;Increased prolactin level;Infertility;Nausea;Neoplasm;Parkinson's disease;Parkinsonism;Parkinsonism post encephalitic;Pituitary tumour;Prolactinoma;Rigors;Tremor,Abdominal discomfort;Aggression;Angiopathy;Anorexia;Anxiety;Asthenia;Binge eating;Blood pressure increased;Cardiac disorder;Cardiac valve disease;Confusional state;Constipation;Cough;Decreased appetite;Dehydration;Dementia;Disorientation;Disturbance in sexual arousal;Dizziness;Dry mouth;Dyspnoea;Erythromelalgia;Fatigue;Feeling abnormal;Gastrointestinal disorder;Hallucination;Headache;Hyperhidrosis;Hyperprolactinaemia;Hypersexuality;Immune system disorder;Infection;Insomnia;Libido increased;Malnutrition;Mediastinal disorder;Mental disorder;Mental disorder due to a general medical condition;Myoclonus;Nervous system disorder;Nightmare;Obstipation;Oedema peripheral;Organic brain syndrome;Orthostatic collapse;Orthostatic hypotension;Palpitations;Pathological gambling;Pericardial effusion;Pericarditis;Peripheral coldness;Pleural effusion;Pleural fibrosis;Pleurisy;Pulmonary fibrosis;Regurgitation;Retroperitoneal fibrosis;Somnolence;Sudden onset of sleep;Sweating;Syncope;Tachycardia;Vertigo;Violent;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"Lisurid; Lisurida; Lisuride; Lisuridum; N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea; Dopamine D2 receptor; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",D(2) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2C; D(1A) dopamine receptor; D(1B) dopamine receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 1B; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; 5-hydroxytryptamine receptor 7, N02CA07;G02CB02
lomefloxacin,Bacteraemia;Bladder pain;Bronchitis chronic;Cystitis;Cystitis noninfective;Infection;Urinary tract infection,Abdominal pain;Abnormal vision;Acidosis;Acute coronary syndrome;Agitation;Agranulocytosis;Albumin high;Albuminuria;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anuria;Anxiety;Aphasia;Arrhythmia;Arthralgia;Asthenia;Ataxia;Back pain;Blood albumin increased;Blood creatinine increased;Blood potassium decreased;Blood urea increased;Bradycardia;Bronchospasm;Bullous eruption;Calculus of kidney;Candida infection;Candiduria;Cardiac failure;Cardio-respiratory arrest;Cardiomyopathy;Cerebral thrombosis;Cerebration impaired;Cerebrovascular disorder;Chest pain;Chills;Coma;Confusional state;Conjunctivitis;Constipation;Convulsion;Cough;Cramps of lower extremities;Creatinine increased;Crystalluria;Cyanosis;Decreased appetite;Depersonalisation;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dysphasia;Dyspnoea;Dysuria;Ear pain;Eczema;Eosinophilia;Epididymitis;Epistaxis;Erythema multiforme;Erythema nodosum;Extrasystoles;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flatulence;Flushing;Fungal infection;Gastrointestinal haemorrhage;Gastrointestinal inflammation;Gastrointestinal pain;Gout;Haematuria;Haemolytic anaemia;Hallucination;Headache;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hiccups;Hot flush;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hypoglycaemia;Hypotension;Ill-defined disorder;Increased appetite;Influenza like illness;Influenza-like symptoms;Insomnia;Intestinal perforation;Lacrimal disorder;Lacrimation abnormal NOS;Leukocytosis;Leukopenia;Leukorrhea;Loss of consciousness;Lymphadenopathy;Malaise;Mania;Manic psychosis;Menopausal symptoms;Menstrual disorder;Mental disability;Metrorrhagia;Micturition disorder;Monocytosis;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Myocardial infarction;Nausea;Nephritis interstitial;Nephrolithiasis;Nervousness;Neuropathy peripheral;Nightmare;Nystagmus;Oedema;Orchitis;Orchitis noninfective;Paraesthesia;Paranoia;Paranoid reaction;Perineal pain;Pharyngitis;Phlebitis;Phobia;Photophobia;Photosensitivity;Photosensitivity reaction;Polyuria;Potassium low;Pruritus;Pseudomembranous colitis;Pulmonary embolism;Pulmonary function test decreased;Pulmonary oedema;Purpura;Rash;Renal failure;Respiratory depression;Respiratory tract infection;Rhinitis;Shock;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Stomatitis;Strangury;Stridor;Sweating increased;Syncope;Tachycardia;Tendonitis;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytosis;Tinnitus;Tongue discolouration;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Urinary retention;Urine output increased;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vascular purpura;Vasculitis;Vertigo;Viral infection;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved; investigational,"(±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; LFLX; Lomefloxacin; Lomefloxacine; Lomefloxacino; Lomefloxacinum; 5.99.1.3; 5.6.2.2; DNA topoisomerase II, beta isozyme; 5.99.1.3; Topoisomerase IV subunit A; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",DNA gyrase subunit A; DNA topoisomerase 2-beta; DNA topoisomerase 4 subunit A; DNA topoisomerase 2-alpha, J01MA07;J01MA07;S01AE04
lomustine,Anaemia;Brain neoplasm;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified,Acute leukaemia;Alopecia;Anorexia;Ataxia;Azotaemia;Blindness;Body temperature increased;Contusion;Decreased appetite;Disorientation;Dysarthria;Dysplasia;Fibrosis;Gastrointestinal toxicity;Haemoglobin;Haemorrhage;Hepatotoxicity;Infection;Lethargy;Leukopenia;Lung infiltration;Myelosuppression;Nausea;Neoplasm;Nephropathy toxic;Nephrotoxicity;Neurologic reaction;Neurological symptom;Optic atrophy;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Pancytopenia;Pulmonary fibrosis;Pulmonary toxicity;Refractory anemia;Refractory cytopenia with unilineage dysplasia;Renal failure;Stomatitis;Throat sore;Thrombocytopenia;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,"1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-chloroethyl)-3-cyclohexylnitrosourea; Chloroethylcyclohexylnitrosourea; CINU; Cyclohexyl chloroethyl nitrosourea; Lomustina; Lomustine; Lomustinum; N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea; RB3; Stathmin-like protein B3; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",DNA; Stathmin-4,L01AD02
loperamide,Chronic diarrhea;Diarrhoea;Hepatic impairment;Inflammatory bowel disease;Liver disorder;Renal failure;Renal impairment,Abdominal bloating;Abdominal colic;Abdominal cramps;Abdominal distension;Abdominal pain;Abdominal pain upper;Acute diarrhea;Altered state of consciousness;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Asthenia;Bullous eruption;Constipation;Depressed level of consciousness;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Distention;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Epigastric pain;Erythema multiforme;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hypersensitivity;Ileus;Ileus paralytic;Immune system disorder;Loss of consciousness;Megacolon;Megacolon toxic;Nausea;Nervous system disorder;Pruritus;Rash;Skin disorder;Somnolence;Stevens-Johnson syndrome;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;Vomiting,small molecule,approved,"Loperamid; Loperamida; Lopéramide; Loperamide; Loperamidum; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; K-OR-1; KOR-1; OPRK; Corticotropin-lipotropin; POMC; BI; Brain calcium channel I; CACH4; CACN3; CACNL1A4; Calcium channel, L type, alpha-1 polypeptide isoform 4; Voltage-gated calcium channel subunit alpha Cav2.1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Mu-type opioid receptor; Delta-type opioid receptor; Kappa-type opioid receptor; Pro-opiomelanocortin; Voltage-dependent P/Q-type calcium channel subunit alpha-1A; Voltage-gated inwardly rectifying potassium channel KCNH2; Calmodulin, A07DA03;A07DA03;A07DA53
loratadine,Eye pruritus;Hypersensitivity;Lacrimation increased;Nasopharyngitis;Perennial allergic rhinitis;Pruritus;Rhinitis perennial;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Skin disorder;Sneezing;Tearing eyes;Urticaria chronic,Abdominal pain;Abdominal pain upper;Agitation;Alopecia;Anaphylactic shock;Angioedema;Arrhythmia;Asthenia;Blister;Body temperature increased;Cardiovascular disorder;Chest pain;Chromaturia;Constipation;Cough;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Dizziness;Drowsiness;Drug interaction;Dry mouth;Dysgeusia;Dyspepsia;Epistaxis;Facial rash;Fatigue;Feeling abnormal;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hepatobiliary disease;Hyperkinesia;Hypertension;Hypotension;Ill-defined disorder;Immune system disorder;Increased appetite;Insomnia;Lethargy;Loss of consciousness;Malaise;Menstruation delayed;Musculoskeletal discomfort;Myalgia;Nasal dryness;Nausea;Nervous system disorder;Nervousness;Nightmare;Pain;Palpitations;Paraesthesia;Pharyngitis;Pollakiuria;Rash;Salivary hypersecretion;Shock;Skin disorder;Somnolence;Stomach ache;Syncope;Tachycardia;Taste altered;Tension;Tinnitus;Unspecified disorder of skin and subcutaneous tissue;Urine color abnormal;Viral infection;Vomiting,small molecule,approved; investigational,"Loratadina; Loratadine; Loratadinum; H1-R; H1R; HH1R; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 2.4.1.17; UDPGT 2B10; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Histamine H1 receptor; Voltage-gated inwardly rectifying potassium channel KCNH2,R06AX13
lorazepam,Anxiety;Anxiety disorder;Anxiety neurosis;Depressive symptom;Drowsiness;Insomnia;Somnolence;Status epilepticus;Tension,Acidosis;Aggression;Agitation;Agranulocytosis;Airway obstruction NOS;Alopecia;Amnesia;Amnesia transient;Anterograde amnesia;Apnoea;Application site pain;Arrhythmia;Arterial spasm;Asthenia;Ataxia;Atrioventricular block;Balance disorder;Bladder pain;Block heart;Blood alkaline phosphatase increased;Body temperature decreased;Bradycardia;Brain oedema;CNS depression NOS;Cardiac arrest;Chills;Coagulopathy;Coma;Confusional state;Constipation;Convulsion;Cystitis;Cystitis noninfective;Delirium;Depressed level of consciousness;Dermatitis;Diplopia;Disinhibition;Disorientation;Dizziness;Drowsiness;Dry mouth;Dysarthria;Erectile dysfunction;Erythema;Euphoric mood;Excitability;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Feeling abnormal;Gangrene;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal symptom NOS;Hallucination;Headache;Hepatocellular injury;Hostility;Hypersensitivity;Hypersomnia;Hypertension;Hyperventilation;Hypochromic anaemia;Hyponatraemia;Hypotension;Hypothermia;Hypoventilation;Hypoxia;Inappropriate antidiuretic hormone secretion;Infection;Injection site pain;Injection site reaction;Instillation site pain;Irritability;Jaundice;Lethargy;Leukocytosis;Liver function test abnormal;Liver injury;Mania;Memory impairment;Mental disability;Myoclonus;Nausea;Nervousness;Neuroleptic malignant syndrome;Obstructive airways disorder;Obstructive sleep apnea syndrome;Osteoarthritis;Oversedation;Pain;Pancytopenia;Paralysis;Pericardial effusion;Phosphatase alkaline increased;Pneumothorax;Psychotic disorder;Pulmonary function test decreased;Pulmonary haemorrhage;Pulmonary hypertension;Pulmonary oedema;Rash;Redness;Respiratory arrest;Respiratory depression;Respiratory failure;Salivary hypersecretion;Sedation;Sleep apnoea syndrome;Sleep disorder;Sleep disturbance;Slurred speech;Somnolence;Stupor;Suicidal ideation;Tachycardia;Tension;Thinking abnormal;Thrombocytopenia;Thrombocytosis;Tremor;Unsteadiness;Urinary incontinence;Ventricular arrhythmia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved,Loracepam; Lorazepam; o-Chlorooxazepam; o-Chloroxazepam; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8,Translocator protein; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site, N05BA06;N05BA06;N05BA56
losartan,Acute coronary syndrome;Cardiac failure;Cerebrovascular accident;Cough;Diabetes mellitus;Diabetic;Diabetic nephropathy;Dilatation ventricular;Essential hypertension;Hypersensitivity;Hypertension;Hypertensive;Left ventricular hypertrophy;Myocardial infarction;Nephropathy;Protein urine present;Proteinuria;Renal failure chronic;Type 2 diabetes mellitus,Abdominal pain;Agitation;Agranulocytosis;Airway obstruction NOS;Alopecia;Anaemia;Anaphylactic shock;Angiitis necrotising;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety disorder;Aplastic anaemia;Arrhythmia;Arthralgia;Arthritis;Asthenia;Ataxia;Atrial fibrillation;Atrioventricular block second degree;Back pain;Blood creatinine increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Breast disorder;Bronchitis;Cataract;Cellulitis;Chest pain;Confusional state;Conjunctivitis;Constipation;Cough;Coxalgia;Cramp muscle;Cutaneous vasculitis;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diabetes mellitus;Diabetic neuropathy;Diabetic vascular disorder;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drug-induced cough;Dry cough;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Ecchymosis;Eosinophilia;Epigastric discomfort;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Essential hypertension;Face oedema;Facial rash;Fatigue;Feeling abnormal;Fibromyalgia;Flatulence;Fluid imbalance;Flushing;Gastric irritation;Gastritis;Gastrointestinal pain;Glycosuria;Gout;Haemolysis;Haemolytic anaemia;Headache;Henoch-Schonlein purpura;Hepatitis;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertrophy;Hyperuricaemia;Hypoaesthesia;Hypoglycaemia;Hyponatraemia;Hypotension;Ill-defined disorder;Infection;Influenza;Injury;Insomnia;Jaundice;Jaundice cholestatic;Joint swelling;Knee pain;Leg pain;Leukopenia;Libido decreased;Localized exfoliation;Loss of consciousness;Malaise;Memory impairment;Migraine;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myositis;Nasal congestion;Nausea;Nephritis interstitial;Nervous system disorder;Nervousness;Neuropathy peripheral;Nocturia;Nose infection NOS;Obstructive airways disorder;Oedema;Orthostatic hypotension;Pain;Pain in arm;Pain in extremity;Palpitations;Pancreatitis;Panic disorder;Paraesthesia;Persistent dry cough;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Pruritus;Pulmonary oedema;Purpura;Rash;Renal failure;Renal impairment;Respiratory distress;Rhabdomyolysis;Rhinitis;Serum creatinine increased;Shock;Shoulder pain;Sialoadenitis;Sinus bradycardia;Sinus disorder;Sinusitis;Skin exfoliation;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Stiffness;Stinging;Sweating;Swelling;Syncope;Tachycardia;Taste disorders;Tension;Thrombocytopenia;Tinnitus;Toothache;Toxic epidermal necrolysis;Trauma;Tremor;Tubulointerstitial nephritis;Upper respiratory tract infection;Urinary tract infection;Urticaria;Vascular purpura;Vasculitis;Vasculitis necrotising;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Vomiting;Weight increased;Xanthopsia,small molecule,approved,"(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; Losartan; EPO-R; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; C19-steroid-specific UDP-glucuronosyltransferase; C19-steroid-specific UDPGT; UDPGT 2B17; UGT2B17; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; OATL4; Organic anion transporter 4-like protein; Renal-specific transporter; RST; URAT1; Urate anion exchanger 1; Urate:anion antiporter SLC22A12; Glucose transporter type 9; GLUT-9; GLUT9; Urate transporter; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Erythropoietin receptor; Type-1 angiotensin II receptor, C09DA01; C09DB06;C09CA01
lovastatin,Acute coronary syndrome;Angina pectoris;Angina unstable;Arteriosclerosis;Arteriosclerosis coronary artery;Atherosclerosis;Blood cholesterol increased;Blood triglycerides increased;Blood triglycerides normal;Cardiovascular disorder;Carotid arteriosclerosis;Carotid artery disease;Cerebrovascular accident;Cholesterol serum elevated;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Dyslipidaemia;Foetor hepaticus;Hepatocellular injury;Heterozygous familial hypercholesterolemia;High density lipoprotein decreased;Hypercholesterolaemia;Hyperlipidaemia;Hyperlipoproteinemia;Hypertension;Hypertriglyceridaemia;Hypothyroidism;Infarction;Lipid metabolism disorder;Liver disorder;Low density lipoprotein increased;Menarche;Myocardial infarction;Nephrotic syndrome;Peripheral vascular disorder;Premature menopause;Triglycerides normal;Type IIa hyperlipidaemia;Type IIb hyperlipidaemia;Type IIb hyperlipoproteinemia,Abdominal discomfort;Abdominal pain;Accidental injury;Ache;Alopecia;Amnesia;Anaphylactic shock;Angioedema;Anorexia;Antinuclear antibody positive;Anxiety;Arthralgia;Arthritis;Asthenia;Back pain;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Body temperature increased;Cataract;Chest pain;Chills;Cognitive disorder;Cognitive impairment;Confusional state;Constipation;Cramp muscle;Creatine phosphokinase increased;Decreased appetite;Dermatitis;Dermatomyositis;Diarrhoea;Discomfort;Dizziness;Drug reaction with eosinophilia and systemic symptoms;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Eosinophilia;Erectile dysfunction;Erythema multiforme;Eye irritation;Facial paresis;Fatigue;Feeling abnormal;Flatulence;Flushing;Forgetfulness;Gastrointestinal pain;Gynaecomastia;Haemolytic anaemia;Headache;Hepatic cancer;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis chronic active;Hepatocellular carcinoma;Hypersensitive syndrome;Hypersensitivity;IIIrd nerve paralysis;Ill-defined disorder;Immune-mediated necrotising myopathy;Infection;Influenza;Injury;Insomnia;Jaundice cholestatic;Leg pain;Lenticular opacities;Leukopenia;Loss of libido;Lupus erythematosus;Lupus-like syndrome;Malaise;Memory impairment;Memory loss;Menarche;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myopathy;Nausea;Neuropathy peripheral;Nodule;Ophthalmoplegia;Pain;Pain in extremity;Pancreatitis;Paraesthesia;Peripheral nerve palsy;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Polymyalgia rheumatica;Pregnancy;Pruritus;Purpura;Rash;Regurgitation;Rhabdomyolysis;Shoulder pain;Sinusitis;Stevens-Johnson syndrome;Systemic lupus erythematosus;Tenderness;Thrombocytopenia;Toxic epidermal necrolysis;Transaminases increased;Tremor;Upset stomach;Urinary tract infection;Urticaria;VIIth nerve paralysis;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Vomiting,small molecule,approved; investigational,"(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate; 2β,6α-dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6-alpha-methylcompactin; 6alpha-methylcompactin; 6α-methylcompactin; Lovastatin; Lovastatina; Lovastatine; Lovastatinum; Mevinolin; 1.1.1.34; HMG-CoA reductase; CD11 antigen-like family member A; CD11A; Leukocyte adhesion glycoprotein LFA-1 alpha chain; Leukocyte function-associated molecule 1 alpha chain; LFA-1A; 3.5.1.98; HD2; Protein deacylase HDAC2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 3.1.1.2; 3.1.1.81; 3.1.8.1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",3-hydroxy-3-methylglutaryl-coenzyme A reductase; Integrin alpha-L; Histone deacetylase 2, C10BA01;C10AA02
loxapine,Agitation;Asthma;Bipolar I disorder;Bipolar disorder;Bronchial hyperreactivity;Chronic obstructive pulmonary disease;Chronic schizophrenia;Dementia;Fasting;Increased activity;Lung disorder;Schizoaffective disorder;Schizophrenia;Tension,Acute dystonia;Agitation;Agranulocytosis;Akathisia;Akinesia;Alopecia;Amenorrhoea;Angiopathy;Asthenia;Bronchospasm;Cerebrovascular accident;Chest discomfort;Chest pain;Chest tightness;Choreoathetoid movements;Choreoathetosis;Confusional state;Constipation;Convulsion;Convulsive seizure;Cough;Dermatitis;Dizziness;Drowsiness;Dry eye;Dry mouth;Dysarthria;Dysgeusia;Dyskinesia;Dysphagia;Dyspnoea;Dystonia;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Feeling abnormal;Gait disturbance;Gait shuffling;Galactorrhoea;Gastrointestinal disorder;Glaucoma;Gynaecomastia;Headache;Hepatitis;Hepatocellular injury;Hyperpyrexia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Ileus paralytic;Insomnia;Jaundice;Leukopenia;Lightheadedness;Liver injury;Loss of consciousness;Masked facies;Mediastinal disorder;Menstruation irregular;Motor restlessness;Movements involuntary;Muscle rigidity;Muscle spasms;Muscle twitching;Nasal congestion;Nausea;Nervous system disorder;Neuroleptic malignant syndrome;Numbness;Oculogyration;Oculogyric crisis;Oedema;Orthostatic hypotension;Paraesthesia;Photosensitivity;Photosensitivity reaction;Phototoxicity;Polydipsia;Protrusion tongue;Pruritus;Psychotic disorder;Pulmonary function test decreased;Rash;Renal failure;Respiratory depression;Salivary hypersecretion;Seborrhoeic dermatitis;Sensory loss;Shock;Slurred speech;Somnolence;Staggering gait;Syncope;Tachycardia;Tardive dyskinesia;Tension;Throat irritation;Throat tightness;Thrombocytopenia;Tremor;Urinary retention;Vision blurred;Vomiting;Weight decreased;Weight increased;Wheezing,small molecule,approved,"2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine; Loxapina; Loxapine; Loxapinum; Oxilapine; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; Dopamine D2 receptor; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT-5; 5-HT-5A; 5-HT5A; Serotonin receptor 5A; 5-HT-6; 5-HT6; Serotonin receptor 6; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; H1-R; H1R; HH1R; Gastric receptor I; H2R; HH2R; AXOR35; G-protein coupled receptor 105; GPCR105; GPRv53; H4R; HH4R; Pfi-013; SP9144; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; Dopamine D1 receptor",5-hydroxytryptamine receptor 2A; D(2) dopamine receptor; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1E; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 5A; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Beta-1 adrenergic receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; D(1) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; D(1B) dopamine receptor; Histamine H1 receptor; Histamine H2 receptor; Histamine H4 receptor; Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent dopamine transporter; D(1A) dopamine receptor,N05AH01
mafenide,Bacterial infection;Burns third degree;Wound,Accidental exposure to product;Accidental ingestion;Acidosis;Blister;Bone marrow depression;Burning sensation;Dermatitis;Dermatitis bullous;Diarrhoea;Disseminated intravascular coagulation;Eosinophilia;Erythema;Excoriation;Face oedema;Glucose-6-phosphate dehydrogenase deficiency;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hyperventilation;Metabolic acidosis;PCO2;Pain;Pancytopenia;Porphyrin metabolism disorder;Pruritus;Rash;Skin maceration;Swelling;Tachypnoea;Urticaria,small molecule,approved; vet_approved; withdrawn,4-(aminomethyl)benzenesulfonamide; 4-Homosufanilamide; Bensulfamide; Mafenide; Maphenidum; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-XII; Carbonate dehydratase XII; Carbonic anhydrase XII; Tumor antigen HOM-RCC-3.1.3; 4.2.1.1; CA-XIV; Carbonate dehydratase XIV; Carbonic anhydrase XIV; 4.2.1.1; CA-IV; Carbonate dehydratase IV; Carbonic anhydrase IV; 4.2.1.1; CA-VI; Carbonate dehydratase VI; Carbonic anhydrase VI; Salivary carbonic anhydrase; Secreted carbonic anhydrase,Carbonic anhydrase 2; Carbonic anhydrase 12; Carbonic anhydrase 14; Carbonic anhydrase 4; Carbonic anhydrase 6, D06BA03;D06BA03;G01AE10
maprotiline,Affective disorder;Anxiety;Apathy;Bipolar I disorder;Bipolar disorder;Depression;Depressive disorder;Dysphoria;Dysthymic disorder;Endogenous depression;Exhaustion;Fatigue;Flat affect;Irritability;Major depression;Menopausal depression;Mental disorder;Neurotic depression;Recurrent depressive disorder,Abdominal cramps;Abdominal disorder;Abdominal pain;Acute coronary syndrome;Adenitis;Aggression;Agitation;Agranulocytosis;Akathisia;Alopecia;Alveolitis allergic;Angiopathy;Anxiety;Arrhythmia;Asthenia;Ataxia;Atrioventricular block;Black hairy tongue;Block heart;Blood and lymphatic system disorders;Blood pressure increased;Body temperature increased;Bone disorder;Bone marrow depression;Breast disorder;Breast enlargement;Bronchospasm;Bundle branch block;Cardiac disorder;Cerebrovascular accident;Conduction disorder;Confusional state;Constipation;Convulsion;Coordination abnormal;Cutaneous vasculitis;Delirium;Delusion;Dental caries;Depersonalisation;Depressed mood;Depressive symptom;Derealisation;Dermatitis;Dermatitis atopic;Diarrhoea;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug fever;Drug withdrawal syndrome;Dry mouth;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Ear and labyrinth disorders;Electrocardiogram QRS complex;Electroencephalogram abnormal;Endocrine disorder;Eosinophilia;Epigastric distress;Erectile dysfunction;Erythema multiforme;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Fatigue;Feeling abnormal;Flushing;Galactorrhoea;Gastrointestinal disorder;Gastrointestinal pain;Gynaecomastia;Hallucination;Headache;Hepatitis;Hepatobiliary disease;Hot flush;Hyperhidrosis;Hyperkinesia;Hypertension;Hypertrophy of breast;Hypoaesthesia;Hypomania;Hypotension;Ileus paralytic;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Infestation;Infestation NOS;Insomnia;Interstitial lung disease;Interstitial pneumonia;Jaundice;Leukopenia;Libido decreased;Libido disorder;Liver function test abnormal;Loss of consciousness;Lymphadenitis;Malnutrition;Mania;Mediastinal disorder;Memory impairment;Menopausal symptoms;Micturition disorder;Muscular weakness;Mydriasis;Myocardial infarction;Myoclonus;Nasal congestion;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Nightmare;Numbness;Oedema;Orthostatic hypotension;Osteoarthritis;Palpitations;Pancytopenia;Paraesthesia;Petechiae;Photosensitivity reaction;Pollakiuria;Pruritus;Psychotic disorder;Purpura;QRS complex;Rash;Salivary hypersecretion;Sensory loss;Shock;Sinus tachycardia;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Syncope;Tachycardia;Taste bitter;Tension;Testicular swelling;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue discolouration;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;Vascular purpura;Ventricular fibrillation;Ventricular tachycardia;Vision blurred;Vomiting;Weight decreased;Weight increased;Withdrawal symptom,small molecule,approved; investigational,Maprotilina; Maprotiline; Maprotilinum; Maprotylina; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; Dopamine D2 receptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1,Sodium-dependent noradrenaline transporter; Histamine H1 receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; Alpha-1 adrenergic receptors; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 7; D(2) dopamine receptor; Alpha-2 adrenergic receptors,N06AA21
mebendazole,Ascariasis;Diarrhoea;Enterobiasis;Hookworm infection;Infection;Infection mixed;Trichuriasis,Abdominal pain;Agranulocytosis;Angioedema;Convulsion;Dermatitis;Gastrointestinal pain;Hepatitis;Hypersensitivity;Menorrhagia;Neutropenia;Prolonged menses;Rash;Urticaria,small molecule,approved; vet_approved,"(5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; MBDZ; Mebendazol; Mébendazole; Mebendazole; Mebendazolum; 3.6.5.-; Alpha-tubulin 3; TUBA3; Tubulin alpha-3 chain; Tubulin B-alpha-1; TUBB2C; Tubulin beta-2 chain; Tubulin beta-2C chain; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2",Tubulin alpha-1A chain; Tubulin beta-4B chain, P02CA01;P02CA01;P02CA51
mebeverine,Abdominal pain;Constipation;Cramp muscle;Diarrhoea;Flatulence;Functional gastrointestinal disorder;Gastrointestinal disorder;Gastrointestinal pain;Irritable bowel syndrome;Muscle spasms;Unspecified disorder of intestine,Anaphylactic shock;Angioedema;Anorexia;Decreased appetite;Dermatitis;Discomfort;Dizziness;Dyspepsia;Face oedema;Feeling abnormal;Headache;Heartburn;Hypersensitivity;Ill-defined disorder;Immune system disorder;Insomnia;Malaise;Rash;Urticaria,small molecule,approved; investigational,Mebeverina; Mebeverine; Mebeverinum,Muscarinic acetylcholine receptor M5,A03AA04
mecamylamine,Essential hypertension;Malignant hypertension,Anorexia;Asthenia;Chorea;Constipation;Convulsion;Decreased appetite;Disturbance in sexual arousal;Dizziness;Dizziness postural;Erectile dysfunction;Fatigue;Fibrosis;Glossitis;Ileus;Libido decreased;Loss of consciousness;Mydriasis;Nausea;Orthostatic hypotension;Paraesthesia;Pulmonary oedema;Shock;Syncope;Tremor;Urinary retention;Vision blurred;Vomiting,small molecule,approved; investigational,Mecamylamine; NACHRA7; NACRA4,Neuronal acetylcholine receptor subunit alpha-2; Neuronal acetylcholine receptor subunit alpha-7; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2,C02BB01
medrysone,Conjunctivitis allergic;Episcleritis;Vernal conjunctivitis,Anterior uveitis;Cataract subcapsular;Conjunctival hyperaemia;Conjunctivitis;Eye infection;Eye irritation;Glaucoma;Hyperadrenocorticism;Hypersensitivity;Impaired healing;Iridocyclitis;Keratitis;Mydriasis;Nerve injury;Pain;Posterior subcapsular cataract;Sensation of foreign body;Stinging;Ulcerative keratitis;Viral infection;Vision blurred;Visual disturbance;Visual impairment,small molecule,approved,"11beta-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; Medrisona; Medrysone; Medrysonum; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; CBG; Serpin A6; Transcortin; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Steroid hormone receptor ERR1; Steroid hormone receptor ERR2; Estrogen-related receptor gamma; Glucocorticoid receptor,S01BA08
mefloquine,Cross resistance;Infection;Malaria;Pathogen resistance;Plasmodium falciparum infection;Plasmodium malariae infection;Plasmodium ovale infection;Plasmodium vivax infection,Abdominal pain;Abnormal dreams;Affect lability;Aggression;Agitation;Agranulocytosis;Alopecia;Anaphylactic shock;Angiopathy;Anxiety;Anxiety disorder;Aphagia;Aplastic anaemia;Appetite absent;Arthralgia;Arthropod bite;Asthenia;Ataxia;Atrioventricular block;Bad dreams;Balance disorder;Blister;Blood and lymphatic system disorders;Body temperature increased;Bradycardia;Breast feeding;Cardiac disorder;Cardio-respiratory arrest;Cardiovascular disorder;Cataract;Chest pain;Chills;Coma;Completed suicide;Conduction disorder;Confusional state;Connective tissue disorder;Convulsion;Coordination abnormal;Cramp muscle;Deafness;Decreased appetite;Dermatitis;Dermatitis bullous;Diarrhoea;Difficulty sleeping;Diffuse alopecia;Discomfort;Dizziness;Drug interaction;Drug tolerance;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Emotional disorder;Emotional disturbance NOS;Emotional problems;Encephalopathy;Epilepsy;Erythema;Erythema multiforme;Extrasystoles;Eye disorder;Fatigue;Feeling abnormal;Flushing;Foetor hepaticus;Forgetfulness;Gastrointestinal disorder;Gastrointestinal pain;Glucose-6-phosphate dehydrogenase deficiency;Haematocrit decreased;Haemolysis;Hallucination;Headache;Hearing impaired;Heart rate abnormal;Heart rate irregular;Hepatic failure;Hepatobiliary disease;Hepatocellular injury;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Ill-defined disorder;Immune status;Immunology test;Influenza like illness;Influenza-like symptoms;Insomnia;Irritability;Leukocytosis;Leukopenia;Liver disorder;Loose stools;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Mental disorder;Mood swings;Mosquito bite;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Nausea;Nervous system disorder;Neuritis;Neuropathy;Neuropathy peripheral;Oedema;Optic nerve disorder;Palpitations;Panic attack;Paraesthesia;Paranoia;Peripheral motor neuropathy;Peripheral sensory neuropathy;Pneumonia;Poor quality sleep;Pregnancy;Pruritus;Psychotic disorder;Pulse irregular;Rash;Renal failure;Respiration abnormal;Respiratory disorder;Retinal disorder;Schizophrenia;Shock;Skin disorder;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Suicidal ideation;Suicide;Sweating;Syncope;Tachycardia;Telogen effluvium;Thrombocytopenia;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,"(DL-ERYTHRO-.ALPHA.-2-PIPERIDYL-2,8-BIS(TRIFLUOROMETHYL)-4-QUINOLINEMETHANOL; [(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol; 4-QUINOLINEMETHANOL, .ALPHA.-2-PIPERIDINYL-2,8-BIS(TRIFLUOROMETHYL)-, (R*,S*)-(±)-; alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Mefloquin; Mefloquina; Méfloquine; Mefloquine; Mefloquinum; ADORA2; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 3.1.1.7; AChE; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Fe(II)-protoporphyrin IX; 80S ribosomal subunit; Adenosine receptor A2a, P01BC02;P01BC02;P01BF02
megestrol,Acquired immunodeficiency syndrome;Adenocarcinoma of the prostate metastatic;Anorexia;Autoimmune disorder;Breast cancer;Cachexia;Carcinoma breast;Decreased appetite;Endometrial adenocarcinoma;Endometrial hyperplasia;Metastatic carcinoma;Metastatic disease;Metastatic neoplasm;Oestrogenic effect;Prostate cancer;Prostate cancer metastatic;Prostate carcinoma;Underweight;Uterine cancer;Weight decreased,Adrenal insufficiency;Affect lability;Alopecia;Asthenia;Cardiac failure;Carpal tunnel syndrome;Constipation;Cushing's syndrome;Cushingoid;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Dyspnoea;Endometrial cancer;Erectile dysfunction;Feeling abnormal;Flatulence;Fluid retention;Glucose tolerance decreased;Glucose tolerance impaired;Gynaecomastia;Hot flush;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hypertension;Hypotension;Ill-defined disorder;Increased appetite;Infection;Lethargy;Malaise;Menopausal symptoms;Metrorrhagia;Mood swings;Nausea;Neoplasm malignant;Oedema;Pain;Pollakiuria;Pulmonary embolism;Rash;Secondary adrenocortical insufficiency;Stress;Sweating;Thrombophlebitis;Tumour flare;Urticaria;Uterine haemorrhage;Vomiting;Weight increased,small molecule,approved,"17-hydroxy-6-methylpregna-4,6-diene-3,20-dione; Chronopil; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR",Progesterone receptor, G03AA04; G03AB01; G03AC05; G03DB02; G03FA08; L02AB01;G03FB04
meloxicam,Acute coronary syndrome;Arthritis;Arthropathy;Cerebrovascular accident;Gastrointestinal disorder;Inflammation;Juvenile idiopathic arthritis;Myocardial infarction;Osteoarthritis;Pain;Rheumatoid arthritis,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abnormal vision;Accident at home;Acute coronary syndrome;Acute retention of urine;Affect lability;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Ankylosing spondylitis;Anxiety;Appetite absent;Arrhythmia;Arthralgia;Arthralgia aggravated;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthma;Asthmatic attack;Back pain;Back pain aggravated;Blood and lymphatic system disorders;Blood count abnormal;Blood creatinine increased;Blood potassium increased;Blood pressure increased;Blood urea increased;Body temperature increased;Bronchitis;Bronchospasm;Bullous eruption;Bursitis;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Carpal tunnel syndrome;Cataract;Colitis;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Creatinine increased;Creatinine renal clearance decreased;Cytopenia;Decreased appetite;Dehydration;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Discomfort;Disorder sight;Disorientation;Dizziness;Drowsiness;Drug interaction;Dry mouth;Duodenal ulcer;Duodenal ulcer perforation;Dysgeusia;Dyspepsia;Dyspepsia aggravated;Dyspeptic signs and symptoms;Dyspnoea;Ear and labyrinth disorders;Ear disorder;Eructation;Erythema;Erythema multiforme;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Flatulence;Flushing;Gamma-glutamyltransferase increased;Gastric ulcer;Gastric ulcer perforation;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;General disorders and administration site conditions;Gravitational oedema;Haematemesis;Haematuria;Haemoglobin;Haemorrhage;Headache;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hot flush;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Influenza-like symptoms;Inner ear disorder;Insomnia;Intestinal perforation;Jaundice;Joint crepitation;Joint effusion;Joint related signs and symptoms;Joint swelling;Kidney function abnormal;Labyrinthine disorder;Laryngitis;Leg edema;Leukopenia;Lightheadedness;Liver function test abnormal;Loss of consciousness;Low back pain;Malaise;Malnutrition;Mediastinal disorder;Melaena;Meningitis;Meningitis aseptic;Menopausal symptoms;Mental disorder;Mood swings;Mouth ulceration;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Nasopharyngitis;Nausea;Nephritis;Nephritis interstitial;Nervous system disorder;Nervousness;Oedema;Oedema peripheral;Oesophagitis;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Peptic ulcer;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pleuritic pain;Pollakiuria;Pruritus;Purpura;Rash;Rash erythematous;Rash maculo-papular;Red blood cell abnormality;Renal failure;Renal failure acute;Renal function test abnormal;Renal impairment;Respiratory tract infection;Rheumatoid arthritis;Rhinitis;Sciatica;Serum creatinine increased;Serum potassium increased;Shock;Sinusitis;Skin disorder;Somnolence;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Type I hypersensitivity;Ulcer;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;Wheezing,small molecule,approved; vet_approved,"Méloxicam; Meloxicam; Meloxicamum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.1.1.44; PGDH; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4",Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1, M01AC06; M01AC56;M01AC06;N01BB59
melphalan,Body temperature increased;Breast cancer;Carcinoma;Carcinoma breast;Diuresis;Malignant melanoma;Neoplasm malignant;Neuroblastoma;Ovarian adenocarcinoma;Ovarian cancer;Ovarian epithelial cancer;Plasma cell myeloma;Plasmacytoma;Polycythaemia vera;Polyuria;Renal failure;Renal impairment;Rhabdomyosarcoma;Sarcoma;Waldenstrom's macroglobulinaemia,Acute leukaemia;Alopecia;Amenorrhoea;Anaemia;Anaphylactic shock;Anorexia;Arrhythmia;Arterial thrombosis;Asthenia;Atrial fibrillation;Bladder irritation;Bladder pain;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood uric acid increased;Bone marrow depression;Bronchospasm;Cardiac arrest;Chest pain;Compartment syndrome;Connective tissue disorder;Convulsion;Cough;Cutaneous hypersensitivity;Cystitis;Cystitis noninfective;Decreased appetite;Dermatitis;Dermatitis atopic;Diarrhoea;Digestion impaired;Dyspepsia;Dyspnoea;Extravasation;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling hot;Flushing;Foetor hepaticus;Gastrointestinal disorder;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hypersensitivity;Hypertonic bladder;Hyperuricaemia;Hyponatraemia;Hypotension;Immune system disorder;Impaired healing;Infection;Infertility;Injection site reaction;Interstitial lung disease;Interstitial pneumonia;Jaundice;Leukaemia;Leukopenia;Liver disorder;Liver function test abnormal;Local reaction;Lymphoma;Mediastinal disorder;Mouth ulceration;Muscle atrophy;Muscle damage;Muscle fibrosis;Muscle injury;Muscle necrosis;Musculoskeletal discomfort;Myalgia;Myelosuppression;Nausea;Neoplasm;Neoplasm malignant;Neuropathy;Neuropathy peripheral;Neutropenia;Non-Hodgkin's lymphoma;Oedema;Pain;Pancytopenia;Paraesthesia;Plasma cell myeloma;Plasmacytoma;Pruritus;Pulmonary fibrosis;Pulmonary toxicity;Radiation myelopathy;Rales;Rash;Renal failure acute;Respiratory distress;Rhabdomyolysis;Sensation of warmth;Skin disorder;Skin exfoliation;Skin necrosis;Skin ulcer;Stomatitis;Tachycardia;Thrombocytopenia;Tingling sensation;Transaminases increased;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Ureteric obstruction;Urethral disorder;Urinary tract disorder;Urticaria;Vasculitis;Venoocclusive disease;Venoocclusive liver disease;Vomiting;Wound,small molecule,approved,"3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-PAM; L-Phenylalanine mustard; L-Sarcolysine; Melfalano; Melphalan; Melphalanum; p-Bis(beta-chloroethyl)aminophenylalanine; p-Di-(2-chloroethyl)amino-L-phenylalanine; p-L-Sarcolysin; p-N-Bis(2-chloroethyl)amino-L-phenylalanine; p-N,N-bis(2-chloroethyl)amino-L-phenylalanine; Phenylalanine mustard; Phenylalanine nitrogen mustard; AGP 1; AGP1; OMD 1; Orosomucoid-1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; 4F2 LC; 4F2 light chain; 4F2LC; CD98 light chain; CD98LC; E16; hLAT1; Integral membrane protein E16; L-type amino acid transporter 1; LAT1; MPE16; Solute carrier family 7 member 5; y+ system cationic amino acid transporter; Asc-1; ASC1; Solute carrier family 7 member 10",DNA,L01AA03
memantine,Dementia;Dementia Alzheimer's type;Epilepsy;Mental disorder due to a general medical condition;Muscle spasticity;Neuralgia;Organic brain syndrome;Parkinson's disease;Parkinsonism;Vascular dementia,Abdominal pain;Abnormal vision;Abrasion NOS;Abscess;Accidental injury;Acute coronary syndrome;Affect lability;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Altered state of consciousness;Amnesia;Anaemia;Angina pectoris;Angiopathy;Anorexia;Antidiuretic hormone abnormality;Anxiety;Aortic valve incompetence;Aortic valve stenosis;Apathy;Aphasia;Apnoea;Apraxia;Arrhythmia;Arrhythmia supraventricular;Arteriosclerosis;Arthralgia;Arthritis;Arthritis aggravated;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atelectasis;Atrial arrhythmia;Atrial fibrillation;Atrioventricular block;Back pain;Bacterial infection;Balance disorder;Basal cell carcinoma;Benign breast neoplasm;Benign gastrointestinal neoplasm;Bladder pain;Blepharitis;Block heart;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood antidiuretic hormone abnormal;Blood creatinine increased;Blood thyroid stimulating hormone increased;Blood urea increased;Blood uric acid increased;Body temperature decreased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Breast cancer female;Breast neoplasm benign female;Bronchial hyperreactivity;Bronchitis;Bronchospasm;Bullous eruption;Bundle branch block;Bursitis;Calculus of kidney;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac murmur;Cardiac valve disease;Cardiomegaly;Cardiovascular disorder;Carpal tunnel syndrome;Cataract;Cellulitis;Cerebral haemorrhage;Cerebral infarction;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Change of bowel habit;Chest pain;Chills;Cholelithiasis;Chronic obstructive pulmonary disease;Claudication;Coagulopathy;Cognitive disorder;Colitis;Coma;Completed suicide;Condition aggravated;Confusional state;Congenital eye disorder;Conjunctival haemorrhage;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Corneal opacity;Coronary artery disease;Cough;Creatinine increased;Crying;Crying abnormal;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Delusion;Dental caries;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diabetes mellitus exacerbated;Diarrhoea;Diplopia;Discomfort;Disorder sight;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Diverticulum;Diverticulum intestinal;Dizziness;Drug hypersensitivity;Dry mouth;Dry skin;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear disorder;Ear pain;Ectropion;Eczema;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Electrocardiogram abnormal specific;Electrocardiogram change;Embolism;Embolism venous;Encephalopathy;Endocrine disorder;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Excoriation;Extrapyramidal disorder;Extrasystoles;Eye disorder;Eye pain;Faecal incontinence;Fatigue;Feeling abnormal;Feeling of body temperature change;Flat affect;Flatulence;Flushing;Foetal disorder;Food poisoning;Fracture;Frequent bowel movements;Fungal infection;Gait disturbance;Gamma-glutamyltransferase increased;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingivitis;Glaucoma;Gout;Grand mal convulsion;Gravitational oedema;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhoids;Hallucination;Headache;Hearing impaired;Hemiplegia;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hernia;Hernia congenital;Herpes zoster;Hot flush;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkeratosis;Hyperkinesia;Hyperlipidaemia;Hypernatraemia;Hypersensitivity;Hypertension;Hypertension worsened;Hyperthyroidism;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hyporeflexia;Hypotension;Hypothermia;Hypothyroidism;Ileus;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Infestation;Infestation NOS;Inflicted injury;Influenza;Influenza like illness;Influenza-like symptoms;Inguinal hernia;Injury;Insomnia;Intermittent claudication;International normalised ratio increased;Irritability;Ischial neuralgia;Kidney function abnormal;Lacrimal disorder;Lacrimation abnormal NOS;Laryngitis;Leg pain;Lethargy;Leukocytosis;Leukopenia;Libido decreased;Libido increased;Liver function test abnormal;Loss of consciousness;Lymphatic disorder;Lymphoma;Macular degeneration;Malaise;Malnutrition;Mania;Mediastinal disorder;Melaena;Melanocytic naevus;Melanosis;Menopausal symptoms;Menstrual disorder;Mental disability;Mental disorder;Mental status changes;Micturition disorder;Mitral valve incompetence;Mood swings;Mouth ulceration;Multiple fractures;Muscle contractions involuntary;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Myocardial infarction;Myoclonus;Myopia;NPN increased;Nasopharyngitis;Nausea;Necrosis;Neoplasm;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Neurosis;Neutropenia;Nevus;Nightmare;Non-Hodgkin's lymphoma;Numbness;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Onychomycosis;Orthostatic hypotension;Osteoarthritis;Osteoporosis;Otitis externa;Otitis media;Pain;Pain in extremity;Pallor;Palpitations;Pancreatitis;Pancreatitis acute;Pancytopenia;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Parkinsonism;Partial hearing loss;Peripheral ischaemia;Personality disorder;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Pneumonia;Pneumonia aspiration;Pneumothorax;Pollakiuria;Polycythaemia;Polydipsia;Polyuria;Prostatic disorder;Pruritus;Psychotic disorder;Pulmonary embolism;Pulmonary oedema;Pulse abnormal;Pulse pressure decreased;Purpura;Pyuria;Raised liver function tests;Rash;Rash erythematous;Rectal haemorrhage;Red blood cell disorders;Red blood cell sedimentation rate increased;Reflexes abnormal;Renal cyst;Renal failure;Renal failure acute;Renal function test abnormal;Renal impairment;Respiratory failure;Respiratory insufficiency;Retinal detachment;Retinal haemorrhage;Rhinitis;Rigors;Sciatica;Sensory disturbance;Sensory loss;Sepsis;Shock;Sinusitis;Skin disorder;Skin exfoliation;Skin ulcer;Sleep disorder;Somnolence;Speech disorder;Squamous cell carcinoma;Stevens-Johnson syndrome;Stupor;Sudden death;Suicidal ideation;Suicide;Suicide attempt;Supraventricular tachycardia;Surgery;Surgical intervention;Sweating increased;Syncope;Tachycardia;Tardive dyskinesia;Tension;Thinking abnormal;Thready pulse;Thrombocytopenia;Thromboembolism;Thrombophlebitis;Thrombotic thrombocytopenic purpura;Thyrotropin high;Tinnitus;Tooth disorder;Toothache;Torsade de pointes;Transient ischaemic attack;Tremor;Ulcerative stomatitis;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vaginal haemorrhage;Varicose vein;Vascular purpura;Venous thrombosis;Ventricular arrhythmia;Vertigo;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting;Weight decreased;Weight increased;Xerophthalmia,small molecule,approved; investigational,"1-Amino-3,5-dimethyladamantane; 1,3-Dimethyl-5-adamantanamine; 3,5-Dimethyl-1-adamantanamine; 3,5-Dimethyl-1-aminoadamantane; 3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine; Memantina; Memantine; Memantinum; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; NACHRA7; Dopamine D2 receptor; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; hOCT2; OCT2; Organic cation transporter 2; APNH; APNH1; Na(+)/H(+) antiporter, amiloride-sensitive; Na(+)/H(+) exchanger 1; NHE-1; NHE1; Solute carrier family 9 member 1; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1","Glutamate (NMDA) receptor; 5-hydroxytryptamine receptor 3A; Neuronal acetylcholine receptor subunit alpha-7; D(2) dopamine receptor; Glutamate receptor ionotropic, NMDA 1; GABA(A) Receptor", N06DA53; N06DX01;N06DA52;N06DX01
meperidine,Acute pain;Analgesic effect;Analgesic therapy;Biliary colic;Chronic pain;Cough;Diarrhoea;Narcosis;Pain;Pancreatitis;Pancreatitis acute;Renal colic;Renal failure;Renal impairment;Stupor,"Affect lability;Agitation;Anaphylactic shock;Anorexia;Anuria;Anxiety;Asthenia;Auditory and visual hallucinations;Bradycardia;CNS depression NOS;Cardiac arrest;Cardiovascular insufficiency;Circulatory depression;Cold sweat;Coma;Complex partial seizures;Confusional state;Constipation;Convulsion;Coordination abnormal;Decreased appetite;Delirium;Depressed level of consciousness;Dermatitis;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry mouth;Dyskinesia;Dysphoria;Erythema;Euphoric mood;Feeling abnormal;Fibrosis;Flushing;Gangrene;Hallucination;Hallucinations, mixed;Headache;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypomania;Hypotension;Induration;Injection site pain;Insomnia;Irritability;Libido decreased;Lightheadedness;Loss of consciousness;Miosis;Mood swings;Muscle movement involuntary;Muscle spasms;Muscle twitching;Mydriasis;Myoclonus;Nausea;Neurotoxicity;Oedema;Orthostatic hypotension;Pallor;Palpitations;Paralysis;Paranoia;Phlebitis;Pruritus;Psychotic disorder;Pulmonary function test decreased;Rash;Respiratory arrest;Respiratory depression;Shock;Skin cold clammy;Somnolence;Sweating;Syncope;Tachycardia;Tremor;Urinary retention;Urticaria;Vasodilation;Vasodilation procedure;Vertigo;Visual disturbance;Visual impairment;Vomiting;Welts;Withdrawal syndrome",small molecule,approved,"Isonipecaïne; Meperidina; Pethidin; Pethidine; Péthidine; Pethidinum; Petidina; Petydyna; K-OR-1; KOR-1; OPRK; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","Kappa-type opioid receptor; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2C; Glutamate receptor ionotropic, NMDA 2D; Muscarinic acetylcholine receptor; Mu-type opioid receptor; Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; Liver carboxylesterase 1", N02AB52; N02AB72; N02AG03;N02AB02
mephenytoin,Temporal lobe epilepsy,Agranulocytosis;Alopecia;Anaemia;Anaemia megaloblastic;Aplastic anaemia;Arthropathy;Asthenia;Ataxia;Blood disorder;Chorea;Confusional state;Conjunctivitis;Convulsion;Dermatitis;Dermatitis exfoliative;Diplopia;Dizziness;Drowsiness;Dysarthria;Eosinophilia;Erythema multiforme;Fatigue;Feeling abnormal;Gingival hyperplasia;Haemolytic anaemia;Hepatitis;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hypersensitivity;Insomnia;Irritability;Jaundice;Leukocytosis;Leukopenia;Lupus erythematosus;Lymphadenopathy;Lymphoma;Monocytosis;Nausea;Nephrosis;Nephrotic syndrome;Nervousness;Neutropenia;Non-Hodgkin's lymphoma;Nystagmus;Oedema;Osteoarthritis;Pancytopenia;Photophobia;Pigmentation disorder;Pigmentation skin;Polyarthropathy;Psychotic disorder;Pulmonary fibrosis;Rash;Somnolence;Stevens-Johnson syndrome;Systemic lupus erythematosus;Tension;Thrombocytopenia;Toxic epidermal necrolysis;Tremor;Vomiting;Weight increased,small molecule,approved; investigational; withdrawn,"mefenitoína; Mephenytoin; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; Serpin A7; T4-binding globulin; TBG",Sodium channel protein type 5 subunit alpha; Nuclear receptor subfamily 1 group I member 2, N03AB54;N03AB04
meprobamate,Anxiety;Anxiety disorder;Tension,Agitation;Agranulocytosis;Anaphylactic shock;Angioedema;Anuria;Aplastic anaemia;Arrhythmia;Asthenia;Ataxia;Body temperature increased;Bronchospasm;Chills;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Dizziness;Drowsiness;Drug eruption;Dysarthria;Ecchymosis;Eosinophilia;Erythema multiforme;Euphoric mood;Excitement;Fixed drug eruption;Headache;Hyperpyrexia;Hypersensitivity;Hypotension;Hypotensive;Leukopenia;Loss of consciousness;Lymphadenopathy;Nausea;Oedema peripheral;Oliguria;Palpitations;Paraesthesia;Petechiae;Proctitis;Pruritus;Purpura;Purpura non-thrombocytopenic;Rash maculo-papular;Shock;Slurred speech;Somnolence;Stevens-Johnson syndrome;Stomatitis;Syncope;Tachycardia;Thrombocytopenic purpura;Vascular purpura;Vertigo;Vomiting,small molecule,approved; illicit,Meprobamat; Meprobamate; Meprobamato; Meprobamatum; Meprobamic acid; 3.5.1.88; PDF1A; Polypeptide deformylase; 2.7.11.13; nPKC-epsilon; PKCE; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6,"Peptide deformylase, mitochondrial; Protein kinase C epsilon type; GABA(A) Receptor; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit alpha-4; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-6", N05BC01; N05CX01;N05BC01;N05BC51
metformin,Acute coronary syndrome;Blood glucose decreased;Coma;Diabetes mellitus;Diabetic;Diabetic ketoacidosis;Fasting;Hyperglycaemia;Hypersensitivity;Ketosis;Lactic acidosis;Metabolic acidosis;Myocardial infarction;Obesity;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Weight decreased,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal distress;Abdominal pain;Abdominal pain upper;Abnormal faeces;Accidental injury;Acetonaemia;Acidosis;Acute prerenal failure;Anaemia megaloblastic;Angina pectoris;Angina unstable;Angiopathy;Anorexia;Appetite absent;Asthenia;Azotaemia;Azotemia prerenal;Blood disorder;Body temperature decreased;Bradycardia;Breast disorder;Cardiac disorder;Chest discomfort;Chest pain;Chills;Connective tissue disorder;Constipation;Contusion;Cramp muscle;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Discomfort;Distention;Dizziness;Drowsiness;Dysgeusia;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Ear pain;Emotional distress;Epigastric discomfort;Erythema;Eye disorder;Fatigue;Feeling abnormal;Flatulence;Flushing;Function kidney decreased;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrointestinal tract irritation;Headache;Heartburn;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hypertension;Hypoaesthesia;Hypoglycaemia;Hypotension;Hypothermia;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Injury;Ketoacidosis;Ketonemia;Ketonuria;Lethargy;Lightheadedness;Liver function test abnormal;Loose stools;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Migraine;Muscle spasms;Muscle strain;Musculoskeletal discomfort;Myalgia;Nail disorder;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Neuropathy;Neuropathy peripheral;Neutropenia;Oedema;Oedema aggravated;Oedema peripheral;Pain in extremity;Palpitations;Pancreatitis;Paraesthesia;Pruritus;Rash;Reaction gastrointestinal;Renal impairment;Respiratory distress;Rhinitis;Rhinitis seasonal;Rhinorrhoea;Rigors;Seasonal allergy;Shock;Sinus congestion;Sinus headache;Skin disorder;Somnolence;Sweating increased;Syncope;Taste disorders;Taste metallic;Thrombocytopenia;Tonsillitis;Tooth abscess;Toothache;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urticaria;Viral diarrhoea;Vision blurred;Vitamin B12 absorption decreased;Vitamin B12 deficiency;Vomiting;White blood cell count increased,small molecule,approved,"1,1-Dimethylbiguanide; Dimethylbiguanid; Metformin; Metformina; Metformine; Metforminum; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; 6.4.1.2; ACC-beta; ACC2; ACCB; 1.5.5.1; Electron-transferring-flavoprotein dehydrogenase; ETF dehydrogenase; ETF-QO; ETF-ubiquinone oxidoreductase; AMPK; AMPK subunit beta-1; AMPKb; 1.1.1.8; GPD-C; GPDH-C; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; ENT4; hENT4; Plasma membrane monoamine transporter; PMAT; Solute carrier family 29 member 4; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2","Multidrug and toxin extrusion protein 1; Acetyl-CoA carboxylase 2; Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial; 5'-AMP-activated protein kinase subunit beta-1; Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic", A10BA02; A10BD02; A10BD03; A10BD05; A10BD07; A10BD08; A10BD10; A10BD11; A10BD13; A10BD14; A10BD15; A10BD16; A10BD17; A10BD18; A10BD20; A10BD22; A10BD25; A10BD26; A10BD27; A10BD28;A10BA02;A10BD23
methadone,Acute pain;Analgesic effect;Analgesic therapy;Convulsion;Dependence on opiates;Drug dependence;Heroin addiction;Opioid naive;Pain;Postoperative pain;Procedural pain;Pulmonary function test decreased;Respiratory depression;Substance abuse;Therapy naive;Withdrawal syndrome,Abdominal cramps;Abdominal pain;Ache;Agitation;Amenorrhoea;Anaphylactic shock;Anorexia;Anxiety;Arrhythmia;Asthenia;Blood testosterone decreased;Body temperature decreased;Body temperature increased;Bowel spasm;Bradycardia;Cardiac arrest;Cardiac failure;Cardiomyopathy;Cardiovascular insufficiency;Chills;Chronic hepatitis;Circulatory depression;Coldness;Confusional state;Constipation;Convulsion;Cutis anserina;Decreased appetite;Dermatitis;Dermatitis contact;Diarrhoea;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug interaction;Drug withdrawal syndrome;Dry mouth;Dysphoria;Electrocardiogram QT prolonged;Electrocardiogram T wave inversion;Erythema;Euphoric mood;Extrasystoles;Feeling abnormal;Feeling cold;Flushing;Fracture;Gastrointestinal pain;Glossitis;Haemorrhagic urticaria;Hallucination;Head injury;Headache;Hyperhidrosis;Hypersensitivity;Hypogonadism;Hypokalaemia;Hypomagnesaemia;Hypotension;Hypotensive;Hypothermia;Insomnia;Intracranial pressure increased;Irritability;Lacrimation;Lacrimation increased;Libido decreased;Lightheadedness;Loss of consciousness;Lung disorder;Miosis;Multiple fractures;Muscle mass;Muscle spasms;Muscle twitching;Mydriasis;Nasopharyngitis;Nausea;Oedema;Orthostatic hypotension;Osteoporosis;Pain;Palpitations;Phlebitis;Piloerection;Pruritus;Pulmonary function test decreased;Pulmonary oedema;Rash;Redness;Respiratory arrest;Respiratory depression;Rhinorrhoea;Serum testosterone decreased;Shock;Sneezing;Somnolence;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Thrombocytopenia;Torsade de pointes;Tremor;Urinary retention;Urticaria;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;Withdrawal symptom;Withdrawal syndrome;Yawning,small molecule,approved,"(+-)-Methadone; (+/-)-Methadone; (±)-methadone; 6-Dimethylamino-4,4-diphenyl-3-heptanone; dl-Methadone; Metadona; Methadone; Methadonum; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; D-OR-1; DOR-1; OPRD; NACHRA7; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; NACHRA3; NACRA4; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Mu-type opioid receptor; NMDA receptor; Delta-type opioid receptor; Neuronal acetylcholine receptor subunit alpha-7; 5-hydroxytryptamine receptor 3A; Neuronal acetylcholine receptor subunit alpha-3; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2, N02AC52;N07BC02
methocarbamol,Discomfort;Epilepsy,Amnesia;Anaphylactic shock;Angioedema;Body temperature increased;Bradycardia;Confusional state;Conjunctivitis;Convulsion;Convulsive seizure;Coordination abnormal;Dermatitis;Diplopia;Dizziness;Drowsiness;Dysgeusia;Dyspepsia;Feeling abnormal;Flushing;Headache;Hypersensitivity;Hypotension;Injury;Insomnia;Jaundice;Jaundice cholestatic;Leukopenia;Lightheadedness;Loss of consciousness;Muscular incoordination;Nasal congestion;Nausea;Nystagmus;Pain;Pruritus;Rash;Shock;Somnolence;Syncope;Taste metallic;Thrombophlebitis;Trauma;Urticaria;Vertigo;Vision blurred;Vomiting,small molecule,approved; vet_approved,(RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate; Methocarbamol; Méthocarbamol; Methocarbamolum; Metocarbamol; Metocarbamolo; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1,Carbonic anhydrase 1, M03BA03; M03BA53;M03BA03;M03BA73
methotrexate,Acute leukaemia;Acute lymphocytic leukaemia;Arthritis;Benign hydatidiform mole;Bladder cancer;Breast cancer;Bronchial carcinoma;Burkitt's lymphoma;Carcinoma of lung;Carcinomatosis;Choriocarcinoma;Cutaneous T-cell lymphoma;Drug interaction;Fungal infection;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hydatidiform mole;Juvenile idiopathic arthritis;Leukaemia;Leukaemic infiltration brain;Lung neoplasm malignant;Lymphocytic leukaemia;Lymphoma;Malignant hydatidiform mole;Malignant neoplasm of esophagus;Meningeal leukemia;Metastasis;Metastatic neoplasm;Mycosis fungoides;Neoplasm;Neoplasm malignant;Non-Hodgkin's lymphoma;Oesophageal carcinoma;Osteosarcoma;Osteosarcoma metastatic;Psoriasis;Psoriasis vulgaris;Psoriatic arthropathy;Rheumatoid arthritis;Squamous cell carcinoma;Testis cancer,Abdominal discomfort;Abdominal distress;Abdominal pain;Abscess;Agranulocytosis;Allergic cutaneous angiitis;Alopecia;Alveolitis;Alveolitis allergic;Anaemia;Anaemia megaloblastic;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Anorexia;Anuria;Aphasia;Aplastic anaemia;Apnoea;Appetite absent;Arachnoiditis;Arterial thrombosis;Arthralgia;Aseptic necrosis;Asthenia;Asthma;Ataxia;Azoospermia;Azotaemia;Back pain;Bacterial infection;Bladder pain;Blindness transient;Blood albumin decreased;Blood and lymphatic system disorders;Blood uric acid increased;Body temperature increased;Bone disorder;Bone marrow depression;Breast disorder;Bronchial hyperreactivity;Burkitt's lymphoma;Burning sensation;CNS toxicity;Carcinogenicity;Cardiac disorder;Cardiac tamponade;Cerebral thrombosis;Cerebrovascular accident;Chest pain;Chills;Chronic hepatitis;Chronic liver disease;Chronic obstructive pulmonary disease;Cognitive disorder;Cognitive impairment;Coma;Confusional state;Conjunctivitis;Convulsion;Cough;Cranial nerve paralysis;Cryptococcosis;Cyanosis;Cyst;Cystitis;Cystitis noninfective;Cytomegalovirus infection;Decreased appetite;Deep vein thrombosis;Dementia;Depressed level of consciousness;Depression;Dermatitis;Dermatitis exfoliative;Dermatitis radiation NOS;Diabetes mellitus;Diabetic;Diarrhoea;Diplegia;Discomfort;Dizziness;Drowsiness;Dry cough;Dysarthria;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ecchymosis;Embolism;Encephalopathy;Enteritis;Eosinophilia;Epistaxis;Erectile dysfunction;Eruption;Erythema;Erythema multiforme;Extravasation;Eye disorder;Fatigue;Febrile neutropenia;Feeling abnormal;Fibrosis;Foetal death;Folliculitis;Fracture;Fungal infection;Furuncle;Furunculosis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal toxicity;Gastrointestinal ulcer;Gastrointestinal ulcer haemorrhage;Gingivitis;Glossitis;Guillain-Barre syndrome;Gynaecomastia;Haematemesis;Haematocrit decreased;Haematuria;Haemoglobin;Haemorrhage;Headache;Hemiparesis;Hepatic atrophy;Hepatic cirrhosis;Hepatic enzyme increased;Hepatic failure;Hepatic fibrosis;Hepatic insufficiency;Hepatitis;Hepatitis acute;Hepatobiliary disease;Hepatotoxicity;Herpes simplex;Herpes simplex hepatitis;Herpes zoster;Hidradenitis;Histoplasmosis;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hyperuricaemia;Hypervigilance;Hypogammaglobulinaemia;Hypotension;Hypoxemia;Hypoxia;Ill-defined disorder;Immune system disorder;Immunodeficiency;Impaired healing;Infection;Infertility;Infestation;Infestation NOS;Inflammation;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal perforation;Irritability;Lethargy;Leukaemia;Leukocytoclastic vasculitis;Leukoderma;Leukoencephalopathy;Leukopenia;Liver disorder;Liver function test abnormal;Loss of libido;Lung disorder;Lung fibrosis interstitial;Lung infection;Lung infiltration;Lymphadenopathy;Lymphoma;Lymphoproliferative disorder;Malabsorption;Malaise;Malnutrition;Mediastinal disorder;Megacolon;Megacolon toxic;Melaena;Meningism;Meningitis aseptic;Mental disorder;Monoplegia;Mood alteration NOS;Mood swings;Motor dysfunction;Mouth ulceration;Mucosal inflammation;Multiple fractures;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Nail changes;Nail disorder;Nausea;Neck stiffness;Necrolysis epidermal;Necrosis;Neoplasm;Nephropathy;Nervous system disorder;Neurological impairment;Neurotoxicity;Neutropenia;Nocardiosis;Nodule;Nuchal rigidity;Obstructive airways disorder;Ocular discomfort;Oligospermia;Oliguria;Opportunistic infection;Osteoarthritis;Osteonecrosis;Osteoporosis;Pain;Pancreatitis;Pancytopenia;Paraesthesia;Paralysis;Paraplegia;Paresis;Paresthesia of limbs;Paronychia;Partial seizures;Pericardial effusion;Pericarditis;Petechiae;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pleurisy;Pneumocystis jirovecii pneumonia;Pneumonia;Pneumonia cytomegaloviral;Polyp;Polyuria;Protein urine present;Proteinuria;Pruritus;Psoriasis;Psoriatic plaque;Pulmonary embolism;Pulmonary fibrosis;Pulmonary lymphoma;Pulmonary oedema;Pulmonary toxicity;Radiation skin injury;Radiculopathy;Raised liver function tests;Rales;Rash;Reaction gastrointestinal;Renal failure;Renal failure acute;Respiratory failure;Retinal disorder;Retinal vein thrombosis;Scald;Sepsis;Septicemia;Serum albumin decreased;Skin depigmentation;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin necrosis;Skin ulcer;Soft tissue necrosis;Somnolence;Speech disorder;Speech impairment NOS;Spinal cord disorder;Stevens-Johnson syndrome;Stomatitis;Stress fracture;Stupor;Sudden death;Sunburn;Sweating;Taste metallic;Telangiectasia;Thermal burn;Thrombocytopenia;Thromboembolic event;Thrombophlebitis;Tinnitus;Toxic epidermal necrolysis;Tumour lysis syndrome;Ulcer;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Ureteric obstruction;Urethral disorder;Urinary tract disorder;Urine output;Urine output increased;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vasculitis;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;X-linked lymphoproliferative syndrome,small molecule,approved,"4-amino-10-methylfolic acid; 4-amino-N(10)-methylpteroylglutamic acid; Amethopterin; Methotrexat; Méthotrexate; Methotrexate; Methotrexatum; Metotrexato; MTX; N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid; 2.1.1.45; TS; TSase; Cyclic dinucleotide:anion antiporter SLC19A1; FLOT1; Folate:anion antiporter SLC19A1; FOLT; hRFC; hSLC19A1; IFC-1; Intestinal folate carrier 1; Placental folate transporter; Reduced folate carrier protein; Reduced folate transporter 1; RFC; RFC1; RFT-1; Solute carrier family 19 member 1; G21; HCP1; Heme carrier protein 1; hPCFT; HsPCFT; PCFT; PCFT/HCP1; Solute carrier family 46 member 1; AICAR transformylase/inosine monophosphate cyclohydrolase; ATIC; PURH; 1.5.1.3; 1.5.1.3; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase; 1.5.1.53; 1.1.1.44; PGDH; 6.3.2.17; Folylpoly-gamma-glutamate synthetase; FPGS; Tetrahydrofolate synthase; Tetrahydrofolylpolyglutamate synthase; 2.1.1.45; TS; TSase; AICAR transformylase/inosine monophosphate cyclohydrolase; ATIC; PURH; 3.4.19.9; Conjugase; Gamma-Glu-X carboxypeptidase; GH; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 3.4.17.11; CPDG2; Folate hydrolase G2; Glutamate carboxypeptidase; Pteroylmonoglutamic acid hydrolase G2; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; MCT 1; MCT1; Solute carrier family 16 member 1; 7.6.2.2; 7.6.2.3; MRP8; Multidrug resistance-associated protein 8; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; OAT-RP-5; OATP-14; OATP-F; OATP-RP5; OATP14; OATP1C1; OATPF; Organic anion transporter 1C1; Organic anion transporter F; Organic anion transporter polypeptide-related protein 5; Organic anion-transporting polypeptide 14; SLC21A14; Solute carrier family 21 member 14; Thyroxine transporter; OATP-D; OATP-RP3; OATP3A1; OATPD; OATPRP3; Organic anion transporter polypeptide-related protein 3; Organic anion-transporting polypeptide D; PGE1 transporter; SLC21A11; Sodium-independent organic anion transporter D; Solute carrier family 21 member 11; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; G21; HCP1; Heme carrier protein 1; hPCFT; HsPCFT; PCFT; PCFT/HCP1; Solute carrier family 46 member 1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; OATP-H; OATP-M1; OATP4C1; OATPX; Organic anion transporter M1; Organic anion transporting polypeptide 4C1; SLC21A20; SLCO4C1; Solute carrier family 21 member 20; Cyclic dinucleotide:anion antiporter SLC19A1; FLOT1; Folate:anion antiporter SLC19A1; FOLT; hRFC; hSLC19A1; IFC-1; Intestinal folate carrier 1; Placental folate transporter; Reduced folate carrier protein; Reduced folate transporter 1; RFC; RFC1; RFT-1; Solute carrier family 19 member 1; Adult folate-binding protein; FBP; Folate receptor 1; Folate receptor, adult; FOLR; FR-alpha; KB cells FBP; Ovarian tumor-associated antigen MOv18; FBP; Folate receptor 2; Folate receptor, fetal/placental; FR-beta; Placental folate-binding protein; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; hPAT1; PAT1; Proton/amino acid transporter 1; Solute carrier family 36 member 1",Thymidylate synthase; Reduced folate transporter; Proton-coupled folate transporter; Bifunctional purine biosynthesis protein ATIC; Dihydrofolate reductase, L01BA01;L01BA01;L04AX03
N-methylscopolamine,Peptic ulcer,Abdominal distension;Accommodation disorder;Ageusia;Anaphylactic shock;Asthenia;Bloated feeling;Confusional state;Constipation;Cycloplegia;Dizziness;Drowsiness;Dry mouth;Erectile dysfunction;Feeling abnormal;Headache;Hypersensitivity;Hypohidrosis;Insomnia;Mydriasis;Nausea;Nervousness;Palpitations;Somnolence;Sweating decreased;Tachycardia;Tension;Urinary hesitation;Urticaria;Vision blurred;Vomiting,small molecule,approved,Methylscopolamine,Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2, A03BB03; S01FA03;A03BB03;A03CB01
methyclothiazide,Cardiac failure congestive;Glomerulonephritis acute;Hepatic cirrhosis;Hypertension;Nephrotic syndrome;Oedema;Renal failure chronic,Agitation;Agranulocytosis;Anaphylactic shock;Angiitis necrotising;Anorexia;Aplastic anaemia;Asthenia;Blood uric acid increased;Body temperature increased;Constipation;Cramp muscle;Cutaneous vasculitis;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Electrolyte imbalance;Epigastric discomfort;Erythema multiforme;Gastric irritation;Glycosuria;Haemolytic anaemia;Headache;Hypercalcaemia;Hyperglycaemia;Hypersensitivity;Hyperuricaemia;Jaundice;Leukopenia;Malnutrition;Muscle spasms;Nausea;Orthostatic hypotension;Pancreatitis;Paraesthesia;Photosensitivity;Photosensitivity reaction;Pneumonia;Pulmonary oedema;Purpura;Rash;Respiratory distress;Sialoadenitis;Stevens-Johnson syndrome;Thrombocytopenia;Urticaria;Vascular purpura;Vasculitis;Vasculitis necrotising;Vertigo;Vision blurred;Vomiting;Xanthopsia,small molecule,withdrawn,Methyclothiazide; BSC1; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; Kidney-specific Na-K-Cl symporter; Na-K-2Cl cotransporter 2; NKCC2; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-IV; Carbonate dehydratase IV; Carbonic anhydrase IV,Solute carrier family 12 member 1; Carbonic anhydrase 1; Carbonic anhydrase 2; Carbonic anhydrase 4, C03AB08;C03AA08
methyldopa,Hypertension;Hypertensive crisis,Abdominal distension;Agranulocytosis;Amenorrhoea;Angina pectoris;Angiopathy;Antinuclear antibody positive;Arthralgia;Asthenia;Bell's palsy;Blood and lymphatic system disorders;Body temperature increased;Bone marrow depression;Bradycardia;Breast disorder;Breast enlargement;Cardiac disorder;Cardiac failure congestive;Carotid sinus hypersensitivity;Carotid sinus syndrome;Cerebrovascular insufficiency;Colitis;Connective tissue disorder;Constipation;Coombs test positive;Dermatitis;Diarrhoea;Distention;Disturbance in sexual arousal;Dizziness;Eczema;Endocrine disorder;Eosinophilia;Erectile dysfunction;Eruption lichenoid;Flatulence;Foetor hepaticus;Gastrointestinal disorder;Gynaecomastia;Haemolytic anaemia;Headache;Heart failure signs and symptoms;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hyperprolactinaemia;Hypersensitivity;Infection;Infestation;Infestation NOS;Jaundice;Joint swelling;Leukopenia;Libido decreased;Lichenoid keratosis;Lightheadedness;Liver disorder;Liver function test abnormal;Liver injury;Lupus-like syndrome;Mediastinal disorder;Mental disorder;Musculoskeletal discomfort;Myalgia;Myocarditis;Nasal congestion;Nausea;Nervous system disorder;Nightmare;Oedema;Orthostatic hypotension;Pancreatitis;Pancytopenia;Paradoxical pressor response;Paraesthesia;Parkinsonism;Pericarditis;Psychotic disorder;Rash;Sialoadenitis;Skin disorder;Tenderness;Thrombocytopenia;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;VIIth nerve paralysis;Vasculitis;Vomiting;Weight increased,small molecule,approved,"(S)-(-)-alpha-Methyldopa; 3-Hydroxy-alpha-methyl-L-tyrosine; Alpha medopa; alpha-Methyl dopa; alpha-methyl-L-dopa; Alphamethyldopa; AMD; Anhydrous methyldopa; L-alpha-Methyldopa; L-Methyl Dopa; Methyl dopa; Methyldopa; Methyldopa anhydrous; metildopa; α-Methyl dopa; α-methyl-L-dopa; Dopamine D2 receptor; 4.1.1.28; AADC; DDC; DOPA decarboxylase; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 2.1.1.6; 4.1.1.28; AADC; DDC; DOPA decarboxylase; 2.8.2.1; Aryl sulfotransferase 1; HAST1/HAST2; P-PST 1; Phenol sulfotransferase 1; Phenol-sulfating phenol sulfotransferase 1; ST1A1; ST1A3; STP; STP1; Thermostable phenol sulfotransferase; Ts-PST; 2.8.2.1; Aryl sulfotransferase 2; P-PST 2; Phenol sulfotransferase 2; Phenol-sulfating phenol sulfotransferase 2; ST1A2; STP2; 2.8.2.1; Aryl sulfotransferase 1A3/1A4; Catecholamine-sulfating phenol sulfotransferase; HAST3; M-PST; Monoamine-sulfating phenol sulfotransferase; Placental estrogen sulfotransferase; ST1A3; STM; Sulfotransferase 1A3/1A4; Sulfotransferase, monoamine-preferring; Thermolabile phenol sulfotransferase; TL-PST; 2.8.2.1; Aryl sulfotransferase 1A3/1A4; ST1A4; Sulfotransferase 1A3/1A4; 2.8.2.1; ST1B1; ST1B2; Sulfotransferase 1B2; Sulfotransferase family cytosolic 1B member 1; SULT1B2; Thyroid hormone sulfotransferase; 2.8.2.1; humSULTC2; ST1C2; Sulfotransferase 1C1; SULT1C#1; SULT1C1; 2.8.2.1; 2.8.2.2; ST1C3; 2.8.2.1; ST1C4; Sulfotransferase 1C2; SULT1C#2; SULT1C2; 2.8.2.2; Bile salt sulfotransferase; Dehydroepiandrosterone sulfotransferase; DHEA-ST; DHEA-ST8; HST; Hydroxysteroid Sulfotransferase; ST2; ST2A1; STD; SULT2A3; 2.8.2.-; Brain sulfotransferase-like protein; hBR-STL; hBR-STL-1; Nervous system sulfotransferase; NST; ST4A1; SULTX3; ST6B1; Thyroxine sulfotransferase; 1.14.17.1; Dopamine beta-monooxygenase; 2.1.1.28; Noradrenaline N-methyltransferase; PENT; PNMTase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1",D(2) dopamine receptor; Aromatic-L-amino-acid decarboxylase; Alpha-2A adrenergic receptor,C02AB01
methylergometrine,Haemoglobin;Haemorrhage;Uterine atony;Uterine haemorrhage;Uterine hypotonus,Abdominal pain;Acute myocardial infarction;Anaphylactic shock;Angina pectoris;Arterial spasm;Atrioventricular block;Bradycardia;Cardiac disorder;Cerebrovascular accident;Chest pain;Convulsion;Cramps of lower extremities;Dermatitis;Diarrhoea;Dizziness;Dyspnoea;Gastrointestinal pain;Haematuria;Hallucination;Headache;Hyperhidrosis;Hypertension;Hypotension;Muscle spasms;Nasal congestion;Nausea;Nervous system disorder;Palpitations;Paraesthesia;Rash;Sweating increased;Tachycardia;Thrombophlebitis;Tinnitus;Uterine contractions;Uterine contractions during pregnancy;Vasospasm;Ventricular fibrillation;Ventricular tachycardia;Vomiting;Water intoxication,small molecule,approved,"9,10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamide; D-lysergic acid 1-butanolamide; Ergotyl; Methylergobasin; Methylergometrin; Méthylergométrine; Methylergometrine; Methylergometrinum; Methylergonovine; Metilergometrina; Metilergometrinio; Dopamine D1 receptor; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",D(1A) dopamine receptor; 5-hydroxytryptamine receptor 2B, G02AB01;G02AB01;G02AC01
methylphenidate,Affect lability;Agitation;Attention deficit disorder;Attention deficit/hyperactivity disorder;Brain injury;Cardiovascular disorder;Cerebral dysfunction;Daytime sleepiness;Distractibility;Drowsiness;Electroencephalogram abnormal;Forgetfulness;Heart disease congenital;Heart malformation;Hyperkinesia;Learning disability;Memory impairment;Mental disability;Mental disorder;Minimal brain dysfunction;Mood swings;Narcolepsy;Nervous system disorder;Psychotic disorder;Somnolence;Sudden death;Ventricular arrhythmia,"Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abnormal behaviour;Abnormal dreams;Abnormal vision;Abscess;Accidental injury;Accommodation disorder;Acute coronary syndrome;Acute overdose;Adverse reaction;Affect lability;Aggression;Agitation;Akathisia;Alanine aminotransferase increased;Albuminuria;Allergic contact dermatitis;Alopecia;Anaemia;Anaphylactic shock;Anger;Angina pectoris;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Apathy;Aplastic anaemia;Appetite absent;Application site reaction;Arrhythmia;Arthralgia;Asthenia;Asthma;Attention deficit disorder;Attention deficit/hyperactivity disorder;Auricular swelling;Back pain;Benign neoplasm;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood disorder;Blood pressure fluctuation;Blood pressure increased;Body odor;Body temperature increased;Bone disorder;Bradycardia;Breast disorder;Bronchitis;Bruxism;Bullous conditions;Cardiac arrest;Cardiac death;Cardiac disorder;Cardiac murmur;Cerebral arteritis;Cerebral haemorrhage;Cerebrovascular accident;Cerebrovascular disorder;Change in blood pressure;Chest discomfort;Chest pain;Chest pain exertional;Chills;Choreoathetoid movements;Choreoathetosis;Coma;Coma hepatic;Completed suicide;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Corneal lesion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Crying;Decreased appetite;Dehydration;Delirium;Dental caries;Depersonalisation;Depressed mood;Depression;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug dependence;Drug effect decreased;Drug eruption;Drug interaction;Dry eye;Dry mouth;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Ear disorder;Ear infection;Ear pain;Ecchymosis;Eczema;Epistaxis;Erectile dysfunction;Eruption;Erythema;Erythema multiforme;Euphoric mood;Excoriation;Exfoliative conditions;Extrasystoles;Eye disorder;Eye pain;Fatigue;Feeling abnormal;Feeling hot;Feeling jittery;Feeling sad;Fixed drug eruption;Flat affect;Flushing;Fungal infection;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal obstruction;Gastrointestinal pain;Glaucoma;Grand mal convulsion;Growth retardation;Gynaecomastia;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoids;Hallucination;Hallucination, auditory;Hallucination, tactile;Hallucination, visual;Headache;Hepatic enzyme increased;Hepatic function abnormal;Hepatobiliary disease;Hernia;Herpes NOS;Herpes virus infection;Hiccups;Hostility;Hot flush;Hyperhidrosis;Hyperkinesia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypertension;Hypervigilance;Hypoglycaemia;Hypomania;Ill-defined disorder;Immune system disorder;Increased appetite;Induration;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Initial insomnia;Injury;Insomnia;Intoxication;Irritability;Joint sprain;Laryngeal pain;Laryngitis;Lethargy;Leukoderma;Leukopenia;Libido decreased;Libido disorder;Ligament sprain;Lip swelling;Liver function test abnormal;Local reaction;Logorrhoea;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mania;Mediastinal disorder;Menopausal symptoms;Mental disability;Mental disorder;Migraine;Mood swings;Motion sickness;Motor tic;Muscle spasms;Muscle tightness;Muscle twitching;Musculoskeletal discomfort;Myalgia;Mydriasis;Myocardial infarction;Nail disorder;Nasal congestion;Nasal polyps;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Neurosis;Obsessive-compulsive disorder;Obstruction;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Otitis media;Overdose;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Panic attack;Papule;Paraesthesia;Paralysis;Peripheral coldness;Peripheral vascular disorder;Personality disorder;Petechiae;Pharyngitis;Pharyngolaryngeal pain;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Platelet count decreased;Pneumonia;Poisoning;Priapism;Pruritus;Pruritus NEC;Psoriasis;Psychotic disorder;Rash;Rash macular;Rash pustular;Reaction aggravation;Rectal disorder;Reversible ischaemic neurological deficit;Rhinitis;Scab;Sensitisation;Serum sickness;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin irritation;Skin odour abnormal;Sleep disorder;Somnolence;Speech disorder;Stereotypy;Stevens-Johnson syndrome;Stomach ache;Sudden cardiac death;Sudden death;Suicidal behaviour;Suicidal ideation;Suicide;Suicide attempt;Supraventricular tachycardia;Sweating;Swelling;Sympathomimetic effect;Syncope;Tachycardia;Tearfulness;Tension;Tension headache;Therapeutic response decreased;Thinking abnormal;Thirst;Throat sore;Thrombocytopenia;Thrombocytopenic purpura;Tic;Toothache;Tourette's disorder;Tremor;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary tract disorder;Urticaria;Vasculitis;Vasculitis necrotising;Ventricular extrasystoles;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vocal tic;Vomiting;Warmth;Weight decreased;Weight gain poor;Weight increased;White blood cell count abnormal",small molecule,approved; investigational,Methyl phenidylacetate; methyl phenyl(piperidin-2-yl)acetate; methyl α-phenyl-α-(2-piperidyl)acetate; methyl α-phenyl-α-2-piperidinylacetate; Methylphenidan; Methylphenidate; Methylphenidatum; Metilfenidato; MPH; α-phenyl-2-piperidineacetic acid methyl ester; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; Carboxylesterase 1A1; CES1A1,Sodium-dependent dopamine transporter; 5-hydroxytryptamine receptor 1A; Sodium-dependent noradrenaline transporter,N06BA04
methylprednisolone,Acute leukaemia;Adrenal insufficiency;Adrenocortical insufficiency acute;Adrenogenital syndrome;Allergic conditions;Alopecia areata;Anaemia;Ankylosing spondylitis;Aplasia pure red cell;Arthritis;Aspiration;Aspiration pneumonitis;Asthma;Azotaemia;Berylliosis;Blood disorder;Brain cancer metastatic;Brain neoplasm;Brain oedema;Bursitis;Cerebritis;Chorioretinitis;Choroiditis;Colitis ulcerative;Collagen disorder;Congenital adrenal hyperplasia;Congenital aplastic anaemia;Conjunctivitis allergic;Corneal ulcer marginal;Cutaneous lupus erythematosus;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatomyositis;Diamond-Blackfan anemia;Discoid lupus erythematosus;Diuresis;Drug hypersensitivity;Drug interaction;Edema cerebral;Encephalitis;Endocrine disorder;Enteritis;Eosinophilic pneumonia;Epicondylitis;Erythema multiforme;Erythema multiforme severe;Erythroblastopenia;Fluid retention;Gastrointestinal disorder;Giant cell arteritis;Gout;Gouty arthritis;Granuloma annulare;Haemolytic anaemia;Hypercalcaemia;Hypoplastic anaemia;Idiopathic thrombocytopenic purpura;Inflammation;Inflammatory bowel disease;Injury;Iridocyclitis;Iritis;Juvenile idiopathic arthritis;Keloid scar;Keratitis;Laryngeal oedema;Leukaemia;Lichen planus;Lichen simplex chronicus;Loeffler's syndrome;Lupus erythematosus;Lymphoma;Malaise;Meningitis;Meningitis tuberculous;Metastases to central nervous system;Multiple sclerosis;Myalgia;Mycosis fungoides;Necrobiosis lipoidica diabeticorum;Neoplasm;Neoplasm malignant;Nephropathy;Nephrotic syndrome;Nephrotic syndrome with lesion of minimal change glomerulonephritis;Neuritis;Neurodermatitis;Neuropathy peripheral;Non-Hodgkin's lymphoma;Oedema;Ophthalmic herpes zoster;Optic neuritis;Osteoarthritis;Pemphigus;Perennial allergic rhinitis;Pneumonia;Pneumonia aspiration;Polymyalgia;Polymyalgia rheumatica;Polymyositis;Polyuria;Posterior uveitis;Proctocolitis;Protein urine present;Proteinuria;Psoriasis;Psoriatic arthropathy;Pulmonary eosinophilia;Pulmonary tuberculosis;Purpura;Renal failure;Rheumatic heart disease;Rheumatoid arthritis;Rhinitis perennial;Rhinitis seasonal;Sarcoidosis;Scar;Seasonal allergy;Seborrhoeic dermatitis;Secondary adrenocortical insufficiency;Secondary thrombocytopenia;Serum sickness;Sickness;Skin disorder;Skin scarring;Stevens-Johnson syndrome;Sympathetic ophthalmia;Synovitis;Systemic lupus erythematosus;Temporal arteritis;Tenosynovitis;Thrombocytopenia;Thyroiditis;Transfusion reaction;Trauma;Trichiniasis;Tuberculosis;Ulcerative keratitis;Uremia;Urticaria;Uveitis;Water retention,Abdominal distension;Abdominal pain;Abnormal behaviour;Abscess;Acne;Acneiform eruption;Acute coronary syndrome;Administration site infection;Affect lability;Affective disorder;Alanine aminotransferase increased;Alkalosis;Alkalosis hypokalaemic;Amenorrhoea;Amnesia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anxiety;Arachnoiditis;Arrhythmia;Arthralgia;Arthropathy;Aseptic necrosis;Asthenia;Atrophy;Benign intracranial hypertension;Bladder dysfunction;Blindness;Blood alkaline phosphatase increased;Blood potassium decreased;Bradycardia;Breast disorder;Bronchospasm;Ca++ increased;Calcinosis;Carbohydrate tolerance decreased;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiomegaly;Cataract subcapsular;Central serous retinopathy;Chorioretinopathy;Cognitive disorder;Confusional state;Connective tissue disorder;Convulsion;Cushingoid;Delusion;Dependence psychological;Depressed mood;Dermatitis;Dermatitis acneiform;Dermatitis perioral;Diabetes mellitus;Diabetic;Diarrhoea;Diplegia;Discomfort;Dizziness;Drug dependence;Drug withdrawal syndrome;Dyspepsia;Ear and labyrinth disorders;Ecchymosis;Electrolyte imbalance;Embolism;Embolism venous;Epidural lipomatosis;Erythema;Erythema facial;Euphoric mood;Exophthalmos;Eye disorder;Fat embolism;Fatigue;Feeling abnormal;Fluid retention;Folliculitis;Fracture;Fungal infection;Gastric haemorrhage;Gastrointestinal pain;Glaucoma;Glucose tolerance impaired;Glycosuria;Growth retardation;Haemoglobin;Haemorrhage;Hallucination;Headache;Hepatomegaly;Hiccups;Hirsutism;Hyperadrenocorticism;Hypercalcaemia;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hypertrichosis;Hypertrophic cardiomyopathy;Hypopituitarism;Hypotension;Ill-defined disorder;Immune system disorder;Impaired healing;Increased appetite;Increased insulin requirement;Increased tendency to bruise;Infarction;Infection;Infestation;Infestation NOS;Inflammation;Injection site exfoliation;Injury;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Irritability;Latent tuberculosis;Leukocytosis;Leukoderma;Lipomatosis;Loss of consciousness;Malaise;Malnutrition;Mania;Mediastinal disorder;Meningitis;Menstruation irregular;Mental disorder;Metabolic acidosis;Miliaria;Monoplegia;Mood swings;Multiple fractures;Muscle atrophy;Muscle mass;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial rupture;Myopathy;Nausea;Necrosis;Nervous system disorder;Neuritis;Neuropathic arthropathy;Neuropathy;Neuropathy peripheral;Nitrogen balance negative;Obesity;Oesophageal candidiasis;Oesophagitis;Oesophagitis ulcerative;Opportunistic infection;Optic neuritis;Osteoarthritis;Osteonecrosis;Osteoporosis;Pancreatitis;Papilloedema;Paraesthesia;Paraparesis;Paraplegia;Peptic ulcer;Peptic ulcer haemorrhage;Personality change;Petechiae;Pituitary-dependent Cushing's syndrome;Pruritus;Psychotic behaviour;Psychotic disorder;Pulmonary oedema;Rash;Rhinitis;Schizophrenia;Scleral thinning;Secondary infection;Shock;Skin atrophy;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin scaly;Skin striae;Skin thinness;Slough injection site;Spinal compression fracture;Steroid myopathy;Steroid withdrawal syndrome;Suicidal ideation;Sweating;Sweating increased;Syncope;Tachycardia;Telangiectasia;Tendon rupture;Thromboembolism;Thrombophlebitis;Tingling sensation;Trauma;Unspecified disorder of skin and subcutaneous tissue;Urine calcium increased;Urticaria;Vasculitis;Vertigo;Visual impairment;Vomiting;Weight increased;Withdrawal symptom,small molecule,approved; vet_approved,"(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione; 1-dehydro-6α-methylhydrocortisone; 6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione; delta(1)-6alpha-Methylhydrocortisone; Methylprednisolon; Methylprednisolone; Methylprednisolonum; Metilprednisolona; GR; GRL; Nuclear receptor subfamily 3 group C member 1; Annexin I; Annexin-1; ANX1; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; LPC1; p35; Phospholipase A2 inhibitory protein; 1.1.1.-; 1.1.1.112; 1.1.1.209; 1.1.1.210; 1.1.1.357; 1.1.1.51; 1.1.1.53; 1.1.1.62; 1.3.1.20; 20-alpha-HSD; 20-alpha-hydroxysteroid dehydrogenase; Chlordecone reductase homolog HAKRC; DD1; DDH; DDH1; Dihydrodiol dehydrogenase 1; HBAB; High-affinity hepatic bile acid-binding protein; 1.-.-.-; 1.1.1.112; 1.1.1.209; 1.1.1.53; 1.1.1.62; 1.3.1.20; 3-alpha-HSD3; Chlordecone reductase homolog HAKRD; DD-2; DD/BABP; DD2; DDH2; Dihydrodiol dehydrogenase 2; Dihydrodiol dehydrogenase/bile acid-binding protein; Type III 3-alpha-hydroxysteroid dehydrogenase; 1.1.1.-; 1.1.1.210; 1.1.1.53; 1.1.1.62; 17-beta-HSD 5; 17-beta-hydroxysteroid dehydrogenase type 5; 3-alpha-HSD type 2; 3-alpha-HSD type II, brain; 3-alpha-hydroxysteroid dehydrogenase type 2; Chlordecone reductase homolog HAKRb; DD-3; DD3; DDH1; Dihydrodiol dehydrogenase 3; Dihydrodiol dehydrogenase type I; HA1753; HSD17B5; KIAA0119; PGFS; Prostaglandin F synthase; Testosterone 17-beta-dehydrogenase 5; 1.1.1.-; 1.1.1.209; 1.1.1.210; 1.1.1.51; 1.1.1.53; 1.1.1.62; 3-alpha-HSD1; 3-alpha-hydroxysteroid dehydrogenase type I; 3alpha-hydroxysteroid 3-dehydrogenase; CDR; CHDR; Chlordecone reductase; DD-4; DD4; Dihydrodiol dehydrogenase 4; HAKRA; 1.1.1.146; 11-beta-HSD1; 11-DH; 7-oxosteroid reductase; Corticosteroid 11-beta-dehydrogenase isozyme 1; HSD11; HSD11L; SDR26C1; Short chain dehydrogenase/reductase family 26C member 1; 1.1.1.-; 11-beta-HSD type II; 11-beta-HSD2; 11-beta-hydroxysteroid dehydrogenase type II; 11-DH2; 11-HSD type II; Corticosteroid 11-beta-dehydrogenase isozyme 2; HSD11K; NAD-dependent 11-beta-hydroxysteroid dehydrogenase; SDR9C3; Short chain dehydrogenase/reductase family 9C member 3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Glucocorticoid receptor; Annexin A1, D07CA02; D10AA02; H02AB04; H02BX01; S01CA08; S03CA07;D07AA01
methyltestosterone,Androgen deficiency;Breast cancer;Cryptorchism;Delayed puberty;Hypogonadism male;Injury;Neoplasm;Orchitis;Orchitis noninfective;Primary hypogonadism;Puberty;Secondary hypogonadism;Testosterone deficiency;Trauma,Alopecia;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Anxiety;Azoospermia;Blood cholesterol increased;Cholesterol serum elevated;Clotting;Coagulopathy;Disturbance in sexual arousal;Embolism venous;Enlarged clitoris;Gynaecomastia;Haemoglobin;Haemorrhage;Headache;Hirsutism;Jaundice cholestatic;Libido decreased;Menstruation irregular;Nausea;Oligospermia;Paraesthesia;Paresthesia generalized;Peliosis hepatis;Polycythaemia;Venous thromboembolism;Virilism,small molecule,approved,"17-beta-Hydroxy-17-methylandrost-4-en-3-one; 17-methyltestosterone; 17alpha-Methyl-3-oxo-4-androsten-17beta-ol; 17alpha-Methyltestosterone; 17beta-Hydroxy-17-methylandrost-4-en-3-one; 17α-methyl-Δ4-androsten-17β-ol-3-one; 17α-methyltestosterone; 4-Androstene-17alpha-methyl-17beta-ol-3-one; Methyltestosterone; Methyltestosteronum; Metiltestosterona; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Androgen receptor; Estrogen receptor, G03EA01; G03EK01;G03BA02
methysergide,Vascular headache,Abdominal pain;Alopecia;Aortic embolus;Arthralgia;Asthenia;Ataxia;Back pain;Blood urea increased;Body temperature increased;Cardiac murmur;Chest pain;Constipation;Convulsion;Dermatitis;Diarrhoea;Discomfort;Dissociation;Dizziness;Drowsiness;Dyspepsia;Dyspnoea;Dysuria;Eosinophilia;Euphoric mood;Fatigue;Feeling abnormal;Flank pain;Flushing;Friction rub;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;General symptom;Gravitational oedema;Heartburn;Hyperaesthesia;Ill-defined disorder;Insomnia;Leg edema;Leg pain;Leriche syndrome;Lightheadedness;Malaise;Musculoskeletal discomfort;Myalgia;Mydriasis;Nausea;Neutropenia;Oedema;Oedema peripheral;Oliguria;Orthostatic hypotension;Pain;Pain in extremity;Paraesthesia;Peyronie's disease;Pleural effusion;Polyuria;Rash;Red blood cell sedimentation rate increased;Retroperitoneal fibrosis;Somnolence;Tachycardia;Telangiectasia;Thrombocytopenia;Thrombophlebitis;Urinary tract obstruction;Urine output increased;Vascular insufficiency;Vomiting;Weight decreased;Weight increased,small molecule,approved,"(+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8β-carboxamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; 1-Methyl-D-lysergic acid butanolamide; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 1-Methyllysergic acid butanolamide; 1-Methylmethylergonovine; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide; Méthysergide; Methysergide; Methysergidum; Metisergida; Metisergido; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 7; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1F; 5-hydroxytryptamine receptor 1E,N02CA04
metoclopramide,Abdominal distension;Abnormal behaviour;Anorexia;Asthma;Azotaemia;Cardiac failure congestive;Cyclic vomiting syndrome;Decreased appetite;Delayed gastric emptying;Diabetes mellitus;Diabetic;Diabetic gastroparesis;Dyspepsia;Fullness abdominal;Gastric atony;Gastrointestinal disorder;Gastrooesophageal reflux disease;Heartburn;Hypertension;Hypertensive;Hypotonia;Impaired gastric emptying;Infection;Malaise;Migraine;Motion sickness;Muscle relaxant therapy;Nausea;Nausea postoperative;Neoplasm malignant;Oesophageal ulcer;Post procedural diarrhoea;Post vagotomy diarrhea;Postoperative vomiting;Procedural nausea;Procedural vomiting;Retention gastric;Sickness;Uremia;Vermiculation;Vomiting,Acute depression;Agitation;Agranulocytosis;Akathisia;Akinesia;Altered state of consciousness;Amenorrhoea;Angioedema;Anxiety;Asthenia;Asthma;Atrial fibrillation;Atrioventricular block;Autonomic dysfunction;Autonomic nervous system imbalance;Block heart;Blood disorder;Body temperature increased;Bradycardia;Bradykinesia;Breast enlargement;Bronchospasm;Cardiac arrest;Cardiac failure congestive;Cardio-respiratory arrest;Cogwheel rigidity;Completed suicide;Confusional state;Consciousness abnormal;Convulsion;Convulsive seizure;Delirium;Depression;Depression suicidal;Dermatitis;Diarrhoea;Dizziness;Drowsiness;Dyskinesia;Dysphoria;Dyspnoea;Dystonia;Dystonic reaction;Erectile dysfunction;Extrapyramidal disorder;Fatigue;Feeling abnormal;Feeling jittery;Fluid retention;Flushing;Function kidney decreased;Galactorrhoea;Grimacing;Gynaecomastia;Hallucination;Headache;Hepatotoxicity;Hyperprolactinaemia;Hyperpyrexia;Hypersensitivity;Hypertension;Hypotension;Incontinence;Insomnia;Jaundice;Laryngeal oedema;Laryngospasm;Lassitude;Leukopenia;Mania;Masked facies;Menstruation irregular;Methaemoglobinaemia;Motor restlessness;Movements involuntary;Muscle rigidity;Muscle spasms;Nausea;Nervousness;Neuroleptic malignant syndrome;Neutropenia;Obsessive rumination;Obsessive thoughts;Oculogyric crisis;Oedema;Opisthotonus;Palpitations;Pollakiuria;Porphyrin metabolism disorder;Priapism;Protrusion tongue;Rash;Rash maculo-papular;Renal impairment;Respiratory failure;Sexual dysfunction;Sinus arrest;Somnolence;Stridor;Suicidal ideation;Suicide;Sulphaemoglobinaemia;Supraventricular tachycardia;Tachycardia;Tardive dyskinesia;Tetanus;Tetanus-like;Torticollis;Tremor;Trismus;Upper airway obstruction;Urinary incontinence;Urticaria;Ventricular fibrillation;Ventricular tachycardia;Visual disturbance;Visual impairment;Wheezing,small molecule,approved; investigational,"2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide; 2-methoxy-5-chloroprocainamide; 4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide; 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide; Metoclopramida; Metoclopramide; Metoclopramidum; 5-HT-4; 5-HT4; Serotonin receptor 4; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; Dopamine D2 receptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 4; 5-hydroxytryptamine receptor 3A; Muscarinic acetylcholine receptor M1; D(2) dopamine receptor,A03FA01
metolazone,Cardiac failure congestive;Discomfort;Diuresis;Essential hypertension;Fluid retention;Foetor hepaticus;Gravitational oedema;Hepatocellular injury;Hypertension;Liver disorder;Nephropathy;Nephrotic syndrome;Oedema;Polyuria;Pregnancy;Water retention,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Agitation;Agranulocytosis;Alkalosis hypochloraemic;Anaemia;Angiitis necrotising;Anorexia;Anxiety;Arthralgia;Asthenia;Back pain;Blood urea increased;Blood uric acid increased;Chest pain;Chills;Constipation;Cough;Cramp muscle;Cutaneous vasculitis;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Epigastric distress;Epistaxis;Erectile dysfunction;Erythema multiforme;Eye pruritus;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal pain;Glycosuria;Headache;Hepatitis;Hypercalcaemia;Hyperglycaemia;Hypersensitivity;Hypertension;Hypertensive;Hyperuricaemia;Hypochloraemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoplastic anaemia;Hypovolaemia;Ill-defined disorder;Insomnia;Jaundice cholestatic;Lassitude;Lethargy;Leukopenia;Lightheadedness;Loss of consciousness;Major depression;Malaise;Muscle spasms;Musculoskeletal discomfort;Nausea;Nervousness;Neuropathy;Neuropathy peripheral;Nocturia;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Pain;Palpitations;Pancreatitis;Paraesthesia;Peripheral coldness;Petechiae;Photosensitivity;Photosensitivity reaction;Pruritus;Psychotic depression;Purpura;Rash;Serum urea increased;Shock;Sinus congestion;Skin exfoliation;Skin necrosis;Somnolence;Stevens-Johnson syndrome;Swelling;Syncope;Taste bitter;Tension;Throat sore;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Urticaria;Vascular purpura;Vasculitis necrotising;Venous thrombosis;Vertigo;Vision blurred;Vomiting,small molecule,approved,"2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide; Metolazon; Metolazona; Métolazone; Metolazone; Metolazonum; Na-Cl cotransporter; Na-Cl symporter; NCC; Thiazide-sensitive sodium-chloride cotransporter; TSC",Solute carrier family 12 member 3, C03BA08; G01AE10;C03BA08;C03EA12
metoprolol,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Anginal attack;Arrhythmia;Atrial fibrillation;Bradycardia;Cardiac disorder;Cardiac failure;Cardiac failure chronic;Cardiogenic shock;Cardiovascular disorder;Cerebrovascular accident;Diabetes mellitus;Diabetic nephropathy;Hepatic cirrhosis;Hyperlipidaemia;Hypertension;Hypertensive;Hypertensive crisis;Hyperthyroidism;Hypotension;Migraine;Myocardial infarction;Myocardial ischaemia;Obstructive airways disorder;Oedema;Palpitations;Renal failure;Renal failure chronic;Supraventricular tachyarrhythmia;Supraventricular tachycardia;Tachycardia;Unspecified circulatory system disorder;Ventricular extrasystoles,Abdominal pain;Abdominal pain upper;Abnormal dreams;Ache;Acute myocardial infarction;Affect lability;Agranulocytosis;Alertness decreased;Alopecia;Alopecia reversible;Altered state of consciousness;Amnesia;Angina pectoris;Angiopathy;Anxiety;Arrhythmia;Arterial insufficiency;Arthralgia;Arthritis;Asthenia;Atrioventricular block;Atrioventricular block complete;Atrioventricular block first degree;Auditory disorder NOS;Block heart;Blood triglycerides increased;Body temperature increased;Bradycardia;Breast disorder;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac output decreased;Cardiogenic shock;Cardiovascular disorder;Catatonia;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Claudication;Cold hands & feet;Coma;Conduction disorder;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Coronary artery disease;Cramp muscle;Cyanosis;Deafness;Depressed level of consciousness;Depression;Dermatitis;Dermatitis psoriasiform;Diabetes mellitus;Diabetes mellitus exacerbated;Diarrhoea;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dyspnoea exertional;Ear and labyrinth disorders;Emotional distress;Erectile dysfunction;Eye disorder;Eye irritation;Eye pruritus;Fatigue;Feeling abnormal;Flatulence;Gangrene;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Hearing impaired;Heartburn;Hepatic cirrhosis;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoglycaemia;Hypotension;Immune system disorder;Insomnia;Intermittent claudication;Jaundice;Laryngospasm;Leukopenia;Libido decreased;Libido disorder;Lightheadedness;Liver function test abnormal;Loss of consciousness;Loss of libido;Mediastinal disorder;Memory impairment;Menopausal symptoms;Mental disability;Mental disorder;Mood swings;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Nausea;Nervous system disorder;Nervousness;Nightmare;Obstructive airways disorder;Oedema;Oedema peripheral;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Pain;Palpitations;Paraesthesia;Peripheral coldness;Personality disorder;Peyronie's disease;Photosensitivity;Photosensitivity reaction;Pneumonia;Precordial pain;Pruritus;Psoriasis;Psoriasis flare-up;Purpura non-thrombocytopenic;Rales;Rash;Raynaud's disease;Raynaud's phenomenon;Respiratory distress;Retroperitoneal fibrosis;Rhinitis;Sexual dysfunction;Shock;Short-term memory loss;Sinus arrest;Skin disorder;Skin lesion;Sleep disorder;Sleep disturbance;Somnolence;Status asthmaticus;Stomach ache;Sweating;Sweating increased;Syncope;Tachycardia;Taste bitter;Tension;Throat sore;Thrombocytopenia;Thrombocytopenic purpura;Tinnitus;Unspecified circulatory system disorder;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vivid dreams;Vomiting;Weight increased;Wheezing,small molecule,approved; investigational,"(RS)-Metoprolol; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; DL-metoprolol; Metoprolol; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; hOCT2; OCT2; Organic cation transporter 2",Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Beta adrenergic receptor, C07AB02; C07BB02; C07BB52; C07CB02; C07FB13; C07FX03; C07FX05;C07AB02;C07FB02
metronidazole,Abdominal abscess;Abdominal infection;Abscess;Amoebiasis;Amoebic colitis;Bacteraemia;Bacterial infection;Bacterial sepsis;Bone and joint infections;Brain abscess;Crohn's disease;Decubitus ulcer;Empyema;Endocarditis;Endometritis;Endomyometritis;Erythema;Foetor hepaticus;Gastrointestinal disorder;Genital infection;Genital infection female;Giardiasis;Gingivitis ulcerative;Gynecological infection;Hepatic amoebiasis;Hepatocellular injury;Herpes simplex;Infection;Leg ulcer;Liver abscess;Liver disorder;Lower respiratory tract infection;Lung abscess;Meningitis;Nervousness;Osteomyelitis;Papule;Parametritis;Pelvic abscess;Pericoronitis;Peritonitis;Pneumonia;Pneumonia necrotising;Post procedural infection;Postoperative infection;Postoperative wound infection;Postpartum sepsis;Pustule;Rash pustular;Rosacea;Sepsis;Septicemia;Sexually transmitted disease;Skin ulcer;Subclinical infection;Tension;Tooth infection;Trichomonal vaginitis;Trichomoniasis;Tubo-ovarian abscess;Unspecified disorder of intestine;Urogenital trichomoniasis;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginitis bacterial;Vaginitis gardnerella;Vulvovaginitis;Vulvovaginitis trichomonal,Abdominal bloating;Abdominal cramps;Abdominal discomfort;Abdominal distension;Abdominal distress;Abdominal pain;Abdominal pain upper;Agranulocytosis;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Aplastic anaemia;Application site reaction;Arthralgia;Asthenia;Asthma;Ataxia;Back pain;Bacterial infection;Basal cell carcinoma;Bladder pain;Blood and lymphatic system disorders;Blood disorder;Body temperature increased;Bone marrow depression;Breast disorder;Breast enlargement;Breast pain;Bronchitis;Burning feeling vagina;Burning sensation;Candida cervicitis;Candida infection;Cardiac disorder;Central nervous system disorder;Cerebellar syndrome;Chest pain;Color vision change;Colour blindness acquired;Condition aggravated;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Convulsive seizure;Coordination abnormal;Cramp muscle;Cystitis;Cystitis noninfective;Decreased appetite;Depressed mood;Depression;Dermatitis;Dermatitis bullous;Dermatitis contact;Diarrhoea;Diplopia;Disorder sight;Disorientation;Distress;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dysmenorrhoea;Dyspareunia;Dyspepsia;Dysuria;Emotional distress;Encephalopathy;Eosinophilia;Epigastric distress;Epigastric pain;Eructation;Eruption;Erythema;Erythema multiforme;Eye disorder;Eye irritation;Fatigue;Feeling abnormal;Flatulence;Flushing;Fungal infection;Galactorrhoea;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal tract irritation;Gingivitis;Glossitis;Gynaecomastia;Hallucination;Headache;Hepatic failure;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hiccups;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Immune system disorder;Incontinence;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Influenza-like symptoms;Insomnia;Irritability;Jaundice;Lacrimation increased;Lactation female;Leukopenia;Leukorrhea;Libido decreased;Liver function test abnormal;Liver injury;Local reaction;Localised oedema;Loose stools;Loss of consciousness;Loss of libido;Malaise;Mediastinal disorder;Meningitis aseptic;Menorrhagia;Mental disorder;Metrorrhagia;Mucosal inflammation;Mucous membrane disorder;Muscle spasms;Musculoskeletal discomfort;Myopia;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm;Neoplasm malignant;Nervous system disorder;Neuritis;Neurological symptom;Neuropathy;Neuropathy peripheral;Neutropenia;Numbness;Numbness of limbs;Nystagmus;Oedema;Oedema genital;Oedema labial genital;Oily skin;Optic nerve disorder;Osteoarthritis;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paresthesia of limbs;Pelvic discomfort;Peripheral sensory neuropathy;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyuria;Pregnancy;Proctitis;Pruritus;Pruritus generalised;Pruritus genital;Pseudomembranous colitis;Psychotic disorder;Pyuria;Rash;Rash erythematous;Rash papular;Rash pustular;Redness;Rhinitis;Rosacea;Salpingitis;Seborrhoeic dermatitis;Sensory loss;Serum sickness;Shock;Sickness;Sinusitis;Skin burning sensation;Skin discomfort;Skin disorder;Skin exfoliation;Skin irritation;Skin tightness;Somnolence;Stevens-Johnson syndrome;Stinging;Stomatitis;Sweating;Syncope;Taste altered;Taste disorders;Taste metallic;Thrombocytopenia;Thrombophlebitis;Tingling sensation;Tinnitus;Tongue coated;Tongue discolouration;Toxic epidermal necrolysis;Traumatic liver injury;Tremor;Unspecified disorder of intestine;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Vaginal discharge;Vaginal dryness;Vaginal infection;Vaginal inflammation;Vaginal itching;Vaginal moniliasis;Vaginal mycosis;Vertigo;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting;Vulval disorder;Vulvovaginal burning sensation;Vulvovaginal candidiasis;Vulvovaginal disorder;Vulvovaginal dryness;Vulvovaginal mycotic infection;Vulvovaginal pruritus;White blood cell count decreased;White blood cell count low;Yeast infection,small molecule,approved,"1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole; 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole; 1-(β-ethylol)-2-methyl-5-nitro-3-azapyrrole; 1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole; 1-(β-oxyethyl)-2-methyl-5-nitroimidazole; 2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole; 2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole; 2-methyl-5-nitroimidazole-1-ethanol; Metronidazol; Métronidazole; Metronidazole; Metronidazolum; 1.-.-.-; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Oxygen-insensitive NADPH nitroreductase; Anaerobic bacterial DNA; Protozoal DNA, A01AB17; A02BD01; A02BD02; A02BD03; A02BD08; A02BD13; A02BD15; D06BX01; G01AF01; G01AF20; J01RA03; J01RA04; J01RA10; J01RA14; J01XD01; P01AB01; P01AB51; P01AB52;A01AB17;A02BD11
metyrapone,Adrenal neoplasm;Adrenocorticotropic hormone deficiency;Agitation;Cushing's syndrome;Hyperaldosteronism;Hyperkinesia;Oedema;Pituitary tumour,Abdominal discomfort;Abdominal pain;Adrenal insufficiency;Allergic rash;Alopecia;Angiopathy;Bone marrow depression;Dermatitis atopic;Dizziness;Endocrine disorder;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hirsutism;Hypertension;Hypotension;Nausea;Nervous system disorder;Pain;Pancytopenia;Skin disorder;Unspecified disorder of skin and subcutaneous tissue;Vomiting;White blood cell count decreased,small molecule,approved; investigational,"Metirapona; Métyrapone; Metyrapone; Metyraponum; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; 1.14.15.1; cyp101; Cytochrome P450-cam; Cytochrome P450cam; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; ALDOS; Aldosterone synthase; Aldosterone-synthesizing enzyme; Corticosterone 18-monooxygenase, CYP11B2; CYPXIB2; Cytochrome P-450Aldo; Cytochrome P-450C18; Steroid 11-beta-hydroxylase, CYP11B2; Steroid 18-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3","Cytochrome P450 11B1, mitochondrial; Camphor 5-monooxygenase",V04CD01
mexiletine,Arrhythmia;Sustained ventricular tachycardia;Ventricular arrhythmia;Ventricular tachycardia,Abdominal discomfort;Abdominal pain;Acute yellow liver atrophy;Agranulocytosis;Alopecia;Amnesia;Angina pectoris;Antinuclear antibody positive;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Asthenia;Ataxia;Atrial arrhythmia;Atrioventricular block;Blood disorder;Body temperature increased;Bradycardia;Cardiac failure congestive;Cardiogenic shock;Chest pain;Confusional state;Constipation;Convulsion;Coordination abnormal;Cramp muscle;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Distress gastrointestinal;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Erectile dysfunction;Erythema multiforme;Fatigue;Feeling abnormal;Gastrointestinal pain;Hallucination;Headache;Heartburn;Hepatitis;Hiccups;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Ill-defined disorder;Leukopenia;Libido decreased;Lightheadedness;Liver function test abnormal;Loss of consciousness;Lung infiltration;Malaise;Menopausal symptoms;Muscle spasms;Musculoskeletal discomfort;Myelofibrosis;Myeloid metaplasia;Nausea;Nervousness;Neutropenia;Numbness;Nystagmus;Oedema;Oesophageal ulcer;Pain;Palpitations;Pancreatitis;Paraesthesia;Peptic ulcer;Pharyngitis;Psychotic disorder;Pulmonary fibrosis;Pulmonary toxicity;Rash;Sensory loss;Shock;Short-term memory loss;Somnolence;Speech disorder;Speech impairment NOS;Stevens-Johnson syndrome;Sweating increased;Syncope;Taste altered;Tension;Thrombocytopenia;Tinnitus;Tremor;Upper gastrointestinal haemorrhage;Urinary hesitation;Ventricular arrhythmia;Ventricular extrasystoles;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,"(±)-1-(2,6-dimethylphenoxy)propan-2-amine; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; 1-(2,6-dimethylphenoxy)-2-propanamine; 1-(2',6'-dimethylphenoxy)-2-aminopropane; 1-methyl-2-(2,6-xylyloxy)ethanamine; Mexiletina; Mexiletine; Mexilétine; Mexiletinum; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Ah receptor; AhR; BHLHE76; Class E basic helix-loop-helix protein 76; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Sodium channel protein type 5 subunit alpha; Aryl hydrocarbon receptor,C01BB02
mianserin,Major depression,Agitation;Agranulocytosis;Anaemia;Angiopathy;Arthralgia;Arthritis;Asthenia;Blood disorder;Bone marrow depression;Bradycardia;Breast disorder;Cardiac arrest;Cardiac disorder;Cardiac failure;Confusional state;Connective tissue disorder;Constipation;Convulsion;Depressive symptom;Dermatitis;Diplopia;Dizziness;Drowsiness;Dry mouth;Ear and labyrinth disorders;Electrocardiogram QT prolonged;Erectile dysfunction;Eye disorder;Fatigue;Feeling abnormal;Gastrointestinal disorder;Gynaecomastia;Headache;Hepatic enzyme increased;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hyperkinesia;Hypertension;Hypomania;Hypotension;Jaundice;Lethargy;Leukopenia;Loss of consciousness;Mediastinal disorder;Mental disorder;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nervous system disorder;Neuroleptic malignant syndrome;Neutropenia;Oedema;Pancytopenia;Paraesthesia;Pruritus;Rash;Restless legs syndrome;Shock;Skin disorder;Somnolence;Suicidal ideation;Syncope;Tachycardia;Thrombocytopenia;Tinnitus;Torsade de pointes;Tremor;Unspecified disorder of skin and subcutaneous tissue;Vertigo;Weight increased,small molecule,approved; investigational,"1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine; Mianserin; Mianserina; Mianserine; Miansérine; Mianserinum; Mianseryna; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; H1-R; H1R; HH1R; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; AXOR35; G-protein coupled receptor 105; GPCR105; GPRv53; H4R; HH4R; Pfi-013; SP9144; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; Dopamine D3 receptor; K-OR-1; KOR-1; OPRK; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; Dopamine D2 receptor; 5-HT-6; 5-HT6; Serotonin receptor 6; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Alpha-2A adrenergic receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2C; Histamine H1 receptor; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; Histamine H4 receptor; 5-hydroxytryptamine receptor 1A; Alpha-2C adrenergic receptor; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 1F; Alpha-2B adrenergic receptor; D(3) dopamine receptor; Kappa-type opioid receptor; Sodium-dependent dopamine transporter; 5-hydroxytryptamine receptor 7; D(2) dopamine receptor; 5-hydroxytryptamine receptor 6; Alpha-1 adrenergic receptors; D(1) dopamine receptor,N06AX03
miconazole,Body tinea;Candida infection;Diabetes mellitus;Diabetic;Immunocompromised;Immunodeficiency;Infection;Infection mixed;Neoplasm malignant;Oral candidiasis;Oropharyngeal candidiasis;Skin candida;Tinea cruris;Tinea pedis;Tinea versicolour;Vaginal moniliasis;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginitis,Abdominal pain;Abdominal pain upper;Ageusia;Allergic conditions;Allergic contact dermatitis;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Application site discomfort;Application site pain;Asthenia;Blood disorder;Burning feeling vagina;Chills;Choking;Cough;Cramp muscle;Decreased appetite;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Dry mouth;Dysgeusia;Erythema multiforme;Fatigue;Feeling abnormal;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gingival pain;Gingival swelling;Glossodynia;Headache;Hepatitis;Hepatobiliary disease;Hypersensitivity;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Instillation site pain;Lymphopenia;Malaise;Mediastinal disorder;Mouth ulceration;Muscle spasms;Nausea;Nervous system disorder;Neutropenia;Oral discomfort;Oral pain;Pain;Pruritus;Rash;Regurgitation;Regurgitation of food;Stevens-Johnson syndrome;Stomatitis;Taste altered;Tongue ulceration;Tooth disorder;Toothache;Toxic epidermal necrolysis;Upper respiratory tract infection;Urticaria;Vomiting;Vulvovaginal burning sensation,small molecule,approved; investigational; vet_approved,"1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole; Miconazol; Miconazole; Miconazolum; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase; 1.14.13.39; cNOS; Constitutive NOS; EC-NOS; Endothelial NOS; eNOS; Nitric oxide synthase, endothelial; NOS type III; NOSIII; 1.14.13.39; HEP-NOS; Hepatocyte NOS; Inducible NO synthase; Inducible NOS; iNOS; NOS type II; NOS2A; Peptidyl-cysteine S-nitrosylase NOS2; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; BK channel; BKCA alpha; Calcium-activated potassium channel, subfamily M subunit alpha-1; hSlo; K(VCA)alpha; KCa1.1; KCNMA; Maxi K channel; MaxiK; SLO; Slo homolog; Slo-alpha; Slo1; Slowpoke homolog; BK channel subunit beta-1; BKbeta; BKbeta1; Calcium-activated potassium channel subunit beta; Calcium-activated potassium channel, subfamily M subunit beta-1; Charybdotoxin receptor subunit beta-1; Hbeta1; K(VCA)beta-1; Maxi K channel subunit beta-1; Slo-beta; Slo-beta-1; BK channel subunit beta-2; BKbeta2; Calcium-activated potassium channel, subfamily M subunit beta-2; Charybdotoxin receptor subunit beta-2; Hbeta2; Hbeta3; K(VCA)beta-2; Maxi K channel subunit beta-2; Slo-beta-2; BK channel subunit beta-3; BKbeta3; Calcium-activated potassium channel, subfamily M subunit beta-3; Charybdotoxin receptor subunit beta-3; Hbeta3; K(VCA)beta-3; KCNMB2; KCNMBL; Maxi K channel subunit beta-3; Slo-beta-3; BK channel subunit beta-4; BKbeta4; Calcium-activated potassium channel, subfamily M subunit beta-4; Charybdotoxin receptor subunit beta-4; Hbeta4; K(VCA)beta-4; Maxi K channel subunit beta-4; Slo-beta-4; Gardos channel; hIK1; hKCa4; hSK4; IK1; IKCA1; KCa3.1; KCA4; Putative Gardos channel; SK4; SKCa 4; SKCa4; hSK1; KCa2.1; SK; SK1; SKCa 1; SKCa1; KCa2.2; SK2; SKCa 2; SKCa2; K3; KCa2.3; SK3; SKCa 3; SKCa3; Potassium voltage-gated channel subfamily D member 1; Shal-type potassium channel KCND1; Voltage-gated potassium channel subunit Kv4.1; KIAA1044; Potassium voltage-gated channel subfamily D member 2; Voltage-gated potassium channel subunit Kv4.2; Potassium voltage-gated channel subfamily D member 3; Voltage-gated potassium channel subunit Kv4.3; Delayed-rectifier K(+) channel alpha subunit 1; Delayed-rectifier potassium channel subunit Kv9.1; hKv9.1; Potassium voltage-gated channel modifier subfamily S member 1; Delayed-rectifier K(+) channel alpha subunit 3; Delayed-rectifier potassium channel subunit Kv9.3; Kv9.3; Potassium voltage-gated channel subfamily S member 3; Voltage-gated K(+) channel HuKI; Voltage-gated potassium channel HBK1; Voltage-gated potassium channel subunit Kv1.1; Voltage-gated potassium channel subunit Kv1.8; NGK1; Voltage-gated K(+) channel HuKIV; Voltage-gated potassium channel HBK5; Voltage-gated potassium channel subunit Kv1.2; HGK5; HLK3; HPCN3; Voltage-gated K(+) channel HuKIII; Voltage-gated potassium channel subunit Kv1.3; HPCN2; KCNA4L; Voltage-gated K(+) channel HuKII; Voltage-gated potassium channel HBK4; Voltage-gated potassium channel HK1; Voltage-gated potassium channel subunit Kv1.4; HPCN1; Voltage-gated potassium channel HK2; Voltage-gated potassium channel subunit Kv1.5; Voltage-gated potassium channel HBK2; Voltage-gated potassium channel subunit Kv1.6; Delayed rectifier potassium channel 1; DRK1; h-DRK1; Voltage-gated potassium channel subunit Kv2.1; Voltage-gated potassium channel subunit Kv2.2; Delayed rectifier potassium channel subunit IsK; IKs producing slow voltage-gated potassium channel subunit beta Mink; Minimal potassium channel; MinK; Minimum potassium ion channel-related peptide 1; MinK-related peptide 1; MiRP1; Potassium channel subunit beta MiRP1; Minimum potassium ion channel-related peptide 2; MinK-related peptide 2; MiRP2; Potassium channel subunit beta MiRP2; Minimum potassium ion channel-related peptide 3; MinK-related peptide 3; MiRP3; Potassium channel subunit beta MiRP3; AMME syndrome candidate gene 2 protein; AMMECR2; KCNE1L; Potassium channel subunit beta MiRP4; Potassium voltage-gated channel subfamily E member 1-like protein; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1; KCNA8; KCNA9; KQT-like 1; KVLQT1; Voltage-gated potassium channel subunit Kv7.1; KQT-like 2; Neuroblastoma-specific potassium channel subunit alpha KvLQT2; Voltage-gated potassium channel subunit Kv7.2; KQT-like 3; Potassium channel subunit alpha KvLQT3; Voltage-gated potassium channel subunit Kv7.3; KQT-like 4; Potassium channel subunit alpha KvLQT4; Voltage-gated potassium channel subunit Kv7.4; KQT-like 5; Potassium channel subunit alpha KvLQT5; Voltage-gated potassium channel subunit Kv7.5; Neuronal potassium channel alpha subunit HNKA; Voltage-gated potassium channel subunit Kv8.1; Voltage-gated potassium channel subunit Kv8.2; EAG; EAG channel 1; EAG1; Ether-a-go-go potassium channel 1; h-eag; hEAG1; Potassium voltage-gated channel subfamily H member 1; Voltage-gated potassium channel subunit Kv10.1; BEC2; Brain-specific eag-like channel 2; ELK channel 1; ELK1; Ether-a-go-go-like potassium channel 1; Potassium voltage-gated channel subfamily H member 4; Voltage-gated potassium channel subunit Kv12.3; EAG2; Ether-a-go-go potassium channel 2; hEAG2; Potassium voltage-gated channel subfamily H member 5; Voltage-gated potassium channel subunit Kv10.2; ELK channel 3; ELK1; ELK3; Ether-a-go-go-like potassium channel 3; hElk-1; Potassium voltage-gated channel subfamily H member 8; Voltage-gated potassium channel subunit Kv12.1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; BEC1; Brain-specific eag-like channel 1; ELK channel 2; ELK2; Ether-a-go-go-like potassium channel 2; KIAA1282; Potassium voltage-gated channel subfamily H member 3; Voltage-gated potassium channel subunit Kv12.2; Eag-related protein 2; ERG-2; ERG2; Ether-a-go-go-related gene potassium channel 2; Ether-a-go-go-related protein 2; hERG-2; hERG2; Potassium voltage-gated channel subfamily H member 6; Voltage-gated potassium channel subunit Kv11.2; Eag-related protein 3; ERG-3; ERG3; Ether-a-go-go-related gene potassium channel 3; Ether-a-go-go-related protein 3; hERG-3; Potassium voltage-gated channel subfamily H member 7; Voltage-gated potassium channel subunit Kv11.3; NGK2; Potassium voltage-gated channel subfamily C member 1; Voltage-gated potassium channel subunit Kv3.1; Voltage-gated potassium channel subunit Kv4; Potassium voltage-gated channel subfamily C member 2; Shaw-like potassium channel; Voltage-gated potassium channel Kv3.2; KSHIIID; Potassium voltage-gated channel subfamily C member 3; Voltage-gated potassium channel subunit Kv3.3; C1orf30; KSHIIIC; Potassium voltage-gated channel subfamily C member 4; Voltage-gated potassium channel subunit Kv3.4; kH1; Potassium voltage-gated channel subfamily F member 1; Voltage-gated potassium channel subunit Kv5.1; kH2; Potassium voltage-gated channel subfamily G member 1; Voltage-gated potassium channel subunit Kv6.1; Cardiac potassium channel subunit; KCNF2; Potassium voltage-gated channel subfamily G member 2; Voltage-gated potassium channel subunit Kv6.2; Potassium voltage-gated channel subfamily G member 3; Voltage-gated potassium channel subunit Kv10.1; Voltage-gated potassium channel subunit Kv6.3; KCNG3; Potassium voltage-gated channel subfamily G member 4; Voltage-gated potassium channel subunit Kv6.3; Voltage-gated potassium channel subunit Kv6.4; 1.1.1.-; K(+) channel subunit beta-1; KCNA1B; Kv-beta-1; 1.1.1.-; hKvbeta2; K(+) channel subunit beta-2; KCNA2B; KCNK2; Kv-beta-2; Inward rectifier K(+) channel Kir2.2; Inward rectifier K(+) channel Kir2.2v; IRK-2; IRK2; KCNJN1; Potassium channel, inwardly rectifying subfamily J member 12; Inward rectifier K(+) channel Kir2.4; IRK-4; IRK4; Potassium channel, inwardly rectifying subfamily J member 14; Cardiac inward rectifier potassium channel; hIRK1; Inward rectifier K(+) channel Kir2.1; IRK-1; IRK1; Potassium channel, inwardly rectifying subfamily J member 2; Hippocampal inward rectifier; HIR; HIRK2; HRK1; Inward rectifier K(+) channel Kir2.3; IRK-3; IRK3; Potassium channel, inwardly rectifying subfamily J member 4; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; 1.14.14.154; CYP51; CYP51A1; CYPLI; Cytochrome P450 51A1; Cytochrome P450-14DM; Cytochrome P45014DM; Cytochrome P450LI; LDM; Sterol 14-alpha demethylase; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","Lanosterol 14-alpha demethylase; Nitric oxide synthase 3; Nitric oxide synthase, inducible; Nuclear receptor subfamily 1 group I member 2; Calcium-activated potassium channel; Voltage-gated Potassium Channels; Inward rectifier potassium channel; Voltage gated L-type calcium channel", A01AB09; D01AC02; D01AC52; G01AF04; G01AF20; J02AB01; S02AA13;A01AB09;A07AC01
midazolam,Amnesia;Anxiety;Apprehension;Convulsion;Convulsive seizure;Distress;Drowsiness;Emotional distress;Epilepsy;Insomnia;Laceration;Memory impairment;Polymenorrhoea;Short period;Somnolence,Affect lability;Aggression;Aggressive reaction;Agitation;Airway obstruction NOS;Alertness decreased;Anaphylactic shock;Anaphylactoid reaction;Anger;Anterograde amnesia;Anxiety;Apnoea;Application site pain;Argumentativeness;Assault;Asthenia;Ataxia;Athetosis;Bradycardia;Bronchospasm;Carbon dioxide increased;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardio-respiratory arrest;Chills;Clonic convulsion;Clonic movements;Clonus;Confusional state;Connective tissue disorder;Constipation;Cough;Delirium;Delusion;Dependence;Dependence physiological;Depressed level of consciousness;Depressed mood;Depression;Dermatitis;Difficulty focusing eyes;Digestion impaired;Diplopia;Disinhibition;Disorientation;Dizziness;Drooling;Drowsiness;Drug withdrawal convulsions;Drug withdrawal syndrome;Dry mouth;Dysarthria;Dyskinesia;Dyspepsia;Dysphonia;Dysphoria;Dyspnoea;Emotional disorder;Erythema;Euphoric mood;Excitement;Extrasystoles;Eye disorder;Fatigue;Feeling abnormal;Feeling hot;Felt faint;Fracture;Gagging;Gastrointestinal disorder;Haematoma;Hallucination;Headache;Hiccups;Hostility;Hypercapnia;Hyperkinesia;Hypersensitivity;Hyperventilation;Hypopnoea;Hypotension;Hypotensive;Hypoventilation;Hypoxia;Immune system disorder;Induration;Injection site coldness;Injection site pain;Injury;Instillation site pain;Irritability;Laryngospasm;Lethargy;Lightheadedness;Local reaction;Mean arterial pressure;Mean arterial pressure decreased;Mediastinal disorder;Mental disorder;Miosis;Mood swings;Movement disorder;Movements involuntary;Multiple fractures;Muscle stiffness;Muscle twitching;Muscular weakness;Musculoskeletal stiffness;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Nightmare;Nodal rhythm;Nystagmus;Obstructive airways disorder;Osteoarthritis;Oversedation;Pain;Pain during injection;Paraesthesia;Phlebitis;Physical assault;Presyncope;Pruritus;Psychotic disorder;Pulmonary function test decreased;Pupils pinpoint;Rash;Redness;Respiratory arrest;Respiratory depression;Respiratory failure;Respiratory insufficiency;Respiratory rate decreased;Retching;Retrograde amnesia;Rhinorrhoea;Rhonchi;Salivary hypersecretion;Salivation;Sedation;Shallow breathing;Shock;Skin disorder;Skin exfoliation;Skin necrosis;Sleep disorder;Sleep disturbance;Slurred speech;Sneezing;Somnolence;Stridor;Swelling;Syncope;Syncope vasovagal;Tachycardia;Tachypnoea;Tenderness;Tension;Therapeutic response decreased;Thrombophlebitis;Thrombosis;Toothache;Tranquillisation excessive;Tremor;Tremor muscle;Unspecified disorder of skin and subcutaneous tissue;Upper airway obstruction;Urticaria;VT;Ventricular bigeminy;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Warmth;Welts;Wheezing;Withdrawal seizures;Withdrawal symptom;Withdrawal syndrome;Yawning,small molecule,approved; illicit,"Midazolam; Midazolamum; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; ADORA2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; EAAT2; GLT1; Glutamate/aspartate transporter II; Sodium-dependent glutamate/aspartate transporter 2; Solute carrier family 1 member 2",Translocator protein; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site; Adenosine receptor A2a,N05CD08
midodrine,Autonomic failure syndrome;Blood pressure increased;Blood pressure systolic increased;Bradycardia;Clotting;Coagulopathy;Diabetes mellitus;Diabetic;Hepatic impairment;Hypotension;Hypotension orthostatic symptomatic;Hypotensive;Liver disorder;Multiple system atrophy;Orthostatic hypotension;Parkinson's disease;Parkinsonism;Reflex bradycardia;Shy-Drager syndrome;Vascular resistance systemic,Abdominal discomfort;Abdominal pain;Agitation;Angiopathy;Anxiety;Aphthous stomatitis;Asthenia;Back pain;Bradycardia;Cardiac disorder;Central retinal vein occlusion;Chills;Confusional state;Cramps of lower extremities;Dermatitis;Distress gastrointestinal;Dizziness;Drug interaction;Dry mouth;Dry skin;Dyspepsia;Dyspnoea;Dysuria;Erythema multiforme;Excitability;Feeling abnormal;Flatulence;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Hair disorder;Headache;Heartburn;Hepatic enzyme increased;Hepatic function abnormal;Hepatobiliary disease;Hyperaesthesia;Hypersensation skin;Hypertension;Insomnia;Irritability;Itchy scalp;Mental disorder;Micturition urgency;Muscle spasms;Nausea;Nervous system disorder;Nervousness;Pain;Paraesthesia;Paresthesia of scalp;Piloerection;Pollakiuria;Pruritus;Rash;Reflex bradycardia;Retinal vein occlusion;Scotoma;Skin disorder;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Stomatitis;Tachycardia;Tension;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Vasodilation;Vasodilation procedure,small molecule,approved,"(±)-2-amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; Midodrin; Midodrina; Midodrine; Midodrinum; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1",Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor,C01CA17
mifepristone,Cushing's syndrome;Dead foetus;Foetal death;Glucose tolerance impaired;Hyperglycaemia;Type 2 diabetes mellitus,Abdominal pain;Adrenal carcinoma;Adrenal gland cancer;Adrenal insufficiency;Angioedema;Angiopathy;Anorexia;Anxiety;Arthralgia;Asthenia;Back pain;Blood potassium decreased;Blood triglycerides increased;Body temperature increased;Breast disorder;Chills;Connective tissue disorder;Constipation;Cramp muscle;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dyspnoea;Ectopic ACTH syndrome;Endometrial cancer;Endometrial hypertrophy;Endometrial thickening;Endometritis;Erythema nodosum;Fatigue;Feeling abnormal;Flank pain;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Headache;Hot flush;Hypersensitivity;Hypertension;Hypoglycaemia;Hypokalaemia;Hypotension;Ill-defined disorder;Infection;Infestation;Infestation NOS;Insomnia;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Metrorrhagia;Multiparous;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Nervous system disorder;Oedema;Oedema peripheral;Pain;Pain in extremity;Pelvic inflammatory disease;Pitting edema;Pituitary-dependent Cushing's syndrome;Pruritus;Rash;Rash maculo-papular;Sinusitis;Skin disorder;Somnolence;Thirst;Thyroid function test abnormal;Toxic epidermal necrolysis;Toxic shock syndrome;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Uterine contractions;Uterine contractions during pregnancy;Uterine rupture;Vaginal haemorrhage;Vomiting,small molecule,approved; investigational,"Mifepriston; Mifepristona; Mifépristone; Mifepristone; Mifepristonum; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 3.4.21.77; APS; Gamma-seminoprotein; Kallikrein-3; P-30 antigen; PSA; Semenogelase; Seminin; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Progesterone receptor; Glucocorticoid receptor; Prostate-specific antigen; Nuclear receptor subfamily 1 group I member 2, G03XB51;G03XB01
milrinone,ADHF;Cardiac failure acute;Cardiac failure congestive;Ventricular arrhythmia,Anaphylactic shock;Angina pectoris;Arrhythmia;Arrhythmia supraventricular;Bronchospasm;Chest pain;Dermatitis;Headache;Hypokalaemia;Hypotension;Infusion site reaction;Liver function test abnormal;Non-sustained ventricular tachycardia;Patent ductus arteriosus;Rash;Sustained ventricular tachycardia;Thrombocytopenia;Torsade de pointes;Tremor;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia,small molecule,approved,"1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; Milrinona; Milrinone; Milrinonum; 3.1.4.17; cGI-PDE; CGI-PDE A; cGMP-inhibited cAMP phosphodiesterase; Cyclic GMP-inhibited phosphodiesterase A","cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A",C01CE02
minoxidil,Cardiac failure high output;Cardiac output increased;Encephalopathy;Fluid retention;Hypertension;Refractory hypertension;Retinal disorder;Vascular resistance systemic;Water retention,Angina pectoris;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Breast disorder;Breast tenderness;Bullous eruption;Cardiac disorder;Cardiac tamponade;Dermatitis;Dermatitis bullous;Electrocardiogram ST segment;Electrocardiogram abnormal;Erythema multiforme;Fluid retention;Gastrointestinal disorder;Hair colour changes;Hair growth abnormal;Hypertrichosis;Hypotension;Leukopenia;Malnutrition;Mediastinal disorder;Nausea;Oedema;Oedema peripheral;Pericardial effusion;Pericarditis;Phosphatase alkaline increased;Pleural effusion;Rash;Serum creatinine increased;Skin disorder;Stevens-Johnson syndrome;Tachycardia;Thrombocytopenia;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Virilism;Vomiting;Water retention;Weight increased,small molecule,approved; investigational,"2,4-Diamino-6-piperidinopyrimidine 3-oxide; 6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide; Minossidile; Minoxidil; Minoxidilum; ATP-regulated potassium channel ROM-K; Inward rectifier K(+) channel Kir1.1; Potassium channel, inwardly rectifying subfamily J member 1; ROMK1; 3.4.23.15; Angiotensinogenase; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1",ATP-sensitive inward rectifier potassium channel 1; Renin; Prostaglandin G/H synthase 1, C02DC01;C02DC01;D11AX01
mirtazapine,"Acute coronary syndrome;Agitation;Angina pectoris;Anxiety;Asthenia;Bradyphrenia;Bradypsychic response;Cardiac disorder;Cerebration impaired;Confusional state;Convulsion;Decreased interest;Depressed mood;Depression;Depressive disorder;Disturbance in attention;Dizziness;Drug abuse;Dysphoria;Dysthymic disorder;Fatigue;Feeling abnormal;Feeling guilty;Hepatic impairment;Hypersomnia;Insomnia;Ischaemic stroke;Liver disorder;Major depression;Major depressive disorder, single episode;Mental disability;Mental disorder;Myocardial infarction;Nephropathy;Renal failure;Renal impairment;Somnolence;Suicidal ideation;Suicide attempt",Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal ejaculation;Accommodation disorder;Acid phosphatase high;Acne;Acute abdomen;Acute coronary syndrome;Affect lability;Ageusia;Aggression;Agitation;Agranulocytosis;Akathisia;Alanine aminotransferase increased;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Angina pectoris;Angiopathy;Angle closure glaucoma;Ankle edema;Anorexia;Anxiety;Apathy;Aphasia;Aphthous stomatitis;Aplastic anaemia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asphyxia;Asthenia;Asthma;Ataxia;Atrial arrhythmia;Back pain;Bladder pain;Blepharitis;Blister;Blood acid phosphatase increased;Blood and lymphatic system disorders;Blood cholesterol increased;Blood triglycerides increased;Body temperature increased;Bone disorder;Bone marrow depression;Bone pain;Bradycardia;Breast engorgement;Breast enlargement;Breast feeding;Breast pain;Bronchitis;Bursitis;Calculus of kidney;Candida infection;Cardiac disorder;Cardiomegaly;Cellulitis;Cerebral ischaemia;Cerebration impaired;Cerebrovascular disorder;Chest pain;Chills;Cholecystitis;Coagulopathy;Colitis;Coma;Confusional state;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cystitis;Cystitis noninfective;Deafness;Deafness transitory;Decreased appetite;Dehydration;Delirium;Delusion;Dementia;Dependence;Dependence physiological;Depersonalisation;Depressed level of consciousness;Depressive symptom;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Diuresis;Dizziness;Drowsiness;Drug dependence;Drug seeking behavior;Drug tolerance;Drug withdrawal syndrome;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Dysuria;Ear pain;Ejaculation disorder;Electric shock;Embolism;Embolism venous;Enlargement abdomen;Eosinophilia;Epilepsy;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Extrasystoles;Eye disorder;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flat affect;Flatulence;Fluid retention;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gingival bleeding;Glaucoma;Glossitis;Goitre;Gout;Grand mal convulsion;Gravitational oedema;Haematuria;Hallucination;Headache;Hepatic cirrhosis;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Herpes simplex;Herpes zoster;Hiccups;High cholesterol;Hostility;Hyperacusis;Hypercholesterolaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertonia;Hypertriglyceridaemia;Hypoaesthesia;Hypoaesthesia oral;Hypokinesia;Hyponatraemia;Hypotension;Hypothyroidism;Hypotonia;Hypovolaemia;Ill-defined disorder;Impaired healing;Increased appetite;Infection;Influenza;Insomnia;Intestinal obstruction;Intraocular pressure increased;Jaundice;Joint swelling;Keratitis;Keratoconjunctivitis;Lacrimal disorder;Lacrimal structural disorder;Laryngitis;Left ventricular failure;Lethargy;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Liver function test abnormal;Local swelling;Localised oedema;Loss of consciousness;Lymphadenopathy;Lymphocytosis;Major depression;Malaise;Malnutrition;Mania;Manic psychosis;Memory impairment;Menorrhagia;Mental disability;Mental disorder;Metrorrhagia;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Movement disorder;Muscle relaxant therapy;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Myoclonus;Myositis;Nausea;Neck pain;Neck stiffness;Nephrolithiasis;Nervous system disorder;Nervousness;Neurosis;Neutropenia;Nightmare;Nuchal rigidity;Nystagmus;Oedema;Oedema mouth;Oedema peripheral;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypertension;Orthostatic hypotension;Osteoarthritis;Osteoporotic fracture;Otitis media;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paraesthesia oral;Paralysis;Paranoia;Paranoid reaction;Parosmia;Partial transitory deafness;Petechiae;Pharyngitis;Phlebitis;Photosensitivity reaction;Pneumonia;Pneumothorax;Pollakiuria;Polyuria;Prostatomegaly;Pruritus;Psychotic depression;Psychotic disorder;Pulmonary embolism;Pulmonary oedema;Rash;Restless legs syndrome;Retrosternal pain;Rhinitis;Salivary gland enlargement;Salivary hypersecretion;Seborrhoeic dermatitis;Self-injurious ideation;Serotonin syndrome;Shock;Sinusitis;Skin disorder;Skin hypertrophy;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Stinging;Stomatitis;Stupor;Suicidal behaviour;Suicidal ideation;Sweating;Sweating increased;Syncope;Tachycardia;Tendon rupture;Tenosynovitis;Tension;Thinking abnormal;Thirst;Throat sore;Thrombocytopenia;Thromboembolism;Tinnitus;Tolerance development;Tongue discolouration;Tongue disorder;Tongue oedema;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Ulcer;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vascular headache;Ventricular arrhythmia;Ventricular bigeminy;Ventricular extrasystoles;Vertigo;Vivid dreams;Vomiting;Weight decreased;Weight increased;Withdrawal symptom;Withdrawal syndrome,small molecule,approved,"1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; 6-Azamianserin; Mepirzapine; Mirtazapin; Mirtazapina; Mirtazapine; Mirtazapinum; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; K-OR-1; KOR-1; OPRK; H1-R; H1R; HH1R; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4",5-hydroxytryptamine receptor 2A; 5HT3 serotonin receptor; Alpha-2A adrenergic receptor; 5-hydroxytryptamine receptor 2C; Alpha-1 adrenergic receptors; Kappa-type opioid receptor; Histamine H1 receptor,N06AX11
mitotane,Adrenal carcinoma;Adrenal gland cancer;Adrenocortical carcinoma;Neoplasm malignant,Ache;Adrenal insufficiency;Aggression;Albuminuria;Amnesia;Anaemia;Angiopathy;Anorexia;Asthenia;Ataxia;Autoimmune hepatitis;Balance disorder;Bleeding time prolonged;Blood and lymphatic system disorders;Blood cholesterol increased;Blood triglycerides increased;Blood uric acid decreased;Body temperature increased;Brain injury;Breast disorder;Cataract;Confusional state;Connective tissue disorder;Cutaneous hypersensitivity;Cystitis haemorrhagic;Decreased appetite;Dermatitis;Dermatitis atopic;Diarrhoea;Digestion impaired;Diplopia;Dizziness;Drowsiness;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Encephalopathy;Endocrine disorder;Epigastric discomfort;Eye disorder;Feeling abnormal;Flushing;Fungal infection;Gastrointestinal disorder;Gastrointestinal toxicity;Generalized aching;Growth retardation;Gynaecomastia;Haematuria;Headache;Hepatic enzyme increased;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hepatocellular injury;Hypercholesterolaemia;Hyperpyrexia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypotension;Hypothyroidism;Hypouricaemia;Infection;Infestation;Infestation NOS;Injury;Irritability;Lenticular opacities;Lethargy;Liver injury;Maculopathy;Malnutrition;Memory loss;Mental disability;Mental disorder;Mental retardation;Mineralocorticoid deficiency;Movement disorder;Mucosal inflammation;Muscular weakness;Myasthenia;Nausea;Neoplasm;Nervous system disorder;Neutropenia;Opportunistic mycosis;Orthostatic hypertension;Orthostatic hypotension;Osteoarthritis;Pain;Paraesthesia;Plasma cholesterol increased;Plasma triglycerides increased;Polyneuropathy;Protein urine present;Proteinuria;Rash;Retinal disorder;Retinal toxicity;Salivary hypersecretion;Secondary adrenocortical insufficiency;Shock;Skin disorder;Skin toxicity;Somnolence;Speech disorder;Speech impairment NOS;Thrombocytopenia;Trauma;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vertigo;Vision blurred;Visual impairment;Vomiting,small molecule,approved,"1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-benzene; Mitotan; Mitotane; Mitotano; Mitotanum; o,p'-DDD; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; Adrenal ferredoxin; ADX; Ferredoxin-1; Hepatoredoxin; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; Serpin A7; T4-binding globulin; TBG; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; CBG; Serpin A6; Transcortin; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","Cytochrome P450 11B1, mitochondrial; Estrogen receptor; Progesterone receptor; Androgen receptor; Adrenodoxin, mitochondrial",L01XX23
mitoxantrone,Acute leukaemia;Acute lymphocytic leukaemia;Acute myeloid leukaemia;Advanced breast cancer;Blast cell crisis;Breast cancer;Chronic myeloid leukaemia;Disability;Hepatic cancer;Hepatic function abnormal;Hepatic impairment;Hepatocellular carcinoma;Hormone-refractory prostate cancer;Leukaemia;Liver disorder;Lymphocytic leukaemia;Lymphoma;Metastatic carcinoma;Metastatic neoplasm;Multiple sclerosis;Neoplasm;Neoplasm malignant;Non-Hodgkin's lymphoma;Pain;Prostate cancer;Relapsing-remitting multiple sclerosis;Solid tumour,Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Acute promyelocytic leukaemia;Affective disorder;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Amenorrhoea;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Anorexia;Anxiety;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blood bilirubin increased;Blood creatinine abnormal;Blood creatinine increased;Blood glucose increased;Blood potassium decreased;Blood urea abnormal;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bone pain;Bradycardia;Breast cancer stage IV;Cardiac failure;Cardiac failure congestive;Cardiomyopathy;Cardiotoxicity;Chest pain;Chills;Chromaturia;Confusional state;Conjunctivitis;Constipation;Contusion;Convulsion;Cough;Creatinine abnormal NOS;Cross resistance;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Discomfort;Drowsiness;Dysgeusia;Dyspepsia;Dyspnoea;Ecchymosis;Ejection fraction decreased;Electrocardiogram abnormal;Elevated liver enzyme levels;Endometritis;Enteritis;Epigastric pain;Erectile dysfunction;Erythema;Extravasation;Fatigue;Febrile neutropenia;Feeling abnormal;Foot and mouth disease;Fungal infection;Fungal skin infection;Gamma-glutamyltransferase increased;Gastrointestinal haemorrhage;Gastrointestinal pain;Glucose increased;Haematuria;Haemoglobin;Haemoglobin decreased;Haemorrhage;Haemorrhage intracranial;Headache;Hepatic enzyme increased;Hepatitis;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hyperuricaemia;Hypocalcaemia;Hypokalaemia;Hyponatraemia;Hypotension;Ill-defined disorder;Infection;Infertility;Interstitial lung disease;Interstitial pneumonia;Ischaemia;Jaundice;Left ventricular ejection fraction decreased;Leukopenia;Local reaction;Lymphocyte abnormal;Lymphocyte count abnormal;Malaise;Menorrhagia;Menstrual disorder;Metastasis;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Myelodysplastic syndrome;Myelosuppression;Myocardial infarction;Myocardial ischaemia;Nail pigmentation;Nausea;Necrosis;Nephropathy toxic;Neutropenia;Non-Hodgkin's lymphoma;Oedema;Onycholysis;Pain;Pancytopenia;Paraesthesia;Pathogen resistance;Petechiae;Pharyngitis;Phlebitis;Platelet count abnormal;Platelet count decreased;Pneumonia;Potassium low;Protein urine present;Proteinuria;Rash;Renal failure;Renal failure acute;Rhinitis;Sepsis;Serum creatinine increased;Shock;Sinus bradycardia;Sinusitis;Skin disorder;Skin infection;Somnolence;Stomach ache;Stomatitis;Sudden death;Sweating;Sweating increased;Swelling;Tachycardia;Taste altered;Thrombocytopenia;Tonsillitis;Tumour lysis syndrome;Ulcer;Upper respiratory tract infection;Ureteric obstruction;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine color abnormal;Urine output;Urticaria;Viral infection;Vision blurred;Vomiting;Weight decreased;Weight increased;White blood cell count decreased,small molecule,approved; investigational,"1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; Mitoxantrona; Mitoxantrone; Mitoxantronum; 5.6.2.2; DNA topoisomerase II, beta isozyme; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",DNA topoisomerase 2-beta; DNA; DNA topoisomerase 2-alpha,L01DB07
moclobemide,Major depression;Social phobia,Abdominal bloating;Abdominal distension;Abdominal pain;Aggression;Agitation;Allergic skin reaction;Angina pectoris;Anorectal discomfort;Anxiety;Anxiety state;Apathy;Appetite absent;Asthenia;Bradycardia;Chest pain;Confusional state;Conjunctivitis;Constipation;Decreased appetite;Delusion;Dermatitis;Dermatitis atopic;Diarrhoea;Discomfort;Disorientation;Dizziness;Drowsiness;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Epigastric discomfort;Extrasystoles;Fatigue;Feeling abnormal;Feeling cold;Flat affect;Flatulence;Flushing;Fullness abdominal;Gastritis;Gastrointestinal pain;Gingivitis;Hallucination;Headache;Heartburn;Hepatic enzyme increased;Hot flush;Hyperhidrosis;Hypertension;Hypotension;Ill-defined disorder;Increased agitation;Insomnia;Irritability;Loss of consciousness;Malaise;Menopausal symptoms;Menstrual cycle prolonged;Metrorrhagia;Migraine;Musculoskeletal discomfort;Myalgia;Nausea;Nervousness;Nightmare;Oligomenorrhoea;Osteoarthritis;Palpitations;Paraesthesia;Photopsia;Polyuria;Proctalgia;Pruritus;Rash;Rectal tenesmus;Shock;Sickness;Sleep disorder;Sleep disturbance;Somnolence;Stomatitis;Sweating;Syncope;Tachycardia;Taste altered;Tension;Tinnitus;Tremor;Urine output increased;Urticaria;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,4-Chlor-N-(2-morpholinoethyl)benzamid; Moclobemid; Moclobemida; Moclobemide; Moclobemidum; p-Chloro-N-(2-morpholinoethyl)benzamide; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B,Amine oxidase [flavin-containing] A; Monoamine oxidase; Amine oxidase [flavin-containing] B,N06AG02
modafinil,Apnoea;Asthenia;Cataplexy;Dyskinesia;Excessive daytime sleepiness;Fatigue;Hypersomnia;Hypopnea syndrome;Narcolepsy;Obstructive sleep apnea syndrome;Poor quality sleep;Sleep apnoea syndrome;Sleep disorder;Somnolence;Wakefulness,Abdominal pain;Abdominal pain upper;Abnormal ejaculation;Abnormal vision;Abscess periodontal;Accidental injury;Affect lability;Aggression;Agitation;Agranulocytosis;Albuminuria;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety depression;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Back pain;Bladder pain;Blood pressure increased;Body temperature decreased;Body temperature increased;Bradycardia;Bronchitis;Cardiac arrest;Cardiac disorder;Cataplexy;Chest pain;Chills;Condition aggravated;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cough increased;Cramps of lower extremities;Cystitis;Cystitis noninfective;Decreased appetite;Delusion;Depressed mood;Depression;Depression aggravated;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug eruption;Dry mouth;Dry skin;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Ear disorder;Ear pain;Ecchymosis;Eczema;Ejaculation disorder;Electrocardiogram abnormal;Eosinophilia;Epistaxis;Erectile dysfunction;Erythema multiforme;Eye pain;Fatigue;Feeling abnormal;Flatulence;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gingivitis;Haematuria;Hallucination;Headache;Hearing impaired;Hepatic enzyme increased;Hepatic function abnormal;Herpes simplex;Hyperacusis;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hypotension;Hypothermia;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Influenza;Influenza like illness;Injury;Insomnia;Irritability;Leukocytosis;Libido decreased;Loose stools;Loss of consciousness;Lung disorder;Malaise;Malnutrition;Mania;Mediastinal disorder;Mental disability;Mental disorder;Migraine;Mood swings;Mouth ulceration;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial ischaemia;Nausea;Neck pain;Neck stiffness;Nervous system disorder;Nervousness;Nuchal rigidity;Obesity;Oedema;Oedema peripheral;Orofacial dyskinesia;Osteoarthritis;Pain;Pain in jaw;Palpitations;Pancytopenia;Paraesthesia;Partial hearing loss;Personality disorder;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Pruritus;Psoriasis;Psychiatric symptom;Psychotic disorder;Pyuria;Rash;Rhinitis;Rhinitis seasonal;Seasonal allergy;Shock;Sinusitis;Skin disorder;Somnolence;Stevens-Johnson syndrome;Stomatitis;Suicidal ideation;Suicide attempt;Sweating;Syncope;Tachycardia;Tardive dyskinesia;Tension;Thinking abnormal;Thirst;Tooth abscess;Tooth disorder;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine odour abnormal;Urine odour foul;Urine output increased;Urticaria;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Vertigo;Viral infection;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"2-((diphenylmethyl)sulfinyl)acetamide; Modafinil; Modafinilo; Modafinilum; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Sodium-dependent dopamine transporter; Alpha-1B adrenergic receptor,N06BA07
mometasone,Asthma;Atonia;Bacterial infection;Dermatitis atopic;Erythema;Hypotonia;Nasal polyps;Papule;Perennial allergic rhinitis;Psoriasis;Psoriasis of scalp;Rhinitis perennial;Rhinitis seasonal;Rhinosinusitis;Seasonal allergy;Seborrhoeic dermatitis;Sensitisation;Sinusitis;Skin disorder;Skin exfoliation,Abdominal pain;Abscess;Accidental injury;Acne;Acneiform eruption;Allergic contact dermatitis;Allergy aggravated;Anaphylactic shock;Angioedema;Anorexia;Arthralgia;Arthropod bite;Asthenia;Back pain;Bacterial infection;Bronchitis;Bronchospasm;Candida infection;Cataract subcapsular;Chest pain;Condition aggravated;Conjunctivitis;Contusion;Cough;Decreased appetite;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Diarrhoea;Dry mouth;Dry skin;Dry throat;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphonia;Dyspnoea;Ear pain;Endocrine disorder;Epistaxis;Erythema;Fatigue;Flatulence;Folliculitis;Furuncle;Furunculosis;Gastroenteritis;Gastrointestinal pain;Growth retardation;Haemoglobin;Haemorrhage;Headache;Hypersensitivity;Hypertrichosis;Infection;Influenza like illness;Influenza-like symptoms;Injury;Insect bite NOS;Insomnia;Laceration;Leukoderma;Menstrual disorder;Miliaria;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasal burning;Nasal discomfort;Nasal irritation;Nasal septum perforation;Nasal ulcer;Nausea;Oral candidiasis;Otitis media;Pain;Paraesthesia;Pharyngitis;Pimples;Plaque psoriasis;Pruritus;Psoriasis;Pustular psoriasis;Respiratory tract infection;Rhinitis;Rhinitis allergic;Rosacea;Secondary adrenocortical insufficiency;Secondary infection;Sensitisation;Sinus congestion;Sinusitis;Skin atrophy;Skin bacterial infection;Skin depigmentation;Skin discolouration;Skin laceration;Skin striae;Sneezing;Stinging;Telangiectasia;Tingling sensation;Trauma;Type I hypersensitivity;Ulcer;Upper respiratory tract infection;Urinary tract infection;Vaginal discharge;Viral infection;Vomiting;Wheezing,small molecule,experimental,"(+)-Mometasone; Mometason; Mometasona; Mométasone; Mometasone; Mometasonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3",Glucocorticoid receptor; Progesterone receptor, R01AD59; R03AK14;R03AL12
montelukast,Asthma;Asthma chronic;Bronchoconstriction;Bronchospasm;Exercise-induced bronchospasm;Perennial allergic rhinitis;Rhinitis allergic;Rhinitis perennial;Rhinitis seasonal;Seasonal allergy;Suicidal ideation,"Abdominal injury;Abdominal pain;Acute bronchitis;Aggression;Agitation;Alanine aminotransferase increased;Allergic granulomatous angiitis;Anaphylactic shock;Angioedema;Anxiety;Arthralgia;Aspartate aminotransferase increased;Asthenia;Asthma;Bleeding tendency;Blood and lymphatic system disorders;Body temperature increased;Bone disorder;Bronchitis;Cardiac disorder;Completed suicide;Conjunctivitis;Connective tissue disorder;Contusion;Convulsion;Cough;Cramp muscle;Dermatitis;Dermatitis atopic;Diarrhoea;Disorientation;Disturbance in attention;Dizziness;Drowsiness;Dyspepsia;Ear infection;Ear pain;Eczema;Enuresis;Eosinophilia;Epistaxis;Erythema multiforme;Erythema nodosum;Fatigue;Foetor hepaticus;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Haemorrhagic disorder;Hallucination;Hallucination, visual;Headache;Hepatic infiltration eosinophilic;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hepatocellular injury;Hostility;Hyperkinesia;Hypersensitivity;Hypoaesthesia;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Irritability;Jaundice;Laryngitis;Leukocytoclastic vasculitis;Liver disorder;Liver injury;Mediastinal disorder;Memory impairment;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myopia;Nasopharyngitis;Nausea;Nervous system disorder;Neuropathy;Neuropathy peripheral;Oedema;Otitis;Otitis media;Pain;Palpitations;Pancreatitis;Paraesthesia;Pharyngitis;Pneumonia;Pruritus;Pulmonary eosinophilia;Pyuria;Rash;Rhinitis;Rhinorrhoea;Sinus headache;Sinusitis;Skin disorder;Skin infection;Sleep disorder;Somnambulism;Somnolence;Stevens-Johnson syndrome;Suicidal behaviour;Suicide;Suicide attempt;Temper tantrum;Thirst;Thrombocytopenia;Tonsillitis;Tooth infection;Toxic epidermal necrolysis;Tracheobronchitis;Trauma;Traumatic liver injury;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Varicella;Vasculitic rash;Vasculitis;Viral infection;Vomiting;Wheezing",small molecule,approved,"(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid; Montelukast; Montélukast; Montelukastum; CYSLT1; CysLTR1; Cysteinyl leukotriene D4 receptor; G-protein coupled receptor HG55; HMTMF81; LTD4 receptor; 1.13.11.-; 5-lipoxygenase; 5-LO; Arachidonate 5-lipoxygenase; LOG5; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9",Cysteinyl leukotriene receptor 1; Polyunsaturated fatty acid 5-lipoxygenase, R03DC53;R03DC03
morphine,Acute coronary syndrome;Acute left ventricular failure;Acute pain;Acute pulmonary oedema;Acute ulcerative colitis;Advanced cancer;Affect lability;Analgesic effect;Analgesic therapy;Antitussive therapy;Anxiety;Apprehension;Asthma;Bedridden;Cancer pain;Carcinoma of lung;Cardiac disorder;Chronic pain;Colitis ulcerative;Constipation;Contusion;Cough;Cough suppression;Dependence psychological;Diarrhoea;Drowsiness;Drug dependence;Dysphoria;Dyspnoea;End stage cancer;Euphoric mood;Fasting;Injection site haemorrhage;Injury;Insomnia;Intractable pain;Left ventricular failure;Lung neoplasm malignant;Miosis;Mood swings;Muscle mass;Myocardial infarction;Nausea;Neoplasm malignant;Pain;Parkinson's disease;Parkinsonism;Postoperative pain;Procedural pain;Proctocolitis;Pulmonary function test decreased;Pulmonary oedema;Renal colic;Renal failure;Renal impairment;Respiratory depression;Sedation;Somnolence;Vomiting,"Abdominal colic;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal ejaculation;Accidental injury;Accidental overdose;Ache;Addison's disease;Affect lability;Agitation;Alcohol abuse;Alcoholism;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Apathy;Apnoea;Appetite absent;Apprehension;Arthralgia;Asthenia;Ataxia;Atelectasis;Atrial fibrillation;Back pain;Balance disorder;Biliary colic;Bladder pain;Bladder spasm;Blister;Body temperature increased;Bone pain;Bradycardia;Brain neoplasm;Breakthrough pain;Breast disorder;Breast feeding;Bronchospasm;CNS depression NOS;Cachexia;Carbon dioxide increased;Cardiac arrest;Cardiovascular disorder;Cardiovascular insufficiency;Chest discomfort;Chest pain;Chest tightness;Cheyne-Stokes respiration;Chills;Circulatory depression;Cold sweat;Coma;Compulsions;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cough decreased;Cramp muscle;Cutis anserina;Cyanosis;Decreased appetite;Decubitus ulcer;Dehydration;Delayed gastric emptying;Delirium;Dependence;Dependence physiological;Dependence psychological;Depressed level of consciousness;Dermatitis;Dermatitis bullous;Dermatitis contact;Diarrhoea;Diplopia;Discomfort;Disease progression;Disorientation;Disturbance in sexual arousal;Diuretic effect;Dizziness;Drowsiness;Drug abuse;Drug dependence;Drug hypersensitivity;Drug interaction;Drug tolerance;Drug withdrawal syndrome;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphoria;Dyspnoea;Dysuria;Ejaculation disorder;Eosinophilia;Erectile dysfunction;Erythema;Euphoric mood;Eye disorder;Eye pain;Faecalith;Faecaloma;Fatal outcomes;Fatigue;Feeling abnormal;Flat affect;Flatulence;Flushing;Footdrop;Function kidney decreased;Gait disturbance;Gastric atony;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Genital swelling;Gynaecomastia;Haematocrit decreased;Haemolytic anaemia;Haemorrhagic urticaria;Hallucination;Hallucination, visual;Head injury;Headache;Heart rate irregular;Hepatitis;Hepatobiliary disease;Hiccups;Hyperaesthesia;Hypercapnia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperpathia;Hypersensitivity;Hypersexuality;Hypertension;Hypertonia;Hypoaesthesia;Hypogonadism;Hypokalaemia;Hyponatraemia;Hypotension;Hypotensive;Hypotonia;Hypoventilation;Hypovolaemic shock;Hypoxia;Ileus;Ileus paralytic;Ill-defined disorder;Impaired gastric emptying;Inappropriate antidiuretic hormone secretion;Induration;Infection;Influenza;Injection site pain;Injury;Insomnia;Intestinal obstruction;Intracranial pressure increased;Lacrimation increased;Laryngospasm;Lethargy;Leukopenia;Libido decreased;Lightheadedness;Liver function test abnormal;Loss of consciousness;Loss of libido;Lung disorder;Malaise;Malnutrition;Mediastinal disorder;Menstruation irregular;Mental disability;Mental disorder;Miosis;Mood swings;Muscle contractions involuntary;Muscle rigidity;Muscle spasms;Muscle tone flaccid;Muscle twitching;Musculoskeletal discomfort;Mydriasis;Myoclonus;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuralgia;Nodule;Non-cardiogenic pulmonary oedema;Nystagmus;Oedema;Oedema peripheral;Oliguria;Opioid abuse;Orthostatic hypotension;Osteoarthritis;Oxygen saturation decreased;Pain;Pain worsened;Pallor;Palpitations;Paraesthesia;Peroneal nerve palsy;Phlebitis;Piloerection;Pneumothorax;Polyuria;Post herpetic neuralgia;Presyncope;Prolonged labour;Pruritus;Psychotic disorder;Pulmonary embolism;Pulmonary function test decreased;Pulmonary oedema;Punding;Pupils pinpoint;Rash;Rectal disorder;Renal failure;Renal impairment;Respiration abnormal;Respiratory arrest;Respiratory depression;Respiratory disorder;Respiratory failure;Respiratory failure aggravated;Respiratory insufficiency;Rhabdomyolysis;Rhinitis;Rhinorrhoea;Rigors;Sedation;Sepsis;Shivering;Shock;Skin disorder;Sleep disorder;Sleep disturbance;Slurred speech;Sneezing;Somnolence;Spasm biliary;Spontaneous penile erection;Stereotypy;Sticky skin;Stomach cramps;Stomatitis;Stupor;Substance abuse;Supraventricular tachycardia;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Taste metallic;Tenderness;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Tranquillisation excessive;Tremor;Tremor muscle;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Unsteadiness;Ureteral spasm;Urethral disorder;Urethral stenosis;Urinary hesitation;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;VT;Vasodilation;Vasodilation procedure;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Welts;Wheezing;Withdrawal symptom;Withdrawal syndrome;Yawning",small molecule,approved; investigational,"(−)-morphine; (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; (5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; (5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol; (5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; (5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; (7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol; Anhydrous morphine; Morfina; Morphia; Morphin; Morphine; Morphinum; Morphium; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; K-OR-1; KOR-1; OPRK; D-OR-1; DOR-1; OPRD; ESOP-1; ESOP1; Ly-96; MD2; Protein MD-2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Mu-type opioid receptor; Kappa-type opioid receptor; Delta-type opioid receptor; Lymphocyte antigen 96, N02AA01; N02AA51; N02AG01;A07DA52;N02AA01
moxifloxacin,Abdominal infection;Abscess;Acne;Acute exacerbation of chronic bronchitis;Acute sinusitis;Bacterial infection;Bronchitis;Bronchitis chronic;Community acquired pneumonia;Conjunctivitis bacterial;Conjunctivitis infective;Diabetic foot infection;Endometritis;Hepatic cirrhosis;Hepatic function abnormal;Hepatic impairment;Hypokalaemia;Infection;Infection mixed;Liver disorder;Overgrowth bacterial;Pathogen resistance;Pelvic inflammatory disease;Pneumonia;Renal failure;Renal impairment;Respiratory tract infection;Salpingitis;Sinusitis;Sinusitis bacterial,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal platelets;Abnormal sensation in eye;Abnormal vision;Activated partial thromboplastin time prolonged;Acute coronary syndrome;Acute myocardial ischemia;Acute yellow liver atrophy;Adverse reaction;Affect lability;Ageusia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Allergic cutaneous angiitis;Allergic oedema;Alveolitis allergic;Amblyopia;Amnesia;Amylase increased;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anosmia;Antibiotic associated colitis;Anxiety;Aphasia;Aphthous stomatitis;Apnoea;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Atrial arrhythmia;Atrial fibrillation;Atrial flutter;Atrioventricular block first degree;Back pain;Balanitis;Bladder pain;Blindness;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood glucose increased;Blood lactate dehydrogenase increased;Blood pressure increased;Blood thromboplastin decreased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bradycardia;Breast disorder;Bronchospasm;Cachexia;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiovascular disorder;Cellulitis;Cerebral infarction;Cerebrovascular accident;Cheilitis;Chest discomfort;Chest pain;Chills;Cholangitis;Clostridium difficile colitis;Coagulopathy;Colitis;Coma;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Corneal deposits;Corneal epithelium defect;Corneal infiltrates;Corneal staining;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Cystitis;Cystitis noninfective;Deafness;Deafness permanent;Decreased appetite;Dehydration;Depersonalisation;Depression;Dermatitis;Dermatitis atopic;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disorientation;Dizziness;Drug ineffective;Drug level increased;Dry eye;Dry mouth;Dry skin;Dysaesthesia;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Eczema;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Endophthalmitis;Enlargement abdomen;Enzyme abnormality;Eosinophil count increased;Eosinophilia;Epistaxis;Eructation;Erythema;Erythema multiforme;Euphoric mood;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Eyelid oedema;Face oedema;Facial pain;Fatigue;Feeling abnormal;Flatulence;Fluid intake reduced;Fungal infection;Fungal skin infection;Gait disturbance;Galactorrhoea;Gamma globulins increased;Gamma-glutamyltransferase increased;Gastric pH decreased;Gastritis;Gastroenteritis;Gastrointestinal candidiasis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingivitis;Glossitis;Gout;Grand mal convulsion;Haematocrit decreased;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Hallucination;Hand pain;Headache;Hearing impaired;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis cholestatic;Hepatitis fulminant;Hepatobiliary disease;Hepatocellular injury;Hernia;Herpes simplex;Hiccups;Hyperacusis;Hyperaesthesia;Hyperbilirubinaemia;Hyperchlorhydria;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypomenorrhoea;Hypophosphataemia;Hypoproteinaemia;Hypotension;Hypotonia;Ill-defined disorder;Immune system disorder;Immunoglobulins increased;Increased appetite;Infestation;Infestation NOS;Inflammation;Infusion site extravasation;Infusion site reactions;Injection site hypersensitivity;Injection site inflammation;Injection site pain;Injection site reaction;Injection site swelling;Injury;Insomnia;Intentional self-injury;International normalised ratio abnormal;International normalised ratio decreased;International normalised ratio increased;Jaundice;Jaundice cholestatic;Keratitis;Keratoconjunctivitis sicca;Kidney function abnormal;Laboratory test abnormal;Lack of drug effect;Lacrimation;Lacrimation increased;Lactation female;Lactic dehydrogenase activity increased;Laryngeal oedema;Laryngeal pain;Leg pain;Lethargy;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Leukorrhea;Lipase increased;Liver function test abnormal;Liver injury;Loss of consciousness;Lung disorder;Lymphangitis;Lymphocytosis;Malaise;Malnutrition;Mediastinal disorder;Melaena;Menstrual disorder;Mental disability;Mental disorder;Migraine;Monocytosis;Mood swings;Mouth ulceration;Multi-organ failure;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myasthenia;Myasthenia gravis;Myocardial infarction;Myocardial ischaemia;NPN increased;Nausea;Neoplasm;Nephritis interstitial;Nephropathy;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Night sweats;Ocular discomfort;Ocular hyperaemia;Oedema;Oedema peripheral;Oesophagitis;Oral candidiasis;Oral fungal infection;Oral infection;Orthostatic hypotension;Osteoarthritis;Otitis media;PCO2;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Panophthalmitis;Paraesthesia;Parosmia;Partial permanent deafness;Pelvic pain;Peripheral vascular disorder;Peritonitis;Personality disorder;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Photophobia;Photosensitivity;Photosensitivity reaction;Phototoxicity;Platelet disorder;Pleural effusion;Pneumonia;Pollakiuria;Polyneuropathy;Polyuria;Prothrombin level increased;Prothrombin time shortened;Pruritus;Pseudomembranous colitis;Psoriasis;Psychotic disorder;Purpura;Purpuric rash;Pyuria;Rash;Rash maculo-papular;Rash pustular;Reaction aggravation;Red blood cell sedimentation rate increased;Renal failure;Renal failure acute;Renal impairment;Renal pain;Retrosternal pain;Rhinitis;Rhinitis atrophic;Salivary gland enlargement;Salpingitis;Self injurious behaviour;Sensation of foreign body;Sepsis;Shock;Sinusitis;Skin disorder;Skin ulcer;Sleep disorder;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stinging;Stomatitis;Subconjunctival hemorrhage;Suicidal ideation;Suicide attempt;Superinfection;Supraventricular tachycardia;Sweating;Syncope;Tachyarrhythmia;Tachycardia;Taste disorders;Tendon disorder;Tendon rupture;Tendonitis;Tension;Tension headache;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thromboplastin decreased;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Torsade de pointes;Toxic epidermal necrolysis;Transaminases increased;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vascular headache;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Vestibular disorder;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vital dye staining cornea present;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginal pruritus;Vulvovaginitis;Weight increased;Wheezing;White blood cell count increased,small molecule,approved; investigational,"1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; Moxifloxacin; Moxifloxacino; 5.99.1.3; 5.99.1.3; 5.99.1.3; 5.99.1.3; Topoisomerase IV subunit A; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 3.1.1.2; 3.1.1.81; 3.1.8.1; A-esterase 1; Aromatic esterase 1; K-45; PON; PON 1; Serum aryldialkylphosphatase 1; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",DNA gyrase subunit A; DNA gyrase subunit B; DNA gyrase subunit A; DNA topoisomerase 4 subunit A; DNA topoisomerase 2-alpha; Serum paraoxonase/arylesterase 1, J01MA14;J01MA14;S01AE07
mupirocin,Arthropod bite;Cross resistance;Crying;Dermatitis atopic;Dermatitis infected;Ecthyma;Eczema;Eczema infected;Epidermolysis bullosa;Folliculitis;Furuncle;Furunculosis;Herpes NOS;Herpes virus infection;Ichthyosis;Ichthyosis acquired;Impetigo;Infection;Insect bite NOS;Laceration;Pathogen resistance;Psoriasis;Pyoderma;Skin disorder;Skin infection;Tearfulness;Ulcer;Wound,Abdominal pain;Anaphylactic shock;Angioedema;Application site burn;Application site pain;Blepharitis;Cellulitis;Cough;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Dizziness;Dry mouth;Dry skin;Dysgeusia;Ear pain;Eczema;Epistaxis;Erythema;Furuncle;Furunculosis;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Hypersensitivity;Immune system disorder;Mouth ulceration;Nausea;Pain;Pharyngitis;Pruritus;Rash;Rash generalised;Rhinitis;Sensitisation;Skin disorder;Stinging;Swelling;Tenderness;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract congestion;Urticaria;Wound infection,small molecule,approved; investigational; vet_approved,"9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid; Mupirocin; Mupirocina; Mupirocine; Mupirocinum; Pseudomonic acid; Pseudomonic acid A; 6.1.1.5; IleRS; Isoleucyl-tRNA synthetase",Isoleucine--tRNA ligase, D06AX09;D06AX09;R01AX06
mycophenolate,Carcinoma;Cytomegalovirus viraemia;Neoplasm malignant;Oral toxicity;Transplant rejection,Abdominal distension;Abdominal pain;Abnormal vision;Abscess;Abscess periodontal;Accidental injury;Acidosis;Acne;Acute coronary syndrome;Adenoma benign;Affect lability;Ageusia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alkalosis;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Amylase increased;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Apathy;Aphasia;Aplasia pure red cell;Aplastic anaemia;Apnoea;Arrhythmia;Arterial thrombosis;Arthralgia;Arthropathy;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Atelectasis;Atrial fibrillation;Atrial flutter;Atrophy;Atypical mycobacterial infection;Azotaemia;Back pain;Balanitis;Benign neoplasm of skin;Bladder neoplasm;Bladder pain;Blepharitis;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood disorder;Blood lactate dehydrogenase increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bone pain;Bradycardia;Breast pain;Bronchitis;Cachexia;Candida infection;Carcinoma of lung;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiomegaly;Cardiomyopathy;Cardiovascular disorder;Cataract;Catatonia;Catatonic reaction;Cellulitis;Central nervous system neoplasm;Cerebral ischaemia;Cerebrovascular accident;Cervix disorder;Cheilitis;Chest pain;Chills;Cholangitis;Cholecystitis;Cholelithiasis;Coagulopathy;Colitis;Colitis ulcerative;Confusional state;Congenital anomaly;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cough increased;Cramps of lower extremities;Creatinine increased;Cryptococcosis;Cushing's syndrome;Cyanosis;Cyst;Cystitis;Cystitis noninfective;Cytomegalovirus colitis;Deafness;Decreased appetite;Dehydration;Delirium;Delusion;Depersonalisation;Depression;Dermatitis;Dermatitis bullous;Developmental delay;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disorder birth;Dizziness;Drug ineffective;Drug level decreased;Drug level increased;Dry mouth;Duodenal ulcer;Duodenal ulcer haemorrhage;Duodenitis;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear disorder;Ear malformation;Ear pain;Ecchymosis;Electrocardiogram abnormal;Encephalitis;Encephalopathy;Endocarditis;Endometrial cancer;Enlargement abdomen;Enteritis;Enzyme abnormality;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Extrasystoles;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Faecal incontinence;Faecalith;Faecaloma;Feeling abnormal;Flat affect;Flatulence;Fluid overload;Fluid retention;Fungaemia;Fungal infection;Fungal skin infection;Furuncle;Furunculosis;Gamma-glutamyltransferase increased;Gammaglobulins decreased;Gangrene;Gastric atony;Gastric ulcer;Gastric ulcer haemorrhage;Gastritis;Gastroenteritis;Gastrointestinal candidiasis;Gastrointestinal carcinoma;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal infection;Gastrointestinal necrosis;Gastrointestinal pain;Generalised oedema;Gingival hyperplasia;Gingivitis;Glossitis;Gout;Granuloma;Gynaecomastia;Haematemesis;Haematuria;Haemoglobin;Haemolysis;Haemolytic anaemia;Haemoptysis;Haemorrhage;Hallucination;Headache;Hemiplegia;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatitis B;Hepatobiliary disease;Hepatocellular injury;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hirsutism;Hormone level abnormal;Hostility;Hydronephrosis;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hyperchloraemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypochloraemia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hypotension;Hypothyroidism;Hypovolaemia;Ileus;Ill-defined disorder;Immunocompromised;Immunodeficiency;Immunoglobulins decreased;Impaired gastric emptying;Impaired healing;Increased bronchial secretion;Infection;Infestation;Infestation NOS;Influenza;Injection site hypersensitivity;Injection site inflammation;Injection site reaction;Injury;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal necrosis;Intestinal perforation;Intestinal ulcer;Jaundice;Jaundice cholestatic;Keratitis;Kidney function abnormal;Laboratory test abnormal;Lack of drug effect;Lacrimal disorder;Lacrimal structural disorder;Lactic dehydrogenase activity increased;Large intestine perforation;Laryngitis;Laryngospasm;Leukocytosis;Leukopenia;Liver function test abnormal;Liver injury;Loss of consciousness;Lung disorder;Lung neoplasm malignant;Lymphadenopathy;Lymphoma;Lymphoproliferative disorder;Malaise;Malignant melanoma;Malnutrition;Mania;Manic psychosis;Marrow hyperplasia;Mediastinal disorder;Melaena;Melanoma skin;Meningitis;Mental disability;Mental disorder;Metrorrhagia;Micturition urgency;Mood swings;Mouth ulceration;Mucocutaneous candidiasis;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myasthenic syndrome;Myocardial infarction;Myocarditis;Myopathy;Nausea;Neck pain;Neonatal disorder;Neoplasm;Nephritis;Nephropathy;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Nocturia;Non-Hodgkin's lymphoma;Nystagmus;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Oliguria;Opisthotonus;Opportunistic infection;Oral candidiasis;Orthostatic hypotension;Osteoarthritis;Osteonecrosis;Osteoporosis;Otitis externa;Otitis media;Pain;Pallor;Palpitations;Pancreatic disorder;Pancreatitis;Pancreatitis haemorrhagic;Pancytopenia;Paraesthesia;Paranoia;Paranoid reaction;Parathyroid disorder;Pelvic pain;Penis disorder;Peptic ulcer;Peptic ulcer perforation;Pericardial effusion;Peripheral gangrene;Peripheral vascular disorder;Peritonitis;Personality disorder;Petechiae;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Pleural disorder;Pleural effusion;Pneumonia;Pneumothorax;Pollakiuria;Polycythaemia;Polyp;Proctitis;Proctocolitis;Progressive multifocal leukoencephalopathy;Prostatic disorder;Prothrombin level increased;Pruritus;Pseudolymphoma;Psychotic disorder;Pulmonary embolism;Pulmonary fibrosis;Pulmonary hypertension;Pulmonary oedema;Pyelonephritis;Pyuria;Rash;Rash maculo-papular;Rash pustular;Rectal disorder;Rectal haemorrhage;Renal abscess;Renal failure;Renal failure acute;Renal graft loss;Renal impairment;Renal pain;Renal tubular necrosis;Respiratory acidosis;Respiratory failure;Respiratory moniliasis;Respiratory tract infection;Reticuloendothelial system stimulated;Reticuloendotheliosis;Retinal disorder;Retinitis;Retrosternal pain;Rhinitis;Scrotal oedema;Seborrhoeic dermatitis;Sepsis;Shift to the left;Shock;Sialoadenitis;Sinusitis;Skin cancer;Skin candida;Skin carcinoma;Skin discolouration;Skin disorder;Skin hypertrophy;Skin ulcer;Somnolence;Speech disorder;Sputum increased;Stomatitis;Subacute bacterial endocarditis;Subacute endocarditis;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thrombosis;Thrombotic thrombocytopenic purpura;Tinnitus;Tooth abscess;Tremor;Tuberculosis;Ulcerative keratitis;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Uremia;Urethral disorder;Urethral pain;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urticaria;Vaginal haemorrhage;Vaginal moniliasis;Vasospasm;Venous pressure increased;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Vestibular disorder;Viraemia;Visual disturbance;Visual impairment;Vocal cord paralysis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;WBC abnormal NOS;Weight decreased;Weight increased;White blood cell disorder;X-linked lymphoproliferative syndrome,small molecule,approved,(±)-cyclopentolate; 1-hydroxy-α-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid β-(dimethylamino)ethyl ester; Ciclopentolato; Cyclopentolate; Cyclopentolatum; α-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; β-(dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; β-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase,Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M5, S01FA04;S01FA54
mycophenolic,Kidney transplant rejection;Lupus nephritis;Transplant rejection,Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Abnormal dreams;Abnormal vision;Abscess;Accidental injury;Acidosis;Acne;Acquired immunodeficiency syndrome;Affect lability;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alkalosis;Alopecia;Amblyopia;Anaemia;Angina pectoris;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Apathy;Aplasia pure red cell;Apnoea;Arrhythmia;Arterial thrombosis;Arthralgia;Arthritis;Arthropathy;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atelectasis;Atrial fibrillation;Atrial flutter;Atrophy;Atypical mycobacterial infection;Autoimmune disorder;BK virus infection;Back pain;Basal cell carcinoma;Benign neoplasm of skin;Bladder pain;Bladder spasm;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood disorder;Blood lactate dehydrogenase increased;Blood pressure increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bradycardia;Breast disorder;Breath odour;Bronchitis;Candida infection;Carcinoma;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiovascular disorder;Cataract;Cellulitis;Cheilitis;Chest pain;Chills;Cholangitis;Coagulopathy;Colitis;Complications of transplant surgery;Confusional state;Congenital anomaly;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatinine increased;Cryptococcosis;Cushing's syndrome;Cytomegalovirus colitis;Cytomegalovirus gastritis;Cytomegalovirus infection;Cytomegalovirus viraemia;Deafness;Decreased appetite;Dehydration;Delirium;Delusional perception;Dermatitis;Dermatitis bullous;Developmental delay;Device related infection;Diabetes mellitus;Diarrhoea;Discomfort;Disorder birth;Dizziness;Drug toxicity;Dry mouth;Duodenal ulcer;Dyspepsia;Dysphagia;Dyspnoea;Dyspnoea exertional;Dysuria;Ear disorder;Ear malformation;Ear pain;Ecchymosis;Edema of lower extremities;Endocrine disorder;Enlargement abdomen;Epistaxis;Erectile dysfunction;Eructation;Extrasystoles;Eye disorder;Eye haemorrhage;Face oedema;Fatal outcomes;Fatigue;Feeling abnormal;Flat affect;Flatulence;Fluid overload;Fluid retention;Foetal death;Fungaemia;Fungal infection;Fungal skin infection;Gamma-glutamyltransferase increased;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal candidiasis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Gingival hyperplasia;Gingivitis;Gout;Graft loss;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Hallucination;Headache;Hemiparesis;Hepatitis;Hepatitis B;Hepatitis C;Hepatobiliary disease;Hepatocellular injury;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hirsutism;Hydronephrosis;Hyperbilirubinaemia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hyperphosphataemia;Hypertension;Hypertension worsened;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypochloraemia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hypotension;Hypothyroidism;Hypovolaemia;Ileus;Ill-defined disorder;Immunocompromised;Immunodeficiency;Impaired healing;Implant infection;Increased bronchial secretion;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Injury;Insomnia;Intestinal perforation;Jaundice;Jaundice cholestatic;Kaposi's sarcoma;Kidney function abnormal;Laboratory test abnormal;Lacrimal disorder;Lacrimal structural disorder;Lactic dehydrogenase activity increased;Laryngeal pain;Leukocytosis;Leukopenia;Lip pain;Lip ulceration;Liver function test abnormal;Liver injury;Local swelling;Loose stools;Loss of consciousness;Lung disorder;Lymphadenopathy;Lymphocele;Lymphoma;Lymphopenia;Lymphoproliferative disorder;Malaise;Malignant melanoma;Malnutrition;Mediastinal disorder;Melaena;Melanoma skin;Meningitis;Mental disability;Mental disorder;Mood swings;Mouth ulceration;Multiple congenital abnormalities;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Nasopharyngitis;Nausea;Neck pain;Neonatal disorder;Neoplasm;Neoplasm malignant;Nephropathy;Nervous system disorder;Nervousness;Neurological symptom;Neuropathy;Neuropathy peripheral;Neutropenia;Nocturia;Non-Hodgkin's lymphoma;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Opportunistic infection;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Osteoarthritis;Osteomyelitis;Osteoporosis;Pain;Pain in extremity;Pallor;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Parathyroid disorder;Parotid duct obstruction;Pelvic pain;Peptic ulcer;Pericardial effusion;Peripheral swelling;Peripheral vascular disorder;Peritonitis;Petechiae;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Pleural effusion;Pneumonia;Pneumothorax;Pollakiuria;Polycythaemia;Polyomavirus-associated nephropathy;Post procedural complication;Post procedural pain;Postoperative complications NOS;Postoperative pain;Postoperative wound complication;Pregnancy;Pregnancy loss;Procedural pain;Progressive multifocal leukoencephalopathy;Prostatic disorder;Prothrombin level increased;Pruritus;Psychotic disorder;Pulmonary congestion;Pulmonary fibrosis;Pulmonary hypertension;Pulmonary oedema;Pyelonephritis;Rash;Rash pustular;Rectal disorder;Renal failure;Renal failure acute;Renal graft loss;Renal impairment;Renal tubular necrosis;Respiratory acidosis;Respiratory failure;Respiratory moniliasis;Respiratory tract congestion;Respiratory tract infection;Rhinitis;Rigors;Scrotal oedema;Sepsis;Shock;Sinus congestion;Sinusitis;Skin cancer;Skin carcinoma;Skin disorder;Skin hypertrophy;Skin papilloma;Skin ulcer;Somnolence;Sputum increased;Squamous cell carcinoma;Stomatitis;Subacute bacterial endocarditis;Subacute endocarditis;Subileus;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating;Swelling;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Throat sore;Thrombocytopenia;Thrombosis;Tinnitus;Tongue discolouration;Toxicity to various agents;Tremor;Tuberculosis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urethral stenosis;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Vasospasm;Venous pressure increased;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Viraemia;Viral infection;Vision blurred;Visual impairment;Vomiting;Weight decreased;Weight increased;Wheezing;Wound infection;X-linked lymphoproliferative syndrome,small molecule,approved; investigational,"(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; Acide mycophenolique; Acido micofenolico; Acidum mycophenolicum; Micofenolico acido; Mycophenolate; Mycophenolic acid; Mycophenolsäure; 1.1.1.205; IMP dehydrogenase 2; IMP dehydrogenase II; IMPD 2; IMPD2; IMPDH 2; IMPDH-II; Inosine-5'-monophosphate dehydrogenase type II; 1.1.1.205; IMP dehydrogenase 1; IMPD 1; IMPD1; IMPDH 1; IMPDH-I; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase",Inosine-5'-monophosphate dehydrogenase 2; Inosine-5'-monophosphate dehydrogenase 1,L04AA06
nabumetone,Arthritis;Osteoarthritis;Rheumatoid arthritis,Abdominal pain;Abnormal vision;Acne;Acute coronary syndrome;Agitation;Agranulocytosis;Albuminuria;Alopecia;Alveolitis allergic;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Asthenia;Asthma;Azotaemia;Blood uric acid increased;Body temperature increased;Bullous eruption;Calculus of kidney;Chills;Confusional state;Congenital anomaly;Constipation;Cough;Decreased appetite;Depression;Dermatitis;Dermatitis bullous;Developmental delay;Diarrhoea;Discomfort;Dizziness;Dry mouth;Duodenal ulcer;Duodenitis;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Eosinophilic pneumonia;Erectile dysfunction;Eructation;Erythema multiforme;Faecal occult blood positive;Fatigue;Feeling abnormal;Flatulence;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingivitis;Glossitis;Haematuria;Haemoglobin;Haemorrhage;Headache;Hepatic failure;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperuricaemia;Hypokalaemia;Ill-defined disorder;Increased appetite;Insomnia;Interstitial lung disease;Interstitial pneumonia;Jaundice;Jaundice cholestatic;Leukopenia;Liver function test abnormal;Loss of consciousness;Malaise;Melaena;Myocardial infarction;Nausea;Nephritic syndrome;Nephritis interstitial;Nephrolithiasis;Nephrotic syndrome;Nervousness;Nightmare;Occult blood positive;Oedema;Palpitations;Pancreatitis;Paraesthesia;Peptic ulcer;Photosensitivity;Photosensitivity reaction;Pneumonia;Pruritus;Pseudoporphyria;Raised liver function tests;Rash;Rectal haemorrhage;Renal failure;Shock;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Syncope;Taste disorders;Tension;Thrombocytopenia;Thrombophlebitis;Tinnitus;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Urticaria;Vaginal haemorrhage;Vasculitis;Vertigo;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved,4-(6-Methoxy-2-naphthalenyl)-2-butanone; 4-(6-Methoxy-2-naphthyl)-2-butanone; Nabumeton; Nabumetona; Nabumétone; Nabumetone; Nabumetonum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.11.2.2; MPO; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.1.1.146; 11-beta-HSD1; 11-DH; 7-oxosteroid reductase; Corticosteroid 11-beta-dehydrogenase isozyme 1; HSD11; HSD11L; SDR26C1; Short chain dehydrogenase/reductase family 26C member 1; 1.1.1.-; 1.1.1.112; 1.1.1.209; 1.1.1.210; 1.1.1.357; 1.1.1.51; 1.1.1.53; 1.1.1.62; 1.3.1.20; 20-alpha-HSD; 20-alpha-hydroxysteroid dehydrogenase; Chlordecone reductase homolog HAKRC; DD1; DDH; DDH1; Dihydrodiol dehydrogenase 1; HBAB; High-affinity hepatic bile acid-binding protein; 1.-.-.-; 1.1.1.112; 1.1.1.209; 1.1.1.53; 1.1.1.62; 1.3.1.20; 3-alpha-HSD3; Chlordecone reductase homolog HAKRD; DD-2; DD/BABP; DD2; DDH2; Dihydrodiol dehydrogenase 2; Dihydrodiol dehydrogenase/bile acid-binding protein; Type III 3-alpha-hydroxysteroid dehydrogenase; 1.1.1.-; 1.1.1.209; 1.1.1.210; 1.1.1.51; 1.1.1.53; 1.1.1.62; 3-alpha-HSD1; 3-alpha-hydroxysteroid dehydrogenase type I; 3alpha-hydroxysteroid 3-dehydrogenase; CDR; CHDR; Chlordecone reductase; DD-4; DD4; Dihydrodiol dehydrogenase 4; HAKRA,Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1,M01AX01
nadolol,Acute coronary syndrome;Angina pectoris;Anginal attack;Anxiety;Arrhythmia;Cardiac failure;Classical migraine;Diabetes mellitus;Diabetic nephropathy;Headache;Hyperlipidaemia;Hypertension;Hyperthyroidism;Hypotension;Migraine;Migraine with aura;Muscular weakness;Myocardial infarction;Pain;Tachycardia;Tremor,Abdominal bloating;Abdominal discomfort;Abdominal distension;Ache;Adams-Stokes syndrome;Affect lability;Agranulocytosis;Alopecia;Alopecia reversible;Amnesia;Anorexia;Arterial thrombosis;Asthenia;Atrioventricular block;Atrioventricular block complete;Blood triglycerides increased;Body temperature increased;Bradycardia;Bronchospasm;Cardiac failure;Cardiac failure congestive;Cardiomegaly;Catatonia;Chest pain;Colitis ischaemic;Conjunctivitis;Constipation;Cough;Decreased appetite;Depression;Dermatitis;Diarrhoea;Diplopia;Disorientation;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dry skin;Dysarthria;Dyspepsia;Dyspnoea;Erectile dysfunction;Extrasystoles;Fatigue;Feeling cold;Flatulence;Fluid retention;Gastritis;Hallucination;Hepatic enzyme increased;Hyperhidrosis;Hypertension;Hypertensive;Hypertriglyceridaemia;Hypotension;Insomnia;Intermittent claudication;Irritability;Laryngospasm;Lethargy;Libido decreased;Loss of consciousness;Mood swings;Myasthenia gravis;Nasal congestion;Nausea;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pancreatitis acute;Paraesthesia;Pemphigoid;Peripheral coldness;Peyronie's disease;Pruritus;Pulmonary oedema;Purpura non-thrombocytopenic;Rash;Rash pemphigoid;Raynaud's disease;Raynaud's phenomenon;Respiratory distress;Shock;Short-term memory loss;Sleep disorder;Sleep disturbance;Slurred speech;Sweating;Swelling face;Syncope;Throat sore;Tinnitus;Vascular insufficiency;Ventricular bigeminy;Ventricular extrasystoles;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight increased,small molecule,approved,Nadolol; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; NF-A1; Oct-1; OCT1; Octamer-binding protein 1; Octamer-binding transcription factor 1; OTF-1; OTF1; Lymphoid-restricted immunoglobulin octamer-binding protein NF-A2; Oct-2; OCT2; Octamer-binding protein 2; Octamer-binding transcription factor 2; OTF-2; OTF2; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2,Beta-1 adrenergic receptor; Beta-2 adrenergic receptor, C07AA12;C07AA12;C07BA12
nalbuphine,Pain,Abdominal pain;Agitation;Anxiety;Asthenia;Asthma;Body temperature increased;Bradycardia;Bronchospasm;Cardiac arrest;Confusional state;Convulsion;Cramp muscle;Delusion;Depersonalisation;Depression;Dermatitis;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dysphoria;Dyspnoea;Erythema;Euphoric mood;Feeling abnormal;Feeling hot;Flushing;Foetal death;Gastrointestinal pain;Hallucination;Headache;Hostility;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Injection site reaction;Laryngeal oedema;Loss of consciousness;Micturition urgency;Muscle spasms;Nausea;Nervousness;Numbness;Oedema;Paraesthesia;Pollakiuria;Pruritus;Pulmonary oedema;Rash;Redness;Respiratory arrest;Respiratory distress;Sensory loss;Shakiness;Shock;Somnolence;Speech disorder;Speech impairment NOS;Stridor;Sweating increased;Swelling;Syncope;Tachycardia;Taste bitter;Tension;Tingling sensation;Tremor;Urticaria;Vertigo;Vision blurred;Vomiting;Warmth;Wheezing,small molecule,approved,"N-cyclobutylmethyl-4,5α-epoxy-3,6α,14-morphinantriol; Nalbufina; Nalbuphin; Nalbuphine; Nalbuphinum; K-OR-1; KOR-1; OPRK; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD",Kappa-type opioid receptor; Mu-type opioid receptor; Delta-type opioid receptor,N02AF02
nalmefene,Alcohol abuse;Alcoholism;Drug withdrawal syndrome;Pulmonary function test decreased;Respiratory depression;Withdrawal symptom,"Abdominal cramps;Abdominal pain;Agitation;Alcohol withdrawal syndrome;Alcoholic psychosis;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Body temperature increased;Bradycardia;Cardiac disorder;Chills;Confusional state;Connective tissue disorder;Decreased appetite;Diarrhoea;Discomfort;Dissociation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry mouth;Dysphoria;Fatigue;Feeling abnormal;Gastrointestinal disorder;Hallucination;Hallucination, auditory;Hallucination, visual;Headache;Hepatitis;Hyperhidrosis;Hypertension;Hypoaesthesia;Hypotension;Ill-defined disorder;Insomnia;Libido decreased;Liver injury;Loss of libido;Malaise;Malnutrition;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myoclonus;Nausea;Nervous system disorder;Nervousness;Palpitations;Paraesthesia;Pharyngitis;Postoperative pain;Procedural pain;Pruritus;Skin disorder;Sleep disorder;Somatic hallucination;Somnolence;Tachycardia;Tension;Traumatic liver injury;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urinary retention;Vomiting;Weight decreased;Withdrawal syndrome",small molecule,approved; investigational; withdrawn,"17-(Cyclopropylmethyl)-4,5α-epoxy-6-methylenemorphinan-3,14-diol; MORPHINAN-3,14-DIOL, 17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-6-METHYLENE-, (5.ALPHA.)-; Nalmefene; Nalmefeno; K-OR-1; KOR-1; OPRK; D-OR-1; DOR-1; OPRD; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3",Kappa-type opioid receptor; Delta-type opioid receptor; Mu-type opioid receptor,N07BB05
naloxone,Blood pressure increased;Dependence;Dependence physiological;Drug withdrawal syndrome;Hypotension;Pulmonary function test decreased;Respiratory depression;Septic shock;Withdrawal symptom,Abdominal cramps;Abdominal pain;Ache;Agitation;Angiopathy;Asthenia;Body temperature increased;Cardiac arrest;Cardiac disorder;Cardiac fibrillation;Chills;Coma;Convulsion;Dependence on opiates;Depression;Diarrhoea;Drug dependence;Dyspnoea;Encephalopathy;Excitement;Flushing;Gastrointestinal disorder;Grand mal convulsion;Hallucination;Hot flush;Hyperhidrosis;Hyperkinesia;Hypertension;Injection site reaction;Irritability;Mediastinal disorder;Menopausal symptoms;Mental disorder;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Pain;Paraesthesia;Piloerection;Pulmonary oedema;Rhinorrhoea;Shivering;Skin disorder;Sneezing;Sweating;Tachycardia;Tension;Trembling;Tremor;Tremulousness;Unspecified disorder of skin and subcutaneous tissue;Ventricular fibrillation;Ventricular tachycardia;Vomiting;Withdrawal syndrome;Yawning,small molecule,approved; vet_approved,"(−)-naloxone; 1-N-Allyl-14-hydroxynordihydromorphinone; 17-allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one; Nalossone; Naloxona; Naloxone; Naloxonum; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; K-OR-1; KOR-1; OPRK; cAMP-responsive element-binding protein 1; CREB-1; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; hToll; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Mu-type opioid receptor; Delta-type opioid receptor; Kappa-type opioid receptor; Cyclic AMP-responsive element-binding protein 1; Estrogen receptor; Toll-like receptor 4; Liver carboxylesterase 1, N02AA53; N02AA55; N02AD51; N02AX51; V03AB15;A06AH04;V03AB15
naltrexone,Alcohol abuse;Alcoholism;Dependence on opiates;Drug dependence,Abdominal cramps;Abdominal discomfort;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abnormal dreams;Abortion missed;Ache;Acute coronary syndrome;Agitation;Alanine aminotransferase increased;Alcohol abuse;Alcohol withdrawal syndrome;Alcoholism;Alopecia;Anaphylactic shock;Angina pectoris;Angina unstable;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety NEC;Anxiety aggravated;Appetite absent;Appetite disorder;Arteriosclerosis coronary artery;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthenic conditions;Atrial fibrillation;Back pain;Bad dreams;Blood and lymphatic system disorders;Blood creatinine normal;Blood pressure fluctuation;Blood pressure increased;Body temperature increased;Bronchial hyperreactivity;Bronchitis;Cardiac disorder;Cardiac failure congestive;Cellulitis;Cerebral arterial aneurysm;Cervical adenitis;Change in blood pressure;Chest discomfort;Chest pain;Chest tightness;Chills;Cholecystitis acute;Cholelithiasis;Chronic obstructive pulmonary disease;Cold feet;Colitis;Completed suicide;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cramp muscle;Creatinine normal;Crying;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Dementia Alzheimer's type;Dependence on opiates;Depressed mood;Depression;Dermatitis;Diarrhoea;Difficulty sleeping;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug dependence;Drug withdrawal syndrome;Dry mouth;Dysgeusia;Dysphonia;Dyspnoea;Ejaculation delayed;Elevated liver enzyme levels;Energy increased;Eosinophilic pneumonia;Epistaxis;Euphoric mood;Excessive flatulence;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Flatulence;Frequent bowel movements;Frequent headaches;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;Groin pain;Haemorrhoids;Hallucination;Headache;Heat exhaustion;Heat stroke;Hepatic enzyme increased;Hepatitis;Hepatitis C;Hepatobiliary disease;Hepatotoxicity;Herpes labialis;Hoarseness;Hot flush;Hypercholesterolaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Idiopathic thrombocytopenic purpura;Ileus paralytic;Ill-defined disorder;Immune system disorder;Increased appetite;Increased thirst;Induration;Infection;Infestation;Infestation NOS;Influenza;Injection site bruising;Injection site haemorrhage;Injection site induration;Injection site pain;Injection site pruritus;Injection site reaction;Injection site tenderness;Insomnia;Intracranial aneurysm;Irritability;Ischaemic stroke;Joint stiffness;Laryngeal pain;Laryngitis;Lethargy;Libido decreased;Loose stools;Loss of consciousness;Lymphadenitis;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disability;Mental disorder;Mental retardation;Migraine;Miliaria;Miliaria rubra;Muscle rigidity;Muscle spasms;Muscle strain;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Night sweats;Nightmare;Nodule;Obesity;Obsessive-compulsive disorder;Oedema;Oily skin;Oral herpes;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pain in extremity;Palpitations;Pancreatitis acute;Panic attack;Paraesthesia;Paranoia;Peripheral coldness;Perirectal abscess;Pharyngitis;Pharyngitis streptococcal;Pharyngolaryngeal pain;Phlebitis;Platelet count decreased;Pneumonia;Poor quality sleep;Pregnancy;Pruritus;Psychotic disorder;Pulmonary embolism;Purpura;Rash;Rash papular;Retinal artery occlusion;Rhinitis seasonal;Rhinorrhoea;Rigors;Seasonal allergy;Seborrhoeic dermatitis;Sexual dysfunction;Shock;Sinus congestion;Sinus headache;Sinusitis;Skin disorder;Sleep disorder;Sluggishness;Sneezing;Somnolence;Stiff back;Stiffness;Suicidal ideation;Suicide;Suicide attempt;Sweating increased;Swelling;Syncope;Tachycardia;Tearfulness;Tension;Thinking abnormal;Thirst;Throat sore;Tinea pedis;Tinnitus;Tooth abscess;Toothache;Tremor;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urinary tract infection;Urticaria;Vision blurred;Vomiting;Weight decreased;Weight increased;White blood cell count increased;Withdrawal symptom;Withdrawal syndrome;Yawning,small molecule,approved; investigational; vet_approved,"17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one; 17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one; N-Cyclopropylmethyl-14-hydroxydihydromorphinone; N-Cyclopropylmethylnoroxymorphone; Naltrexon; Naltrexona; Naltrexone; Naltrexonum; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; K-OR-1; KOR-1; OPRK; D-OR-1; DOR-1; OPRD; Aging-associated gene 8 protein; hSigmaR1; OPRS1; SIG-1R; Sigma 1-type opioid receptor; Sigma1-receptor; Sigma1R; SR-BP; SR31747-binding protein; SRBP; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1",Mu-type opioid receptor; Kappa-type opioid receptor; Delta-type opioid receptor; Sigma non-opioid intracellular receptor 1, A08AA62; N07BB04;N02AA56;N07BB04
nandrolone,Anaemia;Aplastic anaemia;Breast cancer;Carcinoma breast;Chronic renal insufficiency;Osteoporosis;Renal failure;Renal failure acute;Renal failure chronic;Renal impairment,Acne;Amenorrhoea;Azoospermia;Benign prostatic hyperplasia;Dermatitis;Disturbance in sexual arousal;Dysphonia;Epididymitis;Epiphyses premature fusion;Erectile dysfunction;Fluid retention;Furuncle;Furunculosis;Gynaecomastia;Haemoglobin increased;Hepatic function abnormal;Hirsutism;Hoarseness;Hyperlipidaemia;Hypertension;Hypertrophy;Intentional drug misuse;Intentional misuse;Irritability;Jaundice;Libido decreased;Local reaction;Mediastinal disorder;Nausea;Oedema;Oily hair;Oily skin;Oligomenorrhoea;Oligospermia;Peliosis hepatis;Precocious puberty;Priapism;Pruritus;Rash;Seborrhoeic dermatitis;Sperm concentration decreased;Sperm count decreased;Testicular atrophy;Urticaria;Virilism;Water retention,small molecule,experimental; investigational,(17β)-17-hydroxyestr-4-en-3-one; 19-norandrostenolone; 19-nortestosterone; Nandrolona; Nandrolone; Nandrolonum; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4,Androgen receptor, A14AB01;S01XA11
naphazoline,Blanching;Common cold;Conjunctivitis allergic;Eye irritation;Hypersensitivity;Nasopharyngitis;Pallor;Rhinitis;Rhinitis seasonal;Seasonal allergy,Accidental exposure to product;Accidental ingestion;Asthenia;Discomfort;Dizziness;Drowsiness;Endophthalmitis;Erythema;Eye disorder;Eye oedema;Eye pain;Headache;Hyperglycaemia;Hyperhidrosis;Hypertension;Intraocular pressure increased;Keratitis;Lacrimation;Lacrimation increased;Mydriasis;Nausea;Nervousness;Ocular discomfort;Ocular hyperaemia;Punctate keratitis;Redness;Somnolence;Sweating;Tension;Vision blurred;Xerosis,small molecule,approved; investigational,Nafazolin; Nafazolina; Naphazoline; Dopamine D2 receptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c,D(2) dopamine receptor; Alpha-2A adrenergic receptor; Alpha-1A adrenergic receptor, R01AA08; S01GA01; S01GA51;R01AA08;R01AB02
naratriptan,Aura;Cluster headache;Migraine,Abdominal discomfort;Acute coronary syndrome;Aggression;Agitation;Alopecia;Altered state of consciousness;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angiopathy;Anxiety;Aphasia;Arrhythmia;Arteriospasm coronary;Arthralgia;Asthenia;Asthma;Atrial fibrillation;Atrial flutter;Balance disorder;Bilirubin abnormal;Bladder pain;Blood bilirubin abnormal;Blood disorder;Blood pressure increased;Body temperature increased;Bone pain;Bradycardia;Breast discharge;Bronchitis;Burning sensation;Cardiac disorder;Cardiac murmur;Cerebral infarction;Cerebrovascular accident;Chills;Cognitive disorder;Colitis ischaemic;Confusional state;Constipation;Convulsion;Coordination abnormal;Cough;Cramp muscle;Cutaneous hypersensitivity;Cystitis;Cystitis noninfective;Dehydration;Depressed level of consciousness;Depression;Depressive disorder;Dermatitis;Dermatitis atopic;Detachment psychological;Diarrhoea;Discomfort;Dissociation;Disturbance in sexual arousal;Diuresis;Dizziness;Drowsiness;Dry eye;Dry mouth;Dry skin;Dysequilibrium;Dyspeptic signs and symptoms;Dyspnoea;Dysthymic disorder;Electrocardiogram PR prolongation;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Erythema;Eye haemorrhage;Eye pain;Fasciculation;Fatigue;Feeling abnormal;Feeling hot;Feeling strange;Fluid retention;Folliculitis;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal discomfort;Gastrointestinal disorder;Glycosuria;Haemoglobin;Haemorrhage;Haemorrhage urinary tract;Haemorrhoids;Hallucination;Headache;Hostility;Hyperaesthesia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hypersensitivity;Hypoaesthesia;Hypotension;Hypothyroidism;Ill-defined disorder;Immune system disorder;Infection;Inflammation;Ischaemia;Ketonuria;Labyrinthitis;Libido decreased;Liver function test abnormal;Loss of consciousness;Malaise;Mass;Mastitis;Medication overuse headache;Micturition urgency;Migraine;Muscle contractions involuntary;Muscle rigidity;Muscle spasms;Muscle stiffness;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Nervous system disorder;Neuralgia;Neuritis;Neuropathy peripheral;Numbness;Oedema;Oesophagitis;Oral pruritus;Pain;Pain in jaw;Palpitations;Panic reaction;Paraesthesia;Paralysis;Parathyroid tumour;Phonophobia;Photophobia;Photosensitivity;Photosensitivity reaction;Pleurisy;Pneumonia;Pollakiuria;Polydipsia;Polyuria;Prinzmetal angina;Pruritus;Psychomotor retardation;Purpura;Pyelitis;Pyelonephritis;Rash;Regurgitation;Rheumatic disorder;Rheumatism;Rhinitis allergic;Salivary gland enlargement;Salivary gland swelling;Scotoma;Sensation of heat;Sensation of pressure;Sensory loss;Serotonin syndrome;Shock;Sialoadenitis;Sinusitis;Skin disorder;Sleep disorder;Somnolence;Stinging;Subarachnoid haemorrhage;Sweating;Swelling;Syncope;Tachyarrhythmia;Thirst;Thrombocytopenia;Tingling sensation;Tinnitus;Tracheitis;Transient ischaemic attack;Tremor;Ulcer;Urinary incontinence;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasospasm;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Vomiting,small molecule,approved; investigational,N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide; N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide; Naratriptán; Naratriptan; Naratriptanum; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A,5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1F,N02CC02
nateglinide,Blood glucose decreased;Diabetes mellitus;Diabetic;Hyperglycaemia;Type 2 diabetes mellitus;Weight decreased,Abdominal pain;Arthropathy;Asthenia;Back pain;Bronchitis;Cough;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Erythema multiforme;Fatigue;Flu symptoms;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Hepatic enzyme increased;Hepatitis cholestatic;Hepatobiliary disease;Hyperhidrosis;Hypersensitivity;Hypoglycaemia;Immune system disorder;Increased appetite;Influenza;Injury;Jaundice;Malnutrition;Nausea;Neuropathy peripheral;Oedema peripheral;Osteoarthritis;Palpitations;Polyuria;Pruritus;Rash;Sweating;Sweating increased;Thirst;Trauma;Trembling;Tremor;Upper respiratory tract infection;Urine output increased;Urticaria;Vomiting,small molecule,approved; investigational,"Nateglinida; Natéglinide; Nateglinide; Nateglinidum; HRINS; Sulfonylurea receptor 1; SUR; SUR1; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; MCT 1; MCT1; Solute carrier family 16 member 1; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",ATP-binding cassette sub-family C member 8; Peroxisome proliferator-activated receptor gamma,A10BX03
nefazodone,"Agitation;Asthenia;Bradyphrenia;Bradypsychic response;Cerebration impaired;Decreased interest;Depressed mood;Depression;Depressive episode;Disturbance in attention;Drug abuse;Dysphoria;Fatigue;Feeling guilty;Hypersomnia;Insomnia;Major depression;Major depressive disorder, single episode;Mental disability;Suicidal ideation;Suicide attempt",Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal vision;Abscess periodontal;Accidental injury;Accommodation disorder;Affect lability;Ageusia;Agitation;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angle closure glaucoma;Anorexia;Anorgasmia;Anxiety;Apathy;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrioventricular block;Back pain;Bladder pain;Blood lactate dehydrogenase increased;Blood prolactin increased;Body temperature increased;Bradycardia;Breast pain;Breath odour;Bronchitis;Bursitis;Calculus of kidney;Candida infection;Cardiac failure congestive;Cellulitis;Cerebrovascular accident;Chest pain;Chills;Colitis;Colitis ulcerative;Completed suicide;Confusional state;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cramp muscle;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Dependence;Dependence physiological;Depersonalisation;Derealisation;Dermatitis;Dermatitis bullous;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Drug dependence;Drug seeking behavior;Drug tolerance;Dry eye;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dysphoria;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Eczema;Enlargement abdomen;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Euphoric mood;Eye pain;Face oedema;Feeling abnormal;Flat affect;Flatulence;Flushing;Gait disturbance;Galactorrhoea;Gastritis;Gastroenteritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingivitis;Glaucoma;Glossitis;Gout;Grand mal convulsion;Gynaecomastia;Haematocrit decreased;Haematuria;Haemoglobin;Haemorrhage;Hallucination;Hangover;Headache;Hepatic failure;Hepatic necrosis;Hepatitis;Hernia;Hiccups;Hostility;Hyperacusis;Hyperaesthesia;Hypercholesterolaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hyponatraemia;Hypotension;Hypotonia;Ill-defined disorder;Increased appetite;Infection;Influenza;Injury;Insomnia;Keratitis;Keratoconjunctivitis;Lactic dehydrogenase activity increased;Laryngitis;Leukopenia;Libido decreased;Libido increased;Lightheadedness;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Malaise;Malignant syndrome NOS;Memory impairment;Mental disability;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Muscle relaxant therapy;Muscle spasms;Muscle stiffness;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Mydriasis;Myoclonus;Nausea;Neck pain;Neck stiffness;Nephrolithiasis;Neuralgia;Neuroleptic malignant syndrome;Night blindness;Nocturia;Nuchal rigidity;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Oral candidiasis;Orthostatic hypotension;Osteoarthritis;PRL increased;Pain;Pallor;Palpitations;Paraesthesia;Paranoia;Paranoid reaction;Pelvic pain;Peptic ulcer;Pharyngitis;Photophobia;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Priapism;Proctocolitis;Pruritus;Psychomotor retardation;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Rhabdomyolysis;Rhinitis;Salivary hypersecretion;Scotoma;Serotonin syndrome;Shock;Sinus bradycardia;Sinusitis;Somnolence;Stevens-Johnson syndrome;Stomatitis;Suicidal ideation;Suicide;Suicide attempt;Sweating;Syncope;Tachycardia;Tendinous contracture;Tenosynovitis;Thinking abnormal;Thirst;Thrombocytopenia;Tinnitus;Tolerance development;Tonic-clonic seizures;Tooth abscess;Tooth disorder;Tremor;Urinary incontinence;Urinary retention;Urinary tract infection;Urine output increased;Urticaria;Uterine leiomyoma;Vaginal infection;Vaginal inflammation;Varicose vein;Ventricular extrasystoles;Vertigo;Vesiculobullous rash;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;Yawning,small molecule,approved; withdrawn,"1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; Nefazodona; Nefazodone; Nefazodonum; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; CYP2B7; Cytochrome P450 2B7 short isoform; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2C; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 1A; Sodium-dependent noradrenaline transporter; Sodium-dependent dopamine transporter; Alpha-1B adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-1A adrenergic receptor; Voltage-gated inwardly rectifying potassium channel KCNH2,N06AX06
nelfinavir,Immunodeficiency,Abdominal distension;Abdominal pain;Abdominal pain upper;Accidental injury;Affect lability;Agitation;Alanine aminotransferase increased;Amylase increased;Anaemia;Angiopathy;Anorexia;Anxiety;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Back pain;Blood amylase increased;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood triglycerides increased;Blood uric acid increased;Body temperature increased;Breast enlargement;Bronchospasm;Buffalo hump;Calculus of kidney;Completed suicide;Connective tissue disorder;Convulsion;Cramp muscle;Decreased appetite;Dehydration;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Dyspepsia;Dyspnoea;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Epigastric pain;Epistaxis;Erythema;Erythema multiforme;Eye disorder;Fat redistribution;Feeling abnormal;Flatulence;Folliculitis;Fungal skin infection;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Haemoglobin;Haemoglobin decreased;Haemorrhage;Headache;Hepatic enzyme increased;Hepatitis;Hepatobiliary disease;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlactacidaemia;Hyperlipidaemia;Hypersensitivity;Hypertriglyceridaemia;Hypertrophy of breast;Hyperuricaemia;Hypoglycaemia;Ill-defined disorder;Immune system disorder;Inflammation;Injury;Insomnia;Insulin resistance;Iritis;Jaundice;Leukopenia;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Liver function test abnormal;Malaise;Malnutrition;Metabolic acidosis;Migraine;Mood swings;Mouth ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myopathy;Myositis;Nausea;Nephrolithiasis;Neutropenia;Oedema;Opportunistic infection;Pain;Pancreatitis;Paraesthesia;Pharyngitis;Pneumonia;Pruritus;Rash;Rash maculo-papular;Rhabdomyolysis;Rhinitis;Sexual dysfunction;Sinusitis;Skin disorder;Sleep disorder;Somnolence;Stomatitis;Suicide;Sweating;Thrombocytopenia;Torsade de pointes;Unspecified disorder of skin and subcutaneous tissue;Urine abnormality;Urine analysis abnormal;Urticaria;Vomiting,small molecule,approved,"Nelfinavir; Fragment; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",HIV-1 protease,J05AE04
neomycin,Anterior uveitis;Coma hepatic;Conjunctivitis infective;Hepatic encephalopathy;Infection;Injury corneal;Iridocyclitis;Thermal burn,Anaphylactic shock;Cataract subcapsular;Diarrhoea;Erythema;Eye infection;Glaucoma;Hypersensitivity;Impaired healing;Infection;Malabsorption;Nausea;Nephropathy toxic;Nephrotoxicity;Nerve injury;Ototoxicity;Posterior subcapsular cataract;Pruritus;Secondary infection;Sensitisation;Steatorrhoea;Swelling;Ulcerative keratitis;Viral infection;Vomiting,small molecule,approved; vet_approved,Fradiomycin; Kaomycine; Neomicina; Neomycin; Vonamycin; strA; CaR; CaSR; GPRC2A; hCasR; Parathyroid cell calcium-sensing receptor 1; PCAR1,30S ribosomal protein S12; 16S ribosomal RNA; Extracellular calcium-sensing receptor, A01AB08; A07AA01; B05CA09; D06AX04; J01GB05; R02AB01; S01AA03; S02AA07; S03AA01;A01AB08;A07AA51
neostigmine,Abdominal distension;Distention;Dysphagia;Ileus paralytic;Intestinal atony;Myasthenia gravis;Urinary retention,Abdominal cramps;Abdominal pain;Abnormal behaviour;Agitation;Anaphylactic shock;Arrhythmia;Arthralgia;Asthenia;Atrioventricular block;Bradycardia;Bronchospasm;Cardiac arrest;Cardiovascular disorder;Chest discomfort;Chest tightness;Coma;Connective tissue disorder;Convulsion;Cramp muscle;Dermatitis;Diarrhoea;Dizziness;Drowsiness;Dry mouth;Dysarthria;Dyspnoea;Fasciculation;Flatulence;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hyperhidrosis;Hypersensitivity;Hypotension;Incision site complication;Insomnia;Intestinal cramps;Lacrimation;Lacrimation increased;Laryngeal pain;Loss of consciousness;Mediastinal disorder;Mental disorder;Miosis;Muscle contractions involuntary;Muscle spasms;Musculoskeletal discomfort;Nausea;Nervous system disorder;Nodal rhythm;Nystagmus;Osteoarthritis;Paralysis;Pharyngolaryngeal pain;Pollakiuria;Post procedural complication;Post procedural nausea;Postoperative shivering;Procedural complication;Procedural nausea;Procedural pain;Pruritus;Pulmonary function test decreased;Rash;Respiratory arrest;Respiratory depression;Salivary hypersecretion;Salivation;Shock;Skin disorder;Slurred speech;Somnolence;Sweating increased;Syncope;Tachycardia;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urticaria;Vermiculation;Vomiting;Wheezing,small molecule,approved; vet_approved,"(m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; Eustigmin; Eustigmine; m-Trimethylammoniumphenyldimethylcarbamate; Neostigmina; 3.1.1.7; AChE; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase",Acetylcholinesterase, N07AA51; S01EB06;N07AA01
nevirapine,Acquired immunodeficiency syndrome;Autoimmune disorder;Dermatitis;Hepatotoxicity;Infection;Rash,Abdominal pain;Ache;Agranulocytosis;Alanine aminotransferase increased;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Autoimmune disorder;Basedow's disease;Blister;Blood and lymphatic system disorders;Blood phosphorus decreased;Blood pressure increased;Blood triglycerides increased;Body temperature increased;Bone disorder;Breast enlargement;Buffalo hump;Bullous eruption;Chronic hepatitis B;Congenital anomaly;Conjunctivitis;Connective tissue disorder;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Developmental delay;Diarrhoea;Discomfort;Drug eruption;Drug interaction;Drug reaction with eosinophilia and systemic symptoms;Eosinophilia;Erythema;Erythema multiforme;Erythema nodosum;Face oedema;Fat redistribution;Fatigue;Feeling abnormal;Foetor hepaticus;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hepatic enzyme increased;Hepatic failure;Hepatic necrosis;Hepatitis;Hepatitis acute;Hepatitis cholestatic;Hepatitis fulminant;Hepatitis toxic;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hypercholesterolaemia;Hyperglycaemia;Hyperlactacidaemia;Hypersensitive syndrome;Hypersensitivity;Hypertransaminasaemia;Hypertriglyceridaemia;Hypertrophy of breast;Ill-defined disorder;Immune system disorder;Inflammation;Insulin resistance;Jaundice;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Liver disorder;Liver function test abnormal;Liver injury;Lymphadenopathy;Malaise;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Nausea;Necrosis;Nervous system disorder;Neuropathy peripheral;Neutropenia;Oedema;Opportunistic infection;Oral disorder;Oral lesion;Pain;Pancreatitis;Paraesthesia;Paraesthesia skin;Pruritus;Rash;Rash erythematous;Rash maculo-papular;Rash papular;Renal failure;Rhabdomyolysis;Skin disorder;Skin exfoliation;Somnolence;Stevens-Johnson syndrome;Surgery;Surgical intervention;Thrombocytopenia;Toxic epidermal necrolysis;Transaminases increased;Traumatic liver injury;Ulcer;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vertical infection transmission;Vomiting,small molecule,approved,"11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; NEV; Nevirapina; Nevirapine; Nevirapine anhydrous; Nevirapine, anhydrous; NVP; Pr160Gag-Pol; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); hOCT1; OCT1; Organic cation transporter 1",Gag-Pol polyprotein; Reverse transcriptase/RNaseH, J05AR05; J05AR07;J05AG01
nicardipine,Angina pectoris;Arteriosclerosis;Atherosclerosis;Hypertension;Hypertensive;Stable angina pectoris,Abdominal pain;Abnormal dreams;Abnormal vision;Acute coronary syndrome;Agitation;Angina pectoris;Angina pectoris aggravated;Anxiety;Arthralgia;Asthenia;Atrial fibrillation;Atrioventricular block;Block heart;Body temperature increased;Cerebral ischaemia;Chest pain;Confusional state;Conjunctivitis;Constipation;Deep vein thrombosis;Dermatitis;Diarrhoea;Discomfort;Disease progression;Dizziness;Dry mouth;Dyspepsia;Dyspnoea;Ear disorder;Electrocardiogram ST segment depression;Electrocardiogram T wave inversion;Electrocardiogram abnormal;Erectile dysfunction;Extrasystoles;Face oedema;Feeling abnormal;Flushing;Foot edema;Gastrointestinal pain;Haematuria;Haemorrhage intracranial;Headache;Hot flush;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypokalaemia;Hypophosphataemia;Hypotension;Ill-defined disorder;Infection;Injection site pain;Injection site reaction;Insomnia;Local swelling;Loss of consciousness;Malaise;Menopausal symptoms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Neck pain;Nervousness;Nocturia;Oedema;Oedema peripheral;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Oxygen saturation decreased;Pain;Palpitations;Paraesthesia;Pericardial haemorrhage;Pericarditis;Peripheral vascular disorder;Pollakiuria;Polyuria;Rash;Rhinitis;Shock;Sinoatrial node dysfunction;Sinus arrhythmia;Sinusitis;Somnolence;Supraventricular tachycardia;Sweating;Sweating increased;Syncope;Tachycardia;Tension;Throat sore;Thrombocytopenia;Tinnitus;Tremor;Urine output increased;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vision blurred;Visual impairment;Vomiting,small molecule,approved; investigational,"Nicardipine; Nicardipino; Nicardipinum; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; 3.1.4.17; 61 kDa Cam-PDE; Cam-PDE 1A; hCam-1; 3.1.4.17; 63 kDa Cam-PDE; Cam-PDE 1B; PDES1B; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; CACNLG; Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma; Neuronal voltage-gated calcium channel gamma-2 subunit; TARP gamma-2; Transmembrane AMPAR regulatory protein gamma-2; Neuronal voltage-gated calcium channel gamma-3 subunit; TARP gamma-3; Transmembrane AMPAR regulatory protein gamma-3; Neuronal voltage-gated calcium channel gamma-4 subunit; TARP gamma-4; Transmembrane AMPAR regulatory protein gamma-4; Neuronal voltage-gated calcium channel gamma-5 subunit; TARP gamma-5; Transmembrane AMPAR regulatory protein gamma-5; Neuronal voltage-gated calcium channel gamma-6 subunit; Neuronal voltage-gated calcium channel gamma-7 subunit; TARP gamma-7; Transmembrane AMPAR regulatory protein gamma-7; CACNG6; Neuronal voltage-gated calcium channel gamma-8 subunit; TARP gamma-8; Transmembrane AMPAR regulatory protein gamma-8; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; KIAA0558; Voltage-gated calcium channel subunit alpha-2/delta-2; Voltage-gated calcium channel subunit alpha-2/delta-3; Voltage-gated calcium channel subunit alpha-2/delta-4; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; BI; Brain calcium channel I; CACH4; CACN3; CACNL1A4; Calcium channel, L type, alpha-1 polypeptide isoform 4; Voltage-gated calcium channel subunit alpha Cav2.1; BII; Brain calcium channel II; CACH6; CACNL1A6; Calcium channel, L type, alpha-1 polypeptide, isoform 6; Voltage-gated calcium channel subunit alpha Cav2.3; Cav3.1c; KIAA1123; NBR13; Voltage-gated calcium channel subunit alpha Cav3.1; Low-voltage-activated calcium channel alpha1 3.2 subunit; Voltage-gated calcium channel subunit alpha Cav3.2; Ca(v)3.3; KIAA1120; Voltage-gated calcium channel subunit alpha Cav3.3; Cav3.1c; KIAA1123; NBR13; Voltage-gated calcium channel subunit alpha Cav3.1; Low-voltage-activated calcium channel alpha1 3.2 subunit; Voltage-gated calcium channel subunit alpha Cav3.2; Ca(v)3.3; KIAA1120; Voltage-gated calcium channel subunit alpha Cav3.3; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP","Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent L-type calcium channel subunit beta-2; Voltage-dependent calcium channel subunit alpha-2/delta-1; Voltage-dependent L-type calcium channel subunit alpha-1D; Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A; Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; Voltage-dependent calcium channel; Voltage-dependent T-type calcium channel subunit alpha-1G; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent T-type calcium channel subunit alpha-1I; Calmodulin",C08CA04
nifedipine,Acute coronary syndrome;Angina pectoris;Angina unstable;Arteriospasm coronary;Cardiac failure;Cerebrovascular accident;Chronic liver disease;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Diabetic nephropathy;Electrocardiogram ST segment elevation;Essential hypertension;Exercise induced angina;Exhaustion;Fatigue;Gastrointestinal disorder;Hepatic cirrhosis;Hyperlipidaemia;Hypertension;Hypertensive;Hypotension;Hypovolaemia;Liver disorder;Malignant hypertension;Menorrhagia;Myocardial infarction;Pain;Prinzmetal angina;Prolonged menses;Reflex tachycardia;Renal failure;Renal impairment;Short-bowel syndrome;Stable angina pectoris;Tachycardia;Tension;Transient ischaemic attack;Vascular resistance systemic;Vasodilation;Vasodilation procedure;Vasospasm,Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal vision;Acute generalised exanthematous pustulosis;Acute pulmonary oedema;Affect lability;Agitation;Agranulocytosis;Alanine aminotransferase increased;Allergic hepatitis;Allergic oedema;Alopecia;Altered state of consciousness;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angina pectoris aggravated;Angioedema;Angiopathy;Anorexia;Anxiety;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Ataxia;Atrial fibrillation;Back pain;Bezoar;Blindness transient;Blindness unilateral;Blister;Blood and lymphatic system disorders;Blood pressure increased;Body temperature increased;Bradycardia;Breast disorder;Breast engorgement;Breast pain;Bronchospasm;Calculus of kidney;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiogenic shock;Cardiovascular disorder;Cellulitis;Cerebration impaired;Chest pain;Chills;Cholestasis;Cholestasis intrahepatic;Chronic renal insufficiency;Coma;Confusional state;Conjunctivitis;Connective tissue disorder;Consciousness abnormal;Constipation;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry mouth;Dysaesthesia;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Enlargement abdomen;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Erythromelalgia;Extrasystoles;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Fatigue;Feeling abnormal;Feeling hot;Feeling jittery;Flatulence;Flushing;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal obstruction;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;Gastrooesophageal sphincter insufficiency;Gingival bleeding;Gingival disorder;Gingival hyperplasia;Gingivitis;Gout;Gynaecomastia;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Heartburn;Hepatitis;Hepatobiliary disease;Hot flush;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertonia;Hypoaesthesia;Hypotension;Hypovolaemia;Ill-defined disorder;Immune system disorder;Inflammation;Insomnia;Intestinal obstruction;Intestinal ulcer;Intoxication;Jaundice;Joint stiffness;Joint swelling;Laboratory test abnormal;Lacrimal disorder;Lacrimation abnormal NOS;Laryngeal oedema;Leg pain;Leukopenia;Libido decreased;Lightheadedness;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Malaise;Malignant hypertension;Malnutrition;Mediastinal disorder;Melaena;Menopausal symptoms;Menstrual disorder;Mental disability;Mental disorder;Metabolic acidosis;Migraine;Mood swings;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myocardial ischaemia;Myopathy;Nasal congestion;Nausea;Neck pain;Nephrolithiasis;Nervous system disorder;Nervousness;Neurological symptom;Nightmare;Nocturia;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Oropharyngeal discomfort;Oropharyngeal pain;Oropharyngeal swelling;Orthostatic hypotension;Osteoarthritis;Pain;Pain in extremity;Palpable purpura;Palpitations;Paraesthesia;Pelvic pain;Periorbital oedema;Petechiae;Pharyngitis;Phlebitis;Photosensitivity allergic reaction;Photosensitivity reaction;Poisoning;Pollakiuria;Polyuria;Pruritus;Pulmonary congestion;Pulmonary oedema;Purpura;Rales;Rash;Rash erythematous;Rash maculo-papular;Rash pustular;Rebound effect;Renal failure chronic;Renal impairment;Respiratory tract congestion;Retrosternal pain;Rhinitis;Rigors;Sensation of heat;Sexual dysfunction;Shakiness;Shock;Sinusitis;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Stevens-Johnson syndrome;Stridor;Sweating;Sweating increased;Syncope;Tachycardia;Tenderness;Tension;Thirst;Throat sore;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tremor;Ulcer;Unilateral vision loss;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urine output;Urine output increased;Urogenital disorder;Urticaria;Vascular purpura;Vasodilation;Vasodilation procedure;Ventricular arrhythmia;Vertigo;Vesiculobullous rash;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;Wheezing,small molecule,approved,"4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester; Nifedipine; Nifedipino; Nifedipinum; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; Potassium voltage-gated channel subfamily D member 3; Voltage-gated potassium channel subunit Kv4.3; Cav3.1c; KIAA1123; NBR13; Voltage-gated calcium channel subunit alpha Cav3.1; Low-voltage-activated calcium channel alpha1 3.2 subunit; Voltage-gated calcium channel subunit alpha Cav3.2; Ca(v)3.3; KIAA1120; Voltage-gated calcium channel subunit alpha Cav3.3; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent L-type calcium channel subunit alpha-1D; Voltage-dependent L-type calcium channel subunit beta-2; Nuclear receptor subfamily 1 group I member 2; Voltage-dependent L-type calcium channel subunit alpha-1S; A-type voltage-gated potassium channel KCND3; Voltage-dependent T-type calcium channel; Calmodulin, C07FB03; C08CA05; C08GA01;C08CA05;C08CA55
nilutamide,Prostate cancer metastatic,Abdominal pain;Abnormal vision;Alanine aminotransferase increased;Alcohol intolerance;Alopecia;Anaemia;Angina pectoris;Anorexia;Arthritis;Aspartate aminotransferase increased;Asthenia;Back pain;Blood alkaline phosphatase increased;Blood creatinine increased;Blood urea increased;Body hair loss;Body temperature increased;Bone pain;Cardiac failure;Cataract;Chest pain;Chromatopsia;Constipation;Cough;Cough increased;Creatinine increased;Decreased appetite;Depression;Dermatitis;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Dyspepsia;Dyspnoea;Erectile dysfunction;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gynaecomastia;Haematuria;Haptoglobin increased;Headache;Hot flush;Hyperglycaemia;Hyperhidrosis;Hypertension;Hypoaesthesia;Ill-defined disorder;Influenza;Insomnia;Interstitial lung disease;Interstitial pneumonia;Leukopenia;Libido decreased;Loss of consciousness;Lung disorder;Malaise;Melaena;Menopausal symptoms;Nausea;Nervousness;Nocturia;Oedema;Oedema peripheral;Pain;Paraesthesia;Phosphatase alkaline increased;Photophobia;Pneumonia;Pruritus;Rash;Rhinitis;Shock;Sweating;Syncope;Tension;Testicular atrophy;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Visual disturbance;Visual impairment;Vomiting;Weight decreased,small molecule,approved; investigational,"5,5-Dimethyl-3-(α,α,α-trifluoro-4-nitro-m-tolyl)hydantoin; Nilutamida; Nilutamide; Nilutamidum; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.6.2.4; CPR; CYPOR; P450R",Androgen receptor,L02BB02
nimodipine,Berry aneurysm;Cerebral vasoconstriction;Intracranial aneurysm;Subarachnoid haemorrhage;Vasospasm cerebral,Acne;Alanine aminotransferase increased;Anaemia;Angiopathy;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood lactate dehydrogenase increased;Bradycardia;Cardiac disorder;Cardiac failure congestive;Cramp muscle;Deep vein thrombosis;Depression;Dermatitis;Diarrhoea;Disseminated intravascular coagulation;Dizziness;Dyspnoea;Fluid retention;Flushing;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal symptom NOS;Haematoma;Headache;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hypersensitivity;Hypertension;Hyponatraemia;Hypotension;Ileus;Immune system disorder;Infusion site reactions;Jaundice;Lactic dehydrogenase activity increased;Lightheadedness;Liver function test abnormal;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Oedema;Palpitations;Phlebitis;Phosphatase alkaline increased;Platelet count decreased;Pruritus;Rash;Subarachnoid haemorrhage;Sweating increased;Tachycardia;Thrombocytopenia;Vasospasm;Vomiting;Wheezing,small molecule,approved; investigational,"2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-methoxyethyl ester 5-isopropyl ester; isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; Nimodipine; Nimodipino; Nimodipinum; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; Ah receptor; AhR; BHLHE76; Class E basic helix-loop-helix protein 76; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent L-type calcium channel subunit alpha-1D; Voltage-dependent L-type calcium channel subunit alpha-1F; Voltage-dependent L-type calcium channel subunit alpha-1S; Voltage-dependent L-type calcium channel subunit beta-1; Voltage-dependent L-type calcium channel subunit beta-2; Voltage-dependent L-type calcium channel subunit beta-3; Voltage-dependent L-type calcium channel subunit beta-4; Mineralocorticoid receptor; Aryl hydrocarbon receptor,C08CA06
nisoldipine,Hypertension,Abnormal dreams;Abnormal vision;Acute coronary syndrome;Alopecia;Amblyopia;Amnesia;Anaemia;Angioedema;Anorexia;Anxiety;Arthralgia;Arthritis;Asthma;Ataxia;Atrial fibrillation;Atrioventricular block first degree;Blepharitis;Blindness unilateral;Blood urea increased;Body temperature increased;Cardiac failure congestive;Cardiac murmur;Cellulitis;Cerebral ischaemia;Cerebrovascular accident;Chest discomfort;Chest pain;Chest tightness;Chills;Colitis;Confusional state;Conjunctivitis;Cough;Cough increased;Cramps of lower extremities;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Epistaxis;Erectile dysfunction;Eye pruritus;Face oedema;Feeling abnormal;Flatulence;Fungal skin infection;Gastritis;Gastrointestinal haemorrhage;Gingival hyperplasia;Glaucoma;Glossitis;Gout;Gynaecomastia;Haematuria;Headache;Hepatomegaly;Herpes simplex;Herpes zoster;Hyperhidrosis;Hypersensitivity;Hypertonia;Hypoaesthesia;Hypokalaemia;Hypotension;Ill-defined disorder;Increased appetite;Influenza;Insomnia;Keratitis;Keratoconjunctivitis;Lacrimation increased;Laryngitis;Leukopenia;Libido decreased;Liver function test abnormal;Loss of consciousness;Malaise;Melaena;Mental disability;Migraine;Mouth ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myocardial infarction;Myositis;Nausea;Nervousness;Nocturia;Oedema;Oedema peripheral;Orthostatic hypotension;Otitis media;Palpitations;Paraesthesia;Petechiae;Pharyngitis;Pleural effusion;Pollakiuria;Pruritus;Rales;Rash;Rash maculo-papular;Rash pustular;Retinal detachment;Rhinitis;Shock;Sinusitis;Skin discolouration;Skin ulcer;Somnolence;Stomatitis;Supraventricular tachycardia;Sweating;Syncope;Systolic ejection murmur;Tachycardia;Tearing eyes;Tenosynovitis;Tension;Thinking abnormal;Thyroiditis;Tinnitus;Tremor;Unilateral vision loss;Urticaria;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vasodilation;Vasodilation procedure;Venous insufficiency;Ventricular extrasystoles;Vertigo;Visual impairment;Vitreous floaters;Weight decreased;Weight increased;Wheezing;Wheezing inspiratory,small molecule,approved,"isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nisoldipin; Nisoldipina; Nisoldipine; Nisoldipino; Nisoldipinum; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent calcium channel subunit alpha-2/delta-1; Voltage-dependent L-type calcium channel subunit beta-2; Voltage-dependent L-type calcium channel subunit alpha-1D; Voltage-dependent L-type calcium channel subunit alpha-1S,C08CA07
nitrazepam,Anxiety;Bedridden;Epilepsy;Hypsarrhythmia;Infantile spasms;Insomnia;Irritability;Mental disorder;Myoclonic epilepsy;Overwork;Sleep disorder;Sleep disturbance;Tension,Abdominal discomfort;Abnormal behaviour;Abnormal dreams;Aggression;Agitation;Agranulocytosis;Alertness decreased;Amnesia;Anger;Anxiety;Apprehension;Asthenia;Ataxia;Balance disorder;Blood disorder;Body temperature decreased;CNS depression NOS;Confusional state;Congenital anomaly;Constipation;Convulsion;Coordination abnormal;Cramp muscle;Delirium tremens;Depressed level of consciousness;Depression suicidal;Dermatitis;Detachment psychological;Developmental delay;Diarrhoea;Digestion impaired;Diplopia;Disorientation;Dissociation;Dizziness;Dreaming excessive;Drowsiness;Drug withdrawal syndrome;Dysarthria;Dyspepsia;Dysphagia;Dysphoria;Dyspnoea;Excitement;Fatigue;Feeling abnormal;Gait disturbance;Gastrointestinal disorder;Gastrointestinal tract irritation;Hallucination;Hangover;Headache;Heartburn;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypoaesthesia;Hypotension;Hypothermia;Illusion;Infection;Irritability;Jaundice;Lethargy;Leukopenia;Lightheadedness;Loss of consciousness;Malaise;Memory impairment;Memory loss;Mental disability;Muscle spasms;Muscle spasticity;Muscular weakness;Nausea;Nervousness;Nightmare;Numbness;Palpitations;Paraesthesia;Perceptual disturbance;Pneumonia;Pneumonia aspiration;Pregnancy;Pruritus;Psychotic disorder;Rage;Rash;Retrograde amnesia;Salivary hypersecretion;Salivation;Sedation;Sensory loss;Shock;Sickness;Slurred speech;Somnolence;Staggering gait;Sweating;Swollen tongue;Syncope;Tension;Thinking abnormal;Tingling of extremity;Tongue disorder;Tongue oedema;Tremor;Unsteadiness;Upset stomach;Urinary incontinence;Vertigo;Violent behavior;Vision blurred;Vomiting;Withdrawal symptom,small molecule,approved,"1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; 2,3-dihydro-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2-one; 7-nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; N-desmethylnimetazepam; Nitrazépam; Nitrazepam; Nitrazepamum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; NAC1; SCN1; Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J",Gamma-aminobutyric acid receptor subunit alpha-1; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site; Sodium channel protein type 1 subunit alpha,N05CD02
nitrofurantoin,Abscess;Acute cystitis;Angioedema;Arthralgia;Asthma;Bacteriuria;Bladder pain;Body temperature increased;Cystitis;Cystitis noninfective;Dermatitis;Drug fever;Drug hypersensitivity;Infection;Musculoskeletal discomfort;Pancreatitis;Pruritus;Pyelitis;Pyelonephritis;Rash;Sialoadenitis;Urinary tract infection;Urticaria,Abdominal pain;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Amblyopia;Anaemia;Anaemia megaloblastic;Anaphylactic shock;Anorexia;Aplastic anaemia;Aspartate aminotransferase increased;Asthenia;Asthma;Asthmatic attack;Benign intracranial hypertension;Body temperature increased;Bundle branch block;Cardiopulmonary failure;Chest pain;Chills;Chronic liver disease;Confusional state;Constipation;Cough;Cyanosis;Decreased appetite;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dyspepsia;Dyspnoea;Dyspnoea exertional;Electrocardiogram change;Electrolyte imbalance;Eosinophilia;Eruption;Erythema multiforme;Euphoric mood;Feeling abnormal;Fibrosis;Flatulence;Fontanelle bulging;Gastrointestinal disorder;Gastrointestinal pain;Glucose-6-phosphate dehydrogenase deficiency;Haemoglobin decreased;Haemolytic anaemia;Headache;Hepatic necrosis;Hepatitis;Hepatitis chronic active;Hypersensitivity;Hypoaesthesia;Ill-defined disorder;Interstitial lung disease;Interstitial pneumonia;Jaundice cholestatic;Leukopenia;Liver disorder;Lung infiltration;Lupus-like syndrome;Malaise;Methaemoglobinaemia;Muscle atrophy;Musculoskeletal discomfort;Myalgia;Nausea;Neuropathy peripheral;Neurosis;Numbness;Nystagmus;Optic neuritis;Paraesthesia;Pleural effusion;Polyneuropathy;Pseudomembranous colitis;Psychotic disorder;Rash;Reaction gastrointestinal;Renal failure;Renal impairment;Sensory loss;Somnolence;Stevens-Johnson syndrome;Superinfection;Thrombocytopenia;Tingling sensation;Vasculitis;Vertigo;Vitamin B complex deficiency;Vomiting,small molecule,approved; vet_approved,"1-((5-nitro-2-furanyl)methylene)amino-2,4-imidazolidenedione; 1-((5-nitrofurfurylidene)amino)hydantoin; 5-Nitrofurantoin; N-(5-Nitrofurfurylidene)-1-aminohydantoin; Nitrofurantoin; Nitrofurantoin anhydrous; Nitrofurantoin macrocrystal; Nitrofurantoin macrocrystalline; Nitrofurantoin, macrocrystalline; Nitrofurantoin, macrocrystals; nitrofurantoina; nitrofurantoine; nitrofurantoinum; Nitrofurantoinum anhydrous; 1.2.7.-; 1.-.-.-; mda18; mdaA; Modulator of drug activity A; ybjB; nusE; 1.6.2.4; CPR; CYPOR; P450R; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",Probable pyruvate-flavodoxin oxidoreductase; Oxygen-insensitive NADPH nitroreductase; 30S ribosomal protein S10, J01XE51;J01XE01
nitroglycerin,Acute coronary syndrome;Acute myocardial infarction;Acute pulmonary oedema;Anal fissure;Angina pectoris;Anginal attack;Arteriospasm coronary;Cardiac failure congestive;Cardiac index;Cerebrovascular accident;Chronic anal fissure;Coronary artery disease;Coronary heart disease;Discomfort;Drug interaction;Exercise induced angina;Haemorrhoids;Hypertension;Hypotension;Intraoperative hypotension;Left ventricular failure;Myocardial infarction;Nephropathy;Pain;Prinzmetal angina;Procedural hypotension;Pulmonary oedema;Stable angina pectoris;Tachycardia;Tension;Vascular resistance;Vascular resistance systemic;Vasodilation;Vasodilation procedure;Ventricular extrasystoles,Abdominal colic;Abdominal pain;Agitation;Allergic contact dermatitis;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angina pectoris aggravated;Angina unstable;Angioedema;Angiopathy;Application site erythema;Application site irritation;Application site pruritus;Application site reaction;Arrhythmia;Asthenia;Atrioventricular block;Block heart;Blood and lymphatic system disorders;Body temperature increased;Bradycardia;Breath odour;Burning sensation;Cardiac disorder;Cerebral ischaemia;Chest discomfort;Clonic convulsion;Collapse;Coma;Confusional state;Cyanosis;Dermatitis;Dermatitis atopic;Dermatitis contact;Dermatitis exfoliative;Diarrhoea haemorrhagic;Dizziness;Drowsiness;Drug eruption;Drug tolerance;Dyspnoea;Eczema;Erythema;Feeling abnormal;Fixed drug eruption;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Glucose-6-phosphate dehydrogenase deficiency;Headache;Hot flush;Hyperhidrosis;Hyperpnea;Hypersensitivity;Hyperventilation;Hypotension;Hypotensive;Hypovolaemia;Hypoxemia;Hypoxia;Immobile;Immune system disorder;Infection;Infestation;Infestation NOS;Intracranial pressure increased;Ischaemia;Lightheadedness;Localised skin reaction;Loss of consciousness;Mediastinal disorder;Menopausal symptoms;Mental disorder;Methaemoglobinaemia;Nausea;Nervous system disorder;Oedema peripheral;Orthostatic hypotension;Pallor;Palpitations;Paraesthesia;Paralysis;Pharyngitis;Pruritus;Pulse rate decrease marked;Rash;Rash generalised;Rebound hypertension;Redness;Reflex bradycardia;Reflex tachycardia;Renal failure acute;Respiratory rate decreased;Retrosternal discomfort;Rhinitis;Shock;Skin disorder;Skin reaction;Somnolence;Stomatitis;Sweating;Sweating increased;Swollen tongue;Syncope;Tachycardia;Tachypnoea;Throbbing headache;Tolerance development;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vascular headache;Vasodilation;Vasodilation procedure;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Withdrawal hypertension,small molecule,approved; investigational,"1,2,3-propanetrioltrinitrate; 1,2,3-propanetriyl nitrate; Glycerin trinitrate; Glycerol trinitrate; Glycerol, nitric acid triester; Glyceroli trinitratis; Glyceroltrinitrat; Glyceryl trinitrate; NG; Nitroglicerina; Nitroglycerin; Nitroglycerine; Nitroglycerol; Nitromed; Propane-1,2,3-triyl trinitrate; Trinitrine; Trinitroglycerin; Trinitroglycerol; 2.7.10.1; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; 4.6.1.2; GCS-alpha-1; GCS-alpha-3; Guanylate cyclase soluble subunit alpha-3; GUC1A3; GUCSA3; GUCY1A3; Soluble guanylate cyclase large subunit; 4.6.1.2; GCS-beta-1; GCS-beta-3; Guanylate cyclase soluble subunit beta-3; GUC1B3; GUCSB3; GUCY1B3; Soluble guanylate cyclase small subunit; 4.6.1.2; ANP-A; ANPR-A; ANPRA; Atrial natriuretic peptide receptor type A; GC-A; Guanylate cyclase A; NPR-A; 1.2.1.3; ALDH class 2; ALDH-E2; ALDHI; ALDM",Epidermal growth factor receptor; Guanylate cyclase soluble subunit alpha-1; Guanylate cyclase soluble subunit beta-1; Atrial natriuretic peptide receptor 1, C01DA52; C05AE01;C01DA02
nizatidine,Acute duodenal ulcer;Duodenal ulcer;Dyspepsia;Gastric ulcer;Gastrooesophageal reflux disease;Heartburn;Hypergastrinaemia;Hypersensitivity;Oesophagitis;Oesophagitis ulcerative;Renal failure;Renal impairment;Ulcer,Abdominal pain;Abnormal dreams;Amblyopia;Anaemia;Anaphylactic shock;Anorexia;Anxiety;Asthenia;Back pain;Blood uric acid increased;Body temperature increased;Bronchospasm;Chest pain;Confusional state;Constipation;Convulsion;Cough;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Disturbance in sexual arousal;Dizziness;Dry mouth;Dyspepsia;Eosinophilia;Erectile dysfunction;Feeling abnormal;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gout;Gynaecomastia;Headache;Hepatic enzyme increased;Hepatitis;Hepatocellular injury;Hyperhidrosis;Hyperuricaemia;Infection;Insomnia;Irritability;Jaundice;Laryngeal oedema;Libido decreased;Liver injury;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Nephrolithiasis;Nervousness;Pain;Pharyngitis;Pneumonia;Pruritus;Rash;Rhinitis;Serum sickness;Sinusitis;Somnolence;Sweating;Tension;Thrombocytopenia;Thrombocytopenic purpura;Tooth disorder;Urticaria;Vasculitis;Ventricular tachycardia;Vomiting,small molecule,approved,"N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine; Nizatidina; Nizatidine; Nizatidinum; Gastric receptor I; H2R; HH2R; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Histamine H2 receptor,A02BA04
norethisterone,Amenorrhea secondary;Amenorrhoea;Endometriosis;Hormone level abnormal;Imbalance hormonal;Nulliparous;Unintended pregnancy;Uterine cancer;Uterine haemorrhage,Abdominal bloating;Abdominal cramps;Abdominal distension;Abdominal pain;Abortion spontaneous;Acne;Acute coronary syndrome;Adenoma benign;Affect lability;Allergic rash;Alopecia;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Anovulation;Anovulatory cycle;Arterial thromboembolism;Asthenia;Benign hepatic neoplasm;Bleeding breakthrough;Blindness;Breast disorder;Breast enlargement;Breast feeding;Breast pain;Breast tenderness;Carbohydrate tolerance decreased;Carcinoma;Cerebral haemorrhage;Cerebral thrombosis;Chloasma;Connective tissue disorder;Convulsion;Deep vein thrombosis;Depression;Dermatitis;Dermatitis atopic;Dermatitis hemorrhagic;Digestion impaired;Dizziness;Drowsiness;Dyspepsia;Embolism;Embolism arterial;Erythema multiforme;Erythema nodosum;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Genital discharge;Haemoglobin;Haemorrhage;Headache;Hepatitis;Hepatobiliary disease;High density lipoprotein decreased;Hirsutism;Hypersensitivity;Immune system disorder;Infertility;Insomnia;Jaundice cholestatic;Low density lipoprotein increased;Menorrhagia;Menstruation delayed;Menstruation irregular;Mental disorder;Metrorrhagia;Migraine;Mood swings;Myocardial infarction;Nausea;Neoplasm malignant;Nervousness;Oedema;Optic neuritis;Pain in extremity;Photosensitivity;Photosensitivity reaction;Pregnancy;Prurigo;Pruritus;Pulmonary embolism;Purpura;Rash;Renal failure;Renal impairment;Retinal vascular thrombosis;Sexually active;Skin disorder;Somnolence;Spotting menstrual;Suppressed lactation;Tenderness;Tension;Thromboembolic event;Thrombophlebitis;Thrombosis;Thrombosis mesenteric vessel;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Urticaria;Uterine cervical erosion;Vaginal haemorrhage;Virilism;Vomiting;Weight increased;Withdrawal bleed,small molecule,approved,"(17alpha)-17-ethynyl-17-hydroxyestra-4,8(14),9-trien-3-one; 17-hydroxy-19-nor-17-α-pregn-4-en-20-yn-3-one; 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one; 17-α-ethynyl-17-hydroxy-4-estren-3-one; 17-α-ethynyl-19-norandrost-4-en-17-β-ol-3-one; 17-α-ethynyl-19-nortestosterone; 17-α-ethynyl-4-estren-17-ol-3-one; 17-β-hydroxy-19-norpregn-4-en-20-yn-3-one; 17α-ethinyl-19-nortestosterone; 17α-ethinylestra-4-en-17β-ol-3-one; 17α-ethynyl-17-hydroxy-4-estren-3-one; 17α-ethynyl-17β-hydroxy-19-norandrost-4-en-3-one; 17α-ethynyl-19-nor-4-androsten-17β-ol-3-one; 17α-ethynyl-19-norandrost-4-en-17β-ol-3-one; 17α-ethynyl-19-nortestosterone; 17α-ethynyl-4-estren-17-ol-3-one; 17β-hydroxy-19-norpregn-4-en-20-yn-3-one; 19-nor-17-α-ethynyl-17-β-hydroxy-4-androsten-3-one; 19-nor-17-α-ethynylandrosten-17-β-ol-3-one; 19-nor-17-α-ethynyltestosterone; 19-Nor-17alpha-ethynyl-17beta-hydroxy-4-androsten-3-one; 19-nor-17α-ethynyl-17β-hydroxy-4-androsten-3-one; 19-nor-17α-ethynylandrosten-17β-ol-3-one; 19-nor-17α-ethynyltestosterone; 19-nor-ethindrone; 19-norethisterone; 4-estren-17α-ethynyl-17β-ol-3-one; Norethindrone; Norethisteron; Noréthistérone; Norethisterone; Norethisteronum; Noretisterona; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.1.1.-; 1.1.1.209; 1.1.1.210; 1.1.1.51; 1.1.1.53; 1.1.1.62; 3-alpha-HSD1; 3-alpha-hydroxysteroid dehydrogenase type I; 3alpha-hydroxysteroid 3-dehydrogenase; CDR; CHDR; Chlordecone reductase; DD-4; DD4; Dihydrodiol dehydrogenase 4; HAKRA; 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II; 3-beta-HSD adrenal and gonadal type; 3-beta-HSD II; HSDB3B; 1.3.1.22; S5AR 1; SR type 1; Steroid 5-alpha-reductase 1; 1.3.1.22; 5 alpha-SR2; S5AR 2; SR type 2; Steroid 5-alpha-reductase 2; Type II 5-alpha reductase; 1.3.1.94; 3-oxo-5-alpha-steroid 4-dehydrogenase 3; S5AR 3; SR type 3; SRD5A2L; Steroid 5-alpha-reductase 2-like; Steroid 5-alpha-reductase 3; 1.3.1.3; 3-oxo-5-beta-steroid 4-dehydrogenase; Delta(4)-3-ketosteroid 5-beta-reductase; Delta(4)-3-oxosteroid 5-beta-reductase; SRD5B1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Progesterone receptor; Androgen receptor; Glucocorticoid receptor, G03AA05; G03AB04; G03AC01; G03DC02; G03FA01; G03FB05; H01CC54;G03AC01;H01CC53
norfloxacin,Acute gastroenteritis;Bladder pain;Cervicitis;Chronic prostatitis;Cross resistance;Cystitis;Cystitis noninfective;Dysentery;Epididymitis;Gastroenteritis;Gastroenteritis bacterial;Gastrointestinal infection;Gonorrhoea;Infection;Methicillin-resistant Staphylococcus aureus infection;Nephrolithiasis;Neurogenic bladder;Overgrowth bacterial;Pathogen resistance;Pharyngitis;Proctitis;Prostatitis;Pyelitis;Pyelocystitis;Pyelonephritis;Recurrent urinary tract infection;Sexually transmitted disease;Shigella infection;Staphylococcal infection;Traveller's diarrhea;Urethritis gonococcal;Urinary tract infection,Abdominal cramps;Abdominal pain;Acute coronary syndrome;Agitation;Agranulocytosis;Albuminuria;Anal pruritus;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorectal discomfort;Anorexia;Anxiety;Anxiety disorder;Aphasia;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Ataxia;Back pain;Blister;Blood alkaline phosphatase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Bursitis;Candiduria;Chest pain;Chills;Cholestasis;Confusional state;Conjunctivitis;Constipation;Convulsion;Convulsions generalised;Cramp muscle;Creatinine increased;Crystalluria;Deafness;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Diplopia;Disorientation;Dizziness;Drowsiness;Drug eruption;Dry mouth;Dysarthria;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphasia;Dyspnoea;Eosinophilia;Erythema;Erythema multiforme;Erythema periorbital;Euphoric mood;Explosive personality disorder;Eye pain;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal pain;Gingival swelling;Glucose-6-phosphate dehydrogenase deficiency;Glycosuria;Guillain-Barre syndrome;Haematocrit decreased;Haematuria;Haemolytic anaemia;Hallucination;Hand swelling;Headache;Hearing impaired;Heartburn;Hepatic failure;Hepatic necrosis;Hepatitis;Hyperhidrosis;Hypersensitivity;Hypertonia;Hypoaesthesia;Hypoglycaemia;Insomnia;Intermittent explosive disorder;Intracranial pressure increased;Irritability;Jaundice;Jaundice cholestatic;Joint stiffness;Lacrimation increased;Lactic dehydrogenase activity increased;Leukocytoclastic vasculitis;Leukopenia;Lightheadedness;Liver function test abnormal;Local swelling;Loose stools;Metabolic acidosis;Mouth ulceration;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Myocardial infarction;Myoclonus;Nausea;Nephritis interstitial;Nervousness;Neuropathy peripheral;Neutropenia;Nystagmus;Oedema;Orthostatic hypotension;Osteoarthritis;Palpitations;Pancreatitis;Paraesthesia;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Phototoxicity;Platelet count decreased;Polyneuropathy;Proctalgia;Protein urine present;Proteinuria;Pruritus;Pruritus genital;Pseudomembranous colitis;Psychotic disorder;Raised liver function tests;Rash;Renal colic;Renal failure;Serum creatinine increased;Serum urea increased;Sleep disorder;Sleep disturbance;Somnolence;Stevens-Johnson syndrome;Stomatitis;Swelling;Taste altered;Taste bitter;Taste metallic;Tenderness;Tendon rupture;Tendonitis;Tension;Thrombocytopenia;Tingling sensation;Tinnitus;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Urinary protein increased;Urticaria;Vaginal moniliasis;Vaginal swelling;Vasculitis;Ventricular arrhythmia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginal swelling;White blood cell count decreased,small molecule,approved,"1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsäure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; NFLX; Norfloxacin; Norfloxacine; Norfloxacino; Norfloxacinum; 5.99.1.3; 5.99.1.3; 5.99.1.3; Topoisomerase IV subunit A; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 5.99.1.3; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 5.6.2.2; DNA topoisomerase II, beta isozyme; 5.99.1.3; grlA; Topoisomerase IV subunit A; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",DNA gyrase subunit A; DNA gyrase subunit B; DNA topoisomerase 4 subunit A; DNA topoisomerase 2-alpha; DNA gyrase subunit A; DNA topoisomerase 2; DNA topoisomerase 4 subunit A, J01MA06; J01RA13; S01AE02;J01MA06;J01RA14
levonorgestrel,Assisted fertilisation;Breast feeding;Coitus interruptus;Device expulsion;Fertilization;IUD expelled;Male contraception;Menorrhagia;Nulliparous;Obesity;Pregnancy;Sexual abuse;Sexual assault;Sexually transmitted disease;Unintended pregnancy,Abdominal bloating;Abdominal distension;Abdominal pain;Abdominal pain lower;Abnormal vision;Acne;Acute appendicitis;Acute tonsillitis;Affect lability;Alopecia;Amenorrhoea;Anaemia;Angioedema;Anorexia;Anxiety;Appendicitis;Application site reaction;Arrhythmia;Asthenia;Asthma;Back pain;Benign breast neoplasm;Bladder pain;Blood glucose increased;Body temperature increased;Breast cancer;Breast discomfort;Breast disorder;Breast neoplasm;Breast pain;Breast tenderness;Breast tension;Bronchitis;Candida infection;Cardiac disorder;Cervicitis;Cervix disorder;Chapped lips;Chest pain;Chloasma;Connective tissue disorder;Constipation;Contact lens intolerance;Contusion;Corpus luteum cyst;Cough;Cramps of lower extremities;Crying;Cyst;Cystitis;Cystitis noninfective;Decreased appetite;Depressed mood;Depression;Dermatitis;Dermatitis contact;Device breakage;Device expulsion;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry skin;Dysmenorrhoea;Dyspareunia;Dyspepsia;Dyspnoea;Dysuria;Ear infection;Ectopic pregnancy;Eczema;Endocrine disorder;Endometriosis;Endometritis;Enlargement abdomen;Erythema;Exacerbation of acne;Eye disorder;Fatigue;Fibroadenoma of breast;Fibroadenosis of breast;Flatulence;Folliculitis;Galactorrhoea;Gas in stomach;Gastrointestinal disorder;Gastrointestinal pain;Genital discharge;Genital infection;Genital ulceration;Haematoma;Haemoglobin;Haemoglobin decreased;Haemorrhage;Haemorrhoids;Headache;Herpes simplex;Hirsutism;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertrichosis;Hypoaesthesia;Hypochromic anaemia;Hypomenorrhoea;IUD complication;IUD expelled;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Influenza-like symptoms;Insomnia;Leg pain;Leukorrhea;Libido decreased;Libido increased;Lightheadedness;Loss of consciousness;Malnutrition;Mastitis;Mediastinal disorder;Medical device complication;Menometrorrhagia;Menorrhagia;Menstrual disorder;Menstruation delayed;Menstruation irregular;Mental disorder;Metrorrhagia;Migraine;Mood swings;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nausea;Neoplasm;Nervous system disorder;Nervousness;Numbness;Oedema;Oligomenorrhoea;Otitis;Otitis media;Ovarian cyst;Ovarian disorder;Pain;Pain in extremity;Palpitations;Papilloma;Pelvic inflammatory disease;Pelvic pain;Perineal pain;Pharyngitis;Pneumonia;Pollakiuria;Polydipsia;Polymenorrhoea;Polyp;Pregnancy;Premenstrual syndrome;Premenstrual tension;Protein urine present;Pruritus;Pruritus genital;Purpura;Rash;Redness;Rhinitis;Sciatica;Seborrhoeic dermatitis;Sensory loss;Shock;Sinusitis;Skin disorder;Smear cervix normal;Somnolence;Streptococcal sepsis;Sweating increased;Syncope;Tearfulness;Tenderness;Tendonitis;Tension;Tooth disorder;Toothache;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary protein increased;Urinary tract disorder;Urinary tract infection;Urticaria;Uterine cervical lesion;Uterine disorder;Uterine enlargement;Uterine haemorrhage;Uterine leiomyoma;Uterine perforation;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal mycosis;Vaginal neoplasm;Varicose vein;Vascular purpura;Vertigo;Visual impairment;Vomiting;Vulval disorder;Vulvovaginal mycotic infection;Vulvovaginitis;Weight decreased;Weight increased,small molecule,approved; investigational,"(-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; 17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; 17-Ethynyl-18-methyl-19-nortestosterone; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; 17alpha-Ethynyl-18-homo-19-nortestosterone; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; 18-Methylnorethisterone; d(-)-Norgestrel; Lèvonorgestrel; Levonorgestrel; Levonorgestrelum; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; 1.3.1.22; S5AR 1; SR type 1; Steroid 5-alpha-reductase 1; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Progesterone receptor; 3-oxo-5-alpha-steroid 4-dehydrogenase 1; Estrogen receptor; Androgen receptor; Sex hormone-binding globulin; Glucocorticoid receptor, G03AA07; G03AC03; G03AD01; G03FA11; G03FB09;G03AB03;G03AC03
nortriptyline,Depressive symptom;Endogenous depression;Major depression;Nicotine dependence,Abdominal cramps;Abdominal pain;Accommodation disorder;Acute coronary syndrome;Adenitis;Agitation;Agranulocytosis;Alopecia;Angle closure glaucoma;Anorexia;Anxiety;Aplastic anaemia;Appetite absent;Arrhythmia;Asthenia;Ataxia;Atrioventricular block;Black hairy tongue;Block heart;Body temperature increased;Bone marrow depression;Breast enlargement;Bundle branch block;Cerebrovascular accident;Cholestasis;Clumsiness;Conduction disorder;Confusional state;Constipation;Convulsion;Coordination abnormal;Cutaneous hypersensitivity;Decreased appetite;Delirium;Delusion;Dermatitis;Dermatitis atopic;Diarrhoea;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug fever;Drug withdrawal syndrome;Dry mouth;Dysgeusia;Dyspepsia;Electrocardiogram QRS complex;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Eosinophilia;Epigastric distress;Erectile dysfunction;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye pain;Fatigue;Feeling abnormal;Flushing;Galactorrhoea;Gingivitis;Gynaecomastia;Hallucination;Headache;Heart rate irregular;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypomania;Hypotension;Ileus paralytic;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Insomnia;Intraocular pressure increased;Irritability;Jaundice;Leukopenia;Libido decreased;Loss of consciousness;Loss of libido;Lymphadenitis;Malaise;Mania;Menopausal symptoms;Mydriasis;Myocardial infarction;Nausea;Nervousness;Neuropathy peripheral;Nightmare;Nocturia;Numbness;Oedema;Oedema peripheral;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Palpitations;Pancytopenia;Panic reaction;Paraesthesia;Paresthesia of limbs;Parotid gland enlargement;Parotid swelling;Petechiae;Pollakiuria;Pruritus;Psychotic disorder;Purpura;QRS complex;Rash;Sensory loss;Shock;Somnolence;Stomatitis;Suicidal ideation;Sweating;Sweating increased;Swollen tongue;Syncope;Tachycardia;Taste disorders;Taste peculiar;Tension;Testicular swelling;Throat sore;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Torsade de pointes;Tremor;Urinary retention;Urticaria;Vascular purpura;Ventricular fibrillation;Ventricular tachycardia;Vision blurred;Vomiting;Weight decreased;Weight increased;Withdrawal symptom;Yellow skin,small molecule,approved,"10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamine; 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; Demethylamitriptyline; Desmethylamitriptyline; Nortriptylina; Nortriptyline; Nortriptylinum; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; Dopamine D2 receptor; Dap1; HPR6.6; IZA; mPR; PGRMC; Aging-associated gene 8 protein; hSigmaR1; OPRS1; SIG-1R; Sigma 1-type opioid receptor; Sigma1-receptor; Sigma1R; SR-BP; SR31747-binding protein; SRBP; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-hydroxytryptamine receptor 1C; 5ht1c; Htr1c; Serotonin receptor 2C; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; AGP 1; AGP1; OMD 1; Orosomucoid-1; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 1A; Histamine H1 receptor; Alpha-1A adrenergic receptor; Alpha-1D adrenergic receptor; 5-hydroxytryptamine receptor 2C; Alpha-1B adrenergic receptor; Alpha-2 adrenergic receptors; Beta adrenergic receptor; D(2) dopamine receptor; Sigma receptor; 5-hydroxytryptamine receptor 2C; Muscarinic acetylcholine receptor,N06AA10
repaglinide,Blood glucose decreased;Coronary artery disease;Diabetes mellitus;Diabetic;Diabetic complication;Hyperglycaemia;Nephropathy;Neuropathy;Neuropathy peripheral;Obesity;Retinal disorder;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Weight decreased,Abdominal pain;Acute coronary syndrome;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Arrhythmia;Arthralgia;Back pain;Bronchitis;Cardiac disorder;Cardiac failure congestive;Cardiovascular disorder;Chest pain;Constipation;Dermatitis;Diarrhoea;Dyspepsia;Electrocardiogram abnormal;Erythema;Erythema multiforme;Eye disorder;Gastrointestinal disorder;Gastrointestinal pain;Haemolytic anaemia;Headache;Hepatic enzyme increased;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hyperglycaemia;Hypersensitivity;Hypertension;Hypoglycaemia;Hypoglycaemic coma;Hypoglycaemic unconsciousness;Immune system disorder;Ischaemia;Jaundice;Leukopenia;Malnutrition;Musculoskeletal discomfort;Myocardial infarction;Myocardial ischaemia;Nausea;Oedema;Oedema peripheral;Palpitations;Pancreatitis;Paraesthesia;Pruritus;Rash;Refraction disorder;Rhinitis;Sinusitis;Skin disorder;Stevens-Johnson syndrome;Thrombocytopenia;Tooth disorder;Unspecified disorder of skin and subcutaneous tissue;Urinary tract infection;Urticaria;Vasculitis;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,"Repaglinida; Repaglinide; Repaglinidum; Sulfonylurea receptor 2; SUR2; HRINS; Sulfonylurea receptor 1; SUR; SUR1; H1-R; H1R; HH1R; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",ATP-binding cassette sub-family C member 9; ATP-binding cassette sub-family C member 8; Histamine H1 receptor; Peroxisome proliferator-activated receptor gamma, A10BX02;A10BD14;A10BX02
nystatin,Candida infection;Gastrointestinal candidiasis;Infection,Abdominal discomfort;Anaphylactic shock;Anaphylactoid reaction;Bronchospasm;Dermatitis;Diarrhoea;Diarrhoea haemorrhagic;Distress gastrointestinal;Eczema;Erythema multiforme;Gastrointestinal disorder;Gastrointestinal symptom NOS;Gastrointestinal tract irritation;Hypersensitivity;Mouth irritation;Musculoskeletal discomfort;Myalgia;Nausea;Pain;Pruritus;Rash;Sensitisation;Stevens-Johnson syndrome;Stomatitis;Swelling face;Tachycardia;Urticaria;Vomiting,small molecule,approved; vet_approved,Nistatina; NYS; Nystatin; Nystatine; Nystatinum; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8,Ergosterol, A07AA02; G01AA01; G01AA51;A07AA02;D01AA01
ofloxacin,Abscess;Acne;Acute maxillary sinusitis;Acute sinusitis;Bacteraemia;Bacterial infection;Bacterial prostatitis;Bladder pain;Blister;Bronchitis;Bronchitis chronic;Cellulitis;Cervicitis;Chronic suppurative otitis media;Community acquired pneumonia;Conjunctivitis;Conjunctivitis bacterial;Conjunctivitis infective;Convulsion;Cystitis;Cystitis noninfective;Dermatitis bullous;Dermatitis infected;Diabetes mellitus;Diabetic;Furuncle;Gonorrhoea;Hepatic cirrhosis;Hepatic failure;Hepatic function abnormal;Hepatic insufficiency;Hypersensitivity;Impetigo;Infection;Infection mixed;Influenza;Keratitis bacterial;Legionella infection;Mental disorder;Nosocomial pneumonia;Otitis externa;Otitis media acute;Otitis media chronic;Overgrowth bacterial;Pathogen resistance;Pelvic inflammatory disease;Plague;Plague sepsis;Pneumonia;Pneumonia anthrax;Pneumonia legionella;Prostatitis;Pyelonephritis acute;Pyoderma;Renal failure;Renal impairment;Sinusitis bacterial;Tendon rupture;Tendonitis;Ulcerative keratitis;Unspecified non-gonococcal urethritis (NGU);Urethritis;Urinary tract infection;Wound infection,Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal vision;Acidosis;Acute coronary syndrome;Acute cystitis;Acute overdose;Acute renal insufficiency;Acute yellow liver atrophy;Affect lability;Ageusia;Aggression;Agitation;Agranulocytosis;Airway obstruction NOS;Albuminuria;Alcohol abuse;Alopecia;Alveolitis allergic;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anosmia;Anuria;Anxiety;Aphasia;Aplastic anaemia;Apnoea;Application site reaction;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Ascites;Asthenia;Asthma;Ataxia;Atelectasis;Atrial fibrillation;Atrioventricular block;Autonomic neuropathy;Back pain;Benign intracranial hypertension;Block heart;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood electrolytes abnormal;Blood glucose decreased;Blood potassium decreased;Blood urea increased;Body temperature increased;Bone marrow depression;Bone pain;Bradycardia;Breast disorder;Breath odour;Bronchial hyperreactivity;Bronchitis;Bronchospasm;Bullous eruption;CNS depression NOS;Calculus of kidney;Candida infection;Candiduria;Carcinoma;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiovascular disorder;Cataract;Central nervous system disorder;Cerebral thrombosis;Cerebrovascular accident;Cerebrovascular disorder;Cervicitis;Chemical conjunctivitis;Chemical eye injury;Chemosis;Chest pain;Chills;Cholecystitis;Cholelithiasis;Chronic obstructive pulmonary disease;Clostridium difficile colitis;Clotting;Coagulopathy;Colitis;Common cold;Condition aggravated;Confusional state;Congenital eye disorder;Conjunctival oedema;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Coordination abnormal;Corneal erosion;Cough;Cramp muscle;Cramps of lower extremities;Creatinine increased;Cross resistance;Crystalluria;Cystitis;Deafness;Decreased appetite;Dehydration;Depressed level of consciousness;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diabetic;Diarrhoea;Diplopia;Discomfort;Disorder sight;Disorientation;Distress gastrointestinal;Dizziness;Drowsiness;Drug interaction;Dry eye;Dry mouth;Dry skin;Dysaesthesia;Dysarthria;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphasia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear haemorrhage;Ear pain;Ecchymosis;Eczema;Electrocardiogram QT prolonged;Electroencephalogram abnormal;Electrolyte abnormality;Electrolyte imbalance;Encephalopathy;Endocarditis;Enlargement abdomen;Eosinophilia;Epilepsy;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Erythema nodosum;Euphoric mood;Extrapyramidal disorder;Eye disorder;Eye infection;Eye oedema;Eye pain;Eye pruritus;Eyelids pruritus;Face oedema;Fatigue;Feeling abnormal;Feeling of body temperature change;Flatulence;Fluid overload;Flushing;Foot edema;Function kidney decreased;Fungal infection;Gait disturbance;Gangrene;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrooesophageal reflux disease;General disorders and administration site conditions;Genital candidiasis;Glomerulonephritis;Glossitis;Glucose low;Glycosuria;Gonorrhoea;Gout;Haematoma;Haematuria;Haemoglobin;Haemolytic anaemia;Haemoptysis;Haemorrhage;Haemorrhoids;Hallucination;Headache;Hearing impaired;Heartburn;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis acute;Hepatitis symptom;Hepatobiliary disease;Hepatotoxicity;Herpes simplex;Hiccups;Hostility;Hot flush;Hyperaemia;Hyperaesthesia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hypernatraemia;Hypersensitivity;Hypertension;Hypertension worsened;Hypertonia;Hypoaesthesia;Hypoglycaemia;Hypoglycemic reaction;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hyposthenuria;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infection mixed;Infestation;Infestation NOS;Inflammation;Influenza like illness;Influenza-like symptoms;Injection site inflammation;Injection site pain;Injection site reaction;Injection site swelling;Insomnia;Instillation site irritation;Interstitial lung disease;Interstitial pneumonia;Intestinal obstruction;Intestinal perforation;Intracranial pressure increased;Jaundice;Keratitis;Kidney function abnormal;Lacrimation;Lacrimation increased;Laryngeal oedema;Laryngitis;Leg pain;Lenticular opacities;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Leukorrhea;Lightheadedness;Local swelling;Loss of consciousness;Lower respiratory tract infection;Lymphadenopathy;Lymphocytosis;Lymphopenia;Malaise;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Melaena;Menopausal symptoms;Menorrhagia;Mental disorder;Metrorrhagia;Migraine;Mood swings;Multi-organ failure;Muscle contractions involuntary;Muscle enzyme increased;Muscle injury;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Myasthenia gravis;Myocardial infarction;Myositis;Nasopharyngitis;Nausea;Neoplasm;Neoplasm malignant;Nephritis interstitial;Nephrolithiasis;Nephrosis;Nephrotic syndrome;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Neutrophilia;Nightmare;Numbness;Nystagmus;Obstructive airways disorder;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Oropharyngeal swelling;Orthostatic hypotension;Osteoarthritis;Osteomyelitis;Otitis media;Overdose;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paralysis;Paranoia;Parosmia;Partial hearing loss;Pathogen resistance;Pelvic inflammatory disease;Penis disorder;Pertussis;Petechiae;Pharyngitis;Phlebitis;Phobia;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Phototoxicity;Pleural effusion;Pleurisy;Pneumonia;Pneumothorax;Pollakiuria;Polyneuropathy;Polyuria;Potassium low;Prostatitis;Protein urine present;Proteinuria;Prothrombin level decreased;Prothrombin level increased;Pruritus;Pruritus genital;Pseudomembranous colitis;Psychotic disorder;Pulmonary embolism;Pulmonary function test decreased;Pulmonary oedema;Purpura;Pyuria;Rash;Rash erythematous;Rash follicular;Rash maculo-papular;Rash pustular;Red blood cell disorders;Redness;Renal failure;Renal failure acute;Renal impairment;Respiratory arrest;Respiratory depression;Respiratory distress;Respiratory failure;Respiratory insufficiency;Respiratory tract infection;Retrosternal pain;Rhabdomyolysis;Rhinitis;Rhinorrhoea;Rigors;Scotoma;Seborrhoeic dermatitis;Sensation of foreign body;Sensory loss;Sepsis;Serum sickness;Sexually transmitted disease;Shock;Sinusitis;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin ulcer;Sleep disorder;Slurred speech;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stinging;Stomatitis;Stridor;Stupor;Suicidal ideation;Suicide attempt;Sunburn;Supraventricular tachycardia;Sweating increased;Swelling;Swelling face;Swollen tongue;Syncope;Synovitis;Tachycardia;Tachypnoea;Taste bitter;Tendon disorder;Tendon rupture;Tendonitis;Tension;Thirst;Throat irritation;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thrombotic thrombocytopenic purpura;Tingling sensation;Tinnitus;Tongue disorder;Tongue oedema;Tooth disorder;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Tuberculosis;Tubulointerstitial nephritis;Ulcer;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary retention;Urinary tract disorder;Urine output increased;Urticaria;Uveitis;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Viral infection;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vitreous floaters;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;WBC abnormal NOS;Weight decreased;White blood cell disorder;Withdrawal syndrome,small molecule,approved,"8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid; Ofloxacin; Ofloxacine; Ofloxacino; Ofloxacinum; OFLX; 5.99.1.3; 5.99.1.3; 5.99.1.3; 5.99.1.3; Topoisomerase IV subunit A; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",DNA gyrase subunit A; DNA gyrase subunit B; DNA gyrase subunit A; DNA topoisomerase 4 subunit A; DNA topoisomerase 2-alpha, J01RA09; S01AE01; S02AA16;J01MA01
olanzapine,Agitation;Bipolar I disorder;Bipolar disorder;Childhood schizophrenia;Dementia;Depression;Drug abuse;Dyskinesia;Extrapyramidal disorder;Extrapyramidal symptoms;Hyperlipidaemia;Increased activity;Major depression;Mania;Mania acute;Manic episode;Mental disorder;Movement disorder;Psychotic disorder;Schizoaffective disorder;Schizophrenia;Tension;Weight increased,"Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abnormal dreams;Abnormal ejaculation;Abnormal vision;Abscess periodontal;Accidental injury;Accommodation disorder;Acidosis;Acne;Acute schizophrenia;Affect lability;Agitation;Akathisia;Akinesia;Alanine aminotransferase increased;Albumin low;Albuminuria;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Antisocial behaviour;Antisocial personality disorder;Anxiety;Apathy;Aphthous stomatitis;Apnoea;Arteritis;Arthralgia;Arthritis;Arthropathy;Asocial behaviour;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atelectasis;Atrial fibrillation;Atrioventricular block;Back pain;Bilirubin total decreased;Bilirubin total increased;Bilirubin total low;Bladder pain;Blepharitis;Block heart;Blood albumin decreased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin decreased;Blood bilirubin increased;Blood creatine increased;Blood creatine phosphokinase increased;Blood glucose increased;Blood pressure systolic decreased;Blood prolactin increased;Blood triglycerides increased;Blood uric acid increased;Body temperature decreased;Body temperature increased;Bone pain;Bradycardia;Breast disorder;Breast enlargement;Breast pain;Buccoglossal syndrome;Bursitis;Buttock pain;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac fibrillation;Cataract;Cerebrovascular accident;Chest pain;Chills;Choreoathetosis;Circumoral paresthesia;Cogwheel rigidity;Coma;Completed suicide;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Corneal lesion;Cough;Cough increased;Cramps of lower extremities;Creatine increased;Creatine phosphokinase increased;Cyanosis;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Delusion;Dementia;Dementia Alzheimer's type;Dental caries;Dependence;Dependence physiological;Dependence psychological;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Dermatitis contact;Diabetes mellitus;Diabetic coma;Diabetic hyperglycaemic coma;Diabetic ketoacidosis;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Drug dependence;Drug seeking behavior;Drug tolerance;Drug withdrawal syndrome neonatal;Dry eye;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphemia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Ecchymosis;Eczema;Edema of lower extremities;Ejaculation disorder;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram change;Embolism;Embolism venous;Encephalopathy;Endophthalmitis;Enlargement abdomen;Enteritis;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Erythema;Euphoric mood;Extrapyramidal disorder;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Facial paralysis;Faecal incontinence;Faecalith;Faecaloma;Fasting;Fatigue;Feeling abnormal;Flat affect;Flatulence;Fungal skin infection;Gait disturbance;Galactorrhoea;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised spasm;Gingivitis;Glaucoma;Glossitis;Glucose increased;Glycosuria;Goitre;Gout;Gynaecomastia;Haematocrit decreased;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Hallucination;Hallucination, visual;Hangover;Headache;Hepatic enzyme increased;Hepatic failure;Hepatic impairment;Hepatic steatosis;Hepatitis;Hepatobiliary disease;Hiccups;Hirsutism;Hostility;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hypernatraemia;Hypersensitivity;Hypersomnia;Hypertension;Hypertonia;Hypertriglyceridaemia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hypoproteinaemia;Hypotension;Hypothermia;Hypotonia;Hypoventilation;Hypoxia;Ileus;Ill-defined disorder;Immune system disorder;Increased appetite;Increased prolactin level;Induration;Infection;Infestation;Infestation NOS;Influenza;Injection site induration;Injection site mass;Injection site pain;Injection site reaction;Injury;Insomnia;Intentional injury;Intestinal obstruction;Jaundice;Joint stiffness;Keratitis;Keratoconjunctivitis;Ketoacidosis;Ketosis;Lactation female;Laryngeal pain;Laryngitis;Lenticular pigmentation;Lethargy;Leukocytosis;Leukoderma;Leukopenia;Libido decreased;Libido increased;Liver disorder;Liver fatty deposition;Loss of consciousness;Lower respiratory tract infection;Lymphadenopathy;Malaise;Malnutrition;Mania;Manic psychosis;Masked facies;Mastitis;Mediastinal disorder;Melaena;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Metrorrhagia;Micturition urgency;Migraine;Miosis;Mixed liver injury;Mood swings;Mouth ulceration;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myasthenia;Mydriasis;Myoclonus;Myopathy;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Nervous system disorder;Nervousness;Neuralgia;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Neurosis;Neutropenia;Normochromic normocytic anaemia;Normocytic anemia;Nuchal rigidity;Nystagmus;Obesity;Oculogyration;Oculogyric crisis;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Oliguria;Opisthotonus;Oral candidiasis;Orthostatic hypotension;Osteoarthritis;Osteoporosis;PRL increased;Pain;Pain in extremity;Pallor;Palpitations;Pancreatitis;Panophthalmitis;Paraesthesia;Paraesthesia oral;Paralysis;Paranoia;Paranoid reaction;Parkinson's disease;Parkinsonism;Pelvic pain;Personality disorder;Pharyngitis;Pharyngolaryngeal pain;Phobia;Phonological disorder;Phosphatase alkaline increased;Photosensitivity reaction;Platelet count decreased;Pneumonia;Pneumothorax;Pollakiuria;Polyuria;Pregnancy;Premenstrual syndrome;Priapism;Procedural pain;Pruritus;Psychiatric symptom;Pulmonary embolism;Pulmonary oedema;Pyuria;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Respiratory failure;Respiratory tract infection;Respiratory tract infection viral;Rhabdomyolysis;Rheumatoid arthritis;Rhinitis;Salivary hypersecretion;Schizophrenia;Schizophrenic reaction;Schizophreniform disorder;Seborrhoeic dermatitis;Serum prolactin increased;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin ulcer;Sleep disorder;Sneezing;Somnolence;Speech disorder;Stomatitis;Stridor;Stupor;Stuttering;Subarachnoid haemorrhage;Sudden death;Sudden death, cause unknown;Suicide;Suicide attempt;Sweating;Sweating increased;Syncope;Tachycardia;Tardive dyskinesia;Tension;Thinking abnormal;Thirst;Throat tightness;Thrombocytopenia;Thrombocytopenic purpura;Thrombocytosis;Thromboembolic event;Thromboembolism;Tinnitus;Tolerance development;Tongue discolouration;Tongue disorder;Tongue oedema;Tooth abscess;Tooth infection;Toothache;Torsade de pointes;Torticollis;Tremor;Unintended pregnancy;Unspecified disorder of skin and subcutaneous tissue;Upper limb oedema;Upper respiratory tract infection;Urethral disorder;Uric acid high;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urine output increased;Urticaria;Uterine fibroids enlarged;Uterine leiomyoma;VIIth nerve paralysis;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Venous thromboembolism;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Viral infection;Viral upper respiratory tract infection;Visual impairment;Vomiting;Water intoxication;Weight decreased;Weight increased;Withdrawal syndrome",small molecule,approved; investigational,"2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; Olanzapin; Olanzapina; Olanzapine; Olanzapinum; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; Dopamine D2 receptor; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT-6; 5-HT6; Serotonin receptor 6; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 2A; D(2) dopamine receptor; D(1A) dopamine receptor; D(1B) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 6; Histamine H1 receptor; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; D(1) dopamine receptor; Beta adrenergic receptor; 5-hydroxytryptamine receptor 1; GABA(A) Receptor Benzodiazepine Binding Site, N05AH03;N05AH03;N05AH53
omeprazole,Abdominal bloating;Abdominal distension;Abdominal pain upper;Acute hemorrhage;Adenoma benign;Bacterial infection due to helicobacter pylori (H. pylori);Discomfort;Duodenal ulcer;Dyspepsia;Early satiety;Epigastric pain;Erosive oesophagitis;Eructation;Flatulence;Foetor hepaticus;Functional dyspepsia;Gastric haemorrhage;Gastric ulcer;Gastrinoma;Gastritis;Gastrooesophageal reflux disease;Haemorrhage;Heartburn;Helicobacter infection;Hepatocellular injury;Infection;Liver disorder;Nausea;Peptic ulcer;Reflux esophagitis;Regurgitation;Systemic mastocytosis;Ulcer;Vomiting;Zollinger-Ellison syndrome,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal vision;Accidental injury;Ageusia;Aggression;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Allergic cutaneous angiitis;Alopecia;Anaemia;Anal pruritus;Anaphylactic shock;Angina pectoris;Angioedema;Anorectal discomfort;Anorectal disorder;Anorexia;Anterior ischemic optic neuropathy;Anxiety;Apathy;Arthralgia;Arthritis;Arthritis aggravated;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Asthma aggravated;Back pain;Barrett's oesophagus;Bladder pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood gastrin increased;Blood pressure increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bradycardia;Breast disorder;Bronchospasm;Candida infection;Carcinoid tumour;Chest pain;Chills;Colitis microscopic;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Constipation aggravated;Cough;Cramp muscle;Creatinine increased;Cyst;Cystitis;Cystitis noninfective;Decreased appetite;Depression;Depression aggravated;Dermatitis;Diarrhoea;Diplopia;Discomfort;Dizziness;Dry eye;Dry eye syndrome;Dry mouth;Dry skin;Duodenal ulcer haemorrhage;Duodenitis;Dysaesthesia;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysplasia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Elevated liver enzyme levels;Encephalopathy;Enlargement abdomen;Epidermal necrosis;Epigastric pain;Epistaxis;Erectile dysfunction;Eructation;Eruption;Erythema multiforme;Eye disorder;Eye irritation;Face oedema;Faeces discoloured;Fatigue;Feeling abnormal;Fibromyalgia;Flat affect;Flatulence;Fluid retention;Flushing;Foetor hepaticus;Fracture;Functional gastrointestinal disorder;Fundic gland polyp;Fungal infection;Gastric polyps;Gastrinoma;Gastritis;Gastroenteritis;Gastrointestinal candidiasis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Genital candidiasis;Glossitis;Glycosuria;Goitre;Gynaecomastia;Haematuria;Haemolytic anaemia;Hallucination;Headache;Hepatic encephalopathy;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hernia;Hiccups;Hot flush;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Injection site reaction;Injury;Insomnia;Irritability;Irritable bowel syndrome;Jaundice;Lacrimation decreased;Laryngeal oedema;Leg edema;Leg pain;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Lightheadedness;Liver disorder;Lymphadenopathy;Lymphadenopathy cervical;Malaise;Malnutrition;Mediastinal disorder;Melaena;Menopausal symptoms;Menstrual disorder;Mental disorder;Microcytic anaemia;Migraine;Migraine aggravated;Mouth ulceration;Mucosal atrophy;Mucosal discolouration;Multiple fractures;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nausea;Necrosis;Neoplasm;Nephritis interstitial;Nephrosis;Nephrotic syndrome;Nervous system disorder;Nervousness;Neutropenia;Nodule;Oedema peripheral;Oesophageal candidiasis;Oesophageal disorder;Oesophageal stenosis;Oesophageal ulcer;Oesophagitis;Optic atrophy;Optic ischaemic neuropathy;Optic neuritis;Oral disorder;Osteoarthritis;Otitis media;Pain;Pain in extremity;Pain of skin;Painful respiration;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Parosmia;Petechiae;Pharyngeal disorder;Pharyngitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polymyalgia rheumatica;Polyp;Polyuria;Protein urine present;Proteinuria;Pruritus;Pruritus genital;Purpura;Pyuria;Rash;Rash erythematous;Rash maculo-papular;Rectal disorder;Reflux esophagitis;Regurgitation;Renal failure;Renal impairment;Retrosternal pain;Rhinitis;Rigors;Scotoma;Serum gastrin increased;Shock;Sinusitis;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Swelling;Tachycardia;Tachypnoea;Tension;Testicular pain;Thirst;Thrombocytopenia;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Varices oesophageal;Vascular purpura;Vertigo;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vitamin B12 deficiency;Vomiting;Weight decreased;Weight increased;Zollinger-Ellison syndrome,small molecule,approved; investigational; vet_approved,"OMEP; Omeprazol; Omeprazole; Omeprazolum; 7.2.2.19; Gastric H(+)/K(+) ATPase subunit alpha; Proton pump; Gastric H(+)/K(+) ATPase subunit beta; Proton pump beta chain; Ah receptor; AhR; BHLHE76; Class E basic helix-loop-helix protein 76; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Potassium-transporting ATPase alpha chain 1; Potassium-transporting ATPase subunit beta; Aryl hydrocarbon receptor, A02BC01; A02BD01; A02BD05; A02BD16;A02BC01;A02BC51
ondansetron,Nausea;Nausea postoperative;Neoplasm malignant;Procedural nausea;Vomiting,Abdominal pain;Accommodation disorder;Acute coronary syndrome;Agitation;Akathisia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorectal discomfort;Anxiety;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Asthma;Atrial fibrillation;Atrioventricular block second degree;Blindness;Blindness transient;Body temperature increased;Bradycardia;Bronchospasm;Burning rectal;Cardiac disorder;Cardio-respiratory arrest;Cardiovascular disorder;Chest pain;Chills;Constipation;Convulsion;Cough;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dyskinesia;Dyspnoea;Dystonia;Dystonic reaction;Dysuria;Ear disorder;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram ST segment depression;Erythema;Erythema multiforme;Eye disorder;Fatigue;Feeling abnormal;Feeling cold;Feeling hot;Flatulence;Flushing;Foetor hepaticus;Gastrointestinal disorder;Gastrointestinal pain;Genital disorder female;Grand mal convulsion;Haemoglobin;Haemorrhage;Headache;Hepatic failure;Hepatobiliary disease;Hepatocellular injury;Hiccups;Hypersensitivity;Hypokalaemia;Hypotension;Hypoxia;Ill-defined disorder;Immune system disorder;Injection site burning;Injection site pain;Injection site reaction;Laryngeal oedema;Laryngospasm;Liver disorder;Liver function test abnormal;Local reaction;Loss of consciousness;Lymphocyte transformation test positive;Malaise;Mediastinal disorder;Movement disorder;Musculoskeletal pain;Myocardial infarction;Myocardial ischaemia;Nausea postoperative;Neoplasm malignant;Nervous system disorder;Oculogyric crisis;Opisthotonus;Orofacial dyskinesia;Pain;Palpitations;Paraesthesia;Post procedural pain;Procedural nausea;Procedural pain;Pruritus;Raised liver function tests;Rash;Redness;Sensation of warmth;Shivering;Shock;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Stevens-Johnson syndrome;Stridor;Supraventricular tachycardia;Swelling;Syncope;Tachycardia;Tonic-clonic seizures;Torsade de pointes;Toxic epidermal necrolysis;Toxic skin eruption;Tremor;Type I hypersensitivity;Unspecified disorder of skin and subcutaneous tissue;Urinary retention;Urinary tract infection;Urticaria;Ventricular extrasystoles;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Warmth;Wound,small molecule,approved; withdrawn,"Ondansetron; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT-4; 5-HT4; Serotonin receptor 4; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J",5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 4; Mu-type opioid receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B,A04AA01
orlistat,Diabetes mellitus;Diabetic;Drug interaction;Obesity;Type 2 diabetes mellitus;Weight decreased,Abdominal colic;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Acne;Alopecia;Amenorrhoea;Anal irritation;Anal pruritus;Anaphylactic shock;Angioedema;Anorectal discomfort;Anxiety;Appetite absent;Arthritis;Arthropathy;Arthropod bite;Asthenia;Asthma;Autoimmune disorder;Autonomic neuropathy;Avitaminosis;Back pain;Biliary colic;Blood and lymphatic system disorders;Blood disorder;Body temperature increased;Borborygmi;Breast disorder;Bronchospasm;Bullous eruption;Burning anal;Cardiovascular disorder;Chest pain;Cholecystitis;Cholelithiasis;Convulsion;Cough;Cramp muscle;Cramps of lower extremities;Decreased appetite;Depression;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diabetic;Diarrhoea;Discomfort;Diverticulitis;Diverticulum;Dizziness;Drug interaction;Dry mouth;Dry skin;Dyschezia;Dysentery;Dysgeusia;Dysmenorrhoea;Dyspepsia;Ear infection;Eczema;Enteritis;Epigastric pain not food-related;Epilepsy;Eructation;Faecal incontinence;Faeces discoloured;Faeces hard;Fatigue;Feeling abnormal;Flatulence;Foot edema;Fracture;Fullness abdominal;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal sounds abnormal;Gastrointestinal symptom NOS;Gingival disorder;Haemoglobin;Haemorrhage;Haemorrhoids;Hair texture abnormal;Headache;Hepatic failure;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hypersensitivity;Hypoglycaemia;Hypokalaemia;Hypothyroidism;Hypovitaminosis;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Insect bite NOS;Insomnia;International normalised ratio increased;Local swelling;Lower gastrointestinal haemorrhage;Lower respiratory tract infection;Malaise;Malnutrition;Mediastinal disorder;Menopausal disorder;Menopausal symptoms;Menstruation irregular;Mental disorder;Multiple fractures;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nail disorder;Nausea;Neoplasm;Nephropathy;Nervous system disorder;Neuropathy peripheral;Obesity;Oedema;Oedema peripheral;Onychoclasis;Osteoarthritis;Otitis;Pain;Palpitations;Pancreatitis;Paraesthesia;Pharyngitis;Polyuria;Proctalgia;Pruritus;Pruritus genital;Rash;Rash papular;Reaction gastrointestinal;Rectal haemorrhage;Renal failure;Sinusitis;Skin disorder;Sleep disorder;Soft stools;Sweating increased;Taste bitter;Tendonitis;Thirst;Tooth disorder;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vein disorder;Vertigo;Vision blurred;Vomiting;Xeroderma,small molecule,approved; investigational,"(-)-Tetrahydrolipstatin; Orlipastat; Orlipastatum; Orlistat; Tetrahydrolipstatin; 3.1.1.3; Pancreatic lipase; PL; PTL; CANN6; CB-R; CB1; CNR; 3.1.1.3; Gastric lipase; GL; 2.3.1.85; FAS; Type I fatty acid synthase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CPLA2; Phospholipase A2 group IVA; PLA2G4; 2.3.1.85; FAS; Type I fatty acid synthase",Pancreatic triacylglycerol lipase; Cannabinoid receptor 1; Gastric triacylglycerol lipase; Fatty acid synthase,A08AB01
orphenadrine,Discomfort,Agitation;Anaphylactic shock;Aplastic anaemia;Asthenia;Confusional state;Constipation;Dizziness;Drowsiness;Epigastric discomfort;Feeling abnormal;Gastric irritation;Hallucination;Headache;Hypersensitivity;Mydriasis;Nausea;Other dermatoses;Palpitations;Pruritus;Skin disorder;Somnolence;Tachycardia;Tension;Tremor;Urinary hesitation;Urticaria;Vision blurred;Vomiting,small molecule,approved,"2-(phenyl-o-tolylmethoxy)ethyldimethylamine; 2-methyldiphenhydramine; beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Dimethyl-[2-(phenyl-o-tolyl-methoxy)-ethyl]-amine; N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine; N,N-dimethyl-2-(phenyl(o-tolyl)methoxy)ethanamine; N,N-dimethyl-2-[(o-methyl-α-phenylbenzyl)oxy]ethylamine; o-methyldiphenhydramine; o-monomethyldiphenhydramine; Orfenadrina; Orphenadrine; Orphenadrinum; phenyl-o-tolylmethyl dimethyaminoethyl ether; β-dimethylaminoethyl 2-methylbenzhydryl ether; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; H1-R; H1R; HH1R; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase","Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 3B; Glutamate receptor ionotropic, NMDA 3A; Histamine H1 receptor; Sodium-dependent noradrenaline transporter; Sodium channel protein type 10 subunit alpha", M03BC01; N04AB02;M03BC01;M03BC51
oseltamivir,Ache;Asthenia;Asthma;Body temperature increased;Cardiac disorder;Chills;Coryza;Cough;Discomfort;Fatigue;Feeling abnormal;Headache;Hyperhidrosis;Ill-defined disorder;Infection;Influenza;Influenza like illness;Malaise;Musculoskeletal discomfort;Myalgia;Nasal congestion;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Respiratory tract infection;Rhinitis;Sweating;Throat sore,Abdominal pain;Abdominal pain upper;Abnormal behaviour;Accidental injury;Ache;Acute tonsillitis;Agitation;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angina unstable;Angioedema;Anxiety;Arrhythmia;Arthralgia;Asthenia;Asthma;Asthma aggravated;Back pain;Blood and lymphatic system disorders;Blood disorder;Body temperature decreased;Body temperature increased;Bone disorder;Bronchitis;Cardiac disorder;Confusional state;Conjunctivitis;Convulsion;Cough;Delirium;Delusion;Dermatitis;Dermatitis atopic;Dermatitis diaper;Diabetes mellitus;Diarrhoea;Dizziness;Dysmenorrhoea;Dyspepsia;Ear and labyrinth disorders;Ear disorder;Ear pain;Eczema;Eczema allergic atopic;Encephalitis;Encephalopathy;Enterocolitis haemorrhagic;Epistaxis;Erythema multiforme;Eye discharge;Eye disorder;Eye pain;Eye redness;Face oedema;Fatal outcomes;Fatigue;Feeling abnormal;Foetor hepaticus;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Hallucination;Headache;Hemorrhagic colitis;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis fulminant;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Herpes simplex;Humerus fracture;Hypersensitivity;Hypothermia;Immune system disorder;Immunocompromised;Immunodeficiency;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Injury;Insomnia;Jaundice;Liver disorder;Liver function test abnormal;Lymphadenopathy;Mediastinal disorder;Mental disorder;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nightmare;Ocular hyperaemia;Oropharyngeal discomfort;Oropharyngeal pain;Otitis media;Pain;Pain in extremity;Peritonsillar abscess;Pneumonia;Pseudomembranous colitis;Rash;Rhinorrhoea;Sinusitis;Skin disorder;Stevens-Johnson syndrome;Swelling;Throat sore;Thrombocytopenia;Toxic epidermal necrolysis;Tympanic membrane disorder;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Vertigo;Visual disturbance;Visual impairment;Vomiting,small molecule,approved,"(−)-oseltamivir; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; Oseltamivir; Oséltamivir; Oseltamivirum; 3.2.1.18; 3.2.1.18; Acetylneuraminyl hydrolase; G9 sialidase; Lysosomal sialidase; N-acetyl-alpha-neuraminidase 1; NANH; 3.2.1.18; Cytosolic sialidase; N-acetyl-alpha-neuraminidase 2; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Neuraminidase; Sialidase-1; Sialidase-2,J05AH02
oxacillin,Infection;Renal failure;Renal impairment;Staphylococcal infection,Abdominal discomfort;Abdominal pain;Agranulocytosis;Anaphylactic shock;Angioedema;Antibiotic associated colitis;Arthralgia;Aspartate aminotransferase increased;Body temperature increased;Bone marrow depression;Bronchospasm;Clostridium difficile colitis;Colitis;Dermatitis;Diarrhoea;Discomfort;Eosinophilia;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal tract irritation;Haematuria;Hepatotoxicity;Hypersensitivity;Hypotension;Ill-defined disorder;Laryngeal oedema;Laryngospasm;Liver function test abnormal;Malaise;Musculoskeletal discomfort;Myalgia;Nausea;Nephritis interstitial;Nephropathy;Neutropenia;Pancytopenia;Protein urine present;Proteinuria;Pruritus;Pseudomembranous colitis;Rash;Reaction gastrointestinal;Sensitisation;Serum sickness;Shock;Stomatitis;Tongue discolouration;Tongue hairy;Tubulointerstitial nephritis;Urticaria;Vomiting,small molecule,approved; investigational,"(2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5-methyl-3-phenyl-4-isoxazolyl)penicillin; 5-methyl-3-phenyl-4-isoxazolyl-penicillin; 6β-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid; Ossacillina; Oxacilina; Oxacillin; Oxacilline; Oxacillinum; Oxazocillin; Oxazocilline; Putative D-alanyl-D-alanine carboxypeptidase; exp2; Exported protein 2; PBP-1A; pbp2b; PBP1; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; 3.5.2.6; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Penicillin-binding protein 3; Penicillin-binding protein 2a; Penicillin-binding protein 1A; Penicillin-binding protein 2B; Penicillin-binding protein 1b; Penicillin-binding protein 1A; Solute carrier family 15 member 1; Penicillin-binding protein 2; Solute carrier family 15 member 2; Beta-lactamase Toho-1, J01CF04;J01CF04;J01CR50
oxaliplatin,Agranulocytosis;Asthenia;Breast cancer;Carcinoma colon;Carcinoma of lung;Colon cancer;Colon cancer stage III;Colorectal cancer;Colorectal cancer metastatic;Dehydration;Diarrhoea;Dizziness;Fatigue;Germ cell cancer;Hypercalcaemia;Leukopenia;Loss of consciousness;Lung neoplasm malignant;Lymphoma;Neoplasm;Neoplasm malignant;Non-Hodgkin's lymphoma;Shock;Syncope,"Abdominal aortic rupture;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal vision;Accidental injury;Acute interstitial nephritis;Advanced cancer;Agranulocytosis;Alopecia;Anaemia;Anaemias haemolytic immune;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorectal discomfort;Anorexia;Anxiety;Anxiety depression;Aortic rupture;Aphasia;Aphonia;Arthralgia;Ascites;Asthenia;Ataxia;Autoimmune haemolytic anaemia;Autonomic neuropathy;Azotaemia;Back pain;Balance disorder;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Body temperature increased;Bone pain;Bronchospasm;Cardiovascular disorder;Catheter infection;Cellulitis;Cerebral haemorrhage;Cerebral infarction;Chest discomfort;Chest pain;Chest pressure;Chest tightness;Chills;Choking sensation;Clostridium difficile colitis;Coagulopathy;Colitis;Completed suicide;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Cough;Cramp muscle;Cranial nerve paralysis;Creatinine increased;Cyanosis;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Depression;Dermatitis;Device related infection;Diarrhoea;Diarrhoea, Clostridium difficile;Diplopia;Discomfort;Disease progression;Disorder sight;Disorientation;Dizziness;Dry mouth;Dry skin;Dysaesthesia;Dysaesthesia pharynx;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dysphasia;Dysphonia;Dyspnoea;Dysuria;Electrolyte imbalance;Embolism;Embolism venous;Enlargement abdomen;Eosinophilic pneumonia;Epistaxis;Erythema;Erythema multiforme;Extravasation;Eye disorder;Eye pain;Facial pain;Fasciculation;Fatigue;Febrile neutropenia;Fibrosis;Flatulence;Flushing;Foetor hepaticus;Gait disturbance;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingivitis;Guillain-Barre syndrome;Haematemesis;Haematuria;Haemoglobin;Haemolysis;Haemolytic anaemia;Haemolytic uraemic syndrome;Haemoptysis;Haemorrhage;Haemorrhoids;Headache;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hiccups;Hoarseness;Hot flush;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoalbuminaemia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypotension;Ileus;Immune system disorder;Infection;Infestation;Infestation NOS;Inflammation;Injection site reaction;Injury;Insomnia;Interstitial lung disease;Intestinal obstruction;Lacrimal disorder;Lacrimation;Lacrimation abnormal NOS;Lacrimation increased;Laryngopharyngeal dysesthesia;Laryngospasm;Leg edema;Lethargy;Leukopenia;Lhermitte's sign;Liver disorder;Loss of consciousness;Lymphopenia;Malnutrition;Mediastinal disorder;Melaena;Menopausal symptoms;Mental disorder;Metabolic acidosis;Metabolic disorder;Metastatic neoplasm;Mouth ulceration;Mucosal inflammation;Mucosal ulceration;Muscle contractions involuntary;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Myoclonus;Nail changes;Nail disorder;Nasopharyngitis;Nausea;Necrosis;Neoplasm malignant;Nephritis interstitial;Nephropathy;Nephrosis lower nephron;Nervous system disorder;Nervousness;Neuralgia;Neurological symptom;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutropenic sepsis;Nodular regenerative hyperplasia;Oedema;Oedema peripheral;Optic ischaemic neuropathy;Optic neuritis;Oropharyngeal pain;Osteoarthritis;Ototoxicity;Pain;Pain in extremity;Pain in jaw;Pancreatitis;Paraesthesia;Peliosis hepatis;Peripheral sensory neuropathy;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Pneumonia;Pollakiuria;Portal hypertension;Posterior reversible encephalopathy syndrome;Proctalgia;Proctitis;Prothrombin level increased;Pruritus;Pulmonary fibrosis;Pulmonary toxicity;Purpura;Rash;Rash erythematous;Rectal haemorrhage;Rectal tenesmus;Red blood cell disorders;Redness;Renal failure acute;Renal tubular necrosis;Respiratory distress;Rhabdomyolysis;Rhinitis;Rhinitis allergic;Rhinorrhoea;Rigors;Scotoma;Sensory ataxia;Sensory disturbance;Sepsis;Shock;Sinusitis;Skin disorder;Skin exfoliation;Somnolence;Stevens-Johnson syndrome;Stomatitis;Stridor;Suicide;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Temperature intolerance;Tension;Thrombocytopenia;Thromboembolic event;Thromboembolism;Thrombophlebitis;Thrombosis;Transaminases increased;Tremor;Trigeminal neuralgia;Trismus;Tubulointerstitial nephritis;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Uraemic syndrome;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal haemorrhage;Vascular purpura;Venoocclusive disease;Venoocclusive liver disease;Vertigo;Visual acuity reduced;Visual impairment;Vocal cord paralysis;Vomiting;Weight decreased;Weight increased;Wheezing",small molecule,approved; investigational,"(SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUM; Diaminocyclohexane Oxalatoplatinum; L-OHP; Oxalatoplatin; Oxalatoplatinum; Oxaliplatin; oxaliplatine; oxaliplatino; oxaliplatinum; PLATINUM, ((1R,2R)-1,2-CYCLOHEXANEDIAMINE-.KAPPA.N,.KAPPA.N')(ETHANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O2)-, (SP-4-2)-; 2.5.1.18; Glutathione transferase T1-1; GST class-theta-1; Metallothionein-IA; MT-1A; MT-IA; MT1S; CES1; Metallothionein-2A; Metallothionein-II; MT-2; MT-II; MT2; 1.11.2.2; MPO; 1.15.1.1; hSod1; Superoxide dismutase 1; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 2.5.1.18; GST class-mu 1; GST HB subunit 4; GST1; GSTM1-1; GSTM1a-1a; GSTM1b-1b; GTH4; 1.6.5.2; Azoreductase; DIA4; DT-diaphorase; DTD; Menadione reductase; NAD(P)H:quinone oxidoreductase 1; NMOR1; Phylloquinone reductase; QR1; Quinone reductase 1; hOCT2; OCT2; Organic cation transporter 2; Copper transporter 1; COPT1; CTR1; hCTR1; Solute carrier family 31 member 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.2.2.8; Copper pump 2; PWD; WC1; Wilson disease-associated protein; WND; 7.2.2.8; Copper pump 1; MC1; Menkes disease-associated protein; MNK",DNA,L01XA03
oxaprozin,Arthritis;Juvenile idiopathic arthritis;Osteoarthritis;Rheumatoid arthritis,Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Acute interstitial nephritis;Agranulocytosis;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Asthenia;Asthma;Bladder pain;Bleeding time prolonged;Body temperature increased;Cardiac failure congestive;Coma;Confusional state;Conjunctivitis;Constipation;Convulsion;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Distress;Diuresis;Dizziness;Drowsiness;Drug hypersensitivity;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ecchymosis;Emotional distress;Eosinophilia;Epigastric pain;Eructation;Erythema multiforme;Feeling abnormal;Flatulence;Gastritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal ulcer;Glossitis;Haematemesis;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hearing impaired;Heartburn;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hyperglycaemia;Hyperhidrosis;Hypertension;Hypotension;Ill-defined disorder;Infection;Insomnia;Jaundice;Kidney function abnormal;Lethargy;Leukopenia;Loss of consciousness;Lung infection;Lymphadenopathy;Malaise;Melaena;Meningitis;Myocardial infarction;Nausea;Nephritis interstitial;Nephrotic syndrome;Nervousness;Oedema;Oesophagitis;Oliguria;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Peptic ulcer;Photosensitivity;Photosensitivity reaction;Pneumonia;Polyuria;Protein urine present;Proteinuria;Pruritus;Pseudoporphyria;Pulmonary function test decreased;Purpura;Rash;Rectal haemorrhage;Renal failure;Renal failure acute;Renal impairment;Respiratory depression;Sepsis;Serum sickness;Shock;Sinusitis;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Ulcer;Upper respiratory tract signs and symptoms;Urine output increased;Urticaria;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Vomiting,small molecule,approved,Oxaprozin; Oxaprozina; Oxaprozine; Oxaprozinum; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2,Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2,M01AE12
oxazepam,Agitation;Alcohol intoxication;Alcohol poisoning;Alcohol withdrawal syndrome;Anxiety;Anxiety disorder;Confusional state;Feeling abnormal;Irritability;Tension;Tremor;Tremulousness,Abdominal pain;Aggression;Agitation;Agranulocytosis;Amnesia;Amnesia transient;Ataxia;Blood disorder;Body temperature increased;Depressed level of consciousness;Dermatitis;Diplopia;Disorientation;Dizziness;Drowsiness;Drug eruption;Dysarthria;Euphoric mood;Excitement;Fixed drug eruption;Gastrointestinal pain;Hallucination;Headache;Hepatic function abnormal;Hypersensitivity;Hypotension;Incontinence;Jaundice;Lethargy;Leukopenia;Loss of consciousness;Memory impairment;Menstruation irregular;Nausea;Oedema;Paraesthesia;Rash;Shock;Slurred speech;Somnolence;Stupor;Syncope;Tremor;Vertigo;Vision blurred,small molecule,approved,"(+-)-Oxazepam; (RS)-Oxazepam; Oxazepam; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I",GABA(A) Receptor; Translocator protein; GABA(A) Receptor Benzodiazepine Binding Site,N05BA04
oxiconazole,Body tinea;Infection;Pityriasis;Tinea cruris;Tinea infection;Tinea pedis,Allergic contact dermatitis;Dermatitis;Dermatitis contact;Dyshidrotic eczema;Erythema;Folliculitis;Nodule;Pain;Papule;Paraesthesia;Pruritus;Rash;Stinging;Tingling sensation,small molecule,approved,"2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime]; Oxiconazol; Oxiconazole; Oxiconazolum; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase; 2,3-epoxysqualene--lanosterol cyclase; 5.4.99.7; OSC; Oxidosqualene--lanosterol cyclase; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Lanosterol 14-alpha demethylase; Lanosterol synthase; Nuclear receptor subfamily 1 group I member 2, G01AF17; G01AF20;D01AC11
oxprenolol,Angina pectoris;Arrhythmia;Atrial tachycardia;Digitalis intoxication (NOS);Hypertension;Hyperthyroidism;Paroxysmal atrial tachycardia;Sinus tachycardia;Toxicity to various agents;Ventricular extrasystoles,Abdominal colic;Abdominal pain;Abnormal dreams;Arthralgia;Asthenia;Bradycardia;Bronchospasm;Cardiac failure;Coldness;Diarrhoea;Diplopia;Dizziness;Dyspepsia;Emotional distress;Fatigue;Feeling cold;Headache;Hyperhidrosis;Hypersensitivity;Hypoglycaemia;Hypotension;Insomnia;Musculoskeletal discomfort;Nausea;Orthostatic hypotension;Palpitations;Pruritus;Psychotic disorder;Schizophrenia;Sweating increased;Thrombocytopenia;Trigeminal neuralgia;Vivid dreams,small molecule,approved,Oxprenolol; Oxprenololum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; hOCT2; OCT2; Organic cation transporter 2,Beta-1 adrenergic receptor; Beta-3 adrenergic receptor; Beta-2 adrenergic receptor, C07AA02; C07CA02;C07AA02;C07BA02
oxybutynin,Agitation;Constipation;Detrusor instability;Dysuria;Extravasation;Hypertonic bladder;Incontinence;Neurogenic bladder;Overactivity;Pollakiuria;Skin sensitisation;Spina bifida;Urge incontinence;Urinary incontinence,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal vision;Accidental injury;Accommodation disorder;Affect lability;Ageusia;Agitation;Airway obstruction NOS;Akathisia;Amblyopia;Amnesia;Anaphylactic shock;Angioedema;Angiopathy;Angle closure glaucoma;Anorexia;Anxiety;Application site burn;Application site erythema;Application site pain;Application site pruritus;Application site rash;Application site reaction;Application site vesicles;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Back pain;Bladder pain;Bloated feeling;Blood creatinine increased;Blood glucose increased;Blood pressure increased;Breast disorder;Breath odour;Bronchitis;Cardiac disorder;Chest discomfort;Chest pain;Circumoral paresthesia;Cognitive disorder;Colitis;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cough increased;Creatinine increased;Cutaneous hypersensitivity;Cycloplegia;Cystitis;Cystitis noninfective;Decreased appetite;Depersonalisation;Depression;Depressive symptom;Dermatitis;Dermatitis atopic;Dermatitis bullous;Detrusor instability;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug ineffective;Dry eye;Dry mouth;Dry skin;Dry throat;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dysuria;Ear and labyrinth disorders;Enlargement abdomen;Epistaxis;Erectile dysfunction;Eructation;Erythema;Eye disorder;Eye irritation;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flank pain;Flatulence;Fluid retention;Flushing;Frequent bowel movements;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Glaucoma;Glossitis;Haematuria;Hair disorder;Hallucination;Headache;Heat stroke;Hiccups;Hoarseness;Hot flush;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hypertonic bladder;Hypoaesthesia;Hypohidrosis;Hypotension;Ill-defined disorder;Increased appetite;Increased upper airway secretion;Infection;Infestation;Infestation NOS;Inflicted injury;Influenza;Injury;Insomnia;Iritis;Keratoconjunctivitis sicca;Lack of drug effect;Lacrimation decreased;Laryngeal pain;Libido decreased;Liver function test abnormal;Loose stools;Loss of consciousness;Lung disorder;Macule;Malaise;Malnutrition;Mediastinal disorder;Melaena;Memory impairment;Menopausal symptoms;Mental disability;Mental disorder;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Musculoskeletal discomfort;Mydriasis;Nail disorder;Nasal congestion;Nasal dryness;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Nightmare;Nocturia;Obstructive airways disorder;Oedema;Oedema peripheral;Oesophagitis;Oropharyngeal pain;Osteoarthritis;Pain;Pain in extremity;Palpitations;Paraesthesia;Paraesthesia oral;Paranoia;Pharyngitis;Pharyngolaryngeal pain;Pollakiuria;Pruritus;Psychotic disorder;Rash;Rash pustular;Residual urine volume;Rhinitis;Salivary hypersecretion;Shock;Sinus arrhythmia;Sinus congestion;Sinus headache;Sinusitis;Skin discolouration;Skin disorder;Sleep disorder;Somnolence;Stomatitis;Sweating decreased;Syncope;Tachycardia;Taste metallic;Tenosynovitis;Tension;Thinking abnormal;Thirst;Tinnitus;Tongue coated;Tongue discolouration;Tongue disorder;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urethral pain;Urethritis;Urethritis noninfective;Urinary hesitation;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urticaria;Vasodilation;Vasodilation procedure;Vesiculobullous rash;Viral diarrhoea;Vision blurred;Visual impairment;Vomiting,small molecule,approved; investigational,"4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester; 4-Diethylamino-2-butinyl alpha-cyclohexylmandelat; 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate; Oxibutinina; Oxybutynin; Oxybutynine; Oxybutyninum; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; AGP 1; AGP1; OMD 1; Orosomucoid-1",Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M1,G04BD04
oxycodone,Acute pain;Analgesic effect;Analgesic therapy;Cancer pain;Chronic pain;Constipation;Drug interaction;Eye redness;Flushing;Hyperhidrosis;Miosis;Neoplasm malignant;Ocular hyperaemia;Orthostatic hypotension;Pain;Pain at rest;Postoperative pain;Procedural pain;Pruritus;Pulmonary function test decreased;Respiratory depression;Spasm of sphincter of Oddi;Sphincter of Oddi dysfunction;Sweating;Vasodilation;Vasodilation procedure,Abdominal colic;Abdominal cramps;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal vision;Accidental injury;Accidental overdose;Ache;Acute pain;Addison's disease;Affect lability;Agitation;Alcohol abuse;Alcoholism;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Anxiety;Apnoea;Appetite absent;Arthralgia;Arthritis;Asthenia;Asthenic conditions;Asthma;Azotaemia;Back pain;Balance disorder;Bedridden;Biliary colic;Blister;Blood and lymphatic system disorders;Blood pressure increased;Body temperature decreased;Body temperature increased;Bone pain;Bradycardia;Brain cancer metastatic;Breakthrough pain;Breast disorder;Breast feeding;Bronchitis;Bronchoconstriction;Bronchospasm;CNS depression NOS;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiovascular insufficiency;Cellulitis;Chest discomfort;Chest pain;Chest tightness;Cheyne-Stokes respiration;Chills;Choking;Cholestasis;Circulatory depression;Cold sweat;Coma;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cough;Cough increased;Cutis anserina;Cyanosis;Decreased appetite;Deep vein thrombosis;Dehydration;Delayed gastric emptying;Delirium;Dental caries;Dependence;Dependence physiological;Dependence psychological;Depersonalisation;Depressed level of consciousness;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Discomfort;Disease progression;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug abuse;Drug dependence;Drug interaction;Drug tolerance;Drug withdrawal syndrome;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dysphoria;Dyspnoea;Dysuria;Ear and labyrinth disorders;Early satiety;Electrocardiogram ST segment depression;Endocrine disorder;Epistaxis;Erectile dysfunction;Eructation;Euphoric mood;Eye disorder;Face oedema;Faecalith;Faecaloma;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Flushing;Fullness abdominal;Gagging;Gait disturbance;Gastric atony;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gingival bleeding;Gingivitis;Glossitis;Gout;Haematuria;Haemoglobin;Haemorrhage;Hallucination;Head injury;Headache;Hepatic enzyme increased;Hepatitis;Hepatobiliary disease;Hepatomegaly;Herpes simplex;Hiccups;Hyperaesthesia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperpathia;Hypersensitivity;Hypertonia;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypogonadism;Hypokinesia;Hyponatraemia;Hypotension;Hypotensive;Hypothermia;Hypotonia;Ileus;Ileus paralytic;Ill-defined disorder;Immune system disorder;Impaired gastric emptying;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Injection site hypersensitivity;Injury;Insomnia;Intestinal obstruction;Intracranial pressure increased;Iron deficiency anaemia;Irritability;Lacrimal disorder;Lacrimal structural disorder;Lacrimation;Lacrimation increased;Laryngospasm;Leukopenia;Libido decreased;Lightheadedness;Loss of consciousness;Lung disorder;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melaena;Mental disability;Mental disorder;Metastases to central nervous system;Migraine;Miosis;Mood swings;Muscle contractions involuntary;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle tone flaccid;Muscle twitching;Musculoskeletal discomfort;Myalgia;Mydriasis;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Nervousness;Neuralgia;Oedema;Oedema peripheral;Opioid abuse;Opioid naive;Orthostatic hypotension;Pain;Pain worsened;Pallor;Palpitations;Paraesthesia;Personality disorder;Pharyngitis;Photosensitivity reaction;Piloerection;Pneumonia;Polyuria;Post herpetic neuralgia;Post procedural constipation;Postoperative constipation;Pruritus;Pulmonary function test decreased;Rash;Regurgitation;Respiration abnormal;Respiratory arrest;Respiratory depression;Respiratory disorder;Respiratory failure;Retching;Rhinitis;Rhinorrhoea;Sedation;Sepsis;Shivering;Shock;Sinusitis;Skin cold clammy;Skin disorder;Sneezing;Somnolence;Spasm biliary;Speech disorder;Stomach cramps;Stomatitis;Stupor;Substance abuse;Supraventricular tachycardia;Sweating;Swelling;Syncope;Tachycardia;Tension;Therapy naive;Thinking abnormal;Thirst;Thrombophlebitis;Tinnitus;Tooth discolouration;Tranquillisation excessive;Tremor;Tumour invasion;Unspecified disorder of skin and subcutaneous tissue;Unsteadiness;Uremia;Ureteral spasm;Urethral disorder;Urethral stenosis;Urinary abnormalities;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urine output increased;Urticaria;VT;Vasodilation;Vasodilation procedure;Ventricular tachycardia;Vertigo;Visual impairment;Vomiting;Weight decreased;Wheezing;Withdrawal symptom;Withdrawal syndrome;Yawning,small molecule,approved; illicit; investigational,"(-)-14-Hydroxydihydrocodeinone; 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; 4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; Dihydro-14-hydroxycodeinone; Dihydrohydroxycodeinone; Dihydroxycodeinone; Oxicodona; Oxycodone; Oxycodonum; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; K-OR-1; KOR-1; OPRK; D-OR-1; DOR-1; OPRD; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2",Mu-type opioid receptor; Kappa-type opioid receptor; Delta-type opioid receptor, N02AA05; N02AA55; N02AJ17; N02AJ18; N02AJ19;N02AA05;N02AA56
oxymetholone,Anaemia;Aplastic anaemia;Blood disorder;Congenital aplastic anaemia;Hypoplastic anaemia;Myelofibrosis;Myeloid metaplasia;Pyridoxine deficiency;Vitamin B6 deficiency,Acne;Alopecia;Androgenetic alopecia;Azoospermia;Chills;Cramp muscle;Diarrhoea;Disturbance in sexual arousal;Enlarged clitoris;Epididymitis;Erectile dysfunction;Glucose tolerance decreased;Gynaecomastia;Haemoglobin;Haemorrhage;Hepatic necrosis;Hirsutism;Insomnia;Iron deficiency anaemia;Irritability;Jaundice cholestatic;Leukaemia;Libido decreased;Malignant transformation;Menstruation irregular;Muscle spasms;Nausea;Neoplasm;Oedema;Oligospermia;Peliosis hepatis;Priapism;Testicular atrophy;Vomiting,small molecule,approved; illicit,"17β-Hydroxy-2-hydroxymethylidene-17α-methyl-3-androstanone; Oximetolona; Oxymetholon; Oxymétholone; Oxymetholone; Oxymetholonum; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; Brain natriuretic factor prohormone; Gamma-brain natriuretic peptide; Iso-ANP; preproBNP; proBNP; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.3.1.22; S5AR 1; SR type 1; Steroid 5-alpha-reductase 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin",Androgen receptor; Natriuretic peptides B,A14AA05
oxymorphone,Acute pain;Anxiety;Back pain;Dyspnoea;Left ventricular dysfunction;Low back pain;Opioid naive;Pain;Postoperative pain;Procedural pain;Pulmonary oedema;Therapy naive,Abdominal distension;Abdominal pain;Agitation;Altered state of consciousness;Amnesia;Angiopathy;Anorexia;Anxiety;Apnoea;Asthenia;Atelectasis;Biliary colic;Body temperature increased;Bradycardia;Bronchospasm;Cancer pain;Cardiac disorder;Chest pain;Chronic pain;Cold sweat;Confusional state;Constipation;Convulsion;Decreased appetite;Dehydration;Depressed level of consciousness;Dermatitis;Dermatitis atopic;Diarrhoea;Diplopia;Disorientation;Dizziness;Drug abuse;Drug interaction;Dry mouth;Dyspepsia;Dysphoria;Dyspnoea;Euphoric mood;Eye disorder;Fatigue;Feeling abnormal;Feeling jittery;Flatulence;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Head injury;Headache;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Hypotensive;Ileus;Ileus paralytic;Immune system disorder;Injection site reaction;Insomnia;Intracranial pressure increased;Laryngeal oedema;Laryngospasm;Lethargy;Loss of consciousness;Lung disorder;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Mental disability;Mental disorder;Mental retardation;Mental status changes;Miosis;Nausea;Nervous system disorder;Nervousness;Oedema;Oliguria;Orthostatic hypotension;Oxygen saturation decreased;Pain;Palpitations;Pneumonia;Pneumothorax;Pruritus;Pulmonary function test decreased;Respiratory depression;Respiratory distress;Respiratory rate decreased;Shock;Skin disorder;Somnolence;Sticky skin;Sweating increased;Swelling face;Syncope;Tachycardia;Tension;Unspecified disorder of skin and subcutaneous tissue;Ureteral spasm;Urethral disorder;Urinary hesitation;Urinary retention;Urinary tract disorder;Urticaria;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Withdrawal syndrome,small molecule,approved; investigational; vet_approved,"(14S)-14-Hydroxydihydromorphinone; 14-Hydroxydihydromorphinone; Dihydrohydroxymorphinone; Dihydroxymorphinone; Oximorfona; Oximorphonum; Oxymorphone; Oxymorphonum; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Mu-type opioid receptor; Delta-type opioid receptor,N02AA11
paclitaxel,Acquired immunodeficiency syndrome;Acute leukaemia;Acute myeloid leukaemia;Adenocarcinoma pancreas;Advanced breast cancer;Angioedema;Autoimmune disorder;B-cell type acute leukaemia;Breast cancer;Breast cancer stage IV;Burkitt's lymphoma;Carcinoma;Carcinoma breast;Carcinoma of lung;Disease progression;Dizziness;Dyspnoea;Electrocardiogram normal;Fall;Generalized urticaria;Hepatic function abnormal;Hepatic impairment;Hypersensitivity;Hypotension;Kaposi's sarcoma;Kaposi's sarcoma AIDS related;Liver disorder;Loss of consciousness;Lung neoplasm malignant;Metastatic carcinoma;Metastatic disease;Metastatic neoplasm;Neoplasm;Neoplasm malignant;Nephropathy;Node-positive breast cancer;Non-small cell lung cancer;Ovarian cancer;Ovarian carcinoma;Ovarian epithelial cancer;Ovarian epithelial cancer stage IV;Shock;Solid tumour;Syncope;Urticaria,Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abnormal vision;Accidental injury;Acute coronary syndrome;Acute leukaemia;Acute myeloid leukaemia;Adenocarcinoma;Agitation;Alanine aminotransferase increased;Alopecia;Amblyopia;Anaemia;Anaphylactic shock;Anemic;Angioedema;Angiopathy;Anorexia;Anxiety;Areflexia;Arrhythmia;Arthralgia;Ascites;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrial fibrillation;Atrioventricular block;Atrioventricular block complete;Autonomic neuropathy;B-cell type acute leukaemia;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood disorder;Blood electrolytes abnormal;Blood glucose increased;Blood potassium decreased;Blood pressure increased;Blood pressure systolic decreased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Breast cancer stage IV;Breast disorder;Breast pain;Breath sounds abnormal;Bronchitis;Caecitis;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiomyopathy;Catheter related infection;Cellulitis;Cerebrovascular accident;Chest discomfort;Chest pain;Chest wall pain;Chills;Cholangitis;Colitis;Colitis ischaemic;Confusional state;Congenital skin disorder;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Coronary artery stenosis;Cough;Cramp muscle;Cramps of lower extremities;Cranial nerve paralysis;Cryptosporidiosis infection;Cyst;Cystoid macular oedema;Deafness;Deafness neurosensory;Decreased appetite;Dehydration;Depression;Dermatitis;Dermatitis atopic;Dermatitis exfoliative;Device related infection;Diarrhoea;Discomfort;Disorder sight;Dizziness;Dizziness postural;Drug hypersensitivity;Drug interaction;Dry eye;Dry mouth;Dry skin;Dry throat;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dyspnoea exertional;Dysuria;Ear and labyrinth disorders;Ear pain;Electrocardiogram abnormal;Electrolyte abnormality;Electrolyte imbalance;Embolism;Encephalopathy;Encephalopathy acute;Epistaxis;Erythema;Erythema multiforme;Extrasystoles;Extravasation;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Fibrosis;Flank pain;Flatulence;Fluid retention;Flushing;Folliculitis;Fungal infection;Gait disturbance;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalized urticaria;Gingival pain;Glossodynia;Grand mal convulsion;Groin pain;Haematocrit decreased;Haematuria;Haemoglobin;Haemolytic uraemic syndrome;Haemoptysis;Haemorrhage;Headache;Hearing impaired;Hepatic encephalopathy;Hepatic necrosis;Hepatobiliary disease;Hepatomegaly;Herpes simplex;Herpes zoster;Hoarseness;Hot flush;Hyperaesthesia;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperlactacidaemia;Hyperpyrexia;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypoaesthesia oral;Hypoalbuminaemia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hyporeflexia;Hypotension;Hypotensive;Hypotrichosis;Ileus;Ileus paralytic;Ill-defined disorder;Immune system disorder;Immunocompromised;Immunodeficiency;Induration;Infarction;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Influenza-like symptoms;Infusion site extravasation;Infusion site inflammation;Infusion site rash;Infusion site reaction;Injection site infection;Injection site reaction;Injection site swelling;Injury;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal obstruction;Intestinal perforation;Ischaemic stroke;Keratitis;Keratoconjunctivitis sicca;Lacrimation increased;Laryngeal pain;Left ventricular dysfunction;Lethargy;Leukoencephalopathy;Leukopenia;Lightheadedness;Limb discomfort;Liver function test abnormal;Localised oedema;Loose stools;Loss of consciousness;Lymphoedema;Lymphopenia;Macular oedema;Madarosis;Malaise;Malignant neoplasm of pancreas;Malnutrition;Mediastinal disorder;Melaena;Meningitis cryptococcal;Menopausal symptoms;Mental disability;Mental disorder;Metabolic encephalopathy;Metastatic pain;Mood alteration NOS;Mood swings;Mouth ulceration;Mucosal inflammation;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myasthenia;Myelodysplastic syndrome;Myelosuppression;Myocardial infarction;Myocardial ischaemia;Nail bed tenderness;Nail changes;Nail discolouration;Nail discomfort;Nail disorder;Nail pigmentation;Nasal congestion;Nasal dryness;Nasopharyngitis;Nausea;Neck pain;Necrolysis epidermal;Necrosis;Necrotising colitis;Necrotising enterocolitis neonatal;Necrotizing enterocolitis;Neoplasm;Nephropathy toxic;Nerve injury;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neurological symptom;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutropenic colitis;Neutropenic enterocolitis;Neutropenic sepsis;Night sweats;Nocturia;Oedema;Oedema peripheral;Oesophagitis;Onycholysis;Onychomadesis;Opportunistic infection;Oral candidiasis;Oral pain;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Ototoxicity;Pain;Pain in extremity;Pain of skin;Palpitations;Pancreatic carcinoma;Pancreatitis;Pancreatitis acute;Pancytopenia;Paraesthesia;Peripheral coldness;Peripheral motor neuropathy;Peripheral sensory neuropathy;Peritonitis;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Photopsia;Photosensitivity reaction;Pigmentation disorder;Pleural effusion;Pneumonia;Pneumothorax;Pollakiuria;Polydipsia;Polyneuropathy;Polyp;Polyuria;Productive cough;Prurigo;Pruritus;Pruritus generalised;Pseudomembranous colitis;Pulmonary embolism;Pulmonary fibrosis;Pulmonary hypertension;Pulmonary thromboembolism;Radiation pneumonitis;Radiation recall reaction (dermatologic);Raised liver function tests;Rash;Rash erythematous;Rash generalised;Rash macular;Rash maculo-papular;Rash papular;Recall phenomenon;Rectal haemorrhage;Red blood cell count decreased;Redness;Renal failure;Renal failure acute;Renal impairment;Respiratory distress;Respiratory failure;Respiratory sounds decreased;Respiratory tract infection;Rhinitis;Rhinitis allergic;Rhinorrhoea;Rigors;Scintillating scotoma;Scleroderma;Scotoma;Sensory disturbance;Sensory loss;Sepsis;Septic shock;Shock;Sinus bradycardia;Sinus congestion;Sinus tachycardia;Sinusitis;Skin discolouration;Skin disorder;Skin exfoliation;Skin fibrosis;Skin hyperpigmentation;Skin lesion;Skin necrosis;Skin toxicity;Skin ulcer;Somnolence;Squamous cell carcinoma of lung;Stevens-Johnson syndrome;Stomatitis;Supraventricular tachycardia;Sweating increased;Swelling;Swelling face;Syncope;Systemic lupus erythematosus;Tachycardia;Tenderness;Tension;Thinking abnormal;Throat sore;Thrombocytopenia;Thrombophlebitis;Thrombosis;Thrombosis mesenteric vessel;Thrombotic thrombocytopenic purpura;Tingling sensation;Tinnitus;Tonic-clonic seizures;Toxic epidermal necrolysis;Transient ischaemic attack;Tremor;Tumour lysis syndrome;Tumour necrosis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;VIIth nerve paralysis;Venous thrombosis;Ventricular bigeminy;Ventricular extrasystoles;Ventricular failure;Ventricular tachycardia;Vertigo;Viral infection;Vision blurred;Visual acuity reduced;Visual disturbance;Visual evoked potentials abnormal;Visual impairment;Vitiligo;Vitreous floaters;Vocal cord paresis;Vomiting;Weight decreased;Weight increased;Wheezing,small molecule,approved; vet_approved,"5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; ABI-007 COMPONENT PACLITAXEL; BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,; liposomal encapsulated paclitaxel; NAB-PACLITAXEL COMPONENT PACLITAXEL; Nanoparticulate paclitaxel; Paclitaxel; paclitaxel protein-bound particles; Paclitaxel protein-bound particles for injection suspension; Taxol A; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",Tubulin beta-1 chain; Apoptosis regulator Bcl-2; Nuclear receptor subfamily 1 group I member 2, L01CD51;L01CD01
pancuronium,Hypotonia;Mean arterial pressure;Muscle relaxation;Muscle twitching;Renal failure;Vascular resistance systemic,Anaphylactic shock;Anaphylactoid reaction;Apnoea;Bronchospasm;Dermatitis;Drug interaction;Erythema;Flushing;Hypersensitivity;Hypotension;Light anaesthesia;Muscular weakness;Paralysis;Pre-existing disease;Rash;Redness;Respiratory failure;Respiratory insufficiency;Salivary hypersecretion;Salivation;Skeletal muscle paralysis;Tachycardia,small molecule,approved,Pancuronium; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2,Neuronal acetylcholine receptor subunit alpha-2; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3,M03AC01
pantoprazole,Duodenal ulcer;Dyspepsia;Dyspeptic signs and symptoms;Erosive oesophagitis;Gastric ulcer;Gastrinoma;Gastritis;Gastrointestinal disorder;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Heartburn;Infection;Odynophagia;Peptic ulcer;Reflux esophagitis;Regurgitation;Ulcer;Zollinger-Ellison syndrome,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Abnormal dreams;Abnormal faeces;Abnormal vision;Abscess;Abscess periodontal;Acute coronary syndrome;Affect lability;Ageusia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Amblyopia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Anorectal disorder;Anorexia;Anterior ischemic optic neuropathy;Anxiety;Aphthous stomatitis;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Atrial fibrillation;Autonomic neuropathy;Back pain;Balanitis;Biliary colic;Bladder pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood disorder;Blood glucose increased;Blood potassium decreased;Blood potassium increased;Blood pressure increased;Blood triglycerides increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Breast disorder;Breast pain;Breath odour;Bronchitis;Buccal inflammation;Bursitis;Calculus of kidney;Candida infection;Cardiac failure congestive;Cardiac flutter;Cardiovascular disorder;Cataract;Cataract specified;Chest pain;Chills;Cholecystitis;Cholelithiasis;Coagulation time prolonged;Coagulopathy;Colitis;Colitis ulcerative;Colonic polyp;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine increased;Creatinine renal clearance decreased;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Depression;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disorder sight;Disorientation;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Duodenitis;Dysarthria;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dyspeptic signs and symptoms;Dysphagia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Eczema;Electrocardiogram abnormal;Enteritis;Eosinophilia;Epididymitis;Epistaxis;Erectile dysfunction;Erosive oesophagitis;Eructation;Eruption;Eruption lichenoid;Erythema multiforme;External ophthalmoplegia;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Flushing;Fracture;Frequent bowel movements;Fungal skin infection;Gamma-glutamyltransferase increased;Gastric polyps;Gastritis;Gastroenteritis;Gastrointestinal candidiasis;Gastrointestinal carcinoma;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Gingivitis;Glaucoma;Glossitis;Glossodynia;Glucose increased;Glycosuria;Goitre;Gout;Gynaecomastia;Haematemesis;Haematocrit decreased;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoids;Hallucination;Headache;Headache dull;Heat stroke;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hepatocellular injury;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hot flush;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertonia;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypochromic anaemia;Hypokinesia;Hypomagnesaemia;Hyponatraemia;Hyporeflexia;Hypotension;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Injection site reaction;Injection site thrombosis;Injury;Insomnia;Iron deficiency anaemia;Jaundice;Jaundice cholestatic;Laboratory test abnormal;Large intestine polyp;Laryngitis;Leukocytosis;Leukopenia;Libido decreased;Lichenoid keratosis;Liver function test abnormal;Liver injury;Loose stools;Loss of consciousness;Lung disorder;Malaise;Malnutrition;Melaena;Menopausal symptoms;Mental disability;Mental disorder;Metabolic disorder;Migraine;Mood swings;Mouth ulceration;Multiple fractures;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Neoplasm;Nephritis interstitial;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Nocturia;Non-accidental injury;Nuchal rigidity;Oedema;Oedema peripheral;Oesophageal achalasia;Oesophageal haemorrhage;Oesophageal reflux aggravated;Oesophagitis;Ophthalmoplegia;Optic ischaemic neuropathy;Oral candidiasis;Osteoarthritis;Otitis externa;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Periodontitis;Pharyngitis;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Potassium increased;Potassium low;Proctocolitis;Prostatic disorder;Pruritus;Pyelonephritis;Rash;Rash maculo-papular;Rectal disorder;Rectal haemorrhage;Renal pain;Retching;Retinal vascular disorder;Retrosternal pain;Rhabdomyolysis;Rhinitis;Salivary hypersecretion;Scrotal oedema;Sepsis;Shock;Sinus congestion;Sinusitis;Skin disorder;Skin ulcer;Sleep disorder;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stomatitis;Sweating;Sweating increased;Syncope;Tachycardia;Taste bitter;Taste disorders;Taste metallic;Tendonitis;Tenosynovitis;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombophlebitis;Thrombophlebitis injection site;Thrombosis;Tinnitus;Tongue discolouration;Tonsillitis;Tooth abscess;Toothache;Toxic epidermal necrolysis;Transaminases increased;Tremor;Tubulointerstitial nephritis;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urethral pain;Urethritis;Urethritis noninfective;Urinary tract disorder;Urinary tract infection;Urination impaired;Urticaria;Vaginal infection;Vaginal inflammation;Vasodilation;Vasodilation procedure;Vertigo;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;White blood cell disorder,small molecule,approved,"Pantoprazol; Pantoprazole; Pantoprazolum; 7.2.2.19; Gastric H(+)/K(+) ATPase subunit alpha; Proton pump; Gastric H(+)/K(+) ATPase subunit beta; Proton pump beta chain; 3.5.3.18; DDAH; DDAH-1; DDAHI; Dimethylargininase-1; Dimethylarginine dimethylaminohydrolase 1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8","Potassium-transporting ATPase alpha chain 1; Potassium-transporting ATPase subunit beta; N(G),N(G)-dimethylarginine dimethylaminohydrolase 1", A02BC02; A02BD11;A02BC02;A02BD04
papaverine,Abdominal colic;Abdominal pain;Acute myocardial infarction;Angina pectoris;Coronary artery occlusion;Muscle spasms;Peripheral vascular disorder;Pulmonary embolism;Vasospasm,Abdominal discomfort;Anorexia;Blood pressure increased;Constipation;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Feeling abnormal;Flushing;General discomfort;Headache;Hepatitis;Ill-defined disorder;Malaise;Nausea;Rash;Sedation;Tranquillisation excessive;Vertigo,small molecule,approved; investigational,Papaverina; Papaverine; 3.1.4.53; cAMP-specific phosphodiesterase 4D; DPDE3; PDE43; 3.1.4.35; CGB-PDE; cGMP-binding cGMP-specific phosphodiesterase; PDE5; 3.1.4.53; cAMP-specific phosphodiesterase 4B; DPDE4; PDE32; 3.1.4.17; 3.1.4.53; cAMP-specific phosphodiesterase 4D; DPDE3; PDE43; 3.1.4.17; CGI-PDE B; CGIP1; CGIPDE1; Cyclic GMP-inhibited phosphodiesterase B; 3.1.4.35; CGB-PDE; cGMP-binding cGMP-specific phosphodiesterase; PDE5; 3.1.4.17; 63 kDa Cam-PDE; Cam-PDE 1B; PDES1B,"3',5'-cyclic-AMP phosphodiesterase 4D; cGMP-specific 3',5'-cyclic phosphodiesterase; 3',5'-cyclic-AMP phosphodiesterase 4B; cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A; Phosphodiesterase enzymes", A03AD01; G04BE52;A03AD01;G04BE02
paromomycin,Amoebiasis;Amoebic colitis;Coma hepatic;Infection,Abdominal cramps;Abdominal pain;Diarrhoea;Nausea,small molecule,approved; investigational,"(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; Aminosidin; Aminosidine; Catenulin; Crestomycin; Estomycin; Hydroxymycin; Monomycin A; Neomycin E; Paromomicina; Paromomycin; Paromomycin I; Paromomycine; Paromomycinum; Paucimycin; Paucimycinum; Zygomycin A1; 37 kDa laminin receptor precursor; 37/67 kDa laminin receptor; 37LRP; 40S ribosomal protein SA; 67 kDa laminin receptor; 67LR; Colon carcinoma laminin-binding protein; LAMBR; Laminin receptor 1; Laminin-binding protein precursor p40; LamR; LAMR1; LBP/p40; LRP/LR; Multidrug resistance-associated protein MGr1-Ag; NEM/1CHD4; 60S ribosomal protein L10-like; Large ribosomal subunit protein uL16-like",30S ribosomal protein S10; 16S ribosomal RNA; Small ribosomal subunit protein uS2; Ribosomal protein uL16-like,A07AA06
paroxetine,"Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal distress;Affect lability;Affective disorder;Agitation;Agoraphobia;Anger;Anxiety;Asthenia;Bradyphrenia;Bradypsychic response;Breast tenderness;Cerebration impaired;Chest pain;Chills;Choking sensation;Compulsions;Decreased interest;Depersonalisation;Depressed mood;Depression;Depressive disorder;Depressive symptom;Derealisation;Discomfort;Distress;Disturbance in attention;Dizziness;Drug abuse;Dyskinesia;Dysphoria;Dyspnoea;Dysthymic disorder;Emotional distress;Estrangement;Exaggerated startle response;Fatigue;Fear of death;Feeling guilty;Flashback;Flatulence;Generalised anxiety disorder;Haemorrhagic disorder;Headache;Heart pounding;Hemorrhage abnormal;Hepatic impairment;Hot flush;Hyperhidrosis;Hypersomnia;Hypertension;Hypervigilance;Hypoaesthesia;Insomnia;Irritability;Lightheadedness;Liver disorder;Major depression;Major depressive disorder, single episode;Menopausal symptoms;Menopause;Mental disability;Mood swings;Movement disorder;Musculoskeletal discomfort;Myalgia;Nausea;Numbness;Obsessive rumination;Obsessive thoughts;Obsessive-compulsive disorder;Palpitations;Panic attack;Panic disorder;Panic reaction;Paraesthesia;Partner stress;Performance fear;Phobia;Post-traumatic stress disorder;Premenstrual dysphoric disorder;Reduced interest in usual activities;Sensory loss;Sexual dysfunction;Sleep disorder;Sleep disturbance;Social fear;Social phobia;Suicidal behaviour;Suicidal ideation;Suicide attempt;Sweating;Tension;Tingling sensation;Trembling;Tremor;Weight increased",Abdominal pain;Abnormal dreams;Abnormal ejaculation;Abnormal vision;Abortion;Abscess;Accommodation disorder;Acne;Acute coronary syndrome;Acute glaucoma;Adrenergic syndrome;Affect lability;Ageusia;Aggression;Agitation;Agranulocytosis;Akathisia;Akinesia;Alanine aminotransferase increased;Albuminuria;Alcohol abuse;Alopecia;Alveolitis allergic;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Angle closure glaucoma;Anisocytosis;Anorectal disorder;Anorgasmia;Anticholinergic syndrome;Antisocial behaviour;Antisocial personality disorder;Anxiety;Anxiety disorder;Aphasia;Aphthous stomatitis;Aplastic anaemia;Appetite absent;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Arthropathy;Asocial behaviour;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrial arrhythmia;Atrial fibrillation;Atrioventricular block;Azoospermia;Back pain;Basophilia;Bipolar I disorder;Bipolar disorder;Bladder pain;Bleeding time prolonged;Blepharitis;Blister;Block heart;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature decreased;Body temperature increased;Bone disorder;Bradycardia;Bradykinesia;Brain oedema;Breast atrophy;Breast cancer;Breast disorder;Breast enlargement;Breast feeding;Breast neoplasm;Breast pain;Bronchitis;Bruxism;Bulimia;Bulimia nervosa;Bundle branch block;Bursitis;Cachexia;Calculus of kidney;Candida infection;Carcinoma;Carcinoma breast;Cardiac disorder;Cardiac failure congestive;Cardiac output decreased;Cataract;Cataract specified;Cellulitis;Cerebral ischaemia;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Cervix disorder;Chest pain;Chills;Cholelithiasis;Chondropathy;Choreoathetosis;Chronic lymphocytic leukaemia;Circumoral paresthesia;Cogwheel rigidity;Cold symptoms;Colitis;Coma;Compulsive personality disorder;Confusional state;Congenital genitourinary abnormality;Conjunctival oedema;Conjunctivitis;Connective tissue disorder;Constipation;Conversion disorder;Convulsion;Coordination abnormal;Corneal lesion;Cough;Cough increased;Cramp muscle;Crying;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Delayed orgasm;Delirium;Delusion;Dental caries;Dependence;Dependence physiological;Depersonalisation;Depressed level of consciousness;Depression;Depressive symptom;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diabetes mellitus inadequate control;Diarrhoea;Diarrhoea haemorrhagic;Diplopia;Discomfort;Disorientation;Distress;Disturbance in attention;Disturbance in sexual arousal;Diuresis;Dizziness;Dreaming excessive;Drowsiness;Drug abuse;Drug dependence;Drug seeking behavior;Drug tolerance;Drug withdrawal syndrome;Drug-induced liver injury;Dry mouth;Dry skin;Duodenitis;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear disorder;Ear pain;Ecchymosis;Eclampsia;Eczema;Ejaculation delayed;Ejaculation disorder;Electric shock;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Electroencephalogram abnormal;Emotional distress;Emphysema;Endocrine disorder;Endometrial disorder;Enteritis;Eosinophilia;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Erythema nodosum;Euphoric mood;Exophthalmos;Extrapyramidal disorder;Extrapyramidal symptoms;Extrasystoles;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Faecal incontinence;Faecalith;Faecaloma;Fasciculation;Fatal outcomes;Fatigue;Feeling abnormal;Female sexual dysfunction;Fertility female decreased;Fibrocystic breast disease;Flatulence;Fluid retention;Flushing;Fracture;Fungal skin infection;Furuncle;Furunculosis;Gait disturbance;Galactorrhoea;Gamma globulins increased;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Generalised spasm;Genital disorder female;Genital disorder male;Gingival bleeding;Gingival hyperplasia;Gingivitis;Glaucoma;Glossitis;Goitre;Gout;Grand mal convulsion;Guillain-Barre syndrome;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemolytic anaemia;Haemoptysis;Haemorrhage;Haemorrhagic disorder;Haemorrhoids;Hallucination;Headache;Hemorrhage abnormal;Henoch-Schonlein purpura;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatobiliary disease;Hepatosplenomegaly;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hirsutism;Homicidal ideation;Hostility;Hyperacusis;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperpathia;Hyperphosphataemia;Hyperprolactinaemia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertension worsened;Hyperthyroidism;Hypertonia;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypochromic anaemia;Hypoglycaemia;Hypohidrosis;Hypokalaemia;Hypokinesia;Hypomania;Hyponatraemia;Hyporeflexia;Hypotension;Hypothermia;Hypothyroidism;Hysteria;Idiopathic thrombocytopenic purpura;Ileitis;Ileus;Ill-defined disorder;Immune system disorder;Immunoglobulins increased;Inappropriate antidiuretic hormone secretion;Increased appetite;Increased bronchial secretion;Infection;Infertility female;Influenza;Injury;Insomnia;Intestinal obstruction;Iron deficiency anaemia;Jaundice;Keratitis;Keratoconjunctivitis;Ketosis;Kidney function abnormal;Lactation female;Lactic dehydrogenase activity increased;Laryngeal disorder;Laryngitis;Laryngospasm;Lethargy;Leukocytosis;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Lightheadedness;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Lymphocyte abnormal;Lymphocyte count abnormal;Lymphocytosis;Lymphoedema;Lymphopenia;Major depression;Malaise;Male sexual dysfunction;Malignant melanoma;Malnutrition;Mania;Manic psychosis;Mass;Mastitis;Mediastinal disorder;Melaena;Melanoma skin;Meningitis;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Metrorrhagia;Microcytic anaemia;Micturition disorder;Micturition urgency;Migraine;Monocytosis;Mood swings;Mouth ulceration;Movement disorder;Multiple fractures;Muscle contractions involuntary;Muscle spasms;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Mydriasis;Myelitis;Myocardial infarction;Myocardial ischaemia;Myoclonus;Myopathy;Myositis;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Negativism;Neoplasm;Neoplasm malignant;Nephritis;Nephrolithiasis;Nephropathy;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Neurosis;Night blindness;Nightmare;Nocturia;Nodal arrhythmia;Normochromic normocytic anaemia;Normocytic anemia;Nuchal rigidity;Nystagmus;Obesity;Obsessive-compulsive personality disorder;Oculogyric crisis;Oedema;Oedema peripheral;Oesophageal achalasia;Oesophagitis;Oliguria;Oppositional;Optic neuritis;Orgasm abnormal;Orthostatic hypotension;Osteoarthritis;Osteoporosis;Otitis externa;Otitis media;Ovarian cyst;Ovarian disorder;Pain;Pallor;Palpitations;Pancreatitis;Pancreatitis acute;Pancreatitis haemorrhagic;Pancytopenia;Panic attack;Paraesthesia;Paraesthesia oral;Paralysis;Paranoia;Paranoid reaction;Parkinson's disease;Parkinsonism;Parosmia;Pelvic pain;Peptic ulcer;Peripheral vascular disorder;Peritonitis;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Porphyrin metabolism disorder;Postpartum disorder;Premature baby;Premature delivery;Priapism;Prostate cancer;Prostate carcinoma;Prostatic disorder;Prostatitis;Pruritus;Psychotic depression;Psychotic disorder;Pulmonary embolism;Pulmonary fibrosis;Pulmonary hypertension;Pulmonary oedema;Pupils unequal;Purpura;Pyuria;Raised liver function tests;Rash;Rash maculo-papular;Rash pustular;Rectal disorder;Rectal haemorrhage;Renal failure acute;Renal impairment;Renal pain;Reproductive tract disorder;Restless legs syndrome;Retinal haemorrhage;Retrosternal pain;Rheumatoid arthritis;Rhinitis;Salivary gland enlargement;Salivary hypersecretion;Salpingitis;Scotoma;Seborrhoeic dermatitis;Self-injurious ideation;Sepsis;Serotonin syndrome;Sexual dysfunction;Shivering;Shock;Sialoadenitis;Sinus tachycardia;Sinusitis;Skin discolouration;Skin disorder;Skin hypertrophy;Skin ulcer;Sleep disorder;Sleep disturbance;Somnolence;Spermatogenesis arrest;Sputum increased;Status epilepticus;Stevens-Johnson syndrome;Stiffness;Stomatitis;Stress;Stridor;Stupor;Suicidal ideation;Suicide attempt;Supraventricular extrasystoles;Supraventricular tachycardia;Sweat gland disorder;Sweating;Sweating decreased;Sweating increased;Syncope;Tachycardia;Tearfulness;Tendonitis;Tenosynovitis;Tension;Testicular pain;Tetany;Thinking abnormal;Thirst;Throat tightness;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thrombosis;Thyroiditis;Tinnitus;Tolerance development;Tongue discolouration;Tongue disorder;Tongue oedema;Tooth disorder;Tooth malformation;Toothache;Torsade de pointes;Torticollis;Toxic epidermal necrolysis;Toxicity to various agents;Transaminases increased;Trauma;Traumatic fracture;Tremor;Trismus;Type 2 diabetes mellitus;Ulcer;Ulcerative keratitis;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urethritis;Urethritis noninfective;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract infection;Urination impaired;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Uterine fibroids enlarged;Uterine leiomyoma;Uterine neoplasm;Uterine spasm;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Varicose vein;Vascular headache;Vascular purpura;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;WBC abnormal NOS;Weight decreased;Weight increased;White blood cell disorder;Withdrawal syndrome;Yawning,small molecule,approved; investigational,"(−)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; Paroxetina; Paroxetine; Paroxetinum; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; Dopamine D2 receptor; H1-R; H1R; HH1R; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT3-B; 5-HT3B; Serotonin receptor 3B; 5-HT3-C; 5-HT3C; Serotonin receptor 3C; 5-HT3-D; 5-HT3D; Serotonin receptor 3D; 5-HT3-E; 5-HT3E; Serotonin receptor 3E; 5-HT-4; 5-HT4; Serotonin receptor 4; 5-HT-6; 5-HT6; Serotonin receptor 6; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; 5-hydroxytryptamine receptor 2A; Alpha-1 adrenergic receptors; Alpha-2 adrenergic receptors; Beta adrenergic receptor; D(2) dopamine receptor; Histamine H1 receptor; Serotonin Receptors; Muscarinic acetylcholine receptor; 5-hydroxytryptamine receptor 2B; D(1) dopamine receptor,N06AB05
penbutolol,Hypertension,Ache;Affect lability;Agranulocytosis;Alopecia;Alopecia reversible;Amnesia;Arterial thrombosis;Asthenia;Atrioventricular block;Body temperature increased;Bradycardia;Catatonia;Colitis ischaemic;Cough;Depression;Diarrhoea;Disorientation;Dizziness;Dyspepsia;Dyspnoea;Erectile dysfunction;Fatigue;Headache;Hyperhidrosis;Insomnia;Laryngospasm;Mood swings;Nausea;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Peyronie's disease;Rash erythematous;Respiratory distress;Short-term memory loss;Sweating;Throat sore;Thrombocytopenic purpura;Upper respiratory tract infection,small molecule,approved; investigational,(2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol; Penbutolol; Penbutololum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1,Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B, C07AA23;C07AA23;C07CA23
penciclovir,Dermatitis;Genital herpes;Herpes labialis;Herpes zoster;Immunocompromised;Immunodeficiency;Ophthalmic herpes zoster;Oral herpes;Rash,Abdominal pain;Anaemia;Angioedema;Application site reaction;Asthenia;Blood and lymphatic system disorders;Cardiac disorder;Confusional state;Delirium;Dermatitis;Diarrhoea;Disorientation;Dizziness;Dysgeusia;Dysmenorrhoea;Erythema;Erythema multiforme;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal pain;Hallucination;Headache;Hepatobiliary disease;Herpes labialis;Hypersensitivity;Hypoaesthesia;Jaundice cholestatic;Leukocytoclastic vasculitis;Leukopenia;Liver function test abnormal;Local swelling;Mental disorder;Migraine;Nausea;Nervous system disorder;Neutropenia;Oral herpes;Pain;Palpitations;Paraesthesia;Parosmia;Pharyngeal oedema;Pruritus;Rash;Rash erythematous;Renal failure acute;Skin discolouration;Skin disorder;Somnolence;Stevens-Johnson syndrome;Therapeutic response decreased;Thrombocytopenia;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vomiting,small molecule,approved,9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine; 9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine; 9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine; 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine; PCV; PE2; Penciclovir; Penciclovirum; 2.7.1.21; 2.7.7.7; 2.7.1.21; UL23,"Thymidine kinase, cytosolic; DNA polymerase catalytic subunit; Thymidine kinase", J05AB13;D06BB06
D-penicillamine,Ankylosing spondylitis;Arthritis;Blood copper decreased;Cirrhosis liver postnecrotic;Copper deficiency;Cystinuria;Dermatitis;Environmental exposure;Foetor hepaticus;Function kidney decreased;Hepatic cirrhosis;Hepatic function abnormal;Hepato-lenticular degeneration;Hepatocellular injury;Inflammation;Kayser-Fleischer ring;Lead poisoning;Liver disorder;Liver injury;Metal poisoning;Neurological symptom;Rash;Renal impairment;Renal tubular disorder;Rheumatoid arthritis,Abdominal pain upper;Ageusia;Agitation;Agranulocytosis;Alkaline phosphatase serum increased;Alopecia;Alveolitis allergic;Anaemia;Angiopathy;Anorexia;Anxiety;Aplasia pure red cell;Aplastic anaemia;Appetite absent;Arthralgia;Asthma;Atrophy;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Body temperature increased;Bone marrow depression;Breast enlargement;Cheilosis;Cholestasis;Cholestasis intrahepatic;Coagulopathy;Cutaneous vasculitis;Decreased appetite;Dermatitis;Dermatitis exfoliative;Dermatomyositis;Diarrhoea;Drug eruption;Drug-induced lupus erythematosus;Dysgeusia;Elastosis perforans;Eosinophilia;Epigastric pain;Eruption;Extravasation;Gingivostomatitis;Glomerulonephritis;Glomerulonephritis membranous;Glossitis;Goodpasture's syndrome;Guillain-Barre syndrome;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hepatic failure;Hepatic function abnormal;Hepatitis toxic;Hepatobiliary disease;Hyperplasia;Hyperpyrexia;Hypersensitivity;Hypoglycaemia;Injury;Interstitial lung disease;Interstitial pneumonia;Iron deficiency;Leukaemia;Leukocytosis;Leukopenia;Lichen planus;Lupus erythematosus;Lupus-like syndrome;Lymphadenopathy;Mental disorder;Monocytosis;Mouth ulceration;Muscular weakness;Musculoskeletal discomfort;Myasthenia gravis;Nausea;Nephrotic syndrome;Neuropathy;Neuropathy peripheral;Obliterative bronchiolitis;Optic neuritis;Pancreatitis;Pancytopenia;Papule;Pemphigoid;Pemphigus;Peptic ulcer;Peptic ulcer reactivated;Polyarthralgia;Polymyositis;Protein urine present;Proteinuria;Pruritus generalised;Pulmonary fibrosis;Pyridoxine deficiency;Rash;Rash erythematous;Red blood cell sedimentation rate increased;Red cell aplasia;Renal failure;Renal vasculitis;Sideroblastic anaemia;Skin disorder;Skin wrinkling;Stomatitis;Synovitis;Systemic lupus erythematosus;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thrombotic thrombocytopenic purpura;Thyroiditis;Tinnitus;Toxic epidermal necrolysis;Trauma;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vasculitis;Vitamin B6 deficiency;Vomiting;Yellow nail syndrome,small molecule,approved,"(−)-penicillamine; (S)-2-amino-3-mercapto-3-methylbutanoic acid; (S)-3,3-dimethylcysteine; 3-mercapto-D-valine; D-(−)-penicillamine; D-penicillamine; D-β,β-dimethylcysteine; penicilamina; Penicillamine; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Copper,M01CC01
penicillin,Arthritis;Bacteraemia;Cardiac valve disease;Chorea;Empyema;Endocarditis;Endocarditis bacterial;Erysipelas;Gingivitis;Gingivitis ulcerative;Heart disease congenital;Infection;Meningitis;Necrotising ulcerative gingivostomatitis;Pericarditis;Pharyngitis;Pneumococcal infection;Pneumonia;Rheumatic disorder;Rheumatic fever;Scarlet fever;Staphylococcal infection;Streptococcal infection;Trench mouth,Anaphylactic shock;Black hairy tongue;Body temperature increased;Dermatitis exfoliative;Diarrhoea;Dyspepsia;Eosinophilia;Epigastric distress;Eruption;Haemolytic anaemia;Hypersensitivity;Laryngeal oedema;Leukopenia;Nausea;Nephropathy;Neuropathy;Neuropathy peripheral;Rash;Serum sickness;Thrombocytopenia;Tongue discolouration;Urticaria;Vomiting,small molecule,approved,"(−)-penicillamine; (S)-2-amino-3-mercapto-3-methylbutanoic acid; (S)-3,3-dimethylcysteine; 3-mercapto-D-valine; D-(−)-penicillamine; D-penicillamine; D-β,β-dimethylcysteine; penicilamina; Penicillamine; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Copper,J01CE02;M01CC01
pentamidine,Acquired immunodeficiency syndrome;African trypanosomiasis;Autoimmune disorder;Hypersensitivity;Immunocompromised;Immunodeficiency;Kaposi's sarcoma;Leishmaniasis;Pneumocystis jirovecii pneumonia;Pneumonia;Renal failure;Renal impairment,Abdominal cramps;Abdominal pain;Abortion spontaneous;Abscess;Affect lability;Ageusia;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Anosmia;Anxiety;Arrhythmia;Arthralgia;Asthenia;Asthma;Azotaemia;Bad taste;Blepharitis;Blood creatinine increased;Blood urea increased;Body odor;Body temperature decreased;Body temperature increased;Bradycardia;Bronchitis;Bronchospasm;Candida infection;Cerebrovascular accident;Chest discomfort;Chest pain;Chest tightness;Chills;Coagulation time prolonged;Colitis;Confusional state;Conjunctivitis;Constipation;Convulsion;Coryza;Cough;Creatinine increased;Cyanosis;Cytomegalovirus chorioretinitis;Cytomegalovirus retinitis;Cytopenia;Decreased appetite;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Ear infection;Electrocardiogram QT prolonged;Electrocardiogram ST segment;Encephalitis viral;Eosinophilia;Erythema;Erythema multiforme;Extrapulmonary pneumocystosis;Extravasation;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flank pain;Flushing;Gagging;Gait disturbance;Gastric ulcer;Gastritis;Gastrointestinal pain;Gingivitis;Gout;Haematochezia;Haematuria;Haemoptysis;Hallucination;Headache;Hemianopia;Hepatic function abnormal;Hepatitis;Hepatomegaly;Herpes NOS;Herpes virus infection;Herpes zoster;Hiatus hernia;Histoplasmosis;Hyperglycaemia;Hyperkalaemia;Hypersensitivity;Hypertension;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypomagnesaemia;Hypotension;Hypothermia;Inappropriate antidiuretic hormone secretion;Incontinence;Induration;Infection;Influenza;Insomnia;Interstitial lung disease;Interstitial pneumonia;Ketoacidosis;Laryngitis;Laryngospasm;Leg edema;Lethargy;Leukopenia;Lightheadedness;Liver function test abnormal;Local reaction;Loss of consciousness;Lung disorder;Melaena;Memory loss;Meningitis cryptococcal;Mood swings;Mouth ulceration;Muscle necrosis;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nausea;Necrosis;Nephritis;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Neutropenia;Night sweats;Oedema peripheral;Oesophageal candidiasis;Oral candidiasis;Oral herpes;Otitis;Pain;Palpitations;Pancreatitis;Pancreatitis acute;Pancytopenia;Paraesthesia;Paranoia;Paresthesia of limbs;Pharyngitis;Phlebitis;Pleurisy;Pneumocystis jirovecii infection;Pneumonia bacterial;Pneumothorax;Pruritus;Psychotic disorder;Pulmonary congestion;Raised liver function tests;Rales;Rash;Renal failure;Renal failure acute;Renal impairment;Renal pain;Respiratory tract congestion;Retching;Rhabdomyolysis;Rhinitis;Salivary hypersecretion;Sepsis;Serum creatinine increased;Shock;Sinusitis;Skin exfoliation;Skin odour abnormal;Somnolence;Splenomegaly;Stevens-Johnson syndrome;Stomatitis;Syncope;Tachycardia;Tachypnoea;Tension;Thrombocytopenia;Tonsillitis;Torsade de pointes;Tremor;Tuberculosis;Unsteady gait;Urticaria;Vasculitis;Ventricular tachycardia;Vertigo;Vision blurred;Vomiting;Wheezing,small molecule,approved; investigational,"1,5-bis(4-amidinophenoxy)pentane; 4,4'-(1,5-pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(pentamethylenedioxy)dibenzamidine; 4,4'-Diamidinodiphenoxypentane; p,p'-(pentamethylenedioxy)dibenzamidine; Pentamidin; Pentamidina; Pentamidine; Pentamidinum; 3.4.21.59; TPS1; TPS2; TPSB1; Tryptase alpha-1; Tryptase I; Tryptase-1; 2.1.1.204; DNA (cytosine-5)-methyltransferase-like protein 2; DNA methyltransferase homolog HsaIIP; DNA MTase homolog HsaIIP; DNMT2; M.HsaIIP; PuMet; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; 20-HETE synthase; 20-hydroxyeicosatetraenoic acid synthase; CYP4A2; CYP4AII; CYPIVA11; Cytochrome P-450HK-omega; Cytochrome P450HL-omega; Fatty acid omega-hydroxylase; Lauric acid omega-hydroxylase; Long-chain fatty acid omega-monooxygenase",Tryptase alpha/beta-1; tRNA (cytosine(38)-C(5))-methyltransferase; DNA,P01CX01
pentazocine,Acute pain;Pain,Abdominal discomfort;Abdominal distress;Agitation;Agranulocytosis;Anaphylactic shock;Anorexia;Apnoea;Asthenia;Cardiovascular insufficiency;Chills;Circulatory depression;Confusional state;Constipation;Cramp muscle;Decreased appetite;Dermatitis;Diarrhoea;Diplopia;Disorientation;Dizziness;Drug dependence;Dry mouth;Dysgeusia;Dyspnoea;Eosinophilia;Erythema multiforme;Euphoric mood;Excitement;Face oedema;Feeling abnormal;Flushing;Grand mal convulsion;Hallucination;Headache;Hepatic function abnormal;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Induration;Insomnia;Irritability;Lightheadedness;Loss of consciousness;Miosis;Muscle spasms;Nausea;Nodule;Nystagmus;Paraesthesia;Pruritus;Pulmonary function test decreased;Respiratory depression;Shock;Somnolence;Sweating;Sweating increased;Syncope;Tachycardia;Tinnitus;Toxic epidermal necrolysis;Tremor;Tremor muscle;Ulcer;Urinary retention;Uterine contractions;Uterine contractions during pregnancy;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; vet_approved,Pentazocin; Pentazocina; Pentazocine; Pentazocinum; Aging-associated gene 8 protein; hSigmaR1; OPRS1; SIG-1R; Sigma 1-type opioid receptor; Sigma1-receptor; Sigma1R; SR-BP; SR31747-binding protein; SRBP; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; K-OR-1; KOR-1; OPRK; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1,Sigma non-opioid intracellular receptor 1; Mu-type opioid receptor; Kappa-type opioid receptor, N02AD01;N02AD01;N02AD51
pentobarbital,Cholera;Eclampsia;Insomnia;Meningitis;Status epilepticus;Tetanus,Agitation;Anaemia megaloblastic;Angioedema;Anxiety;Apnoea;Ataxia;Body temperature increased;Bradycardia;CNS depression NOS;Confusional state;Constipation;Depressed level of consciousness;Dermatitis;Dermatitis exfoliative;Dizziness;Feeling abnormal;Hallucination;Headache;Hepatocellular injury;Hyperkinesia;Hypersensitivity;Hypotension;Hypoventilation;Hypoxia;Injection site reaction;Liver injury;Loss of consciousness;Nausea;Nervousness;Nightmare;Rash;Respiratory failure;Shock;Somnolence;Syncope;Tension;Vomiting,small molecule,approved; investigational; vet_approved,"5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-ethyl-5-(1-methylbutyl)barbituric acid; 5-ethyl-5-(sec-pentyl)barbituric acid; Pentobarbital; Pentobarbitone; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; NACRA4; NACHRA7; AMPA-selective glutamate receptor 2; GluA2; GluR-2; GluR-B; GluR-K2; GLUR2; Glutamate receptor ionotropic, AMPA 2; EAA4; Excitatory amino acid receptor 4; GluK2; GluR-6; GLUR6; Glutamate receptor 6; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase","Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit alpha-4; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-6; GABA(A) Receptor; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit alpha-7; Glutamate receptor 2; Glutamate receptor ionotropic, kainate 2; NMDA receptor; Nuclear receptor subfamily 1 group I member 2", N05CA01;N05CA01;N05CB01
pentostatin,Hairy cell leukaemia,Abdominal pain;Abnormal dreams;Abnormal vision;Abscess;Acne;Acute leukaemia;Affect lability;Agitation;Agranulocytosis;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Angina pectoris;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Arthralgia;Arthritis;Asthenia;Asthma;Ataxia;Atrioventricular block;Bacterial infection;Blood creatinine increased;Body temperature increased;Bradycardia;Breast mass;Bronchitis;Bronchospasm;CNS toxicity;Calculus of kidney;Candida infection;Cardiac arrest;Cardiac failure;Cellulitis;Chest pain;Chills;Confusional state;Conjunctivitis;Constipation;Convulsion;Cough;Cough increased;Creatinine increased;Deafness;Decreased appetite;Depression;Dermatitis;Diarrhoea;Dizziness;Dry eye;Dry skin;Dysarthria;Dyspepsia;Dysphagia;Dyspnoea;Ear pain;Eczema;Encephalitis;Erectile dysfunction;Face oedema;Fatigue;Feeling abnormal;Flatulence;Foetor hepaticus;Fungal infection;Furuncle;Furunculosis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Gingivitis;Glossitis;Gout;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Hangover;Headache;Hepatic enzyme increased;Hepatocellular injury;Herpes simplex;Herpes zoster;Hostility;Hypercalcaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hyponatraemia;Hypotension;Ileus;Infection;Influenza like illness;Influenza-like symptoms;Insomnia;Kidney function abnormal;Labyrinthitis;Lacrimal disorder;Lacrimal structural disorder;Lacrimation increased;Laryngeal oedema;Leukopenia;Liver disorder;Liver function test abnormal;Loss of consciousness;Loss of libido;Lung disorder;Meningism;Mental disability;Mood swings;Muscle twitching;Musculoskeletal discomfort;Myalgia;Nausea;Neoplasm;Nephrolithiasis;Nephropathy;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neurosis;Neurotoxicity;Oedema peripheral;Osteoarthritis;Osteomyelitis;Pain;Paraesthesia;Paralysis;Pericardial effusion;Petechiae;Pharyngitis;Phlebitis;Photophobia;Photosensitivity reaction;Pneumonia;Pruritus;Pulmonary embolism;Raised liver function tests;Rash;Renal failure;Renal impairment;Retinal disorder;Rhinitis;Sepsis;Shock;Sinus arrest;Sinusitis;Skin disorder;Somnolence;Stomatitis;Sweating;Sweating increased;Syncope;Tachycardia;Tearing eyes;Tension;Thinking abnormal;Thrombocytopenia;Thrombophlebitis;Tinnitus;Upper respiratory tract infection;Urinary tract infection;Urogenital disorder;Urticaria;Uveitis;Vasculitis;Ventricular extrasystoles;Vertigo;Viral infection;Visual impairment;Vomiting,small molecule,approved; investigational,Co-vidarabine; Pentostatin; Pentostatina; Pentostatine; Pentostatinum; 3.5.4.4; ADA1; Adenosine aminohydrolase,Adenosine deaminase,L01XX08
pentoxifylline,Angiopathy;Arterial occlusive disease;Cardiovascular disorder;Diabetes mellitus;Diabetic;Gangrene;Intermittent claudication;Leg ulcer;Obstruction;Peripheral vascular disorder;Skin ulcer;Trophic disorders;Ulcer;Unspecified circulatory system disorder,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Agitation;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Asthenia;Back pain;Bad taste;Blood fibrinogen decreased;Body temperature increased;Bronchospasm;Chest pain;Cholecystitis;Cholestasis;Cholestasis intrahepatic;Confusional state;Conjunctivitis;Constipation;Convulsion;Cramps of lower extremities;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Ear pain;Emotional distress;Epistaxis;Eructation;Erythema;Feeling abnormal;Fibrinogen decreased;Flatulence;Flushing;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Heartburn;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza like illness;Influenza-like symptoms;Insomnia;Jaundice;Lacrimation;Lacrimation increased;Laryngitis;Leukaemia;Leukopenia;Lightheadedness;Malaise;Meningitis aseptic;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nausea;Nervousness;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Palpitations;Pancytopenia;Pruritus;Purpura;Rash;Salivary hypersecretion;Salivation;Scotoma;Shock;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Sweating;Swelling;Tachycardia;Tension;Thirst;Throat sore;Thrombocytopenia;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vascular purpura;Vision blurred;Vomiting,small molecule,approved; investigational,Oxpentifylline; Pentoxifilina; Pentoxifyllin; Pentoxifylline; Pentoxifyllinum; ADORA2; Cachectin; TNF-a; TNF-alpha; TNFA; TNFSF2; Tumor necrosis factor ligand superfamily member 2; 3.1.3.35; 3.1.3.5; 3.1.3.89; 3.1.3.91; 3.1.3.99; 5'-deoxynucleotidase; 5'-NT; Ecto-5'-nucleotidase; IMP-specific 5'-nucleotidase; NT5; NTE; Thymidylate 5'-phosphatase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase,Adenosine receptor A2a; Tumor necrosis factor; Phosphodiesterase enzymes; 5'-nucleotidase; Adenosine receptor A1, R03DA20;C04AD03
pergolide,Dyskinesia;Parkinson's disease;Parkinsonism,Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal vision;Abscess;Abscess periodontal;Accidental injury;Acidosis;Acute abdomen;Acute coronary syndrome;Acute lymphocytic leukaemia;Adenoma benign;Affect lability;Agitation;Akathisia;Akinesia;Alopecia;Amenorrhoea;Amnesia;Anaemia;Anaemia megaloblastic;Angina pectoris;Anorexia;Anxiety;Apathy;Aphthous stomatitis;Apnoea;Arrhythmia;Arthralgia;Arthritis;Asthenia;Asthma;Ataxia;Atrial fibrillation;Atrioventricular block;Back pain;Benign neoplasm of skin;Bladder cancer;Bladder carcinoma;Bladder pain;Blindness;Block heart;Blood uric acid increased;Body temperature decreased;Body temperature increased;Bone pain;Bone sarcoma;Bradycardia;Brain oedema;Breast cancer;Breast engorgement;Breast pain;Bronchitis;Bursitis;Cachexia;Calculus of kidney;Calculus urinary;Candida infection;Carcinoma breast;Carcinoma of lung;Cardiac arrest;Cardiac failure congestive;Cataract;Cellulitis;Cerebral haemorrhage;Cerebral ischaemia;Cerebrovascular accident;Cervix carcinoma;Chest pain;Chills;Cholecystitis;Cholelithiasis;Choreoathetosis;Colitis;Coma;Confusional state;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cyanosis;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Delirium;Delusion;Dental caries;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Duodenitis;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Eczema;Electrocardiogram abnormal;Electrolyte imbalance;Emphysema;Endocrine disorder;Enlargement abdomen;Eosinophilia;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Eruption lichenoid;Euphoric mood;Extrapyramidal disorder;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Facial paralysis;Faecal incontinence;Feeling abnormal;Fibrocystic breast disease;Flat affect;Flatulence;Fungal skin infection;Gait disturbance;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal pain;Gingivitis;Glaucoma;Glossitis;Gout;Haematemesis;Haematuria;Haemoptysis;Haemothorax;Hallucination;Headache;Hemiplegia;Hepatitis;Hepatomegaly;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hirsutism;Hostility;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypertension;Hypertonia;Hyperuricaemia;Hyperuricosuria;Hyperventilation;Hypoglycaemia;Hypogonadism;Hypokalaemia;Hypokinesia;Hypotension;Hypothermia;Hypothyroidism;Hypotonia;Hypoventilation;Hypoxia;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Influenza;Injury;Insomnia;Intestinal obstruction;Intracranial pressure increased;Iron deficiency anaemia;Jaundice;Laryngeal oedema;Laryngitis;Leukocytosis;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Lichenoid keratosis;Liver function test abnormal;Loss of consciousness;Lung neoplasm malignant;Lymphadenopathy;Lymphocytosis;Malaise;Mania;Manic psychosis;Melaena;Meningitis;Menopause;Menorrhagia;Mental disability;Metrorrhagia;Migraine;Mood swings;Muscle atrophy;Muscle relaxant therapy;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myelitis;Myocardial infarction;Myoclonus;Myositis;Nausea;Neck pain;Neoplasm;Nephrolithiasis;Nephrosis;Nephrotic syndrome;Nervousness;Neuralgia;Neuritis;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Neurosis;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Orthostatic hypotension;Osteomyelitis;Osteoporosis;Otitis media;Pain;Pain in jaw;Palpitations;Pancreatitis;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Pelvic pain;Peptic ulcer;Pericarditis;Personality disorder;Petechiae;Pharyngitis;Photophobia;Pleural effusion;Pneumonia;Pneumothorax;Pollakiuria;Polycythaemia;Priapism;Pruritus;Psychotic disorder;Pulmonary embolism;Pulmonary fibrosis;Pulmonary hypertension;Pulmonary oedema;Purpura;Pyelonephritis;Pyuria;Rash;Rash pustular;Renal failure;Respiratory failure;Retinal detachment;Retinal vascular disorder;Rhinitis;Salivary gland enlargement;Salpingitis;Scotoma;Seborrhoeic dermatitis;Sepsis;Shock;Sialoadenitis;Sinusitis;Skin cancer;Skin carcinoma;Skin discolouration;Skin mass;Skin nodule;Skin ulcer;Somnolence;Speech disorder;Splenomegaly;Stupor;Subcutaneous nodule;Sweating;Syncope;Systemic lupus erythematosus;Tachycardia;Tenosynovitis;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thyroid adenoma;Tinnitus;Tooth abscess;Torticollis;Tremor;Urethral pain;Uricaciduria;Urinary incontinence;Urinary retention;Urinary tract infection;Urolithiasis;Uterine haemorrhage;VIIth nerve paralysis;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Varicose vein;Vascular purpura;Vasculitis;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Visual impairment;Vomiting;Weight decreased;Weight increased;Withdrawal bleed,small molecule,approved; investigational; vet_approved; withdrawn,"Pergolida; Pergolide; Pergolidum; Dopamine D2 receptor; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D1 receptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",D(2) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; D(1B) dopamine receptor; D(1A) dopamine receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 1D; Alpha-2 adrenergic receptors; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 2C; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor,N04BC02
perhexiline,Angina pectoris;Anginal attack;Coronary artery disease;Diabetes mellitus;Diabetic,Abdominal pain;Anorexia;Asthenia;Ataxia;Balance disorder;Blood triglycerides increased;Cachexia;Convulsion;Decreased appetite;Dermatitis;Diplopia;Dizziness;Extrapyramidal disorder;Fatigue;Flushing;Gait disturbance;Gastrointestinal pain;Headache;Hepatitis;Hepatitis viral;Hepatocellular injury;Hyperhidrosis;Hypertriglyceridaemia;Hypoglycaemia;Insomnia;Lassitude;Liver injury;Loss of consciousness;Muscular weakness;Nausea;Nervousness;Neuropathy peripheral;Optic neuritis;Papilloedema;Paraesthesia;Polyneuropathy;Polyradiculoneuritis;Rash;Shock;Sweating;Syncope;Tension;Torsade de pointes;Tremor;Unsteadiness;Urogenital disorder;Urticaria;Vomiting;Walking disability;Weight decreased,small molecule,approved; investigational,"Perhexilene; Perhexilina; Perhexiline; Perhexilinum; 2.3.1.21; Carnitine O-palmitoyltransferase I, liver isoform; Carnitine palmitoyltransferase 1A; CPT I; CPT1; CPT1-L; CPTI-L; Succinyltransferase CPT1A; 2.3.1.21; Carnitine O-palmitoyltransferase I, muscle isoform; Carnitine palmitoyltransferase 1B; Carnitine palmitoyltransferase I-like protein; CPT I; CPT1-M; CPTI-M; KIAA1670; 2.3.1.21; Carnitine palmitoyltransferase II; CPT II; CPT1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase","Carnitine O-palmitoyltransferase 1, liver isoform; Carnitine O-palmitoyltransferase 1, muscle isoform; Carnitine O-palmitoyltransferase 2, mitochondrial; Voltage-gated inwardly rectifying potassium channel KCNH2",C08EX02
propericiazine,Aggression;Agitation;Anxiety;Psychotic disorder;Schizophrenia;Tension;Violent,"Abnormal pigmentation;Aggression;Agitation;Agranulocytosis;Akathisia;Akinesia;Altered state of consciousness;Amenorrhoea;Angioedema;Arrhythmia;Arrhythmia supraventricular;Asthma;Atrial arrhythmia;Atrioventricular block;Autonomic nervous system imbalance;Body temperature increased;Cardiac disorder;Cardiac fibrillation;Confusional state;Consciousness abnormal;Constipation;Deep vein thrombosis;Dental caries;Dermatitis;Diarrhoea;Drowsiness;Dry mouth;Dyskinesia;Dyspnoea;Electrocardiogram ST segment depression;Electrocardiogram U wave present;Electrocardiogram U-wave abnormality;Embolism venous;Eosinophilia;Erectile dysfunction;Galactorrhoea;Glaucoma;Gynaecomastia;Hyperglycaemia;Hyperhidrosis;Hyperprolactinaemia;Hyperpyrexia;Hypersensitivity;Hypokalaemia;Hypotension;Ileus paralytic;Increased appetite;Infection;Insomnia;Jaundice;Jaundice cholestatic;Labile blood pressure;Laryngeal oedema;Liver injury;Menorrhagia;Menstruation irregular;Movements involuntary;Muscle rigidity;Nasal congestion;Nausea;Neuroleptic malignant syndrome;Oedema;Parkinsonism;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pneumonia;Pneumonia hypostatic;Pregnancy test false positive;Priapism;Prolonged menses;Protrusion tongue;Pulmonary embolism;Pulmonary function test decreased;Rash;Respiratory depression;Somnolence;Sudden death;Sudden death, cause unknown;Sweating increased;Tachycardia;Tardive dyskinesia;Toxic confusional state;Traumatic liver injury;Tremor;Venous thromboembolism;Ventricular tachycardia;Vision blurred;Vomiting;Weight increased",small molecule,approved; investigational,10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile; 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine; 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine; Periciazina; Périciazine; Periciazine; Periciazinum; Pericyazine; Piperocyanomazine; Propericiazine; Dopamine D1 receptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4,D(1A) dopamine receptor; Alpha-2A adrenergic receptor; Alpha-1B adrenergic receptor; Androgen receptor,N05AC01
perphenazine,Electroencephalogram abnormal;Nausea;Schizophrenia;Vomiting,Abnormal dreams;Ache;Agitation;Agranulocytosis;Akathisia;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorexia;Asphyxia;Asthma;Ataxia;Bizarre dreams;Blood disorder;Body temperature increased;Bradycardia;Brain oedema;Breast enlargement;Breast enlargement female;Cardiac arrest;Catatonia;Cholestasis;Confusional state;Constipation;Convulsion;Convulsive seizure;Cough;Decreased appetite;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Dizziness;Drowsiness;Dry mouth;Dysarthria;Dyskinesia;Dysphagia;Dyspnoea;Eczema;Edema cerebral;Eosinophilia;Erythema;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Faecalith;Faecaloma;Galactorrhoea;Glaucoma;Glycosuria;Gynaecomastia;Haemolytic anaemia;Headache;Hepatitis A;Hepatocellular injury;Hyperglycaemia;Hyperkinesia;Hyperphagia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoglycaemia;Hypotension;Hypotensive;Ileus paralytic;Inappropriate antidiuretic hormone secretion;Incontinence;Infection;Insomnia;Jaundice;Jaundice cholestatic;Laryngeal oedema;Lenticular opacities;Lethargy;Leukopenia;Liver injury;Loss of consciousness;Lupus erythematosus;Motor restlessness;Movements involuntary;Muscle spasms;Muscular weakness;Mydriasis;Nasal congestion;Neurogenic bladder;Neuroleptic malignant syndrome;Nocturnal confusion;Numbness of limbs;Obstipation;Oculogyric crisis;Oedema peripheral;Opisthotonus;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Pain;Pallor;Pancytopenia;Paralysis of bladder;Parkinsonism;Parotid gland enlargement;Parotid swelling;Photophobia;Photosensitivity;Photosensitivity reaction;Polyuria;Pregnancy test false positive;Protrusion tongue;Pruritus;Psychotic disorder;Retinal disorder;Salivary hypersecretion;Salivation;Shock;Slurred speech;Somnolence;Sudden death;Syncope;Systemic lupus erythematosus;Tachycardia;Tardive dyskinesia;Throat sore;Throat tightness;Thrombocytopenic purpura;Torticollis;Trismus;Urinary retention;Urine output increased;Urticaria;Vision blurred,small molecule,approved,"2-(4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol; 2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine; 4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol; 4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazineethanol; Chlorpiprazine; Etaperazin; Etaperazine; Ethaperazine; Perfenazina; Perfenazine; Perphenazin; Perphénazine; Perphenazine; Perphenazinum; γ-(4-(β-hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; Dopamine D2 receptor; Dopamine D1 receptor; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",D(2) dopamine receptor; D(1A) dopamine receptor; Calmodulin,N05AB03
phenobarbital,Agitation;Anxiety;Cardiac failure;Cerebral haemorrhage;Cholera;Chorea;Convulsion;Eclampsia;Epilepsy;Essential hypertension;Excitability;Febrile convulsion;Haemoglobin;Haemorrhage;Hyperthyroidism;Insomnia;Labyrinthitis;Meningitis;Motion sickness;Nausea;Partial seizures;Pylorospasm;Status epilepticus;Tension;Tetanus;Vomiting,Affect lability;Agitation;Anaemia megaloblastic;Angioedema;Anxiety;Apnoea;Arthralgia;Arthritic pains;Asthma;Ataxia;Blister;Body temperature decreased;Body temperature increased;Bradycardia;CNS depression NOS;Coma;Confusional state;Congenital anomaly;Constipation;Delirium;Depressed level of consciousness;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Developmental delay;Dizziness;Drowsiness;Emotional disorder;Emotional disturbance NOS;Erythema;Erythema multiforme;Excitement;Extravasation;Feeling abnormal;Folate deficiency;Hallucination;Hangover;Headache;Hepatitis;Hepatocellular injury;Hyperkinesia;Hypersensitivity;Hypocalcaemia;Hypotension;Hypothermia;Hypoventilation;Hypoxia;Injection site reaction;Irritability;Laryngospasm;Lethargy;Liver injury;Localised oedema;Loss of consciousness;Mental disability;Mood swings;Musculoskeletal discomfort;Myalgia;Nausea;Necrosis;Nervousness;Nightmare;Nystagmus;Osteomalacia;Pain;Phobia;Pulmonary function test decreased;Rash;Renal failure;Respiratory depression;Respiratory failure;Shock;Somnolence;Stevens-Johnson syndrome;Suicidal behaviour;Suicidal ideation;Syncope;Tension;Thinking abnormal;Toxic epidermal necrolysis;Urticaria;Vertigo;Vitamin K deficiency;Vomiting,small molecule,approved; investigational,"5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione; 5-Ethyl-5-phenylbarbituric acid; 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Phenyl-5-ethylbarbituric acid; Fenobarbital; Phenobarbital; Phenobarbitol; Phenobarbitone; Phenobarbituric Acid; Phenyläthylbarbitursäure; Phenylethylbarbiturate; Phenylethylbarbituric Acid; Phenylethylbarbitursäure; Phenylethylmalonylurea; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; NACRA4; NACHRA7; AMPA-selective glutamate receptor 2; GluA2; GluR-2; GluR-B; GluR-K2; GLUR2; Glutamate receptor ionotropic, AMPA 2; EAA4; Excitatory amino acid receptor 4; GluK2; GluR-6; GLUR6; Glutamate receptor 6; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIVB1; Cytochrome P450-HP; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; OATP2A1; PGT; PHOAR2; Prostaglandin transporter; SLC21A2; SLCO2A1; Solute carrier family 21 member 2; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2","Gamma-aminobutyric acid receptor subunit alpha-1; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit alpha-7; Glutamate receptor 2; Glutamate receptor ionotropic, kainate 2; NMDA receptor; Nuclear receptor subfamily 1 group I member 2", N03AA02;N03AA02;N05CB01
phentermine,Diabetes mellitus;Glucose tolerance impaired;Insulin resistant diabetes;Obesity;Sleep apnoea syndrome;Weight decreased,Abdominal cramps;Abdominal pain;Acute coronary syndrome;Agitation;Allergic urticaria;Angina pectoris;Asthenia;Cardiac arrest;Cardiac failure;Cardiac valve disease;Cerebrovascular accident;Chest pain;Constipation;Dependence;Dermatitis;Diarrhoea;Digestion impaired;Dizziness;Drug abuse;Dry mouth;Dyspepsia;Dysphoria;Dyspnoea exertional;Erectile dysfunction;Euphoric mood;Fatigue;Gastrointestinal disorder;Hallucination;Headache;Hypertension;Insomnia;Myocardial infarction;Nausea;Nervousness;Oedema;Palpitations;Precordial pain;Primary pulmonary hypertension;Psychotic disorder;Psychotic episode;Pulmonary arterial hypertension;Pulmonary hypertension;Rash;Tachycardia;Tension;Tremor;Urticaria;Vomiting,small molecule,approved; illicit,"alpha,alpha-Dimethylphenethylamine; Fentermina; Phentermine; Phentermine resin; Phenterminum; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; Sodium-dependent dopamine transporter; Amine oxidase [flavin-containing] A; Amine oxidase [flavin-containing] B; Pro-neuropeptide Y, A08AA51;A08AA01
phenylephrine,Accommodation disorder;Cardiovascular disorder;Cycloplegia;Hypersensitivity;Hypertension;Hypertensive;Iris adhesions;Mydriasis;Open angle glaucoma;Paroxysmal supraventricular tachycardia;Posterior synechiae of iris;Shock;Supraventricular tachycardia;Uveitis,Abdominal pain upper;Acute coronary syndrome;Agitation;Angiopathy;Arrhythmia;Arteriospasm coronary;Atrioventricular block;Blanching;Blanching of skin;Blood pressure increased;Bradycardia;Cardiac disorder;Chest pain;Corneal oedema;Dizziness;Dyspnoea;Epigastric pain;Excitability;Extrasystoles;Extravasation;Eye pain;Gastrointestinal disorder;Headache;Hyperaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertensive crisis;Immune system disorder;Ischaemia;Keratitis;Lacrimation;Lacrimation increased;Loss of consciousness;Mediastinal disorder;Mental disorder;Miosis;Myocardial infarction;Myocardial ischaemia;Nausea;Neck pain;Nervous system disorder;Nervousness;Orthostatic hypotension;Pain;Pallor;Palpitations;Paraesthesia;Photophobia;Piloerection;Pruritus;Pulmonary oedema;Rales;Reflex bradycardia;Sensitisation;Shock;Skin disorder;Skin exfoliation;Skin necrosis;Stinging;Subarachnoid haemorrhage;Sweating increased;Syncope;Tachycardia;Tension;Trembling;Tremor;Underweight;Unspecified disorder of skin and subcutaneous tissue;Ventricular arrhythmia;Ventricular extrasystoles;Vision blurred;Vitreous floaters;Vomiting,small molecule,approved,"(−)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol; Fenilefrina; l-(3-Hydroxyphenyl)-N-methylethanolamine; Phenylephrine; Phenylephrinum; R(-)-Phenylephrine; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Dopamine D2 receptor; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 2.8.2.1; Aryl sulfotransferase 1A3/1A4; Catecholamine-sulfating phenol sulfotransferase; HAST3; M-PST; Monoamine-sulfating phenol sulfotransferase; Placental estrogen sulfotransferase; ST1A3; STM; Sulfotransferase 1A3/1A4; Sulfotransferase, monoamine-preferring; Thermolabile phenol sulfotransferase; TL-PST; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",Alpha-1A adrenergic receptor; D(2) dopamine receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor, C01CA06; C05AX06; R01AA04; R01AB01; R01BA03; R01BA53; S01FB51; S01GA05; S01GA55;C01CA06;S01FB01
phenylpropanolamine,Ache;Body temperature increased;Common cold;Cough;Discomfort;Headache;Hypersensitivity;Nasal congestion;Nasopharyngitis;Pain;Rhinitis;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Sinusitis;Sneezing,Agitation;Antitussive therapy;Anxiety;Arrhythmia;Ataxia;Blood pressure increased;Confusional state;Constipation;Coordination abnormal;Cough suppression;Dermatitis;Dizziness;Drowsiness;Dyskinesia;Dysphoria;Dyspnoea;Euphoric mood;Feeling abnormal;Flushing;Hallucination;Hepatocellular injury;Hypersensitivity;Hypotension;Insomnia;Irritability;Liver injury;Nausea;Nephrosis lower nephron;Nervousness;Psychotic disorder;Pulmonary function test decreased;Rash;Renal tubular necrosis;Respiratory depression;Serotonin syndrome;Somnolence;Tachycardia;Tension;Tremor;Urinary hesitation;Urinary retention;Vision blurred;Vomiting,small molecule,approved; vet_approved; withdrawn,(+-)-Norephedrine; (+-)-Phenylpropanolamine; Fenilpropanolamina; Norephedrine; Phenylpropanolamin; Phenylpropanolamina; Phenylpropanolamine; Phénylpropanolamine; Phenylpropanolaminum; PPA; Dopamine D1 receptor; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A,D(1A) dopamine receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Alpha-2 adrenergic receptors, R01BA01;A08AA07;R01BA51
moxonidine,Hypertension,Abdominal pain;Angioedema;Anxiety;Asthenia;Back pain;Bronchitis;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Gastrointestinal pain;Headache;Hypotension;Infection;Insomnia;Nausea;Oedema peripheral;Orthostatic hypotension;Pain;Pharyngitis;Pruritus;Rash;Sinusitis;Sleep disorder;Sleep disturbance;Somnolence;Urticaria;Vertigo,small molecule,approved; investigational,"(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid; Moxonidina; Moxonidine; Moxonidinum; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; hIRAS; I-1; I-1 receptor candidate protein; I1R; I1R candidate protein; Imidazoline receptor 1; Imidazoline receptor antisera-selected protein; Imidazoline-1 receptor; Imidazoline-1 receptor candidate protein; IR1; IRAS; KIAA0975",Alpha-2C adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2A adrenergic receptor; Nischarin, C02LC05;C02AC05
physostigmine,Anticholinergic syndrome,Bradycardia;Convulsion;Nausea;Salivary hypersecretion;Salivation;Vomiting,small molecule,approved; investigational,Eserine; Physostigmine; Physostol; 3.1.1.7; AChE; NACRA4,Acetylcholinesterase; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2, V03AB19;S01EB05
vitamin,Biliary fistula;Coagulation factor decreased;Coagulopathy;Coeliac disease;Colitis ulcerative;Cystic fibrosis;Enteritis;Factor II deficiency;Gastrointestinal disorder;Haemoglobin;Haemorrhage;Haemorrhagic disease of newborn;Hypoprothrombinaemia;Hypovitaminosis;Jaundice cholestatic;Malabsorption;Proctocolitis;Sprue;Unspecified disorder of intestine;Vitamin K deficiency,Anaphylactic shock;Anaphylactoid reaction;Atrophy;Cyanosis;Dizziness;Dyspnoea;Erythema;Flushing;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypotension;Immune system disorder;Inflammation;Injection site pain;Injection site reaction;Injection site tenderness;Necrosis;Pain;Phlebitis;Pulse abnormal;Pulse pressure decreased;Scleroderma;Sweating;Sweating increased;Swelling;Thready pulse,small molecule,approved; nutraceutical; vet_approved,"(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; all-trans-retinol; all-trans-retinyl alcohol; all-trans-vitamin A alcohol; Retinol; Retinolum; Vitamin A1; NR2B3; Nuclear receptor subfamily 2 group B member 3; Retinoid X receptor gamma; Apo-D; ApoD; 5.3.99.2; Beta-trace protein; Cerebrin-28; Glutathione-independent PGD synthase; L-PGDS; Lipocalin-type prostaglandin-D synthase; PDS; PGD2 synthase; PGDS; PGDS2; Prostaglandin-D2 synthase; 1.1.1.300; All-trans and 9-cis retinol dehydrogenase; SDR7C2; Short chain dehydrogenase/reductase family 7C member 2; 1.1.1.209; 1.1.1.315; 1.1.1.53; 11-cis RDH; 11-cis retinol dehydrogenase; 11-cis RoDH; 9-cis retinol dehydrogenase; 9cRDH; HSD17B9; RDH1; SDR9C5; Short chain dehydrogenase/reductase family 9C member 5; 1.1.1.300; SDR7C3; Short chain dehydrogenase/reductase family 7C member 3; 1.2.1.36; Aldehyde dehydrogenase family 1 member A2; ALDH1A2; RALDH 2; RALDH(II); RALDH2; Retinaldehyde-specific dehydrogenase type 2; 1.2.1.19; 1.2.1.28; 1.2.1.3; 1.2.1.36; 3-deoxyglucosone dehydrogenase; ALDC; Aldehyde dehydrogenase family 1 member A1; Aldehyde dehydrogenase, cytosolic; ALDH-E1; ALDH1; ALHDII; PUMB1; RALDH 1; RalDH1; Retinal dehydrogenase 1; 2.3.1.135; Phosphatidylcholine--retinol O-acyltransferase; 1.1.1.300; DD83.1; RDH17; Retinal short-chain dehydrogenase/reductase 1; Retinol dehydrogenase 17; retSDR1; SDR16C1; Short chain dehydrogenase/reductase family 16C member 1; 1.2.1.36; Aldehyde dehydrogenase 6; Aldehyde dehydrogenase family 1 member A3; ALDH1A3; ALDH6; RALDH-3; RalDH3; 1.3.99.23; All-trans-13,14-dihydroretinol saturase; PPAR-alpha-regulated and starvation-induced gene protein; PPSIG; RetSat; 1.1.1.300; Androgen-regulated short-chain dehydrogenase/reductase 1; ARSDR1; HCV core-binding protein HCBP12; Prostate short-chain dehydrogenase/reductase 1; PSDR1; RalR1; Retinal reductase 1; SDR7C1; Short chain dehydrogenase/reductase family 7C member 1; 1.1.1.184; CR; humNRDR; NADPH-dependent carbonyl reductase; NADPH-dependent retinol dehydrogenase/reductase; NRDR; Peroxisomal short-chain alcohol dehydrogenase; Protein SDR25C2; PSCD; SCAD-SRL; SDR25C2; Short chain dehydrogenase/reductase family 25C member 2; Short-chain dehydrogenase/reductase family member 4; 1.1.1.300; Alcohol dehydrogenase PAN2; PAN2; SDR7C4; Short chain dehydrogenase/reductase family 7C member 4; 1.1.1.300; Photoreceptor outer segment all-trans retinol dehydrogenase; PRRDH; SDR28C2; Short chain dehydrogenase/reductase family 28C member 2; 1.14.13.-; CYP26; CYP26A1; Cytochrome P450 retinoic acid-inactivating 1; Cytochrome P450RAI; hP450RAI; P450RAI1; Retinoic acid 4-hydroxylase; Retinoic acid-metabolizing cytochrome; Cellular retinaldehyde-binding protein; CRALBP; Interphotoreceptor retinoid-binding protein; Interstitial retinol-binding protein; IRBP; Cellular retinol-binding protein; Cellular retinol-binding protein I; CRBP; CRBP-I; CRBP1; Cellular retinol-binding protein III; CRBP-III; HRBPiso; Cellular retinoic acid-binding protein 4; Cellular retinoic acid-binding protein IV; CRABP-IV; CRABP4; CRBP4; Plasma retinol-binding protein; PRBP; RBP; Cellular retinol-binding protein II; CRBP-II; CRBP2; Retinol-binding protein receptor STRA6; Stimulated by retinoic acid gene 6 protein homolog","Retinoic acid receptor RXR-gamma; Apolipoprotein D; Prostaglandin-H2 D-isomerase; Retinol dehydrogenase 12; Retinol dehydrogenase 5; Retinol dehydrogenase 13; Retinal dehydrogenase 2; Aldehyde dehydrogenase 1A1; Lecithin retinol acyltransferase; Short-chain dehydrogenase/reductase 3; Retinaldehyde dehydrogenase 3; All-trans-retinol 13,14-reductase; Retinol dehydrogenase 11; Dehydrogenase/reductase SDR family member 4; Retinol dehydrogenase 14; Retinol dehydrogenase 8", A11CA01; D10AD02; R01AX02; V04CB01;B02BA01;S01XA02
pilocarpine,Acute angle-closure glaucoma;Angle closure glaucoma;Cardiovascular disorder;Dry mouth;Glaucoma;Miosis;Myopia;Neoplasm malignant;Ocular hypertension;Open angle glaucoma;Sjogren's syndrome;Tension,"Abdominal pain;Abnormal dreams;Abnormal platelets;Abnormal vision;Accidental injury;Acute coronary syndrome;Affect lability;Ageusia;Agitation;Alopecia;Amblyopia;Angina pectoris;Anorexia;Anxiety;Aphasia;Arrhythmia;Arthralgia;Arthritis;Asthenia;Atrioventricular block;Back pain;Blepharospasm;Body odor;Body temperature decreased;Body temperature increased;Bone disorder;Bradycardia;Breast pain;Bronchitis;Bronchoconstriction;Bronchospasm;Candida infection;Cataract;Chest pain;Chills;Cholelithiasis;Ciliary muscle spasm;Colitis;Confusional state;Congenital anomaly;Conjunctivitis;Constipation;Cough;Cough increased;Cramps of lower extremities;Cyst;Deafness;Decreased appetite;Delusion;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Developmental delay;Diarrhoea;Discomfort;Dizziness;Dry eye;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear disorder;Ear pain;Eczema;Epistaxis;Eructation;Erythema nodosum;Eye disorder;Eye haemorrhage;Eye irritation;Eye pain;Face oedema;Feeling abnormal;Flatulence;Flushing;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gingivitis;Glossitis;Haematuria;Haemorrhage intracranial;Hallucination, visual;Headache;Hepatitis;Herpes simplex;Hiccups;Hyperbilirubinaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoglycaemia;Hypotension;Hypothermia;Increased appetite;Increased bronchial secretion;Infection;Influenza;Injury;Insomnia;Keratitis;Lacrimal disorder;Lacrimal structural disorder;Lacrimation;Lacrimation increased;Laryngitis;Laryngospasm;Lenticular opacities;Leukopenia;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Macular hole;Mastitis;Melaena;Menorrhagia;Mental disability;Metrorrhagia;Micturition urgency;Migraine;Mood swings;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Nausea;Neck pain;Neck stiffness;Nervousness;Nuchal rigidity;Oedema;Oedema peripheral;Oesophagitis;Ovarian disorder;Overactivity;Pain;Palpitations;Pancreatitis;Paraesthesia;Parotid gland enlargement;Pharyngitis;Photosensitivity reaction;Platelet disorder;Pneumonia;Pollakiuria;Presyncope;Pruritus;Pulmonary oedema;Pyuria;Rash;Rash pustular;Retinal detachment;Retinal disorder;Rhinitis;Salivary gland enlargement;Salivary hypersecretion;Salivation;Salpingitis;Seborrhoeic dermatitis;Shock;Sinusitis;Skin odour abnormal;Skin ulcer;Somnolence;Speech disorder;Sputum increased;Stinging;Stomatitis;Stridor;Sweating;Syncope;Syncope vasovagal;Tachycardia;Tendon disorder;Tenosynovitis;Tension;Thinking abnormal;Thrombocytopenia;Thrombocytosis;Thrombosis;Tinnitus;Tongue disorder;Tooth disorder;Tremor;Urethral pain;Urinary incontinence;Urinary tract infection;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vesiculobullous rash;Viral infection;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;WBC abnormal NOS;White blood cell disorder;Yawning",small molecule,approved; investigational,"2(3H)-FURANONE, 3-ETHYLDIHYDRO-4-((1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-, (3S-CIS)-; OCUCARPINE; Pilocarpina; Pilocarpine; PILOKARPIN; SPERSACARPINE; SYNCARPINE; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 3.1.1.2; 3.1.1.81; 3.1.8.1; A-esterase 1; Aromatic esterase 1; K-45; PON; PON 1; Serum aryldialkylphosphatase 1",Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M5; Muscarinic acetylcholine receptor M4, S01EB01; S01EB51;N07AX01
pindolol,Angina pectoris;Arrhythmia;Atrial fibrillation;Atrial fibrillation and flutter;Atrial flutter;Atrial tachycardia;Cardiac fibrillation;Extrasystoles;Hyperkinetic heart syndrome;Hypertension;Hypertensive;Neurocirculatory asthenia;Sinus tachycardia;Somatoform disorder cardiovascular;Supraventricular extrasystoles;Supraventricular tachycardia;Tachycardia;Tachycardia paroxysmal;Ventricular extrasystoles,Abdominal discomfort;Abdominal pain;Abnormal dreams;Ache;Aggression;Angiopathy;Anxiety;Arthralgia;Asthenia;Atrioventricular block;Atrioventricular block second degree;Block heart;Bradycardia;Bronchospasm;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Chest pain;Claudication;Conduction disorder;Confusional state;Conjunctivitis;Constipation;Coronary artery insufficiency;Cramp muscle;Depression;Dermatitis;Dermatitis psoriasiform;Diarrhoea;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Dyspnoea;Erectile dysfunction;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Heartburn;Hot flush;Hyperhidrosis;Hypotension;Insomnia;Intermittent claudication;Keratitis;Lethargy;Lightheadedness;Loss of consciousness;Mediastinal disorder;Menopausal symptoms;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Nausea;Nervous system disorder;Nervousness;Nightmare;Ocular discomfort;Oculomucocutaneous syndrome;Oedema;Orthostatic hypotension;Pain;Palpitations;Paraesthesia;Peripheral coldness;Pollakiuria;Pruritus;Psoriasis;Rash;Shock;Sleep disorder;Sleep disturbance;Somnolence;Sweating;Syncope;Tachycardia;Tension;Tinnitus;Transaminases increased;Tremor;Vertigo;Visual disturbance;Visual impairment;Vivid dreams;Vomiting;Weight increased;Wheezing,small molecule,approved; investigational,"1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; 4-(2-hydroxy-3-isopropylaminopropoxy)-indole; Pindolol; Pindololum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.8.2.1; Aryl sulfotransferase 1; HAST1/HAST2; P-PST 1; Phenol sulfotransferase 1; Phenol-sulfating phenol sulfotransferase 1; ST1A1; ST1A3; STP; STP1; Thermostable phenol sulfotransferase; Ts-PST; 2.8.2.1; Aryl sulfotransferase 2; P-PST 2; Phenol sulfotransferase 2; Phenol-sulfating phenol sulfotransferase 2; ST1A2; STP2; 2.8.2.1; Aryl sulfotransferase 1A3/1A4; Catecholamine-sulfating phenol sulfotransferase; HAST3; M-PST; Monoamine-sulfating phenol sulfotransferase; Placental estrogen sulfotransferase; ST1A3; STM; Sulfotransferase 1A3/1A4; Sulfotransferase, monoamine-preferring; Thermolabile phenol sulfotransferase; TL-PST; 2.8.2.1; Aryl sulfotransferase 1A3/1A4; ST1A4; Sulfotransferase 1A3/1A4; 2.8.2.1; ST1B1; ST1B2; Sulfotransferase 1B2; Sulfotransferase family cytosolic 1B member 1; SULT1B2; Thyroid hormone sulfotransferase; 2.8.2.1; humSULTC2; ST1C2; Sulfotransferase 1C1; SULT1C#1; SULT1C1; 2.8.2.1; 2.8.2.2; ST1C3; 2.8.2.1; ST1C4; Sulfotransferase 1C2; SULT1C#2; SULT1C2; 2.8.2.2; Bile salt sulfotransferase; Dehydroepiandrosterone sulfotransferase; DHEA-ST; DHEA-ST8; HST; Hydroxysteroid Sulfotransferase; ST2; ST2A1; STD; SULT2A3; 2.8.2.-; Brain sulfotransferase-like protein; hBR-STL; hBR-STL-1; Nervous system sulfotransferase; NST; ST4A1; SULTX3; ST6B1; Thyroxine sulfotransferase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; hOCT2; OCT2; Organic cation transporter 2",Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Beta-3 adrenergic receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B, C07AA03;C07AA03;C07CA03
pioglitazone,Anovulatory cycle;Carcinogenicity;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Diabetes mellitus;Diabetic ketoacidosis;Foetor hepaticus;Hepatocellular injury;Insulin resistance;Liver disorder;Macroangiopathy;Macrovascular disease;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Weight decreased,Abdominal pain upper;Abnormal vision;Accidental injury;Acute coronary syndrome;Alanine aminotransferase increased;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Arthralgia;Asthenia;Back pain;Bladder cancer;Bladder neoplasm;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Breast disorder;Breast feeding;Bronchitis;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cerebrovascular accident;Chest pain;Congenital anomaly;Connective tissue disorder;Cramps of lower extremities;Cyst;Developmental delay;Diabetes mellitus;Diabetes mellitus exacerbated;Diabetic;Diarrhoea;Discomfort;Dizziness;Drug-induced liver injury;Dyspnoea;Ear and labyrinth disorders;Electrocardiogram abnormal;Erectile dysfunction;Eye disorder;Fatal outcomes;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Fracture;Gastroenteritis;Gastrointestinal disorder;Generalised oedema;Glycosuria;Glycosylated haemoglobin decreased;Haematuria;Headache;Hepatic enzyme decreased;Hepatic enzyme increased;Hepatic failure;Hepatic impairment;Hepatitis;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoglycaemia;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Ischaemia;Liver disorder;Liver function test abnormal;Macular oedema;Malaise;Malnutrition;Mediastinal disorder;Multiple fractures;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Neoplasm;Nervous system disorder;Oedema;Oedema peripheral;Pain in extremity;Pharyngitis;Pitting edema;Polyp;Pregnancy;Protein urine present;Proteinuria;Pulmonary oedema;Respiratory tract infection;Sinusitis;Skin disorder;Sweating;Tooth abscess;Tooth disorder;Transient ischaemic attack;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vertigo;Visual acuity reduced;Visual disturbance;Visual impairment;Volume blood increased;Volume plasma increased;Weight decreased;Weight increased;Worsening of diabetes,small molecule,approved; investigational,"(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; Pioglitazona; Pioglitazone; Pioglitazonum; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Peroxisome proliferator-activated receptor gamma; Amine oxidase [flavin-containing] B, A10BD05; A10BD06; A10BD12; A10BG03;A10BD09;A10BG03
piperacillin,Abdominal infection;Bacteraemia;Bacterial infection;Bone and joint infections;Cystic fibrosis;Endometritis;Genital infection female;Gynecological infection;Infection;Infection mixed;Lower respiratory tract infection;Parametritis;Pelvic inflammatory disease;Sepsis;Septicemia;Urethritis;Urethritis gonococcal;Urethritis noninfective;Urinary tract infection,Abdominal pain;Activated partial thromboplastin time prolonged;Agranulocytosis;Alanine aminotransferase increased;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Arthralgia;Aspartate aminotransferase increased;Asthenia;Bleeding time prolonged;Blood albumin decreased;Blood alkaline phosphatase increased;Blood bilirubin increased;Blood creatinine increased;Blood glucose decreased;Blood potassium decreased;Blood urea increased;Body temperature increased;Bone disorder;Candida infection;Chills;Constipation;Convulsion;Coombs direct test positive;Deep vein thrombosis;Dermatitis;Dermatitis bullous;Diarrhoea;Diarrhoea haemorrhagic;Dizziness;Drug fever;Drug interaction;Dry mouth;Dyspepsia;Ecchymosis;Eczema;Eosinophilia;Epistaxis;Eruption;Erythema;Erythema multiforme;Fatigue;Flushing;Foetor hepaticus;Gamma-glutamyltransferase increased;Gastrointestinal pain;Haematoma;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hepatitis;Hepatitis cholestatic;Hepatocellular injury;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypokalaemia;Hypotension;Hypotonia;Immune system disorder;Induration;Infestation;Infestation NOS;Injection site reaction;Insomnia;Jaundice;Leukopenia;Liver disorder;Local reaction;Loose stools;Malnutrition;Muscle relaxation;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nausea;Nephritis interstitial;Nervous system disorder;Neutropenia;Oedema;Pain;Pancytopenia;Phlebitis;Prothrombin level increased;Pruritus;Pseudomembranous colitis;Purpura;Rash;Renal failure;Rigors;Serum potassium decreased;Shock;Skin disorder;Stevens-Johnson syndrome;Stomatitis;Superinfection;Sweating increased;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vascular purpura;Vomiting,small molecule,approved,"(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Piperacilina; Piperacillin; Piperacillin anhydrous; Piperacillina; Pipéracilline; Piperacillinum; Putative D-alanyl-D-alanine carboxypeptidase; pbp2b; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Penicillin-binding protein 3; Penicillin-binding protein 2B; Penicillin-binding protein 2a; Penicillin-binding protein 1b, J01CA12;J01CA12;J01CR50
pirbuterol,Asthma;Bronchospasm,Abdominal pain;Agitation;Alopecia;Anorexia;Anxiety;Asthenia;Back pain;Chest pain;Confusional state;Contusion;Cough;Cramp muscle;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Drowsiness;Dry mouth;Dysphonia;Extrasystoles;Fatigue;Feeling abnormal;Flushing;Gastrointestinal pain;Glossitis;Headache;Hoarseness;Hyperkinesia;Hypoaesthesia;Hypotension;Insomnia;Ischaemia;Loss of consciousness;Migraine;Muscle spasms;Nasal congestion;Nausea;Nervousness;Numbness;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Palpitations;Productive cough;Pruritus;Rash;Sensory loss;Shock;Skipped beats;Somnolence;Stomatitis;Syncope;Tachycardia;Tension;Throat sore;Tremor;Vomiting;Weight increased;Wheezing,small molecule,approved,(+/-)-pirbuterol; Pirbuterol; Pirbuterolum; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor,Beta-2 adrenergic receptor; Beta-1 adrenergic receptor, R03AC08;R03AC08;R03CC07
polymyxin,Bacteraemia;Infection;Urinary tract infection,Albuminuria;Apnoea;Ataxia;Azotaemia;Body temperature increased;Dizziness;Drowsiness;Drug fever;Flushing;Headache;Meningism;Musculoskeletal stiffness;Neck stiffness;Nuchal rigidity;Pain;Paraesthesia;Somnolence;Thrombophlebitis;Urticaria,biotech,approved; vet_approved,"Polimixina B; Polymyxin B; Polymyxine B; Polymyxinum B; 2.5.1.15; dhpS; Dihydropteroate pyrophosphorylase; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Bacterial outer membrane; Dihydropteroate synthase, A07AA05; J01XB02; S01AA18; S03AA03;A07AA05;S02AA11
polythiazide,Cardiac failure congestive;Glomerulonephritis acute;Hepatic cirrhosis;Hypertension;Nephrotic syndrome;Oedema;Renal failure chronic,Agitation;Agranulocytosis;Angiitis necrotising;Anorexia;Aplastic anaemia;Asthenia;Blood uric acid increased;Constipation;Cramp muscle;Cutaneous vasculitis;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Epigastric discomfort;Gastric irritation;Glycosuria;Headache;Hyperglycaemia;Hypersensitivity;Hyperuricaemia;Jaundice;Jaundice cholestatic;Leukopenia;Muscle spasms;Nausea;Orthostatic hypotension;Pancreatitis;Paraesthesia;Photosensitivity;Photosensitivity reaction;Purpura;Rash;Thrombocytopenia;Urticaria;Vascular purpura;Vasculitis;Vasculitis necrotising;Vertigo;Vomiting;Xanthopsia,small molecule,approved,Polythiazide; Na-Cl cotransporter; Na-Cl symporter; NCC; Thiazide-sensitive sodium-chloride cotransporter; TSC; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8,Solute carrier family 12 member 3, C03AB05; G01AE10;C03AA05
pramipexole,Parkinson's disease;Parkinsonism;Restless legs syndrome,"Abdominal discomfort;Abdominal distension;Abdominal neoplasm;Abdominal pain;Abdominal pain upper;Abnormal behaviour;Abnormal dreams;Abnormal sensation in eye;Abscess;Accidental injury;Accommodation disorder;Acne;Acute coronary syndrome;Acute tonsillitis;Adenocarcinoma;Adenoma benign;Affect lability;Ageusia;Aggression;Agitation;Akathisia;Akinesia;Alopecia;Altered state of consciousness;Amaurosis fugax;Amenorrhoea;Amnesia;Anaemia;Aneurysm;Angina pectoris;Angiopathy;Anorexia;Anticholinergic syndrome;Anxiety;Apathy;Aphasia;Aphthous stomatitis;Apnoea;Appendicitis;Arrhythmia supraventricular;Arteriosclerosis;Arthralgia;Arthritis;Ascites;Asthenia;Asthma;Ataxia;Atrial arrhythmia;Atrial fibrillation;Atrial septal defect;Atrioventricular block first degree;Atrioventricular block second degree;Back pain;Balance disorder;Basal cell carcinoma;Biliary colic;Binge eating;Blacked-out (not amnesia);Bladder cancer;Bladder pain;Blepharitis;Blepharospasm;Blood and lymphatic system disorders;Blood triglycerides increased;Blood uric acid increased;Body temperature increased;Bone pain;Bowel spasm;Bradycardia;Bradyphrenia;Brain oedema;Breast cancer;Breast discomfort;Breast disorder;Breast neoplasm;Breast pain;Bronchial hyperreactivity;Bronchiolitis;Bronchitis;Bronchopneumonia;Bruxism;Bundle branch block;Bursitis;Cachexia;Calculus of kidney;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiomegaly;Carotid artery occlusion;Carpal tunnel syndrome;Cataract;Cellulitis;Cerebral artery embolism;Cerebral haemorrhage;Cerebral infarction;Cerebral ischaemia;Cheilitis;Chest discomfort;Chest pain;Chills;Choking;Cholecystitis;Cholecystitis chronic;Cholelithiasis;Chorea;Chromaturia;Chronic lymphocytic leukaemia;Chronic obstructive pulmonary disease;Cognitive deterioration;Cognitive disorder;Cold sweat;Colitis;Colitis ulcerative;Colorectal cancer;Coma;Completed suicide;Compulsions;Compulsive sexual behaviour;Compulsive shopping;Confusional state;Congenital foot malformation;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Coronary artery occlusion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Cyanosis;Cystitis;Cystitis noninfective;Dacryostenosis acquired;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Delusion;Delusional disorders;Dementia;Dental caries;Depressed level of consciousness;Depression;Dermal cyst;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis infected;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disorientation;Dissociation;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Dizziness;Dizziness postural;Drowsiness;Drug hypersensitivity;Drug withdrawal syndrome;Dry eye;Dry mouth;Dry skin;Dry throat;Duodenal ulcer;Duodenal ulcer haemorrhage;Dysarthria;Dysgeusia;Dysgraphia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dysphoria;Dyspnoea;Dyspnoea exertional;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear infection;Ear pain;Ecchymosis;Eczema;Embolism;Emotional distress;Endocrine disorder;Endometrial cancer;Enlargement abdomen;Enteritis;Epicondylitis;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Erythema;Euphoric mood;Excessive daytime sleepiness;Excitability;Extrapyramidal disorder;Extrasystoles;Eye disorder;Eye haemorrhage;Eye infection;Eye irritation;Eye oedema;Eye pain;Eyelid oedema;Eyelid ptosis;Face oedema;Facial paralysis;Faecal incontinence;Fall;Fasciitis;Fatigue;Feeling abnormal;Feeling drunk;Feeling hot;Feeling jittery;Flank pain;Flat affect;Flatulence;Flight of ideas;Fluid retention;Flushing;Folliculitis;Functional gastrointestinal disorder;Fungal infection;Furuncle;Gait disturbance;Gallbladder cancer;Gangrene;Gastric pH decreased;Gastric ulcer;Gastric ulcer haemorrhage;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal neoplasm;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival infection;Gingivitis;Glaucoma;Glycosuria;Goitre;Gout;Grand mal convulsion;Gynaecomastia;Haemangioma;Haematemesis;Haematochezia;Haematoma;Haematuria;Haemoptysis;Haemorrhoids;Hallucination;Hallucination, auditory;Hallucination, visual;Headache;Hearing impaired;Hemianopia;Hemiplegia;Hepatic cancer;Hepatic neoplasm;Hepatobiliary disease;Herpes simplex;Herpes zoster;Hiatus hernia;Hiccups;Hordeolum;Hot flush;Hyperaesthesia;Hyperchlorhydria;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkeratosis;Hyperkinesia;Hyperlipidaemia;Hyperphagia;Hyperreflexia;Hypersensitivity;Hypersexuality;Hypertension;Hypertensive crisis;Hyperthyroidism;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hyporeflexia;Hypotension;Hypotension orthostatic symptomatic;Hypothyroidism;Hypotonia;Hypovitaminosis;Ileus;Ill-defined disorder;Immune system disorder;Impaired healing;Impulse-control disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Increased bronchial secretion;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Inguinal hernia;Initial insomnia;Injury;Insomnia;Intervertebral disc disorder;Intervertebral disc protrusion;Intervertebral discitis;Intestinal obstruction;Iron deficiency anaemia;Irritability;Irritable bowel syndrome;Joint effusion;Joint stiffness;Joint swelling;Keratitis;Lacrimal disorder;Lacrimal structural disorder;Lacrimation;Lacrimation increased;Laryngeal pain;Laryngitis;Laryngospasm;Left ventricular failure;Lethargy;Leukocytosis;Leukopenia;Libido decreased;Libido disorder;Libido increased;Lipase increased;Livedo reticularis;Lobar pneumonia;Localised oedema;Loss of consciousness;Loss of libido;Lung cancer metastatic;Lung neoplasm malignant;Lymphadenitis;Lymphadenopathy;Lymphoedema;Lymphoma;Macular degeneration;Malaise;Malignant melanoma;Malnutrition;Mania;Mediastinal disorder;Melanocytic naevus;Memory impairment;Menopausal symptoms;Menorrhagia;Mental disorder;Metabolic alkalosis;Metrorrhagia;Middle insomnia;Migraine;Monarthritis;Mood swings;Motion sickness;Muscle contractions involuntary;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Myoclonus;Myopathy;Myopia;Myositis;Nail infection;Narcolepsy;Nasal congestion;Nasal disorder;Nasal dryness;Nasal polyps;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Neoplasm malignant;Neoplasm prostate;Neoplasm skin;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neurogenic bladder;Neuroma;Neuropathy;Neuropathy peripheral;Night sweats;Nightmare;Nocturia;Nodal arrhythmia;Non-Hodgkin's lymphoma;Nuchal rigidity;Nystagmus;Obsessive thoughts;Obsessive-compulsive disorder;Obstructive airways disorder;Oedema;Oedema peripheral;Oesophageal spasm;Oesophageal stenosis;Oesophagitis;Oliguria;Onychomycosis;Oral candidiasis;Oral neoplasm benign;Orchitis;Orchitis noninfective;Orthostatic hypotension;Osteoarthritis;Osteomyelitis;Osteonecrosis;Osteoporosis;Otitis externa;Otitis media;Ovarian cancer;Ovarian cyst;Pain;Pain in extremity;Pallor;Palpitations;Pancreatitis;Panic reaction;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Parasomnia;Parkinson's disease;Parkinsonism;Paronychia;Parosmia;Pathological gambling;Periodontitis;Periorbital oedema;Peripheral vascular disorder;Personality disorder;Petechiae;Pharyngeal oedema;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Photophobia;Photosensitivity allergic reaction;Photosensitivity reaction;Pitting edema;Plasma cell myeloma;Plasmacytoma;Pleurisy;Pneumonia;Pneumonia aspiration;Pneumothorax;Pollakiuria;Polymyalgia;Postnasal drip;Presyncope;Priapism;Proctocolitis;Productive cough;Prostate cancer;Prostatic adenoma;Prostatic disorder;Prostatitis;Protein urine present;Proteinuria;Pruritus;Pseudolymphoma;Psoriasis;Psychotic disorder;Pulmonary embolism;Pulmonary oedema;Purpura;Pyelonephritis;Pyoderma;Rash;Rash erythematous;Rash maculo-papular;Rash papular;Rectal haemorrhage;Reflux esophagitis;Renal artery stenosis;Renal colic;Renal cyst;Renal failure;Renal impairment;Renal neoplasm;Respiratory alkalosis;Respiratory distress;Respiratory failure;Respiratory tract congestion;Retinal detachment;Retinal vascular disorder;Rhabdomyolysis;Rheumatoid arthritis;Rhinitis;Rhinitis allergic;Rhinorrhoea;Road traffic accident;Rosacea;Salivary hypersecretion;Sciatica;Scotoma;Seborrhoeic dermatitis;Sensory disturbance;Sepsis;Sexual dysfunction;Shock;Shoulder pain;Sinus arrhythmia;Sinus bradycardia;Sinus congestion;Sinus headache;Sinus tachycardia;Sinusitis;Skin burning sensation;Skin cancer;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin hypertrophy;Skin infection;Skin irritation;Skin mass;Skin nodule;Skin odour abnormal;Skin papilloma;Skin ulcer;Sleep apnoea syndrome;Sleep attacks;Sleep disorder;Sleep phase rhythm disturbance;Sleep talking;Sneezing;Snoring;Somnambulism;Somnolence;Speech disorder;Spine malformation;Squamous cell carcinoma;Stupor;Sudden onset of sleep;Suicidal ideation;Suicide;Sunburn;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating;Syncope;Syncope vasovagal;Tachycardia;Tachypnoea;Tendon rupture;Tendonitis;Tenosynovitis;Tension;Tension headache;Thirst;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thrombosis;Thyroid neoplasm;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Tongue ulceration;Tonsillitis;Tooth abscess;Tooth disorder;Tooth infection;Toothache;Tremor;Umbilical hernia;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upper-airway cough syndrome;Upset stomach;Urethral disorder;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Uterine haemorrhage;Uterine leiomyoma;VIIth nerve paralysis;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal moniliasis;Varicose vein;Vascular purpura;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular fibrillation;Ventricular hypertrophy;Vertigo;Vestibular ataxia;Viral infection;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vitreous floaters;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased;Weight increased;Wheezing;Wound infection;Yawning",small molecule,approved; investigational,"(-)-Pramipexole; (S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; Pramipexol; Pramipexole; Pramipexolum; Dopamine D3 receptor; Dopamine D2 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3",D(3) dopamine receptor; D(2) dopamine receptor; D(4) dopamine receptor; 5-hydroxytryptamine receptor 1A; Alpha-2A adrenergic receptor,N04BC05
pravastatin,Acute coronary syndrome;Alcohol abuse;Alcoholism;Angina pectoris;Angina unstable;Arteriosclerosis;Arteriosclerosis coronary artery;Atherosclerosis;Blood cholesterol increased;Blood cholesterol normal;Cardiovascular disorder;Carotid artery disease;Cerebrovascular accident;Cholesterol serum elevated;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Diabetic;Disease progression;Dyslipidaemia;Dyslipoproteinaemia;Foetor hepaticus;Hepatocellular injury;Heterozygous familial hypercholesterolemia;High density lipoprotein decreased;Homozygous familial hypercholesterolaemia;Hypercholesterolaemia;Hyperlipidaemia;Hyperlipoproteinemia;Hypertension;Hypothyroidism;Liver disorder;Low density lipoprotein increased;Myocardial infarction;Nephrotic syndrome;Peripheral vascular disorder;Premature menopause;Serum cholesterol normal;Transient ischaemic attack;Type II hyperlipidaemia;Type III hyperlipidaemia;Type IIa hyperlipidaemia,Abdominal distension;Abdominal pain;Abnormal faeces;Abnormalities of the hair;Ache;Acute coronary syndrome;Affect lability;Alanine aminotransferase increased;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Anorexia;Antinuclear antibody positive;Anxiety;Anxiety depression;Arrhythmia;Arthralgia;Arthritis;Asthenia;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Body temperature increased;Breast feeding;Cardiac disorder;Cardiac pain;Cataract;Chest pain;Chills;Cognitive disorder;Cognitive impairment;Common cold;Confusional state;Constipation;Cough;Cramp muscle;Creatine phosphokinase increased;Deafness;Decreased appetite;Depression;Dermatitis;Dermatomyositis;Diarrhoea;Diplopia;Discomfort;Distention;Dizziness;Drug interaction;Drug reaction with eosinophilia and systemic symptoms;Dry skin;Dysgeusia;Dyslipidaemia;Dyspepsia;Dyspnoea;Dysuria;Endophthalmitis;Eosinophilia;Erectile dysfunction;Erythema multiforme;Facial paresis;Fatigue;Feeling abnormal;Flatulence;Flushing;Foetor hepaticus;Forgetfulness;Gamma-glutamyltransferase increased;Gastrointestinal pain;Gynaecomastia;Haemolytic anaemia;Hair disorder;Headache;Hearing impaired;Heartburn;Hepatic cancer;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis chronic active;Hepatocellular carcinoma;Hepatocellular injury;Hot flush;Hyperhidrosis;Hypersensitive syndrome;Hypersensitivity;Hypertension;Hypoaesthesia;IIIrd nerve paralysis;Ill-defined disorder;Immune-mediated necrotising myopathy;Infection;Influenza;Injury;Insomnia;Interstitial lung disease;Jaundice;Jaundice cholestatic;Lenticular opacities;Leukopenia;Liver disorder;Liver function test abnormal;Loss of libido;Lung infection;Lupus erythematosus;Malaise;Memory impairment;Memory loss;Menopausal symptoms;Mood swings;Muscle spasms;Muscle swelling;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Myoglobin urine present;Myoglobinuria;Myopathy;Nasopharyngitis;Nausea;Nervousness;Neuropathy;Neuropathy peripheral;Nightmare;Nocturia;Nodule;Numbness;Oedema;Ophthalmoplegia;Pain;Pain localised;Pancreatitis;Panophthalmitis;Paraesthesia;Peripheral nerve palsy;Pharmacokinetic interaction;Pharyngitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Polymyalgia;Polymyalgia rheumatica;Pruritus;Purpura;Raised liver function tests;Rash;Renal failure acute;Respiratory tract infection;Rhabdomyolysis;Rhinitis;Sensory loss;Sexual dysfunction;Sinusitis;Sleep disorder;Sleep disturbance;Stevens-Johnson syndrome;Sweating increased;Systemic lupus erythematosus;Tenderness;Tension;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tracheobronchitis;Transaminases increased;Trauma;Tremor;Upper respiratory tract infection;Urinary tract infection;Urticaria;VIIth nerve paralysis;Vascular purpura;Vasculitis;Vertigo;Viral infection;Vision blurred;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved,"(+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid; Pravastatin; Pravastatin acid; Pravastatina; Pravastatine; Pravastatinum; 1.1.1.34; HMG-CoA reductase; 3.5.1.98; HD2; Protein deacylase HDAC2; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; MCT 1; MCT1; Solute carrier family 16 member 1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",3-hydroxy-3-methylglutaryl-coenzyme A reductase; Histone deacetylase 2, C10BA03; C10BA11; C10BA12; C10BX02;C10AA03
praziquantel,Hepatic impairment;Infection;Infestation;Liver disorder,Abdominal discomfort;Abdominal pain;Anorexia;Arrhythmia;Asthenia;Atrioventricular block;Body temperature increased;Bone disorder;Bradycardia;Cardiac disorder;Convulsion;Decreased appetite;Dermatitis;Diarrhoea;Diarrhoea haemorrhagic;Discomfort;Dizziness;Drowsiness;Eosinophilia;Fatigue;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hypersensitivity;Ill-defined disorder;Immune system disorder;Malaise;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Polyserositis;Pruritus;Rash;Skin disorder;Somnolence;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Ventricular fibrillation;Vertigo;Vomiting,small molecule,approved; investigational; vet_approved,"Praziquantel; 5.3.99.2; Glutathione S-transferase; Glutathione-dependent PGD synthase; Glutathione-requiring prostaglandin D synthase; GST class-sigma; GSTS; H-PGDS; PGDS; Prostaglandin-H2 D-isomerase; PTGDS2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3",Hematopoietic prostaglandin D synthase; Schistosome calcium ion (Ca2+) channels,P02BA01
prazosin,Acute coronary syndrome;Angina pectoris;Benign prostatic hyperplasia;Cardiac failure;Cardiac failure congestive;Cerebrovascular disorder;Diabetes mellitus;Diabetic nephropathy;Hyperlipidaemia;Hypertension;Hypertensive;Hypotension;Myocardial infarction;Raynaud's disease;Raynaud's phenomenon;Renal failure;Renal impairment;Urinary tract obstruction,Abdominal discomfort;Alopecia;Angina pectoris;Antinuclear antibody positive;Arthralgia;Asthenia;Body temperature increased;Bradycardia;Cataract;Constipation;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dyspnoea;Epistaxis;Erectile dysfunction;Eye pain;Fatigue;Feeling abnormal;Floppy iris syndrome;Flushing;Gynaecomastia;Hallucination;Headache;Hyperhidrosis;Hypersensitivity;Ill-defined disorder;Incontinence;Insomnia;Intraoperative floppy iris syndrome;Lichen planus;Loss of consciousness;Malaise;Miosis;Musculoskeletal discomfort;Narcolepsy;Nasal congestion;Nausea;Nervousness;Oedema;Orthostatic hypotension;Pain;Palpitations;Pancreatitis;Paraesthesia;Pollakiuria;Priapism;Pruritus;Rash;Retinal disorder;Shock;Somnolence;Sweating increased;Syncope;Tachycardia;Tension;Tinnitus;Urinary incontinence;Urticaria;Vasculitis;Vertigo;Vision blurred;Vomiting,small molecule,approved,"1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; Prazosin; Prazosina; Prazosine; Prazosinum; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; AGP 1; AGP1; OMD 1; Orosomucoid-1; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Voltage-gated inwardly rectifying potassium channel KCNH2; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-1 adrenergic receptors, C02CA01;C02CA01;C02LE01
prednisolone,Acute leukaemia;Adrenogenital syndrome;Allergic asthma;Allergic conditions;Alveolitis allergic;Anaemia;Ankylosing spondylitis;Aplasia pure red cell;Arthritis;Aspiration pneumonitis;Asthma;Azotaemia;Berylliosis;Blood disorder;Bronchial hyperreactivity;Bronchopulmonary aspergillosis allergic;Bursitis;Carditis;Chorioretinitis;Choroiditis;Chronic obstructive pulmonary disease;Colitis ulcerative;Collagen disorder;Congenital adrenal hyperplasia;Congenital aplastic anaemia;Conjunctivitis allergic;Conjunctivitis infective;Corneal ulcer marginal;Cyclitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatomyositis;Diabetes mellitus;Diabetic;Diamond-Blackfan anemia;Diuresis;Drug hypersensitivity;Dyspnoea;Endocrine disorder;Enteritis;Eosinophilic pneumonia;Epicondylitis;Erythema multiforme;Erythema multiforme severe;Erythroblastopenia;Eye disorder;Gastrointestinal disorder;Gout;Gouty arthritis;Haemolytic anaemia;Herpes zoster keratitis;Hypercalcaemia;Hypoplastic anaemia;Hypoxemia;Hypoxia;Idiopathic pulmonary fibrosis;Idiopathic thrombocytopenic purpura;Inflammation;Injury corneal;Iridocyclitis;Iritis;Juvenile idiopathic arthritis;Keratitis;Leukaemia;Loeffler's syndrome;Lupus erythematosus;Lymphoma;Meningitis tuberculous;Multiple sclerosis;Mycosis fungoides;Neoplasm malignant;Nephritic syndrome;Nephrotic syndrome;Nephrotic syndrome with lesion of minimal change glomerulonephritis;Non-Hodgkin's lymphoma;Obliterative bronchiolitis;Oedema;Ophthalmic herpes zoster;Optic neuritis;Organising pneumonia;Osteoarthritis;Pemphigus;Perennial allergic rhinitis;Pericardial effusion;Pneumocystis jirovecii pneumonia;Pneumonia aspiration;Polychondritis;Polymyalgia rheumatica;Polymyositis;Polyuria;Posterior uveitis;Proctocolitis;Protein urine present;Proteinuria;Psoriasis;Psoriatic arthropathy;Pulmonary eosinophilia;Pulmonary tuberculosis;Punctate keratitis;Purpura;Relapsing polychondritis;Rheumatic heart disease;Rheumatoid arthritis;Rhinitis perennial;Rosacea;Sarcoidosis;Seborrhoeic dermatitis;Secondary adrenocortical insufficiency;Secondary thrombocytopenia;Serum sickness;Sjogren's syndrome;Skin disorder;Stevens-Johnson syndrome;Sympathetic ophthalmia;Synovitis;Systemic lupus erythematosus;Temporal arteritis;Tenosynovitis;Thermal burn;Thrombocytopenia;Thyroiditis;Trichiniasis;Tuberculosis;Ulcerative keratitis;Uremia;Uveitis;Vasculitis,Abdominal distension;Abscess;Acne;Acute coronary syndrome;Affect lability;Alkalosis hypokalaemic;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anterior uveitis;Arachnoiditis;Arrhythmia;Arthropathy;Aseptic necrosis;Atrophy;Benign intracranial hypertension;Blister;Bradycardia;Carbohydrate tolerance decreased;Cardiac arrest;Cardiac failure congestive;Cardiomegaly;Cataract subcapsular;Conjunctival hyperaemia;Conjunctivitis;Convulsion;Dermatitis;Dermatitis atopic;Dermatitis bullous;Diabetes mellitus;Diplegia;Discomfort;Dizziness;Dry scalp;Dry skin;Ecchymosis;Embolism;Embolism venous;Erythema;Erythema facial;Euphoric mood;Exophthalmos;Eye infection;Eye irritation;Fat embolism;Feeling abnormal;Fluid retention;Glaucoma;Glucose tolerance impaired;Haemoglobin;Haemorrhage;Headache;Hepatomegaly;Herpes simplex;Hiccups;Hirsutism;Hyperadrenocorticism;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hypertrophic cardiomyopathy;Ill-defined disorder;Impaired healing;Increased appetite;Increased insulin requirement;Injury;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Iridocyclitis;Keratitis;Leukoderma;Loss of consciousness;Malaise;Meningitis;Menstruation irregular;Monoplegia;Mood swings;Muscle mass;Muscular weakness;Mydriasis;Myocardial infarction;Myocardial rupture;Myopathy;Nausea;Nerve injury;Neuritis;Neuropathy;Neuropathy peripheral;Nitrogen balance negative;Oedema;Oesophagitis ulcerative;Optic neuritis;Osteoarthritis;Osteonecrosis;Osteoporosis;Pain;Pancreatitis;Pancreatitis haemorrhagic;Papilloedema;Paraesthesia;Paraparesis;Paraplegia;Peptic ulcer;Personality change;Petechiae;Posterior subcapsular cataract;Pulmonary oedema;Rash;Sensation of foreign body;Shock;Sickness;Skin striae;Spinal compression fracture;Steroid myopathy;Stinging;Stress;Sweating increased;Syncope;Tachycardia;Tendon rupture;Thromboembolism;Thrombophlebitis;Trauma;Ulcerative keratitis;Urticaria;Vasculitis;Vertigo;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Weight increased,small molecule,approved; vet_approved,"(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione; 1,4-pregnadiene-11β,17α,21-triol-3,20-dione; 1,4-pregnadiene-3,20-dione-11β,17α,21-triol; 3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene; delta-dehydrocortisol; delta-dehydrohydrocortisone; delta-hydrocortisone; delta(1)-Dehydrocortisol; delta(1)-Dehydrohydrocortisone; delta(1)-Hydrocortisone; Hydroretrocortine; Metacortandralone; PRDL; Prednisolona; Prednisolone; Prednisolonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Glucocorticoid receptor, A01AC04; A01AC54; A07EA01; C05AA04; D07BA01; D07CA03; D07XA02; H02AB06; L02BX53; R01AD02; R01AD52; S01BA04; S01BB02; S01CA02; S01CB02; S02BA03; S02CA01; S03BA02; S03CA02; V03AB05;A07EA01;D07AA03
prednisolone,Acute leukaemia;Adrenogenital syndrome;Allergic conditions;Alveolitis allergic;Ankylosing spondylitis;Aplasia pure red cell;Arthritis;Aspiration pneumonitis;Asthma;Azotaemia;Blood disorder;Brain cancer metastatic;Brain oedema;Bronchial hyperreactivity;Bronchopulmonary aspergillosis allergic;Chronic obstructive pulmonary disease;Colitis ulcerative;Congenital adrenal hyperplasia;Congenital aplastic anaemia;Conjunctivitis allergic;Conjunctivitis infective;Crohn's disease;Cyclitis;Dendritic keratitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatomyositis;Diamond-Blackfan anemia;Diuresis;Drug hypersensitivity;Edema cerebral;Eosinophilic pneumonia;Erythema multiforme;Erythema multiforme severe;Fungal infection;Gastrointestinal disorder;Gout;Gouty arthritis;Haemolytic anaemia;Head injury;Herpes zoster keratitis;Hypercalcaemia of malignancy;Hypersensitivity;Hypoxemia;Hypoxia;Idiopathic pulmonary fibrosis;Idiopathic thrombocytopenic purpura;Infection;Inflammation;Injury corneal;Iritis;Juvenile idiopathic arthritis;Lung disorder;Lupus erythematosus;Lymphoma;Meningitis tuberculous;Metastases to central nervous system;Multiple sclerosis;Mycobacterial infection;Mycosis fungoides;Nephrotic syndrome;Non-Hodgkin's lymphoma;Obliterative bronchiolitis;Oedema;Ophthalmic herpes simplex;Ophthalmic herpes zoster;Organising pneumonia;Pemphigus;Perennial allergic rhinitis;Pneumocystis jirovecii pneumonia;Pneumonia aspiration;Polychondritis;Polymyalgia rheumatica;Polymyositis;Polyuria;Proctocolitis;Protein urine present;Proteinuria;Psoriatic arthropathy;Pulmonary tuberculosis;Punctate keratitis;Purpura;Relapsing polychondritis;Rheumatoid arthritis;Rhinitis perennial;Rosacea;Sarcoidosis;Secondary adrenocortical insufficiency;Secondary thrombocytopenia;Serum sickness;Sjogren's syndrome;Skin disorder;Stevens-Johnson syndrome;Sympathetic ophthalmia;Systemic lupus erythematosus;Thermal burn;Thrombocytopenia;Thyroiditis;Trichiniasis;Uremia;Uveitis;Vaccinia;Vaccinia virus infection;Varicella;Vasculitis;Viral infection,Abdominal distension;Abscess;Acne;Acute coronary syndrome;Affect lability;Alkalosis hypokalaemic;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anterior uveitis;Arachnoiditis;Arrhythmia;Arthropathy;Aseptic necrosis;Atrophy;Benign intracranial hypertension;Bradycardia;Carbohydrate tolerance decreased;Cardiac arrest;Cardiac failure congestive;Cardiomegaly;Cataract subcapsular;Conjunctival hyperaemia;Conjunctivitis;Convulsion;Corneal perforation;Dermatitis;Diabetes mellitus;Diabetic;Diplegia;Discomfort;Dizziness;Dry scalp;Dry skin;Dysgeusia;Ecchymosis;Embolism;Embolism venous;Erythema;Erythema facial;Euphoric mood;Exophthalmos;Eye infection;Eye irritation;Eye penetration;Fat embolism;Feeling abnormal;Fluid retention;Glaucoma;Glucose tolerance impaired;Haemoglobin;Haemorrhage;Headache;Hepatomegaly;Hiccups;Hirsutism;Hyperadrenocorticism;Hyperhidrosis;Hypernatraemia;Hypertension;Hypertrophic cardiomyopathy;Ill-defined disorder;Impaired healing;Increased appetite;Increased insulin requirement;Injury;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Iridocyclitis;Keratitis;Leukoderma;Loss of consciousness;Malaise;Meningitis;Menstruation irregular;Monoplegia;Mood swings;Muscle mass;Muscular weakness;Mydriasis;Myocardial infarction;Myocardial rupture;Myopathy;Nausea;Nerve injury;Neuritis;Neuropathy;Neuropathy peripheral;Nitrogen balance negative;Oedema;Oesophagitis ulcerative;Optic neuritis;Osteoarthritis;Osteonecrosis;Osteoporosis;Pain;Pancreatitis;Papilloedema;Paraesthesia;Paraparesis;Paraplegia;Peptic ulcer;Personality change;Petechiae;Posterior subcapsular cataract;Pruritus;Pulmonary oedema;Rash;Shock;Skin striae;Spinal compression fracture;Steroid myopathy;Stinging;Sweating increased;Syncope;Tachycardia;Tendon rupture;Thromboembolism;Thrombophlebitis;Trauma;Ulcerative keratitis;Urticaria;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Weight increased,small molecule,approved; vet_approved,"(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione; 1,4-pregnadiene-11β,17α,21-triol-3,20-dione; 1,4-pregnadiene-3,20-dione-11β,17α,21-triol; 3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene; delta-dehydrocortisol; delta-dehydrohydrocortisone; delta-hydrocortisone; delta(1)-Dehydrocortisol; delta(1)-Dehydrohydrocortisone; delta(1)-Hydrocortisone; Hydroretrocortine; Metacortandralone; PRDL; Prednisolona; Prednisolone; Prednisolonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Glucocorticoid receptor, A01AC04; A01AC54; A07EA01; C05AA04; D07BA01; D07CA03; D07XA02; H02AB06; L02BX53; R01AD02; R01AD52; S01BA04; S01BB02; S01CA02; S01CB02; S02BA03; S02CA01; S03BA02; S03CA02; V03AB05;D07AA03
prednisolone,Acute leukaemia;Adrenogenital syndrome;Allergic asthma;Allergic conditions;Alveolitis allergic;Ankylosing spondylitis;Aplasia pure red cell;Arthritis;Asthma;Azotaemia;Blood disorder;Bronchial hyperreactivity;Bronchopulmonary aspergillosis allergic;Bursitis;Chronic obstructive pulmonary disease;Colitis ulcerative;Congenital adrenal hyperplasia;Congenital aplastic anaemia;Conjunctivitis allergic;Conjunctivitis infective;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatomyositis;Diabetes mellitus;Diabetic;Diamond-Blackfan anemia;Diuresis;Drug hypersensitivity;Dyspnoea;Endocrine disorder;Enteritis;Eosinophilic pneumonia;Epicondylitis;Erythema multiforme;Erythema multiforme severe;Gastrointestinal disorder;Gout;Gouty arthritis;Haemolytic anaemia;Hypercalcaemia;Hypoxemia;Hypoxia;Idiopathic pulmonary fibrosis;Idiopathic thrombocytopenic purpura;Juvenile idiopathic arthritis;Lupus erythematosus;Lymphoma;Meningitis tuberculous;Mental disorder;Multiple sclerosis;Mycosis fungoides;Neoplasm malignant;Nephrotic syndrome;Nephrotic syndrome with lesion of minimal change glomerulonephritis;Non-Hodgkin's lymphoma;Obliterative bronchiolitis;Oedema;Organising pneumonia;Pemphigus;Perennial allergic rhinitis;Pericardial effusion;Pneumocystis jirovecii pneumonia;Polychondritis;Polymyalgia rheumatica;Polymyositis;Polyuria;Proctocolitis;Protein urine present;Proteinuria;Psoriatic arthropathy;Pulmonary tuberculosis;Purpura;Relapsing polychondritis;Rheumatoid arthritis;Rhinitis perennial;Sarcoidosis;Secondary adrenocortical insufficiency;Secondary thrombocytopenia;Serum sickness;Sjogren's syndrome;Skin disorder;Stevens-Johnson syndrome;Sympathetic ophthalmia;Systemic lupus erythematosus;Temporal arteritis;Tenosynovitis;Thrombocytopenia;Thyroiditis;Trichiniasis;Tuberculosis;Uremia;Uveitis;Vasculitis,Abdominal distension;Acneiform eruption;Adrenal insufficiency;Adrenocortical insufficiency acute;Affect lability;Agitation;Alkalosis hypokalaemic;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Arrhythmia;Arthralgia;Aseptic necrosis;Aseptic necrosis of bone;Asthenia;Benign intracranial hypertension;Blindness;Blood in stool;Blood triglycerides increased;Body temperature increased;Carbohydrate tolerance decreased;Cardiac arrest;Cardiac failure congestive;Cataract subcapsular;Cognitive disorder;Cognitive impairment;Constipation;Convulsion;Cushing's syndrome;Decreased appetite;Delusion;Dermatitis;Dermatitis acneiform;Dermatitis atopic;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Drug withdrawal syndrome;Dyspepsia;Ecchymosis;Electroencephalogram abnormal;Embolism;Embolism venous;Epigastric discomfort;Epilepsy;Erythema;Erythema facial;Euphoric mood;Exophthalmos;Eye disorder;Eye irritation;Eyelid oedema;Face oedema;Fatigue;Feeling abnormal;Fluid retention;Gastric irritation;Glaucoma;Glucose tolerance impaired;Haematochezia;Haemoglobin;Haemorrhage;Hallucination;Headache;Hirsutism;Hyperadrenocorticism;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypertrophic cardiomyopathy;Hypoglycaemia;Hypokalaemia;Hypoparathyroidism;Hypotension;Ill-defined disorder;Impaired healing;Increased appetite;Increased insulin requirement;Increased tendency to bruise;Infection;Injury;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Irritability;Ischaemic neuropathy;Joint stiffness;Laryngeal pain;Lethargy;Leukocytosis;Malaise;Mania;Menstruation irregular;Mood swings;Muscle mass;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myopathy;Nausea;Nervousness;Nitrogen balance negative;Oesophagitis;Oesophagitis ulcerative;Opportunistic infection;Optic neuritis;Osteonecrosis;Osteoporosis;Pancreatitis;Papilloedema;Paranoia;Paranoid state;Peptic ulcer;Personality change;Petechiae;Pharyngolaryngeal pain;Pruritus;Psychotic disorder;Psychotic episode;Purpura;Purpura senile;Rash;Renal failure;Schizophrenia;Skin atrophy;Skin striae;Skin thinness;Spinal compression fracture;Steroid myopathy;Suicidal ideation;Sweating increased;Telangiectasia;Tendon rupture;Tension;Thromboembolism;Trauma;Tuberculosis;Ulcer;Urticaria;Vascular purpura;Vertigo;Viral infection;Vomiting;Water retention;Weight decreased;Weight increased;Withdrawal symptom,small molecule,approved; vet_approved,"(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione; 1,4-pregnadiene-11β,17α,21-triol-3,20-dione; 1,4-pregnadiene-3,20-dione-11β,17α,21-triol; 3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene; delta-dehydrocortisol; delta-dehydrohydrocortisone; delta-hydrocortisone; delta(1)-Dehydrocortisol; delta(1)-Dehydrohydrocortisone; delta(1)-Hydrocortisone; Hydroretrocortine; Metacortandralone; PRDL; Prednisolona; Prednisolone; Prednisolonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Glucocorticoid receptor, A01AC04; A01AC54; A07EA01; C05AA04; D07BA01; D07CA03; D07XA02; H02AB06; L02BX53; R01AD02; R01AD52; S01BA04; S01BB02; S01CA02; S01CB02; S02BA03; S02CA01; S03BA02; S03CA02; V03AB05;D07AA03
prednisone,Acquired hemolytic anemia;Acute leukaemia;Adrenogenital syndrome;Alkalosis hypokalaemic;Allergic conditions;Anaemia;Ankylosing spondylitis;Aplasia pure red cell;Arteritis;Arthritis;Aspiration pneumonitis;Asthma;Autoimmune haemolytic anaemia;Azotaemia;Berylliosis;Blood disorder;Bursitis;Carditis;Chorioretinitis;Choroiditis;Colitis ulcerative;Collagen disorder;Congenital adrenal hyperplasia;Conjunctivitis allergic;Connective tissue disorder;Convulsion;Corneal ulcer marginal;Crohn's disease;Demyelinating polyneuropathy;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatomyositis;Diabetes mellitus;Diabetic;Diuresis;Drug eruption;Drug hypersensitivity;Eczema;Emphysema;Endocrine disorder;Enteritis;Epicondylitis;Epilepsy;Erythema multiforme;Erythema multiforme severe;Erythroblastopenia;Fluid retention;Foetor hepaticus;Gastrointestinal disorder;Gout;Gouty arthritis;Haemolytic anaemia;Hepatitis chronic active;Hepatocellular injury;Herpes zoster;Hyperadrenocorticism;Hypercalcaemia;Hyperplasia adrenal;Hypersensitivity;Hypokalaemia;Hypoplastic anaemia;Hypotension;Idiopathic thrombocytopenic purpura;Inflammation;Inflammatory bowel disease;Intracranial pressure increased;Iridocyclitis;Iritis;Juvenile idiopathic arthritis;Keratitis;Leukaemia;Liver disorder;Loeffler's syndrome;Lupus erythematosus;Lymphoma;Mendelson's syndrome;Meningitis;Meningitis tuberculous;Metabolic alkalosis;Multiple sclerosis;Musculoskeletal stiffness;Mycosis fungoides;Neonatal respiratory distress syndrome;Neoplasm malignant;Nephritic syndrome;Nephropathy;Nephrotic syndrome;Nervous system disorder;Non-Hodgkin's lymphoma;Oedema;Ophthalmic herpes zoster;Optic neuritis;Osteoarthritis;Pemphigus;Pemphigus vulgaris;Perennial allergic rhinitis;Periarthritis;Pneumonia;Pneumonia aspiration;Polyarteritis nodosa;Polymyositis;Polyuria;Posterior uveitis;Proctocolitis;Protein urine present;Proteinuria;Psoriasis;Psoriatic arthropathy;Pulmonary eosinophilia;Pulmonary fibrosis;Pulmonary tuberculosis;Purpura;Rheumatic disorder;Rheumatic fever;Rheumatic heart disease;Rheumatoid arthritis;Rhinitis perennial;Sarcoidosis;Seborrhoeic dermatitis;Secondary adrenocortical insufficiency;Secondary thrombocytopenia;Serum sickness;Skin disorder;Skin exfoliation;Status asthmaticus;Stevens-Johnson syndrome;Stiffness;Sympathetic ophthalmia;Synovitis;Systemic lupus erythematosus;Tenosynovitis;Thrombocytopenia;Thrombocytopenic purpura;Thyroiditis;Trichiniasis;Ulcer;Ulcerative keratitis;Uremia,Abdominal distension;Abdominal pain;Abscess;Acne;Acneiform eruption;Acute coronary syndrome;Adrenal atrophy;Adrenal cortex atrophy;Adrenal insufficiency;Adrenocortical insufficiency acute;Affect lability;Agitation;Alanine aminotransferase increased;Alkalosis;Alopecia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Angiitis necrotising;Angioedema;Angiopathy;Anorexia;Anxiety;Arachnoiditis;Arrhythmia;Arthralgia;Arthropathy;Aseptic necrosis;Asthenia;Atrophy;Benign intracranial hypertension;Blood and lymphatic system disorders;Blood potassium decreased;Blood potassium increased;Blood triglycerides increased;Body temperature increased;Bradycardia;Buffalo hump;Capillary fragility increased;Carbohydrate tolerance decreased;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Cardiomegaly;Cataract;Cataract subcapsular;Central serous retinopathy;Chorioretinopathy;Cognitive disorder;Cognitive impairment;Connective tissue disorder;Constipation;Contusion;Convulsion;Cushing's syndrome;Cushingoid;Decreased appetite;Delirium;Delusion;Dementia;Dependence psychological;Depression;Dermatitis;Dermatitis acneiform;Dermatitis atopic;Diabetes mellitus;Diarrhoea;Diplegia;Discomfort;Distention;Dizziness;Drug dependence;Drug withdrawal syndrome;Dry scalp;Dry skin;Dyspepsia;Ecchymosis;Electroencephalogram abnormal;Embolism;Embolism venous;Endocrine disorder;Endophthalmitis;Eosinopenia;Epigastric discomfort;Epilepsy;Erectile dysfunction;Erythema;Erythema facial;Euphoric mood;Exophthalmos;Eye disorder;Face oedema;Fat atrophy;Fat embolism;Fatigue;Febrile neutropenia;Feeling abnormal;Fluid retention;Flushing;Fracture;Fungal infection;Gastric irritation;Gastrointestinal haemorrhage;Gastrointestinal pain;Glaucoma;Glucose tolerance decreased;Glucose tolerance impaired;Glycosuria;Growth retardation;Haemoglobin;Haemorrhage;Hallucination;Headache;Hepatomegaly;Hiccups;Hirsutism;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypernatraemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertrichosis;Hypertriglyceridaemia;Hypertrophic cardiomyopathy;Hypokalaemia;Hypothyroidism;Ill-defined disorder;Immune system disorder;Impaired healing;Increased appetite;Increased insulin requirement;Infection;Injury;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Irritability;Ischaemic neuropathy;Lethargy;Leukocytosis;Leukoderma;Lipids abnormal;Lipoatrophy;Lipohypertrophy;Long-term memory loss;Loss of consciousness;Lymphopenia;Malaise;Malnutrition;Mania;Memory impairment;Memory loss;Meningitis;Menstruation irregular;Mental disorder;Monoplegia;Mood swings;Multiple fractures;Muscle atrophy;Muscle mass;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial rupture;Myopathy;Nausea;Necrosis;Nerve injury;Nervous system disorder;Neuritis;Neuropathy;Neuropathy peripheral;Neutropenia;Nitrogen balance negative;Obesity;Oedema;Oesophageal candidiasis;Oesophageal ulcer;Oesophagitis;Oesophagitis ulcerative;Opportunistic infection;Optic neuritis;Oropharyngeal candidiasis;Osteoarthritis;Osteonecrosis;Osteoporosis;Pancreatitis;Pancreatitis acute;Pancreatitis haemorrhagic;Panophthalmitis;Papilloedema;Paraesthesia;Paraparesis;Paraplegia;Peptic ulcer;Personality change;Petechiae;Pigmentation disorder;Pigmentation skin;Polycythaemia;Potassium deficiency;Potassium increased;Proximal myopathy;Pruritus;Psychiatric symptom;Psychotic disorder;Pulmonary oedema;Purpura;Rash;Rosacea;Schizophrenia;Scleral thinning;Secondary adrenocortical insufficiency;Sepsis;Shock;Skin atrophy;Skin disorder;Skin exfoliation;Skin scaly;Skin striae;Skin thinness;Spinal compression fracture;Steroid acne;Steroid myopathy;Steroid psychosis;Steroid withdrawal syndrome;Substance-induced psychotic disorder;Suicidal ideation;Sweating increased;Syncope;Tachycardia;Telangiectasia;Tendon rupture;Thromboembolism;Thrombophlebitis;Trauma;Tuberculosis;Ulcer;Ulcerative keratitis;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vascular purpura;Vasculitis;Vasculitis necrotising;Vertigo;Viral infection;Vision blurred;Vomiting;Water retention;Weight decreased;Weight increased;Withdrawal symptom;Withdrawal syndrome;Wound,small molecule,approved; vet_approved,"1,2-Dehydrocortisone; 1,4-Pregnadiene-17α,21-diol-3,11,20-trione; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; Dehydrocortisone; Prednisona; Prednisone; Prednisonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.1.1.146; 11-beta-HSD1; 11-DH; 7-oxosteroid reductase; Corticosteroid 11-beta-dehydrogenase isozyme 1; HSD11; HSD11L; SDR26C1; Short chain dehydrogenase/reductase family 26C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3",Glucocorticoid receptor, H02AB07;A07EA03
prilocaine,Agitation;Cardiac arrest;Cardiovascular insufficiency;Circulatory depression;Convulsion;Excitable;Foetal acidosis;Ischaemia;Methaemoglobinaemia,Acidosis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Anemic;Anxiety;Apprehension;Arachnoiditis;Arrhythmia;Arterial occlusion;Arterial occlusive disease;Asthenia;Blood pH decreased;Bradycardia;Brain hypoxia;Bronchospasm;CNS depression NOS;Cardiac arrest;Cardiac failure;Carotid pulse;Circumoral paresthesia;Confusional state;Cyanosis;Depressed level of consciousness;Dermatitis atopic;Diplopia;Disorientation;Dizziness;Drowsiness;Dysarthria;Euphoric mood;Extravasation;Feeling abnormal;Feeling hot;Haemoglobin normal;Hyperacusis;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoaesthesia oral;Hypoesthesia tongue;Hypotension;Hypoxemia;Hypoxia;Injury;Lightheadedness;Loss of consciousness;Low pH;Muscle twitching;Myocardial depression;Nausea;Nerve injury;Nervous system disorder;Nervousness;Neurologic reaction;Neurological impairment;Neurological symptom;Neuropathy;Neuropathy peripheral;Neurotoxicity;Numbness;Numbness of tongue;Oedema;Osteoarthritis;Oxygen saturation decreased;Pain;Paraesthesia;Paraesthesia oral;Paralysis;Paresthesia lips;Pulmonary function test decreased;Respiratory arrest;Respiratory depression;Respiratory failure;Respiratory insufficiency;Sensation of heat;Sensory loss;Shock;Somnolence;Sweating;Swelling;Syncope;Tension;Tinnitus;Trauma;Tremor;Urticaria;Vision blurred;Vomiting,small molecule,approved,2-(Propylamino)-o-propionotoluidide; 2-Methyl-alpha-propylaminopropionanilide; alpha-n-Propylamino-2-methylpropionanilide; N-(2-Methylphenyl)-2-(propylamino)propanamide; o-Methyl-2-propylaminopropionanilide; o-Methyl-alpha-propylaminopropionanilide; Prilocain; Prilocaina; Prilocaïne; Prilocaine; Prilocaine base; Prilocainum; Propitocaine; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5,Sodium channel protein type 5 subunit alpha, N01BB04;N01BB04;N01BB54
primaquine,Plasmodium vivax infection;Vivax malaria,Abdominal cramps;Abdominal pain;Dyspepsia;Epigastric distress;Haemolytic anaemia;Leukopenia;Methaemoglobinaemia;Nausea;Vomiting,small molecule,approved,"6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; Primachin; Primachina; Primachinum; Primaquin; Primaquina; Primaquine; Primaquinum; CK-7; Cytokeratin-7; K7; Keratin-7; Sarcolectin; SCL; Type-II keratin Kb7; 1.10.5.1; NMOR2; NRH dehydrogenase [quinone] 2; NRH:quinone oxidoreductase 2; QR2; Quinone reductase 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","Fe(II)-protoporphyrin IX; Keratin, type II cytoskeletal 7; Ribosyldihydronicotinamide dehydrogenase [quinone]",P01BA03
primidone,Bone disorder;Epilepsy;Grand mal convulsion;Jacksonian seizures;Myoclonus;Simple partial seizures;Tonic-clonic seizures,Agranulocytosis;Anaemia;Anaemia megaloblastic;Anorexia;Apathy;Aplasia;Arthralgia;Asthenia;Ataxia;Blood and lymphatic system disorders;Blood disorder;Connective tissue disorder;Decreased appetite;Depression;Dermatitis;Diplopia;Dizziness;Drowsiness;Emotional disorder;Emotional disturbance NOS;Eruption;Eye disorder;Fatigue;Flat affect;Gastrointestinal disorder;Headache;Malnutrition;Mental disorder;Muscle contracture;Musculoskeletal discomfort;Nausea;Nervous system disorder;Nystagmus;Personality change;Psychotic disorder;Rash;Skin disorder;Somnolence;Suicidal behaviour;Suicidal ideation;Systemic lupus erythematosus;Unspecified disorder of skin and subcutaneous tissue;Vertigo;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; vet_approved,"2-deoxyphenobarbital; 5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione; Primidon; Primidona; Primidone; Primidonum; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; NACRA4; NACHRA7; AMPA-selective glutamate receptor 2; GluA2; GluR-2; GluR-B; GluR-K2; GLUR2; Glutamate receptor ionotropic, AMPA 2; EAA4; Excitatory amino acid receptor 4; GluK2; GluR-6; GLUR6; Glutamate receptor 6; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; KIAA1616; Long transient receptor potential channel 3; LTrpC-3; LTRPC3; Melastatin-2; MLSN2","Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit alpha-4; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-6; GABA(A) Receptor; Gamma-aminobutyric acid receptor subunit alpha-1; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit alpha-7; Glutamate receptor 2; Glutamate receptor ionotropic, kainate 2", N03AA03;N03AA03;N05CB01
probenecid,Blood uric acid increased;Gout;Gouty arthritis;Hypertension;Hyperuricaemia;Oedema,Alopecia;Anaemia;Anaphylactic shock;Anorexia;Aplastic anaemia;Body temperature increased;Decreased appetite;Dermatitis;Dizziness;Erythema multiforme;Flushing;Gingival pain;Haematuria;Haemolytic anaemia;Headache;Hepatic necrosis;Hypersensitivity;Leukopenia;Nausea;Nephrotic syndrome;Pain;Pollakiuria;Pruritus;Renal colic;Stevens-Johnson syndrome;Toxic epidermal necrolysis;Urticaria;Vomiting,small molecule,approved; investigational,"4-((Dipropylamino)sulfonyl)benzoic acid; 4-(Di-n-propylsulfamoyl)benzoesäure; 4-(N,N-Dipropylsulfamoyl)benzoesäure; p-(Dipropylsulfamoyl)benzoic acid; Probenecid; Probenecid acid; Probenecida; Probenecide; Probenecidum; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; MRS1; PANX1; T2R16; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.-; 7.6.2.2; MOAT-C; MRP5; Multi-specific organic anion transporter C; Multidrug resistance-associated protein 5; pABC11; SMRP; MCT 2; MCT2; Solute carrier family 16 member 7; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; 7.6.2.-; 7.6.2.3; Anthracycline resistance-associated protein; ARA; MOAT-E; MRP6; Multi-specific organic anion transporter E; Multidrug resistance-associated protein 6; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; MCT 1; MCT1; Solute carrier family 16 member 1; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; OAT5; Organic anion transporter 5; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; 7.6.2.3; MRP8; Multidrug resistance-associated protein 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; OAT-RP-5; OATP-14; OATP-F; OATP-RP5; OATP14; OATP1C1; OATPF; Organic anion transporter 1C1; Organic anion transporter F; Organic anion transporter polypeptide-related protein 5; Organic anion-transporting polypeptide 14; SLC21A14; Solute carrier family 21 member 14; Thyroxine transporter; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; OATL4; Organic anion transporter 4-like protein; Renal-specific transporter; RST; URAT1; Urate anion exchanger 1; Urate:anion antiporter SLC22A12; Glucose transporter type 9; GLUT-9; GLUT9; Urate transporter",Solute carrier family 22 member 6; Solute carrier family 22 member 11; Organic anion transporter 3; Pannexin-1; Taste receptor type 2 member 16, G01AE10; M04AC51;M04AB01
procainamide,Agranulocytosis;Arrhythmia;Blood disorder;Leukopenia;Sustained ventricular tachycardia;Ventricular arrhythmia;Ventricular tachycardia,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Agranulocytosis;Anaemias haemolytic immune;Angioedema;Anorexia;Antinuclear antibody positive;Arthralgia;Arthritis;Asthenia;Atrial fibrillation;Atrial tachycardia;Atrioventricular block second degree;Blood creatinine decreased;Body temperature increased;Bradycardia;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac fibrillation;Chills;Confusional state;Convulsion;Creatinine low;Decreased appetite;Defect conduction intraventricular;Depression;Diarrhoea;Discomfort;Dizziness;Drug fever;Drug-induced lupus erythematosus;Dysgeusia;Electrocardiogram QRS complex;Electrocardiogram change;Eosinophilia;Feeling abnormal;Flushing;Function kidney decreased;Gastrointestinal pain;Gastrointestinal tract irritation;Haemolytic anaemia;Hallucination;Hepatic enzyme increased;Hepatic failure;Hepatomegaly;Hypergammaglobulinaemia;Hypersensitivity;Hypotension;Hypotensive;Ill-defined disorder;Junctional tachycardia;Lethargy;Lightheadedness;Lupus erythematosus;Lupus-like syndrome;Malaise;Musculoskeletal discomfort;Myalgia;Nausea;Neutropenia;Oliguria;Paroxysmal atrial tachycardia;Pericarditis;Pleural effusion;Pruritus;Psychotic disorder;QRS complex;Rash maculo-papular;Renal failure;Renal impairment;Right upper quadrant pain;Shock;Supraventricular tachycardia;Systemic lupus erythematosus;Taste bitter;Thrombocytopenia;Urticaria;Vasculitis;Ventricular fibrillation;Ventricular tachycardia;Vomiting;pH urine decreased,small molecule,approved,p-Amino-N-(2-diethylaminoethyl)benzamide; p-Aminobenzoic diethylaminoethylamide; Procainamida; Procainamide; Procaïnamide; Procainamidum; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; 2.1.1.37; AIM; CXXC-type zinc finger protein 9; CXXC9; DNA methyltransferase HsaI; DNA MTase HsaI; DNMT; Dnmt1; M.HsaI; MCMT; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2,Voltage-gated inwardly rectifying potassium channel KCNH2; Sodium channel protein type 5 subunit alpha; DNA (cytosine-5)-methyltransferase 1,C01BA02
procarbazine,Brain neoplasm;Carcinoma of lung;Glioma;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Lung neoplasm malignant;Lymphoma;Malignant melanoma;Neoplasm;Non-Hodgkin's lymphoma;Plasma cell myeloma;Plasmacytoma,Abdominal pain;Acute leukaemia;Acute myeloid leukaemia;Alopecia;Amenorrhoea;Anaemia;Angina pectoris;Anisocytosis;Anorexia;Anxiety;Apprehension;Arrhythmia;Arthralgia;Ascites;Asthenia;Ataxia;Azoospermia;Balance disorder;Bleeding tendency;Body temperature increased;Carcinoma of lung;Cardiotoxicity;Chills;Coma;Confusional state;Constipation;Convulsion;Cough;Deafness;Decreased appetite;Dermatitis;Diarrhoea;Diplopia;Disorientation;Dizziness;Drowsiness;Dry mouth;Dysarthria;Dysphagia;Dysphonia;Eosinophilia;Epistaxis;Fatigue;Febrile neutropenia;Feeling abnormal;Flushing;Footdrop;Gastrointestinal pain;Gynaecomastia;Haematemesis;Haematuria;Haemoglobin;Haemolytic anaemia;Haemoptysis;Haemorrhage;Haemorrhagic disorder;Hallucination;Headache;Hearing impaired;Hepatic function abnormal;Herpes NOS;Herpes virus infection;Hoarseness;Hyperhidrosis;Hypersensitivity;Hypertension;Hyporeflexia;Hypotension;Infection;Infertility;Insomnia;Jaundice;Lethargy;Leukopenia;Loss of consciousness;Lung cancer metastatic;Lung neoplasm malignant;Lymphocytosis;Melaena;Menopause;Metastatic neoplasm;Musculoskeletal discomfort;Myalgia;Nausea;Neoplasm malignant;Nephritis;Nervousness;Neuropathy;Neuropathy peripheral;Nightmare;Nocturia;Nystagmus;Oedema;Optic neuritis;Osteonecrosis;Ovarian failure;Pain;Pancreatitis;Pancytopenia;Papilloedema;Paraesthesia;Pericarditis;Peroneal nerve palsy;Petechiae;Photophobia;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pneumonia;Poikilocytosis;Pollakiuria;Pruritus;Pulmonary toxicity;Purpura;Rash;Raynaud's disease;Raynaud's phenomenon;Retinal haemorrhage;Shock;Skin hyperpigmentation;Slurred speech;Somnolence;Stomatitis;Sweating;Sweating increased;Syncope;Tachycardia;Tension;Thrombocytopenia;Thrombosis;Toxic epidermal necrolysis;Tremor;Type IV hypersensitivity reaction;Unsteadiness;Urticaria;Vascular purpura;Vomiting,small molecule,approved; investigational,1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; N-Isopropyl-α-(2-methylhydrazino)-p-toluamide; p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; Procarbazin; Procarbazina; Procarbazine; Procarbazinum; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; XDHA,Monoamine oxidase; DNA,L01XB01
prochlorperazine,Agitated depression;Anxiety;Electroencephalogram abnormal;Generalised anxiety disorder;Labyrinthitis;Mania;Mania acute;Meniere's disease;Migraine;Mitral valve incompetence;Nausea;Psychotic disorder;Schizophrenia;Tardive dyskinesia;Vertigo;Vomiting,"Abnormal pigmentation;Agitation;Agranulocytosis;Akathisia;Altered state of consciousness;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Aplastic anaemia;Apnoea;Arrhythmia;Asphyxia;Asthma;Autonomic dysfunction;Autonomic nervous system imbalance;Blood disorder;Body temperature increased;Brain injury;Brain oedema;Cardiac arrest;Catatonia;Cholestasis;Cogwheel rigidity;Colon atonic;Coma;Consciousness abnormal;Constipation;Convulsion;Corneal deposits;Cough;Cyanosis;Deep vein thrombosis;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Dizziness;Drooling;Drowsiness;Drug withdrawal syndrome neonatal;Dry mouth;Dyskinesia;Dysphagia;Dyspnoea;Dystonia;Dystonic reaction;Eczema;Edema cerebral;Embolism venous;Eosinophilia;Erectile dysfunction;Eruption;Erythema;Erythema multiforme;Extrapyramidal disorder;Extrapyramidal symptoms;Feeling jittery;Gait disturbance;Gait shuffling;Galactorrhoea;Glycosuria;Gynaecomastia;Haemolytic anaemia;Headache;Hepatocellular injury;Hyperglycaemia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypoglycaemia;Hypotension;Ileus paralytic;Increased appetite;Infection;Influenza;Insomnia;Jaundice;Jaundice cholestatic;Keratopathy;Laryngeal oedema;Laryngospasm;Leukopenia;Liver injury;Masked facies;Megacolon;Menstruation irregular;Miosis;Motor restlessness;Movements involuntary;Muscle rigidity;Muscle spasms;Mydriasis;Nasal congestion;Nervousness;Neuroleptic malignant syndrome;Obstipation;Oculogyric crisis;Oedema;Oedema peripheral;Opisthotonus;Orofacial dyskinesia;Oropharyngeal discomfort;Oropharyngeal pain;Pancytopenia;Parkinsonian rest tremor;Parkinsonism;Petit mal epilepsy;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Pill rolling;Pregnancy;Pregnancy test false positive;Priapism;Protrusion tongue;Pruritus;Pseudoparkinsonism;Pulmonary embolism;Pulmonary function test decreased;Rash;Respiratory depression;Retinal disorder;Skin disorder;Somnolence;Sudden death;Sudden death, cause unknown;Systemic lupus erythematosus;Tardive dyskinesia;Tetanus;Tetanus-like;Throat sore;Throat tightness;Thrombocytopenia;Thrombocytopenic purpura;Tremor;Urinary retention;Urticaria;Venous thromboembolism;Vision blurred;Weight increased",small molecule,approved; vet_approved,2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; Capazine; Chlormeprazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Chloropernazine; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; Prochlorperazin; Prochlorpérazine; Prochlorperazine; Prochlorperazinum; Prochlorpermazine; Prochlorpromazine; Procloperazine; Proclorperazina; Dopamine D2 receptor; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase,D(2) dopamine receptor; Histamine H1 receptor; Alpha-1 adrenergic receptors; Alpha-2 adrenergic receptors,N05AB04
progesterone,Abdominal bloating;Abdominal distension;Abdominal pain;Abdominal pain upper;Abortion spontaneous;Acute coronary syndrome;Affect lability;Amenorrhea secondary;Amenorrhoea;Anxiety;Arthralgia;Arthritis;Assisted fertilisation;Asthenia;Back pain;Blindness;Body temperature increased;Bone pain;Breast cancer;Breast pain;Breast tenderness;Bronchitis;Cerebrovascular accident;Chest pain;Cleft palate;Clotting;Coagulopathy;Confusional state;Congenital eye disorder;Constipation;Cough;Cramp muscle;Cramps of lower extremities;Depression;Diarrhoea;Diplopia;Disability;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Exophthalmos;Eye disorder;Fatigue;Feeling abnormal;Fertilization;Flatulence;Fluid retention;Foetor hepaticus;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Heartburn;Hepatocellular injury;Hormone level abnormal;Hot flush;Hypertension;Imbalance hormonal;Infection;Infertility;Irritability;Liver disorder;Menopausal symptoms;Menopause;Menstruation irregular;Migraine;Mood swings;Muscle spasms;Musculoskeletal discomfort;Myocardial infarction;Nasal congestion;Nausea;Night sweats;Oestrogenic effect;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Personality disorder;Pulmonary embolism;Sleep disorder;Somnolence;Stomach ache;Swelling;Throat sore;Unspecified visual loss;Upper respiratory tract infection;Urinary tract infection;Uterine cancer;Uterine haemorrhage;Uterine leiomyoma;Vaginal discharge;Vaginal dryness;Vaginal infection;Vaginal inflammation;Viral infection;Vision blurred;Vomiting;Vulvovaginal dryness;Worry,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal vision;Abortion spontaneous;Abscess;Accidental injury;Acne;Affect lability;Aggression;Alanine aminotransferase increased;Alopecia;Amenorrhoea;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Arthralgia;Arthritis;Aspartate aminotransferase increased;Assisted fertilisation;Asthenia;Asthma;Autonomic neuropathy;Back pain;Bladder pain;Bleeding breakthrough;Blood and lymphatic system disorders;Blood glucose increased;Blood pressure increased;Body temperature increased;Bone pain;Breast cancer;Breast discharge;Breast discomfort;Breast disorder;Breast enlargement;Breast pain;Breast swelling;Breast tenderness;Bronchitis;Carcinoma breast;Cardiac disorder;Cerebral thrombosis;Cerebration impaired;Chest pain;Chloasma;Choking;Cholestasis;Chorea;Cleft lip;Cleft palate;Clotting;Coagulopathy;Common wart;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coronary artery thrombosis;Cough;Cramp muscle;Cramps of lower extremities;Crying;Crying abnormal;Cystitis;Cystitis noninfective;Decreased appetite;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis hemorrhagic;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disorder sight;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug interaction;Dry mouth;Dysarthria;Dysmenorrhoea;Dyspareunia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Embolism;Embolism venous;Endocrine disorder;Endometrial cancer;Endometrial hyperplasia;Endometriosis;Eructation;Erythema;Erythema multiforme;Erythema nodosum;Exacerbation of asthma;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Feeling drunk;Fertilization;Flatulence;Fluid retention;Foetal death;Foetor hepaticus;Forgetfulness;Gait disturbance;Galactorrhoea;Gallbladder disorder;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Genital candidiasis;Glucose tolerance decreased;Haemangioma;Haemoglobin;Haemorrhage;Hand swelling;Headache;Heart disease congenital;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hepatocellular injury;Herpes simplex;Hiatus hernia;Hirsutism;Hot flush;Hyperglycaemia;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypocalcaemia;Hypotension;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infertility;Infestation;Infestation NOS;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Irritability;Jaundice;Jaundice cholestatic;Leg pain;Leukorrhea;Libido decreased;Lightheadedness;Liver disorder;Liver function test abnormal;Local swelling;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Menorrhagia;Menstrual disorder;Menstruation irregular;Mental disability;Mental disorder;Metrorrhagia;Migraine;Mood swings;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Myalgia;Myopathy;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm;Neoplasm malignant;Nervous system disorder;Nervousness;Neuritis;Neuropathy peripheral;Night sweats;Nocturia;Oedema;Oedema peripheral;Optic neuritis;Osteoarthritis;Ovarian cancer;Ovarian cyst;Ovarian failure;Ovarian hyperstimulation syndrome;Pain;Pain in extremity;Palpitations;Pancreatitis acute;Paraesthesia;Patent ductus arteriosus;Pelvic venous thrombosis;Perineal pain;Perineal pain female;Personality disorder;Pharyngitis;Pneumonia;Pollakiuria;Porphyrin metabolism disorder;Pregnancy;Premature labour;Premenstrual syndrome;Premenstrual tension;Pruritus;Pruritus genital;Pulmonary embolism;Purpura;Raised liver function tests;Rash;Rash generalised;Redness;Rhinitis;Seborrhoeic dermatitis;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin papilloma;Sleep disorder;Slurred speech;Somnolence;Speech disorder;Stillbirth;Stupor;Suicidal ideation;Sweating increased;Swelling;Swollen tongue;Syncope;Tachycardia;Tenderness;Tension;Thirst;Throat tightness;Thromboembolism;Thrombophlebitis;Thrombosis;Tinnitus;Tooth disorder;Toothache;Transaminases increased;Transient ischaemic attack;Tremor;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Uterine cervical erosion;Uterine leiomyoma;Uterine spasm;Vaginal burning sensation;Vaginal discharge;Vaginal dryness;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal irritation;Vaginal itching;Vaginal mycosis;Vascular purpura;Ventricular septal defect;Vertigo;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal burning sensation;Vulvovaginal discomfort;Vulvovaginal dryness;Vulvovaginal mycotic infection;Vulvovaginal pruritus;Walking disability;Water retention;Weight decreased;Weight increased;Withdrawal bleed;Worry;Xerophthalmia,small molecule,approved; vet_approved,"(S)-4-Pregnene-3,20-dione; (S)-Pregn-4-en-3,20-dione; (S)-Progesterone; 17alpha-Progesterone; 17α-progesterone; 4-Pregnene-3,20-dione; Agolutin; Akrolutin; Corpus Luteum Hormone; delta(4)-Pregnene-3,20-dione; Gelbkörperhormon; Luteohormone; Lutogynon; Pregn-4-ene-3,20-dione; Progesteron; Progesterona; Progestérone; Progesterone; Progesteronum; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; 1.14.14.19; 17-alpha-hydroxyprogesterone aldolase; CYP17; CYPXVII; Cytochrome P450 17A1; Cytochrome P450-C17; Cytochrome P450c17; S17AH; Steroid 17-alpha-monooxygenase; K-OR-1; KOR-1; OPRK; AGP 1; AGP1; OMD 1; Orosomucoid-1; GR; GRL; Nuclear receptor subfamily 3 group C member 1; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; 1.14.14.19; 17-alpha-hydroxyprogesterone aldolase; CYP17; CYPXVII; Cytochrome P450 17A1; Cytochrome P450-C17; Cytochrome P450c17; S17AH; Steroid 17-alpha-monooxygenase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8","Progesterone receptor; Mineralocorticoid receptor; Estrogen receptor; Steroid 17-alpha-hydroxylase/17,20 lyase; Kappa-type opioid receptor; Alpha-1-acid glycoprotein 1; Glucocorticoid receptor; Androgen receptor; Sex hormone-binding globulin; Estrogen receptor beta", G03DA04;G03DA04;G03FA04
proguanil,Drug interaction;Plasmodium falciparum infection;Renal failure;Renal impairment,Abdominal pain;Amylase increased;Anorexia;Blood and lymphatic system disorders;Body temperature increased;Cough;Decreased appetite;Dermatitis;Diarrhoea;Elevated liver enzyme levels;Erythema;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Hepatic enzyme increased;Hepatobiliary disease;Immune system disorder;Malnutrition;Mediastinal disorder;Mental disorder;Nausea;Nervous system disorder;Pancytopenia;Rash;Skin disorder;Stomatitis;Unspecified disorder of skin and subcutaneous tissue;Vomiting,small molecule,approved,1-(p-Chlorophenyl)-5-isopropylbiguanide; Chlorguanide; Chloroguanide; Proguanil; Proguanile; Proguanilo; Proguanilum; 1.5.1.3; 3.5.1.88; PDF1A; Polypeptide deformylase; DHFR-TS; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase,"Dihydrofolate reductase; Peptide deformylase, mitochondrial; Bifunctional dihydrofolate reductase-thymidylate synthase", P01BB51; P01BB52;P01BB01
promethazine,Allergic conditions;Allergic contact dermatitis;Anaphylactic shock;Angioedema;Anxiety;Apprehension;Arthropod bite;Arthropod sting;Conjunctivitis allergic;Dermatitis contact;Hypersensitivity;Insect bite NOS;Light sleep;Measles;Mechanical urticaria;Motion sickness;Nausea;Pain;Poor quality sleep;Postoperative pain;Postoperative vomiting;Procedural pain;Procedural vomiting;Pruritus;Rhinitis allergic;Rhinitis seasonal;Seasonal allergy;Sting;Urticaria;Urticaria physical;Varicella;Vasomotor rhinitis;Vomiting;Wakefulness,Abscess;Agitation;Agranulocytosis;Anaphylactic shock;Anxiety;Aplastic anaemia;Apnoea;Appetite absent;Arrhythmia;Asthenia;Asthma;Bradycardia;Catatonia;Coma;Confusional state;Constipation;Conversion disorder;Convulsion;Convulsive seizure;Coordination abnormal;Decreased appetite;Delirium;Depression;Dermatitis;Dermatitis contact;Diarrhoea;Diplopia;Disorientation;Dizziness;Drowsiness;Dry mouth;Dyskinesia;Dyspepsia;Epigastric distress;Erythema;Euphoric mood;Extrapyramidal disorder;Extrapyramidal symptoms;Extravasation;Fatigue;Feeling abnormal;Gangrene;Hallucination;Headache;Hypotension;Hysteria;Injection site phlebitis;Injection site reaction;Insomnia;Irritability;Jaundice;Jaundice cholestatic;Lassitude;Leukopenia;Loss of consciousness;Muscle spasms;Nasal congestion;Necrosis;Nerve injury;Nervousness;Neuroleptic malignant syndrome;Nightmare;Oculogyric crisis;Oedema;Pain;Palpitations;Paralysis;Phlebitis;Photosensitivity;Photosensitivity reaction;Protrusion tongue;Pruritus;Pulmonary function test decreased;Rash;Respiration irregularity;Respiratory depression;Respiratory disorder;Sensory loss;Shock;Somnolence;Surgery;Surgical intervention;Swelling;Syncope;Tachycardia;Tardive dyskinesia;Tension;Thrombocytopenia;Thrombocytopenic purpura;Thrombophlebitis;Tinnitus;Torticollis;Tremor;Urinary hesitation;Urinary retention;Venous thrombosis;Vision blurred,small molecule,approved; investigational,"(2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine; 10-(2-Dimethylaminopropyl)phenothiazine; 10-[2-(dimethylamino)propyl]phenothiazine; N-(2'-dimethylamino-2'-methyl)ethylphenothiazine; N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamine; N,N,α-trimethyl-10H-phenothiazine-10-ethanamine; Proazamine; Prometazina; Promethazine; Promethazinum; H1-R; H1R; HH1R; Dopamine D2 receptor; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; Gastric receptor I; H2R; HH2R; G-protein coupled receptor 23; GPR23; LPA receptor 4; LPA-4; LPA4; P2RY9; P2Y purinoceptor 9; P2Y5-like receptor; P2Y9; Purinergic receptor 9; LPA receptor 6; LPA-6; Oleoyl-L-alpha-lysophosphatidic acid receptor; P2RY5; P2Y purinoceptor 5; P2Y5; Purinergic receptor 5; RB intron encoded G-protein coupled receptor; ATP receptor; P2X1; Purinergic receptor; ATP receptor; P2X2; Purinergic receptor; ATP receptor; P2X3; Purinergic receptor; ATP receptor; P2X4; Purinergic receptor; ATP receptor; P2X5; P2X5FL; Purinergic receptor; ATP receptor; P2RXL1; P2X6; P2XM; Purinergic receptor; Purinergic receptor P2X-like 1; ATP receptor; P2X7; P2Z receptor; Purinergic receptor; ADP receptor; P2Y1; Purinergic receptor; P2Y11; ADP-glucose receptor; ADPG-R; HORK3; P2T(AC); P2Y(AC); P2Y(ADP); P2Y(cyc); P2Y12; P2Y12 platelet ADP receptor; SP1999; G-protein coupled receptor 86; G-protein coupled receptor 94; GPR86; GPR94; P2Y13; G-protein coupled receptor 105; GPR105; KIAA0001; P2Y14; UDP-glucose receptor; ATP receptor; P2RU1; P2U purinoceptor 1; P2U receptor 1; P2U1; P2Y2; Purinergic receptor; NRU; P2P; P2Y4; UNR; Uridine nucleotide receptor; P2Y8; P2Y-like receptor; P2Y10; NAC1; SCN1; Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; HBA; HBSC II; NAC2; SCN2A1; SCN2A2; Sodium channel protein brain II subunit alpha; Sodium channel protein type II subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.2; KIAA1356; NAC3; Sodium channel protein brain III subunit alpha; Sodium channel protein type III subunit alpha; Voltage-gated sodium channel subtype III; Voltage-gated sodium channel subunit alpha Nav1.3; SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Atypical sodium channel Nav2.1; Nax channel; SCN6A; Sodium channel protein type VII subunit alpha; MED; Sodium channel protein type VIII subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.6; hNE-Na; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Sodium channel protein type IX subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.7; Potassium voltage-gated channel subfamily D member 1; Shal-type potassium channel KCND1; Voltage-gated potassium channel subunit Kv4.1; KIAA1044; Potassium voltage-gated channel subfamily D member 2; Voltage-gated potassium channel subunit Kv4.2; Potassium voltage-gated channel subfamily D member 3; Voltage-gated potassium channel subunit Kv4.3; Delayed-rectifier K(+) channel alpha subunit 1; Delayed-rectifier potassium channel subunit Kv9.1; hKv9.1; Potassium voltage-gated channel modifier subfamily S member 1; Delayed-rectifier K(+) channel alpha subunit 3; Delayed-rectifier potassium channel subunit Kv9.3; Kv9.3; Potassium voltage-gated channel subfamily S member 3; Voltage-gated K(+) channel HuKI; Voltage-gated potassium channel HBK1; Voltage-gated potassium channel subunit Kv1.1; Voltage-gated potassium channel subunit Kv1.8; NGK1; Voltage-gated K(+) channel HuKIV; Voltage-gated potassium channel HBK5; Voltage-gated potassium channel subunit Kv1.2; HGK5; HLK3; HPCN3; Voltage-gated K(+) channel HuKIII; Voltage-gated potassium channel subunit Kv1.3; HPCN2; KCNA4L; Voltage-gated K(+) channel HuKII; Voltage-gated potassium channel HBK4; Voltage-gated potassium channel HK1; Voltage-gated potassium channel subunit Kv1.4; HPCN1; Voltage-gated potassium channel HK2; Voltage-gated potassium channel subunit Kv1.5; Voltage-gated potassium channel HBK2; Voltage-gated potassium channel subunit Kv1.6; Delayed rectifier potassium channel 1; DRK1; h-DRK1; Voltage-gated potassium channel subunit Kv2.1; Voltage-gated potassium channel subunit Kv2.2; Delayed rectifier potassium channel subunit IsK; IKs producing slow voltage-gated potassium channel subunit beta Mink; Minimal potassium channel; MinK; Minimum potassium ion channel-related peptide 1; MinK-related peptide 1; MiRP1; Potassium channel subunit beta MiRP1; Minimum potassium ion channel-related peptide 2; MinK-related peptide 2; MiRP2; Potassium channel subunit beta MiRP2; Minimum potassium ion channel-related peptide 3; MinK-related peptide 3; MiRP3; Potassium channel subunit beta MiRP3; AMME syndrome candidate gene 2 protein; AMMECR2; KCNE1L; Potassium channel subunit beta MiRP4; Potassium voltage-gated channel subfamily E member 1-like protein; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1; KCNA8; KCNA9; KQT-like 1; KVLQT1; Voltage-gated potassium channel subunit Kv7.1; KQT-like 2; Neuroblastoma-specific potassium channel subunit alpha KvLQT2; Voltage-gated potassium channel subunit Kv7.2; KQT-like 3; Potassium channel subunit alpha KvLQT3; Voltage-gated potassium channel subunit Kv7.3; KQT-like 4; Potassium channel subunit alpha KvLQT4; Voltage-gated potassium channel subunit Kv7.4; KQT-like 5; Potassium channel subunit alpha KvLQT5; Voltage-gated potassium channel subunit Kv7.5; Neuronal potassium channel alpha subunit HNKA; Voltage-gated potassium channel subunit Kv8.1; Voltage-gated potassium channel subunit Kv8.2; EAG; EAG channel 1; EAG1; Ether-a-go-go potassium channel 1; h-eag; hEAG1; Potassium voltage-gated channel subfamily H member 1; Voltage-gated potassium channel subunit Kv10.1; BEC2; Brain-specific eag-like channel 2; ELK channel 1; ELK1; Ether-a-go-go-like potassium channel 1; Potassium voltage-gated channel subfamily H member 4; Voltage-gated potassium channel subunit Kv12.3; EAG2; Ether-a-go-go potassium channel 2; hEAG2; Potassium voltage-gated channel subfamily H member 5; Voltage-gated potassium channel subunit Kv10.2; ELK channel 3; ELK1; ELK3; Ether-a-go-go-like potassium channel 3; hElk-1; Potassium voltage-gated channel subfamily H member 8; Voltage-gated potassium channel subunit Kv12.1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; BEC1; Brain-specific eag-like channel 1; ELK channel 2; ELK2; Ether-a-go-go-like potassium channel 2; KIAA1282; Potassium voltage-gated channel subfamily H member 3; Voltage-gated potassium channel subunit Kv12.2; Eag-related protein 2; ERG-2; ERG2; Ether-a-go-go-related gene potassium channel 2; Ether-a-go-go-related protein 2; hERG-2; hERG2; Potassium voltage-gated channel subfamily H member 6; Voltage-gated potassium channel subunit Kv11.2; Eag-related protein 3; ERG-3; ERG3; Ether-a-go-go-related gene potassium channel 3; Ether-a-go-go-related protein 3; hERG-3; Potassium voltage-gated channel subfamily H member 7; Voltage-gated potassium channel subunit Kv11.3; NGK2; Potassium voltage-gated channel subfamily C member 1; Voltage-gated potassium channel subunit Kv3.1; Voltage-gated potassium channel subunit Kv4; Potassium voltage-gated channel subfamily C member 2; Shaw-like potassium channel; Voltage-gated potassium channel Kv3.2; KSHIIID; Potassium voltage-gated channel subfamily C member 3; Voltage-gated potassium channel subunit Kv3.3; C1orf30; KSHIIIC; Potassium voltage-gated channel subfamily C member 4; Voltage-gated potassium channel subunit Kv3.4; kH1; Potassium voltage-gated channel subfamily F member 1; Voltage-gated potassium channel subunit Kv5.1; kH2; Potassium voltage-gated channel subfamily G member 1; Voltage-gated potassium channel subunit Kv6.1; Cardiac potassium channel subunit; KCNF2; Potassium voltage-gated channel subfamily G member 2; Voltage-gated potassium channel subunit Kv6.2; Potassium voltage-gated channel subfamily G member 3; Voltage-gated potassium channel subunit Kv10.1; Voltage-gated potassium channel subunit Kv6.3; KCNG3; Potassium voltage-gated channel subfamily G member 4; Voltage-gated potassium channel subunit Kv6.3; Voltage-gated potassium channel subunit Kv6.4; 1.1.1.-; K(+) channel subunit beta-1; KCNA1B; Kv-beta-1; 1.1.1.-; hKvbeta2; K(+) channel subunit beta-2; KCNA2B; KCNK2; Kv-beta-2; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4",Histamine H1 receptor; D(2) dopamine receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; Alpha adrenergic receptor; Histamine H2 receptor; P2 Purinoceptors; Voltage-gated sodium channel alpha subunit; Voltage-gated Potassium Channels; Calmodulin, D04AA10; R06AD02; V03AB05;D04AA10;R06AD52
propafenone,Acute coronary syndrome;Agitation;Arrhythmia;Atrial fibrillation;Atrial flutter;Cardiac disorder;Cardiac flutter;Cardiac index;Chronic atrial fibrillation;Excitability;Hepatic failure;Hepatic insufficiency;Menorrhagia;Myocardial infarction;Paroxysmal atrial fibrillation;Paroxysmal supraventricular tachycardia;Permanent atrial fibrillation;Prolonged menses;Renal failure;Renal impairment;Sudden death;Supraventricular extrasystoles;Supraventricular tachycardia;Sustained ventricular tachycardia;Vascular resistance;Vascular resistance systemic;Ventricular arrhythmia;Ventricular tachycardia;Wolff-Parkinson-White syndrome,Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal vision;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Amnesia;Anaemia;Angina pectoris;Angina unstable;Angiopathy;Anorexia;Antinuclear antibody positive;Anxiety;Apnoea;Arrhythmia;Arrhythmia supraventricular;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Ataxia;Atelectasis;Atrial arrhythmia;Atrial fibrillation;Atrial flutter;Atrial hypertrophy;Atrioventricular block;Atrioventricular block first degree;Atrioventricular block second degree;Atrioventricular dissociation;Bleeding time prolonged;Blister;Block heart;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood disorder;Blood glucose increased;Blood pressure increased;Blood prolactin increased;Blood triglycerides increased;Body temperature increased;Bone disorder;Bradycardia;Brain injury;Breast disorder;Breast pain;Breath odour;Breath sounds abnormal;Bronchial hyperreactivity;Bundle branch block;Bundle branch block left;Bundle branch block right;Bursitis;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac flutter;Cardiac murmur;Cardioactive drug level above therapeutic;Carotid bruit;Cerebrovascular accident;Chest pain;Cholestasis;Chronic obstructive pulmonary disease;Collagen-vascular disease;Coma;Conduction disorder;Confusional state;Connective tissue disorder;Constipation;Contusion;Convulsion;Coronary artery disease;Costochondritis;Cough;Cramp muscle;Deafness;Decreased appetite;Defect conduction intraventricular;Dehydration;Dementia;Depression;Dermatitis;Dermatitis bullous;Device capturing issue;Diabetes mellitus;Diarrhoea;Digestion impaired;Discomfort;Disturbance in sexual arousal;Diuresis;Dizziness;Drowsiness;Dry mouth;Dry skin;Dry throat;Duodenitis;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ecchymosis;Electrocardiogram QRS complex;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Embolism arterial (limb);Emotional disorder;Emotional disturbance NOS;Endophthalmitis;Eosinophil count increased;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Erythema;Extrasystoles;Eye disorder;Eye haemorrhage;Eye irritation;Eyelid ptosis;Fatigue;Feeling abnormal;Feeling hot;Flatulence;Flushing;Gait disturbance;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival bleeding;Gingival pain;Glossitis;Glossodynia;Glucose increased;Glycosuria;Gout;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Headache;Hearing impaired;Heart rate irregular;Heart sounds abnormal;Hepatic enzyme increased;Hepatic function abnormal;Hepatitis;Hepatitis fulminant;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hot flush;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlactacidaemia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertensive crisis;Hypertonia;Hypoaesthesia;Hypokalaemia;Hyponatraemia;Hypotension;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Intestinal obstruction;Jaundice;Ketonuria;Labile blood pressure;Leukopenia;Libido decreased;Liver function test abnormal;Liver injury;Loss of consciousness;Lung disorder;Lupus-like syndrome;Lymphadenopathy;Malaise;Malnutrition;Mania;Mediastinal disorder;Melaena;Memory loss;Menopausal symptoms;Mental disorder;Miosis;Monocyte count increased;Mouth ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nail abnormality NOS;Nail disorder;Nausea;Neck pain;Nephrotic syndrome;Nervous system disorder;Nervousness;Neuropathy peripheral;Neurosis;Nightmare;Nocturia;Nodal arrhythmia;Numbness;Oedema;Oesophagitis;Oliguria;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Osteoarthritis;Pain;Pain in jaw;Pallor;Palpitations;Pancreatitis;Panophthalmitis;Paraesthesia;Paralysis;Paroxysmal atrial fibrillation;Peptic ulcer;Pericarditis;Peripheral coldness;Peripheral embolism;Peripheral vascular disorder;Petechiae;Platelet count decreased;Pleural effusion;Pneumothorax;Pollakiuria;Polyuria;Presyncope;Proarrhythmia;Prostatism;Protein urine present;Proteinuria;Prothrombin level increased;Pruritus;Psychotic disorder;Pulmonary congestion;Pulse abnormal;Purpura;Pyuria;QRS complex;Rales;Rash;Rectal haemorrhage;Red blood cell count decreased;Renal failure;Respiratory failure;Respiratory sounds decreased;Respiratory tract congestion;Retinal disorder;Rhinitis;Sciatica;Sensory loss;Shock;Sick sinus syndrome;Sinoatrial block;Sinus arrest;Sinus arrhythmia;Sinus bradycardia;Skin disorder;Sleep disorder;Somnolence;Speech disorder;Speech impairment NOS;Sperm concentration decreased;Sperm count decreased;Spleen disorder;Stomatitis;Supraventricular tachycardia;Sweating increased;Syncope;Systemic lupus erythematosus;Tachycardia;Tendonitis;Tension;Throat sore;Throat tightness;Thrombocytopenia;Thrombosis;Tinnitus;Torsade de pointes;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urine abnormality;Urine analysis abnormal;Urticaria;Vascular purpura;Venous thrombosis;Ventricular extrasystoles;Ventricular fibrillation;Ventricular hypertrophy;Ventricular tachycardia;Vertigo;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting;Weight decreased;Weight increased;Wheezing;White blood cell count increased;Wide complex tachycardia,small molecule,approved,"1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; 2-(2'-hydroxy-3'-propylaminopropoxy)-ω-phenylpropiophenone; Propafenona; Propafenone; Propafenonum; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium channel protein type 5 subunit alpha; Voltage-gated inwardly rectifying potassium channel KCNH2; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor,C01BC03
propantheline,Acute enterocolitis;Cholecystitis;Colitis ulcerative;Diarrhoea;Diverticulitis;Enterocolitis;Functional gastrointestinal disorder;Gastritis;Hyperhidrosis;Irritable bowel syndrome;Pancreatitis;Peptic ulcer;Proctocolitis;Renal colic,Abdominal distension;Accommodation disorder;Anaphylactic shock;Anhidrosis;Asthenia;Bloated feeling;Confusional state;Constipation;Cycloplegia;Dermatitis;Dermatitis atopic;Dizziness;Drowsiness;Dry mouth;Dysphagia;Erectile dysfunction;Feeling abnormal;Flushing;Headache;Heat stroke;Hypersensitivity;Hypohidrosis;Insomnia;Mydriasis;Nausea;Nervousness;Palpitations;Rash;Salivary hypersecretion;Salivation;Somnolence;Sweating decreased;Tachycardia;Tension;Thirst;Urinary hesitation;Urticaria;Vision blurred;Vomiting,small molecule,approved,Propantheline,Muscarinic acetylcholine receptor M1, A03CA34;A03AB05
propranolol,Acute coronary syndrome;Angina pectoris;Arrhythmia;Arrhythmia supraventricular;Arteriosclerosis coronary artery;Atrial fibrillation;Atrial flutter;Atrial tachycardia;Cardiac failure;Conduction disorder;Diabetes mellitus;Diabetic nephropathy;Digitalis intoxication (NOS);Dizziness;Essential tremor;Familial tremor;Haemangioma;Haemangioma of skin;Headache;Hemangioma simplex;Hyperlipidaemia;Hypertension;Hyperthyroidism;Hypertrophic cardiomyopathy;Hypotension;Idiopathic hypertrophic subaortic stenosis;Loss of consciousness;Migraine;Migraine without aura;Myocardial depression;Myocardial infarction;Neoplasm;Pain;Palpitations;Shock;Sinus rhythm;Supraventricular tachycardia;Syncope;Tachyarrhythmia;Thyrotoxicosis;Toxicity to various agents;Tremor;Ulcer;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular tachycardia;Wolff-Parkinson-White syndrome,Abdominal cramps;Abdominal pain;Abnormal dreams;Ache;Affect lability;Agitation;Agranulocytosis;Alopecia;Amnesia;Anaphylactic shock;Anaphylactoid reaction;Arterial insufficiency;Arterial thrombosis;Asthenia;Atrioventricular block;Atrioventricular block second degree;Block heart;Blood and lymphatic system disorders;Blood glucose decreased;Body temperature increased;Bradycardia;Bronchiolitis;Bronchitis;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiac failure congestive;Catatonia;Central nervous system disorder;Coldness;Colitis ischaemic;Constipation;Convulsion;Cough;Decreased appetite;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Disorientation;Dizziness;Dry eye;Dyspepsia;Dyspnoea;Epigastric distress;Erectile dysfunction;Erythema;Erythema multiforme;Fatigue;Feeling cold;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Hyperkalaemia;Hypersensitivity;Hypersomnia;Hypoglycaemia;Hypoglycaemic seizure;Infection;Infestation;Infestation NOS;Insomnia;Irritability;Laryngospasm;Lassitude;Lethargy;Lightheadedness;Lower respiratory tract infection;Mental disorder;Mood swings;Myopathy;Myotonia;Nausea;Nervous system disorder;Neutropenia;Nightmare;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Paraesthesia;Paraesthesia hand;Peripheral arterial disease;Peripheral arterial occlusive disease;Peripheral coldness;Peyronie's disease;Pharyngitis;Poor quality sleep;Purpura;Purpura non-thrombocytopenic;Rash;Rash erythematous;Raynaud's disease;Raynaud's phenomenon;Respiratory distress;Respiratory tract infection;Short-term memory loss;Skin disorder;Skin ulcer;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Systemic lupus erythematosus;Throat sore;Thrombocytopenic purpura;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vascular purpura;Vertigo;Visual disturbance;Visual impairment;Vivid dreams;Vomiting,small molecule,approved; investigational,"1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; beta-Propranolol; Propanalol; Propanolol; Propranolol; Propranololo; Propranololum; β-Propranolol; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; AGP 1; AGP1; OMD 1; Orosomucoid-1; hOCT2; OCT2; Organic cation transporter 2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Beta-3 adrenergic receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B, C07AA05; C07BA05;C07AA05;C07FX01
protriptyline,Depression,Abdominal cramps;Abdominal pain;Accommodation disorder;Acute coronary syndrome;Adenitis;Agitation;Agranulocytosis;Alopecia;Anorexia;Anxiety;Arrhythmia;Asthenia;Ataxia;Atrioventricular block;Black hairy tongue;Block heart;Body temperature increased;Bone marrow depression;Breast enlargement;Cerebrovascular accident;Confusional state;Constipation;Convulsion;Coordination abnormal;Decreased appetite;Delusion;Dermatitis;Diarrhoea;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug fever;Drug withdrawal syndrome;Dry mouth;Dysgeusia;Dyspepsia;Eosinophilia;Epigastric distress;Erectile dysfunction;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Feeling abnormal;Flushing;Galactorrhoea;Gynaecomastia;Hallucination;Headache;Hyperpyrexia;Hypertension;Hypoaesthesia;Hypomania;Hypotension;Ileus paralytic;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Insomnia;Intraocular pressure increased;Jaundice;Leukopenia;Libido decreased;Lymphadenitis;Malaise;Mydriasis;Myocardial infarction;Nausea;Neuropathy peripheral;Nightmare;Nocturia;Numbness;Oedema;Orthostatic hypotension;Palpitations;Pancytopenia;Panic reaction;Paraesthesia;Paresthesia of limbs;Parotid gland enlargement;Parotid swelling;Petechiae;Pollakiuria;Pruritus;Psychotic disorder;Purpura;Rash;Sensory loss;Somnolence;Stomatitis;Tachycardia;Taste peculiar;Testicular swelling;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue discolouration;Tremor;Urinary retention;Urticaria;Vascular purpura;Vision blurred;Vomiting;Weight increased;Withdrawal symptom,small molecule,approved,"3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 3-(5H-dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene; 7-(3-methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene; Amimetilina; N-methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; Protriptilina; Protriptylin; Protriptyline; Protriptylinum; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter,N06AA11
pyrantel,Hookworm infection;Infestation;Infestation NOS,Abdominal discomfort;Anorexia;Asthenia;Cramp muscle;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Drowsiness;Fatigue;Headache;Insomnia;Muscle spasms;Nausea;Rash;Somnolence;Vomiting,small molecule,approved; vet_approved,Pirantel; Pyrantel; Pyrantelum; KYNA receptor; Kynurenic acid receptor; 1.14.14.1; 20-HETE synthase; 20-hydroxyeicosatetraenoic acid synthase; CYP4A2; CYP4AII; CYPIVA11; Cytochrome P-450HK-omega; Cytochrome P450HL-omega; Fatty acid omega-hydroxylase; Lauric acid omega-hydroxylase; Long-chain fatty acid omega-monooxygenase,G-protein coupled receptor 35; Muscarinic acetylcholine receptor M1,P02CC01
pyridostigmine,Breast feeding;Ileus paralytic;Myasthenia gravis;Urinary retention,"Abdominal bloating;Abdominal cramps;Abdominal distension;Abdominal pain;Abnormal behaviour;Acute bronchitis;Agitation;Alopecia;Amblyopia;Asthenia;Asthma;Blood pressure increased;Borborygmi;Bradycardia;Bronchitis;Cardiac arrest;Chest discomfort;Chest tightness;Cholinergic crisis;Cholinergic syndrome;Confusional state;Convulsion;Cramp muscle;Delusion;Depressed mood;Dermatitis;Diarrhoea;Drowsiness;Dry skin;Dysmenorrhoea;Epistaxis;Eye pain;Faecal incontinence;Fasciculation;Feeling abnormal;Flatulence;Gastrointestinal pain;Gastrointestinal sounds abnormal;Hallucination, visual;Headache;Hyperhidrosis;Hypersensitivity;Hypertonia;Hypoaesthesia;Hypoaesthesia oral;Hypoesthesia tongue;Hypotension;Increased bronchial secretion;Lacrimation;Lacrimation increased;Lethargy;Loss of consciousness;Miosis;Muscle contractions involuntary;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Nausea;Neck pain;Nicotinic effects;Numbness of tongue;Pallor;Pallor of skin;Paraesthesia;Paranoid delusions;Pollakiuria;Pulmonary oedema;Rash;Respiratory paralysis;Salivary hypersecretion;Somnolence;Sputum increased;Stiffness;Sweating increased;Thrombophlebitis;Tingling of extremity;Tracheobronchitis;Urinary incontinence;Urticaria;Vermiculation;Vertigo;Vomiting",small molecule,approved; investigational,"Piridostigmina; Pyridostigmine cation; 3.4.21.6; Stuart factor; Stuart-Prower factor; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 3.1.1.7; AChE; 3.1.1.7; AChE; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Coagulation factor X; Cholinesterase; Acetylcholinesterase,N07AA02
mepyramine,Arthropod sting;Bite;Nettle rash;Sting;Urticaria,Skin sensitisation,small molecule,approved; vet_approved,"Mepiramina; Mepyramine; N-(p-methoxybenzyl)-N',N'-dimethyl-N-(α-pyridyl)ethylenediamine; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N',N'-dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine; Pyranisamine; Pyrilamine; H1-R; H1R; HH1R; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5",Histamine H1 receptor, R06AC01;D04AA02
pyrimethamine,Malaria;Toxoplasmosis,Anaemia megaloblastic;Anaphylactic shock;Anorexia;Atrophic glossitis;Decreased appetite;Erythema multiforme;Haematuria;Hypersensitivity;Leukopenia;Pancytopenia;Pulmonary eosinophilia;Stevens-Johnson syndrome;Thrombocytopenia;Toxic epidermal necrolysis;Vomiting,small molecule,approved; investigational; vet_approved,"2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(P-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; CD; Chloridine; Chloridyn; Diaminopyritamin; Ethylpyrimidine; Pirimetamina; Primethamine; Pyrimethamine; Pyriméthamine; Pyrimethaminum; 1.5.1.3; Adult folate-binding protein; FBP; Folate receptor 1; Folate receptor, adult; FOLR; FR-alpha; KB cells FBP; Ovarian tumor-associated antigen MOv18; DHFR-TS; 3.2.1.52; Beta-N-acetylhexosaminidase subunit beta; Cervical cancer proto-oncogene 7 protein; HCC-7; Hexosaminidase subunit B; N-acetyl-beta-glucosaminidase subunit beta; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2",Dihydrofolate reductase; Folate receptor alpha; Bifunctional dihydrofolate reductase-thymidylate synthase; Beta-hexosaminidase subunit beta, P01BD01; P01BD51; P01BF04;P01BD01;P01BF09
quazepam,Chronic insomnia;Insomnia,Asthenia;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Fatigue;Headache;Mental disability;Somnolence;Thinking abnormal;Withdrawal syndrome,small molecule,approved; illicit,"Quazepam; Quazepamum; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Translocator protein; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site,N05CD10
quetiapine,Akathisia;Bipolar I disorder;Bipolar II disorder;Bipolar depression;Bipolar disorder;Childhood schizophrenia;Cogwheel rigidity;Dementia;Depression;Extrapyramidal disorder;Extrapyramidal symptoms;Generalised anxiety disorder;Hepatic impairment;Hyperglycaemia;Liver disorder;Major depression;Mania;Mania acute;Mental disorder;Neutropenia;Nuchal rigidity;Psychotic disorder;Schizoaffective disorder;Schizophrenia;Tremor;White blood cell count decreased,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal ejaculation;Abnormal vision;Accidental injury;Accidental overdose;Accommodation disorder;Acne;Acute depression;Acute schizophrenia;Affect lability;Aggression;Agitation;Agranulocytosis;Akathisia;Akinesia;Alanine aminotransferase increased;Alcohol intolerance;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Apathy;Aphasia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrial fibrillation;Atrioventricular block first degree;Back pain;Balance disorder;Bipolar I disorder;Bladder pain;Blepharitis;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood cholesterol increased;Blood creatinine increased;Blood disorder;Blood glucose increased;Blood pressure diastolic decreased;Blood prolactin increased;Body temperature decreased;Body temperature increased;Bone pain;Bradycardia;Brain neoplasm;Breast cancer;Breast disorder;Breast swelling;Bronchitis;Bruxism;Buccoglossal syndrome;Bundle branch block;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure congestive;Cardiomyopathy;Cardiovascular disorder;Cataract;Catatonia;Catatonic reaction;Central nervous system disorder;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Chills;Choreoathetosis;Completed suicide;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatinine increased;Cyanosis;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Delusion;Dental caries;Depersonalisation;Depressed level of consciousness;Depression;Depressive episode;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diabetic coma;Diabetic hyperglycaemic coma;Diabetic ketoacidosis;Diarrhoea;Discomfort;Disorder sight;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dizziness postural;Drooling;Drug interaction;Drug screen positive;Drug withdrawal syndrome;Drug withdrawal syndrome neonatal;Dry eye;Dry mouth;Dry skin;Dry throat;Dysarthria;Dysgeusia;Dyskinesia;Dyslipidaemia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphemia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear pain;Ecchymosis;Eczema;Edema hands;Ejaculation disorder;Electrocardiogram QRS complex prolonged;Electrocardiogram QT prolonged;Electrocardiogram ST segment elevation;Electrocardiogram T wave inversion;Electrocardiogram abnormal;Electrocardiogram change;Embolism venous;Endocrine disorder;Enlargement abdomen;Enuresis;Eosinophilia;Epistaxis;Erectile dysfunction;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye pain;Face oedema;Faecal incontinence;Fasting;Fatal outcomes;Fatigue;Feeling abnormal;Flat affect;Flatulence;Gait disturbance;Galactorrhoea;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival bleeding;Gingivitis;Glaucoma;Glossitis;Glucose increased;Glycosuria;Gout;Gynaecomastia;Haematemesis;Haemoglobin;Haemoglobin decreased;Haemorrhage;Haemorrhoids;Hallucination;Headache;Heart rate irregular;Hemiplegia;Hepatic enzyme increased;Hepatitis;Hepatobiliary disease;Hiccups;High cholesterol;High density lipoprotein decreased;Hormone level abnormal;Hostility;Hot flush;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hyperphagia;Hyperprolactinaemia;Hypersensitivity;Hypersomnia;Hypertension;Hyperthyroidism;Hypertonia;Hyperventilation;Hypoaesthesia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hypotension;Hypothermia;Hypothyroidism;Ileus;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Increased prolactin level;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Intestinal obstruction;Irritability;Jaundice;Lactation female;Laryngeal pain;Lenticular opacities;Lethargy;Leukocytosis;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Loss of consciousness;Low density lipoprotein increased;Lymphadenopathy;Malaise;Malignant syndrome NOS;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Melaena;Menopausal symptoms;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Mental retardation;Metrorrhagia;Migraine;Mood swings;Mouth ulceration;Movement disorder;Movements involuntary;Muscle contractions involuntary;Muscle rigidity;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocarditis;Myoclonus;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Neoplasm;Nervous system disorder;Nervousness;Neuralgia;Neuroleptic malignant syndrome;Neutropenia;Neutrophil count decreased;Night sweats;Nightmare;Nocturia;Nocturnal enuresis;Nuchal rigidity;Obesity;Oculogyration;Oculogyric crisis;Oedema peripheral;Orchitis;Orchitis noninfective;Orthostatic hypotension;Osteoarthritis;Pain;Pain in extremity;Pallor;Palpitations;Pancreatitis;Paraesthesia;Paranoia;Paranoid reaction;Parkinsonian gait;Parkinsonism;Pelvic pain;Pharyngitis;Pharyngolaryngeal pain;Phosphatase alkaline increased;Photosensitivity reaction;Platelet count decreased;Pneumonia;Pollakiuria;Polydipsia;Polyuria;Pregnancy;Priapism;Pruritus;Psoriasis;Psychotic disorder;Pulmonary embolism;Pulse irregular;Rash;Rash maculo-papular;Rectal haemorrhage;Renal failure acute;Restless legs syndrome;Retrograde amnesia;Rhabdomyolysis;Rhinitis;Rhinitis seasonal;Salivary hypersecretion;Schizophrenia;Seasonal allergy;Seborrhoeic dermatitis;Sexual dysfunction;Shock;Sinus congestion;Sinus headache;Sinus tachycardia;Sinusitis;Skin discolouration;Skin disorder;Skin ulcer;Sleep disorder;Sluggishness;Somnambulism;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stomatitis;Stupor;Stuttering;Subdural haematoma;Sudden death;Sudden death, cause unknown;Suicidal ideation;Suicide;Suicide attempt;Sweating;Syncope;Tachycardia;Tardive dyskinesia;Tension;Thinking abnormal;Thirst;Throat tightness;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tongue disorder;Tongue oedema;Tooth abscess;Toothache;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine drug screen positive;Urine output increased;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Venous thromboembolism;Ventricular arrhythmia;Vertigo;Viral diarrhoea;Vision blurred;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginitis;Water intoxication;Weight decreased;Weight increased",small molecule,approved,"2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; Quetiapina; Quetiapine; Quétiapine; Quetiapinum; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; Dopamine D2 receptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT-6; 5-HT6; Serotonin receptor 6; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 2A; D(2) dopamine receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1E; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; D(1A) dopamine receptor; D(1B) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; Histamine H1 receptor; Alpha-1 adrenergic receptors; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5,N05AH04
quinapril,Angioedema;Cardiac failure;Cardiac failure congestive;Essential hypertension;Hypertension;Hypotension;Renovascular hypertension,Abdominal pain;Acute coronary syndrome;Agranulocytosis;Alopecia;Amblyopia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Arrhythmia;Arthralgia;Asthenia;Back pain;Blood and lymphatic system disorders;Blood urea increased;Breast disorder;Cardiac disorder;Cardiogenic shock;Cerebrovascular accident;Chest pain;Connective tissue disorder;Constipation;Cough;Depression;Dermatitis;Dermatitis exfoliative;Dermatomyositis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dyspepsia;Dyspnoea;Erectile dysfunction;Eye disorder;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Haemolytic anaemia;Headache;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hyperkalaemia;Hypertensive crisis;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Insomnia;Laryngeal oedema;Liver function test abnormal;Loss of consciousness;Malaise;Mediastinal disorder;Mental disorder;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Oedema;Orthostatic hypotension;Palpitations;Pancreatitis;Paraesthesia;Pemphigus;Pharyngitis;Photosensitivity reaction;Pregnancy;Pruritus;Pulmonary eosinophilia;Rash;Renal failure;Renal failure acute;Shock;Skin disorder;Somnolence;Sweating increased;Syncope;Tachycardia;Tension;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Vasodilation;Vasodilation procedure;Vertigo;Viral infection;Vomiting,small molecule,approved; investigational,"Quinapril; Quinaprilum; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Angiotensin-converting enzyme, C09BA06;C09AA06
rabeprazole,Chronic gastritis;Duodenal ulcer;Dyspepsia;Gastric ulcer;Gastrinoma;Gastritis;Gastrooesophageal reflux disease;Heartburn;Infection;Non-erosive reflux disease;Peptic ulcer;Regurgitation;Ulcer;Zollinger-Ellison syndrome,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal faeces;Abnormal platelets;Abnormal vision;Abscess;Abscess periodontal;Acute coronary syndrome;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Apnoea;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Ascites;Asthenia;Asthma;Back pain;Benign neoplasm of skin;Bicytopenia;Bladder pain;Blepharitis;Blood creatine phosphokinase increased;Blood disorder;Body temperature increased;Bone pain;Bradycardia;Breast enlargement;Breast neoplasm;Breast pain;Bronchitis;Bundle branch block;Bursitis;Calculus of kidney;Candida infection;Capillary fragility increased;Carcinoma;Carcinoma of lung;Cardiovascular disorder;Cataract;Cellulitis;Cerebral haemorrhage;Chest pain;Chills;Cholangitis;Cholecystitis;Cholelithiasis;Colitis;Colitis ulcerative;Coma;Confusional state;Congenital cystic kidney disease;Conjunctivitis;Constipation;Convulsion;Corneal opacity;Coronary artery disease;Cough;Cramps of lower extremities;Creatine phosphokinase increased;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Delirium;Dementia;Dental caries;Dermatitis;Dermatitis contact;Diabetes mellitus;Diarrhoea;Diarrhoea haemorrhagic;Diplopia;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drug eruption;Dry eye;Dry mouth;Dry skin;Duodenitis;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear disorder;Ear pain;Ecchymosis;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Embolism;Embolus;Enlargement abdomen;Epistaxis;Erectile dysfunction;Eructation;Eruption;Erythema;Erythema multiforme;Extrapyramidal disorder;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Feeling abnormal;Flatulence;Fracture;Fungal skin infection;Gastritis;Gastroenteritis;Gastrointestinal carcinoma;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingivitis;Glaucoma;Glossitis;Gout;Gynaecomastia;Haematuria;Haemolytic anaemia;Hangover;Headache;Hepatic cancer;Hepatic cirrhosis;Hepatic encephalopathy;Hepatic function abnormal;Hepatic steatosis;Hepatitis;Hepatocellular carcinoma;Hernia;Herpes NOS;Herpes simplex;Herpes virus infection;Herpes zoster;Hiccups;Hyperammonaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hyperventilation;Hypochromic anaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypotension;Hypothyroidism;Hypoventilation;Hypoxia;Ileal ulcer;Ill-defined disorder;Increased appetite;Injection site haemorrhage;Injection site pain;Injection site reaction;Insomnia;Interstitial lung disease;Interstitial pneumonia;Iron deficiency anaemia;Jaundice;Lacrimal disorder;Lacrimal structural disorder;Laryngitis;Leukocytosis;Leukopenia;Leukorrhea;Libido decreased;Liver fatty deposition;Liver function test abnormal;Loss of consciousness;Lung disorder;Lung neoplasm malignant;Lymphadenopathy;Malaise;Malignant melanoma;Malnutrition;Mastitis;Melaena;Melanoma skin;Menorrhagia;Menstrual disorder;Metrorrhagia;Migraine;Mouth ulceration;Mucous membrane disorder;Multiple fractures;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nail disorder;Nausea;Neck pain;Neck stiffness;Neoplasm;Neoplasm malignant;Nephritis interstitial;Nephrolithiasis;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Neutropenia;Nuchal rigidity;Oedema;Oedema peripheral;Oesophageal stenosis;Oesophagitis;Orchitis;Orchitis noninfective;Osteoarthritis;Otitis externa;Otitis media;Pain;Palpitations;Pancreatic disorder;Pancreatitis;Pancytopenia;Paraesthesia;Pelvic pain;Pharyngitis;Photosensitivity;Photosensitivity reaction;Platelet disorder;Pneumonia;Pollakiuria;Polycystic kidney;Polyuria;Proctitis;Proctocolitis;Prostatic disorder;Prostatic specific antigen increased;Pruritus;Psoriasis;Pulmonary embolism;Rash;Rectal disorder;Rectal haemorrhage;Red blood cell abnormality;Respiratory failure;Retinal degeneration;Retinal disorder;Retrosternal pain;Rhabdomyolysis;Rheumatoid arthritis;Rhinitis;Right upper quadrant pain;Salivary gland enlargement;Seborrhoeic dermatitis;Shock;Sinus bradycardia;Sinusitis;Skin cancer;Skin carcinoma;Skin discolouration;Skin hypertrophy;Skin mass;Skin nodule;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sudden death;Suicide attempt;Supraventricular tachycardia;Sweating;Swelling face;Syncope;Tachycardia;Tendon disorder;Tension;Thirst;Thrombocytopenia;Thrombophlebitis;Thrombosis;Tinnitus;Tooth abscess;Tooth disorder;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Ulcerative stomatitis;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Uterine haemorrhage;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Varicose vein;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vestibular disorder;Vision blurred;Visual impairment;Vitreous disorder;Vomiting;WBC abnormal NOS;Weight decreased;Weight increased;White blood cell disorder,small molecule,approved; investigational,"Clofezone; Rabeprazole; 7.2.2.19; Gastric H(+)/K(+) ATPase subunit alpha; Proton pump; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Potassium-transporting ATPase alpha chain 1, A02BC04; A02BC54; A02BD13; M01AA05; M02AA03;A02BC04;A02BD12
ephedrine,Adams-Stokes syndrome;Asthma;Atrioventricular block complete;Bronchospasm;Cardiac disorder;Common cold;Headache;Hypersensitivity;Hypertension;Hypotension;Hypotensive;Myasthenia gravis;Narcolepsy;Nasal congestion;Nasopharyngitis;Rhinitis;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Shock;Sinus congestion;Sinus headache;Sinus pain;Swelling,Acute retention of urine;Agitation;Angina pectoris;Anorexia;Anxiety;Arrhythmia;Asthenia;Benign prostatic hyperplasia;Blood pressure increased;Body temperature increased;Bradycardia;Cerebral haemorrhage;Chest pain;Confusional state;Decreased appetite;Delirium;Dependence;Dependence physiological;Dermatitis;Dizziness;Dyspepsia;Dyspnoea;Dysuria;Epigastric distress;Euphoric mood;Extrasystoles;Feeling abnormal;Hallucination;Headache;Hyperhidrosis;Hypertension;Insomnia;Irritability;Lightheadedness;Muscle spasms;Nasal dryness;Nausea;Nervousness;Pain;Pallor;Palpitations;Paranoia;Precordial pain;Prostatic hypertrophy;Prostatism;Psychotic disorder;Rash;Sweating;Tachycardia;Tension;Trembling;Tremor;Urinary retention;Ventricular fibrillation;Vertigo;Vomiting,small molecule,approved,"(-)-Ephedrine; (1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane; Efedrina; Ephedrine; L-Ephedrine; L-erythro-2-(Methylamino)-1-phenylpropan-1-ol; L(−)-ephedrine; Dopamine D2 receptor; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 3.1.1.7; AChE; Solute carrier family 18 member 2; SVMT; VAT2; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT2",D(2) dopamine receptor; Alpha-1A adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Sodium-dependent noradrenaline transporter, A08AA56; C01CA26; R01AA03; R01AB05; R03CA02;R01AA03;S01FB02
raloxifene,Breast cancer;Breast cancer invasive NOS;Hip fracture;Menarche;Menopausal symptoms;Menopause;Osteoporosis;Osteoporosis postmenopausal,Abdominal pain;Angiopathy;Arthralgia;Arthritis;Aspartate aminotransferase increased;Bladder cancer;Bladder pain;Blood and lymphatic system disorders;Blood pressure increased;Body temperature increased;Breast disorder;Breast pain;Bronchitis;Cardiac disorder;Cerebrovascular accident;Chest pain;Cholelithiasis;Conjunctivitis;Connective tissue disorder;Coronary artery disease;Coronary heart disease;Cough;Cough increased;Cramps of lower extremities;Cystitis;Cystitis noninfective;Deep vein thrombosis;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Dizziness;Dyspepsia;Embolism;Embolism venous;Endometrial cancer;Endometrial disorder;Flatulence;Flushing;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Headache;Hot flush;Hyperhidrosis;Hypoaesthesia;Infection;Influenza;Insomnia;Laryngitis;Leukorrhea;Loss of consciousness;Menopausal symptoms;Migraine;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Neoplasm malignant;Nervous system disorder;Neuralgia;Oedema peripheral;Ovarian cancer;Pain;Pharyngitis;Pneumonia;Pulmonary embolism;Rash;Retinal vein occlusion;Retinal vein thrombosis;Rhinitis;Shock;Sinusitis;Skin disorder;Sweating;Syncope;Tenderness;Tendon disorder;Thrombocytopenia;Thromboembolic event;Thrombophlebitis superficial;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Uterine disorder;Uterine haemorrhage;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Varicose vein;Vasodilation;Vasodilation procedure;Venous thromboembolism;Vertigo;Vomiting;Weight increased,small molecule,approved; investigational,"(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone; Raloxifène; Raloxifene; Raloxifeno; Raloxifenum; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; CAP-3; CAP3; Cytoplasmic antiproteinase 3; Peptidase inhibitor 9; PI-9; PI9; BCEI; Breast cancer estrogen-inducible protein; hP1.A; PNR-2; Polypeptide P1.A; Protein pS2; PS2; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; AGP 1; AGP1; OMD 1; Orosomucoid-1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4",Estrogen receptor; Estrogen receptor beta; Serpin B9; Trefoil factor 1,G03XC01
ramipril,Acute coronary syndrome;Acute myocardial infarction;Angioedema;Angiopathy;Cardiac failure;Cardiac failure congestive;Cerebrovascular accident;Essential hypertension;Hypertension;Hypertensive;Hypotension;Left ventricular dysfunction;Microalbuminuria;Myocardial infarction;Nephropathy;Post MI;Progressive renal failure;Protein urine present;Proteinuria;Renal artery stenosis;Renal failure;Renal impairment;Renovascular hypertension,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Acute hepatic failure;Ageusia;Agitation;Agranulocytosis;Alopecia;Alopecia reversible;Amnesia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Antinuclear antibody increased;Antinuclear antibody positive;Anxiety;Arrhythmia;Arthralgia;Arthritis;Asthenia;Asthma;Asthma aggravated;Atrial fibrillation;Balance disorder;Bilirubin conjugated increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood potassium increased;Blood urea increased;Body temperature increased;Bone marrow depression;Breast disorder;Bronchitis;Bronchospasm;Burning sensation;Cardiac failure;Cerebral ischaemia;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cough increased;Cramp muscle;Creatinine increased;Cytolytic hepatitis;Deafness;Decreased appetite;Depressed mood;Dermatitis;Dermatitis exfoliative;Dermatitis psoriasiform;Diarrhoea;Digestion impaired;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug interaction;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Enanthema;Endocrine disorder;Eosinophilia;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Fatal outcomes;Fatigue;Feeling abnormal;Flushing;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal inflammation;Gastrointestinal pain;Glossitis;Gynaecomastia;Haemolytic anaemia;Headache;Hearing impaired;Heart failure signs and symptoms;Hepatic failure;Hepatic necrosis;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hyperhidrosis;Hypersensitivity;Hypoglycaemia;Hyponatraemia;Hypoperfusion;Hypotension;Hypotension symptomatic;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Infarction;Influenza;Insomnia;Ischaemic stroke;Jaundice;Jaundice cholestatic;Kidney function abnormal;Laryngospasm;Leukocytosis;Leukopenia;Libido decreased;Lightheadedness;Liver function test abnormal;Liver injury;Loss of consciousness;Lower respiratory tract infection;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Nasal congestion;Nausea;Nervous system disorder;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Neutropenia;Oedema;Oedema peripheral;Onycholysis;Orthostatic hypotension;Palpitations;Pancreatic enzymes increased;Pancreatitis;Pancytopenia;Paraesthesia;Parosmia;Pemphigoid;Pemphigus;Peripheral vascular disorder;Photosensitivity;Photosensitivity reaction;Polyneuritis;Polyneuropathy;Polyuria;Protein urine present;Proteinuria;Pruritus;Psoriasis;Psoriasis flare-up;Psychomotor skills impaired;Pulmonary eosinophilia;Purpura;Rash;Rash maculo-papular;Red blood cell sedimentation rate increased;Renal artery stenosis;Renal failure;Renal failure acute;Renal impairment;Salivary hypersecretion;Serum potassium increased;Shock;Sinusitis;Skin disorder;Sleep disorder;Sleep disturbance;Small bowel angioedema;Somnolence;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Sweating;Sweating increased;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Transient ischaemic attack;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urine output increased;Urticaria;Vascular purpura;Vascular stenosis;Vasculitis;Vertigo;Visual impairment;Vomiting;Weight increased;White blood cell count decreased,small molecule,approved,"(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; Ramipril; Ramiprilum; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; B1R; BK-1 receptor; BRADYB1; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Angiotensin-converting enzyme; B1 bradykinin receptor, C09AA05; C09BA05; C09BB05; C09BB07; C09BX05; C10BX04; C10BX06; C10BX17; C10BX18;C09AA05;C09BX03
ranitidine,Abdominal discomfort;Acid indigestion;Bacterial infection due to helicobacter pylori (H. pylori);Discomfort;Duodenal ulcer;Dyspepsia;Erosive oesophagitis;Gastric pH decreased;Gastric ulcer;Gastrinoma;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal symptom NOS;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Heartburn;Helicobacter infection;Hyperchlorhydria;Infection;Mendelson's syndrome;Obesity;Oesophagitis;Peptic ulcer;Reflux esophagitis;Scleroderma;Sour stomach;Systemic mastocytosis;Ulcer;Ulcer haemorrhage;Upper gastrointestinal haemorrhage;Upset stomach;Zollinger-Ellison syndrome,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Acute interstitial nephritis;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Anaemias haemolytic immune;Anaphylactic shock;Angina pectoris;Angioedema;Aplasia;Aplastic anaemia;Arrhythmia;Arthralgia;Atrioventricular block;Blood creatinine increased;Blood disorder;Blood pH decreased;Body temperature increased;Bone marrow depression;Bradycardia;Breast disorder;Breast feeding;Bronchospasm;Cardiac arrest;Chest pain;Confusional state;Constipation;Delirium;Delusion;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Dizziness;Dyskinesia;Dysphagia;Dyspnoea;Emotional distress;Eosinophilia;Erectile dysfunction;Erythema;Erythema multiforme;Feeling abnormal;Foetor hepaticus;Galactorrhoea;Gynaecomastia;Haematemesis;Hallucination;Headache;Hepatic failure;Hepatitis;Hepatocellular injury;Hyperhidrosis;Hypersensitivity;Hypotension;Ill-defined disorder;Insomnia;Jaundice;Jaundice cholestatic;Leukopenia;Lightheadedness;Liver disorder;Loss of libido;Low pH;Malaise;Mania;Meningitis;Movements involuntary;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nausea;Nephropathy;Nephropathy toxic;Nephrotoxicity;Neutropenia;Pain;Pancreatitis;Pancreatitis acute;Pancytopenia;Photosensitivity;Photosensitivity reaction;Pneumonia;Porphyrin metabolism disorder;Pruritus;Rash;Serum creatinine increased;Shoulder pain;Somnolence;Stomach ache;Sweating;Tachycardia;Thrombocytopenia;Tubulointerstitial nephritis;Urticaria;Vasculitis;Ventricular extrasystoles;Vertigo;Vision blurred;Vomiting;Weight decreased;Wheezing,small molecule,approved; withdrawn,"Ranitidina; Ranitidine; Ranitidinum; Gastric receptor I; H2R; HH2R; 3.1.1.7; AChE; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 3.1.1.7; AChE; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; hOCT1; OCT1; Organic cation transporter 1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hOCT2; OCT2; Organic cation transporter 2",Histamine H2 receptor; Acetylcholinesterase, A02BA02;A02BA02;A02BA07
rapamycin,Hepatic impairment;Hypercholesterolaemia;Kidney transplant rejection;Liver disorder;Ovarian cyst;Rejection acute renal;Renal failure;Renal impairment;Skin cancer;Skin carcinoma,Abdominal distension;Abdominal pain;Abnormal vision;Abscess;Accidental injury;Acidosis;Acne;Acute allograft rejection;Affect lability;Agitation;Alanine aminotransferase increased;Albuminuria;Allergic cutaneous angiitis;Alveolar proteinosis;Amenorrhoea;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Arterial anomaly;Arthralgia;Arthropathy;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Atelectasis;Atrial fibrillation;Azoospermia;Azotaemia;Back pain;Bacterial infection;Basal cell carcinoma;Benign neoplasm of skin;Bladder pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Breast disorder;Bronchiolitis obliterans with organizing pneumonia;Bronchitis;Candida infection;Carcinogenicity;Carcinoma;Cardiac disorder;Cardiac failure congestive;Cardiomegaly;Cataract;Cataract specified;Cellulitis;Chest pain;Chills;Cholesterol serum elevated;Chronic allograft nephropathy;Circumoral paresthesia;Confusional state;Congenital arterial malformation;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cough increased;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine increased;Cushing's syndrome;Cyclosporine toxicity;Cyst;Cytomegalovirus infection;Deafness;Decreased appetite;Decreased tolerance;Deep vein thrombosis;Dehydration;Dermatitis;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Drug tolerance decreased;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Effusion;Embolism venous;Enlargement abdomen;Enterocolitis;Epistaxis;Epstein-Barr virus infection;Erectile dysfunction;Eructation;Face oedema;Fatal outcomes;Feeling abnormal;Flatulence;Fluid overload;Fluid retention;Focal segmental glomerulosclerosis;Fungal skin infection;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gingival hyperplasia;Gingivitis;Glycosuria;Gout;Graft loss;Haematuria;Haemoglobin;Haemolytic uraemic syndrome;Haemoptysis;Haemorrhage;Hallucination;Headache;Hepatic artery thrombosis;Hepatic failure;Hepatic necrosis;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hirsutism;Hormone level abnormal;Hydronephrosis;Hyperbilirubinaemia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlactacidaemia;Hyperlipidaemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypertonia;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hypotension;Hypotonia;Ileus;Ill-defined disorder;Immune system disorder;Impaired healing;Incisional hernia;Increased appetite;Infection;Infection susceptibility increased;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Interstitial lung disease;Kidney function abnormal;Laboratory test abnormal;Lactic dehydrogenase activity increased;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Liver function test abnormal;Liver injury;Local reaction;Loss of consciousness;Lymphadenopathy;Lymphocele;Lymphoedema;Lymphoma;Lymphoproliferative disorder;Malaise;Malignant melanoma;Malnutrition;Mediastinal disorder;Melanoma skin;Menorrhagia;Menstrual disorder;Metrorrhagia;Mood swings;Mouth ulceration;Muscle relaxant therapy;Muscle spasms;Musculoskeletal discomfort;Myalgia;Mycobacterial infection;Nail disorder;Nausea;Neoplasm;Neoplasm malignant;Nephropathy;Nephropathy toxic;Nephrotic syndrome;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Nocturia;Non-Hodgkin's lymphoma;Obliterative bronchiolitis;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Oral candidiasis;Organising pneumonia;Orthostatic hypotension;Osteoarthritis;Osteonecrosis;Osteoporosis;Otitis media;Ovarian cyst;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paraesthesia oral;Parathyroid disorder;Pelvic pain;Pericardial effusion;Peripheral vascular disorder;Peritonitis;Pharyngitis;Phosphatase alkaline increased;Pleural effusion;Pneumocystis jirovecii pneumonia;Pneumonia;Pneumothorax;Pollakiuria;Polycythaemia;Polyp;Polyuria;Post transplant lymphoproliferative disorder;Progressive multifocal leukoencephalopathy;Protein urine present;Proteinuria;Pruritus;Pulmonary embolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary oedema;Pyelonephritis;Pyuria;Rash;Rectal disorder;Renal graft loss;Renal impairment;Renal pain;Renal tubular necrosis;Rhinitis;Scrotal oedema;Sepsis;Serum triglycerides increased;Shock;Sinusitis;Skin cancer;Skin carcinoma;Skin disorder;Skin hypertrophy;Skin ulcer;Somnolence;Squamous cell carcinoma;Stomatitis;Sweating;Syncope;Tachycardia;Tension;Testicular disorder;Tetany;Thrombocytopenia;Thrombocytopenic purpura;Thrombophlebitis;Thrombosis;Thrombotic thrombocytopenic purpura;Tinnitus;Toxicity to various agents;Transplant rejection;Tremor;Tuberculosis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Uremia;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Venous thromboembolism;Viral infection;Visual impairment;Vomiting;Weight decreased;Weight increased;Wound;Wound infection;X-linked lymphoproliferative syndrome,small molecule,experimental; vet_approved,"4-O-((8R)-2-amino-8-O-(4-amino-4-deoxy-α-D-glucopyranosyl)-2,3,7-trideoxy-7-(methylamino)-D-glycero-α-D-allo-octodialdo-1,5:8,4-dipyranos-1-yl)-2-deoxy-D-streptamine; 4-O-(3α-amino-6α-((4-amino-4-deoxy-α-D-glucopyranosyl)oxy)-2,3,4,5aβ,6,7,8,8aα-octahydro-8β-hydroxy-7β-(methylamino)pyrano(3,2-b)pyran-2α-yl)-2-deoxy-D-streptamine; Apramicina; Apramycin; Apramycine; Apramycinum; Nebramycin II",16S ribosomal RNA,L04AA10
rescinnamine,Erythema;Papule;Pustule;Rash pustular;Rosacea,Abdominal pain;Abscess;Accidental injury;Acute coronary syndrome;Angina pectoris;Back pain;Bronchitis;Bullous eruption;Bursitis;Conjunctivitis;Constipation;Cough;Cough increased;Dermatitis;Dermatitis bullous;Dermatitis contact;Discomfort;Dizziness;Dysgeusia;Endocrine disorder;Erythema;Eye irritation;Eyelid oedema;Gastritis;Gastrointestinal pain;Gingivitis;Headache;Herpes zoster;Hypersensitivity;Hypertension;Hypertonia;Hypertrichosis;Hypoaesthesia;Hypothyroidism;Infection;Influenza;Injury;Insomnia;Lacrimation increased;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Numbness of limbs;Oedema;Osteoporosis;Pain;Paraesthesia;Pharyngitis;Photosensitivity reaction;Pigmentation disorder;Pruritus;Psoriasis;Rash;Redness;Rhinitis;Rosacea;Seborrhoeic dermatitis;Sinusitis;Skin cancer;Skin carcinoma;Skin discolouration;Skin discomfort;Skin hyperpigmentation;Skin infection;Skin irritation;Stinging;Sunburn;Taste metallic;Tearing eyes;Tingling sensation;Tooth disorder;Urinary tract infection;Urticaria;Vaginal infection;Vaginal inflammation,small molecule,approved,"3,4,5-Trimethoxycinnamoyl methyl reserpate; Rescinnamine; Trimethoxy cinnamoyl reserpate de methyl; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II",Angiotensin-converting enzyme, C02AA01; C02LA02;C02AA01;C02LA52
reserpine,Agitation;Essential hypertension;Hypertension;Psychotic disorder;Schizophrenia,Ache;Angina pectoris;Anorexia;Anxiety;Arrhythmia;Bradycardia;Breast engorgement;Conjunctival hyperaemia;Deafness;Decreased appetite;Dermatitis;Diarrhoea;Disturbance in sexual arousal;Dizziness;Drowsiness;Dyspnoea;Dysuria;Epistaxis;Erectile dysfunction;Glaucoma;Gynaecomastia;Headache;Libido decreased;Loss of consciousness;Nasal congestion;Nausea;Nervousness;Nightmare;Oedema;Optic atrophy;Pain;Parkinsonism;Pruritus;Purpura;Rash;Shock;Somnolence;Syncope;Tension;Uveitis;Vascular purpura;Vomiting;Weight increased,small molecule,approved; investigational; withdrawn,"(−)-reserpine; (3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; 3,4,5-trimethoxybenzoyl methyl reserpate; Reserpin; Reserpine; Solute carrier family 18 member 2; SVMT; VAT2; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT2; Solute carrier family 18 member 1; VAT1; Vesicular amine transporter 1; VMAT1; API4; Apoptosis inhibitor 4; Apoptosis inhibitor survivin; IAP4; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; hOCT2; OCT2; Organic cation transporter 2; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9",Synaptic vesicular amine transporter; Chromaffin granule amine transporter; Baculoviral IAP repeat-containing protein 5, C02AA02; C02AA52; C02LA01; C02LA71;C02AA02;C02LA51
ribavirin,Alanine aminotransferase increased;Blood bilirubin increased;Bronchial hyperreactivity;Chronic hepatitis;Chronic hepatitis C;Chronic obstructive pulmonary disease;Compensated cirrhosis;Cor pulmonale;Disease progression;Dysgeusia;Environmental exposure;Fibrosis;Foetor hepaticus;Heart disease congenital;Hepatic cirrhosis;Hepatic failure;Hepatitis;Hepatitis C;Hepatocellular injury;Infection;Infection mixed;Inflammation;Influenza;Liver disorder;Lower respiratory tract infection;Respiratory syncytial virus infection;Respiratory tract infection;Viral infection;Weight decreased,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal behaviour;Abnormal dreams;Abnormal vision;Absolute neutrophil count decreased;Acute coronary syndrome;Affect lability;Ageusia;Aggression;Agitation;Alopecia;Amenorrhoea;Amnesia;Amylase increased;Anaemia;Anaphylactic shock;Anger;Angina pectoris;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anti-thyroid antibody positive;Anxiety;Apathy;Aphthous stomatitis;Aplasia pure red cell;Aplastic anaemia;Apnoea;Application site inflammation;Arrhythmia;Arthralgia;Arthritis;Ascariasis;Asthenia;Asthenic conditions;Asthma;Ataxia;Atelectasis;Auditory disorder NOS;Back pain;Bacterial infection;Behavior disorder;Bipolar I disorder;Bipolar disorder;Blindness transient;Blood amylase increased;Blood and lymphatic system disorders;Blood disorder;Blood thyroid stimulating hormone increased;Blood triglycerides increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Breast disorder;Breast pain;Bronchitis;Bronchoconstriction;Bronchospasm;CD4 lymphocytes decreased;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac murmur;Cardiomyopathy;Cellulitis;Cerebral haemorrhage;Cerebral ischaemia;Cerebration impaired;Cheilitis;Cheilosis;Chest discomfort;Chest pain;Chills;Cholangitis;Colitis;Colitis ischaemic;Colitis ulcerative;Coma;Completed suicide;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Cotton wool spots;Cough;Crying;Crying abnormal;Cutaneous sarcoidosis;Cyanosis;Cyst;Cytolytic hepatitis;Deafness;Death;Decreased appetite;Dehydration;Depressed mood;Depression;Dermatitis;Dermatitis atopic;Diabetes mellitus;Diarrhoea;Digitalis toxicity;Discomfort;Disorder sight;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug abuse;Drug hypersensitivity;Dry cough;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphonia;Dyspnoea;Dyspnoea exertional;Ear and labyrinth disorders;Ear pain;Eczema;Emotional disorder;Encephalopathy;Endocarditis;Endocrine disorder;Enterobiasis;Enuresis;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Extrasystoles;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Face oedema;Facial pain;Facial paralysis;Fatigue;Feeling abnormal;Flat affect;Flatulence;Flushing;Found dead (cause undetermined);Fungal infection;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gilbert's syndrome;Gingival bleeding;Gingivitis;Glossitis;Gout;Haemoglobin;Haemoglobin decreased;Haemolysis;Haemolytic anaemia;Haemorrhage;Hair texture abnormal;Hallucination;Headache;Hearing impaired;Hepatic cirrhosis;Hepatic failure;Hepatic function abnormal;Hepatic steatosis;Hepatitis;Hepatobiliary disease;Hepatomegaly;Hepatotoxicity;Herpes simplex;Herpes zoster;Hoarseness;Homicidal ideation;Hyperaesthesia;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlactacidaemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypotension;Hypothyroidism;Hypoventilation;Hypoxia;Idiopathic thrombocytopenic purpura;Ill-defined disorder;Immune system disorder;Increased appetite;Increased upper airway secretion;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Influenza-like symptoms;Injection site dermatitis;Injection site dryness;Injection site erythema;Injection site induration;Injection site infection;Injection site inflammation;Injection site necrosis;Injection site pain;Injection site pruritus;Injection site reaction;Insomnia;Interstitial lung disease;Interstitial pneumonia;Irritability;Jaundice;Keratitis;Laceration;Lacrimal disorder;Lacrimal gland disorder;Lacrimation;Lacrimation increased;Lactic acidosis;Laryngeal pain;Lethargy;Leukopenia;Libido decreased;Lipase increased;Lipodystrophy acquired;Liver fatty;Loose stools;Loss of consciousness;Lower respiratory tract infection;Lung infection;Lung infiltration;Lymphadenopathy;Lymphopenia;Macular oedema;Malaise;Malnutrition;Mania;Mediastinal disorder;Memory impairment;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Micturition disorder;Migraine;Mitochondrial toxicity;Mononeuropathy;Mood alteration NOS;Mood swings;Mouth ulceration;Muscle contracture;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Myocardial ischaemia;Myositis;Nail disorder;Nasal congestion;Nasal discomfort;Nasal irritation;Nasopharyngitis;Nausea;Neoplasm;Nephrotic syndrome;Nervous system disorder;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Neutropenia;Neutrophil count decreased;Night sweats;Nightmare;Oedema;Oedema peripheral;Optic neuritis;Oral candidiasis;Oral herpes;Oral pain;Oropharyngeal discomfort;Oropharyngeal pain;Osteomyelitis;Otitis media;Ovarian disorder;Pain;Pain in extremity;Pallor;Palpitations;Pancreatitis;Panic attack;Papilloedema;Paraesthesia;Peptic ulcer;Pericardial effusion;Pericarditis;Periodontal disease;Peripheral ischaemia;Pharyngitis;Pharyngitis streptococcal;Pharyngolaryngeal pain;Photophobia;Photosensitivity reaction;Pigmentation disorder;Pneumonia;Pneumonia bacterial;Pneumothorax;Pollakiuria;Polyneuropathy;Polyp;Polyuria;Poor quality sleep;Proctocolitis;Prostatitis;Protein urine present;Proteinuria;Pruritus;Psoriasis;Psoriasis flare-up;Psychiatric evaluation abnormal;Psychotic disorder;Pulmonary embolism;Pulmonary hypertension;Pulmonary oedema;Purpura;Pyelonephritis;Rash;Rash erythematous;Rash maculo-papular;Rectal disorder;Renal failure;Renal impairment;Respiratory failure;Respiratory tract congestion;Respiratory tract infection;Reticulocytosis;Retinal artery occlusion;Retinal detachment;Retinal disorder;Retinal exudates;Retinal haemorrhage;Retinal vein occlusion;Rhabdomyolysis;Rheumatoid arthritis;Rhinitis;Rhinorrhoea;Right upper quadrant pain;Rigors;Sarcoidosis;Sepsis;Serous retinal detachment;Sexual dysfunction;Shock;Sinus congestion;Sinusitis;Skin discolouration;Skin disorder;Skin exfoliation;Skin laceration;Sleep disorder;Sneezing;Somnambulism;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sudden death;Suicidal behaviour;Suicidal ideation;Suicide;Suicide attempt;Sweating increased;Syncope;Systemic lupus erythematosus;Tachycardia;Tachypnoea;Taste disorders;Tenderness;Tension;Testicular pain;Thirst;Throat sore;Thrombocytopenia;Thrombocytopenic purpura;Thrombotic thrombocytopenic purpura;Thyroglobulin increased;Thyroid disorder;Thyrotropin high;Tinnitus;Tongue pigmentation;Tooth abscess;Tooth disorder;Toothache;Toxic epidermal necrolysis;Toxicity to various agents;Tremor;Type 1 diabetes mellitus;Ulcer;Ulcerative keratitis;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Uric acid level increased;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;VIIth nerve paralysis;Vaginal disorder;Vaginal infection;Vaginal inflammation;Vasculitis;Venous occlusion;Ventricular bigeminy;Ventricular extrasystoles;Vertigo;Viraemia;Viral infection;Virilism;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vogt-Koyanagi-Harada syndrome;Vomiting;Weight decreased;Weight increased;Wheezing,small molecule,approved,"1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; RBV; Ribavirin; Ribavirina; Ribavirine; Ribavirinum; Tribavirin; 1.1.1.205; IMP dehydrogenase 1; IMPD 1; IMPD1; IMPDH 1; IMPDH-I; Large structural protein; Protein L; Replicase; Transcriptase; 3.4.21.91; NS1; 1.1.1.205; IMP dehydrogenase 2; IMP dehydrogenase II; IMPD 2; IMPD2; IMPDH 2; IMPDH-II; Inosine-5'-monophosphate dehydrogenase type II; 2.7.7.48; PB1; Polymerase basic protein 1; RNA-directed RNA polymerase subunit P1; 3.1.3.5; 3.1.3.99; cN-II; Cytosolic 5'-nucleotidase II; Cytosolic IMP/GMP-specific 5'-nucleotidase; Cytosolic nucleoside phosphotransferase 5'N; High Km 5'-nucleotidase; NT5B; NT5CP; PNT5; 2.7.1.20; Adenosine 5'-phosphotransferase; AK; CNT 3; CNT3; Concentrative Na(+)-nucleoside cotransporter 3; hCNT3; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1",Inosine-5'-monophosphate dehydrogenase 1; RNA-directed RNA polymerase L; Genome polyprotein; Inosine-5'-monophosphate dehydrogenase 2; RNA-directed RNA polymerase catalytic subunit,J05AB04;J05AP01
riluzole,Amyotrophic lateral sclerosis;Anterior horn cell disease;Lower motor neurone lesion;Motor neurone disease;Neurodegenerative disorder,Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal dreams;Abscess;Accidental injury;Acrodynia;Acute coronary syndrome;Adverse reaction;Affect lability;Ageusia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Alveolitis allergic;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angina unstable;Angioedema;Angiopathy;Anorectal discomfort;Anorexia;Anxiety;Apathy;Aplastic anaemia;Apnoea;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asphyxia;Asthenia;Asthma;Ataxia;Atrial fibrillation;Back pain;Biliary colic;Blepharitis;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin abnormal;Blood bilirubin increased;Blood creatine phosphokinase increased;Body temperature decreased;Body temperature increased;Bone disorder;Bone neoplasm;Bradycardia;Breast abscess;Breast disorder;Breast pain;Bronchitis;Bundle branch block;CNS depression NOS;Calculus of kidney;Candida infection;Carcinoma of lung;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac murmur;Cataract;Cellulitis;Cerebral artery embolism;Cerebral haemorrhage;Cerebral ischaemia;Cheilitis;Chest pain;Chills;Cholecystitis;Circumoral paresthesia;Coma;Completed suicide;Condition aggravated;Confusional state;Congenital central nervous system anomaly;Congenital foot malformation;Congestive cardiomyopathy;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cor pulmonale;Cough;Cough increased;Cramps of lower extremities;Cyanosis;Cyst;Deafness;Decreased appetite;Dehydration;Delirium;Delusion;Dementia;Dental caries;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diabetes insipidus;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disseminated intravascular coagulation;Disturbance in sexual arousal;Dizziness;Dry mouth;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Ecchymosis;Eczema;Embolism;Embolus;Endocrine disorder;Endophthalmitis;Enlargement abdomen;Epistaxis;Erectile dysfunction;Erythema multiforme;Erythropenia;Euphoric mood;Exomphalos;Extrapyramidal disorder;Eye disorder;Face oedema;Facial paralysis;Faecal incontinence;Faecalith;Faecaloma;Fatigue;Feeling abnormal;Flat affect;Flatulence;Fluid retention;Fungal skin infection;Furuncle;Furunculosis;Gait disturbance;Gamma-glutamyltransferase increased;Gastric ulcer;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal tract irritation;Generalised oedema;Gingival bleeding;Glaucoma;Glossitis;Glycosuria;Gout;Granuloma skin;Haematemesis;Haematocrit decreased;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Hallucination;Headache;Hemiplegia;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hernia;Hiccups;Hostility;Hyperacusis;Hypercalcaemia;Hypercholesterolaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypoaesthesia oral;Hypochromic anaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hypotension;Hypothermia;Hypotonia;Hypoventilation;Hypoxia;Ileus;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Injection site reaction;Injury;Insomnia;Intentional injury;Interstitial lung disease;Intestinal obstruction;Iron deficiency anaemia;Jaundice;Laryngitis;Leukocytosis;Leukopenia;Libido decreased;Libido increased;Liver function test abnormal;Liver injury;Loss of consciousness;Lung disorder;Lung neoplasm malignant;Lymphadenopathy;Lymphopenia;Major depression;Malaise;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Melaena;Mental disability;Mental disorder;Mesenteric occlusion;Methaemoglobinaemia;Metrorrhagia;Micturition urgency;Migraine;Mood swings;Motor dysfunction;Muscle relaxant therapy;Muscle spasms;Muscle spasticity;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Myocardial ischaemia;Myoclonus;Nausea;Neck pain;Neoplasm;Nephritis;Nephrolithiasis;Nervous system disorder;Nervousness;Neuritis;Neuropathy peripheral;Neutropenia;Nocturia;Normochromic normocytic anaemia;Oedema;Oedema peripheral;Oesophageal stenosis;Oral candidiasis;Orthostatic hypotension;Osteoarthritis;Osteonecrosis;Osteoporosis;Pain;Palpitations;Pancreatitis;Pancytopenia;Panophthalmitis;Paraesthesia;Paraesthesia NEC;Paraesthesia oral;Paranoia;Paranoid reaction;Parathyroid disorder;Pericarditis;Peripheral vascular disorder;Peritonitis;Personality change;Personality disorder;Petechiae;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Platelet count decreased;Pleural disorder;Pleural effusion;Pneumonia;Pneumonia aspiration;Pneumothorax;Pollakiuria;Polyp;Priapism;Proctalgia;Proctitis;Prostate cancer;Prostate carcinoma;Prothrombin time shortened;Pruritus;Pseudomembranous colitis;Pseudomembranous enterocolitis;Psoriasis;Psychotic depression;Psychotic disorder;Pulmonary embolism;Pulmonary function test decreased;Pulmonary oedema;Purpura;Pyelonephritis;Radial nerve palsy;Rash;Reaction aggravation;Rectal tenesmus;Red blood cell count decreased;Renal pain;Respiratory acidosis;Respiratory depression;Respiratory distress;Respiratory failure;Respiratory moniliasis;Rheumatoid arthritis;Rhinitis;Salivary gland enlargement;Schizophrenic reaction;Schizophreniform disorder;Seborrhoeic dermatitis;Sepsis;Shock;Sinusitis;Skin candida;Skin disorder;Skin mass;Skin nodule;Skin ulcer;Somnolence;Stiffness;Stomatitis;Stridor;Stupor;Subarachnoid haemorrhage;Subdural haematoma;Suicide attempt;Supraventricular tachycardia;Sweating;Syncope;Tachycardia;Talipes;Tension;Tetany;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytopenic purpura;Thrombosis;Thyroid neoplasm;Tongue discolouration;Tooth disorder;Traumatic liver injury;Tremor;Trismus;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upset stomach;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urticaria;Uterine fibroids enlarged;Uterine haemorrhage;Uterine leiomyoma;VIIth nerve paralysis;Vaginal moniliasis;Vascular purpura;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vestibular disorder;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased;Weight increased;White blood cell count decreased;White blood cell count increased;Wrist drop;Yawning,small molecule,approved; investigational,Riluzol; Riluzole; Riluzolum; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; Amino acid transport system xc-; Calcium channel blocker resistance protein CCBR1; Solute carrier family 7 member 11; xCT; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter,Sodium channel protein type 5 subunit alpha; Sodium channel protein type 11 subunit alpha; Cystine/glutamate transporter,N07XX02
rimantadine,Body temperature increased;Infection;Influenza;Influenza like illness,Abdominal pain;Ageusia;Agitation;Anorexia;Anxiety;Asthenia;Ataxia;Atrioventricular block;Block heart;Bronchospasm;Cardiac failure;Cerebration impaired;Cerebrovascular disorder;Chills;Confusional state;Constipation;Convulsion;Cough;Decreased appetite;Depression;Dermatitis;Diarrhoea;Disturbance in attention;Dizziness;Dry mouth;Dyspepsia;Dysphagia;Dyspnoea;Euphoric mood;Eye pain;Fatigue;Feeling abnormal;Foot edema;Gait disturbance;Galactorrhoea;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Hallucination;Headache;Hyperhidrosis;Hyperkinesia;Hypertension;Hypoaesthesia;Insomnia;Lacrimation increased;Local swelling;Loss of consciousness;Mental disability;Nausea;Nervousness;Oedema peripheral;Pallor;Palpitations;Parosmia;Pollakiuria;Rash;Rigors;Shock;Somnolence;Stomatitis;Sweating increased;Syncope;Tachycardia;Tension;Tinnitus;Tremor;Vomiting,small molecule,approved; investigational,alpha-Methyl-1-adamantanemethylamine; alpha-Methyladamantanemethylamine; Rimantadina; Rimantadine; Rimantadinum; Proton channel protein M2,Matrix protein 2,J05AC02
risperidone,Abnormal behaviour;Aggression;Agitation;Anxiety;Autism;Behavior disorder;Bipolar I disorder;Bipolar disorder;Breast cancer;Carcinogenicity;Chronic schizophrenia;Delusion;Dementia;Dementia Alzheimer's type;Dementia with Lewy bodies;Diabetes mellitus;Distractibility;Hallucination;Hepatic impairment;Hostility;Irritability;Liver disorder;Mania;Mania acute;Mental disability;Mental disorder;Mental retardation;Nephropathy;Parkinson's disease;Parkinsonism;Physical wandering;Pituitary tumour;Poverty of speech;Pressure of speech;Psychotic disorder;Racing thoughts;Renal failure;Renal impairment;Schizoaffective disorder;Schizophrenia;Schizophrenia and other psychotic disorders;Social avoidant behaviour;Social withdrawal;Suspiciousness;Tachyphrenia;Temper tantrum;Violence,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal involuntary movements;Abnormal vision;Abscess;Acarodermatitis;Accommodation disorder;Acne;Acute coronary syndrome;Adenocarcinoma;Adenoma benign;Affect lability;Affective disorder;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Akathisia;Akinesia;Alanine aminotransferase increased;Albinism;Allergy aggravated;Alopecia;Altered state of consciousness;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anorgasmia;Antidiuretic hormone abnormality;Anxiety;Apathy;Aphasia;Apnoea;Apraxia;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Athetosis;Atrial fibrillation;Atrial septal defect;Atrioventricular block;Atrioventricular block first degree;Automatism;Autonomic nervous system imbalance;Back pain;Balance disorder;Bipolar I disorder;Bipolar disorder;Bladder pain;Blepharitis;Blepharospasm;Blood and lymphatic system disorders;Blood antidiuretic hormone abnormal;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood disorder;Blood glucose increased;Blood insulin increased;Blood iron decreased;Blood prolactin increased;Blood testosterone decreased;Blood triglycerides increased;Blood uric acid increased;Blunted affect;Body temperature decreased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Bradykinesia;Brain neoplasm;Breast discharge;Breast discomfort;Breast disorder;Breast engorgement;Breast enlargement;Breast feeding;Breast pain;Breast pain female;Breast pain male;Bronchitis;Bronchopneumonia;Bronchospasm;Bullous eruption;Bundle branch block;Bundle branch block left;Bundle branch block right;Bursitis;Buttock pain;C1 esterase deficiency acquired;Cachexia;Cardiac arrest;Cardiac disorder;Cardio-respiratory arrest;Cardiovascular disorder;Catatonia;Catatonic reaction;Cellulitis;Central nervous system disorder;Cerebral ischaemia;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Cheilitis;Chest discomfort;Chest pain;Chills;Choking;Cholecystitis;Cholelithiasis;Cholinergic syndrome;Chorea;Choreoathetosis;Circumoral oedema;Clotting;Coagulopathy;Cogwheel rigidity;Colitis;Coma;Common wart;Completed suicide;Conduction disorder;Confusional state;Congenital central nervous system anomaly;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Corpus callosum agenesis;Cough;Cramps of lower extremities;Creatine phosphokinase increased;Crying;Crying abnormal;Cystitis;Cystitis noninfective;Dandruff;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Delusion;Dementia;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diabetes mellitus exacerbated;Diabetic;Diabetic coma;Diabetic hyperglycaemic coma;Diabetic ketoacidosis;Diarrhoea;Diplopia;Discomfort;Disorder sight;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Dizziness;Dizziness postural;Drooling;Drowsiness;Drug eruption;Drug fever;Drug hypersensitivity;Drug withdrawal syndrome;Drug withdrawal syndrome neonatal;Drug-induced parkinsonism;Dry eye;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyskinesia;Dyslipidaemia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear infection;Ear pain;Eczema;Ejaculation delayed;Ejaculation disorder;Ejaculation failure;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT interval abnormal;Electrocardiogram QT prolonged;Electrocardiogram ST segment depression;Electrocardiogram T wave inversion;Electrocardiogram abnormal;Electrocardiogram change;Elevated liver enzyme levels;Emprosthotonus;Endocrine disorder;Endophthalmitis;Enlargement abdomen;Enuresis;Eosinophil count increased;Epistaxis;Erectile dysfunction;Eructation;Eruption lichenoid;Erythema;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Extrapyramidal symptoms;Eye discharge;Eye disorder;Eye infection;Eye movement disorder;Eye pain;Eye rolling;Eye swelling;Eyelid margin crusting;Eyelid oedema;Face oedema;Facial spasm;Faecal incontinence;Faeces discoloured;Fatigability;Fatigue;Feeling abnormal;Flat affect;Flatulence;Floppy iris syndrome;Fluid retention;Flushing;Foramen ovale patent;Function kidney decreased;Functional gastrointestinal disorder;Fungal infection;Furuncle;Furunculosis;Gait disturbance;Galactorrhoea;Gamma-glutamyltransferase increased;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Gingivitis;Glabellar reflex abnormal;Glaucoma;Glycosuria;Grand mal convulsion;Gynaecomastia;Haematemesis;Haematocrit decreased;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Haemorrhoids;Head titubation;Headache;Hearing impaired;Heat stroke;Hepatic enzyme increased;Hepatic failure;Hepatic steatosis;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hereditary angioedema;Hyperacusis;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperinsulinism;Hyperkeratosis;Hyperkinesia;Hyperlipidaemia;Hyperphagia;Hyperphosphataemia;Hyperprolactinaemia;Hyperreflexia;Hypersensitivity;Hypersomnia;Hypertension;Hypertonia;Hypertrichosis;Hypertriglyceridaemia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypochromic anaemia;Hypoglycaemia;Hypohidrosis;Hypokalaemia;Hypokinesia;Hyponatraemia;Hypoproteinaemia;Hyporeflexia;Hypotension;Hypothermia;Hypothyroidism;Hypotonia;Ileus;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Induration;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Influenza-like symptoms;Initial insomnia;Injection site abscess;Injection site cellulitis;Injection site cyst;Injection site haematoma;Injection site induration;Injection site necrosis;Injection site pain;Injection site reaction;Injection site swelling;Injection site ulcer;Insomnia;Intermittent claudication;Intestinal obstruction;Irritable bowel syndrome;Jaundice;Joint stiffness;Joint swelling;Lacrimal disorder;Lacrimation abnormal NOS;Lacrimation increased;Laryngeal oedema;Laryngeal pain;Laryngospasm;Laryngotracheal oedema;Lassitude;Leg pain;Lethargy;Leukocytosis;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Lichenoid keratosis;Lip swelling;Liver fatty;Liver injury;Localised infection;Long QT syndrome;Long QT syndrome congenital;Loss of consciousness;Lower respiratory tract infection;Lymphadenopathy;Lymphadenopathy cervical;Lymphopenia;Major depression;Malaise;Malignant syndrome NOS;Malnutrition;Mania;Manic psychosis;Masked facies;Mastitis;Mediastinal disorder;Melaena;Menorrhagia;Menstrual disorder;Menstruation delayed;Menstruation irregular;Mental disability;Mental disorder;Mental state abnormal;Metrorrhagia;Middle insomnia;Migraine;Mood swings;Mouth ulceration;Movement disorder;Muscle contractions involuntary;Muscle contracture;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Myocarditis;Myoclonus;Myoglobin urine present;Myoglobinuria;Myotonia;Nasal congestion;Nasal oedema;Nasopharyngitis;Nausea;Neck pain;Necrosis;Neoplasm;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Neuropathy peripheral;Neutropenia;Nightmare;Nodule;Normochromic normocytic anaemia;Normocytic anemia;Nuchal rigidity;Numbness;Obesity;Ocular hyperaemia;Oculo-respiratory syndrome;Oculogyration;Oculogyric crisis;Oculorespiratory syndrome;Oedema;Oedema mouth;Oedema peripheral;Oesophageal motility disorder;Oesophagitis;Oligomenorrhoea;Onychomycosis;Opisthotonus;Oropharyngeal spasm;Orthostatic hypotension;Osteoarthritis;Osteodystrophy;Otitis media;Otitis media chronic;Pain;Pain during injection;Pain in extremity;Pallor;Palpitations;Pancreatic neoplasm;Pancreatitis;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Parkinson's disease;Parkinson's disease aggravated;Parkinsonian rest tremor;Parkinsonism;Partial hearing loss;Perineal pain;Periorbital oedema;Peripheral coldness;Pharyngitis;Pharyngolaryngeal pain;Phenylketonuria;Phlebitis;Phlebitis superficial;Photophobia;Photopsia;Photosensitivity;Photosensitivity reaction;Pitting edema;Pituitary adenoma;Pituitary tumour benign;Platelet count decreased;Platelet production decreased;Plateletcrit decreased;Pleurothotonus;Pneumonia;Pneumonia aspiration;Pollakiuria;Polydipsia;Polyuria;Postural orthostatic tachycardia syndrome;Posture abnormal;Precocious puberty;Pregnancy;Priapism;Procedural pain;Productive cough;Pruritus;Pruritus generalised;Pruritus genital;Psoriasis;Psoriasis flare-up;Psychotic depression;Psychotic disorder;Pulmonary congestion;Pulmonary embolism;Pulmonary oedema;Purpura;Rales;Rash;Rash erythematous;Rash generalised;Rash maculo-papular;Rash papular;Rectal haemorrhage;Red blood cell disorders;Redness;Reflex tachycardia;Renal failure;Renal failure acute;Renal impairment;Renal pain;Reproductive toxicity;Respiratory tract congestion;Respiratory tract infection;Restless legs syndrome;Retinal artery occlusion;Retrograde ejaculation;Reye's syndrome;Rhabdomyolysis;Rhinitis;Rhinorrhoea;Rigors;Risus sardonicus;Salivary hypersecretion;Salivation;Sarcoidosis;Seborrhoeic dermatitis;Sensory loss;Sepsis;Serum iron decreased;Serum prolactin increased;Sexual dysfunction;Shock;Sinus arrhythmia;Sinus bradycardia;Sinus congestion;Sinus tachycardia;Sinusitis;Skin discolouration;Skin disorder;Skin exfoliation;Skin lesion;Skin papilloma;Skin ulcer;Sleep apnoea syndrome;Sleep disorder;Sluggishness;Small bowel angioedema;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stillbirth;Stomatitis;Stridor;Stupor;Subcutaneous abscess;Sudden death;Sudden death, cause unknown;Suicide;Suicide attempt;Supraventricular extrasystoles;Surgery;Surgical intervention;Sweating;Sweating decreased;Sweating increased;Swelling;Swollen tongue;Syncope;Tachycardia;Tardive dyskinesia;Taste bitter;Tendonitis;Tension;Tension headache;Testosterone low;Tetany;Thinking abnormal;Thirst;Throat tightness;Thrombocytopenia;Thrombophlebitis;Thrombotic thrombocytopenic purpura;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Tongue paralysis;Tongue spasm;Tonsillitis;Tooth disorder;Toothache;Torsade de pointes;Torticollis;Toxicity to various agents;Tracheobronchitis;Transaminases increased;Transient ischaemic attack;Tremor;Trismus;Ulcer;Ulcerative stomatitis;Unresponsive to stimuli;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vaginal discharge;Vaginal dryness;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vascular purpura;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Viral infection;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting;Vulvovaginal dryness;Water intoxication;Weight decreased;Weight increased;Wheezing;White blood cell count decreased;Withdrawal syndrome;Xerophthalmia;Yawning",small molecule,approved; investigational,"Risperidona; Risperidone; Rispéridone; Risperidonum; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; Dopamine D2 receptor; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; H1-R; H1R; HH1R; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; Dopamine D1 receptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 2A; D(2) dopamine receptor; Alpha-1B adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-1A adrenergic receptor; Alpha-2C adrenergic receptor; Histamine H1 receptor; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 7; D(1A) dopamine receptor,N05AX08
ritonavir,Acquired immunodeficiency syndrome;Autoimmune disorder;Diabetes mellitus;Factor VIII deficiency,Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal faeces;Abnormal vision;Abscess periodontal;Accidental injury;Acne;Acute coronary syndrome;Acute leukaemia;Acute myeloid leukaemia;Adrenal cortical hypofunction;Adrenal insufficiency;Affect lability;Ageusia;Agitation;Albuminuria;Alcohol intolerance;Amblyopia;Amnesia;Anaemia;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anxiety;Aphasia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrioventricular block complete;Atrioventricular block first degree;Atrioventricular block second degree;Avitaminosis;Back pain;Bladder pain;Blepharitis;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood triglycerides increased;Blood urea increased;Body temperature decreased;Body temperature increased;Bone disorder;Bone pain;Breast disorder;Breast pain;Bronchitis;Bundle branch block right;Cachexia;Calculus of kidney;Candida infection;Cardiac disorder;Cardiovascular disorder;Cerebral ischaemia;Cerebral venous thrombosis;Cheilitis;Chest pain;Chills;Cholangitis;Circumoral paresthesia;Colitis;Colitis ulcerative;Coma;Coma hepatic;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Cushing's syndrome;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Dementia;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diarrhoea haemorrhagic;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug interaction;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Eczema;Electrolyte imbalance;Electroretinogram abnormal;Endocrine disorder;Enlargement abdomen;Enzyme abnormality;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Euphoric mood;External ophthalmoplegia;Eye disorder;Eye pain;Face oedema;Facial pain;Factor VIII deficiency;Faecal incontinence;Fasting;Fat redistribution;Fatigue;Feeling abnormal;Feeling hot;Flatulence;Flushing;Folliculitis;Fungal skin infection;Furuncle;Furunculosis;Gait disturbance;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrooesophageal reflux disease;Gingivitis;Glycosuria;Gout;Grand mal convulsion;Haematuria;Haemoglobin;Haemophilia;Haemorrhage;Hallucination;Headache;Hearing impaired;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hepatosplenomegaly;Hepatotoxicity;Hiccups;Hormone level abnormal;Hyperaesthesia;Hyperamylasaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypoaesthesia;Hypotension;Hypothermia;Hypoventilation;Hypovitaminosis;Hypoxia;Ileitis;Ileus;Ill-defined disorder;Immune system disorder;Influenza;Injury;Insomnia;Interstitial lung disease;Interstitial pneumonia;Iritis;Ischaemia;Jaundice;Jaundice cholestatic;Kidney function abnormal;Laryngeal oedema;Leukopenia;Libido decreased;Lipodystrophy acquired;Liver function test abnormal;Liver injury;Local throat irritation;Loss of consciousness;Lung disorder;Lymphadenopathy;Lymphocytosis;Malaise;Malignant melanoma;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Melaena;Melanoma skin;Menorrhagia;Mental disability;Mental disorder;Migraine;Molluscum contagiosum;Mood swings;Mouth ulceration;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myeloproliferative disorder;Myocardial infarction;Myopathy;Myositis;Nausea;Neck pain;Neck stiffness;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Neutropenia;Nocturia;Nuchal rigidity;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Onychomycosis;Ophthalmoplegia;Oral candidiasis;Oropharyngeal pain;Orthostatic hypotension;Osteoarthritis;Pain;Palpitations;Pancreatitis;Paraesthesia;Paraesthesia oral;Paralysis;Parosmia;Pelvic pain;Penis disorder;Peripheral coldness;Peripheral sensory neuropathy;Peripheral vascular disorder;Personality disorder;Pharyngitis;Phlebitis;Photophobia;Photosensitivity reaction;Pollakiuria;Polyuria;Proctalgia;Proctocolitis;Pruritus;Pseudomembranous colitis;Psoriasis;Pyelonephritis;Rash;Rash maculo-papular;Rash pustular;Rectal disorder;Rectal haemorrhage;Rectal tenesmus;Renal failure;Renal failure acute;Renal impairment;Renal pain;Respiratory failure;Retinogram abnormal;Retrosternal pain;Rhinitis;Scotoma;Seborrhoeic dermatitis;Secondary adrenocortical insufficiency;Shock;Sialoadenitis;Sinusitis;Skin discolouration;Skin disorder;Skin hypertrophy;Sleep disorder;Somnolence;Speech disorder;Stomatitis;Stupor;Subdural haematoma;Sweating;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Throat irritation;Thrombocytopenia;Thrombosis;Tinnitus;Tongue disorder;Tongue oedema;Tooth abscess;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urethritis;Urethritis noninfective;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Uveitis;Vaginal infection;Vaginal inflammation;Vasodilation;Vasodilation procedure;Vasospasm;Vertigo;Vesiculobullous rash;Vestibular disorder;Vision blurred;Visual impairment;Vitreous disorder;Vomiting;Weight decreased;Xanthomatosis,small molecule,approved; investigational,"Ritonavir; Ritonavirum; Pr160Gag-Pol; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Gag-Pol polyprotein; Pol polyprotein; Nuclear receptor subfamily 1 group I member 2, J05AE03; J05AE30; J05AP52; J05AR10; J05AR23; J05AR26;J05AE03;J05AP53
rivastigmine,Decreased appetite;Dementia;Dementia Alzheimer's type;Diarrhoea;Nausea;Parkinson's disease;Parkinsonism;Vomiting,"Abdominal pain;Abdominal pain upper;Abnormal chest sounds NOS;Abnormal vision;Abscess;Acute coronary syndrome;Adams-Stokes syndrome;Adenocarcinoma;Affect lability;Ageusia;Aggression;Aggressive reaction;Agitation;Albuminuria;Alopecia;Amnesia;Amylase increased;Anaemia;Anaemia vitamin B12 deficiency;Aneurysm;Angina pectoris;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anxiety;Anxiety depression;Apathy;Aphasia;Apnoea;Appetite absent;Application site burn;Application site eczema;Application site erythema;Application site hypersensitivity;Application site irritation;Application site oedema;Application site pain;Application site pruritus;Application site rash;Apraxia;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthenic conditions;Ataxia;Atrial fibrillation;Atrioventricular block;Atrophic vulvovaginitis;Back pain;Bacterial infection;Balance disorder;Basal cell carcinoma;Benign prostatic hyperplasia;Bladder cancer;Bladder carcinoma;Bladder disorder;Bladder pain;Blepharitis;Blepharospasm;Blister;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood prolactin increased;Body temperature decreased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Bradykinesia;Brain disorder NOS;Breast cancer;Breast disorder;Breast pain;Breath odour;Breath sounds abnormal;Bronchial hyperreactivity;Bronchitis;Bronchospasm;Bullous eruption;Bundle branch block;Bursitis;Cachexia;Calculus of kidney;Candida infection;Carcinoma;Carcinoma colon;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac fibrillation;Cardiovascular disorder;Cataract;Cellulitis;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Chills;Cholecystitis;Cholelithiasis;Chronic obstructive pulmonary disease;Coagulopathy;Cogwheel rigidity;Cold sweat;Colitis;Collagen disorder;Colon cancer;Coma;Common wart;Confusional state;Congenital eye disorder;Congenital joint malformation;Conjunctival haemorrhage;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Coronary artery disease;Cough;Cramp muscle;Cramps of lower extremities;Cutaneous hypersensitivity;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Delirium;Delusion;Dementia;Dental caries;Depersonalisation;Depression;Dermal cyst;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disorder sight;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Dizziness;Drooling;Drowsiness;Dry mouth;Dry skin;Duodenal ulcer;Duodenitis haemorrhagic;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear pain;Eczema;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Emphysema;Endometrial hypertrophy;Epilepsy;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Extrapyramidal disorder;Extrapyramidal symptoms;Extrasystoles;Eye disorder;Eye pain;Eyelid disorder;Face oedema;Faecal incontinence;Fatigue;Feeling abnormal;Flat affect;Flatulence;Fluid retention;Flushing;Fracture;Freezing phenomenon;Fungal infection;Furuncle;Furunculosis;Gait disturbance;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Gingivitis;Glaucoma;Glossitis;Goitre;Gout;Haematemesis;Haematochezia;Haematoma;Haematuria;Haemoglobin;Haemorrhage;Haemorrhage intracranial;Haemorrhoids;Hallucination;Hallucination, visual;Headache;Heart sounds abnormal;Hemiparesis;Hepatitis;Hepatobiliary disease;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hip fracture;Hot flush;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkeratosis;Hyperkinesia;Hyperlipidaemia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hyporeflexia;Hypotension;Hypothermia;Hypothyroidism;Ill-defined disorder;Increased appetite;Increased prolactin level;Infection;Infection parasitic;Infestation;Infestation NOS;Inflammation;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Intestinal obstruction;Kidney function abnormal;Lacrimal disorder;Lacrimation abnormal NOS;Large intestine polyp;Laryngitis;Leg pain;Leukocytosis;Libido decreased;Libido increased;Lipase increased;Liver function test abnormal;Loss of consciousness;Lung disorder;Lymphadenopathy;Malaise;Malnutrition;Mastitis;Mediastinal disorder;Melaena;Meniere's disease;Menopausal symptoms;Mental disability;Mental disorder;Metrorrhagia;Micturition disorder;Micturition urgency;Migraine;Mood swings;Motor dysfunction;Mouth ulceration;Movement disorder;Multiple fractures;Muscle contractions involuntary;Muscle rigidity;Muscle spasms;Muscle stiffness;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Myoclonus;Nail disorder;Nasopharyngitis;Nausea;Neoplasm;Neoplasm malignant;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neurogenic bladder;Neuropathy;Neuropathy peripheral;Neurosis;Nightmare;Nocturia;Nystagmus;Oedema;Oedema peripheral;Oesophageal rupture;Oesophagitis;Oliguria;Onychomycosis;Orthostatic hypotension;Osteoarthritis;Osteoporosis;Otitis externa;Otitis media;Pain;Pain in extremity;Pallor;Palpitations;Pancreatitis;Paraesthesia;Paranoia;Paranoid reaction;Paresis;Parkinson's disease;Parkinsonism;Peptic ulcer;Periorbital oedema;Peripheral ischaemia;Peritonitis;Personality disorder;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photosensitivity reaction;Pleural effusion;Pneumonia;Pollakiuria;Polyuria;Presyncope;Proctalgia;Prostatic adenoma;Prostatic disorder;Pruritus;Pruritus genital;Psychotic disorder;Pulmonary embolism;Pulmonary oedema;Purpura;Pyuria;Raised liver function tests;Rash;Rash erythematous;Rash maculo-papular;Rectal disorder;Rectal haemorrhage;Rectal tenesmus;Red blood cell disorders;Renal cyst;Renal failure;Renal failure acute;Renal impairment;Respiratory failure;Respiratory insufficiency;Restless legs syndrome;Retinal disorder;Retrosternal pain;Rheumatoid arthritis;Rhinitis;Rigors;Salivary hypersecretion;Seborrhoeic dermatitis;Sepsis;Shock;Sick sinus syndrome;Sinusitis;Skin cancer;Skin cold clammy;Skin discolouration;Skin disorder;Skin exfoliation;Skin hypertrophy;Skin irritation;Skin papilloma;Skin ulcer;Sleep disorder;Somnolence;Speech disorder;Spine malformation;Stevens-Johnson syndrome;Stiffness;Stinging;Stomach ache;Subdural haematoma;Sudden cardiac death;Suicidal ideation;Suicide attempt;Sunburn;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating;Sweating increased;Syncope;Syncope vasovagal;Tachycardia;Tendon disorder;Tendonitis;Tension;Thirst;Thrombocytopenia;Thrombophlebitis;Thrombosis;Tinnitus;Tooth disorder;Transient ischaemic attack;Trauma;Trembling;Tremor;Ulcerative stomatitis;Unspecified circulatory system disorder;Unspecified disorder of skin and subcutaneous tissue;Unwell;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Uterine disorder;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginitis atrophic;Varicose vein;Vascular purpura;Vasculitis;Vertigo;Vestibular disorder;Viral infection;Vision blurred;Visual impairment;Vomiting;Weight decreased;Weight increased",small molecule,approved; investigational,(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; Rivastigmina; Rivastigmine; 3.1.1.7; AChE; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase,Acetylcholinesterase; Cholinesterase,N06DA03
rizatriptan,Aura;Cluster headache;Migraine,Abdominal discomfort;Abdominal distension;Acute coronary syndrome;Agitation;Akinesia;Allergic conditions;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anxiety;Apprehension;Arrhythmia;Arteriospasm coronary;Arthralgia;Asthenia;Ataxia;Blood pressure increased;Body temperature increased;Bradycardia;Bradykinesia;Cerebrovascular accident;Chest pain;Chills;Confusional state;Constipation;Convulsion;Coordination abnormal;Cough;Cramp muscle;Deafness;Decreased appetite;Dehydration;Depersonalisation;Dermatitis;Diarrhoea;Disorientation;Disturbance in attention;Dizziness;Dry eye;Dry mouth;Dry throat;Dysaesthesia;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Epistaxis;Eructation;Erythema;Euphoric mood;Eye burns;Eye irritation;Eye pain;Eye pruritus;Eye swelling;Face oedema;Fatigue;Feeling abnormal;Feeling cold;Flatulence;Flushing;Gait disturbance;Gastritis;Gastrointestinal disorder;Hallucination;Hangover;Headache;Hearing impaired;Heat intolerance;Hiccups;Hoarseness;Hot flush;Hyperacusis;Hyperaesthesia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypersomnia;Hypertension;Hypoaesthesia;Hyporeflexia;Increased appetite;Insomnia;Irritability;Ischaemia;Lacrimation;Lacrimation increased;Loss of consciousness;Medication overuse headache;Memory impairment;Menopausal symptoms;Menstrual disorder;Mental disorder;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Nasal dryness;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Oedema;Osteoarthritis;Pain;Pain in jaw;Palpitations;Paraesthesia;Paralysis;Parosmia;Peripheral coldness;Pharyngeal oedema;Pharyngitis;Photophobia;Photopsia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyuria;Presyncope;Prinzmetal angina;Pruritus;Rash;Regurgitation;Rhinorrhoea;Sensation of pressure;Serotonin syndrome;Shock;Sinus disorder;Sneezing;Somnolence;Stiffness;Sweating;Swelling;Swollen tongue;Syncope;Tachycardia;Tachypnoea;Temperature intolerance;Tension;Thirst;Tinnitus;Tongue disorder;Tongue oedema;Toxic epidermal necrolysis;Tremor;Upper respiratory tract infection;Urine output increased;Urticaria;Vasospasm;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Vomiting;Wheezing;Yawning,small molecule,approved,"N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine; N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine; Risatriptan; Rizatriptán; Rizatriptan; Rizatriptanum; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1E; 5-hydroxytryptamine receptor 1F; 5-hydroxytryptamine receptor 7,N02CC04
rofecoxib,Acute pain;Arthritis;Aura;Cluster headache;Dysmenorrhoea;Juvenile idiopathic arthritis;Migraine;Osteoarthritis;Pain;Primary dysmenorrhea;Rheumatoid arthritis,Abdominal distension;Abdominal pain;Abdominal pain upper;Abdominal tenderness;Abrasion NOS;Abscess;Acute coronary syndrome;Agranulocytosis;Allergic cutaneous angiitis;Alopecia;Alveolar osteitis;Alveolitis;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angina unstable;Angioedema;Ankle sprain;Anxiety;Aphthous stomatitis;Aplastic anaemia;Arthralgia;Arthropod bite;Asthenia;Asthma;Atrial fibrillation;Back pain;Back strain;Basal cell carcinoma;Bladder pain;Blister;Body temperature increased;Bradycardia;Breast cancer;Breast mass;Bronchitis;Bronchospasm;Bursitis;Calculus urinary;Cardiac failure congestive;Cellulitis;Cerebrovascular accident;Cerumen impaction;Chest pain;Chills;Cholecystitis;Colitis;Confusional state;Congenital anomaly;Conjunctivitis;Constipation;Contusion;Cough;Cramp muscle;Cystitis;Cystitis noninfective;Deep vein thrombosis;Dental caries;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Developmental delay;Diaphragmatic hernia;Diarrhoea;Disability;Dizziness;Dry mouth;Dry throat;Duodenal perforation;Duodenal ulcer;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear infection;Edema of lower extremities;Epigastric discomfort;Epigastric pain;Epilepsy;Epilepsy aggravated;Epistaxis;Erythema;Erythema multiforme;Excoriation;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Flushing;Fungal infection;Gastric disorder;Gastric flu;Gastric perforation;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrooesophageal reflux disease;Haematochezia;Haematoma;Haemorrhoids;Hallucination;Headache;Heart rate irregular;Heartburn;Hepatic failure;Hepatitis;Herpes simplex;Herpes zoster;Hypercholesterolaemia;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertensive crisis;Hypoaesthesia;Hyponatraemia;Infarction;Infection;Influenza;Injury;Insect bite NOS;Insomnia;Intestinal obstruction;Jaundice;Joint swelling;Laceration;Laryngitis;Leukocytoclastic vasculitis;Leukopenia;Ligament sprain;Loss of consciousness;Lymphoma;Meningitis aseptic;Menopausal symptoms;Menstrual disorder;Mental disorder;Mouth ulceration;Muscle spasms;Muscle strain;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myopathy;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm malignant;Nephritis interstitial;Neuropathy;Neuropathy peripheral;Nocturia;Non-Hodgkin's lymphoma;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Oral disorder;Oral infection;Oral lesion;Otitis;Otitis media;Pain in arm;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Pelvic pain;Pharyngitis;Photosensitivity reaction;Pneumonia;Postoperative pain;Procedural pain;Pruritus;Pseudoporphyria;Pulmonary congestion;Pulmonary embolism;Pulmonary oedema;Rash;Renal failure acute;Renal failure chronic;Respiratory tract congestion;Respiratory tract infection;Rhinitis;Rhinitis allergic;Sciatica;Shock;Sinusitis;Somnolence;Stevens-Johnson syndrome;Stomatitis;Syncope;Tachycardia;Tendonitis;Thrombocytopenia;Tinnitus;Tonsillitis;Toothache;Toxic epidermal necrolysis;Transient ischaemic attack;Trauma;Traumatic arthropathy;Tubulointerstitial nephritis;Upper limb oedema;Upper respiratory tract infection;Urinary retention;Urinary tract infection;Urolithiasis;Urticaria;Vaginal infection;Vaginal inflammation;Venous insufficiency;Ventricular extrasystoles;Vertigo;Viral diarrhoea;Viral infection;Viral syndrome;Vision blurred;Vomiting;Weight increased;Wrist fracture;Xerosis,small molecule,approved; investigational; withdrawn,"3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; Rofécoxib; Rofecoxib; Rofecoxibum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; Tropoelastin; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4",Prostaglandin G/H synthase 2; Elastin,M01AH02
ropinirole,Agitation;Bradycardia;Bradykinesia;Hyperkinesia;Hypertension;Hypertensive;Hypokinesia;Hypotension;Hypotensive;Immobile;Muscle rigidity;Parkinson's disease;Parkinsonism;Restless legs syndrome;Stereotypy;Tachycardia;Vascular resistance systemic;Vomiting,Abdominal adhesions;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abnormal dreams;Abnormal vision;Abscess;Accommodation disorder;Acidosis;Acne;Actinic keratosis;Acute bronchitis;Acute coronary syndrome;Adenocarcinoma;Adenocarcinoma of prostate;Affect lability;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Amenorrhoea;Amnesia;Amylase increased;Anaemia;Anaemia vitamin B12 deficiency;Anaplastic thyroid cancer;Aneurysm;Angina pectoris;Angina pectoris aggravated;Angina unstable;Angioedema;Angiomyolipoma;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anxiety;Apathy;Aphasia;Appendicitis;Arrhythmia;Arteriosclerosis;Arteritis;Arthralgia;Arthritis;Arthritis aggravated;Arthropathy;Ascites;Aseptic necrosis of bone;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atherosclerosis;Atrial fibrillation;Atrioventricular block;Aura;Azotaemia;Back pain;Bacterial infection;Balance disorder;Balanoposthitis;Basal cell carcinoma;Benign intracranial hypertension;Biliary colic;Bladder cancer;Bladder carcinoma;Bladder infection;Bladder pain;Blepharitis;Blepharospasm;Blindness;Blindness transient;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood cholesterol increased;Blood disorder;Blood electrolytes abnormal;Blood iron decreased;Blood lactate dehydrogenase increased;Blood phosphorus increased;Blood pressure increased;Blood urea increased;Blood uric acid increased;Blood urine present;Body temperature increased;Bone disorder;Bone pain;Bone spur;Bradycardia;Brain neoplasm benign;Breast cancer;Breast cyst;Breast disorder;Breast enlargement;Breast neoplasm;Breath odour;Bronchitis;Bruxism;Bullous eruption;Bundle branch block;Burning sensation;Bursitis;Calculus bladder;Calculus of kidney;Candida infection;Carcinoma;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac fibrillation;Cardiac valve disease;Cardiomegaly;Cardiovascular disorder;Carpal tunnel syndrome;Cataract;Cellulitis;Cerebral atrophy;Cerebration impaired;Cerebrovascular disorder;Chest discomfort;Chest pain;Chills;Cholecystitis;Cholelithiasis;Choreoathetosis;Clotting;Coagulopathy;Cold sweat;Colitis;Coma;Compulsions;Concussion;Confusional state;Congenital eye disorder;Conjunctival haemorrhage;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Coronary artery disease;Cough;Cramp muscle;Cramps of lower extremities;Cyanosis;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Delirium;Delusion;Dementia;Dental caries;Depersonalisation;Depressed level of consciousness;Depressed mood;Depression;Depression aggravated;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermoid cyst;Diabetes mellitus;Diabetes mellitus exacerbated;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Dizziness;Dizziness postural;Drug level increased;Dry eye;Dry mouth;Dry skin;Dry throat;Duodenal ulcer;Duodenitis;Dupuytren's contracture;Dysentery;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear infection;Ear pain;Eczema;Ejaculation disorder;Ejaculation failure;Electrocardiogram abnormal;Electrolyte abnormality;Electrolyte imbalance;Embolism;Endocrine disorder;Endometrial cancer;Endometrial neoplasm malignant;Enlargement abdomen;Enzyme abnormality;Eosinophilia;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Euphoric mood;Exostosis;Extrapyramidal disorder;Extrasystoles;Eye disorder;Eye irritation;Eye pain;Face oedema;Faecal incontinence;Fall;Fatigue;Feeling abnormal;Feeling hot;Fibroadenoma of breast;Fibroadenosis of breast;Flat affect;Flatulence;Fluid overload;Fluid retention;Flushing;Folliculitis;Functional gastrointestinal disorder;Fungal infection;Fungal skin infection;Furuncle;Furunculosis;Gait disturbance;Gallbladder disorder;Gamma-glutamyltransferase increased;Gangrene;Gastric disorder;Gastric haemorrhage;Gastric polyps;Gastric ulcer;Gastritis;Gastritis haemorrhagic;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal infection;Gastrointestinal pain;Gastrointestinal stromal tumour;Gastrooesophageal reflux disease;Generalised oedema;Genital candidiasis;Gingival bleeding;Gingivitis;Glaucoma;Glossitis;Glycosuria;Goitre;Gout;Grand mal convulsion;Gravitational oedema;Groin pain;Gynaecomastia;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Haemorrhoids;Hallucination;Head discomfort;Headache;Hearing impaired;Hemianopia;Hemiparesis;Hemiplegia;Hepatic enzyme increased;Hepatobiliary disease;Hepatocellular injury;Herpes simplex;Herpes zoster;Hiatus hernia;Hiccups;Hoarseness;Hot flush;Hunger;Hydrocephalus;Hyperacusis;Hyperaesthesia;Hyperbilirubinaemia;Hyperbilirubinemia aggravated;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkeratosis;Hyperkinesia;Hyperphosphataemia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypersexuality;Hypersomnia;Hypertension;Hypertension worsened;Hyperthyroidism;Hypertonia;Hypertonic bladder;Hyperuricaemia;Hypoaesthesia;Hypochloraemia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hypotension;Hypotension symptomatic;Hypothyroidism;Hypotonia;Ill-defined disorder;Illusion;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Infected cyst;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Influenza-like symptoms;Inner ear disorder;Insomnia;Interstitial lung disease;Intervertebral disc degeneration;Intervertebral disc protrusion;Intestinal obstruction;Irritability;Irritable bowel syndrome;Ischaemic hepatitis;Joint stiffness;Joint swelling;Keratitis;Keratoconjunctivitis sicca;Labyrinthine disorder;Lacrimal disorder;Lacrimation abnormal NOS;Lactase deficiency;Lactic dehydrogenase activity increased;Lactose intolerance;Laryngeal cancer;Laryngeal pain;Laryngitis;Leg edema;Lethargy;Leukocytosis;Leukopenia;Libido decreased;Libido increased;Lipoma;Liver injury;Localised infection;Localized osteoarthritis;Loose stools;Loss of consciousness;Loss of libido;Lower limb fracture;Lower respiratory tract infection;Lymphadenopathy;Lymphocytosis;Lymphoedema;Lymphoma;Lymphopenia;Macular degeneration;Major depression;Malaise;Malaise and fatigue;Malignant melanoma;Malnutrition;Mania;Manic psychosis;Mastitis;Mediastinal disorder;Melaena;Melanocytic naevus;Memory impairment;Menopausal symptoms;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Metrorrhagia;Micturition disorder;Middle ear effusion;Migraine;Migraine without aura;Mitral valve incompetence;Monarthritis;Mood swings;Mouth ulceration;Muscle atrophy;Muscle contractions involuntary;Muscle contracture;Muscle relaxant therapy;Muscle spasms;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Myositis;Nail disorder;Nasal congestion;Nasal mucosal disorder;Nasal polyps;Nasopharyngitis;Nausea;Neck pain;Necrosis;Neoplasm;Neoplasm malignant;Nephritis;Nephrolithiasis;Nerve root lesion;Nervous system disorder;Nervousness;Neuralgia;Neuroma;Neuropathy;Neuropathy peripheral;Neurosis;Nevus;Night sweats;Nightmare;Nocturia;Non-Hodgkin's lymphoma;Obesity;Oedema;Oedema peripheral;Oesophageal carcinoma;Oesophageal stenosis;Oesophageal ulcer;Oesophagitis;Oliguria;Orthostatic hypotension;Osteoarthritis;Osteonecrosis;Osteoporosis;Otitis externa;Otitis media;Pain;Pain in extremity;Pallor;Palpitations;Pancreatitis;Pancreatitis acute;Panic attack;Paraesthesia;Paralysis;Paranoia;Paranoid reaction;Paresis;Parkinson's disease;Parkinson's disease aggravated;Parkinsonism;Parkinsonism aggravated;Parosmia;Partial hearing loss;Pathological gambling;Pelvic peritoneal adhesions;Penis disorder;Peptic ulcer;Perineal pain;Periodontitis;Periorbital oedema;Peripheral gangrene;Peripheral ischaemia;Peritoneal adhesions;Personality disorder;Peyronie's disease;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phlebitis superficial;Phosphatase alkaline increased;Phosphate increased;Photophobia;Photopsia;Photosensitivity allergic reaction;Photosensitivity reaction;Pleurisy;Pneumonia;Poliomyelitis;Pollakiuria;Polycythaemia;Polymyalgia rheumatica;Polyuria;Post procedural haemorrhage;Post procedural infection;Postoperative infection;Precordial pain;Premenstrual syndrome;Presyncope;Procedural complication;Proctalgia;Prostate cancer;Prostatic disorder;Prostatitis;Protein urine present;Proteinuria;Prurigo;Pruritus;Psoriasis;Psoriasis flare-up;Psychotic depression;Psychotic disorder;Pulmonary embolism;Pulmonary oedema;Purpura;Pyelonephritis;Pyuria;Radiculopathy;Rash;Rash erythematous;Rash maculo-papular;Rectal cancer;Rectal disorder;Rectal haemorrhage;Rectal tenesmus;Reflux esophagitis;Renal cyst;Renal failure acute;Renal pain;Respiratory failure;Respiratory insufficiency;Respiratory tract congestion;Respiratory tract infection;Retinal disorder;Retrosternal pain;Rheumatoid arthritis;Rhinitis;Rhinorrhoea;Rigors;Road traffic accident;Rotator cuff syndrome;Sacroiliitis;Saliva altered;Salivary duct obstruction;Salivary hypersecretion;Sciatica;Scotoma;Seborrhoeic dermatitis;Seborrhoeic keratosis;Sedation;Sensory disturbance;Sepsis;Serum iron decreased;Shock;Sick sinus syndrome;Sinus congestion;Sinus headache;Sinusitis;Skin cancer;Skin discolouration;Skin disorder;Skin exfoliation;Skin hypertrophy;Skin lesion;Skin odour abnormal;Skin papilloma;Skin ulcer;Sleep apnoea syndrome;Sleep disorder;Sneezing;Somnambulism;Somnolence;Speech disorder;Spine malformation;Squamous cell carcinoma;Stomatitis;Stress;Stress symptoms;Stupor;Subarachnoid haemorrhage;Sudden onset of sleep;Suicide attempt;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating increased;Syncope;Syncope vasovagal;Synovitis;Tachycardia;Tendonitis;Tension;Tension headache;Terminal insomnia;Testicular disorder;Therapeutic response decreased;Therapeutic response increased;Thinking abnormal;Thirst;Thrombocytopenia;Thrombophlebitis;Thrombosis;Tinnitus;Tongue disorder;Tongue oedema;Tonsillitis;Tooth abscess;Tooth caries aggravated NOS;Tooth disorder;Tooth infection;Toothache;Torticollis;Tracheobronchitis;Transient ischaemic attack;Tremor;Type 2 diabetes mellitus;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Uremia;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Uterine disorder;Uterine haemorrhage;Uterine leiomyoma;Uterine neoplasm;Vaginal haemorrhage;Vaginal infection;Vaginal moniliasis;Vaginal mycosis;Varicose vein;Vascular purpura;Vein disorder;Ventricular tachycardia;Vertigo;Vestibular disorder;Viral diarrhoea;Viral infection;Viral upper respiratory tract infection;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vitamin B12 deficiency;Vitreous detachment;Vocal cord paralysis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased;Weight increased;Wheezing;Wound infection;Xerophthalmia;Yawning,small molecule,approved; investigational,Ropinirol; Ropinirole; Ropinirolum; Dopamine D3 receptor; Dopamine D2 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase,D(3) dopamine receptor; D(2) dopamine receptor; D(4) dopamine receptor; Alpha adrenergic receptor,N04BC04
roxithromycin,Acute bronchitis;Acute pharyngitis;Acute tonsillitis;Bronchitis;Bronchitis chronic;Community acquired pneumonia;Hepatic function abnormal;Impetigo;Infection;Lower respiratory tract infection;Pharyngitis;Pneumonia;Renal failure;Renal impairment;Sinusitis;Tonsillitis;Tooth infection;Tracheobronchitis;Unspecified non-gonococcal urethritis (NGU);Upper respiratory tract infection;Urethritis,Abdominal pain upper;Acute cholestatic hepatitis;Anaphylactic shock;Angioedema;Anorexia;Asthma;Bronchospasm;Candida infection;Deafness;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Dyspepsia;Eosinophilia;Epigastric pain;Erythema multiforme;Feeling abnormal;Flatulence;Fluid retention;Generalised oedema;Glottic edema;Hallucination;Headache;Hearing impaired;Hepatitis cholestatic;Hepatocellular injury;Hypersensitivity;Ill-defined disorder;Jaundice;Laryngeal oedema;Liver injury;Malaise;Nail discolouration;Nausea;Pancreatitis;Paraesthesia;Pruritus;Purpura;Rash;Stevens-Johnson syndrome;Thrombocytosis;Tinnitus;Urticaria;Vascular purpura;Vertigo;Vomiting,small molecule,approved; investigational; withdrawn,"(9E)-erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime); Roxithromycin; Roxithromycine; Roxithromycinum; Roxitromicina; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",50S ribosomal protein L10; ATP-dependent translocase ABCB1,J01FA06
salmeterol,Airway obstruction NOS;Asthma;Asthma exercise induced;Bronchial hyperreactivity;Bronchitis chronic;Bronchospasm;Chronic obstructive pulmonary disease;Dyspnoea;Emphysema;Exercise-induced bronchospasm;Obstructive airways disorder;Reversible airways obstruction,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Acute bronchitis;Anaphylactic shock;Angioedema;Anxiety;Arrhythmia;Arthralgia;Asthenia;Asthma;Atrial fibrillation;Back pain;Body temperature increased;Bone pain;Bronchitis;Bronchospasm;Bronchospasm paradoxical;Candida infection;Cardiac disorder;Chest discomfort;Chest pain;Choking;Cold symptoms;Common cold;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cramp muscle;Cramps of lower extremities;Dental discomfort;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dysmenorrhoea;Dyspepsia;Dyspeptic signs and symptoms;Ear infection;Ear pain;Eczema;Epistaxis;Extrasystoles;Eye infection;Fatigue;Feeling abnormal;Fever of unknown origin;Food allergy;Gastroenteritis;Gastrointestinal infection;Gastrointestinal pain;Gastrointestinal signs and symptoms;Headache;Heartburn;Hyperglycaemia;Hypersensitivity;Hypertension;Ill-defined disorder;Immune system disorder;Infection;Inflammation;Influenza;Injury;Insomnia;Keratitis;Laryngitis;Laryngospasm;Lower respiratory tract infection;Malaise;Malnutrition;Mediastinal disorder;Migraine;Muscle injury;Muscle rigidity;Muscle spasms;Muscle stiffness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myositis;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Nervousness;Oedema;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pain in arm;Pain in extremity;Pain localised;Pallor;Palpitations;Paraesthesia;Pharyngitis;Pneumonia;Protein allergy;Pulmonary congestion;Rash;Respiratory tract congestion;Respiratory tract infection;Rheumatic disorder;Rheumatism;Rhinitis;Rhinitis allergic;Rhinorrhoea;Shoulder pain;Sinus congestion;Sinus headache;Sinusitis;Sleep disorder;Sleep disturbance;Sneezing;Stomach ache;Stridor;Supraventricular tachycardia;Sustained ventricular tachycardia;Swelling;Tachycardia;Tenderness;Tension;Throat irritation;Throat sore;Toothache;Tracheitis;Tracheobronchitis;Tremor;Type I hypersensitivity;Upper respiratory tract infection;Upset stomach;Urinary tract infection;Urticaria;Varicella;Vasodilation;Vasodilation procedure;Ventricular tachycardia;Viral diarrhoea;Viral infection;Vomiting,small molecule,approved,"Salmaterol; Salmeterol; Salmeterolum; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; hOCT2; OCT2; Organic cation transporter 2",Beta-2 adrenergic receptor; Beta-1 adrenergic receptor; Beta-3 adrenergic receptor, R03AC12; R03AK12;R03AC12;R03AK06
stavudine,Immunodeficiency;Infection;Lactic acidosis;Pancreatitis,Abdominal pain;Abnormal dreams;Accidental injury;Acne;Affect lability;Anaemia;Anorexia;Anxiety;Arthralgia;Asthenia;Asymptomatic hyperlactatemia;Autoimmune disorder;Back pain;Basedow's disease;Blood and lymphatic system disorders;Blood disorder;Blood triglycerides increased;Body temperature increased;Breast enlargement;Bronchitis;Buffalo hump;Calculus of kidney;Chills;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cough increased;Decreased appetite;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysuria;Endocrine disorder;Eructation;Fat redistribution;Fatigue;Flatulence;Foetor hepaticus;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Guillain-Barre syndrome;Gynaecomastia;Haematuria;Haemoglobin decreased;Headache;Hepatic failure;Hepatic function abnormal;Hepatic steatosis;Hepatitis;Hepatitis B;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hepatotoxicity;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlactacidaemia;Hypersensitivity;Hypertriglyceridaemia;Hypertrophy of breast;Hypoaesthesia;Inflammation;Influenza;Injury;Insomnia;Insulin resistance;Jaundice;Lactic acidosis;Lactic acidosis syndrome;Leukopenia;Lipoatrophy;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Liver disorder;Lung disorder;Malnutrition;Mental disability;Mental disorder;Metabolic disorder;Mitochondrial toxicity;Mood swings;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Nausea;Nephrolithiasis;Nervous system disorder;Neuritis;Neurological symptom;Neuropathy;Neuropathy peripheral;Neutropenia;Numbness;Opportunistic infection;Osteonecrosis;Pain;Pancreatitis;Paraesthesia;Peripheral sensory neuropathy;Pharyngitis;Polyneuropathy;Pruritus;Rash;Respiratory failure;Rhinitis;Sensory loss;Sinusitis;Skin disorder;Somnolence;Stillbirth;Stomatitis;Sweating;Symptomatic hyperlactatemia;Thinking abnormal;Thrombocytopenia;Tingling sensation;Unspecified disorder of skin and subcutaneous tissue;Urinary tract infection;Urticaria;Vomiting;Weight decreased,small molecule,approved; investigational,"1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; 2',3'-Didehydro-3'-deoxythimidine; 3'-Deoxy-2'-thymidinene; Estavudina; Sanilvudine; Stavudin; Stavudine; Stavudinum; STV; Pr160Gag-Pol; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; CNT 1; CNT1; Concentrative nucleoside transporter 1; hCNT1; Na(+)/nucleoside cotransporter 1; Sodium-coupled nucleoside transporter 1; Solute carrier family 28 member 1",Gag-Pol polyprotein; Reverse transcriptase/RNaseH, J05AF04; J05AR07;J05AF04;J05AR28
salsalate,Arthritis;Osteoarthritis;Rheumatic disorder;Rheumatoid arthritis,Abdominal pain;Anaphylactic shock;Angioedema;Blood creatinine decreased;Bronchospasm;Creatinine low;Deafness;Dermatitis;Diarrhoea;Gastrointestinal pain;Haemoglobin;Haemorrhage;Hearing impaired;Hepatitis;Hypotension;Nausea;Nephritis;Rash;Tinnitus;Urticaria;Vertigo,small molecule,approved,2-Carboxyphenyl salicylate; Disalicylic acid; Disalicylsäure; O-Salicylcylsalicylsäure; o-Salicylsalicylic acid; Salicylic acid bimolecular ester; Salicyloxysalicylic acid; Salicyloylsalicylic acid; Salicylsalicylic acid; Salsalate; Salsalato; Salsalatum; Sasapyrin; Sasapyrine; Sasapyrinum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1,Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1,N02BA06
scopolamine,Accommodation disorder;Amnesia;Cycloplegia;Delirium tremens;Iridocyclitis;Motion sickness;Mydriasis;Nausea;Salivary hypersecretion;Salivation;Vomiting,"Abdominal cramps;Abdominal pain;Accommodation disorder;Acute psychosis;Agitation;Amblyopia;Amnesia;Angle closure glaucoma;Application site burn;Application site pain;Arrhythmia;Asthenia;Body temperature increased;Bradycardia;CNS depression NOS;Confusional state;Conjunctivitis;Constipation;Cycloplegia;Dental caries;Depressed level of consciousness;Dermatitis;Disorientation;Disturbance in attention;Dizziness;Drowsiness;Drug withdrawal syndrome;Dry eye;Dry mouth;Dry skin;Dysphagia;Dysuria;Ear and labyrinth disorders;Eczema;Erythema;Excitement;Eye disorder;Eyelid irritation;Fatigue;Feeling abnormal;Flushing;Follicular conjunctivitis;Hallucination;Hallucination, visual;Headache;Heat exhaustion;Heat intolerance;Heat stroke;Hyperhidrosis;Hypotension;Intoxication;Irritability;Mental disorder;Muscular weakness;Mydriasis;Nausea;Nausea postoperative;Nervous system disorder;Oedema;Pain;Paranoia;Pharyngitis;Photophobia;Poisoning;Procedural nausea;Pruritus;Psychotic disorder;Rash;Rash generalised;Redness;Skin disorder;Skin irritation;Somnolence;Speech disorder;Strangury;Sweating;Tachycardia;Temperature intolerance;Thirst;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Vertigo;Vision blurred;Visual impairment;Vomiting",small molecule,approved; investigational,"(-)-hyoscine; (-)-scopolamine; (1S,3S,5R,6R,7S)-6,7-Epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate; 6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate; 6,7-Epoxytropine tropate; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; Hyoscine; scopine (-)-tropate; scopine (−)-tropate; Scopolamine; Scopolamine hydrobromide; NACRA4; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase","Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2; Sucrase-isomaltase, intestinal", A04AD01; A04AD51; S01FA02;A04AD01;N05CM05
secobarbital,Insomnia,Agitation;Anaemia megaloblastic;Angioedema;Anxiety;Apnoea;Ataxia;Body temperature increased;Bradycardia;CNS depression NOS;Confusional state;Constipation;Depressed level of consciousness;Dermatitis;Dermatitis exfoliative;Dizziness;Feeling abnormal;Hallucination;Headache;Hepatocellular injury;Hyperkinesia;Hypersensitivity;Hypotension;Hypoventilation;Hypoxia;Injection site reaction;Liver injury;Loss of consciousness;Mental disability;Nausea;Nervousness;Nightmare;Rash;Respiratory failure;Shock;Somnolence;Syncope;Tension;Thinking abnormal;Vomiting,small molecule,approved; vet_approved,"(±)-secobarbital; 5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-allyl-5-(1-methylbutyl)barbituric acid; 5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione; Quinalbarbitone; Secobarbital; Secobarbitalum; Secobarbitone; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; NACRA4; NACHRA7; AMPA-selective glutamate receptor 2; GluA2; GluR-2; GluR-B; GluR-K2; GLUR2; Glutamate receptor ionotropic, AMPA 2; EAA4; Excitatory amino acid receptor 4; GluK2; GluR-6; GLUR6; Glutamate receptor 6; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase","Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit alpha-4; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-6; Gamma-aminobutyric acid receptor subunit alpha-1; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit alpha-7; Glutamate receptor 2; Glutamate receptor ionotropic, kainate 2; NMDA receptor", N05CA06;N05CA06;N05CB01
sertraline,"Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal distress;Affect lability;Affective disorder;Agitation;Agoraphobia;Anger;Anxiety;Asthenia;Bradyphrenia;Bradypsychic response;Breast tenderness;Cerebration impaired;Chest pain;Chills;Choking sensation;Compulsions;Convulsion;Decreased interest;Depersonalisation;Depressed mood;Depression;Depressive disorder;Depressive symptom;Derealisation;Discomfort;Distress;Disturbance in attention;Dizziness;Drug interaction;Dysphoria;Dyspnoea;Dysthymic disorder;Emotional distress;Estrangement;Exaggerated startle response;Fatigue;Fear;Fear of death;Feeling guilty;Flashback;Flatulence;Headache;Heart pounding;Hepatic impairment;Hot flush;Hyperhidrosis;Hypervigilance;Hypoaesthesia;Irritability;Lightheadedness;Liver disorder;Major depression;Major depressive disorder, single episode;Mania;Menopausal symptoms;Mental disability;Mood swings;Musculoskeletal discomfort;Myalgia;Nausea;Nephropathy;Numbness;Obsessive rumination;Obsessive thoughts;Obsessive-compulsive disorder;Palpitations;Panic attack;Panic disorder;Panic reaction;Paraesthesia;Partner stress;Post-traumatic stress disorder;Premenstrual dysphoric disorder;Sensory loss;Sexual dysfunction;Sleep disorder;Sleep disturbance;Social phobia;Suicidal ideation;Suicide attempt;Sweating;Tension;Tingling sensation;Trembling;Tremor;Weight increased",Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal vision;Accommodation disorder;Acute coronary syndrome;Adenoma benign;Adhesion;Affect lability;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Akathisia;Alanine aminotransferase increased;Alopecia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Angle closure glaucoma;Anorectal discomfort;Anorexia;Anxiety;Anxiety disorder;Apathy;Aphasia;Aphthous stomatitis;Aplastic anaemia;Apnoea;Appetite absent;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthropathy;Asthenia;Ataxia;Atrial arrhythmia;Atrioventricular block;Atrophic vulvovaginitis;Autonomic neuropathy;Back pain;Balanoposthitis;Benign neoplasm;Bladder pain;Blindness;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood cholesterol increased;Body temperature increased;Bradycardia;Breast disorder;Breast enlargement;Breast feeding;Breast pain;Breast pain female;Breath odour;Bronchitis;Bronchospasm;Bruxism;Bullous eruption;Bundle branch block;Call-Fleming syndrome;Cardiac disorder;Cataract;Cerebral vasoconstriction;Cerebration impaired;Cerebrovascular disorder;Chest pain;Chills;Cholesterol serum elevated;Choreoathetosis;Cold sweat;Colitis;Coma;Completed suicide;Compulsive personality disorder;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Conversion disorder;Convulsion;Coordination abnormal;Cough;Cramp muscle;Cramps of lower extremities;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Delirium;Delusion;Dental caries;Depersonalisation;Depressed level of consciousness;Depression;Depression aggravated;Depressive symptom;Dermatitis;Dermatitis bullous;Dermatitis contact;Diabetes mellitus;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Diuresis;Diverticulitis;Dizziness;Dizziness postural;Drowsiness;Dry mouth;Dry skin;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphasia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Eczema;Ejaculation delayed;Ejaculation disorder;Ejaculation failure;Electric shock;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Endocrine disorder;Enlargement abdomen;Enuresis;Enzyme induction;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Euphoric mood;Exophthalmos;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Faecal incontinence;Fatal outcomes;Fatigue;Feeling abnormal;Feeling jittery;Female sexual dysfunction;Flat affect;Flatulence;Fluid retention;Flushing;Fracture;Gait disturbance;Galactorrhoea;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Gingival hyperplasia;Glaucoma;Glossitis;Gravitational oedema;Gynaecomastia;Haematoma;Haematuria;Haemoglobin;Haemoglobinuria;Haemoptysis;Haemorrhage;Haemorrhagic disorder;Haemorrhoids;Hair texture abnormal;Hallucination;Headache;Hemorrhage abnormal;Hepatic adenoma;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatocellular adenoma;Hepatomegaly;Hernia;Hiccups;High cholesterol;Hostility;Hot flush;Hyperacusis;Hyperaesthesia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperplasia;Hyperprolactinaemia;Hypersensitivity;Hypertension;Hypertension worsened;Hypertonia;Hypertrichosis;Hypertrophy;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypoglycemic reaction;Hypokinesia;Hyponatraemia;Hyporeflexia;Hypotension;Hypothyroidism;Hypotonia;Hypouricaemia;Hypoventilation;Hypoxia;Hysteria;Ill-defined disorder;Illusion;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Inner ear disorder;Insomnia;Intentional self-injury;Jaundice;Labored breathing;Labyrinthine disorder;Lacrimal disorder;Lacrimation abnormal NOS;Laryngitis;Laryngospasm;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Limb paresis;Loose stools;Loss of consciousness;Lupus-like syndrome;Lymphadenopathy;Lymphoma;Malaise;Male sexual dysfunction;Malnutrition;Mania;Manic psychosis;Mastitis;Mastitis acute female;Mediastinal disorder;Melaena;Menopausal symptoms;Menorrhagia;Menstrual disorder;Menstruation irregular;Mental disability;Mental disorder;Metrorrhagia;Micturition disorder;Migraine;Monoparesis;Mood swings;Mouth ulceration;Movement disorder;Multiple fractures;Muscle contractions involuntary;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Mydriasis;Myocardial infarction;Myoclonus;Nausea;Necrolysis epidermal;Necrosis;Neoplasm;Neoplasm malignant;Nervous system disorder;Nervousness;Neuritis;Neuroleptic malignant syndrome;Neuropathy peripheral;Neurosis;Nightmare;Nocturia;Non-Hodgkin's lymphoma;Nystagmus;Obsessive-compulsive personality disorder;Oculogyric crisis;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Optic neuritis;Orthostatic hypotension;Osteoarthritis;Otitis media;Pain;Pallor;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paranoia;Paranoid reaction;Peptic ulcer;Periorbital oedema;Peripheral ischaemia;Peritoneal haemorrhage;Pharyngitis;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyuria;Precordial pain;Pregnancy;Premature ejaculation;Priapism;Proctalgia;Proctitis;Pruritus;Psychotic disorder;Pulmonary hypertension;Purpura;Pyelonephritis;Rash;Rash erythematous;Rash follicular;Rash maculo-papular;Rash pustular;Rectal tenesmus;Renal failure acute;Renal pain;Respiratory failure;Respiratory rate decreased;Respiratory tract infection;Retrosternal pain;Reversible cerebral vasoconstriction syndrome;Rhinitis;Rigors;Salivary hypersecretion;Salivation;Scotoma;Self injurious behaviour;Self-injurious ideation;Serotonin syndrome;Serum sickness;Sexual dysfunction;Shock;Sinusitis;Skin cold clammy;Skin discolouration;Skin disorder;Skin odour abnormal;Soft stools;Somnambulism;Somnolence;Speech disorder;Stereotypy;Stevens-Johnson syndrome;Sticky skin;Stomatitis;Strangury;Stridor;Stupor;Suicidal ideation;Suicide;Suicide attempt;Sweating;Sweating increased;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Tinnitus;Tongue disorder;Tongue oedema;Tongue ulceration;Tooth caries aggravated NOS;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Ulcerative stomatitis;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urine output increased;Urticaria;Vaginal discharge;Vaginal haemorrhage;Vaginitis atrophic;Varicose vein;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Vasospasm cerebral;Ventricular tachycardia;Vertigo;Visual impairment;Vomiting;Weight decreased;Weight increased;Withdrawal syndrome;Xerophthalmia;Yawning,small molecule,approved,"(+)-Sertraline; (1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; (1S,4S)-sertraline; cis-(+)-sertraline; Sertralina; Sertraline; Sertralinum; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; Dap1; HPR6.6; IZA; mPR; PGRMC; Aging-associated gene 8 protein; hSigmaR1; OPRS1; SIG-1R; Sigma 1-type opioid receptor; Sigma1-receptor; Sigma1R; SR-BP; SR31747-binding protein; SRBP; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; ENT4; hENT4; Plasma membrane monoamine transporter; PMAT; Solute carrier family 29 member 4; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; CYP2B7; Cytochrome P450 2B7 short isoform; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent serotonin transporter; Sodium-dependent dopamine transporter; Sigma receptor; Sodium-dependent noradrenaline transporter; Equilibrative nucleoside transporter 4,N06AB06
sevoflurane,Convulsion,Acidosis;Agitation;Airway obstruction NOS;Albuminuria;Amblyopia;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Apnoea;Arrhythmia;Arrhythmia supraventricular;Asthenia;Atrial arrhythmia;Atrial fibrillation;Atrioventricular block complete;Atrioventricular block second degree;Body temperature decreased;Body temperature increased;Bone disorder;Bradycardia;Breath holding;Breath holding attack;Bronchospasm;Cardiac arrest;Cardiac disorder;Chest discomfort;Chest pain;Chills;Confusional state;Conjunctivitis;Convulsion;Cough;Cough increased;Dermatitis;Dermatitis contact;Dizziness;Dry mouth;Dysgeusia;Dyspnoea;Dysuria;Electrocardiogram QT prolonged;Electrocardiogram ST segment depression;Electrocardiogram T wave inversion;Extrasystoles;Eyelid oedema;Feeling abnormal;Fluoride increased;Fluorosis;Gastrointestinal disorder;Glycosuria;Haemoglobin;Haemorrhage;Headache;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatobiliary disease;Hiccups;Hyperbilirubinaemia;Hyperglycaemia;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypophosphataemia;Hypotension;Hypothermia;Hypoventilation;Hypoxia;Immune system disorder;Increased bronchial secretion;Insomnia;Intracranial pressure increased;Jaundice;Laryngospasm;Leukocytosis;Liver function test abnormal;Loss of consciousness;Malnutrition;Mediastinal disorder;Mental disorder;Muscle rigidity;Muscle twitching;Nausea;Nervous system disorder;Nervousness;Obstructive airways disorder;Occupational exposures;Oedema;Oliguria;Pain;Pancreatitis;Pharyngitis;Pruritus;Pulmonary function test decreased;Rash;Renal failure;Renal failure acute;Respiratory depression;Respiratory failure;Rhabdomyolysis;Salivary hypersecretion;Shivering;Shock;Skin disorder;Somnolence;Sputum increased;Stridor;Supraventricular extrasystoles;Swelling face;Syncope;Tachycardia;Tension;Thrombocytopenia;Tonic clonic movements;Torsade de pointes;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urination impaired;Urine abnormality;Urine analysis abnormal;Urticaria;Ventricular bigeminy;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vomiting;Wheezing,small molecule,approved; vet_approved,"1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane; Sevofluran; Sevoflurane; Sevoflurano; Sevofluranum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; Glycine receptor 48 kDa subunit; Glycine receptor strychnine-binding subunit; AMPA-selective glutamate receptor 1; GLUA1; GLUH1; GluR-1; GluR-A; GluR-K1; GLUR1; Glutamate receptor ionotropic, AMPA 1; 7.2.2.10; ATP-dependent Ca(2+) pump PMR1; ATPase 2C1; Ca(2+)/Mn(2+)-ATPase 2C1; KIAA1347; PMR1L; Secretory pathway Ca(2+)-transporting ATPase type 1; SPCA1; 7.2.2.10; ATPase 2C2; Ca(2+)/Mn(2+)-ATPase 2C2; KIAA0703; Secretory pathway Ca(2+)-transporting ATPase type 2; SPCA2; 7.2.2.10; Plasma membrane calcium ATPase isoform 1; Plasma membrane calcium pump isoform 1; PMCA1; 7.2.2.10; Plasma membrane calcium ATPase isoform 2; Plasma membrane calcium pump isoform 2; PMCA2; 7.2.2.10; Plasma membrane calcium ATPase isoform 3; Plasma membrane calcium pump isoform 3; PMCA3; 7.2.2.10; ATP2B2; Matrix-remodeling-associated protein 1; MXRA1; Plasma membrane calcium ATPase isoform 4; Plasma membrane calcium pump isoform 4; PMCA4; 7.2.2.10; Calcium pump 1; Calcium-transporting ATPase sarcoplasmic reticulum type, fast twitch skeletal muscle isoform; Endoplasmic reticulum class 1/2 Ca(2+) ATPase; SERCA1; SR Ca(2+)-ATPase 1; 7.2.2.10; ATP2B; Calcium pump 2; Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform; Endoplasmic reticulum class 1/2 Ca(2+) ATPase; SERCA2; SR Ca(2+)-ATPase 2; Coiled-coil domain-containing protein 51; MITOK; 7.1.1.2; MTND1; NADH dehydrogenase subunit 1; NADH1; ND1; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",GABA(A) Receptor; Glycine receptor subunit alpha-1; Glutamate receptor 1; Calcium transporting ATPases; Mitochondrial potassium channel; NADH-ubiquinone oxidoreductase chain 1,N01AB08
sibutramine,Agitation;Increased activity;Obesity;Weight decreased,"Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal ejaculation;Abnormal faeces;Abnormal vision;Abscess;Abscess periodontal;Accidental injury;Acne;Acute coronary syndrome;Acute interstitial nephritis;Acute nephritis;Affect lability;Agitation;Akathisia;Alanine aminotransferase increased;Albuminuria;Alcohol intolerance;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Anger;Angina pectoris;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Apathy;Apnoea;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrial fibrillation;Auditory and visual hallucinations;Back pain;Bladder pain;Blister;Blood alkaline phosphatase increased;Blood creatinine increased;Blood pressure increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Brain neoplasm;Breast enlargement;Breath odour;Bronchitis;Bundle branch block;Bursitis;Carcinoma;Cardiac arrest;Cardiac failure congestive;Cardiovascular disorder;Cataract;Cellulitis;Cerebral ischaemia;Cerebration impaired;Cerebrovascular accident;Cheilitis;Chest discomfort;Chest pain;Chest pressure;Chest tightness;Chills;Cholecystitis;Cholelithiasis;Circumoral paresthesia;Colitis;Completed suicide;Confusional state;Conjunctivitis;Constipation;Contusion;Convulsion;Cough;Cough increased;Cramps of lower extremities;Creatinine increased;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Delusion;Dental caries;Depression;Depression aggravated;Dermatitis;Dermatitis bullous;Dermatitis contact;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dry skin;Duodenal ulcer;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear disorder;Ear pain;Ecchymosis;Eczema;Ejaculation disorder;Electrocardiogram abnormal;Enlargement abdomen;Enteritis;Eosinophilia;Epididymitis;Epilepsy;Epistaxis;Erectile dysfunction;Eructation;Eruption;Euphoric mood;Eye disorder;Eye pain;Face oedema;Facial paralysis;Feeling abnormal;Flat affect;Flatulence;Fluid retention;Furuncle;Furunculosis;Gait disturbance;Gamma-glutamyltransferase increased;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Gingivitis;Glaucoma;Glomerulonephritis membranoproliferative;Glossitis;Goitre;Gout;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoids;Hair disorder;Hallucinations, mixed;Hangover;Headache;Henoch-Schonlein purpura;Hepatic function abnormal;Hepatic steatosis;Hernia;Herpes simplex;Herpes zoster;Hormone level abnormal;Hostility;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hypotension;Hypothyroidism;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Inflammation;Influenza;Injury;Insomnia;Intestinal obstruction;Intraocular pressure increased;Iritis;Iron deficiency anaemia;Laboratory test abnormal;Lacrimal disorder;Lacrimal structural disorder;Laryngitis;Leukocytosis;Leukopenia;Libido decreased;Libido increased;Liver fatty;Liver function test abnormal;Loss of consciousness;Lung disorder;Lymphadenopathy;Lymphocytosis;Major depression;Malaise;Malignant hypertension;Malnutrition;Mania;Manic psychosis;Menstrual disorder;Mental disability;Metrorrhagia;Migraine;Monocytosis;Mood swings;Mouth ulceration;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myocardial infarction;Myoclonus;Myopathy;Nail disorder;Nasal congestion;Nausea;Neck pain;Neoplasm;Neoplasm malignant;Neoplasm skin;Nephritic syndrome;Nephritis;Nephritis interstitial;Nervousness;Neuralgia;Neuritis;Neuropathy peripheral;Neurosis;Nightmare;Oedema;Oedema peripheral;Oesophagitis;Orthostatic hypotension;Osteoarthritis;Osteoporosis;Otitis externa;Otitis media;Pain;Pain in extremity;Palpitations;Paraesthesia;Paraesthesia oral;Parosmia;Pelvic pain;Peripheral vascular disorder;Personality disorder;Petechiae;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Pruritus;Psoriasis;Psychotic depression;Psychotic disorder;Psychotic episode;Purpura;Rash;Rash macular;Rash pustular;Rash vesicular;Rectal disorder;Rectal haemorrhage;Renal failure;Renal impairment;Retinal disorder;Retrosternal pain;Rheumatoid arthritis;Rhinitis;Right ventricular failure;Salivary hypersecretion;Sepsis;Septicemia;Serotonin syndrome;Shock;Short-term memory loss;Sinusitis;Skin disorder;Skin hypertrophy;Skin mass;Skin nodule;Skin ulcer;Sleep disorder;Somnolence;Speech disorder;Stomatitis;Sudden death;Sudden death, cause unknown;Suicidal ideation;Suicide;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating;Syncope;Tachycardia;Tenosynovitis;Tension;Therapeutic response unexpected;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytosis;Thyroid disorder;Tinnitus;Tongue disorder;Tongue oedema;Tooth abscess;Tooth disorder;Torsade de pointes;Torticollis;Tourette's disorder;Transient ischaemic attack;Tremor;Tubulointerstitial nephritis;Unexpected therapeutic effect;Urinary incontinence;Urinary retention;Urinary tract infection;Urticaria;VIIth nerve paralysis;Vaginal haemorrhage;Varicose vein;Vascular headache;Vascular purpura;Vasculitic rash;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vestibular disorder;Vision blurred;Visual impairment;Vomiting;Weight increased;Yawning",small molecule,approved; illicit; investigational; withdrawn,"Sibutramina; Sibutramine; Sibutraminum; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Sodium-dependent dopamine transporter; Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter,A08AA10
sildenafil,Connective tissue disorder;Diabetes mellitus;Diabetic;Erectile dysfunction;Fasting;Heart disease congenital;Hepatic cirrhosis;Hepatic failure;Hepatic impairment;Hepatic insufficiency;Hypertension;Hypotonia;Liver disorder;Muscle relaxation;Muscle rigidity;Primary pulmonary hypertension;Pulmonary arterial hypertension;Pulmonary hypertension;Pulmonary hypertension secondary;Renal failure;Renal impairment;Spinal cord injury,AION;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal ejaculation;Abnormal sensation in eye;Abnormal vision;Accidental injury;Acute coronary syndrome;Agitation;Alanine aminotransferase increased;Alopecia;Anaemia;Angina pectoris;Angina unstable;Angiopathy;Anorectal disorder;Anorexia;Anorgasmia;Anxiety;Anxiety depression;Arrhythmia;Arteriosclerotic retinopathy;Arteritic anterior ischaemic optic neuropathy;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthenopia;Asthma;Ataxia;Atrial fibrillation;Atrioventricular block;Back pain;Balanitis;Bladder pain;Blindness;Blindness transient;Blood and lymphatic system disorders;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Breast disorder;Breast enlargement;Bronchitis;Bronchopneumonia;Burning sensation;Carcinoma of lung;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiogenic shock;Cardiomyopathy;Cardiovascular disorder;Cataract;Cellulitis;Cerebral haemorrhage;Cerebral thrombosis;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Chills;Chloropsia;Chromatopsia;Colitis;Conjunctival disorder;Conjunctival hyperaemia;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Cough;Cough increased;Cyanopsia;Cystitis;Cystitis noninfective;Deafness;Deafness neurosensory;Decreased appetite;Dental caries;Depression;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Detachment psychological;Device malfunction;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disorder sight;Dissociation;Dizziness;Drug effect increased;Dry eye;Dry mouth;Dyspepsia;Dysphagia;Dyspnoea;Dyspnoea exacerbated;Ear and labyrinth disorders;Ear disorder;Ear pain;Ejaculation disorder;Electrocardiogram abnormal;Endocrine disorder;Endophthalmitis;Enterocolitis;Epistaxis;Erectile dysfunction;Erection increased;Erection prolonged;Eructation;Erythema;Erythema multiforme;Erythropsia;Eye disorder;Eye haemorrhage;Eye irritation;Eye oedema;Eye pain;Eye swelling;Eyelid oedema;Face oedema;Fatigue;Feeling abnormal;Feeling hot;Flatulence;Fluid overload;Fluid retention;Flushing;Furuncle;Furunculosis;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingivitis;Glaucoma;Glossitis;Gout;Gynaecomastia;Haematospermia;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhoids;Halo vision;Headache;Hearing impaired;Hernia;Herpes simplex;Hot flush;Hyperaesthesia;Hyperglycaemia;Hyperhidrosis;Hyperlipidaemia;Hypernatraemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypoaesthesia oral;Hypoglycaemia;Hypoglycemic reaction;Hypokalaemia;Hyporeflexia;Hypotension;Hypotensive;Hypoxia;Ill-defined disorder;Immune system disorder;Increased appetite;Increased bronchial secretion;Increased effect;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;International normalised ratio increased;Intraocular pressure increased;Iris disorder;Irritability;Lacrimal disorder;Lacrimal structural disorder;Lacrimation increased;Laryngeal pain;Laryngitis;Leukopenia;Liver function test abnormal;Loss of consciousness;Lower respiratory tract infection;Lung neoplasm malignant;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Migraine;Migraine without aura;Mouth ulceration;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myasthenia;Mydriasis;Myocardial infarction;Myocardial ischaemia;Myopia;Nail disorder;Nasal congestion;Nasal dryness;Nasal oedema;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Night sweats;Nocturia;Ocular hyperaemia;Oculogyric crisis;Oedema;Oedema genital;Oedema peripheral;Oesophagitis;Optic ischaemic neuropathy;Orthostatic hypotension;Osteoarthritis;Other disorders of eye;Pain;Pain in extremity;Pain in jaw;Palpitations;Paraesthesia;Penile haemorrhage;Pharyngitis;Pharyngolaryngeal pain;Photophobia;Photopsia;Photosensitivity reaction;Pneumonia;Pollakiuria;Priapism;Prostatic disorder;Pruritus;Pulmonary haemorrhage;Pulmonary hypertension;Rash;Rectal disorder;Rectal haemorrhage;Redness;Renal failure;Respiratory tract infection;Retinal disorder;Retinal haemorrhage;Retinal oedema;Retinal vascular occlusion;Retinal vein occlusion;Rhinitis;Rhinorrhoea;Right ventricular failure;Scleral discolouration;Scotoma;Sexual dysfunction;Sexually transmitted disease;Shock;Shoulder pain;Sickle cell anaemia;Sickle cell anaemia with crisis;Sinus congestion;Sinusitis;Skin cancer;Skin carcinoma;Skin disorder;Skin hypertrophy;Skin ulcer;Soft tissue disorder;Somnolence;Speech disorder;Sputum increased;Stevens-Johnson syndrome;Stomatitis;Stridor;Sudden cardiac death;Sudden hearing loss;Sweating;Swelling;Syncope;Synovitis;Tachycardia;Tendon rupture;Tenosynovitis;Tension;Testicular disorder;Thirst;Throat tightness;Tinnitus;Tooth disorder;Toxic epidermal necrolysis;Transient global amnesia;Transient ischaemic attack;Tremor;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urticaria;Varicose vein;Vascular anomaly;Vaso-occlusive crisis;Vasodilation;Vasodilation procedure;Ventricular arrhythmia;Vertigo;Viral diarrhoea;Vision blurred;Visual acuity reduced;Visual brightness;Visual colour distortions;Visual disturbance;Visual impairment;Vitreous detachment;Vitreous floaters;Vomiting;Weight increased;Xanthopsia,small molecule,approved; investigational,"1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; Sildenafil; Sildenafilo; C1 esterase inhibitor; C1 Inh; C1-inhibiting factor; C1IN; C1Inh; C1NH; Serpin G1; 3.1.4.35; CGB-PDE; cGMP-binding cGMP-specific phosphodiesterase; PDE5; 3.1.4.35; GMP-PDE gamma; PDEG; 3.1.4.35; GMP-PDE gamma; 4.1.1.17; ODC; B7 homolog 1; B7-H1; B7H1; hPD-L1; PD-L1; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL1; Programmed death ligand 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.-; 7.6.2.2; MOAT-C; MRP5; Multi-specific organic anion transporter C; Multidrug resistance-associated protein 5; pABC11; SMRP; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","Plasma protease C1 inhibitor; cGMP-specific 3',5'-cyclic phosphodiesterase; Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma; Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma; Ornithine decarboxylase; Programmed cell death 1 ligand 1", G04BE03;G01AE10;G04BE03
silver,Burns third degree;Wound sepsis,Agranulocytosis;Aplastic anaemia;Bacterial colonisation;Bacterial disease carrier;Blood disorder;Burning sensation;Dermatitis;Dermatitis exfoliative;Erythema multiforme;Gastrointestinal disorder;Haemolytic anaemia;Hepatic necrosis;Hepatitis;Hypersensitivity;Leukopenia;Muscle contracture;Nephritis interstitial;Nephrosis;Nephrotic syndrome;Partner stress;Rash;Reaction gastrointestinal;Separation;Sepsis;Skin discolouration;Skin exfoliation;Skin necrosis;Stevens-Johnson syndrome;Thrombocytopenia;Tubulointerstitial nephritis,small molecule,approved; investigational,"Argentum metallicum; Colloidal silver; Nanosilver; Silver colloidal; Silver nanoparticles; Silver, colloidal; MRE-binding transcription factor; Transcription factor MTF-1; Metallothionein-IA; MT-1A; MT-IA; MT1S; Metallothionein-IB; MT-1B; MT-IB; MT1Q; Metallothionein-IE; MT-1E; MT-IE; Metallothionein-IF; MT-1F; MT-IF; Metallothionein-1K; Metallothionein-IG; MT-1G; MT-1K; MT-IG; MT1K; MT1M; Metallothionein-0; Metallothionein-IH; MT-0; MT-1H; MT-IH; Metallothionein-IL; MT-1L; MT-IL; Metallothionein-IM; MT-1M; MT-IM; MT1K; Metallothionein-IX; MT-1X; MT-IX; CES1; Metallothionein-2A; Metallothionein-II; MT-2; MT-II; MT2; GIF; GIFB; Growth inhibitory factor; Metallothionein-III; MT-3; MT-III; Metallothionein-IV; MT-4; MT-IV; MTM; Metallothionein-like 5, testis-specific; MTL5; Testis-specific metallothionein-like protein; Cuproxidase ceruloplasmin; Ferroxidase ceruloplasmin; Glutathione peroxidase ceruloplasmin; Glutathione-dependent peroxiredoxin ceruloplasmin; Alpha-2-M; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5; CPAMD5",Metallothionein; Ceruloplasmin; Albumin; Alpha-2-macroglobulin,D06BA01;D08AL30
sulfadiazine,"Acquired immunodeficiency syndrome;Autoimmune disorder;Bladder pain;Burns third degree;Cerebral toxoplasmosis;Chancroid;Cystitis;Cystitis noninfective;Inclusion conjunctivitis;Infection;Malaria;Meningitis;Meningitis meningococcal;Nocardiosis;Otitis media acute;Pneumonia due to Streptococcus, group b;Pneumonia streptococcal;Pyelitis;Pyelonephritis;Rheumatic disorder;Rheumatic fever;Trachoma;Urinary tract infection;Urinary tract obstruction;Wound sepsis",Abdominal pain;Agranulocytosis;Anaphylactic shock;Anaphylactoid reaction;Anorexia;Anuria;Aplastic anaemia;Arthralgia;Ataxia;Bacterial colonisation;Bacterial disease carrier;Blood disorder;Body temperature increased;Burning sensation;Chills;Convulsion;Crystalluria;Decreased appetite;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Diuresis;Drug fever;Eosinophilic myocarditis;Eruption;Erythema multiforme;Gastrointestinal disorder;Gastrointestinal pain;Goitre;Haemolytic anaemia;Hallucination;Headache;Hepatic necrosis;Hepatitis;Hypersensitivity;Hypoglycaemia;Insomnia;Leukopenia;Lupus erythematosus;Methaemoglobinaemia;Muscle contracture;Musculoskeletal discomfort;Nausea;Necrolysis epidermal;Nephritis interstitial;Nephrosis;Nephrotic syndrome;Neuritis;Neuropathy peripheral;Oliguria;Pancreatitis;Partner stress;Periorbital oedema;Polyarteritis nodosa;Polyuria;Pruritus;Purpura;Rash;Reaction gastrointestinal;Scleral hyperaemia;Separation;Sepsis;Serum sickness;Skin discolouration;Skin exfoliation;Skin necrosis;Stevens-Johnson syndrome;Stomatitis;Systemic lupus erythematosus;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Urticaria;Vascular purpura;Vertigo;Vomiting,small molecule,approved; investigational; vet_approved,"2-sulfanilamidopyrimidine; 2-sulfanilylaminopyrimidine; 4-amino-N-2-pyrimidinylbenzenesulfonamide; N(1)-2-Pyrimidinylsulfanilamide; N(1)-2-Pyrimidylsulfanilamide; Sulfadiazin; Sulfadiazina; Sulfadiazine; Sulfadiazinum; Sulfapyrimidine; Sulphadiazine; EC 2.5.1.15; 2.5.1.15; dhpS; Dihydropteroate pyrophosphorylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Dihydropteroate synthetase; Dihydropteroate synthase, G01AE10; J01EC02; J01EE02;J01EC02;J01EE06
sotalol,Arrhythmia;Arrhythmia supraventricular;Atrial fibrillation;Atrial flutter;Cardiac disorder;Cardiac failure congestive;Cardiac flutter;Cardiac index;Cardiomegaly;Cerebrovascular accident;Diabetes mellitus;Diabetic;Hepatic impairment;Hypertension;Hypertensive;Hypotension;Liver disorder;Mean arterial pressure;Myocardial ischaemia;Non-sustained ventricular tachycardia;Pulmonary arterial wedge pressure increased;Renal failure;Renal impairment;Sinus rhythm;Sudden death;Sustained ventricular tachycardia;Tachycardia;Vascular resistance systemic;Ventricular arrhythmia;Ventricular tachycardia,Abdominal distension;Abdominal pain;Ache;Acute coronary syndrome;Affect lability;Agranulocytosis;Alopecia;Alopecia reversible;Altered state of consciousness;Amnesia;Angina pectoris;Angiopathy;Anxiety;Appetite disorder;Arrhythmia;Arterial thrombosis;Asthenia;Asthma;Atrioventricular block;Atrioventricular block first degree;Atrophy;Back pain;Blood insulin increased;Body temperature increased;Bradycardia;Bronchospasm;Cardiac failure;Cardiac pain;Cardiogenic shock;Cardiovascular disorder;Catatonia;Cerebrovascular accident;Chest pain;Colitis ischaemic;Consciousness abnormal;Coordination abnormal;Cough;Cramp muscle;Decreased appetite;Depression;Dermatitis;Diarrhoea;Disorientation;Distention;Dizziness;Drowsiness;Dysgeusia;Dyspepsia;Dyspnoea;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Eosinophilia;Eye irritation;Fatigue;Flatulence;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Heartburn;Hyperglycaemia;Hyperhidrosis;Hyperinsulinism;Hyperlipidaemia;Hypertension;Hypotension;Infection;Influenza;Insomnia;Laryngospasm;Lethargy;Leukopenia;Lightheadedness;Loss of consciousness;Mood swings;Multifocal ventricular tachycardia;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Neuropathy peripheral;Non-sustained ventricular tachycardia;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pain in extremity;Pain localised;Palpitations;Paraesthesia;Paralysis;Peripheral coldness;Peripheral vascular disorder;Peyronie's disease;Photophobia;Photosensitivity reaction;Presyncope;Proarrhythmia;Pruritus;Pulmonary oedema;Purpura;Rash;Respiratory distress;Retroperitoneal fibrosis;Sexual dysfunction;Shock;Short-term memory loss;Sleep disorder;Sleep disturbance;Somnolence;Sudden death;Sustained ventricular tachycardia;Syncope;Tachyarrhythmia;Throat sore;Thrombocytopenia;Torsade de pointes;Tracheobronchitis;Upper respiratory tract infection;Urogenital disorder;Vascular purpura;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved,4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide; Sotalol; Sotalolo; Sotalolum; β-cardone; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase,Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Voltage-gated inwardly rectifying potassium channel KCNH2, C07BA07; C07FX02;C07AA07
sparfloxacin,Bronchitis chronic;Community acquired pneumonia;Infection;Overgrowth bacterial;Pathogen resistance;Pneumonia,Abdominal pain;Abdominal pain upper;Abnormal dreams;Accidental injury;Accommodation disorder;Acidosis;Affect lability;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Amblyopia;Amnesia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anosmia;Anxiety;Aphasia;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Ataxia;Atrial fibrillation;Atrial flutter;Atrioventricular block complete;Atrioventricular block first degree;Atrioventricular block second degree;Back pain;Blepharitis;Blood urine;Blood urine present;Body temperature increased;Breast pain;Bronchitis;Bullous eruption;Calculus of kidney;Candida infection;Candiduria;Cardio-respiratory arrest;Cardiovascular disorder;Cellulitis;Cerebral thrombosis;Chest pain;Chills;Confusional state;Conjunctivitis;Constipation;Convulsion;Cough;Cough increased;Crystalluria;Cyanosis;Decreased appetite;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphasia;Dyspnoea;Dysuria;Ear disorder;Ear pain;Ecchymosis;Electrocardiogram PR shortened;Electrocardiogram abnormal;Embolism;Epistaxis;Erythema multiforme;Erythema nodosum;Euphoric mood;Eye pain;Face oedema;Feeling abnormal;Flatulence;Fungal skin infection;Furuncle;Furunculosis;Gait disturbance;Gastroenteritis;Gastrointestinal pain;Generalized aching;Gingivitis;Gout;Haematuria;Haemoglobin;Haemolytic anaemia;Haemoptysis;Haemorrhage;Hallucination;Headache;Hepatic failure;Hepatic necrosis;Hepatitis;Herpes simplex;Herpes zoster;Hiccups;Hyperaesthesia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypokinesia;Ill-defined disorder;Increased appetite;Injury;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal perforation;Jaundice;Lacrimal disorder;Lacrimal structural disorder;Laryngospasm;Leukorrhea;Lightheadedness;Lung disorder;Lymphadenopathy;Malaise;Mania;Manic psychosis;Menorrhagia;Mental disability;Metrorrhagia;Migraine;Mood swings;Mouth ulceration;Mucous membrane disorder;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Nausea;Neck pain;Nephritis interstitial;Nephrolithiasis;Nervousness;Nocturia;Numbness;Nystagmus;Oedema peripheral;Oral candidiasis;Orthostatic hypotension;Osteoarthritis;Otitis media;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Peripheral vascular disorder;Petechiae;Pharyngitis;Phobia;Photophobia;Photosensitivity reaction;Pleural disorder;Pneumonia;Polyuria;Pruritus;Pseudomembranous colitis;Psychotic disorder;Pulmonary oedema;Rash;Rash maculo-papular;Rash pustular;Renal failure acute;Renal pain;Rhabdomyolysis;Rheumatoid arthritis;Rhinitis;Salivary hypersecretion;Salivation;Sensory disturbance;Sensory loss;Sinus bradycardia;Sinusitis;Skin discolouration;Skin hyperpigmentation;Sleep disorder;Somnolence;Squamous cell carcinoma;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Supraventricular extrasystoles;Sweating;Tachycardia;Tendon rupture;Tendonitis;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytopenic purpura;Tinnitus;Tongue disorder;Tooth disorder;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Urinary retention;Urinary tract infection;Urine output increased;Urticaria;Uveitis;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vasculitis;Ventricular extrasystoles;Vertigo;Vesiculobullous rash;Vomiting;Vulvovaginal candidiasis;Vulvovaginal disorder;Vulvovaginal mycotic infection,small molecule,approved; investigational; withdrawn,"cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; Sparfloxacin; 5.99.1.3; 5.99.1.3; 5.99.1.3; 5.99.1.3; Topoisomerase IV subunit A; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",DNA gyrase subunit A; DNA gyrase subunit B; DNA gyrase subunit A; DNA topoisomerase 4 subunit A; DNA topoisomerase 2-alpha,J01MA09
spironolactone,Acute coronary syndrome;Adenoma benign;Alkalosis hypokalaemic;Angina pectoris;Ascites;Benign essential hypertension;Cardiac failure;Cardiac failure congestive;Coma hepatic;Diabetes mellitus;Diabetic nephropathy;Digitalis intoxication (NOS);Discomfort;Diuresis;Essential hypertension;Gravitational oedema;Hepatic cirrhosis;Hirsutism;Hyperadrenocorticism;Hyperaldosteronism;Hyperlipidaemia;Hypernatraemia;Hyperplasia adrenal;Hypertension;Hypokalaemia;Hypotension;Hypotensive;Hypovolaemia;Idiopathic edema;Malignant hypertension;Myocardial infarction;Nephrotic syndrome;Oedema;Polyuria;Pre-eclampsia;Pregnancy;Primary hyperaldosteronism;Secondary aldosteronism;Toxicity to various agents,Agranulocytosis;Alopecia;Amenorrhoea;Anaphylactic shock;Ataxia;Benign breast neoplasm;Body temperature increased;Breast cancer;Breast enlargement;Breast pain;Carcinoma breast;Confusional state;Cramp muscle;Cramps of lower extremities;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drowsiness;Drug eruption;Drug fever;Eosinophilia;Erectile dysfunction;Erythema multiforme;Feeling abnormal;Gastric haemorrhage;Gastritis;Gastrointestinal disorder;Gastrointestinal symptom NOS;Gynaecomastia;Headache;Hyperkalaemia;Hypersensitivity;Hypertrichosis;Ill-defined disorder;Lethargy;Leukopenia;Malaise;Menstruation irregular;Muscle spasms;Nausea;Pruritus;Rash;Rash erythematous;Renal failure;Renal failure acute;Semen abnormal;Semen analysis abnormal;Somnolence;Stevens-Johnson syndrome;Thrombocytopenia;Toxic epidermal necrolysis;Ulcer;Urticaria;Vasculitis;Vomiting,small molecule,approved,"Espironolactona; Spironolactone; Spironolactonum; Spironolattone; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; GR; GRL; Nuclear receptor subfamily 3 group C member 1; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; BI; Brain calcium channel I; CACH4; CACN3; CACNL1A4; Calcium channel, L type, alpha-1 polypeptide isoform 4; Voltage-gated calcium channel subunit alpha Cav2.1; CYP11B1; CYPXIB1; Cytochrome P-450c11; Cytochrome P450C11; S11BH; Steroid 11-beta-hydroxylase, CYP11B1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ALDOS; Aldosterone synthase; Aldosterone-synthesizing enzyme; Corticosterone 18-monooxygenase, CYP11B2; CYPXIB2; Cytochrome P-450Aldo; Cytochrome P-450C18; Steroid 11-beta-hydroxylase, CYP11B2; Steroid 18-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Mineralocorticoid receptor; Glucocorticoid receptor; Androgen receptor; Progesterone receptor; Estrogen receptor; Nuclear receptor subfamily 1 group I member 2; Voltage-dependent L-type calcium channel,C03DA01
imatinib,Acute lymphocytic leukaemia;Aggressive systemic mastocytosis;Blast cell crisis;Cardiac failure congestive;Chromosome analysis abnormal;Chronic eosinophilic leukaemia;Chronic myeloid leukaemia;Chronic phase chronic myeloid leukemia;Dermatofibrosarcoma protuberans;Gastrointestinal stromal tumour;Hypereosinophilic syndrome;Infection;Leukaemia;Neutropenia;Philadelphia chromosome positive;Pleural effusion;Renal failure;Systemic mastocytosis,Abdominal distension;Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Acute febrile neutrophilic dermatosis;Acute generalised exanthematous pustulosis;Acute hepatic failure;Acute respiratory failure;Agranulocytosis;Alanine aminotransferase increased;Allergic cutaneous angiitis;Alopecia;Amylase increased;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Arthralgia;Arthritis;Ascites;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Back pain;Bladder cancer;Blast cell crisis;Blepharitis;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood in stool;Blood lactate dehydrogenase increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone marrow depression;Bone pain;Brain oedema;Breast disorder;Breast enlargement;Bullous eruption;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac tamponade;Cataract;Cellulitis;Cerebral haemorrhage;Cheilitis;Chest pain;Chills;Chronic eosinophilic leukaemia;Chronic myeloid leukaemia;Chronic phase chronic myeloid leukemia;Colitis;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Cough;Cramp muscle;Creatine phosphokinase increased;Creatinine increased;Cyst;Cytopenia;Deafness;Decreased appetite;Dehydration;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Digestion impaired;Discomfort;Disturbance in sexual arousal;Diverticulitis;Dizziness;Drug eruption;Drug interaction;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dyspnoea exertional;Ear and labyrinth disorders;Ecchymosis;Eczema;Edema cerebral;Edema of lower extremities;Embolism;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Eye disorder;Eye irritation;Eye oedema;Eye pain;Eyelid oedema;Face oedema;Fatigue;Febrile neutropenia;Feeling abnormal;Flatulence;Fluid retention;Flushing;Folliculitis;Fungal infection;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal obstruction;Gastrointestinal pain;Gastrointestinal perforation;Gastrointestinal stromal tumour;Gastrooesophageal reflux disease;Generalised oedema;Glaucoma;Gout;Growth retardation;Gynaecomastia;Haematemesis;Haematochezia;Haematological malignancy;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemorrhage;Haemorrhagic ovarian cyst;Headache;Hearing impaired;Heartburn;Hepatic failure;Hepatic necrosis;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hepatotoxicity;Herpes simplex;Herpes zoster;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hyperuricaemia;Hypoaesthesia;Hypoalbuminaemia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hypotension;Hypotrichosis;Hypoxia;Ileus;Ill-defined disorder;Immune system disorder;Increased appetite;Increased tendency to bruise;Infection;Infestation;Infestation NOS;Inflammatory bowel disease;Influenza;Influenza like illness;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal obstruction;Intracranial pressure increased;Jaundice;Joint swelling;Lacrimation increased;Lactic dehydrogenase activity increased;Laryngeal pain;Lethargy;Leukocytoclastic vasculitis;Leukoderma;Leukopenia;Libido decreased;Lichen planus;Lichenoid keratosis;Lightheadedness;Loose stools;Loss of consciousness;Lower respiratory tract infection;Lymphadenopathy;Lymphopenia;Macular oedema;Malaise;Malnutrition;Mastocytosis;Mediastinal disorder;Melaena;Memory impairment;Menorrhagia;Menstruation irregular;Mental disorder;Migraine;Mouth ulceration;Mucosal inflammation;Muscle spasms;Muscle stiffness;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myelosuppression;Myocardial infarction;Myopathy;Nail discolouration;Nail disorder;Nasopharyngitis;Nausea;Necrosis;Necrosis ischaemic;Neoplasm;Neoplasm malignant;Nervous system disorder;Neuropathy peripheral;Neutropenia;Neutrophil count decreased;Night sweats;Nipple pain;Oedema;Oedema aggravated;Oedema peripheral;Oesophagitis;Onychoclasis;Optic neuritis;Orbital oedema;Oropharyngeal discomfort;Oropharyngeal pain;Osteonecrosis;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Papilloedema;Paraesthesia;Pericardial effusion;Pericarditis;Periorbital oedema;Peripheral coldness;Petechiae;Pharyngeal mucositis;Pharyngitis;Pharyngolaryngeal pain;Phosphatase alkaline increased;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Platelet count decreased;Pleural effusion;Pleuritic pain;Pneumonia;Pollakiuria;Polyp;Post procedural haemorrhage;Prostate cancer;Pruritus;Psoriasis;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary hypertension;Pulmonary oedema;Purpura;Rash;Rash pustular;Rash vesicular;Renal cancer;Renal failure;Renal failure acute;Renal pain;Restless legs syndrome;Retinal haemorrhage;Rhabdomyolysis;Rhinitis;Rigors;Sciatica;Scleral haemorrhage;Scrotal oedema;Sepsis;Sexual dysfunction;Shock;Sinusitis;Skin cancer;Skin carcinoma;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin toxicity;Somnolence;Stevens-Johnson syndrome;Stomatitis;Subdural haematoma;Sweating;Sweating increased;Syncope;Tachycardia;Throat sore;Thrombocytopenia;Thrombocytosis;Thrombosis;Tinnitus;Toxic epidermal necrolysis;Tremor;Tumour haemorrhage;Tumour lysis syndrome;Tumour necrosis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Vitreous haemorrhage;Vomiting;Weight decreased;Weight increased;White blood cell count decreased,small molecule,approved,"Imatinib; Imatinibum; α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide; 2.7.11.1; BCR1; D22S11; Renal carcinoma antigen NY-REN-26; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; Bcl2-L-3; BCL2L3; mcl1/EAT; 2.7.10.1; p145 c-kit; PBT; Piebald trait protein; Proto-oncogene c-Kit; SCFR; Tyrosine-protein kinase Kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; 2.7.10.1; Cadherin family member 12; CDHF12; CDHR16; Proto-oncogene c-Ret; PTC; 2.7.10.1; Alpha platelet-derived growth factor receptor; Alpha-type platelet-derived growth factor receptor; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; PDGFR-2; PDGFR-alpha; PDGFR2; Platelet-derived growth factor alpha receptor; Platelet-derived growth factor receptor 2; RHEPDGFRA; 2.7.10.2; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; ABL; JTK7; p150; Proto-oncogene c-Abl; 2.7.10.1; Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; PDGF-R-beta; PDGFR; PDGFR-1; PDGFR-beta; PDGFR1; Platelet-derived growth factor receptor 1; 2.7.10.1; gp140trk; MTC; Neurotrophic tyrosine kinase receptor type 1; p140-TrkA; TRK; Trk-A; TRK1-transforming tyrosine kinase protein; TRKA; Tropomyosin-related kinase A; Tyrosine kinase receptor; Tyrosine kinase receptor A; CSF-1 receptor; CSF-1-R; CSF-1R; FMS; M-CSF-R; Proto-oncogene c-Fms; 2.7.10.1; CAK; CD167 antigen-like family member A; Cell adhesion kinase; Discoidin receptor tyrosine kinase; EDDR1; Epithelial discoidin domain receptor 1; HGK2; Mammary carcinoma kinase 10; MCK-10; NEP; NTRK4; Protein-tyrosine kinase 3A; Protein-tyrosine kinase RTK-6; PTK3A; RTK6; TRK E; TRKE; Tyrosine kinase DDR; Tyrosine-protein kinase CAK; 2.7.10.1; CD167 antigen-like family member B; Discoidin domain receptor 2; Discoidin domain-containing receptor tyrosine kinase 2; Neurotrophic tyrosine kinase, receptor-related 3; NTRKR3; Receptor protein-tyrosine kinase TKT; TKT; TYRO10; Tyrosine-protein kinase TYRO10; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; hOCT1; OCT1; Organic cation transporter 1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT2; OCT2; Organic cation transporter 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.1; ABC-C transporter; ABC3; ATP-binding cassette 3; ATP-binding cassette sub-family A member 3; ATP-binding cassette transporter 3; Xenobiotic-transporting ATPase ABCA3; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3",Breakpoint cluster region protein; Induced myeloid leukemia cell differentiation protein Mcl-1; Mast/stem cell growth factor receptor Kit; Proto-oncogene tyrosine-protein kinase receptor Ret; Platelet-derived growth factor receptor alpha; Tyrosine-protein kinase ABL1; Platelet-derived growth factor receptor beta; High affinity nerve growth factor receptor; Macrophage colony-stimulating factor 1 receptor; Epithelial discoidin domain-containing receptor 1; Discoidin domain-containing receptor 2,L01EA01;L01XE01
streptomycin,Bacteraemia;Chancroid;Granuloma inguinale;Infection;Plague;Pneumonia klebsiella;Tuberculosis;Tularaemia;Urinary tract infection,Abasia;Amblyopia;Anaphylactic shock;Angioedema;Azotaemia;Body temperature increased;Deafness;Dermatitis;Dermatitis exfoliative;Eosinophilia;Haemolytic anaemia;Leukopenia;Muscular weakness;Nausea;Nephropathy toxic;Nephrotoxicity;Ototoxicity;Pancytopenia;Paraesthesia;Rash;Renal failure;Renal impairment;Thrombocytopenia;Unable to walk;Urticaria;Vertigo;Vomiting,small molecule,approved; vet_approved,"2,4-diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; Estreptomicina; Streptomicina; Streptomycin; Streptomyzin; strA; 3.5.3.15; HL-60 PAD; PAD4; PADI5; PDI5; Peptidylarginine deiminase IV; Protein-arginine deiminase type IV",16S ribosomal RNA; 23S ribosomal RNA; 30S ribosomal protein S12; Cytoplasmic membrane; Bacterial outer membrane; Protein-arginine deiminase type-4, A07AA04; A07AA54; J01GA01;A07AA04;J04AM01
streptozotocin,Carcinoid tumour;Carcinoma;Cell death;Diabetes mellitus;Malignant neoplasm of islets of Langerhans;Metastatic disease;Metastatic neoplasm;Neoplasm;Neoplasm malignant;Nephropathy toxic;Pancreatic carcinoma,Aggression;Aminoaciduria;Anaemia;Anuria;Azotaemia;Blood bilirubin increased;Blood urea increased;Body temperature increased;Burning sensation;Confusional state;Diarrhoea;Eosinophilia;Erythema;Extravasation;Fanconi syndrome acquired;Febrile neutropenia;Feeling abnormal;Glucose tolerance impaired;Glycosuria;Haematocrit decreased;Hepatic enzyme increased;Hepatotoxicity;Hyperchloraemia;Hypoalbuminaemia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypophosphataemia;Inflammation;Injection site pain;Insulinoma;Ketonuria;Lethargy;Leukopenia;Myelosuppression;Nausea;Necrosis;Neoplasm malignant;Nephrogenic diabetes insipidus;Nephropathy toxic;Nephrotoxicity;Neutropenia;Oedema;Pain;Pancytopenia;Protein urine present;Proteinuria;Proximal renal tubular acidosis;Renal failure chronic;Renal tubular acidosis;Road traffic accident;Shock hypoglycaemic;Shock insulin;Syndrome Fanconi-like;Tenderness;Thrombocytopenia;Violent;Vomiting,small molecule,approved; investigational,"1-METHYL-1-NITROSO-3-((2R,3R,4S,5R)-3,4,5,6-TETRAHYDROXY-1-OXOHEXAN-2-YL)UREA; 1-METHYL-1-NITROSO-3-((3R,4R,5S,6R)-2,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3-YL)UREA; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; D-GLUCOPYRANOSE, 2-DEOXY-2-(((METHYLNITROSOAMINO)CARBONYL)AMINO)-; Estreptozocina; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; Streptozocin; Streptozocine; Streptozocinium; Streptozocinum; Streptozotocin; 3.2.1.169; Beta-hexosaminidase; Beta-N-acetylglucosaminidase; Beta-N-acetylhexosaminidase; Hexosaminidase B; N-acetyl-beta-glucosaminidase; Glucose transporter type 2, liver; GLUT-2; GLUT2; 3.2.1.169; Beta-hexosaminidase; Beta-N-acetylglucosaminidase; Beta-N-acetylhexosaminidase; HEXC; KIAA0679; MEA5; Meningioma-expressed antigen 5; MGEA5; N-acetyl-beta-D-glucosaminidase; N-acetyl-beta-glucosaminidase; NCOAT; Nuclear cytoplasmic O-GlcNAcase and acetyltransferase; OGA; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","O-GlcNAcase BT_4395; DNA; Solute carrier family 2, facilitated glucose transporter member 2; Protein O-GlcNAcase",L01AD04
vorinostat,Cutaneous T-cell lymphoma;Mycosis fungoides,Abscess;Acute coronary syndrome;Alopecia;Anaemia;Angioedema;Anorexia;Asthenia;Blood creatinine increased;Body temperature increased;Chest pain;Chills;Cholecystitis;Constipation;Cough;Decreased appetite;Deep vein thrombosis;Dehydration;Dermatitis exfoliative;Diarrhoea;Dizziness;Dry mouth;Dysgeusia;Embolism;Embolism venous;Enterococcal infection;Fatigue;Fistula;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal symptom NOS;Gastrointestinal toxicity;Headache;Hyperglycaemia;Hypokalaemia;Infection;Ischaemic stroke;Lethargy;Leukopenia;Lobar pneumonia;Loss of consciousness;Muscle spasms;Myelosuppression;Myocardial infarction;Nausea;Neoplasm malignant;Neutropenia;Oedema peripheral;Pancytopenia;Pelvi-ureteric obstruction;Protein urine present;Proteinuria;Pruritus;Pulmonary embolism;Sepsis;Serum creatinine increased;Shock;Spinal cord injury;Squamous cell carcinoma;Streptococcal sepsis;Syncope;T-cell lymphoma;Taste disorders;Thrombocytopenia;Thromboembolism;Upper respiratory tract infection;Ureteric obstruction;Vomiting;Weight decreased,small molecule,approved; investigational,Octanedioic acid hydroxyamide phenylamide; SAHA; SHH; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat; Vorinostatum; 3.5.1.98; HD1; Protein deacetylase HDAC1; Protein deacylase HDAC1; RPD3L1; 3.5.1.98; HD2; Protein deacylase HDAC2; 3.5.1.98; HD3; Protein deacetylase HDAC3; Protein deacylase HDAC3; RPD3-2; SMAP45; 3.5.1.98; HD6; KIAA0901; Protein deacetylase HDAC6; Tubulin-lysine deacetylase HDAC6; 3.5.1.98; HD8; HDACL1; Protein deacetylase HDAC8; Protein decrotonylase HDAC8; 3.5.1.98; HD1; Protein deacetylase HDAC1; Protein deacylase HDAC1; RPD3L1; 3.5.1.98; HD11; 3.5.1.98; HD2; Protein deacylase HDAC2; 3.5.1.98; HD3; Protein deacetylase HDAC3; Protein deacylase HDAC3; RPD3-2; SMAP45; 3.5.1.98; HD4; KIAA0288; 3.5.1.98; Antigen NY-CO-9; HD5; KIAA0600; 3.5.1.98; HD6; KIAA0901; Protein deacetylase HDAC6; Tubulin-lysine deacetylase HDAC6; 3.5.1.98; HD7; HD7a; HDAC7A; Histone deacetylase 7A; Protein deacetylase HDAC7; 3.5.1.98; HD8; HDACL1; Protein deacetylase HDAC8; Protein decrotonylase HDAC8; 3.5.1.98; HD7; HD7b; HD9; HDAC7; HDAC7B; HDRP; Histone deacetylase 7B; Histone deacetylase-related protein; KIAA0744; MEF2-interacting transcription repressor MITR; MITR; 3.5.1.48; 3.5.1.62; HD10; Histone deacetylase 10,Histone deacetylase 1; Histone deacetylase 2; Histone deacetylase 3; Histone deacetylase 6; Histone deacetylase 8; Acetoin utilization protein; Histone deacetylase,L01XH01;L01XX38
succinylcholine,Hypotonia;Muscle relaxation,Anaphylactic shock;Anaphylactoid reaction;Apnoea;Arrhythmia;Body temperature increased;Bradycardia;Bronchospasm;Cardiac arrest;Dermatitis;Fasciculation;Flushing;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertonia;Hypotension;Increased bronchial secretion;Intraocular pressure increased;Muscle contractions involuntary;Muscle rigidity;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Myoglobin urine present;Myoglobinaemia;Myoglobinuria;Porphyrin metabolism disorder;Pulmonary function test decreased;Pulmonary oedema;Rash;Renal failure;Renal failure acute;Respiratory depression;Respiratory failure;Rhabdomyolysis;Salivary hypersecretion;Shock;Sputum increased;Tachycardia;Tachyphylaxis;Trismus;Urticaria;Ventricular fibrillation,small molecule,approved,"2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium); Dicholine succinate; Succinocholine; Succinoylcholine; Succinylbischoline; Succinyldicholine; Suxamethonium; NACHR alpha-10; NACHRA10; Nicotinic acetylcholine receptor subunit alpha-10; NACHRA3; NACRA4; NACHRA5; NACHRA7; NACHR alpha-9; NACHRA9; Nicotinic acetylcholine receptor subunit alpha-9; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase",Neuronal Acetylcholine (nACh) Receptor Subunits; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3,M03AB01
sulconazole,Body tinea;Infection;Tinea cruris;Tinea pedis;Tinea versicolour,Culture negative;Erythema;Pain;Pruritus;Redness;Stinging,small molecule,approved,Sulconazole; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; Sterol 14-alpha demethylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase,Lanosterol 14-alpha demethylase,D01AC09
sulfacetamide,Acne;Acne vulgaris;Bacterial infection;Conjunctivitis;Dandruff;Eye infection;Pneumonia;Rosacea;Seborrhoeic dermatitis;Sjogren's syndrome;Skin disorder;Syndrome sicca;Trachoma;Ulcerative keratitis,Agranulocytosis;Aplastic anaemia;Blister;Blood disorder;Conjunctival hyperaemia;Conjunctival irritation;Dermatitis bullous;Erythema;Erythema multiforme;Fatal outcomes;Hepatic necrosis;Hypersensitivity;Infection;Lupus erythematosus;Oedema;Pain;Pruritus;Secondary infection;Stevens-Johnson syndrome;Stinging;Systemic lupus erythematosus;Toxic epidermal necrolysis,small molecule,approved,Acetosulfamine; N-((p-Aminophenyl)sulfonyl)acetamide; N-(p-Aminobenzenesulfonyl)acetamide; N-[(p-Aminophenyl)sulfonyl]acetamide; N-Acetyl-4-aminobenzenesulfonamide; N-Acetylsulfanilamide; N-Sulfanilylacetamide; N-Sulphanilylacetamide; N'-acetylsulfanilamide; N(1)-Acetyl-4-aminophenylsulfonamide; N(1)-Acetylsulfanilamide; p-Aminobenzenesulfonacetamide; p-Aminobenzenesulfonoacetamide; Sulfacetamid; Sulfacetamida; Sulfacétamide; Sulfacetamide; Sulfacetamidum; Sulfanilazetamid; Sulphacetamide; Sulphacetamidum; 2.5.1.15; dhpS; Dihydropteroate pyrophosphorylase; 2.5.1.15; DHPS; Dihydropteroate pyrophosphorylase type I; Dihydropteroate synthase type I; sul1; 4.1.2.25; DHNA,Dihydropteroate synthase; Dihydropteroate synthase type-1; Folic acid synthesis protein FOL1, G01AE10; S01AB04;D10AF06;S01AB04
sulfamethoxazole,Acquired immunodeficiency syndrome;Autoimmune disorder;Bronchitis chronic;Dysentery;Enteritis;Infection;Otitis media acute;Pneumocystis jirovecii pneumonia;Traveller's diarrhea;Urinary tract infection,Abdominal pain;Agranulocytosis;Anaemia megaloblastic;Anaphylactic shock;Angioedema;Anorexia;Anuria;Apathy;Aplastic anaemia;Arthralgia;Asthenia;Ataxia;Blood disorder;Body temperature increased;Chills;Convulsion;Cough;Crystalluria;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Digestion impaired;Diuresis;Drug fever;Dyspepsia;Dyspnoea;Eosinophilia;Eosinophilic myocarditis;Eruption;Erythema multiforme;Fatigue;Flat affect;Gastrointestinal disorder;Gastrointestinal pain;Glossitis;Haemolytic anaemia;Hallucination;Headache;Henoch-Schonlein purpura;Hepatic necrosis;Hepatitis;Hyperkalaemia;Hypersensitivity;Hypoglycaemia;Idiopathic thrombocytopenic purpura;Insomnia;Jaundice cholestatic;Leukopenia;Lung infiltration;Meningitis aseptic;Methaemoglobinaemia;Musculoskeletal discomfort;Myalgia;Nausea;Nephritis interstitial;Nephropathy toxic;Nephrosis;Nephrotic syndrome;Nephrotoxicity;Nervousness;Neuritis;Neuropathy peripheral;Neutropenia;Oliguria;Pancreatitis;Photosensitivity;Photosensitivity reaction;Polyarteritis nodosa;Polyuria;Pruritus;Pseudomembranous colitis;Pseudomembranous enterocolitis;Purpura;Rash;Renal failure;Rhabdomyolysis;Scleral hyperaemia;Serum sickness;Stevens-Johnson syndrome;Stomatitis;Systemic lupus erythematosus;Tension;Thrombocytopenia;Thrombocytopenic purpura;Tinnitus;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Urticaria;Vertigo;Vomiting,small molecule,approved,"3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 3-Sulfanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; SMX; Sulfamethoxazole; Sulfametoxazol; Sulphamethoxazole; 2.5.1.15; dhpS; Dihydropteroate pyrophosphorylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.3.1.5; AAC1; Arylamide acetylase 1; MNAT; Monomorphic arylamine N-acetyltransferase; N-acetyltransferase type 1; NAT-1; 2.3.1.5; AAC2; Arylamide acetylase 2; N-acetyltransferase type 2; N-hydroxyarylamine O-acetyltransferase; NAT-2; PNAT; Polymorphic arylamine N-acetyltransferase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Dihydropteroate synthase, G01AE10; J01EC01; J01EE01;J01EC01;J04AM08
sulfonamide,Vulvovaginitis,Burning sensation;Discomfort,small molecule,approved,4-aminobenzene sulfonic acid amide; 4-azanylbenzenesulfonamide; p-aminobenzenesulfamide; p-aminobenzenesulfonamide; para-aminobenzenesulfonamide; Prontosil album; SA; Streptocide; Sulfamine; Sulfanilamida; Sulfanilamide; Sulfanilamidum; Sulphanilamide; 2.5.1.15; dhpS; Dihydropteroate pyrophosphorylase,Dihydropteroate synthase, D06BA05; J01EB06;D06BA05;G01AE10
sulindac,Ankylosing spondylitis;Arthritis;Back pain;Bedridden;Bursitis;Chronic pain;Gout;Gouty arthritis;Low back pain;Mixed connective tissue disease;Osteoarthritis;Pain;Rheumatic disorder;Rheumatism;Rheumatoid arthritis;Rotator cuff syndrome;Subacromial bursitis;Supraspinatus tendonitis;Systemic lupus erythematosus;Tenosynovitis,Acute psychosis;Adenitis;Ageusia;Agranulocytosis;Allergic cutaneous angiitis;Alopecia;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Aplastic anaemia;Arrhythmia;Arthralgia;Arthritis;Asthenia;Biliary sludge;Body temperature increased;Bone marrow depression;Bronchospasm;Calculus of kidney;Cardiac failure congestive;Cellulitis gangrenous;Chest pain;Chills;Cholecystitis;Cholelithiasis;Cholestasis;Chromaturia;Colitis;Coma;Conjunctivitis;Constipation;Convulsion;Crystalluria;Decreased appetite;Depressed level of consciousness;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Disseminated intravascular coagulation;Dizziness;Drug reaction with eosinophilia and systemic symptoms;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ecchymosis;Eosinophilia;Epistaxis;Erythema multiforme;Fatal outcomes;Fatigue;Feeling abnormal;Flatulence;Flushing;Gastritis;Gastroenteritis;Gastrointestinal cramps;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Glossitis;Gynaecomastia;Haematuria;Haemolytic anaemia;Headache;Hearing impaired;Hepatic failure;Hepatitis;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitive syndrome;Hypersensitivity;Hypertension;Hypotension;Ill-defined disorder;Insomnia;Jaundice;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Loss of consciousness;Lymphadenitis;Malaise;Meningitis aseptic;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nausea;Necrotising fasciitis;Nephritic syndrome;Nephritis interstitial;Nephrolithiasis;Nephrotic syndrome;Nervousness;Neuritis;Neuropathy peripheral;Neutropenia;Oedema;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Partial hearing loss;Peptic ulcer;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pneumonia;Protein urine present;Proteinuria;Prothrombin level increased;Pruritus;Purpura;Rash;Renal failure;Renal impairment;Shock;Somnolence;Stevens-Johnson syndrome;Stomatitis;Stupor;Sweating;Sweating increased;Syncope;Tachycardia;Taste bitter;Tenderness;Tension;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Urine color abnormal;Urine output;Urticaria;Vaginal haemorrhage;Vascular purpura;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; Sulindac; Sulindaco; Sulindacum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.1.1.21; 1.1.1.300; 1.1.1.372; 1.1.1.54; Aldehyde reductase; Aldose reductase; ALDR1; ALR2; AR; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 2.7.11.24; ERK-1; ERK1; ERT2; Extracellular signal-regulated kinase 1; Insulin-stimulated MAP2 kinase; MAP kinase 3; MAP kinase isoform p44; MAPK 3; Microtubule-associated protein 2 kinase; p44-ERK1; p44-MAPK; PRKM3; NR1C2; NUC1; NUCI; Nuclear hormone receptor 1; Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferator-activated receptor beta; PPAR-beta; PPAR-delta; PPARB; Chemoattractant receptor-homologous molecule expressed on Th2 cells; CRTH2; DL1R; G-protein coupled receptor 44; GPR44; 1.1.1.300; 1.1.1.54; AKR1B11; Aldose reductase-like; Aldose reductase-related protein; ARL-1; ARP; hARP; SI reductase; Small intestine reductase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1,Prostaglandin G/H synthase 2; Aldo-keto reductase family 1 member B1; Prostaglandin G/H synthase 1; Mitogen-activated protein kinase 3; Peroxisome proliferator-activated receptor delta; Prostaglandin D2 receptor 2; Aldo-keto reductase family 1 member B10,M01AB02
sumatriptan,Acute migraine;Asthma;Aura;Basilar migraine;Cardiac disorder;Cluster headache;Convulsion;Headache;Hemiplegic migraine;Hepatic impairment;Hypertension;Liver disorder;Migraine;Nausea;Pain;Phonophobia;Photophobia;Vomiting,Abdominal aortic aneurysm;Abdominal discomfort;Abdominal distension;Abdominal pain;Abortion;Acute coronary syndrome;Aggression;Agitation;Akathisia;Akinesia;Allergic contact dermatitis;Allergic cutaneous angiitis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anxiety;Aortic aneurysm;Apathy;Aphasia;Application site discolouration;Application site discomfort;Application site haematoma;Application site irritation;Application site pain;Application site paraesthesia;Application site pruritus;Application site warmth;Arrhythmia;Arteriosclerosis;Arteriospasm coronary;Arthralgia;Arthritis;Asthenia;Asthma;Atherosclerosis;Atrial fibrillation;Atrioventricular block;Atrophy;Back pain;Bladder pain;Blindness;Blister;Block heart;Blood disorder;Blood pressure increased;Blood thyroid stimulating hormone increased;Body temperature increased;Bradycardia;Bradycardia-tachycardia syndrome;Breast cancer;Breast discharge;Breast feeding;Breast swelling;Bronchitis;Bronchospasm;Burning sensation;Burning tongue;Calculus of kidney;Cardiomyopathy;Cerebellar infarction;Cerebral ischaemia;Cerebrovascular accident;Chest discomfort;Chest pain;Chest pressure;Chest tightness;Chills;Choreoathetoid movements;Choreoathetosis;Cluster headache;Colitis;Colitis ischaemic;Completed suicide;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Conversion disorder;Convulsion;Coordination abnormal;Cough;Cramp muscle;Cutaneous hypersensitivity;Cyanosis;Cyanosis peripheral;Cyst;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Depression;Depressive disorder;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Detachment psychological;Diarrhoea;Diplegia;Diplopia;Discomfort;Disorder sight;Dissociation;Dizziness;Drowsiness;Drug abuse;Dry mouth;Dysaesthesia;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspeptic signs and symptoms;Dysphagia;Dysphasia;Dysphonia;Dyspnoea;Dysthymic disorder;Dystonia;Dystonic reaction;Dysuria;Ear infection;Ear pain;Eczema;Electrocardiogram change;Endometriosis;Epilepsy;Epistaxis;Eructation;Eruption;Erythema;Euphoric mood;Extrapyramidal disorder;Extrasystoles;Eye disorder;Eye haemorrhage;Eye irritation;Eye oedema;Eye pain;Eye pruritus;Facial pain;Facial paralysis;Fatigue;Feeling abnormal;Feeling cold;Feeling hot;Feeling hot and cold;Feeling of body temperature change;Feeling strange;Flat affect;Flatulence;Fluid retention;Flushing;Gait disturbance;Galactorrhoea;Gastritis;Gastroenteritis;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Globus hystericus;Glossodynia;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Haemorrhage subcutaneous;Hallucination;Head pressure;Headache;Hearing impaired;Heart rate irregular;Heat intolerance;Hemiplegia;Hemiplegia transient;Herpes NOS;Herpes virus infection;Hiccups;Hunger;Hyperaesthesia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertensive crisis;Hypertensive episode;Hypervigilance;Hypoaesthesia;Hypoaesthesia oral;Hypoglycaemia;Hypotension;Hypothyroidism;Hysteria;Ill-defined disorder;Immune system disorder;Induration;Infarction;Infection;Inflammation;Influenza;Injection site bruising;Injection site haemorrhage;Injection site pain;Injection site reaction;Injection site stinging;Instillation site pain;Intervertebral disc disorder;Intestinal obstruction;Intoxication;Intracranial pressure increased;Ischaemia;Keratitis;Lacrimation;Lacrimation increased;Leukocytoclastic vasculitis;Lightheadedness;Lipoatrophy;Lipohypertrophy;Liver function test abnormal;Localized exfoliation;Loss of consciousness;Lower respiratory tract infection;Lymphadenopathy;Lymphocyte count decreased;Malaise;Mass;Mediastinal disorder;Medication overuse headache;Melaena;Memory impairment;Meniere's disease;Menstrual cycle abnormal;Menstrual disorder;Metrorrhagia;Migraine;Monoplegia;Motor dysfunction;Movement disorder;Muscle atrophy;Muscle fatigue;Muscle rigidity;Muscle spasms;Muscle stiffness;Muscle tightness;Muscle twitching;Musculoskeletal deformity;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Mydriasis;Myocardial infarction;Myocardial ischaemia;Myopathy;Nasal inflammation;Nausea;Neck pain;Neck tightness;Nephrolithiasis;Nervous system disorder;Neuralgia;Neurosis;Nodule;Numbness;Numbness of tongue;Nystagmus;Oedema;Optic ischaemic neuropathy;Oral pruritus;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Otitis externa;Pain;Pain in jaw;Pain of skin;Pallor;Palpitations;Pancreatitis;Pancytopenia;Panic disorder;Paraesthesia;Paralysis;Parkinsonism;Peptic ulcer;Personality change;Phlebitis;Phobia;Phonophobia;Photophobia;Photopsia;Photosensitivity;Photosensitivity reaction;Pituitary tumour;Poisoning;Pollakiuria;Polydipsia;Pregnancy;Prinzmetal angina;Pruritus;Pulmonary embolism;Pulse abnormal;Radiculopathy;Raised liver function tests;Rash;Rectal haemorrhage;Redness;Redness of face;Renal failure acute;Respiration abnormal;Respiratory disorder;Retching;Retinal artery occlusion;Retinal vascular occlusion;Retinal vein thrombosis;Rhinitis allergic;Salivary gland enlargement;Salivary gland swelling;Salivary hypersecretion;Scotoma;Seborrhoeic dermatitis;Sensation of heat;Sensation of pressure;Sensory disturbance;Sensory loss;Serotonin syndrome;Shivering;Shock;Sick sinus syndrome;Sinus arrhythmia;Sinusitis;Skin breakdown;Skin disorder;Skin exfoliation;Skin irritation;Skin scaly;Skin tenderness;Skin tightness;Skin wrinkling;Sleep disorder;Sleep disturbance;Somnolence;Speech disorder;Speech impairment NOS;Stiffness;Stinging;Subarachnoid haemorrhage;Subcutaneous bleeding;Suicide;Sunburn;Supraventricular extrasystoles;Sweating;Swelling;Swelling face;Syncope;Tachycardia;Taste bitter;Temperature intolerance;Temporal arteritis;Tenderness;Tetany;Thirst;Throat sore;Thrombocytopenia;Thrombophlebitis;Thrombosis;Thyrotropin high;Tingling sensation;Tinnitus;Toothache;Transient ischaemic attack;Tremor;Unspecified visual loss;Urethritis;Urethritis noninfective;Urogenital disorder;Urticaria;VIIth nerve paralysis;Vasculitis;Vasodilation;Vasodilation procedure;Vasospasm;Venous thrombosis;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Viral infection;Vision decreased;Visual acuity reduced;Visual disturbance;Visual impairment;Voice disturbance;Vomiting;Walking disability;Warmth;Weight decreased;Weight increased;Yawning,small molecule,approved; investigational,(3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide; Sumatriptan; Sumatriptán; Sumatriptanum; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6,5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1F, G01AE10; N02CC51;N02CC01
suprofen,Miosis,Bleeding tendency;Chemosis;Conjunctival oedema;Discomfort;Erythema;Haemoglobin;Haemorrhage;Haemorrhagic disorder;Hypersensitivity;Iritis;Pain;Photophobia;Pruritus;Redness;Stinging,small molecule,approved; withdrawn,"(±)-2-(p-(2-thenoyl)phenyl)propionic acid; 2-(4-(2-Thenoyl)phenyl)propionsäure; 2-[4-(Thiophene-2-carbonyl)-phenyl]-propionic acid; 4-(2-Thenoyl)hydratropsäure; p-2-thenoylhydratropic acid; Suprofen; Suprofene; Suprofeno; Suprofenum; Sutoprofen; α-methyl-4-(2-thienylcarbonyl)benzeneacetic acid; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; OATL4; Organic anion transporter 4-like protein; Renal-specific transporter; RST; URAT1; Urate anion exchanger 1; Urate:anion antiporter SLC22A12",Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2,M01AE07
tacrolimus,Arthralgia;Arthritis;Dermatitis atopic;Diabetes mellitus;Encephalomyelitis;Fasting;Graft loss;Graft versus host disease;Hepatic failure;Hepatic function abnormal;Hepatic impairment;Hepatic insufficiency;Hepatitis C positive;Hepatitis C virus test positive;Hypercholesterolaemia;Hyperlipidaemia;Hypertension;Immune status;Immunocompromised;Immunodeficiency;Immunology test;Infection;Infection susceptibility increased;Joint swelling;Joint tenderness;Kidney transplant rejection;Liver disorder;Liver transplant rejection;Lymphoma;Lymphoproliferative disorder;Musculoskeletal discomfort;Neoplasm malignant;Non-Hodgkin's lymphoma;Pain;Partner stress;Renal failure;Renal impairment;Rheumatoid arthritis;Sensitisation;Separation;Swelling;Transplant failure;Transplant rejection;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Type IV hypersensitivity reaction;X-linked lymphoproliferative syndrome,"Abdominal bloating;Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal vision;Abscess;Abscess periodontal;Accidental injury;Acidosis;Acne;Activated partial thromboplastin time prolonged;Acute coronary syndrome;Acute respiratory distress syndrome;Affect lability;Affective disorder;Agitation;Agranulocytosis;Albuminuria;Alcohol intolerance;Alkalosis;Alopecia;Altered state of consciousness;Amblyopia;Amnesia;Amylase increased;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angiopathy;Anogenital warts;Anorectal disorder;Anorexia;Anuria;Anxiety;Anxiety symptoms NOS;Aphasia;Aphthous stomatitis;Aplasia pure red cell;Application site burn;Application site erythema;Application site irritation;Application site oedema;Application site pain;Application site paraesthesia;Application site pruritus;Application site rash;Application site warmth;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Arthropathy;Ascites;Asthenia;Asthenic conditions;Asthma;Atelectasis;Atrial fibrillation;Atrial flutter;Back pain;Bacterial infection;Basal cell carcinoma;Bile duct disorders;Bile duct stenosis;Bladder and urethral symptoms;Bladder cancer;Bladder pain;Bladder spasm;Blepharitis;Blindness;Blindness cortical;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood iron decreased;Blood lactate dehydrogenase increased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bradycardia;Breast disorder;Breast neoplasm;Bronchitis;Bullous impetigo;Burning sensation;Bursitis;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac fibrillation;Cardiac hypertrophy;Cardiac valve disease;Cardiomyopathy;Cardiopulmonary failure;Cardiovascular disorder;Carpal tunnel syndrome;Cataract;Cellulitis;Cerebral haemorrhage;Cerebral infarction;Cerebral ischaemia;Chest discomfort;Chest pain;Chest pressure sensation of;Chest tightness;Chills;Cholangitis;Cholestasis;Coagulopathy;Colitis;Coma;Confusional state;Congenital cystic kidney disease;Conjunctival oedema;Conjunctivitis;Connective tissue disorder;Consciousness abnormal;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatinine increased;Cushing's syndrome;Cutaneous T-cell lymphoma;Cyst;Cystitis;Cystitis haemorrhagic;Cystitis noninfective;Cytomegalovirus infection;Deafness;Deafness neurosensory;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Dental caries;Depressed level of consciousness;Depressed mood;Depression;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diabetic nephropathy;Diarrhoea;Discomfort;Disorientation;Disseminated intravascular coagulation;Dizziness;Drug ineffective;Drug level increased;Dry eye;Dry mouth;Dry skin;Duodenitis;Dysarthria;Dysgeusia;Dysgraphia;Dysmenorrhoea;Dyspepsia;Dyspeptic signs and symptoms;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear infection;Ear pain;Ecchymosis;Echocardiogram abnormal;Eczema;Eczema herpeticum;Electrocardiogram QRS complex abnormal;Electrocardiogram QT prolonged;Electrocardiogram ST segment abnormal;Electrocardiogram T wave abnormal;Electrocardiogram abnormal;Elevated mood;Emphysema;Encephalopathy;Endocrine disorder;Enlargement abdomen;Enterocolitis;Epistaxis;Epstein-Barr virus infection;Erythema;Erythema multiforme;Eye disorder;Eye pain;Face oedema;Factor II deficiency;Fasting;Fat tissue increased;Fatigue;Febrile disorders;Feeling abnormal;Feeling hot;Feeling jittery;Flatulence;Fluid overload;Fluid retention;Flushing;Folliculitis;Function kidney decreased;Fungal skin infection;Furuncle;Furunculosis;Gamma-glutamyltransferase increased;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal inflammatory conditions;Gastrointestinal pain;Gastrointestinal perforation;Gastrointestinal signs and symptoms;Gastrointestinal ulcer perforation;Gastrooesophageal reflux disease;Gastrooesophagitis;Generalised oedema;Generalised spasm;Glomerulonephritis;Glycosuria;Gout;Graft dysfunction;Graft loss;Graft versus host disease;Granulomatous liver disease;Haematocrit increased;Haematuria;Haemoglobin;Haemoglobin abnormal;Haemolytic anaemia;Haemolytic uraemic syndrome;Haemorrhage;Haemorrhagic stroke;Hallucination;Headache;Hearing impaired;Hemiparesis;Hemiplegia;Hepatic artery thrombosis;Hepatic failure;Hepatic necrosis;Hepatic steatosis;Hepatitis;Hepatitis granulomatous;Hepatobiliary disease;Hepatocellular injury;Hepatosplenic T-cell lymphoma;Hepatotoxicity;Hernia;Herpes dermatitis;Herpes labialis;Herpes simplex;Herpes simplex dermatitis;Herpes virus infection;Herpes zoster;Hiccups;Hirsutism;Hot flush;Hydronephrosis;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlactacidaemia;Hyperlipidaemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypertensive nephropathy;Hypertonia;Hypertriglyceridaemia;Hypertrophic cardiomyopathy;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hypoprothrombinaemia;Hypotension;Hypothyroidism;Hypotrichosis;Ileus;Ileus paralytic;Ill-defined disorder;Immune system disorder;Impaired gastric emptying;Impaired healing;Impetigo;Incision site complication;Increased appetite;Infarction;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Instillation site pain;Interstitial lung disease;Intestinal obstruction;Ischaemic coronary artery disorders;Jaundice;Jaundice cholestatic;Kaposi's sarcoma;Kaposi's varicelliform eruption;Kidney function abnormal;Lack of drug effect;Laryngitis;Leukaemia;Leukocytosis;Leukoderma;Leukoencephalopathy;Leukopenia;Liver fatty;Liver function test abnormal;Liver injury;Loose stools;Loss of consciousness;Lung disorder;Lung infiltration;Lymphadenopathy;Lymphoma;Lymphoproliferative disorder;Malaise;Malignant melanoma;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disability;Mental disorder;Mental status changes;Metabolic acidosis;Micturition disorder;Migraine;Mobility decreased;Monoparesis;Mood swings;Mouth ulceration;Multi-organ failure;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Mutism;Myalgia;Myasthenia;Mycosis fungoides;Myocardial hypertrophy;Myocardial infarction;Myocardial ischaemia;Myoclonus;Nail disorder;Nasal congestion;Nausea;Neck pain;Neoplasm;Neoplasm malignant;Neoplasm skin;Nephropathy;Nephropathy toxic;Nephrosclerosis;Nephrotoxicity;Nerve compression;Nerve injury;Nervous system disorder;Nervousness;Netherton's syndrome;Neuralgia;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Nightmare;Nocturia;Non-Hodgkin's lymphoma;Nystagmus;Oedema;Oedema peripheral;Oesophagitis;Oesophagitis ulcerative;Oliguria;Opportunistic infection;Optic atrophy;Oral candidiasis;Oral herpes;Orthostatic hypotension;Osteoarthritis;Osteomyelitis;Osteopenia;Osteoporosis;Otitis;Otitis externa;Otitis media;Pain;Pain in extremity;Palpitations;Pancreatic pseudocyst;Pancreatitis;Pancreatitis acute;Pancreatitis acute on chronic;Pancreatitis haemorrhagic;Pancreatitis necrotising;Pancytopenia;Papillary thyroid cancer;Paraesthesia;Paraesthesias and dysaesthesias;Paralysis;Paralysis flaccid;Paresis;Pericardial effusion;Peripheral vascular disorder;Peritonitis;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Phototoxicity;Pleural effusion;Pneumonia;Pneumonia due to Streptococcus, group b;Pneumonia streptococcal;Pneumothorax;Pollakiuria;Polyarthritis;Polycystic kidney;Polycythaemia;Polyomavirus infections;Polyomavirus-associated nephropathy;Polyp;Post procedural pain;Post transplant diabetes mellitus;Post transplant lymphoproliferative disorder;Posterior reversible encephalopathy syndrome;Primary graft dysfunction;Procedural complication;Procedural pain;Productive cough;Progressive multifocal leukoencephalopathy;Protein urine present;Proteinuria;Prothrombin level decreased;Pruritus;Psychomotor skills impaired;Psychotic disorder;Pulmonary function test decreased;Pulmonary hypertension;Pulmonary oedema;Pyuria;Quadriparesis;Quadriplegia;Rash;Rash maculo-papular;Rash pustular;Rectal disorder;Renal failure;Renal failure acute;Renal impairment;Renal tubular necrosis;Respiratory depression;Respiratory distress;Respiratory failure;Respiratory tract infection;Rhabdomyolysis;Rhinitis;Rhinitis allergic;Rosacea;Seborrhoeic dermatitis;Sensation of warmth;Sepsis;Septicemia;Serum iron decreased;Shock;Sinusitis;Skin cancer;Skin candida;Skin carcinoma;Skin discolouration;Skin disorder;Skin hyperpigmentation;Skin hypertrophy;Skin infection;Skin irritation;Skin papilloma;Skin ulcer;Somnolence;Speech and language abnormalities;Speech disorder;Squamous cell carcinoma;Status epilepticus;Stevens-Johnson syndrome;Stomatitis;Stupor;Subileus;Sunburn;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating;Sweating increased;Syncope;Tachycardia;Temperature intolerance;Tendon disorder;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytopenic purpura;Thrombophlebitis;Thrombosis;Thrombotic microangiopathy;Thrombotic thrombocytopenic purpura;Tinea versicolour;Tingling skin;Tinnitus;Tooth abscess;Tooth disorder;Torsade de pointes;Toxic epidermal necrolysis;Tremor;Ulcer;Unintended pregnancy;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urge incontinence;Urinary abnormalities;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Uterine haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Varicella;Varicella zoster;Vascular hypotensive disorders;Venoocclusive liver disease;Venous thrombosis deep limb;Ventricular arrhythmia;Ventricular dysfunction;Ventricular extrasystoles;Ventricular fibrillation;Ventricular hypertrophy;Vertigo;Vesiculobullous rash;Vision blurred;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Warts;Weight decreased;Weight fluctuation;Weight increased;Writing impaired;X-linked lymphoproliferative syndrome",small molecule,approved; investigational,"Anhydrous tacrolimus; Tacrolimus; Tacrolimus anhydrous; Tacrolimus, anhydrous; 3.1.3.16; Calcineurin A alpha; Calmodulin-dependent calcineurin A subunit alpha isoform; CALNA; CAM-PRP catalytic subunit; CNA; CNA alpha; Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform; 12 kDa FK506-binding protein; 12 kDa FKBP; 5.2.1.8; Calstabin-1; FK506-binding protein 1A; FKBP-12; FKBP-1A; FKBP1; FKBP12; Immunophilin FKBP12; PPIase FKBP1A; Rotamase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; ATP-binding cassette sub-family A member 5; KIAA1888; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Protein phosphatase 3 catalytic subunit alpha; Peptidyl-prolyl cis-trans isomerase FKBP1A, L04AD02;D11AH01
tamoxifen,Adenocarcinoma;Advanced breast cancer;Albright's disease;Bone cancer metastatic;Bone pain;Brain neoplasm;Breast cancer;Breast cancer invasive NOS;Breast cancer stage IV;Carcinoid tumour;Carcinoma in situ of breast ductal;Cerebrovascular accident;Contralateral breast cancer;Deep vein thrombosis;Embolism;Endometrial cancer;Hyperplasia;Intraductal proliferative breast lesion;Lobular breast carcinoma in situ;Malignant melanoma;Malignant neoplasm of pancreas;Menarche;Neoplasm;Neoplasm malignant;Node-negative breast cancer;Node-positive breast cancer;Pancreatic carcinoma;Pulmonary embolism;Sarcoma;Soft tissue disorder;Thrombocytopenia;Thromboembolic event,Abdominal cramps;Abdominal discomfort;Abdominal pain;Accidental exposure to product;Accidental ingestion;Accidental injury;Acute coronary syndrome;Adenocarcinoma;Alanine aminotransferase increased;Alopecia;Amenorrhoea;Anaemia;Angina pectoris;Angioedema;Ankle edema;Anorexia;Anxiety;Appetite absent;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Back pain;Benign neoplasm;Blindness;Blister;Blood bilirubin increased;Blood creatinine increased;Blood triglycerides increased;Bone pain;Breast cancer male;Breast feeding;Breast neoplasm;Breast pain;Bronchitis;Cardiovascular disorder;Cataract;Cataract specified;Chest pain;Cholestasis;Constipation;Contusion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatinine increased;Cutaneous lupus erythematosus;Cutaneous vasculitis;Cyst;Decreased appetite;Deep vein thrombosis;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Disease progression;Dizziness;Drug interaction;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Embolism;Endometrial adenocarcinoma;Endometrial cancer;Endometriosis;Erectile dysfunction;Erythema;Erythema multiforme;Fatigue;Febrile neutropenia;Fluid retention;Flushing;Fracture;Gait disturbance;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Hepatic cyst;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatic steatosis;Hepatitis;Hepatocellular injury;Hepatotoxicity;High density lipoprotein decreased;Hip fracture;Hot flush;Hypercalcaemia;Hypercholesterolaemia;Hyperhidrosis;Hyperlipidaemia;Hyperplasia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypoaesthesia;Infection;Inflammation;Influenza;Injury;Insomnia;Interstitial lung disease;Interstitial pneumonia;Joint swelling;Leukopenia;Leukorrhea;Lightheadedness;Liver fatty;Liver function test abnormal;Liver injury;Loss of libido;Lymphoedema;Macular degeneration;Macular oedema;Menopausal symptoms;Menopause;Menstrual disorder;Menstruation irregular;Metastatic disease;Metastatic neoplasm;Mood alteration NOS;Mood swings;Multiple fractures;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myelosuppression;Myocardial infarction;Myocardial ischaemia;Nail changes;Nail disorder;Nausea;Neoplasm;Nettle rash;Neutropenia;Night sweats;Numbness;Ocular toxicity;Oedema;Oedema peripheral;Oestrogenic effect;Oligomenorrhoea;Optic nerve disorder;Optic neuritis;Osteoarthritis;Osteoporosis;Ovarian cyst;Pain;Pancreatitis;Pancytopenia;Paraesthesia;Paralysis;Peliosis hepatis;Pelvic pain;Pemphigoid;Pharyngitis;Phlebitis superficial;Platelet count decreased;Pneumonia;Polyp;Porphyria cutanea tarda;Porphyria non-acute;Precocious puberty;Priapism;Pruritus;Pruritus vulvae;Pulmonary embolism;Raised liver function tests;Rash;Redness;Retinal disorder;Sarcoma;Sarcoma uterus;Sensory loss;Sepsis;Sinusitis;Skin exfoliation;Stevens-Johnson syndrome;Sweating;Swelling;Tenderness;Thirst;Throat irritation;Thrombocytopenia;Thromboembolic event;Thrombosis;Tumour flare;Tumour pain;Upset stomach;Urinary incontinence;Urinary tract infection;Urticaria;Uterine cancer;Uterine leiomyoma;Uterine polyp;Vaginal discharge;Vaginal dryness;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vasculitis;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal dryness;Vulvovaginal pruritus;Vulvovaginitis;Walking disability;Weight decreased;Weight increased,small molecule,approved,"(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Tamoxifen; Tamoxifène; Tamoxifene; Tamoxifeno; Tamoxifenum; trans-Tamoxifen; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; 2.7.11.13; PKC-A; PKC-alpha; PKCA; PRKACA; 2.7.11.13; PKC-B; PKC-beta; PKCB; PRKCB1; 2.7.11.13; nPKC-delta; PKCD; Tyrosine-protein kinase PRKCD; 2.7.11.13; nPKC-epsilon; PKCE; 2.7.11.13; PKC-gamma; PKCG; 2.7.11.13; aPKC-lambda/iota; Atypical protein kinase C-lambda/iota; DXS1179E; nPKC-iota; PRKC-lambda/iota; 2.7.11.13; nPKC-theta; PRKCT; 2.7.11.13; nPKC-zeta; PKC2; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; 5.3.3.5; Cholestenol Delta-isomerase; D8-D7 sterol isomerase; Delta(8)-Delta(7) sterol isomerase; Emopamil-binding protein; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; 2.7.11.24; c-Jun N-terminal kinase 1; JNK-46; JNK1; MAP kinase 8; MAPK 8; PRKM8; SAPK1; SAPK1C; Stress-activated protein kinase 1c; Stress-activated protein kinase JNK1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.13.148; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 1; Dimethylaniline oxidase 1; Fetal hepatic flavin-containing monooxygenase 1; FMO 1; Trimethylamine monooxygenase; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.8.2.1; Aryl sulfotransferase 1; HAST1/HAST2; P-PST 1; Phenol sulfotransferase 1; Phenol-sulfating phenol sulfotransferase 1; ST1A1; ST1A3; STP; STP1; Thermostable phenol sulfotransferase; Ts-PST; 2.8.2.2; Bile salt sulfotransferase; Dehydroepiandrosterone sulfotransferase; DHEA-ST; DHEA-ST8; HST; Hydroxysteroid Sulfotransferase; ST2; ST2A1; STD; SULT2A3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; C19-steroid-specific UDP-glucuronosyltransferase; C19-steroid-specific UDPGT; UDPGT 2B17; UGT2B17; 2.8.2.4; EST-1; Estrogen sulfotransferase; ST1E1; STE; Sulfotransferase, estrogen-preferring; Serpin A7; T4-binding globulin; TBG; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 7.6.2.1; ABC-1; ABC1; ATP-binding cassette 1; ATP-binding cassette sub-family A member 1; ATP-binding cassette transporter 1; CERP; Cholesterol efflux regulatory protein","Estrogen receptor; Estrogen receptor beta; Protein kinase C; Sex hormone-binding globulin; 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase; Androgen receptor; Voltage-gated inwardly rectifying potassium channel KCNH2; Nuclear receptor subfamily 1 group I member 2; Estrogen-related receptor gamma; Mitogen-activated protein kinase 8",L02BA01
gatifloxacin,Abscess;Acute sinusitis;Bladder pain;Bronchitis chronic;Cellulitis;Community acquired pneumonia;Conjunctivitis bacterial;Conjunctivitis infective;Cystitis;Cystitis noninfective;Dacryocystitis;Folliculitis;Furuncle;Gonorrhoea;Infection;Pneumonia;Pyelonephritis;Urinary tract infection;Wound infection,Abdominal pain;Abnormal vision;Acute allergic reaction;Ageusia;Agitation;Alanine aminotransferase increased;Alcohol intolerance;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Arthralgia;Arthritis;Asthenia;Asthma;Ataxia;Back pain;Blepharitis allergic;Body temperature increased;Bone pain;Bradycardia;Breast pain;Breath odour;Bronchospasm;Candida infection;Cheilitis;Chemosis;Chest pain;Chills;Chronic conjunctivitis;Colitis;Confusional state;Conjunctival cyst;Conjunctival disorder;Conjunctival haemorrhage;Conjunctival irritation;Conjunctival oedema;Conjunctivitis;Conjunctivitis papillary;Constipation;Convulsion;Corneal defect;Corneal deposits;Corneal disorder;Corneal opacity;Corneal perforation;Corneal thinning;Cramps of lower extremities;Cyanosis;Dacryocystitis;Decreased appetite;Depersonalisation;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Dizziness;Dry eye;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Eczema eyelids;Endophthalmitis;Epistaxis;Erythema;Erythema multiforme;Euphoric mood;Eye discharge;Eye disorder;Eye irritation;Eye pain;Eye redness;Eyelid oedema;Face oedema;Feeling abnormal;Flatulence;Fluid retention;Gastritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Generalized urticaria;Gingivitis;Glossitis;Haematemesis;Haematuria;Hallucination;Headache;Hepatitis;Hostility;Hyperaesthesia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoglycaemia;Hypoglycaemic coma;Hypotension;Infection;Injection site reaction;Insomnia;Iritis;Keratitis;Keratoconjunctivitis;Kidney function abnormal;Lacrimation increased;Loss of consciousness;Lymphadenopathy;Macular oedema;Mental disability;Methicillin-resistant Staphylococcus aureus infection;Metrorrhagia;Migraine;Mouth ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Nasopharyngitis;Nausea;Neck pain;Nervousness;Neutropenia;Ocular hyperaemia;Oedema;Oedema mouth;Oedema peripheral;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Palpitations;Pancreatitis;Panic attack;Panophthalmitis;Paraesthesia;Paranoia;Parosmia;Pharyngitis;Photophobia;Photosensitivity;Photosensitivity reaction;Pruritus;Pseudomembranous colitis;Psychotic disorder;Punctate keratitis;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Redness;Renal failure acute;Renal impairment;Retrosternal pain;Rhinorrhoea;Shock;Sneezing;Somnolence;Staphylococcal infection;Stevens-Johnson syndrome;Stomatitis;Subepithelial opacities;Sweating;Syncope;Tachycardia;Tendon rupture;Tension;Thinking abnormal;Thirst;Throat sore;Thrombocytopenia;Tinnitus;Tongue disorder;Tongue oedema;Torsade de pointes;Tremor;Ulcerative keratitis;Urticaria;Uveitis;Vaginal infection;Vaginal inflammation;Vertigo;Vesiculobullous rash;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting,small molecule,approved; investigational; withdrawn,"1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylic acid; Gatifloxacin; Gatifloxacin anhydrous; Gatifloxacine; Gatifloxacino; Gatifloxacinum; 5.99.1.3; 5.99.1.3; 5.99.1.3; 5.99.1.3; 5.99.1.3; Topoisomerase IV subunit A; 5.99.1.3; Topoisomerase IV subunit B; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",DNA gyrase subunit A; DNA gyrase subunit B; DNA gyrase subunit A; DNA gyrase subunit B; DNA topoisomerase 4 subunit A; DNA topoisomerase 4 subunit B, J01MA16;J01MA16;S01AE06
tazarotene,Acne;Acne vulgaris;Actinic elastosis;Actinic keratosis;Lentigo;Lentigo maligna;Leukoderma;Neoplasm skin;Photodermatosis;Plaque psoriasis;Psoriasis;Seborrhoeic keratosis;Skin wrinkling,Acne;Application site dryness;Application site erythema;Application site exfoliation;Application site irritation;Application site pain;Application site pruritus;Application site rash;Blister;Blood triglycerides increased;Burning sensation;Cheilitis;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis irritant contact;Discomfort;Dry skin;Eczema;Erythema;Facial pain;Haemoglobin;Haemorrhage;Hypertriglyceridaemia;Impetigo;Inflammation;Instillation site pain;Leukoderma;Localised oedema;Localized exfoliation;Oedema;Oedema peripheral;Pain;Pain of skin;Photosensitivity reaction;Phototoxicity;Pruritus;Rash;Sensitisation;Skin discolouration;Skin exfoliation;Skin hyperpigmentation;Skin irritation;Stinging;Swelling,small molecule,approved; investigational,Tazarotene; Tazarotène; Tazaroteno; Tazarotenum; NR1B1; Nuclear receptor subfamily 1 group B member 1; RAR-alpha; NR2B2; Nuclear receptor subfamily 2 group B member 2; Retinoid X receptor beta; NR1B3; Nuclear receptor subfamily 1 group B member 3; RAR-gamma; HAP; HBV-activated protein; NR1B2; Nuclear receptor subfamily 1 group B member 2; RAR-beta; RAR-epsilon; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase,Retinoic acid receptor alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor gamma; Retinoic acid receptor beta, D05AX05;D05AX05;D05AX55
temazepam,Insomnia;Terminal insomnia,Abdominal discomfort;Abnormal dreams;Ageusia;Aggression;Agitation;Agranulocytosis;Alkaline phosphatase serum increased;Alopecia;Amnesia;Anorexia;Anxiety;Apnoea;Asthenia;Ataxia;Back pain;Balance disorder;Blood alkaline phosphatase increased;Body temperature decreased;CNS depression NOS;Coma;Confusional state;Constipation;Convulsion;Cramps of lower extremities;Decreased appetite;Depressed level of consciousness;Depression;Diarrhoea;Diplopia;Disinhibition;Disorientation;Dizziness;Dreaming excessive;Drowsiness;Dry mouth;Dysarthria;Dyspnoea;Equilibrium loss;Erectile dysfunction;Euphoric mood;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Feeling abnormal;Gastrointestinal tract irritation;Hallucination;Hangover;Headache;Hostility;Hyperhidrosis;Hypersensitivity;Hyponatraemia;Hypotension;Hypothermia;Inappropriate antidiuretic hormone secretion;Irritability;Jaundice;Lethargy;Leukocytosis;Loss of consciousness;Muscle spasms;Nausea;Nervousness;Nightmare;Nystagmus;Obstructive airways disorder;Osteoarthritis;Palpitations;Protein urine present;Proteinuria;Pruritus;Pulmonary function test decreased;Rash macular;Respiratory depression;Sciatica;Shock;Sleep apnoea syndrome;Sleep disorder;Sleep disturbance;Slurred speech;Somnolence;Suicidal ideation;Syncope;Tachycardia;Tension;Thrombocytopenia;Tremor;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vivid dreams;Vomiting,small molecule,approved; investigational,"Temazepam; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Translocator protein; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site,N05CD07
temozolomide,Anaplastic astrocytoma;Astrocytoma;Brain cancer metastatic;Disease progression;Glioblastoma;Glioblastoma multiforme;Glioma;Malignant glioma;Malignant melanoma;Metastases to central nervous system;Metastatic malignant melanoma;Metastatic melanoma;Neoplasm;Neoplasm malignant,Abdominal distension;Abdominal pain;Abnormal behaviour;Abnormal pigmentation;Abnormal platelets;Abnormal vision;Acute leukaemia;Affect lability;Agitation;Alanine aminotransferase increased;Alopecia;Altered state of consciousness;Alveolitis;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety depression;Apathy;Aphasia;Aplastic anaemia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Astrocytoma;Ataxia;Back pain;Behavior disorder;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Body temperature increased;Brain oedema;Brain stem glioma;Breast disorder;Breast pain;Bronchitis;Candida infection;Cardiac disorder;Cerebral haemorrhage;Cerebral ischaemia;Cerebration impaired;Chills;Cholestasis;Clotting;Coagulopathy;Condition aggravated;Confusional state;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Depressed level of consciousness;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disorder sight;Disturbance in attention;Dizziness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dysphasia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Edema cerebral;Embolism;Endocrine disorder;Erectile dysfunction;Erythema;Erythema multiforme;Extrapyramidal disorder;Eye disorder;Eye pain;Face oedema;Faecal incontinence;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Flat affect;Flushing;Gait disturbance;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemorrhage;Haemorrhage intracranial;Haemorrhoids;Hallucination;Headache;Hearing impaired;Hemianopia;Hemiparesis;Hemiplegia;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatotoxicity;Herpes simplex;Herpes zoster;Hot flush;Hyperacusis;Hyperadrenocorticism;Hyperaesthesia;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypokalaemia;Ill-defined disorder;Immune system disorder;Infection;Infertility;Infestation;Infestation NOS;Influenza like illness;Influenza-like symptoms;Insomnia;Interstitial lung disease;Interstitial pneumonia;Leg edema;Leukopenia;Liver injury;Lung disorder;Lung infection;Lymphopenia;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Menorrhagia;Mental disability;Mental disorder;Metastatic neoplasm;Mood swings;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myelodysplastic syndrome;Myeloid leukaemia;Myelosuppression;Myopathy;Nasal congestion;Nausea;Neoplasm;Nervous system disorder;Neuropathy;Neuropathy peripheral;Neutropenia;Oedema;Oedema peripheral;Opportunistic infection;Oral candidiasis;Otitis media;Pain;Palpitations;Pancytopenia;Paraesthesia;Paresis;Parosmia;Partial seizures;Petechiae;Pharyngitis;Phosphatase alkaline increased;Photosensitivity reaction;Pigmentation disorder;Platelet disorder;Pneumocystis jirovecii pneumonia;Pneumonia;Pollakiuria;Pruritus;Pulmonary embolism;Pulmonary fibrosis;Purpura;Radiation injury;Rash;Respiratory failure;Rigors;Scotoma;Sensory disturbance;Sinusitis;Skin disorder;Skin exfoliation;Somnolence;Speech disorder;Status epilepticus;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Thirst;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tongue discolouration;Tooth disorder;Toxic epidermal necrolysis;Transient ischaemic attack;Traumatic liver injury;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vascular purpura;Vertigo;Viral infection;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting;Weight decreased;Weight increased;Wound infection,small molecule,approved; investigational,"(S)-perillyl alcohol temozolomide; 3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; Methazolastone; Temozolodida; Temozolomid; Temozolomida; Temozolomide; Témozolomide; Temozolomidum; TMZ; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",DNA,L01AX03
teniposide,Acute lymphocytic leukaemia;Bone marrow depression;Brain neoplasm;Carcinoma of lung;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Lung neoplasm malignant;Neoplasm malignant;Neuroblastoma;Non-Hodgkin's lymphoma;Pancytopenia;Retinoblastoma;Trisomy 21,Abdominal pain;Acute leukaemia;Acute myeloid leukaemia;Agitation;Alopecia;Anaemia;Anaemias haemolytic immune;Anorexia;Arrhythmia;Asthenia;Body temperature increased;Bone marrow depression;Bronchospasm;Cardiotoxicity;Chemical phlebitis;Chest pain;Chills;Confusional state;Cyanosis;Decreased appetite;Dermatitis;Diarrhoea;Dyspnoea;Electrocardiogram change;Extravasation;Feeling abnormal;Flushing;Gastrointestinal pain;Gastrointestinal toxicity;Haematological malignancy;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic function abnormal;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Hypotensive;Infection;Leukaemia;Leukopenia;Liver function test abnormal;Metabolic acidosis;Mucosal inflammation;Myelosuppression;Nausea;Neoplasm;Nephropathy toxic;Nephrotoxicity;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Oedema;Pallor;Pancytopenia;Phlebitis;Pruritus;Raised liver function tests;Rash;Sepsis;Solid tumour;Stomatitis;Sudden death;Sweating;Tachycardia;Thrombocytopenia;Urticaria;Vomiting,small molecule,approved,"4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); Epidophyllotoxin; Teniposid; Teniposide; Téniposide; Teniposido; Teniposidum; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 5.6.2.2; DNA topoisomerase II, beta isozyme; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.-; 7.6.2.3; Anthracycline resistance-associated protein; ARA; MOAT-E; MRP6; Multi-specific organic anion transporter E; Multidrug resistance-associated protein 6; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",DNA topoisomerase 2-alpha; DNA topoisomerase 2-beta,L01CB02
terazosin,Benign prostatic hyperplasia;Bladder neck contracture;Bladder neck obstruction;Bladder neck stricture;Calculus bladder;Diabetes mellitus;Diuresis;Drug interaction;Hypertension;Hypertensive;Neurogenic bladder;Parkinsonism;Peak expiratory flow rate;Peak flow;Polyuria;Urinary tract obstruction,Abdominal pain;Abnormal dreams;Abnormal vision;Amblyopia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Anxiety;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Atrial fibrillation;Back pain;Body temperature increased;Bronchitis;Cardiac failure;Cerebrovascular accident;Chest pain;Cold symptoms;Confusional state;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Decreased appetite;Depression;Dermatitis;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Epistaxis;Erectile dysfunction;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Flatulence;Floppy iris syndrome;Flu symptoms;Gastritis;Gastrointestinal pain;Gout;Headache;Hyperhidrosis;Hypersensitivity;Hypokalaemia;Hypophosphataemia;Hypotension;Hypotensive;Ill-defined disorder;Influenza;Insomnia;Intraoperative floppy iris syndrome;Jaundice;Laryngospasm;Lassitude;Libido decreased;Loss of consciousness;Loss of libido;Malaise;Malnutrition;Menopause;Migraine;Miosis;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Nervousness;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Pain;Pain in extremity;Palpitations;Paraesthesia;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pollakiuria;Priapism;Pruritus;Rash;Rhinitis;Shock;Shoulder pain;Sinusitis;Somnolence;Speech disorder;Sweating;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Tremor;Urinary incontinence;Urinary tract infection;Vasodilation;Vasodilation procedure;Vertigo;Vision blurred;Visual impairment;Vomiting;Weight increased,small molecule,approved,"1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; Terazosin; Terazosina; Terazosine; Térazosine; Terazosinum; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; TGFB; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; Eag-related protein 2; ERG-2; ERG2; Ether-a-go-go-related gene potassium channel 2; Ether-a-go-go-related protein 2; hERG-2; hERG2; Potassium voltage-gated channel subfamily H member 6; Voltage-gated potassium channel subunit Kv11.2; Eag-related protein 3; ERG-3; ERG3; Ether-a-go-go-related gene potassium channel 3; Ether-a-go-go-related protein 3; hERG-3; Potassium voltage-gated channel subfamily H member 7; Voltage-gated potassium channel subunit Kv11.3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Transforming growth factor beta-1 proprotein; Voltage-gated inwardly rectifying potassium channel KCNH2; Voltage-gated inwardly rectifying potassium channel KCNH6; Voltage-gated inwardly rectifying potassium channel KCNH7,G04CA03
terbinafine,Body tinea;Fungal infection;Fungal skin infection;Infection;Onychomycosis;Pityriasis;Skin infection;Tinea cruris;Tinea infection;Tinea pedis;Tinea versicolour;Yeast infection,Abdominal cramps;Abdominal discomfort;Abdominal pain;Abdominal pain upper;Acute generalised exanthematous pustulosis;Ageusia;Agranulocytosis;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Anosmia;Anxiety;Appetite absent;Arthralgia;Arthritis;Asthenia;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood disorder;Blood urea increased;Body temperature increased;Bullous eruption;Chest pain;Cholestasis;Confusional state;Connective tissue disorder;Cough;Cramp muscle;Deafness;Decreased appetite;Depressive symptom;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatitis psoriasiform;Diarrhoea;Discomfort;Dizziness;Drug eruption;Dry mouth;Dysgeusia;Dyspepsia;Ear and labyrinth disorders;Ear disorder;Eczema;Eosinophilia;Eructation;Eruption;Erythema;Erythema multiforme;Eye disorder;Fatal outcomes;Fatigue;Feeling abnormal;Flatulence;Foetor hepaticus;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Haematocrit decreased;Headache;Hearing impaired;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hypersensitivity;Hypoaesthesia;Hypogeusia;Hypoglycaemia;Hyposmia;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Jaundice;Jaundice cholestatic;Laryngeal pain;Lightheadedness;Liver disorder;Liver injury;Lupus erythematosus;Malaise;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Neutropenia;Pain;Pancreatitis;Pancytopenia;Paraesthesia;Partial hearing loss;Pharyngolaryngeal pain;Photodermatosis;Photosensitivity;Photosensitivity allergic reaction;Photosensitivity reaction;Polymorphic light eruption;Pruritus;Psoriasis;Psoriasis flare-up;Rash;Rash erythematous;Rash generalised;Redness;Rhabdomyolysis;Rhinorrhoea;Scotoma;Serum sickness;Serum sickness-like reaction;Serum urea increased;Sickness;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Stevens-Johnson syndrome;Stinging;Systemic lupus erythematosus;Thrombocytopenia;Thrombotic thrombocytopenic purpura;Tinnitus;Toothache;Toxic epidermal necrolysis;Toxic skin eruption;Traumatic liver injury;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Vasculitis;Vasculitis gastrointestinal;Vertigo;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Weight decreased,small molecule,approved; investigational; vet_approved,"(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; Terbinafina; Terbinafine; Terbinafinum; 1.14.14.17; SE; Squalene epoxidase; 1.14.14.17; ERG1; SE; Squalene epoxidase; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; Multidrug resistance protein 2",Squalene monooxygenase; Squalene monooxygenase, D01BA02;D01AE15
terbutaline,Asthma;Bronchitis;Bronchospasm;Emphysema,Allergic cutaneous angiitis;Anxiety;Asthenia;Chest discomfort;Chest pain;Cramp muscle;Dermatitis;Dizziness;Drowsiness;Dry mouth;Dyspnoea;Flushing;Hallucination;Headache;Hyperhidrosis;Hypertonia;Injection site pain;Insomnia;Leukocytoclastic vasculitis;Muscle spasms;Nausea;Nervousness;Palpitations;Paraesthesia;Rash;Somnolence;Sweating;Tachycardia;Tension;Tremor;Ventricular extrasystoles;Vomiting,small molecule,approved,"Terbutalin; Terbutalina; Terbutaline; Terbutalinum; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; 2.8.2.1; Aryl sulfotransferase 1; HAST1/HAST2; P-PST 1; Phenol sulfotransferase 1; Phenol-sulfating phenol sulfotransferase 1; ST1A1; ST1A3; STP; STP1; Thermostable phenol sulfotransferase; Ts-PST; 2.8.2.1; Aryl sulfotransferase 2; P-PST 2; Phenol sulfotransferase 2; Phenol-sulfating phenol sulfotransferase 2; ST1A2; STP2; 2.8.2.1; Aryl sulfotransferase 1A3/1A4; Catecholamine-sulfating phenol sulfotransferase; HAST3; M-PST; Monoamine-sulfating phenol sulfotransferase; Placental estrogen sulfotransferase; ST1A3; STM; Sulfotransferase 1A3/1A4; Sulfotransferase, monoamine-preferring; Thermolabile phenol sulfotransferase; TL-PST; 2.8.2.1; Aryl sulfotransferase 1A3/1A4; ST1A4; Sulfotransferase 1A3/1A4; 2.8.2.1; ST1B1; ST1B2; Sulfotransferase 1B2; Sulfotransferase family cytosolic 1B member 1; SULT1B2; Thyroid hormone sulfotransferase; 2.8.2.1; humSULTC2; ST1C2; Sulfotransferase 1C1; SULT1C#1; SULT1C1; 2.8.2.1; 2.8.2.2; ST1C3; 2.8.2.1; ST1C4; Sulfotransferase 1C2; SULT1C#2; SULT1C2; 2.8.2.2; Bile salt sulfotransferase; Dehydroepiandrosterone sulfotransferase; DHEA-ST; DHEA-ST8; HST; Hydroxysteroid Sulfotransferase; ST2; ST2A1; STD; SULT2A3; 2.8.2.-; Brain sulfotransferase-like protein; hBR-STL; hBR-STL-1; Nervous system sulfotransferase; NST; ST4A1; SULTX3; ST6B1; Thyroxine sulfotransferase; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; hOCT2; OCT2; Organic cation transporter 2",Beta-2 adrenergic receptor; Beta-3 adrenergic receptor; Beta-1 adrenergic receptor, R03AC03; R03CC03;R03AC03;R03CC53
terconazole,Candida infection;Vulvovaginal candidiasis;Vulvovaginitis,Abdominal pain;Anaphylactic shock;Arthralgia;Asthenia;Body temperature increased;Bronchospasm;Chills;Dermatitis;Discomfort;Dizziness;Dysmenorrhoea;Face oedema;Feeling abnormal;Gastrointestinal pain;Headache;Hypersensitivity;Ill-defined disorder;Influenza like illness;Malaise;Musculoskeletal discomfort;Myalgia;Nausea;Pain;Pruritus;Rash;Toxic epidermal necrolysis;Urticaria;Vomiting;Vulvovaginal pruritus,small molecule,approved,Terconazole; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase,Lanosterol 14-alpha demethylase,G01AG02
testosterone,Anaphylactic shock;Androgen deficiency;Application site erythema;Application site irritation;Asthenia;Azoospermia;Blood testosterone decreased;Blood testosterone increased;Breast cancer;Cryptorchism;Delayed puberty;Depressed mood;Dermatitis;Dermatitis contact;Disturbance in sexual arousal;Dry skin;Erectile dysfunction;Erythema;Fatigue;Gamma-glutamyltransferase increased;Haematocrit increased;Hypoactive sexual desire disorder;Hypogonadism;Hypogonadism male;Injury;Klinefelter's syndrome;Libido decreased;Menopause;Neoplasm;Orchitis;Orchitis noninfective;Primary hypogonadism;Prostatic specific antigen increased;Prostatomegaly;Pruritus;Puberty;Pulmonary oil microembolism;Redness;Secondary hypogonadism;Serum testosterone decreased;Serum testosterone increased;Skin irritation;Tenderness;Testosterone deficiency;Trauma,Abdominal cramps;Abdominal pain;Abdominal pain upper;Abdominal symptom;Abnormal clotting factor;Abnormal dreams;Acne;Activated partial thromboplastin time prolonged;Acute coronary syndrome;Administration site reaction;Affect lability;Affective disorder;Aggression;Agitation;Alanine aminotransferase increased;Allergic contact dermatitis;Alopecia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Androgenetic alopecia;Anger;Angina pectoris;Angioedema;Angiopathy;Anxiety;Appetite disorder;Application site burn;Application site dryness;Application site erythema;Application site exfoliation;Application site induration;Application site irritation;Application site oedema;Application site pain;Application site pruritus;Application site rash;Application site reaction;Application site vesicles;Application site warmth;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthma;Atrophy;Azoospermia;Back pain;Bad taste;Balance disorder;Benign prostatic hyperplasia;Benign prostatic hypertrophy;Bilirubin total increased;Blister;Blood and lymphatic system disorders;Blood bilirubin increased;Blood cholesterol increased;Blood creatinine increased;Blood glucose increased;Blood pressure diastolic decreased;Blood pressure increased;Blood pressure systolic increased;Blood prolactin increased;Blood testosterone decreased;Blood testosterone increased;Blood triglycerides increased;Blood urea normal;Breast cyst;Breast disorder;Breast enlargement;Breast induration;Breast pain;Breast tenderness;Bronchial hyperreactivity;Bronchitis;Buccal inflammation;Buccal mucosal roughening;Burn;Carcinoma;Cardiac arrest;Cardiac disorder;Cardiac failure;Cerebral infarction;Cerebrovascular accident;Cerebrovascular insufficiency;Cheilitis;Chest discomfort;Chest pain;Chest tightness;Chills;Cholesterol serum elevated;Chronic obstructive pulmonary disease;Clitoral engorgement;Clotting;Coagulopathy;Cognitive disorder;Cognitive impairment;Confusional state;Connective tissue disorder;Contusion;Coronary artery disease;Coronary artery occlusion;Cough;Creatinine increased;Cyst;Deep vein thrombosis;Depression;Depression suicidal;Dermatitis;Dermatitis acneiform;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Detachment psychological;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Dissociation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Eczema;Ejaculation disorder;Embolism;Embolism venous;Endocrine disorder;Enlarged clitoris;Epidermal necrosis;Epididymitis;Epiphyses premature fusion;Erectile dysfunction;Erythema;Erythropoiesis abnormal;Eye disorder;Eye redness;Fatigue;Feeling abnormal;Fluid retention;Folliculitis;Free prostate-specific antigen increased;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal hypomotility;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Gingival blister;Gingival erythema;Gingival oedema;Gingival pain;Gingival recession;Gingival swelling;Gingivitis;Glucose tolerance impaired;Growth accelerated;Gynaecomastia;Haemarthrosis;Haematocrit increased;Haematuria;Haemoglobin;Haemoglobin abnormal;Haemoglobin increased;Haemorrhage;Hair colour changes;Hair discoloration;Hair growth abnormal;Headache;Hepatic cancer;Hepatic function abnormal;Hepatic neoplasm;Hepatobiliary disease;Hepatocellular carcinoma;High density lipoprotein decreased;Hirsutism;Hostility;Hot flush;Hyperaesthesia;Hypercholesterolaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hyperparathyroidism;Hypersensitivity;Hypertension;Hypertension worsened;Hypertriglyceridaemia;Hyperventilation;Hypogeusia;Hypoglycaemia;Hypogonadism;Hypokalaemia;Ill-defined disorder;Immune system disorder;Impatience;Incontinence;Increased appetite;Induration;Infection;Infestation;Infestation NOS;Inflammation;Influenza like illness;Injection site abscess;Injection site discomfort;Injection site erythema;Injection site haematoma;Injection site irritation;Injection site pain;Injection site reaction;Insomnia;International normalised ratio increased;Intraocular pressure increased;Irritability;Irritation gum;Jaundice cholestatic;Kidney function abnormal;Korsakoff's psychosis (non-alcoholic);Laboratory test abnormal;Lacrimation;Lacrimation increased;Laryngeal pain;Leukocytoclastic vasculitis;Leukoplakia;Libido decreased;Libido increased;Lip pain;Lip swelling;Lip ulceration;Lipids abnormal;Lipids increased;Liver function test abnormal;Loss of consciousness;Malaise;Male orgasmic disorder;Malnutrition;Mediastinal disorder;Menopausal symptoms;Menstruation irregular;Mental disorder;Micturition urgency;Migraine;Mood swings;Mouth irritation;Mouth ulceration;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Nasal congestion;Nasal oedema;Nasopharyngitis;Nausea;Neoplasm;Neoplasm malignant;Neoplasm prostate;Nephrolithiasis;Nervous system disorder;Nervousness;Nipple disorder;Nipple pain;Nocturia;Ocular hyperaemia;Oedema;Oedema peripheral;Oestradiol increased;Oligospermia;Oral disorder;Oral lesion;Osteopenia;Osteoporosis;Pain;Pain in extremity;Palpitations;Paraesthesia;Paraesthesia oral;Paresthesia generalized;Parosmia;Peliosis hepatis;Pelvic pain;Penile pain;Penis disorder;Peripheral vascular disorder;Personality disorder;Pharyngeal oedema;Pharyngolaryngeal pain;Pneumonia;Pollakiuria;Polycythaemia;Polyp;Polyuria;Poor urinary stream;Precocious puberty;Priapism;Procedural pain;Prostate cancer;Prostate carcinoma;Prostate examination abnormal;Prostate induration;Prostate infection;Prostatic adenoma;Prostatic disorder;Prostatic dysplasia;Prostatic intraepithelial neoplasia;Prostatic specific antigen increased;Prostatitis;Prostatomegaly;Prothrombin level increased;Pruritus;Pruritus genital;Pulmonary embolism;Pulmonary microemboli;Pulmonary oil microembolism;Raised serum lipid levels;Rash;Rash papular;Rash pustular;Red blood cell count increased;Redness gum;Renal colic;Renal failure;Renal impairment;Renal pain;Respiratory distress;Rhinitis;Rosacea;Seborrhoeic dermatitis;Sensitisation;Serum sickness;Serum testosterone decreased;Shock;Sinusitis;Skin disorder;Skin irritation;Sleep apnoea syndrome;Sleep disorder;Snoring;Soft tissue disorder;Spermatocele;Spontaneous penile erection;Stinging;Stomatitis;Strangury;Sudden hearing loss;Surgery;Surgical intervention;Sweating;Sweating increased;Swelling;Syncope;Systemic lupus erythematosus;Tachycardia;Taste bitter;Taste disorders;Tenderness;Tension;Testicular atrophy;Testicular disorder;Testicular pain;Testosterone low;Thermal burn;Throat tightness;Thrombocytopenia;Thromboembolism;Thrombosis;Tinnitus;Toothache;Transaminases increased;Transient ischaemic attack;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urine flow decreased;Urine output increased;Urogenital disorder;Urticaria;Vaginal burning sensation;Varicocele;Vasodilation;Vasodilation procedure;Venous insufficiency;Venous thromboembolism;Vertigo;Vesiculobullous rash;Virilism;Vitreous detachment;Vomiting;Vulvovaginal burning sensation;Weight increased;Wernicke-Korsakoff syndrome,small molecule,approved; investigational,"17beta-hydroxy-4-androsten-3-one; 4-androsten-17β-ol-3-one; Testosteron; Testosterona; Testosterone; Testostérone; Testosteronum; Virosterone; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.14.15.6; Cholesterol desmolase; CYP11A; CYPXIA1; Cytochrome P450 11A1; Cytochrome P450(scc); 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIA13; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Androgen receptor; Estrogen receptor; Mineralocorticoid receptor, G03EA02;G03BA03
testosterone,Androgen deficiency;Breast cancer;Cryptorchism;Delayed puberty;Hypogonadism;Hypogonadism male;Injury;Neoplasm;Orchitis;Orchitis noninfective;Primary hypogonadism;Puberty;Secondary hypogonadism;Testosterone deficiency;Trauma,Abdominal pain;Aggression;Alopecia;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Androgenetic alopecia;Anger;Angiopathy;Anxiety;Application site burn;Application site erythema;Application site induration;Application site pain;Application site rash;Application site vesicles;Arthralgia;Asthenia;Azoospermia;Blood cholesterol increased;Blood testosterone decreased;Breast disorder;Breast pain;Cholesterol serum elevated;Clotting;Coagulopathy;Cognitive disorder;Cognitive impairment;Confusional state;Connective tissue disorder;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dyspnoea;Dysuria;Endocrine disorder;Enlarged clitoris;Epididymitis;Erectile dysfunction;Erythropoiesis abnormal;Fatigue;Feeling abnormal;Free prostate-specific antigen increased;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glucose tolerance impaired;Growth accelerated;Gynaecomastia;Haematuria;Haemoglobin;Haemorrhage;Headache;Hepatic neoplasm;Hepatobiliary disease;Hirsutism;Hypercholesterolaemia;Hypersensitivity;Hypertension;Ill-defined disorder;Immune system disorder;Incontinence;Increased appetite;Inflammation;Injection site inflammation;Injection site pain;Insomnia;Irritability;Jaundice cholestatic;Leukopenia;Libido decreased;Libido increased;Liver function test abnormal;Malaise;Malnutrition;Mediastinal disorder;Menstruation irregular;Mental disorder;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Oedema;Oligospermia;Paraesthesia;Paresthesia generalized;Peliosis hepatis;Personality disorder;Polycythaemia;Precocious puberty;Priapism;Prostate cancer;Prostate carcinoma;Prostatomegaly;Pruritus;Rash;Rash pustular;Seborrhoeic dermatitis;Skin disorder;Sleep apnoea syndrome;Testicular atrophy;Testosterone low;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vesiculobullous rash;Virilism;Vomiting;Weight increased,small molecule,approved; investigational,"17beta-hydroxy-4-androsten-3-one; 4-androsten-17β-ol-3-one; Testosteron; Testosterona; Testosterone; Testostérone; Testosteronum; Virosterone; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.14.15.6; Cholesterol desmolase; CYP11A; CYPXIA1; Cytochrome P450 11A1; Cytochrome P450(scc); 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIA13; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Androgen receptor; Estrogen receptor; Mineralocorticoid receptor, G03EA02;G03BA03
testosterone,Androgen deficiency;Hypogonadism;Testosterone deficiency,Abdominal pain;Aggression;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Androgenetic alopecia;Anger;Angiopathy;Anxiety;Application site burn;Application site erythema;Application site induration;Application site pain;Application site rash;Application site vesicles;Arthralgia;Asthenia;Azoospermia;Blood testosterone decreased;Breast disorder;Breast pain;Clotting;Coagulopathy;Cognitive disorder;Cognitive impairment;Confusional state;Connective tissue disorder;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dyspnoea;Dysuria;Endocrine disorder;Epididymitis;Erectile dysfunction;Erythropoiesis abnormal;Fatigue;Feeling abnormal;Free prostate-specific antigen increased;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glucose tolerance impaired;Growth accelerated;Gynaecomastia;Haematuria;Haemoglobin;Haemorrhage;Headache;Hepatic neoplasm;Hepatobiliary disease;Hirsutism;Hypercholesterolaemia;Hypersensitivity;Hypertension;Ill-defined disorder;Immune system disorder;Incontinence;Increased appetite;Inflammation;Insomnia;Irritability;Jaundice cholestatic;Libido decreased;Liver function test abnormal;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Musculoskeletal discomfort;Myalgia;Nausea;Neoplasm;Nervous system disorder;Oedema;Oligospermia;Pain;Paraesthesia;Paresthesia generalized;Peliosis hepatis;Personality disorder;Polycythaemia;Precocious puberty;Priapism;Prostate cancer;Prostate carcinoma;Prostatomegaly;Pruritus;Rash;Rash pustular;Seborrhoeic dermatitis;Skin disorder;Sleep apnoea syndrome;Testicular atrophy;Testosterone low;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vesiculobullous rash;Vomiting;Weight increased,small molecule,approved; investigational,"17beta-hydroxy-4-androsten-3-one; 4-androsten-17β-ol-3-one; Testosteron; Testosterona; Testosterone; Testostérone; Testosteronum; Virosterone; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.14.15.6; Cholesterol desmolase; CYP11A; CYPXIA1; Cytochrome P450 11A1; Cytochrome P450(scc); 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIA13; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Androgen receptor; Estrogen receptor; Mineralocorticoid receptor, G03EA02;G03BA03
thalidomide,Erythema nodosum leprosum;Graft versus host disease;Malignant melanoma;Myelodysplastic syndrome;Plasma cell myeloma;Plasmacytoma;Pregnancy;Prostate cancer;Renal cell carcinoma;Type 2 lepra reaction,Abdominal distension;Abdominal pain;Accidental injury;Acne;Acquired immunodeficiency syndrome;Acute coronary syndrome;Acute leukaemia;Acute myeloid leukaemia;Affect lability;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Altered state of consciousness;Amblyopia;Amenorrhoea;Amnesia;Amyloidosis;Anaemia;Anaemia macrocytic;Anaemia megaloblastic;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety depression;Aphthous stomatitis;Aplastic anaemia;Apnoea;Arrhythmia;Arterial thromboembolism;Arterial thrombosis;Arthralgia;Arthritis;Arthropathy;Ascites;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrial fibrillation;Atrioventricular block;Autoimmune disorder;Avitaminosis;Back pain;Benign neoplasm of skin;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine decreased;Blood creatinine increased;Blood disorder;Blood lactate dehydrogenase increased;Blood phosphorus decreased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Bone tenderness;Bradycardia;Breast disorder;Bronchitis;Bronchopneumonia;Bronchopneumopathy;Bronchospasm;Burning sensation;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Causalgia;Cellulitis;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Chills;Cholangitis;Cholestasis;Chronic myeloid leukaemia;Circumoral paresthesia;Colitis;Complex regional pain syndrome;Confusional state;Conjunctivitis;Consciousness abnormal;Constipation;Convulsion;Coordination abnormal;Cough;Cramp muscle;Cramps of lower extremities;Creatinine increased;Creatinine low;Cyanosis;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Dementia;Demyelination;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diplopia;Disability;Discomfort;Disease progression;Disorder periosteal;Disturbance in sexual arousal;Diverticular perforation;Dizziness;Drowsiness;Drug interaction;Dry eye;Dry mouth;Dry skin;Dysaesthesia;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Eczema;Electrolyte imbalance;Embolism;Embolism arterial;Embolism venous;Emphysema;Endocrine disorder;Enlargement abdomen;Enuresis;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Erythema nodosum;Erythroleukaemia;Euphoric mood;Eye disorder;Eye pain;Face oedema;Fatigue;Febrile neutropenia;Feeling abnormal;Flatulence;Foetor hepaticus;Footdrop;Fungal skin infection;Gait disturbance;Galactorrhoea;Gastric ulcer;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Gingival disorder;Grand mal convulsion;Gynaecomastia;Haematuria;Hangover;Headache;Hearing impaired;Hepatitis;Hepatocellular injury;Hepatomegaly;Hernia;Herpes simplex;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hormone level abnormal;Hostility;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypoalgesia;Hypocalcaemia;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypoproteinaemia;Hyporeflexia;Hypotension;Hypothyroidism;Hypovitaminosis;Ichthyosis;Ichthyosis acquired;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Injury;Inner ear disorder;Insomnia;Interstitial lung disease;Intestinal obstruction;Intestinal perforation;Jaundice cholestatic;Labyrinthine disorder;Lacrimal disorder;Lacrimal structural disorder;Lactic dehydrogenase activity increased;Lethargy;Leukaemia;Leukocytosis;Leukopenia;Libido decreased;Lightheadedness;Lipase increased;Liver disorder;Liver function test abnormal;Loss of consciousness;Lung disorder;Lymphadenopathy;Lymphoedema;Lymphopenia;Malaise;Malnutrition;Mediastinal disorder;Meningitis;Menopause;Menstrual disorder;Mental disability;Mental disorder;Mental state abnormal;Mental status changes;Metrorrhagia;Microcytic anaemia;Migraine;Mood alteration NOS;Mood swings;Multiple congenital abnormalities;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myelodysplastic syndrome;Myocardial infarction;Myocardial ischaemia;Myxoedema;Nail disorder;Nausea;Neck pain;Neck stiffness;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neutropenia;Nuchal rigidity;Numbness;Nystagmus;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Oral candidiasis;Orchitis;Orchitis noninfective;Orthostatic hypotension;Osteoarthritis;Pain;Pain in arm;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paraesthesia oral;Parkinson's disease;Parkinsonism;Parotid gland enlargement;Pericarditis;Periodontitis;Peripheral sensory neuropathy;Peripheral vascular disorder;Peritonitis;Peroneal nerve palsy;Petechiae;Pharyngitis;Phosphatase alkaline increased;Phosphorus low;Photosensitivity;Photosensitivity reaction;Platelet count decreased;Pleural effusion;Pneumocystis jirovecii pneumonia;Pneumonia;Pollakiuria;Polyneuropathy;Posterior reversible encephalopathy syndrome;Protein urine present;Proteinuria;Pruritus;Psoriasis;Psychotic disorder;Pulmonary embolism;Pulmonary oedema;Purpura;Pyuria;Raised liver function tests;Rales;Rash;Rash maculo-papular;Rash pustular;Renal failure;Renal failure acute;Retinitis;Rhinitis;Seborrhoeic dermatitis;Sensory loss;Sepsis;Septic shock;Serum creatinine increased;Sexual dysfunction;Shock;Sick sinus syndrome;Sinus bradycardia;Sinusitis;Skin discolouration;Skin disorder;Skin exfoliation;Skin necrosis;Skin ulcer;Somnolence;Spleen palpable;Status epilepticus;Stevens-Johnson syndrome;Stomatitis;Stupor;Suicide attempt;Sweating;Syncope;Tachycardia;Tension;Teratogenicity;Thinking abnormal;Thrombocytopenia;Thromboembolic event;Thromboembolism;Thrombophlebitis;Thrombosis;Tingling sensation;Tinnitus;Tongue discolouration;Tooth disorder;Toothache;Toxic epidermal necrolysis;Toxic skin eruption;Transient ischaemic attack;Tremor;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Vascular purpura;Vasodilation;Vasodilation procedure;Venous thrombosis;Vertigo;Vesiculobullous rash;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;White blood cell count decreased;White blood cell count low,small molecule,approved; investigational; withdrawn,"(+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide; (+-)-Thalidomide; (±)-N-(2,6-dioxo-3-piperidyl)phthalimide; (±)-thalidomide; 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline; 2,6-dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide; alpha-(N-Phthalimido)glutarimide; alpha-N-Phthalylglutaramide; N-(2,6-dioxo-3-piperidyl)phthalimide; N-Phthaloylglutamimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalylglutamic acid imide; Talidomida; Thalidomide; Thalidomidum; α-(N-phthalimido)glutarimide; α-N-phthalylglutaramide; α-phthalimidoglutarimide; Cachectin; TNF-a; TNF-alpha; TNFA; TNFSF2; Tumor necrosis factor ligand superfamily member 2; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2",Tumor necrosis factor; Protein cereblon; DNA; alpha1-acid glycoprotein,L04AX02
thiabendazole,Ascariasis;Body temperature increased;Cutaneous larva migrans;Enterobiasis;Eosinophilia;Eruption;Hookworm infection;Infestation;Infestation NOS;Rash;Strongyloidiasis;Trichiniasis;Trichuriasis;Visceral larva migrans,Abdominal pain;Anaphylactic shock;Angioedema;Anorexia;Asthenia;Chills;Cholestasis;Confusional state;Conjunctival hyperaemia;Convulsion;Coordination abnormal;Crystalluria;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Drowsiness;Dyspepsia;Enuresis;Epigastric distress;Erythema multiforme;Fatigue;Feeling abnormal;Flushing;Gastrointestinal pain;Haematuria;Headache;Hepatic failure;Hepatocellular injury;Hyperglycaemia;Hypersensitivity;Hypoaesthesia;Hypotension;Jaundice;Leukopenia;Liver injury;Lymphadenopathy;Nausea;Numbness;Pruritus;Rash;Sensory loss;Sjogren's syndrome;Somnolence;Stevens-Johnson syndrome;Syndrome sicca;Tinnitus;Vision blurred;Vision decreased;Visual acuity reduced;Visual impairment;Vomiting;Xanthopsia,small molecule,approved; vet_approved,"2-(1,3-thiazole-4-yl)-1H-benzimidazole; 2-(4-thiazolyl)-1H-benzimidazole; 2-(thiazol-4-yl)benzimidazole; 4-(2-benzimidazolyl)thiazole; TBDZ; Thiabendazole; Tiabendazol; Tiabendazole; Tiabendazolum; 1.3.5.4; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase",Fumarate reductase flavoprotein subunit, P02CA02;D01AC06
thiotepa,Meningeal neoplasm;Neoplasm;Neoplasm malignant,Abdominal pain;Acute graft versus host disease;Acute leukaemia;Acute myeloid leukaemia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Amenorrhoea;Amylase increased;Anaemia;Angiopathy;Anorexia;Anxiety;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Ataxia;Azoospermia;Back pain;Bladder disorder;Bladder pain;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood electrolytes abnormal;Blood urea increased;Blood uric acid increased;Body temperature increased;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiomyopathy;Cardiovascular insufficiency;Cataract;Cerebral haemorrhage;Chemical cystitis;Chills;Chronic graft versus host disease;Cognitive disorder;Colitis;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cyst;Cystitis;Cystitis haemorrhagic;Cystitis noninfective;Cytopenia;Deafness;Decreased appetite;Dehydration;Delirium;Dermatitis;Dermatitis contact;Diarrhoea;Dizziness;Dyspepsia;Dysuria;Ear and labyrinth disorders;Embolism;Encephalopathy;Endocrine disorder;Enteritis;Eosinophilic cystitis;Epistaxis;Erythema;Erythrodermic psoriasis;Extrapyramidal disorder;Extravasation;Eye disorder;Fatigue;Febrile neutropenia;Feeling abnormal;Fluid retention;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal perforation;Gastrointestinal ulcer;Generalised oedema;Graft versus host disease;Growth retardation;Haematuria;Haemoglobin;Haemorrhage;Hallucination;Headache;Hearing impaired;Hepatic failure;Hepatobiliary disease;Hepatomegaly;Hyperbilirubinaemia;Hyperglycaemia;Hypersensitivity;Hypertension;Hyperuricaemia;Hypogonadism;Hypopituitarism;Hypothyroidism;Hypoxia;Idiopathic pneumonia syndrome;Ileus;Immune system disorder;Infection;Infection susceptibility increased;Infertility female;Infertility male;Infestation;Infestation NOS;Injection site inflammation;Injection site pain;Intestinal obstruction;Intracranial aneurysm;Jaundice;Leukoderma;Leukopenia;Lymphoedema;Malnutrition;Mediastinal disorder;Memory impairment;Meningism;Meningitis chemical;Menopause;Mental disorder;Mental status changes;Mucosal inflammation;Multi-organ failure;Musculoskeletal discomfort;Myalgia;Myelodysplastic syndrome;Myeloid leukaemia;Myelosuppression;Myocarditis;Nausea;Neoplasm malignant;Nervous system disorder;Nervousness;Oesophagitis;Oliguria;Ototoxicity;Pain;Pancytopenia;Paraesthesia;Paresis;Photophobia;Pigmentation disorder;Pneumonia;Polyp;Pruritus;Pulmonary oedema;Rash;Renal failure;Respiratory arrest;Sepsis;Septicemia;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Somnolence;Stomatitis;Tachycardia;Tension;Thrombocytopenia;Thrombocytopenic purpura;Tinnitus;Toxic shock syndrome;Transaminases increased;Transaminitis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;Vaginal haemorrhage;Venoocclusive liver disease;Vision blurred;Vomiting;Weight increased,small molecule,approved; investigational,"Thiotepa; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1",DNA,L01AC01
thiothixene,Mental disability;Mental retardation;Schizophrenia,Abnormal behaviour;Agitation;Agranulocytosis;Akathisia;Amenorrhoea;Anaphylactic shock;Anorexia;Asphyxia;Asthenia;Brain oedema;Breast enlargement;Cardiac arrest;Constipation;Convulsion;Cough;Decreased appetite;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Dizziness;Drowsiness;Dry mouth;Dyskinesia;Dysphagia;Dyspnoea;Edema cerebral;Eosinophilia;Erectile dysfunction;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Glycosuria;Gynaecomastia;Haemolytic anaemia;Hyperglycaemia;Hyperhidrosis;Hyperprolactinaemia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypoglycaemia;Hypotension;Ileus paralytic;Insomnia;Jaundice;Leukocytosis;Leukopenia;Lightheadedness;Loss of consciousness;Menstruation irregular;Miosis;Movements involuntary;Muscle spasms;Mydriasis;Nasal congestion;Nausea;Neuroleptic malignant syndrome;Oedema peripheral;Pancytopenia;Parkinsonism;Photosensitivity;Photosensitivity reaction;Polydipsia;Pregnancy test false positive;Protrusion tongue;Pruritus;Pseudoparkinsonism;Psychotic disorder;Rash;Salivary hypersecretion;Shock;Somnolence;Sweating increased;Syncope;Tachycardia;Tardive dyskinesia;Throat tightness;Thrombocytopenia;Urticaria;Vermiculation;Vision blurred;Vomiting,small molecule,approved,cis-thiothixene; Thiothixene; Tiotixene; Tiotixeno; Tiotixenum; Dopamine D2 receptor; Dopamine D1 receptor; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; hOCT1; OCT1; Organic cation transporter 1,D(2) dopamine receptor; D(1A) dopamine receptor; 5-hydroxytryptamine receptor 2A,N05AF04
tiagabine,Convulsion;Drug interaction;Electroencephalogram abnormal;Epilepsy;Partial seizures,Abdominal pain;Abnormal dreams;Abnormal faeces;Abnormal vision;Abortion;Abscess;Abscess periodontal;Accidental injury;Acute coronary syndrome;Affect lability;Ageusia;Agitation;Alopecia;Amblyopia;Amenorrhoea;Anaemia;Angina pectoris;Anorexia;Anxiety;Apathy;Apnoea;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Ataxia;Attention concentration difficulty;Back pain;Benign neoplasm of skin;Bladder pain;Blepharitis;Blindness;Body temperature increased;Breast enlargement;Breast pain;Breath odour;Bronchitis;Bursitis;Cellulitis;Central nervous system neoplasm;Cerebral ischaemia;Cerebration impaired;Chest pain;Chills;Cholecystitis;Cholelithiasis;Choreoathetosis;Circumoral paresthesia;Coma;Confusional state;Conjunctivitis;Constipation;Coordination abnormal;Cough;Cough increased;Cramps of lower extremities;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Delusion;Dental caries;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Eczema;Electrocardiogram abnormal;Encephalopathy;Epistaxis;Erectile dysfunction;Eructation;Euphoric mood;Eye pain;Face oedema;Faecal incontinence;Fatigue;Feeling abnormal;Fibrocystic breast disease;Flat affect;Flatulence;Furuncle;Furunculosis;Gait disturbance;Gastritis;Gastroenteritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised spasm;Gingival hyperplasia;Gingivitis;Glossitis;Goitre;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Hallucination;Headache;Hemiplegia;Hepatomegaly;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hirsutism;Hostility;Hyperacusis;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hyporeflexia;Hypotension;Hypothyroidism;Hypotonia;Ill-defined disorder;Increased appetite;Infection;Influenza;Injury;Insomnia;Irritability;Keratitis;Keratoconjunctivitis;Laryngitis;Leukopenia;Libido decreased;Libido increased;Lightheadedness;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Malaise;Melaena;Menorrhagia;Mental disability;Metrorrhagia;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Movement disorder;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Myoclonus;Nausea;Neck pain;Neck stiffness;Neoplasm;Nervousness;Neuritis;Neuropathy peripheral;Neurosis;Nocturia;Nodule;Nuchal rigidity;Nystagmus;Oedema;Oedema peripheral;Oesophagitis;Orthostatic hypotension;Osteoarthritis;Otitis externa;Otitis media;Pain;Pallor;Palpitations;Papanicolaou smear suspicious;Paraesthesia;Paraesthesia oral;Paralysis;Paranoia;Paranoid reaction;Parosmia;Pelvic pain;Peripheral vascular disorder;Personality disorder;Petechiae;Pharyngitis;Phlebitis;Photophobia;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Pruritus;Psoriasis;Psychotic disorder;Pyelonephritis;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Red blood cell abnormality;Renal failure;Rhinitis;Salivary hypersecretion;Salpingitis;Scotoma;Sepsis;Shock;Sinusitis;Skin cancer;Skin carcinoma;Skin mass;Skin ulcer;Smear cervix abnormal;Somnolence;Speech disorder;Stomatitis;Stupor;Subcutaneous nodule;Sudden death;Suicide attempt;Sweating;Syncope;Tachycardia;Tendinous contracture;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tooth abscess;Tremor;Ulcerative stomatitis;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary retention;Urinary tract infection;Urine output increased;Urticaria;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vasodilation;Vasodilation procedure;Vertigo;Vesiculobullous rash;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"Tiagabina; Tiagabine; Tiagabinum; GABATR; GABT1; GAT-1; GAT1; Solute carrier family 6 member 1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Sodium- and chloride-dependent GABA transporter 1,N03AG06
tiaprofenic,Arthritis;Osteoarthritis;Rheumatoid arthritis,Abdominal pain;Abdominal pain upper;Acute interstitial nephritis;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Anorexia;Anxiety;Asthenia;Asthma;Bladder pain;Bullous eruption;Chest pain;Conjunctivitis;Constipation;Contusion;Cramp muscle;Cystitis;Cystitis noninfective;Decreased appetite;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Disorientation;Dizziness;Drowsiness;Dry mouth;Dry skin;Duodenal ulcer;Dyspepsia;Dyspnoea;Dysuria;Enterocolitis;Epigastric pain;Epistaxis;Erythema;Erythema multiforme;Eye pruritus;Eye redness;Eye ulcer;Fatigue;Flatulence;Gastrointestinal haemorrhage;Gastrointestinal pain;Haematuria;Haemoglobin;Haemorrhage;Headache;Heartburn;Hot flush;Hyperhidrosis;Hypersensitivity;Incontinence;Insomnia;Melaena;Meningitis aseptic;Menopausal symptoms;Metrorrhagia;Muscle spasms;Nausea;Ocular hyperaemia;Oedema;Oliguria;Onycholysis;Palpitations;Paraesthesia;Paresthesia of fingers;Peptic ulcer;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyuria;Pruritus;Purpura;Rash;Sneezing;Somnolence;Spotting vaginal;Stevens-Johnson syndrome;Stomatitis;Sweating;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Urine output increased;Urticaria;Vaginal haemorrhage;Vascular purpura;Vertigo;Vision blurred;Vomiting;Weight increased,small molecule,approved,2-(5-Benzoyl-thiophen-2-yl)-propionic acid; 2-(5-Benzyl-2-thienyl)propionsäure; 5-benzoyl-α-methyl-2-thiopheneacetic acid; 5-benzoyl-α-methylthiophene-2-acetic acid; Acide tiaprofenique; Acido tiaprofenico; Acidum tiaprofenicum; Tiaprofenic acid; Tiaprofensäure; α-methyl-5-benzoyl-2-thienylacetic acid; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2,Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2,M01AE11
tibolone,Artificial menopause;Breast cancer;Cardiovascular disorder;Menopause;Oestrogen deficiency;Osteoporotic fracture;Surgical menopause,Abdominal discomfort;Abdominal pain lower;Acne;Acute coronary syndrome;Arthralgia;Breast discomfort;Breast disorder;Breast tenderness;Cerebrovascular accident;Cervical dysplasia;Cervix carcinoma;Chloasma;Dementia;Dermatitis;Dizziness;Embolism venous;Endometrial cancer;Erythema multiforme;Erythema nodosum;Fungal infection;Gallbladder disorder;Gastrointestinal disorder;Gastrointestinal tract irritation;Genital discharge;Hair growth abnormal;Headache;Hyperaesthesia;Migraine;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Neoplasm;Nipple pain;Oedema;Pelvic pain;Pelvic venous thrombosis;Pruritus;Pruritus genital;Pulmonary embolism;Rash;Skin disorder;Smear cervix abnormal;Unspecified disorder of skin and subcutaneous tissue;Vaginal discharge;Vaginal haemorrhage;Vaginal moniliasis;Vaginal mycosis;Vascular purpura;Venous thromboembolism;Vision blurred;Visual disturbance;Visual impairment;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginitis;Weight increased,small molecule,approved; investigational,17-hydroxy-7alpha-methyl-19-nor-17alpha-pregn-5(10)-en-20-yn-3-one; tibolona; Tibolone; tibolonum; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; 3.1.6.2; ARSC1; Arylsulfatase C; ASC; Estrone sulfatase; Steroid sulfatase; Steryl-sulfate sulfohydrolase; 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type I; 3-beta-HSD I; 3-beta-hydroxy-5-ene steroid dehydrogenase; 3-beta-hydroxy-Delta(5)-steroid dehydrogenase; 3-beta-hydroxysteroid 3-dehydrogenase; 3BH; Delta-5-3-ketosteroid isomerase; Dihydrotestosterone oxidoreductase; HSDB3A; Steroid Delta-isomerase; Trophoblast antigen FDO161G; 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II; 3-beta-HSD adrenal and gonadal type; 3-beta-HSD II; HSDB3B; 2.8.2.1; Aryl sulfotransferase 1; HAST1/HAST2; P-PST 1; Phenol sulfotransferase 1; Phenol-sulfating phenol sulfotransferase 1; ST1A1; ST1A3; STP; STP1; Thermostable phenol sulfotransferase; Ts-PST,Estrogen receptor,G03CX01
ticlopidine,Agranulocytosis;Aplastic anaemia;Blood disorder;Cerebrovascular accident;Neutropenia;Thrombosis;Thrombotic thrombocytopenic purpura,Abdominal distension;Alveolitis allergic;Anaphylactic shock;Angioedema;Anorexia;Antinuclear antibody positive;Arthralgia;Arthropathy;Asthenia;Blood cholesterol increased;Body temperature increased;Bone marrow depression;Cholesterol serum elevated;Colitis;Colitis microscopic;Conjunctival haemorrhage;Contusion;Cramp muscle;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diarrhoea haemorrhagic;Dizziness;Dyspepsia;Ecchymosis;Eosinophilia;Epistaxis;Erythema multiforme;Flatulence;Gastrointestinal fullness;Gastrointestinal haemorrhage;Gastrointestinal pain;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic failure;Hepatic necrosis;Hepatitis;Hypersensitivity;Hyponatraemia;Jaundice cholestatic;Jaundice hepatocellular;Leukaemia;Liver function test abnormal;Lung disorder;Lupus erythematosus;Lymphocytic colitis;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myositis;Nausea;Nephritis interstitial;Nephropathy;Nephrotic syndrome;Neuropathy peripheral;Operative bleeding;Osteoarthritis;Pain;Pancytopenia;Peptic ulcer;Procedural haemorrhage;Pruritus;Purpura;Rash;Renal failure;Reticulocytosis;Sepsis;Serum sickness;Stevens-Johnson syndrome;Systemic lupus erythematosus;Thrombocytopenia;Thrombocytosis;Tinnitus;Traumatic haemorrhage;Tubulointerstitial nephritis;Urticaria;Vascular purpura;Vasculitis;Vomiting,small molecule,approved,"Ticlopidina; Ticlopidine; Ticlopidinum; PAF-R; PAFR; ADP-glucose receptor; ADPG-R; HORK3; P2T(AC); P2Y(AC); P2Y(ADP); P2Y(cyc); P2Y12; P2Y12 platelet ADP receptor; SP1999; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.11.2.2; MPO; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J",Platelet-activating factor receptor; P2Y purinoceptor 12,B01AC05
timolol,Acute coronary syndrome;Angina pectoris;Atrial fibrillation;Cardiac flutter;Chronic open angle glaucoma;Classical migraine;Diabetes mellitus;Diabetic;Essential hypertension;Glaucoma;Hyperkinetic heart syndrome;Hypertension;Hypertensive;Migraine;Migraine with aura;Myocardial infarction;Myocardial ischaemia;Ocular hypertension;Open angle glaucoma;Primary open angle glaucoma,Abdominal pain;Abnormal dreams;Abnormal vision;Ache;Affect lability;Agranulocytosis;Alopecia;Alopecia reversible;Amnesia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Aphakic cystoid macular oedema;Arrhythmia;Arterial insufficiency;Arterial thrombosis;Arthralgia;Arthropathy;Asthenia;Asthma;Atrioventricular block;Blepharitis;Block heart;Blood urea increased;Body temperature increased;Bradycardia;Breast disorder;Bronchial obstruction;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure acute;Cardiac failure congestive;Cataract;Catatonia;Cerebral ischaemia;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Choroidal detachment;Claudication;Cold hands & feet;Colitis ischaemic;Common cold;Confusional state;Conjunctival hyperaemia;Conjunctivitis;Connective tissue disorder;Corneal sensitivity decreased;Coronary artery disease;Cough;Cystoid macular oedema;Decreased appetite;Depression;Dermatitis;Dermatitis exfoliative;Dermatitis psoriasiform;Device capturing issue;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Dreaming excessive;Dry eye;Dry mouth;Dyspepsia;Dyspnoea;Dysuria;Ear infection;Erectile dysfunction;Erythema;Erythema of eyelid;Exacerbation of asthma;Eye disorder;Eye irritation;Eye pain;Eyelid ptosis;Fatigue;Feeling abnormal;Fibrosis;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Hepatomegaly;Hyperaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia eye;Hypoglycaemia;Hypotension;Immune system disorder;Infection;Insomnia;Intermittent claudication;Keratitis;Lacrimation;Lacrimation increased;Laryngospasm;Libido decreased;Liver function test abnormal;Loss of consciousness;Lupus erythematosus;Macular oedema;Malnutrition;Mediastinal disorder;Memory loss;Mental disorder;Mood swings;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Nightmare;Oedema;Oedema peripheral;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Otitis;Pain;Pain in extremity;Palpitations;Paraesthesia;Peripheral coldness;Peyronie's disease;Photophobia;Pruritus;Psoriasis;Psoriasis flare-up;Pulmonary oedema;Purpura non-thrombocytopenic;Raised liver function tests;Rales;Rash;Rash erythematous;Rash generalised;Respiratory distress;Respiratory failure;Respiratory tract infection;Retinal vascular disorder;Retroperitoneal fibrosis;Rhinitis;Scab;Sensation of foreign body;Serositis;Sexual dysfunction;Shock;Short-term memory loss;Sinoatrial block;Sinusitis;Sjogren's syndrome;Skin disorder;Skin irritation;Somnolence;Stinging;Strangury;Sweating;Syncope;Syndrome sicca;Systemic lupus erythematosus;Tension;Throat sore;Thrombocytopenic purpura;Tinnitus;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Vasodilation;Vasodilation procedure;Vertigo;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Weight decreased,small molecule,approved,"(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; Timolol; Timolol anhydrous; Timololo; Timololum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 3.2.1.17; Lysis protein; Lysozyme; Muramidase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Endolysin, C07BA06; C07DA06; S01ED01; S01ED51;C07AA06
tinidazole,Amoebiasis;Amoebic colitis;Foetor hepaticus;Giardiasis;Hepatic amoebiasis;Hepatocellular injury;Herpes simplex;Infection;Liver disorder;Sexually transmitted disease;Trichomoniasis;Upper respiratory tract infection;Vaginal infection;Vaginal inflammation;Vaginitis bacterial;Vaginitis gardnerella;Vulvovaginitis,Abdominal pain;Angioedema;Angiopathy;Anorexia;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Ataxia;Blood bilirubin increased;Blood urea increased;Body temperature increased;Bronchospasm;Burning sensation;Candida infection;Chromaturia;Coma;Confusional state;Constipation;Convulsion;Cramp muscle;Decreased appetite;Dermatitis;Dermatitis atopic;Diarrhoea;Discomfort;Dizziness;Drowsiness;Drug hypersensitivity;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Eosinophil count increased;Epigastric discomfort;Erythema multiforme;Fatigue;Feeling abnormal;Flatulence;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Glossitis;Haemoglobin decreased;Headache;Hyperhidrosis;Hypersensitivity;Hypoaesthesia;Ill-defined disorder;Immune system disorder;Insomnia;Leukopenia;Malaise;Malnutrition;Menorrhagia;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Neuropathy peripheral;Neutropenia;Numbness;Oral candidiasis;Palpitations;Paraesthesia;Pelvic pain;Pharyngitis;Pruritus;Rash;Salivary hypersecretion;Salivation;Sensory loss;Skin disorder;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating;Taste bitter;Thirst;Thrombocytopenia;Tongue discolouration;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urticaria;Vaginal discharge;Vaginal odour;Vertigo;Vomiting;Vulvovaginal discomfort,small molecule,approved; investigational,"1-(2-(Ethylsulfonyl)ethyl)-2-methyl-5-nitroimidazole; Timidazole; Tinidazol; Tinidazole; Tinidazolum; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",DNA, A02BD09; G01AF20; G01AF21; J01RA13; J01XD02; P01AB02;J01RA11;J01XD02
tirofiban,Acute coronary syndrome;Angina pectoris;Angina unstable;Diabetes mellitus;Ischaemia;Myocardial infarction;Thrombocytopenia,Acute myocardial infarction;Anaphylactic shock;Body temperature increased;Bradycardia;Cardiac tamponade;Chills;Dizziness;Frank hematuria;Haematemesis;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Headache;Hypercholesterolaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Myocardial infarction;Nausea;Non-Q wave MI;Oedema;Pain;Pericardial haemorrhage;Retroperitoneal haemorrhage;ST segment elevation myocardial infarction;Spinal epidural haematoma;Sweating;Swelling;Thrombocytopenia;Urticaria,small molecule,approved,(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; Tirofiban; Tirofibán; Tirofibanum; GP2B; GPalpha IIb; GPIIb; ITGAB; Platelet membrane glycoprotein IIb; GP3A; GPIIIa; Platelet membrane glycoprotein IIIa,Integrin alpha-IIb; Integrin beta-3,B01AC17
tizanidine,Multiple sclerosis;Muscle spasticity;Spinal cord injury,Abdominal pain;Abnormal dreams;Abscess;Acute coronary syndrome;Adrenal cortical hypofunction;Adrenal insufficiency;Affect lability;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Amblyopia;Anaemia;Anaphylactic shock;Angina pectoris;Angiopathy;Anxiety;Arrhythmia;Arthralgia;Arthritis;Asthenia;Asthma;Autonomic nervous system imbalance;Back pain;Bladder pain;Blood and lymphatic system disorders;Body temperature increased;Bradycardia;Bronchitis;Bursitis;Calculus of kidney;Candida infection;Carcinoma;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardio-respiratory arrest;Cellulitis;Cerebral infarction;Cerebrovascular accident;Cholelithiasis;Confusional state;Congenital anomaly;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coronary artery disease;Cystitis;Cystitis noninfective;Deafness;Dementia;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis exfoliative;Developmental delay;Diarrhoea;Discomfort;Disseminated intravascular coagulation;Dizziness;Drowsiness;Drug withdrawal syndrome;Dry mouth;Dry skin;Dysautonomia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Ear pain;Ecchymosis;Electrocardiogram QT prolonged;Erythema multiforme;Euphoric mood;Eye pain;Faecalith;Faecaloma;Fatigue;Feeling abnormal;Flatulence;Flu symptoms;Foetor hepaticus;Gastroenteritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Glaucoma;Glycosuria;Haematemesis;Haematuria;Haemoglobin;Haemorrhage;Hallucination;Hemiplegia;Hepatic cancer;Hepatic cirrhosis;Hepatic failure;Hepatic fibrosis;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis fulminant;Hepatobiliary disease;Hepatocellular carcinoma;Hepatocellular injury;Hepatotoxicity;Herpes simplex;Herpes zoster;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertonia;Hypokalaemia;Hyponatraemia;Hypoproteinaemia;Hypotension;Hypothyroidism;Ill-defined disorder;Immune system disorder;Infection;Influenza;Intestinal obstruction;Iritis;Jaundice;Keratitis;Leukocytosis;Leukopenia;Liver disorder;Liver function test abnormal;Liver injury;Loss of consciousness;Malaise;Mediastinal disorder;Melaena;Menorrhagia;Mental disability;Mental disorder;Metrorrhagia;Micturition urgency;Migraine;Mood swings;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myasthenia;Myocardial infarction;Nausea;Neck pain;Neoplasm malignant;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Oedema;Optic atrophy;Optic neuritis;Orthostatic hypotension;Otitis media;Paraesthesia;Paralysis;Petechiae;Pharyngitis;Phlebitis;Pneumonia;Pollakiuria;Prolonged menses;Pruritus;Psychotic disorder;Pulmonary embolism;Pulmonary oedema;Purpura;Pyelonephritis;Rash;Renal failure;Renal failure acute;Respiratory acidosis;Retinal haemorrhage;Rhabdomyolysis;Rhinitis;Scotoma;Sepsis;Shock;Sinusitis;Skin cancer;Skin carcinoma;Skin disorder;Skin ulcer;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stupor;Suicide attempt;Sweating;Syncope;Tachycardia;Tension;Thinking abnormal;Thrombocytopenia;Thrombocytosis;Tinnitus;Torsade de pointes;Traumatic liver injury;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;Uterine fibroids enlarged;Uterine leiomyoma;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vascular purpura;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased;Withdrawal symptom,small molecule,approved; investigational,"5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole; Tizanidin; Tizanidina; Tizanidine; Tizanidinum; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; hIRAS; I-1; I-1 receptor candidate protein; I1R; I1R candidate protein; Imidazoline receptor 1; Imidazoline receptor antisera-selected protein; Imidazoline-1 receptor; Imidazoline-1 receptor candidate protein; IR1; IRAS; KIAA0975; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",Alpha-1 adrenergic receptors; Alpha-2 adrenergic receptors; Nischarin,M03BX02
tobramycin,Abdominal infection;Acute bronchitis;Bacterial infection;Bladder pain;Bronchitis;Bronchopneumonia;Central nervous system infection;Cystic fibrosis;Cystitis;Cystitis noninfective;Deafness;Gastrointestinal infection;Hearing impaired;Infection;Lower respiratory tract infection;Lung infection;Meningitis;Myasthenia gravis;Nephropathy toxic;Nephrotoxicity;Peritonitis;Pneumonia;Pyelonephritis;Recurrent urinary tract infection;Renal failure;Renal impairment;Respiratory tract infection;Sepsis;Sepsis neonatal;Septicemia;Soft tissue infection;Staphylococcal infection;Tracheobronchitis;Urinary tract infection,Abdominal pain;Agranulocytosis;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Aphonia;Apnoea;Application site pain;Aspartate aminotransferase increased;Asthenia;Asthma;Back pain;Blood alkaline phosphatase increased;Blood bilirubin increased;Blood calcium decreased;Blood creatinine decreased;Blood creatinine increased;Blood glucose increased;Body temperature increased;Bone disorder;Bronchitis;Bronchospasm;Chest discomfort;Chest pain;Cochlear toxicity;Confusional state;Conjunctival disorder;Conjunctival oedema;Connective tissue disorder;Corneal abrasion;Cough;Cough increased;Creatinine increased;Creatinine low;Deafness;Deafness unilateral;Decreased appetite;Dehydration;Delirium;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Disorientation;Dizziness;Drug interaction;Dry eye;Dry skin;Dysgeusia;Dysphonia;Dyspnoea;Ear and labyrinth disorders;Ear pain;Ear roaring;Endophthalmitis;Eosinophilia;Epistaxis;Erythema;Erythema of eyelid;Eye allergy;Eye discharge;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Eyelid disorder;Eyelid oedema;Eyelids pruritus;Feeling abnormal;Forced expiratory volume decreased;Foreign body sensation in eyes;Function kidney decreased;Gastrointestinal disorder;Gastrointestinal pain;Haemoptysis;Headache;Hearing impaired;High frequency deafness;Hypersensitivity;Hyperventilation;Hypoalbuminaemia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hypophosphataemia;Hypouricaemia;Ill-defined disorder;Immune system disorder;Immunoglobulins increased;Increased bronchial secretion;Infestation;Infestation NOS;Injection site pain;Instillation site pain;Keratitis;Lacrimation;Lacrimation increased;Laryngeal pain;Laryngitis;Lethargy;Leukocytosis;Leukoderma;Leukopenia;Local reaction;Lower respiratory tract infection;Lung disorder;Madarosis;Malaise;Mediastinal disorder;Metabolic syndrome;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nausea;Nephritis interstitial;Nephropathy toxic;Nephrotoxicity;Nervous system disorder;Neuropathy peripheral;Neurotoxicity;Ocular discomfort;Ocular hyperaemia;Ocular toxicity;Oliguria;Oropharyngeal pain;Ototoxicity;Pain;Paraesthesia;Pharyngitis;Pharyngolaryngeal pain;Phosphatase alkaline increased;Platelet count decreased;Productive cough;Protein urine present;Proteinuria;Pruritus;Pulmonary function test decreased;Punctate keratitis;Rales;Rash;Rash maculo-papular;Red blood cell sedimentation rate increased;Renal failure;Renal failure acute;Renal impairment;Respiratory depression;Rhinitis;Serum bilirubin increased;Serum calcium decreased;Serum creatinine increased;Serum transaminase increased;Sinusitis;Skin disorder;Sputum increased;Stinging;Stomatitis;Swelling;Throat irritation;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tonsillitis;Transaminases increased;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Vertigo;Vision blurred;Visual impairment;Vomiting;Weight decreased;Wheezing,small molecule,approved; investigational,"3'-Deoxykanamycin B; Nebramycin 6; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine; Tobramicina; Tobramycin; Tobramycine; Tobramycinum",16S ribosomal RNA; 23S ribosomal RNA; Bacterial outer membrane; Cytoplasmic membrane, J01GB01;J01GB01;S01AA12
tolazamide,Blood glucose decreased;Diabetes mellitus;Diabetic;Hyperglycaemia;Obesity;Type 2 diabetes mellitus;Weight decreased,Abdominal distension;Agranulocytosis;Alcohol intolerance;Aplastic anaemia;Asthenia;Digestion impaired;Discomfort;Disulfiram like reaction;Dizziness;Dyspepsia;Epigastric fullness;Eruption;Erythema;Fatigue;Feeling abnormal;Gastrointestinal disorder;Haemolytic anaemia;Headache;Heartburn;Hypoglycaemia;Hyponatraemia;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Jaundice cholestatic;Leukopenia;Malaise;Nausea;Pancytopenia;Photosensitivity reaction;Porphyria cutanea tarda;Porphyria hepatic;Porphyria non-acute;Pruritus;Rash;Reaction gastrointestinal;Thrombocytopenia;Urticaria;Vertigo,small molecule,approved; investigational,"1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; Tolazamid; Tolazamida; Tolazamide; Tolazamidum; HRINS; Sulfonylurea receptor 1; SUR; SUR1; IKATP; Inward rectifier K(+) channel Kir6.2; Potassium channel, inwardly rectifying subfamily J member 11; ATP-dependent inwardly rectifying potassium channel Kir4.1; Inward rectifier K(+) channel Kir1.2; Potassium channel, inwardly rectifying subfamily J member 10; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase","Sulfonylurea receptor 1, Kir6.2; ATP-sensitive inward rectifier potassium channel 10", G01AE10;A10BB05
tolbutamide,Blood glucose decreased;Diabetes mellitus;Diabetic;Hyperglycaemia;Obesity;Type 2 diabetes mellitus;Weight decreased,Abdominal distension;Agranulocytosis;Alcohol intolerance;Aplastic anaemia;Digestion impaired;Disulfiram like reaction;Dyspepsia;Epigastric fullness;Eruption;Erythema;Gastrointestinal disorder;Haemolytic anaemia;Headache;Heartburn;Hypoglycaemia;Hyponatraemia;Inappropriate antidiuretic hormone secretion;Jaundice cholestatic;Leukopenia;Nausea;Pancytopenia;Photosensitivity reaction;Porphyria cutanea tarda;Porphyria hepatic;Porphyria non-acute;Pruritus;Rash;Reaction gastrointestinal;Thrombocytopenia;Urticaria,small molecule,approved; investigational,"1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-Butyl-3-(p-tolylsulfonyl)urea; 1-Butyl-3-tosylurea; 1-p-Toluenesulfonyl-3-butylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-(p-Methylbenzenesulfonyl)-N'-butylurea; N-(Sulfonyl-p-methylbenzene)-N'-N-butylurea; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-p-toluenesulfonylurea; N-n-Butyl-N'-tosylurea; Tolbutamida; Tolbutamide; Tolbutamidum; Tolylsulfonylbutylurea; Sulfonylurea receptor 2; SUR2; HRINS; Sulfonylurea receptor 1; SUR; SUR1; ATP-regulated potassium channel ROM-K; Inward rectifier K(+) channel Kir1.1; Potassium channel, inwardly rectifying subfamily J member 1; ROMK1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9",ATP-binding cassette sub-family C member 9; ATP-binding cassette sub-family C member 8; ATP-sensitive inward rectifier potassium channel 1, A10BB03; G01AE10;A10BB03;V04CA01
tolmetin,Arthritis;Juvenile idiopathic arthritis;Osteoarthritis;Peptic ulcer;Rheumatoid arthritis;Ulcer,Abdominal discomfort;Abdominal pain;Agranulocytosis;Anaphylactic shock;Anaphylactoid reaction;Asthenia;Blood pressure increased;Blood urea increased;Body temperature increased;Cardiac failure congestive;Chest pain;Constipation;Diarrhoea;Distress gastrointestinal;Dizziness;Drowsiness;Dyspepsia;Dysuria;Epistaxis;Erythema multiforme;Flatulence;Gastritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Glossitis;Haematuria;Haemolytic anaemia;Headache;Hepatitis;Lymphadenopathy;Nausea;Oedema;Optic nerve disorder;Protein urine present;Proteinuria;Purpura;Renal failure;Serum sickness;Skin irritation;Somnolence;Stomatitis;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Urinary tract infection;Urticaria;Vascular purpura;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved,"1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid; Tolmetin; Tolmetina; Tolmétine; Tolmetino; Tolmetinum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.13.11.11; TDO; TO; TRPO; Tryptamin 2,3-dioxygenase; Tryptophan oxygenase; Tryptophan pyrrolase; Tryptophanase; 1.11.2.2; MPO; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1, M02AA21;M01AB03
tolterodine,Dementia;Hypertonic bladder;Pollakiuria;Urge incontinence,Abdominal pain;Abnormal vision;Accommodation disorder;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anxiety;Arthralgia;Asthenia;Bronchitis;Chest pain;Confusional state;Constipation;Delusion;Dementia;Diarrhoea;Disorientation;Dizziness;Dry eye;Dry mouth;Dry skin;Dyspepsia;Dysuria;Fatigue;Feeling abnormal;Flatulence;Flushing;Gastrointestinal pain;Gastrooesophageal reflux disease;Hallucination;Headache;Hypersensitivity;Infection;Influenza like illness;Influenza-like symptoms;Memory impairment;Musculoskeletal discomfort;Oedema;Oedema peripheral;Pain;Palpitations;Sinusitis;Somnolence;Tachycardia;Upper respiratory tract infection;Urinary retention;Urinary tract infection;Vertigo;Visual impairment;Weight increased;Xerophthalmia,small molecule,approved; investigational,"(+)-(R)-2-(alpha-(2-(Diisopropylamino)ethyl)benzyl)-p-cresol; (+)-Tolterodine; Tolterodina; Tolterodine; Tolterodinum; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M5; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M4,G04BD07
topiramate,Asthenia;Bipolar I disorder;Bipolar disorder;Cerebration impaired;Chronic migraine;Cluster headache;Convulsion;Disturbance in attention;Drop attacks;Drug interaction;Epilepsy;Fatigue;Foetor hepaticus;Grand mal convulsion;Headache;Hepatocellular injury;Hypersensitivity;Lennox-Gastaut syndrome;Liver disorder;Mental disability;Migraine;Nephrolithiasis;Nervousness;Partial epilepsy;Partial seizures;Pharmacokinetic interaction;Renal failure;Renal failure chronic;Renal impairment;Tension;Tonic-clonic seizures,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Abnormal behaviour;Abnormal sensation in eye;Abnormal vision;Accommodation disorder;Acidosis;Acidosis hyperchloraemic;Acne;Action tremor;Administration site reaction;Affect lability;Ageusia;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Akinesia;Alanine aminotransferase increased;Albuminuria;Alcohol intolerance;Alkaline phosphatase serum increased;Allergic oedema;Alopecia;Altered state of consciousness;Altered visual depth perception;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anger;Angina pectoris;Angiopathy;Angle closure glaucoma;Anhidrosis;Anorexia;Anorgasmia;Anosmia;Anxiety;Anxiety depression;Apathy;Aphasia;Apraxia;Arthralgia;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrioventricular block;Attention concentration difficulty;Auditory disorder NOS;Aura;Autonomic neuropathy;Back pain;Balance disorder;Bicarbonate level;Bipolar I disorder;Bipolar disorder;Bladder pain;Bleeding breakthrough;Blepharospasm;Blindness transient;Blindness unilateral;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bicarbonate;Blood bicarbonate decreased;Blood creatinine increased;Blood potassium decreased;Body odor;Body temperature decreased;Body temperature increased;Bone marrow depression;Bone pain;Bradycardia;Bradyphrenia;Breast discharge;Breast disorder;Breast pain;Breast pain female;Breath odour;Bronchitis;Burning sensation;Calcinosis;Calculus of kidney;Calculus ureteric;Candida infection;Cardiac disorder;Cardiovascular disorder;Cerebellar syndrome;Cerebration impaired;Chest pain;Chills;Chloasma;Circadian rhythm sleep disorder;Clotting;Clumsiness;Coagulopathy;Cognitive disorder;Cognitive impairment;Collagen disorder;Completed suicide;Confusional state;Congenital eye disorder;Conjunctival oedema;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Convulsions aggravated;Coordination abnormal;Cough;Cramps of lower extremities;Creatinine increased;Crying;Crystal urine present;Cystitis;Cystitis noninfective;Deafness;Deafness neurosensory;Deafness unilateral;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Delusion;Dependence;Depersonalisation;Depressed level of consciousness;Depressed mood;Depression;Depression aggravated;Dermatitis;Dermatitis atopic;Diabetes mellitus;Diabetic;Diabetic neuropathy;Diabetic peripheral neuropathy;Diarrhoea;Diplopia;Discomfort;Disorder sight;Disorientation;Distractibility;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dizziness postural;Drooling;Drug - food interaction;Drug abuse;Drug interaction;Dry eye;Dry mouth;Dysaesthesia;Dysarthria;Dysgeusia;Dysgraphia;Dyskinesia;Dyslexia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphasia;Dysphemia;Dysphonia;Dyspnoea;Dyspnoea exertional;Dysuria;Ear and labyrinth disorders;Ear discomfort;Ear pain;Eczema;Effusion;Ejaculation disorder;Electrocardiogram abnormal;Electroencephalogram abnormal;Elevated mood;Embolism;Encephalopathy;Endocrine disorder;Endophthalmitis;Enlargement abdomen;Eosinophilia;Epigastric discomfort;Epilepsy;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Essential tremor;Euphoric mood;Expressive language disorder;Eye disorder;Eye movement disorder;Eye pain;Eye redness;Eyelid oedema;Face oedema;Faecal incontinence;Familial tremor;Fatigue;Feeling abnormal;Feeling drunk;Feeling jittery;Feeling of despair;Flank pain;Flat affect;Flatulence;Fluid intake increased;Fluid retention;Flushing;Food interaction;Formication;Gait disturbance;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Genital candidiasis;Gingival bleeding;Gingival hyperplasia;Gingivitis;Glaucoma;Glossitis;Glossodynia;Grand mal convulsion;Haematoma;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoids;Hair texture abnormal;Hallucination;Hallucination, auditory;Hallucination, visual;Headache;Hearing impaired;Heat intolerance;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hot flush;Hyperaesthesia;Hyperammonaemia;Hyperchloraemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hypernatraemia;Hyperplasia;Hypersensitivity;Hypersomnia;Hypertension;Hyperthyroidism;Hypertonia;Hypertrichosis;Hypoaesthesia;Hypoaesthesia facial;Hypoaesthesia oral;Hypocalcaemia;Hypocholesterolaemia;Hypogeusia;Hypoglycaemia;Hypohidrosis;Hypokalaemia;Hypokinesia;Hypomania;Hyponatraemia;Hypophosphataemia;Hyporeflexia;Hyposmia;Hypotension;Hypothermia;Ill-defined disorder;Immune system disorder;Incontinence;Increased appetite;Infection;Infestation;Infestation NOS;Influenza like illness;Influenza-like symptoms;Initial insomnia;Insomnia;Intraocular pressure increased;Iritis;Irritability;Joint swelling;Ketogenic diet;Lack of spontaneous speech;Lacrimal disorder;Lacrimation abnormal NOS;Lacrimation increased;Laryngitis;Learning disability;Leg pain;Lethargy;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Limb discomfort;Liver function test abnormal;Loss of consciousness;Loss of libido;Lymphadenopathy;Lymphocytosis;Lymphopenia;Maculopathy;Malaise;Malnutrition;Mania;Manic psychosis;Mastitis;Mediastinal disorder;Melaena;Memory impairment;Menopausal symptoms;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Mental retardation;Metabolic acidosis;Metrorrhagia;Micturition urgency;Middle insomnia;Migraine;Migraine aggravated;Mood alteration NOS;Mood swings;Mouth ulceration;Muscle contractions involuntary;Muscle fatigue;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Mydriasis;Myopia;Nail disorder;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm;Nephrolithiasis;Nephropathy;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neurosis;Neutropenia;Night blindness;Nocturia;Nystagmus;Obesity;Ocular hyperaemia;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Oral pain;Orgasmic sensation decreased;Orthostatic hypotension;Osteoarthritis;Osteomalacia;Otitis media;Pain;Pain in extremity;Pallor;Palpitations;Pancreatitis;Pancreatitis acute;Pancytopenia;Panic attack;Panic disorder;Panic reaction;Paraesthesia;Paraesthesia oral;Paranasal sinus hypersecretion;Paranoia;Paranoid reaction;Parosmia;Partial seizures;Pemphigoid;Pemphigus;Periorbital oedema;Peripheral coldness;Perseveration;Personality disorder;Pharyngeal oedema;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Photopsia;Photosensitivity reaction;Pneumonia;Pollakiuria;Polycythaemia;Polydipsia;Polyuria;Poor quality sleep;Potassium low;Premature ejaculation;Presbyopia;Presyncope;Prostatic disorder;Prothrombin level increased;Pruritus;Pruritus generalised;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Pulmonary embolism;Purpura;Raised liver function tests;Rash;Rash erythematous;Rash macular;Rash maculo-papular;Red blood cell disorders;Redness;Renal colic;Renal failure;Renal pain;Renal tubular acidosis;Repetitive speech;Respiratory alkalosis;Respiratory tract infection;Rhinitis;Rhinorrhoea;Rickets;Rigors;Road traffic accident;Salivary hypersecretion;Scintillating scotoma;Scotoma;Seborrhoeic dermatitis;Sensory disturbance;Sensory loss;Serum potassium decreased;Sexual dysfunction;Shock;Sinus bradycardia;Sinusitis;Skin discolouration;Skin disorder;Skin odour abnormal;Sleep disorder;Sluggishness;Somnolence;Speech disorder;Status epilepticus;Stevens-Johnson syndrome;Stomatitis;Stupor;Sudden unexplained death in epilepsy;Suicidal behaviour;Suicidal ideation;Suicide;Suicide attempt;Sweating decreased;Sweating increased;Swelling face;Syncope;Tachycardia;Tandem gait test abnormal;Taste disorders;Tearfulness;Temperature intolerance;Tension;Terminal insomnia;Testicular disorder;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytosis;Thromboembolic event;Tinnitus;Tongue disorder;Tongue oedema;Tongue paralysis;Tooth disorder;Toothache;Toxic epidermal necrolysis;Tremor;Ulcerative stomatitis;Unintended pregnancy;Unresponsive to stimuli;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Upper motor neurone lesion;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Urticaria localised;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasodilation;Vasodilation procedure;Vasospasm;Vertigo;Viral infection;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;White blood cell count decreased;Word finding difficulty;Xerophthalmia",small molecule,approved,"2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate; 2,3:4,5-di-O-isopropylidene-β-D-fructopyranose sulfamate; Tipiramate; Tipiramato; Topiramate; Topiramato; Topiramatum; TPM; EAA3; Excitatory amino acid receptor 3; GluK1; GluR-5; GLUR5; Glutamate receptor 5; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; NAC1; SCN1; Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; HBA; HBSC II; NAC2; SCN2A1; SCN2A2; Sodium channel protein brain II subunit alpha; Sodium channel protein type II subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.2; KIAA1356; NAC3; Sodium channel protein brain III subunit alpha; Sodium channel protein type III subunit alpha; Voltage-gated sodium channel subtype III; Voltage-gated sodium channel subunit alpha Nav1.3; SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Atypical sodium channel Nav2.1; Nax channel; SCN6A; Sodium channel protein type VII subunit alpha; MED; Sodium channel protein type VIII subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.6; hNE-Na; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Sodium channel protein type IX subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.7; EAA3; Excitatory amino acid receptor 3; GluK1; GluR-5; GLUR5; Glutamate receptor 5; EAA4; Excitatory amino acid receptor 4; GluK2; GluR-6; GLUR6; Glutamate receptor 6; EAA5; Excitatory amino acid receptor 5; GluK3; GluR-7; GLUR7; Glutamate receptor 7; EAA1; Excitatory amino acid receptor 1; GluK4; Glutamate receptor KA-1; GRIK; KA1; EAA2; Excitatory amino acid receptor 2; GluK5; Glutamate receptor KA-2; GRIK2; KA2; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-IV; Carbonate dehydratase IV; Carbonic anhydrase IV; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 4.2.1.1; CA-III; Carbonate dehydratase III; Carbonic anhydrase III; BII; Brain calcium channel II; CACH6; CACNL1A6; Calcium channel, L type, alpha-1 polypeptide, isoform 6; Voltage-gated calcium channel subunit alpha Cav2.3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 2.7.11.1; ACACA kinase; Acetyl-CoA carboxylase kinase; AMPK subunit alpha-1; AMPK1; HMGCR kinase; Hydroxymethylglutaryl-CoA reductase kinase; Tau-protein kinase PRKAA1; 2.7.11.1; ACACA kinase; Acetyl-CoA carboxylase kinase; AMPK; AMPK subunit alpha-2; AMPK2; HMGCR kinase; Hydroxymethylglutaryl-CoA reductase kinase; AMPK; AMPK subunit beta-1; AMPKb; AMPK subunit beta-2; AMPK gamma1; AMPK subunit gamma-1; AMPKg; AMPK gamma2; AMPK subunit gamma-2; H91620p; AMPK gamma3; AMPK subunit gamma-3; AMPKG3","Glutamate receptor ionotropic, kainate 1; Gamma-aminobutyric acid receptor subunit alpha-1; Voltage-gated sodium channel alpha subunit; Kainate receptors; Carbonic anhydrase 2; Carbonic anhydrase 4; Voltage gated L-type calcium channel; Carbonic anhydrase 1; Carbonic anhydrase 3; Voltage-dependent R-type calcium channel", N03AX11;A08AA51;N03AX11
topotecan,Carcinoma of lung;Cervix carcinoma;Glioma;Leukaemia;Lung neoplasm malignant;Malignant neoplasm of pancreas;Metastatic carcinoma;Metastatic neoplasm;Myelodysplastic syndrome;Neoplasm malignant;Neuroblastoma;Non-small cell lung cancer;Ovarian cancer;Ovarian carcinoma;Ovarian epithelial cancer recurrent;Ovarian epithelial cancer stage IV;Pancreatic carcinoma;Plasma cell myeloma;Plasmacytoma;Retinoblastoma;Rhabdomyosarcoma;Sarcoma;Small cell lung cancer;Small cell lung cancer recurrent,Abdominal pain;Acute leukaemia;Acute respiratory distress syndrome;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blood and lymphatic system disorders;Blood bilirubin increased;Body temperature increased;Bone pain;Bullous eruption;Cardiac arrest;Chest pain;Chills;Colitis;Constipation;Cough;Cramp muscle;Decreased appetite;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Dizziness;Dysmenorrhoea;Dyspareunia;Dyspepsia;Dyspnoea;Ear pain;Epistaxis;Extravasation;Fatigue;Febrile neutropenia;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Heartburn;Hepatic pain;Hepatobiliary disease;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypoaesthesia;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Interstitial lung disease;Intestinal obstruction;Lethargy;Leukopenia;Lung disorder;Lung neoplasm malignant;Malaise;Malnutrition;Mediastinal disorder;Metastatic carcinoma;Metastatic neoplasm;Mucosal inflammation;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myelosuppression;Nausea;Neoplasm;Nervous system disorder;Neuralgia;Neuropathy;Neuropathy peripheral;Neutropenia;Neutropenic colitis;Pain;Pancytopenia;Paraesthesia;Paresis;Pelvic pain;Pharyngitis;Pleural effusion;Pleuritic pain;Pneumonia;Pruritus;Pulmonary embolism;Rash;Rash erythematous;Rash maculo-papular;Respiratory failure;Rhinitis;Rigors;Sepsis;Skin disorder;Stomatitis;Sweating;Thrombocytopenia;Thrombocytopenia aggravated;Tumour pain;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vomiting;Weight increased,small molecule,approved; investigational,9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin; Topotecan; Topotecane; Topotecanum; 5.6.2.1; DNA topoisomerase I; 5.6.2.1; TOP1mt; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2,"DNA topoisomerase 1; DNA; DNA topoisomerase I, mitochondrial",L01CE01;L01XX17
toremifene,Bone cancer metastatic;Breast cancer stage IV;Neoplasm,Abnormal vision;Acute coronary syndrome;Affect lability;Alopecia;Angina pectoris;Angiopathy;Anorexia;Appetite absent;Arrhythmia;Arthritis;Asthenia;Ataxia;Back pain;Breast disorder;Cardiac failure;Cataract;Chest pain;Chills;Constipation;Coordination abnormal;Corneal opacity;Cyst;Decreased appetite;Deep vein thrombosis;Dermatitis;Diplopia;Disorder sight;Dizziness;Dry eye;Dyspnoea;Ear and labyrinth disorders;Embolism;Endometrial cancer;Endometrial hyperplasia;Endometrial hypertrophy;Eye disorder;Fatigue;Foetor hepaticus;Gastrointestinal disorder;Glaucoma;Headache;Hepatitis toxic;Hepatobiliary disease;Hepatocellular injury;Hot flush;Hypercalcaemia;Hyperhidrosis;Insomnia;Jaundice;Keratopathy;Lethargy;Leukopenia;Leukorrhea;Liver disorder;Liver function test abnormal;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Metabolic disorder;Mood swings;Musculoskeletal stiffness;Myocardial infarction;Nausea;Nervous system disorder;Neuropathy peripheral;Oedema;Oestrogenic effect;Pain;Paresis;Polyp;Pruritus;Pulmonary embolism;Rash;Rigors;Skin discolouration;Skin disorder;Stiffness;Sweating;Thrombocytopenia;Thromboembolic event;Thrombophlebitis;Thrombosis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Uterine haemorrhage;Uterine polyp;Vaginal discharge;Vaginal haemorrhage;Vertigo;Vision blurred;Visual impairment;Vomiting;Weight increased,small molecule,approved; investigational,"Toremifene; Toremifeno; Toremifenum; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Estrogen receptor; Sex hormone-binding globulin,L02BA02
tramadol,Acute pain;Back pain;Chronic pain;Low back pain;Osteoarthritis;Pain;Postoperative pain;Procedural pain,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Abnormal behaviour;Abnormal dreams;Abnormal ejaculation;Abnormal faeces;Abnormal vision;Abrasion NOS;Abscess limb;Accidental injury;Acute bronchitis;Acute coronary syndrome;Acute myocardial infarction;Acute sinusitis;Affect lability;Agitation;Alanine aminotransferase decreased;Alanine aminotransferase increased;Albuminuria;Amblyopia;Amnesia;Amylase increased;Anaemia;Analgesic effect;Analgesic therapy;Anaphylactic shock;Angina pectoris;Angina unstable;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anosmia;Anxiety;Anxiety NEC;Aortic aneurysm;Apathy;Appendicitis;Arrhythmia;Arthralgia;Arthralgia of temporomandibular joint;Arthritis;Arthropathy;Arthropod bite;Aspartate aminotransferase decreased;Aspartate aminotransferase increased;Asthenia;Asthma;Asthma aggravated;Ataxia;Atrial fibrillation;Atrial flutter;Back disorder;Back injury;Back pain;Bacteriuria;Band neutrophil count increased;Benign breast neoplasm;Biliary tract disorder;Bipolar I disorder;Bipolar disorder;Bladder infection;Bladder pain;Blepharitis;Blister;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood calcium decreased;Blood cholesterol abnormal;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose abnormal;Blood glucose increased;Blood in stool;Blood lactate dehydrogenase increased;Blood potassium abnormal;Blood potassium decreased;Blood potassium increased;Blood pressure increased;Blood sodium increased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Bone spur;Bradycardia;Breast cancer;Breast cancer invasive NOS;Breast disorder;Breast pain;Breath odour;Bronchitis;Bronchospasm;Burning sensation;Bursitis;C-reactive protein increased;Ca++ increased;Calculus of kidney;Cardiac disorder;Cardiac murmur;Cardiovascular disorder;Carpal tunnel syndrome;Cataract;Cellulitis;Cerebration impaired;Cerumen impaction;Change of bowel habit;Chest discomfort;Chest pain;Chest tightness;Chest wall pain;Chills;Cholecystitis;Cholelithiasis;Cognitive disorder;Cognitive impairment;Cold sweat;Coma;Completed suicide;Concussion;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Constipation aggravated;Contusion;Convulsion;Coordination abnormal;Coordination disturbance;Coronary artery insufficiency;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatinine increased;Crystalluria calcium;Cutis anserina;Cyst;Cyst epidermal;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Delusion;Depersonalisation;Depression;Derealisation;Dermal cyst;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermoid cyst;Diabetes mellitus;Diarrhoea;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Diverticulum;Dizziness;Dizziness aggravated;Drug abuse;Drug interaction;Drug tolerance;Drug withdrawal syndrome;Dry eye;Dry mouth;Dry skin;Dry throat;Duodenal ulcer;Duodenal ulcer aggravated;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dyspepsia aggravated;Dysphagia;Dysphoria;Dyspnoea;Dyssomnia;Dysthymic disorder;Dysuria;Ear and labyrinth disorders;Ear congestion;Ear discomfort;Ear infection;Ear pain;Ecchymosis;Eczema;Eczema exacerbated;Edema of lower extremities;Effusion of knee;Ejaculation disorder;Electrocardiogram abnormal;Emotional disorder;Emotional disturbance NOS;Encephalopathy;Endocrine disorder;Eosinophil count increased;Epigastric discomfort;Epistaxis;Erectile dysfunction;Eructation;Erysipelas;Erythema;Erythema multiforme;Essential hypertension;Euphoric mood;Eustachian tube disorder;Exacerbation of hot flushes;Excoriation;Exostosis;Extrasystoles;Eye disorder;Eye injury;Eye pain;Eyelid disorder;Face injury;Faecalith;Faecaloma;Faeces discoloured;Fatigue;Feeling abnormal;Feeling hot;Feeling jittery;Flat affect;Flatulence;Flushing;Food aversion;Food poisoning;Foot infection fungal NOS;Functional gastrointestinal disorder;Fungal infection;Gait disturbance;Gamma-glutamyltransferase increased;Gastric irritation;Gastritis;Gastritis aggravated;Gastroduodenitis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal infection;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;Genital itching female;Genitourinary tract infection;Gout;Groin pain;Gynaecomastia;Haematemesis;Haematochezia;Haematocrit decreased;Haematocrit increased;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoglobin increased;Haemolytic anaemia;Haemoptysis;Haemorrhage;Hair disorder;Hallucination;Hand fracture;Head injury;Headache;Headache aggravated;Helicobacter infection;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatobiliary disease;Herpangina;Herpes simplex;Herpes zoster;Hiccups;High density lipoprotein decreased;Hordeolum;Hot flush;Hyperaesthesia;Hypercalcaemia;Hypercalciuria;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkeratosis;Hyperkinesia;Hyperlipidaemia;Hyperreflexia;Hypersensitivity;Hypersomnia;Hypertension;Hypertension worsened;Hypertonia;Hypertriglyceridaemia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hypophosphataemia;Hypotension;Hypothyroidism;Hypotonia;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Infestation;Infestation NOS;Inflammation;Inflammation localised;Influenza;Influenza like illness;Ingrowing nail;Injury;Insomnia;Insomnia NEC;Irritability;Irritable bowel syndrome;Ischaemic stroke;Joint crepitation;Joint effusion;Joint sprain;Joint stiffness;Joint swelling;Labyrinthitis;Laceration;Lacrimal disorder;Lacrimal structural disorder;Lacrimation increased;Lactic dehydrogenase activity increased;Laryngeal pain;Laryngitis;Lethargy;Libido decreased;Ligament injury;Ligament sprain;Limb injury;Lip blister;Liver function test abnormal;Local swelling;Loose stools;Loss of consciousness;Low density lipoprotein increased;Lymphadenopathy;Lymphatic disorder;Lymphocyte count decreased;Lymphocyte count increased;Malaise;Malnutrition;Mammogram abnormal;Mean platelet volume decreased;Mediastinal disorder;Melaena;Menometrorrhagia;Menopausal symptoms;Menstrual disorder;Mental disability;Mental disorder;Mental retardation;Micturition urgency;Migraine;Miosis;Monocyte count increased;Mood swings;Movement disorder;Muscle contractions involuntary;Muscle injury;Muscle relaxant therapy;Muscle spasms;Muscle spasticity;Muscle strain;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal stiffness;Myalgia;Mydriasis;Myocardial infarction;Myocardial ischaemia;Myoclonus;Myopathy;Nasal congestion;Nasal oedema;Nasopharyngitis;Nausea;Neck injury;Neck pain;Neck stiffness;Neoplasm;Nephritis interstitial;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neurosis;Neutrophil count decreased;Neutrophil count increased;Night sweats;Nightmare;Nocturia;Nuchal rigidity;Oedema peripheral;Oral pain;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic dysregulation;Orthostatic hypotension;Orthostatic intolerance;Osteoarthritis;Osteoarthritis aggravated;Osteopenia;Osteoporosis;Otitis externa;Otitis media;Otitis media serous;Pain;Pain in extremity;Pain worsened;Pallor;Palpitations;Pancreatitis;Pancreatitis aggravated;Panic attack;Paraesthesia;Paraesthesia NEC;Paranoia;Parkinsonism;Parkinsonism aggravated;Pelvic pain;Peripheral ischaemia;Peripheral swelling;Peripheral vascular disorder;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Photodermatosis;Photopsia;Photosensitivity;Photosensitivity reaction;Piloerection;Plantar fasciitis;Platelet count decreased;Pneumonia;Pollakiuria;Polyarthralgia;Polyp;Polyuria;Poor peripheral circulation;Postoperative wound complication;Potassium abnormal NOS;Productive cough;Prostatic disorder;Prostatitis;Prostatomegaly;Protein total decreased;Protein urine present;Proteinuria;Prurigo;Pruritus;Pruritus generalised;Pruritus genital;Psychotic disorder;Pulmonary embolism;Pulmonary function test decreased;Pulmonary oedema;Purpura;Pyelonephritis chronic;Rales;Rash;Rectal disorder;Rectal haemorrhage;Rectal prolapse;Red blood cell count decreased;Red blood cell count increased;Red blood cell sedimentation rate increased;Red cell distribution width increased;Renal failure;Renal impairment;Renal pain;Respiratory depression;Respiratory tract infection viral;Retching;Rheumatoid arthritis;Rhinitis;Rhinitis allergic;Rhinitis seasonal;Rhinorrhoea;Rhonchi;Rigors;Rosacea;Sciatica;Scleral haemorrhage;Seasonal allergy;Serotonin syndrome;Sexual dysfunction;Shivering;Shock;Sinus congestion;Sinus headache;Sinus pain;Sinus tachycardia;Sinusitis;Skin disorder;Skin ulcer;Sleep apnoea syndrome;Sleep disorder;Sleep disturbance;Small intestinal obstruction;Sneezing;Soft tissue injury;Somnolence;Sore mouth;Speech disorder;Speech impairment NOS;Stevens-Johnson syndrome;Sticky skin;Stomatitis;Strangury;Stress;Stress symptoms;Suicidal ideation;Suicidal tendency;Suicide;Sweating;Sweating increased;Syncope;Tachycardia;Tachypnoea;Temporomandibular joint syndrome;Tendon disorder;Tendon injury;Tendonitis;Tension;Thinking abnormal;Thirst;Throat irritation;Throat sore;Thrombocytopenia;Thrombocytosis;Thrombophlebitis superficial;Thyroid neoplasm;Tinea pedis;Tinnitus;Tolerance development;Tongue disorder;Tooth abscess;Tooth disorder;Tooth infection;Toothache;Toxic epidermal necrolysis;Tracheitis;Tracheobronchitis;Trembling;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urea increased;Urethral disorder;Uric acid increased;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urogenital disorder;Urticaria;Uterine leiomyoma;Vaginal cyst;Vaginal discharge;Vaginal haemorrhage;Vascular insufficiency;Vascular pain;Vascular purpura;Vasodilation;Vasodilation procedure;Vein pain;Vertigo;Viral diarrhoea;Viral infection;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Weight decreased;White blood cell count increased;White blood cells urine positive;Withdrawal symptom;Withdrawal syndrome;Wound haemorrhage;Wound infection;Wrist fracture;Yawning,small molecule,approved; investigational,"Tramadol; Tramadolum; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; HBA; HBSC II; NAC2; SCN2A1; SCN2A2; Sodium channel protein brain II subunit alpha; Sodium channel protein type II subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.2; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; K-OR-1; KOR-1; OPRK; D-OR-1; DOR-1; OPRD; NACHRA7; NK-1 receptor; NK-1R; NK1R; SPR; TAC1R; Tachykinin receptor 1; Capsaicin receptor; Osm-9-like TRP channel 1; OTRPC1; TrpV1; Vanilloid receptor 1; VR1; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Mu-type opioid receptor; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; Sodium channel protein type 2 subunit alpha; NMDA receptor; Adenosine receptor A1; Alpha-2 adrenergic receptors; 5-hydroxytryptamine receptor 2C; Kappa-type opioid receptor; Delta-type opioid receptor; Neuronal acetylcholine receptor subunit alpha-7; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1; Substance-P receptor; Transient receptor potential cation channel subfamily V member 1, N02AJ13; N02AJ14; N02AX02;N02AJ16;N02AX02
tramazoline,Common cold;Nasal congestion;Nasopharyngitis;Rhinitis;Rhinitis seasonal;Seasonal allergy,Agitation;Arrhythmia;Asthenia;Blood pressure increased;Cardiac disorder;Dermatitis;Dizziness;Dysgeusia;Epistaxis;Fatigue;Gastrointestinal disorder;Hallucination;Headache;Hypersensitivity;Immune system disorder;Insomnia;Mediastinal disorder;Mental disorder;Mucosal swelling;Nasal congestion;Nasal discomfort;Nasal dryness;Nasal oedema;Nasopharyngitis;Nausea;Nervous system disorder;Oedema;Oedema mucosal;Palpitations;Pruritus;Rash;Rhinorrhoea;Skin disorder;Skin oedema;Sneezing;Somnolence;Tachycardia;Unspecified disorder of skin and subcutaneous tissue,small molecule,investigational,Tramazolina; Tramazoline; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR,Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor,R01AA09
trandolapril,Acute coronary syndrome;Acute myocardial infarction;Angioedema;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Essential hypertension;Heart failure signs and symptoms;Hypertension;Hypertensive;Ischaemia;Left ventricular dysfunction;Myocardial infarction;Renal artery stenosis;Renal failure;Renal impairment;Renovascular hypertension,Abdominal distension;Abdominal pain;Acute coronary syndrome;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Angina pectoris;Angioedema;Angiopathy;Anorexia;Antinuclear antibody positive;Anxiety;Apathy;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Asthenia;Atrial flutter;Atrioventricular block;Atrioventricular block first degree;Azotaemia;Back pain;Blepharitis;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine decreased;Blood creatinine increased;Blood potassium increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone pain;Bradycardia;Breast disorder;Bronchitis;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiogenic shock;Cerebral haemorrhage;Cerebrovascular accident;Chest pain;Congenital arterial malformation;Conjunctival oedema;Connective tissue disorder;Constipation;Cough;Cramp muscle;Creatinine increased;Decreased appetite;Depression;Dermatitis;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Eczema;Electrocardiogram abnormal;Enzyme abnormality;Eosinophilia;Epistaxis;Erectile dysfunction;Erythema multiforme;Eye disorder;Fatigue;Feeling abnormal;Flat affect;Flatulence;Flushing;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gout;Haematemesis;Haematocrit decreased;Haemoglobin decreased;Haemolytic anaemia;Hallucination;Headache;Hepatic enzyme increased;Hepatitis;Hepatobiliary disease;Hot flush;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hypersensitivity;Hyperuricaemia;Hypocalcaemia;Hyponatraemia;Hypotension;Hypotension symptomatic;Ichthyosis;Ichthyosis acquired;Ileus;Ill-defined disorder;Immune system disorder;Infarction;Infection;Infestation;Infestation NOS;Insomnia;Intermittent claudication;Jaundice cholestatic;Laboratory test abnormal;Laryngeal oedema;Laryngeal pain;Leukocytosis;Leukopenia;Libido decreased;Liver function test abnormal;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Migraine;Migraine without aura;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Myoclonus;Nausea;Nervous system disorder;Neutropenia;Oedema;Oedema peripheral;Osteoarthritis;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Pemphigus;Peripheral vascular disorder;Pharyngitis;Pharyngolaryngeal pain;Photosensitivity;Photosensitivity reaction;Platelet count decreased;Platelet disorder;Pollakiuria;Polyuria;Potassium increased;Presyncope;Productive cough;Pruritus;Psoriasis;Pulmonary eosinophilia;Rash;Red blood cell sedimentation rate increased;Renal failure;Renal failure acute;Rhinitis;Serum creatinine decreased;Shock;Skin disorder;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Sweating;Syncope;Tachycardia;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Transaminases increased;Transient ischaemic attack;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract congestion;Upper respiratory tract infection;Upper respiratory tract inflammation;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Varicose vein;Vasculitis;Ventricular tachycardia;Vertigo;Visual disturbance;Visual impairment;Vomiting;White blood cell count decreased,small molecule,approved,"Trandolapril; Trandolaprilum; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Angiotensin-converting enzyme, C09BB10;C09AA10
tranexamic,Angioedema;Coagulopathy;Colitis ulcerative;Epistaxis;Foetor hepaticus;Gastrointestinal haemorrhage;Haemoglobin;Haemophilia;Haemorrhage;Hepatic impairment;Hepatocellular injury;Hyphaema;Intracranial aneurysm;Leukaemia;Liver disorder;Malignant neoplasm of pancreas;Menorrhagia;Nephropathy;Pancreatic carcinoma;Post procedural haemorrhage;Postoperative hemorrhage;Postpartum haemorrhage;Premature separation of placenta;Proctocolitis;Renal failure;Renal impairment,Abdominal discomfort;Abdominal pain;Abdominal tenderness;Acute coronary syndrome;Acute sinusitis;Allergic sinusitis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Aneurysm;Angina pectoris;Angiopathy;Aortic dissection;Arrhythmia;Arthralgia;Asthenia;Atrial fibrillation;Atrioventricular block;Back pain;Block heart;Cardiac disorder;Cardiogenic shock;Cardiovascular disorder;Central nervous system disorder;Cerebral thrombosis;Cerebrovascular accident;Chest pain;Chromatopsia;Colour blindness;Convulsion;Cramp muscle;Deep vein thrombosis;Dermatitis atopic;Diarrhoea;Digestion impaired;Discomfort;Diuresis;Dizziness;Dyspepsia;Dyspnoea;Embolism;Embolus;Eye disorder;Fatigue;Feeling abnormal;Flushing;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Haemoglobin;Haemophilia;Haemorrhage;Headache;Hemiparesis;Hemiparesis (left);Hypersensitivity;Hypotension;Ill-defined disorder;Immune system disorder;Intestinal infarction;Intoxication;Joint stiffness;Loss of consciousness;Malaise;Mediastinal disorder;Migraine;Multiple allergies;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Nervous system disorder;Poisoning;Polyuria;Pulmonary embolism;Pulmonary oedema;Renal cortical necrosis;Renal failure;Respiratory failure;Rhinitis seasonal;Seasonal allergy;Sinus congestion;Sinus headache;Sinus pain;Sinusitis;Swelling;Tension headache;Thromboembolic event;Venous occlusion;Venous thrombosis;Ventricular arrhythmia;Ventricular tachycardia;Visual disturbance;Visual impairment;Vomiting,small molecule,approved,Acide tranéxamique; ácido tranexámico; Acidum tranexamicum; Tranexamic acid; Tranexamsaeure; Tranexmic acid; Tranhexamic acid; Trans AMCHA; trans-4-(Aminomethyl)cyclohexanecarboxylic acid; trans-4-aminomethylcyclohexane-1-carboxylic acid; trans-Amcha; trans-Tranexamic acid; 3.4.21.7,Plasminogen,B02AA02
tranylcypromine,"Agitation;Bradyphrenia;Bradypsychic response;Cerebration impaired;Decreased interest;Depression;Depressive disorder;Disturbance in attention;Dysphoria;Dysthymic disorder;Fatigability;Fatigue;Feeling guilty;Major depression;Major depressive disorder, single episode;Melancholia;Mental disability;Sexual dysfunction;Suicidal ideation",Abdominal pain;Acne cystic;Agitation;Agranulocytosis;Akinesia;Alopecia;Amnesia;Anaemia;Anorexia;Anxiety;Asthenia;Ataxia;Blood disorder;Blood pressure increased;Body temperature increased;Bradycardia;Chills;Circumscribed scleroderma;Confusional state;Constipation;Decreased appetite;Dermatitis;Diarrhoea;Disorientation;Dizziness;Drowsiness;Dry mouth;Erectile dysfunction;Feeling abnormal;Flushing;Frequent headaches;Gastrointestinal pain;Haemoglobin;Haemorrhage;Haemorrhage intracranial;Headache;Hepatitis;Hyperhidrosis;Hypertension;Hypertension paroxysmal;Hypertensive;Hypertensive crisis;Hypoaesthesia;Hypotension;Hypotensive;Inappropriate antidiuretic hormone secretion;Insomnia;Leukopenia;Loss of consciousness;Memory loss;Morphoea;Muscle spasms;Musculoskeletal stiffness;Mydriasis;Myoclonus;Nausea;Neck stiffness;Nuchal rigidity;Numbness;Occipital headache;Oedema;Pain;Pallor;Palpitations;Paraesthesia;Pollakiuria;Rash;Sensory loss;Shock;Somnolence;Stiffness;Subarachnoid haemorrhage;Sweating;Syncope;Tachycardia;Tenderness;Thrombocytopenia;Tinnitus;Tremor;Urinary incontinence;Urinary retention;Urticaria;Vision blurred;Vomiting,small molecule,approved; investigational,"(±)-trans-2-phenylcyclopropylamine; (1R*,2S*)-2-phenylcyclopropan-1-amine; dl-tranylcypromine; Racemic Tranylcypromine; Tranilcipromina; trans-2-phenylcyclopropylamine; trans-DL-2-Phenylcyclopropylamine; Transamine; Tranylcypromin; Tranylcypromine; Tranylcyprominum; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Amine oxidase [flavin-containing] B; Amine oxidase [flavin-containing] A,N06AF04
trazodone,"Agitation;Anxiety;Bradyphrenia;Bradypsychic response;Cerebration impaired;Decreased interest;Depression;Depressive disorder;Disturbance in attention;Drug interaction;Dysphoria;Dysthymic disorder;Fatigability;Fatigue;Feeling guilty;Major depression;Major depressive disorder, single episode;Mental disability;Sexual dysfunction;Suicidal ideation",Abdominal discomfort;Abdominal pain;Abnormal dreams;Ache;Acute coronary syndrome;Agitation;Akathisia;Alopecia;Amnesia;Amylase increased;Anaemia;Anger;Angle closure glaucoma;Anorexia;Anxiety;Aphasia;Apnoea;Arrhythmia;Arthralgia;Asthenia;Ataxia;Atrial fibrillation;Atrioventricular block;Back pain;Bad taste;Balance disorder;Bladder pain;Block heart;Body temperature increased;Bradycardia;Breast enlargement;Cardiac arrest;Cardiac failure congestive;Cerebration impaired;Cerebrovascular accident;Chest pain;Chills;Cholestasis;Cold sweat;Completed suicide;Confusional state;Constipation;Coordination abnormal;Deafness;Death;Decreased appetite;Delusion;Depressed level of consciousness;Dermatitis;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Diuresis;Dizziness;Drowsiness;Dry eye;Dry mouth;Dysarthria;Dysgeusia;Dyskinesia;Dyspnoea;Electrocardiogram PR prolongation;Electrocardiogram QT prolonged;Erectile dysfunction;Eruption;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Eye pain;Eye pruritus;Eye redness;Fatigue;Feeling abnormal;Flatulence;Flushing;Found dead (cause undetermined);Gait disturbance;Gastric disorder;Gastrointestinal discomfort;Gastrointestinal pain;Gastrooesophageal reflux disease;Grand mal convulsion;Haematuria;Haemolytic anaemia;Haemorrhagic disorder;Hallucination;Headache;Hearing impaired;Hemorrhage abnormal;Hirsutism;Hostility;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypokinesia;Hypomania;Hyponatraemia;Hypotension;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Incontinence;Increased appetite;Insomnia;Jaundice;Jaundice cholestatic;Lethargy;Leukocytoclastic vasculitis;Leukocytosis;Leukonychia;Libido decreased;Libido increased;Lightheadedness;Loss of consciousness;Malaise;Mean arterial pressure;Memory impairment;Menstruation irregular;Mental disability;Methaemoglobinaemia;Micturition urgency;Migraine;Miosis;Movements involuntary;Muscle stiffness;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nail discolouration;Nasal congestion;Nausea;Nervousness;Night sweats;Nightmare;Numbness;Ocular hyperaemia;Oedema;Oesophageal achalasia;Orgasm abnormal;Orthostatic hypotension;Pain;Palpitations;Paraesthesia;Paranoia;Paranoid reaction;Photophobia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyuria;Poor quality sleep;Priapism;Pruritus;Psoriasis;Psychotic disorder;Rash;Reflux esophagitis;Retrograde ejaculation;Salivary hypersecretion;Sedation;Sensory loss;Serotonin syndrome;Sexual dysfunction;Shock;Sinus bradycardia;Sinus congestion;Slurred speech;Somnolence;Speech disorder;Speech impairment NOS;Sticky skin;Stupor;Suicide;Suicide attempt;Surgery;Surgical intervention;Sweating;Syncope;Tachycardia;Tardive dyskinesia;Taste peculiar;Tension;Tingling of extremity;Tinnitus;Tonic-clonic seizures;Torsade de pointes;Tranquillisation excessive;Tremor;Urinary incontinence;Urinary retention;Urticaria;Vasculitis;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vivid dreams;Vomiting;Wakefulness;Weight decreased;Weight increased,small molecule,approved; investigational,"2-(3-[4-(3-chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; Trazodona; Trazodone; Trazodonum; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-hydroxytryptamine receptor 1C; 5ht1c; Htr1c; Serotonin receptor 2C; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2C; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 1A; Histamine H1 receptor; Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; 5-hydroxytryptamine receptor 2C,A06AC07;N06AX05
retinoic,Acne;Acne conglobata;Acne cystic;Acne vulgaris;Acquired immunodeficiency syndrome;Actinic elastosis;Actinic keratosis;Acute promyelocytic leukaemia;Alcohol abuse;Alcoholism;Asthma;Autoimmune disorder;Chloasma;Comedone;Completed suicide;Congenital anomaly;Cutis laxa;Depressive symptom;Developmental delay;Diabetes mellitus;Dry skin;Hyperkeratosis;Kaposi's sarcoma;Kaposi's sarcoma AIDS related;Lentigo;Lipid metabolism disorder;Localized exfoliation;Myelodysplastic syndrome;Neoplasm skin;Nodule;Obesity;Papule;Photodermatosis;Pustule;Rash pustular;Seborrhoeic keratosis;Skin cancer;Skin exfoliation;Skin hyperpigmentation;Skin roughness;Skin wrinkling;Suicide;Telangiectasia;Ulcer;Yellow skin,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal behaviour;Abnormalities of the hair;Acidosis;Acne;Acne fulminans;Acneiform eruption;Acquired immunodeficiency syndrome;Acute coronary syndrome;Acute febrile neutrophilic dermatosis;Affect lability;Aggression;Agitation;Agnosia;Agranulocytosis;Allergic contact dermatitis;Allergic cutaneous angiitis;Alopecia;Alopecia reversible;Anaemia;Anaphylactic shock;Anger;Angiopathy;Anorexia;Anxiety;Aphasia;Application site erythema;Application site oedema;Application site pain;Application site pruritus;Application site rash;Application site reaction;Application site stinging;Arrhythmia;Arthralgia;Arthritis;Ascites;Asterixis;Asthenia;Asthenopia;Asthma;Auditory disorder NOS;Autoimmune disorder;Back pain;Bacterial infection;Basophilia;Behavior disorder;Benign intracranial hypertension;Bladder pain;Blepharitis;Blindness;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose increased;Blood lactate dehydrogenase increased;Blood triglycerides increased;Blood uric acid increased;Body temperature decreased;Body temperature increased;Bone pain;Brain oedema;Bronchospasm;Buccal mucosa ulceration;CNS depression NOS;Candida infection;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Cardiac murmur;Cardiomegaly;Cardiomyopathy;Cardiomyopathy secondary NOS;Cardiovascular disorder;Cataract;Cellulitis;Central nervous system disorder;Cerebellar oedema;Cerebellar syndrome;Cerebral haemorrhage;Cerebrovascular accident;Chapped lips;Cheilitis;Chest discomfort;Chest pain;Chills;Clotting;Coagulopathy;Colitis;Coma;Completed suicide;Confusional state;Conjunctivitis;Constipation;Contact lens intolerance;Contusion;Convulsion;Corneal opacity;Cough;Creatine phosphokinase increased;Creatine phosphokinase serum increased;Crohn's disease;Cushingoid;Cutaneous hypersensitivity;Cyanosis;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Decreased night vision;Decreased tolerance;Dehydration;Dementia;Depressed level of consciousness;Depression;Depression aggravated;Dermatitis;Dermatitis acneiform;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatitis perioral;Diabetes mellitus;Diarrhoea;Discomfort;Disorder sight;Disseminated intravascular coagulation;Distress;Dizziness;Drowsiness;Drug interaction;Drug tolerance decreased;Dry eye;Dry eye syndrome;Dry mouth;Dry scalp;Dry skin;Dry throat;Duodenal ulcer;Dysarthria;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear buzzing;Ear disorder;Ear pain;Eczema;Edema of lower extremities;Embolism;Emotional distress;Encephalopathy;Endophthalmitis;Epiphyses premature fusion;Epistaxis;Eruptive xanthoma;Erythema;Erythema facial;Erythema multiforme;Erythema nodosum;Eschar;Euphoric mood;Excessive granulation tissue;Excoriation;Exostosis;Eye disorder;Eye irritation;Face oedema;Facial paralysis;Fasciitis;Fatigue;Febrile neutropenia;Feeling abnormal;Flank pain;Flatulence;Fluid imbalance;Fluid overload;Flushing;Foetor hepaticus;Folliculitis;Forgetfulness;Frank hematuria;Gait disturbance;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal symptom NOS;Generalized aching;Genital ulceration;Gingivitis;Glomerulonephritis;Gout;Granulomatosis with polyangiitis;Groin pain;Haematuria;Haemoglobin;Haemorrhage;Hair disorder;Hallucination;Hallucination, auditory;Headache;Headache occurring;Hearing impaired;Hemiplegia;Hepatitis;Hepatocellular injury;Hepatosplenomegaly;Hepatotoxicity;Herpes simplex;Hirsutism;Hoarseness;Hordeolum;Hyperaesthesia;Hypercalcaemia;Hypercholesterolaemia;Hyperhidrosis;Hyperlipidaemia;Hyperostosis;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hyperuricaemia;Hypervitaminosis A;Hypoaesthesia;Hyporeflexia;Hypotension;Hypothermia;Hypoxemia;Hypoxia;IIIrd nerve paralysis;Ileitis;Ileitis regional;Ill-defined disorder;Impaired healing;Infection;Infestation;Infestation NOS;Inflammation;Inflammatory bowel disease;Injection site reaction;Insomnia;Intracranial pressure increased;Irritability;Ischaemia;Keratitis;Lacrimation decreased;Lacrimation increased;Lactic dehydrogenase activity increased;Laryngeal oedema;Lethargy;Leukocytoclastic vasculitis;Leukocytosis;Leukoderma;Lightheadedness;Lip dry;Liver disorder;Lividity;Local reaction;Localized exfoliation;Loss of consciousness;Lung disorder;Lung infiltration;Lymphadenopathy;Malaise;Malnutrition;Memory impairment;Menstrual disorder;Mental disorder;Miliaria;Mood swings;Mouth ulceration;Mucosal dryness;Mucosal inflammation;Multi-organ failure;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocarditis;Myositis;Nail disorder;Nail dystrophy;Nasal congestion;Nasal dryness;Nasopharyngitis;Nausea;Neck pain;Neoplasm malignant;Nervous system disorder;Nervousness;Neurologic reaction;Neurological symptom;Neuropathy peripheral;Neutropenia;Night blindness;Numbness;Ochronosis;Ocular hyperaemia;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Ophthalmoplegia;Optic neuritis;Osteitis;Osteoarthritis;Ototoxicity;Pain;Pain in extremity;Pain of skin;Pallor;Palpitations;Pancreatitis;Pancreatitis acute;Panic attack;Papilloedema;Papule;Paraesthesia;Paronychia;Partial hearing loss;Pericardial effusion;Pericarditis;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pneumonia;Pollakiuria;Post-traumatic pain;Pregnancy;Prostatomegaly;Protein urine present;Proteinuria;Pruritus;Psychotic disorder;Pulmonary hypertension;Pulmonary oedema;Pyogenic granuloma;Rales;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Red blood cell sedimentation rate increased;Redness;Renal failure;Renal failure acute;Renal impairment;Renal infarct;Renal tubular necrosis;Respiratory distress;Respiratory failure;Respiratory insufficiency;Respiratory tract infection;Retinal haemorrhage;Retinoic acid syndrome;Rhabdomyolysis;Rosacea;Scab;Scotoma;Scrotal ulcer;Seborrhoeic dermatitis;Secondary infection;Sensitisation;Sensory disturbance;Sensory loss;Sepsis;Septicemia;Serum creatinine increased;Shivering;Shock;Sinusitis;Skin atrophy;Skin burning sensation;Skin discolouration;Skin disorder;Skin exfoliation;Skin fragility;Skin hyperpigmentation;Skin infection;Skin irritation;Skin striae;Skin tenderness;Skin ulcer;Slow speech;Somnolence;Spinal cord disorder;Stevens-Johnson syndrome;Stinging;Stomatitis;Suicidal ideation;Suicide;Suicide attempt;Sunburn;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Tachypnoea;Telangiectasia;Tenderness;Tendonitis;Tension;Teratogenicity;Thrombocytopenia;Thrombocytosis;Thrombosis;Tingling sensation;Tinnitus;Toxic epidermal necrolysis;Tremor;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;VIIth nerve paralysis;Vasculitis;Vesiculobullous rash;Violent;Violent behavior;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Wegener's granulomatosis;Weight decreased;Weight fluctuation;Weight increased;Wheezing;Wheezing expiratory;White blood cell count decreased;Xanthoma;Xeroderma;Xerophthalmia",small molecule,approved; investigational; nutraceutical,"(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL); Acide retinoique; all trans Retinoic acid; all trans-Retinoic acid; all-(E)-Retinoic acid; all-trans-beta-Retinoic acid; all-trans-Retinoic acid; all-trans-Tretinoin; all-trans-Vitamin A acid; all-trans-Vitamin A1 acid; ATRA; beta-Retinoic acid; Retinoic acid; Retionic acid; trans-Retinoic acid; Tretin M; Tretinoin; Tretinoina; Trétinoïne; Tretinoinum; Vitamin A acid; NR1B1; Nuclear receptor subfamily 1 group B member 1; RAR-alpha; HAP; HBV-activated protein; NR1B2; Nuclear receptor subfamily 1 group B member 2; RAR-beta; RAR-epsilon; NR1B3; Nuclear receptor subfamily 1 group B member 3; RAR-gamma; NR2B2; Nuclear receptor subfamily 2 group B member 2; Retinoid X receptor beta; NR2B3; Nuclear receptor subfamily 2 group B member 3; Retinoid X receptor gamma; NR2B1; Nuclear receptor subfamily 2 group B member 1; Retinoid X receptor alpha; Cellular retinoic acid-binding protein I; CRABP-I; RBP5; PEIG1; PERG-1; Phorbol ester-induced gene 1 protein; RAR-responsive protein TIG1; Tazarotene-induced gene 1 protein; TIG1; 1.2.1.19; 1.2.1.28; 1.2.1.3; 1.2.1.36; 3-deoxyglucosone dehydrogenase; ALDC; Aldehyde dehydrogenase family 1 member A1; Aldehyde dehydrogenase, cytosolic; ALDH-E1; ALDH1; ALHDII; PUMB1; RALDH 1; RalDH1; Retinal dehydrogenase 1; 1.2.1.36; Aldehyde dehydrogenase family 1 member A2; ALDH1A2; RALDH 2; RALDH(II); RALDH2; Retinaldehyde-specific dehydrogenase type 2; G-protein coupled receptor family C group 5 member A; GPCR5A; PEIG-1; Phorbol ester induced gene 1; RAI3; RAIG-1; RAIG1; Retinoic acid-induced gene 1 protein; Tear lipocalin; Tear prealbumin; Tlc; TP; VEG protein; VEGP; von Ebner gland protein; OBPIIa; Odorant-binding protein IIa; Plasma retinol-binding protein; PRBP; RBP; 2.7.11.2; PDHK4; Pyruvate dehydrogenase kinase isoform 4; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 20-HETE synthase; 20-hydroxyeicosatetraenoic acid synthase; CYP4A2; CYP4AII; CYPIVA11; Cytochrome P-450HK-omega; Cytochrome P450HL-omega; Fatty acid omega-hydroxylase; Lauric acid omega-hydroxylase; Long-chain fatty acid omega-monooxygenase; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.13.-; CYP26; CYP26A1; Cytochrome P450 retinoic acid-inactivating 1; Cytochrome P450RAI; hP450RAI; P450RAI1; Retinoic acid 4-hydroxylase; Retinoic acid-metabolizing cytochrome; Cellular retinoic acid-binding protein I; CRABP-I; RBP5; Cellular retinoic acid-binding protein II; CRABP-II","Retinoic acid receptor alpha; Retinoic acid receptor beta; Retinoic acid receptor gamma; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Retinoic acid receptor RXR-alpha; Cellular retinoic acid-binding protein 1; Retinoic acid receptor responder protein 1; Aldehyde dehydrogenase 1A1; Retinal dehydrogenase 2; Retinoic acid-induced protein 3; Lipocalin-1; Odorant-binding protein 2a; Retinol-binding protein 4; [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial; Carcinoembryonic antigen", D10AD01; D10AD51;D10AD01;L01XF01
triamcinolone,Adrenogenital syndrome;Allergic conditions;Alopecia areata;Ankylosing spondylitis;Aplasia pure red cell;Arthritis;Asthma;Berylliosis;Blood disorder;Brain cancer metastatic;Brain oedema;Bursitis;Colitis;Colitis ulcerative;Congenital adrenal hyperplasia;Congenital aplastic anaemia;Cutaneous lupus erythematosus;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatomyositis;Diamond-Blackfan anemia;Discoid lupus erythematosus;Diuresis;Drug hypersensitivity;Edema cerebral;Endocrine disorder;Enteritis ulcerative;Eosinophilic pneumonia;Epicondylitis;Erythema multiforme;Erythema multiforme severe;Gastrointestinal disorder;Gout;Gouty arthritis;Granuloma annulare;Haemolytic anaemia;Hypercalcaemia;Inflammatory bowel disease;Injury;Juvenile idiopathic arthritis;Keloid scar;Leukaemia;Lichen planus;Lichen simplex chronicus;Lupus erythematosus;Lymphoma;Meningitis tuberculous;Metastases to central nervous system;Multiple sclerosis;Mycosis fungoides;Necrobiosis lipoidica diabeticorum;Neoplasm;Neoplasm malignant;Nephropathy;Nephrotic syndrome;Nephrotic syndrome with lesion of minimal change glomerulonephritis;Neurodermatitis;Non-Hodgkin's lymphoma;Osteoarthritis;Pemphigus;Perennial allergic rhinitis;Polymyositis;Polyuria;Protein urine present;Proteinuria;Psoriatic arthropathy;Pulmonary tuberculosis;Rheumatic heart disease;Rheumatoid arthritis;Rhinitis allergic;Rhinitis perennial;Rhinitis seasonal;Sarcoidosis;Seasonal allergy;Secondary adrenocortical insufficiency;Secondary thrombocytopenia;Serum sickness;Skin disorder;Stevens-Johnson syndrome;Sympathetic ophthalmia;Synovitis;Systemic lupus erythematosus;Temporal arteritis;Tenosynovitis;Thrombocytopenia;Thyroiditis;Transfusion reaction;Trauma;Trichiniasis;Ulcer;Uveitis,Abdominal distension;Abrasion NOS;Abscess;Acne;Acneiform eruption;Acute coronary syndrome;Affect lability;Alkalosis hypokalaemic;Allergic contact dermatitis;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Application site reaction;Arachnoiditis;Arrhythmia;Arthropathy;Aseptic necrosis;Asthenia;Asthma;Atrophy;Back pain;Benign intracranial hypertension;Bladder dysfunction;Blindness;Blister;Blood cortisol decreased;Body temperature increased;Bradycardia;Bronchitis;Calcinosis;Candida albicans infection;Candida infection;Cardiac arrest;Cardiac failure congestive;Cardiomegaly;Cataract;Cataract subcapsular;Conjunctivitis;Convulsion;Cough;Cough increased;Cushing's syndrome;Cushingoid;Dermatitis;Dermatitis acneiform;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis perioral;Diabetes mellitus;Diplegia;Discomfort;Dizziness;Dry mouth;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Ear infection;Ecchymosis;Embolism;Embolism venous;Epistaxis;Erythema;Euphoric mood;Excoriation;Exophthalmos;Fat embolism;Fatigue;Feeling abnormal;Fluid retention;Folliculitis;Glaucoma;Glucose tolerance impaired;Glycosuria;Haemoglobin;Haemorrhage;Headache;Hepatomegaly;Hiccups;Hirsutism;Hyperadrenocorticism;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hypertrichosis;Hypertrophic cardiomyopathy;Ill-defined disorder;Impaired healing;Increased appetite;Increased insulin requirement;Infection;Influenza;Injury;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Leukoderma;Localized exfoliation;Loss of consciousness;Lupus erythematosus;Malaise;Meningitis;Menstruation irregular;Miliaria;Monoplegia;Mood swings;Muscle mass;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial rupture;Myopathy;Nasal burning;Nasal discomfort;Nasal irritation;Nasal septum perforation;Nausea;Neuritis;Neuropathy;Neuropathy peripheral;Nitrogen balance negative;Oedema;Oesophagitis ulcerative;Optic neuritis;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Osteonecrosis;Osteoporosis;Otitis;Pain;Pancreatitis;Papilloedema;Paraesthesia;Paraparesis;Paraplegia;Peptic ulcer;Personality change;Petechiae;Pharyngitis;Pruritus;Pulmonary oedema;Purpura;Rash;Rhinitis;Secondary infection;Shock;Sinus congestion;Skin atrophy;Skin exfoliation;Skin hyperpigmentation;Skin scaly;Skin striae;Sneezing;Spinal compression fracture;Steroid myopathy;Stinging;Sweating increased;Syncope;Systemic lupus erythematosus;Tachycardia;Tendon rupture;Throat sore;Thromboembolism;Thrombophlebitis;Tooth disorder;Trauma;Ulcer;Upper respiratory tract infection;Urticaria;Vascular purpura;Vasculitis;Vertigo;Vomiting;Weight increased;Wheezing,small molecule,approved; vet_approved,"11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione; 9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9α-fluoro-16α-hydroxyprednisolone; Fluoxyprednisolone; Tiamcinolonum; Triamcinolona; Triamcinolone; Triamcinolonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; CBG; Serpin A6; Transcortin",Glucocorticoid receptor, A01AC01; C05AA12; D07BB03; D07CB01; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05; S02CA04;A01AC01;D07AB09
triamterene,Cardiac failure congestive;Discomfort;Diuresis;Diuretic effect;Gravitational oedema;Idiopathic edema;Nephrotic syndrome;Oedema;Polyuria;Pre-eclampsia;Pregnancy;Secondary aldosteronism,Acute interstitial nephritis;Anaemia megaloblastic;Anaphylactic shock;Asthenia;Azotaemia;Blood urea increased;Calculus of kidney;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Fatigue;Headache;Hyperkalaemia;Hypersensitivity;Hypokalaemia;Irreversible renal failure;Jaundice;Nausea;Nephrolithiasis;Photosensitivity;Photosensitivity reaction;Rash;Renal failure acute;Renal failure chronic;Thrombocytopenia;Tubulointerstitial nephritis;Vomiting,small molecule,approved,"6-phenylpteridine-2,4,7-triamine; Teridin; Triamteren; Triamterena; Triamtérène; Triamterene; Triamtereno; Triamterenum; ENaCG; Epithelial Na(+) channel subunit gamma; Gamma-ENaC; Gamma-NaCH; Nonvoltage-gated sodium channel 1 subunit gamma; SCNEG; Alpha-ENaC; Alpha-NaCH; ENaCA; Epithelial Na(+) channel subunit alpha; Nonvoltage-gated sodium channel 1 subunit alpha; SCNEA; SCNN1; Beta-ENaC; Beta-NaCH; ENaCB; Epithelial Na(+) channel subunit beta; Nonvoltage-gated sodium channel 1 subunit beta; SCNEB; Delta-ENaC; Delta-NaCH; DNACH; ENaCD; Epithelial Na(+) channel subunit delta; Nonvoltage-gated sodium channel 1 subunit delta; SCNED; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",Amiloride-sensitive sodium channel subunit gamma; Amiloride-sensitive sodium channel subunit alpha; Amiloride-sensitive sodium channel subunit beta; Amiloride-sensitive sodium channel subunit delta,C03DB02
triazolam,Insomnia,Abdominal pain;Affect lability;Aggression;Agitation;Amnesia;Amnestic symptoms;Anorexia;Anterograde amnesia;Anxiety;Asthenia;Ataxia;Burning tongue;CNS depression NOS;Chest pain;Confusional state;Consciousness clouding;Constipation;Coordination abnormal;Cramp muscle;Deafness;Decreased appetite;Delusion;Depersonalisation;Depressed level of consciousness;Derealisation;Dermatitis;Diarrhoea;Discomfort;Disorientation;Dizziness;Drowsiness;Drug abuse;Drug withdrawal syndrome;Dry mouth;Dysaesthesia;Dysarthria;Dysgeusia;Dyspnoea;Dysuria;Erythema;Euphoric mood;Eye irritation;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal pain;Glossitis;Glossodynia;Hallucination;Headache;Hearing impaired;Hepatic failure;Hyperhidrosis;Hypersensitivity;Hypertension;Ill-defined disorder;Incontinence;Insomnia;Irritability;Jaundice;Lightheadedness;Loss of consciousness;Malaise;Mania;Memory impairment;Menstruation irregular;Mental disability;Mood swings;Mouth irritation;Muscle spasms;Muscle spasticity;Muscle tone disorder;Muscular weakness;Nausea;Nervousness;Nightmare;Oedema;Osteoarthritis;Pain;Palpitations;Paraesthesia;Pruritus;Redness;Respiratory tract infection;Sexual dysfunction;Shock;Sleep disorder;Sleep disturbance;Slurred speech;Somnambulism;Somnolence;Stomatitis;Strangury;Sweating increased;Syncope;Tachycardia;Tension;Thinking abnormal;Tinnitus;Transient insomnia;Tremor;Urinary retention;Visual disturbance;Visual impairment;Vomiting;Withdrawal symptom,small molecule,approved; investigational,"Triazolam; Triazolamum; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3",Translocator protein; GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site,N05CD05
triclosan,Dental caries,Hypersensitivity,small molecule,approved; investigational,"2,4,4'-Trichloro-2'-hydroxydiphenyl ether; 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol; Triclosán; Triclosan; Triclosanum; 1.3.1.9; ENR; envM; NADH-dependent enoyl-ACP reductase; 1.3.1.9; ENR; FAS-II enoyl-ACP reductase; NADH-dependent 2-trans-enoyl-ACP reductase; 1.3.1.9; ENR; NADH-dependent enoyl-ACP reductase; 1.3.1.9; 1.3.1.39; ENR; NADPH-dependent enoyl-ACP reductase; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; CAR; Constitutive activator of retinoid response; Constitutive active response; Constitutive androstane receptor; Orphan nuclear receptor MB67; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; 1.11.1.8; TPO",Enoyl-[acyl-carrier-protein] reductase [NADH] FabI; Enoyl-[acyl-carrier-protein] reductase [NADH]; Enoyl-[acyl-carrier-protein] reductase [NADH] FabI; Enoyl-[acyl-carrier-protein] reductase [NADH]; Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI; Nuclear receptor subfamily 1 group I member 2; Androgen receptor; Nuclear receptor subfamily 1 group I member 3; Peroxisome proliferator-activated receptor gamma; Thyroid peroxidase, D09AA06;D08AE04
trifluoperazine,"Aggression;Agitated depression;Agitation;Alcohol abuse;Alcoholism;Anxiety;Bipolar I disorder;Bipolar disorder;Brain injury;Catatonia;Delusion;Electroencephalogram abnormal;Generalised anxiety disorder;Hallucination;Mental deficiency;Mental retardation;Mitral valve incompetence;Neurosis;Psychotic disorder;Schizophrenia;Schizophrenia, paranoid type;Senile psychosis;Tardive dyskinesia;Tension;Tremor;Tremulousness",Agitation;Agranulocytosis;Akathisia;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorexia;Aplastic anaemia;Asphyxia;Asthenia;Asthma;Blood disorder;Body temperature increased;Brain injury;Brain oedema;Bronchospasm;Cardiac arrest;Carpo-pedal spasm;Catatonia;Cholestasis;Cogwheel rigidity;Colon atonic;Constipation;Convulsion;Corneal deposits;Cough;Decreased appetite;Dermatitis;Dermatitis exfoliative;Dizziness;Drooling;Drowsiness;Dry mouth;Dyskinesia;Dysphagia;Dyspnoea;Eczema;Edema cerebral;Eosinophilia;Erectile dysfunction;Erythema;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Feeling jittery;Gait disturbance;Gait shuffling;Galactorrhoea;Glycosuria;Gynaecomastia;Haemolytic anaemia;Headache;Hepatocellular injury;Hyperglycaemia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypoglycaemia;Hypotension;Ileus;Ileus paralytic;Increased appetite;Insomnia;Jaundice;Keratopathy;Laryngeal oedema;Leukopenia;Liver injury;Lupus-like syndrome;Masked facies;Megacolon;Menstruation irregular;Miosis;Motor restlessness;Movements involuntary;Muscle rigidity;Muscle spasms;Muscular weakness;Mydriasis;Nasal congestion;Nausea;Nervousness;Neuroleptic malignant syndrome;Obstipation;Oculogyric crisis;Oedema peripheral;Opisthotonus;Orofacial dyskinesia;Pancytopenia;Parkinsonian rest tremor;Parkinsonism;Petit mal epilepsy;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Pill rolling;Pregnancy test false positive;Priapism;Protrusion tongue;Pruritus;Pseudoparkinsonism;Rash;Retinal disorder;Skin disorder;Somnolence;Sudden death;Systemic lupus erythematosus;Tetany;Throat tightness;Thrombocytopenic purpura;Torsade de pointes;Torticollis;Tremor;Trismus;Urinary retention;Urticaria;Ventricular arrhythmia;Vision blurred;Weight increased,small molecule,approved; investigational,10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; Trifluoperazina; Trifluopérazine; Trifluoperazine; Trifluoperazinum; trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; Trifluoroperazine; Trifluperazine; Dopamine D2 receptor; CALM; CAM; CAM1; CALML2; CAM3; CAMC; CAMIII; CAM2; CAMB; DRD1IP; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; TN-C; TNNC; Calvasculin; CAPL; Metastasin; MTS1; Placental calcium-binding protein; Protein Mts1; S100 calcium-binding protein A4; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; XDHA; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1,"D(2) dopamine receptor; Calmodulin-1; Calmodulin-3; Calmodulin-2; Neuron-specific vesicular protein calcyon; Alpha-1A adrenergic receptor; Troponin C, slow skeletal and cardiac muscles; Protein S100-A4; Calmodulin",N05AB06
trihexyphenidyl,Arteriosclerosis;Extrapyramidal disorder;Parkinsonism,Accommodation disorder;Agitation;Angle closure glaucoma;Asthenia;Blindness;Chorea;Cognitive disorder;Cognitive impairment;Confusional state;Constipation;Cycloplegia;Delusion;Dermatitis;Dizziness;Drowsiness;Dry skin;Euphoric mood;Feeling abnormal;Forgetfulness;Hallucination;Headache;Hyperkinesia;Ileus paralytic;Intraocular pressure increased;Memory impairment;Mydriasis;Nausea;Nervousness;Neuroleptic malignant syndrome;Paranoia;Parotitis;Psychotic disorder;Rash;Sinus bradycardia;Somnolence;Tachycardia;Tension;Urinary hesitation;Vision blurred;Vomiting;Weight decreased,small molecule,approved,Trihexifenidilo; Trihexyphenidyl; Trihexyphénidyle; Trihexyphenidylum; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor,Muscarinic acetylcholine receptor M1; Beta-3 adrenergic receptor; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5,N04AA01
trimethadione,Petit mal epilepsy,Abdominal pain;Agranulocytosis;Albuminuria;Alopecia;Anorexia;Aplastic anaemia;Asthenia;Blindness day;Blood pressure fluctuation;Change in blood pressure;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diplopia;Discomfort;Distress;Drowsiness;Emotional distress;Eosinophilia;Epistaxis;Erythema multiforme;Fatigue;Feeling abnormal;Gastrointestinal pain;Gingival bleeding;Grand mal convulsion;Haemoglobin;Haemorrhage;Headache;Hepatitis;Hepatosplenomegaly;Hiccups;Hypoplastic anaemia;Ill-defined disorder;Insomnia;Irritability;Leukopenia;Lupus erythematosus;Lymphadenopathy;Lymphoma;Malaise;Myasthenia gravis-like syndrome;Myasthenic syndrome;Nausea;Nephrosis;Nephrotic syndrome;Neutropenia;Non-Hodgkin's lymphoma;Pancytopenia;Paraesthesia;Personality change;Photophobia;Pruritus;Rash;Somnolence;Systemic lupus erythematosus;Thrombocytopenia;Tonic-clonic seizures;Vaginal haemorrhage;Vertigo;Vomiting;Weight decreased,small molecule,approved,"Trimetadiona; Trimethadion; Trimethadione; Triméthadione; Trimethadionum; Trimethinum; Troxidone; Cav3.1c; KIAA1123; NBR13; Voltage-gated calcium channel subunit alpha Cav3.1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Voltage-dependent T-type calcium channel subunit alpha-1G,N03AC02
trimethobenzamide,Gastroenteritis;Nausea;Nausea postoperative;Procedural nausea;Vomiting,Blood disorder;Coma;Convulsion;Cramp muscle;Diarrhoea;Disorientation;Dizziness;Drowsiness;Headache;Hypersensitivity;Hypotension;Jaundice;Muscle spasms;Opisthotonus;Sensitisation;Somnolence;Vision blurred,small molecule,approved; investigational,"N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide; Trimethobenzamide; Trimethobenzamidum; Trimetobenzamida; Dopamine D2 receptor",D(2) dopamine receptor,R06AA10
trimethoprim,Chronic UTI;Infection;Otitis media acute;Urinary tract infection,Abdominal pain;Abnormal behaviour;Agitation;Agranulocytosis;Allergic cutaneous angiitis;Anaemia megaloblastic;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Aplastic anaemia;Arthralgia;Ataxia;Blood and lymphatic system disorders;Body temperature increased;Bone marrow depression;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cough;Decreased appetite;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Dizziness;Drug eruption;Drug fever;Dyskinesia;Dyspepsia;Dyspnoea;Eosinophilia;Epigastric distress;Epistaxis;Eruption;Erythema;Erythema multiforme;Eye disorder;Feeling abnormal;Fixed drug eruption;Gastrointestinal disorder;Gastrointestinal pain;Glossitis;Haematuria;Haemolysis;Haemolytic anaemia;Hallucination;Headache;Hepatic necrosis;Hepatobiliary disease;Hyperkalaemia;Hypersensitivity;Hypoglycaemia;Hyponatraemia;Immune system disorder;Insomnia;Jaundice cholestatic;Lethargy;Leukocytoclastic vasculitis;Leukopenia;Loss of consciousness;Malnutrition;Mediastinal disorder;Meningitis aseptic;Mental disorder;Methaemoglobinaemia;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Neuritis;Neuropathy peripheral;Neutropenia;Nightmare;Pancreatitis;Pancytopenia;Photosensitivity;Photosensitivity reaction;Pruritus;Pseudomembranous colitis;Purpura;Rash;Reaction gastrointestinal;Renal failure;Renal impairment;Shock;Skin disorder;Stevens-Johnson syndrome;Stomatitis;Syncope;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Uveitis;Vascular purpura;Vertigo;Vomiting;Wheezing,small molecule,approved; vet_approved,"2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine; 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine; Trimethoprim; Triméthoprime; Trimethoprimum; Trimetoprima; 1.5.1.3; 1.5.1.3; tmrA; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2",Dihydrofolate reductase; Dihydrofolate reductase, J01EA01; J01EE01; J01EE02; J01EE04; J01EE05; J01EE07; J04AM08;J01EA01;J01EE03
trimetrexate,Acquired immunodeficiency syndrome;Autoimmune disorder;Immunocompromised;Immunodeficiency;Pneumocystis jirovecii pneumonia,Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Asthenia;Blood alkaline phosphatase increased;Blood bilirubin increased;Blood creatinine increased;Body temperature increased;Confusional state;Dermatitis;Electrolyte imbalance;Fatigue;Feeling abnormal;Hepatotoxicity;Hypocalcaemia;Hyponatraemia;Nausea;Neutropenia;Phosphatase alkaline increased;Pruritus;Rash;Serum creatinine increased;Thrombocytopenia;Vomiting,small molecule,approved; investigational,Trimetrexate; Trimetrexato; Trimetrexatum; 3.5.1.88; PDF1A; Polypeptide deformylase; 1.5.1.3; Cyclic dinucleotide:anion antiporter SLC19A1; FLOT1; Folate:anion antiporter SLC19A1; FOLT; hRFC; hSLC19A1; IFC-1; Intestinal folate carrier 1; Placental folate transporter; Reduced folate carrier protein; Reduced folate transporter 1; RFC; RFC1; RFT-1; Solute carrier family 19 member 1,"Peptide deformylase, mitochondrial; Dihydrofolate reductase",P01AX07
trimipramine,Depressive symptom;Endogenous depression;Major depression,Abdominal cramps;Abdominal pain;Accommodation disorder;Acute coronary syndrome;Adenitis;Agitation;Agranulocytosis;Alopecia;Anorexia;Anxiety;Arrhythmia;Asthenia;Ataxia;Atrioventricular block;Black hairy tongue;Block heart;Body temperature increased;Bone marrow depression;Breast enlargement;Cerebrovascular accident;Confusional state;Constipation;Convulsion;Coordination abnormal;Decreased appetite;Delusion;Dermatitis;Diarrhoea;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug withdrawal syndrome;Dry mouth;Dysgeusia;Dyspepsia;Eosinophilia;Epigastric distress;Erectile dysfunction;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Feeling abnormal;Flushing;Galactorrhoea;Gynaecomastia;Hallucination;Headache;Hypertension;Hypoaesthesia;Hypomania;Hypotension;Ileus paralytic;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Insomnia;Jaundice;Libido decreased;Lymphadenitis;Malaise;Mydriasis;Myocardial infarction;Nausea;Neuropathy peripheral;Nightmare;Numbness;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Palpitations;Pancytopenia;Paraesthesia;Paresthesia of limbs;Parotid gland enlargement;Parotid swelling;Petechiae;Pollakiuria;Pruritus;Psychotic disorder;Purpura;Rash;Sensory loss;Somnolence;Stomatitis;Tachycardia;Taste peculiar;Testicular swelling;Throat sore;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue discolouration;Tremor;Urinary retention;Urticaria;Vascular purpura;Vision blurred;Vomiting;Weight increased;Withdrawal symptom,small molecule,approved,"10,11-dihydro-N,N,β-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; 5-(γ-dimethylamino-β-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; beta-Methylimipramine; Trimeprimina; Trimeprimine; Trimeproprimine; Trimipramina; Trimipramine; Trimipraminum; β-methylimipramine; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; Dopamine D2 receptor; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; H1-R; H1R; HH1R; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-hydroxytryptamine receptor 1C; 5ht1c; Htr1c; Serotonin receptor 2C; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent dopamine transporter; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 1A; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; D(2) dopamine receptor; Alpha-2B adrenergic receptor; Histamine H1 receptor; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 1D; Alpha-2A adrenergic receptor; D(1) dopamine receptor; Beta adrenergic receptor; Muscarinic acetylcholine receptor; 5-hydroxytryptamine receptor 2C,N06AA06
troglitazone,Type 2 diabetes mellitus,Abdominal pain;Alanine aminotransferase increased;Anaemia;Anorexia;Asthenia;Body temperature increased;Cardiac failure congestive;Decreased appetite;Discomfort;Dizziness;Fatigue;Feeling abnormal;Gastrointestinal pain;Hepatic function abnormal;Hepatitis;Hyperglycaemia;Idiosyncratic drug reaction;Ill-defined disorder;Jaundice;Laboratory test abnormal;Liver function test abnormal;Loss of consciousness;Malaise;Nausea;Oedema;Shock;Syncope;Volume blood increased;Volume plasma increased;Vomiting;Weight increased,small molecule,approved; investigational; withdrawn,"Troglitazona; Troglitazone; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; NR1C2; NUC1; NUCI; Nuclear hormone receptor 1; Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferator-activated receptor beta; PPAR-beta; PPAR-delta; PPARB; NR1C1; Nuclear receptor subfamily 1 group C member 1; PPAR; PPAR-alpha; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 6.2.1.3; ACS4; Arachidonate--CoA ligase; FACL4; LACS 4; LACS4; Long-chain acyl-CoA synthetase 4; Endothelial plasminogen activator inhibitor; PAI; PAI-1; PAI1; PLANH1; Serpin E1; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-G; UDPGT 1-7; UGT-1G; UGT1; UGT1-07; UGT1.7; UGT1*7; UGT1A7; UGT1G; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Peroxisome proliferator-activated receptor gamma; Estrogen-related receptor gamma; Steroid hormone receptor ERR1; Peroxisome proliferator-activated receptor delta; Peroxisome proliferator-activated receptor alpha; Glutathione S-transferase P; Long-chain-fatty-acid--CoA ligase 4; Plasminogen activator inhibitor 1; Equilibrative nucleoside transporter 1,A10BG01
tropicamide,Accommodation disorder;Cycloplegia;Mydriasis,Anaphylactic shock;Arrhythmia;Asthenia;Bronchospasm;Cerebration impaired;Constipation;Corneal irritation;Corneal staining;Disturbance in attention;Drowsiness;Dysphagia;Dysuria;Fatigue;Flushing;Headache;Hyperhidrosis;Hypersensitivity;Intraocular pressure increased;Keratitis;Mental disability;Muscle rigidity;Nausea;Oedema;Pain;Pallor;Palpitations;Photophobia;Pruritus;Psychotic disorder;Punctate keratitis;Rash erythematous;Rhinitis;Smarting;Somnolence;Stinging;Strangury;Sweating increased;Tachycardia;Thirst;Vision blurred;Vital dye staining cornea present;Vomiting,small molecule,approved; investigational,Tropicamid; Tropicamida; Tropicamide; Tropicamidum,Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3, S01FA56;S01FA06
tropisetron,Nausea;Nausea postoperative;Procedural nausea;Vomiting,Abdominal pain;Anaphylactic shock;Angiopathy;Anorexia;Asthenia;Bradycardia;Bronchospasm;Chest discomfort;Chest pain;Chills;Constipation;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dyspnoea;Erythema;Fatigue;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Generalized urticaria;Headache;Hypersensitivity;Hypertension;Hypotension;Immune system disorder;Loss of consciousness;Mediastinal disorder;Nervous system disorder;Rash;Shivering;Shock;Skin disorder;Somnolence;Syncope;Unspecified disorder of skin and subcutaneous tissue;Urticaria,small molecule,approved; investigational,Tropisetron; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor,5-hydroxytryptamine receptor 3A,A04AA03
trospium,Hypertonic bladder;Pollakiuria;Urge incontinence;Urinary incontinence,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal vision;Accommodation disorder;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Asthenia;Back pain;Bladder pain;Blood and lymphatic system disorders;Blood uric acid increased;Breast disorder;Cardiac disorder;Chest pain;Confusional state;Connective tissue disorder;Constipation;Constipation aggravated;Coronary artery disease;Cramp muscle;Decreased appetite;Delirium;Dermatitis;Dermatitis contact;Dizziness;Dry eye;Dry mouth;Dry skin;Dry throat;Dysgeusia;Dyspepsia;Dysphonia;Dysuria;Ear and labyrinth disorders;Ear pain;Eczema;Electrocardiogram abnormal;Endocrine disorder;Erythema multiforme;Eye disorder;Eye pain;Faeces hard;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Flushing;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Haematuria;Hair growth abnormal;Hallucination;Headache;Hoarseness;Hot flush;Hyperhidrosis;Hypertensive crisis;Hyperuricaemia;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Local swelling;Loss of consciousness;Lymphadenopathy;Malnutrition;Mediastinal disorder;Menopausal symptoms;Micturition disorder;Micturition urgency;Migraine;Mouth ulceration;Muscle spasms;Nasal dryness;Nasopharyngitis;Nausea;Nervous system disorder;Oedema;Oedema peripheral;Orthostatic hypotension;Pain in jaw;Palpitations;Peripheral swelling;Photosensitivity reaction;Pollakiuria;Pruritus;QRS axis abnormal;Rash;Rash erythematous;Renal pain;Residual urine volume;Respiratory tract congestion;Rhabdomyolysis;Rhinitis;Shock;Skin disorder;Somnolence;Stevens-Johnson syndrome;Stomatitis;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating increased;Syncope;Tachycardia;Thirst;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary hesitation;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine odour abnormal;Urticaria;Vaginal pain;Vision blurred;Visual impairment;Vomiting;Vulvovaginal pain;Weight increased,small molecule,approved,1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase,Muscarinic acetylcholine receptor M5; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1, G04BD09;A03DA06;G04BD09
delavirdine,Achlorhydria;Cross resistance;Pathogen resistance,Abdominal cramps;Abdominal distension;Abdominal pain;Abdominal pain generalised;Abscess;Ache;Acquired immunodeficiency syndrome;Activated partial thromboplastin time prolonged;Acute overdose;Affect lability;Agitation;Alcohol intolerance;Alkaline phosphatase serum increased;Alopecia;Amenorrhoea;Amnesia;Amylase increased;Anaemia;Angioedema;Anorectal disorder;Anorexia;Anxiety;Aphagia;Aphthous stomatitis;Application site pruritus;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Autoimmune disorder;Back pain;Blepharitis;Blister;Blood alkaline phosphatase increased;Blood creatinine increased;Blood in stool;Blood triglycerides increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Breast enlargement;Breast feeding;Bronchitis;Buffalo hump;Candida infection;Cardiac failure;Cardiomyopathy;Cerebration impaired;Chest pain;Chills;Chromaturia;Cognitive disorder;Cognitive impairment;Colitis;Confusional state;Conjunctivitis;Constipation;Contusion;Coordination abnormal;Cough;Cramp muscle;Cramps of lower extremities;Cyst epidermal;Decreased appetite;Depressive symptom;Dermal cyst;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Dermoid cyst;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Dizziness;Drug interaction;Dry eye;Dry mouth;Dry skin;Duodenitis;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear pain;Ecchymosis;Enteritis;Eosinophilia;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Euphoric mood;Faecal incontinence;Fat redistribution;Fatigue;Feeling abnormal;Flank pain;Flatulence;Folliculitis;Fungal skin infection;Gagging;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival bleeding;Gingivitis;Glossitis;Granulocytosis;Haematochezia;Haematospermia;Haematuria;Haemolytic anaemia;Hallucination;Headache;Hepatic failure;Hepatitis;Hepatomegaly;Herpes zoster;Hiccups;Hyperaesthesia;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertonia;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Ill-defined disorder;Increased appetite;Increased thirst;Infection;Inflammation;Influenza;Injury;Insomnia;Jaundice;Laryngospasm;Lethargy;Leukocytoclastic vasculitis;Leukopenia;Libido decreased;Lip oedema;Lipase increased;Lipoedema;Lipohypertrophy;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mental disability;Metrorrhagia;Migraine;Mood swings;Mouth ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Nail disorder;Nausea;Neck stiffness;Necrosis;Nephropathy;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Nightmare;Nocturia;Nuchal rigidity;Nystagmus;Oedema;Oedema peripheral;Oesophagitis;Opportunistic infection;Orthostatic hypotension;Otitis media;Overdose;Pain;Pain localised;Pallor;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paralysis;Parosmia;Peripheral vascular disorder;Petechiae;Pharyngitis;Photophobia;Pneumonia;Polymenorrhoea;Polyuria;Protein urine present;Proteinuria;Prothrombin level increased;Pruritus;Pulmonary congestion;Purpura;Rash;Rash maculo-papular;Rash pustular;Rectal disorder;Renal failure acute;Renal pain;Respiratory tract congestion;Retching;Rhabdomyolysis;Rhinitis;Salivary hypersecretion;Seborrhoeic dermatitis;Serum creatinine increased;Shock;Short period;Sialoadenitis;Sickness;Sinusitis;Skin disorder;Skin exfoliation;Skin hypertrophy;Skin mass;Skin nodule;Skin papilloma;Somnolence;Spleen disorder;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Swelling;Syncope;Tachycardia;Tendon disorder;Tenosynovitis;Tension;Testicular pain;Tetany;Thirst;Thrombocytopenia;Tingling sensation;Tinnitus;Tongue disorder;Tongue oedema;Tooth abscess;Toothache;Toxic epidermal necrolysis;Trauma;Tremor;Tuberculosis;Ulcer;Upper respiratory tract infection;Urinary tract infection;Urine output increased;Urticaria;Vaginal moniliasis;Vascular purpura;Vasodilation;Vasodilation procedure;Vertigo;Vesiculobullous rash;Viral infection;Vision blurred;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Warts;Weight increased,small molecule,approved,"(N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); 1-(3-((1-methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 2-(4-(5-methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine; Delavirdin; Delavirdina; Delavirdine; Delavirdinum; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; Pr160Gag-Pol; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Gag-Pol polyprotein; Reverse transcriptase/RNaseH,J05AG02
valsartan,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Cardiac failure;Cardiac failure chronic;Diabetes mellitus;Diabetic nephropathy;Essential hypertension;Hyperlipidaemia;Hypertension;Hypertensive;Hypotension;Left ventricular dysfunction;Left ventricular failure;Left ventricular systolic dysfunction;Myocardial infarction;Nephropathy;Pulmonary oedema,Abdominal pain;Abdominal pain upper;Acute interstitial pneumonitis;Ageusia;Alopecia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anxiety;Arthralgia;Asthenia;Atrial fibrillation;Back pain;Blood and lymphatic system disorders;Blood creatinine increased;Blood potassium increased;Blood pressure increased;Blood urea increased;Bronchitis;Cardiac disorder;Cardiac failure;Chest pain;Connective tissue disorder;Constipation;Cough;Cramp muscle;Decreased appetite;Dermatitis;Dermatitis bullous;Diarrhoea;Dizziness;Dizziness postural;Drug interaction;Dry cough;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Epistaxis;Erectile dysfunction;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemorrhage;Hamman-Rich syndrome;Headache;Hepatic enzyme increased;Hepatitis;Hyperkalaemia;Hypersensitivity;Hypogeusia;Hyponatraemia;Hypotension;Idiopathic pulmonary fibrosis;Immune system disorder;Infection;Infestation;Infestation NOS;Insomnia;Loss of consciousness;Loss of libido;Malnutrition;Mediastinal disorder;Mental disorder;Microcytic anaemia;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myositis;Nausea;Nervous system disorder;Neutropenia;Oedema;Orthostatic hypotension;Palpitations;Paraesthesia;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pruritus;Rash;Renal failure;Renal failure acute;Renal failure chronic;Renal impairment;Rhabdomyolysis;Rhinitis;Serum creatinine increased;Serum potassium increased;Serum sickness;Shock;Sinusitis;Skin disorder;Somnolence;Swelling;Syncope;Taste disorders;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Vasculitis;Vertigo;Viral infection;Vision blurred;Vomiting,small molecule,approved; investigational,(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; Valsartan; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2,Type-1 angiotensin II receptor, C09CA03; C09DA03; C09DB01; C09DB08; C09DX01; C09DX02; C09DX04; C10BX10;C09CA03;C09DX05
Vancocine,Burn;Cardiac valve disease;Diarrhoea;Endocarditis;Endocarditis bacterial;Endocarditis staphylococcal;Enterocolitis;Gastroenteritis staphylococcal;Infection;Intestinal infection due to staphylococcus;Lower respiratory tract infection;Osteomyelitis;Pneumonia;Prosthetic valve endocarditis;Pseudomembranous colitis;Sepsis;Septicemia;Soft tissue infection;Staphylococcal infection;Thermal burn,Abdominal pain;Agranulocytosis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Asthenia;Azotaemia;Back pain;Blood creatinine increased;Body temperature increased;Bradycardia;Chemical peritonitis;Chills;Clostridium difficile colitis;Connective tissue disorder;Constipation;Creatinine increased;Deafness;Deafness neurosensory;Deafness permanent;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Dizziness;Drug abuse;Drug eruption;Drug fever;Dyspnoea;Eosinophilia;Erythema;Erythema multiforme;Extravasation;Fatigue;Flatulence;Flushing;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Generalized flushing;Headache;Hearing impaired;Hypersensitivity;Hypokalaemia;Hypotension;Infection;Infestation;Infestation NOS;Injection site inflammation;Insomnia;Kidney function abnormal;Linear IgA disease;Malnutrition;Muscle spasms;Nausea;Necrosis;Nephritis interstitial;Nephropathy toxic;Nephrotoxicity;Nervous system disorder;Neutropenia;Oedema peripheral;Ototoxicity;Pain;Palpitations;Phlebitis;Pregnancy;Pruritus;Rash;Rash macular;Red man syndrome;Red neck;Renal failure;Renal impairment;Rigors;Serum creatinine increased;Skin disorder;Stevens-Johnson syndrome;Tachycardia;Tenderness;Thrombocytopenia;Thrombophlebitis;Tinnitus;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Uremia;Urinary tract infection;Urticaria;Vasculitis;Vertigo;Vomiting;Wheezing,small molecule,approved,Vancomicina; Vancomycin; Vancomycine; Vancomycinum; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; Bphs; H1R,D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan, A07AA09; S01AA28;A07AA09;J01XA01
venlafaxine,"Abdominal discomfort;Abdominal distress;Agitation;Agoraphobia;Anxiety;Asthenia;Bradyphrenia;Bradypsychic response;Cerebration impaired;Chest pain;Chills;Choking sensation;Decreased interest;Depersonalisation;Depressed mood;Depression;Derealisation;Discomfort;Distress;Disturbance in attention;Dizziness;Drug abuse;Dysphoria;Dyspnoea;Emotional distress;Fatigue;Fear;Fear of death;Feeling guilty;Generalised anxiety disorder;Heart pounding;Hot flush;Hyperhidrosis;Hypersomnia;Hypoaesthesia;Insomnia;Irritability;Lightheadedness;Major depression;Major depressive disorder, single episode;Malaise;Melancholia;Menopausal symptoms;Mental disability;Nausea;Numbness;Palpitations;Panic attack;Panic disorder;Paraesthesia;Performance fear;Phobia;Sensory loss;Sexual dysfunction;Sickness;Sleep disorder;Sleep disturbance;Social fear;Social phobia;Suicidal ideation;Suicide attempt;Sweating;Tension;Tingling sensation;Trembling;Tremor",Abdominal distension;Abdominal pain;Abnormal behaviour;Abnormal dreams;Abnormal ejaculation;Abnormal vision;Abortion;Accidental injury;Accommodation disorder;Acute coronary syndrome;Adjustment disorder;Affect lability;Ageusia;Aggression;Agitation;Agranulocytosis;Akathisia;Akinesia;Alanine aminotransferase increased;Albuminuria;Alcohol abuse;Alcohol intolerance;Alopecia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angle closure glaucoma;Anorectal disorder;Anorexia;Anorgasmia;Anuria;Anxiety;Anxiety disorder;Aortic aneurysm;Apathy;Aphasia;Aplastic anaemia;Appendicitis;Appetite absent;Arrhythmia;Arteritis;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atelectasis;Atrial fibrillation;Atrioventricular block first degree;Azotaemia;Back pain;Bacteraemia;Balanitis;Basophilia;Biliary colic;Bladder pain;Bleeding time prolonged;Blepharitis;Blood alkaline phosphatase increased;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood disorder;Blood lactate dehydrogenase increased;Blood pressure diastolic increased;Blood pressure increased;Blood prolactin increased;Blood urea increased;Blood uric acid increased;Body odor;Body temperature increased;Bone pain;Bone spur;Bradycardia;Bradykinesia;Breast discharge;Breast engorgement;Breast enlargement;Breast pain;Breath odour;Bronchitis;Bruxism;Buccoglossal syndrome;Bundle branch block;Bursitis;Calculus of kidney;Calculus urinary;Candida infection;Capillary fragility;Carcinoma;Cardiac arrest;Cardiac disorder;Cardiac failure congestive;Cardiovascular disorder;Cataract;Catatonia;Cellulitis;Cerebral ischaemia;Cerebrovascular accident;Cervicitis;Cheilitis;Chest pain;Chills;Cholecystitis;Cholelithiasis;Cholesterol serum elevated;Chromatopsia;Circumoral paresthesia;Cold feet;Cold hands;Colitis;Completed suicide;Confusional state;Congenital anomaly;Congenital genitourinary abnormality;Conjunctival haemorrhage;Conjunctival oedema;Conjunctivitis;Constipation;Conversion disorder;Convulsion;Coordination abnormal;Corneal lesion;Coronary artery disease;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine increased;Crystalluria calcium;Cyanosis;Cyst;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Delayed orgasm;Delirium;Delusion;Dementia;Dependence;Dependence psychological;Depersonalisation;Depressed level of consciousness;Depression;Depressive disorder;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Developmental delay;Diabetes mellitus;Diarrhoea;Difficulty focusing eyes;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Dreaming excessive;Drug dependence;Drug interaction;Drug seeking behavior;Drug tolerance;Dry eye;Dry mouth;Dry skin;Duodenitis;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphoria;Dyspnoea;Dysthymic disorder;Dysuria;Ecchymosis;Eczema;Ejaculation delayed;Ejaculation disorder;Electric shock;Endometriosis;Energy increased;Eosinophilia;Epidermal necrosis;Epistaxis;Erectile dysfunction;Erection increased;Erection prolonged;Eructation;Eruption lichenoid;Erythema;Erythema multiforme;Erythema nodosum;Euphoric mood;Exophthalmos;Exostosis;Extrapyramidal disorder;Extrapyramidal symptoms;Extrasystoles;Eye haemorrhage;Eye pain;Face oedema;Facial paralysis;Fasciculation;Fatigue;Feeling abnormal;Feeling drunk;Fibrocystic breast disease;Flat affect;Flatulence;Flushing;Fracture;Furuncle;Furunculosis;Gait disturbance;Galactorrhoea;Gastric pH decreased;Gastritis;Gastroenteritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal ulcer;Gastrooesophageal reflux disease;Gingival bleeding;Gingivitis;Glaucoma;Glossitis;Glycosuria;Goitre;Gout;Grand mal convulsion;Granuloma;Guillain-Barre syndrome;Gynaecomastia;Haematemesis;Haematoma;Haematuria;Haemochromatosis;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhoids;Hair colour changes;Hair discoloration;Hallucination;Headache;Hepatic steatosis;Hepatitis;Hepatitis fulminant;Hepatocellular injury;Hiccups;High cholesterol;High density lipoprotein decreased;Hirsutism;Homicidal ideation;Hostility;Hot flush;Hyperacusis;Hyperaesthesia;Hyperbilirubinaemia;Hypercalciuria;Hyperchlorhydria;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hyperphosphataemia;Hyperreflexia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypocholesterolaemia;Hypoglycaemia;Hypohidrosis;Hypokalaemia;Hypokinesia;Hypomania;Hypomenorrhoea;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hyporeflexia;Hypotension;Hypothyroidism;Hypotonia;Hypoventilation;Hypoxia;Hysteria;Ileitis;Ill-defined disorder;Impaired healing;Inappropriate antidiuretic hormone secretion;Increased appetite;Increased bronchial secretion;Infection;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Intentional injury;Interstitial lung disease;Intestinal obstruction;Irritability;Ischaemia;Jaundice;Keratitis;Kidney function abnormal;Labyrinthitis;Lactation female;Lactic dehydrogenase activity increased;Laryngeal oedema;Laryngitis;Laryngospasm;Leukocytosis;Leukoderma;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Lichenoid keratosis;Liver fatty;Liver function test abnormal;Liver injury;Liver tenderness;Loss of consciousness;Loss of libido;Low density lipoprotein increased;Lung disorder;Lymphadenopathy;Lymphocytosis;Major depression;Malaise;Mania;Manic psychosis;Mastitis;Melaena;Menopausal symptoms;Menopause;Menorrhagia;Menstrual disorder;Mental disability;Metrorrhagia;Micturition urgency;Migraine;Miliaria;Miosis;Mitral valve disease;Mood swings;Motion sickness;Mouth ulceration;Movements involuntary;Multiple fractures;Muscle contractions involuntary;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Mydriasis;Myocardial infarction;Myoclonus;Myopathy;Nausea;Neck pain;Neck stiffness;Necrosis;Neoplasm malignant;Nephrolithiasis;Nervousness;Neuralgia;Neuritis;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Neutropenia;Night sweats;Nightmare;Nocturia;Nuchal rigidity;Nystagmus;Oedema;Oesophageal spasm;Oesophagitis;Oliguria;Onychoclasis;Optic neuritis;Oral candidiasis;Orchitis;Orchitis noninfective;Orgasm abnormal;Orthostatic hypotension;Osteoarthritis;Osteoporosis;Osteosclerosis;Otitis externa;Otitis media;Ovarian cyst;PRL increased;Pain;Pallor;Palpitations;Pancreatitis;Pancytopenia;Panic reaction;Papilloedema;Paraesthesia;Paraesthesia oral;Paranoia;Paranoid reaction;Paresis;Parosmia;Parotitis;Pelvic pain;Periodontitis;Peripheral coldness;Peripheral vascular disorder;Petechiae;Pharyngitis;Phosphatase alkaline increased;Photophobia;Photosensitivity reaction;Plantar fasciitis;Plasma cell myeloma;Plasmacytoma;Pleurisy;Pneumonia;Pneumothorax;Pollakiuria;Polycythaemia vera;Polyuria;Proctitis;Prostatic disorder;Prostatitis;Prostatomegaly;Protein urine present;Proteinuria;Prurigo;Pruritus;Psoriasis;Psychotic depression;Psychotic disorder;Pulmonary congestion;Pulmonary embolism;Pulmonary eosinophilia;Purpura;Pyelonephritis;Pyuria;Rash;Rash maculo-papular;Rash pustular;Rectal disorder;Rectal haemorrhage;Renal failure;Renal impairment;Renal pain;Respiratory failure;Respiratory tract congestion;Retinal haemorrhage;Retrosternal pain;Rhabdomyolysis;Rheumatoid arthritis;Rhinitis;Salivary gland enlargement;Salivary hypersecretion;Salpingitis;Scleritis;Scotoma;Seborrhoeic dermatitis;Serotonin syndrome;Sexual dysfunction;Shock;Sinus arrhythmia;Sinusitis;Skin atrophy;Skin discolouration;Skin hypertrophy;Skin odour abnormal;Skin striae;Sleep apnoea syndrome;Sleep disorder;Sleep disturbance;Soft stools;Somnolence;Speech disorder;Speech impairment NOS;Sputum increased;Stevens-Johnson syndrome;Stomatitis;Stupor;Subconjunctival hemorrhage;Suicidal ideation;Suicide;Suicide attempt;Supraventricular tachycardia;Sweating;Sweating decreased;Syncope;Tachycardia;Tardive dyskinesia;Taste altered;Tendon rupture;Tenosynovitis;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thyroid neoplasm;Thyroid nodule;Thyroiditis;Tinnitus;Tolerance development;Tongue discolouration;Tongue disorder;Tongue oedema;Tonic-clonic seizures;Torsade de pointes;Torticollis;Toxic epidermal necrolysis;Trauma;Tremor;Trismus;Unintended pregnancy;Upper respiratory tract infection;Uremia;Urinary incontinence;Urinary retention;Urination impaired;Urine abnormality;Urine analysis abnormal;Urine output increased;Urolithiasis;Urticaria;Uterine haemorrhage;Uterine spasm;Uveitis;VIIth nerve paralysis;Vaginal discharge;Vaginal dryness;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Varicose vein;Vascular purpura;Vasodilation;Vasodilation procedure;Venous insufficiency;Ventricular bigeminy;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Vision blurred;Visual disturbance;Visual impairment;Vitreous disorder;Vivid dreams;Vomiting;Vulvovaginal dryness;Weight decreased;Weight increased;Withdrawal syndrome;Yawning,small molecule,approved,"Venlafaxina; Venlafaxine; Venlafaxinum; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent dopamine transporter,N06AX16
vigabatrin,Complex partial seizures;Convulsion;Epilepsy;Grand mal convulsion;Infantile spasms;Myoclonic epilepsy;Partial epilepsy;Partial seizures;Tonic-clonic seizures,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal behaviour;Abnormal dreams;Abnormal vision;Acne;Acute psychosis;Affect lability;Aggression;Aggressive reaction;Agitation;Amnesia;Anaemia;Angioedema;Anxiety;Apathy;Arthralgia;Arthropathy;Asthenia;Asthenopia;Ataxia;Atrophy;Back pain;Blood and lymphatic system disorders;Body temperature increased;Breast disorder;Bronchitis;Candida infection;Cerebration impaired;Chest pain;Cholestasis;Confusional state;Congenital anomaly;Congenital genital malformation;Congenital hydronephrosis;Congenital oral malformation;Congenital vesicoureteric reflux;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Cough;Croup infectious;Cytotoxic oedema;Deafness;Decreased appetite;Delayed puberty;Delirium;Dentofacial anomaly;Depressed level of consciousness;Depressed mood;Depression;Dermatitis;Developmental coordination disorder;Developmental delay;Developmental hip dysplasia;Diarrhoea;Diplopia;Discomfort;Disorientation;Disturbance in attention;Dizziness;Drowsiness;Dysarthria;Dyskinesia;Dysmenorrhoea;Dysmorphism;Dyspepsia;Ear disorder;Ear infection;Ear pain;Electroencephalogram abnormal;Encephalopathy;Endocrine disorder;Erectile dysfunction;Erythema multiforme;Expressive language disorder;Eye disorder;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flat affect;Foetal anticonvulsant syndrome;Forgetfulness;Gait disturbance;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Haemangioma congenital;Hallucination;Hamartoma;Headache;Hepatobiliary disease;Hip dysplasia;Hyperkinesia;Hyperreflexia;Hypersensitivity;Hypertonia;Hypoaesthesia;Hypomania;Hyporeflexia;Hypotonia;Ill-defined disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Irritability;Joint sprain;Laryngeal oedema;Laryngeal pain;Lethargy;Ligament sprain;Limb malformation;Limb reduction defect;Low set ears;Malaise;Malnutrition;Mania;Memory impairment;Menstrual disorder;Mental disability;Mental disorder;Mental retardation;Mood swings;Movement disorder;Multi-organ failure;Muscle relaxant therapy;Muscle spasms;Muscle spasticity;Muscle strain;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Myoclonic epilepsy;Myoclonus;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Neurotoxicity;Nystagmus;Oedema;Oedema peripheral;Oesophagitis;Optic atrophy;Optic neuritis;Osteoarthritis;Otitis media;Otitis media acute;Pain;Pain in extremity;Pallor;Paraesthesia;Paranoia;Paranoid reaction;Personality disorder;Pharyngolaryngeal pain;Pneumonia;Postictal state;Pruritus;Psychotic disorder;Pulmonary congestion;Pulmonary embolism;Purpura;Rash;Rash maculo-papular;Renal aplasia;Respiratory failure;Respiratory tract congestion;Retinal atrophy;Retinal degeneration;Retinal disorder;Retinitis;Salivary hypersecretion;Scotoma;Sensory disturbance;Sensory loss;Sinus headache;Sinusitis;Skin disorder;Somnolence;Speech disorder;Status epilepticus;Stevens-Johnson syndrome;Strabismus;Stridor;Stupor;Suicidal behaviour;Suicide attempt;Supernumerary nipple;Talipes;Tension;Thinking abnormal;Thirst;Throat irritation;Tinnitus;Tooth disorder;Toothache;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urinary tract infection;Urticaria;Vascular purpura;Vertigo;Viral diarrhoea;Viral infection;Vision blurred;Visual field constriction;Visual impairment;Vomiting;Wave slowing;Weight increased;Wound secretion,small molecule,approved,4-Amino-5-hexenoic acid; Gamma vinyl GABA; gamma-Vinyl GABA; gamma-Vinyl-gamma-aminobutyric acid; GVG; Vigabatrin; Vigabatrina; Vigabatrine; Vigabatrinum; Vinyl gamma-aminobutyric acid; (S)-3-amino-2-methylpropionate transaminase; 2.6.1.19; GABA aminotransferase; GABA transaminase; GABA-AT; GABA-T; GABAT; Gamma-amino-N-butyrate transaminase; L-AIBAT; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; hPAT1; PAT1; Proton/amino acid transporter 1; Solute carrier family 36 member 1,"4-aminobutyrate aminotransferase, mitochondrial",N03AG04
vinorelbine,Advanced breast cancer;Breast cancer;Breast cancer stage IV;Carcinoma of lung;Cardiovascular disorder;Cervix carcinoma;Cystitis haemorrhagic;Inappropriate antidiuretic hormone secretion;Lung neoplasm malignant;Metastatic disease;Metastatic neoplasm;Neoplasm;Neoplasm malignant;Neuropathy;Neuropathy peripheral;Non-small cell lung cancer;Non-small cell lung cancer metastatic;Non-small cell lung cancer stage III;Ovarian cancer,Abdominal pain;Ache;Acute coronary syndrome;Acute dyspnea;Acute myocardial ischemia;Acute pain;Adenocarcinoma;Agranulocytosis;Alopecia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Aplastic anaemia;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Autonomic neuropathy;Back pain;Bacterial infection;Bilirubin total increased;Blister;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Body temperature increased;Bone marrow depression;Bronchospasm;Carcinoma of lung;Cardiac disorder;Cardiac failure;Cerebrovascular accident;Chemical phlebitis;Chest pain;Connective tissue disorder;Constipation;Cough;Creatinine increased;Cystitis haemorrhagic;Deafness;Decreased appetite;Deep vein thrombosis;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Diuresis;Dizziness;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Electrolyte imbalance;Embolism;Endocrine disorder;Erythema;Extravasation;Fatigue;Febrile neutropenia;Feeling abnormal;Flushing;Gait disturbance;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal toxicity;Headache;Hearing impaired;Hepatic failure;Hepatic insufficiency;Hepatobiliary disease;Hyperaesthesia;Hypersensitivity;Hypertension;Hypoaesthesia;Hyponatraemia;Hyporeflexia;Hypotension;Hypoxemia;Hypoxia;Ileus;Ileus paralytic;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Infection;Infestation;Infestation NOS;Injection site dermatitis;Injection site pain;Injection site reaction;Intestinal obstruction;Lethargy;Leukopenia;Local reaction;Localized rash;Lung disorder;Lung neoplasm malignant;Malaise;Malnutrition;Mediastinal disorder;Mucosal inflammation;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myelosuppression;Myocardial infarction;Myocardial ischaemia;Nausea;Necrosis;Nephropathy toxic;Nervous system disorder;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutropenic sepsis;Numbness;Oesophagitis;Ototoxicity;Pain;Pain burning;Pain in jaw;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paresis;Peripheral coldness;Phlebitis;Pneumonia;Polyuria;Pruritus;Pulmonary embolism;Pulmonary oedema;Pulmonary toxicity;Radiation recall reaction (dermatologic);Rash;Recall phenomenon;Respiratory failure;Respiratory tract infection;Sensory loss;Sepsis;Septicemia;Skin disorder;Skin exfoliation;Skin necrosis;Small cell lung cancer;Stomatitis;Tachycardia;Thrombocytopenia;Thromboembolic event;Thrombophlebitis;Thrombosis;Transaminases increased;Tumour pain;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vasodilation;Vasodilation procedure;Vein discolouration;Vertigo;Vestibular disorder;Vomiting;Weight decreased,small molecule,approved; investigational,"5'-Noranhydrovinblastine; Vinorelbin; Vinorelbina; Vinorelbine; Vinorelbinum; TUBB5; Tubulin beta-5 chain; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Tubulin beta chain,L01CA04
zafirlukast,Asthma;Drug interaction,Abdominal discomfort;Abdominal pain;Accidental injury;Agranulocytosis;Allergic granulomatous angiitis;Angioedema;Arthralgia;Asthenia;Back pain;Blister;Blood disorder;Body temperature increased;Contusion;Dermatitis;Dermatitis bullous;Diarrhoea;Digestion impaired;Discomfort;Dizziness;Dyspepsia;Eosinophilia;Eosinophilic pneumonia;Fatigue;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Haematemesis;Haemoglobin;Haemoptysis;Haemorrhage;Headache;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis fulminant;Hepatotoxicity;Hyperbilirubinaemia;Hypersensitivity;Hypoaesthesia;Ill-defined disorder;Increased tendency to bruise;Infection;Influenza like illness;Injury;Insomnia;Jaundice;Leukocytoclastic vasculitis;Liver function test abnormal;Liver injury;Malaise;Musculoskeletal discomfort;Myalgia;Nausea;Neuropathy;Neuropathy peripheral;Neutropenia;Numbness;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pruritus;Raised liver function tests;Rash;Rectal haemorrhage;Sensory loss;Sinusitis;Swelling;Throat sore;Thrombocytopenia;Traumatic liver injury;Upset stomach;Urticaria;Vasculitic rash;Vasculitis;Vomiting,small molecule,approved; investigational,"4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Zafirlukast; CYSLT1; CysLTR1; Cysteinyl leukotriene D4 receptor; G-protein coupled receptor HG55; HMTMF81; LTD4 receptor; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1",Cysteinyl leukotriene receptor 1,R03DC01
zalcitabine,Acquired immunodeficiency syndrome;Autoimmune disorder;Disease progression;Drug intolerance,Abdominal bloating;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal vision;Ache;Acute stress disorder;Affect lability;Ageusia;Agitation;Albuminuria;Alopecia;Amnesia;Anaemia;Anorexia;Anxiety;Aphasia;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Ataxia;Atrial fibrillation;Back pain;Bell's palsy;Bladder pain;Blister;Blood alkaline phosphatase increased;Blood creatinine increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bullous eruption;Bursitis;Cachexia;Calculus of kidney;Candida infection;Carbuncle;Cardiac failure;Cardiomyopathy;Cellulitis;Cerebration impaired;Cervix disorder;Chest discomfort;Chest tightness;Chills;Cholecystitis;Colitis;Common cold;Confusional state;Congenital eye disorder;Conjunctivitis bacterial;Conjunctivitis infective;Convulsion;Convulsive seizure;Coordination abnormal;Cough;Cramp muscle;Cramps of lower extremities;Creatinine increased;Cyanosis;Deafness;Decreased appetite;Dementia;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear pain;Endophthalmitis;Enlargement abdomen;Eosinophilia;Epigastric pain;Epistaxis;Eructation;Euphoric mood;Eye disorder;Eye haemorrhage;Eye irritation;Eye pain;Eye pruritus;Eye redness;Facial pain;Fat redistribution;Fatigue;Feeling abnormal;Flank pain;Flatulence;Flushing;Furuncle;Gagging;Gastritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Genital lesion;Gingival bleeding;Gingival disorder;Gingival pain;Gingivitis;Glossitis;Glossodynia;Glycosuria;Gout;Grand mal convulsion;Granulocytosis;Groin pain;Haematocrit decreased;Haemoglobinaemia;Haemoptysis;Haemorrhoids;Hallucination;Headache;Hearing impaired;Heart racing;Heartburn;Hepatitis;Hepatocellular injury;Hepatomegaly;Herpes labialis;Hot flush;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hypernatraemia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hypocalcaemia;Hypogeusia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Ill-defined disorder;Impetigo;Infection;Inflammation;Influenza like illness;Influenza-like symptoms;Insomnia;Intestinal mass;Jaundice;Joint swelling;Kidney function abnormal;Lactic acidosis;Leukopenia;Libido decreased;Liver injury;Loose stools;Loss of consciousness;Lymphadenopathy;Malaise;Mania;Manic psychosis;Melaena;Memory loss;Menopausal symptoms;Mental disability;Migraine;Mood swings;Muscle spasms;Muscle stiffness;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myopathy;Myositis;Nail disorder;Nasal dryness;Nasopharyngitis;Neck pain;Neck stiffness;Nephrolithiasis;Nephropathy toxic;Nerve paralysis;Nervousness;Neuralgia;Neuritis;Neuropathy peripheral;Neutropenia;Neutrophilia;Night sweats;Nocturia;Nuchal rigidity;Ocular hyperaemia;Ocular icterus;Odynophagia;Oedema;Oesophageal pain;Oesophageal ulcer;Oesophagitis;Oral disorder;Oral herpes;Oral lesion;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancreatitis acute;Pancreatitis haemorrhagic;Panophthalmitis;Paralysis;Paranoia;Paranoid state;Parosmia;Penile oedema;Peripheral coldness;Pharyngitis;Phosphatase alkaline increased;Photophobia;Photosensitivity reaction;Pollakiuria;Polyuria;Proctalgia;Prurigo;Pruritus;Psychotic disorder;Pulmonary congestion;Purpura;Rales;Rash;Rash erythematous;Rash follicular;Rash maculo-papular;Rash papular;Rectal haemorrhage;Rectal mass;Rectal ulcer;Renal cyst;Renal failure acute;Renal impairment;Respiratory distress;Respiratory tract congestion;Retching;Rhinitis;Rhinorrhoea;Rhonchi;Rib pain;Rigors;Salivary gland enlargement;Salivary hypersecretion;Scleral icterus;Shock;Sinus congestion;Sinus headache;Sinus pain;Sinusitis;Skin disorder;Skin exfoliation;Skin fissures;Skin ulcer;Somnolence;Speech disorder;Status epilepticus;Stupor;Subarachnoid haemorrhage;Suicide attempt;Sweating increased;Swelling;Syncope;Tachycardia;Tenderness;Tension;Testicular swelling;Throat sore;Thrombocytopenia;Tinnitus;Tongue disorder;Tongue ulceration;Tonic-clonic seizures;Tooth abscess;Toothache;Tremor;Ulcer;Urinary retention;Urine output increased;Urticaria;VIIth nerve paralysis;Vaginal discharge;Vaginal infection;Vaginal itching;Vaginal pain;Vaginal ulceration;Vascular purpura;Ventricular extrasystoles;Vertigo;Vision blurred;Visual impairment;Vomiting;Vulvovaginal pain;Vulvovaginal pruritus;Weight decreased;Wheezing;Xerophthalmia,small molecule,approved; investigational,"2',3'-Dideoxycytidine; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; DDC; DDCYD; Dideoxycytidine; Zalcitabine; Pr160Gag-Pol; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1; 36 kDa nucleolar protein HNP36; Delayed-early response protein 12; DER12; ENT2; Equilibrative NBMPR-insensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter; hENT2; HNP36; Hydrophobic nucleolar protein, 36 kDa; Nucleoside transporter, ei-type; Solute carrier family 29 member 2",Gag-Pol polyprotein; Reverse transcriptase/RNaseH,J05AF03
zaleplon,Distress;Emotional distress;Insomnia,Abdominal pain;Abnormal vision;Accommodation disorder;Affect lability;Ageusia;Aggression;Agitation;Alanine aminotransferase increased;Albuminuria;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Anger;Angina pectoris;Angioedema;Anorexia;Anterograde amnesia;Anxiety;Apathy;Aphthous stomatitis;Apnoea;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Back pain;Biliary colic;Bladder pain;Blepharitis;Blood uric acid increased;Body temperature increased;Breast disorder;Breast pain;Bronchitis;Bruxism;Bundle branch block;Bursitis;Calculus of kidney;Cataract;Cataract specified;Cerebral ischaemia;Cheilitis;Chest pain;Chills;Cholelithiasis;Circumoral paresthesia;Colitis;Confusional state;Conjunctivitis;Constipation;Coordination abnormal;Corneal erosion;Cyanosis;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Delusion;Dependence;Dependence physiological;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Dermatitis contact;Diabetes mellitus;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dry skin;Duodenal ulcer;Dysarthria;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Ecchymosis;Eczema;Enteritis;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Euphoric mood;Extrasystoles;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Facial paralysis;Feeling abnormal;Flat affect;Flatulence;Fluid retention;Gait disturbance;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gingival bleeding;Gingivitis;Glaucoma;Glossitis;Goitre;Gout;Haematuria;Hallucination;Hangover;Headache;Hepatobiliary disease;Hepatotoxicity;Hiccups;Hostility;Hyperacusis;Hyperaesthesia;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperreflexia;Hypertension;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypoglycemic reaction;Hypokinesia;Hyporeflexia;Hypotension;Hypothyroidism;Hypotonia;Ill-defined disorder;Immune system disorder;Increased appetite;Increased bronchial secretion;Insomnia;Intestinal obstruction;Irritability;Ketosis;Labyrinthitis;Lacrimation increased;Lactase deficiency;Lactose intolerance;Laryngitis;Leukocytosis;Leukorrhea;Libido decreased;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Lymphocytosis;Malaise;Malnutrition;Melaena;Melanosis;Menopause;Menorrhagia;Menstruation delayed;Mental disability;Mental disorder;Metrorrhagia;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Muscle relaxant therapy;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myoclonus;Myositis;Nausea;Neck stiffness;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Nightmare;Nuchal rigidity;Nystagmus;Oedema;Oedema peripheral;Oesophageal achalasia;Oesophagitis;Orthostatic hypotension;Osteoarthritis;Osteoporosis;Pain;Palpitations;Paraesthesia;Paraesthesia oral;Parosmia;Peptic ulcer;Pericardial effusion;Photophobia;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pneumonia;Pollakiuria;Pruritus;Psoriasis;Psychomotor retardation;Psychotic disorder;Pulmonary embolism;Purpura;Rage;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Renal pain;Retinal detachment;Retrosternal pain;Salivary hypersecretion;Scotoma;Shock;Sinus bradycardia;Skin discolouration;Skin disorder;Skin hypertrophy;Sleep talking;Slurred speech;Snoring;Somnambulism;Somnolence;Speech disorder;Sputum increased;Stiffness;Stomatitis;Stupor;Sweating;Swelling;Syncope;Tachycardia;Tearing eyes;Tenosynovitis;Tension;Thinking abnormal;Thirst;Thrombophlebitis;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Tremor;Trismus;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary retention;Urticaria;VIIth nerve paralysis;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vascular purpura;Ventricular bigeminy;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Visual impairment;Weight decreased;Weight increased,small molecule,approved; illicit; investigational,"3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide; Zaleplon; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase",Gamma-aminobutyric acid receptor subunit alpha-1,N05CF03
zanamivir,Bronchial hyperreactivity;Chronic obstructive pulmonary disease;Infection;Influenza,Abdominal pain;Abnormal behaviour;Agitation;Anaphylactic shock;Anaphylactoid reaction;Anorexia;Anxiety;Arrhythmia;Arthralgia;Asthenia;Asthma;Body temperature increased;Bronchitis;Bronchospasm;Chills;Confusional state;Convulsion;Cough;Decreased appetite;Dehydration;Delirium;Delusion;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dyspnoea;Ear pain;Erythema multiforme;Face oedema;Fatigue;Feeling abnormal;Gastrointestinal pain;Haemoglobin;Haemorrhage;Hallucination;Headache;Hypersensitivity;Ill-defined disorder;Increased appetite;Infection;Influenza;Influenza like illness;Influenza-like symptoms;Loss of consciousness;Lung disorder;Lymphopenia;Malaise;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasal inflammation;Nausea;Neutropenia;Nightmare;Oropharyngeal swelling;Pain;Rash;Respiratory tract infection;Rheumatic disorder;Rheumatism;Shock;Sinusitis;Skin disorder;Stevens-Johnson syndrome;Syncope;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vomiting,small molecule,approved; investigational,"(2R,3R,4S)-3-(acetylamino)-4-carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid; 4-guanidino-Neu5Ac2en; 5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid; 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid; GANA; Zanamivir; 3.2.1.18; 3.2.1.18; 3.2.1.18; Cytosolic sialidase; N-acetyl-alpha-neuraminidase 2",Neuraminidase; Neuraminidase; Sialidase-2,J05AH01
zidovudine,Acquired immunodeficiency syndrome;Autoimmune disorder;Disease progression;Immunodeficiency;Infection;Opportunistic infection;Pregnancy;Teratogenicity,Abdominal cramps;Abdominal pain;Acidosis;Acne;Acquired immunodeficiency syndrome;Affect lability;Agranulocytosis;Amblyopia;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Aplasia pure red cell;Aplastic anaemia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Auricular swelling;Autoimmune disorder;Back pain;Bacteraemia;Bladder pain;Blood and lymphatic system disorders;Blood lactate dehydrogenase increased;Body odor;Body temperature increased;Bone marrow depression;Breast disorder;Breath sounds abnormal;Cardiac disorder;Cardiac failure congestive;Cardiomyopathy;Chest pain;Chills;Confusional state;Congenital anomaly;Connective tissue disorder;Constipation;Convulsion;Cough;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dermatitis;Developmental delay;Diarrhoea;Discomfort;Dizziness;Drug interaction;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Epistaxis;Eructation;Erythema;Erythema multiforme;Fat redistribution;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Foetor hepaticus;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Generalized aching;Gingival bleeding;Gynaecomastia;Haematuria;Haemolytic anaemia;Headache;Hearing impaired;Hepatitis;Hepatitis C;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hoarseness;Hyperaesthesia;Hyperbilirubinaemia;Hyperhidrosis;Hyperlactacidaemia;Hyperpathia;Hyporeflexia;Hypoxemia;Hypoxia;Ill-defined disorder;Influenza;Insomnia;Irritability;Jaundice;Lactic acidosis;Lactic dehydrogenase activity increased;Leukopenia;Liver disorder;Local reaction;Localised oedema;Loss of consciousness;Lymphadenopathy;Macular oedema;Malaise;Malnutrition;Mania;Mediastinal disorder;Mental disorder;Mood swings;Mouth ulceration;Mucosal pigmentation;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myopathy;Myositis;Nail pigmentation;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Night sweats;Oedema;Oedema auricular;Pain;Pancreatitis;Pancytopenia;Paraesthesia;Pharyngitis;Phlebitis;Photophobia;Pigmentation disorder;Pigmentation skin;Pollakiuria;Polyuria;Pruritus;Rash;Rash erythematous;Rash follicular;Rash maculo-papular;Rectal haemorrhage;Red cell aplasia;Rhabdomyolysis;Rhinitis;Rhinorrhoea;Rigors;Sensitisation;Shock;Sickness;Sinusitis;Skin discolouration;Skin disorder;Skin odour abnormal;Somnolence;Splenomegaly;Stevens-Johnson syndrome;Stomatitis;Sweating;Sweating increased;Swollen tongue;Syncope;Tension;Thrombocytopenia;Tongue disorder;Tongue oedema;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary hesitation;Urinary tract disorder;Urine output increased;Urticaria;Vasculitis;Vasodilation;Vasodilation procedure;Vertigo;Vomiting;Weight decreased;Wheezing,small molecule,approved,"Azidothymidine; AZT; ZDV; Zidovudina; Zidovudine; Zidovudinum; 2.7.10.1; CD135; Fetal liver kinase-2; FL cytokine receptor; FLK-2; FLK2; FLT-3; Fms-like tyrosine kinase 3; Stem cell tyrosine kinase 1; STK-1; STK1; Pr160Gag-Pol; 2.7.7.49; EST2; HEST2; TCS1; Telomerase catalytic subunit; Telomerase-associated protein 2; TP2; TRT; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.7.1.21; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; hOCT2; OCT2; Organic cation transporter 2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; CNT 1; CNT1; Concentrative nucleoside transporter 1; hCNT1; Na(+)/nucleoside cotransporter 1; Sodium-coupled nucleoside transporter 1; Solute carrier family 28 member 1; 36 kDa nucleolar protein HNP36; Delayed-early response protein 12; DER12; ENT2; Equilibrative NBMPR-insensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter; hENT2; HNP36; Hydrophobic nucleolar protein, 36 kDa; Nucleoside transporter, ei-type; Solute carrier family 29 member 2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.-; 7.6.2.2; MOAT-C; MRP5; Multi-specific organic anion transporter C; Multidrug resistance-associated protein 5; pABC11; SMRP; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Receptor-type tyrosine-protein kinase FLT3; Reverse transcriptase/RNaseH; Gag-Pol polyprotein; Telomerase reverse transcriptase, J05AF01; J05AR01; J05AR05;J05AF01;J05AR04
zolmitriptan,Aura;Cluster headache;Hypersensitivity;Hypertension;Migraine,Abdominal pain;Abnormal dreams;Abortion spontaneous;Acute coronary syndrome;Acute migraine;Adverse reaction;Affect lability;Agitation;Akathisia;Amblyopia;Amnesia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Apathy;Apnoea;Arrhythmia;Arteriospasm coronary;Arthralgia;Arthritis;Arthropathy;Asthenia;Ataxia;Atrial fibrillation;Back pain;Bladder pain;Blood alkaline phosphatase increased;Blood pressure increased;Body temperature increased;Bone pain;Bradycardia;Breast cancer;Breast neoplasm;Bronchitis;Bronchospasm;Burning sensation;Carcinoma breast;Cardiac disorder;Cellulitis;Cerebral ischaemia;Chest discomfort;Chest heaviness;Chest pain;Chest pressure;Chest tightness;Chills;Circumoral paresthesia;Colitis;Colitis ischaemic;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cramps of lower extremities;Cyanosis;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Depersonalisation;Dermatitis;Diarrhoea;Diarrhoea haemorrhagic;Diplopia;Discomfort;Dizziness;Dry eye;Dry mouth;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Ear pain;Ecchymosis;Eczema;Electrocardiogram abnormal;Eosinophilia;Epistaxis;Eructation;Erythema;Euphoric mood;Extrasystoles;Eye pain;Face oedema;Feeling abnormal;Feeling cold;Flat affect;Gastritis;Gastroenteritis;Gastrointestinal carcinoma;Gastrointestinal disorder;Gastrointestinal pain;Genitourinary tract neoplasm;Gingivitis;Haematemesis;Haematuria;Hair disorder;Hallucination;Headache;Hepatic neoplasm;Hiccups;Hyperacusis;Hyperaesthesia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hyperventilation;Hypoaesthesia;Hypotonia;Ill-defined disorder;Immune system disorder;Increased appetite;Infarction;Infection;Influenza;Insomnia;Intestinal obstruction;Irritability;Jaundice;Laboratory test abnormal;Lacrimation;Lacrimation increased;Laryngeal oedema;Laryngitis;Leukopenia;Loss of consciousness;Lymphadenopathy;Malaise;Mania;Manic psychosis;Medication overuse headache;Melaena;Menorrhagia;Mental disability;Metrorrhagia;Micturition urgency;Migraine;Mood swings;Muscle relaxant therapy;Muscle spasms;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Myocardial ischaemia;Nausea;Neck pain;Neck tightness;Necrosis;Neoplasm;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Oedema;Oedema peripheral;Oesophagitis;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Osteoarthritis;Osteoporosis;Pain;Pain in jaw;Palpitations;Pancreatitis;Paraesthesia;Paraesthesia oral;Parosmia;Pharyngitis;Phenylketonuria;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Prinzmetal angina;Pruritus;Psychotic disorder;Pulmonary oedema;Pyelonephritis;Rash;Reaction aggravation;Renal pain;Rhinitis;Salivary hypersecretion;Scotoma;Sensation of heaviness;Serotonin syndrome;Shock;Sialoadenitis;Sinusitis;Skin disorder;Somnolence;Speech disorder;Splenic infarction;Stiffness;Stomatitis;Subarachnoid haemorrhage;Sweating;Syncope;Tachycardia;Tardive dyskinesia;Tenderness;Tenosynovitis;Tension;Tetany;Thinking abnormal;Thirst;Throat sore;Throat tightness;Thrombocytopenia;Thrombophlebitis;Tingling sensation;Tinnitus;Tongue disorder;Tongue oedema;Transient cerebral ischemia;Transient ischaemic attack;Tremor;Ulcer;Unintended pregnancy;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Uterine disorder;Uterine fibroids enlarged;Uterine leiomyoma;Vaginal infection;Vaginal inflammation;Vasodilation;Vasodilation procedure;Vasospasm;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vomiting;Weight increased;Yawning,small molecule,approved; investigational,"(S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one; Zolmitriptan; Zolmitriptán; Zolmitriptanum; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1F; 5-hydroxytryptamine receptor 1E; 5-hydroxytryptamine receptor 7; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B,N02CC03
zolpidem,Insomnia;Primary insomnia,Abdominal discomfort;Abdominal pain;Abdominal tenderness;Abnormal behaviour;Abnormal dreams;Abnormal vision;Abscess;Accommodation disorder;Acute coronary syndrome;Affect lability;Aggression;Aggressive reaction;Agitation;Alanine aminotransferase increased;Alertness decreased;Allergy aggravated;Altered state of consciousness;Altered visual depth perception;Amnesia;Anaemia;Anaemia macrocytic;Anaphylactic shock;Anaphylactoid reaction;Anger;Angina pectoris;Angioedema;Anorectal discomfort;Anorexia;Anterograde amnesia;Anxiety;Apathy;Aphasia;Appetite disorder;Arrhythmia;Arteritis;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthenopia;Ataxia;Back pain;Balance disorder;Binge eating;Bladder pain;Blood alkaline phosphatase increased;Blood pressure increased;Blood urea increased;Body temperature increased;Breast disorder;Breast neoplasm;Breast pain;Bronchitis;Bronchospasm;Bullous eruption;Burning sensation;Cardiac disorder;Cerebration impaired;Cerebrovascular disorder;Chest discomfort;Chest pain;Chills;Chronic insomnia;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Conversion disorder;Cough;Cramp muscle;Cramps of lower extremities;Cystitis;Cystitis noninfective;Decreased appetite;Delusion;Dementia;Dental caries;Depersonalisation;Depressed level of consciousness;Depressed mood;Depression;Depression aggravated;Dermatitis;Dermatitis bullous;Diarrhoea;Diplopia;Discomfort;Disinhibition;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dizziness postural;Drowsiness;Drug interaction;Drug tolerance;Drug withdrawal syndrome;Dry mouth;Dry throat;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dysphasia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Enteritis;Epistaxis;Erectile dysfunction;Eructation;Erythema;Euphoric mood;Exposure to poisonous plant;Exposure to toxic agent;Extrasystoles;Eye disorder;Eye irritation;Eye pain;Eye redness;Face oedema;Fatigue;Feeling abnormal;Feeling strange;Fibroadenoma of breast;Fibroadenosis of breast;Flat affect;Flatulence;Flushing;Frequent bowel movements;Furuncle;Furunculosis;Gait disturbance;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Glaucoma;Gout;Haemoglobinaemia;Haemorrhoids;Hallucination;Headache;Hepatic enzyme increased;Herpes simplex;Herpes zoster;Hiccups;Hot flush;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhemoglobinemia;Hyperhidrosis;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertension worsened;Hypoaesthesia;Hypokinesia;Hypotension;Hypotonia;Hysteria;Ill-defined disorder;Illusion;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Influenza-like symptoms;Injection site inflammation;Injury;Insomnia;Insomnia exacerbated;Intestinal obstruction;Irritability;Labyrinthitis;Lacrimal disorder;Lacrimation abnormal NOS;Laryngitis;Lethargy;Leukopenia;Libido decreased;Libido disorder;Lightheadedness;Loss of consciousness;Lower respiratory tract infection;Lymphadenopathy;Major depression;Malaise;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Memory impairment;Menopausal symptoms;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Migraine;Mood swings;Mouth irritation;Muscle contractions involuntary;Muscle relaxant therapy;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nasopharyngitis;Nausea;Neck injury;Neck pain;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neurosis;Nightmare;Nocturia;Ocular hyperaemia;Oedema;Oesophageal spasm;Orthostatic hypotension;Osteoarthritis;Otitis externa;Otitis media;Pain;Pallor;Palpitations;Panic attack;Paraesthesia;Paresis;Parosmia;Perceptual disturbance;Periorbital oedema;Personality disorder;Pharmacokinetic interaction;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photopsia;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Proctalgia;Pruritus;Psychiatric symptom;Psychomotor retardation;Pulmonary embolism;Pulmonary function test decreased;Pulmonary oedema;Purpura;Pyelonephritis;Rage;Rash;Rectal haemorrhage;Rectal tenesmus;Red blood cell sedimentation rate increased;Renal failure acute;Renal pain;Respiratory depression;Restless legs syndrome;Rhinitis;Rigors;Saliva altered;Salivary hypersecretion;Sciatica;Scleritis;Shock;Sinusitis;Skin disorder;Skin wrinkling;Sleep disorder;Somnambulism;Somnolence;Speech disorder;Stomatitis;Stress;Stress symptoms;Stupor;Suicide attempt;Sweating increased;Syncope;Tachycardia;Tendonitis;Tension;Tetany;Thinking abnormal;Thirst;Throat irritation;Thrombosis;Tinnitus;Trauma;Tremor;Ulcerative keratitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Varicose vein;Vascular purpura;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal dryness;Weight decreased;Withdrawal symptom;Yawning,small molecule,approved,"N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide; Zolpidem; Zolpidemum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit gamma-3; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit gamma-2,N05CF02
zonisamide,Epilepsy;Partial seizures;Sudden unexplained death in epilepsy,Abdominal pain;Abnormal dreams;Accidental injury;Acute psychosis;Affect lability;Aggression;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anger;Anhidrosis;Anorexia;Anxiety;Aplastic anaemia;Apnoea;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrial fibrillation;Bladder pain;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood disorder;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Bradycardia;Bradyphrenia;CNS depression NOS;Calculus bladder;Cardiac failure;Cerebrovascular accident;Chest pain;Cholangitis;Cholecystitis;Cholecystitis acute;Cholecystitis and cholelithiasis;Cholelithiasis;Circumoral paresthesia;Cognitive disorder;Cognitive impairment;Colitis;Coma;Confusional state;Congenital anomaly;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cramps of lower extremities;Creatine phosphokinase increased;Deafness;Decreased appetite;Dehydration;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Developmental delay;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug eruption;Drug reaction with eosinophilia and systemic symptoms;Drug-induced hypersensitivity syndrome;Dry mouth;Dry skin;Duodenitis;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ecchymosis;Eczema;Encephalopathy;Enuresis;Eosinophilia;Erectile dysfunction;Erythema multiforme;Euphoric mood;Eye disorder;Face oedema;Facial paralysis;Faecal incontinence;Fatigue;Feeling abnormal;Flank pain;Flatulence;Gait disturbance;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gingival bleeding;Gingival hyperplasia;Gingivitis;Glaucoma;Glossitis;Grand mal convulsion;Gynaecomastia;Haematemesis;Haematuria;Haemoptysis;Hallucination;Headache;Heat stroke;Hepatobiliary disease;Hepatocellular injury;Hirsutism;Hydronephrosis;Hyperaesthesia;Hyperhidrosis;Hyperkinesia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertonia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hypotension;Hypotonia;Ill-defined disorder;Immune system disorder;Immunodeficiency;Infection;Influenza;Influenza like illness;Injury;Insomnia;Iritis;Irritability;Jaundice cholestatic;Lactic dehydrogenase activity increased;Leukocytosis;Leukopenia;Libido decreased;Liver function test abnormal;Liver injury;Loss of consciousness;Lupus erythematosus;Lymphadenopathy;Malaise;Malnutrition;Mastitis;Mediastinal disorder;Melaena;Memory impairment;Menorrhagia;Mental disorder;Metabolic acidosis;Microcytic anaemia;Micturition urgency;Mood swings;Mouth ulceration;Movement disorder;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Myasthenic syndrome;Myoclonus;Nausea;Neck stiffness;Nephrolithiasis;Nervous system disorder;Nervousness;Neuritis;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Nocturia;Nuchal rigidity;Nystagmus;Oculogyric crisis;Oedema;Oedema peripheral;Oesophagitis;Osteoarthritis;Palpitations;Pancreatitis;Pancreatitis acute;Pancytopenia;Paraesthesia;Paraesthesia oral;Parosmia;Peptic ulcer;Petechiae;Pharyngitis;Photophobia;Pneumonia;Pneumonia aspiration;Pollakiuria;Polyuria;Pruritus;Psychotic disorder;Pulmonary embolism;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Renal failure;Renal tubular acidosis;Rhabdomyolysis;Rhinitis;Road traffic accident;Scotoma;Shock;Skin disorder;Somnolence;Speech and language abnormalities;Speech disorder;Speech impairment NOS;Status epilepticus;Stevens-Johnson syndrome;Stomatitis;Suicidal ideation;Suicide attempt;Sweating;Syncope;Systemic lupus erythematosus;Tachycardia;Tension;Thirst;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tonic-clonic seizures;Toxic epidermal necrolysis;Tremor;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;VIIth nerve paralysis;Vascular insufficiency;Ventricular extrasystoles;Vertigo;Vesiculobullous rash;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"1,2-Benzisoxazole-3-methanesulfonamide; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; Benzo[d]isoxazol-3-yl-methanesulfonamide; Zonisamida; Zonisamide; Zonisamidum; NAC1; SCN1; Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1; HBA; HBSC II; NAC2; SCN2A1; SCN2A2; Sodium channel protein brain II subunit alpha; Sodium channel protein type II subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.2; KIAA1356; NAC3; Sodium channel protein brain III subunit alpha; Sodium channel protein type III subunit alpha; Voltage-gated sodium channel subtype III; Voltage-gated sodium channel subunit alpha Nav1.3; SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; hNE-Na; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Sodium channel protein type IX subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.7; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; KIAA1158; Cav3.1c; KIAA1123; NBR13; Voltage-gated calcium channel subunit alpha Cav3.1; Low-voltage-activated calcium channel alpha1 3.2 subunit; Voltage-gated calcium channel subunit alpha Cav3.2; Ca(v)3.3; KIAA1120; Voltage-gated calcium channel subunit alpha Cav3.3; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-III; Carbonate dehydratase III; Carbonic anhydrase III; 4.2.1.1; CA-IV; Carbonate dehydratase IV; Carbonic anhydrase IV; 4.2.1.1; CA-VA; CA5; Carbonate dehydratase VA; Carbonic anhydrase VA; 4.2.1.1; CA-VB; Carbonate dehydratase VB; Carbonic anhydrase VB; 4.2.1.1; CA-VI; Carbonate dehydratase VI; Carbonic anhydrase VI; Salivary carbonic anhydrase; Secreted carbonic anhydrase; 4.2.1.1; CA-VII; Carbonate dehydratase VII; Carbonic anhydrase VII; CA-VIII; CALS; Carbonic anhydrase VIII; CARP; 4.2.1.1; CA-IX; CAIX; Carbonate dehydratase IX; Carbonic anhydrase IX; G250; Membrane antigen MN; MN; P54/58N; pMW1; RCC-associated antigen G250; Renal cell carcinoma-associated antigen G250; CA-RP X; Carbonic anhydrase-related protein X; CARP X; Cerebral protein 15; CA-RP II; CA-RP XI; CA-XI; Carbonic anhydrase-related protein 2; CARP XI; CARP-2; CARP2; 4.2.1.1; CA-XII; Carbonate dehydratase XII; Carbonic anhydrase XII; Tumor antigen HOM-RCC-3.1.3; 4.2.1.1; CA-XIII; Carbonate dehydratase XIII; Carbonic anhydrase XIII; 4.2.1.1; CA-XIV; Carbonate dehydratase XIV; Carbonic anhydrase XIV; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","Sodium channel protein type 1 subunit alpha; Sodium channel protein type 2 subunit alpha; Sodium channel protein type 3 subunit alpha; Sodium channel protein type 4 subunit alpha; Sodium channel protein type 5 subunit alpha; Sodium channel protein type 9 subunit alpha; Sodium channel protein type 11 subunit alpha; Sodium channel regulatory subunit beta-1; Sodium channel regulatory subunit beta-2; Sodium channel regulatory subunit beta-3; Sodium channel regulatory subunit beta-4; Voltage-dependent T-type calcium channel subunit alpha-1G; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent T-type calcium channel subunit alpha-1I; Carbonic anhydrase 1; Carbonic anhydrase 2; Carbonic anhydrase 3; Carbonic anhydrase 4; Carbonic anhydrase 5A, mitochondrial; Carbonic anhydrase 5B, mitochondrial; Carbonic anhydrase 6; Carbonic anhydrase 7; Carbonic anhydrase-related protein; Carbonic anhydrase 9; Carbonic anhydrase-related protein 10; Carbonic anhydrase-related protein 11; Carbonic anhydrase 12; Carbonic anhydrase 13; Carbonic anhydrase 14; Amine oxidase [flavin-containing] B; Amine oxidase [flavin-containing] A; GABA(A) Receptor Benzodiazepine Binding Site", G01AE10;N03AX15
zopiclone,Chronic insomnia;Electroencephalogram abnormal;Insomnia;Mental disorder;Middle insomnia;Nocturnal awakening;Sleep disorder;Sleep disturbance;Wave slowing,Abdominal pain;Abnormal behaviour;Abnormal dreams;Accidental injury;Affect lability;Aggression;Agitation;Alcohol intoxication;Alcohol poisoning;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anger;Angioedema;Anorexia;Anterograde amnesia;Anxiety;Apathy;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Back pain;Behavior disorder;Bladder pain;Body temperature increased;Breast engorgement;Breast enlargement;Breast neoplasm;Breast pain;Breath odour;Bronchitis;Bursitis;Calculus of kidney;Cellulitis;Chest pain;Chills;Cholelithiasis;Colitis;Confusional state;Congenital anomaly;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cramp muscle;Cramps of lower extremities;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Delirium;Delusion;Depersonalisation;Depressed level of consciousness;Depression;Derealisation;Dermatitis;Dermatitis bullous;Dermatitis contact;Developmental delay;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug hypersensitivity;Drug intolerance;Drug withdrawal syndrome;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dysmenorrhoea;Dysosmia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Eczema;Ejaculation failure;Epistaxis;Erectile dysfunction;Erythema multiforme;Euphoric mood;Face oedema;Fatigue;Feeling abnormal;Flat affect;Furuncle;Furunculosis;Gait disturbance;Galactorrhoea;Gastric ulcer;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gout;Gynaecomastia;Haematuria;Hallucination;Headache;Heartburn;Heat stroke;Hepatitis;Hepatocellular injury;Hepatomegaly;Hernia;Herpes zoster;Hiccups;Hirsutism;Hostility;Hyperacusis;Hyperaesthesia;Hypercholesterolaemia;Hyperhidrosis;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypokalaemia;Hypokinesia;Hyporeflexia;Hypotonia;Ill-defined disorder;Illusion;Increased appetite;Infection;Influenza;Injury;Insomnia;Iritis;Irritability;Laboratory test abnormal;Lactation female;Laryngitis;Libido decreased;Libido disorder;Lightheadedness;Liver injury;Lymphadenopathy;Malaise;Mastitis;Melaena;Memory impairment;Memory loss;Menorrhagia;Mental disability;Metrorrhagia;Migraine;Mood swings;Mouth ulceration;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Mydriasis;Myopathy;Nausea;Neck stiffness;Nephrolithiasis;Nervousness;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neurosis;Nightmare;Nuchal rigidity;Numbness;Nystagmus;Oedema peripheral;Oliguria;Osteoarthritis;Otitis externa;Otitis media;Pain;Palpitations;Panic attack;Paraesthesia;Parosmia;Pharyngitis;Photophobia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Pregnancy;Prolonged menses;Pruritus;Pyelonephritis;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Renal pain;Respiratory tract infection;Retrograde amnesia;Rhinitis;Salivary hypersecretion;Sedation;Sensory loss;Sickness;Skin discolouration;Somnambulism;Somnolence;Speech disorder;Stiffness;Stomatitis;Stupor;Suicidal ideation;Sweating;Swelling;Tachycardia;Taste bitter;Taste metallic;Tension;Thinking abnormal;Thirst;Thrombophlebitis;Tingling of extremity;Tingling sensation;Tinnitus;Tongue coated;Tongue disorder;Tongue oedema;Tremor;Ulcerative stomatitis;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary tract infection;Urticaria;Uterine haemorrhage;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vertigo;Vesiculobullous rash;Vestibular disorder;Viral infection;Vision blurred;Vomiting;Weight decreased;Weight increased;Withdrawal symptom;Withdrawal syndrome,small molecule,approved,"(+-)-zopiclone; (±)-zopiclone; 6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylate; Zopiclona; Zopiclone; Zopiclonum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; BZRP; MBR; Mitochondrial benzodiazepine receptor; PBR; Peripheral-type benzodiazepine receptor; PKBS; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1",Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit alpha-5; Translocator protein,N05CF01
mitomycin,Disseminated adenocarcinoma;Metastatic neoplasm;Neoplasm malignant,Acute respiratory distress syndrome;Alopecia;Anaemia;Anorexia;Aspiration;Asthenia;Bladder fibrosis;Body temperature increased;Bone marrow toxicity;Burning sensation;Cardiac failure congestive;Cardiotoxicity;Confusional state;Cough;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry cough;Dyspnoea;Erythema;Extravasation;Fatigue;Feeling abnormal;Fraction of inspired oxygen;Function kidney decreased;Haematemesis;Haemolytic uraemic syndrome;Headache;Hypertension;Ill-defined disorder;Injection site cellulitis;Injection site reaction;Irreversible renal failure;Leukopenia;Loss of consciousness;Lung infiltration;Malaise;Metastatic disease;Metastatic neoplasm;Microangiopathic haemolytic anaemia;Myelosuppression;Nausea;Necrosis;Nephropathy toxic;Oedema;Pain;Pancytopenia;Pulmonary oedema;Pulmonary toxicity;Rash;Renal failure;Renal failure chronic;Renal impairment;Shock;Somnolence;Stinging;Stomatitis;Syncope;Thrombocytopenia;Thrombophlebitis;Ulcer;Vision blurred;Vomiting,small molecule,approved,7-Amino-9alpha-methoxymitosane; Ametycine; Mitamycin; Mitocin-C; Mitomycin; Mitomycin C; Mitomycin-C; MMC; 1.6.2.4; CPR; CYPOR; P450R,DNA,L01DC03
oxytocin,Abortion missed;Cardiovascular disorder;Gestational diabetes;Gestational hypertension;Haemoglobin;Haemorrhage;Imminent abortion;Inevitable abortion;Postpartum haemorrhage;Pre-eclampsia;Pregnancy;Uterine atony;Uterine contractions;Uterine contractions during pregnancy;Uterine hypotonus,Acute pulmonary oedema;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Apgar score low;Arrhythmia;Asphyxia;Blood and lymphatic system disorders;Bradycardia;Brain injury;Cardiac disorder;Coma;Convulsion;Convulsion neonatal;Dermatitis;Disseminated intravascular coagulation;Dyspnoea;Effusion;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Factor I deficiency;Fluid overload;Flushing;Foetal death;Foetal distress syndrome;Gastrointestinal disorder;Headache;Hypersensitivity;Hypertension;Hypertensive episode;Hypertonia;Hypertonicity;Hyponatraemia;Hypotension;Immune system disorder;Jaundice neonatal;Malnutrition;Mediastinal disorder;Muscle spasms;Myocardial ischaemia;Nausea;Neonatal hyponatraemia;Nervous system disorder;Pelvic haematoma;Rash;Reflex tachycardia;Retinal haemorrhage;Shock;Skin disorder;Subarachnoid haemorrhage;Tachycardia;Unspecified disorder of skin and subcutaneous tissue;Ventricular extrasystoles;Vomiting;Water intoxication,biotech,approved; vet_approved,Oxitocina; Oxytocin; OT-R; Antidiuretic hormone receptor 1b; AVPR V1b; AVPR V3; AVPR3; V1bR; Vasopressin V3 receptor; VPR3; ADHR; Antidiuretic hormone receptor; AVPR V2; DIR; DIR3; Renal-type arginine vasopressin receptor; V2R; Antidiuretic hormone receptor 1a; AVPR V1a; AVPR1; V1aR; Vascular/hepatic-type arginine vasopressin receptor; 3.4.21.26; PE; PEP; Post-proline cleaving enzyme; 3.4.11.3; Cystinyl aminopeptidase; Insulin-regulated membrane aminopeptidase; Insulin-responsive aminopeptidase; IRAP; OTASE; Oxytocinase; P-LAP; Placental leucine aminopeptidase; OT; OT-NPI; RAGE; Receptor for advanced glycosylation end products,Oxytocin receptor; Vasopressin V1b receptor; Vasopressin V2 receptor; Vasopressin V1a receptor, H01BB02;G02AC01;H01BB02
phentolamine,Extravasation;Hypertension;Hypertensive episode;Necrosis;Phaeochromocytoma,Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Angina pectoris;Angiopathy;Arrhythmia;Asthenia;Blood pressure increased;Bradycardia;Cardiac disorder;Chest pain;Diarrhoea;Dizziness;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hypertension;Hypotension;Hypotensive;Injection site pain;Injection site reaction;Mediastinal disorder;Myocardial infarction;Nasal congestion;Nausea;Nervous system disorder;Oral pain;Orthostatic hypotension;Pain;Pain in jaw;Paraesthesia;Peptic ulcer;Post procedural pain;Procedural pain;Pruritus;Swelling face;Tachycardia;Tenderness;Vomiting,small molecule,approved,"2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline; 3-((4,5-DIHYDRO-1H-IMIDAZOL-2-YLMETHYL)(4-METHYLPHENYL)AMINO)PHENOL; Fentolamina; Phentolamin; Phentolamine; Phentolaminum; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; Dopamine D2 receptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; IKATP; Inward rectifier K(+) channel Kir6.2; Potassium channel, inwardly rectifying subfamily J member 11",Alpha-1 adrenergic receptors; D(2) dopamine receptor; Alpha-2 adrenergic receptors; ATP-sensitive inward rectifier potassium channel 11, C04AB01;C04AB01;V03AB36
oxandrolone,Bone pain,Acne;Androgenetic alopecia;Azoospermia;Blood creatinine increased;Bronchial hyperreactivity;COPD exacerbation;Chronic obstructive pulmonary disease;Creatinine increased;Enlarged clitoris;Epididymitis;Erectile dysfunction;Fluid retention;Glucose tolerance decreased;Gynaecomastia;Haemoglobin;Haemorrhage;Hepatic necrosis;Hirsutism;Insomnia;Irritability;Jaundice cholestatic;Menstruation irregular;Necrosis;Neoplasm;Oedema;Oligospermia;Peliosis hepatis;Priapism;Testicular atrophy;Virilism,small molecule,approved; investigational,Ossandrolone; Oxandrolon; Oxandrolona; Oxandrolone; Oxandrolonum; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase,Androgen receptor,A14AA08
vincristine,Acute leukaemia;Acute lymphocytic leukaemia;Breast cancer;Cervix carcinoma;Ewing's sarcoma;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hypersensitivity;Idiopathic thrombocytopenic purpura;Leukaemia;Lymphoma;Malignant melanoma;Mycosis fungoides;Neoplasm;Nephroblastoma;Neuroblastoma;Non-Hodgkin's lymphoma;Osteosarcoma;Peroneal muscular atrophy;Purpura;Rhabdomyosarcoma;Small cell carcinoma;Small cell lung cancer,Abdominal colic;Abdominal cramps;Abdominal pain;Acute abdomen;Acute coronary syndrome;Adrenal disorder;Agitation;Alopecia;Altered state of consciousness;Anaemia;Anaphylactic shock;Angiopathy;Anorexia;Aspartate aminotransferase increased;Asthenia;Ataxia;Atonic urinary bladder;Azotaemia;Back pain;Blindness;Blindness cortical;Blood and lymphatic system disorders;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bone pain;Brain infarction;Cardiac arrest;Cardiac disorder;Cerebral haemorrhage;Cerebral infarction;Colonic pseudo-obstruction;Coma;Complete hearing loss;Connective tissue disorder;Consciousness abnormal;Constipation;Convulsion;Coronary artery disease;Cranial nerve paralysis;Deafness;Decreased appetite;Decreased vibratory sense;Dehydration;Depression;Dermatitis;Diarrhoea;Dizziness;Drug interaction;Dysuria;Erectile dysfunction;Extravasation;Facial paralysis;Fatal outcomes;Fatigue;Febrile neutropenia;Footdrop;Gait disturbance;Gastrointestinal disorder;Gastrointestinal necrosis;Gastrointestinal pain;Hallucination;Headache;Hepatic failure;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperuricaemia;Hypoaesthesia;Hyponatraemia;Hyporeflexia;Hypotension;Ileus;Ileus paralytic;Inappropriate antidiuretic hormone secretion;Infection;Insomnia;Intestinal necrosis;Intestinal obstruction;Leukaemia;Leukopenia;Mediastinal disorder;Menorrhagia;Mental disorder;Mental status changes;Mouth ulceration;Multi-organ failure;Muscle atrophy;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myelosuppression;Myocardial infarction;Myoclonus;Nausea;Nervous system disorder;Neuritis;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Numbness;Nystagmus;Oedema;Optic atrophy;Pain;Pain in extremity;Pain in jaw;Pancytopenia;Paraesthesia;Paralysis;Paresis;Peripheral motor neuropathy;Peroneal nerve palsy;Photosensitivity reaction;Pneumonia;Polyuria;Prolonged menses;Pulmonary haemorrhage;Rash;Respiratory distress;Respiratory failure;Sensory loss;Septic shock;Staphylococcal bacteraemia;Stomatitis;Sudden cardiac death;Sweating;Thrombocytopenia;Tumour lysis syndrome;Urate nephropathy;Urethral disorder;Urinary retention;Urinary tract disorder;Urine output increased;Urine sodium increased;VIIth nerve paralysis;Venoocclusive liver disease;Vertigo;Vocal cord paralysis;Vomiting;Walking disability;Weight decreased,small molecule,approved; investigational,"22-Oxovincaleukoblastin; 22-Oxovincaleukoblastine; Leurocristine; Vincristin; Vincristina; Vincristine; Vincristinum; TUBB5; Tubulin beta-5 chain; 3.6.5.-; Alpha-tubulin 1; Testis-specific alpha-tubulin; TUBA1; Tubulin alpha-1 chain; Tubulin H2-alpha; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 76 kDa Ral-interacting protein; Dinitrophenyl S-glutathione ATPase; DNP-SG ATPase; Ral-interacting protein 1; RalBP1; RLIP; RLIP1; RLIP76; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Tubulin beta chain; Tubulin alpha-4A chain,L01CA02
tetrabenazine,Ballismus;Chorea;Dyskinesia;Hemiballismus;Huntington's disease;Movement disorder;Tardive dyskinesia,Abdominal pain upper;Agitation;Akathisia;Angiopathy;Anxiety;Anxiety aggravated;Asthenia;Ataxia;Autonomic dysfunction;Autonomic nervous system imbalance;Balance difficulty;Balance disorder;Blood disorder;Body temperature decreased;Body temperature increased;Bradycardia;Bradykinesia;Breast disorder;Bronchitis;Cardiac disorder;Confusional state;Constipation;Decreased appetite;Depression;Diarrhoea;Disorientation;Dizziness;Drooling;Drowsiness;Dry mouth;Dysarthria;Dysphagia;Dyspnoea;Dysuria;Ecchymosis;Epigastric pain;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Fatigue;Feeling abnormal;Gait disturbance;Headache;Hyperhidrosis;Hypotension;Hypotensive;Hypothermia;Insomnia;Irritability;Laceration;Leukopenia;Memory impairment;Menstruation irregular;Mental disorder;Muscle damage;Muscle injury;Muscle rigidity;Nausea;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Obsessional neurosis;Obsessive-compulsive disorder;Oculogyric crisis;Orthostatic hypotension;Osteoarthritis;Parkinsonism;Photophobia;Skin disorder;Sleep disorder;Somnolence;Sweating;Tension;Trembling;Tremor;Unspecified disorder of skin and subcutaneous tissue;Unsteady gait;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Vomiting,small molecule,approved; investigational,"1,2,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 2-oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine; Tetrabenazina; Tetrabenazine; Tetrabenazinum; Solute carrier family 18 member 2; SVMT; VAT2; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT2; Dopamine D2 receptor; 1.1.1.184; 15-hydroxyprostaglandin dehydrogenase [NADP(+)]; 20-beta-hydroxysteroid dehydrogenase; Alcohol dehydrogenase [NAD(P)+] CBR1; CBR; CRN; NADPH-dependent carbonyl reductase 1; PG-9-KR; Prostaglandin 9-ketoreductase; Prostaglandin-E(2) 9-reductase; SDR21C1; Short chain dehydrogenase/reductase family 21C member 1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Synaptic vesicular amine transporter; D(2) dopamine receptor,N07XX06
cysteamine,Cystinosis;Renal failure,Abdominal pain;Affect lability;Agitation;Anaemia;Anaphylactic shock;Anorexia;Appetite absent;Asthenia;Ataxia;Benign intracranial hypertension;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Body temperature increased;Bone disorder;Bone lesion;Breath odour;Cerebral ischaemia;Compression fracture;Confusional state;Connective tissue disorder;Constipation;Convulsion;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Diffuse large B-cell lymphoma;Discomfort;Dizziness;Duodenitis;Dyspepsia;Encephalopathy;Erythema;Eye pain;Fatigue;Feeling abnormal;Feeling jittery;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal ulcer;Gastrointestinal ulcer haemorrhage;Genu valgum;Glomerulonephritis membranous;Hair colour changes;Hallucination;Headache;Hepatic function abnormal;Hyperkinesia;Hypersensitivity;Hypertension;Immune system disorder;Intravascular large B-cell lymphoma;Joint hyperextension;Knee deformity;Leg pain;Lethargy;Leukopenia;Liver function test abnormal;Malnutrition;Mass;Mental disability;Mental disorder;Mood swings;Nausea;Nephritis interstitial;Nephrotic syndrome;Nervous system disorder;Nervousness;Nightmare;Optic neuritis;Osteopenia;Pain in extremity;Papilloedema;Phosphatase alkaline increased;Pseudotumor;Rash;Redness;Renal failure;Scoliosis;Scotoma;Skin disorder;Skin fragility;Skin odour abnormal;Skin striae;Somnolence;Tension;Thinking abnormal;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine odour abnormal;Urticaria;Vomiting,small molecule,approved; investigational,2-amino-1-ethanethiol; 2-amino-ethanethiol; 2-aminoethanethiol; beta-aminoethanethiol; beta-Mercaptoethylamine; Cysteamine; MEA; Mercaptamina; Mercaptamine; Mercaptaminum; Thioethanolamine; β-aminoethylthiol; β-MEA; Growth hormone release-inhibiting factor; NPY-Y2 receptor; NPY2-R; Y2 receptor; 1.11.2.2; MPO,Somatostatin; Cystine; Neuropeptide Y receptor type 2, S01XA21;A16AA04
calcium,Hyperphosphataemia;Renal failure chronic,Anorexia;Calcinosis;Coma;Confusional state;Constipation;Decreased appetite;Delirium;Depressed level of consciousness;Feeling abnormal;Hypercalcaemia;Hypersensitivity;Nausea;Pruritus;Stupor;Vomiting,small molecule,nutraceutical,"Calcio; Calcium, elemental; Elemental calcium; Kalzium; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; 7.2.2.10; ATP-dependent Ca(2+) pump PMR1; ATPase 2C1; Ca(2+)/Mn(2+)-ATPase 2C1; KIAA1347; PMR1L; Secretory pathway Ca(2+)-transporting ATPase type 1; SPCA1; TN-C; TNNC; Beta-II spectrin; Fodrin beta chain; Spectrin, non-erythroid beta chain 1; SPTB2; S-100 protein beta chain; S-100 protein subunit beta; S100 calcium-binding protein B; Calpain inhibitor; Sperm BS-17 component; COMP; Thrombospondin-5; TSP5; 1.4.3.22; ABP; ABP1; Amiloride-binding protein; Amiloride-binding protein 1; Amine oxidase copper domain-containing protein 1; DAO; Diamine oxidase; Histaminase; KAO; KDAO; Kidney amine oxidase; S100 calcium-binding protein A13; 3.1.3.1; Alkaline phosphatase Regan isozyme; Placental alkaline phosphatase 1; PLAP; PLAP-1; CAGA; Calgranulin-A; Calprotectin L1L subunit; CFAG; Cystic fibrosis antigen; Leukocyte L1 complex light chain; Migration inhibitory factor-related protein 8; MRP-8; MRP8; p8; S100 calcium-binding protein A8; Urinary stone protein band A; CAGB; Calgranulin-B; Calprotectin L1H subunit; CFAG; Leukocyte L1 complex heavy chain; Migration inhibitory factor-related protein 14; MRP-14; MRP14; p14; S100 calcium-binding protein A9; CAN19; Protein S-100L; S100 calcium-binding protein A2; S100L; Cuproxidase ceruloplasmin; Ferroxidase ceruloplasmin; Glutathione peroxidase ceruloplasmin; Glutathione-dependent peroxiredoxin ceruloplasmin; BMP-2B; BMP-4; BMP2B; Bone morphogenetic protein 2B; DVR4; Cell growth-inhibiting gene 36 protein; MGLAP; MGP; KIAA1313; ALG-2; ALG2; Apoptosis-linked gene 2 protein homolog; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII","Voltage-dependent L-type calcium channel subunit alpha-1C; Calcium-transporting ATPase type 2C member 1; Troponin C, skeletal muscle; Troponin C, slow skeletal and cardiac muscles; Spectrin beta chain, non-erythrocytic 1; Protein S100-B; Calpastatin; Cartilage oligomeric matrix protein; Diamine oxidase [copper-containing]; Protein S100-A13; Alkaline phosphatase, placental type; Protein S100-A8; Protein S100-A9; Protein S100-A2; Ceruloplasmin; Bone morphogenetic protein 4; Matrix Gla protein; Protocadherin-19; Programmed cell death protein 6; Calmodulin", A11AA02; A11GB01; M05BB02; M05BB04; M05BB05; M05BB08;M05BB01
trifluorothymidine,Herpes simplex;Hypersensitivity;Keratitis;Keratoconjunctivitis;Ocular toxicity,Corneal oedema;Corneal stromal edema;Dry eye;Eyelid oedema;Hyperaemia;Hypersensitivity;Intraocular pressure increased;Keratitis sicca;Keratopathy;Nausea;Pain;Punctate keratitis;Stinging;Superficial punctate keratopathy;Vision blurred,small molecule,experimental,6.1.1.10; Methionyl-tRNA synthetase; MetRS; 3.4.11.18; MAP; Peptidase M,Methionine--tRNA ligase; Methionine aminopeptidase,S01AD02
triamcinolone,Adrenogenital syndrome;Allergic conditions;Alopecia areata;Ankylosing spondylitis;Aplasia pure red cell;Arthritis;Asthma;Berylliosis;Blood disorder;Brain cancer metastatic;Brain oedema;Bursitis;Colitis;Colitis ulcerative;Congenital adrenal hyperplasia;Congenital aplastic anaemia;Connective tissue disorder;Cutaneous lupus erythematosus;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatomyositis;Diamond-Blackfan anemia;Discoid lupus erythematosus;Diuresis;Drug hypersensitivity;Eczema;Eczema nummular;Edema cerebral;Endocrine disorder;Enteritis ulcerative;Eosinophilic pneumonia;Epicondylitis;Erythema multiforme;Erythema multiforme severe;Gastrointestinal disorder;Gout;Gouty arthritis;Granuloma annulare;Haemolytic anaemia;Head injury;Hypercalcaemia;Hypersensitivity;Inflammatory bowel disease;Injury;Juvenile idiopathic arthritis;Keloid scar;Leukaemia;Lichen planus;Lichen simplex chronicus;Lupus erythematosus;Lymphoma;Meningitis tuberculous;Menorrhagia;Metastases to central nervous system;Multiple sclerosis;Mycosis fungoides;Necrobiosis lipoidica diabeticorum;Neoplasm;Neoplasm malignant;Nephropathy;Nephrotic syndrome;Nephrotic syndrome with lesion of minimal change glomerulonephritis;Neurodermatitis;Non-Hodgkin's lymphoma;Osteoarthritis;Otitis externa;Pemphigus;Perennial allergic rhinitis;Polymyositis;Polyuria;Prolonged menses;Protein urine present;Proteinuria;Pruritus vulvae;Psoriasis;Psoriatic arthropathy;Pulmonary tuberculosis;Rheumatic heart disease;Rheumatoid arthritis;Rhinitis allergic;Rhinitis perennial;Rhinitis seasonal;Sarcoidosis;Seasonal allergy;Seborrhoeic dermatitis;Secondary adrenocortical insufficiency;Secondary thrombocytopenia;Serum sickness;Skin disorder;Stevens-Johnson syndrome;Sympathetic ophthalmia;Synovitis;Systemic lupus erythematosus;Temporal arteritis;Tenosynovitis;Thrombocytopenia;Thyroiditis;Transfusion reaction;Trauma;Trichiniasis;Ulcer;Uveitis;Vulvovaginal pruritus,Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal sensation in eye;Abscess;Ache;Acne;Acneiform eruption;Acute coronary syndrome;Adrenocortical insufficiency acute;Affect lability;Alkalosis hypokalaemic;Allergic conditions;Allergic contact dermatitis;Anaphylactic shock;Anaphylactoid reaction;Angiitis necrotising;Angioedema;Anorexia;Anterior chamber flare;Anxiety;Arachnoiditis;Arrhythmia;Arthropathy;Aseptic necrosis;Asthenia;Asthma;Atrophy;Back pain;Benign intracranial hypertension;Bladder dysfunction;Bladder pain;Blindness;Blindness cortical;Blister;Blood cholesterol increased;Blood cortisol decreased;Blood potassium decreased;Blood triglycerides increased;Body temperature increased;Bradycardia;Breast feeding;Bronchitis;Bursitis;Calcinosis;Candida albicans infection;Candida infection;Carbohydrate tolerance decreased;Cardiac arrest;Cardiac failure congestive;Cardiomegaly;Cataract;Cataract cortical;Cataract nuclear;Cataract subcapsular;Cerebrovascular accident;Cleft palate;Cognitive disorder;Cognitive impairment;Conjunctival haemorrhage;Conjunctivitis;Contusion;Convulsion;Cough;Cough increased;Cushingoid;Cystitis;Cystitis noninfective;Decreased appetite;Dependence psychological;Dermatitis;Dermatitis acneiform;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis infected;Dermatitis perioral;Detachment of retinal pigment epithelium;Diabetes mellitus;Diabetic;Diarrhoea;Diplegia;Discomfort;Dizziness;Drug dependence;Drug withdrawal syndrome;Dry mouth;Dry scalp;Dry skin;Dry throat;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphonia;Dyspnoea;Ear infection;Ecchymosis;Eczema;Embolism;Embolism venous;Endophthalmitis;Epistaxis;Eruption;Erythema;Erythema facial;Euphoric mood;Excoriation;Exophthalmos;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Face oedema;Fat embolism;Fatigue;Feeling abnormal;Fluid retention;Folliculitis;Foreign body sensation in eyes;Fracture;Fungal infection;Gastrointestinal pain;Gastrointestinal tract irritation;Glaucoma;Glucose tolerance impaired;Glycosuria;Granuloma;Growth retardation;Haemoglobin;Haemorrhage;Headache;Hepatomegaly;Hiccups;High cholesterol;Hirsutism;Hoarseness;Hydrocephalus;Hyperadrenocorticism;Hyperglycaemia;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hypertrichosis;Hypertriglyceridaemia;Hypertrophic cardiomyopathy;Hypokalaemia;Hypokinesia;Hypopyon;Hypotension;Ill-defined disorder;Impaired healing;Increased appetite;Increased insulin requirement;Increased tendency to bruise;Infection;Inflammation;Influenza;Injection site haemorrhage;Injection site irritation;Injection site reaction;Injury;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Irritability;Itch burning;Lacrimation increased;Laryngeal pain;Lethargy;Leukocytosis;Leukoderma;Localized exfoliation;Loss of consciousness;Lupus erythematosus;Malaise;Meningitis;Menstruation irregular;Mental disorder;Miliaria;Monoplegia;Mood swings;Multiple fractures;Muscle mass;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial rupture;Myopathy;Nasal burning;Nasal congestion;Nasal discomfort;Nasal irritation;Nasal septum perforation;Nasopharyngitis;Nausea;Nerve injury;Neuritis;Neuropathy;Neuropathy peripheral;Nitrogen balance negative;Oedema;Oesophageal candidiasis;Oesophagitis;Oesophagitis ulcerative;Opportunistic infection;Optic disc vascular disorder;Optic neuritis;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Osteonecrosis;Osteoporosis;Otitis;Otitis media;Pain;Pancreatitis;Panophthalmitis;Papilloedema;Paraesthesia;Paraparesis;Paraplegia;Peptic ulcer;Personality change;Petechiae;Pharyngitis;Pharyngolaryngeal pain;Photosensitivity;Photosensitivity reaction;Posterior subcapsular cataract;Potassium deficiency;Pruritus;Psychotic disorder;Pulmonary congestion;Pulmonary oedema;Purpura;Pyoderma;Quadriplegia;Rash;Respiratory tract congestion;Rhinitis;Rhinitis perennial;Rhinorrhoea;Rosacea;Secondary adrenocortical insufficiency;Secondary infection;Shock;Sinus congestion;Sinusitis;Skin atrophy;Skin exfoliation;Skin hyperpigmentation;Skin scaly;Skin striae;Sneezing;Spinal compression fracture;Spinal cord infarction;Steroid myopathy;Steroid withdrawal syndrome;Stinging;Suicidal ideation;Sweating increased;Syncope;Systemic lupus erythematosus;Tachycardia;Telangiectasia;Tendon rupture;Tenosynovitis;Teratogenicity;Throat sore;Thromboembolism;Thrombophlebitis;Tooth disorder;Toothache;Trauma;Tuberculosis;Ulcer;Urinary tract infection;Urticaria;Vascular purpura;Vasculitis;Vasculitis necrotising;Vertigo;Vision blurred;Visual acuity reduced;Vitreous detachment;Vitreous floaters;Vomiting;Weight decreased;Weight increased;Wheezing;Withdrawal symptom,small molecule,approved; vet_approved,"11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione; 9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9α-fluoro-16α-hydroxyprednisolone; Fluoxyprednisolone; Tiamcinolonum; Triamcinolona; Triamcinolone; Triamcinolonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; CBG; Serpin A6; Transcortin",Glucocorticoid receptor, A01AC01; C05AA12; D07BB03; D07CB01; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05; S02CA04;D07AB09
methsuximide,Convulsion;Petit mal epilepsy,"Abdominal pain;Aggression;Anorexia;Ataxia;Confusional state;Constipation;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Drowsiness;Eosinophilia;Erythema multiforme;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Haematuria;Hallucination, auditory;Headache;Hiccups;Hyperaemia;Insomnia;Irritability;Leukopenia;Microscopic hematuria;Monocytosis;Nausea;Nervousness;Pancytopenia;Periorbital oedema;Photophobia;Protein urine present;Proteinuria;Psychotic disorder;Rash;Somnolence;Stevens-Johnson syndrome;Suicidal behaviour;Tension;Urticaria;Vision blurred;Vomiting;Weight decreased",small molecule,approved,"(RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion; 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine; 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione; 1,3-Dimethyl-3-phenylsuccinimide; alpha-Methyl-alpha-phenyl N-methyl succinimide; alpha-Methylphensuximide; Mesuximida; Mesuximide; Mesuximidum; Methsuximid; Methsuximide; Metosuccimmide; N-methyl-alpha-methyl-alpha-phenylsuccinimide; N,2-Dimethyl-2-phenylsuccinimide; Cav3.1c; KIAA1123; NBR13; Voltage-gated calcium channel subunit alpha Cav3.1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Voltage-dependent T-type calcium channel subunit alpha-1G,N03AD03
cyclizine,Breast cancer;Malaise;Meniere's disease;Motion sickness;Nausea;Postoperative vomiting;Procedural vomiting;Regurgitation;Sickness;Vertigo;Vomiting,"Agitation;Agranulocytosis;Altered state of consciousness;Anaphylactic shock;Angioedema;Apnoea;Asthenia;Auditory and visual hallucinations;Blister;Bronchospasm;Chills;Chorea;Connective tissue disorder;Constipation;Convulsion;Depressed level of consciousness;Dermatitis bullous;Disorientation;Dizziness;Drowsiness;Drug eruption;Dyskinesia;Erythema;Eye disorder;Fixed drug eruption;Hallucinations, mixed;Headache;Hepatic function abnormal;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hypersensitivity;Hypertension;Hypotension;Injection site reaction;Insomnia;Jaundice cholestatic;Mental disorder;Muscle spasms;Muscle twitching;Nervous system disorder;Nervousness;Oculogyric crisis;Pain;Paraesthesia;Pruritus;Sensation of heaviness;Skin disorder;Somnolence;Speech disorder;Tachycardia;Tension;Thrombophlebitis;Tremor;Urinary retention;Urticaria;Vision blurred",small molecule,approved,"(±)-1-diphenylmethyl-4-methylpiperazine; (N-Benzhydryl)(N'-methyl)diethylenediamine; 1-(Diphenylmethyl)-4-methylpiperazine; 1-Benzhydryl-4-methylpiperazin; Ciclizina; Cyclizine; Cyclizinum; N-Benzhydryl-N'-methylpiperazine; N-methyl-N'-benzhydrylpiperazine; H1-R; H1R; HH1R; 2.8.2.4; EST-1; Estrogen sulfotransferase; ST1E1; STE; Sulfotransferase, estrogen-preferring; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Histamine H1 receptor; Sulfotransferase 1E1, R06AE53;R06AE03
phenylbutyric,Amino acid metabolism disorder;Argininosuccinate synthetase deficiency;Carbamoyl phosphate synthetase deficiency;Cognitive disorder;Cognitive impairment;Disorders of urea cycle metabolism;Hyperammonaemia;Hyperammonaemic encephalopathy;Immobile;Mental deterioration;Mental disability;Mental retardation;Neoplasm malignant;Nervous system disorder;Neurological impairment;Ornithine transcarbamoylase deficiency;Pregnancy,Abdominal pain;Acidosis;Alkalosis;Amenorrhoea;Anaemia;Aplastic anaemia;Arrhythmia;Asthenia;Bad taste;Blood alkaline phosphatase increased;Blood uric acid increased;Body odor;Constipation;Deafness;Decreased appetite;Dermatitis;Disorientation;Dizziness;Dysgeusia;Ecchymosis;Fatigue;Frequent headaches;Gastritis;Gastrointestinal pain;Headache;Hearing impaired;Hyperbilirubinaemia;Hyperchloraemia;Hypernatraemia;Hyperphosphataemia;Hyperuricaemia;Hypoalbuminaemia;Hypokalaemia;Hypophosphataemia;Leukocytosis;Leukopenia;Lightheadedness;Loss of consciousness;Memory impairment;Menstruation irregular;Nausea;Neuropathy;Neuropathy peripheral;Neurotoxicity;Oedema;Pancreatitis;Peptic ulcer;Phosphatase alkaline increased;Protein total decreased;Rash;Rectal haemorrhage;Renal tubular acidosis;Road traffic accident;Shock;Skin odour abnormal;Somnolence;Syncope;Thrombocytopenia;Thrombocytosis;Vomiting;Weight increased,small molecule,approved; investigational,4-Phenyl-n-butyric acid; 4-phenylbutyrate; 4-phenylbutyric acid; Benzenebutyric acid; PBA; Phenylbutyrate; γ-Phenyl-n-butyric acid; γ-phenylbutyric acid; ω-Phenylbutanoic acid; ω-phenylbutyric acid; 3.5.1.98; HD1; Protein deacetylase HDAC1; Protein deacylase HDAC1; RPD3L1; 2.7.11.13; PKC-A; PKC-alpha; PKCA; PRKACA; 2.6.1.57; ARAT; 3.5.1.98; HD1; Protein deacetylase HDAC1; Protein deacylase HDAC1; RPD3L1; 3.5.1.98; HD11; 3.5.1.98; HD2; Protein deacylase HDAC2; 3.5.1.98; HD3; Protein deacetylase HDAC3; Protein deacylase HDAC3; RPD3-2; SMAP45; 3.5.1.98; HD4; KIAA0288; 3.5.1.98; Antigen NY-CO-9; HD5; KIAA0600; 3.5.1.98; HD6; KIAA0901; Protein deacetylase HDAC6; Tubulin-lysine deacetylase HDAC6; 3.5.1.98; HD7; HD7a; HDAC7A; Histone deacetylase 7A; Protein deacetylase HDAC7; 3.5.1.98; HD8; HDACL1; Protein deacetylase HDAC8; Protein decrotonylase HDAC8; 3.5.1.98; HD7; HD7b; HD9; HDAC7; HDAC7B; HDRP; Histone deacetylase 7B; Histone deacetylase-related protein; KIAA0744; MEF2-interacting transcription repressor MITR; MITR; 3.5.1.48; 3.5.1.62; HD10; Histone deacetylase 10,Histone deacetylase 1; Protein kinase C alpha type; Aromatic-amino-acid aminotransferase; Histone deacetylase, A16AX03;N07XX19
diethylpropion,Anorexia;Decreased appetite;Diabetes mellitus;Hyperlipidaemia;Hypertension;Obesity;Weight decreased,Abdominal discomfort;Agitation;Agranulocytosis;Alopecia;Anxiety;Arrhythmia;Blood pressure increased;Bone marrow depression;Cardiac valve disease;Cerebrovascular accident;Chest pain;Constipation;Convulsion;Convulsive disorder;Dermatitis;Diarrhoea;Digestion impaired;Discomfort;Dizziness;Drowsiness;Dry mouth;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphoria;Dyspnoea;Dysuria;Ecchymosis;Electrocardiogram change;Emotional distress;Epilepsy;Erectile dysfunction;Erythema;Euphoric mood;Feeling abnormal;Feeling jittery;Gastrointestinal disorder;Gynaecomastia;Headache;Hyperhidrosis;Ill-defined disorder;Insomnia;Leukopenia;Malaise;Musculoskeletal discomfort;Myalgia;Mydriasis;Nausea;Nervousness;Palpitations;Pancytopenia;Polyuria;Precordial pain;Primary pulmonary hypertension;Psychotic disorder;Psychotic episode;Pulmonary arterial hypertension;Pulmonary hypertension;Rash;Somnolence;Sweating increased;Tachycardia;Tension;Tremor;Urine output increased;Urticaria;Vision blurred;Vomiting,small molecule,approved; illicit,(±)-diethylpropion; 1-phenyl-2-diethylamino-1-propanone; 2-(diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)propiophenone; alpha-Benzoyltriethylamine; alpha-Diethylaminopropiophenone; Amfepramone; Amfépramone; Amfepramonum; Anfepramona; Diethylcathinone; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; DA transporter; DAT; DAT1; Solute carrier family 6 member 3,Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; Sodium-dependent dopamine transporter,A08AA03
monobenzone,Cafe au lait spots;Chloasma;Dermatitis;Leukoderma;Malignant melanoma;Melanocytic naevus;Skin hyperpigmentation;Vitiligo,Burning sensation;Sensitisation;Skin irritation,small molecule,approved,4-(Benzyloxy)phenol; 4-(Benzyloxyl)phenol; 4-(Phenylmethoxy)phenol; 4-Benzyloxy-phenol; 4-Benzyloxyphenol; Benzyl p-hydroxyphenyl ether; Hydrochinon monobenzylether; Hydroquinone benzyl ether; Hydroquinone monobenzyl ether; Monobenzona; Monobenzone; Monobenzonum; Monobenzyl hydroquinone; p-(Benzyloxy)phenol; p-Hydroxyphenyl benzyl ether; 1.14.18.1; LB24-AB; Monophenol monooxygenase; SK29-AB; Tumor rejection antigen AB,Tyrosinase,D11AX13
benzonatate,Cough;Intoxication;Poisoning,"Abdominal discomfort;Agitation;Bronchospasm;CNS depression NOS;Clonic convulsion;Confusional state;Constipation;Convulsion;Depressed level of consciousness;Dizziness;Eruption;Feeling abnormal;Gastrointestinal tract irritation;Hallucination, visual;Headache;Hypersensitivity;Hypoaesthesia;Laryngospasm;Nasal congestion;Nausea;Numbness;Pruritus;Rash;Sensory loss;Shock;Tremor",small molecule,approved,"2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate; 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl p-(butylamino)benzoate; 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate; 4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; Benzonatat; Benzonatate; Benzonatato; Benzonatatum; Benzononatine; nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; p-butylaminobenzoic acid ω-O-methylnonaethyleneglycol ester; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase",Sodium channel protein type 5 subunit alpha,R05DB01
argenine,Abdominal distension;Diabetes insipidus,Abdominal cramps;Abdominal pain;Anaphylactic shock;Angina pectoris;Arrhythmia;Bronchoconstriction;Bronchospasm;Cardiac arrest;Cardiac output decreased;Gangrene;Hyperhidrosis;Hypersensitivity;Myocardial ischaemia;Nausea;Pallor;Shock;Sweating;Tremor;Urticaria;Vasoconstriction;Vasoconstriction peripheral;Vertigo;Vomiting,small molecule,investigational; nutraceutical,"(2S)-2-amino-5-(carbamimidamido)pentanoic acid; (2S)-2-amino-5-guanidinopentanoic acid; (S)-2-amino-5-guanidinopentanoic acid; (S)-2-Amino-5-guanidinovaleric acid; Arg; Arginina; Arginine; L-(+)-Arginine; L-Arg; L-Arginin; L-arginine; R; ATRC3; CAT-3; CAT3; Cationic amino acid transporter y+; Solute carrier family 7 member 3; ADC; ARGDC; Arginine decarboxylase; AzI2; KIAA1945; ODC-like protein; ODC-p; ODCP; ornithine decarboxylase paralog; Ornithine decarboxylase-like protein; 4.3.2.1; Arginosuccinase; ASAL; 1.14.13.39; HEP-NOS; Hepatocyte NOS; Inducible NO synthase; Inducible NOS; iNOS; NOS type II; NOS2A; Peptidyl-cysteine S-nitrosylase NOS2; ATRC1; CAT-1; CAT1; Ecotropic retroviral leukemia receptor homolog; Ecotropic retrovirus receptor homolog; ERR; REC1L; Solute carrier family 7 member 1; System Y+ basic amino acid transporter; 3.5.3.1; Arginase II; Kidney-type arginase; Non-hepatic arginase; Type II arginase; CAT-4; CAT4; Solute carrier family 7 member 4; 6.3.4.5; ASS; Citrulline--aspartate ligase; 1.14.13.39; cNOS; Constitutive NOS; EC-NOS; Endothelial NOS; eNOS; Nitric oxide synthase, endothelial; NOS type III; NOSIII; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Aromatic amino acid transporter 1; MCT 10; MCT10; Solute carrier family 16 member 10; T-type amino acid transporter 1; TAT1; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H","Cationic amino acid transporter 3; Antizyme inhibitor 2; Argininosuccinate lyase; Nitric oxide synthase, inducible; High affinity cationic amino acid transporter 1; Arginase-2, mitochondrial; Cationic amino acid transporter 4; Argininosuccinate synthase; Nitric oxide synthase 3", B05XB01;H01BA06;V03AF11
nafcillin,Hepatic failure;Hepatic insufficiency;Infection;Staphylococcal infection,Abdominal discomfort;Abdominal pain;Agranulocytosis;Anaphylactic shock;Angioedema;Arthralgia;Aspartate aminotransferase increased;Body temperature increased;Bone marrow depression;Bronchospasm;Dermatitis;Diarrhoea;Discomfort;Eosinophilia;Extravasation;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal tract irritation;Haematuria;Hepatotoxicity;Hypersensitivity;Hypotension;Ill-defined disorder;Inflammation;Laryngeal oedema;Laryngospasm;Liver function test abnormal;Local reaction;Malaise;Musculoskeletal discomfort;Myalgia;Nausea;Necrosis;Nephritis interstitial;Nephropathy;Neutropenia;Pain;Pancytopenia;Phlebitis;Protein urine present;Proteinuria;Pruritus;Pseudomembranous colitis;Rash;Reaction gastrointestinal;Renal failure;Renal impairment;Sensitisation;Serum sickness;Shock;Skin exfoliation;Skin necrosis;Stomatitis;Swelling;Thrombophlebitis;Tongue discolouration;Tongue hairy;Tubulointerstitial nephritis;Urticaria;Vomiting,small molecule,approved; investigational,"(2-ethoxy-1-naphthalenyl)penicillin; (2-ethoxy-1-naphthyl)penicillin; (2S,5R,6R)-6-[(2-ethoxy-1-naphthoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; Nafcilina; Nafcillin; Nafcilline; Nafcillinum; Naphcillin; pbp2b; Putative D-alanyl-D-alanine carboxypeptidase; exp2; Exported protein 2; PBP-1A; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",Penicillin-binding protein 1b; Penicillin-binding protein 2B; Penicillin-binding protein 2a; Penicillin-binding protein 3; Penicillin-binding protein 1A, J01CF06;J01CR50
aminophylline,Asthma;Asthma chronic;Bronchial hyperreactivity;Bronchitis chronic;Bronchospasm;Cardiac failure congestive;Cerebral vasoconstriction;Chronic obstructive pulmonary disease;Cor pulmonale;Diuresis;Dyspnoea;Emphysema;Foetor hepaticus;Hepatocellular injury;Left ventricular failure;Liver disorder;Lung disorder;Nervous system disorder;Polyuria;Pulmonary oedema;Vascular resistance systemic,Abdominal cramps;Abdominal pain;Abdominal pain upper;Acute overdose;Agitation;Albuminuria;Anorexia;Anxiety;Arrhythmia;Atrial fibrillation;Atrial tachycardia;Body temperature increased;Bronchial hyperreactivity;Cardiac flutter;Chronic obstructive pulmonary disease;Convulsion;Decreased appetite;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Disorientation;Diuresis;Dizziness;Dyspepsia;Epigastric pain;Excitement;Extrasystoles;Flushing;Gastrointestinal pain;Haematemesis;Haemodynamic instability;Headache;Heartburn;Hyperglycaemia;Hypersensitivity;Hypokalaemia;Hypotension;Insomnia;Intoxication;Irritability;Lightheadedness;Multifocal atrial tachycardia;Nausea;Nervousness;Overdose;Palpitations;Persistent vomiting;Poisoning;Polyuria;Rash;Rhabdomyolysis;Shock;Sinus tachycardia;Skin exfoliation;Skin necrosis;Supraventricular tachycardia;Tachycardia;Tachypnoea;Tension;Tremor;Tremor muscle;Urticaria;Ventricular arrhythmia;Ventricular extrasystoles;Vomiting,small molecule,approved,"Aminofilina; Aminophyllin; Aminophylline; Aminophyllinum; Theophyline ethylenediamine; Theophylline ethylenediamine; 3.1.4.17; cGI-PDE; CGI-PDE A; cGMP-inhibited cAMP phosphodiesterase; Cyclic GMP-inhibited phosphodiesterase A; 3.5.1.98; HD2; Protein deacylase HDAC2; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase","cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A; Adenosine receptor A1; Adenosine receptor A3; Histone deacetylase 2", R03DA05; R03DA20; R03DB05;R03DA05;R03DA55
nandrolone,Anaemia;Renal failure;Renal impairment,Acne;Alopecia;Azoospermia;Diarrhoea;Disturbance in sexual arousal;Drug interaction;Enlarged clitoris;Epididymitis;Erectile dysfunction;Glucose tolerance decreased;Gynaecomastia;Haemoglobin;Haemorrhage;Hirsutism;Insomnia;Irritability;Libido decreased;Menstruation irregular;Nausea;Neoplasm;Oedema;Oligospermia;Peliosis hepatis;Priapism;Testicular atrophy;Vomiting,small molecule,experimental; investigational,(17β)-17-hydroxyestr-4-en-3-one; 19-norandrostenolone; 19-nortestosterone; Nandrolona; Nandrolone; Nandrolonum; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4,Androgen receptor, A14AB01;A14AB01;S01XA11
propoxyphene,Pain,Abdominal pain;Abnormal behaviour;Acute coronary syndrome;Arrhythmia;Asthenia;Ataxia;Bradycardia;Cardiac arrest;Cardiac disorder;Cardiac failure congestive;Cardio-respiratory arrest;Coma;Completed suicide;Confusional state;Constipation;Convulsion;Dermatitis;Diarrhoea;Dizziness;Drug ineffective;Drug interaction;Drug tolerance;Drug withdrawal syndrome;Dysphoria;Dyspnoea;Euphoric mood;Eye disorder;Eye swelling;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Hallucination;Headache;Hepatic function abnormal;Hepatic steatosis;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hip fracture;Hypersensitivity;Hypotension;Immune system disorder;Jaundice;Jaundice cholestatic;Lightheadedness;Liver function test abnormal;Liver injury;Loss of consciousness;Malnutrition;Mediastinal disorder;Metabolic acidosis;Myocardial infarction;Myopathy;Nausea;Nervous system disorder;Pancreatitis acute;Pulmonary function test decreased;Rash;Respiratory arrest;Respiratory depression;Shock;Somnolence;Syncope;Tachycardia;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,withdrawn,(-)-Propoxyphene; (l)-Propoxyphene; levopropoxifeno; Levopropoxyphene; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor,Mu-type opioid receptor,N02AC04
echothiophate,Accommodative component in esotropia;Angle closure glaucoma;Chronic angle-closure glaucoma;Chronic open angle glaucoma;Esotropia;Glaucoma;Open angle glaucoma;Primary open angle glaucoma;Strabismus,Cyst;Erythema;Iritis;Lacrimation;Lacrimation increased;Lenticular opacities;Muscle twitching;Myopia;Pain;Redness;Retinal detachment;Stinging;Uveitis;Vision blurred,small molecule,approved,"2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodide; Echothiophate; Ecothiopate; Ecothiopatum; Phospholine; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 3.1.1.7; AChE",Cholinesterase; Acetylcholinesterase,S01EB03
dimenhydrinate,Meniere's disease;Motion sickness;Nausea;Vertigo;Vomiting,Agitation;Anorexia;Decreased appetite;Dermatitis;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Dysuria;Epigastric distress;Fatigue;Headache;Insomnia;Lassitude;Nervousness;Rash;Somnolence;Tachycardia;Tension;Vision blurred,small molecule,approved,"(O-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate; 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1); Benzhydryl-β-dimethylaminoethylether 8-chlorotheophylline; Dimenhidrinato; Dimenhydrinate; Dimenhydrinatum; diphenhydramine 8-chlorotheophyllinate; diphenhydramine 8-chlorotheophylline; Diphenhydramine theoclate; N,N-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate; O-benzhydryldimethylaminoethanol 8-chlorotheophyllinate; β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine; H1-R; H1R; HH1R",Histamine H1 receptor, R06AA61;R06AA11
zuclopenthixol,Aggression;Agitation;Bipolar I disorder;Bipolar disorder;Chronic schizophrenia;Confusional state;Delusion;Disorientation;Feeling abnormal;Hallucination;Hostility;Mania;Mental disability;Mental retardation;Psychotic disorder;Schizophrenia;Senile dementia;Violence,"Abdominal pain;Abnormal dreams;Abnormal vision;Accommodation disorder;Agitation;Agranulocytosis;Akathisia;Alanine aminotransferase increased;Amenorrhoea;Amnesia;Anaphylactic shock;Angiopathy;Anorexia;Anxiety;Apathy;Arrhythmia;Asthenia;Ataxia;Blood and lymphatic system disorders;Blood bilirubin increased;Body temperature decreased;Body temperature increased;Breast disorder;Breast enlargement;Cardiac disorder;Coldness;Connective tissue disorder;Constipation;Convulsion;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dizziness postural;Drowsiness;Drug withdrawal syndrome;Drug withdrawal syndrome neonatal;Dry mouth;Dyskinesia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ejaculation failure;Electrocardiogram QT prolonged;Embolism venous;Endocrine disorder;Eosinophilia;Erectile dysfunction;Erythema;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Fatigue;Feeling abnormal;Feeling cold;Feeling hot;Female orgasmic disorder;Flat affect;Flatulence;Gait disturbance;Galactorrhoea;Gastrointestinal disorder;Gastrointestinal pain;Glaucoma;Glucose tolerance impaired;Glycosuria;Gynaecomastia;Haemolytic anaemia;Headache;Hepatitis cholestatic;Hepatobiliary disease;Hot flush;Hyperacusis;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hyperprolactinaemia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertonia;Hypokinesia;Hypotension;Hypothermia;Hypotonia;Ileus paralytic;Ill-defined disorder;Immune system disorder;Increased appetite;Injection site reaction;Insomnia;Jaundice;Lenticular opacities;Leukopenia;Libido decreased;Libido increased;Liver function test abnormal;Loss of consciousness;Malaise;Malnutrition;Menopausal symptoms;Menstrual disorder;Menstruation irregular;Mental disorder;Micturition disorder;Migraine;Miosis;Movements involuntary;Muscle relaxant therapy;Muscle rigidity;Musculoskeletal discomfort;Myalgia;Mydriasis;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Neutropenia;Nightmare;Oculogyration;Oculogyric crisis;Oedema peripheral;Opisthotonus;Pain;Palpitations;Pancytopenia;Paraesthesia;Parkinsonism;Photosensitivity reaction;Pigmentation disorder;Polyuria;Pregnancy;Pregnancy test false positive;Priapism;Protrusion tongue;Pruritus;Pseudoparkinsonism;Purpura;Purpura non-thrombocytopenic;Rash;Rhinorrhoea;Salivary hypersecretion;Seborrhoeic dermatitis;Shock;Skin discolouration;Skin disorder;Somnolence;Speech disorder;Strangury;Sudden death;Sudden death, cause unknown;Sweating;Sweating increased;Syncope;Tachycardia;Tardive dyskinesia;Tension;Thirst;Thrombocytopenia;Thyroid disorder;Tinnitus;Torsade de pointes;Torticollis;Tremor;Trismus;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urine output increased;Vascular purpura;Venous thromboembolism;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Visual impairment;Vomiting;Vulvovaginal dryness;Warmth;Weight decreased;Weight increased;Withdrawal symptom",small molecule,approved; investigational,"(Z)-4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol; Zuclopenthixol; Zuclopenthixolum; Zuclopentixol; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D2 receptor; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; H1-R; H1R; HH1R; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",D(1A) dopamine receptor; D(1B) dopamine receptor; D(2) dopamine receptor; Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; 5-hydroxytryptamine receptor 2A; Histamine H1 receptor,N05AF02;N05AF05
desonide,Dermatitis atopic;Skin disorder,Acneiform eruption;Allergic contact dermatitis;Application site atrophy;Application site burn;Application site erythema;Application site irritation;Application site pain;Application site pruritus;Application site rash;Application site reaction;Asthma;Atrophy;Blood pressure increased;Cough;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Erythema;Folliculitis;Headache;Hyperglycaemia;Hyperhidrosis;Induration;Infection;Infestation;Infestation NOS;Irritability;Leukoderma;Mediastinal disorder;Mental disorder;Miliaria;Nervous system disorder;Oedema peripheral;Pain;Pharyngitis;Pharyngitis streptococcal;Pruritus;Rash;Rash pustular;Secondary infection;Skin atrophy;Skin disorder;Skin exfoliation;Skin striae;Stinging;Sweating;Swelling face;Telangiectasia;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Viral infection,small molecule,approved; investigational,"11β,21-dihydroxy-16α,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11β,21-dihydroxy-16α,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11β,21-dihydroxy-16α,17α-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16α-hydroxyprednisole-16,17-acetonide; 16α-hydroxyprednisolone-16α,17-acetonide; 16α,17α-isopropylidenedioxyprednisolone; Desfluorotriamcinolone acetonide; Desonida; Desonide; Desonidum; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Steroid hormone receptor ERR1; Steroid hormone receptor ERR2; Estrogen-related receptor gamma; Glucocorticoid receptor, D07AB08; D07BB02;D07AB08;S01BA11
benzydamine,Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pharyngeal mucositis;Pharyngitis;Throat sore,Cough;Drowsiness;Headache;Hypoaesthesia;Nausea;Numbness;Pain;Sensory loss;Somnolence;Stinging;Thirst;Throat irritation;Vomiting,small molecule,approved,Bencidamina; Benzydamine; Benzydaminum; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2,Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2, G02CC03; M01AX07; M02AA05; R02AX03;A01AD02
erythromycin,Amoebiasis;Amoebic colitis;Cardiac valve disease;Conjunctivitis;Endocarditis;Endocarditis bacterial;Erythrasma;Gonorrhoea;Heart disease congenital;Infection;Legionella infection;Lower respiratory tract infection;Otitis media;Pelvic inflammatory disease;Pertussis;Pharyngitis;Pharyngitis streptococcal;Pneumonia;Pneumonia legionella;Primary syphilis;Renal failure;Renal impairment;Respiratory tract infection;Rheumatic disorder;Rheumatic fever;Soft tissue infection;Stress;Syphilis;Upper respiratory tract infection,Abdominal pain;Anaphylactic shock;Anorexia;Confusional state;Convulsion;Deafness;Decreased appetite;Diarrhoea;Electrocardiogram QT prolonged;Eruption;Erythema multiforme;Feeling abnormal;Gastrointestinal pain;Hallucination;Hearing impaired;Hepatic function abnormal;Hepatitis;Hepatitis symptom;Hypersensitivity;Liver function test abnormal;Nausea;Nephritis interstitial;Pancreatitis;Pseudomembranous colitis;Rash;Stevens-Johnson syndrome;Tinnitus;Torsade de pointes;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Urticaria;Ventricular arrhythmia;Ventricular tachycardia;Vertigo;Vomiting,small molecule,approved; investigational; vet_approved,"3''-O-demethylerythromycin; Abomacetin; Eritromicina; Erythromycin; Erythromycin A; Erythromycin C; érythromycine; Erythromycinum; G-protein coupled receptor 38; GPR38; MTLR; MTLR1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3",23S ribosomal RNA; Motilin receptor; Voltage-gated inwardly rectifying potassium channel KCNH2, D10AF02; D10AF52; S01AA17;J01FA01
Tadenan,Herpes labialis;Herpes simplex;Oral herpes;Pregnancy;Teratogenicity,Acne;Application site reaction;Dermatitis;Dry skin;Headache;Pruritus;Rash,small molecule,investigational,Tozadenant; ADORA2,Adenosine receptor A2a,D06BB11
lormetazepam,Distress;Drug abuse;Emotional distress;Insomnia;Mental disorder due to a general medical condition;Organic brain syndrome;Sleep disorder,Abdominal pain upper;Abnormal behaviour;Acute psychosis;Aggression;Agitation;Altered state of consciousness;Amnesia;Anger;Angioedema;Anterograde amnesia;Anxiety;Asthenia;Ataxia;Behavior disorder;Bradyphrenia;Cardiac disorder;Completed suicide;Confusional state;Constipation;Delusion;Dependence;Dependence physiological;Dependence psychological;Depersonalisation;Depressed level of consciousness;Depression;Derealisation;Dermatitis;Diplopia;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug dependence;Drug withdrawal syndrome;Dry mouth;Dysgeusia;Emotional disorder;Epilepsy;Fatigue;Feeling abnormal;Gastrointestinal disorder;Hallucination;Headache;Hyperacusis;Hyperhidrosis;Hypersensitivity;Immune system disorder;Irritability;Libido decreased;Mental disorder;Micturition disorder;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Nightmare;Paraesthesia;Pruritus;Psychotic disorder;Rage;Rash;Skin disorder;Somnolence;Speech disorder;Suicide;Suicide attempt;Tachycardia;Tension;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Visual impairment;Vomiting;Withdrawal symptom;Withdrawal syndrome,small molecule,approved,"(±)-Lormetazepam; (RS)-Lormetazepam; 7-Chloro-1,3-dihydro-5-(o-chlorophenyl)-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one; Lormetazepam; Methyllorazepam; N-Methyllorazepam; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3",GABA(A) Receptor; GABA(A) Receptor Benzodiazepine Binding Site,N05CD06
vinblastine,Breast cancer;Carcinoma;Carcinoma breast;Carcinoma testes;Choriocarcinoma;Germ cell cancer;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Kaposi's sarcoma;Langerhans' cell histiocytosis;Letterer-Siwe disease;Lymphoma;Mycosis fungoides;Neoplasm malignant;Non-Hodgkin's lymphoma;Testis cancer,Abdominal pain;Acute coronary syndrome;Agranulocytosis;Alopecia;Anaemia;Angina pectoris;Anorexia;Asthenia;Bone pain;Cellulitis;Cerebrovascular accident;Chronic peptic ulcer;Complete hearing loss;Constipation;Convulsion;Deafness;Decreased appetite;Depression;Diarrhoea;Discomfort;Dizziness;Enterocolitis haemorrhagic;Extravasation;Feeling abnormal;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Hypersensitivity;Hypertension;Hypoaesthesia;Ileus;Ileus paralytic;Ill-defined disorder;Inappropriate antidiuretic hormone secretion;Ischaemia;Leukopenia;Malaise;Myelosuppression;Myocardial infarction;Nausea;Neoplasm;Neuritis;Neuropathy peripheral;Numbness;Nystagmus;Pain;Pain in jaw;Pancytopenia;Paraesthesia;Peptic ulcer;Pharyngitis;Phlebitis;Photophobia;Rectal haemorrhage;Sensory loss;Thrombocytopenia;Vertigo;Vomiting,small molecule,approved,"Vinblastin; Vinblastina; Vinblastine; Vinblastinum; Vincaleukoblastine; TUBB2; Tubulin beta class IIa; 3.6.5.-; Alpha-tubulin 3; TUBA3; Tubulin alpha-3 chain; Tubulin B-alpha-1; TUBB5; Tubulin beta-5 chain; Delta-tubulin; TUBD; Gamma-1-tubulin; Gamma-tubulin complex component 1; GCP-1; TUBG; Epsilon-tubulin; TUBE; Activator protein 1; AP1; p39; Proto-oncogene c-Jun; Transcription factor AP-1 subunit Jun; V-jun avian sarcoma virus 17 oncogene homolog; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; 7.6.2.3; Anthracycline resistance-associated protein; ARA; MOAT-E; MRP6; Multi-specific organic anion transporter E; Multidrug resistance-associated protein 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Tubulin beta-2A chain; Tubulin alpha-1A chain; Tubulin beta chain; Tubulin delta chain; Tubulin gamma-1 chain; Tubulin epsilon chain; Transcription factor Jun,L01CA01
benzathine,Asthma;Bacteraemia;Chorea;Glomerulonephritis acute;Hypersensitivity;Infection;Pharyngitis;Pinta;Rheumatic disorder;Rheumatic fever;Rheumatic heart disease;Rhinitis seasonal;Seasonal allergy;Streptococcal infection;Syphilis;Urticaria;Yaws,"Abscess;Acute interstitial nephritis;Aggravation of existing disorder;Agitation;Allergic cutaneous angiitis;Anaphylactic shock;Anaphylactoid reaction;Anxiety;Apnoea;Arthralgia;Arthritis;Arthropathy;Asthenia;Atrophy;Auditory and visual hallucinations;Blindness;Blood in stool;Blood urea increased;Body temperature increased;Cardiac arrest;Cellulitis;Cerebrovascular accident;Chills;Coma;Condition aggravated;Confusional state;Convulsion;Cyanosis;Dermatitis exfoliative;Dizziness;Dyspnoea;Ecchymosis;Eosinophilia;Erectile dysfunction;Eruption;Euphoric mood;Fatigue;Feeling abnormal;Feeling hot;Gangrene;Gastrointestinal necrosis;Haematochezia;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucinations, mixed;Headache;Hoigne's syndrome;Hyperhidrosis;Hypoaesthesia;Hypotension;Hypoxia;Inflammation;Injection site reaction;Intestinal necrosis;Jarisch-Herxheimer reaction;Laryngeal oedema;Leukocytoclastic vasculitis;Leukopenia;Loss of consciousness;Lymphadenopathy;Mass;Musculoskeletal discomfort;Myelitis transverse;Myoglobin urine present;Myoglobinuria;Nausea;Necrosis;Nephropathy;Nervousness;Neurogenic bladder;Neuropathy;Neuropathy peripheral;Numbness of limbs;Oedema;Osteoarthritis;Pain;Pallor;Palpitations;Periostitis;Priapism;Prostration;Protein urine present;Proteinuria;Pruritus;Pseudomembranous colitis;Psychotic disorder;Pulmonary embolism;Pulmonary hypertension;Rash;Renal failure;Rhabdomyolysis;Serum sickness;Shock;Skin ulcer;Somnolence;Sweating increased;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Tremor;Tubulointerstitial nephritis;Vasodilation;Vasodilation procedure;Vasospasm;Vision blurred;Vomiting;Warmth",small molecule,approved,"3-alpha-(diphenylmethoxy)tropane; 3endo-benzhydryloxytropane; 3α-(diphenylmethoxy)-1αH,5αH-tropane; 3α-(diphenylmethoxy)tropane; 3α-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; Benzatropina; Benzatropine; Benzatropinum; benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether; Benztropine; Tropine benzohydryl ether; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; H1-R; H1R; HH1R; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2",Muscarinic acetylcholine receptor M1; Sodium-dependent dopamine transporter; Histamine H1 receptor; Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter,J01CE08;N04AC01
amiloride,Arrhythmia;Ascites;Atrioventricular block;Atrioventricular block complete;Block heart;Blood potassium decreased;Blood sodium increased;Cardiac failure congestive;Digitalis intoxication (NOS);Diuresis;Electrolyte imbalance;Essential hypertension;Foetor hepaticus;Hepatic cirrhosis;Hepatocellular injury;Hypertension;Hypokalaemia;Irritability;Liver disorder;Metabolic alkalosis;Oedema;Polyuria;Potassium low;Sodium high;Toxicity to various agents;Weight decreased,Abdominal distension;Abdominal pain;Alopecia;Angina pectoris;Anorexia;Aplastic anaemia;Arthralgia;Asthenia;Back pain;Blood potassium increased;Blood uric acid increased;Bradycardia;Chest pain;Coma;Confusional state;Constipation;Cough;Cramp muscle;Decreased appetite;Depression;Dermatitis;Diarrhoea;Digestion impaired;Disturbance in sexual arousal;Diuresis;Dizziness;Dyspepsia;Dyspnoea;Dysuria;Encephalopathy;Erectile dysfunction;Fatigability;Fatigue;Feeling abnormal;Flatulence;Foetor hepaticus;Fullness abdominal;Gas pain;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gynaecomastia;Haemoglobin;Haemorrhage;Headache;Heartburn;Hepatic encephalopathy;Hepatic function abnormal;Hepatocellular injury;Hyperkalaemia;Hyperuricaemia;Hyponatraemia;Insomnia;Intraocular pressure increased;Jaundice;Libido decreased;Liver disorder;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Nasal congestion;Nausea;Neck pain;Nervousness;Neutropenia;Oral pruritus;Orthostatic hypotension;Pain;Pain in extremity;Palpitations;Paraesthesia;Paralysis flaccid;Peptic ulcer;Pollakiuria;Polyuria;Pruritus;Rash;Serum potassium increased;Shock;Somnolence;Tension;Thirst;Tinnitus;Tremor;Urine output increased;Vertigo;Visual disturbance;Visual impairment;Vomiting,small molecule,approved,"3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amilorid; Amilorida; Amiloride; Amiloridum; Amipramidin; Amipramidine; Amyloride; N-amidino-3,5-diamino-6-chloropyrazinecarboxamide; Alpha-ENaC; Alpha-NaCH; ENaCA; Epithelial Na(+) channel subunit alpha; Nonvoltage-gated sodium channel 1 subunit alpha; SCNEA; SCNN1; Beta-ENaC; Beta-NaCH; ENaCB; Epithelial Na(+) channel subunit beta; Nonvoltage-gated sodium channel 1 subunit beta; SCNEB; ENaCG; Epithelial Na(+) channel subunit gamma; Gamma-ENaC; Gamma-NaCH; Nonvoltage-gated sodium channel 1 subunit gamma; SCNEG; Delta-ENaC; Delta-NaCH; DNACH; ENaCD; Epithelial Na(+) channel subunit delta; Nonvoltage-gated sodium channel 1 subunit delta; SCNED; 1.4.3.22; ABP; ABP1; Amiloride-binding protein; Amiloride-binding protein 1; Amine oxidase copper domain-containing protein 1; DAO; Diamine oxidase; Histaminase; KAO; KDAO; Kidney amine oxidase; ACCN; ACCN1; Amiloride-sensitive brain sodium channel; Amiloride-sensitive cation channel 1, neuronal; Amiloride-sensitive cation channel neuronal 1; ASIC2; BNAC1; BNC1; Brain sodium channel 1; Mammalian degenerin homolog; MDEG; ACCN2; Amiloride-sensitive cation channel 2, neuronal; ASIC1; BNAC2; Brain sodium channel 2; APNH; APNH1; Na(+)/H(+) antiporter, amiloride-sensitive; Na(+)/H(+) exchanger 1; NHE-1; NHE1; Solute carrier family 9 member 1; 3.4.21.73; U-plasminogen activator; uPA; 1.4.3.22; ABP; ABP1; Amiloride-binding protein; Amiloride-binding protein 1; Amine oxidase copper domain-containing protein 1; DAO; Diamine oxidase; Histaminase; KAO; KDAO; Kidney amine oxidase; 1.4.3.22; ABP1; Amiloride-binding protein 1; Amine oxidase copper domain-containing protein 1; DAO; Histaminase; hOCT2; OCT2; Organic cation transporter 2; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H",Amiloride-sensitive sodium channel subunit alpha; Amiloride-sensitive sodium channel subunit beta; Amiloride-sensitive sodium channel subunit gamma; Amiloride-sensitive sodium channel subunit delta; Diamine oxidase [copper-containing]; Acid-sensing ion channel 2; Acid-sensing ion channel 1; Sodium/hydrogen exchanger 1; Urokinase-type plasminogen activator,C03DB01
pimozide,Agitation;Chronic schizophrenia;Excitement;Hyperkinesia;Schizophrenia;Sedation;Tourette's disorder,Abdominal discomfort;Abnormal behaviour;Abnormal dreams;Agitation;Agranulocytosis;Akathisia;Akinesia;Amenorrhoea;Anaemia;Anorexia;Aplastic anaemia;Asthenia;Blood disorder;Body temperature decreased;Bradykinesia;Breast disorder;Cardiac disorder;Cataract;Chest pain;Cogwheel rigidity;Connective tissue disorder;Constipation;Convulsion;Cramp muscle;Decreased appetite;Depression;Dermatitis;Diarrhoea;Distress gastrointestinal;Dizziness;Drowsiness;Dry mouth;Dyskinesia;Dysphagia;Electrocardiogram QT prolonged;Electrocardiogram U wave present;Electrocardiogram U-wave abnormality;Electrocardiogram abnormal;Electrocardiogram change;Electroencephalogram abnormal;Endocrine disorder;Eosinophilia;Erectile dysfunction;Eructation;Excitement;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Faecal incontinence;Galactorrhoea;Gastrointestinal disorder;Gingival hyperplasia;Grand mal convulsion;Gynaecomastia;Haemolytic anaemia;Headache;Hyperhidrosis;Hyperkinesia;Hyperprolactinaemia;Hyperpyrexia;Hyperreflexia;Hypertension;Hyponatraemia;Hypotension;Hypothermia;Increased appetite;Insomnia;Leukopenia;Loss of consciousness;Loss of libido;Menstrual disorder;Mental disorder;Motor restlessness;Movements involuntary;Muscle rigidity;Muscle spasms;Muscle tightness;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Neuroleptic malignant syndrome;Nocturia;Nuchal rigidity;Oculogyration;Oculogyric crisis;Opisthotonus;Orthostatic hypotension;Palpitations;Pancytopenia;Parkinsonism;Periorbital oedema;Pollakiuria;Protrusion tongue;Pruritus;Rash;Salivary hypersecretion;Schizophrenia;Shock;Skin disorder;Skin irritation;Somnolence;Speech disorder;Spots before eyes;Sweating;Syncope;Tachycardia;Tardive dyskinesia;Thrombocytopenic purpura;Tonic-clonic seizures;Torsade de pointes;Torticollis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urinary retention;Urticaria;Ventricular fibrillation;Ventricular tachycardia;Vermiculation;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved,"Pimozida; Pimozide; Pimozidum; Dopamine D2 receptor; Dopamine D3 receptor; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; CALM; CAM; CAM1; CAM2; CAMB; CALML2; CAM3; CAMC; CAMIII; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",D(2) dopamine receptor; D(3) dopamine receptor; Voltage-gated inwardly rectifying potassium channel KCNH2; Calmodulin,N05AG02
betamethasone,Dandruff;Dermatitis atopic;Dermatitis contact;Eczema infantile;Eczema nummular;Inflammation;Neurodermatitis;Psoriasis;Seborrhoeic dermatitis;Senile pruritus;Skin disorder;Solar dermatitis;Stasis dermatitis,Acneiform eruption;Allergic contact dermatitis;Cushing's syndrome;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Endocrine disorder;Erythema;Folliculitis;Hypersensitivity;Hypertrichosis;Immune system disorder;Infection;Leukoderma;Miliaria;Paraesthesia;Pruritus;Pustular psoriasis;Rash follicular;Secondary infection;Skin atrophy;Skin disorder;Skin striae;Telangiectasia;Tingling sensation;Unspecified disorder of skin and subcutaneous tissue,small molecule,approved; vet_approved,"16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione; 9-Fluoro-16β-methylprednisolone; 9α-Fluoro-16β-methylprednisolone; beta-Methasone alcohol; Betadexamethasone; Betametasona; Betamethasone; Bétaméthasone; Betamethasonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Glucocorticoid receptor, A07EA04; C05AA05; D07AC01; D07BC01; D07CC01; D07XC01; H02AB01; R03BA04; S01BA06; S01BB04; S01CA05; S01CB04; S02BA07; S03BA03; S03CA06;R01AD06
fluorescein,Injury corneal,Abdominal discomfort;Abdominal pain;Ache;Acute myocardial infarction;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angiopathy;Aphasia;Asthenia;Asthma;Basilar artery syndrome;Bradycardia;Bronchospasm;Cardiac arrest;Cardiac disorder;Cerebrovascular accident;Chest pain;Chills;Chromaturia;Cold sweat;Convulsion;Cough;Dermatitis;Diabetic retinopathy;Discomfort;Distress gastrointestinal;Dizziness;Dysgeusia;Dysphasia;Dyspnoea;Eczema;Erythema;Extravasation;Feeling abnormal;Feeling hot;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Hypoventilation;Hypoxia;Ill-defined disorder;Immune system disorder;Injection site thrombosis;Intermittent claudication;Laryngeal oedema;Loss of consciousness;Macular degeneration;Macular oedema;Malaise;Mediastinal disorder;Menopausal symptoms;Nasal congestion;Nasal oedema;Nausea;Neoplasm;Nervous system disorder;Obstruction;Oedema;Pain;Pallor;Paraesthesia;Peripheral vascular disorder;Pruritus;Pulmonary oedema;Rash;Respiratory arrest;Respiratory failure;Retching;Shock;Skin discolouration;Skin disorder;Sneezing;Syncope;Tachycardia;Throat tightness;Thrombophlebitis;Thrombophlebitis injection site;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urine color abnormal;Urticaria;Vasodilation;Vasodilation procedure;Vasospasm;Vertebrobasilar insufficiency;Vomiting,small molecule,approved,"3,6-fluorandiol; 3',6'-dihydroxyfluoran; 9-(o-carboxyphenyl)-6-hydroxy-3-isoxanthenone; 9-(o-carboxyphenyl)-6-hydroxy-3H-xanthen-3-one; C.I. Solvent Yellow 94; D and C Yellow No. 7; D&C Yellow No. 7; Fluorescein; Fluoresceina; Fluoresceína; Fluoresceine; Fluoreszein; Japan Yellow 201; Resorcinolphthalein; Solvent Yellow 94; Yellow fluorescein; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Ig kappa chain V-II region RPMI 6410; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1",Organic anion transporter 3; Immunoglobulin kappa variable 2-30; DNA, S01JA51;S01JA01
5-aza-2'-deoxycytidine,Acute leukaemia;Acute myeloid leukaemia;Chronic myelomonocytic leukaemia;Hepatic function abnormal;Myelodysplastic syndrome;Refractory anaemia with an excess of blasts;Refractory anemia;Refractory cytopenia with unilineage dysplasia,Abdominal distension;Abdominal pain;Abdominal pain upper;Abrasion NOS;Acute coronary syndrome;Acute febrile neutrophilic dermatosis;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Anorexia;Anxiety;Arthralgia;Ascites;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Back pain;Bacteraemia;Blood albumin decreased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bicarbonate decreased;Blood bicarbonate increased;Blood bilirubin decreased;Blood bilirubin increased;Blood chloride decreased;Blood disorder;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Bone pain;Breath sounds abnormal;Bronchitis;Bronchopulmonary aspergillosis;Candida infection;Cardiac disorder;Cardiac failure congestive;Cardiac murmur;Cardio-respiratory arrest;Cardiomyopathy;Catheter related infection;Catheter site erythema;Catheter site haemorrhage;Catheter site pain;Cellulitis;Central line infection;Cheilitis;Chest discomfort;Chest pain;Chest wall pain;Chills;Cholecystitis;Colonic abscess;Confusional state;Connective tissue disorder;Constipation;Contusion;Cough;Decreased appetite;Dehydration;Depression;Dermatitis;Device related infection;Diarrhoea;Discomfort;Dizziness;Drug hypersensitivity;Dry skin;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Ecchymosis;Epistaxis;Erythema;Excoriation;Eye disorder;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival bleeding;Gingival pain;Glossodynia;Haematoma;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhoids;Headache;Hepatobiliary disease;Hyperbilirubinaemia;Hyperglycaemia;Hyperkalaemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoalbuminaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypotension;Hypoxia;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Injection site swelling;Insomnia;Intermittent fever;Laryngeal pain;Lethargy;Leukopenia;Lip pain;Lip ulceration;Liver function test abnormal;Loose stools;Lung infection;Lung infiltration;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Mental status changes;Mouth haemorrhage;Mucosal inflammation;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Mycobacterium avium complex infection;Mycobacterium test;Myelosuppression;Myocardial infarction;Nasopharyngitis;Nausea;Neoplasm malignant;Nervous system disorder;Neutropenia;Night sweats;Oedema;Oedema peripheral;Oral candidiasis;Oral disorder;Oral herpes;Oral mucosal petechiae;Oral pain;Oral soft tissue disorder NOS;Pain;Pain in extremity;Pallor;Pancytopenia;Peridiverticular abscess;Petechiae;Pharyngitis;Pharyngolaryngeal pain;Pleural effusion;Pneumonia;Pollakiuria;Post procedural haemorrhage;Post procedural pain;Postnasal drip;Procedural pain;Protein total decreased;Pruritus;Pulmonary embolism;Pulmonary mass;Pulmonary oedema;Rales;Rash;Renal failure;Respiratory arrest;Respiratory sounds decreased;Respiratory tract infection;Rigors;Sepsis;Septic shock;Sinus congestion;Sinusitis;Skin disorder;Skin lesion;Splenomegaly;Staphylococcal bacteraemia;Staphylococcal infection;Stomatitis;Supraventricular tachycardia;Swelling face;Tachycardia;Tenderness;Thrombocytopenia;Thrombocytosis;Tongue ulceration;Tooth abscess;Toothache;Transfusion reaction;Unspecified disorder of skin and subcutaneous tissue;Upper gastrointestinal haemorrhage;Upper respiratory tract infection;Upper-airway cough syndrome;Urethral disorder;Urethral haemorrhage;Urinary tract disorder;Urinary tract infection;Urticaria;Vision blurred;Vomiting;Weight decreased,small molecule,experimental; investigational,"1-(2-deoxy-.beta.-d-ribofuranosyl)cytosine; 1-(2-Deoxy-β-D-ribofuranosyl)cytosine; 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-; 4-amino-1-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-2(1h)-pyrimidinone; 4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-2(1H)-pyrimidinone; CYTIDINE, 2'-DEOXY-; dC; dCYD; DEOXYCYTIDINE; Deoxyribose cytidine; Doxecitine; MT-1621 COMPONENT 2'-DEOXYCYTIDINE; 2.7.1.21; 2.7.1.21; 2'-deoxyuridine kinase TK2; Deoxycytidine kinase TK2; Mt-TK; 3.1.3.2; CBAP; napA; yjbP; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase","Thymidine kinase, cytosolic; Thymidine kinase 2, mitochondrial; Class B acid phosphatase; Deoxycytidine kinase",L01BC08
estramustine,Neoplasm malignant;Prostate cancer;Prostate carcinoma,Abdominal discomfort;Acute coronary syndrome;Affect lability;Alopecia;Anorexia;Anxiety;Burning in throat;Cardiac arrest;Cardiac failure congestive;Cerebrovascular accident;Chest pain;Congenital anomaly;Cramps of lower extremities;Decreased appetite;Depression;Dermatitis;Developmental delay;Diarrhoea;Disturbance in sexual arousal;Dry skin;Dysphonia;Dyspnoea;Embolism;Embolism venous;Erectile dysfunction;Eye pain;Flatulence;Flushing;Gastrointestinal haemorrhage;Gastrointestinal tract irritation;Glucose tolerance decreased;Gynaecomastia;Headache;Hoarseness;Hot flush;Hypercalcaemia;Hypernatraemia;Increased tendency to bruise;Insomnia;Lacrimation;Lacrimation increased;Lethargy;Leukopenia;Libido decreased;Liver function test abnormal;Menopausal symptoms;Mood swings;Muscle spasms;Myelosuppression;Myocardial infarction;Nausea;Night sweats;Oedema;Pancytopenia;Pruritus;Raised liver function tests;Rash;Skin exfoliation;Tenderness;Thirst;Throat irritation;Thrombocytopenia;Thromboembolism;Thrombophlebitis;Tinnitus;Vomiting,small molecule,approved; investigational,"17β-Estradiol 3-(bis(2-chloroethyl)carbamate); Estradiol 3-(N,N-bis(2-chloroethyl)carbamate); Estramustina; Estramustine; Estramustinum; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; MAP-2; MAP-1A; MAP1L; Proliferation-related protein p80; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Estrogen receptor beta; Estrogen receptor; Microtubule-associated protein 2; Microtubule-associated protein 1A,L01XX11
megestrol,Acquired immunodeficiency syndrome;Anorexia;Autoimmune disorder;Breast cancer;Cachexia;Carcinoma breast;Decreased appetite;Metastatic disease;Metastatic neoplasm;Underweight,Abdominal pain;Adrenal insufficiency;Affect lability;Albuminuria;Alopecia;Amblyopia;Anaemia;Asthenia;Bleeding breakthrough;Blood lactate dehydrogenase increased;Body temperature increased;Candida infection;Cardiac failure;Cardiomyopathy;Carpal tunnel syndrome;Chest pain;Confusional state;Constipation;Convulsion;Cough;Cushingoid;Deep vein thrombosis;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dry mouth;Dyspepsia;Dyspnoea;Embolism;Embolism venous;Erectile dysfunction;Feeling abnormal;Flatulence;Fluid retention;Gastrointestinal pain;Glucose tolerance impaired;Gynaecomastia;Headache;Hepatomegaly;Herpes NOS;Herpes virus infection;Hot flush;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Ill-defined disorder;Increased appetite;Infection;Insomnia;Lactic dehydrogenase activity increased;Lethargy;Leukopenia;Libido decreased;Lung disorder;Malaise;Menopausal symptoms;Mental disability;Metrorrhagia;Mood swings;Nausea;Neuropathy;Neuropathy peripheral;Oedema;Oedema peripheral;Oral candidiasis;Pain;Palpitations;Paraesthesia;Pharyngitis;Pneumonia;Pollakiuria;Pregnancy;Pruritus;Pulmonary embolism;Rash;Rash pustular;Salivary hypersecretion;Skin disorder;Sweating;Thinking abnormal;Thromboembolism;Thrombophlebitis;Tumour flare;Urinary incontinence;Urinary tract infection;Vesiculobullous rash;Vomiting;Weight increased,small molecule,approved,"17-hydroxy-6-methylpregna-4,6-diene-3,20-dione; Chronopil; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR",Progesterone receptor, G03AA04; G03AB01; G03AC05; G03DB02; G03FA08; L02AB01;G03AC05;G03FB04
choline,Alcohol abuse;Alcoholic liver disease;Alcoholism;Asthma;Bronchial hyperreactivity;Bronchitis chronic;Bronchoconstriction;Bronchospasm;Cardiac failure congestive;Chronic obstructive pulmonary disease;Cigarette smoker;Diuresis;Emphysema;Fatigability;Fatigue;Foetor hepaticus;Gout;Hepatocellular injury;Liver disorder;Non-smoker;Non-tobacco user;Polyuria;Tobacco abuse,Abdominal cramps;Abdominal discomfort;Abdominal pain;Abdominal pain upper;Agitation;Albuminuria;Alopecia;Angioedema;Anorexia;Convulsion;Decreased appetite;Dermatitis;Dermatitis contact;Diarrhoea;Dizziness;Epigastric pain;Excitement;Extrasystoles;Flushing;Haematemesis;Haemorrhagic disorder;Headache;Hyperglycaemia;Hypotension;Inappropriate antidiuretic hormone secretion;Insomnia;Intestinal haemorrhage;Irritability;Leukopenia;Lightheadedness;Muscle twitching;Nausea;Nervousness;Palpitations;Peptic ulcer;Pruritus generalised;Rash;Shock;Sinus tachycardia;Tachycardia;Tachypnoea;Tension;Thrombocytopenia;Upper abdominal discomfort;Urticaria;Ventricular arrhythmia;Vomiting,small molecule,approved; nutraceutical,"Bilineurine; Choline ion; N-trimethylethanolamine; N,N,N-trimethylethanol-ammonium; trimethylethanolamine; Vitamin J; NACHRA7; 2.7.7.15; CCT B; CCT-beta; CCTB; CT B; CTP:phosphocholine cytidylyltransferase B; Phosphorylcholine transferase B; 3.1.1.7; AChE; 2.7.7.15; CCT A; CCT-alpha; CT A; CTP:phosphocholine cytidylyltransferase A; CTPCT; PCYT1; Phosphorylcholine transferase A; 3.1.4.4; Choline phosphatase 2; hPLD2; Phosphatidylcholine-hydrolyzing phospholipase D2; PLD 2; PLD1C; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 3.1.4.4; Choline phosphatase 1; hPLD1; Phosphatidylcholine-hydrolyzing phospholipase D1; PLD 1; 3.1.3.75; 1-alkenyl-2-acylglycerol choline phosphotransferase; 2.7.8.1; 2.7.8.2; hCEPT1; CHETK; CHKL; Choline kinase beta; Choline kinase-like protein; choline/ethanolamine kinase beta; CK; CKB; CKEKB; EK; EKB; Ethanolamine kinase; Ethanolamine kinase beta; 2.3.1.6; ChAT; CHOACTase; Choline acetylase; 2.7.1.32; CHETK-alpha; CHK; CK; CKI; EK; Ethanolamine kinase; 1.1.99.1; CDH; CHD; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; CD92; CDW92; CTL1; Solute carrier family 44 member 1; C6orf29; CTL4; hTPPT1; NG22; Solute carrier family 44 member 4; Thiamine pyrophosphate transporter 1; TPPT1; CTL2; Solute carrier family 44 member 2; CTL3; Solute carrier family 44 member 3; CHT; CHT1; hCHT1; Hemicholinium-3-sensitive choline transporter; Solute carrier family 5 member 7",Neuronal acetylcholine receptor subunit alpha-2; Neuronal acetylcholine receptor subunit alpha-7; Choline-phosphate cytidylyltransferase B; Acetylcholinesterase; Choline-phosphate cytidylyltransferase A; Phospholipase D2; Cholinesterase; Phospholipase D1; Phosphoethanolamine/phosphocholine phosphatase,R03DA02
clocortolone,Skin disorder,Allergic contact dermatitis;Dermatitis;Dermatitis contact;Dermatitis perioral;Eruption;Folliculitis;Hypertrichosis;Infection;Leukoderma;Miliaria;Pruritus;Rash;Secondary infection;Skin atrophy;Skin striae,small molecule,approved,"9-chloro-6alpha-Fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione; 9-chloro-6alpha-Fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione; Clocortolon; Clocortolona; Clocortolone; Clocortolonum; 3.1.1.4; Group IB phospholipase A2; Phosphatidylcholine 2-acylhydrolase 1B; PLA2; PLA2A; PPLA2; GR; GRL; Nuclear receptor subfamily 3 group C member 1",Phospholipase A2; Glucocorticoid receptor,D07AB21
betamethasone,Dermatitis atopic;Dermatitis contact;Eczema infantile;Eczema nummular;Intertrigo;Lichen planus;Neurodermatitis;Psoriasis;Senile pruritus;Skin disorder,Acneiform eruption;Allergic contact dermatitis;Atrophy;Contusion;Cushing's syndrome;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Dry skin;Erythema;Folliculitis;Glycosuria;Hyperaesthesia;Hyperglycaemia;Hypertension;Hypertrichosis;Infection;Leukoderma;Loss of skin markings;Miliaria;Pain;Papule;Paraesthesia;Pruritus;Rash erythematous;Rash follicular;Secondary infection;Skin atrophy;Skin depigmentation;Skin striae;Stinging;Telangiectasia;Tingling sensation;Urticaria,small molecule,approved; vet_approved,"16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione; 9-Fluoro-16β-methylprednisolone; 9α-Fluoro-16β-methylprednisolone; beta-Methasone alcohol; Betadexamethasone; Betametasona; Betamethasone; Bétaméthasone; Betamethasonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Glucocorticoid receptor, A07EA04; C05AA05; D07AC01; D07BC01; D07CC01; D07XC01; H02AB01; R03BA04; S01BA06; S01BB04; S01CA05; S01CB04; S02BA07; S03BA03; S03CA06;R01AD06
hydrocodone,Pain,Abdominal discomfort;Abdominal pain;Affect lability;Agranulocytosis;Angiopathy;Anxiety;Arthralgia;Asthenia;Back pain;Body temperature increased;Connective tissue disorder;Constipation;Contusion;Convulsion;Cough;Deafness;Dehydration;Dermatitis;Dizziness;Drowsiness;Drug interaction;Dry mouth;Dysphoria;Dyspnoea;Fatigue;Foot fracture;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Headache;Hearing impaired;Hot flush;Hyperhidrosis;Hypersensitivity;Hypokalaemia;Hypotension;Hypotensive;Insomnia;Joint injury;Joint sprain;Laceration;Lethargy;Ligament sprain;Lightheadedness;Low back pain;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Migraine;Mood swings;Muscle spasms;Muscle strain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nausea;Neck pain;Nervous system disorder;Night sweats;Non-cardiac chest pain;Oedema peripheral;Osteoarthritis;Pain in extremity;Paraesthesia;Pruritus;Pulmonary function test decreased;Rash;Respiratory depression;Skin disorder;Skin laceration;Somnolence;Thrombocytopenia;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Ureteral spasm;Urinary retention;Urinary tract infection;Vomiting;Withdrawal syndrome,small molecule,approved; illicit; investigational,"(-)-Dihydrocodeinone; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; Dihydrocodeinone; Hidrocodona; Hydrocodon; Hydrocodone; Hydrocodonum; Hydrocone; Hydroconum; Idrocodone; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; Aging-associated gene 8 protein; hSigmaR1; OPRS1; SIG-1R; Sigma 1-type opioid receptor; Sigma1-receptor; Sigma1R; SR-BP; SR31747-binding protein; SRBP; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Mu-type opioid receptor; Delta-type opioid receptor; Sigma non-opioid intracellular receptor 1, N02AJ22; N02AJ23;R05DA03
procaine,Gingivitis ulcerative;Gonorrhoea;Infection;Necrotising ulcerative gingivostomatitis;Pharyngitis;Pneumococcal infection;Scarlet fever;Staphylococcal infection;Streptococcal infection;Syphilis;Trench mouth;Upper respiratory tract infection,Anaphylactic shock;Anxiety;Arthralgia;Body temperature increased;Chills;Depersonalisation;Dermatitis;Dermatitis exfoliative;Diarrhoea;Disorientation;Eosinophilia;Eruption;Fatigue;Haemolytic anaemia;Hallucination;Hypersensitivity;Jarisch-Herxheimer reaction;Laryngeal oedema;Leukopenia;Musculoskeletal discomfort;Nausea;Nephropathy;Neuropathy;Neuropathy peripheral;Oedema;Prostration;Psychotic behaviour;Rash;Serum sickness;Tachycardia;Thrombocytopenia;Urticaria;Vomiting,small molecule,approved; investigational; vet_approved,"2-Diethylaminoethyl p-aminobenzoate; 4-aminobenzoic acid 2-diethylaminoethyl ester; Novocaine; p-Aminobenzoic acid 2-diethylaminoethyl ester; Procaina; Procaine; Procainum; Vitamin H3; β-(diethylamino)ethyl 4-aminobenzoate; β-(diethylamino)ethyl p-aminobenzoate; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; BK channel; BKCA alpha; Calcium-activated potassium channel, subfamily M subunit alpha-1; hSlo; K(VCA)alpha; KCa1.1; KCNMA; Maxi K channel; MaxiK; SLO; Slo homolog; Slo-alpha; Slo1; Slowpoke homolog; BK channel subunit beta-1; BKbeta; BKbeta1; Calcium-activated potassium channel subunit beta; Calcium-activated potassium channel, subfamily M subunit beta-1; Charybdotoxin receptor subunit beta-1; Hbeta1; K(VCA)beta-1; Maxi K channel subunit beta-1; Slo-beta; Slo-beta-1; BK channel subunit beta-2; BKbeta2; Calcium-activated potassium channel, subfamily M subunit beta-2; Charybdotoxin receptor subunit beta-2; Hbeta2; Hbeta3; K(VCA)beta-2; Maxi K channel subunit beta-2; Slo-beta-2; BK channel subunit beta-3; BKbeta3; Calcium-activated potassium channel, subfamily M subunit beta-3; Charybdotoxin receptor subunit beta-3; Hbeta3; K(VCA)beta-3; KCNMB2; KCNMBL; Maxi K channel subunit beta-3; Slo-beta-3; BK channel subunit beta-4; BKbeta4; Calcium-activated potassium channel, subfamily M subunit beta-4; Charybdotoxin receptor subunit beta-4; Hbeta4; K(VCA)beta-4; Maxi K channel subunit beta-4; Slo-beta-4; Gardos channel; hIK1; hKCa4; hSK4; IK1; IKCA1; KCa3.1; KCA4; Putative Gardos channel; SK4; SKCa 4; SKCa4; hSK1; KCa2.1; SK; SK1; SKCa 1; SKCa1; KCa2.2; SK2; SKCa 2; SKCa2; K3; KCa2.3; SK3; SKCa 3; SKCa3; CPLA2; Phospholipase A2 group IVA; PLA2G4; 3.1.1.5; C14orf76; LysoLP; Lysophospholipase-transacylase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 2.1.1.37; AIM; CXXC-type zinc finger protein 9; CXXC9; DNA methyltransferase HsaI; DNA MTase HsaI; DNMT; Dnmt1; M.HsaI; MCMT; 2.1.1.37; Cysteine methyltransferase DNMT3A; DNA methyltransferase HsaIIIA; DNA MTase HsaIIIA; Dnmt3a; M.HsaIIIA; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4","Sodium channel protein type 10 subunit alpha; Glutamate receptor ionotropic, NMDA 3A; 5-hydroxytryptamine receptor 3A; Sodium-dependent dopamine transporter; Neuronal acetylcholine receptor subunit alpha-2; Calcium-activated potassium channel; Cytosolic phospholipase A2; 60 kDa lysophospholipase; Monoamine oxidase; DNA (cytosine-5)-methyltransferase 1; DNA (cytosine-5)-methyltransferase 3A", C05AD05; N01BA02; S01HA05;J01CE09;N01BA52
ogen,Anxiety;Asthenia;Atrophic vulvovaginitis;Atrophy;Breast tenderness;Carcinoma;Endometrial hyperplasia;Fatigue;Flushing;Headache;Hyperhidrosis;Hypogonadism;Insomnia;Menopausal symptoms;Menopause;Nausea;Neoplasm malignant;Oedema;Osteoporosis postmenopausal;Ovarian failure;Postmenopausal syndrome;Primary ovarian failure;Sweating;Vulvovaginal atrophy;Weight increased,Abdominal bloating;Abdominal cramps;Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal withdrawal bleeding;Acute coronary syndrome;Anaphylactic shock;Angioedema;Arthralgia;Asthma;Bladder pain;Bleeding breakthrough;Blister;Blood pressure increased;Breast cancer;Breast discharge;Breast discomfort;Breast swelling;Breast tenderness;Cardiovascular disorder;Cerebrovascular accident;Chloasma;Chorea;Coronary artery thrombosis;Cramp muscle;Cramps of lower extremities;Cystitis;Cystitis noninfective;Dementia;Depression;Dermatitis;Dermatitis bullous;Dermatitis hemorrhagic;Dizziness;Dysmenorrhoea;Dyspareunia;Dysuria;Ectropion of cervix;Embolism;Embolism venous;Endometrial cancer;Endometriosis;Epilepsy;Erythema;Erythema multiforme;Erythema nodosum;Exacerbation of asthma;Fibrocystic breast disease;Flatulence;Fluid retention;Galactorrhoea;Gallbladder disorder;Glucose tolerance decreased;Haemangioma;Headache;Hepatic function abnormal;Hirsutism;Hypercalcaemia;Hyperglycaemia;Hypernatraemia;Hypersensitivity;Hypocalcaemia;Inflammation;Irritability;Jaundice cholestatic;Leg pain;Metrorrhagia;Migraine;Mood alteration NOS;Mood swings;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myocardial infarction;Nausea;Neoplasm;Neoplasm malignant;Nervousness;Neuritis;Neuropathy peripheral;Oedema;Oestrogen deficiency;Optic neuritis;Ovarian cancer;Pain;Pain in extremity;Palpitations;Pancreatitis;Porphyrin metabolism disorder;Pruritus;Pulmonary embolism;Purpura;Rash;Retinal vascular thrombosis;Superficial phlebothrombosis;Tenderness;Tension;Thromboembolism;Thrombophlebitis;Thrombophlebitis superficial;Thrombosis;Urticaria;Uterine cervical erosion;Uterine leiomyoma;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal itching;Vaginal moniliasis;Varicose vein;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginal pruritus;Withdrawal bleed,small molecule,approved; vet_approved,Dioxygen; Molecular oxygen; Oxigeno gaseoso; Oxygen; Oxygen USP; Pure oxygen; 7.1.1.9; COI; COXI; Cytochrome c oxidase polypeptide I; MTCO1; 1.6.3.-; Mitogenic oxidase 1; MOX-1; MOX1; NADH/NADPH mitogenic oxidase subunit P65-MOX; NOH-1; NOH1; NOX-1; Beta-globin; Hemoglobin beta chain; Alpha-globin; Hemoglobin alpha chain,Cytochrome c oxidase subunit 1; NADPH oxidase 1,V03AN01
molindone,Schizophrenia;Tardive dyskinesia,Agitation;Akathisia;Akinesia;Amenorrhoea;Constipation;Dermatitis;Disturbance in sexual arousal;Drowsiness;Dry mouth;Dyskinesia;Dysphagia;Dyspnoea;Euphoric mood;Extrapyramidal disorder;Extrapyramidal symptoms;Galactorrhoea;Gynaecomastia;Hyperkinesia;Hypotension;Immobile;Lenticular opacities;Leukocytosis;Leukopenia;Libido increased;Motor restlessness;Movements involuntary;Muscle rigidity;Muscle spasms;Nausea;Pigmentation disorder;Pigmentation skin;Priapism;Protrusion tongue;Rash;Salivary hypersecretion;Salivation;Somnolence;Surgery;Surgical intervention;Tachycardia;Throat tightness;Tremor;Urinary retention;Vision blurred;Weight decreased;Weight increased,small molecule,approved,(+/-)-molindone; Molindona; Molindone; Molindonum; Dopamine D2 receptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A,D(2) dopamine receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; Muscarinic acetylcholine receptor M1,N05AE02
silver,Burns third degree;Wound sepsis,Bacterial colonisation;Bacterial disease carrier;Burning sensation;Dermatitis;Erythema multiforme;Leukopenia;Muscle contracture;Nephritis interstitial;Partner stress;Rash;Separation;Sepsis;Skin discolouration;Skin exfoliation;Skin necrosis;Tubulointerstitial nephritis,small molecule,approved; investigational,"Argentum metallicum; Colloidal silver; Nanosilver; Silver colloidal; Silver nanoparticles; Silver, colloidal; MRE-binding transcription factor; Transcription factor MTF-1; Metallothionein-IA; MT-1A; MT-IA; MT1S; Metallothionein-IB; MT-1B; MT-IB; MT1Q; Metallothionein-IE; MT-1E; MT-IE; Metallothionein-IF; MT-1F; MT-IF; Metallothionein-1K; Metallothionein-IG; MT-1G; MT-1K; MT-IG; MT1K; MT1M; Metallothionein-0; Metallothionein-IH; MT-0; MT-1H; MT-IH; Metallothionein-IL; MT-1L; MT-IL; Metallothionein-IM; MT-1M; MT-IM; MT1K; Metallothionein-IX; MT-1X; MT-IX; CES1; Metallothionein-2A; Metallothionein-II; MT-2; MT-II; MT2; GIF; GIFB; Growth inhibitory factor; Metallothionein-III; MT-3; MT-III; Metallothionein-IV; MT-4; MT-IV; MTM; Metallothionein-like 5, testis-specific; MTL5; Testis-specific metallothionein-like protein; Cuproxidase ceruloplasmin; Ferroxidase ceruloplasmin; Glutathione peroxidase ceruloplasmin; Glutathione-dependent peroxiredoxin ceruloplasmin; Alpha-2-M; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5; CPAMD5",Metallothionein; Ceruloplasmin; Albumin; Alpha-2-macroglobulin,D08AL30
zinc,Foetor hepaticus;Hepato-lenticular degeneration;Hepatocellular injury;Liver disorder,Epigastric discomfort;Gastric irritation;Pancreatitis,small molecule,approved; investigational,"Zinc, chelated; Zinc, elemental; Zincum metallicum; Zn; B1R; BK-1 receptor; BRADYB1; 2.1.1.63; 6-O-methylguanine-DNA methyltransferase; MGMT; O-6-methylguanine-DNA-alkyltransferase; 4.1.2.13; ALDA; Lung cancer antigen NY-LU-1; Muscle-type aldolase; 3.6.5.-; EEF1A; eEF1A-1; EF-1-alpha-1; EF-Tu; EF1A; Elongation factor Tu; Eukaryotic elongation factor 1 A-1; LENG7; Leukocyte receptor cluster member 7; 2-phospho-D-glycerate hydro-lyase; 4.2.1.11; C-myc promoter-binding protein; ENO1L1; Enolase 1; MBP-1; MBPB1; MPB-1; MPB1; NNE; Non-neural enolase; Phosphopyruvate hydratase; Plasminogen-binding protein; 1.2.1.12; GAPD2; GAPDH-2; GAPDH2; GAPDS; Spermatogenic cell-specific glyceraldehyde 3-phosphate dehydrogenase 2; Spermatogenic glyceraldehyde-3-phosphate dehydrogenase; 2.7.4.6; GAAD; Granzyme A-activated DNase; Metastasis inhibition factor nm23; NDK A; NDP kinase A; NDPKA; NM23; NM23-H1; Tumor metastatic process-associated protein; 5.3.4.1; Cellular thyroid hormone-binding protein; ERBA2L; p55; PDI; PDIA1; PO4DB; Prolyl 4-hydroxylase subunit beta; 5.3.4.1; 58 kDa glucose-regulated protein; 58 kDa microsomal protein; Disulfide isomerase ER-60; Endoplasmic reticulum resident protein 57; Endoplasmic reticulum resident protein 60; ER protein 57; ER protein 60; ERP57; ERP60; GRP58; p58; 1.11.1.24; Natural killer cell-enhancing factor A; NKEF-A; PAG; PAGA; PAGB; Proliferation-associated gene protein; TDPX2; Thioredoxin peroxidase 2; Thioredoxin-dependent peroxide reductase 2; Thioredoxin-dependent peroxiredoxin 1; 3.1.3.3; L-3-phosphoserine phosphatase; O-phosphoserine phosphohydrolase; PSP; PSPase; 5.3.1.1; Methylglyoxal synthase; TIM; TPI; Triose-phosphate isomerase; EF-Tu; P43; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; Hematopoietic growth factor; IL-3; Mast cell growth factor; MCGF; Multipotential colony-stimulating factor; P-cell-stimulating factor; CES1; Metallothionein-2A; Metallothionein-II; MT-2; MT-II; MT2; Superoxide dismutase copper chaperone; 3.5.1.98; HD1; Protein deacetylase HDAC1; Protein deacylase HDAC1; RPD3L1; 3.5.1.98; HD4; KIAA0288; 3-alkyladenine DNA glycosylase; 3-methyladenine DNA glycosidase; 3.2.2.21; AAG; ADPG; ANPG; MID1; N-methylpurine-DNA glycosylase; Cancer/testis antigen 103; Semenogelin I; SEMG; SGI; 1.15.1.1; hSod1; Superoxide dismutase 1; 3.5.1.98; HD8; HDACL1; Protein deacetylase HDAC8; Protein decrotonylase HDAC8; CD27-binding protein; CD27BP; SIVA; Glycine receptor 48 kDa subunit; Glycine receptor strychnine-binding subunit; 2.3.2.27; Double minute 2 protein; Hdm2; Oncoprotein Mdm2; p53-binding protein Mdm2; RING-type E3 ubiquitin transferase Mdm2; DMDL; DRP-1; DRP1; Dystrophin-related protein 1; 3.5.1.15; ACY-2; ACY2; Aminoacylase-2; ASP; CAGA; Calgranulin-A; Calprotectin L1L subunit; CFAG; Cystic fibrosis antigen; Leukocyte L1 complex light chain; Migration inhibitory factor-related protein 8; MRP-8; MRP8; p8; S100 calcium-binding protein A8; Urinary stone protein band A; CAGB; Calgranulin-B; Calprotectin L1H subunit; CFAG; Leukocyte L1 complex heavy chain; Migration inhibitory factor-related protein 14; MRP-14; MRP14; p14; S100 calcium-binding protein A9; 3.4.24.35; 92 kDa gelatinase; 92 kDa type IV collagenase; CLG4B; Gelatinase B; GELB; MMP-9; p53-like transcription factor; p53-related protein; P73; CAN19; Protein S-100L; S100 calcium-binding protein A2; S100L; Antigen NY-CO-13; P53; Phosphoprotein p53; Tumor suppressor p53; GIF; GIFB; Growth inhibitory factor; Metallothionein-III; MT-3; MT-III; ALG-2; ALG2; Apoptosis-linked gene 2 protein homolog; CER2; Cerberus-like protein 2; Cerl-2; CKTSF1B3; Cysteine knot superfamily 1, BMP antagonist 3; GREM3; Gremlin-3; SP1; Metallothionein-IA; MT-1A; MT-IA; MT1S; Alpha-1-B glycoprotein; Alpha-2-M; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5; CPAMD5; Serpin A8; SERPINA8; Alpha-2-Z-globulin; Ba-alpha-2-glycoprotein; FETUA; Fetuin-A; 9.5S alpha-1-glycoprotein; PTX2; SAP; Apo-AI; ApoA-I; Apolipoprotein A1; Apo-AII; ApoA-II; Apolipoprotein A2; Apo-AIV; ApoA-IV; Apolipoprotein A4; apoB-48R; APOB48R; Apolipoprotein B-100 receptor; Apolipoprotein B-48 receptor; Apolipoprotein B48 receptor; Apo-E; Apo-L; APOL; ApoL-I; Apolipoprotein L; Apolipoprotein L-I; C1QG; 3.4.21.41; Complement component 1 subcomponent r; 3.4.21.42; C1 esterase; Complement component 1 subcomponent s; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1; CPAMD1; Basic complement C4; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3; CO4; CPAMD3; C4BP; Proline-rich protein; PRP; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4; CPAMD4; 3.4.19.-; BRCA1-A complex subunit BRCC36; BRCA1/BRCA2-containing complex subunit 3; BRCA1/BRCA2-containing complex subunit 36; BRCC36; BRISC complex subunit BRCC36; C6.1A; CXorf53; Complement component 8 subunit alpha; Complement component 8 subunit beta; 3.4.21.47; BF; BFD; C3/C5 convertase; GBG; Glycine-rich beta glycoprotein; PBF2; Properdin factor B; H factor 1; HF; HF1; HF2; 3.4.21.45; C3B/C4B inactivator; IF; Aging-associated gene 4 protein; Apo-J; APOJ; Apolipoprotein J; CLI; Complement cytolysis inhibitor; Complement-associated protein SP-40,40; Ku70-binding protein 1; KUB1; NA1/NA2; SGP-2; Sulfated glycoprotein 2; Testosterone-repressed prostate message 2; TRPM-2; Cuproxidase ceruloplasmin; Ferroxidase ceruloplasmin; Glutathione peroxidase ceruloplasmin; Glutathione-dependent peroxiredoxin ceruloplasmin; 3.4.17.3; ACBP; Anaphylatoxin inactivator; Arginine carboxypeptidase; Carboxypeptidase N polypeptide 1; Carboxypeptidase N small subunit; CPN; Kininase-1; Lysine carboxypeptidase; Plasma carboxypeptidase B; SCPN; Serum carboxypeptidase N; ACBP; Carboxypeptidase N 83 kDa chain; Carboxypeptidase N large subunit; Carboxypeptidase N polypeptide 2; Carboxypeptidase N regulatory subunit; 3.4.-.-; AIDD; DSEP; Preproteolysin; 250/210 kDa paraneoplastic pemphigus antigen; DP; 3.4.21.38; HAF; Hageman factor; Fibrin-stabilizing factor B subunit; Protein-glutamine gamma-glutamyltransferase B chain; Transglutaminase B chain; 3.4.21.5; Coagulation factor II; Collagen/fibrinogen domain-containing lectin 3 p35; Collagen/fibrinogen domain-containing protein 3; FCNH; HAKA1; Hakata antigen; CIG; Cold-insoluble globulin; FN; Actin-depolymerizing factor; ADF; AGEL; Brevin; Alpha-globin; Hemoglobin alpha chain; Beta-globin; Hemoglobin beta chain; S100A18; ALS; Ig alpha-1 chain C region; Ig alpha-1 chain C region BUR; Ig alpha-1 chain C region TRO; Ig mu chain C region; Ig mu chain C region BOT; Ig mu chain C region GAL; Ig mu chain C region OU; Ig kappa chain V-I region Gal; Ig kappa chain V-I region WEA; Ig kappa chain V-III region B6; Ig kappa chain V-III region GOL; Ig kappa chain V-III region HAH; Ig kappa chain V-III region HIC; Ig kappa chain V-III region IARC/BL41; Ig kappa chain V-III region NG9; Ig kappa chain V-III region SIE; Ig kappa chain V-III region Ti; Ig kappa chain V-III region WOL; Ig lambda chain V-III region LOI; Ig lambda chain V-V region DEL; Ig lambda chain V-VII region MOT; IGHEP1; Inter-alpha-inhibitor heavy chain 1; Inter-alpha-trypsin inhibitor complex component III; ITI heavy chain H1; ITI-HC1; Serum-derived hyaluronan-associated protein; SHAP; IGHEP2; Inter-alpha-inhibitor heavy chain 2; Inter-alpha-trypsin inhibitor complex component II; ITI heavy chain H2; ITI-HC2; Serum-derived hyaluronan-associated protein; SHAP; Inter-alpha-inhibitor heavy chain 3; ITI heavy chain H3; ITI-HC3; Serum-derived hyaluronan-associated protein; SHAP; Gp120; IHRP; Inter-alpha-inhibitor heavy chain 4; Inter-alpha-trypsin inhibitor family heavy chain-related protein; ITI heavy chain H4; ITI-HC4; ITIHL1; PK-120; PK120; Plasma kallikrein sensitive glycoprotein 120; IGCJ; IGJ; Joining chain of multimeric IgA and IgM; Catenin gamma; CTNNG; Desmoplakin III; Desmoplakin-3; DP3; 3.4.21.34; Fletcher factor; Kininogenin; KLK3; PKK; Plasma prekallikrein; Alpha-2-thiol proteinase inhibitor; BDK; Fitzgerald factor; High molecular weight kininogen; HMWK; KNG; Williams-Fitzgerald-Flaujeac factor; 67 kDa cytokeratin; CK-1; Cytokeratin-1; Hair alpha protein; K1; Keratin-1; KRTA; Type-II keratin Kb1; CK-10; Cytokeratin-10; K10; Keratin-10; KPP; CK-14; Cytokeratin-14; K14; Keratin-14; CK-16; Cytokeratin-16; K16; Keratin-16; KRT16A; CK-2e; Cytokeratin-2e; Epithelial keratin-2e; K2e; Keratin-2 epidermis; Keratin-2e; KRT2A; KRT2E; Type-II keratin Kb2; 58 kDa cytokeratin; CK-5; Cytokeratin-5; K5; Keratin-5; Type-II keratin Kb5; CK-6A; CK-6D; Cytokeratin-6A; Cytokeratin-6D; K6A; Keratin-6A; KRT6D; Type-II keratin Kb6; CK-9; Cytokeratin-9; K9; Keratin-9; AGP 2; AGP2; OMD 2; Orosomucoid-2; 3.5.1.28; Peptidoglycan recognition protein 2; Peptidoglycan recognition protein long; PGLYRPL; PGRP-L; PGRPL; 3.1.1.2; 3.1.1.81; 3.1.8.1; A-esterase 1; Aromatic esterase 1; K-45; PON; PON 1; Serum aryldialkylphosphatase 1; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 6; CPAMD6; PSOR1; Psoriasin; S100 calcium-binding protein A7; S100A7C; SELP; SeP; SEPP1; AAT; Alpha-1 protease inhibitor; Alpha-1-antiproteinase; PI; Serpin A1; AACT; ACT; Cell growth-inhibiting gene 24/25 protein; Serpin A3; Kallikrein inhibitor; KST; Peptidase inhibitor 4; PI-4; PI4; Serpin A4; CBG; Serpin A6; Transcortin; HC-II; HCF2; Heparin cofactor II; HLS2; Protease inhibitor leuserpin-2; Serpin D1; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; Beta-1 metal-binding globulin; Siderophilin; Transferrin; ATTR; PALB; Prealbumin; TBPA; S-protein; Serum-spreading factor; V75; VN; Amyloid beta (A4) precursor-like protein 1; Amyloid-like protein 1; APLP; APLP-1; Amyloid beta (A4) precursor-like protein 2; Amyloid protein homolog; Amyloid-like protein 2; APLP-2; APPH; APPL2; CDEBP; CDEI box-binding protein; Sperm membrane protein YWK-II; A4; ABPP; AD1; Alzheimer disease amyloid A4 protein homolog; Alzheimer disease amyloid protein; Amyloid precursor protein; Amyloid-beta (A4) precursor protein; Amyloid-beta A4 protein; APP; APPI; Cerebral vascular amyloid peptide; CVAP; PN-II; PreA4; Protease nexin-II; 2.4.2.30; ADP-ribosyltransferase diphtheria toxin-like 1; ADPRT; ADPRT 1; ARTD1; DNA ADP-ribosyltransferase PARP1; NAD(+) ADP-ribosyltransferase 1; PARP-1; Poly[ADP-ribose] synthase 1; PPOL; Protein poly-ADP-ribosyltransferase PARP1; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1","B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5; Metallothionein-1A; Alpha-1B-glycoprotein; Alpha-2-macroglobulin; Angiotensinogen; Alpha-2-HS-glycoprotein; Serum amyloid P-component; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein A-IV; Apolipoprotein B receptor; Apolipoprotein E; Apolipoprotein L1; Complement C1q subcomponent subunit B; Complement C1q subcomponent subunit C; Complement C1r subcomponent; Complement C1s subcomponent; Complement C3; Complement C4-B; C4b-binding protein alpha chain; C4b-binding protein beta chain; Complement C5; Lys-63-specific deubiquitinase BRCC36; Complement component C8 alpha chain; Complement component C8 beta chain; Complement component C8 gamma chain; Complement factor B; Complement factor H; Complement factor I; Clusterin; Ceruloplasmin; Carboxypeptidase N catalytic chain; Carboxypeptidase N subunit 2; Dermcidin; Desmoplakin; Coagulation factor XII; Coagulation factor XIII B chain; Prothrombin; Ficolin-3; Fibrinogen alpha chain; Fibronectin; Gelsolin; Hemoglobin subunit alpha; Hemoglobin subunit beta; Haptoglobin-related protein; Hornerin; Insulin-like growth factor-binding protein complex acid labile subunit; Immunoglobulin heavy constant alpha 1; Immunoglobulin heavy constant mu; Immunoglobulin kappa variable 1-17; Immunoglobulin kappa variable 3-20; Immunoglobulin lambda variable 3-21; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; Inter-alpha-trypsin inhibitor heavy chain H3; Inter-alpha-trypsin inhibitor heavy chain H4; Immunoglobulin J chain; Junction plakoglobin; Plasma kallikrein; Kininogen-1; Keratin, type II cytoskeletal 1; Keratin, type I cytoskeletal 10; Keratin, type I cytoskeletal 14; Keratin, type I cytoskeletal 16; Keratin, type II cytoskeletal 2 epidermal; Keratin, type II cytoskeletal 5; Keratin, type II cytoskeletal 6A; Keratin, type I cytoskeletal 9; Alpha-1-acid glycoprotein 2; N-acetylmuramoyl-L-alanine amidase; Serum paraoxonase/arylesterase 1; Pregnancy zone protein; Protein S100-A7; Selenoprotein P; Alpha-1-antitrypsin; Alpha-1-antichymotrypsin; Kallistatin; Corticosteroid-binding globulin; Heparin cofactor 2; Sex hormone-binding globulin; Serotransferrin; Transthyretin; Vitronectin; Amyloid beta precursor like protein 1; Amyloid beta precursor like protein 2; Amyloid-beta precursor protein; Poly [ADP-ribose] polymerase 1",C05AX04
potassium,Hypophosphataemia,Acute coronary syndrome;Anxiety;Asthenia;Bradycardia;Confusional state;Convulsion;Cramp muscle;Dizziness;Dyspnoea;Fatigue;Feeling abnormal;Fluid retention;Foot edema;Headache;Hyperkalaemia;Hypernatraemia;Hyperphosphataemia;Hypoaesthesia;Hypocalcaemia;Hypomagnesaemia;Hypophosphataemic rickets;Hypotension;Increased thirst;Local swelling;Muscle spasms;Myocardial infarction;Nephrocalcinosis;Numbness;Oedema peripheral;Oliguria;Pain;Paraesthesia;Pollakiuria;Renal failure acute;Sensory loss;Tachycardia;Thirst;Tingling sensation;Tremor;Weight increased,small molecule,approved; experimental,"K; Kalium; Potasio; Potassium metal; Potassium, elemental; Potassium, metal; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1; BSC1; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; Kidney-specific Na-K-Cl symporter; Na-K-2Cl cotransporter 2; NKCC2",Sodium/potassium-transporting ATPase subunit alpha-1, C03AB01; C03AB02; C03AB04; C03AB05; C03AB06; C03AB07; C03AB08; C03AB09; C03BB02; C03BB03; C03BB04; C03BB05; C03BB07; C03CB01; C03CB02;C03AB03
pizotifen,Migraine;Tension headache;Vascular headache,Asthenia;Confusional state;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Epigastric distress;Erectile dysfunction;Fatigue;Feeling abnormal;Headache;Hypotension;Increased appetite;Musculoskeletal discomfort;Myalgia;Nausea;Nervousness;Oedema;Somnolence;Tension;Weight increased,small molecule,approved,Pizotifen; pizotifeno; Pizotyline; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 2.4.1.17; UDPGT 2B10,Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B; Histamine H1 receptor; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor,N02CX01
isosorbide-5-mononitrate,Acute coronary syndrome;Angina pectoris;Anginal attack;Cardiac failure chronic;Coronary artery disease;Myocardial infarction;Myocardial ischaemia,Abdominal pain;Abnormal vision;Acne;Acute coronary syndrome;Acute myocardial infarction;Affect lability;Agitation;Alanine aminotransferase increased;Albuminuria;Amaurosis fugax;Amblyopia;Amnesia;Anaemia;Angina pectoris;Angina pectoris aggravated;Anorectal discomfort;Anorexia;Anxiety;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Atrial arrhythmia;Atrial fibrillation;Atrioventricular block;Atrophic vulvovaginitis;Autonomic neuropathy;Back pain;Bacterial infection;Biliary colic;Bladder diverticulum;Blood uric acid increased;Body temperature increased;Bradycardia;Breast pain;Breast pain female;Bronchitis;Bronchospasm;Bundle branch block;Calculus of kidney;Candida infection;Cardiac disorder;Cardiac failure;Cardiac murmur;Cardiovascular disorder;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Chest pain;Chills;Cholecystitis;Coagulopathy;Cold sweat;Confusional state;Conjunctivitis;Constipation;Coordination abnormal;Cough;Cough increased;Cramp muscle;Decreased appetite;Dermatitis;Dermatitis psoriasiform;Diabetes mellitus;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disorder sight;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry mouth;Duodenal ulcer;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear pain;Eczema;Electrocardiogram abnormal;Epistaxis;Erectile dysfunction;Eructation;Extrasystoles;Fatigue;Feeling abnormal;Feeling hot;Flatulence;Flushing;Frozen shoulder;Gamma-glutamyltransferase increased;Gastric ulcer;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Glossitis;Glycosuria;Gout;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoids;Hair texture abnormal;Headache;Heart sounds abnormal;Heartburn;Hepatomegaly;Hot flush;Hypercholesterolaemia;Hyperhidrosis;Hyperlipidaemia;Hypersensitivity;Hypertension;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypochromic anaemia;Hypokalaemia;Hypokinesia;Hypotension;Ill-defined disorder;Increased appetite;Infection;Influenza like illness;Influenza-like symptoms;Insomnia;Intermittent claudication;Intestinal obstruction;Leg ulcer;Leukocytosis;Leukopenia;Libido decreased;Loose stools;Loss of consciousness;Lung infiltration;Malaise;Malnutrition;Melaena;Menopausal symptoms;Mental disability;Mental disorder;Methaemoglobinaemia;Migraine;Mood swings;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myositis;Nasal congestion;Nausea;Neck pain;Neck stiffness;Nephrolithiasis;Nervous system disorder;Nervousness;Neuritis;Neuropathy peripheral;Nightmare;Nuchal rigidity;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Pain;Pallor;Palpitations;Paraesthesia;Paresis;Periarthritis;Peripheral ischaemia;Pharyngeal disorder;Pharyngitis;Photophobia;Pneumonia;Pollakiuria;Polyuria;Proctalgia;Prostatic disorder;Pruritus;Purpura;Rales;Rash;Rash erythematous;Rash psoriaform;Rectal tenesmus;Red blood cell disorders;Respiratory tract infection;Rhinitis;Rigors;Sensation of warmth;Shock;Sinusitis;Skin disorder;Skin mass;Skin nodule;Skin ulcer;Sleep disorder;Sleep disturbance;Somnolence;Supraventricular tachycardia;Sweating;Sweating increased;Syncope;Tachycardia;Taste bitter;Tendon disorder;Tension;Thirst;Thrombocytopenia;Tinnitus;Tooth disorder;Torticollis;Tremor;Tympanic membrane perforation;Unspecified disorder of autonomic nervous system;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Vaginitis atrophic;Varicose vein;Vascular purpura;Vasospasm;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Viral infection;Vision blurred;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved,IS 5-MN; IS-5-MN; IS-5MN; ISMN; Iso-5-mononitrate; Isosorbide 5-mononitrate; Isosorbide 5-nitrate; Isosorbide mononitrate; Isosorbide-5-mononitrate; Isosorbidi mononitras; Mononitrate d'isosorbide; Mononitrato de isosorbida; Monosorbitrate; 4.6.1.2; GCS-alpha-2; GUC1A2; GUCSA2; 2.5.1.18; GST class-mu 1; GST HB subunit 4; GST1; GSTM1-1; GSTM1a-1a; GSTM1b-1b; GTH4; XDHA; 1.1.1.1; ADHX; Alcohol dehydrogenase 5; Alcohol dehydrogenase class chi chain; Alcohol dehydrogenase class-III; FALDH; FDH; Glutathione-dependent formaldehyde dehydrogenase; GSH-FDH; S-(hydroxymethyl)glutathione dehydrogenase,Guanylate cyclase soluble subunit alpha-2,C01DA14
desmopressin,Blood osmolarity decreased;Central diabetes insipidus;Diabetes insipidus;Diuresis;Enuresis;Factor IX deficiency;Factor VIII deficiency;Haemarthrosis;Haemoglobin;Haemorrhage;Head injury;Hematoma muscle;Injury;Menorrhagia;Mucosal bleeding;Mucosal haemorrhage;Muscle haemorrhage;Nasal congestion;Nasal mucosa atrophy;Nasopharyngitis;Nephrogenic diabetes insipidus;Nocturia;Nocturnal enuresis;Nocturnal polyuria;Plasma osmolality decreased;Pollakiuria;Polydipsia;Polyuria;Primary nocturnal enuresis;Rhinitis atrophic;Rhinorrhoea;Trauma;Urine output increased;Von Willebrand's disease,Abdominal bloating;Abdominal cramps;Abdominal distension;Abdominal pain;Abnormal behaviour;Acute myocardial infarction;Affect lability;Aggression;Agitation;Altered state of consciousness;Anaphylactic shock;Angiopathy;Anorexia;Antidiuresis;Anxiety;Anxiety symptoms NOS;Aspartate aminotransferase increased;Aspartate aminotransferase normal;Asthenia;Balanitis;Bladder and urethral symptoms;Blood pressure fluctuation;Body temperature increased;Cardiac disorder;Change in blood pressure;Chest pain;Chills;Coma;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cramp muscle;Decreased appetite;Dehydration;Depressed level of consciousness;Depressed mood;Depression;Dermatitis;Dermatitis atopic;Diarrhoea;Discomfort;Disturbance in attention;Dizziness;Drug interaction;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Emotional disorder;Emotional disturbance NOS;Enuresis;Epistaxis;Erythema;Eye disorder;Eye oedema;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Flushing;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Hepatic enzyme increased;Hyperhidrosis;Hyperkinesia;Hypernatraemia;Hypersensitivity;Hypertension;Hypokalaemia;Hyponatraemia;Hyponatraemic;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Infection;Influenza;Influenza like illness;Insomnia;Intermittent headache;Irritability;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Mental disability;Mental disorder;Mood swings;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasal discomfort;Nausea;Nervous system disorder;Nervousness;Nightmare;Oedema;Oedema peripheral;Oliguria;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Pain;Pain burning;Painful respiration;Palpitations;Paraesthesia;Pruritus;Rash;Rash both legs;Respiratory tract infection;Rhinitis;Shock;Skin disorder;Somnolence;Sweating;Swelling;Syncope;Tachycardia;Tension;Thinking abnormal;Throat sore;Thrombosis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Vasodilation;Vasodilation procedure;Vertigo;Visual impairment;Vomiting;Water intoxication;Water retention;Weight increased;Wheezing,small molecule,approved,1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin; 1-deamino-8-D-arginine vasopressin; 1-desamino-8-D-arginine vasopressin; dDAVP; Desmopresina; Desmopressin; Desmopressine; Desmopressinum; OT-R; ADHR; Antidiuretic hormone receptor; AVPR V2; DIR; DIR3; Renal-type arginine vasopressin receptor; V2R; Antidiuretic hormone receptor 1a; AVPR V1a; AVPR1; V1aR; Vascular/hepatic-type arginine vasopressin receptor; Antidiuretic hormone receptor 1b; AVPR V1b; AVPR V3; AVPR3; V1bR; Vasopressin V3 receptor; VPR3; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1,Oxytocin receptor; Vasopressin V2 receptor; Vasopressin V1a receptor; Vasopressin V1b receptor,H01BA02
chlorhexidine,Gingival bleeding;Gingivitis;Infection;Inflammation,Anaphylactic shock;Deafness;Dry mouth;Dysgeusia;Glossitis;Haematuria;Hypersensitivity;Hypoaesthesia;Injury;Mouth irritation;Oral mucosal exfoliation;Paraesthesia;Sialoadenitis;Skin exfoliation;Stomatitis;Swelling;Tongue coated;Tongue disorder;Tongue geographic;Tongue oedema;Trauma;Tympanic membrane perforation;Ulcer,small molecule,approved; vet_approved; withdrawn,"1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); Chlorhexidin; Chlorhexidine; Chlorhexidinum; Cloresidina; Clorhexidina; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide",Bacterial outer membrane, A01AB03; A01AB53; B05CA02; D08AC02; D08AC52; D09AA12; S01AX09; S02AA09; S03AA04;R02AA05
dexrazoxane,Breast cancer;Breast cancer stage IV;Cardiomyopathy;Extravasation;Neoplasm,Abdominal pain;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Angiopathy;Anorexia;Aspartate aminotransferase increased;Asthenia;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Body temperature increased;Breast disorder;Ca++ increased;Cardiac disorder;Cardiac failure congestive;Cardiotoxicity;Connective tissue disorder;Constipation;Cough;Creatinine increased;Decreased appetite;Depression;Diarrhoea;Discomfort;Disease progression;Dizziness;Dry mouth;Dysphagia;Dyspnoea;Erythema;Extravasation;Fatigue;Febrile neutropenia;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemoglobin decreased;Haemorrhage;Headache;Hypercalcaemia;Hyponatraemia;Ill-defined disorder;Infection;Infestation;Infestation NOS;Infusion site burning;Infusion site pain;Injection site erythema;Injection site induration;Injection site pain;Injection site phlebitis;Injection site reaction;Injection site swelling;Insomnia;Lactic dehydrogenase activity increased;Leukopenia;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Musculoskeletal discomfort;Myalgia;Myelosuppression;Nausea;Neoplasm malignant;Nervous system disorder;Neurotoxicity;Neutropenia;Neutropenic infection;Oedema peripheral;Oesophagitis;Pain;Pancytopenia;Phlebitis;Phosphatase alkaline increased;Platelet count decreased;Pneumonia;Post procedural infection;Postoperative infection;Pruritus;Sensory loss;Sepsis;Shock;Skin disorder;Sodium decreased;Somnolence;Stomatitis;Syncope;Thrombocytopenia;Thrombophlebitis superficial;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vaginal haemorrhage;Venous thrombosis limb;Vomiting;Weight decreased;White blood cell count decreased;Wound complication,small molecule,approved; withdrawn,"(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; Dexrazoxan; Dexrazoxane; Dexrazoxano; Dexrazoxanum; Dextrorazoxane; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 5.6.2.2; DNA topoisomerase II, beta isozyme",DNA topoisomerase 2-alpha; DNA topoisomerase 2-beta,V03AF02
carbimazole,Hyperthyroidism;Thyrotoxicosis;Toxic nodular goitre,Ageusia;Agranulocytosis;Alopecia;Angioedema;Angiopathy;Aplastic anaemia;Arthralgia;Blood and lymphatic system disorders;Body temperature increased;Bone marrow depression;Contusion;Cutaneous vasculitis;Dermatitis;Discomfort;Distress;Emotional distress;Eosinophilia;Feeling abnormal;Foetor hepaticus;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatitis;Hepatitis cholestatic;Hepatocellular injury;Hypersensitivity;Hypogeusia;Ill-defined disorder;Infection;Jaundice;Jaundice cholestatic;Leukopenia;Liver disorder;Liver function test abnormal;Malaise;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Myopathy;Nausea;Nervous system disorder;Neutropenia;Oropharyngeal discomfort;Oropharyngeal pain;Pancytopenia;Pruritus;Rash;Skin disorder;Stomatitis;Throat sore;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urticaria,small molecule,approved; investigational,Athyromazole; Carbethoxymethimazole; Carbimazol; Carbimazole; Carbimazolo; Carbimazolum; Carbinazole; Ethyl 3-methyl-2-thioimidazoline-1-carboxylate; 1.11.1.8; TPO; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase,Thyroid peroxidase,H03BB01
fludrocortisone,Addison's disease;Adrenogenital syndrome;Breast cancer;Neoplasm malignant;Orthostatic hypotension;Secondary adrenocortical insufficiency,Abdominal distension;Acneiform eruption;Affect lability;Alkalosis hypokalaemic;Amenorrhoea;Anaphylactic shock;Anaphylactoid reaction;Angiitis necrotising;Aseptic necrosis;Asthenia;Atrophy;Benign intracranial hypertension;Carbohydrate tolerance decreased;Cardiac failure congestive;Cardiomegaly;Cataract;Cataract subcapsular;Contusion;Convulsion;Cutaneous hypersensitivity;Dermatitis acneiform;Dermatitis atopic;Diabetes mellitus;Diabetic;Ecchymosis;Erythema;Erythema facial;Exophthalmos;Fat atrophy;Fluid retention;Fracture;Glaucoma;Glucose tolerance decreased;Glucose tolerance impaired;Glycosuria;Haemoglobin;Haemorrhage;Headache;Hirsutism;Hyperglycaemia;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Impaired healing;Increased insulin requirement;Infection;Injury;Insomnia;Intracranial pressure increased;Intraocular pressure increased;Lipoatrophy;Menstruation irregular;Mood swings;Multiple fractures;Muscle atrophy;Muscle mass;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myopathy;Neoplasm;Nitrogen balance negative;Oedema;Oesophagitis;Oesophagitis ulcerative;Optic neuritis;Osteonecrosis;Osteoporosis;Pancreatitis;Papilloedema;Peptic ulcer;Petechiae;Purpura;Rash maculo-papular;Skin hyperpigmentation;Skin striae;Spinal compression fracture;Steroid myopathy;Sweating increased;Thrombophlebitis;Trauma;Urticaria;Vascular purpura;Vasculitis necrotising;Vertigo,small molecule,approved; investigational,"9alpha-Fluorocortisol; Fludrocortison; Fludrocortisona; Fludrocortisone; Fludrocortisonum; Fluohydrocortisone; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.1.1.-; 11-beta-HSD type II; 11-beta-HSD2; 11-beta-hydroxysteroid dehydrogenase type II; 11-DH2; 11-HSD type II; Corticosteroid 11-beta-dehydrogenase isozyme 2; HSD11K; NAD-dependent 11-beta-hydroxysteroid dehydrogenase; SDR9C3; Short chain dehydrogenase/reductase family 9C member 3; 1.1.1.146; 11-beta-HSD1; 11-DH; 7-oxosteroid reductase; Corticosteroid 11-beta-dehydrogenase isozyme 1; HSD11; HSD11L; SDR26C1; Short chain dehydrogenase/reductase family 26C member 1; CBG; Serpin A6; Transcortin",Androgen receptor; Mineralocorticoid receptor; Glucocorticoid receptor, H02AA02; S01CA06; S03CA05;H02AA02;S02CA07
metipranolol,Ocular hypertension;Open angle glaucoma,Abnormal vision;Acute coronary syndrome;Angina pectoris;Anxiety;Arthritis;Asthenia;Atrial fibrillation;Blepharitis;Bradycardia;Bronchitis;Conjunctivitis;Cough;Dermatitis;Dermatitis eyelid;Discomfort;Dizziness;Dyspnoea;Epistaxis;Headache;Hypersensitivity;Hypertension;Lacrimation;Lacrimation increased;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Nervousness;Oedema;Palpitations;Photophobia;Rash;Rhinitis;Somnolence;Tension;Uveitis;Vision blurred;Visual impairment,small molecule,approved,"(±)-metipranolol; Acetic acid 4-(2-hydroxy-3-isopropylamino-propoxy)-2,3,6-trimethyl-phenyl ester; Metipranolol; Metipranololum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Beta-1 adrenergic receptor; Beta-2 adrenergic receptor, C07BA68; S01ED04;S01ED04;S01ED54
Protirelin,Goiter diffuse;Goitre;Hypothyroidism;Pituitary tumour;Primary hypothyroidism,Abdominal discomfort;Amaurosis;Anxiety;Bad taste;Blood pressure fluctuation;Brain injury;Breast enlargement;Change in blood pressure;Convulsion;Dizziness;Drowsiness;Dry mouth;Dysgeusia;Epilepsy;Extravasation;Headache;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Lightheadedness;Loss of consciousness;Nausea;Paraesthesia;Pituitary apoplexy;Pituitary haemorrhage;Shock;Somnolence;Sweating;Syncope;Tingling sensation,small molecule,approved; investigational,5-oxo-L-prolyl-L-histidyl-L-prolinamide; L-pyroglutamyl-L-histidyl-L-prolineamide; Protirelin; Protirelina; Thyroliberin; Thyrotropic releasing hormone; Thyrotropic-releasing factor; Thyrotropin releasing hormone; Thyrotropin-releasing factor; TRH; TSH-releasing factor; TSH-releasing hormone; Thyroliberin receptor; TRH-R,Thyrotropin-releasing hormone receptor,H01AB01;V04CJ02
clindamycin,Abdominal abscess;Abdominal infection;Acne;Acne vulgaris;Bone and joint infections;Comedone;Diarrhoea;Diarrhoea haemorrhagic;Empyema;Endometritis;Genital infection female;Gynecological infection;Herpes simplex;Infection;Lower respiratory tract infection;Lung abscess;Osteomyelitis;Papule;Parametritis;Peritonitis;Pneumonia;Pseudomembranous colitis;Pustule;Rash pustular;Respiratory tract infection;Sepsis;Septicemia;Soft tissue infection;Tubo-ovarian abscess;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginitis bacterial;Vaginitis gardnerella;Vulvovaginitis,Abdominal bloating;Abdominal cramps;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain generalised;Abdominal pain localised;Abnormal labour;Abscess;Agranulocytosis;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Antibiotic associated colitis;Anxiety;Aphonia;Azotaemia;Bacterial infection;Bladder infection;Blister;Breath odour;Burning sensation;Candida infection;Cardio-respiratory arrest;Chest discomfort;Chest tightness;Clostridium difficile colitis;Colitis;Constipation;Cough;Cystitis;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Digestion impaired;Distress gastrointestinal;Dizziness;Dry skin;Dysgeusia;Dyspepsia;Dysuria;Endometriosis;Eosinophilia;Epistaxis;Eruption;Erythema;Erythema facial;Erythema multiforme;Eye irritation;Flatulence;Folliculitis;Fracture;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Headache;Heartburn;Hepatic enzyme increased;Hypersensitivity;Hyperthyroidism;Hypoaesthesia;Hypotension;Induration;Infestation;Infestation NOS;Inflammation;Inflammatory swelling;Jaundice;Laryngitis;Leukopenia;Local reaction;Localized exfoliation;Menstrual disorder;Mental disorder;Metrorrhagia;Multiple fractures;Nausea;Neutropenia;Numbness facial;Oedema;Oesophagitis;Oily skin;Oliguria;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Polyarthritis;Protein urine present;Proteinuria;Pruritus;Pseudomembranous colitis;Rash;Rash maculo-papular;Rectal haemorrhage;Seborrhoeic dermatitis;Sinusitis;Skin discolouration;Skin exfoliation;Skin irritation;Stevens-Johnson syndrome;Stinging;Swelling face;Tachycardia;Taste metallic;Throat sore;Thrombocytopenia;Thrombophlebitis;Tonsillitis;Tracheitis;Trichomonal vaginitis;Upper respiratory tract infection;Urinary tract infection;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vaginal pain;Vertigo;Vomiting;Vulvovaginal candidiasis;Vulvovaginal disorder;Vulvovaginal mycotic infection;Vulvovaginal pain;Vulvovaginitis;Vulvovaginitis trichomonal;Weight decreased;Welts,small molecule,approved; vet_approved,"7-CDL; 7(S)-Chloro-7-deoxylincomycin; Clindamicina; Clindamycin; Clindamycine; Clindamycinum; Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",50S ribosomal protein L1, D10AF51; G01AA10; J01FF01;D10AF01
clobetasol,Dermatitis atopic;Non-scalp psoriasis;Plaque psoriasis;Psoriasis;Psoriasis of scalp;Skin disorder,Acneiform eruption;Allergic contact dermatitis;Alopecia;Application site atrophy;Application site burn;Application site discolouration;Application site dryness;Application site irritation;Application site pain;Application site pigmentation changes;Application site pruritus;Application site reaction;Asteatosis;Atopy;Burning sensation;Chapped skin;Cushing's syndrome;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis irritant contact;Dermatitis perioral;Discomfort;Dizziness;Dry skin;Endocrine disorder;Erythema;Excoriation;Eye irritation;Eye pain;Folliculitis;Glycosuria;Hair colour changes;Headache;Hyperglycaemia;Hypertrichosis;Hypoaesthesia;Induration;Infection;Infestation;Infestation NOS;Influenza;Instillation site pain;Leukoderma;Lichenification;Localized exfoliation;Miliaria;Nasopharyngitis;Nausea;Numbness in fingers;Oedema;Pain;Pain of skin;Paraesthesia;Pharyngitis streptococcal;Pruritus;Psoriasis;Pustule;Rash;Rash pustular;Secondary adrenocortical insufficiency;Secondary infection;Skin atrophy;Skin disorder;Skin exfoliation;Skin fissures;Skin irritation;Skin striae;Skin tightness;Stinging;Telangiectasia;Tenderness;Tingling sensation;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Vision blurred,small molecule,approved; experimental; investigational,"Clobetasol; 3.1.1.4; Group IB phospholipase A2; Phosphatidylcholine 2-acylhydrolase 1B; PLA2; PLA2A; PPLA2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3",Phospholipase A2, D07CD01;D07AD01
oxcarbazepine,Convulsion;Epilepsy;Grand mal convulsion;Partial epilepsy;Partial seizures;Tonic-clonic seizures,AGEP;Abdominal pain;Abdominal pain upper;Abnormal vision;Accommodation disorder;Acne;Acute generalised exanthematous pustulosis;Affect lability;Aggression;Aggressive reaction;Agitation;Agranulocytosis;Alopecia;Altered state of consciousness;Amnesia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anxiety;Apathy;Aphasia;Aplastic anaemia;Arrhythmia;Arthralgia;Asthenia;Asthma;Ataxia;Atrioventricular block;Aura;Back pain;Balance disorder;Biliary colic;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood in stool;Blood uric acid increased;Body temperature increased;Bone disorder;Bone marrow depression;Bradycardia;Bronchitis;Bronchospasm;Calculus of kidney;Cardiac disorder;Cardiac failure;Cataract;Cerebellar syndrome;Cerebral haemorrhage;Cerebration impaired;Chest pain;Chills;Cholelithiasis;Colitis;Confusional state;Conjunctival haemorrhage;Constipation;Contusion;Conversion disorder;Convulsion;Convulsions aggravated;Coordination abnormal;Cough;Decreased appetite;Delirium;Delusion;Depressed level of consciousness;Dermatitis;Dermatitis contact;Diarrhoea;Diplopia;Discomfort;Disorder sight;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug eruption;Drug intolerance;Dry mouth;Duodenal ulcer;Dysgeusia;Dysmenorrhoea;Dysmetria;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear infection;Ear pain;Eczema;Electroencephalogram abnormal;Encephalopathy;Enteritis;Eosinophilia;Epistaxis;Eructation;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Eye disorder;Eye oedema;Facial rash;Fall;Fatigue;Feeling abnormal;Feeling drunk;Flat affect;Flatulence;Fluid retention;Flushing;Folate deficiency;Folliculitis;Fracture;Gait disturbance;Gamma-glutamyltransferase increased;Gastric ulcer;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gingival bleeding;Gingival hyperplasia;Haematemesis;Haematochezia;Haematuria;Haemorrhoids;Headache;Hemianopia;Hemiplegia;Hepatic encephalopathy;Hepatic enzyme increased;Hepatitis;Hepatobiliary disease;Hiccups;Hot flush;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperplasia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypokinesia;Hyponatraemia;Hyporeflexia;Hypotension;Hypothyroidism;Hypotonia;Hysteria;Ill-defined disorder;Immune system disorder;Impetigo;Increased appetite;Infection;Infection parasitic;Infestation;Infestation NOS;Insomnia;Interstitial lung disease;Irritability;Joint swelling;Laryngospasm;Leg edema;Leg pain;Lethargy;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Ligament sprain;Liver function test abnormal;Loss of consciousness;Lupus erythematosus;Lymphadenopathy;Malaise;Malnutrition;Mania;Manic psychosis;Menopausal symptoms;Menorrhagia;Mental disability;Mental disorder;Metrorrhagia;Migraine;Miliaria;Miliaria rubra;Mood swings;Mouth ulceration;Multiple fractures;Muscle contractions involuntary;Muscle relaxant therapy;Muscular weakness;Musculoskeletal discomfort;Myalgia;Mydriasis;Nasopharyngitis;Nausea;Nephritis interstitial;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neutropenia;Nightmare;Nystagmus;Oculogyric crisis;Oedema peripheral;Oesophagitis;Orthostatic hypotension;Osteopenia;Osteoporosis;Otitis externa;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Panic disorder;Paralysis;Personality disorder;Pharyngitis;Photophobia;Photosensitivity reaction;Pleurisy;Pneumonia;Pollakiuria;Polyuria;Priapism;Protein urine present;Proteinuria;Pruritus;Pruritus genital;Psoriasis;Psychotic disorder;Pulmonary oedema;Purpura;Rash;Rash erythematous;Rash maculo-papular;Rectal haemorrhage;Renal failure;Renal pain;Retching;Rhinitis;Rigors;Scotoma;Serum transaminase increased;Shock;Sialoadenitis;Sinusitis;Skin disorder;Somnolence;Speech disorder;Splenomegaly;Sprain;Status epilepticus;Stevens-Johnson syndrome;Stomatitis;Stupor;Suicidal behaviour;Suicidal ideation;Sweating increased;Syncope;Systemic lupus erythematosus;Tachycardia;Tension;Tetany;Thinking abnormal;Thirst;Thrombocytopenia;Thyroid function abnormal;Thyroid function test abnormal;Tinnitus;Toothache;Toxic epidermal necrolysis;Transaminases increased;Tremor;Tubulointerstitial nephritis;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urinary tract pain;Urine output increased;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vascular purpura;Vertigo;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Vitiligo;Vomiting;Weight decreased;Weight increased;Xerophthalmia,small molecule,approved,"10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; OCBZ; Oxcarbamazepine; Oxcarbazepina; Oxcarbazepine; Oxcarbazepinum; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; NAC1; SCN1; Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; HBA; HBSC II; NAC2; SCN2A1; SCN2A2; Sodium channel protein brain II subunit alpha; Sodium channel protein type II subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.2; KIAA1356; NAC3; Sodium channel protein brain III subunit alpha; Sodium channel protein type III subunit alpha; Voltage-gated sodium channel subtype III; Voltage-gated sodium channel subunit alpha Nav1.3; SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Atypical sodium channel Nav2.1; Nax channel; SCN6A; Sodium channel protein type VII subunit alpha; MED; Sodium channel protein type VIII subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.6; hNE-Na; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Sodium channel protein type IX subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.7; KIAA1158; 1.1.1.-; 1.1.1.112; 1.1.1.209; 1.1.1.210; 1.1.1.357; 1.1.1.51; 1.1.1.53; 1.1.1.62; 1.3.1.20; 20-alpha-HSD; 20-alpha-hydroxysteroid dehydrogenase; Chlordecone reductase homolog HAKRC; DD1; DDH; DDH1; Dihydrodiol dehydrogenase 1; HBAB; High-affinity hepatic bile acid-binding protein; 1.-.-.-; 1.1.1.112; 1.1.1.209; 1.1.1.53; 1.1.1.62; 1.3.1.20; 3-alpha-HSD3; Chlordecone reductase homolog HAKRD; DD-2; DD/BABP; DD2; DDH2; Dihydrodiol dehydrogenase 2; Dihydrodiol dehydrogenase/bile acid-binding protein; Type III 3-alpha-hydroxysteroid dehydrogenase; 1.1.1.-; 1.1.1.210; 1.1.1.53; 1.1.1.62; 17-beta-HSD 5; 17-beta-hydroxysteroid dehydrogenase type 5; 3-alpha-HSD type 2; 3-alpha-HSD type II, brain; 3-alpha-hydroxysteroid dehydrogenase type 2; Chlordecone reductase homolog HAKRb; DD-3; DD3; DDH1; Dihydrodiol dehydrogenase 3; Dihydrodiol dehydrogenase type I; HA1753; HSD17B5; KIAA0119; PGFS; Prostaglandin F synthase; Testosterone 17-beta-dehydrogenase 5; 1.1.1.-; 1.1.1.209; 1.1.1.210; 1.1.1.51; 1.1.1.53; 1.1.1.62; 3-alpha-HSD1; 3-alpha-hydroxysteroid dehydrogenase type I; 3alpha-hydroxysteroid 3-dehydrogenase; CDR; CHDR; Chlordecone reductase; DD-4; DD4; Dihydrodiol dehydrogenase 4; HAKRA; 1.1.1.184; 15-hydroxyprostaglandin dehydrogenase [NADP(+)]; 20-beta-hydroxysteroid dehydrogenase; Alcohol dehydrogenase [NAD(P)+] CBR1; CBR; CRN; NADPH-dependent carbonyl reductase 1; PG-9-KR; Prostaglandin 9-ketoreductase; Prostaglandin-E(2) 9-reductase; SDR21C1; Short chain dehydrogenase/reductase family 21C member 1; 1.1.1.184; NADPH-dependent carbonyl reductase 3; Quinone reductase CBR3; SDR21C2; Short chain dehydrogenase/reductase family 21C member 2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium channel protein type 11 subunit alpha; Sodium channel protein,N03AF02
gonadorelin,Anovulatory cycle;Endometrial cancer;Infertility;Uterine haemorrhage,Abdominal discomfort;Abdominal pain;Abortion spontaneous;Adnexal torsion;Anaphylactic shock;Angiopathy;Asthenia;Breast disorder;Breast pain;Breast pain female;Congenital anomaly;Constipation;Contusion;Developmental delay;Diarrhoea;Dysmenorrhoea;Ectopic pregnancy;Embolism;Embolism venous;Erythema;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Haematoma;Headache;Hypersensitivity;Immune system disorder;Injection site reaction;Menopause;Nausea;Nervous system disorder;Ovarian cyst;Ovarian disorder;Ovarian enlargement;Ovarian hyperstimulation;Ovarian hyperstimulation syndrome;Ovarian neoplasm;Pain;Pelvic pain;Peritoneal haemorrhage;Premature labour;Pruritus;Puerperal pyrexia;Redness;Secondary hypogonadism;Shock;Swelling;Thromboembolism;Upper respiratory tract infection;Vomiting,biotech,approved; investigational; vet_approved,GnRH; Gonadorelin; Gonadorelina; Gonadoréline; Gonadorelinum; Gonadotropin-releasing hormone; GnRH receptor; GnRH-R; GRHR; GnRH II receptor; GnRH-II-R; Type II GnRH receptor,Gonadotropin-releasing hormone receptor; Putative gonadotropin-releasing hormone II receptor, H01CA01;H01CA01;V04CM01
dobutamine,Atrial fibrillation;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac failure high output;Cardiac index;Cardiac output increased;Cerebrovascular accident;Decompensation cardiac;Hypertension;Hypertensive;Urine output;Vascular resistance systemic,Angina pectoris;Blood pressure systolic increased;Chest pain;Dyspnoea;Headache;Hypokalaemia;Hypotension;Nausea;Palpitations;Phlebitis;Pruritus;Skin exfoliation;Skin necrosis;Tachycardia;Thrombocytopenia;Ventricular extrasystoles,small molecule,approved,"(±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol; 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine; 4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol; DL-dobutamine; Dobutamin; Dobutamina; Dobutamine; Dobutaminum; rac-dobutamine; racemic-dobutamine; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; 2.1.1.6",Alpha-1 adrenergic receptors; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Estrogen receptor,C01CA07
halofantrine,Infection;Malaria;Plasmodium vivax infection,Abdominal distension;Abdominal pain;Abnormal vision;Altered state of consciousness;Anaemias haemolytic immune;Anaphylactic shock;Anorexia;Arrhythmia;Arthralgia;Asthenia;Back pain;Cerebrovascular accident;Chest pain;Chills;Confusional state;Constipation;Convulsion;Cough;Decreased appetite;Depressed level of consciousness;Dermatitis;Diarrhoea;Disability;Discomfort;Dizziness;Dyspepsia;Face oedema;Fatigue;Feeling abnormal;Gastrointestinal pain;Haematocrit decreased;Haemolysis;Haemolytic anaemia;Headache;Hemolytic reaction;Hypertensive crisis;Ill-defined disorder;Malaise;Musculoskeletal discomfort;Myalgia;Nausea;Orthostatic hypotension;Palpitations;Paraesthesia;Platelet count decreased;Pollakiuria;Pruritus;Pulmonary oedema;Rash;Rigors;Sleep disorder;Stomatitis;Tetany;Tinnitus;Urticaria;Visual impairment;Vomiting;White blood cell count increased,small molecule,approved,"Halofantrina; Halofantrine; Halofantrinum; CALM; CAM; CAM1; CALML2; CAM3; CAMC; CAMIII; CAM2; CAMB; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 3.4.23.39; Aspartic hemoglobinase II; PFAPD; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase",Fe(II)-protoporphyrin IX; Calmodulin-1; Calmodulin-3; Calmodulin-2; Voltage-gated inwardly rectifying potassium channel KCNH2; Plasmepsin-2,P01BX01
pentosan,Bladder pain;Cystitis interstitial;Discomfort,Abdominal discomfort;Abdominal pain;Affect lability;Agitation;Alopecia;Amblyopia;Amenorrhoea;Anaemia;Angina pectoris;Anorexia;Appetite absent;Arthralgia;Chronic myeloid leukaemia;Colitis;Conjunctivitis;Constipation;Cystitis interstitial;Decreased appetite;Dehydration;Depression;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dyspepsia;Dyspnoea;Ecchymosis;Epistaxis;Feeling abnormal;Flatulence;Gastritis;Gastrointestinal discomfort;Gastrointestinal pain;Gingival bleeding;Haematuria;Headache;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Ill-defined disorder;Infection;Insomnia;Jaundice;Lacrimation;Lacrimation increased;Leukopenia;Liver function test abnormal;Malaise;Menorrhagia;Micturition urgency;Mood swings;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Nausea;Nystagmus;Oedema;Oesophagitis;Optic neuritis;Paraesthesia;Pelvic pain;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pollakiuria;Prostate cancer;Prothrombin level increased;Pruritus;Raised liver function tests;Rash;Rectal haemorrhage;Retinal haemorrhage;Rhinitis;Sickness;Sinusitis;Stomatitis;Subarachnoid haemorrhage;Sweating;Sweating increased;Thrombocytopenia;Tinnitus;Urethritis;Urethritis noninfective;Urticaria;Vaginal infection;Vaginal inflammation;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,Co-vidarabine; Pentostatin; Pentostatina; Pentostatine; Pentostatinum; 3.5.4.4; ADA1; Adenosine aminohydrolase,Adenosine deaminase,C05BA04;L01XX08
carboplatin,Anaphylactic shock;Bladder cancer;Brain neoplasm;Breast cancer;Carcinoma;Carcinoma of lung;Carcinoma testes;Cervix carcinoma;Endometrial cancer;Ewing's sarcoma;Leukaemia;Lung neoplasm malignant;Lymphoma;Malignant melanoma;Neoplasm;Neoplasm malignant;Nephroblastoma;Neuroblastoma;Neurotoxicity;Neutropenia;Non-Hodgkin's lymphoma;Osteosarcoma;Ovarian cancer;Ovarian carcinoma;Renal failure;Renal impairment;Retinoblastoma;Rhabdomyosarcoma;Sarcoma;Small cell lung cancer;Testis cancer,Abdominal discomfort;Abdominal pain;Acute coronary syndrome;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angiopathy;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Blindness;Blindness cortical;Blood alkaline phosphatase increased;Blood bilirubin increased;Blood creatinine decreased;Blood creatinine increased;Blood urea increased;Body temperature increased;Bone marrow depression;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiac failure;Cerebrovascular accident;Chills;Connective tissue disorder;Constipation;Creatinine low;Deafness;Decreased appetite;Dehydration;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Diuresis;Drug interaction;Dysgeusia;Dyspnoea;Embolism;Erythema;Extravasation;Eye disorder;Fatigue;Febrile neutropenia;Feeling abnormal;Gastrointestinal pain;Gastrointestinal toxicity;Gastrointestinal tract irritation;Haemoglobin;Haemolytic uraemic syndrome;Haemorrhage;Hearing impaired;Hepatotoxicity;Hypersensitivity;Hypertension;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hyporeflexia;Hypotension;Ill-defined disorder;Infection;Influenza like illness;Influenza-like symptoms;Injection site reaction;Ischaemic coronary artery disorders;Kidney function abnormal;Leukaemia;Leukopenia;Liver function test abnormal;Malaise;Malnutrition;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Myelodysplastic syndrome;Myelosuppression;Myocardial infarction;Myocardial ischaemia;Nausea;Nausea alone;Necrosis;Neoplasm malignant;Nephropathy toxic;Nephrotoxicity;Neurological symptom;Neuropathy peripheral;Neurotoxicity;Neutropenia;Ototoxicity;Pain;Palmar erythema;Pancytopenia;Paraesthesia;Paraesthesia oral;Perioral tingling;Peripheral sensory neuropathy;Phosphatase alkaline increased;Polyuria;Pruritus;Rash;Rash erythematous;Redness;Renal failure acute;Renal function test abnormal;Renal impairment;Rigors;Serum creatinine increased;Skin disorder;Stomatitis;Swelling;Tachycardia;Tendon reflex decreased;Thrombocytopenia;Tinnitus;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Urticaria;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Wheezing,small molecule,approved,"Carboplatin; Carboplatine; Carboplatino; CBDCA; cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II); cis-diammine(1,1-cyclobutanedicarboxylato)platinum; cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II); XDHA; 1.11.2.2; MPO; 2.5.1.18; Glutathione transferase T1-1; GST class-theta-1; Metallothionein-IA; MT-1A; MT-IA; MT1S; CES1; Metallothionein-2A; Metallothionein-II; MT-2; MT-II; MT2; 1.15.1.1; hSod1; Superoxide dismutase 1; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 2.5.1.18; GST class-mu 1; GST HB subunit 4; GST1; GSTM1-1; GSTM1a-1a; GSTM1b-1b; GTH4; 1.6.5.2; Azoreductase; DIA4; DT-diaphorase; DTD; Menadione reductase; NAD(P)H:quinone oxidoreductase 1; NMOR1; Phylloquinone reductase; QR1; Quinone reductase 1; Copper transporter 1; COPT1; CTR1; hCTR1; Solute carrier family 31 member 1; Copper transporter 2; COPT2; CTR2; hCTR2; Solute carrier family 31 member 2; 7.2.2.8; Copper pump 1; MC1; Menkes disease-associated protein; MNK; 7.2.2.8; Copper pump 2; PWD; WC1; Wilson disease-associated protein; WND; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",DNA,L01XA02
bezafibrate,Arteriosclerosis;Arteriosclerosis coronary artery;Atheroma;Combined hyperlipidaemia;Coronary artery disease;Dyslipidaemia;Hypercholesterolaemia;Hyperlipidaemia;Hypertriglyceridaemia;Infarction;Pancreatitis;Postinfarction;Renal failure;Type IV hyperlipidaemia,Abdominal pain;Acute coronary syndrome;Alanine aminotransferase increased;Alopecia;Anaemia;Aspartate aminotransferase increased;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Blood creatinine increased;Bronchitis;Cholelithiasis;Cholestasis;Constipation;Cramp muscle;Creatine phosphokinase increased;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Eczema;Epigastric distress;Erectile dysfunction;Erythema;Erythema multiforme;Flatulence;Gastritis;Gastrointestinal pain;Headache;Hypersensitivity;Infection;Influenza;Insomnia;Liver function test abnormal;Migraine;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myositis;Nausea;Pain;Pancytopenia;Pharyngitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pruritus;Purpura;Rash;Renal failure acute;Rhabdomyolysis;Serum creatinine increased;Stevens-Johnson syndrome;Tenosynovitis;Thrombocytopenia;Toxic epidermal necrolysis;Transaminases increased;Urethral disorder;Urinary tract disorder;Urticaria;Vascular purpura,small molecule,approved; investigational,"2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; Bezafibrate; Bezafibrato; Bezafibratum; NR1C2; NUC1; NUCI; Nuclear hormone receptor 1; Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferator-activated receptor beta; PPAR-beta; PPAR-delta; PPARB; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; NR1C1; Nuclear receptor subfamily 1 group C member 1; PPAR; PPAR-alpha; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; NR2B1; Nuclear receptor subfamily 2 group B member 1; Retinoid X receptor alpha; NR2B2; Nuclear receptor subfamily 2 group B member 2; Retinoid X receptor beta; NR2B3; Nuclear receptor subfamily 2 group B member 3; Retinoid X receptor gamma; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Peroxisome proliferator-activated receptor delta; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Nuclear receptor subfamily 1 group I member 2; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma,C10AB02
rimexolone,Anterior uveitis;Inflammation;Iridocyclitis,Cataract subcapsular;Conjunctival oedema;Corneal erosion;Corneal oedema;Corneal staining;Corneal thinning;Discomfort;Dry eye;Dysgeusia;Eye infection;Eye pain;Headache;Herpes simplex;Hyperaemia;Hypotension;Intraocular pressure increased;Keratitis;Lacrimation;Lacrimation increased;Nerve injury;Oedema;Pharyngitis;Photophobia;Posterior subcapsular cataract;Pruritus;Rhinitis;Scab;Sensation of foreign body;Ulcerative keratitis;Vision blurred;Vital dye staining cornea present,small molecule,approved,"Rimexolon; Rimexolona; Rimexolone; GR; GRL; Nuclear receptor subfamily 3 group C member 1; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; CBG; Serpin A6; Transcortin",Glucocorticoid receptor; Steroid hormone receptor ERR1, S01BA13;H02AB12
stiripentol,Convulsion;Grand mal convulsion;Myoclonic epilepsy;Tonic-clonic seizures,Aggression;Agitation;Anorexia;Appetite absent;Asthenia;Ataxia;Blood and lymphatic system disorders;Cutaneous hypersensitivity;Decreased appetite;Dermatitis;Dermatitis atopic;Diplopia;Drowsiness;Eye disorder;Fatigue;Gastrointestinal disorder;Hyperkinesia;Hypotonia;Insomnia;Irritability;Liver function test abnormal;Malnutrition;Mental disorder;Muscle relaxant therapy;Nausea;Nervous system disorder;Neutropenia;Photosensitivity;Photosensitivity reaction;Rash;Skin disorder;Sleep disorder;Somnolence;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vomiting;Weight decreased,small molecule,approved,"1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol; 4,4-Dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol; Estiripentol; Stiripentol; Stiripentolum; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; 1.1.1.27; Cell proliferation-inducing gene 19 protein; LDH muscle subunit; LDH-A; LDH-M; Renal carcinoma antigen NY-REN-59; 1.1.1.27; LDH heart subunit; LDH-B; LDH-H; Renal carcinoma antigen NY-REN-46; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",GABA(A) Receptor; Gamma-aminobutyric acid receptor subunit gamma-3; L-lactate dehydrogenase A chain; L-lactate dehydrogenase B chain,N03AX17
vecuronium,Hypotonia;Muscle relaxation,Acute urticaria;Airway complication of anaesthesia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Apnoea;Bronchospasm;Cardiac disorder;Connective tissue disorder;Delayed recovery from anaesthesia;Dermatitis;Drug ineffective;Erythema;Face oedema;Flushing;Hypersensitivity;Hypotension;Immune system disorder;Injection site pain;Injection site reaction;Mediastinal disorder;Muscle atrophy;Muscular weakness;Myopathy;Nervous system disorder;Neuromuscular block prolonged;Paralysis;Paralysis flaccid;Pulmonary function test decreased;Rash;Rash erythematous;Redness;Respiratory depression;Respiratory failure;Respiratory insufficiency;Shock;Skeletal muscle paralysis;Skin disorder;Steroid myopathy;Tachycardia;Therapeutic response increased;Unspecified disorder of skin and subcutaneous tissue;Urticaria,small molecule,approved; investigational,Vecuronio; Vecuronium cation; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1,Neuronal acetylcholine receptor subunit alpha-2,M03AC03
nabilone,Alcohol abuse;Mental disorder;Nausea;Neoplasm malignant;Substance abuse;Vomiting,Abdominal pain;Abnormal dreams;Affect lability;Agitation;Akathisia;Amblyopia;Anaemia;Anhidrosis;Anorexia;Anxiety;Apathy;Aphthous stomatitis;Appetite exaggerated;Arrhythmia;Arthralgia;Asthenia;Ataxia;Back pain;Bacterial infection;Body temperature decreased;Body temperature increased;CNS depression NOS;Cerebration impaired;Cerebrovascular accident;Chest pain;Chills;Circumoral paresthesia;Coma;Confusional state;Constipation;Convulsion;Coordination abnormal;Coordination disturbance;Cough;Decreased appetite;Depersonalisation;Depersonalization syndrome;Depressed level of consciousness;Depression;Dermatitis;Diarrhoea;Discomfort;Disorientation;Dissociation;Disturbance in attention;Dizziness;Dizziness postural;Drowsiness;Drug interaction;Dry eye;Dry mouth;Dry throat;Dyspepsia;Dysphoria;Dyspnoea;Emotional disorder;Epistaxis;Euphoric mood;Eye disorder;Eye irritation;Eye swelling;Eyelid disorder;Face oedema;Fatigue;Feeling abnormal;Flat affect;Flushing;Gastritis;Gastrointestinal pain;Hallucination;Headache;Hot flush;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Hypotensive;Hypothermia;Hypotonia;Ill-defined disorder;Illusion;Increased appetite;Infection;Insomnia;Irritability;Leukopenia;Lightheadedness;Loss of consciousness;Malaise;Memory impairment;Menopausal symptoms;Mental disability;Mood swings;Mouth irritation;Muscle relaxant therapy;Muscle twitching;Musculoskeletal discomfort;Myalgia;Mydriasis;Nasal congestion;Nasal dryness;Nausea;Neck pain;Nervousness;Nightmare;Numbness;Orthostatic hypotension;Pain;Palpitations;Panic disorder;Paraesthesia;Paraesthesia oral;Paranoia;Perceptual disturbance;Pharyngitis;Phobia;Photophobia;Photosensitivity;Photosensitivity reaction;Pollakiuria;Pruritus;Psychiatric symptom;Psychotic disorder;Psychotic episode;Pulmonary function test decreased;Rash;Respiratory depression;Scotoma;Sensory loss;Shock;Sinus headache;Sleep disorder;Sleep disturbance;Somnolence;Speech disorder;Stomatitis;Stupor;Sweating increased;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Tinnitus;Tongue disorder;Tongue oedema;Tremor;Urinary retention;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Wheezing,small molecule,approved; investigational,"Nabilon; Nabilona; Nabilone; Nabilonum; CB-2; CB2; CB2A; CB2B; CX5; hCB2; CANN6; CB-R; CB1; CNR; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.-; Albendazole monooxygenase (hydroxylating); Albendazole monooxygenase (sulfoxide-forming); Arachidonic acid epoxygenase; CYPIIJ2; Hydroperoxy icosatetraenoate isomerase",Cannabinoid receptor 2; Cannabinoid receptor 1,A04AD11
permethrin,Acarodermatitis;Scabies,Abdominal pain;Body temperature increased;Dermatitis;Diarrhoea;Dizziness;Erythema;Gastrointestinal pain;Headache;Hypoaesthesia;Nausea;Numbness;Pain;Paraesthesia;Pruritus;Rash;Sensory loss;Stinging;Tingling sensation;Vomiting,small molecule,approved; investigational,"(3-Phenoxyphenyl)methyl (±)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; 3-(2,2-Dichloroethenyl)-2,2-dimethylcyclopropane carboxylic acid, (3-phenoxyphenyl) methyl ester; Permethrin; NAC1; SCN1; Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1",Sodium channel protein type 1 subunit alpha; Estrogen receptor; Nuclear receptor subfamily 1 group I member 2, P03AC04;P03AC04;P03AC54
pirfenidone,Idiopathic pulmonary fibrosis,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Alanine aminotransferase increased;Angiopathy;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Blood bilirubin increased;Connective tissue disorder;Constipation;Cough;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Erythema;Fatigue;Flatulence;Gamma-glutamyltransferase increased;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Headache;Hepatobiliary disease;Hot flush;Infection;Infestation;Infestation NOS;Insomnia;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Non-cardiac chest pain;Photosensitivity reaction;Productive cough;Prurigo;Pruritus;Rash;Rash erythematous;Rash macular;Serum bilirubin increased;Skin disorder;Somnolence;Sunburn;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urinary tract infection;Vomiting;Weight decreased,small molecule,approved; investigational,"Pirfenidona; Pirfenidone; TGFB; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Transforming growth factor beta-1 proprotein,L04AX05
pinaverium,Abdominal pain;Discomfort;Functional gastrointestinal disorder;Gastrointestinal pain;Irritable bowel syndrome,Abdominal pain upper;Anaphylactic shock;Angioedema;Constipation;Cutaneous hypersensitivity;Dermatitis atopic;Diarrhoea;Drowsiness;Dyspepsia;Epigastric pain;Headache;Heartburn;Hypersensitivity;Nausea;Somnolence;Vertigo,small molecule,approved,"CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Voltage-dependent L-type calcium channel subunit alpha-1S,A03AX04
acitretin,Congenital anomaly;Developmental delay;Headache;Keratosis follicular;Lichen planus;Lymphoma;Non-Hodgkin's lymphoma;Other dermatoses;Palmoplantar keratoderma;Psoriasis;Skin disorder,Abdominal pain;Acne;Acute myocardial infarction;Adenocarcinoma pancreas;Ageusia;Alanine aminotransferase increased;Alcohol abuse;Alcohol intolerance;Alcoholism;Alopecia;Angioedema;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anus disorder;Anxiety;Arthralgia;Arthritis;Arthropathy;Asthenia;Atrophic vulvovaginitis;Back pain;Balanoposthitis;Benign intracranial hypertension;Bleeding time prolonged;Blepharitis;Blood creatinine increased;Blood sodium increased;Blood triglycerides increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Breast pain;Bullous eruption;Bursitis;Candida infection;Capillary leak syndrome;Carcinoma of lung;Cataract;Cataract subcapsular;Cerebrovascular accident;Cerumen impaction;Ceruminosis;Chalazion;Cheilitis;Chest pain;Chills;Cold sweat;Common wart;Congenital anomaly;Congenital eye disorder;Conjunctival haemorrhage;Conjunctivitis;Constipation;Cough;Cramps of lower extremities;Creatinine increased;Cyanosis;Cyst;Cytopenia;Deafness;Decreased appetite;Decreased night vision;Decreased tolerance;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Dermatitis psoriasiform;Developmental delay;Diabetes mellitus;Diabetic;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Drug tolerance decreased;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphonia;Dysuria;Ear pain;Ectropion;Eczema;Embolism;Embolism venous;Epistaxis;Erectile dysfunction;Erythema;Exostosis;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Eyebrow loss of;Fasting;Fatigue;Febrile neutropenia;Feeling abnormal;Flushing;Fungal infection;Furuncle;Furunculosis;Gait disturbance;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gingival bleeding;Gingival hyperplasia;Gingivitis;Glossitis;Glycosuria;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoids;Hair colour changes;Hair discoloration;Hair texture abnormal;Headache;Hepatic function abnormal;Hepatitis;Hepatitis F;Herpes simplex;High density lipoprotein decreased;Hordeolum;Hot flush;Hyperaesthesia;Hypercholesterolaemia;Hyperhidrosis;Hyperkeratosis;Hyperlipidaemia;Hyperostosis;Hypersensitivity;Hypertonia;Hypertrichosis;Hypertriglyceridaemia;Hypervitaminosis A;Hypoaesthesia;Ill-defined disorder;Immune system disorder;Impaired healing;Increased appetite;Infection;Influenza like illness;Influenza-like symptoms;Insomnia;Intentional self-injury;Intermittent claudication;Intracranial pressure increased;Iritis;Jaundice;Ketonuria;Laboratory test abnormal;Lacrimal disorder;Lacrimation abnormal NOS;Laryngitis;Leukorrhea;Libido decreased;Lip dry;Liver function test abnormal;Lung neoplasm malignant;Madarosis;Malaise;Melaena;Menopausal symptoms;Migraine;Monocyte count decreased;Mouth ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myopathy;Nail disorder;Nausea;Nervousness;Neuritis;Neuropathy peripheral;Night blindness;Obesity;Oedema;Oedema peripheral;Oesophagitis;Olecranon bursitis;Optic neuritis;Osteoarthritis;Otitis externa;Otitis media;Pain;Pancreatitis;Pancytopenia;Papilloedema;Paraesthesia;Paronychia;Penis disorder;Peripheral ischaemia;Pharyngitis;Photophobia;Photosensitivity;Photosensitivity reaction;Posterior subcapsular cataract;Proctalgia;Protein urine present;Proteinuria;Pruritus;Psoriasis;Psoriasis flare-up;Purpura;Pyogenic granuloma;Raised liver function tests;Rash;Rash erythematous;Rectal tenesmus;Redness;Retinal haemorrhage;Rhinitis;Rigors;Saliva altered;Salivary hypersecretion;Scab;Scleroderma;Scotoma;Seborrhoeic dermatitis;Self injurious behaviour;Senile ankylosing vertebral hyperostosis;Sinusitis;Skin atrophy;Skin disorder;Skin exfoliation;Skin fissures;Skin fragility;Skin hypertrophy;Skin irritation;Skin mass;Skin nodule;Skin odour abnormal;Skin papilloma;Skin thinness;Skin ulcer;Sodium high;Somnolence;Sticky skin;Stomatitis;Suicidal ideation;Sunburn;Sweat gland disorder;Sweating increased;Tendonitis;Tension;Thirst;Thromboembolism;Tinnitus;Tongue disorder;Tongue ulceration;Ulcerative keratitis;Ulcerative stomatitis;Uric acid level increased;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urticaria;Vaginal discharge;Vaginitis atrophic;Vascular purpura;Vasculitis;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Vulvovaginitis;Weight decreased;Weight increased;White blood cell count decreased;White blood cell count increased;Xerophthalmia,small molecule,approved,"(all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; Acitretin; Acitretina; Acitretine; Acitretinum; all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; Etretin; NR2B1; Nuclear receptor subfamily 2 group B member 1; Retinoid X receptor alpha; Acute-phase response factor; APRF; NR1B1; Nuclear receptor subfamily 1 group B member 1; RAR-alpha; HAP; HBV-activated protein; NR1B2; Nuclear receptor subfamily 1 group B member 2; RAR-beta; RAR-epsilon; NR1B3; Nuclear receptor subfamily 1 group B member 3; RAR-gamma; NR2B3; Nuclear receptor subfamily 2 group B member 3; Retinoid X receptor gamma; NR2B2; Nuclear receptor subfamily 2 group B member 2; Retinoid X receptor beta; Cellular retinol-binding protein; Cellular retinol-binding protein I; CRBP; CRBP-I; CRBP1",Retinoic acid receptor RXR-alpha; Signal transducer and activator of transcription 3; Retinoic acid receptor alpha; Retinoic acid receptor beta; Retinoic acid receptor gamma; Retinoic acid receptor RXR-gamma; Retinoic acid receptor RXR-beta; Retinol-binding protein 1; Retinoic acid receptor RXR,D05BB02
nitazoxanide,Diarrhoea;Immunodeficiency,Abdominal pain;Alanine aminotransferase increased;Amenorrhoea;Anaemia;Anorexia;Asthenia;Back pain;Blood creatinine increased;Body temperature increased;Chills;Chromaturia;Constipation;Cramps of lower extremities;Creatinine increased;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dyspepsia;Dysuria;Ear pain;Epistaxis;Feeling abnormal;Flatulence;Gastrointestinal pain;Headache;Hypersensitivity;Hypertension;Hypoaesthesia;Ill-defined disorder;Increased appetite;Infection;Influenza;Insomnia;Leukocytosis;Loss of consciousness;Lung disorder;Malaise;Metrorrhagia;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Oedema;Pain;Pelvic pain;Pharyngitis;Pruritus;Rash;Renal pain;Rhinitis;Shock;Somnolence;Syncope;Tachycardia;Thirst;Tremor;Urine color abnormal;Vomiting,small molecule,approved; investigational; vet_approved,Nitaxozanid; Nitaxozanide; Nitazoxanida; Nitazoxanide; Nitazoxanidum; 1.2.7.1; POR; Pyruvate-ferredoxin oxidoreductase.,Pyruvate synthase,P01AX11
sufentanil,Pain,Anaphylactic shock;Apnoea;Arrhythmia;Body temperature increased;Bradycardia;Bronchospasm;Cardiac arrest;Chills;Confusional state;Dermatitis;Dizziness;Erythema;Euphoric mood;Feeling abnormal;Headache;Hypersensitivity;Hypertension;Hypopnoea;Hypotension;Injection site pain;Laryngospasm;Miosis;Muscle rigidity;Nausea;Pruritus;Pulmonary function test decreased;Rash;Respiratory depression;Shivering;Somnolence;Tachycardia;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Vomiting,small molecule,approved; investigational,"N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; Sufentanil; Sufentanilo; Sufentanilum; Sufentanyl; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; K-OR-1; KOR-1; OPRK; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Mu-type opioid receptor; Delta-type opioid receptor; Kappa-type opioid receptor,N01AH03
valrubicin,Carcinoma in situ,Abdominal pain;Ageusia;Anaemia;Anorectal discomfort;Asthenia;Back pain;Bladder pain;Bladder spasm;Blood urea increased;Body temperature increased;Chest pain;Cystitis;Cystitis noninfective;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dysuria;Feeling abnormal;Flatulence;Gastrointestinal pain;Haematuria;Headache;Hyperglycaemia;Ill-defined disorder;Irritability;Local reaction;Malaise;Micturition urgency;Musculoskeletal discomfort;Myalgia;NPN increased;Nausea;Nocturia;Oedema peripheral;Pelvic pain;Pneumonia;Pollakiuria;Proctalgia;Pruritus;Rash;Rectal tenesmus;Skin irritation;Urethral pain;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary retention;Urinary tract infection;Vasodilation;Vasodilation procedure;Vomiting,small molecule,approved,"(8S, 10S)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione 8²-valerate; 2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate; Valrubicin; Valrubicina; Valrubicine; Valrubicinum; 5.6.2.2; DNA topoisomerase II, beta isozyme; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2",DNA; DNA topoisomerase 2-beta; DNA topoisomerase 2-alpha,L01DB09
acarbose,Diabetes mellitus;Type 2 diabetes mellitus,Abdominal pain;Angiopathy;Blood and lymphatic system disorders;Constipation;Dermatitis;Diarrhoea;Dyspepsia;Erythema;Fatal outcomes;Flatulence;Foetor hepaticus;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Hepatic function abnormal;Hepatitis;Hepatitis fulminant;Hepatobiliary disease;Hepatocellular injury;Hypersensitivity;Ileus;Immune system disorder;Intestinal haemorrhage;Intestinal obstruction;Intestinal perforation;Intussusception;Jaundice;Liver disorder;Liver function test abnormal;Liver injury;Nausea;Oedema;Pneumatosis;Pneumatosis cystoides intestinalis;Pneumatosis intestinalis;Pneumoperitoneum;Rash;Rectal haemorrhage;Subileus;Thrombocytopenia;Traumatic liver injury;Urticaria;Volvulus;Vomiting,small molecule,approved; investigational,"Acarbosa; Acarbose; Acarbosum; Alpha-1,4-glucosidase; MGA; MGAML; 1,4-alpha-D-glucan glucanohydrolase; 3.2.1.1; PA; 3.2.1.20; Acid maltase; Aglucosidase alfa","Maltase-glucoamylase; Sucrase-isomaltase, intestinal; Pancreatic alpha-amylase; Lysosomal alpha-glucosidase", A10BF01;A10BD17;A10BF01
torasemide,Cardiac failure congestive;Diuresis;Foetor hepaticus;Hepatocellular injury;Hypertension;Liver disorder;Nephropathy;Oedema;Polyuria;Renal failure;Renal failure chronic;Renal impairment,Alkalosis hypochloraemic;Angioedema;Arthralgia;Arthritis;Asthenia;Atrial fibrillation;Blood uric acid increased;Chest pain;Constipation;Cough;Dehydration;Dermatitis;Diarrhoea;Digitalis intoxication (NOS);Dizziness;Dyspepsia;Erectile dysfunction;Erythema multiforme;Excessive thirst;Gastrointestinal haemorrhage;Gout;Haemoglobin;Haemorrhage;Headache;Hyperglycaemia;Hyperuricaemia;Hypokalaemia;Hyponatraemia;Hypotension;Hypovolaemia;Insomnia;Leukopenia;Loss of consciousness;Musculoskeletal discomfort;Myalgia;Nausea;Nervousness;Oedema;Oesophageal haemorrhage;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pancreatitis;Rash;Rectal haemorrhage;Rhinitis;Shock;Shunt thrombosis;Stevens-Johnson syndrome;Syncope;Tension;Thirst;Throat sore;Thrombocytopenia;Toxic epidermal necrolysis;Toxicity to various agents;Ventricular tachycardia;Vomiting,small molecule,approved,1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; Torasemida; Torasemide; Torasémide; Torasemidum; Torsemide; Basolateral Na-K-Cl symporter; BSC2; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2; hNKCC1; Na-K-2Cl cotransporter 1; NKCC1; BSC1; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1; Kidney-specific Na-K-Cl symporter; Na-K-2Cl cotransporter 2; NKCC2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6,Solute carrier family 12 member 2; Solute carrier family 12 member 1, G01AE10;C03CA04
desflurane,Apnoea;Cough,Abdominal pain;Acute coronary syndrome;Agitation;Alanine aminotransferase increased;Ammonia increased;Angiopathy;Apnoea;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Asthma;Atrial fibrillation;Blindness transient;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Body temperature increased;Bone disorder;Bradycardia;Breath holding;Breath holding attack;Bronchospasm;Carbon dioxide increased;Cardiac arrest;Cardiac disorder;Cholestasis;Coagulation test abnormal;Coagulopathy;Conjunctival hyperaemia;Conjunctivitis;Convulsion;Cough;Cough increased;Creatinine increased;Cyanosis;Cytolytic hepatitis;Discomfort;Dizziness;Drug administration error;Dyspnoea;Electrocardiogram ST-T change;Electrocardiogram T wave inversion;Electrocardiogram abnormal;Encephalopathy;Endophthalmitis;Erythema;Extrasystoles;Eye burns;Eye disorder;Eye irritation;Eye pain;Fatigue;Feeling abnormal;Fluid overload;Foetor hepaticus;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemoptysis;Haemorrhage;Headache;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hypercapnia;Hyperkalaemia;Hypertension;Hypokalaemia;Hypotension;Hypoxia;Ill-defined disorder;Infection;Infestation;Infestation NOS;Jaundice;Keratitis;Laryngospasm;Light anaesthesia;Liver disorder;Liver function test abnormal;Malaise;Malignant hypertension;Malnutrition;Mediastinal disorder;Mental disorder;Metabolic acidosis;Migraine;Muscle rigidity;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Nervous system disorder;Nodal arrhythmia;Ocular hyperaemia;Ocular icterus;Oxygen saturation decreased;Palpitations;Pancreatitis acute;Pharyngitis;Pruritus;Pulmonary function test decreased;Renal failure;Respiratory arrest;Respiratory depression;Respiratory distress;Respiratory failure;Rhabdomyolysis;Salivary hypersecretion;Shock;Skin burning sensation;Tachyarrhythmia;Tachycardia;Tachypnoea;Torsade de pointes;Transaminases increased;Ulcerative keratitis;Urticaria;Vasodilation;Vasodilation procedure;Ventricular bigeminy;Ventricular extrasystoles;Ventricular failure;Ventricular hypokinesia;Visual acuity reduced;Vomiting,small molecule,approved,"(±)-2-difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane; Desflurane; Desflurano; Desfluranum; Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; GABA(A) receptor subunit alpha-1; GABAAR subunit alpha-1; GABA(A) receptor subunit alpha-2; GABAAR subunit alpha-2; GABA(A) receptor subunit alpha-3; GABAAR subunit alpha-3; GABA(A) receptor subunit alpha-4; GABAAR subunit alpha-4; GABA(A) receptor subunit alpha-5; GABAAR subunit alpha-5; GABA(A) receptor subunit alpha-6; GABAAR subunit alpha-6; GABA(A) receptor subunit beta-1; GABAAR subunit beta-1; GABA(A) receptor subunit beta-2; GABAAR subunit beta-2; GABA(A) receptor subunit beta-3; GABAAR subunit beta-3; GABA(A) receptor subunit delta; GABAAR subunit delta; GABA(A) receptor subunit epsilon; GABAAR subunit epsilon; GABA(A) receptor subunit gamma-1; GABAAR subunit gamma-1; GABA(A) receptor subunit gamma-2; GABAAR subunit gamma-2; GABA(A) receptor subunit gamma-3; GABAAR subunit gamma-3; GABA(A) receptor subunit pi; GABAAR subunit pi; GABA(A) receptor subunit theta; GABAAR subunit theta; Glycine receptor 48 kDa subunit; Glycine receptor strychnine-binding subunit; AMPA-selective glutamate receptor 1; GLUA1; GLUH1; GluR-1; GluR-A; GluR-K1; GLUR1; Glutamate receptor ionotropic, AMPA 1; Voltage-gated K(+) channel HuKI; Voltage-gated potassium channel HBK1; Voltage-gated potassium channel subunit Kv1.1; 7.1.1.2; MTND1; NADH dehydrogenase subunit 1; NADH1; ND1; 7.2.2.10; ATP-dependent Ca(2+) pump PMR1; ATPase 2C1; Ca(2+)/Mn(2+)-ATPase 2C1; KIAA1347; PMR1L; Secretory pathway Ca(2+)-transporting ATPase type 1; SPCA1; 7.2.2.10; ATPase 2C2; Ca(2+)/Mn(2+)-ATPase 2C2; KIAA0703; Secretory pathway Ca(2+)-transporting ATPase type 2; SPCA2; 7.2.2.10; Plasma membrane calcium ATPase isoform 1; Plasma membrane calcium pump isoform 1; PMCA1; 7.2.2.10; Plasma membrane calcium ATPase isoform 2; Plasma membrane calcium pump isoform 2; PMCA2; 7.2.2.10; Plasma membrane calcium ATPase isoform 3; Plasma membrane calcium pump isoform 3; PMCA3; 7.2.2.10; ATP2B2; Matrix-remodeling-associated protein 1; MXRA1; Plasma membrane calcium ATPase isoform 4; Plasma membrane calcium pump isoform 4; PMCA4; 7.2.2.10; Calcium pump 1; Calcium-transporting ATPase sarcoplasmic reticulum type, fast twitch skeletal muscle isoform; Endoplasmic reticulum class 1/2 Ca(2+) ATPase; SERCA1; SR Ca(2+)-ATPase 1; 7.2.2.10; ATP2B; Calcium pump 2; Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform; Endoplasmic reticulum class 1/2 Ca(2+) ATPase; SERCA2; SR Ca(2+)-ATPase 2; ATP synthase F1 subunit delta; ATP5D; F-ATPase delta subunit; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J","GABA(A) Receptor; Glycine receptor subunit alpha-1; Glutamate receptor 1; Potassium voltage-gated channel subfamily A member 1; NADH-ubiquinone oxidoreductase chain 1; Calcium transporting ATPases; ATP synthase subunit delta, mitochondrial",N01AB07
misoprostol,Discomfort;Duodenal ulcer;Erosive gastroduodenitis;Gastric ulcer;Gastritis erosive;Gastrointestinal pain;Mucosal bleeding;Mucosal haemorrhage;Peptic ulcer;Ulcer,Abdominal pain;Abnormal vision;Abortion incomplete;Ache;Acute coronary syndrome;Alopecia;Amniotic fluid embolism;Anaemia;Anaphylactic shock;Anaphylactoid syndrome of pregnancy;Anorectal disorder;Anxiety;Arrhythmia;Arterial thrombosis;Arthralgia;Asthenia;Back pain;Blood alkaline phosphatase increased;Body temperature increased;Breast disorder;Breast pain;Bronchitis;Bronchospasm;Cardiac enzymes increased;Chest pain;Chills;Confusional state;Congenital anomaly;Conjunctivitis;Constipation;Cramp muscle;Deafness;Dehydration;Dermatitis;Developmental delay;Diarrhoea;Dizziness;Drowsiness;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Embolism;Epistaxis;Erectile dysfunction;Fatigue;Feeling abnormal;Flatulence;Foetal death;Gastrointestinal haemorrhage;Gastrointestinal pain;Genital disorder female;Gingivitis;Glycosuria;Gout;Haematuria;Headache;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Immune system disorder;Infection;Inflammation;Inflammatory bowel disease;Loss of consciousness;Loss of libido;Menorrhagia;Menstrual disorder;Metrorrhagia;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nausea;Neuropathy;Neuropathy peripheral;Neurosis;Oedema;Pain;Pallor;Phlebitis;Phosphatase alkaline increased;Pneumonia;Polyuria;Pregnancy;Premature baby;Premature delivery;Pulmonary embolism;Purpura;Rash;Rectal disorder;Red blood cell sedimentation rate increased;Retained placenta;Retained placenta or membranes;Rigors;Shock;Somnolence;Stiffness;Sweating increased;Syncope;Thirst;Thrombocytopenia;Thromboembolic event;Tinnitus;Upper respiratory tract infection;Urinary tract infection;Urine output increased;Uterine contractions;Uterine contractions during pregnancy;Uterine cramps;Uterine haemorrhage;Uterine rupture;Uterine spasm;Vaginal haemorrhage;Vascular purpura;Visual impairment;Vomiting,small molecule,approved,Misoprostol; Misoprostolum; PGI receptor; PGI2 receptor; PRIPR; Prostaglandin I2 receptor; Prostanoid IP receptor; PGE receptor EP3 subtype; PGE2 receptor EP3 subtype; PGE2-R; Prostanoid EP3 receptor; PGE receptor EP2 subtype; PGE2 receptor EP2 subtype; Prostanoid EP2 receptor; PGE receptor EP1 subtype; PGE2 receptor EP1 subtype; Prostanoid EP1 receptor; PGE receptor EP4 subtype; PGE2 receptor EP4 subtype; Prostanoid EP4 receptor; PTGER2,Prostacyclin receptor; Prostaglandin E2 receptor EP3 subtype; Prostaglandin E2 receptor EP2 subtype; Prostaglandin E2 receptor EP1 subtype; Prostaglandin E2 receptor EP4 subtype, A02BB01; M01AE56;A02BB01;G02AD06
cisatracurium,Hypotonia;Muscle relaxation,Anaphylactic shock;Anaphylactoid reaction;Angioedema;Bradycardia;Bronchospasm;Cardiac arrest;Cardiovascular disorder;Convulsion;Dermatitis;Dyspnoea;Erythema;Flushing;Generalised erythema;Generalized flushing;Hypersensitivity;Hypertension;Hypotension;Hypoxemia;Hypoxia;Laryngospasm;Mean arterial pressure;Muscular weakness;Myopathy;Neuromuscular block prolonged;Pruritus;Rash;Tachycardia;Urticaria;Wheezing,small molecule,approved; investigational,"(1r,2r,1'r,2'r)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]; Cisatracurium cation; Cisatracurium ion; NACHR alpha-10; NACHRA10; Nicotinic acetylcholine receptor subunit alpha-10; NACHRA3; NACRA4; NACHRA5; NACHRA7; NACHR alpha-9; NACHRA9; Nicotinic acetylcholine receptor subunit alpha-9; ACHRA; CHNRA",Neuronal acetylcholine receptor subunit alpha-2; Neuronal Acetylcholine (nACh) Receptor Subunits; Acetylcholine receptor subunit alpha; Muscarinic acetylcholine receptor M2,M03AC11
cefuroxime,Acute bronchitis;Bacterial infection;Bronchitis;Bronchitis chronic;Erythema migrans;Gonorrhoea;Hypersensitivity;Impetigo;Infection;Lyme disease;Maxillary sinusitis;Otitis media bacterial;Pharyngitis;Renal failure;Renal impairment;Rheumatic disorder;Rheumatic fever;Sinusitis;Streptococcal infection;Tonsillitis;Tracheobronchitis;Urinary tract infection,Abdominal cramps;Abdominal pain;Agitation;Agranulocytosis;Anaphylactic shock;Angioedema;Anorexia;Aplastic anaemia;Arthralgia;Blood alkaline phosphatase increased;Blood bilirubin increased;Blood creatinine increased;Blood urea increased;Body temperature increased;Chest pain;Chills;Cholestasis;Convulsion;Cough;Cramp muscle;Creatinine increased;Decreased appetite;Dermatitis;Dermatitis diaper;Diarrhoea;Digestion impaired;Disability;Dizziness;Drowsiness;Dyspepsia;Dyspnoea;Dysuria;Eosinophilia;Erythema;Erythema multiforme;Flatulence;Gastrointestinal disorder;Gastrointestinal infection;Gastrointestinal pain;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic enzyme increased;Hepatic impairment;Hepatitis;Hyperkinesia;Irritability;Jarisch-Herxheimer reaction;Jaundice;Joint swelling;Leukopenia;Liver disorder;Lockjaw;Loose stools;Mouth ulceration;Muscle spasms;Muscle stiffness;Muscle tightness;Musculoskeletal discomfort;Musculoskeletal stiffness;Nausea;Neck tightness;Nephropathy toxic;Neutropenia;Pancytopenia;Phosphatase alkaline increased;Prothrombin level increased;Pruritus;Pruritus vulvae;Pseudomembranous colitis;Rash;Renal pain;Salivary hypersecretion;Serum sickness-like reaction;Sinusitis;Somnolence;Stevens-Johnson syndrome;Stomatitis;Swollen tongue;Tachycardia;Thirst;Thrombocytopenia;Toxic epidermal necrolysis;Trismus;Upper respiratory tract infection;Urethral pain;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal itching;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginal pruritus,small molecule,approved,"(6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefuroxim; Cefuroxima; Cefuroxime; Cefuroximo; Cefuroximum; Cephuroxime; PBP1; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Penicillin-binding protein 1A, J01DC02; J01RA03;S01AA27
butoconazole,Drug interaction;Infection;Vulvovaginal candidiasis,Abdominal pain;Burning feeling vagina;Cramp muscle;Gastrointestinal pain;Muscle spasms;Pruritus;Swelling;Tenderness;Vulvovaginal burning sensation,small molecule,approved,"1-[4-(4-Chloro-phenyl)-2-(2,6-dichloro-phenylsulfanyl)-butyl]-1H-imidazole; Butoconazol; Butoconazole; Butoconazolum; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase",Ergosterol; Lanosterol 14-alpha demethylase, G01AF15;G01AF15;G01AF20
nicorandil,Acute coronary syndrome;Angina pectoris;Arteriospasm coronary;Myocardial infarction;Myocardial ischaemia;Stable angina pectoris,Abdominal pain;Abscess;Acute coronary syndrome;Anal fissure;Angina pectoris;Angioedema;Anorexia;Arrhythmia;Asthenia;Back pain;Blood and lymphatic system disorders;Body temperature increased;Bronchitis;Chest pain;Cholestasis;Conjunctival ulcer;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cough increased;Decreased appetite;Dermatitis;Diarrhoea;Diplopia;Discomfort;Dizziness;Dyspepsia;Dyspnoea;Epistaxis;Eye disorder;Face oedema;Feeling abnormal;Flushing;Foetor hepaticus;Foot and mouth disease;Gastrointestinal disorder;Gastrointestinal pain;Genital ulceration;Headache;Hepatitis;Hepatocellular injury;Hyperhidrosis;Hypertension;Hypotension;Ill-defined disorder;Infection;Insomnia;Jaundice;Large intestinal ulcer;Leg pain;Lethargy;Liver disorder;Loss of consciousness;Malaise;Metabolic disorder;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Neck pain;Nervousness;Oedema;Oedema peripheral;Orthostatic hypotension;Pain;Pain in extremity;Palpitations;Paraesthesia;Peripheral vascular disorder;Pruritus;Rash;Shock;Skin disorder;Sleep disorder;Small intestine ulcer;Somnolence;Stomatitis;Sweating;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinnitus;Tongue ulceration;Ulcer;Ulcerative keratitis;Unspecified disorder of skin and subcutaneous tissue;Vasodilation;Vasodilation procedure;Vertigo;Vestibular disorder;Vomiting,small molecule,approved; investigational,2-Nicotinamidoethyl nitrate; N-(2-Hydroxyethyl)nicotinamide nitrate; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); Nicorandil; Nicorandilum; Sulfonylurea receptor 2; SUR2,ATP-binding cassette sub-family C member 9,C01DX16
naftifine,Body tinea;Tinea cruris;Tinea pedis,Agranulocytosis;Blister;Burning sensation;Dermatitis;Dermatitis bullous;Dizziness;Erythema;Headache;Inflammation;Leukopenia;Pain;Pain of skin;Pruritus;Rash;Redness;Scab;Skin tenderness;Stinging;Swelling,small molecule,approved,Naftifin; Naftifina; Naftifine; Naftifinum; 1.14.14.17; ERG1; SE; Squalene epoxidase,Squalene monooxygenase,D01AE22
Goserelin,Advanced breast cancer;Anaemia;Bone cancer metastatic;Breast cancer;Endometriosis;Menorrhagia;Metastasis;Metrorrhagia;Neoplasm malignant;Pain;Prostate cancer;Prostate carcinoma;Urinary tract obstruction;Uterine leiomyoma,Abdominal pain;Acne;Acute coronary syndrome;Adverse reaction;Affect lability;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Angina pectoris;Angiopathy;Anorexia;Anxiety;Application site reaction;Arrhythmia;Arthralgia;Arthropathy;Asthenia;Back pain;Bladder neoplasm;Bladder pain;Bleeding breakthrough;Blood cholesterol increased;Blood pressure abnormal;Blood pressure fluctuation;Blood testosterone decreased;Blood uric acid increased;Body hair loss;Body temperature increased;Bone cancer metastatic;Bone density decreased;Bone disorder;Bone pain;Breast atrophy;Breast disorder;Breast enlargement;Breast pain;Breast swelling;Breast tenderness;Bronchial hyperreactivity;Bronchitis;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cerebral ischaemia;Cerebrovascular accident;Change in blood pressure;Chest pain;Chills;Chronic obstructive pulmonary disease;Condition aggravated;Confusional state;Constipation;Convulsion;Cough;Cough increased;Cramps of lower extremities;Cyst;Cystitis;Cystitis noninfective;Decreased appetite;Deep vein thrombosis;Degeneration of uterine fibroid;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drowsiness;Drug hypersensitivity;Dry eye;Dry mouth;Dry skin;Dysmenorrhoea;Dyspareunia;Dyspepsia;Dyspnoea;Dysuria;Ecchymosis;Endocrine disorder;Epistaxis;Erectile dysfunction;Erythema;Extravasation;Eye disorder;Fatigue;Febrile neutropenia;Feeling abnormal;Flatulence;Fracture;Galactorrhoea;Gastrointestinal pain;Glucose tolerance impaired;Gout;Gynaecomastia;Haematemesis;Haematuria;Haemoglobin;Haemorrhage;Hair disorder;Headache;Hepatic function abnormal;Hepatitis;Herpes simplex;Herpes zoster;High cholesterol;High density lipoprotein decreased;Hirsutism;Hot flush;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hypotension;IIIrd nerve paralysis;Ill-defined disorder;Immune system disorder;Incontinence;Increased appetite;Infarction;Infection;Influenza;Injection site irritation;Injection site reaction;Insomnia;Jaundice;Lethargy;Leukopenia;Libido decreased;Libido increased;Loss of libido;Low density lipoprotein increased;Lower urinary tract symptoms;Lupus-like syndrome;Lymphoedema;Malaise;Malnutrition;Memory loss;Menopausal symptoms;Menorrhagia;Mental disability;Mental disorder;Mental state abnormal;Metrorrhagia;Migraine;Mood swings;Multiple fractures;Muscle mass;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Neoplasm;Nervous system disorder;Nervousness;Nocturia;Nodule;Oedema;Oedema peripheral;Ophthalmoplegia;Osteoarthritis;Osteoporosis;Ovarian cyst;Ovarian hyperstimulation syndrome;Pain;Palpitations;Paraesthesia;Pelvic pain;Peripheral vascular disorder;Pharyngitis;Photosensitivity reaction;Pituitary adenoma;Pituitary apoplexy;Pituitary haemorrhage;Pituitary infarction;Pituitary tumour;Pituitary tumour benign;Pneumonia;Pollakiuria;Polyp;Proctitis;Pruritus;Psychotic disorder;Pulmonary embolism;Rash;Reaction aggravation;Rectal haemorrhage;Renal failure;Renal impairment;Rhinitis;Seborrhoeic dermatitis;Sepsis;Sexual dysfunction;Shock;Sinusitis;Skin discolouration;Skin disorder;Sleep disorder;Somnolence;Spinal cord compression;Sudden cardiac death;Sweating;Swelling;Tachycardia;Tenderness;Tension;Testosterone low;Thinking abnormal;Thirst;Thrombocytopenia;Thrombophlebitis;Transient ischaemic attack;Tumour flare;Tumour pain;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Ureteric obstruction;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urticaria;Uterine haemorrhage;Uterine leiomyoma;Vaginal dryness;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Varicose vein;Vasodilation;Vasodilation procedure;Vision blurred;Vomiting;Vulvovaginal dryness;Vulvovaginitis;Weight increased,small molecule,approved,Goserelin; Goserelina; LCGR; LGR2; LH/CG-R; LHR; LHRHR; LSH-R; Luteinizing hormone receptor; GNRH; GRH; LHRH; Progonadoliberin I; GnRH receptor; GnRH-R; GRHR,Lutropin-choriogonadotropic hormone receptor; Progonadoliberin-1; Gonadotropin-releasing hormone receptor,L02AE03
nedocromil,Asthma;Asthma exercise induced;Asthma late onset;Bronchial hyperreactivity;Bronchitis;Bronchitis asthmatic;Bronchospasm;Conjunctivitis allergic;Cough;Neutropenia;Pruritus,Abdominal pain;Anaphylactic shock;Arthritis;Asthenia;Bad taste;Body temperature increased;Bronchitis;Chest pain;Conjunctivitis;Cough;Cough increased;Dermatitis;Diarrhoea;Disorder sight;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dysphonia;Dyspnoea;Ear pain;Eczema;Eosinophilia;Eye redness;Fatigue;Feeling hot;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hypersensitivity;Increased bronchial secretion;Influenza;Leukopenia;Loeffler's syndrome;Nasal congestion;Nausea;Ocular hyperaemia;Otitis media;Pain;Pharyngitis;Photophobia;Pneumonia;Pulmonary eosinophilia;Rash;Rash erythematous;Rhinitis;Sensation of warmth;Sinusitis;Sputum increased;Stinging;Tremor;Upper gastrointestinal symptoms;Upper respiratory tract infection;Urticaria;Viral infection;Visual impairment;Vomiting,small molecule,approved; investigational,"9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsäure; 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid; Nédocromil; Nedocromil; Nedocromilo; Nedocromilum; CYSLT1; CysLTR1; Cysteinyl leukotriene D4 receptor; G-protein coupled receptor HG55; HMTMF81; LTD4 receptor; CYSLT2; CYSLT2R; CysLTR2; G-protein coupled receptor GPCR21; G-protein coupled receptor HG57; hGPCR21; HPN321; fMLP receptor; FPR; N-formyl peptide receptor; N-formylpeptide chemoattractant receptor; PGD receptor; PGD2 receptor; Prostanoid DP receptor; 3.6.4.10; Heat shock 86 kDa; Heat shock protein family C member 1; HSP 86; HSP86; HSP90A; HSPC1; HSPCA; LAP-2; Lipopolysaccharide-associated protein 2; LPS-associated protein 2; Renal carcinoma antigen NY-REN-38",Cysteinyl leukotriene receptor 1; Cysteinyl leukotriene receptor 2; fMet-Leu-Phe receptor; Prostaglandin D2 receptor; Heat shock protein HSP 90-alpha, R01AC07; S01GX04;R01AC07;R03BC03
cefotetan,"Abdominal infection;Bacterial sepsis;Blood creatinine increased;Bone and joint infections;Genital infection female;Gynecological infection;Infection;Lower respiratory tract infection;Nephropathy toxic;Nephrotoxicity;Pelvic inflammatory disease;Renal failure;Renal impairment;Septicaemia due to gram-negative organism, unspecified;Serum creatinine increased;Urinary tract infection",Abdominal pain;Agranulocytosis;Anaphylactic shock;Aplastic anaemia;Blood bilirubin increased;Body temperature increased;Cholestasis;Colitis;Convulsion;Dermatitis;Diarrhoea;Discomfort;Eosinophilia;Erythema multiforme;Gastrointestinal pain;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hepatic function abnormal;Hypersensitivity;Leukopenia;Nausea;Nephropathy toxic;Neutropenia;Pancytopenia;Phlebitis;Prothrombin level increased;Pruritus;Pseudomembranous colitis;Rash;Stevens-Johnson syndrome;Superinfection;Thrombocytopenia;Thrombocytosis;Toxic epidermal necrolysis;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved,"(6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid; Cefotetan; Cefotetanum; Putative D-alanyl-D-alanine carboxypeptidase",Penicillin-binding protein 3,J01DC05
alfentanil,Bradycardia;Euphoric mood;Hepatic impairment;Liver disorder;Miosis;Muscle rigidity;Nausea postoperative;Pain;Procedural nausea;Pulmonary function test decreased;Renal failure;Renal impairment;Respiratory depression;Vomiting,Agitation;Agitation postoperative;Airway complication of anaesthesia;Anaesthetic complication neurological;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Apnoea;Arrhythmia;Asthenia;Blood pressure increased;Body temperature increased;Bradycardia;Bronchospasm;Carbon dioxide increased;Cardiac arrest;Cardiac disorder;Chills;Confusion postoperative;Confusional state;Connective tissue disorder;Convulsion;Cough;Dependence on opiates;Dermatitis;Dermatitis atopic;Disorientation;Dizziness;Drowsiness;Drug dependence;Dyskinesia;Endotracheal intubation complication;Epistaxis;Erythema;Euphoric mood;Eye disorder;Fatal outcomes;Fatigue;Feeling abnormal;Gastrointestinal disorder;Headache;Hiccups;Hypercapnia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Immune system disorder;Injection site pain;Laryngospasm;Loss of consciousness;Mediastinal disorder;Mental disorder;Movement disorder;Muscle rigidity;Myoclonus;Nausea;Nervous system disorder;Pain;Procedural complication;Procedural pain;Pruritus;Pulmonary function test decreased;Rash;Respiratory arrest;Respiratory depression;Respiratory rate decreased;Shivering;Skin disorder;Somnolence;Tachycardia;Unresponsive to stimuli;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vascular pain;Vein pain;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; illicit,"Alfentanil; Alfentanilo; Alfentanilum; Alfentanyl; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Mu-type opioid receptor,N01AH02
miglitol,Type 2 diabetes mellitus,Abdominal distension;Abdominal pain;Constipation;Dermatitis;Diarrhoea;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Ileus;Ileus paralytic;Intestinal haemorrhage;Intestinal obstruction;Intestinal perforation;Intussusception;Nausea;Pneumatosis cystoides intestinalis;Pneumatosis intestinalis;Pneumoperitoneum;Rash;Rectal haemorrhage;Subileus;Volvulus,small molecule,approved,"Miglitol; Miglitolum; 3.2.1.20; Acid maltase; Aglucosidase alfa; 3.2.1.207; Alpha-glucosidase 2; G2AN; Glucosidase II subunit alpha; KIAA0088; 3.2.1.20; Alpha-1,4-glucosidase; MGA; MGAML; 1,4-alpha-D-glucan glucanohydrolase; 3.2.1.1; PA",Lysosomal alpha-glucosidase; Neutral alpha-glucosidase AB; Neutral alpha-glucosidase C; Maltase-glucoamylase,A10BF02
miglustat,Gaucher's disease;Hypersensitivity;Poor venous access,Abdominal bloating;Abdominal distension;Abdominal distension gaseous;Abdominal pain;Abdominal pain upper;Administration site reaction;Amnesia;Anorexia;Appetite absent;Asthenia;Ataxia;Back pain;Bladder cancer;Blood and lymphatic system disorders;Cerebellar syndrome;Chills;Coagulopathy;Cognitive disorder;Cognitive impairment;Congenital eye disorder;Connective tissue disorder;Constipation;Convulsion;Cramp muscle;Cramps of lower extremities;Decreased appetite;Depression;Diarrhoea;Discomfort;Disorder sight;Disturbance in sexual arousal;Dizziness;Dry mouth;Dyspepsia;Epigastric pain not food-related;Eye disorder;Fatigue;Feeling abnormal;Feeling jittery;Flatulence;Gait disturbance;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin;Haemorrhage;Headache;Heaviness in limbs;Hypoaesthesia;Ill-defined disorder;Influenza like illness;Influenza-like symptoms;Insomnia;Leg pain;Libido decreased;Localised numbness;Malaise;Malnutrition;Memory impairment;Memory loss;Menstrual disorder;Menstruation irregular;Mental disorder;Migraine;Monoclonal gammopathy;Muscle spasms;Muscular weakness;Musculoskeletal disorder;Nausea;Nerve conduction studies abnormal;Nervous system disorder;Nervousness;Neuritis;Neurological symptom;Neuropathy;Neuropathy peripheral;Numbness;Pain;Pain in extremity;Paraesthesia;Polyneuropathy;Sensation of heaviness;Sensory loss;Thrombocytopenia;Tingling sensation;Tremor;Unsteady gait;Vertigo;Visual disturbance;Visual impairment;Vitamin B12 deficiency;Vomiting;Weight decreased,small molecule,approved,"1,5-(butylimino)-1,5-dideoxy, D-glucitol; AT2221; BuDNJ; Butyldeoxynojirimycin; Miglustat; Miglustatum; N-(n-Butyl)deoxynojirimycin; n-Butyl deoxynojirimycin; N-butyl-1-deoxynojirimycin; N-butyl-deoxynojirimycin; N-Butylmoranoline; NB-DNJ; 2.4.1.80; GCS; GLCT-1; Glucosylceramide synthase; Glycosylceramide synthase; UDP-glucose ceramide glucosyltransferase; UDP-glucose:N-acylsphingosine D-glucosyltransferase",Ceramide glucosyltransferase,A16AX06
prednicarbate,Dermatitis atopic;Skin disorder,Acneiform eruption;Allergic contact dermatitis;Atrophy;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis irritant contact;Dermatitis perioral;Eruption;Folliculitis;Hypertrichosis;Infection;Leukoderma;Miliaria;Oedema;Pain;Paraesthesia;Pruritus;Rash;Secondary infection;Skin atrophy;Skin striae;Telangiectasia;Urticaria,small molecule,approved; investigational,"Prednicarbate; Prednicarbato; GR; GRL; Nuclear receptor subfamily 3 group C member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Glucocorticoid receptor; Steroid hormone receptor ERR2; Estrogen-related receptor gamma; Steroid hormone receptor ERR1,D07AC18
iloprost,Hypertension;Primary pulmonary hypertension;Pulmonary arterial hypertension,Angiopathy;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Bronchospasm;Cardiac disorder;Cardiac failure congestive;Chest discomfort;Chest pain;Connective tissue disorder;Cough;Cough increased;Cramp muscle;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drug interaction;Dysgeusia;Dyspnoea;Epistaxis;Flushing;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gingival bleeding;Glossitis;Glossodynia;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Headache;Hypersensitivity;Hypotension;Immune system disorder;Influenza;Insomnia;Laboratory test abnormal;Laryngeal pain;Loss of consciousness;Mediastinal disorder;Muscle spasms;Nasal congestion;Nausea;Nervous system disorder;Oedema peripheral;Pain;Pain in jaw;Palpitations;Pharyngolaryngeal pain;Phosphatase alkaline increased;Pneumonia;Rash;Renal failure;Shock;Skin disorder;Supraventricular tachycardia;Syncope;Tachycardia;Throat irritation;Thrombocytopenia;Tongue irritation;Trismus;Unspecified disorder of skin and subcutaneous tissue;Vasodilation;Vasodilation procedure;Vomiting;Wheezing,small molecule,approved; investigational,"(5E)-[3aS,4R,5R,6aS)-5-Hydroxy-4-[(1E)-(3S,4RS)-3-hydroxy-4-methyloct-1-en-6-ynyl]-hexahydropentalen-2(1H)-ylidene]pentanoic acid; (E)-(3aS, 4R, 5R, 6aS)-hexahydro-5-hydroxy-4-[(E)-(3S,4RS)­ 3-hydroxy-4-methyl-1-octen-6-ynyl]-Δ2(1H),Δ-pentalenevaleric acid; Iloprost; PENTANOIC ACID, 5-((3AS,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-((1E,3S)-3-HYDROXY-4-METHYL-1-OCTEN-6-YNYL)-2(1H)-PENTALENYLIDENE)-, (5E)-; PGI receptor; PGI2 receptor; PRIPR; Prostaglandin I2 receptor; Prostanoid IP receptor; PGE receptor EP2 subtype; PGE2 receptor EP2 subtype; Prostanoid EP2 receptor; PGE receptor EP1 subtype; PGE2 receptor EP1 subtype; Prostanoid EP1 receptor; 3.1.4.53; cAMP-specific phosphodiesterase 4A; DPDE2; PDE46; 3.1.4.53; cAMP-specific phosphodiesterase 4B; DPDE4; PDE32; 3.1.4.53; cAMP-specific phosphodiesterase 4C; DPDE1; PDE21; 3.1.4.53; cAMP-specific phosphodiesterase 4D; DPDE3; PDE43; 3.4.21.68; t-PA; t-plasminogen activator; tPA; Chemoattractant receptor-homologous molecule expressed on Th2 cells; CRTH2; DL1R; G-protein coupled receptor 44; GPR44; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; OATP2A1; PGT; PHOAR2; Prostaglandin transporter; SLC21A2; SLCO2A1; Solute carrier family 21 member 2; OATP-D; OATP-RP3; OATP3A1; OATPD; OATPRP3; Organic anion transporter polypeptide-related protein 3; Organic anion-transporting polypeptide D; PGE1 transporter; SLC21A11; Sodium-independent organic anion transporter D; Solute carrier family 21 member 11","Prostacyclin receptor; Prostaglandin E2 receptor EP2 subtype; Prostaglandin E2 receptor EP1 subtype; 3',5'-cyclic-AMP phosphodiesterase 4A; 3',5'-cyclic-AMP phosphodiesterase 4B; 3',5'-cyclic-AMP phosphodiesterase 4C; 3',5'-cyclic-AMP phosphodiesterase 4D; Tissue-type plasminogen activator; Prostaglandin D2 receptor 2",B01AC11
fosfomycin,Acute cystitis;Bacteriuria;Cystitis;Urinary tract infection,Abdominal pain;Abnormal faeces;Alanine aminotransferase increased;Anaphylactic shock;Angioedema;Anorexia;Aplastic anaemia;Aspartate aminotransferase increased;Asthenia;Asthma;Back pain;Blood alkaline phosphatase increased;Blood bilirubin increased;Body temperature increased;Constipation;Deafness;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Dyspepsia;Dysuria;Ear disorder;Eosinophil count increased;Eosinophilia;Flatulence;Gastrointestinal pain;Haematocrit decreased;Haematuria;Haemoglobin decreased;Headache;Hearing impaired;Hepatic necrosis;Infection;Influenza;Insomnia;Jaundice cholestatic;Lymphadenopathy;Megacolon;Megacolon toxic;Menstrual disorder;Migraine;Musculoskeletal discomfort;Myalgia;Nausea;Nervousness;Optic neuritis;Pain;Paraesthesia;Pharyngitis;Phosphatase alkaline increased;Platelet count decreased;Pruritus;Rash;Rhinitis;Skin disorder;Somnolence;Tension;Vaginal infection;Vaginal inflammation;Vomiting;White blood cell count decreased,small molecule,approved,"(-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid; (1R,2S)-epoxypropylphosphonic acid; (2R-cis)-(3-Methyloxiranyl)phosphonic acid; 1R-cis-(1,2-epoxypropyl)phosphonic acid; cis-(1R,2S)-epoxypropylphosphonic acid; FCM; Fosfocina; Fosfomicina; Fosfomycin; Fosfomycine; Fosfomycinum; L-cis-1,2-epoxypropylphosphonic acid; Phosphomycin; Phosphonemycin; Phosphonomycin; 2.5.1.7; Enoylpyruvate transferase; EPT; murZ; UDP-N-acetylglucosamine enolpyruvyl transferase",UDP-N-acetylglucosamine 1-carboxyvinyltransferase, J01XX01;S02AA17
Octreotide,Abscess;Acromegaly;Arthralgia;Asthenia;Carcinoid syndrome;Carcinoid tumour;Carpal tunnel syndrome;Diarrhoea;Endocrine neoplasm;Fatigue;Flushing;Gastrinoma;Gastroesophageal varices;Glucagonoma;Haemoglobin;Haemorrhage;Headache;Hyperhidrosis;Hypoglycaemia;Hypokalaemia;Insulinoma;Intestinal obstruction;Malignant neoplasm of pancreas;Metastasis;Musculoskeletal discomfort;Neoplasm;Neuroendocrine tumour;Oesophageal varices haemorrhage;Pancreatic carcinoma;Pancreatic fistula;Pancreatitis acute;Paraesthesia;Pituitary adenoma;Pituitary tumour benign;Portal hypertension;Post procedural complication;Postoperative complications NOS;Sepsis;Swelling;Thymoma;Varices oesophageal;Vipoma;Watery diarrhoea;Zollinger-Ellison syndrome,Abdominal bloating;Abdominal cramps;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abdominal tenderness;Abnormal faeces;Acne;Acne cystic;Adrenal insufficiency;Agitation;Alopecia;Amenorrhoea;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Anorectal discomfort;Anorectal disorder;Anorexia;Anxiety;Appendicitis;Appetite absent;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Back pain;Basal cell carcinoma;Bell's palsy;Biliary sludge;Bladder pain;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Blood growth hormone increased;Blood thyroid stimulating hormone decreased;Body temperature increased;Bradycardia;Breast feeding;Breast mass;Breast neoplasm;Breast pain;Breast pain female;Bronchitis;Bronchospasm;Burning sensation;Candida infection;Cardiac disorder;Cardiac failure congestive;Cellulitis;Chest pain;Cholecystitis;Cholelithiasis;Cholestasis;Clotting;Coagulopathy;Cold symptoms;Conjunctivitis;Constipation;Contusion;Convulsion;Cough;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dehydration;Depression;Dermatitis;Diabetes insipidus;Diabetes mellitus;Diabetic;Diarrhoea;Discomfort;Distention;Dizziness;Drowsiness;Drug interaction;Dry mouth;Dry skin;Dysfunction thyroid;Dyspepsia;Dyspnoea;Dysuria;Ear disorder;Ear infection;Endocrine disorder;Epigastric pain;Epistaxis;Eructation;Erythema;Extravasation;Faeces discoloured;Fatigue;Feeling abnormal;Flatulence;Flu symptoms;Flushing;Foot pain;Fracture;Galactorrhoea;Gallbladder disorder;Gallbladder polyp;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal symptom NOS;Glucose tolerance decreased;Glucose tolerance impaired;Goitre;Growth hormone overproduction;Gynaecomastia;Haematoma;Haematuria;Haemorrhoids;Headache;Hearing impaired;Hepatic steatosis;Hepatitis;Hepatitis acute;Hepatitis cholestatic;Hepatobiliary disease;Hernia;Herpes simplex;Herpes zoster;Hot flush;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hypersensitivity;Hypertension;Hypertension worsened;Hypertensive;Hypoaesthesia;Hypochromic anaemia;Hypoglycaemia;Hypogonadism;Hypothyroidism;Ill-defined disorder;Immune system disorder;Increased activity;Infection;Influenza;Influenza like illness;Influenza-like symptoms;Injection site haematoma;Injection site pain;Injection site reaction;Injury;Insomnia;Intestinal obstruction;Intraocular pressure increased;Iron deficiency;Irritability;Ischaemia;Jaundice;Jaundice cholestatic;Joint effusion;Liver fatty;Local reaction;Loose stools;Loss of consciousness;Loss of libido;Lung nodule;Malabsorption;Malaise;Malnutrition;Menopausal symptoms;Menstrual disorder;Mental disorder;Metrorrhagia;Mouth ulceration;Multiple fractures;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nail disorder;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm malignant;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Numbness;Oedema;Oedema peripheral;Oily skin;Oligomenorrhoea;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Osteonecrosis;Otitis;Otitis media;Otorrhoea;Pain;Pain in extremity;Pain localised;Palpitations;Pancreatitis;Pancreatitis acute;Paraesthesia;Paranoia;Peptic ulcer;Petechiae;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Pituitary apoplexy;Pituitary haemorrhage;Pneumonia;Pollakiuria;Polymenorrhoea;Polyuria;Pregnancy;Proctalgia;Prostatic disorder;Prostatitis;Pruritus;Pruritus generalised;Psychotic disorder;Pulmonary mass;Rash;Rectal disorder;Rectal haemorrhage;Rectal tenesmus;Redness;Renal pain;Rhinitis;Seborrhoeic dermatitis;Sensory loss;Shock;Sinus bradycardia;Sinusitis;Skin disorder;Sleep disorder;Somnolence;Status asthmaticus;Steatorrhoea;Stinging;Stomach ache;Sweating increased;Syncope;Tachycardia;Tension;Throat sore;Thrombocytopenia;Thrombophlebitis;Thyroid disorder;Thyrotropin low;Thyroxine free decreased;Tingling sensation;Tinnitus;Tired and heavy;Transaminases increased;Trauma;Tremor;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urine output increased;Urticaria;VIIth nerve paralysis;Vaginal infection;Vaginal inflammation;Vaginal itching;Varicose vein;Vertigo;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal pruritus;Weight decreased;Weight increased;Wheezing,biotech,approved; investigational,"Octreotida; Octreotide; Octreotidum; Octrotide; SRIF-1; SS-2-R; SS2-R; SS2R; SST2; 1.11.2.2; MPO; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",Somatostatin receptor type 2; Somatostatin receptor,H01CB02
simvastatin,Acute coronary syndrome;Alcohol abuse;Alcoholism;Angina pectoris;Arteriosclerosis;Arteriosclerosis coronary artery;Atheroma;Blood cholesterol increased;Blood triglycerides increased;Blood triglycerides normal;Cardiac failure congestive;Cardiovascular disorder;Carotid artery disease;Cerebrovascular accident;Cerebrovascular disorder;Cholesterol serum elevated;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Dyslipidaemia;Foetor hepaticus;Fredrickson Type III lipidemia;Heart failure signs and symptoms;Hepatocellular injury;Heterozygous familial hypercholesterolemia;High density lipoprotein decreased;Homozygous familial hypercholesterolaemia;Hypercholesterolaemia;Hyperlipidaemia;Hyperlipoproteinemia;Hypertension;Hypertriglyceridaemia;Hypothyroidism;Leg ulcer;Lipid metabolism disorder;Liver disorder;Low density lipoprotein increased;Menarche;Myocardial infarction;Nephrotic syndrome;Obstruction;Peripheral vascular disorder;Premature menopause;Skin ulcer;Triglycerides normal;Type II hyperlipidaemia;Type III hyperlipidaemia;Type IIa hyperlipidaemia;Type IIb hyperlipidaemia;Type IV hyperlipidaemia,Abdominal discomfort;Abdominal pain;Ache;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Antinuclear antibody positive;Anxiety;Arthralgia;Arthritis;Asthenia;Atrial fibrillation;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Body temperature increased;Breast feeding;Bronchitis;Cataract;Chest pain;Chills;Cognitive disorder;Cognitive impairment;Confusional state;Constipation;Cramp muscle;Creatine phosphokinase increased;Decreased appetite;Depression;Dermatitis;Dermatomyositis;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Drug interaction;Drug reaction with eosinophilia and systemic symptoms;Dysgeusia;Dyspepsia;Dyspnoea;Eczema;Endocrine disorder;Eosinophilia;Erectile dysfunction;Erythema;Erythema multiforme;Facial paresis;Fatigue;Feeling abnormal;Flatulence;Flushing;Foetor hepaticus;Forgetfulness;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gynaecomastia;Haemolytic anaemia;Headache;Hepatic cancer;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis chronic active;Hepatocellular carcinoma;Hepatocellular injury;Hypersensitive syndrome;Hypersensitivity;IIIrd nerve paralysis;Ill-defined disorder;Immune-mediated necrotising myopathy;Infection;Inflammation;Insomnia;Interstitial lung disease;Jaundice;Jaundice cholestatic;Lenticular opacities;Leukopenia;Liver disorder;Loss of libido;Lupus erythematosus;Lupus-like syndrome;Malaise;Memory impairment;Memory loss;Menarche;Mental disorder;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Myopathy;Nausea;Neuropathy peripheral;Nightmare;Nodule;Oedema;Ophthalmoplegia;Pain;Pancreatitis;Paraesthesia;Peripheral nerve palsy;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Polymyalgia rheumatica;Polyneuropathy;Pregnancy;Protein urine present;Proteinuria;Pruritus;Purpura;Rash;Red blood cell sedimentation rate increased;Regurgitation;Rhabdomyolysis;Sensory disturbance;Sexual dysfunction;Sinusitis;Sleep disorder;Sleep disturbance;Stevens-Johnson syndrome;Swelling;Systemic lupus erythematosus;Tenderness;Thrombocytopenia;Toxic epidermal necrolysis;Transaminases increased;Tremor;Upper respiratory tract infection;Upset stomach;Urticaria;VIIth nerve paralysis;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Vomiting,small molecule,approved,"2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; Simvastatin; Simvastatina; Simvastatine; Simvastatinum; 1.1.1.34; HMG-CoA reductase; CD11 antigen-like family member A; CD11A; Leukocyte adhesion glycoprotein LFA-1 alpha chain; Leukocyte function-associated molecule 1 alpha chain; LFA-1A; 3.5.1.98; HD2; Protein deacylase HDAC2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 3.1.1.84; Carboxylesterase 2; CE-2; hCE-2; ICE; Methylumbelliferyl-acetate deacetylase 2; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",3-hydroxy-3-methylglutaryl-coenzyme A reductase; Integrin alpha-L; Histone deacetylase 2, C10AA01; C10BA02; C10BA04; C10BX01; C10BX04;A10BH51;C10AA01
cefpodoxime,Abscess;Acute maxillary sinusitis;Acute sinusitis;Bladder pain;Bronchitis chronic;Community acquired pneumonia;Cystitis;Cystitis noninfective;Diarrhoea;Ear infection;Gonorrhoea;Infection;Influenza;Otitis;Otitis media acute;Pharyngitis;Pneumonia;Renal failure;Renal impairment;Rheumatic disorder;Rheumatic fever;Skin infection;Tonsillitis;Urinary tract infection,Abdominal cramps;Abdominal distension;Abdominal pain;Abdominal pain generalised;Abdominal pain localised;Abortion spontaneous;Activated partial thromboplastin time prolonged;Acute liver injury;Ageusia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Anorectal discomfort;Anorectal disorder;Anorexia;Anxiety;Aplastic anaemia;Aspartate aminotransferase increased;Asthenia;Asthma;Back pain;Bacterial infection;Basophilia;Blepharitis;Body temperature increased;Bronchitis;Candida infection;Cardiac failure congestive;Cerebral infarction;Cerebration impaired;Chest pain;Chills;Cholestasis;Colitis ulcerative;Confusional state;Constipation;Convulsion;Cough;Decreased appetite;Dehydration;Dermatitis;Dermatitis bullous;Dermatitis diaper;Dermatitis exfoliative;Dermatitis eyelid;Diarrhoea;Diarrhoea haemorrhagic;Digestion impaired;Disability;Discomfort;Disseminated intravascular coagulation;Disturbance in attention;Dizziness;Dry mouth;Dry skin;Dry throat;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Eosinophilia;Epistaxis;Eructation;Erythema multiforme;Eye irritation;Face oedema;Fatigue;Feeling abnormal;Flatulence;Fungal infection;Fungal skin infection;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Generalized aching;Gout;Granulocytosis;Haematocrit decreased;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hepatic function abnormal;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hypersensitivity;Hypertension;Hypoalbuminaemia;Hypoglycaemia;Hyponatraemia;Hypoproteinaemia;Hypotension;Ill-defined disorder;Increased thirst;Insomnia;Leukocytosis;Leukopenia;Liver injury;Localised oedema;Loose stools;Loss of consciousness;Lung infiltration;Lymphocytosis;Lymphopenia;Malaise;Mental disability;Metrorrhagia;Migraine;Monocytosis;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Nausea;Nephritis;Nephropathy toxic;Nervousness;Neutropenia;Nightmare;Nocturia;Oedema peripheral;Oral candidiasis;Oral disorder;Oral lesion;Pain;Pain localised;Palpitations;Pancytopenia;Paraesthesia;Penile infection;Photosensitivity reaction;Pleural effusion;Pneumonia;Pollakiuria;Proctalgia;Proctocolitis;Protein urine present;Proteinuria;Prothrombin level increased;Pruritus;Pseudomembranous colitis;Rash;Rash maculo-papular;Rash pustular;Rectal disorder;Rectal haemorrhage;Rectal tenesmus;Renal failure;Renal impairment;Rhinitis;Serum sickness;Serum sickness-like reaction;Shakiness;Shock;Sinusitis;Skin exfoliation;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sunburn;Sweating increased;Syncope;Tension;Thirst;Thrombocytopenia;Thrombocytopenic purpura;Thrombocytosis;Tinnitus;Tongue disorder;Tooth disorder;Toothache;Toxic epidermal necrolysis;Tremor;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal pain;Vasodilation;Vasodilation procedure;Vertigo;Vesiculobullous rash;Vomiting;Vulvovaginal pain;Weight increased;Wheezing,small molecule,approved; vet_approved,Cefpodoxima; Cefpodoxime; Cefpodoximum; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3,Peptidoglycan synthase FtsI,J01DD13
clarithromycin,Abscess;Acquired immunodeficiency syndrome;Acute bronchitis;Acute exacerbation of chronic bronchitis;Acute maxillary sinusitis;Acute sinusitis;Atypical pneumonia;Autoimmune disorder;Bacterial infection due to helicobacter pylori (H. pylori);Blood culture negative;Bronchitis;Bronchitis chronic;Cellulitis;Community acquired pneumonia;Disseminated mycobacterium avium complex infection;Duodenal ulcer;Helicobacter infection;Immunocompromised;Immunodeficiency;Impetigo;Infection;Mycobacterial infection;Mycobacterium avium complex infection;Otitis media;Otitis media acute;Peptic ulcer;Pharyngitis;Pharyngitis streptococcal;Pneumonia;Pneumonia mycoplasmal;Renal failure;Renal impairment;Rheumatic disorder;Rheumatic fever;Skin infection;Streptococcal infection;Tonsillitis;Tracheobronchitis;Ulcer,Abdominal distension;Abdominal pain;Abnormal behaviour;Abnormal dreams;Accidental injury;Ache;Acquired immunodeficiency syndrome;Ageusia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albumin globulin ratio abnormal;Amylase increased;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Anosmia;Anxiety;Aspartate aminotransferase increased;Asthenia;Asthma;Atrial fibrillation;Autoimmune disorder;Back pain;Bacteraemia;Bad dreams;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood disorder;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Breast disorder;Candida infection;Cardiac arrest;Cardiac disorder;Cellulitis;Chest pain;Chills;Cholestasis;Chromaturia;Community acquired pneumonia;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Corneal opacity;Cough;Cough increased;Cyst;Deafness;Deafness transitory;Decreased appetite;Depersonalisation;Depression;Dermatitis;Dermatitis bullous;Dermatitis diaper;Diarrhoea;Discomfort;Disorientation;Dizziness;Drug eruption;Drug interaction;Dry mouth;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dysosmia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Electrocardiogram QT prolonged;Enteritis;Eosinophilia;Epidermal necrosis;Epistaxis;Eructation;Eruption;Erysipelas;Erythema multiforme;Erythrasma;Extrasystoles;Eye disorder;Fatal outcomes;Fatigue;Feeling abnormal;Flatulence;Flushing;Functional gastrointestinal disorder;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrooesophageal reflux disease;Gingival bleeding;Glossitis;Haematuria;Haemoglobin;Haemoglobin decreased;Haemorrhage;Hallucination;Headache;Hearing impaired;Heartburn;Henoch-Schonlein purpura;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hepatomegaly;Hepatotoxicity;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypoglycaemia;Ill-defined disorder;Immune system disorder;Immunocompromised;Immunodeficiency;Infection;Infestation;Infestation NOS;Influenza;Injury;Inner ear disorder;Insomnia;International normalised ratio increased;Jaundice;Jaundice cholestatic;Jaundice hepatocellular;Labyrinthine disorder;Leukopenia;Liver function test abnormal;Loss of consciousness;Malaise;Malnutrition;Mania;Mediastinal disorder;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myopathy;Nausea;Neoplasm;Nephritis;Nephritis interstitial;Nervous system disorder;Nervousness;Neutropenia;Nightmare;Nuchal rigidity;Oesophagitis;Oral candidiasis;Otitis media;Pain;Palpitations;Pancreatitis;Pancreatitis acute;Paraesthesia;Parosmia;Partial transitory deafness;Pharyngitis;Photophobia;Platelet count decreased;Pneumonia;Polyp;Proctalgia;Prothrombin level increased;Pruritus;Pseudomembranous colitis;Psychotic disorder;Pulmonary embolism;Purpura;Purpuric rash;Rash;Rash maculo-papular;Rash pustular;Renal failure;Renal impairment;Rhabdomyolysis;Rhinitis;Serum creatinine increased;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Stevens-Johnson syndrome;Stomatitis;Tension;Testicular atrophy;Thrombocytopenia;Thrombocytosis;Tinnitus;Tongue discolouration;Tooth discolouration;Torsade de pointes;Toxic epidermal necrolysis;Transient cerebrovascular events;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine color abnormal;Urticaria;Vaginal infection;Vaginal moniliasis;Ventricular arrhythmia;Ventricular tachycardia;Vertigo;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;White blood cell count decreased;White blood cell count low,small molecule,approved,"6-O-methyl erythromycin; 6-O-methylerythromycin; 6-O-methylerythromycin A; CLA; Clarithromycin; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",50S ribosomal protein L10; Voltage-gated inwardly rectifying potassium channel KCNH2; Solute carrier organic anion transporter family member 1B1; Solute carrier organic anion transporter family member 1B3, A02BD04; A02BD05; A02BD06; A02BD07; A02BD09; A02BD11; A02BD14; J01FA09;A02BD12;J01FA09
treprostinil,Connective tissue disorder;Hepatic function abnormal;Hypertension;Infection;Menorrhagia;Obesity;Portopulmonary hypertension;Prolonged menses;Renal failure;Renal impairment,Abdominal discomfort;Abdominal pain;Anaemia;Angioedema;Anorexia;Anxiety;Arthralgia;Asthenia;Back pain;Battery;Blood culture positive;Body temperature increased;Bone pain;Bradycardia;Bronchitis;Cardiac failure;Cardiac failure congestive;Cellulitis;Chest pain;Contusion;Cough;Cramps of lower extremities;Decreased appetite;Dehydration;Depression;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dyspepsia;Dyspnoea;Ecchymosis;Epistaxis;Erythema;Fatigue;Feeling abnormal;Flushing;Gastrointestinal pain;Gout;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Headache;Hypokalaemia;Hypotension;Hypoxia;Ill-defined disorder;Induration;Infection;Influenza;Infusion site infection;Infusion site pain;Infusion site reaction;Infusion site reactions;Insomnia;Laryngeal pain;Local swelling;Loss of consciousness;Malaise;Melaena;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Neck pain;Nervousness;Oedema;Oedema peripheral;Pain;Pain in extremity;Pain in jaw;Pallor;Palpitations;Paraesthesia;Pharyngitis;Pharyngolaryngeal pain;Physical assault;Pneumonia;Pruritus;Pseudomonal sepsis;Pseudomonas infection;Pulmonary embolism;Pulmonary hypertension;Rash;Rectal haemorrhage;Rhinitis;Sepsis;Shock;Sinusitis;Swollen arm;Syncope;Tachycardia;Tension;Throat irritation;Thrombocytopenia;Thrombophlebitis;Urinary tract infection;Viral infection;Vomiting;Wheezing,small molecule,approved; investigational,Tréprostinil; Treprostinil; Treprostinilo; Treprostinilum; PGI receptor; PGI2 receptor; PRIPR; Prostaglandin I2 receptor; Prostanoid IP receptor; PGE receptor EP2 subtype; PGE2 receptor EP2 subtype; Prostanoid EP2 receptor; PGD receptor; PGD2 receptor; Prostanoid DP receptor; NR1C2; NUC1; NUCI; Nuclear hormone receptor 1; Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferator-activated receptor beta; PPAR-beta; PPAR-delta; PPARB; ADP-glucose receptor; ADPG-R; HORK3; P2T(AC); P2Y(AC); P2Y(ADP); P2Y(cyc); P2Y12; P2Y12 platelet ADP receptor; SP1999; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase,Prostacyclin receptor; Prostaglandin E2 receptor EP2 subtype; Prostaglandin D2 receptor; Peroxisome proliferator-activated receptor delta; P2Y purinoceptor 12,B01AC21
atomoxetine,Agitation;Angle closure glaucoma;Attention deficit disorder;Attention deficit/hyperactivity disorder;Body temperature increased;Coma;Delirium;Epilepsy;Forgetfulness;Hepatic failure;Hepatic insufficiency;Hyperkinesia;Hypersensitivity;Memory impairment;Mental disorder;Mental status changes;Muscle rigidity;Mydriasis;Myoclonus;Neuroleptic malignant syndrome;Psychotic disorder,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abnormal behaviour;Abnormal dreams;Affect lability;Aggression;Agitation;Angiopathy;Anorexia;Anxiety;Arthralgia;Asthenia;Autonomic nervous system imbalance;Back pain;Blood pressure increased;Body temperature increased;Bone disorder;Breast disorder;Cardiac disorder;Chest pain;Chills;Coma;Completed suicide;Conjunctivitis;Constipation;Convulsion;Cough;Crying;Decreased appetite;Delirium;Dependence;Dependence psychological;Depressed mood;Depression;Depressive symptom;Dermatitis;Diarrhoea;Disorientation;Disturbance in sexual arousal;Dizziness;Drug abuse;Drug dependence;Drug interaction;Dry mouth;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphoria;Dysuria;Ear infection;Ejaculation delayed;Ejaculation disorder;Ejaculation failure;Epigastric discomfort;Erectile dysfunction;Erection increased;Erection prolonged;Excoriation;Fatigue;Feeling abnormal;Feeling jittery;Female sexual dysfunction;Flatulence;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Genital pain;Genital pain male;Hallucination;Headache;Hepatic failure;Hepatic insufficiency;Hostility;Hot flush;Hyperhidrosis;Hypoaesthesia;Infection;Infestation;Infestation NOS;Influenza;Initial insomnia;Insomnia;Irritability;Laryngeal pain;Lethargy;Libido decreased;Loss of consciousness;Major depression;Malnutrition;Mania;Mediastinal disorder;Menopausal symptoms;Menstrual disorder;Menstruation delayed;Menstruation irregular;Mental disorder;Mental status changes;Micturition urgency;Middle insomnia;Mood swings;Muscle rigidity;Muscle spasms;Musculoskeletal discomfort;Myalgia;Mydriasis;Myoclonus;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Orgasm abnormal;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Palpitations;Paraesthesia;Pelvic pain;Peripheral coldness;Pharyngolaryngeal pain;Pollakiuria;Pre-existing disease;Presyncope;Prostatitis;Pruritus;Psychotic disorder;Rash;Rhinorrhoea;Rigors;Sexual dysfunction;Shock;Sinus congestion;Sinus headache;Sinus tachycardia;Sinusitis;Skin disorder;Sleep disorder;Somnolence;Strangury;Suicidal behaviour;Suicidal ideation;Suicide attempt;Sweating increased;Syncope;Syncope vasovagal;Tachycardia;Tearfulness;Tension;Terminal insomnia;Testicular pain;Therapeutic response unexpected;Thirst;Throat sore;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary hesitation;Urinary retention;Urinary tract disorder;Urine flow decreased;Urticaria;Vertigo;Viral diarrhoea;Vision blurred;Vomiting;Weight decreased,small molecule,approved,"(-)-Tomoxetine; Atomoxetina; Atomoxetine; Tomoxetina; Tomoxetine; Tomoxetinum; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; GIRK-1; GIRK1; Inward rectifier K(+) channel Kir3.1; Potassium channel, inwardly rectifying subfamily J member 3; K-OR-1; KOR-1; OPRK; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; Fc-gamma RI; Fc-gamma RIA; FCG1; FcgammaRIa; FCGR1; FcRI; IGFR1; IgG Fc receptor I",Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; NMDA receptor; G protein-activated inward rectifier potassium channel 1; Kappa-type opioid receptor,N06BA09
milnacipran,Fibromyalgia;Major depression,Abdominal distension;Abdominal pain;Accommodation disorder;Aggression;Agitation;Anger;Angina pectoris;Angiopathy;Angle closure glaucoma;Anorexia;Anxiety;Asthenia;Bladder pain;Blood and lymphatic system disorders;Blood cholesterol increased;Blood pressure increased;Body temperature increased;Breast disorder;Bruxism;Cardiac disorder;Chest discomfort;Chest pain;Chills;Conjunctival haemorrhage;Connective tissue disorder;Constipation;Contusion;Convulsion;Cystitis;Cystitis noninfective;Decreased appetite;Delirium;Dermatitis;Diarrhoea;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ejaculation disorder;Ejaculation failure;Endocrine disorder;Erectile dysfunction;Erythema multiforme;Extrapyramidal disorder;Eye disorder;Fatigue;Flatulence;Flushing;Galactorrhoea;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematuria;Haemorrhagic disorder;Hallucination;Headache;Hemorrhage abnormal;Hepatitis;Hepatobiliary disease;Homicidal ideation;Hot flush;Hypercholesterolaemia;Hyperhidrosis;Hyperprolactinaemia;Hypersensitivity;Hypertension;Hypertensive crisis;Hypoaesthesia;Hypomania;Hyponatraemia;Hypotension;Infection;Insomnia;Irritability;Leukopenia;Libido decreased;Liver function test abnormal;Loss of consciousness;Malnutrition;Mania;Mediastinal disorder;Menopausal symptoms;Mental disorder;Migraine;Nausea;Nervous system disorder;Neuroleptic malignant syndrome;Neutropenia;Night sweats;Oedema peripheral;Palpitations;Panic attack;Paraesthesia;Parkinsonism;Pollakiuria;Prostatitis;Protein urine present;Proteinuria;Pruritus;Rash;Renal failure acute;Rhabdomyolysis;Scrotal pain;Serotonin syndrome;Shock;Skin disorder;Somnolence;Stevens-Johnson syndrome;Suicidal ideation;Supraventricular tachycardia;Syncope;Tachycardia;Tension;Tension headache;Testicular pain;Testicular swelling;Thirst;Thrombocytopenia;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urethral pain;Urinary hesitation;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine flow decreased;Urticaria;Ventricular extrasystoles;Vision blurred;Vomiting;Weight decreased;Yawning,small molecule,approved; investigational,"(+-)-Milnacipran; Midalcipran; Milnacipran; Milnacipranum; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; NMDA receptor,N06AX17
fosphenytoin,Cerebellar syndrome;Confusional state;Convulsion;Delirium;Diabetes mellitus;Diabetic;Encephalopathy;Epilepsy;Feeling abnormal;Hepatic function abnormal;Hyperglycaemia;Nervous system disorder;Psychotic disorder;Status epilepticus;Status epilepticus grand mal,Accidental injury;Acidosis;Affect lability;Ageusia;Agitation;Akathisia;Albuminuria;Alkalosis;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Anorectal discomfort;Anorexia;Aphasia;Apnoea;Arthralgia;Asthenia;Asthma;Ataxia;Atelectasis;Atrial flutter;Back pain;Body temperature increased;Bradycardia;Brain oedema;Bronchitis;Bundle branch block;CNS depression NOS;Cachexia;Cardiac arrest;Cardiac failure congestive;Cardiomegaly;Cerebral haemorrhage;Cerebral infarction;Chills;Circumoral paresthesia;Coma;Confusional state;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cramps of lower extremities;Cryptococcosis;Cyanosis;Deafness;Decreased appetite;Dehydration;Delirium;Depersonalisation;Depressed level of consciousness;Dermatitis;Dermatitis contact;Diabetes insipidus;Diarrhoea;Diplopia;Discomfort;Dizziness;Dry mouth;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Encephalitis;Encephalopathy;Epistaxis;Extensor plantar response;Extrapyramidal disorder;Eye pain;Face oedema;Feeling abnormal;Flatulence;Fluid retention;Gastritis;Gastrointestinal haemorrhage;Generalised oedema;Haemoptysis;Headache;Hemiplegia;Hostility;Hyperacusis;Hyperaesthesia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperreflexia;Hypertension;Hyperventilation;Hypoaesthesia;Hypochromic anaemia;Hypokalaemia;Hypokinesia;Hypophosphataemia;Hyporeflexia;Hypotension;Hypotonia;Ileus;Ill-defined disorder;Increased bronchial secretion;Infection;Influenza;Injection site haemorrhage;Injection site inflammation;Injection site pain;Injection site reaction;Injection site swelling;Injury;Insomnia;Intracranial pressure increased;Ketosis;Leukocytosis;Leukopenia;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Malaise;Meningitis;Mental disability;Migraine;Mood swings;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Mydriasis;Myoclonus;Myopathy;Nausea;Nervousness;Neurosis;Nystagmus;Oedema genital;Oliguria;Orthostatic hypotension;Osteoarthritis;Palpitations;Paraesthesia;Paraesthesia oral;Paralysis;Parosmia;Pelvic pain;Personality disorder;Petechiae;Pharyngitis;Photophobia;Photosensitivity reaction;Pneumonia;Pneumonia aspiration;Pneumothorax;Polyuria;Proctalgia;Pruritus;Psychotic disorder;Pulmonary embolism;Rash;Rash maculo-papular;Rash pustular;Rectal tenesmus;Renal failure;Rhinitis;Salivary hypersecretion;Scotoma;Sepsis;Shock;Sinus bradycardia;Sinusitis;Skin discolouration;Skin mass;Skin nodule;Somnolence;Speech disorder;Sputum increased;Stupor;Subdural haematoma;Sweating;Syncope;Tachycardia;Tension;Thinking abnormal;Thrombocytopenia;Thrombophlebitis;Tingling sensation;Tinnitus;Tongue disorder;Tongue oedema;Tremor;Urethral pain;Urinary incontinence;Urinary retention;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Ventricular extrasystoles;Vertigo;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved; investigational,"(3-Phosphoryloxymethyl)phenytoin; Fosfenitoina; Fosphenytoin; Fosphenytoine; Fosphenytoinum; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 2.4.1.17; GNT1; Phenol-metabolizing UDP-glucuronosyltransferase; UDP-glucuronosyltransferase 1-F; UDP-glucuronosyltransferase 1A6; UDPGT 1-6; UGT-1F; UGT1; UGT1-06; UGT1.6; UGT1*6; UGT1F; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; Serpin A7; T4-binding globulin; TBG",Sodium channel protein type 5 subunit alpha,N03AB05
ranolazine,Acute coronary syndrome;Angina pectoris;Bronchial hyperreactivity;Cardiac failure;Chronic obstructive pulmonary disease;Diabetes mellitus;Obstructive airways disorder;Renal failure;Renal impairment;Stable angina pectoris,Abdominal discomfort;Abdominal pain;Altered state of consciousness;Amnesia;Angioedema;Angiopathy;Anorexia;Anxiety;Arrhythmia;Asthenia;Blood creatinine increased;Blood urea increased;Bradycardia;Breast disorder;Cardiac disorder;Chromaturia;Cold sweat;Confusional state;Connective tissue disorder;Constipation;Coordination abnormal;Cough;Cramp muscle;Creatinine increased;Decreased appetite;Dehydration;Depressed level of consciousness;Dermatitis;Dermatitis atopic;Diplopia;Disorientation;Dizziness;Dizziness postural;Dry mouth;Duodenitis haemorrhagic;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Electrocardiogram QT prolonged;Eosinophilia;Epistaxis;Erectile dysfunction;Eye disorder;Fatigue;Feeling abnormal;Flatulence;Gait disturbance;Gastrointestinal disorder;Gastrointestinal pain;Haematuria;Hallucination;Headache;Hearing impaired;Hot flush;Hyperhidrosis;Hypoaesthesia;Hypoaesthesia oral;Hypotension;Insomnia;Joint swelling;Lethargy;Leukopenia;Loss of consciousness;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Muscle spasms;Nausea;Nephropathy toxic;Nervous system disorder;Oedema peripheral;Orthostatic hypotension;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Parosmia;Partial hearing loss;Peripheral coldness;Proarrhythmic effect;Pruritus;Pulmonary fibrosis;Rash;Renal failure;Renal failure acute;Serum creatinine increased;Shock;Skin disorder;Somnolence;Syncope;Throat tightness;Thrombocytopenia;Thrombocytosis;Tinnitus;Tremor;Underweight;Unspecified disorder of skin and subcutaneous tissue;Upset stomach;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased,small molecule,approved; investigational,"Ranolazina; Ranolazine; 3.4.21.7; NAC1; SCN1; Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; HBA; HBSC II; NAC2; SCN2A1; SCN2A2; Sodium channel protein brain II subunit alpha; Sodium channel protein type II subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.2; KIAA1356; NAC3; Sodium channel protein brain III subunit alpha; Sodium channel protein type III subunit alpha; Voltage-gated sodium channel subtype III; Voltage-gated sodium channel subunit alpha Nav1.3; SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; Atypical sodium channel Nav2.1; Nax channel; SCN6A; Sodium channel protein type VII subunit alpha; MED; Sodium channel protein type VIII subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.6; hNE-Na; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Sodium channel protein type IX subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.7; KIAA1158; Inward rectifier K(+) channel Kir2.2; Inward rectifier K(+) channel Kir2.2v; IRK-2; IRK2; KCNJN1; Potassium channel, inwardly rectifying subfamily J member 12; Inward rectifier K(+) channel Kir2.4; IRK-4; IRK4; Potassium channel, inwardly rectifying subfamily J member 14; Cardiac inward rectifier potassium channel; hIRK1; Inward rectifier K(+) channel Kir2.1; IRK-1; IRK1; Potassium channel, inwardly rectifying subfamily J member 2; Hippocampal inward rectifier; HIR; HIRK2; HRK1; Inward rectifier K(+) channel Kir2.3; IRK-3; IRK3; Potassium channel, inwardly rectifying subfamily J member 4; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1; hMATE-2; Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; Solute carrier family 47 member 2",Plasminogen; Sodium channel protein; Inward rectifier potassium channel; Voltage gated L-type calcium channel; Alpha-1 adrenergic receptors; Beta-1 adrenergic receptor; Fatty acid,C01EB18
imiquimod,Actinic keratosis;Anogenital warts;Anorectal human papilloma virus infection;Basal cell carcinoma;Basal cell naevus syndrome;Carcinogenicity;Hyperkeratosis;Immunocompromised;Immunodeficiency;Keratosis;Molluscum contagiosum;Neoplasm;Papilloma;Perianal warts;Seborrhoeic keratosis;Superficial basal cell carcinoma;Viral infection;Xeroderma pigmentosum,Abdominal pain;Abrasion NOS;Absolute neutrophil count decreased;Actinic keratosis;Acute coronary syndrome;Agitation;Allergy aggravated;Alopecia;Angioedema;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anxiety;Application site burn;Application site cellulitis;Application site discharge;Application site dryness;Application site erosion;Application site erythema;Application site excoriation;Application site exfoliation;Application site haemorrhage;Application site hyperaesthesia;Application site inflammation;Application site irritation;Application site oedema;Application site pain;Application site papules;Application site paraesthesia;Application site pruritus;Application site rash;Application site reaction;Application site scab;Application site scar;Application site skin breakdown;Application site swelling;Application site ulcer;Application site vesicles;Application site warmth;Arrhythmia;Arthralgia;Arthritis;Asthenia;Atrial fibrillation;Atrophic vulvovaginitis;Back pain;Bacterial infection;Basal cell carcinoma;Blood and lymphatic system disorders;Blood glucose increased;Body temperature increased;Bone pain;Breast disorder;Bronchitis;Capillary leak syndrome;Cardiac failure;Cardiomyopathy;Cardiovascular disorder;Cerebrovascular accident;Cheilitis;Chest pain;Chills;Common wart;Completed suicide;Congenital central nervous system anomaly;Congenital eye disorder;Conjunctival irritation;Conjunctivitis;Connective tissue disorder;Convulsion;Cough;Crying;Cutaneous lupus erythematosus;Cyst;Decreased appetite;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Disorder sight;Dizziness;Dry mouth;Dyspareunia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Eczema;Erectile dysfunction;Erythema;Erythema multiforme;Excoriation;Exencephaly;Eye disorder;Eye infection;Eyelid oedema;Face oedema;Fatigue;Febrile convulsion;Feeling abnormal;Feeling hot;Flushing;Folliculitis;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Genital candidiasis;Genital pain;Genital pain male;Gout;Haemoglobin;Haemoglobin decreased;Haemorrhage;Headache;Henoch-Schonlein purpura;Hepatic enzyme increased;Hepatic function abnormal;Hepatic lymphoma;Hepatobiliary disease;Hernia;Herpes simplex;Herpes zoster;Hyperaesthesia;Hypercholesterolaemia;Hyperhidrosis;Hyperkeratosis;Hypersensitivity;Hypertension;Hypertrophic scar;Idiopathic thrombocytopenic purpura;Ill-defined disorder;Immobile;Immune system disorder;Induration;Infection;Infestation;Infestation NOS;Inflammation;Inflicted injury;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Instillation site pain;Irritability;Ischaemia;Laryngeal pain;Lethargy;Leukoderma;Local reaction;Loss of consciousness;Low set ears;Lymphadenopathy;Lymphoma;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Migraine;Multiple sclerosis;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nasal congestion;Nausea;Nervous system disorder;Neuropathy peripheral;Neutrophil count decreased;Non-Hodgkin's lymphoma;Oedema;Oral herpes;Otitis media;Pain;Pain in extremity;Palpitations;Pancytopenia;Papule;Paraesthesia;Paresis;Penis disorder;Pharyngitis;Pharyngolaryngeal pain;Photosensitivity reaction;Phototoxicity;Platelet count decreased;Postoperative pain;Pre-existing disease;Pregnancy;Procedural pain;Procedural site reaction;Proctalgia;Protein urine present;Proteinuria;Pruritus;Psoriasis;Psoriasis flare-up;Pulmonary congestion;Pulmonary oedema;Purpura;Pustule;Rash;Rash erythematous;Rash pustular;Rectal disorder;Rectal tenesmus;Respiratory tract congestion;Rhinitis;Rigors;Scab;Scar;Scrotal erythema;Scrotal oedema;Scrotal pain;Scrotal ulcer;Seborrhoeic keratosis;Shock;Sinusitis;Skin breakdown;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin infection;Skin oedema;Skin papilloma;Skin ulcer;Somnolence;Squamous cell carcinoma;Stevens-Johnson syndrome;Stinging;Suicide;Supraventricular tachycardia;Sweating increased;Swelling;Syncope;Tachycardia;Tearfulness;Tenderness;Teratogenicity;Thyroiditis;Tinea cruris;Tingling sensation;Tinnitus;Tooth disorder;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Uterovaginal prolapse;Vaginal infection;Vaginal inflammation;Vaginal pain;Vaginitis atrophic;Vaginitis bacterial;Viral infection;Visual impairment;Vomiting;Vulval disorder;Vulvitis;Vulvovaginal pain;Warmth;Warts;White blood cell count decreased,small molecule,approved; investigational,"1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; Imiquimod; Imiquimodum; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Toll-like receptor 7; Toll-like receptor 8,D06BB10
rotigotine,Parkinson's disease;Parkinsonism;Restless legs syndrome,Abnormal dreams;Abnormal vision;Aggression;Agitation;Angioedema;Angiopathy;Anorexia;Application and instillation site reactions;Arthralgia;Asthenia;Asthenic conditions;Balance disorder;Binge eating;Breast disorder;Compulsions;Compulsive shopping;Confusional state;Connective tissue disorder;Constipation;Contusion;Cough;Decreased appetite;Depression;Dermatitis;Diarrhoea;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Dizziness postural;Dry mouth;Dysaesthesia;Dyskinesia;Dyspepsia;Ear and labyrinth disorders;Eating disorder;Eczema;Electrocardiogram T wave abnormal;Erectile dysfunction;Erythema;Excessive daytime sleepiness;Fall;Fatigue;Feeling abnormal;Fluid retention;Gastrointestinal disorder;Haematocrit decreased;Haemoglobin decreased;Hallucination;Headache;Hiccups;Hot flush;Hyperhidrosis;Hyperpyrexia;Hypersensitivity;Hypersexuality;Hypertension;Hypotension;Hypotension symptomatic;Ill-defined disorder;Immune system disorder;Impulse-control disorder;Infection;Infestation;Infestation NOS;Inflammation;Insomnia;Irritability;Laryngeal pain;Lethargy;Libido increased;Lip oedema;Lipoedema;Loss of consciousness;Malaise;Malignant melanoma;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nightmare;Obsessive-compulsive disorder;Oedema peripheral;Orthostatic hypotension;Pain;Papule;Paraesthesia;Pathological gambling;Pharyngolaryngeal pain;Prurigo;Pruritus;Psychotic disorder;Punding;Rash;Road traffic accident;Serum ferritin decreased;Sexual desire disorders;Shock;Sinus congestion;Sinusitis;Skin disorder;Skin exfoliation;Sleep attacks;Sleep disorder;Somnolence;Stereotypy;Sudden onset of sleep;Sweating increased;Swelling;Syncope;Terminal insomnia;Tinnitus;Tongue disorder;Tongue oedema;Traffic accident;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Vertigo;Visual impairment;Vomiting;Weight decreased;Weight increased;White blood cells urine positive,small molecule,approved,"(6S)-6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; Rotigotina; Rotigotine; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; Dopamine D2 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D1 receptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",D(3) dopamine receptor; D(4) dopamine receptor; D(2) dopamine receptor; D(1B) dopamine receptor; D(1A) dopamine receptor; 5-hydroxytryptamine receptor 1A; Alpha-2B adrenergic receptor,N04BC09
levetiracetam,Convulsion;Epilepsy;Grand mal convulsion;Idiopathic generalised epilepsy;Intractable epilepsy;Juvenile myoclonic epilepsy;Myoclonic epilepsy;Partial seizures;Renal failure;Renal impairment;Tonic-clonic seizures,Abdominal pain;Abdominal pain upper;Abnormal behaviour;Accidental injury;Affect lability;Aggression;Agitation;Agranulocytosis;Albuminuria;Alopecia;Amblyopia;Amnesia;Anger;Anorexia;Antisocial behaviour;Antisocial personality disorder;Anxiety;Apathy;Arthralgia;Asocial behaviour;Asthenia;Asthma;Ataxia;Back pain;Balance disorder;Blood and lymphatic system disorders;Blood disorder;Body temperature increased;Bronchitis;Chest pain;Choreoathetosis;Common cold;Community acquired infection;Completed suicide;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Cough;Cough increased;Decreased appetite;Dehydration;Dependence;Depersonalisation;Depressed mood;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Diplopia;Disturbance in attention;Dizziness;Drowsiness;Drug abuse;Drug interaction;Drug level increased;Drug withdrawal convulsions;Dyskinesia;Dysmenorrhoea;Dyspepsia;Ear and labyrinth disorders;Ear pain;Ecchymosis;Eczema;Eosinophilia;Epistaxis;Erythema multiforme;Euphoric mood;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Flat affect;Foetor hepaticus;Function kidney decreased;Fungal infection;Gait disturbance;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gingivitis;Hallucination;Head injury;Headache;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hostility;Hyperkinesia;Hyperreflexia;Hypersensitivity;Hypersomnia;Hyponatraemia;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Irritability;Joint sprain;Laryngeal pain;Lethargy;Leukopenia;Ligament sprain;Liver disorder;Liver function test abnormal;Lower respiratory tract infection;Major depression;Malnutrition;Mediastinal disorder;Memory impairment;Mental disability;Mental disorder;Metabolic disorder;Mood swings;Mouth ulceration;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Nervousness;Neurosis;Neutropenia;Oropharyngeal discomfort;Oropharyngeal pain;Otitis media;Pain;Pancreatitis;Pancytopenia;Panic attack;Paraesthesia;Paranoia;Paranoid reaction;Personality disorder;Pharyngitis;Pharyngolaryngeal pain;Pregnancy;Procedural complication;Progesterone;Progesterone levels;Pruritus;Psychiatric symptom;Psychotic depression;Psychotic disorder;Raised liver function tests;Rash;Rash pustular;Renal impairment;Respiratory failure;Rhinitis;Rhinorrhoea;Sinusitis;Skin discolouration;Skin disorder;Somnolence;Status epilepticus;Stevens-Johnson syndrome;Stomatitis;Suicidal behaviour;Suicidal ideation;Suicide;Suicide attempt;Tension;Teratogenicity;Thinking abnormal;Throat sore;Thrombocytopenia;Tooth disorder;Toothache;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary incontinence;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Vertigo;Vesiculobullous rash;Viral infection;Vision blurred;Vomiting;Weight decreased;Weight increased;White blood cell count decreased;Withdrawal seizures,small molecule,approved,"Levetiracetam; Levetiracetame; Levetiracetamum; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; KIAA0736; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 3A; Voltage-dependent N-type calcium channel subunit alpha-1B; Synaptic vesicle glycoprotein 2A,N03AX14
esmolol,Atrial fibrillation;Atrial flutter;Coronary artery disease;Hypertension;Sinus tachycardia;Supraventricular tachycardia;Tachycardia,Abdominal discomfort;Abnormal vision;Acute coronary syndrome;Agitation;Angina pectoris;Angina unstable;Angioedema;Angiopathy;Anorexia;Anxiety;Arterial spasm;Arteriospasm coronary;Asthenia;Atelectasis;Atrioventricular block;Blister;Block heart;Body temperature increased;Bradycardia;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Chest pain;Chills;Cold sweat;Common cold;Confusional state;Constipation;Convulsion;Decreased appetite;Dermatitis bullous;Dizziness;Drowsiness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ecchymosis;Electrocardiogram ST segment depression;Electrocardiogram abnormal;Erythema;Extravasation;Fatigue;Feeling abnormal;Flushing;Gastrointestinal disorder;Grand mal convulsion;Headache;Hyperhidrosis;Hypertensive crisis;Hypotension;Hypotension asymptomatic;Hypotension symptomatic;Induration;Inferior myocardial infarction;Inflammation;Infusion site reactions;Irritability;Lightheadedness;Loss of consciousness;Mental disability;Mental disorder;Myocardial infarction;Myocardial ischaemia;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Neuropathy;Neuropathy peripheral;Nodal rhythm;Oedema;Oliguria;Pain;Pallor;Paraesthesia;Peripheral ischaemia;Pharyngitis;Pleural effusion;Pleuritic pain;Pneumothorax;Pruritus;Psoriasis;Pulmonary oedema;Pulseless electrical activity;Rales;Renal tubular necrosis;Respiratory failure;Rhinitis;Rhonchi;Rigors;Shock;Sinus arrest;Skin discolouration;Skin disorder;Skin exfoliation;Skin necrosis;Somnolence;Speech disorder;Sticky skin;Supraventricular extrasystoles;Sweating increased;Syncope;Thinking abnormal;Thrombophlebitis;Tonic-clonic seizures;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;Ventricular extrasystoles;Ventricular fibrillation;Visual impairment;Vomiting;Wheezing,small molecule,approved; withdrawn,(±)-esmolol; (±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; 3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester; Esmolol; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase,Beta-1 adrenergic receptor,C07AB09
tamsulosin,Benign prostatic hyperplasia;Lower urinary tract symptoms,Abdominal pain;Abnormal ejaculation;Accidental injury;Amblyopia;Angioedema;Angiopathy;Arrhythmia;Arthralgia;Arthritis;Asthenia;Atrial fibrillation;Back pain;Blood pressure diastolic decreased;Blood pressure systolic decreased;Body temperature increased;Breast disorder;Cardiac disorder;Cataract;Chest pain;Chills;Common cold;Congenital genitourinary abnormality;Connective tissue disorder;Constipation;Cough;Cough increased;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Disorder sight;Disturbance in sexual arousal;Dizziness;Dizziness aggravated;Dizziness postural;Dizzy spells;Drug interaction;Dyspepsia;Dyspnoea;Dysuria;Ejaculation delayed;Ejaculation disorder;Ejaculation failure;Epistaxis;Erectile dysfunction;Erythema multiforme;Fatigue;Feeling abnormal;Fever chills;Floppy iris syndrome;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hypotension;Hypotension orthostatic symptomatic;Ill-defined disorder;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Intraoperative floppy iris syndrome;Libido decreased;Lightheadedness;Loss of consciousness;Lung disorder;Malaise;Malnutrition;Mediastinal disorder;Miosis;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasal obstruction;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Oedema peripheral;Orthostatic hypotension;Pain;Palpitations;Paraesthesia;Pharyngitis;Priapism;Pruritus;Rash;Reaction gastrointestinal;Retrograde ejaculation;Rhinitis;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Shock;Sinus congestion;Sinusitis;Skin disorder;Skin exfoliation;Somnolence;Stevens-Johnson syndrome;Sweating;Syncope;Tachycardia;Tooth disorder;Unspecified disorder of skin and subcutaneous tissue;Urinary tract infection;Urticaria;Vertigo;Vision blurred;Visual impairment;Vomiting,small molecule,approved; investigational,"(−)-tamsulosin; (R)-(−)-tamsulosin; (R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; Tamsulosin; Tamsulosina; Tamsulosine; Tamsulosinum; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1",Alpha-1A adrenergic receptor; Alpha-1D adrenergic receptor; Alpha-1B adrenergic receptor, G01AE10; G04CA02; G04CA53; G04CA54;G04CA02;G04CA52
adapalene,Acne;Acne pustular;Acne vulgaris;Comedone,Abrasion NOS;Angioedema;Application site pain;Burning sensation;Conjunctivitis;Convulsion;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatitis irritant contact;Drug ineffective;Dry skin;Eczema;Erythema;Erythema of eyelid;Excoriation;Eye pain;Eyelid irritation;Eyelid oedema;Eyelids pruritus;Face oedema;Feeling hot;Foetal disorder;Hepatitis;Herpes labialis;Herpes simplex;Hypersensitivity;Instillation site pain;Keratitis;Keratoconjunctivitis;Lack of drug effect;Lip swelling;Optic neuritis;Oral herpes;Pain;Pain of skin;Papilloedema;Photosensitivity reaction;Phototoxicity;Pruritus;Rash;Rash pustular;Rash vesicular;Redness;Seborrhoeic dermatitis;Sensation of warmth;Skin discolouration;Skin discomfort;Skin exfoliation;Skin irritation;Skin oedema;Skin swelling;Stinging;Sunburn;Swelling of eyelid;Urticaria;Vesiculobullous rash,small molecule,approved,"6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid; Adapalene; Adapalène; Adapaleno; Adapalenum; HAP; HBV-activated protein; NR1B2; Nuclear receptor subfamily 1 group B member 2; RAR-beta; RAR-epsilon; NR1B3; Nuclear receptor subfamily 1 group B member 3; RAR-gamma; NR2B2; Nuclear receptor subfamily 2 group B member 2; Retinoid X receptor beta; NR2B3; Nuclear receptor subfamily 2 group B member 3; Retinoid X receptor gamma; NR2B1; Nuclear receptor subfamily 2 group B member 1; Retinoid X receptor alpha; Activator protein 1; AP1; p39; Proto-oncogene c-Jun; Transcription factor AP-1 subunit Jun; V-jun avian sarcoma virus 17 oncogene homolog; TIL4; Toll/interleukin-1 receptor-like protein 4; NR1B1; Nuclear receptor subfamily 1 group B member 1; RAR-alpha; 2.6.1.1; 2.6.1.3; cAspAT; cCAT; Cysteine aminotransferase, cytoplasmic; Cysteine transaminase, cytoplasmic; Glutamate oxaloacetate transaminase 1; Transaminase A","Retinoic acid receptor beta; Retinoic acid receptor gamma; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Retinoic acid receptor RXR-alpha; Transcription factor Jun; Toll-like receptor 2; Retinoic acid receptor alpha; Aspartate aminotransferase, cytoplasmic", D10AD53;D10AD03
perindopril,Acute coronary syndrome;Angioedema;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Coronary artery disease;Essential hypertension;Hypertension;Hypertensive;Myocardial infarction,Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal vision;Agitation;Agranulocytosis;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorexia;Antinuclear antibody positive;Anxiety;Arrhythmia;Arthralgia;Arthritis;Asthenia;Asthma;Back pain;Blood creatinine increased;Blood pressure increased;Blood uric acid increased;Body temperature increased;Bone pain;Bradycardia;Bronchitis;Bronchospasm;Calculus of kidney;Cardiac arrest;Cardiac murmur;Cerebrovascular accident;Chest pain;Chills;Claudication;Cognitive disorder;Cognitive impairment;Confusional state;Conjunctivitis;Constipation;Cough;Cramp muscle;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Drug intolerance;Dry mouth;Dry skin;Dyspepsia;Dysphonia;Dyspnoea;Ear infection;Ear pain;Ecchymosis;Electrocardiogram abnormal;Eosinophilia;Epistaxis;Erythema;Erythema multiforme;Face oedema;Fatigue;Feeling abnormal;Flank pain;Flatulence;Fluid retention;Gastroenteritis;Gastrointestinal pain;Gout;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic failure;Herpes labialis;Hoarseness;Hot flush;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hypertension;Hypertensive;Hypertonia;Hyponatraemia;Hypotension;Ill-defined disorder;Illusion;Increased appetite;Infarction mesenteric;Intermittent claudication;Intestinal infarction;Jaundice;Lacrimation;Lacrimation increased;Leukocytosis;Leukopenia;Local swelling;Loss of consciousness;Malaise;Male sexual dysfunction;Memory impairment;Menopausal symptoms;Menstrual disorder;Migraine;Mood alteration NOS;Mood swings;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Nasopharyngitis;Nausea;Neck pain;Nephritis;Nephrolithiasis;Nervousness;Neutropenia;Nocturia;Oedema;Oedema peripheral;Oliguria;Oral herpes;Orthostatic hypotension;Pain;Pain in arm;Pain in extremity;Palpitations;Pancreatitis acute;Pancytopenia;Paraesthesia;Pemphigoid;Pemphigus;Perceptual distortions;Peripheral coldness;Pharyngitis;Pneumonia;Pollakiuria;Polyuria;Postnasal drip;Protein urine present;Proteinuria;Pruritus;Psoriasis;Psychosexual disorder;Pulmonary eosinophilia;Pulmonary fibrosis;Purpura;Raised serum uric acid;Rash;Red blood cell sedimentation rate increased;Renal failure;Renal failure acute;Renal impairment;Rhinitis;Rhinitis seasonal;Rhinorrhoea;Scrotal oedema;Seasonal allergy;Serositis;Serum creatinine increased;Shock;Sinusitis;Skin infection;Sleep disorder;Sleep disturbance;Sneezing;Somnolence;Speech disorder;Speech impairment NOS;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Sweating;Swelling of legs;Syncope;Tension;Thirst;Thrombocytopenia;Tinea infection;Tinnitus;Tremor;Upper respiratory tract infection;Upper-airway cough syndrome;Urinary incontinence;Urinary retention;Urinary tract infection;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Vertigo;Viral infection;Visual impairment;Vomiting,small molecule,approved,"(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid; Perindopril; Perindoprilum; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; Frizzled protein, human endometrium; FRPHE; sFRP-4; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Angiotensin-converting enzyme; Secreted frizzled-related protein 4, C09AA04; C09BA04; C09BB04; C09BX02; C09BX04; C09BX06; C10BX11; C10BX12; C10BX13; C10BX14; C10BX15; C10BX21;C09BX01
perindopril,Acute coronary syndrome;Angioedema;Cardiac arrest;Cardiac failure;Cardiac failure congestive;Coronary artery disease;Essential hypertension;Hypertension;Hypertensive;Myocardial infarction,Abdominal pain;Acute coronary syndrome;Agranulocytosis;Amnesia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anxiety;Arrhythmia;Arthralgia;Arthritis;Asthenia;Back pain;Blood creatinine increased;Blood pressure increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Breast disorder;Bronchitis;Bronchospasm;Calculus of kidney;Cardiac disorder;Cardiac murmur;Cerebrovascular accident;Chest pain;Chills;Confusional state;Conjunctivitis;Constipation;Cough;Cramp muscle;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drowsiness;Drug interaction;Drug intolerance;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphonia;Dyspnoea;Ear infection;Ear pain;Ecchymosis;Eczema;Electrocardiogram abnormal;Eosinophilia;Eosinophilic pneumonia;Epistaxis;Erectile dysfunction;Erythema;Eye disorder;Face oedema;Feeling abnormal;Flank pain;Flatulence;Fluid retention;Flushing;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gout;Haematoma;Haematuria;Haemolytic anaemia;Hallucination;Headache;Hepatitis;Hepatobiliary disease;Herpes labialis;Hoarseness;Hyperhidrosis;Hyperkalaemia;Hypertonia;Hyponatraemia;Hypotension;Ill-defined disorder;Increased appetite;Insomnia;Leukopenia;Loss of consciousness;Malaise;Male sexual dysfunction;Malnutrition;Mediastinal disorder;Menstrual disorder;Mental disorder;Migraine;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nasopharyngitis;Nausea;Neck pain;Nephrolithiasis;Nervous system disorder;Nervousness;Neutropenia;Oedema;Oedema peripheral;Oral herpes;Orthostatic hypotension;Pain;Pain in arm;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Pharyngitis;Photosensitivity reaction;Pollakiuria;Postnasal drip;Protein urine present;Proteinuria;Prothrombin time ratio;Pruritus;Psychosexual disorder;Pulmonary fibrosis;Purpura;Raised serum uric acid;Rash;Renal failure;Renal failure acute;Renal impairment;Rhinitis;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Serum creatinine increased;Shock;Sinusitis;Skin disorder;Skin infection;Sleep disorder;Sleep disturbance;Sneezing;Somnolence;Sweating;Syncope;Tachycardia;Tension;Thrombocytopenia;Tinea infection;Tinnitus;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upper-airway cough syndrome;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Ventricular extrasystoles;Vertigo;Viral infection;Visual impairment;Vomiting,small molecule,approved,"(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid; Perindopril; Perindoprilum; 3.4.15.1; ACE; DCP; DCP1; Dipeptidyl carboxypeptidase I; Kininase II; Frizzled protein, human endometrium; FRPHE; sFRP-4; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2",Angiotensin-converting enzyme; Secreted frizzled-related protein 4, C09AA04; C09BA04; C09BB04; C09BX02; C09BX04; C09BX06; C10BX11; C10BX12; C10BX13; C10BX14; C10BX15; C10BX21;C09AA04;C09BX01
exemestane,Advanced breast cancer;Bone cancer metastatic;Breast cancer;Contralateral breast cancer;Lymphopenia,Abdominal pain;Acute coronary syndrome;Acute generalised exanthematous pustulosis;Alopecia;Angina pectoris;Anorexia;Anxiety;Arthralgia;Arthritis;Asthenia;Back pain;Body temperature increased;Bone disorder;Bone pain;Bronchitis;Cardiac disorder;Cardiac failure;Cardiovascular disorder;Carpal tunnel syndrome;Cerebrovascular accident;Chest pain;Confusional state;Constipation;Coronary artery disease;Cough;Cramp muscle;Decreased appetite;Deep vein thrombosis;Depression;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Dysphonia;Dyspnoea;Embolism;Embolism venous;Endometrial hyperplasia;Erythema multiforme;Fatigue;Feeling abnormal;Fracture;Gastric ulcer;Gastrointestinal disorder;Gastrointestinal pain;Genital disorder female;Haemoglobin;Haemorrhage;Headache;Hepatic impairment;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hoarseness;Hot flush;Hypercholesterolaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertrichosis;Hypoaesthesia;Immune system disorder;Increased appetite;Infection;Influenza like illness;Influenza-like symptoms;Insomnia;Joint stiffness;Leg edema;Leukopenia;Liver disorder;Lymphoedema;Malaise;Menopausal symptoms;Mental disorder;Multi-organ failure;Multiple fractures;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Neoplasm;Neoplasm malignant;Nervous system disorder;Neuropathy;Neuropathy peripheral;Oedema;Oedema peripheral;Opportunistic infection;Osteoarthritis;Osteochondrosis;Osteoporosis;Osteoporotic fracture;Pain;Pain in extremity;Paraesthesia;Pharyngitis;Polyp;Pruritus;Pulmonary embolism;Rash;Rhinitis;Sickness;Sinusitis;Skin disorder;Sweating;Sweating increased;Tendonitis;Thrombocytopenia;Thromboembolism;Trigger finger;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urticaria;Uterine polyp;Vaginal dryness;Vaginal haemorrhage;Viral infection;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal dryness;Weight increased,small molecule,approved; investigational,"6-methyleneandrosta-1,4-diene-3,17-dione; Exemestane; Exemestano; Exemestanum; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Aromatase,L02BG06
amlodipine,Angina pectoris;Bronchial hyperreactivity;Cardiac failure congestive;Chronic obstructive pulmonary disease;Coronary artery disease;Diabetes mellitus;Hypertension;Hypotension;Myocardial ischaemia;Peripheral vascular disorder;Prinzmetal angina;Stable angina pectoris;Vasospasm,Abdominal pain;Abnormal dreams;Abnormal vision;Accommodation disorder;Acute coronary syndrome;Affect lability;Agitation;Alopecia;Amnesia;Angioedema;Angiopathy;Anorexia;Anxiety;Apathy;Arrhythmia;Arthralgia;Arthropathy;Asthenia;Ataxia;Atrial fibrillation;Back pain;Blood and lymphatic system disorders;Bradycardia;Breast disorder;Cardiac disorder;Cardiac failure;Chest pain;Chills;Cholestasis;Cold sweat;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cramp muscle;Decreased appetite;Depersonalisation;Dermatitis;Diarrhoea;Diplopia;Discomfort;Dizziness;Dizziness postural;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Epistaxis;Erectile dysfunction;Erythema multiforme;Extrasystoles;Eye disorder;Eye pain;Fatigue;Feeling abnormal;Flat affect;Flatulence;Flushing;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gingival hyperplasia;Gynaecomastia;Headache;Hepatitis;Hot flush;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertonia;Hypoaesthesia;Ill-defined disorder;Immune system disorder;Increased appetite;Insomnia;Jaundice;Leukopenia;Loose stools;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Micturition disorder;Migraine;Mood swings;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Nocturia;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Pain;Palpitations;Pancreatitis;Paraesthesia;Parosmia;Peripheral ischaemia;Pollakiuria;Polyuria;Pruritus;Purpura;Rash;Rash erythematous;Rash maculo-papular;Rhinitis;Rigors;Sexual dysfunction;Shock;Skin cold clammy;Skin discolouration;Skin disorder;Somnolence;Sweating increased;Syncope;Tachycardia;Tension;Thirst;Thrombocytopenia;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;Vascular purpura;Vasculitis;Ventricular tachycardia;Vertigo;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;Xerophthalmia,small molecule,approved,"(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; Amlodipine; Amlodipine free base; Amlodipino; Amlodipinum; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; Ca(v)3.3; KIAA1120; Voltage-gated calcium channel subunit alpha Cav3.3; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; Voltage-gated calcium channel subunit alpha-2/delta-3; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 3.1.4.12; 3.1.4.3; Acid sphingomyelinase; ASM; aSMase; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent calcium channel subunit alpha-2/delta-1; Voltage-dependent T-type calcium channel subunit alpha-1I; Voltage-dependent N-type calcium channel subunit alpha-1B; Voltage-dependent L-type calcium channel subunit beta-1; Voltage-dependent calcium channel subunit alpha-2/delta-3; Carbonic anhydrase 1; Sphingomyelin phosphodiesterase; Voltage-dependent N-type calcium channel, C07FB07; C07FB12; C07FB13; C08CA01; C08CA51; C08GA02; C09BB03; C09BB04; C09BB07; C09BX01; C09BX03; C09BX04; C09BX06; C09DB01; C09DB02; C09DB04; C09DB05; C09DB06; C09DB07; C09DB09; C09DX01; C09DX03; C09DX06; C09DX07; C09DX08; C09XA53; C09XA54; C10BX03; C10BX07; C10BX09; C10BX11; C10BX14; C10BX18; C10BX19;C09BB13
dexmedetomidine,Agitation;Bradycardia,Abdominal distension;Abdominal pain;Abnormal vision;Acidosis;Acute coronary syndrome;Acute respiratory distress syndrome;Agitation;Alanine aminotransferase increased;Anaemia;Angiopathy;Anxiety;Apnoea;Arrhythmia;Aspartate aminotransferase increased;Atelectasis;Atrial fibrillation;Atrioventricular block;Atrioventricular block first degree;Block heart;Blood alkaline phosphatase increased;Blood pressure fluctuation;Blood urea increased;Body temperature decreased;Body temperature increased;Bradycardia;Bronchospasm;Carbon dioxide increased;Cardiac arrest;Cardiac disorder;Cardiac output decreased;Cardiovascular disorder;Chills;Confusional state;Constipation;Convulsion;Decubitus ulcer;Delirium;Dermatitis;Diarrhoea;Diastolic hypertension;Disorder sight;Dizziness;Drug ineffective;Dry mouth;Dyspnoea;Electrocardiogram T wave inversion;Electrolyte imbalance;Extrasystoles;Feeling abnormal;Fluid overload;Fluid retention;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Haemoglobin;Haemoglobin decreased;Haemorrhage;Hallucination;Headache;Hepatic function abnormal;Hyperbilirubinaemia;Hypercapnia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypernatraemia;Hyperpyrexia;Hypertension;Hypertension worsened;Hypoalbuminaemia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hypophosphataemia;Hypotension;Hypothermia;Hypoventilation;Hypovolaemia;Hypoxia;Illusion;Infarction;Infection;Laryngeal pain;Leukocytosis;Light anaesthesia;Malnutrition;Mediastinal disorder;Mental disorder;Metabolic acidosis;Myocardial infarction;Myocardial ischaemia;Nausea;Nephropathy;Neuralgia;Neuritis;Neuropathy peripheral;Oedema peripheral;Oliguria;Pain;Pharyngolaryngeal pain;Phosphatase alkaline increased;Photopsia;Pleural effusion;Pneumonia;Pneumothorax;Post procedural haemorrhage;Pregnancy;Pulmonary congestion;Pulmonary function test decreased;Pulmonary oedema;Rash;Red blood cell disorders;Renal failure acute;Respiratory acidosis;Respiratory depression;Respiratory failure;Respiratory rate decreased;Respiratory tract congestion;Rigors;Sepsis;Septic shock;Sinus arrest;Sinus tachycardia;Somnolence;Speech disorder;Supraventricular tachycardia;Sweating increased;Systolic hypertension;Tachycardia;Thirst;Thrombocytopenia;Urea increased;Urinary tract infection;Ventricular arrhythmia;Ventricular tachycardia;Visual impairment;Vomiting;Wheezing;Withdrawal syndrome,small molecule,approved; vet_approved,"(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; (+)-4-((S)-α,2,3-trimethylbenzyl)imidazole; Dexmedetomidin; Dexmedetomidina; Dexmédétomidine; Dexmedetomidine; Dexmedetomidinum; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Alpha-2A adrenergic receptor,N05CM18
cidofovir,Acquired immunodeficiency syndrome;Autoimmune disorder;Cytomegalovirus chorioretinitis;Cytomegalovirus infection;Cytomegalovirus retinitis;Gastroenteritis;Malaise;Pneumonia;Retinitis;Sickness,Abdominal pain;Abnormal dreams;Abnormal vision;Absolute neutrophil count decreased;Accidental injury;Adrenal cortical hypofunction;Adrenal insufficiency;Agitation;Alanine aminotransferase increased;Alopecia;Amblyopia;Aminoaciduria;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anterior uveitis;Anxiety;Aphthous stomatitis;Aplastic anaemia;Arthralgia;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Back pain;Blindness;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine decreased;Blood creatinine increased;Blood urea increased;Body temperature decreased;Body temperature increased;Bone pain;Bronchitis;Cachexia;Calculus of kidney;Candida infection;Cardiac failure congestive;Cardiomyopathy;Cardiovascular disorder;Cataract;Cellulitis;Cerebrovascular disorder;Chest pain;Chills;Cholangitis;Colitis;Confusional state;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Corneal lesion;Corneal opacity;Cough;Cough increased;Cramps of lower extremities;Creatinine low;Cryptococcosis;Deafness;Decreased appetite;Dehydration;Delirium;Dementia;Dental caries;Dermatitis;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear pain;Eczema;Encephalopathy;Epistaxis;Erythema multiforme;Eye disorder;Eye pain;Face oedema;Facial paralysis;Faecal incontinence;Fanconi syndrome;Fanconi syndrome acquired;Feeling abnormal;Fever chills;Flatulence;Flushing;Furuncle;Furunculosis;Gait disturbance;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingival pain;Gingivitis;Glycosuria;Haematuria;Haemolytic anaemia;Haemoptysis;Hallucination;Headache;Hearing impaired;Hemiplegia;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatocellular injury;Hepatomegaly;Hepatosplenomegaly;Herpes simplex;Hiccups;Hyperacusis;Hyperaesthesia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypocalcaemia;Hypochromic anaemia;Hypoglycaemia;Hypoglycemic reaction;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hypotension;Hypothermia;Hypotony of eye;Hypouricaemia;Ill-defined disorder;Infection;Injection site reaction;Injury;Insomnia;Iridocyclitis;Iritis;Jaundice;Keratitis;Laryngeal oedema;Leukocytosis;Leukopenia;Libido increased;Liver injury;Loss of consciousness;Lung disorder;Lymphadenopathy;Malaise;Mastitis;Mediastinal disorder;Melaena;Metabolic acidosis;Migraine;Miosis;Mouth ulceration;Mucous membrane disorder;Multiple congenital abnormalities;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myoclonus;Nail disorder;Nausea;Neck pain;Neoplasm malignant;Nephrolithiasis;Nephropathy toxic;Nephrotic syndrome;Nephrotoxicity;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Neutrophil count decreased;Nocturia;Oedema;Oedema peripheral;Oesophagitis;Oral candidiasis;Orthostatic hypotension;Osteoarthritis;Osteonecrosis;Otitis externa;Otitis media;Pain;Pallor;Pancreatitis;Pancytopenia;Paraesthesia;Peripheral vascular disorder;Personality disorder;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photosensitivity reaction;Pneumonia;Pneumothorax;Pollakiuria;Polyuria;Proctitis;Prostatic disorder;Protein urine present;Proteinuria;Pruritus;Pseudolymphoma;Rash;Rectal disorder;Refraction disorder;Renal failure;Renal failure acute;Renal tubular disorder;Respiratory alkalosis;Retinal detachment;Retinal disorder;Rhinitis;Scotoma;Seborrhoeic dermatitis;Sepsis;Shock;Sickness;Sinusitis;Skin discolouration;Skin disorder;Skin hypertrophy;Skin ulcer;Somnolence;Speech disorder;Spleen disorder;Splenomegaly;Stevens-Johnson syndrome;Stomatitis;Sweating;Syncope;Tachycardia;Tension;Thirst;Thrombocytopenia;Thrombocytopenic purpura;Tinnitus;Tongue discolouration;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Uveitis;VIIth nerve paralysis;Vertigo;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved,"({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; (S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine; (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine; (S)-HPMPC; [(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid; [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine; CDV; Cidofovir; Cidofovir anhydrous; Cidofovirum; 2.7.7.7; 2.7.7.7; HFLF2; 2.4.2.4; ECGF1; Gliostatin; PD-ECGF; Platelet-derived endothelial cell growth factor; TdRPase; TP; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1",DNA polymerase catalytic subunit; DNA polymerase catalytic subunit,J05AB12
etoposide,Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Hypersensitivity;Leukaemia;Lymphocytic leukaemia;Lymphoma;Neoplasm;Neutropenia;Non-Hodgkin's lymphoma;Small cell carcinoma;Small cell lung cancer;Testicular neoplasm,Abdominal pain;Acute leukaemia;Alopecia;Alopecia reversible;Anaemia;Anorexia;Apnoea;Asthenia;Back pain;Blindness cortical;Body temperature increased;Bronchospasm;CNS toxicity;Cardiac arrest;Cardiac failure;Cellulitis;Chills;Constipation;Convulsion;Cough;Cyanosis;Cyst;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dysgeusia;Dysphagia;Dyspnoea;Erythema multiforme;Extravasation;Fatal outcomes;Fatigue;Feeling abnormal;Flushing;Gastrointestinal pain;Gastrointestinal toxicity;Hepatic enzyme increased;Hepatotoxicity;Hyperhidrosis;Hypertension;Hypotension;Ill-defined disorder;Infection;Inflammation;Interstitial lung disease;Interstitial pneumonia;Laryngospasm;Leukopenia;Loss of consciousness;Malaise;Metabolic acidosis;Mucosal inflammation;Myelosuppression;Nausea;Necrosis;Neoplasm malignant;Neuropathy;Neuropathy peripheral;Neurotoxicity;Oesophagitis;Optic neuritis;Pain;Pancytopenia;Phlebitis;Polyp;Pruritus;Pulmonary fibrosis;Radiation recall reaction (dermatologic);Rash;Rash maculo-papular;Recall phenomenon;Rigors;Skin exfoliation;Skin necrosis;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Swelling;Swollen tongue;Tachycardia;Throat tightness;Thrombocytopenia;Toxic epidermal necrolysis;Urticaria;Vomiting,small molecule,approved,"(−)-etoposide; 4-demethylepipodophyllotoxin β-D-ethylideneglucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one; Etoposide; Etoposido; Etoposidum; trans-Etoposide; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 5.6.2.2; DNA topoisomerase II, beta isozyme; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.5.1.18; Glutathione transferase T1-1; GST class-theta-1; 2.5.1.18; FAEES3; GST class-pi; GST3; GSTP1-1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; 7.6.2.3; Anthracycline resistance-associated protein; ARA; MOAT-E; MRP6; Multi-specific organic anion transporter E; Multidrug resistance-associated protein 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.2; 7.6.2.3; MRP7; Multidrug resistance-associated protein 7; SIMRP7; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",DNA topoisomerase 2-alpha; DNA topoisomerase 2-beta,L01CB01
rocuronium,Hypotonia;Muscle relaxation,Anaphylactic shock;Anaphylactoid reaction;Apnoea;Arrhythmia;Asthma;Bronchospasm;Cardiovascular disorder;Dermatitis;Electrocardiogram abnormal;Hiccups;Hypersensitivity;Hypertension;Hypotension;Injection site swelling;Muscular weakness;Myopathy;Nausea;Paralysis;Pruritus;Rash;Respiratory failure;Respiratory insufficiency;Rhonchi;Shock;Skeletal muscle paralysis;Tachycardia;Vascular resistance;Vascular resistance pulmonary increased;Vascular resistance systemic;Vomiting;Wheezing,small molecule,approved,Rocuronio; Rocuronium; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; hOCT1; OCT1; Organic cation transporter 1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3,Neuronal acetylcholine receptor subunit alpha-2; Muscarinic acetylcholine receptor M2; 5-hydroxytryptamine receptor 3A,M03AC09
meropenem,Abdominal infection;Appendicitis;Bacteraemia;Bacterial infection;Bacterial sepsis;Community acquired pneumonia;Convulsion;Febrile neutropenia;Genital infection female;Gynecological infection;Infection;Infection mixed;Lower respiratory tract infection;Meningitis;Meningitis bacterial;Nosocomial pneumonia;Pelvic inflammatory disease;Peritonitis;Pneumonia;Renal failure;Renal impairment;Sepsis;Septicemia;Urinary tract infection,Abdominal distension;Abdominal pain;Accidental injury;Acute coronary syndrome;Agitation;Agranulocytosis;Alanine aminotransferase increased;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Apnoea;Application site pain;Aspartate aminotransferase increased;Asthenia;Asthma;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Bradycardia;Candida infection;Cardiac arrest;Cardiac failure;Chest pain;Chills;Cholestasis;Colitis;Confusional state;Constipation;Cough;Cough increased;Creatinine increased;Decreased appetite;Delirium;Dermatitis;Diarrhoea;Dizziness;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Enlargement abdomen;Eosinophilia;Epistaxis;Erythema;Erythema multiforme;Feeling abnormal;Flatulence;Fluid overload;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glossitis;Haematocrit decreased;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hepatic failure;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hypersensitivity;Hypertension;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hypotension;Ileus;Immune system disorder;Infection;Infestation;Infestation NOS;Inflammation;Injection site inflammation;Injection site pain;Injection site reaction;Injury;Insomnia;Instillation site pain;Intestinal obstruction;Jaundice;Jaundice cholestatic;Leukocytosis;Leukopenia;Loss of consciousness;Malaise;Melaena;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neutropenia;Oedema;Oedema peripheral;Oral candidiasis;Pain;Paraesthesia;Pelvic pain;Peripheral vascular disorder;Peritoneal haemorrhage;Pharyngitis;Phlebitis;Platelet count decreased;Pleural effusion;Pneumonia;Prothrombin time abnormal;Pruritus;Pseudomembranous colitis;Pulmonary embolism;Pulmonary oedema;Rash;Renal failure;Respiratory failure;Sepsis;Shock;Sickness;Skin disorder;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Sweating;Syncope;Tachycardia;Tension;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urinary incontinence;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;White blood cell count decreased,small molecule,approved; investigational,"(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meropenem; Meropenem anhydrous; Meropenemum; 3.4.16.4; D-alanyl-D-alanine endopeptidase; DD-carboxypeptidase; DD-endopeptidase; PBP-4; Penicillin-binding protein 4; 3.5.2.6; Beta-lactamase PSE-2; oxa10; pse2; 3.4.13.19; Beta-lactamase; Dehydropeptidase-I; hRDP; MDP; Microsomal dipeptidase; RDP; Renal dipeptidase",D-alanyl-D-alanine carboxypeptidase DacB, J01DH52;J01DH02
bromfenac,Corneal erosion;Eye pain;Eyelid oedema;Inflammation,Abnormal sensation in eye;Anterior chamber inflammation;Asthma;Conjunctival hyperaemia;Corneal disorder;Corneal epithelium defect;Corneal epithelium disorder;Corneal erosion;Corneal infiltrates;Corneal oedema;Corneal perforation;Corneal scar;Corneal thinning;Cough;Epistaxis;Eye discharge;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Eye redness;Eyelid bleeding;Headache;Iritis;Mediastinal disorder;Nasal sinus drainage;Ocular discomfort;Ocular hyperaemia;Pain;Photophobia;Retinal disorder;Retinal exudates;Scleromalacia;Sensation of foreign body;Sinus operation;Stinging;Swelling face;Ulcerative keratitis;Vision blurred;Visual acuity reduced,small molecule,approved; withdrawn,[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid; 2-amino-3-(4-bromobenzoyl)benzeneacetic acid; Bromfenac; Bromfenaco; Bromfenacum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2,Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1,S01BC11
ibutilide,Arrhythmia;Arrhythmia supraventricular;Atrial arrhythmia;Atrial fibrillation;Atrial flutter;Sinus rhythm,Atrioventricular block;Bradycardia;Bundle branch block;Cardiac failure congestive;Dizziness;Headache;Hypertension;Hypotension;Loss of consciousness;Monomorphic ventricular tachycardia;Multifocal ventricular tachycardia;Nausea;Nodal arrhythmia;Orthostatic hypotension;Palpitations;Renal failure;Rhythm idioventricular;Shock;Sinus bradycardia;Sinus tachycardia;Supraventricular extrasystoles;Supraventricular tachycardia;Syncope;Tachycardia;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular tachycardia,small molecule,approved,"Ibutilid; Ibutilida; Ibutilide; Ibutilidum; N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; CACNLG; Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma; HOHO1; Inward rectifying potassium channel protein TWIK-1; KCNO1; Potassium channel K2P1; Potassium channel KCNO1; TWIK1; Inward rectifying potassium channel protein TWIK-2; TOSS; TWIK-originated similarity sequence; TWIK2; Eag-related protein 2; ERG-2; ERG2; Ether-a-go-go-related gene potassium channel 2; Ether-a-go-go-related protein 2; hERG-2; hERG2; Potassium voltage-gated channel subfamily H member 6; Voltage-gated potassium channel subunit Kv11.2; Eag-related protein 3; ERG-3; ERG3; Ether-a-go-go-related gene potassium channel 3; Ether-a-go-go-related protein 3; hERG-3; Potassium voltage-gated channel subfamily H member 7; Voltage-gated potassium channel subunit Kv11.3; IKATP; Inward rectifier K(+) channel Kir6.2; Potassium channel, inwardly rectifying subfamily J member 11",Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent L-type calcium channel subunit beta-1; Voltage-gated inwardly rectifying potassium channel KCNH2; Voltage-dependent calcium channel subunit alpha-2/delta-1; Voltage-dependent calcium channel gamma-1 subunit; Potassium channel subfamily K member 1; Potassium channel subfamily K member 6; Voltage-gated inwardly rectifying potassium channel KCNH6; Voltage-gated inwardly rectifying potassium channel KCNH7; ATP-sensitive inward rectifier potassium channel 11,C01BD05
saquinavir,Acquired immunodeficiency syndrome;Autoimmune disorder;Disease progression,Abdominal colic;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abscess;Acne;Acquired lipoatrophic diabetes;Acute leukaemia;Acute myeloid leukaemia;Acute renal insufficiency;Acute tonsillitis;Agitation;Alanine aminotransferase increased;Alopecia;Amnesia;Amylase increased;Anaemia;Anal pruritus;Angiopathy;Anorectal discomfort;Anorexia;Anxiety;Anxiety attack;Aphthous stomatitis;Arthralgia;Arthritis;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atopic rhinitis;Autoimmune disorder;Back pain;Bacterial infection;Basedow's disease;Blepharitis;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose decreased;Blood glucose increased;Blood thyroid stimulating hormone increased;Blood triglycerides increased;Body temperature increased;Breast enlargement;Bronchitis;Buccal mucosa ulceration;Buffalo hump;Cachexia;Calculus of kidney;Candida infection;Cardiac disorder;Cardiac murmur;Cardiac valve disease;Cardiovascular disorder;Cellulitis;Cerebral haemorrhage;Cerebrovascular accident;Chalazion;Cheilitis;Chest pain;Chills;Cholangitis sclerosing;Cholelithiasis;Chronic liver disease;Clotting;Coagulopathy;Common wart;Confusional state;Congenital generalised lipodystrophy;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine increased;Cyanosis;Cyst;Cytomegalovirus chorioretinitis;Cytomegalovirus retinitis;Deafness;Decreased appetite;Dehydration;Depression;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dreaming excessive;Drug eruption;Drug fever;Drug interaction;Dry eye;Dry eye syndrome;Dry mouth;Dry skin;Dysaesthesia;Dysarthria;Dyschezia;Dysentery;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Ear infection;Ear pain;Eczema;Endocrine disorder;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Euphoric mood;Eye disorder;Eye irritation;Facial pain;Factor XI deficiency;Faecal incontinence;Faeces discoloured;Fat redistribution;Fat tissue increased;Fatigue;Feces bloodstained;Feeling abnormal;Flatulence;Folliculitis;Frequent bowel movements;Fungal infection;Furuncle;Furunculosis;Gamma-glutamyltransferase increased;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal inflammation;Gastrointestinal pain;Gastrointestinal symptom NOS;Gastrointestinal ulcer;Gastrooesophageal reflux disease;Gingivitis;Glossitis;Haemarthrosis;Haematochezia;Haematoma;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhage urinary tract;Haemorrhoids;Hallucination;Headache;Hearing impaired;Heartburn;Hepatitis;Hepatitis chronic active;Hepatobiliary disease;Hepatomegaly;Hepatosplenomegaly;Herpes simplex;Herpes zoster;Hot flush;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlactacidaemia;Hypernatraemia;Hyperphosphataemia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypertrophy of breast;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hyponatraemia;Hypophosphataemia;Hyporeflexia;Hypotension;Hypothyroidism;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Injury;Insomnia;Insulin resistance;Intestinal obstruction;Intoxication;Irritability;Jaundice;Kaposi's sarcoma;Ketoacidosis;Lacrimation decreased;Laryngitis;Lethargy;Leukaemia;Leukopenia;Libido decreased;Libido disorder;Lightheadedness;Lip dry;Lipoatrophy;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Liver disorder;Liver function test abnormal;Loose stools;Loss of consciousness;Low back pain;Lung disorder;Lymphadenopathy;Lymphocyte count decreased;Malaise;Malnutrition;Mediastinal disorder;Melaena;Menopausal symptoms;Menstrual disorder;Menstruation irregular;Mental disorder;Metabolic disorder;Micturition disorder;Molluscum contagiosum;Mouth ulceration;Mucosal inflammation;Mucosal ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myopathy;Myositis;Nail disorder;Nausea;Neoplasm;Nephrolithiasis;Nervous system disorder;Neuropathy;Neuropathy peripheral;Neutropenia;Night sweats;Nocturia;Numbness facial;Numbness of limbs;Oedema;Oesophageal ulcer;Oesophagitis;Opportunistic infection;Osteoarthritis;Other bacterial diseases;Otitis;Overdose effect;Pain;Pain in jaw;Pancreatitis;Pancytopenia;Papilloma;Papillomatosis;Paraesthesia;Paresis;Partial hearing loss;Pelvic pain;Penis disorder;Peritonsillar abscess;Pharyngitis;Phosphatase alkaline increased;Photosensitivity reaction;Platelet count decreased;Pneumonia;Poisoning;Poliomyelitis;Polyarthritis;Polyp;Portal hypertension;Progressive multifocal leukoencephalopathy;Prostatomegaly;Prurigo;Pruritus;Pruritus genital;Psoriasis;Psychic disturbance;Psychotic disorder;Raised liver function tests;Rash;Rash maculo-papular;Rash papular;Rectal haemorrhage;Redness of face;Renal colic;Renal failure;Renal failure acute;Renal impairment;Retrosternal pain;Rhabdomyolysis;Rhinitis;Rhinitis allergic;Salivary gland disorder;Seborrhoeic dermatitis;Shivering;Shock;Sinusitis;Skin disorder;Skin mass;Skin nodule;Skin papilloma;Skin ulcer;Sleep disorder;Somnolence;Speech disorder;Splenomegaly;Staphylococcal infection;Stevens-Johnson syndrome;Stiffness;Stomach ache;Stomatitis;Suicide attempt;Sweating increased;Syncope;Thirst;Thrombocytopenia;Thrombophlebitis;Thyrotropin high;Tinnitus;Tooth disorder;Toothache;Torsade de pointes;Toxicity to various agents;Transaminases increased;Trauma;Tremor;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal discharge;Vasoconstriction;Vasoconstriction peripheral;Vasodilatation;Vein distended;Vertigo;Visual disturbance;Visual impairment;Vomiting;Wasting generalized;Weight decreased;Weight increased;White blood cell count decreased;Xeroderma;Xerophthalmia,small molecule,approved; investigational,"Saquinavir; Pr160Gag-Pol; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Gag-Pol polyprotein; Pol polyprotein,J05AE01
aripiprazole,Aggression;Agitation;Autism;Bipolar I disorder;Bipolar disorder;Childhood schizophrenia;Demented;Dementia;Dementia Alzheimer's type;Dyskinesia;Increased activity;Irritability;Jaundice;Major depression;Malaise;Mania;Manic episode;Mental disorder;Psychotic disorder;Schizophrenia;Sickness;Temper tantrum;Tension,"Abasia;Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Abnormal dreams;Abnormal ejaculation;Abnormal faeces;Abnormal involuntary movements;Abscess periodontal;Accidental injury;Action tremor;Acute coronary syndrome;Acute psychosis;Affect lability;Aggression;Agitation;Agoraphobia;Agranulocytosis;Akathisia;Akinaesthesia;Akinesia;Alanine aminotransferase increased;Albuminuria;Alcohol abuse;Alcohol poisoning;Alcoholism;Alopecia;Altered state of consciousness;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Anaemia macrocytic;Anal pruritus;Anaphylactic shock;Anger;Angina pectoris;Angioedema;Angiopathy;Anorectal discomfort;Anorexia;Anorgasmia;Anxiety;Apathy;Aphasia;Apnoea;Appendicitis;Appetite disorder;Arthralgia;Arthritis;Arthropathy;Arthropod bite;Aspartate aminotransferase increased;Asphyxia;Asthenia;Asthma;Ataxia;Atrial fibrillation;Atrial flutter;Atrioventricular block;Atrioventricular block complete;Azotaemia;Back pain;Bacteria urine identified;Bacterial test positive;Balance disorder;Benign prostatic hyperplasia;Bladder discomfort;Bladder pain;Blepharitis;Blepharospasm;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood cholesterol decreased;Blood cholesterol increased;Blood creatine phosphokinase MB increased;Blood creatine phosphokinase abnormal;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose decreased;Blood glucose fluctuation;Blood glucose increased;Blood insulin increased;Blood lactate dehydrogenase increased;Blood potassium decreased;Blood potassium increased;Blood pressure abnormal;Blood pressure fluctuation;Blood pressure increased;Blood prolactin decreased;Blood prolactin increased;Blood triglycerides decreased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Blood urine present;Blunted affect;Body temperature decreased;Body temperature increased;Body tinea;Bone pain;Bradycardia;Bradykinesia;Bradyphrenia;Bradypsychic response;Breast discharge;Breast disorder;Breast pain;Breast tenderness;Bronchial hyperreactivity;Bronchopneumopathy;Bruxism;Buccoglossal syndrome;Bundle branch block;Burning sensation;Bursitis;Buttock pain;Calculus of kidney;Calculus urinary;Candida infection;Carbohydrate tolerance decreased;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac murmur;Cardio-respiratory arrest;Cardiomegaly;Cardiomyopathy;Cardiopulmonary failure;Carpal tunnel syndrome;Cataract;Catatonia;Cellulitis;Cerebral haemorrhage;Cerebral ischaemia;Cerebration impaired;Cerebrovascular accident;Cervicitis;Chapped lips;Cheilitis;Chest discomfort;Chest pain;Chest tightness;Chest wall pain;Chills;Cholecystitis;Cholelithiasis;Choreoathetosis;Chromaturia;Chronic obstructive pulmonary disease;Circumoral paresthesia;Clavicle fracture;Coccydynia;Cognitive deterioration;Cognitive disorder;Cogwheel rigidity;Cold sweat;Colitis;Coma;Completed suicide;Condition aggravated;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Costochondritis;Cough;Cramp muscle;Creatine phosphokinase increased;Creatinine increased;Cyanosis;Cyst;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Decreased immune responsiveness;Decubitus ulcer;Deep vein thrombosis;Dehydration;Delirium;Delusion;Delusional perception;Dental caries;Depersonalisation;Depressed level of consciousness;Depressed mood;Depression;Depressive symptom;Derealisation;Dermal cyst;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diabetes mellitus inadequate control;Diabetic hyperosmolar coma;Diabetic ketoacidosis;Diarrhoea;Diet refusal;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dizziness exertional;Dizziness postural;Drooling;Drug eruption;Drug withdrawal syndrome neonatal;Dry eye;Dry mouth;Dry skin;Dry throat;Duodenal ulcer;Dysarthria;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphasia;Dysphemia;Dysphonia;Dysphoria;Dyspnoea;Dysuria;ECG signs of myocardial ischaemia;Ear and labyrinth disorders;Ear canal erythema;Ear pain;Early menarche;Eating disorder;Ecchymosis;Eczema;Ejaculation disorder;Electrocardiogram PR prolongation;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram ST segment abnormal;Electrocardiogram T wave abnormal;Electrocardiogram T wave amplitude decreased;Electrocardiogram T wave inversion;Electrocardiogram abnormal;Embolism venous;Emotional distress;Endocrine disorder;Energy increased;Enlargement abdomen;Enuresis;Eosinophil count increased;Eosinophilia;Epididymitis;Epilepsy;Epistaxis;Erectile dysfunction;Eructation;Erythema;Euphoric mood;Excitability;Exfoliative rash;Exostosis;Extrapyramidal disorder;Extrapyramidal symptoms;Extrasystoles;Eye discharge;Eye disorder;Eye haemorrhage;Eye infection;Eye irritation;Eye movement disorder;Eye pain;Eye penetration;Eye redness;Eyelid function disorder;Eyelid oedema;Eyelid ptosis;Face oedema;Facial pain;Facial paralysis;Faecal incontinence;Faecalith;Faecaloma;Faeces discoloured;Faeces hard;Fatigue;Feeling abnormal;Feeling hot;Feeling jittery;Femoral neck fracture;Flank pain;Flat affect;Flatulence;Fluid retention;Flushing;Folliculitis;Formication;Fracture;Frequent bowel movements;Functional gastrointestinal disorder;Gait disturbance;Galactorrhoea;Gamma-glutamyltransferase increased;Gastric pH decreased;Gastric ulcer haemorrhage;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Gaze palsy;General physical health deterioration;Generalised oedema;Genital itching female;Gingival bleeding;Gingival pain;Gingivitis;Glossitis;Glossodynia;Glucose tolerance decreased;Glucose tolerance impaired;Glycosuria;Glycosylated haemoglobin decreased;Glycosylated haemoglobin increased;Goitre;Gout;Grand mal convulsion;Groin pain;Gynaecomastia;Haematemesis;Haematochezia;Haematocrit decreased;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhoids;Hallucination;Hallucination, auditory;Hallucination, visual;Head discomfort;Head injury;Head lag abnormal;Headache;Hearing impaired;Heart rate irregular;Heat exhaustion;Heat stroke;Heaviness of head;Hemiparesis;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatomegaly;Herpes simplex;Hiccups;Hip fracture;Hirsutism;Hoarseness;Homicidal ideation;Hostility;Hot flush;Humerus fracture;Hyperacusis;Hyperaemia;Hyperaesthesia;Hyperbilirubinaemia;Hyperchlorhydria;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperinsulinism;Hyperkalaemia;Hyperkeratosis;Hyperkinesia;Hyperlipidaemia;Hypernatraemia;Hyperparathyroidism;Hyperreflexia;Hypersensitivity;Hypersexuality;Hypersomnia;Hypertension;Hyperthyroidism;Hypertonia;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypoaesthesia oral;Hypochromic anaemia;Hypoglycaemia;Hypoglycemic reaction;Hypokalaemia;Hypokinesia;Hypomania;Hyponatraemia;Hypophagia;Hyporeflexia;Hypotension;Hypothermia;Hypothyroidism;Hypotonia;Idiopathic thrombocytopenic purpura;Ill-defined disorder;Immune system disorder;Incontinence;Increased appetite;Induration;Infection;Infestation;Infestation NOS;Inflammation;Inflammation localised;Influenza;Influenza like illness;Inguinal hernia;Injection site burning;Injection site discomfort;Injection site erythema;Injection site induration;Injection site pain;Injection site pruritus;Injection site reaction;Injection site stinging;Injection site swelling;Injury;Injury asphyxiation;Insomnia;Intentional self-injury;Intestinal obstruction;Intestinal perforation;Iron deficiency anaemia;Irritability;Irritable bowel syndrome;Ischaemic stroke;Jaundice;Jaw disorder;Joint contracture;Joint dislocation;Joint range of motion decreased;Joint sprain;Joint swelling;Judgement impaired;Kyphosis;Laceration;Lacrimation increased;Lactation female;Lactic dehydrogenase activity increased;Laryngeal pain;Laryngitis;Laryngospasm;Lethargy;Leukocytosis;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Ligament sprain;Lightheadedness;Lip dry;Liver function test abnormal;Local swelling;Localised infection;Localized osteoarthritis;Logorrhoea;Loose stools;Loss of consciousness;Loss of libido;Lower respiratory tract infection;Lymphadenopathy;Malaise;Malnutrition;Mania;Manic psychosis;Markedly reduced dietary intake;Masked facies;Mastication disorder;Mediastinal disorder;Melaena;Memory impairment;Mendelson's syndrome;Menopausal symptoms;Menorrhagia;Menstruation irregular;Mental disability;Mental disorder;Mental retardation;Mental status changes;Micturition burning;Micturition urgency;Migraine;Mobility decreased;Mood swings;Mouth injury;Mouth ulceration;Movement disorder;Movements involuntary;Multiple fractures;Muscle contractions involuntary;Muscle enzyme increased;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle strain;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myasthenia;Myocardial infarction;Myocardial ischaemia;Myoclonus;Myopathy;Nasal congestion;Nasal dryness;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Neck tightness;Neoplasm;Nephrolithiasis;Nerve compression;Nerve injury;Nervous system disorder;Nervousness;Neuralgia;Neurodermatitis;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Neutropenia;Neutrophil count decreased;Neutrophil count increased;Night cramps;Night sweats;Nightmare;Nocturia;Nuchal rigidity;Obesity;Obsessive thoughts;Obsessive-compulsive disorder;Ocular hyperaemia;Oculogyration;Oculogyric crisis;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Onychomycosis;Open wound;Oral candidiasis;Oral neoplasm;Oral pain;Oropharyngeal discomfort;Oropharyngeal pain;Oropharyngeal spasm;Orthostatic hypertension;Orthostatic hypotension;Osteoarthritis;Osteopenia;Osteoporosis;Otitis externa;Otitis media;Ovarian cyst;Pain;Pain during injection;Pain in extremity;Pain in jaw;Painful respiration;Pallor;Palpitations;Pancreatitis;Panic attack;Panic disorder;Panic reaction;Paraesthesia;Paraesthesia oral;Paranasal sinus hypersecretion;Paranoia;Paranoid reaction;Parkinson's disease;Parkinsonian gait;Parkinsonian rest tremor;Parkinsonism;Parosmia;Parotid gland enlargement;Parotitis;Pathological gambling;Pelvic pain;Pemphigus;Peptic ulcer;Periodontitis;Periorbital haematoma;Periorbital oedema;Petechiae;Pharyngeal erythema;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Photophobia;Photopsia;Photosensitivity;Photosensitivity reaction;Pneumonia;Pneumonia aspiration;Pollakiuria;Polydipsia;Polyp;Polyuria;Pregnancy;Premature ejaculation;Premenstrual syndrome;Presyncope;Priapism;Productive cough;Prostatitis;Protein urine present;Proteinuria;Pruritus;Pruritus genital;Psoriasis;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Pulmonary congestion;Pulmonary embolism;Pulmonary oedema;Purpura;Pyelonephritis;Rash;Rash erythematous;Rash maculo-papular;Rash papular;Rash pustular;Rash scaly;Rash vesicular;Rectal haemorrhage;Red blood cell count decreased;Redness;Reflux esophagitis;Renal failure;Respiratory arrest;Respiratory distress;Respiratory failure;Respiratory tract congestion;Respiratory tract infection;Restless legs syndrome;Retching;Rhabdomyolysis;Rheumatoid arthritis;Rhinitis;Rhinitis allergic;Rhinorrhoea;Rhonchi;Road traffic accident;Rosacea;Salivary hypersecretion;Scab;Schizoaffective disorder;Schizophrenic reaction;Schizophreniform disorder;Sciatica;Scratch;Seborrhoeic dermatitis;Self mutilation;Sensation of heaviness;Septic shock;Serotonin syndrome;Serum prolactin decreased;Sexual dysfunction;Shock;Sinus congestion;Sinus headache;Sinus pain;Sinus tachycardia;Sinusitis;Skin discolouration;Skin disorder;Skin induration;Skin irritation;Skin laceration;Skin papilloma;Skin ulcer;Sleep apnoea syndrome;Sleep disorder;Sleep phase rhythm disturbance;Sleep talking;Sluggishness;Sneezing;Social avoidant behaviour;Somatoform disorder;Somnambulism;Somnolence;Speech disorder;Spontaneous penile erection;Stiffness;Stomatitis;Stupor;Subarachnoid haemorrhage;Sudden death;Sudden death, cause unknown;Suicidal ideation;Suicide;Suicide attempt;Sunburn;Supraventricular tachycardia;Suspiciousness;Sweating;Swelling;Swelling face;Swollen tongue;Syncope;Syncope vasovagal;Tachycardia;Tardive dyskinesia;Taste altered;Temperature regulation disorder;Tenderness;Tendonitis;Tenosynovitis;Tension;Testicular pain;Thinking abnormal;Thirst;Throat sore;Throat tightness;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Tightness in jaw;Tinnitus;Tongue discolouration;Tongue disorder;Tongue dry;Tongue oedema;Tongue paralysis;Tongue spasm;Tonic-clonic seizures;Tonsillar hypertrophy;Tooth abscess;Tooth fracture;Toothache;Torsade de pointes;Torticollis;Transaminases increased;Transient ischaemic attack;Tremor;Tremor limb;Trismus;Tuberculin test positive;Type 2 diabetes mellitus;Ulcer;Unresponsive to stimuli;Unresponsive to verbal stimuli;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral discharge;Urethral disorder;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine ketone body present;Urine output increased;Urolithiasis;Urosepsis;Urticaria;Uterine haemorrhage;VIIth nerve paralysis;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vaginal mycosis;Varicose vein;Vasodilation;Vasodilation procedure;Venipuncture site bruise;Venous thromboembolism;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vertigo positional;Vesiculobullous rash;Vessel puncture site bruise;Viral diarrhoea;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal dryness;Vulvovaginal mycotic infection;Waist circumference increased;Walking disability;Weight decreased;Weight fluctuation;Weight increased;Wheezing;White blood cell count decreased;White blood cell count increased;White blood cells urine positive;Wound;Xerosis",small molecule,approved; investigational,"Aripiprazol; Aripiprazole; Aripiprazolum; Dopamine D2 receptor; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; Dopamine D3 receptor; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; H1-R; H1R; HH1R; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT-6; 5-HT6; Serotonin receptor 6; Dopamine D1 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-5; 5-HT-5A; 5-HT5A; Serotonin receptor 5A; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; Gastric receptor I; H2R; HH2R; G-protein coupled receptor 97; GPCR97; H3R; HH3R; AXOR35; G-protein coupled receptor 105; GPCR105; GPRv53; H4R; HH4R; Pfi-013; SP9144; K-OR-1; KOR-1; OPRK; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; D-OR-1; DOR-1; OPRD; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",D(2) dopamine receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 1A; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; D(3) dopamine receptor; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 7; Alpha-2A adrenergic receptor; Alpha-2C adrenergic receptor; Histamine H1 receptor; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 6; D(1A) dopamine receptor; D(4) dopamine receptor; Alpha-2B adrenergic receptor; 5-hydroxytryptamine receptor 1E; D(1B) dopamine receptor; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 5A; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Histamine H2 receptor; Histamine H3 receptor; Histamine H4 receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; Kappa-type opioid receptor; Mu-type opioid receptor; Delta-type opioid receptor; Glutamate (NMDA) receptor; Sodium-dependent dopamine transporter; Sodium-dependent serotonin transporter,N05AX12
tiotropium,Acute coronary syndrome;Angle closure glaucoma;Atrial fibrillation;Breast feeding;Bronchial hyperreactivity;Bronchitis chronic;Bronchospasm;Cardiac disorder;Cardiac failure;Chronic obstructive pulmonary disease;Dyspnoea;Dysuria;Emphysema;Function kidney decreased;Myocardial infarction;Myocardial ischaemia;Prostatomegaly;Renal impairment;Strangury,Abdominal pain;Accident;Acute glaucoma;Aneurysm;Angina pectoris;Angina pectoris aggravated;Angioedema;Angiopathy;Angle closure glaucoma;Application site irritation;Arrhythmia;Arthralgia;Arthritis;Back pain;Benign prostatic hyperplasia;Bladder neck obstruction;Bone pain;Bronchospasm paradoxical;Candida infection;Cardiac death;Cataract;Chest pain;Connective tissue disorder;Constipation;Cough;Dehydration;Dermatitis;Disorder sight;Dizziness;Dry mouth;Dry skin;Dyspepsia;Dysphagia;Dysphonia;Dysuria;Epistaxis;Eye disorder;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingivitis;Glaucoma;Glossitis;Headache;Herpes zoster;Hoarseness;Hypercholesterolaemia;Hyperglycaemia;Hypersensitivity;Hypertension;Ileus paralytic;Immune system disorder;Infection;Influenza like illness;Influenza-like symptoms;Insomnia;Intestinal obstruction;Intraocular pressure increased;Joint swelling;Laryngeal pain;Laryngitis;Leg pain;Loss of consciousness;Malnutrition;Mediastinal disorder;Mental disorder;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Oedema;Oedema peripheral;Oral candidiasis;Oropharyngeal candidiasis;Pain in extremity;Palpitations;Paraesthesia;Pharyngitis;Pharyngo-oral irritation;Pharyngolaryngeal pain;Prostatic hypertrophy;Pruritus;Rash;Renal failure;Rhinitis;Shock;Sinusitis;Skin disorder;Skin infection;Skin ulcer;Stomatitis;Strangury;Supraventricular tachycardia;Syncope;Tachycardia;Throat irritation;Type I hypersensitivity;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Ventricular tachycardia;Vision blurred;Visual impairment;Vomiting,small molecule,approved,"1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H",Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5, R03AL10; R03BB04; R03BB54;R03AL06;R03BB04
duloxetine,"Agitation;Anxiety;Anxiety disorder;Asthenia;Back pain;Bradyphrenia;Bradypsychic response;Cerebration impaired;Chronic pain;Decreased interest;Depressed mood;Depression;Depressive disorder;Diabetes mellitus;Diabetic;Diabetic neuropathy;Diabetic peripheral neuropathic pain;Diabetic peripheral neuropathy;Distress;Disturbance in attention;Dysphoria;Dysthymic disorder;Emotional distress;Fatigue;Feeling guilty;Fibromyalgia;Generalised anxiety disorder;Hypersensitivity;Hypersomnia;Insomnia;Irritability;Low back pain;Major depression;Major depressive disorder, single episode;Mental disability;Musculoskeletal pain;Neuralgia;Osteoarthritis;Pain;Pregnancy;Sleep disorder;Sleep disturbance;Stress urinary incontinence;Suicidal ideation;Suicide attempt;Tension;Urethral disorder;Urinary tract disorder;Weight decreased",Abdominal discomfort;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Abnormal dreams;Acute coronary syndrome;Acute liver injury;Affect lability;Aggression;Agitation;Akathisia;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Anger;Angioedema;Angiopathy;Angle closure glaucoma;Anorexia;Anorgasmia;Anxiety;Apathy;Aphthous stomatitis;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrial fibrillation;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood disorder;Blood glucose increased;Blood in stool;Blood potassium increased;Blood pressure diastolic decreased;Blood pressure diastolic increased;Blood pressure increased;Blood pressure systolic increased;Blood triglycerides increased;Body temperature increased;Breast disorder;Breath odour;Bruxism;Bundle branch block right;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac fibrillation;Chest pain;Chills;Cold sweat;Colitis;Completed suicide;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Coronary artery disease;Cough;Cramp muscle;Creatine phosphokinase increased;Decreased appetite;Dehydration;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diabetic;Diarrhoea;Diastolic hypertension;Diplopia;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Dizziness;Drug withdrawal syndrome;Dry eye;Dry mouth;Dysarthria;Dysgeusia;Dyskinesia;Dyslipidaemia;Dyspepsia;Dysphagia;Dysuria;Ear and labyrinth disorders;Ear pain;Ecchymosis;Eczema;Ejaculation delayed;Ejaculation disorder;Ejaculation failure;Electric shock;Endocrine disorder;Epigastric discomfort;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Essential hypertension;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Face oedema;Fasting blood glucose increased;Fatigue;Feeling abnormal;Feeling hot;Feeling jittery;Flat affect;Flatulence;Flushing;Functional gastrointestinal disorder;Gait disturbance;Galactorrhoea;Gamma-glutamyltransferase increased;Gastric irritation;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Genital hypoaesthesia;Gingivitis;Glaucoma;Glycosylated haemoglobin increased;Haematochezia;Haemoglobin;Haemorrhage;Haemorrhagic disorder;Hallucination;Headache;Hemorrhage abnormal;Hepatic enzyme increased;Hepatic failure;Hepatic steatosis;Hepatitis;Hepatobiliary disease;Hepatotoxicity;Hot flush;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkeratosis;Hyperlipidaemia;Hyperprolactinaemia;Hypersensitivity;Hypersomnia;Hypertension;Hypertensive crisis;Hypertriglyceridaemia;Hypoaesthesia;Hypoaesthesia facial;Hypoglycaemia;Hyponatraemia;Hypothyroidism;Ill-defined disorder;Immune system disorder;Impaired gastric emptying;Inappropriate antidiuretic hormone secretion;Increased appetite;Increased tendency to bruise;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Initial insomnia;Insomnia;Irritability;Irritable bowel syndrome;Jaundice;Labile hypertension;Laryngeal pain;Laryngitis;Lethargy;Leukopenia;Libido decreased;Liver function test abnormal;Liver injury;Loose stools;Loss of consciousness;Loss of libido;Low back pain;Lymphadenopathy;Macular degeneration;Maculopathy;Malaise;Malnutrition;Mania;Mediastinal disorder;Melaena;Menopausal symptoms;Menstrual disorder;Mental disorder;Micturition urgency;Middle insomnia;Migraine;Mood swings;Muscle spasms;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Mydriasis;Myocardial infarction;Myoclonus;Nasopharyngitis;Nausea;Neck pain;Nephropathy;Nervous system disorder;Nervousness;Night sweats;Nightmare;Nocturia;Oedema;Oedema peripheral;Oesophageal stenosis;Oesophageal stenosis acquired;Oliguria;Orgasm abnormal;Oropharyngeal pain;Oropharyngeal swelling;Orthostatic hypertension;Orthostatic hypotension;Osteoarthritis;Pain;Pain in extremity;Palpitations;Pancreatitis;Paraesthesia;Paraesthesia oral;Penis disorder;Peripheral coldness;Pharyngeal oedema;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Photopsia;Photosensitivity reaction;Pollakiuria;Polyuria;Poor quality sleep;Pressure of speech;Prurigo;Pruritus;Rash;Rash erythematous;Renal failure;Renal impairment;Restless legs syndrome;Retinal detachment;Rhabdomyolysis;Rhinitis seasonal;Rigors;Seasonal allergy;Secondary hypertension;Serotonin syndrome;Sexual dysfunction;Shock;Sjogren's syndrome;Skin disorder;Skin ulcer;Sleep disorder;Sleep disturbance;Sluggishness;Somnolence;Stevens-Johnson syndrome;Stomatitis;Suicidal behaviour;Suicidal ideation;Suicide attempt;Supraventricular tachycardia;Sweating increased;Syncope;Syndrome sicca;Systolic hypertension;Tachycardia;Tension;Terminal insomnia;Testicular pain;Thirst;Throat tightness;Thrombocytopenia;Tinnitus;Traumatic liver injury;Tremor;Trismus;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine flow decreased;Urine odour abnormal;Urine output increased;Urticaria;Ventricular arrhythmia;Vertigo;Viral diarrhoea;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;White blood cell count increased;Withdrawal symptom;Yawning,small molecule,approved,"(3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (S)-duloxetine; Duloxetina; Duloxetine; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent dopamine transporter,N06AX21
pemetrexed,Breast cancer;Mesothelioma;Non-small cell lung cancer;Pleural mesothelioma malignant,Abdominal pain;Acute coronary syndrome;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Angina pectoris;Anorexia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Aspartate aminotransferase increased;Asthenia;Blood and lymphatic system disorders;Blood creatinine decreased;Blood creatinine increased;Body temperature increased;Bullous conditions;Caecitis;Cerebrovascular accident;Chest pain;Colitis;Conjunctivitis;Constipation;Creatinine increased;Creatinine low;Creatinine renal clearance decreased;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Dizziness;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Embolism;Erythema;Erythema multiforme;Extremity necrosis;Eye disorder;Fatigue;Febrile neutropenia;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal necrosis;Gastrointestinal obstruction;Gastrointestinal pain;Glomerular filtration rate decreased;Haemoglobin decreased;Haemolytic anaemia;Heartburn;Hepatic cancer metastatic;Hepatitis;Hepatobiliary disease;Hypersensitivity;Hypertension;Infection;Infestation;Infestation NOS;Interstitial lung disease;Interstitial pneumonia;Intestinal necrosis;Intestinal perforation;Lacrimation increased;Leukopenia;Loss of consciousness;Malnutrition;Mesothelioma;Metastases to liver;Mood alteration NOS;Mood swings;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Neoplasm malignant;Nephropathy;Nervous system disorder;Neuritis;Neuropathy;Neuropathy peripheral;Neutropenia;Ocular surface disease;Odynophagia;Oedema;Oesophagitis;Pain;Pancreatitis;Pancytopenia;Peripheral ischaemia;Peripheral motor neuropathy;Peripheral sensory neuropathy;Pharyngitis;Platelet count decreased;Pruritus;Pulmonary embolism;Radiation oesophagitis;Radiation pneumonitis;Rash;Rectal haemorrhage;Renal failure;Renal failure acute;Respiratory failure;Respiratory insufficiency;Sepsis;Shock;Skin disorder;Skin exfoliation;Stevens-Johnson syndrome;Stomatitis;Syncope;Thrombocytopenia;Thrombosis;Toxic epidermal necrolysis;Transient ischaemic attack;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Ventricular tachycardia;Vomiting;White blood cell count decreased,small molecule,approved; investigational,"Pemetrexed; 2.1.1.45; TS; TSase; 2.1.1.45; CDC21; TS; TSA1; AICAR transformylase/inosine monophosphate cyclohydrolase; ATIC; PURH; 1.5.1.3; PGFT; PRGS; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Cyclic dinucleotide:anion antiporter SLC19A1; FLOT1; Folate:anion antiporter SLC19A1; FOLT; hRFC; hSLC19A1; IFC-1; Intestinal folate carrier 1; Placental folate transporter; Reduced folate carrier protein; Reduced folate transporter 1; RFC; RFC1; RFT-1; Solute carrier family 19 member 1; G21; HCP1; Heme carrier protein 1; hPCFT; HsPCFT; PCFT; PCFT/HCP1; Solute carrier family 46 member 1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; 7.6.2.2; MOAT-C; MRP5; Multi-specific organic anion transporter C; Multidrug resistance-associated protein 5; pABC11; SMRP; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4",Thymidylate synthase; Thymidylate synthase; Bifunctional purine biosynthesis protein ATIC; Dihydrofolate reductase; Trifunctional purine biosynthetic protein adenosine-3,L01BA04
ibandronate,Asthma;Bone cancer metastatic;Bone density decreased;Bone disorder;Bone mass decreased;Breast cancer;Dyspepsia;Fracture;Gastrointestinal disorder;Hypercalcaemia;Metastasis;Multiple fractures;Neoplasm;Neoplasm malignant;Osteoporosis;Osteoporosis postmenopausal;Osteoporotic fracture;Peptic ulcer,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Acute phase reaction;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anxiety;Appetite absent;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Atypical femur fracture;Azotaemia;Back pain;Benign neoplasm of skin;Bladder pain;Blood and lymphatic system disorders;Blood calcium decreased;Blood creatinine increased;Blood disorder;Blood parathyroid hormone increased;Body temperature decreased;Body temperature increased;Bone pain;Breast disorder;Bronchitis;Bronchoconstriction;Bronchospasm;Bundle branch block;Candida infection;Cardiac disorder;Cardiovascular disorder;Cataract;Cerebrovascular disorder;Cheilitis;Chest pain;Chills;Cholelithiasis;Circumoral paresthesia;Connective tissue disorder;Constipation;Cramp muscle;Creatinine increased;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Depression;Dermatitis;Dermatitis atopic;Diarrhoea;Discomfort;Dizziness;Drug eruption;Dry mouth;Duodenal ulcer;Duodenitis;Dysgeusia;Dyspepsia;Dysphagia;Ear and labyrinth disorders;Ecchymosis;Endocrine disorder;Endophthalmitis;Episcleritis;Erythema;Exacerbation of asthma;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Feeling hot;Femur fracture;Femur shaft fracture;Flatulence;Fracture;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Headache;Hepatobiliary disease;Hypercholesterolaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hypocalcaemia;Hypomagnesaemia;Hypophosphataemia;Hypothermia;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Influenza-like symptoms;Injection site pain;Injection site reaction;Injury;Insomnia;Iritis;Local reaction;Localized osteoarthritis;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Migraine;Mouth ulceration;Multiple fractures;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial ischaemia;Nasopharyngitis;Nausea;Nephropathy toxic;Nerve root lesion;Nervous system disorder;Neuralgia;Oedema peripheral;Oesophagitis;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Osteomyelitis;Osteonecrosis;Osteonecrosis of jaw;Osteopenia;Other scleritis;Pain;Pain in extremity;Palpitations;Panophthalmitis;Paraesthesia;Paraesthesia oral;Parathyroid disorder;Parosmia;Pelvic pain;Pharyngitis;Pneumonia;Prurigo;Pruritus;Pulmonary oedema;Radiculopathy;Rash;Rash erythematous;Rash generalised;Rash macular;Rash papular;Redness;Renal cyst;Renal failure;Renal failure acute;Renal impairment;Rigors;Scleritis;Sensation of heat;Serum calcium decreased;Shock;Skin disorder;Sleep disorder;Stomatitis;Stridor;Sweating;Swelling;Thirst;Throat sore;Tooth disorder;Trauma;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Uremia;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Uveitis;Vaginal infection;Vaginal inflammation;Vertigo;Vomiting;Weight decreased,small molecule,approved; investigational,"ácido ibandrónico; Ibandronic acid; (2E,6E)-farnesyl diphosphate synthase; 2.5.1.-; Dimethylallyltranstransferase; Farnesyl diphosphate synthase; Farnesyltranstransferase; Geranylgeranyl diphosphate synthase; Geranyltranstransferase; GGPP synthase; GGPPSase; (2E,6E)-farnesyl diphosphate synthase; 2.5.1.10; Dimethylallyltranstransferase; Farnesyl diphosphate synthase; FPP synthase; FPS; Geranyltranstransferase; KIAA1293",Hydroxylapatite; Geranylgeranyl pyrophosphate synthase; Farnesyl pyrophosphate synthase, M05BB09;M05BA06
ziprasidone,"Acute coronary syndrome;Agitation;Bipolar I disorder;Bipolar disorder;Breast cancer;Cardiac disorder;Convulsion;Decreased interest;Dementia;Depressed mood;Dermatitis;Diabetes mellitus;Electrocardiogram QT prolonged;Increased activity;Irritability;Major depression;Major depressive disorder, single episode;Malaise;Mania;Mania acute;Manic episode;Myocardial infarction;Pituitary tumour;Psychotic disorder;Rash;Schizophrenia;Sickness;Sudden death;Tension;Torsade de pointes",Abdominal discomfort;Abdominal pain;Abnormal ejaculation;Abnormal vision;Accidental injury;Acne;Agitation;Akathisia;Akinesia;Albuminuria;Alopecia;Amblyopia;Amenorrhoea;Amnesia;Anaemia;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anorgasmia;Anxiety;Arrhythmia;Arthralgia;Arthropathy;Asthenia;Ataxia;Atrial fibrillation;Atrioventricular block;Atrioventricular block first degree;Autonomic nervous system imbalance;Back pain;Basophilia;Blepharitis;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood prolactin increased;Blood urea increased;Blood uric acid increased;Body temperature decreased;Body temperature increased;Bradycardia;Bradykinesia;Bradyphrenia;Breast disorder;Breast feeding;Buccoglossal syndrome;Bundle branch block;Bundle branch block right;Cardiac disorder;Cardiomegaly;Cataract;Cerebral infarction;Cerebrovascular accident;Chest pain;Chills;Choreoathetosis;Circumoral paresthesia;Cogwheel rigidity;Cold symptoms;Completed suicide;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Coordination abnormal;Cough;Cough increased;Cramp muscle;Creatine phosphokinase increased;Creatinine increased;Decreased appetite;Dehydration;Delirium;Dementia Alzheimer's type;Dependence;Dependence physiological;Dependence psychological;Dermatitis;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Diabetes mellitus;Diabetic;Diabetic coma;Diabetic hyperglycaemic coma;Diarrhoea;Diplopia;Disturbance in attention;Dizziness;Dizziness postural;Drooling;Drug abuse;Drug dependence;Drug fever;Drug interaction;Drug seeking behavior;Drug tolerance;Dry eye;Dry mouth;Dysarthria;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Ecchymosis;Eczema;Ejaculation disorder;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Embolism venous;Enuresis;Eosinophil count abnormal;Eosinophil count increased;Eosinophilia;Epistaxis;Erectile dysfunction;Erection increased;Erythema;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye haemorrhage;Eye pruritus;Face oedema;Facial paresis;Faecalith;Faecaloma;Fatigue;Feeling abnormal;Feeling hot;Female sexual dysfunction;Flank pain;Flat affect;Flatulence;Fungal skin infection;Furuncle;Furunculosis;Gait disturbance;Galactorrhoea;Gamma-glutamyltransferase increased;Gastritis;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival bleeding;Glucose tolerance decreased;Glycosuria;Gout;Grand mal convulsion;Gynaecomastia;Haematemesis;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Headache;Heart rate irregular;Heat stroke;Hepatic enzyme increased;Hepatic impairment;Hepatic steatosis;Hepatitis;Hepatomegaly;Hiccups;Hostility;Hyperchloraemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hyperphagia;Hyperprolactinaemia;Hyperpyrexia;Hyperreflexia;Hypersensitivity;Hypersomnia;Hypertension;Hyperthyroidism;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypochloraemia;Hypocholesterolaemia;Hypochromic anaemia;Hypoglycaemia;Hypoglycemic reaction;Hypokalaemia;Hypokinesia;Hypomagnesaemia;Hypomania;Hyponatraemia;Hypoproteinaemia;Hypotension;Hypothermia;Hypothyroidism;Hypotonia;Immune system disorder;Increased appetite;Increased prolactin level;Infection;Infestation;Infestation NOS;Influenza;Injection site pain;Injury;Insomnia;Jaundice;Jaundice cholestatic;Joint stiffness;Keratitis;Keratoconjunctivitis;Ketosis;Lactation female;Lactic dehydrogenase activity increased;Laryngospasm;Lethargy;Leukocytosis;Leukopenia;Leukoplakia oral;Lightheadedness;Liver disorder;Liver fatty deposition;Liver function test abnormal;Loose stools;Loss of consciousness;Lymphadenopathy;Lymphocytosis;Lymphoedema;Male sexual dysfunction;Malnutrition;Mania;Mediastinal disorder;Melaena;Menorrhagia;Mental disorder;Mental state abnormal;Metrorrhagia;Monocytosis;Movement disorder;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocarditis;Myoclonus;Myoglobin urine present;Myoglobinuria;Myopathy;Nasopharyngitis;Nausea;Neoplasm;Nervous system disorder;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Nightmare;Nocturia;Nystagmus;Oculogyric crisis;Oedema peripheral;Oesophageal motility disorder;Oliguria;Opisthotonus;Orofacial oedema;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Osteoarthritis;Pain in extremity;Palpitations;Panic attack;Paraesthesia;Paraesthesia oral;Paralysis;Paresis;Parkinsonism;Personality disorder;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Photosensitivity reaction;Pneumonia;Pneumonia aspiration;Polycythaemia;Polydipsia;Polyuria;Pregnancy;Priapism;Psoriasis;Psychotic disorder;Pulmonary embolism;Pulse irregular;Rash;Rash maculo-papular;Rash papular;Rash pustular;Rectal haemorrhage;Renal failure;Renal failure acute;Renal impairment;Respiratory alkalosis;Respiratory tract infection;Restless legs syndrome;Rhabdomyolysis;Rhinitis;Salivary hypersecretion;Scotoma;Sepsis;Serotonin syndrome;Serum prolactin increased;Shock;Skin disorder;Skin irritation;Sluggishness;Somnambulism;Somnolence;Speech disorder;Suicide;Suicide attempt;Surgery;Surgical intervention;Sweating;Sweating increased;Swelling face;Swollen tongue;Syncope;Tachycardia;Tardive dyskinesia;Tenosynovitis;Teratogenicity;Thirst;Throat sore;Throat tightness;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thyroiditis;Tinnitus;Tolerance development;Tongue disorder;Tongue oedema;Tonic-clonic seizures;Tooth disorder;Torsade de pointes;Torticollis;Tremor;Trismus;Underweight;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urine output increased;Urticaria;Uterine haemorrhage;VIIth nerve paralysis;Vaginal haemorrhage;Vasodilation;Vasodilation procedure;Venous thromboembolism;Ventricular septal defect;Vertigo;Vertigo positional;Vesiculobullous rash;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;Withdrawal syndrome,small molecule,approved,"Ziprasidona; Ziprasidone; Ziprasidonum; Dopamine D2 receptor; NACHRA7; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; Dopamine D1 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1E; 5-HT1E; S31; Serotonin receptor 1E; 5-HT-6; 5-HT6; Serotonin receptor 6; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 5-HT3-B; 5-HT3B; Serotonin receptor 3B; 5-HT3-C; 5-HT3C; Serotonin receptor 3C; 5-HT3-D; 5-HT3D; Serotonin receptor 3D; 5-HT3-E; 5-HT3E; Serotonin receptor 3E; 5-HT-5; 5-HT-5A; 5-HT5A; Serotonin receptor 5A; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",D(2) dopamine receptor; Neuronal acetylcholine receptor subunit alpha-7; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 2C; D(1A) dopamine receptor; D(1B) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1E; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; Histamine H1 receptor; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; 5-hydroxytryptamine 3 receptor; 5-hydroxytryptamine receptor 5A,N05AE04
olopatadine,Conjunctivitis allergic;Eye pruritus;Nasal septum perforation;Perennial allergic rhinitis;Rhinitis perennial;Rhinitis seasonal;Seasonal allergy,Abdominal pain;Anosmia;Asthenia;Back pain;Blepharospasm;Body temperature increased;Conjunctival disorder;Conjunctival follicles;Conjunctivitis;Corneal calcification;Corneal deposits;Corneal disorder;Corneal epithelium defect;Corneal epithelium disorder;Corneal erosion;Corneal oedema;Corneal staining;Cough;Cough increased;Depression;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Dizziness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspnoea;Endophthalmitis;Epistaxis;Erythema;Erythema of eyelid;Eye discharge;Eye disorder;Eye irritation;Eye oedema;Eye pain;Eye swelling;Eyelid disorder;Eyelid margin crusting;Eyelid oedema;Fatigue;Feeling abnormal;Foreign body sensation in eyes;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hyperaemia;Hypersensitivity;Hypoaesthesia;Hyposmia;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Keratitis;Lacrimation increased;Laryngeal pain;Malaise;Mediastinal disorder;Muscle spasms;Mydriasis;Nasal discomfort;Nasal dryness;Nasopharyngitis;Nausea;Nervous system disorder;Ocular discomfort;Ocular hyperaemia;Oedema;Oropharyngeal pain;Pain;Pharyngitis;Pharyngolaryngeal pain;Photophobia;Postnasal drip;Pruritus;Punctate keratitis;Rash;Rhinitis;Rhinitis allergic;Sensation of foreign body;Sinusitis;Skin burning sensation;Skin disorder;Somnolence;Stinging;Swelling face;Taste bitter;Thirst;Throat irritation;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upper-airway cough syndrome;Urinary tract infection;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vital dye staining cornea present;Vomiting;Weight increased;White blood cell disorder,small molecule,approved,"Olopatadin; Olopatadina; Olopatadine; Olopatadinum; H1-R; H1R; HH1R; Gastric receptor I; H2R; HH2R; G-protein coupled receptor 97; GPCR97; H3R; HH3R; S-100 protein alpha chain; S-100 protein subunit alpha; S100 calcium-binding protein A1; S100A; CAAF1; CAGC; Calcium-binding protein in amniotic fluid 1; Calgranulin-C; CGRP; EN-RAGE; Extracellular newly identified RAGE-binding protein; Migration inhibitory factor-related protein 6; MRP-6; Neutrophil S100 protein; p6; S100 calcium-binding protein A12; S-100 protein beta chain; S-100 protein subunit beta; S100 calcium-binding protein B; S100 calcium-binding protein A13; CAN19; Protein S-100L; S100 calcium-binding protein A2; S100L; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.13.148; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 1; Dimethylaniline oxidase 1; Fetal hepatic flavin-containing monooxygenase 1; FMO 1; Trimethylamine monooxygenase; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Histamine H1 receptor; Histamine H2 receptor; Histamine H3 receptor; Protein S100-A1; Protein S100-A12; Protein S100-B; Protein S100-A13; Protein S100-A2, R01AC08;R01AC08;S01GX09
levosimendan,ADHF;Cardiac failure acute;Cardiac failure chronic,Angiopathy;Atrial fibrillation;Cardiac disorder;Cardiac failure;Constipation;Diarrhoea;Dizziness;Extrasystoles;Gastrointestinal disorder;Haemoglobin decreased;Headache;Hypokalaemia;Hypotension;Insomnia;Malnutrition;Mental disorder;Myocardial ischaemia;Nausea;Nervous system disorder;Tachycardia;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vomiting,small molecule,approved; investigational,"Lévosimendan; Levosimendan; Levosimendán; Levosimendanum; TN-C; TNNC; IKATP; Inward rectifier K(+) channel Kir6.2; Potassium channel, inwardly rectifying subfamily J member 11; Inward rectifier K(+) channel Kir6.1; Potassium channel, inwardly rectifying subfamily J member 8; uKATP-1; 3.1.4.17; cGI-PDE; CGI-PDE A; cGMP-inhibited cAMP phosphodiesterase; Cyclic GMP-inhibited phosphodiesterase A","Troponin C, slow skeletal and cardiac muscles; ATP-sensitive inward rectifier potassium channel 11; ATP-sensitive inward rectifier potassium channel 8; cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A",C01CX08
adefovir,Alanine aminotransferase increased;Chronic hepatitis B;Cross resistance;Fibrosis;Foetor hepaticus;Hepatitis B;Hepatitis B e antigen positive;Hepatocellular injury;Infection;Inflammation;Liver disorder;Pathogen resistance;Renal failure;Renal impairment;Viral infection,Abdominal pain;Alanine aminotransferase increased;Anaemia;Anorexia;Asthenia;Back pain;Blood creatinine increased;Blood phosphorus decreased;Body temperature increased;Bone pain;Chest pain;Connective tissue disorder;Cough;Cough increased;Creatinine increased;Decreased appetite;Dermatitis;Diarrhoea;Dyspepsia;Fanconi syndrome;Flatulence;Foetor hepaticus;Fracture;Gastrointestinal disorder;Gastrointestinal pain;Glycosuria;Haematuria;Headache;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis B e antigen positive;Hepatobiliary disease;Hepatocellular injury;Hyperkalaemia;Hypophosphataemia;Jaundice;Kidney function abnormal;Liver disorder;Liver function test abnormal;Malnutrition;Multiple fractures;Musculoskeletal discomfort;Myalgia;Myopathy;Nausea;Nephropathy toxic;Nephrotoxicity;Nervous system disorder;Osteomalacia;Pancreatitis;Pharyngitis;Phosphorus low;Pruritus;Rash;Renal failure;Renal impairment;Renal tubular disorder;Serum creatinine increased;Sinusitis;Skin disorder;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vomiting;Weight decreased,small molecule,investigational,9-(2-(phosphonomethoxy)ethyl)adenine; 9-(2-phosphonylmethoxyethyl)adenine; Adéfovir; Adefovir; Adefovirum; 2.7.7.7; 2.7.7.7,Protein P; DNA polymerase catalytic subunit,J05AF08
emtricitabine,Alcohol abuse;Alcoholism;Blood bilirubin increased;HIV infection;Human immunodeficiency virus type;Imprisonment;Infection;Renal failure;Renal impairment;Sexually transmitted disease;Viral infection,Abdominal pain;Abnormal dreams;Alanine aminotransferase increased;Amylase increased;Anaemia;Angioedema;Anogenital warts;Anxiety;Arthralgia;Asthenia;Autoimmune disorder;Back pain;Basedow's disease;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose decreased;Blood triglycerides increased;Body temperature increased;Bone pain;Breast disorder;Breast enlargement;Buffalo hump;Connective tissue disorder;Cough;Cough increased;Creatine phosphokinase increased;Creatinine increased;Depression;Depressive disorder;Dermatitis;Dermatitis bullous;Diarrhoea;Dizziness;Dyspepsia;Dyspnoea;Dysthymic disorder;Exfoliative rash;Fanconi syndrome;Fasting;Fatigue;Fracture;Function kidney decreased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Genital ulceration;Glucose low;Glycosuria;Haematuria;Haemoglobin decreased;Headache;Hepatic steatosis;Hepatitis;Hepatitis B;Hepatobiliary disease;Hepatomegaly;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperlactacidaemia;Hypersensitivity;Hypertriglyceridaemia;Hypertrophy of breast;Hypokalaemia;Hypophosphataemia;Immune system disorder;Infection;Infection mixed;Infestation;Infestation NOS;Inflammation;Insomnia;Insulin resistance;Lactic acidosis;Lipase increased;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Malnutrition;Mediastinal disorder;Mental disorder;Multiple fractures;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myopathy;Nasopharyngitis;Nausea;Nephritis interstitial;Nephrogenic diabetes insipidus;Nephrosis lower nephron;Nervous system disorder;Neuritis;Neuropathy;Neuropathy peripheral;Neutropenia;Opportunistic infection;Osteomalacia;Osteonecrosis;Otitis media;Pain;Pancreatitis;Paraesthesia;Pharyngitis;Pneumonia;Polyuria;Protein urine present;Proteinuria;Prurigo;Pruritus;Rash;Rash generalised;Rash macular;Rash maculo-papular;Rash pustular;Rash vesicular;Renal failure;Renal failure acute;Renal impairment;Renal tubular disorder;Renal tubular necrosis;Rhabdomyolysis;Rhinitis;Secondary syphilis;Sinusitis;Skin discolouration;Skin disorder;Skin hyperpigmentation;Syphilis;Thrombocytopenia;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urethritis;Urethritis noninfective;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vesiculobullous rash;Vomiting;Weight decreased,small molecule,approved; investigational,"(−)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (−)-2'-deoxy-5-fluoro-3'-thiacytidine; (−)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (−)-FTC; (−)-β-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; 4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one; 5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; Emtricitabin; Emtricitabina; Emtricitabine; Emtricitabinum; Pr160Gag-Pol; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1",Reverse transcriptase/RNaseH; Gag-Pol polyprotein, J05AF09; J05AR03; J05AR06; J05AR08; J05AR09; J05AR17; J05AR18; J05AR20; J05AR22;J05AF09;J05AR19
eprosartan,Anaemia;Essential hypertension;Hyperkalaemia;Hypertension;Leukopenia;Neutropenia,Abdominal pain;Abnormal vision;Alanine aminotransferase increased;Albuminuria;Alcohol intolerance;Angina pectoris;Angioedema;Anorexia;Anxiety;Arthralgia;Arthritis;Arthritis aggravated;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrial fibrillation;Back pain;Bladder pain;Blood creatinine increased;Blood triglycerides increased;Body temperature increased;Bone pain;Bradycardia;Bronchitis;Calculus of kidney;Cardiac failure;Chest pain;Chills;Conjunctivitis;Constipation;Cough;Cramps of lower extremities;Cystitis;Cystitis noninfective;Decreased appetite;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dyspepsia;Dyspnoea;Eczema;Electrocardiogram T wave inversion;Electrocardiogram abnormal;Epistaxis;Extrasystoles;Face oedema;Fatigue;Feeling abnormal;Flatulence;Furuncle;Furunculosis;Gastritis;Gastroenteritis;Gastrointestinal pain;Gingivitis;Glycosuria;Gout;Gravitational oedema;Haematuria;Headache;Herpes simplex;Hot flush;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertriglyceridaemia;Hypokalaemia;Hyponatraemia;Hypotension;Ill-defined disorder;Influenza like illness;Influenza-like symptoms;Insomnia;Leg edema;Loss of consciousness;Malaise;Menopausal symptoms;Migraine;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myositis;Nausea;Nephrolithiasis;Nervousness;Neuritis;Neuropathy peripheral;Oedema peripheral;Oesophagitis;Orthostatic hypotension;Osteoarthritis;Otitis externa;Otitis media;Pain;Palpitations;Paraesthesia;Periodontitis;Peripheral ischaemia;Pharyngitis;Pollakiuria;Polyuria;Pruritus;Purpura;Rash;Rash maculo-papular;Renal artery stenosis;Renal failure;Retrosternal pain;Rhabdomyolysis;Rhinitis;Rigors;Serum creatinine increased;Shock;Sinusitis;Somnolence;Sweating increased;Swelling;Syncope;Tachycardia;Tendonitis;Tension;Thrombocytopenia;Tinnitus;Toothache;Tremor;Upper respiratory tract infection;Urinary incontinence;Urinary tract infection;Urine output increased;Urticaria;Vascular purpura;Vertigo;Viral infection;Visual impairment;Vomiting;Xerophthalmia,small molecule,approved,(E)-2-butyl-1-(p-carboxybenzyl)-α-2-thenylimidazole-5-acrylic acid; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; (E)-α{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; Éprosartan; Eprosartan; Eprosartanum; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2,Type-1 angiotensin II receptor, C09CA02;C09CA02;C09DA02
capecitabine,Breast cancer;Breast cancer stage IV;Cardiotoxicity;Colon cancer;Colorectal cancer;Colorectal cancer metastatic;Colorectal carcinoma;Hyperbilirubinaemia;Neoplasm;Neoplasm malignant;Renal failure;Renal impairment,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abnormal vision;Actinic keratosis;Acute coronary syndrome;Acute overdose;Ageusia;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Altered state of consciousness;Amnesia;Anaemia;Angina pectoris;Angina unstable;Angiopathy;Anorectal disorder;Anorexia;Anxiety;Aphasia;Appetite disorder;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrial arrhythmia;Atrial fibrillation;Back pain;Balance disorder;Balanoposthitis;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood calcium decreased;Blood creatinine increased;Blood in stool;Blood potassium decreased;Blood pressure increased;Blood triglycerides increased;Body temperature increased;Bone marrow depression;Bone pain;Bradycardia;Breast disorder;Bronchitis;Bronchopneumonia;Bronchospasm;Burning mouth syndrome;Ca++ increased;Cachexia;Calcaneal spur;Calcium low;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac pain;Cardiomyopathy;Cataract;Cellulitis;Cerebrovascular accident;Chest discomfort;Chest mass NOS;Chest pain;Chest tightness;Chills;Chromaturia;Coagulopathy;Colitis;Coma hepatic;Confusional state;Congenital anomaly;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Coordination abnormal;Corneal disorder;Cough;Creatinine renal clearance decreased;Cutaneous lupus erythematosus;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Depressed level of consciousness;Depressed mood;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Developmental delay;Diabetes mellitus;Diarrhoea;Diarrhoea haemorrhagic;Diplopia;Discomfort;Disorder sight;Disturbance in sexual arousal;Dizziness;Drug hypersensitivity;Dry eye;Dry mouth;Dry skin;Duodenitis;Dysaesthesia;Dysaesthesia pharynx;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dysphasia;Dysphonia;Dyspnoea;Dyspnoea exertional;Dysuria;Ear and labyrinth disorders;Ear discomfort;Ear feels clogged;Ear pain;Ecchymosis;Edema of lower extremities;Embolism;Encephalopathy;Enteritis;Epistaxis;Erythema;Erythema multiforme;Exostosis;Extrasystoles;Eye disorder;Eye irritation;Eye pain;Face oedema;Facial pain;Facial paralysis;Fatigue;Febrile neutropenia;Feeling abnormal;Fibrosis;Flatulence;Fluid retention;Flushing;Food allergy;Food intolerance;Fungal infection;Gait disturbance;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal candidiasis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal motility disorder;Gastrointestinal pain;Gastrointestinal perforation;Gastrointestinal toxicity;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;Haematemesis;Haematochezia;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemoptysis;Haemorrhage;Haemorrhoids;Hand and foot syndrome secondary to sickle cell anaemia;Headache;Hearing impaired;Hepatic cancer metastatic;Hepatic failure;Hepatic fibrosis;Hepatic function abnormal;Hepatic pain;Hepatic steatosis;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hepatomegaly;Hepatotoxicity;Herpes simplex;Herpes virus infection;Herpes zoster;Hiccups;Hirsutism;Hoarseness;Hot flush;Hydronephrosis;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkeratosis;Hypersensitivity;Hypertension;Hypertensive crisis;Hypertriglyceridaemia;Hypoaesthesia;Hypoaesthesia oral;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypotension;Hypothyroidism;Idiopathic thrombocytopenic purpura;Ileus;Ileus paralytic;Ill-defined disorder;Immune system disorder;Incisional hernia;Increased appetite;Infarction;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Infusion related reaction;Infusion site pain;Injection site infection;Injection site pain;Injection site reaction;Insomnia;Intertrigo;Intestinal obstruction;Irritability;Jaundice;Joint stiffness;Joint swelling;Keratitis;Keratoconjunctivitis;Lacrimation increased;Laryngeal pain;Laryngitis;Leg ulcer;Lethargy;Leukopenia;Libido decreased;Lipoma;Liver fatty;Liver function test abnormal;Localised infection;Localised oedema;Localised skin reaction;Localized exfoliation;Loss of confidence;Loss of consciousness;Lower respiratory tract infection;Lymphoedema;Lymphopenia;Malaise;Malnutrition;Mass;Mediastinal disorder;Melaena;Memory impairment;Menopausal symptoms;Mental disability;Mental disorder;Mental retardation;Metastases to liver;Metrorrhagia;Migraine;Mood alteration NOS;Mood swings;Mouth ulceration;Mucosal inflammation;Mucosal ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Myocarditis;Myoclonus;Nail changes;Nail discolouration;Nail disorder;Nasal ulcer;Nasopharyngitis;Nausea;Neck oedema of;Neck pain;Necrotising colitis;Necrotising enterocolitis neonatal;Necrotizing enterocolitis;Neoplasm;Nervous system disorder;Neuralgia;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutropenic sepsis;Night sweats;Nipple disorder;Nocturia;Odynophagia;Oedema;Oedema due to cardiac disease;Oedema peripheral;Oesophageal candidiasis;Oesophageal ulcer;Oesophagitis;Onycholysis;Oral candidiasis;Oral discomfort;Oral herpes;Oral pain;Oropharyngeal discomfort;Oropharyngeal pain;Orthopnoea;Orthostatic hypotension;Osteoarthritis;Otitis media;Overdose;Pain;Pain in extremity;Pain in jaw;Palmar erythema;Palmar-plantar erythrodysaesthesia syndrome;Palpitations;Pancytopenia;Panic attack;Paraesthesia;Paraesthesia oral;Pericardial effusion;Peripheral coldness;Peripheral sensory neuropathy;Peroneal nerve palsy;Personality change;Petechiae;Pharyngeal disorder;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Platelet count decreased;Pleural disorder;Pleural effusion;Pneumonia;Pneumothorax;Polyneuropathy;Polyuria;Post procedural complication;Postoperative complications NOS;Potassium low;Pre-menstrual tension syndrome;Premenstrual syndrome;Premenstrual tension;Proctalgia;Protein urine present;Proteinuria;Prothrombin level decreased;Prothrombin level increased;Prurigo;Pruritus;Pruritus genital;Psychiatric symptom;Pulmonary embolism;Punctate keratitis;Purpura;Radiation recall reaction (dermatologic);Radiation recall syndrome;Rales;Rash;Rash erythematous;Rash macular;Recall phenomenon;Rectal disorder;Rectal haemorrhage;Redness of face;Renal failure;Renal failure acute;Renal impairment;Respiratory distress;Rhinitis;Rhinorrhoea;Rigors;Rosacea;Scab;Scratch;Seborrhoeic keratosis;Sensory disturbance;Sepsis;Serum creatinine increased;Shivering;Shock;Sinus tachycardia;Skin discolouration;Skin disorder;Skin exfoliation;Skin fissures;Skin hyperpigmentation;Skin lesion;Skin reaction;Skin ulcer;Sleep disorder;Sneezing;Sodium decreased;Somatoform disorder;Stevens-Johnson syndrome;Stomatitis;Sudden death;Sudden death, cause unknown;Superinfection;Supraventricular tachycardia;Sweating increased;Swelling;Swelling face;Syncope;Tachycardia;Temperature intolerance;Thirst;Throat sore;Thrombocytopenia;Thromboembolic event;Thrombophlebitis;Thrombosis;Tingling sensation;Tinnitus;Tongue disorder;Tonsillitis;Tooth abscess;Torsade de pointes;Toxic dilatation of intestine;Toxic epidermal necrolysis;Transient ischaemic attack;Tremor;Trismus;Ulcer;Ulcer foot;Unspecified disorder of skin and subcutaneous tissue;Upper gastrointestinal haemorrhage;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine color abnormal;Urine output increased;Urticaria;VIIth nerve paralysis;Vaginal haemorrhage;Vaginal pain;Varicose vein;Vascular purpura;Vasospasm;Venous thrombosis;Ventricular extrasystoles;Ventricular fibrillation;Vertigo;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting;Vulvovaginal pain;WBC abnormal NOS;Walking disability;Weight decreased;Weight increased;White blood cell disorder;Wound discharge increased;Wound secretion",small molecule,approved; investigational,"(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; Capecitabin; Capecitabina; Capecitabine; Capécitabine; Capecitabinum; Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; 2.1.1.45; CDC21; TS; TSA1; 2.1.1.45; TS; TSase; 2.4.2.4; ECGF1; Gliostatin; PD-ECGF; Platelet-derived endothelial cell growth factor; TdRPase; TP; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; 3.5.4.5; CDD; Cytidine aminohydrolase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.4.2.3; UP; UPase 1; UrdPase 1; 2.4.2.3; UPase 2; UrdPase 2",Thymidylate synthase; DNA; RNA; Thymidylate synthase,L01BC06
doxycycline,Actinomycosis;Amoebic colitis;Anthrax;Bartonellosis;Body temperature increased;Brucellosis;Cat scratch disease;Chancroid;Cholera;Gingivitis ulcerative;Gonorrhoea;Granuloma inguinale;Inclusion conjunctivitis;Infection;Listeriosis;Lymphogranuloma venereum;Necrotising ulcerative gingivostomatitis;Plague;Pneumonia anthrax;Pneumonia chlamydial;Psittacosis;Q fever;Relapsing fever;Respiratory tract infection;Rickettsialpox;Rocky mountain spotted fever;Syphilis;Trachoma;Trench mouth;Tularaemia;Typhus;Unspecified non-gonococcal urethritis (NGU);Upper respiratory tract infection;Urethritis;Urinary tract infection;Yaws,Anaphylactic shock;Angioedema;Anorexia;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Dysphagia;Enterocolitis;Eosinophilia;Fontanelle bulging;Glossitis;Haemolytic anaemia;Henoch-Schonlein purpura;Hepatotoxicity;Hypersensitivity;Intracranial pressure increased;Menorrhagia;Nausea;Nephropathy toxic;Neutropenia;Oesophageal ulcer;Oesophagitis;Pericarditis;Photosensitivity;Photosensitivity reaction;Prolonged menses;Rash;Serum sickness;Systemic lupus erythematosus;Thrombocytopenia;Urticaria;Vomiting,small molecule,approved; investigational; vet_approved,"5-hydroxy-α-6-deoxytetracycline; 6-alpha-deoxy-5-oxytetracycline; 6alpha-deoxy-5-oxytetracycline; 6α-deoxy-5-oxytetracycline; Anhydrous doxycycline; Doxiciclina; Doxycyclin; Doxycycline; Doxycycline (anhydrous); Doxycycline anhydrous; Doxycyclinum; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; ABCB5 P-gp; P-glycoprotein ABCB5",30S ribosomal protein, A01AB22; J01AA20;J01AA02
colestipol,High density lipoprotein decreased;Hypercholesterolaemia;Low density lipoprotein increased,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Ache;Angina pectoris;Anorexia;Arthralgia;Arthritis;Asthenia;Back pain;Chest pain;Cholecystitis;Cholelithiasis;Constipation;Cramp muscle;Decreased appetite;Dermatitis;Diarrhoea;Digestion impaired;Dizziness;Dyspepsia;Dysphagia;Dyspnoea;Fatigue;Flatulence;Fluid intake increased;Gastrointestinal disorder;Gastrointestinal pain;Haemorrhoidal haemorrhage;Haemorrhoids;Headache;Heartburn;Hypersensitivity;Insomnia;Lightheadedness;Loose stools;Migraine;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Nausea;Oesophageal obstruction;Pain;Peptic ulcer;Rash;Sinus headache;Swelling;Tachycardia;Urticaria;Vomiting,small molecule,approved,Colestipol; Colestipolum; Copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxirane; Epichlorohydrin-tetraethylenepentamine polymer,Bile acids,C10AC02
fluticasone,Asthma;Dermatitis atopic;Eczema;Exacerbation of asthma;Food allergy;Perennial allergic rhinitis;Protein allergy;Rhinitis;Rhinitis allergic;Rhinitis perennial;Rhinitis seasonal;Seasonal allergy;Skin disorder,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abscess;Ache;Acneiform eruption;Affective disorder;Ageusia;Aggression;Agitation;Allergic contact dermatitis;Allergic granulomatous angiitis;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anxiety;Aphonia;Arthralgia;Asthenia;Asthma;Atrophy;Back pain;Bacterial infection;Blepharoconjunctivitis;Blister;Body temperature increased;Breast cancer;Bronchitis;Bronchospasm;Bronchospasm paradoxical;Candida albicans infection;Candida infection;Cataract;Chest discomfort;Chest tightness;Cholecystitis;Common cold;Common wart;Conjunctivitis;Contusion;Cough;Cramp muscle;Cushing's syndrome;Cutaneous hypersensitivity;Dental caries;Dental discomfort;Dermatitis;Dermatitis acneiform;Dermatitis atopic;Dermatitis bullous;Dermatitis contact;Dermatitis irritant contact;Dermatitis perioral;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dry skin;Dyspeptic signs and symptoms;Dysphonia;Dyspnoea;Ear infection;Ecchymosis;Eczema;Eczema herpeticum;Eczema infected;Epistaxis;Eruption;Erythema;Exacerbation of asthma;Excoriation;Extrasystoles;Face oedema;Fatigue;Feeling abnormal;Folliculitis;Food allergy;Fungal infection;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal infection;Gastrointestinal pain;Gastrointestinal signs and symptoms;Glaucoma;Glycosuria;Growth retardation;Haematoma;Haemoglobin;Haemorrhage;Headache;Herpes simplex;Hoarseness;Hyperadrenocorticism;Hyperglycaemia;Hyperkinesia;Hypersensitivity;Hypertension;Hypertrichosis;Hypoaesthesia;Hypogeusia;Ill-defined disorder;Immune system disorder;Impaired healing;Impetigo;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Intervertebral disc protrusion;Intraocular pressure increased;Irritability;Keratitis;Laceration;Laryngeal pain;Laryngitis;Leukocytoclastic vasculitis;Leukoderma;Leukopenia;Lightheadedness;Malaise;Mediastinal disorder;Migraine;Miliaria;Mouth ulceration;Muscle injury;Muscle rigidity;Muscle spasms;Muscle stiffness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Nasal burning;Nasal congestion;Nasal discomfort;Nasal dryness;Nasal irritation;Nasal septum perforation;Nasal soreness;Nasal ulcer;Nasopharyngitis;Nausea;Numbness in fingers;Oedema;Oesophageal candidiasis;Oral candidiasis;Oral discomfort;Oropharyngeal candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Oropharyngeal swelling;Osteoporosis;Pain;Pain of skin;Palpitations;Paralysis;Pharyngitis;Pharyngolaryngeal pain;Plaque psoriasis;Pneumocystis jirovecii pneumonia;Pneumonia;Polyp;Postnasal drip;Procedural pain;Protein allergy;Pruritus;Psoriasis;Pustular psoriasis;Pustule;Rash;Rash erythematous;Rash pustular;Respiratory tract infection;Rheumatic disorder;Rheumatism;Rhinalgia;Rhinitis;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Secondary adrenocortical insufficiency;Secondary infection;Sepsis;Sinusitis;Skin atrophy;Skin discolouration;Skin infection;Skin irritation;Skin papilloma;Skin striae;Sleep disorder;Soft tissue injury;Stinging;Stinging skin;Stomatitis;Subarachnoid haemorrhage;Swelling;Telangiectasia;Telangiectasis facial;Tenderness;Throat irritation;Throat sore;Throat tightness;Thrombocytopenia;Tongue disorder;Tooth discolouration;Toothache;Trauma;Type IV hypersensitivity reaction;Ulcer;Upper respiratory tract infection;Upper-airway cough syndrome;Urticaria;Vasculitis;Viral diarrhoea;Viral infection;Vision blurred;Vomiting;Weight increased;Wheezing;Wound,small molecule,approved; experimental,"Fluticason; Fluticasona; Fluticasone; Fluticasonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; CPLA2; Phospholipase A2 group IVA; PLA2G4; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; CBG; Serpin A6; Transcortin; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Glucocorticoid receptor; Progesterone receptor; Cytosolic phospholipase A2; Mineralocorticoid receptor, D07AC17; R01AD08; R01AD58; R03AK06; R03AK11;D07AC17;R03BA05
trovafloxacin,Abdominal infection;Abortion infected;Community acquired pneumonia;Diabetic foot infection;Endometritis;Endomyometritis;Infection;Nosocomial pneumonia;Osteomyelitis;Parametritis;Pelvic infection;Pneumonia,Abdominal pain;Abnormal dreams;Abnormal vision;Acute yellow liver atrophy;Affect lability;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alcohol intolerance;Amnesia;Anaemia;Anal pruritus;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Anorectal discomfort;Anorectal disorder;Anorexia;Anxiety;Aplastic anaemia;Arthralgia;Arthropathy;Asthenia;Asthma;Ataxia;Back pain;Bacterial prostatitis;Balanoposthitis;Blood urea increased;Body temperature increased;Bone pain;Bradycardia;Breath odour;Bronchospasm;Candida infection;Cerebration impaired;Cheilitis;Chest pain;Chills;Cold sweat;Colitis;Confusional state;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cough;Cramp muscle;Decreased appetite;Depersonalisation;Dermatitis;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dizziness postural;Dry mouth;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Encephalopathy;Enteritis;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Euphoric mood;Eye pain;Face oedema;Faeces discoloured;Fatigue;Feeling abnormal;Flatulence;Flushing;Fungal skin infection;Gait disturbance;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gingivitis;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Hallucination;Headache;Hepatic failure;Hepatic function abnormal;Hepatitis;Hiccups;Hot flush;Hyperacusis;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypokinesia;Hyponatraemia;Hypotension;Ill-defined disorder;Increased appetite;Inflammation;Insomnia;Jaundice;Kidney function abnormal;Leukopenia;Leukorrhea;Libido decreased;Lightheadedness;Loose stools;Loss of consciousness;Malaise;Melaena;Menopausal symptoms;Menstrual disorder;Mental disability;Migraine;Mood swings;Muscle contractions involuntary;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nausea;Nephritis interstitial;Nervousness;Nightmare;Oedema;Oedema peripheral;Osteoarthritis;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Periorbital oedema;Peripheral ischaemia;Photophobia;Photosensitivity;Photosensitivity reaction;Phototoxicity;Pollakiuria;Prothrombin level decreased;Pruritus;Pruritus genital;Pseudomembranous colitis;Rash;Rectal disorder;Renal failure acute;Renal impairment;Respiratory failure;Respiratory insufficiency;Rhinitis;Saliva altered;Salivary hypersecretion;Scotoma;Seborrhoeic dermatitis;Sepsis;Shock;Sinusitis;Skin cold clammy;Skin disorder;Skin exfoliation;Skin ulcer;Sodium decreased;Somnolence;Speech disorder;Stevens-Johnson syndrome;Stomatitis;Stridor;Sweating increased;Syncope;Tachycardia;Tendonitis;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Tinnitus;Tongue disorder;Tongue oedema;Tongue paralysis;Tooth disorder;Tremor;Tubulointerstitial nephritis;Upper respiratory tract infection;Urinary incontinence;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vertigo;Visual impairment;Vomiting;Weight decreased;Weight increased;Xerophthalmia,small molecule,approved; investigational; withdrawn,"Trovafloxacin; trovafloxacino; 5.99.1.3; 5.99.1.3; 5.99.1.3; 5.99.1.3; Topoisomerase IV subunit A; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",DNA gyrase subunit A; DNA gyrase subunit B; DNA gyrase subunit A; DNA topoisomerase 4 subunit A; DNA topoisomerase 2-alpha,J01MA13
beclomethasone,Asthma,Angioedema;Asthma;Back pain;Bronchospasm;Cough;Dermatitis;Dysmenorrhoea;Dysphonia;Headache;Infection;Nausea;Oropharyngeal candidiasis;Pain;Pharyngitis;Rash;Rhinitis;Sinusitis;Type IV hypersensitivity reaction;Upper respiratory tract infection;Urticaria,small molecule,approved,"(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 7α-Chloro-16α-methylprednisolone; Alclometasone; CBG; Serpin A6; Transcortin; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin",Corticosteroid-binding globulin; Glucocorticoid receptor, S01BA10;D07AB10
valganciclovir,Acquired immunodeficiency syndrome;Autoimmune disorder;Cytomegalovirus chorioretinitis;Cytomegalovirus infection;Cytomegalovirus retinitis;Retinitis,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal vision;Acne;Agitation;Alopecia;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Angiopathy;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Arthralgia;Ascites;Asthenia;Ataxia;Attention deficit/hyperactivity disorder;Back pain;Blindness;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine decreased;Blood creatinine increased;Blood disorder;Blood glucose decreased;Blood lactate dehydrogenase increased;Blood urine;Blood urine present;Body temperature increased;Bone marrow depression;Bronchitis;Cachexia;Candida infection;Cardiac disorder;Catheter related infection;Chills;Cholangitis;Coma;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cough;Cramp muscle;Creatinine low;Cytomegalovirus infection;Cytomegalovirus syndrome;Deafness;Decreased appetite;Dehydration;Depression;Dermatitis;Dermatitis exfoliative;Device related infection;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Edema of lower extremities;Emotional disorder;Emotional disturbance NOS;Eosinophilia;Erectile dysfunction;Eructation;Eye disorder;Eye haemorrhage;Eye pain;Faecal incontinence;Fatigue;Feeling abnormal;Flatulence;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glaucoma;Haematuria;Haemoglobin;Haemorrhage;Hallucination;Headache;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertonia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hypophosphataemia;Hypoproteinaemia;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Insomnia;Jaundice;Kaposi's sarcoma;Lactic dehydrogenase activity increased;Leukocytosis;Leukopenia;Libido decreased;Lymphadenopathy;Macular oedema;Malaise;Malnutrition;Mediastinal disorder;Mental disability;Mental disorder;Migraine;Mouth ulceration;Mucous membrane disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myasthenic syndrome;Myoclonus;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm;Nervous system disorder;Nervousness;Neuropathy peripheral;Neutropenia;Night sweats;Oedema;Oedema peripheral;Oesophageal candidiasis;Oesophagitis;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pain in extremity;Pancreatitis;Pancytopenia;Paraesthesia;Pharyngitis;Phlebitis;Photosensitivity reaction;Pleural effusion;Pneumocystis jirovecii pneumonia;Pneumonia;Pollakiuria;Post procedural complication;Postoperative complications NOS;Postoperative pain;Postoperative wound infection;Procedural complication;Procedural pain;Productive cough;Pruritus;Psychotic disorder;Renal failure;Renal impairment;Retinal detachment;Rhinorrhoea;Rigors;Sepsis;Serum creatinine increased;Sinus congestion;Sinusitis;Skin disorder;Somnolence;Splenomegaly;Stomatitis;Sweating increased;Tachycardia;Tension;Thinking abnormal;Throat sore;Thrombocytopenia;Thrombophlebitis;Tinnitus;Tongue disorder;Transplant rejection;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Ventricular arrhythmia;Vertigo;Viral infection;Vision blurred;Visual impairment;Vitreous disorder;Vitreous floaters;Vomiting;Weight decreased;Wound dehiscence;Wound discharge increased;Wound secretion,small molecule,approved; investigational,"Valganciclovir; 2.7.7.7; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; Amino acid transporter ATB0+; Solute carrier family 6 member 14",DNA polymerase catalytic subunit; DNA,J05AB14
Meropenem,Abdominal infection;Appendicitis;Bacteraemia;Bacterial infection;Convulsion;Infection;Influenza;Meningitis;Meningitis bacterial;Peritonitis;Renal failure;Renal impairment,Abdominal distension;Abdominal pain;Accidental injury;Acute coronary syndrome;Agitation;Agranulocytosis;Alanine aminotransferase increased;Anaemia;Angioedema;Anorexia;Anxiety;Apnoea;Application site pain;Asthenia;Asthma;Back pain;Blood creatinine increased;Blood urea increased;Body temperature increased;Bradycardia;Candida infection;Cardiac arrest;Cardiac failure;Central nervous system infection;Chest pain;Chills;Confusional state;Constipation;Cough;Cough increased;Creatinine increased;Decreased appetite;Delirium;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Dyspnoea;Dysuria;Enlargement abdomen;Eosinophilia;Epistaxis;Erythema multiforme;Feeling abnormal;Flatulence;Fluid overload;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glossitis;Haematocrit decreased;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hepatic failure;Hyperhidrosis;Hypersensitivity;Hypertension;Hypochromic anaemia;Hypoglycaemia;Hypokalaemia;Hypotension;Ileus;Injection site inflammation;Injection site pain;Injection site reaction;Injury;Insomnia;Instillation site pain;Intestinal obstruction;Jaundice;Jaundice cholestatic;Leukocytosis;Leukopenia;Loss of consciousness;Melaena;Myocardial infarction;Nausea;Nervousness;Neutropenia;Oedema;Oedema peripheral;Oral candidiasis;Pain;Paraesthesia;Pelvic pain;Peripheral vascular disorder;Peritoneal haemorrhage;Pharyngitis;Phlebitis;Platelet count decreased;Pleural effusion;Pneumonia;Pruritus;Pulmonary embolism;Pulmonary oedema;Rash;Renal failure;Sepsis;Shock;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Sweating;Syncope;Tachycardia;Tension;Thrombocytosis;Thrombophlebitis;Toxic epidermal necrolysis;Urinary incontinence;Urticaria;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;White blood cell count decreased,small molecule,approved; investigational,"(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meropenem; Meropenem anhydrous; Meropenemum; 3.4.16.4; D-alanyl-D-alanine endopeptidase; DD-carboxypeptidase; DD-endopeptidase; PBP-4; Penicillin-binding protein 4; 3.5.2.6; Beta-lactamase PSE-2; oxa10; pse2; 3.4.13.19; Beta-lactamase; Dehydropeptidase-I; hRDP; MDP; Microsomal dipeptidase; RDP; Renal dipeptidase",D-alanyl-D-alanine carboxypeptidase DacB, J01DH52;J01DH02
fenofibric,Abdominal aortic aneurysm;Aortic aneurysm;Blood triglycerides increased;Carotid artery disease;Diabetes mellitus;Diabetic;Dyslipidaemia;High density lipoprotein decreased;Hypercholesterolaemia;Hypertriglyceridaemia;Hypothyroidism;Low density lipoprotein increased;Obesity;Peripheral arterial disease;Peripheral arterial occlusive disease;Weight decreased,Abdominal pain;Alanine aminotransferase increased;Anaemia;Angiopathy;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blood creatine phosphokinase increased;Bronchitis;Connective tissue disorder;Constipation;Cough;Creatine phosphokinase increased;Diarrhoea;Dizziness;Dyspepsia;Fatigue;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hepatic enzyme increased;Hepatitis;Hypertension;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Laryngeal pain;Liver function test abnormal;Malnutrition;Mediastinal disorder;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasopharyngitis;Nausea;Nervous system disorder;Pain;Pain in extremity;Pancreatitis;Pharyngolaryngeal pain;Raised liver function tests;Renal failure;Renal failure acute;Rhabdomyolysis;Rhinitis;Sinusitis;Upper respiratory tract infection;Urinary tract infection,small molecule,approved,NR1C1; Nuclear receptor subfamily 1 group C member 1; PPAR; PPAR-alpha; FABPL; Fatty acid-binding protein 1; L-FABP; Liver-type fatty acid-binding protein; 3.4.24.-; Leukolysin; Membrane-type matrix metalloproteinase 6; Membrane-type-6 matrix metalloproteinase; MMP-25; MMP20; MMPL1; MT-MMP 6; MT6-MMP; MT6MMP; MTMMP6; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; NR1C2; NUC1; NUCI; Nuclear hormone receptor 1; Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferator-activated receptor beta; PPAR-beta; PPAR-delta; PPARB; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR,"Peroxisome proliferator-activated receptor alpha; Fatty acid-binding protein, liver; Matrix metalloproteinase-25; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta; Nuclear receptor subfamily 1 group I member 2",C10AB11
testosterone,Androgen deficiency;Hypogonadism male;Testosterone deficiency,Abdominal pain;Acne;Aggression;Agitation;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Androgenetic alopecia;Anger;Angiopathy;Anxiety;Application site burn;Application site erythema;Application site induration;Application site pain;Application site rash;Application site vesicles;Arthralgia;Aspartate aminotransferase increased;Asthenia;Azoospermia;Benign prostatic hyperplasia;Blood and lymphatic system disorders;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood pressure increased;Blood testosterone decreased;Blood testosterone free increased;Blood testosterone increased;Blood triglycerides increased;Breast disorder;Breast induration;Breast pain;Bronchitis;Cardiovascular disorder;Chest pain;Chills;Cognitive disorder;Cognitive impairment;Confusional state;Connective tissue disorder;Cough;Cramp muscle;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry skin;Dysphonia;Dyspnoea;Dysuria;Emotional disorder;Endocrine disorder;Epididymitis;Erectile dysfunction;Erythema;Erythropoiesis abnormal;Fatigue;Feeling abnormal;Fluid retention;Flushing;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glucose tolerance impaired;Glycosylated haemoglobin increased;Growth accelerated;Gynaecomastia;Haematocrit increased;Haematuria;Haemoglobin;Haemoglobin increased;Haemorrhage;Headache;Hepatic neoplasm;Hepatobiliary disease;Hirsutism;Hostility;Hot flush;Hypercholesterolaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypogonadism;Ill-defined disorder;Immune system disorder;Incontinence;Increased appetite;Influenza;Injection site discomfort;Injection site erythema;Injection site haematoma;Injection site irritation;Injection site pain;Injection site reaction;Insomnia;Irritability;Jaundice;Jaundice cholestatic;Leukopenia;Libido decreased;Libido increased;Lipids abnormal;Liver function test abnormal;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Microembolism;Migraine;Mood alteration NOS;Mood swings;Muscle spasms;Muscle strain;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Nausea;Nephropathy;Nervous system disorder;Nervousness;Night sweats;Nocturia;Oedema;Oestradiol increased;Oligospermia;Pain;Pain in extremity;Paraesthesia;Paresthesia generalized;Peliosis hepatis;Personality disorder;Polycythaemia;Precocious puberty;Priapism;Prostate cancer;Prostate carcinoma;Prostate examination abnormal;Prostate induration;Prostatic disorder;Prostatic dysplasia;Prostatic intraepithelial neoplasia;Prostatic specific antigen increased;Prostatitis;Prostatomegaly;Pruritus;Rash;Rash papular;Rash pustular;Red blood cell count increased;Rhinitis;Seborrhoeic dermatitis;Shock;Sinusitis;Skin disorder;Sleep apnoea syndrome;Snoring;Syncope;Tension;Testicular atrophy;Testicular pain;Testosterone low;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary retention;Urinary tract disorder;Urine flow decreased;Urticaria;Vesiculobullous rash;Vomiting;Water retention;Weight increased,small molecule,approved; investigational,"17beta-hydroxy-4-androsten-3-one; 4-androsten-17β-ol-3-one; Testosteron; Testosterona; Testosterone; Testostérone; Testosteronum; Virosterone; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.14.15.6; Cholesterol desmolase; CYP11A; CYPXIA1; Cytochrome P450 11A1; Cytochrome P450(scc); 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIA13; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Androgen receptor; Estrogen receptor; Mineralocorticoid receptor, G03EA02;G03BA03
bendamustine,Chronic lymphocytic leukaemia,Abdominal distension;Abdominal pain;Abdominal pain upper;Anaemia;Anaphylactic shock;Angiopathy;Anorexia;Anxiety;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atypical pneumonia;Back pain;Blood bilirubin increased;Blood creatinine increased;Blood uric acid increased;Body temperature increased;Bone pain;Candida infection;Cardiac disorder;Cardiac failure;Catheter site pain;Chest pain;Chills;Connective tissue disorder;Constipation;Cough;Creatinine increased;Decreased appetite;Dehydration;Depression;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Erythema;Extravasation;Fatigue;Febrile neutropenia;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haemoglobin decreased;Headache;Herpes simplex;Herpes zoster;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertensive crisis;Hyperuricaemia;Hypocalcaemia;Hypokalaemia;Hyponatraemia;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Infusion site pain;Infusion site reactions;Insomnia;Laryngeal pain;Leukopenia;Lymphocyte count decreased;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Mucosal inflammation;Musculoskeletal discomfort;Myelodysplastic syndrome;Myelosuppression;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm malignant;Nervous system disorder;Neutropenia;Night sweats;Oedema peripheral;Oral candidiasis;Pain;Pain in extremity;Pancytopenia;Pharyngolaryngeal pain;Phlebitis;Platelet count decreased;Pneumocystis jirovecii pneumonia;Pneumonia;Pruritus;Pulmonary fibrosis;Rash;Renal failure acute;Sepsis;Sinusitis;Skin disorder;Skin exfoliation;Skin necrosis;Somnolence;Stomatitis;Swelling;Tachycardia;Taste disorders;Thrombocytopenia;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Vomiting;Weight decreased;Wheezing;White blood cell count decreased,small molecule,approved; investigational,Bendamustina; Bendamustine; Ribomustine; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase,DNA,L01AA09
reboxetine,Cardiovascular disorder;Depression;Depressive disorder;Depressive symptom;Dysthymic disorder;Major depression,Abdominal pain;Accommodation disorder;Agitation;Akathisia;Alanine aminotransferase increased;Albuminuria;Amenorrhoea;Anaemia;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anorgasmia;Anxiety;Aphasia;Asthenia;Blood creatinine increased;Blood pressure fluctuation;Blood pressure systolic increased;Blood uric acid increased;Body temperature increased;Bradycardia;Breast disorder;Breath odour;Bronchitis;Cardiac disorder;Cerebral ischaemia;Change in blood pressure;Cheilitis;Chest pain;Chills;Conduction disorder;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Coordination abnormal;Decreased appetite;Dehydration;Delusion;Depersonalisation;Dermatitis;Diarrhoea;Dilatation ventricular;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Duodenal ulcer;Dysgeusia;Dyspareunia;Dyspepsia;Dyspnoea;Dysuria;Ejaculation disorder;Electrocardiogram abnormal;Electrocardiogram change;Epistaxis;Erectile dysfunction;Euphoric mood;Eye disorder;Face oedema;Feeling abnormal;Flank pain;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Glaucoma;Glossitis;Hair colour changes;Hair disorder;Hallucination;Headache;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hyperuricaemia;Hyperuricosuria;Hyperventilation;Hyponatraemia;Hypotension;Hypoventilation;Hypoxia;Ill-defined disorder;Immune system disorder;Incomplete bladder emptying;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Irritability;Laboratory test abnormal;Left ventricular hypertrophy;Leukopenia;Libido decreased;Liver function test abnormal;Loss of consciousness;Malaise;Malnutrition;Mania;Mediastinal disorder;Menstrual disorder;Mental disability;Mental disorder;Muscular weakness;Mydriasis;Myocardial ischaemia;Nausea;Neck pain;Nervous system disorder;Nervousness;Neurosis;Nuchal rigidity;Orthostatic hypotension;Palpitations;Paraesthesia;Paranoia;Penis disorder;Peripheral coldness;Peripheral vascular disorder;Personality disorder;Pharyngitis;Pollakiuria;Proctalgia;Prostatic disorder;Psychotic disorder;Rash;Rectal tenesmus;Red blood cell abnormality;Respiratory failure;Retrosternal pain;Rhinitis;Salivary hypersecretion;Seborrhoeic dermatitis;Sexual dysfunction;Shock;Sinus tachycardia;Sinusitis;Skin disorder;Somnolence;Speech disorder;Sweating;Syncope;Tachycardia;Tension;Testicular disorder;Testicular pain;Thinking abnormal;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urethral pain;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urine abnormality;Urine analysis abnormal;Urogenital disorder;Urticaria;Ventricular extrasystoles;Vertigo;Viral infection;Visual impairment;Vomiting;Weight decreased;Withdrawal syndrome,small molecule,approved; experimental,"Reboxetina; Reboxetine; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium-dependent noradrenaline transporter,N06AX18
sertaconazole,Sensitisation;Tinea pedis,Application site reaction;Dermatitis contact;Dry skin;Erythema;Pain of skin;Pruritus;Skin burning sensation;Skin exfoliation;Skin hyperpigmentation;Skin tenderness,small molecule,approved; investigational,Sertaconazol; Sertaconazole; Sertaconazolum; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase,Lanosterol 14-alpha demethylase, D01AC14; G01AF20;D01AC14;G01AF19
lercanidipine,Angina pectoris;Diabetes mellitus;Diabetic;Hypertension;Hypertensive,Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Alveolitis allergic;Anaemia;Angina pectoris;Angioedema;Angiopathy;Anorexia;Antinuclear antibody positive;Anxiety;Aphthous stomatitis;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthma;Autoimmune disorder;Blood and lymphatic system disorders;Blood creatinine increased;Blood triglycerides increased;Blood urea increased;Body temperature increased;Bone marrow depression;Breast disorder;Bronchospasm;Cardiac disorder;Cardiac failure;Cardiovascular disorder;Cerebrovascular accident;Chest pain;Cholestasis;Confusional state;Connective tissue disorder;Constipation;Cough;Cramp muscle;Cramps of lower extremities;Decreased appetite;Dermatitis;Dermatitis atopic;Dermatitis exfoliative;Diabetes mellitus;Diabetic;Diarrhoea;Discomfort;Dizziness;Dizziness postural;Dry mouth;Dry throat;Dysgeusia;Dyspepsia;Dysphonia;Dyspnoea;Ear and labyrinth disorders;Eosinophilic pneumonia;Erectile dysfunction;Erythema;Erythema multiforme;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Feeling hot;Flushing;Foetor hepaticus;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Gingival hypertrophy;Glossitis;Gynaecomastia;Haemoglobin decreased;Headache;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hoarseness;Hypercholesterolaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertriglyceridaemia;Hypoglycaemia;Hyponatraemia;Hypotension;Hypotension symptomatic;Ileus;Ill-defined disorder;Immune system disorder;Insomnia;Jaundice;Laryngeal pain;Leukocytosis;Liver disorder;Loss of consciousness;Lung infiltration;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Migraine;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myositis;Nasopharyngitis;Nausea;Necrosis;Nervous system disorder;Nervousness;Neuropathy peripheral;Neutropenia;Nocturia;Oedema peripheral;Oliguria;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Pemphigus;Peptic ulcer;Periorbital oedema;Pharyngolaryngeal pain;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyuria;Precordial pain;Protein urine present;Proteinuria;Pruritus;Rash;Renal failure;Rhinitis;Rhinorrhoea;Serositis;Serum creatinine increased;Shock;Skin disorder;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Syncope;Tachycardia;Tension;Throat sore;Thrombocytopenia;Tinnitus;Tongue disorder;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;Vasculitis;Vertigo;Vision blurred;Vomiting,small molecule,approved; investigational,"Lercanidipine; Lercanidipino; CACNLG; Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2",Voltage-dependent calcium channel gamma-1 subunit; Voltage-dependent calcium channel subunit alpha-2/delta-1, C08CA13; C09BB02;C08CA13;C09DB08
telmisartan,Acute coronary syndrome;Angina pectoris;Cardiac failure;Cardiovascular disorder;Cerebrovascular accident;Coronary artery disease;Coronary heart disease;Cough;Diabetes mellitus;Diabetic;Diabetic nephropathy;Essential hypertension;Hyperlipidaemia;Hypertension;Hypertensive;Hypotension;Myocardial infarction;Peripheral arterial disease;Peripheral arterial occlusive disease;Transient ischaemic attack;Type 2 diabetes mellitus,Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal vision;Abscess;Acute coronary syndrome;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety depression;Arrhythmia;Arthralgia;Arthritis;Arthritis aggravated;Arthropathy;Asthenia;Asthma;Atrial fibrillation;Autonomic neuropathy;Back pain;Bladder pain;Blood and lymphatic system disorders;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood pressure increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bradycardia;Breast disorder;Bronchitis;Bronchospasm;Bursitis;Cardiac disorder;Cardiac failure congestive;Cardiovascular disorder;Cerebrovascular disorder;Chest pain;Chills;Cholesterol serum elevated;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cramp muscle;Cramps of lower extremities;Cystitis;Cystitis noninfective;Decreased appetite;Depression;Dermatitis;Diabetes mellitus;Diabetic;Diarrhoea;Discomfort;Disorder sight;Dizziness;Drug eruption;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Eczema;Edema of lower extremities;Electrocardiogram abnormal;Electrocardiogram abnormal specific;Enlargement abdomen;Enteritis;Eosinophilia;Epistaxis;Erectile dysfunction;Erythema;Eye disorder;Face oedema;Fatal outcomes;Fatigue;Feeling abnormal;Flatulence;Flushing;Foetor hepaticus;Fungal infection;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Genital candidiasis;Gout;Gravitational oedema;Haematuria;Haemoglobin decreased;Haemorrhoids;Headache;Hepatic enzyme increased;Hepatic function abnormal;Hepatobiliary disease;Hepatocellular injury;Hypercholesterolaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertension worsened;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hypotension;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza like illness;Influenza-like symptoms;Insomnia;Intermittent claudication;Interstitial lung disease;Leg edema;Leg pain;Liver disorder;Loss of consciousness;Lung disorder;Malaise;Malnutrition;Mediastinal disorder;Melaena;Mental disorder;Micturition disorder;Migraine;Migraine aggravated;Muscle contractions involuntary;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myositis;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Oedema;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Otitis media;Pain;Pain in extremity;Palpitations;Paraesthesia;Pharyngitis;Plantar fasciitis;Pneumonia;Pollakiuria;Pruritus;Purpura;Raised serum uric acid;Rash;Red blood cell disorders;Renal failure;Renal failure acute;Renal impairment;Rhabdomyolysis;Rhinitis;Rigors;Sciatica;Sepsis;Shock;Sinusitis;Skin disorder;Skin ulcer;Somnolence;Sweating increased;Syncope;Tachycardia;Tendon pain;Tendonitis;Tenosynovitis;Tension;Thrombocytopenia;Tinnitus;Toothache;Toxic skin eruption;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Uric acid increased;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal infection;Vaginal inflammation;Vascular purpura;Vertigo;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,"4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; 4'-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid; Telmisartan; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Peroxisome proliferator-activated receptor gamma; Type-1 angiotensin II receptor, C09CA07; C09DA07; C09DX08; C10BX20;C09CA07;C09DB04
atosiban,Foetal heart rate;Premature baby;Premature delivery;Uterine contractions;Uterine contractions during pregnancy,Angiopathy;Body temperature increased;Breast disorder;Cardiac disorder;Dermatitis;Dizziness;Dyspnoea;Gastrointestinal disorder;Headache;Hot flush;Hyperglycaemia;Hypersensitivity;Hypotension;Immune system disorder;Injection site reaction;Insomnia;Malnutrition;Menopausal symptoms;Mental disorder;Multiple pregnancy;Nausea;Nervous system disorder;Pruritus;Pulmonary oedema;Rash;Skin disorder;Tachycardia;Unspecified disorder of skin and subcutaneous tissue;Uterine atony;Uterine haemorrhage;Uterine hypotonus;Vomiting,small molecule,approved; investigational,Atosiban; OT-R; Antidiuretic hormone receptor 1a; AVPR V1a; AVPR1; V1aR; Vascular/hepatic-type arginine vasopressin receptor; Antidiuretic hormone receptor 1b; AVPR V1b; AVPR V3; AVPR3; V1bR; Vasopressin V3 receptor; VPR3; ADHR; Antidiuretic hormone receptor; AVPR V2; DIR; DIR3; Renal-type arginine vasopressin receptor; V2R,Oxytocin receptor; Vasopressin V1a receptor; Vasopressin V1b receptor; Vasopressin V2 receptor,G02CX01
zoledronic,Anaemia;Analgesic asthma syndrome;Asthma;Asthma aspirin-sensitive;Atrial fibrillation;Blood creatinine increased;Bone cancer metastatic;Cardiac failure;Fluid overload;Fracture;Hip fracture;Hydraemia;Hypercalcaemia;Hypercalcaemia of malignancy;Hyperparathyroidism;Hypovolaemia;Injury;Menopause;Multiple fractures;Neoplasm;Neoplasm malignant;Osteitis deformans;Osteoporosis;Osteoporosis postmenopausal;Plasma cell myeloma;Plasmacytoma;Prostate cancer;Renal failure;Renal impairment;Serum creatinine increased;Solid tumour;Spinal cord compression;Spinal fracture;Trauma;Urine output,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Acute phase reaction;Advanced breast cancer;Agitation;Agranulocytosis;Alopecia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety NEC;Anxiety depression;Arrhythmia;Arthralgia;Arthritis;Asthenia;Asthma;Atrial fibrillation;Atrial flutter;Atypical femur fracture;Azotaemia;Back pain;Blood and lymphatic system disorders;Blood calcium decreased;Blood creatinine abnormal;Blood creatinine decreased;Blood creatinine increased;Blood electrolytes abnormal;Blood urea increased;Body temperature increased;Bone density decreased;Bone disorder;Bone mass decreased;Bone pain;Bradycardia;Breast cancer;Bronchoconstriction;Bronchospasm;C-reactive protein increased;Candida infection;Cardiac disorder;Cardiac fibrillation;Cataract;Chest pain;Chills;Coagulopathy;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cramp muscle;Creatinine low;Creatinine renal clearance decreased;Decreased appetite;Dehydration;Depression;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Edema of lower extremities;Electrolyte abnormality;Electrolyte imbalance;Endophthalmitis;Episcleritis;Erythema;Exacerbation of asthma;Eye disorder;Eye pain;Fatal outcomes;Fatigue;Feeling abnormal;Femur fracture;Flank pain;Flushing;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematuria;Headache;Hyperaesthesia;Hyperhidrosis;Hyperkalaemia;Hypermagnesaemia;Hypernatraemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypocalcaemia;Hypogonadism;Hypokalaemia;Hypomagnesaemia;Hypophosphataemia;Hypotension;Ill-defined disorder;Immune system disorder;Induration;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Influenza-like symptoms;Infusion related reaction;Infusion site reaction;Injection site reaction;Insomnia;Insomnia NEC;Interstitial lung disease;Iridocyclitis;Iritis;Joint stiffness;Joint swelling;Leg edema;Lethargy;Leukopenia;Local reaction;Loss of consciousness;Malaise;Malignant neoplasm progression;Malnutrition;Mediastinal disorder;Mental disorder;Metastasis;Mucosal inflammation;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Nasopharyngitis;Nausea;Neck pain;Necrosis ischaemic;Neoplasm;Neoplasm malignant;Neoplasm malignant aggravated;Nephropathy toxic;Nervous system disorder;Neutropenia;Night sweats;Non-cardiac chest pain;Numbness;Ocular hyperaemia;Oedema;Oedema peripheral;Oesophagitis;Oral disorder;Orbital oedema;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Osteomyelitis;Osteonecrosis;Osteonecrosis of jaw;Osteopenia;Pain;Pain in extremity;Pain in jaw;Palpitations;Pancytopenia;Panophthalmitis;Paraesthesia;Paraesthesia NEC;Plasma cell myeloma;Plasmacytoma;Pleural effusion;Pollakiuria;Prostate cancer;Protein urine present;Proteinuria;Pruritus;Rash;Rash macular;Reaction gastrointestinal;Redness;Renal cancer;Renal failure;Renal failure acute;Renal failure chronic;Renal impairment;Rigors;Scleritis;Sensory loss;Serum creatinine abnormal;Shock;Shoulder pain;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Spinal fracture;Stiffness;Stomatitis;Sweating increased;Swelling;Syncope;Tachycardia;Tetany;Thirst;Throat sore;Thrombocytopenia;Toothache;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Uveitis;Vertigo;Vision blurred;Vomiting;Weight decreased;Weight increased,small molecule,approved,"(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; ácido zoledrónico; Anhydrous Zoledronic Acid; Nanoparticles containing Zoledronic acid; Zol; Zoledronate; Zoledronic acid; Zoledronic Acid Anhydrous; Zoledronic Acid, Anhydrous; (2E,6E)-farnesyl diphosphate synthase; 2.5.1.-; Dimethylallyltranstransferase; Farnesyl diphosphate synthase; Farnesyltranstransferase; Geranylgeranyl diphosphate synthase; Geranyltranstransferase; GGPP synthase; GGPPSase; (2E,6E)-farnesyl diphosphate synthase; 2.5.1.10; Dimethylallyltranstransferase; Farnesyl diphosphate synthase; FPP synthase; FPS; Geranyltranstransferase; KIAA1293; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1",Geranylgeranyl pyrophosphate synthase; Hydroxylapatite; Farnesyl pyrophosphate synthase, M05BA08;M05BA08;M05BB08
brinzolamide,Hypotony of eye;Ocular hypertension;Open angle glaucoma,Abdominal discomfort;Abdominal pain upper;Abnormal sensation in eye;Abnormal vision;Ageusia;Agitation;Alopecia;Amnesia;Angina pectoris;Angiopathy;Apathy;Arrhythmia;Arthralgia;Asthenia;Asthenopia;Asthma;Back pain;Blepharitis;Blood and lymphatic system disorders;Blood chloride increased;Blood pressure increased;Bradycardia;Breast disorder;Bronchial hyperreactivity;Bronchitis;Cardiac disorder;Cardio-respiratory distress;Chest discomfort;Chest pain;Conjunctival hyperaemia;Conjunctivitis;Conjunctivitis allergic;Connective tissue disorder;Corneal disorder;Corneal epithelium defect;Corneal epithelium disorder;Corneal erosion;Corneal oedema;Corneal staining;Cough;Decreased appetite;Depersonalisation;Deposit eye;Depressed mood;Dermatitis;Diarrhoea;Digestion impaired;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Endophthalmitis;Epistaxis;Erectile dysfunction;Erythema;Erythema of eyelid;Eye allergy;Eye discharge;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Eye swelling;Eyelid disorder;Eyelid margin crusting;Eyelids pruritus;Fatigue;Feeling abnormal;Feeling jittery;Flat affect;Flatulence;Foreign body in eye;Foreign body sensation in eyes;Frequent bowel movements;Gastrointestinal disorder;Headache;Heart rate irregular;Hepatobiliary disease;Hyperaemia;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypoaesthesia eye;Hypoaesthesia oral;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Insomnia;Intraocular pressure increased;Irritability;Keratitis;Keratoconjunctivitis;Keratoconjunctivitis sicca;Keratopathy;Lacrimation;Lacrimation increased;Laryngeal pain;Libido decreased;Liver function test abnormal;Madarosis;Malaise;Malnutrition;Mediastinal disorder;Medication residue;Medication residue present;Meibomianitis;Memory impairment;Mental disorder;Motor dysfunction;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasal dryness;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Nightmare;Ocular discomfort;Ocular hyperaemia;Oedema peripheral;Oesophagitis;Optic nerve cupping;Oropharyngeal pain;Pain;Pain in extremity;Palpitations;Paraesthesia;Paraesthesia oral;Periorbital oedema;Pharyngitis;Pharyngolaryngeal pain;Photophobia;Photopsia;Pollakiuria;Pruritus;Pruritus generalised;Pterygium;Punctate keratitis;Rash;Rash maculo-papular;Red blood cell count decreased;Renal pain;Rhinitis;Rhinorrhoea;Scab;Scleral pigmentation;Sensation of foreign body;Sinus congestion;Sinusitis;Skin disorder;Skin tightness;Sneezing;Somnolence;Subconjunctival cyst;Tachycardia;Tension;Throat irritation;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract congestion;Upper-airway cough syndrome;Upset stomach;Urethral disorder;Urinary tract disorder;Urticaria;Vertigo;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vital dye staining cornea present;Vomiting,small molecule,approved,"Brinzolamida; Brinzolamide; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-I; CAB; Carbonate dehydratase I; Carbonic anhydrase B; Carbonic anhydrase I; Cyanamide hydratase CA1; 4.2.1.1; CA-IV; Carbonate dehydratase IV; Carbonic anhydrase IV; 4.2.1.1; CA-VA; CA5; Carbonate dehydratase VA; Carbonic anhydrase VA; 4.2.1.1; CA-III; Carbonate dehydratase III; Carbonic anhydrase III; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase","Carbonic anhydrase 2; Carbonic anhydrase 1; Carbonic anhydrase 4; Carbonic anhydrase 5A, mitochondrial; Carbonic anhydrase 3", G01AE10; S01EC04;S01EC04;S01EC54
acamprosate,Alcohol abuse;Alcoholism,Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal ejaculation;Abnormal vision;Abscess;Accidental injury;Acute coronary syndrome;Agitation;Alanine aminotransferase increased;Alcohol craving;Alcoholism;Alopecia;Amblyopia;Amnesia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Anorexia;Anxiety;Apathy;Arthralgia;Arthritis;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Avitaminosis;Back pain;Blood alkaline phosphatase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood uric acid increased;Body temperature increased;Breast disorder;Bronchitis;Calculus of kidney;Cardiac failure;Cardiomyopathy;Chest pain;Chills;Cholecystitis;Colitis;Confusional state;Constipation;Convulsion;Cough;Cough increased;Cramps of lower extremities;Creatinine increased;Deafness;Decreased appetite;Depersonalisation;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Duodenal ulcer;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ecchymosis;Eczema;Ejaculation disorder;Encephalopathy;Endophthalmitis;Enlargement abdomen;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Face oedema;Feeling abnormal;Female sexual arousal disorder;Flat affect;Flatulence;Fracture;Frigidity;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Goitre;Gout;Haematemesis;Haematuria;Haemoglobin;Haemorrhage;Hallucination;Headache;Hepatic cancer;Hepatic cirrhosis;Hepatitis;Hepatocellular carcinoma;Hernia;Hostility;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertension;Hyperuricaemia;Hypoaesthesia;Hyponatraemia;Hypotension;Hypothyroidism;Hypovitaminosis;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Influenza;Injury;Insomnia;Intentional injury;Lactic dehydrogenase activity increased;Laryngospasm;Leukopenia;Libido decreased;Libido increased;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Lymphocytosis;Malaise;Malnutrition;Mania;Manic psychosis;Melaena;Menorrhagia;Mental disability;Mental disorder;Mesenteric occlusion;Metrorrhagia;Micturition urgency;Migraine;Monocytosis;Mouth ulceration;Multiple fractures;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myopathy;Nausea;Neck pain;Nephrolithiasis;Nervousness;Neuralgia;Neurosis;Nocturia;Oedema peripheral;Oesophagitis;Orthostatic hypotension;Pain;Palpitations;Pancreatitis;Panophthalmitis;Paraesthesia;Paranoia;Paranoid reaction;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Pruritus;Psoriasis;Psychotic disorder;Pulmonary embolism;Rash;Rash maculo-papular;Rash pustular;Rectal haemorrhage;Renal failure acute;Rheumatoid arthritis;Rhinitis;Salivary hypersecretion;Sexual dysfunction;Shock;Skin disorder;Somnolence;Stomatitis;Sudden death;Suicidal ideation;Suicide attempt;Sweating;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombophlebitis;Tinnitus;Torticollis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urinary incontinence;Urinary tract infection;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Varicose vein;Vertigo;Vesiculobullous rash;Visual impairment;Vomiting;Weight decreased;Weight increased;Withdrawal syndrome,small molecule,approved; investigational,3-Acetamido-1-propanesulfonic acid; Acamprosate; Acamprosato; Acamprosatum; N-acetyl homotaurine; N-Acetylhomotaurine; GluN1; Glutamate [NMDA] receptor subunit zeta-1; hNR1; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDAR1; GluN2A; Glutamate [NMDA] receptor subunit epsilon-1; hNR2A; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; GluN2B; Glutamate [NMDA] receptor subunit epsilon-2; hNR3; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NMDAR2B; NR2B; NR3; GluN2C; Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C; NMDAR2C; NR2C; EB11; GluN2D; Glutamate [NMDA] receptor subunit epsilon-4; N-methyl D-aspartate receptor subtype 2D; NMDAR2D; NR2D; GluN3A; KIAA1973; N-methyl-D-aspartate receptor subtype 3A; NMDAR-L; NMDAR3A; NR3A; GluN3B; N-methyl-D-aspartate receptor subtype 3B; NMDAR3B; NR3B; GPRC1E; MGLUR5; GABA-B receptor 1; GABA-B-R1; GABA-BR1; GABABR1; Gb1; GPRC3A; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1,Glutamate (NMDA) receptor; Metabotropic glutamate receptor 5; Gamma-aminobutyric acid type B receptor subunit 1,N07BB03
ropivacaine,Acute pain;Labour pain;Pain;Postoperative pain;Pregnancy;Procedural pain,Abdominal distension;Abdominal pain;Abnormal labour;Acidosis;Acute coronary syndrome;Affect lability;Agitation;Alanine aminotransferase increased;Albuminuria;Amnesia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorectal discomfort;Anterior spinal artery syndrome;Anxiety;Apgar score low;Apnoea;Application site reaction;Arachnoiditis;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atelectasis;Atrial fibrillation;Atrioventricular block;Back pain;Block heart;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Blood urea decreased;Body temperature decreased;Body temperature increased;Bradycardia;Bradycardia foetal;Breast disorder;Breast feeding;Bronchospasm;CNS depression NOS;CNS toxicity;Carbon dioxide increased;Cardiac arrest;Cardiac disorder;Cardiac output decreased;Cauda equina syndrome;Central nervous system stimulation;Chest pain;Chills;Coma;Confusional state;Constipation;Convulsion;Cough;Cramp muscle;Cranial nerve paralysis;Creatine phosphokinase increased;Deep vein thrombosis;Depressed level of consciousness;Depression;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dysarthria;Dyskinesia;Dyspepsia;Dyspnoea;Dysuria;Electrocardiogram ST segment;Enlargement abdomen;Erythema;Excitation cerebral;Excitement;Extradural abscess;Extrasystoles;Faecal incontinence;Feeling abnormal;Fever neonatal;Foetal acidosis;Foetal distress syndrome;Gastrointestinal pain;Grand mal convulsion;Haematuria;Hallucination;Headache;Heart disease congenital;Heart malformation;Hepatic function abnormal;Horner's syndrome;Hypercapnia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypoglycaemia neonatal;Hypokalaemia;Hypokinesia;Hypomagnesaemia;Hypoproteinaemia;Hypotension;Hypothermia;Hypotonia;Hypoxia;Ileus;Ill-defined disorder;Infection;Injection site inflammation;Injection site pain;Injection site reaction;Injury associated with device;Insomnia;Jaundice;Jaundice neonatal;Laboratory test abnormal;Laryngeal oedema;Laryngospasm;Leukocytosis;Loss of consciousness;Malaise;Meningism;Meningitis;Mental disorder;Metabolic disorder;Micturition disorder;Miosis;Mood swings;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Needle injury;Neonatal infection;Neonatal tachypnoea;Nervousness;Neurologic reaction;Neurological symptom;Neuropathy;Neuropathy peripheral;Neurotoxicity;Nightmare;Oedema peripheral;Oliguria;Orthostatic hypotension;Osteoarthritis;Pain;Paraesthesia;Paralysis;Paresis;Phlebitis;Phosphatase alkaline increased;Pleural effusion;Pneumothorax;Post procedural complication;Postoperative complications NOS;Postpartum haemorrhage;Proctalgia;Prolonged labour;Prothrombin level decreased;Pruritus;Pulmonary embolism;Pulmonary function test decreased;Purpura;Pyuria;Rales;Rash;Rectal tenesmus;Respiratory arrest;Respiratory depression;Respiratory disorder neonatal;Respiratory failure;Respiratory insufficiency;Respiratory paralysis;Rhinitis;Rigors;Sepsis neonatal;Shock;Skin disorder;Sneezing;Somnolence;Spinal anaesthesia;Spinal haematoma;Stupor;Sweating increased;Syncope;Tachycardia;Tachycardia foetal;Tachypnoea;Tension;Therapeutic response unexpected;Thrombocytopenia;Thrombocytosis;Tinnitus;Total spinal block;Tremor;Unexpected therapeutic effect;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urticaria;Uterine atony;Uterine hypotonus;Vascular purpura;Vasospasm;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Vomiting;Vomiting neonatal,small molecule,approved,"(S)-(−)-1-propyl-2',6'-pipecoloxylidide; (S)-ropivacaine; L-N-n-propylpipecolic acid-2,6-xylidide; Ropivacaina; Ropivacaine; Ropivacainum; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; AGP 1; AGP1; OMD 1; Orosomucoid-1",Sodium channel protein type 10 subunit alpha,N01BB09
nebivolol,Acute coronary syndrome;Angina pectoris;Cardiac failure;Cardiovascular disorder;Diabetes mellitus;Diabetic nephropathy;Hyperlipidaemia;Hypertension;Hypertensive;Hypotension;Myocardial infarction,Abdominal pain;Acute coronary syndrome;Acute pulmonary oedema;Allergic cutaneous angiitis;Angioedema;Aspartate aminotransferase increased;Asthenia;Atrioventricular block;Bradycardia;Bronchospasm;Cardiac disorder;Chest pain;Claudication;Dermatitis;Diarrhoea;Dizziness;Dyspnoea;Erectile dysfunction;Fatigue;Gastrointestinal disorder;Gastrointestinal pain;Headache;High density lipoprotein decreased;Hypercholesterolaemia;Hypersensitivity;Insomnia;Intermittent claudication;Leukocytoclastic vasculitis;Loss of consciousness;Malnutrition;Mental disorder;Myocardial infarction;Nausea;Nervous system disorder;Oedema peripheral;Paraesthesia;Peripheral ischaemia;Pruritus;Psoriasis;Rash;Renal failure acute;Shock;Skin disorder;Somnolence;Syncope;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vertigo;Vomiting,small molecule,approved; investigational,"Narbivolol; Nebivolol; Nebivololum; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Beta-3 adrenergic receptor, C07AB12; C07BB12; C09BX07; C09DX05;C07AB12;C07FB12
mivacurium,Hypotonia;Muscle relaxation,Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Arrhythmia;Bradycardia;Bronchospasm;Cardiac disorder;Dermatitis;Dizziness;Erythema;Flushing;Hypotension;Hypoxemia;Hypoxia;Immune system disorder;Injection site reaction;Mediastinal disorder;Muscle spasms;Neuromuscular block prolonged;Phlebitis;Rash;Skin disorder;Tachycardia;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Wheezing,small molecule,approved,Mivacurium; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase,Neuronal acetylcholine receptor subunit alpha-2; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Cholinesterase,M03AC10
dofetilide,Arrhythmia supraventricular;Atrial fibrillation;Atrial flutter;Cardiac disorder;Cardiac flutter;Sinus rhythm;Ventricular arrhythmia,Abdominal pain;Accidental injury;Acute coronary syndrome;Angina pectoris;Angioedema;Anxiety;Arrhythmia;Arthralgia;Asthenia;Atrioventricular block;Back pain;Block heart;Bradycardia;Bundle branch block;Cardiac arrest;Cardiac failure;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Cough;Cough increased;Dermatitis;Diarrhoea;Dizziness;Dyspnoea;Facial paralysis;Gastrointestinal pain;Headache;Hepatocellular injury;Hyperhidrosis;Hypertension;Infarction;Influenza;Injury;Insomnia;Liver injury;Loss of consciousness;Migraine;Musculoskeletal discomfort;Myocardial infarction;Nausea;Oedema;Oedema peripheral;Pain;Palpitations;Paraesthesia;Paralysis;Paralysis flaccid;Postinfarction;Rash;Respiratory tract infection;Shock;Sudden death;Supraventricular tachycardia;Sweating;Syncope;Torsade de pointes;Urinary tract infection;VIIth nerve paralysis;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia,small molecule,approved; investigational,"beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; Dofetilida; Dofetilide; Dofetilidum; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; K2P2.1; Outward rectifying potassium channel protein TREK-1; TREK; TREK-1 K(+) channel subunit; TREK1; Two pore domain potassium channel TREK1; Two pore potassium channel TPKC1; Inward rectifier K(+) channel Kir2.2; Inward rectifier K(+) channel Kir2.2v; IRK-2; IRK2; KCNJN1; Potassium channel, inwardly rectifying subfamily J member 12; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; hOCT2; OCT2; Organic cation transporter 2",Voltage-gated inwardly rectifying potassium channel KCNH2; Potassium channel subfamily K member 2; ATP-sensitive inward rectifier potassium channel 12,C01BD04
lanreotide,Acromegaly;Carcinoid syndrome;Carcinoid tumour;Hepatic impairment;Hypersensitivity;Liver disorder;Pituitary tumour,Abdominal discomfort;Abdominal distension;Abdominal pain;Acute coronary syndrome;Alanine aminotransferase increased;Allergic skin reaction;Alopecia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anxiety;Aortic valve incompetence;Aortic valve stenosis;Arrhythmia supraventricular;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrial arrhythmia;Atrial septal defect;Atrioventricular block;Autonomic nervous system imbalance;Back pain;Block heart;Blood alkaline phosphatase increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood glucose increased;Bone pain;Bradycardia;Bronchitis;Bundle branch block;Bursitis;Cardiac disorder;Cardiac murmur;Cardiac valve disease;Cardiomegaly;Cardiovascular disorder;Cataract;Change of bowel habit;Chest pain;Cholecystitis;Cholelithiasis;Connective tissue disorder;Constipation;Corneal deposits;Decreased appetite;Depression;Dermatitis atopic;Diabetes mellitus;Diabetes mellitus exacerbated;Diarrhoea;Discomfort;Disorder sight;Dizziness;Dysaesthesia;Dysautonomia;Dyspepsia;Dyspnoea;Dysuria;Electrocardiogram abnormal;Endocrine disorder;Endometrial disorder;Erectile dysfunction;Fatigue;Feeling abnormal;Flatulence;Gait disturbance;Gallbladder disorder;Gallbladder sludge;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Glycosylated haemoglobin increased;Haemorrhoids;Hair disorder;Headache;Hepatic neoplasm;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hepatosplenomegaly;Hot flush;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertension worsened;Hypoaesthesia;Hypoglycaemia;Hyponatraemia;Hypothyroidism;Hypotrichosis;Ill-defined disorder;Increased appetite;Induration;Inflammation;Injection site haemorrhage;Injection site inflammation;Injection site mass;Injection site nodule;Injection site pain;Injection site reaction;Insomnia;Leukopenia;Liver injury;Loose stools;Malaise;Malnutrition;Menopausal symptoms;Mental disorder;Mitral valve incompetence;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nail disorder;Nausea;Neoplasm;Nervous system disorder;Nervousness;Neuropathy peripheral;Nodule;Oedema;Pain;Pancreatitis;Paraesthesia;Peripheral ischaemia;Phosphatase alkaline increased;Pruritus;Reaction gastrointestinal;Red blood cell disorders;Regurgitation;Renal pain;Rhinitis;Sinus bradycardia;Skin disorder;Steatorrhoea;Sweating increased;Tension;Tinnitus;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Ventricular arrhythmia;Vertigo;Visual impairment;Vitamin B12 deficiency;Vomiting;Weight decreased,small molecule,approved,"Lanreotida; Lanreotide; SRIF-1; SS-2-R; SS2-R; SS2R; SST2; SS-5-R; SS5-R; SS5R; SST5; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Somatostatin receptor type 2; Somatostatin receptor type 5,H01CB03
iloperidone,Schizophrenia;Sudden death;Torsade de pointes,Abdominal discomfort;Affect lability;Aggression;Agitation;Akathisia;Amenorrhoea;Amnesia;Anaemia;Angiopathy;Anorgasmia;Aphthous stomatitis;Arrhythmia;Arthralgia;Asthenia;Asthma;Atrioventricular block first degree;Blepharitis;Blood disorder;Body temperature increased;Bradykinesia;Breast disorder;Breast pain;Bulimia nervosa;Cardiac disorder;Cardiac failure;Cataract;Catatonia;Cheilitis;Cholelithiasis;Confusional state;Conjunctivitis;Connective tissue disorder;Dehydration;Delirium;Delusion;Dermatitis;Diarrhoea;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dry throat;Duodenal ulcer;Dyskinesia;Dyspnoea;Dyspnoea exertional;Dysuria;Ear and labyrinth disorders;Ejaculation failure;Endocrine disorder;Enuresis;Epistaxis;Erectile dysfunction;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye swelling;Eyelid oedema;Faecal incontinence;Fatigue;Feeling abnormal;Fluid retention;Gait disturbance;Gastric pH decreased;Gastritis;Gastrointestinal disorder;Gastrooesophageal reflux disease;Gynaecomastia;Haematocrit decreased;Haemoglobin decreased;Hepatobiliary disease;Hiatus hernia;Hostility;Hyperaemia;Hyperchlorhydria;Hypokalaemia;Hypotension;Hypothyroidism;Impulse-control disorder;Increased appetite;Infection;Iron deficiency anaemia;Lenticular opacities;Lethargy;Leukopenia;Libido decreased;Lip pain;Lip ulceration;Major depression;Malnutrition;Mania;Mediastinal disorder;Menorrhagia;Menstruation irregular;Mental disorder;Metrorrhagia;Mood swings;Mouth ulceration;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Nasal congestion;Nasal dryness;Nasopharyngitis;Nausea;Nephrolithiasis;Nervous system disorder;Neutrophil count increased;Nystagmus;Obsessive-compulsive disorder;Oedema;Orthostatic hypotension;Palpitations;Panic attack;Paraesthesia;Paranoia;Parkinsonism;Pollakiuria;Polydipsia psychogenic;Prostatitis;Psychotic disorder;Rash;Reflux esophagitis;Renal failure acute;Restless legs syndrome;Retrograde ejaculation;Rhinorrhoea;Salivary hypersecretion;Sinus congestion;Sleep apnoea syndrome;Somnolence;Stomatitis;Tachycardia;Testicular pain;Thirst;Tinnitus;Torticollis;Tremor;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Vertigo;Vision blurred;Walking disability;Weight decreased;Weight increased,small molecule,approved,"1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone; 4'-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone; Iloperidona; Ilopéridone; Iloperidone; Iloperidonum; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; Dopamine D2 receptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-6; 5-HT6; Serotonin receptor 6; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; Dopamine D1 receptor; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; D(5) dopamine receptor; D1beta dopamine receptor; Dopamine D5 receptor; DRD1B; DRD1L2; H1-R; H1R; HH1R; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",5-hydroxytryptamine receptor 2A; D(2) dopamine receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; D(1A) dopamine receptor; D(3) dopamine receptor; D(4) dopamine receptor; D(1B) dopamine receptor; Histamine H1 receptor,N05AX14
erythromycin,Gonorrhoea;Infection;Pertussis,Abdominal pain;Anaphylactic shock;Angioedema;Chest pain;Cramp muscle;Deafness neurosensory;Dermatitis;Diarrhoea;Dizziness;Gastrointestinal pain;Hypersensitivity;Injury;Muscle spasms;Nausea;Ototoxicity;Palpitations;Pruritus;Rash;Thrombophlebitis;Torsade de pointes;Trauma;Urticaria;Ventricular arrhythmia;Ventricular tachycardia;Vomiting,small molecule,approved; investigational; vet_approved,"3''-O-demethylerythromycin; Abomacetin; Eritromicina; Erythromycin; Erythromycin A; Erythromycin C; érythromycine; Erythromycinum; G-protein coupled receptor 38; GPR38; MTLR; MTLR1; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3",23S ribosomal RNA; Motilin receptor; Voltage-gated inwardly rectifying potassium channel KCNH2, D10AF02; D10AF52; S01AA17;J01FA01
voriconazole,Aspergillosis;Aspergillus infection;Candida infection;Candidemia;Fungal infection;Haematological malignancy;Hepatosplenic candidiasis;Hypokalaemia;Infection;Oesophageal candidiasis;Systemic candida;Wound,Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal vision;Accommodation disorder;Acute coronary syndrome;Acute hepatic failure;Acute respiratory distress syndrome;Adrenal cortical hypofunction;Adrenal insufficiency;Ageusia;Agitation;Agranulocytosis;Akathisia;Alanine aminotransferase increased;Albuminuria;Alopecia;Amnesia;Anaemia;Anaemia megaloblastic;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Anuria;Anxiety;Aplastic anaemia;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Arthritis;Ascites;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrial arrhythmia;Atrial fibrillation;Atrioventricular block complete;Azotaemia;Back pain;Bacterial infection;Bleeding time prolonged;Blepharitis;Blighted ovum;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone marrow depression;Bone pain;Bradycardia;Brain oedema;Bundle branch block;Cardiac arrest;Cardiac disorder;Cardiac failure congestive;Cardiomegaly;Cardiomyopathy;Cellulitis;Cerebral haemorrhage;Cerebral ischaemia;Cerebrovascular accident;Cheilitis;Chest discomfort;Chest pain;Chest tightness;Chills;Cholecystitis;Cholelithiasis;Cholestasis;Chromatopsia;Color vision change;Colour blindness;Colour blindness acquired;Coma;Coma hepatic;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Corneal opacity;Cough;Cough increased;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine increased;Creatinine renal clearance decreased;Cutaneous lupus erythematosus;Cyanosis;Cystitis haemorrhagic;Deafness;Decreased appetite;Delirium;Dementia;Depersonalisation;Depression;Dermatitis;Dermatitis atopic;Dermatitis contact;Dermatitis exfoliative;Diabetes insipidus;Diarrhoea;Diplopia;Discoid lupus erythematosus;Discomfort;Disseminated intravascular coagulation;Disturbance in sexual arousal;Dizziness;Drug eruption;Drug hypersensitivity;Drug interaction;Dry eye;Dry mouth;Dry skin;Duodenal ulcer perforation;Duodenitis;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Ecchymosis;Eczema;Electrocardiogram QT corrected interval;Electrocardiogram QT interval;Electrocardiogram QT prolonged;Encephalitis;Encephalopathy;Endocarditis;Endocrine disorder;Enlargement abdomen;Eosinophilia;Epididymitis;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Extrapyramidal symptoms;Extrasystoles;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Feeling abnormal;Fixed drug eruption;Flank pain;Flatulence;Fluid overload;Fluorosis;Flushing;Foetor hepaticus;Function kidney decreased;Furuncle;Furunculosis;Gastric ulcer;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingival bleeding;Gingival hyperplasia;Gingivitis;Glossitis;Glucose tolerance decreased;Glycosuria;Graft versus host disease;Graft versus host reaction;Grand mal convulsion;Granuloma;Guillain-Barre syndrome;Haematemesis;Haematuria;Haemolytic anaemia;Haemoptysis;Hallucination;Headache;Hearing impaired;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Herpes NOS;Herpes simplex;Herpes virus infection;Hydronephrosis;Hyperbilirubinaemia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypermagnesaemia;Hypernatraemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Hypothyroidism;Ill-defined disorder;Immune system disorder;Immunocompromised;Immunodeficiency;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Influenza-like symptoms;Injection site infection;Injection site pain;Injection site reaction;Insomnia;Intestinal perforation;Intestinal ulcer;Intracranial pressure increased;Jaundice;Jaundice cholestatic;Keratitis;Keratoconjunctivitis;Kidney function abnormal;Leukopenia;Libido decreased;Liver disorder;Liver function test abnormal;Liver injury;Loss of consciousness;Lymphadenopathy;Lymphangitis;Malaise;Malignant melanoma;Malnutrition;Mediastinal disorder;Melaena;Melanosis;Mental disorder;Metrorrhagia;Microcytic;Microcytosis;Mouth ulceration;Mucous membrane disorder;Multi-organ failure;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Mydriasis;Myocardial infarction;Myopathy;Nausea;Nephritis;Nephrosis;Nephrotic syndrome;Nervous system disorder;Neuralgia;Neuropathy;Neuropathy peripheral;Night blindness;Nodal arrhythmia;Nodal rhythm;Nystagmus;Oculogyration;Oculogyric crisis;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Oliguria;Optic atrophy;Optic nerve disorder;Optic neuritis;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Osteomalacia;Osteonecrosis;Osteoporosis;Otitis externa;Pain;Palpitations;Pancreatitis;Pancytopenia;Papilloedema;Paracoccidioides infection;Paraesthesia;Parotid gland enlargement;Pelvic pain;Periodontitis;Periostitis;Peritonitis;Petechiae;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photophobia;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pneumonia;Proctitis;Protein urine present;Proteinuria;Pruritus;Pseudomembranous colitis;Pseudoporphyria;Psoriasis;Psychotic disorder;Pulmonary embolism;Pulmonary oedema;Purpura;Raised liver function tests;Rash;Rash macular;Rash maculo-papular;Rash papular;Rectal disorder;Rectal haemorrhage;Renal failure acute;Renal impairment;Renal pain;Renal tubular necrosis;Respiratory distress;Respiratory distress syndrome;Respiratory tract infection;Retinal haemorrhage;Retinal toxicity;Retinitis;Retrosternal pain;Rhinitis;Scleritis;Scotoma;Scrotal oedema;Sepsis;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin lesion;Somnolence;Splenomegaly;Squamous cell carcinoma;Stevens-Johnson syndrome;Stomatitis;Suicidal ideation;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating;Swollen tongue;Syncope;Tachycardia;Taste altered;Throat sore;Thrombocytopenia;Thrombophlebitis;Thrombotic thrombocytopenic purpura;Tinnitus;Tongue disorder;Tongue oedema;Torsade de pointes;Toxic epidermal necrolysis;Traumatic liver injury;Tremor;Unspecified disorder of skin and subcutaneous tissue;Uremia;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Uterine haemorrhage;Uveitis;Vaginal haemorrhage;Vascular purpura;Ventricular arrhythmia;Ventricular bigeminy;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting,small molecule,approved,"(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (αR,βS)-α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VCZ; Voriconazol; Voriconazole; Voriconazolum; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase; 1.14.13.148; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 1; Dimethylaniline oxidase 1; Fetal hepatic flavin-containing monooxygenase 1; FMO 1; Trimethylamine monooxygenase; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1",Lanosterol 14-alpha demethylase,J02AC03
darifenacin,Benign prostatic hyperplasia;Benign prostatic hypertrophy;Detrusor hyperreflexia;Functional gastrointestinal disorder;Hypertonic bladder;Infection;Irritable bowel syndrome;Nocturia;Pollakiuria;Urge incontinence,Abdominal pain;Abnormal vision;Accidental injury;Acute retention of urine;Airway obstruction NOS;Alanine aminotransferase increased;Anaphylactic shock;Angioedema;Angiopathy;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Bladder pain;Breast disorder;Bronchitis;Cerebrovascular accident;Confusional state;Constipation;Constipation chronic;Cough;Cough increased;Depressed mood;Dermatitis;Diarrhoea;Dizziness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Erectile dysfunction;Erythema multiforme;Eye disorder;Face oedema;Feeling abnormal;Flatulence;Flu symptoms;Gallbladder disorder;Gastrointestinal disorder;Gastrointestinal pain;Granuloma annulare;Hallucination;Headache;Hyperhidrosis;Hypersensitivity;Hypertension;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Loss of consciousness;Mediastinal disorder;Mental disability;Mental disorder;Mouth ulceration;Musculoskeletal discomfort;Nasal dryness;Nausea;Nervous system disorder;Obstructive airways disorder;Oedema;Oedema peripheral;Pain;Palpitations;Pharyngitis;Pruritus;Rash;Respiratory tract infection;Rhinitis;Shock;Sinusitis;Skin disorder;Somnolence;Stomatitis;Sweating;Syncope;Tachycardia;Thinking abnormal;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Vaginal infection;Vaginal inflammation;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight increased,small molecule,approved; investigational,"(S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-α,α-diphenyl-3-pyrrolidineacetamide; Darifenacin; Darifenacina; Darifénacine; Darifenacinum; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5,G04BD10
Terlipressin,Acute renal insufficiency;Ascites;Hepatorenal syndrome;Oesophageal varices haemorrhage;Renal failure acute,Abdominal cramps;Abdominal pain;Acute coronary syndrome;Angiopathy;Atrial fibrillation;Blood creatinine decreased;Bradycardia;Cardiac disorder;Cardiac failure;Chest pain;Cyanosis;Cyanosis peripheral;Diarrhoea;Dyspnoea;Fluid overload;Gastrointestinal disorder;Headache;Hot flush;Hypertension;Hyponatraemia;Injection site necrosis;Intestinal ischaemia;Malnutrition;Menopausal symptoms;Mesenteric vascular insufficiency;Myocardial infarction;Nausea;Nervous system disorder;Pallor;Pallor facial;Peripheral ischaemia;Pregnancy;Pulmonary oedema;Respiratory distress;Respiratory failure;Serum creatinine decreased;Skin disorder;Skin exfoliation;Skin necrosis;Tachycardia;Torsade de pointes;Unspecified disorder of skin and subcutaneous tissue;Uterine hypertonus;Vasoconstriction;Vasoconstriction peripheral;Ventricular extrasystoles;Ventricular fibrillation;Vomiting,biotech,approved; investigational,Terlipresina; Terlipressin; Terlipressina; Terlipressine; Terlipressinum; Antidiuretic hormone receptor 1a; AVPR V1a; AVPR1; V1aR; Vascular/hepatic-type arginine vasopressin receptor; Antidiuretic hormone receptor 1b; AVPR V1b; AVPR V3; AVPR3; V1bR; Vasopressin V3 receptor; VPR3; ADHR; Antidiuretic hormone receptor; AVPR V2; DIR; DIR3; Renal-type arginine vasopressin receptor; V2R,Vasopressin V1a receptor; Vasopressin V1b receptor; Vasopressin V2 receptor,H01BA04
rifaximin,Body temperature increased;Chronic hepatic failure;Diarrhoea;Dysentery;End stage liver disease;Hepatic encephalopathy;Hepatic function abnormal;Infection;Traveller's diarrhea,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Abnormal dreams;Ageusia;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorectal discomfort;Anorexia;Arthralgia;Ascites;Aspartate aminotransferase increased;Asthenia;Back pain;Blood and lymphatic system disorders;Blood in stool;Body temperature increased;Bone disorder;Cellulitis;Chest pain;Choluria;Cold sweat;Colitis;Confusional state;Constipation;Contusion;Cough;Decreased appetite;Defaecation urgency;Dehydration;Depression;Dermatitis;Dermatitis atopic;Dermatitis exfoliative;Diarrhoea;Discomfort;Disturbance in attention;Dizziness;Dry mouth;Dry throat;Dysentery;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear pain;Epistaxis;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gingival disorder;Haematochezia;Haematuria;Haemoglobin;Haemorrhage;Headache;Hot flush;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypoaesthesia;Hypoglycaemia;Hyponatraemia;Hypotension;Ill-defined disorder;Infection;Infestation;Infestation NOS;Influenza like illness;Inguinal hernia;Insomnia;Laryngeal pain;Lip dry;Loss of consciousness;Lymphocytosis;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Mental disorder;Migraine;Monocytosis;Motion sickness;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasal discomfort;Nasal passage irritation;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Neutropenia;Oedema peripheral;Pain;Pain in extremity;Pharyngitis;Pharyngolaryngeal pain;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Procedural pain;Proctalgia;Protein urine present;Proteinuria;Pruritus;Rash;Rectal tenesmus;Respiratory tract infection;Rhinitis;Rhinorrhoea;Shock;Skin disorder;Sticky skin;Sunburn;Sweating increased;Swelling face;Syncope;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;Vertigo;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"Rifamycin L 105; Rifamycin L 105SV; Rifaxidin; Rifaximin; Rifaximina; Rifaximine; Rifaximinun; 2.7.7.6; groN; nitB; rif; RNA polymerase subunit beta; RNAP subunit beta; ron; stl; stv; tabD; Transcriptase subunit beta; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase",DNA-directed RNA polymerase subunit beta; Nuclear receptor subfamily 1 group I member 2, D06AX11;A07AA11
bleomycin,Carcinoma testes;Choriocarcinoma;Dysplasia;Function kidney decreased;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Lymphoma;Malignant pleural effusion;Neoplasm;Neoplasm malignant;Non-Hodgkin's lymphoma;Pleural effusion;Pulmonary toxicity;Renal impairment;Squamous cell carcinoma;Testis cancer,Acute chest pain;Acute coronary syndrome;Acute interstitial pneumonitis;Aggression;Alopecia;Anaemia;Anaphylactic shock;Anorexia;Arteritis;Arthritis;Asthenia;Bladder pain;Body temperature increased;Bronchospasm;Cerebral arteritis;Cerebrovascular accident;Chest X-ray normal;Chest pain;Chills;Confusional state;Cough;Cystitis;Cystitis haemorrhagic;Cystitis noninfective;Decreased appetite;Dermatitis;Discomfort;Disorientation;Dry cough;Dyspnoea;Erythema;Extravasation;Febrile neutropenia;Feeling abnormal;Flushing;Fraction of inspired oxygen;Haematuria;Haemoglobin;Haemorrhage;Hamman-Rich syndrome;Hyperaesthesia;Hyperkeratosis;Hypersensitivity;Hypoaesthesia;Hypomagnesaemia;Hypotension;Ichthyosis;Ichthyosis acquired;Idiopathic pulmonary fibrosis;Ill-defined disorder;Induration;Infection;Infectious pneumonitis;Injury;Interstitial lung disease;Leukopenia;Local reaction;Localized exfoliation;Lung fibrosis interstitial;Lung infiltration;Malaise;Metaplasia;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Myelosuppression;Myocardial infarction;Nail changes;Nail disorder;Nausea;Nephropathy toxic;Oedema;Pain;Pain of skin;Pancytopenia;Paraesthesia;Periorbital oedema;Phlebitis;Pleuritic pain;Pleuropericarditis;Pneumonia;Pruritus;Pulmonary fibrosis;Radiation pneumonitis;Rales;Rash;Reaction febrile;Scleroderma;Skin exfoliation;Skin hyperpigmentation;Skin hypertrophy;Skin striae;Skin tenderness;Skin thickening;Skin toxicity;Stomatitis;Tenderness;Thrombocytopenia;Thrombotic microangiopathy;Trauma;Ulcer;Urticaria;Vomiting;Weight decreased;Wheezing,small molecule,approved; investigational,Bleocin; Bleomicin; Bleomicina; Bleomycin; Bleomycine; Bleomycinum; 6.5.1.1; DNA ligase I; Polydeoxyribonucleotide synthase [ATP] 1; 6.5.1.1; DNA ligase III; Polydeoxyribonucleotide synthase [ATP] 3; 3.4.22.40; BH; BLM hydrolase; BMH,DNA; DNA ligase 1; DNA ligase 3,L01DC01
gemifloxacin,Bronchitis chronic;Community acquired pneumonia;Hepatic impairment;Infection;Liver disorder;Pneumonia;Respiratory tract infection,Abdominal pain;Abnormal dreams;Abnormal vision;Agranulocytosis;Alanine aminotransferase increased;Albumin low;Anaemia;Anaphylactic shock;Angiopathy;Anorexia;Antibiotic associated colitis;Aphasia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Bilirubin total increased;Blood albumin decreased;Blood alkaline phosphatase increased;Blood bilirubin increased;Blood calcium decreased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood potassium decreased;Blood potassium increased;Blood sodium increased;Blood urea increased;Body temperature increased;Breast disorder;Ca++ increased;Calcium low;Candida infection;Cardiac disorder;Clostridium difficile colitis;Congestive cardiomyopathy;Connective tissue disorder;Constipation;Coordination abnormal;Cramps of lower extremities;Creatine phosphokinase increased;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Eczema;Electrocardiogram QT prolonged;Eosinophilia;Eructation;Erythema multiforme;Eye disorder;Face oedema;Fatigue;Flatulence;Flushing;Fungal infection;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Genital candidiasis;Glossitis;Haematocrit decreased;Haematocrit increased;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoglobin increased;Haemorrhage;Headache;Hepatitis cholestatic;Hepatobiliary disease;Hot flush;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyponatraemia;Hypovolaemia;Immune system disorder;Infestation;Infestation NOS;Insomnia;Jaundice hepatocellular;Lactic dehydrogenase activity increased;Leukopenia;Loss of consciousness;Mediastinal disorder;Megacolon;Menopausal symptoms;Mental disorder;Moniliasis genital female;Mouth ulceration;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Neutrophil count decreased;Neutrophil count increased;Oedema;Oedema peripheral;Oral mucosal blistering;Pain;Palpitations;Pancreatitis;Pharyngitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Phototoxicity;Platelet count decreased;Pneumonia;Potassium increased;Potassium low;Protein total decreased;Pruritus;Pruritus genital;Rash;Red blood cell count decreased;Red blood cell count increased;Renal failure;Renal failure acute;Respiratory arrest;Retching;Retinal haemorrhage;Serum creatinine increased;Shock;Skin disorder;Skin exfoliation;Sodium decreased;Sodium high;Somnolence;Stomatitis;Supraventricular tachycardia;Swelling face;Swollen tongue;Syncope;Tachycardia;Tendon rupture;Tension;Thrombocytopenia;Thrombocytosis;Transient ischaemic attack;Tremor;Type 2 diabetes mellitus;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine abnormality;Urine analysis abnormal;Urticaria;Uveitis;Vaginal infection;Vaginal inflammation;Vaginal mucosal blistering;Vertigo;Visual impairment;Vomiting,small molecule,approved; investigational,Gemifloxacin; 5.99.1.3; 5.99.1.3; 5.99.1.3; 5.99.1.3; Topoisomerase IV subunit A; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase,DNA gyrase subunit A; DNA gyrase subunit B; DNA gyrase subunit A; DNA topoisomerase 4 subunit A,J01MA15
doripenem,Abdominal infection;Bacteraemia;Infection;Nosocomial pneumonia;Pneumonia;Pyelonephritis;Urinary tract infection;Ventilator associated pneumonia,Anaemia;Anaphylactic shock;Angiopathy;Blood and lymphatic system disorders;Candida infection;Clostridium difficile colitis;Colitis;Convulsion;Dermatitis;Diarrhoea;Drug interaction;Erythema multiforme;Gastrointestinal disorder;Headache;Hepatic enzyme increased;Hepatobiliary disease;Hypersensitivity;Immune system disorder;Infection;Infestation;Infestation NOS;Interstitial lung disease;Interstitial pneumonia;Leukopenia;Nausea;Necrolysis epidermal;Nervous system disorder;Neutropenia;Oral candidiasis;Phlebitis;Pneumonia;Pruritus;Rash;Skin disorder;Stevens-Johnson syndrome;Thrombocytopenia;Thrombocytopenia toxic;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue,small molecule,approved; investigational,Doripenem; 2.5.1.15; dhpS; Dihydropteroate pyrophosphorylase; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; PBP-2; pbpA; ftsI; ftsI_1; ftsI_2; Penicillin-binding protein 3; Peptidoglycan synthase FtsI; 3.4.13.19; Beta-lactamase; Dehydropeptidase-I; hRDP; MDP; Microsomal dipeptidase; RDP; Renal dipeptidase; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8,Dihydropteroate synthase; Penicillin-binding protein 1A; Penicillin-binding protein 1B; Penicillin-binding protein 2; Cell division protein; Penicillin-binding protein 4,J01DH04
telithromycin,Acute exacerbation of chronic bronchitis;Acute sinusitis;Bronchitis;Community acquired pneumonia;Infection;Pharyngitis;Pneumonia;Tonsillitis,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abdominal tenderness;Abnormal dreams;Ageusia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anosmia;Antibiotic associated colitis;Anxiety;Aphthous stomatitis;Arrhythmia;Arrhythmia supraventricular;Arthralgia;Asthenia;Atrial arrhythmia;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Bradycardia;Breast disorder;Bundle branch block;Candida infection;Cardiac disorder;Cardiovascular disorder;Cholestasis;Chromaturia;Clostridium difficile colitis;Coagulopathy;Confusional state;Connective tissue disorder;Constipation;Cramp muscle;Creatinine renal clearance decreased;Decreased appetite;Dermatitis;Dermatitis atopic;Diarrhoea;Diplopia;Disturbance in attention;Dizziness;Drug hypersensitivity;Dry mouth;Dysgeusia;Dysmenorrhoea;Dyspepsia;Ear and labyrinth disorders;Eczema;Electrocardiogram QT prolonged;Eosinophil count increased;Eosinophilia;Eructation;Erythema multiforme;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Flatulence;Flushing;Frequent bowel movements;Fungal infection;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;Glossitis;Glossodynia;Hallucination;Headache;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatitis;Hepatitis fulminant;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypokalaemia;Hypotension;Immune system disorder;Infestation;Infestation NOS;Insomnia;Jaundice;Jaundice cholestatic;Laryngeal pain;Leukopenia;Lip dry;Liver function test abnormal;Liver injury;Loose stools;Loss of consciousness;Malnutrition;Mental disorder;Mouth ulceration;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myasthenia gravis;Nausea;Nervous system disorder;Nervousness;Neutropenia;Nightmare;Oedema peripheral;Oral candidiasis;Palpitations;Pancreatitis;Paraesthesia;Paraesthesia oral;Parosmia;Pharyngolaryngeal pain;Phosphatase alkaline increased;Polyuria;Pruritus;Pseudomembranous colitis;Rash;Reflux esophagitis;Shock;Sinusitis;Skin disorder;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Syncope;Tension;Thrombocytosis;Torsade de pointes;Toxic epidermal necrolysis;Transaminases increased;Traumatic liver injury;Unspecified disorder of skin and subcutaneous tissue;Upset stomach;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vaginal irritation;Vaginal moniliasis;Ventricular arrhythmia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal discomfort;Vulvovaginal mycotic infection,small molecule,approved,"Telithromycin; telitromicina; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",23S ribosomal RNA,J01FA15
atovaquone,Acquired immunodeficiency syndrome;Autoimmune disorder;Bacterial infection;Death;Lymphoma;Mycotic aneurysm;Non-Hodgkin's lymphoma;Pneumocystis jirovecii pneumonia;Pneumothorax;Sepsis;Vomiting,Abdominal pain;Alanine aminotransferase increased;Amylase increased;Anaemia;Angioedema;Anorexia;Anxiety;Aspartate aminotransferase increased;Asthenia;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Body temperature increased;Bronchospasm;Constipation;Cough;Cough increased;Creatinine increased;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dysgeusia;Dyspepsia;Dyspnoea;Erythema multiforme;Eye disorder;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hepatic failure;Hepatitis;Hepatobiliary disease;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypoglycaemia;Hyponatraemia;Hypotension;Immune system disorder;Infection;Influenza;Insomnia;Keratopathy;Laboratory test abnormal;Leukopenia;Methaemoglobinaemia;Musculoskeletal discomfort;Myalgia;Nausea;Neutropenia;Pain;Pancreatitis;Phosphatase alkaline increased;Pruritus;Rash;Renal failure;Renal impairment;Rhinitis;Sinusitis;Skin disorder;Skin exfoliation;Stevens-Johnson syndrome;Sweating;Throat tightness;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vomiting,small molecule,approved,"2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; Atovacuona; Atovaquone; COB; Complex III subunit 3; Complex III subunit III; CYTB; Cytochrome b-c1 complex subunit 3; MTCYB; Ubiquinol-cytochrome-c reductase complex cytochrome b subunit; 1.3.5.2; DHOdehase; Dihydroorotate oxidase; 1.3.5.2; DHOdehase; Dihydroorotate oxidase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","Cytochrome b; Dihydroorotate dehydrogenase (quinone), mitochondrial; Dihydroorotate dehydrogenase (quinone), mitochondrial", P01BB51;P01AX06
frovatriptan,Aura;Cluster headache;Migraine,Abdominal pain;Abnormal vision;Acute coronary syndrome;Affect lability;Agitation;Amnesia;Anaphylactic shock;Anorexia;Anxiety;Arrhythmia;Arteriospasm coronary;Arthralgia;Arthropathy;Asthenia;Ataxia;Back pain;Body temperature increased;Bone pain;Bradycardia;Bullous eruption;Cardiovascular disorder;Cerebration impaired;Change of bowel habit;Cheilitis;Chest discomfort;Chest pain;Chest tightness;Chills;Coagulopathy;Confusional state;Conjunctivitis;Constipation;Convulsion;Cramps of lower extremities;Decreased appetite;Dehydration;Depersonalisation;Depression;Depression aggravated;Dermatitis bullous;Diarrhoea;Discomfort;Disorder sight;Disturbance in attention;Dizziness;Dry mouth;Dysaesthesia;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear pain;Electrocardiogram abnormal;Epistaxis;Eructation;Euphoric mood;Eye pain;Fatigue;Feeling abnormal;Feeling cold;Feeling of relaxation;Flatulence;Flushing;Gait disturbance;Gastrointestinal pain;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Headache;Hiccups;Hot flush;Hyperacusis;Hyperaesthesia;Hyperhidrosis;Hypersensitivity;Hypertonia;Hyperventilation;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypotonia;Ill-defined disorder;Insomnia;Lacrimal disorder;Lacrimation abnormal NOS;Laryngitis;Leg pain;Loss of consciousness;Malaise;Malnutrition;Medication overuse headache;Menopausal symptoms;Mental disability;Mental disorder;Migraine;Migraine aggravated;Mood swings;Muscle contractions involuntary;Muscle relaxant therapy;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Nervousness;Nocturia;Numbness;Oedema mouth;Oesophageal spasm;Osteoarthritis;Pain;Pain in extremity;Pain in jaw;Palpitations;Paraesthesia;Peptic ulcer;Personality disorder;Pharyngitis;Pollakiuria;Polyuria;Prinzmetal angina;Pruritus;Purpura;Reflexes abnormal;Renal pain;Rhinitis;Rigors;Salivary gland pain;Salivary hypersecretion;Sensory loss;Serotonin syndrome;Shock;Sinusitis;Somnolence;Speech disorder;Stomatitis;Sweating increased;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Throat tightness;Tingling sensation;Tinnitus;Tongue paralysis;Toothache;Tremor;Urethral disorder;Urinary tract disorder;Urine abnormality;Urine analysis abnormal;Urine output increased;Vascular purpura;Vasospasm;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Visual impairment;Vomiting,small molecule,approved; investigational,Frovatriptan; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase,5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1B,N02CC07
eletriptan,Aura;Basilar migraine;Cluster headache;Hypertension;Migraine;Uncontrolled hypertension,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal vision;Abscess;Accidental injury;Accommodation disorder;Acute coronary syndrome;Affect lability;Agitation;Alopecia;Amnesia;Anaemia;Angina pectoris;Angioedema;Anorectal disorder;Anorexia;Anxiety;Apathy;Aphasia;Arrhythmia;Arteriospasm coronary;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Ataxia;Atrial fibrillation;Atrioventricular block;Back pain;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Blood pressure increased;Body temperature decreased;Body temperature increased;Bone neoplasm;Bone pain;Bradycardia;Breast pain;Breath odour;Bronchitis;Burning sensation;Candida infection;Catatonia;Catatonic reaction;Cerebrovascular disorder;Chest discomfort;Chest tightness;Chills;Choking sensation;Colitis ischaemic;Confusional state;Conjunctivitis;Constipation;Conversion disorder;Convulsion;Coordination abnormal;Cough;Cough increased;Cramp muscle;Creatine phosphokinase increased;Cyanosis;Decreased appetite;Dementia;Depersonalisation;Depressed level of consciousness;Dermatitis;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Dizziness;Drowsiness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear disorder;Ear pain;Eczema;Enlargement abdomen;Epistaxis;Erectile dysfunction;Eructation;Euphoric mood;Eye haemorrhage;Eye pain;Face oedema;Fatigue;Feeling abnormal;Feeling hot;Flat affect;Flatulence;Flushing;Gait disturbance;Gastritis;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal pain;Gingivitis;Glossitis;Goitre;Haematemesis;Hallucination;Headache;Hemiplegia;Hernia;Hiccups;Hyperaesthesia;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperpathia;Hypersensitivity;Hypertension;Hypertensive crisis;Hypertonia;Hyperventilation;Hypoaesthesia;Hypokinesia;Hypotension;Hypothermia;Hysteria;Ill-defined disorder;Immune system disorder;Increased appetite;Increased bronchial secretion;Influenza;Injury;Insomnia;Laboratory test abnormal;Lacrimal disorder;Lacrimal structural disorder;Laryngitis;Leukopenia;Leukorrhea;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Major depression;Malaise;Mania;Manic psychosis;Medication overuse headache;Menorrhagia;Menstrual disorder;Mental disability;Migraine;Monocytosis;Mood swings;Muscle atrophy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myocardial infarction;Myocardial ischaemia;Myopathy;Nausea;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Neurosis;Numbness;Oculogyric crisis;Oedema;Oedema peripheral;Oesophagitis;Osteoarthritis;Otitis media;Pain;Pain in jaw;Palpitations;Paraesthesia;Paralysis;Parosmia;Peripheral vascular disorder;Pharyngitis;Phosphatase alkaline increased;Photophobia;Pollakiuria;Polyuria;Prinzmetal angina;Pruritus;Psoriasis;Psychotic depression;Purpura;Rash;Rash maculo-papular;Rectal disorder;Renal pain;Respiratory tract infection;Rheumatoid arthritis;Rhinitis;Salivary hypersecretion;Sensation of warmth;Sensory loss;Serotonin syndrome;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin hypertrophy;Sleep disorder;Somnolence;Speech disorder;Sputum increased;Stomach ache;Stomatitis;Stupor;Sweating;Syncope;Tachycardia;Tenosynovitis;Tension;Thinking abnormal;Thirst;Throat tightness;Thrombophlebitis;Thyroid adenoma;Thyroiditis;Tingling sensation;Tinnitus;Tongue disorder;Tongue oedema;Tooth disorder;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasospasm;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Viral infection;Visual impairment;Vomiting;Weight decreased;Weight increased;Yawning,small molecule,approved; investigational,"Eletriptan; élétriptan; Eletriptán; Eletriptanum; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-1F; 5-HT1F; HTR1EL; Serotonin receptor 1F; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1F; 5-hydroxytryptamine receptor 1A,N02CC06
paricalcitol,Chronic kidney disease;Chronic renal insufficiency;Hyperparathyroidism secondary;Renal failure chronic;Renal impairment,Abdominal discomfort;Abdominal pain;Acne;Adverse reaction;Ageusia;Agitation;Alopecia;Anaemia;Angioedema;Angiopathy;Anorexia;Anxiety;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Atrial flutter;Back pain;Bleeding time prolonged;Blister;Blood and lymphatic system disorders;Blood urea increased;Body temperature increased;Bone pain;Breast cancer;Breast disorder;Breast pain;Breast tenderness;Calcinosis;Carcinoma breast;Cardiac arrest;Cardiac disorder;Cerebral ischaemia;Cerebrovascular accident;Chest discomfort;Chest pain;Chills;Colitis;Condition aggravated;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cough increased;Decreased appetite;Dehydration;Delirium;Depersonalisation;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Ear discomfort;Ear disorder;Endocrine disorder;Endophthalmitis;Epistaxis;Erectile dysfunction;Eructation;Eye disorder;Fatigue;Feeling abnormal;Fluid overload;Fungal infection;Gait disturbance;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Glaucoma;Headache;Heart rate irregular;Hepatic enzyme abnormal;Hirsutism;Hypercalcaemia;Hypercholesterolaemia;Hyperhidrosis;Hyperkalaemia;Hyperparathyroidism;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypoparathyroidism;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Injection site extravasation;Injection site pain;Insomnia;Intestinal ischaemia;Intoxication;Joint stiffness;Laboratory test abnormal;Laryngeal oedema;Leukopenia;Libido decreased;Lightheadedness;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Mesenteric vascular insufficiency;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myoclonus;Nasopharyngitis;Nausea;Neoplasm;Nervous system disorder;Nervousness;Night sweats;Ocular hyperaemia;Oedema;Oedema peripheral;Oropharyngeal pain;Orthopnoea;Osteoarthritis;Pain;Palpitations;Pancreatitis;Paraesthesia;Parathyroid disorder;Peritonitis;Pharyngitis;Photophobia;Pneumonia;Poisoning;Prurigo;Pruritus;Psychotic disorder;Pulmonary oedema;Rash;Rash pustular;Reaction aggravation;Rectal haemorrhage;Renal failure chronic;Rhinorrhoea;Sepsis;Shock;Sinusitis;Skin burning sensation;Skin disorder;Skin ulcer;Somnolence;Stupor;Sweating;Swelling;Syncope;Taste metallic;Tension;Thirst;Unresponsive to stimuli;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal infection;Vaginal inflammation;Vasodilation;Vasodilation procedure;Vertigo;Vesiculobullous rash;Viral infection;Vomiting;Weight decreased;Wheezing,small molecule,approved; investigational,"19-Nor-1alpha,25-dihydroxyvitamin D2; Paricalcitol; 1,25-dihydroxyvitamin D3 receptor; NR1I1; Nuclear receptor subfamily 1 group I member 1; VDR; 1.14.15.16; 24-OHase; CYP24; Cytochrome P450 24A1; Cytochrome P450-CC24; Vitamin D(3) 24-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D",Vitamin D3 receptor,H05BX02
rosiglitazone,Diabetes mellitus;Diabetic;Diabetic ketoacidosis;Insulin resistance;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Weight decreased,Acute coronary syndrome;Anaemia;Anaphylactic shock;Angioedema;Anion gap increased;Arthralgia;Asthenia;Back pain;Blood and lymphatic system disorders;Blood cholesterol increased;Blood triglycerides increased;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cerebrovascular accident;Connective tissue disorder;Constipation;Dermatitis;Diabetes mellitus;Diarrhoea;Dizziness;Erythema multiforme;Eye disorder;Fatal outcomes;Fatigue;Fluid retention;Fracture;Gastrointestinal disorder;Haematocrit decreased;Headache;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;High cholesterol;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperlipidaemia;Hypertension;Hypertriglyceridaemia;Hypoglycaemia;Immune system disorder;Increased appetite;Infection;Ischaemia;Ketonuria;Leukopenia;Ligament sprain;Macular oedema;Malnutrition;Multiple fractures;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Nasopharyngitis;Nausea;Nervous system disorder;Oedema;Oedema peripheral;Parotid gland enlargement;Pleural effusion;Pruritus;Pulmonary oedema;Rash;Sinusitis;Sprain;Stevens-Johnson syndrome;Thrombocytopenia;Upper respiratory tract infection;Urticaria;Visual acuity reduced;Volume blood increased;Volume plasma increased;Weight increased;Worsening of diabetes,small molecule,approved; investigational,"(±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione; (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion; Rosiglitazon; Rosiglitazona; Rosiglitazone; Rosiglitazonum; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; 6.2.1.3; ACS4; Arachidonate--CoA ligase; FACL4; LACS 4; LACS4; Long-chain acyl-CoA synthetase 4; NR1C1; Nuclear receptor subfamily 1 group C member 1; PPAR; PPAR-alpha; NR1C2; NUC1; NUCI; Nuclear hormone receptor 1; Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferator-activated receptor beta; PPAR-beta; PPAR-delta; PPARB; NR2B1; Nuclear receptor subfamily 2 group B member 1; Retinoid X receptor alpha; NR2B2; Nuclear receptor subfamily 2 group B member 2; Retinoid X receptor beta; NR2B3; Nuclear receptor subfamily 2 group B member 3; Retinoid X receptor gamma; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1",Peroxisome proliferator-activated receptor gamma; Long-chain-fatty-acid--CoA ligase 4; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor delta; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma, A10BD03; A10BG02;A10BD04;A10BG02
bexarotene,Cutaneous T-cell lymphoma;Mycosis fungoides;Neoplasm malignant,Abdominal distension;Abdominal pain;Abnormal faeces;Acne;Affect lability;Agitation;Alanine aminotransferase increased;Albuminuria;Alopecia;Amylase increased;Anaemia;Angina pectoris;Angiopathy;Anorectal discomfort;Anorexia;Anxiety;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Ataxia;Back pain;Bacterial infection;Blepharitis;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood disorder;Blood lactate dehydrogenase increased;Blood thromboplastin decreased;Blood triglycerides increased;Blood uric acid increased;Body odor;Body temperature increased;Bone marrow depression;Bone pain;Breast enlargement;Breast pain;Bronchitis;Candida infection;Carcinoma;Cardiac disorder;Cardiac failure congestive;Cardiac failure right;Cataract;Cellulitis;Cerebrovascular accident;Cheilitis;Chest pain;Chills;Cholecystitis;Circumoral paresthesia;Coagulation time prolonged;Coagulopathy;Colitis;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Corneal lesion;Cough;Cough increased;Cramps of lower extremities;Creatinine increased;Deafness;Decreased appetite;Dehydration;Depressed level of consciousness;Dermatitis;Dermatitis bullous;Dermatitis contact;Dermatitis exfoliative;Dermatitis irritant contact;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear pain;Ecchymosis;Endocrine disorder;Enlargement abdomen;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Eruption lichenoid;Erythema;Excoriation;Eye disorder;Eye pain;Face oedema;Fasting;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Flatulence;Fluid retention;Furuncle;Furunculosis;Gait disturbance;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gingivitis;Gout;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Headache;Hepatic failure;Hepatocellular injury;Herpes simplex;Herpes zoster;High density lipoprotein decreased;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hypernatraemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypocholesterolaemia;Hypochromic anaemia;Hypokalaemia;Hypolipidaemia;Hypomagnesaemia;Hyponatraemia;Hypoproteinaemia;Hypothyroidism;Hypovolaemia;Ill-defined disorder;Increased appetite;Infection;Infection parasitic;Influenza;Insomnia;Jaundice;Jaundice cholestatic;Keratitis;Kidney function abnormal;Laboratory test abnormal;Lacrimal disorder;Lacrimal structural disorder;Lactic dehydrogenase activity increased;Laryngospasm;Lethargy;Leukopenia;Libido decreased;Lichenoid keratosis;Lipase increased;Liver function test abnormal;Liver injury;Loss of consciousness;Lung disorder;Lymphadenopathy;Lymphocytosis;Malaise;Malnutrition;Melaena;Mental disability;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Nausea;Neoplasm;Neoplasm malignant;Nervous system disorder;Nervousness;Neuritis;Neuropathy;Neuropathy peripheral;Neutropenia;Night blindness;Nocturia;Nystagmus;Oedema;Oedema peripheral;Oral candidiasis;Osteoarthritis;Otitis externa;Pain;Pallor;Palpitations;Pancreatitis;Pancreatitis acute;Pancytopenia;Paraesthesia;Paraesthesia oral;Pelvic pain;Peripheral vascular disorder;Petechiae;Pharyngitis;Phosphatase alkaline increased;Photosensitivity reaction;Pleural disorder;Pleural effusion;Pneumonia;Pollakiuria;Polyuria;Proctalgia;Pruritus;Pseudolymphoma;Psoriasis;Pulmonary oedema;Purpura;Rash;Rash bullous;Rash maculo-papular;Rash papular;Rash pustular;Rectal tenesmus;Redness;Renal impairment;Rhinitis;Right ventricular failure;Scotoma;Seborrhoeic dermatitis;Sepsis;Shock;Sinusitis;Skin disorder;Skin hypertrophy;Skin mass;Skin nodule;Skin odour abnormal;Skin ulcer;Somnolence;Stomatitis;Stupor;Subdural haematoma;Sweating;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombocytosis;Thromboplastin decreased;Thyroid disorder;Tinnitus;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Varicose vein;Vascular anomaly;Vascular purpura;Vertigo;Viral infection;Vomiting;WBC abnormal NOS;Weight decreased;Weight increased;White blood cell disorder,small molecule,approved; investigational,"4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid; 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid; Bexaroten; Bexarotène; Bexarotene; Bexaroteno; Bexarotenum; p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; NR2B1; Nuclear receptor subfamily 2 group B member 1; Retinoid X receptor alpha; NR2B2; Nuclear receptor subfamily 2 group B member 2; Retinoid X receptor beta; NR2B3; Nuclear receptor subfamily 2 group B member 3; Retinoid X receptor gamma; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma,L01XF03;L01XX25
agomelatine,Major depression,Abdominal pain;Abnormal dreams;Aggression;Agitation;Angioedema;Anxiety;Asthenia;Back pain;Blood alkaline phosphatase increased;Connective tissue disorder;Constipation;Depression;Diarrhoea;Dizziness;Dry mouth;Dyspepsia;Ear and labyrinth disorders;Eczema;Eye disorder;Face oedema;Fatigue;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Hepatic failure;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hypomania;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Irritability;Jaundice;Mania;Mental disorder;Migraine;Nasopharyngitis;Nausea;Nervous system disorder;Nightmare;Paraesthesia;Phosphatase alkaline increased;Pruritus;Rash erythematous;Restless legs syndrome;Skin disorder;Somnolence;Suicidal ideation;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vertigo;Vision blurred;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,Agomelatina; Agomelatine; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; Mel-1A-R; Mel1a receptor; Mel-1B-R; Mel1b receptor; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase,5-hydroxytryptamine receptor 2C; Melatonin receptor type 1A; Melatonin receptor type 1B,N06AX22
ketorolac,Abdominal discomfort;Acute pain;Asthma;Breakthrough pain;Conjunctivitis allergic;Eye pain;Eye pruritus;Hypersensitivity;Inflammation;Injury;Musculoskeletal pain;Nephropathy;Osteoarthritis;Pain;Photophobia;Renal failure;Renal impairment;Stinging;Trauma;Ulcer;Upset stomach;Uterine cramps;Uterine spasm,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal vision;Acute coronary syndrome;Agitation;Agranulocytosis;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Anxiety;Aplastic anaemia;Arrhythmia;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Azotaemia;Back pain;Bladder pain;Bleeding time prolonged;Blepharitis;Blood and lymphatic system disorders;Blood creatinine increased;Blood disorder;Blood urea increased;Blood uric acid increased;Body temperature increased;Bradycardia;Breast disorder;Breast feeding;Bronchospasm;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cerebration impaired;Chest pain;Chills;Coagulopathy;Colitis;Colitis ulcerative;Coma;Confusional state;Conjunctival hyperaemia;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Corneal deposits;Corneal erosion;Corneal infiltrates;Corneal lesion;Corneal oedema;Corneal perforation;Corneal thinning;Cough;Cough increased;Creatinine increased;Crohn's disease;Cystitis;Cystitis noninfective;Cystoid macular oedema;Deafness;Decreased appetite;Depressed level of consciousness;Dermatitis;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drowsiness;Dry eye;Dry mouth;Duodenal ulcer;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear disorder;Ear pain;Ecchymosis;Endophthalmitis;Eosinophilia;Epidermal necrosis;Epistaxis;Eructation;Erythema;Erythema multiforme;Euphoric mood;Exacerbation of asthma;Excessive thirst;Extrapyramidal disorder;Extrapyramidal symptoms;Eye burns;Eye disorder;Eye infection;Eye irritation;Eye oedema;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flank pain;Flatulence;Fluid retention;Flushing;Foetor hepaticus;Gastric ulcer;Gastritis;Gastrointestinal disorder;Gastrointestinal fullness;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Generalised oedema;Glaucoma;Glossitis;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemolytic anaemia;Haemolytic uraemic syndrome;Haemorrhage;Hallucination;Headache;Hearing impaired;Heartburn;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hernia;Hiccups;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hypersensitivity;Hypertension;Hyperuricaemia;Hypokalaemia;Hyponatraemia;Hypotension;Hypovolaemia;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infertility;Infertility female;Inflammatory bowel disease;Injection site pain;Injection site reaction;Injury;Insomnia;Iritis;Jaundice;Jaundice cholestatic;Keratic precipitates;Keratitis;Kidney function abnormal;Lacrimal disorder;Lacrimal structural disorder;Laryngeal oedema;Leukopenia;Libido increased;Ligament sprain;Lightheadedness;Liver disorder;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melaena;Meningitis aseptic;Mental disability;Mental disorder;Metabolic acidosis;Migraine;Mouth ulceration;Muscle twitching;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nasal dryness;Nasopharyngitis;Nausea;Neck pain;Nephritis;Nephritis interstitial;Nephrotic syndrome;Nervous system disorder;Nervousness;Oedema;Oesophagitis;Oliguria;Oral pain;Oropharyngeal discomfort;Oropharyngeal pain;Osteoarthritis;Pain;Pallor;Palpitations;Pancreatitis;Pancreatitis acute;Pancytopenia;Panophthalmitis;Paraesthesia;Paranoia;Paranoid reaction;Peptic ulcer;Photophobia;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Post procedural haemorrhage;Postoperative hemorrhage;Proctocolitis;Protein urine present;Proteinuria;Pruritus;Psychotic disorder;Pulmonary embolism;Pulmonary function test decreased;Pulmonary oedema;Pupillary disorder;Purpura;Rash;Rash maculo-papular;Rectal haemorrhage;Redness;Renal failure;Renal failure acute;Renal impairment;Respiratory depression;Retinal haemorrhage;Retrosternal pain;Rhinitis;Rhinorrhoea;Sensation of foreign body;Sepsis;Serum urea increased;Shock;Skin burning sensation;Skin disorder;Somnolence;Sore mouth;Speech disorder;Sprain;Stevens-Johnson syndrome;Stinging;Stomach ache;Stomatitis;Stupor;Subcutaneous haematoma;Sweating;Sweating increased;Swelling;Syncope;Tachycardia;Tension;Thinking abnormal;Thirst;Throat sore;Thrombocytopenia;Tinnitus;Tongue disorder;Tongue oedema;Toxic epidermal necrolysis;Trauma;Tremor;Tubulointerstitial nephritis;Ulcerative keratitis;Ulcerative stomatitis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasculitis;Vasodilation;Vasodilation procedure;Ventricular tachycardia;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight increased;Wheezing;Wound haemorrhage,small molecule,approved,"Ketorolac; Kétorolac; Ketorolaco; Ketorolacum; rac-Ketorolac; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1, S01BC05; S01FB51;M01AB15
bortezomib,Cerebrovascular accident;Diarrhoea;Disease progression;Haematological malignancy;Mantle cell lymphoma;Neuropathy peripheral;Plasma cell myeloma;Plasmacytoma;Sepsis,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal faeces;Abnormal vision;Acidosis;Acne;Acute coronary syndrome;Acute febrile neutrophilic dermatosis;Acute respiratory distress syndrome;Adjustment disorder;Affective disorder;Agitation;Alcohol intolerance;Amnesia;Amyloidosis;Anaemia;Anal fissure;Anal sphincter atony;Anaphylactic shock;Angina pectoris;Angina unstable;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety disorder;Aplasia;Apnoea;Arrhythmia;Arthralgia;Arthritis;Ascites;Aspergillosis;Aspergillus infection;Asthenia;Asthenic conditions;Ataxia;Atelectasis;Atrial fibrillation;Atrial flutter;Atrioventricular block;Atrioventricular block complete;Autonomic nervous system imbalance;Autonomic neuropathy;Azotaemia;Back pain;Bacteraemia;Bacterial infection;Bilateral hydronephrosis;Bladder irritation;Bladder pain;Bladder spasm;Blindness;Blister;Blood and lymphatic system disorders;Blood disorder;Blood gases abnormal;Blood glucose abnormal;Blood test abnormal;Blood uric acid abnormal;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Bradycardia;Brain oedema;Brain stem syndrome;Breast disorder;Breast disorder female;Bronchial disorder;Bronchial hyperreactivity;Bronchitis;Bronchopneumonia;Bronchospasm;Budd-Chiari syndrome;Burn;C-reactive protein increased;COPD exacerbation;Calculus of kidney;Candida infection;Carbon dioxide decreased;Cardiac amyloidosis;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac fibrillation;Cardiac tamponade;Cardiac valve disease;Cardio-respiratory arrest;Cardiogenic shock;Cardiomyopathy;Cardiotoxicity;Cardiovascular disorder;Catheter related complication;Catheter related infection;Catheter site pain;Cellulitis;Cerebral haemorrhage;Cerebrovascular disorder;Change of bowel habit;Cheilitis;Chest discomfort;Chest pain;Chills;Cholelithiasis;Cholestasis;Chronic fatigue syndrome;Chronic obstructive pulmonary disease;Coagulopathy;Cognitive disorder;Cold sweat;Colitis;Colitis ischaemic;Coma;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Corneal lesion;Coronary artery insufficiency;Cough;Cramp muscle;Cushing's syndrome;Cutaneous vasculitis;Cyst;Cystitis haemorrhagic;Cytomegalovirus hepatitis;Dacryoadenitis acquired;Deafness;Deafness bilateral;Decreased appetite;Decubitus ulcer;Deep vein thrombosis;Dehydration;Delirium;Dementia;Dermatitis;Dermatitis bullous;Device related infection;Diabetes mellitus;Diarrhoea;Diplopia;Disability;Discomfort;Disseminated intravascular coagulation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drooling;Drug hypersensitivity;Dry eye;Dry skin;Dry throat;Duodenitis haemorrhagic;Dysacusis;Dysaesthesia;Dysarthria;Dysautonomia;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dyspnoea exertional;Ear and labyrinth disorders;Ear discomfort;Ear disorder;Ear haemorrhage;Ear infection;Ecchymosis;Edema of lower extremities;Ejection fraction decreased;Electrolyte imbalance;Encephalitis;Encephalopathy;Endocrine disorder;Endophthalmitis;Enteritis;Enzyme abnormality;Epididymal tenderness;Epididymitis;Epilepsy;Epistaxis;Epstein-Barr virus infection;Erectile dysfunction;Erythema;Erythema multiforme;Erythromelalgia;Erythrosis;Exophthalmos;Extravasation;Eye discharge;Eye disorder;Eye haemorrhage;Eye irritation;Eye pain;Eye swelling;Eyelid infection;Face injury;Face oedema;Faecal incontinence;Faecalith;Faecaloma;Failure to thrive;Fatigue;Febrile neutropenia;Feeling abnormal;Feeling of body temperature change;Fibrillation atrial aggravated;Fistula;Flatulence;Fluid overload;Fluid retention;Flushing;Foetor hepaticus;Fracture;Frequent bowel movements;Functional gastrointestinal disorder;Fungal infection;Gait disturbance;Gastric pH decreased;Gastritis;Gastritis haemorrhagic;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal inflammation;Gastrointestinal malformation;Gastrointestinal motility disorder;Gastrointestinal obstruction;Gastrointestinal pain;Gastrointestinal toxicity;Gastrointestinal ulcer perforation;Gastrooesophageal reflux disease;General physical health deterioration;Genital herpes;Genital pain;Gingival bleeding;Gingival hypertrophy;Gout;Grand mal convulsion;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemolytic anaemia;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhage subcutaneous;Haemorrhagic disorder;Haemorrhagic stroke;Hair disorder;Hallucination;Headache;Hearing impaired;Hepatic failure;Hepatic haemorrhage;Hepatic vein occlusion;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hepatotoxicity;Hernia;Herpes NOS;Herpes simplex;Herpes virus infection;Herpes zoster;Hiccups;Hordeolum;Hydronephrosis;Hyperaemia;Hyperbilirubinaemia;Hypercalcaemia;Hyperchloraemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypermagnesaemia;Hypernatraemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonic bladder;Hyperuricaemia;Hyperventilation;Hyperviscosity syndrome;Hypoaesthesia;Hypocalcaemia;Hypocapnia;Hypochloraemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Hypothyroidism;Hypotonia;Hypovolaemia;Hypovolaemic shock;Hypoxemia;Hypoxia;Ichthyosis;Ichthyosis acquired;Ileus;Ileus paralytic;Ill-defined disorder;Immune system disorder;Impaired healing;Inappropriate antidiuretic hormone secretion;Increased appetite;Increased upper airway secretion;Infarction;Infection;Infertility;Infestation;Infestation NOS;Inflammation;Influenza;Injection site erythema;Injection site haemorrhage;Injection site pain;Injection site phlebitis;Injection site reaction;Insomnia;International normalised ratio abnormal;Interstitial lung disease;Intestinal obstruction;Irritability;Irritable bowel syndrome;Ischaemia;Jessner's lymphocytic infiltration;Joint effusion;Joint injury;Joint stiffness;Joint swelling;Laceration;Lacrimation increased;Large intestinal obstruction;Large intestine perforation;Laryngeal oedema;Left ventricular ejection fraction decreased;Lethargy;Leukaemia;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Libido decreased;Lip pain;Lip swelling;Listeriosis;Livedo reticularis;Liver disorder;Local reaction;Loss of consciousness;Lower respiratory tract infection;Lung disorder;Lung infiltration;Lymphadenopathy;Lymphocytic infiltration;Lymphoedema;Lymphoma;Lymphopenia;Malaise;Malnutrition;Mantle cell lymphoma;Mastoiditis;Mediastinal disorder;Medical device complication;Megacolon;Melaena;Memory loss;Meningitis;Meningitis bacterial;Meningoencephalitis;Meningoencephalitis herpetic;Mental disorder;Metabolic disorder;Micturition disorder;Migraine;Motor dysfunction;Mouth haemorrhage;Mouth ulceration;Multi-organ failure;Multiple fractures;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Mycosis fungoides;Myocardial infarction;Myocardial ischaemia;Myopathy;Nail disorder;Nasopharyngitis;Nausea;Neoplasm;Neoplasm malignant;Nephritis;Nephrolithiasis;Nerve root lesion;Nervous system disorder;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Night sweats;Non-Hodgkin's lymphoma;Non-cardiac chest pain;Numbness;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Ophthalmic herpes simplex;Ophthalmic herpes zoster;Optic nerve disorder;Oral candidiasis;Oral disorder;Oral mucosal petechiae;Oropharyngeal blistering;Oropharyngeal pain;Orthopnoea;Orthostatic hypotension;Osteoarthritis;Pain;Pain in extremity;Pain in jaw;Pallor;Palpitations;Pancreatitis;Pancreatitis acute;Pancytopenia;Panophthalmitis;Papule;Paraesthesia;Paralysis;Paresis;Parosmia;Pelvic pain;Pericardial effusion;Pericarditis;Periodontitis;Peripheral embolism;Peripheral motor neuropathy;Peripheral neuropathy aggravated;Peripheral sensorimotor neuropathy;Peripheral sensory neuropathy;Peritonitis;Petechiae;Phlebitis;Photophobia;Photopsia;Photosensitivity reaction;Pigmentation disorder;Plasma cell leukaemia;Plasma cell myeloma;Plasmacytoma;Platelet aggregation increased;Platelet count decreased;Platelet disorder;Pleural effusion;Pleurisy;Pneumonia;Pneumonia aspiration;Pneumothorax;Pollakiuria;Polyneuropathy;Polyp;Poor peripheral circulation;Portal vein thrombosis;Post herpetic neuralgia;Posterior reversible encephalopathy syndrome;Presyncope;Procedural pain;Proctalgia;Progressive multifocal leukoencephalopathy;Prostatitis;Protein urine present;Proteinuria;Pruritus;Psoriasis;Psychotic disorder;Pulmonary alveolar haemorrhage;Pulmonary embolism;Pulmonary fibrosis;Pulmonary hypertension;Pulmonary oedema;Pulmonary toxicity;Purpura;Radiation injury;Radiculitis;Radiculopathy;Rash;Rectal discharge;Redness;Reflexes abnormal;Renal cell carcinoma;Renal failure;Renal failure acute;Renal failure chronic;Renal impairment;Respiratory alkalosis;Respiratory distress;Respiratory failure;Respiratory insufficiency;Respiratory tract congestion;Respiratory tract infection;Restless legs syndrome;Retinitis;Rhabdomyolysis;Rhinorrhoea;Rigors;Salivary gland disorder;Sciatica;Scotoma;Seborrhoeic dermatitis;Sensation of foreign body;Sensation of heaviness;Sensory loss;Sepsis;Septic shock;Shock;Sinus arrest;Sinusitis;Skin discolouration;Skin disorder;Skin induration;Skin infection;Skin lesion;Skin mass;Skin ulcer;Sleep disorder;Small intestinal obstruction;Solid tumour;Speech disorder;Spinal cord compression;Staphylococcal infection;Stevens-Johnson syndrome;Stomatitis;Subdural haematoma;Sudden death;Suicidal ideation;Syncope;Synovial cyst;Tachycardia;Tachypnoea;Temporomandibular joint syndrome;Tenderness;Testicular disorder;Thermal burn;Thirst;Throat irritation;Throat tightness;Thrombocytopenia;Thrombocytopenic purpura;Thrombocytosis;Thrombophlebitis;Tinnitus;Tongue coated;Tongue disorder;Tongue oedema;Tonsillitis;Tooth infection;Torsade de pointes;Toxic epidermal necrolysis;Toxic skin eruption;Toxoplasmosis;Transfusion reaction;Transient ischaemic attack;Tremor;Troponin I increased;Tumour lysis syndrome;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upper-airway cough syndrome;Ureteric obstruction;Urethral disorder;Uric acid abnormal;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urinary tract signs and symptoms;Urine analysis abnormal;Urine output;Urticaria;Vaginal haemorrhage;Vascular purpura;Vasculitis;Vein discolouration;Venoocclusive liver disease;Venous insufficiency;Ventricular dysfunction;Ventricular tachycardia;Vertigo;Vestibular neuronitis;Viral infection;Vision blurred;Visual impairment;Vitamin B complex deficiency;Vitamin B12 deficiency;Vomiting;Vulval ulceration;Vulvitis;Weight decreased;Weight increased;Wheezing,small molecule,approved; investigational,"[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid; Bortezomib; N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; 3.4.25.1; beta-5; LMPX; Macropain epsilon chain; MB1; Multicatalytic endopeptidase complex epsilon chain; Proteasome chain 6; Proteasome epsilon chain; Proteasome subunit beta-5; Proteasome subunit MB1; Proteasome subunit X; X; 3.4.21.4; Anionic trypsin I; Anionic trypsin-I; Beta-trypsin; Cationic trypsinogen; Pretrypsinogen I; TRP1; TRY1; TRYP1; Trypsin I; Trypsin-1; beta-6; Macropain subunit C5; Multicatalytic endopeptidase complex subunit C5; Proteasome component C5; Proteasome gamma chain; Proteasome subunit beta-6; PSC5; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Proteasome subunit beta type-5; Serine protease 1; Proteasome subunit beta type-1,L01XG01;L01XX32
nelarabine,Acute lymphocytic leukaemia;Lymphoblastic lymphoma;Non-Hodgkin's lymphoma;T-cell type acute leukaemia,Abdominal distension;Abdominal pain;Altered state of consciousness;Amnesia;Anaemia;Angiopathy;Anorexia;Aphasia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Ataxia;Back pain;Bacteraemia;Balance disorder;Blood albumin decreased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood calcium decreased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood disorder;Blood glucose decreased;Blood magnesium decreased;Blood potassium decreased;Blood uric acid increased;Body temperature increased;Burning sensation;Cardiac disorder;Cerebral haemorrhage;Chest pain;Chills;Chronic lymphocytic leukaemia;Coma;Confusional state;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cyst;Decreased appetite;Dehydration;Demyelination;Depressed level of consciousness;Depression;Diarrhoea;Disturbance in attention;Dizziness;Dysarthria;Dysgeusia;Dyspnoea;Encephalopathy;Epistaxis;Eye disorder;Fatigue;Febrile neutropenia;Feeling abnormal;Fungal infection;Gait disturbance;Gastrointestinal disorder;Gastrointestinal pain;Grand mal convulsion;Guillain-Barre syndrome;Haemorrhage intracranial;Headache;Hemiparesis;Hepatobiliary disease;Hydrocephalus;Hyperbilirubinaemia;Hyperglycaemia;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyporeflexia;Hypotension;Infection;Infestation;Infestation NOS;Insomnia;Lethargy;Leukoencephalopathy;Leukopenia;Loss of consciousness;Malnutrition;Mediastinal disorder;Mental disability;Mental disorder;Mental retardation;Metabolic encephalopathy;Motor dysfunction;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nausea;Neoplasm;Nerve paralysis;Nervous system disorder;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Non-cardiac chest pain;Nystagmus;Oedema;Oedema peripheral;Opportunistic infection;Osteoarthritis;Pain;Pain in extremity;Paraesthesia;Paralysis;Peripheral motor neuropathy;Peripheral sensory neuropathy;Peroneal nerve palsy;Petechiae;Pleural effusion;Pneumonia;Pneumonia fungal;Pneumothorax;Polyp;Progressive multifocal leukoencephalopathy;Respiratory arrest;Rhabdomyolysis;Rigors;Sciatica;Sensory disturbance;Sensory loss;Sepsis;Sinus headache;Sinus tachycardia;Sinusitis;Somnolence;Speech disorder;Status epilepticus;Stomatitis;Thrombocytopenia;Transaminases increased;Tremor;Tumour lysis syndrome;Urethral disorder;Urinary tract disorder;Vision blurred;Vomiting;Wheezing,small molecule,approved; investigational,"2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine; Nelarabina; Nelarabine; Nelzarabine; 2.7.7.7; DNA polymerase alpha catalytic subunit p180; POLA; 6.5.1.1; DNA ligase I; Polydeoxyribonucleotide synthase [ATP] 1; 2.7.7.102; DNA primase 49 kDa subunit; p49; 1.17.4.1; Ribonucleoside-diphosphate reductase subunit M1; Ribonucleotide reductase large subunit; RR1; 3.5.4.4; ADA1; Adenosine aminohydrolase; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; 2.7.1.113; Deoxyadenosine kinase, mitochondrial; DGK; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1",DNA; DNA polymerase alpha catalytic subunit; DNA ligase 1; DNA primase small subunit; Ribonucleoside-diphosphate reductase large subunit,L01BB07
rasburicase,Blood uric acid increased;Haematological malignancy;Hyperuricaemia;Leukaemia;Lymphoma;Neoplasm;Neoplasm malignant;Non-Hodgkin's lymphoma;Solid tumour,Abdominal pain;Agranulocytosis;Alanine aminotransferase increased;Anaemia;Anaphylactic shock;Anxiety;Arrhythmia supraventricular;Arthralgia;Back pain;Blood disorder;Body temperature increased;Bone pain;Bronchospasm;Chest pain;Constipation;Cough;Dermatitis;Diarrhoea;Dyspnoea;Epistaxis;Fluid overload;Gastrointestinal disorder;Gastrointestinal infection;Gastrointestinal pain;Glucose-6-phosphate dehydrogenase deficiency;Haemolysis;Haemolytic anaemia;Headache;Hyperbilirubinaemia;Hyperglycaemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypocalcaemia;Hypophosphataemia;Hypotension;Injection site irritation;Injection site pain;Injection site reaction;Ischaemic coronary artery disorders;Laryngeal pain;Methaemoglobinaemia;Mucosal inflammation;Musculoskeletal discomfort;Nausea;Nervous system disorder;Oedema peripheral;Pain;Pharyngitis;Pharyngolaryngeal pain;Pulmonary haemorrhage;Rash;Respiratory failure;Rhinitis;Sepsis;Thrombocytopenia;Tumour lysis syndrome;Urticaria;Vomiting,biotech,approved; investigational,Rasburicasa; Rasburicase; Recombinant urate oxidase; Urate oxidase,Uric acid, M04AX01;M04AX01;V03AF07
raltitrexed,Breast cancer;Cardiotoxicity;Colorectal cancer;Gastrooesophageal cancer;Mesothelioma;Neoplasm malignant,Abdominal pain;Alopecia;Anaemia;Anorexia;Arrhythmia;Arthralgia;Asthenia;Atrial fibrillation;Body temperature increased;Cardiac failure congestive;Cellulitis;Colorectal cancer metastatic;Conjunctivitis;Constipation;Cough;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Discomfort;Dysgeusia;Dyspepsia;Extravasation;Febrile neutropenia;Feeling abnormal;Gastrointestinal pain;Headache;Hepatic failure;Hyperhidrosis;Hypertonia;Ill-defined disorder;Infection;Influenza like illness;Influenza-like symptoms;Leukopenia;Malaise;Mouth ulceration;Musculoskeletal discomfort;Nausea;Necrosis;Neutropenia;Oedema;Pain;Pruritus;Rash;Renal failure;Renal impairment;Sepsis;Sinus tachycardia;Skin exfoliation;Stomatitis;Supraventricular tachycardia;Sweating;Thrombocytopenia;Vomiting;Weight decreased,small molecule,approved; investigational,Raltitrexed; 2.1.1.45; CDC21; TS; TSA1; 2.1.1.45; TS; TSase; 6.3.2.17; Folylpoly-gamma-glutamate synthetase; FPGS; Tetrahydrofolate synthase; Tetrahydrofolylpolyglutamate synthase,"Thymidylate synthase; Thymidylate synthase; Folylpolyglutamate synthase, mitochondrial",L01BA03
fotemustine,Malignant melanoma;Metastasis,Abdominal pain;Acute respiratory distress syndrome;Ageusia;Anaemia;Body temperature increased;Cyst;Diarrhoea;Drug interaction;Erythema;Extravasation;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal toxicity;Hepatitis;Hepatobiliary disease;Leukopenia;Mediastinal disorder;Nausea;Neoplasm;Nervous system disorder;Pain;Pancytopenia;Paraesthesia;Phlebitis;Polyp;Pruritus;Redness;Skin disorder;Swelling;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vomiting,small molecule,investigational,"(+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; (±)-DIETHYL (1-(3-(2-CHLOROETHYL)-3-NITROSOUREIDO)ETHYL)PHOSPHONATE; Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate; Fotemustina; Fotemustine; Fotemustinum; Mustoforan; PHOSPHONIC ACID, (1-((((2-CHLOROETHYL)NITROSOAMINO)CARBONYL)AMINO)ETHYL)-, DIETHYL ESTER; PHOSPHONIC ACID, P-(1-((((2-CHLOROETHYL)NITROSOAMINO)CARBONYL)AMINO)ETHYL)-, DIETHYL ESTER; 1.8.1.9; Gene associated with retinoic and IFN-induced mortality 12 protein; Gene associated with retinoic and interferon-induced mortality 12 protein; GRIM-12; GRIM12; KDRF; KM-102-derived reductase-like factor; Peroxidase TXNRD1; Thioredoxin reductase TR1; TR","Thioredoxin reductase 1, cytoplasmic",L01AD05
rimonabant,Diabetes mellitus;Diabetic;Obesity;Weight decreased,Abdominal discomfort;Abdominal pain;Aggression;Amnesia;Anger;Angiopathy;Anorexia;Anxiety;Asthenia;Connective tissue disorder;Contusion;Convulsion;Cramp muscle;Decreased appetite;Delusion;Depression;Depressive disorder;Depressive symptom;Dermatitis;Diarrhoea;Disturbance in attention;Dizziness;Dry mouth;Dysphoria;Dysthymic disorder;Emotional disorder;Fatigue;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Hiccups;Hot flush;Hyperhidrosis;Hypoaesthesia;Hypoglycaemia;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Irritability;Joint sprain;Lethargy;Ligament sprain;Malnutrition;Mediastinal disorder;Memory loss;Menopausal symptoms;Mental disorder;Metabolic disorder;Mood alteration NOS;Mood alterations with depressive symptoms;Mood swings;Muscle spasms;Nausea;Nervous system disorder;Nervousness;Night sweats;Panic reaction;Paraesthesia;Paranoia;Parasomnia;Pruritus;Psychotic disorder;Rash;Sciatica;Sinusitis;Skin disorder;Sleep disorder;Suicidal ideation;Tendonitis;Tension;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Vomiting,small molecule,approved; investigational,"Rimonabant; CANN6; CB-R; CB1; CNR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Cannabinoid receptor 1; G-protein coupled receptor 55,A08AX01
bosentan,Cardiac failure chronic;Connective tissue disorder;Digital ulcer;Heart disease congenital;Hepatotoxicity;Hypertension;Immunodeficiency;Lung disorder;Primary pulmonary hypertension;Pulmonary arterial hypertension;Pulmonary hypertension;Pulmonary hypertension secondary;Pulmonary veno-occlusive disease;Scleroderma;Skin ulcer;Systemic sclerosis;Ulcer,Abdominal distension;Abdominal pain;Abdominal pain upper;Acute bronchitis;Acute coronary syndrome;Affect lability;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Arthralgia;Ascites;Asthenia;Asthma;Atrial fibrillation;Atrioventricular block complete;Azoospermia;Back pain;Bladder pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood lactate dehydrogenase increased;Blood pressure systolic decreased;Body temperature increased;Bone disorder;Bone marrow toxicity;Bradycardia;Bronchitis;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiac failure;Cerebrovascular accident;Chest pain;Chills;Chromaturia;Conjunctivitis;Constipation;Contusion;Cough;Cramp muscle;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry mouth;Dry skin;Duodenal ulcer;Dyspepsia;Dyspnoea;Dysuria;Ecchymosis;Eczema;Edema of lower extremities;Electrocardiogram change;Endophthalmitis;Eosinophil count increased;Eosinophilia;Epistaxis;Erythema;Erythema multiforme;Eye disorder;Eye irritation;Fatigue;Feeling hot;Flatulence;Fluid retention;Flushing;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Glucose tolerance impaired;Gout;Haematocrit decreased;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Headache;Hemiparesis;Hepatic cirrhosis;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hydrocephalus;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypoaesthesia;Hypoglycaemia;Hypokalaemia;Hyponatraemia;Hypotension;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Insomnia;Intestinal obstruction;Irritability;Jaundice;Leg edema;Lethargy;Leukopenia;Libido increased;Liver function test abnormal;Liver injury;Loose stools;Loss of consciousness;Lower respiratory tract infection;Malnutrition;Mediastinal disorder;Mental disorder;Mood swings;Mouth ulceration;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Myocardial infarction;Nasal congestion;Nasopharyngitis;Nausea;Nephropathy;Nervous system disorder;Neutropenia;Nightmare;Oedema;Oedema peripheral;Oligospermia;Orthostatic hypotension;Pain;Pain in extremity;Pain in jaw;Palpitations;Panic attack;Panophthalmitis;Paraesthesia;Peripheral ischaemia;Photophobia;Pneumonia;Pollakiuria;Presyncope;Pruritus;Pulmonary function test decreased;Pulmonary hypertension;Pulmonary oedema;Rash;Rectal haemorrhage;Renal failure;Renal impairment;Respiratory depression;Respiratory failure;Respiratory tract infection;Restless legs syndrome;Sensation of heaviness;Shivering;Shock;Sinusitis;Skin discolouration;Skin disorder;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Stomatitis;Subarachnoid haemorrhage;Sweating increased;Syncope;Syncope vasovagal;Tachycardia;Thirst;Thrombocytopenia;Tinnitus;Toothache;Tracheobronchitis;Traumatic liver injury;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine color abnormal;Urticaria;Venoocclusive disease;Ventricular arrhythmia;Ventricular tachycardia;Vertigo;Vision blurred;Vomiting;Weight decreased;Weight increased;Wheezing;Xerophthalmia,small molecule,approved; investigational,"4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; bosentán; Bosentan; bosentan anhydrous; bosentanum; p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; Endothelin receptor non-selective type; ET-B; ET-BR; ETRB; Endothelin receptor type A; ET-A; ETA; ETA-R; ETRA; hET-AR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Endothelin receptor type B; Endothelin-1 receptor, C02KX01;C02KX01;G01AE10
vardenafil,Erectile dysfunction;Hypertension,AION;Abdominal pain;Abdominal pain upper;Abnormal ejaculation;Abnormal sensation in eye;Abnormal vision;Accidental injury;Accommodation disorder;Acute coronary syndrome;Alanine aminotransferase increased;Allergic oedema;Amnesia;Anaphylactic shock;Angina pectoris;Angina unstable;Angioedema;Angiopathy;Anxiety;Arteritic anterior ischaemic optic neuropathy;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blindness;Blindness transient;Blood creatine phosphokinase increased;Blood creatinine increased;Breast disorder;Burning sensation;Cardiac disorder;Cardiovascular disorder;Chest pain;Chromatopsia;Color vision change;Colour blindness acquired;Conjunctivitis;Connective tissue disorder;Convulsion;Cramp muscle;Creatine phosphokinase increased;Creatinine increased;Cyanopsia;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dysaesthesia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Ejaculation disorder;Endophthalmitis;Epistaxis;Erection increased;Erythema;Eye disorder;Eye haemorrhage;Eye irritation;Eye pain;Eye redness;Face oedema;Feeling abnormal;Feeling hot;Flushing;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Glaucoma;Haematemesis;Haematospermia;Haematuria;Haemoglobin;Haemorrhage;Headache;Hepatic enzyme increased;Hepatobiliary disease;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertonia;Hypoaesthesia;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Injury;Insomnia;Intraocular pressure increased;Lacrimation increased;Laryngeal oedema;Liver function test abnormal;Loss of consciousness;Malaise;Mediastinal disorder;Menopausal symptoms;Mental disorder;Muscle rigidity;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Nasal congestion;Nausea;Neck pain;Nervous system disorder;Ocular discomfort;Ocular hyperaemia;Oedema mucosal;Oesophagitis;Optic ischaemic neuropathy;Orthostatic hypotension;Pain;Palpitations;Paraesthesia;Penile haemorrhage;Pharyngitis;Photophobia;Photosensitivity reaction;Premature ejaculation;Priapism;Pruritus;Pulmonary haemorrhage;Rash;Redness;Reflux esophagitis;Retinal vein occlusion;Rhinitis;Scotoma;Shock;Sinus congestion;Sinus headache;Sinus pain;Sinusitis;Skin disorder;Sleep disorder;Somnolence;Sudden cardiac death;Sudden deafness;Sudden hearing loss;Sweating;Syncope;Tachyarrhythmia;Tachycardia;Tearing eyes;Tinnitus;Transient global amnesia;Transient ischaemic attack;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Urethral disorder;Urinary tract disorder;Ventricular arrhythmia;Vertigo;Vision blurred;Vision decreased;Visual acuity reduced;Visual brightness;Visual colour distortions;Visual disturbance;Visual impairment;Vomiting,small molecule,approved,"Vardénafil; Vardenafil; Vardenafilo; Vardenafilum; 3.1.4.35; CGB-PDE; cGMP-binding cGMP-specific phosphodiesterase; PDE5; 3.1.4.35; GMP-PDE gamma; PDEG; 3.1.4.35; GMP-PDE gamma; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","cGMP-specific 3',5'-cyclic phosphodiesterase; Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma; Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma",G04BE09
tadalafil,Benign prostatic hyperplasia;Collagen-vascular disease;Connective tissue disorder;Diabetes mellitus;Erectile dysfunction;Hypertension;Primary pulmonary hypertension;Pulmonary arterial hypertension,AION;Abdominal discomfort;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Acute coronary syndrome;Amnesia;Amnesia transient;Angina pectoris;Angina unstable;Angioedema;Angiopathy;Arteritic anterior ischaemic optic neuropathy;Arthralgia;Asthenia;Back pain;Blindness;Bone disorder;Breast disorder;Bronchitis;Cardiac disorder;Cardiovascular disorder;Cerebrovascular accident;Chest pain;Color vision change;Colour blindness acquired;Conjunctival hyperaemia;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Deafness;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Epistaxis;Erection increased;Erection prolonged;Erythema multiforme;Eye disorder;Eye pain;Face oedema;Fatigue;Flushing;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematospermia;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoidal haemorrhage;Headache;Hearing impaired;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Immune system disorder;Infarction;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Lacrimation;Lacrimation increased;Limb discomfort;Liver function test abnormal;Loose stools;Loss of consciousness;Mediastinal disorder;Menometrorrhagia;Menopausal symptoms;Menorrhagia;Mental disorder;Metrorrhagia;Migraine;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Non-cardiac chest pain;Oedema;Oedema peripheral;Oesophagitis;Optic ischaemic neuropathy;Orthostatic hypotension;Pain;Pain in extremity;Palpitations;Paraesthesia;Penile haemorrhage;Pharyngitis;Priapism;Pruritus;Pulmonary hypertension;Rash;Rectal haemorrhage;Renal failure;Renal impairment;Respiratory tract infection;Retinal artery occlusion;Retinal vascular occlusion;Retinal vein occlusion;Rhinitis;Scotoma;Shock;Sinus bradycardia;Sinus congestion;Skin disorder;Somnolence;Spontaneous penile erection;Stevens-Johnson syndrome;Sudden cardiac death;Sudden hearing loss;Sweating;Swelling;Syncope;Tachycardia;Therapeutic response unexpected;Tinnitus;Transient global amnesia;Transient ischaemic attack;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Uterine haemorrhage;Vaginal haemorrhage;Ventricular arrhythmia;Vertigo;Viral diarrhoea;Vision blurred;Vomiting,small molecule,approved; investigational,"(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; Tadalafil; Tadalafilo; 3.1.4.35; CGB-PDE; cGMP-binding cGMP-specific phosphodiesterase; PDE5; 3.1.4.35; 3.1.4.53; cAMP and cGMP phosphodiesterase 11A; 3.1.4.35; GMP-PDE gamma; PDEG; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase","cGMP-specific 3',5'-cyclic phosphodiesterase; Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A; Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma", C02KX52; C02KX54; G04CA54; G04CB51;G04BE08
eslicarbazepine,Convulsion;Epilepsy,Abdominal pain;Anaphylactic shock;Angioedema;Angiopathy;Asthenia;Ataxia;Balance disorder;Blood cholesterol increased;Constipation;Cough;Depression;Dermatitis;Diarrhoea;Diplopia;Dizziness;Drug-induced liver injury;Dysarthria;Ear and labyrinth disorders;Eosinophilia;Eye disorder;Fatigue;Gait disturbance;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Headache;High cholesterol;Hypersensitivity;Hypertension;Hyponatraemia;Infection;Infestation;Infestation NOS;Insomnia;Malnutrition;Mediastinal disorder;Memory impairment;Mental disorder;Nausea;Nervous system disorder;Nystagmus;Oedema peripheral;Osteoarthritis;Rash;Skin disorder;Somnolence;Suicidal behaviour;Thyroid function abnormal;Thyroid function test abnormal;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urinary tract infection;Vertigo;Vision blurred;Visual impairment;Vomiting,small molecule,approved,"Eslicarbazepina; Eslicarbazepine; S(+)-Liscarbazepine; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; ATP receptor; P2X4; Purinergic receptor; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Sodium channel protein type 11 subunit alpha; P2X purinoceptor 4,N03AF04
paliperidone,Acute coronary syndrome;Breast cancer;Carcinogenicity;Cardiac disorder;Dementia;Dementia with Lewy bodies;Malaise;Myocardial infarction;Parkinson's disease;Parkinsonism;Pituitary tumour;Psychotic disorder;Schizoaffective disorder;Schizophrenia;Sickness,"Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abnormal involuntary movements;Acarodermatitis;Acne;Adenocarcinoma;Adenoma benign;Aggression;Agitation;Agranulocytosis;Akathisia;Akinesia;Alanine aminotransferase increased;Albinism;Alopecia;Altered state of consciousness;Amenorrhoea;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anorgasmia;Anxiety;Arthralgia;Aspartate aminotransferase increased;Asthenia;Athetosis;Atrial fibrillation;Atrioventricular block;Atrioventricular block first degree;Back pain;Balance disorder;Bipolar I disorder;Bipolar disorder;Bladder pain;Blepharospasm;Blood and lymphatic system disorders;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood insulin increased;Blood pressure increased;Blood prolactin increased;Blood testosterone decreased;Blood triglycerides increased;Blunted affect;Body temperature decreased;Body temperature increased;Bradycardia;Bradykinesia;Breast discharge;Breast discomfort;Breast disorder;Breast engorgement;Breast enlargement;Breast feeding;Breast pain;Breast tenderness;Bronchitis;Bundle branch block;Bundle branch block left;Cardiac arrest;Cardiac disorder;Cellulitis;Cerebral ischaemia;Cerebrovascular accident;Cerebrovascular disorder;Cheilitis;Chest discomfort;Chest pain;Chills;Chorea;Choreoathetosis;Cogwheel rigidity;Completed suicide;Conduction disorder;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cystitis;Cystitis noninfective;Dandruff;Decreased appetite;Deep vein thrombosis;Depressed level of consciousness;Depression;Dermatitis;Diabetes mellitus;Diabetic coma;Diabetic hyperglycaemic coma;Diabetic ketoacidosis;Diarrhoea;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dizziness postural;Drooling;Drug eruption;Drug withdrawal syndrome;Drug withdrawal syndrome neonatal;Dry eye;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear infection;Ear pain;Eczema;Ejaculation delayed;Ejaculation disorder;Ejaculation inhibited;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram T wave abnormal;Electrocardiogram T wave inversion;Electrocardiogram abnormal;Embolism venous;Emprosthotonus;Endocrine disorder;Endophthalmitis;Eosinophil count increased;Epistaxis;Erectile dysfunction;Erythema;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye infection;Eye movement disorder;Eye rolling;Face oedema;Facial spasm;Faecal incontinence;Fatigue;Feeling abnormal;Flatulence;Floppy iris syndrome;Fluid retention;Flushing;Gait disturbance;Galactorrhoea;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal obstruction;Gastrointestinal pain;Generalised oedema;Glabellar reflex abnormal;Glaucoma;Glycosuria;Grand mal convulsion;Gynaecomastia;Haematocrit decreased;Head titubation;Headache;Hepatic enzyme increased;Hepatobiliary disease;Hyperglycaemia;Hyperinsulinism;Hyperkeratosis;Hyperkinesia;Hyperprolactinaemia;Hypersensitivity;Hypertension;Hypertonia;Hypertriglyceridaemia;Hyperventilation;Hypoaesthesia;Hypoglycaemia;Hypokinesia;Hypotension;Hypothermia;Hypotonia;Ileus;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Increased appetite;Increased prolactin level;Induration;Infection;Infestation;Infestation NOS;Influenza;Initial insomnia;Injection site pain;Injection site reaction;Insomnia;Insulin C-peptide increased;Intestinal obstruction;Ischaemia;Jaundice;Joint stiffness;Joint swelling;Lacrimation increased;Laryngeal pain;Laryngospasm;Lethargy;Leukopenia;Libido decreased;Loss of consciousness;Malaise;Malnutrition;Mania;Masked facies;Mediastinal disorder;Menorrhagia;Menstrual disorder;Menstruation delayed;Menstruation irregular;Mental disorder;Middle insomnia;Movement disorder;Muscle contractions involuntary;Muscle contracture;Muscle relaxant therapy;Muscle rigidity;Muscle spasms;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myoclonus;Myotonia;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Neutropenia;Nightmare;Nuchal rigidity;Ocular hyperaemia;Oculogyration;Oculogyric crisis;Oedema;Oedema peripheral;Oligomenorrhoea;Onychomycosis;Opisthotonus;Oromandibular dystonia;Oropharyngeal spasm;Orthostatic hypotension;Osteoarthritis;Pain;Pain during injection;Pain in extremity;Palpitations;Pancreatic neoplasm;Pancreatitis;Paraesthesia;Parkinsonian gait;Parkinsonian rest tremor;Parkinsonism;Pharyngolaryngeal pain;Photophobia;Pitting edema;Pleurothotonus;Pneumonia;Pneumonia aspiration;Pollakiuria;Polydipsia;Postural orthostatic tachycardia syndrome;Posture abnormal;Pregnancy;Priapism;Pruritus;Pruritus generalised;Pulmonary congestion;Pulmonary embolism;Rales;Rash;Rash papular;Redness;Respiratory distress;Respiratory tract congestion;Respiratory tract infection;Restless legs syndrome;Retrograde ejaculation;Rhabdomyolysis;Rhinitis;Risus sardonicus;Salivary hypersecretion;Seborrhoeic dermatitis;Serum prolactin increased;Serum testosterone decreased;Sexual dysfunction;Shock;Shoulder pain;Sinus arrhythmia;Sinus tachycardia;Sinusitis;Skin discolouration;Skin disorder;Sleep apnoea syndrome;Sleep disorder;Small intestinal obstruction;Somnolence;Stillbirth;Stupor;Sudden death;Sudden death, cause unknown;Suicidal ideation;Suicide;Swelling;Swollen tongue;Syncope;Tachycardia;Tardive dyskinesia;Tension;Teratogenicity;Tetany;Thirst;Throat tightness;Thrombocytopenia;Thrombotic thrombocytopenic purpura;Tinnitus;Tongue paralysis;Tongue spasm;Tonsillitis;Toothache;Torsade de pointes;Torticollis;Transaminases increased;Transient ischaemic attack;Tremor;Trismus;Unresponsive to stimuli;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal discharge;Venous thromboembolism;Venous thrombosis;Ventricular arrhythmia;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Viral infection;Vision blurred;Vomiting;Waist circumference increased;Water intoxication;Weight decreased;Weight increased;Wheezing;White blood cell count decreased",small molecule,approved,"9-hydroxyrisperidone; Paliperidona; Paliperidone; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; Dopamine D2 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; Dopamine D3 receptor; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; H1-R; H1R; HH1R; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; Dopamine D1 receptor; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 2A; D(2) dopamine receptor; D(4) dopamine receptor; D(3) dopamine receptor; 5-hydroxytryptamine receptor 2C; Histamine H1 receptor; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; 5-hydroxytryptamine receptor 1D; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; 5-hydroxytryptamine receptor 1A; D(1A) dopamine receptor; 5-hydroxytryptamine receptor 7,N05AX13
clofarabine,Acute leukaemia;Acute lymphocytic leukaemia;Acute myeloid leukaemia,Abdominal pain;Abdominal pain upper;Agitation;Alanine aminotransferase increased;Alopecia;Anaemia;Angiopathy;Anorexia;Anxiety;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atypical pneumonia;Back pain;Bacteraemia;Bacterial infection;Bilirubin total increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood uric acid increased;Body temperature increased;Bone disorder;Bone pain;Caecitis;Candida infection;Capillary leak syndrome;Cardiac disorder;Catheter related infection;Cellulitis;Chest wall pain;Chills;Cholecystitis acute;Cholelithiasis;Clostridium colitis;Clostridium difficile colitis;Colitis;Connective tissue disorder;Contusion;Cough;Creatinine increased;Cyst;Deafness;Death;Decreased appetite;Dehydration;Dermatitis;Device related infection;Diarrhoea;Dizziness;Dry skin;Dyspnoea;Ear and labyrinth disorders;Enterococcal bacteraemia;Enterocolitis;Epistaxis;Erythema;Erythema multiforme;Escherichia bacteraemia;Escherichia sepsis;Exfoliative conditions;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Feeling hot;Flushing;Fungal infection;Fungal sepsis;Gastroenteritis adenovirus;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised erythema;Gingival bleeding;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemorrhage;Headache;Hearing impaired;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Herpes simplex;Herpes zoster;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperuricaemia;Hypotension;Hypotensive;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Irritability;Jaundice;Lethargy;Leukopenia;Liver injury;Lymphopenia;Malnutrition;Mediastinal disorder;Menorrhagia;Mental disorder;Mouth haemorrhage;Mouth ulceration;Mucosal inflammation;Multi-organ failure;Musculoskeletal chest pain;Musculoskeletal discomfort;Myalgia;Nausea;Necrosis;Neoplasm;Nephropathy toxic;Nervous system disorder;Neuropathy peripheral;Neutropenia;Oedema;Oedema peripheral;Oral candidiasis;Oral mucosal petechiae;Pain;Pain in extremity;Pancreatitis;Pancytopenia;Paraesthesia;Parainfluenzae virus infection;Pericardial effusion;Pericarditis;Petechiae;Pleural effusion;Pneumonia;Pneumonia fungal;Pneumonia mycoplasmal;Polyp;Proctalgia;Prolonged menses;Prurigo;Pruritus;Pulmonary oedema;Rash;Rash erythematous;Rash generalised;Rash maculo-papular;Renal failure;Renal failure acute;Respiratory distress;Respiratory failure;Respiratory syncytial virus infection;Sepsis;Septic shock;Sinusitis;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Somnolence;Staphylococcal bacteraemia;Staphylococcal infection;Stevens-Johnson syndrome;Stomatitis;Systemic inflammatory response syndrome;Tachycardia;Tachypnoea;Thrombocytopenia;Toxic epidermal necrolysis;Tremor;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Venoocclusive disease;Viral infection;Vomiting;Weight decreased,small molecule,approved; investigational,"(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine; 2-chloro-9-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)adenine; CAFdA; Cl-F-Ara-A; Clofarabin; Clofarabina; Clofarabine; Clofarabinum; 1.17.4.1; p53-inducible ribonucleotide reductase small subunit 2-like protein; P53R2; TP53-inducible ribonucleotide reductase M2 B; 1.17.4.1; Ribonucleotide reductase small chain; Ribonucleotide reductase small subunit; RR2; 2.7.7.7; DNA polymerase alpha catalytic subunit p180; POLA; 1.17.4.1; Ribonucleoside-diphosphate reductase subunit M1; Ribonucleotide reductase large subunit; RR1; 2.7.1.74; dCK; Deoxyadenosine kinase; Deoxyguanosine kinase; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",DNA; Ribonucleoside-diphosphate reductase subunit M2 B; Ribonucleoside-diphosphate reductase subunit M2; DNA polymerase alpha catalytic subunit; Ribonucleoside-diphosphate reductase large subunit,L01BB06
benzylpenicilloyl,Hypersensitivity;Sensitisation,Anaphylactic shock;Angioedema;Dyspnoea;Generalised erythema;Hypersensitivity;Hypotension;Pruritus;Systemic allergic reaction;Urticaria;Venous occlusion,small molecule,approved; vet_approved,"(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-phenylacetamido)penicillanic acid; Bencilpenicilina; Bensylpenicillin; Benzyl benicillin; Benzylpenicillin; Benzylpénicilline; Benzylpenicillinic acid; Benzylpenicillinum; Free penicillin II; PCG; Penicillin G; PG; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; PBP-1c; yfgN; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; 3.5.2.6; IRT-4; Penicillinase; TEM-1; TEM-16/CAZ-7; TEM-2; TEM-24/CAZ-6; TEM-3; TEM-4; TEM-5; TEM-6; TEM-8/CAZ-2; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Ergothioneine transporter; ET transporter; ETT; ETTh; OCTN1; Organic cation/carnitine transporter 1; UT2H; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; Colon organic anion transporter; OATP-E; OATP-RP1; OATP1; OATP4A1; OATPE; OATPRP1; Organic anion transporter polypeptide-related protein 1; Organic anion-transporting polypeptide E; POAT; SLC21A12; Sodium-independent organic anion transporter E; Solute carrier family 21 member 12; OATP-D; OATP-RP3; OATP3A1; OATPD; OATPRP3; Organic anion transporter polypeptide-related protein 3; Organic anion-transporting polypeptide D; PGE1 transporter; SLC21A11; Sodium-independent organic anion transporter D; Solute carrier family 21 member 11; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Peptidoglycan synthase FtsI; Penicillin-binding protein 1A; Penicillin-binding protein 1B; Penicillin-binding protein 1C; Penicillin-binding protein 3; Organic anion transporter 3; Solute carrier family 15 member 1; Solute carrier family 15 member 2, J01CE01; J01CE08; S01AA14;J01CR50
valdecoxib,Arthritis;Dysmenorrhoea;Osteoarthritis;Primary dysmenorrhea;Rheumatoid arthritis,Abdominal bloating;Abdominal distension;Abdominal pain;Abnormal faeces;Abnormal vision;Acne;Acute coronary syndrome;Alanine aminotransferase increased;Albuminuria;Allergy aggravated;Alopecia;Amenorrhoea;Anaemia;Anaphylactic shock;Aneurysm;Angina pectoris;Angina unstable;Angioedema;Anorectal discomfort;Anorexia;Anxiety;Aortic valve stenosis;Apnoea;Appendicitis;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Atrioventricular block;Autonomic neuropathy;Back pain;Basal cell carcinoma;Bladder cancer;Bladder carcinoma;Bladder pain;Block heart;Blood alkaline phosphatase increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bradycardia;Brain neoplasm benign;Breast neoplasm;Breath odour;Breath sounds abnormal;Bronchitis;Bronchospasm;Calculus of kidney;Candida infection;Carcinoma;Carcinoma of lung;Carcinoma stomach;Cardiac failure congestive;Cardiac murmur;Cardiac valve disease;Cardiomyopathy;Carotid artery stenosis;Cataract;Cellulitis;Cerebrovascular disorder;Cervical dysplasia;Chest pain;Chills;Cholelithiasis;Clotting;Coagulopathy;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Constipation;Convulsion;Coronary artery disease;Coronary artery thrombosis;Cough;Creatine phosphokinase increased;Creatinine increased;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Depression;Depression aggravated;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Dermatitis psoriasiform;Diabetes mellitus;Diarrhoea;Discomfort;Diverticulum;Diverticulum intestinal;Dizziness;Dry mouth;Dry skin;Duodenal ulcer;Duodenitis;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Eczema;Electrocardiogram abnormal;Embolism;Emphysema;Enterocolitis haemorrhagic;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Erythema multiforme;Eye pain;Eye swelling;Face oedema;Faecal incontinence;Fatigue;Feeling abnormal;Flatulence;Fluid retention;Fracture;Fullness abdominal;Fungal infection;Fungal skin infection;Gastric cancer;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Genital candidiasis;Glycosuria;Goitre;Gout;Haemangioma;Haematemesis;Haematochezia;Haematoma;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoidal haemorrhage;Haemorrhoids;Headache;Hemangioma acquired;Hemorrhagic colitis;Hepatic function abnormal;Hepatitis;Herpes simplex;Herpes zoster;Hiatus hernia;Hot flush;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hyperparathyroidism;Hypersensitivity;Hypertension;Hypertension worsened;Hypertensive encephalopathy;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypokalaemia;Hypotension;Ileus;Ill-defined disorder;Increased appetite;Increased thirst;Infection;Influenza like illness;Influenza-like symptoms;Insomnia;Intermittent claudication;Intestinal obstruction;Keratitis;Lactic dehydrogenase activity increased;Laryngitis;Leukocytosis;Leukopenia;Leukorrhea;Lipoma;Loss of consciousness;Lung neoplasm malignant;Lymphadenopathy;Lymphangitis;Lymphopenia;Malaise;Malignant melanoma;Malignant ovarian cyst;Mania;Manic psychosis;Mastitis;Melaena;Menopausal symptoms;Menorrhagia;Menstrual disorder;Migraine;Mitral valve incompetence;Multiple fractures;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Neck stiffness;Neoplasm;Neoplasm malignant;Nephrolithiasis;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Nuchal rigidity;Oedema peripheral;Oesophageal perforation;Oesophagitis;Osteomyelitis;Osteoporosis;Otitis media;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Pericarditis;Periorbital swelling;Peritonitis;Pharyngitis;Phosphatase alkaline increased;Photosensitivity allergic reaction;Photosensitivity reaction;Pleural effusion;Pleurisy;Pneumonia;Pollakiuria;Proctalgia;Prostate cancer;Prostate carcinoma;Prostatic disorder;Pruritus;Pseudolymphoma;Psychotic disorder;Pulmonary embolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary infarction;Pulmonary oedema;Pyelonephritis;Pyuria;Rash;Rash erythematous;Rash maculo-papular;Rash psoriaform;Rectal tenesmus;Renal failure acute;Respiratory failure;Respiratory insufficiency;Retinal detachment;Rhinitis;Sepsis;Shock;Sinusitis;Skin hypertrophy;Skin ulcer;Soft tissue infection;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Syncope;Synovitis;Tachycardia;Tendonitis;Tension;Thirst;Thrombocytopenia;Thrombophlebitis;Thrombosis;Tinnitus;Tooth disorder;Toxic epidermal necrolysis;Tremor;Unspecified disorder of autonomic nervous system;Upper respiratory tract infection;Urinary incontinence;Urinary tract infection;Urticaria;Vaginal discharge;Vaginal haemorrhage;Varicose vein;Vasospasm;Ventricular fibrillation;Vertigo;Viral infection;Vision blurred;Visual impairment;Vomiting;Weight decreased;Weight increased;Xerophthalmia,small molecule,approved; investigational; withdrawn,"Valdecoxib; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 4.2.1.1; CA-II; CAC; Carbonate dehydratase II; Carbonic anhydrase C; Carbonic anhydrase II; Cyanamide hydratase CA2; 4.2.1.1; CA-III; Carbonate dehydratase III; Carbonic anhydrase III; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Prostaglandin G/H synthase 2; Carbonic anhydrase 2; Carbonic anhydrase 3, G01AE10;M01AH03
parecoxib,Postoperative pain;Procedural pain,Abdominal pain;Acute coronary syndrome;Agitation;Alanine aminotransferase increased;Alveolar osteitis;Anaemia postoperative;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Bradycardia;Bronchospasm;Cardiac disorder;Cardiac failure congestive;Cerebrovascular disorder;Connective tissue disorder;Constipation;Creatine phosphokinase increased;Decreased appetite;Dermatitis;Dermatitis exfoliative;Dizziness;Dry mouth;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Ear pain;Ecchymosis;Erythema multiforme;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal sounds abnormal;Gastrooesophageal reflux disease;Hepatitis;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypokalaemia;Hypotension;Immune system disorder;Infection;Infestation;Infestation NOS;Injection site pain;Injection site reaction;Insomnia;Lactic dehydrogenase activity increased;Malnutrition;Mediastinal disorder;Musculoskeletal discomfort;Myocardial infarction;Nausea;Nervous system disorder;Oedema mouth;Oedema peripheral;Oesophagitis;Oliguria;Orthostatic hypotension;Pancreatitis;Pharyngitis;Post procedural complication;Pruritus;Pulmonary embolism;Rash;Renal failure;Renal failure acute;Respiratory failure;Respiratory insufficiency;Shock;Skin disorder;Stevens-Johnson syndrome;Swelling;Tachycardia;Thrombocytopenia;Toxic epidermal necrolysis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vomiting;Wound infection,small molecule,approved,"N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide; Parecoxib; Parécoxib; Parecoxibum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 3.4.21.-; GIG12; Growth-inhibiting protein 12; Lactoferrin; LF; Talalactoferrin; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Prostaglandin G/H synthase 2; Lactotransferrin,M01AH04
tenofovir,Chronic hepatitis B;Cross resistance;Foetor hepaticus;Hepatitis B e antigen positive;Hepatocellular injury;Infection;Liver disorder;Pathogen resistance;Renal failure;Renal impairment;Viral infection,Abdominal pain;Abdominal pain upper;Abnormal dreams;Acute interstitial nephritis;Alanine aminotransferase increased;Amylase increased;Anaemia;Angioedema;Anorexia;Anxiety;Arthralgia;Asthenia;Autoimmune disorder;Back pain;Basedow's disease;Blood and lymphatic system disorders;Blood creatinine increased;Blood triglycerides increased;Body temperature increased;Bone pain;Breast enlargement;Buffalo hump;Chest pain;Connective tissue disorder;Creatinine increased;Decreased appetite;Depression;Dermatitis;Dermatitis bullous;Diarrhoea;Dizziness;Dyspepsia;Dyspnoea;Exfoliative rash;Fanconi syndrome;Fasting;Fatigue;Flatulence;Fracture;Gastrointestinal disorder;Gastrointestinal pain;Glycosuria;Haematuria;Haemoglobin decreased;Headache;Hepatic steatosis;Hepatitis;Hepatitis B;Hepatobiliary disease;Hepatomegaly;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlactacidaemia;Hypersensitivity;Hypertriglyceridaemia;Hypertrophy of breast;Hypokalaemia;Hypophosphataemia;Immune system disorder;Infestation;Infestation NOS;Inflammation;Insomnia;Insulin resistance;Lactic acidosis;Laryngeal pain;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Malnutrition;Mediastinal disorder;Mental disorder;Metabolic disorder;Multiple fractures;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myopathy;Nasopharyngitis;Nausea;Nephritis;Nephritis interstitial;Nephrogenic diabetes insipidus;Nephrosis lower nephron;Nervous system disorder;Neuritis;Neuropathy;Neuropathy peripheral;Opportunistic infection;Osteomalacia;Osteonecrosis;Pain;Pancreatitis;Paraesthesia;Pharyngolaryngeal pain;Pneumonia;Polyuria;Procedural pain;Protein urine present;Proteinuria;Prurigo;Pruritus;Rash;Rash generalised;Rash macular;Rash maculo-papular;Rash pustular;Rash vesicular;Renal failure;Renal failure acute;Renal impairment;Renal tubular disorder;Renal tubular necrosis;Rhabdomyolysis;Serum creatinine increased;Sinusitis;Skin disorder;Somnolence;Sweating;Symptomatic hyperlactatemia;Thrombocytopenia;Transaminases increased;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;Vesiculobullous rash;Vomiting;Weight decreased,small molecule,experimental; investigational,(R)-PMPA; Anhydrous tenofovir; Tenofovir; Tenofovir (anh.); Tenofovir (anhydrous); Tenofovir anhydrous; Pr160Gag-Pol; 2.7.7.7; 2.7.4.6; GAAD; Granzyme A-activated DNase; Metastasis inhibition factor nm23; NDK A; NDP kinase A; NDPKA; NM23; NM23-H1; Tumor metastatic process-associated protein; 2.7.4.6; C-myc purine-binding transcription factor PUF; Histidine protein kinase NDKB; NDK B; NDP kinase B; nm23-H2; NM23B; 2.7.4.3; 2.7.4.4; 2.7.4.6; Adenylate monophosphate kinase; AK 1; ATP-AMP transphosphorylase 1; ATP:AMP phosphotransferase; Myokinase; 2.7.4.3; Adenylate monophosphate kinase; ADK2; AK 2; ATP-AMP transphosphorylase 2; ATP:AMP phosphotransferase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4,Reverse transcriptase/RNaseH; Gag-Pol polyprotein; Reverse transcriptase; DNA polymerase,J05AF07
ustekinumab,Dermatitis;Latent tuberculosis;Plaque psoriasis;Psoriasis;Psoriatic arthropathy;Rash;Urticaria,Acute coronary syndrome;Anaphylactic shock;Angioedema;Anxiety;Appendicitis;Arthralgia;Asthenia;Back pain;Breast cancer;Cellulitis;Cerebrovascular accident;Cholecystitis;Connective tissue disorder;Contusion;Depression;Dermatitis;Diarrhoea;Diverticulitis;Dizziness;Erythrodermic psoriasis;Facial paralysis;Fatigue;Gastroenteritis;Gastrointestinal disorder;Haematoma;Haemoglobin;Haemorrhage;Headache;Herpes zoster;Hypersensitivity;Immune system disorder;Induration;Infection;Infestation;Infestation NOS;Injection site erythema;Injection site pain;Injection site reaction;Laryngeal pain;Malignant melanoma;Mediastinal disorder;Melanoma skin;Mental disorder;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm malignant;Nervous system disorder;Oropharyngeal pain;Osteomyelitis;Pain;Pharyngolaryngeal pain;Pneumonia;Posterior reversible encephalopathy syndrome;Pruritus;Pustular psoriasis;Rash;Sepsis;Skin cancer;Skin carcinoma;Skin disorder;Swelling;Tooth infection;Tuberculosis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urticaria;VIIth nerve paralysis;Viral infection;Viral upper respiratory tract infection,biotech,approved; investigational,Stelera; Ustekinumab; Ustekinumab-auub; CLMF p40; Cytotoxic lymphocyte maturation factor 40 kDa subunit; IL-12 subunit p40; IL-12B; NK cell stimulatory factor chain 2; NKSF2; IL-23 subunit alpha; IL-23-A; IL-23p19; Interleukin-23 subunit p19; SGRF; CLMF p40; Cytotoxic lymphocyte maturation factor 40 kDa subunit; IL-12 subunit p40; IL-12B; NK cell stimulatory factor chain 2; NKSF2,Interleukin-23; Interleukin-12 subunit beta,L04AC05
retigabine,Convulsion;Epilepsy,Alopecia;Amnesia;Anxiety;Aphasia;Asthenia;Balance disorder;Chromaturia;Coma;Confusional state;Constipation;Coordination abnormal;Dermatitis;Diplopia;Discomfort;Disorientation;Disturbance in attention;Dizziness;Drug withdrawal convulsions;Dry mouth;Dysarthria;Dyspepsia;Dysphagia;Dysphasia;Dyspnoea;Dysuria;Encephalopathy;Euphoric mood;Eye disorder;Fatigue;Feeling abnormal;Gait disturbance;Gastrointestinal disorder;Haematuria;Hallucination;Hepatobiliary disease;Hyperhidrosis;Hypokinesia;Ill-defined disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Leukopenia;Liver function test abnormal;Loss of consciousness;Malaise;Malnutrition;Memory impairment;Mental disorder;Muscle spasms;Myoclonus;Nail discolouration;Nausea;Nephrolithiasis;Nervous system disorder;Neurological symptom;Neutropenia;Nystagmus;Oedema peripheral;Osteoarthritis;Paraesthesia;Psychiatric symptom;Psychotic disorder;Raised liver function tests;Rash;Renal colic;Shock;Skin discolouration;Somnolence;Suicidal behaviour;Syncope;Thrombocytopenia;Tremor;Urethral disorder;Urinary hesitation;Urinary retention;Urinary tract disorder;Vertigo;Vision blurred;Visual impairment;Weight increased;Withdrawal seizures,small molecule,approved; investigational,"Tiagabina; Tiagabine; Tiagabinum; GABATR; GABT1; GAT-1; GAT1; Solute carrier family 6 member 1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Sodium- and chloride-dependent GABA transporter 1,N03AG06
rasagiline,Parkinson's disease;Parkinsonism,Abdominal pain;Abnormal dreams;Abnormal ejaculation;Accidental injury;Acute coronary syndrome;Affect lability;Ageusia;Agitation;Albuminuria;Alopecia;Amenorrhoea;Amnesia;Anaemia;Anaemia macrocytic;Angina pectoris;Angiopathy;Anorexia;Anuria;Anxiety;Apathy;Aphasia;Apnoea;Arrhythmia supraventricular;Arterial thrombosis;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Ataxia;Atrial arrhythmia;Atrioventricular block complete;Atrioventricular block second degree;Autonomic nervous system imbalance;Back pain;Balance disorder;Binge eating;Bipolar I disorder;Bipolar disorder;Blepharitis;Blindness;Blood and lymphatic system disorders;Blood pressure increased;Body temperature increased;Bundle branch block;Bursitis;Calculus of kidney;Cardiac disorder;Cardiac failure;Carpal tunnel syndrome;Cerebral haemorrhage;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Chills;Circumoral paresthesia;Colitis;Compulsions;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Cough increased;Cramps of lower extremities;Cyst;Deafness;Decreased appetite;Delirium;Delusion;Dementia;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Drug interaction;Dry mouth;Dysaesthesia;Dysarthria;Dysautonomia;Dysgeusia;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ecchymosis;Eczema;Ejaculation disorder;Emphysema;Epididymitis;Epistaxis;Erectile dysfunction;Extrasystoles;Eye disorder;Eye haemorrhage;Eye pain;Face oedema;Facial paralysis;Faecal incontinence;Fall;Feeling abnormal;Flank pain;Flat affect;Flatulence;Footdrop;Gait disturbance;Gastric ulcer;Gastritis haemorrhagic;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingivitis;Glaucoma;Gynaecomastia;Haematemesis;Haematuria;Haemoglobin;Haemorrhage;Hallucination;Headache;Hemiplegia;Hernia;Hostility;Hydroureter;Hyperhidrosis;Hyperkinesia;Hyperpyrexia;Hypersensitivity;Hypersexuality;Hypertension;Hypertensive crisis;Hypertonia;Hypoaesthesia;Hypocalcaemia;Hypotension;Ill-defined disorder;Immune system disorder;Impulse-control disorder;Infection;Infestation;Infestation NOS;Influenza;Injury;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal obstruction;Intestinal perforation;Intestinal stenosis;Jaundice;Keratitis;Large intestine perforation;Laryngeal oedema;Laryngospasm;Leukoderma;Leukopenia;Leukorrhea;Libido decreased;Libido increased;Liver function test abnormal;Loss of consciousness;Major depression;Malaise;Malignant melanoma;Malnutrition;Mania;Manic psychosis;Mediastinal disorder;Megacolon;Melaena;Melanoma skin;Mental disorder;Micturition urgency;Migraine;Mood swings;Mouth ulceration;Muscle atrophy;Muscle rigidity;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myasthenia;Myelitis;Myocardial infarction;Myoclonus;Nausea;Neck pain;Neoplasm;Nephrolithiasis;Nervous system disorder;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neurosis;Nocturia;Obsessive thoughts;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Orthostatic hypotension;Osteoarthritis;Osteonecrosis;Paraesthesia;Paraesthesia oral;Paranoia;Paranoid reaction;Parosmia;Pathological gambling;Peroneal nerve palsy;Personality disorder;Phlebitis;Photophobia;Photosensitivity reaction;Pleural effusion;Pneumothorax;Pollakiuria;Polyp;Polyuria;Priapism;Pruritus;Psychotic depression;Psychotic disorder;Pulmonary fibrosis;Purpura;Radial nerve palsy;Rash;Rash pustular;Renal failure acute;Retinal degeneration;Retinal detachment;Retinal haemorrhage;Rhinitis;Scotoma;Scrotal oedema;Serotonin syndrome;Sexual dysfunction;Shock;Skin cancer;Skin carcinoma;Skin disorder;Skin ulcer;Somnolence;Stomatitis;Stupor;Sweating;Syncope;Tenosynovitis;Thrombocytosis;Thrombophlebitis;Tongue disorder;Tongue oedema;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urination impaired;Urine output increased;Urticaria;VIIth nerve paralysis;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vascular purpura;Ventricular bigeminy;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Vestibular disorder;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased;Wrist drop,small molecule,approved,(1R)-N-propargylindan-1-amine; (R)-indan-1-yl-prop-2-ynyl-amine; (R)-N-2-Propynyl-1-indanamine; RAS; Rasagilina; Rasagiline; 1.4.3.21; 1.4.3.4; MAO-B; Monoamine oxidase type B; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase,Amine oxidase [flavin-containing] B; Apoptosis regulator Bcl-2,N04BD02
SU5416,Haemoglobin;Haemorrhage;Thrombocytopenia;Thrombocytopenic purpura,Abdominal discomfort;Abdominal pain;Abnormal dreams;Accommodation disorder;Acne;Acute coronary syndrome;Alcohol intolerance;Alopecia;Anaemia;Angioedema;Angiopathy;Anorexia;Aplastic anaemia;Arthralgia;Asthenia;Back pain;Blindness;Blood and lymphatic system disorders;Blood lactate dehydrogenase increased;Blood pressure increased;Body temperature increased;Bone marrow disorder;Bone pain;Breast disorder;Breath odour;Cardiac disorder;Chest pain;Clonus;Conjunctival haemorrhage;Connective tissue disorder;Constipation;Contusion;Cough;Cyst;Decreased appetite;Deep vein thrombosis;Dehydration;Depression;Dermatitis;Dermatitis contact;Diarrhoea;Discomfort;Disease progression;Dizziness;Dry skin;Dry throat;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Ecchymosis;Eczema;Erythema;Erythromelalgia;Exfoliative rash;Eye disorder;Eye pruritus;Face oedema;Fatigue;Feeling abnormal;Feeling hot;Feeling jittery;Fever chills;Flushing;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gout;Haematochezia;Haemoglobin;Haemorrhage;Hair growth abnormal;Headache;Hepatobiliary disease;Hypersensitivity;Hypoaesthesia;Hypogeusia;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Injection site haemorrhage;Injection site reaction;Insomnia;Irritability;Lacrimation increased;Leukocytosis;Localised infection;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Migraine;Mouth haemorrhage;Muscle spasms;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myelodysplastic syndrome;Myelofibrosis;Myeloid metaplasia;Myocardial infarction;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm;Nervous system disorder;Nervousness;Neuropathy peripheral;Oedema peripheral;Optic neuritis;Pain;Pain in extremity;Painful respiration;Palpitations;Pancytopenia;Papilloedema;Paraesthesia;Peripheral embolism;Peripheral ischaemia;Phlebitis;Photosensitivity reaction;Plasma cell myeloma;Plasmacytoma;Platelet count abnormal;Polyp;Portal vein thrombosis;Protein urine present;Prurigo;Pruritus;Pulmonary embolism;Purpura;Rash;Rash papular;Rectal haemorrhage;Refractory anaemia with an excess of blasts;Rhinorrhoea;Shoulder pain;Skin disorder;Skin mass;Skin nodule;Skin odour abnormal;Splenomegaly;Stomatitis;Tachycardia;Thrombocytopenia;Thrombocytosis;Thrombophlebitis superficial;Thrombosis;Tooth discolouration;Transverse sinus thrombosis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary tract disorder;Urticaria;Vaginal haemorrhage;Vascular purpura;Vertigo;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,experimental,2.7.11.22; CDKN2; Cell division protein kinase 2; p33 protein kinase; 2.7.11.1; CDKN5; Cell division protein kinase 5; Cyclin-dependent-like kinase 5; PSSALRE; Serine/threonine-protein kinase PSSALRE; Tau protein kinase II catalytic subunit; TPKII catalytic subunit; 2.7.11.22; 2.7.11.23; CDC2; CDC28A; CDK1; CDKN1; Cell division control protein 2 homolog; Cell division protein kinase 1; p34 protein kinase; P34CDC2,Cyclin-dependent kinase 2; Cyclin-dependent kinase 5; Cyclin-dependent kinase 1,B02BX04
travoprost,Iritis;Ocular hypertension;Open angle glaucoma;Uveitis,Abdominal pain;Abnormal sensation in eye;Abnormal vision;Accidental injury;Angina pectoris;Angiopathy;Anterior chamber cell;Anterior chamber flare;Anterior chamber inflammation;Anterior chamber pigmentation;Anxiety;Arthralgia;Arthritis;Asthenia;Asthenopia;Asthma;Asthma aggravated;Back pain;Blepharitis;Blood pressure diastolic decreased;Blood pressure increased;Blood pressure systolic increased;Bone disorder;Bradycardia;Bronchitis;Cardiac disorder;Cataract;Chest pain;Choroidal nevus;Conjunctival disorder;Conjunctival follicles;Conjunctival haemorrhage;Conjunctival hyperaemia;Conjunctival oedema;Conjunctivitis;Conjunctivitis allergic;Connective tissue disorder;Constipation;Corneal epithelium defect;Corneal erosion;Corneal pigmentation;Corneal staining;Cough;Dark circles under eyes;Depression;Dermatitis;Dermatitis atopic;Dermatitis contact;Diarrhoea;Discomfort;Dizziness;Drug hypersensitivity;Dry eye;Dry mouth;Dysgeusia;Dyspepsia;Dysphonia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ectropion;Eczema eyelids;Endophthalmitis;Erythema;Erythema of eyelid;Eye allergy;Eye discharge;Eye disorder;Eye irritation;Eye naevus;Eye pain;Eye pruritus;Eye swelling;Eyelash discolouration;Eyelash thickening;Eyelid disorder;Eyelid irritation;Eyelid margin crusting;Eyelid oedema;Eyelid pain;Eyelids pruritus;Fatigue;Feeling abnormal;Foreign body sensation in eyes;Gastrointestinal disorder;Gastrointestinal pain;Growth of eyelashes;Hair colour changes;Hair growth abnormal;Hair texture abnormal;Halo vision;Headache;Heart rate irregular;Herpes simplex;Hyperaemia;Hypercholesterolaemia;Hypersensitivity;Hypertension;Hypertrichosis;Hypoaesthesia eye;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Injury;Iridocyclitis;Iris hyperpigmentation;Iritis;Keratitis;Keratoconjunctivitis sicca;Lacrimation;Lacrimation increased;Lid sulcus deepened;Macular degeneration;Macular oedema;Madarosis;Malaise;Mediastinal disorder;Meibomianitis;Mental disorder;Metrorrhagia;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Mydriasis;Nasal congestion;Nasal discomfort;Nasal dryness;Nausea;Nervous system disorder;Ocular discomfort;Ocular hyperaemia;Oedema;Ophthalmic herpes simplex;Oropharyngeal pain;Pain;Palpitations;Panophthalmitis;Peptic ulcer;Peptic ulcer reactivated;Periorbital oedema;Pharyngitis;Photophobia;Photopsia;Pigment dispersion syndrome;Prostatic disorder;Prostatic specific antigen increased;Pruritus;Punctate keratitis;Rash;Retinal detachment;Retinal haemorrhage;Retinal pigmentation;Rhinitis;Rhinitis seasonal;Scab;Scleral hyperaemia;Scotoma;Seasonal allergy;Sensation of foreign body;Shoulder pain;Sinusitis;Skin discolouration;Skin disorder;Skin hyperpigmentation;Subconjunctival hemorrhage;Sunken eyes;Tachycardia;Tenderness;Throat irritation;Tinnitus;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Uveitis;Vertigo;Vision blurred;Visual acuity reduced;Visual impairment;Vital dye staining cornea present;Vitreous detachment,small molecule,approved,"(1R-(1.ALPHA.(Z),2.BETA.(1E,3R*),3.ALPHA.,5.ALPHA.))-7-(3,5-DIHYDROXY-2-(3-HYDROXY-4-(3-(TRIFLUOROMETHYL)PHENOXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOIC ACID, 1-METHYLETHYL ESTER; ISOPROPYL (Z)-7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-((1E,3R)-3-HYDROXY-4-((.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)OXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOATE; isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; OTX-TP; Travoprost; TRAVOPROST COMPONENT OF DUOTRAV; Travoprostum; PGF receptor; PGF2-alpha receptor; Prostanoid FP receptor",Prostaglandin F2-alpha receptor,S01EE04
almotriptan,Aura;Cluster headache;Migraine;Nausea;Pain;Phonophobia;Photophobia,Abdominal cramps;Abdominal discomfort;Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Acute myocardial infarction;Agitation;Anaphylactic shock;Angina pectoris;Angioedema;Anxiety;Arteriospasm coronary;Arthralgia;Arthritis;Asthenia;Back pain;Blepharospasm;Body temperature increased;Bone disorder;Breast disorder;Breast pain;Bronchitis;Cardiac disorder;Cerebration impaired;Chest pain;Chills;Cold sweat;Colitis;Colitis ischaemic;Confusional state;Conjunctivitis;Convulsion;Coordination abnormal;Depressive symptom;Dermatitis;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Dizziness;Dry eye;Dry mouth;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Ear pain;Epistaxis;Erythema;Euphoric mood;Eye disorder;Eye irritation;Eye pain;Fatigue;Feeling abnormal;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Headache;Hemiplegia;Hyperacusis;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperreflexia;Hypersensitivity;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypoaesthesia oral;Ill-defined disorder;Immune system disorder;Increased thirst;Insomnia;Ischaemia;Laryngitis;Laryngospasm;Loss of consciousness;Malaise;Mental disability;Mental disorder;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Myopathy;Nausea;Neck pain;Nervous system disorder;Nervousness;Neuropathy;Neuropathy peripheral;Nightmare;Nystagmus;Otitis media;Pain;Pain in extremity;Palpitations;Paraesthesia;Parosmia;Peripheral coldness;Pharyngitis;Photosensitivity reaction;Pruritus;Rash;Rhinitis;Salivary hypersecretion;Scotoma;Serotonin syndrome;Shakiness;Shock;Sinusitis;Skin disorder;Sneezing;Somnolence;Sweating increased;Swollen tongue;Syncope;Tachycardia;Tension;Thirst;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Vasodilation;Vasodilation procedure;Vasospasm;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vision blurred;Visual impairment;Vomiting,small molecule,approved; investigational,"1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine; Almotriptan; 5-HT-1D; 5-HT-1D-alpha; 5-HT1D; HTR1DA; HTRL; Serotonin 1D alpha receptor; Serotonin receptor 1D; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.4.3.21; 1.4.3.4; MAO-A; Monoamine oxidase type A; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase",5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1B,N02CC05
Eptifibatide,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Angina unstable;Chest pain;Electrocardiogram ST segment depression;Electrocardiogram ST segment elevation;Electrocardiogram T wave inversion;Myocardial infarction;Pregnancy;ST segment elevation myocardial infarction;Thrombocytopenia,Abdominal pain;Acute coronary syndrome;Anaphylactic shock;Angiopathy;Arterial anomaly;Atrial fibrillation;Atrioventricular block;Blood and lymphatic system disorders;Blood disorder;Body temperature increased;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cerebral haemorrhage;Cerebral infarction;Cerebral ischaemia;Cerebrovascular accident;Chest pain;Congenital arterial malformation;Coronary artery disease;Coronary artery occlusion;Dermatitis;Dyspepsia;Dyspnoea;Epistaxis;Frank hematuria;Gastrointestinal haemorrhage;Gastrointestinal pain;Haematemesis;Haematocrit decreased;Haematoma;Haematuria;Haemoglobin;Haemorrhage;Haemorrhage intracranial;Haemorrhagic stroke;Headache;Hepatic impairment;Hypersensitivity;Hypertension;Hypotension;Immune system disorder;Infarction;Infection;Injection site reaction;Injury;Liver disorder;Lymphoma;Major bleed;Myocardial infarction;Nausea;Nervous system disorder;Neuropathy peripheral;Non-Hodgkin's lymphoma;Pain;Pericardial effusion;Phlebitis;Pneumonia;Pulmonary haemorrhage;Rash;Renal failure;Renal impairment;Retroperitoneal haemorrhage;Shock;Skin disorder;Thrombocytopenia;Thrombophlebitis;Trauma;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Ventricular fibrillation;Ventricular tachycardia,biotech,approved; investigational,"Eptifibatida; Eptifibatide; Integrelin; Intrifiban; GP3A; GPIIIa; Platelet membrane glycoprotein IIIa; GP2B; GPalpha IIb; GPIIb; ITGAB; Platelet membrane glycoprotein IIb; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2",Integrin beta-3; Integrin alpha-IIb; Voltage-dependent N-type calcium channel,B01AC16
fondaparinux,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Angina unstable;Cardiac failure;Deep vein thrombosis;Embolism;Haemoglobin;Haemorrhage;Hip fracture;Myocardial infarction;Myocardial reinfarction;Pulmonary embolism;ST segment elevation myocardial infarction;Superficial phlebothrombosis;Thromboembolic event;Thrombophlebitis superficial,Abdominal pain;Acute coronary syndrome;Alanine aminotransferase increased;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anxiety;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Back pain;Blister;Blood and lymphatic system disorders;Body temperature increased;Bullous eruption;Cardiac arrest;Cardiac failure;Cardiac tamponade;Catheter thrombosis;Cerebral haemorrhage;Chest pain;Coagulopathy;Confusional state;Constipation;Contusion;Cough;Dermatitis;Dermatitis bullous;Diarrhoea;Dizziness;Drug interaction;Dyspepsia;Dyspnoea;Epistaxis;Eruption;Eye haemorrhage;Fatigue;Feeling abnormal;Flushing;Foetor hepaticus;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gingival bleeding;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhagic stroke;Headache;Heparin-induced thrombocytopenia;Hepatic enzyme increased;Hepatic function abnormal;Hepatobiliary disease;Hepatocellular injury;Hot flush;Hyperbilirubinaemia;Hypersensitivity;Hypokalaemia;Hypotension;Immune system disorder;Infection;Infestation;Infestation NOS;Injection site haemorrhage;Insomnia;Leg pain;Liver disorder;Local reaction;Loss of consciousness;Malnutrition;Mediastinal disorder;Menopausal symptoms;Nausea;Nervous system disorder;Oedema;Oedema genital;Oedema peripheral;Pain;Pain in extremity;Post procedural haemorrhage;Postoperative hemorrhage;Postoperative wound infection;Procedural site reaction;Prothrombin level decreased;Pruritus;Purpura;Rash;Retroperitoneal haemorrhage;Shock;Skin disorder;Somnolence;Spinal haematoma;Surgery;Surgical intervention;Surgical site reaction;Syncope;Thrombocytopenia;Thrombocytosis;Thrombosis;Thrombosis in device;Unspecified disorder of skin and subcutaneous tissue;Urinary retention;Urinary tract infection;Vascular purpura;Ventricular tachycardia;Vertigo;Vomiting;Wound discharge increased;Wound secretion,small molecule,approved; investigational,Natural heparin pentasaccharide; 3.4.21.6; Stuart factor; Stuart-Prower factor; AT3; ATIII; Serpin C1,Coagulation factor X; Antithrombin-III,B01AX05
etoricoxib,Acute pain;Ankylosing spondylitis;Arthritis;Back pain;Dysmenorrhoea;Gout;Gouty arthritis;Low back pain;Musculoskeletal pain;Osteoarthritis;Pain;Primary dysmenorrhea;Rheumatoid arthritis,Abdominal discomfort;Abdominal distension;Abdominal pain;Acute coronary syndrome;Agitation;Alanine aminotransferase increased;Alopecia;Alveolar osteitis;Alveolitis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angina unstable;Angioedema;Angiopathy;Anorexia;Anxiety;Aphthous stomatitis;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Atrial flutter;Back strain;Bacterial infection;Basal cell carcinoma;Bladder pain;Bloated feeling;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood pressure increased;Blood urea increased;Blood uric acid increased;Blood urine;Blood urine present;Breast cancer;Breast disorder;Bronchitis;Bronchospasm;Bursitis;Cardiac arrest;Cardiac disorder;Cardiac failure congestive;Cataract;Cellulitis;Cerebrovascular accident;Chest pain;Cholecystitis;Chronic pain;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Corneal abrasion;Coronary artery disease;Costochondritis;Cough;Coxalgia;Cramp muscle;Creatine phosphokinase increased;Cyst;Cystitis;Cystitis noninfective;Decreased appetite;Dermatitis;Diabetes mellitus;Diarrhoea;Diastolic hypertension;Distress gastrointestinal;Dizziness;Drug eruption;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Ecchymosis;Eczema;Epigastric discomfort;Epistaxis;Erythema;Erythema multiforme;Eye disorder;Fatigue;Feeling abnormal;Fixed drug eruption;Flatulence;Flushing;Folliculitis;Foot pain;Functional gastrointestinal disorder;Fungal infection;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival disorder;Glycosuria;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoids;Hallucination;Headache;Heartburn;Hepatic failure;Hepatic steatosis;Hepatitis;Hepatobiliary disease;Hepatotoxicity;Herpes simplex;Herpes zoster;Hyperglycaemia;Hyperkalaemia;Hypersensitivity;Hypertension;Hypertensive crisis;Hypoaesthesia;Hyporeflexia;Immune system disorder;Increased thirst;Infection;Infestation;Infestation NOS;Injury;Insomnia;Irritable bowel syndrome;Jaundice;Knee sprain;Laceration;Lacunar infarction;Laryngitis;Ligament sprain;Liver fatty;Lumbar radiculopathy;Malnutrition;Mediastinal disorder;Melaena;Memory impairment;Mental disorder;Monocyte count increased;Mouth ulceration;Muscle spasms;Muscle strain;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myocardial infarction;Nausea;Neck pain;Neoplasm;Neoplasm malignant;Nephritis interstitial;Nephropathy toxic;Nephrotic syndrome;Nephrotoxicity;Nervous system disorder;Neuropathy;Neuropathy peripheral;Nocturia;Oedema;Oedema peripheral;Onychomycosis;Oral disorder;Oral lesion;Orthostatic hypotension;Ovarian cyst;Pain;Pain in extremity;Pain in fingers;Painful ankle;Palpitations;Pancreatitis;Peptic ulcer;Periarthritis;Pharyngitis;Phosphatase alkaline increased;Photosensitivity reaction;Platelet count decreased;Pneumonia;Polyp;Protein urine present;Proteinuria;Pruritus;Rales;Rash;Red blood cell count increased;Renal failure;Renal impairment;Rosacea;Sciatica;Serum creatinine increased;Shock;Shoulder pain;Sinus congestion;Sinusitis;Sjogren's syndrome;Skin disorder;Skin infection;Skin mass;Skin nodule;Skin ulcer;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sunburn;Syndrome sicca;Tendonitis;Tenosynovitis;Thirst;Thrombocytopenia;Tinea pedis;Tinnitus;Tongue disorder;Tongue oedema;Toothache;Toxic epidermal necrolysis;Transient ischaemic attack;Trauma;Traumatic arthropathy;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper limb oedema;Upper respiratory tract infection;Urethral disorder;Uric acid increased;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal haemorrhage;Vaginal infection;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight increased;White blood cell count decreased,small molecule,approved; investigational,"5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine; 5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl; 5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; étoricoxib; Etoricoxib; Etoricoxibum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Prostaglandin G/H synthase 2,M01AH05
mometasone,Asthma;Dermatitis atopic;Drug interaction;Nasal polyps;Psoriasis;Rhinitis allergic;Skin disorder,Abdominal pain;Acneiform eruption;Allergic contact dermatitis;Anaphylactic shock;Angioedema;Anorexia;Arthralgia;Asthenia;Asthma;Back pain;Bacterial infection;Body temperature increased;Bronchitis;Bronchospasm;Candida albicans infection;Candida infection;Cataract;Chest pain;Colitis ulcerative;Colonic polyp;Conjunctivitis;Contusion;Cough;Decreased appetite;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Diarrhoea;Dry mouth;Dry throat;Dysmenorrhoea;Dyspepsia;Dysphonia;Dyspnoea;Ear pain;Endocrine disorder;Endometriosis;Epistaxis;Fatigue;Folliculitis;Furuncle;Furunculosis;Gastroenteritis;Gastrointestinal pain;Glaucoma;Haemoptysis;Headache;Hyperadrenocorticism;Hypertrichosis;Immune system disorder;Impaired healing;Infection;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Large intestine polyp;Leukoderma;Mediastinal disorder;Miliaria;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasal burning;Nasal congestion;Nasal discomfort;Nasal irritation;Nasal septum perforation;Nasal ulcer;Nasopharyngitis;Nausea;Oral candidiasis;Otitis media;Pain;Paraesthesia;Pharyngitis;Proctocolitis;Pruritus;Rash;Rhinitis;Rhinitis allergic;Rhinitis seasonal;Rosacea;Seasonal allergy;Secondary adrenocortical insufficiency;Secondary infection;Sensitisation;Sinus congestion;Sinus headache;Sinusitis;Skin atrophy;Skin bacterial infection;Skin depigmentation;Skin discolouration;Skin striae;Stinging;Telangiectasia;Tingling sensation;Trauma;Type IV hypersensitivity reaction;Ulcer;Upper respiratory tract infection;Urinary tract infection;Viral infection;Vomiting;Wheezing,small molecule,experimental,"(+)-Mometasone; Mometason; Mometasona; Mométasone; Mometasone; Mometasonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3",Glucocorticoid receptor; Progesterone receptor, R01AD59; R03AK14;D07AC13;R03AL12
gefitinib,Haemoglobin;Haemorrhage;Idiopathic pulmonary fibrosis;Neoplasm;Neoplasm malignant;Non-small cell lung cancer,Abdominal pain;Acne;Alanine aminotransferase increased;Alopecia;Alveolitis;Amblyopia;Anaemia;Angioedema;Angiopathy;Anorectal disorder;Anorexia;Appetite absent;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Bladder pain;Blepharitis;Blood and lymphatic system disorders;Body temperature increased;Bullous conditions;Bundle branch block;Cancer pain;Cardiac disorder;Conjunctivitis;Constipation;Corneal erosion;Cough;Cutaneous vasculitis;Cystitis;Cystitis haemorrhagic;Cystitis noninfective;Decreased appetite;Dehydration;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diarrhoea;Drug interaction;Dry eye;Dry mouth;Dry skin;Dyspnoea;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Epistaxis;Eruption;Erythema multiforme;Eye disorder;Eye pain;Eye redness;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling sick;Gastric ulcer;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal perforation;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Hepatic failure;Hepatitis;Hepatobiliary disease;Hypersensitivity;Hypokalaemia;Hypomagnesaemia;Hypoproteinaemia;Hypotension;Hypoxia;Infection;Infestation;Infestation NOS;Interstitial lung disease;Interstitial pneumonia;Ischaemia;Keratitis;Lip swelling;Malaise;Malnutrition;Mediastinal disorder;Melaena;Mouth ulceration;Nail disorder;Nausea;Necrolysis epidermal;Nervous system disorder;Nettle rash;Ocular hyperaemia;Oedema peripheral;Oral pain;Pain;Pancreatitis;Paronychia;Pleural effusion;Pneumonia;Protein urine present;Proteinuria;Pruritus;Pulmonary haemorrhage;Pulmonary toxicity;Rash;Rash pustular;Rectal disorder;Respiratory failure;Scrotal oedema;Seborrhoeic dermatitis;Shock;Sinoatrial node dysfunction;Sinus arrhythmia;Skin disorder;Skin fissures;Sore mouth;Stevens-Johnson syndrome;Stomatitis;Tenderness;Thrombocytopenia;Thrombophlebitis;Toxic epidermal necrolysis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vesiculobullous rash;Vomiting;Weight decreased,small molecule,approved; investigational,"4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; Gefitinib; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine; 2.7.10.1; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Epidermal growth factor receptor,L01EB01;L01XE02
desloratadine,Chronic spontaneous urticaria;Cough;Erythema;Lacrimation;Lacrimation increased;Nasopharyngitis;Perennial allergic rhinitis;Pruritus;Redness;Rhinitis allergic;Rhinitis perennial;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Sneezing;Urticaria,Abdominal pain;Affect lability;Agitation;Anaphylactic shock;Angioedema;Anorexia;Asthenia;Autonomic neuropathy;Blood bilirubin increased;Body temperature increased;Breast disorder;Bronchitis;Cardiac disorder;Connective tissue disorder;Convulsion;Cough;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Dyskinesia;Dysmenorrhoea;Dyspepsia;Dyspnoea;Electrocardiogram abnormal;Epistaxis;Erythema;Excitability;Extrapyramidal disorder;Extrapyramidal symptoms;Fatigue;Gastrointestinal disorder;Gastrointestinal pain;Hallucination;Headache;Hepatic enzyme increased;Hepatitis;Hepatobiliary disease;Hyperkinesia;Hypersensitivity;Increased appetite;Infection;Infection parasitic;Infestation;Infestation NOS;Insomnia;Irritability;Mental disorder;Mood swings;Movement disorder;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Nervous system disorder;Oedema;Otitis media;Palpitations;Pharyngitis;Pruritus;Rash;Rash maculo-papular;Rhinorrhoea;Somnolence;Tachycardia;Unspecified disorder of autonomic nervous system;Upper respiratory tract infection;Urinary tract infection;Urticaria;Varicella;Viral infection;Vomiting,small molecule,approved; investigational,"8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; Descarboethoxyloratadine; Desloratadina; Desloratadine; H1-R; H1R; HH1R; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Histamine H1 receptor,R06AX27
desvenlafaxine,"Agitation;Asthenia;Bradyphrenia;Bradypsychic response;Cerebration impaired;Decreased interest;Depressed mood;Disturbance in attention;Dysphoria;Fatigue;Feeling guilty;Hypersomnia;Insomnia;Major depression;Major depressive disorder, single episode;Mental disability;Suicidal ideation;Suicide attempt",Abnormal dreams;Acute coronary syndrome;Alopecia;Angioedema;Angiopathy;Angle closure glaucoma;Anorgasmia;Anxiety;Asthenia;Blood cholesterol increased;Blood pressure increased;Blood prolactin increased;Blood triglycerides increased;Bone disorder;Breast disorder;Bruxism;Cardiac disorder;Cerebrovascular disorder;Chills;Connective tissue disorder;Constipation;Convulsion;Coronary artery occlusion;Decreased appetite;Depersonalisation;Dermatitis;Diarrhoea;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dry mouth;Dysgeusia;Ear and labyrinth disorders;Ejaculation delayed;Ejaculation disorder;Ejaculation failure;Eosinophilic pneumonia;Epistaxis;Erectile dysfunction;Erythema multiforme;Extrapyramidal disorder;Eye disorder;Fasting;Fatigue;Feeling jittery;Gastrointestinal disorder;Gastrointestinal haemorrhage;Haemorrhagic disorder;Hallucination;Headache;Hemorrhage abnormal;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypomania;Hyponatraemia;Immune system disorder;Insomnia;Interstitial lung disease;Irritability;Libido decreased;Liver function test abnormal;Loss of consciousness;Malnutrition;Mania;Mediastinal disorder;Menopausal symptoms;Mental disorder;Musculoskeletal stiffness;Mydriasis;Myocardial infarction;Myocardial ischaemia;Nausea;Nervous system disorder;Nervousness;Orgasm abnormal;Orthostatic hypotension;Palpitations;Paraesthesia;Peripheral coldness;Photosensitivity reaction;Protein urine present;Proteinuria;Rash;Serotonin syndrome;Sexual dysfunction;Shock;Skin disorder;Somnolence;Stevens-Johnson syndrome;Suicidal ideation;Syncope;Tachycardia;Tension;Tinnitus;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary hesitation;Urinary retention;Urinary tract disorder;Vertigo;Vision blurred;Vomiting;Weight decreased;Weight increased;Withdrawal syndrome;Yawning,small molecule,approved; investigational,"Desvenlafaxina; Desvenlafaxine; O-desmethylvenlafaxine; ODV; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; DA transporter; DAT; DAT1; Solute carrier family 6 member 3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; C19-steroid-specific UDP-glucuronosyltransferase; C19-steroid-specific UDPGT; UDPGT 2B17; UGT2B17; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; Sodium-dependent dopamine transporter,N06AX23
pregabalin,Convulsion;Diabetic neuropathy;Diabetic peripheral neuropathy;Epilepsy;Fibromyalgia;Generalised anxiety disorder;Neuralgia;Partial seizures;Post herpetic neuralgia;Renal failure;Renal impairment;Spinal cord injury,Abdominal distension;Abdominal pain;Abnormal dreams;Abnormal ejaculation;Abnormal faeces;Abnormal vision;Abscess;Abscess periodontal;Accidental injury;Accommodation disorder;Acidosis;Action tremor;Acute coronary syndrome;Adenoma benign;Adrenal insufficiency;Affect lability;Ageusia;Aggression;Agitation;Akathisia;Alanine aminotransferase increased;Albuminuria;Alcohol intolerance;Alopecia;Altered visual depth perception;Amblyopia;Amenorrhoea;Amnesia;Amylase increased;Anaemia;Anaemia macrocytic;Anaemia megaloblastic;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Anorectal discomfort;Anorectal disorder;Anorexia;Anorgasmia;Anxiety;Aortic valve stenosis;Apathy;Aphasia;Aphthous stomatitis;Apnoea;Arachnoiditis;Arrhythmia;Arrhythmia supraventricular;Arterial anomaly;Arteriosclerosis;Arthralgia;Arthritis;Arthritis bacterial;Arthropathy;Ascites;Aspartate aminotransferase increased;Asthenia;Asthenopia;Asthma;Ataxia;Atelectasis;Atrial arrhythmia;Atrial fibrillation;Atrial flutter;Atrioventricular block;Atrioventricular block complete;Atrioventricular block first degree;Atrioventricular block second degree;Autonomic nervous system imbalance;Avitaminosis;Azotaemia;Back pain;Bacterial infection;Balance disorder;Balanitis;Benign neoplasm of skin;Biliary colic;Bladder cancer;Bladder carcinoma;Bladder neoplasm;Bladder pain;Blepharitis;Blindness;Block heart;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose increased;Blood potassium decreased;Blood prolactin increased;Blood sodium increased;Blood urea increased;Blood uric acid increased;Body odor;Body temperature decreased;Body temperature increased;Bone disorder;Bone neoplasm;Bone pain;Bradycardia;Bradyphrenia;Bradypsychic response;Brain oedema;Breast abscess;Breast cancer;Breast discharge;Breast disorder;Breast enlargement;Breast neoplasm;Breast pain;Breath odour;Bronchiectasis;Bronchiolitis;Bronchitis;Bundle branch block;Burning sensation;Bursitis;CNS depression NOS;Calcium metabolism disorder;Calculus bladder;Calculus of kidney;Calculus urinary;Candida infection;Capillary fragility increased;Carcinoma;Carcinoma breast;Carcinoma of lung;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiomegaly;Cardiomyopathy;Cardiovascular disorder;Carotid artery occlusion;Carotid artery thrombosis;Cataract;Cataract specified;Cellulitis;Central nervous system neoplasm;Cerebellar syndrome;Cerebral haemorrhage;Cerebral infarction;Cerebral ischaemia;Cerebration impaired;Cerebrovascular accident;Cerebrovascular disorder;Cervicitis;Cervix disorder;Cervix neoplasm;Cheilitis;Chest discomfort;Chest pain;Chest tightness;Chills;Cholecystitis;Cholelithiasis;Chondrodystrophy;Chronic leukaemia;Circumoral paresthesia;Coagulopathy;Cognitive disorder;Cogwheel rigidity;Cold sweat;Colitis;Colitis ulcerative;Colour blindness;Coma;Completed suicide;Confusional state;Congenital arterial malformation;Congenital cystic kidney disease;Congenital genitourinary abnormality;Congenital musculoskeletal anomaly;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cor pulmonale;Corneal lesion;Corneal opacity;Coronary artery disease;Coronary artery occlusion;Cough;Cough increased;Cramp muscle;Cramps of lower extremities;Creatine phosphokinase increased;Creatinine increased;Creatinine renal clearance decreased;Crystalluria;Crystalluria calcium;Cyanosis;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Decreased tolerance;Decubitus ulcer;Dehydration;Delirium;Delusion;Dementia;Dental caries;Dependence;Dependence physiological;Depersonalisation;Depressed level of consciousness;Depressed mood;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diabetic neuropathy;Diarrhoea;Diarrhoea haemorrhagic;Digitalis intoxication (NOS);Diplopia;Discomfort;Disinhibition;Disorder calcium (NOS);Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Dizziness postural;Drug abuse;Drug dependence;Drug effect increased;Drug level decreased;Drug level increased;Drug tolerance decreased;Drug withdrawal syndrome;Dry eye;Dry mouth;Dry skin;Duodenal ulcer;Dysarthria;Dysautonomia;Dysgeusia;Dysgraphia;Dyskinesia;Dysmenorrhoea;Dyspareunia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Ear disorder;Ear pain;Ecchymosis;Eczema;Ejaculation delayed;Ejaculation disorder;Electrocardiogram QT prolonged;Electrocardiogram QT shortened;Electrocardiogram ST segment depression;Electrocardiogram ST segment elevation;Electrocardiogram T wave inversion;Electrocardiogram abnormal;Elevated mood;Embolus leg;Emphysema;Encephalopathy;Endocarditis;Endometrial cancer;Endometrial disorder;Enlargement abdomen;Enteritis;Enterocolitis;Enzyme abnormality;Eosinophilia;Epididymitis;Epistaxis;Erectile dysfunction;Eructation;Eruption lichenoid;Erythema multiforme;Euphoric mood;Exophthalmos;External ophthalmoplegia;Extrapyramidal disorder;Extrasystoles;Eye disorder;Eye haemorrhage;Eye irritation;Eye pain;Eye redness;Eye swelling;Eyelid oedema;Face oedema;Facial paralysis;Faecal incontinence;Faecalith;Faecaloma;Fatigue;Feeling abnormal;Feeling drunk;Fibrocystic breast disease;Flat affect;Flatulence;Fluid retention;Flushing;Footdrop;Fungal infection;Fungal skin infection;Furuncle;Furunculosis;Gait disturbance;Galactorrhoea;Gamma globulins increased;Gamma-glutamyltransferase increased;Gangrene;Gastric atony;Gastric ulcer;Gastric ulcer haemorrhage;Gastritis;Gastritis haemorrhagic;Gastroenteritis;Gastrointestinal carcinoma;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Generalised spasm;Genitourinary tract neoplasm;Gingival bleeding;Gingival hyperplasia;Gingivitis;Glaucoma;Glomerulitis;Glomerulonephritis;Glossitis;Glucose tolerance decreased;Glycosuria;Goitre;Gout;Grand mal convulsion;Granuloma;Guillain-Barre syndrome;Gynaecomastia;Haematemesis;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Hair disorder;Hallucination;Hangover;Headache;Hemiplegia;Henoch-Schonlein purpura;Hepatic cancer;Hepatic steatosis;Hepatitis;Hepatocellular carcinoma;Hepatomegaly;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hirsutism;Hormone level abnormal;Hostility;Hot flush;Hydronephrosis;Hyperacusis;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hypercalciuria;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hypernatraemia;Hyperpathia;Hyperreflexia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hyperuricaemia;Hyperventilation;Hypoaesthesia;Hypoaesthesia oral;Hypoalgesia;Hypocalcaemia;Hypochloraemia;Hypochromic anaemia;Hypoglycaemia;Hypoglycemic reaction;Hypohidrosis;Hypokalaemia;Hypokinesia;Hypomagnesaemia;Hypomenorrhoea;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hyporeflexia;Hypotension;Hypothermia;Hypothyroidism;Hypotonia;Hypoventilation;Hypovitaminosis;Hypoxia;IIIrd nerve paralysis;Ichthyosis;Ichthyosis acquired;Ileus paralytic;Ill-defined disorder;Immune system disorder;Immunoglobulins increased;Impaired gastric emptying;Impaired healing;Incontinence;Increased appetite;Increased bronchial secretion;Infection;Infestation;Infestation NOS;Influenza;Injection site haemorrhage;Injection site pain;Injection site reaction;Injury;Insomnia;Intentional injury;Intestinal obstruction;Intestinal perforation;Intestinal stenosis;Intestinal ulcer;Intracranial aneurysm;Intracranial pressure increased;Iritis;Iron deficiency anaemia;Irritability;Jaundice;Jaundice cholestatic;Joint swelling;Keratitis;Keratoconjunctivitis;Ketosis;Kidney function abnormal;Laboratory test abnormal;Lacrimal disorder;Lacrimal structural disorder;Lacrimation increased;Lactation female;Lactic acidosis;Laryngeal neoplasm;Laryngeal pain;Laryngitis;Laryngospasm;Left ventricular failure;Lethargy;Leukaemoid reaction;Leukocytosis;Leukopenia;Leukoplakia oral;Leukorrhea;Libido decreased;Libido increased;Lichenoid keratosis;Liver fatty deposition;Liver function test abnormal;Liver tenderness;Local swelling;Loss of consciousness;Lung disorder;Lung neoplasm malignant;Lupus erythematosus;Lymphadenopathy;Lymphangitis;Lymphocytosis;Lymphoedema;Major depression;Malaise;Malignant melanoma;Malnutrition;Mania;Manic psychosis;Mastitis;Mediastinal disorder;Melaena;Melanoma skin;Melanosis;Memory impairment;Meningitis;Menopausal symptoms;Menopause;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Mental retardation;Metrorrhagia;Micturition urgency;Migraine;Miliaria;Miosis;Mood swings;Mouth ulceration;Movement disorder;Mucous membrane disorder;Multiple sclerosis;Muscle atrophy;Muscle relaxant therapy;Muscle spasms;Muscle spasticity;Muscle stiffness;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myasthenia;Mydriasis;Myelitis;Myelofibrosis;Myeloid metaplasia;Myocardial infarction;Myocardial ischaemia;Myoclonus;Myopathy;Myositis;NPN increased;Nail disorder;Nasal congestion;Nasal dryness;Nasal septum disorder;Nasopharyngitis;Nausea;Neck pain;Neck stiffness;Neoplasm;Neoplasm malignant;Neoplasm prostate;Nephritis;Nephrolithiasis;Nephrosis;Nephrotic syndrome;Nervous system disorder;Nervousness;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neurosis;Neutropenia;Night blindness;Nocturia;Nodal arrhythmia;Nodal tachycardia;Nuchal rigidity;Nystagmus;Obesity;Ocular hyperaemia;Oedema;Oedema peripheral;Oesophageal achalasia;Oesophageal stenosis;Oesophageal ulcer;Oesophagitis;Oliguria;Ophthalmoplegia;Optic atrophy;Optic neuritis;Oral candidiasis;Orchitis;Orchitis noninfective;Orthostatic hypotension;Oscillopsia;Osteoarthritis;Osteomyelitis;Osteoporosis;Otitis externa;Otitis media;Ovarian cancer;Ovarian disorder;PRL increased;Pain;Pain in extremity;Pallor;Palpitations;Pancreatic disorder;Pancreatitis;Pancreatitis necrotising;Pancytopenia;Panic attack;Papanicolaou smear suspicious;Papilloedema;Paraesthesia;Paraesthesia oral;Paralysis;Paranoia;Paranoid reaction;Parathyroid disorder;Parosmia;Pelvic pain;Penis disorder;Peptic ulcer;Periodontitis;Peripheral coldness;Peripheral embolism;Peripheral gangrene;Peripheral swelling;Peripheral vascular disorder;Peroneal nerve palsy;Personality disorder;Petechiae;Pharyngitis;Pharyngolaryngeal pain;Phlebitis;Phosphatase alkaline increased;Photophobia;Photopsia;Photosensitivity reaction;Platelet count decreased;Pleural disorder;Pleural effusion;Pneumonia;Pneumonia aspiration;Pneumothorax;Pollakiuria;Polycystic kidney;Polycythaemia;Polyuria;Proctalgia;Proctocolitis;Prostate cancer;Prostate carcinoma;Prostatic disorder;Prostatic specific antigen increased;Prothrombin level decreased;Pruritus;Pseudolymphoma;Pseudomembranous colitis;Psoriasis;Psychotic depression;Psychotic disorder;Pulmonary embolism;Pulmonary fibrosis;Pulmonary function test decreased;Pulmonary hypertension;Pulmonary oedema;Pupils unequal;Purpura;Purpuric rash;Pyelonephritis;Pyuria;Rash;Rash maculo-papular;Rash papular;Rash pustular;Rectal disorder;Rectal haemorrhage;Rectal tenesmus;Red blood cell abnormality;Red blood cell sedimentation rate increased;Refraction disorder;Renal failure;Renal failure acute;Renal impairment;Renal pain;Respiratory depression;Respiratory failure;Retinal artery occlusion;Retinal degeneration;Retinal depigmentation;Retinal detachment;Retinal disorder;Retinal haemorrhage;Retinal oedema;Retinal vascular disorder;Retinal vein thrombosis;Retroperitoneal fibrosis;Retrosternal pain;Rhabdomyolysis;Rheumatoid arthritis;Rhinitis;Salivary gland enlargement;Salivary hypersecretion;Salpingitis;Sarcoidosis;Schizophrenic reaction;Schizophreniform disorder;Scleritis;Scotoma;Seborrhoeic dermatitis;Sepsis;Sexual dysfunction;Shock;Sialoadenitis;Sinus arrhythmia;Sinus bradycardia;Sinus tachycardia;Sinusitis;Skin atrophy;Skin cancer;Skin candida;Skin carcinoma;Skin discolouration;Skin disorder;Skin exfoliation;Skin hypertrophy;Skin mass;Skin necrosis;Skin nodule;Skin odour abnormal;Skin ulcer;Sleep disorder;Smear cervix abnormal;Snoring;Somnolence;Speech disorder;Splenic rupture;Splenomegaly;Sputum increased;Stevens-Johnson syndrome;Stomatitis;Stupor;Subarachnoid haemorrhage;Subcutaneous nodule;Sudden death;Suicide;Suicide attempt;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating;Sweating decreased;Swelling face;Swollen tongue;Syncope;Systemic lupus erythematosus;Tachycardia;Tendinous contracture;Tendon disorder;Tendon rupture;Tenosynovitis;Tension;Therapeutic response unexpected;Thinking abnormal;Thirst;Throat tightness;Thrombocytopenia;Thrombocytopenic purpura;Thrombocytosis;Thrombophlebitis;Thrombosis;Thyroid cancer;Thyroid carcinoma;Thyroid disorder;Thyroid neoplasm;Thyroiditis;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Tooth abscess;Tooth disorder;Torticollis;Toxicity to various agents;Tremor;Trismus;Ulcerative keratitis;Ulcerative stomatitis;Unexpected therapeutic effect;Unintended pregnancy;Unspecified disorder of skin and subcutaneous tissue;Urate crystalluria;Uremia;Urethral disorder;Urethral pain;Urethritis;Urethritis noninfective;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urination impaired;Urine abnormality;Urine analysis abnormal;Urine output increased;Urogenital disorder;Urolithiasis;Urticaria;Uterine disorder;Uterine fibroids enlarged;Uterine haemorrhage;Uterine leiomyoma;Uveitis;VIIth nerve paralysis;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Varicose vein;Vascular anomaly;Vascular headache;Vascular purpura;Vasculitis;Ventricular arrhythmia;Ventricular bigeminy;Ventricular extrasystoles;Ventricular fibrillation;Ventricular tachycardia;Vertigo;Vesiculobullous rash;Vestibular disorder;Viral infection;Virilism;Vision blurred;Visual acuity reduced;Visual brightness;Visual disturbance;Visual impairment;Vitreous disorder;Vomiting;Vulvovaginal candidiasis;Vulvovaginal disorder;Vulvovaginal mycotic infection;Weight decreased;Weight increased;White blood cell count decreased;Withdrawal symptom;Withdrawal syndrome;Word finding difficulty;Yawning,small molecule,approved; investigational,(S)-3-Isobutyl GABA; 3-Isobutyl GABA; Pregabalin; Pregabalina; CACNL2A; CCHL2A; MHS3; Voltage-gated calcium channel subunit alpha-2/delta-1; EAAC1; EAAT3; Excitatory amino-acid carrier 1; HEAAC1; Neuronal and epithelial glutamate transporter; Sodium-dependent glutamate/aspartate transporter 3; Solute carrier family 1 member 1; 4F2 LC; 4F2 light chain; 4F2LC; CD98 light chain; CD98LC; E16; hLAT1; Integral membrane protein E16; L-type amino acid transporter 1; LAT1; MPE16; Solute carrier family 7 member 5; y+ system cationic amino acid transporter,Voltage-dependent calcium channel subunit alpha-2/delta-1,N02BF02;N03AX16
bimatoprost,Chronic open angle glaucoma;Glaucoma;Hypotrichosis;Ocular hypertension;Open angle glaucoma;Primary open angle glaucoma,Angiopathy;Anxiety;Arthritis;Asthenia;Asthenopia;Asthma;Bladder pain;Blepharal pigmentation;Blepharitis;Blepharospasm;Bronchitis;Burning sensation;Burning sensation in eye;COPD exacerbation;Cataract;Chalazion;Chest pain;Chronic obstructive pulmonary disease;Common cold;Conjunctival bleb;Conjunctival disorder;Conjunctival haemorrhage;Conjunctival hyperaemia;Conjunctival oedema;Conjunctivitis allergic;Connective tissue disorder;Corneal calcification;Corneal deposits;Corneal erosion;Corneal oedema;Cough;Cough increased;Cystitis;Cystitis noninfective;Cystoid macular oedema;Depression;Dermatitis;Diplopia;Dizziness;Dry eye;Dry mouth;Dry skin;Dyspepsia;Dyspnoea;Enophthalmos;Erythema;Erythema of eyelid;Erythema periorbital;Exacerbation of asthma;Eye discharge;Eye disorder;Eye irritation;Eye oedema;Eye pain;Eye pruritus;Eye swelling;Eyelash darkening;Eyelash discolouration;Eyelash hyperpigmentation;Eyelid irritation;Eyelid margin crusting;Eyelid oedema;Eyelid pain;Eyelid retraction;Eyelids pruritus;Gastrointestinal disorder;Growth of eyelashes;Hair growth abnormal;Headache;Hirsutism;Hordeolum;Hypercholesterolaemia;Hypertension;Hypertrichosis;Infection;Inflammation;Insomnia;Instillation site irritation;Iris hyperpigmentation;Iritis;Keratitis;Lacrimation;Lacrimation increased;Liver function test abnormal;Macular oedema;Madarosis;Mediastinal disorder;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Oedema peripheral;Pain;Palpitations;Pharyngitis;Photophobia;Pruritus;Punctate keratitis;Rash;Retinal haemorrhage;Rhinitis;Scotoma;Sensation of foreign body;Sinusitis;Skin discolouration;Skin disorder;Skin hyperpigmentation;Somnolence;Stinging;Tension;Trichorrhexis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urine abnormality;Urine analysis abnormal;Uveitis;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vitreous floaters,small molecule,approved; investigational,"(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide; Bimatoprost; Bimatoprostum; PGF receptor; PGF2-alpha receptor; Prostanoid FP receptor; PGE receptor EP1 subtype; PGE2 receptor EP1 subtype; Prostanoid EP1 receptor; PGE receptor EP3 subtype; PGE2 receptor EP3 subtype; PGE2-R; Prostanoid EP3 receptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3",Prostaglandin F2-alpha receptor; Prostaglandin E2 receptor EP1 subtype; Prostaglandin E2 receptor EP3 subtype,S01EE03
rufinamide,Convulsion;Epilepsy;Lennox-Gastaut syndrome,Abdominal pain upper;Acne;Aggression;Agitation;Anaemia;Anorexia;Anxiety;Asthenia;Ataxia;Atrioventricular block first degree;Back pain;Balance disorder;Blood and lymphatic system disorders;Bone disorder;Breast disorder;Bronchitis;Bundle branch block right;Cardiac disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Decreased appetite;Dermatitis;Diarrhoea;Diplopia;Disturbance in attention;Dizziness;Dyspepsia;Dysuria;Ear and labyrinth disorders;Ear infection;Eating disorder;Enuresis;Epilepsy;Epistaxis;Eye disorder;Fatigue;Gait disturbance;Gastrointestinal disorder;Gastrointestinal symptom NOS;Haematuria;Head injury;Headache;Hepatobiliary disease;Hypersensitivity;Immune system disorder;Incontinence;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Iron deficiency anaemia;Leukopenia;Lymphadenopathy;Malnutrition;Mediastinal disorder;Mental disorder;Nasopharyngitis;Nausea;Nephrolithiasis;Nervous system disorder;Neutropenia;Nocturia;Nystagmus;Oligomenorrhoea;Other forms of epilepsy;Pneumonia;Pollakiuria;Polyuria;Pruritus;Rash;Rhinitis;Sinusitis;Skin disorder;Somnolence;Status epilepticus;Thrombocytopenia;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urine output increased;Vertigo;Vision blurred;Vomiting;Weight decreased,small molecule,approved,"Rufinamida; Rufinamide; Xilep ; hNE-Na; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Sodium channel protein type IX subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.7; GPRC1E; MGLUR5; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Sodium channel protein type 9 subunit alpha; Metabotropic glutamate receptor 5,N03AF03
rosuvastatin,Acute coronary syndrome;Alcohol abuse;Alcoholism;Arteriosclerosis;Atherosclerosis;Blood triglycerides increased;Cardiovascular disorder;Cerebrovascular accident;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Dyslipidaemia;Foetor hepaticus;Hepatocellular injury;Heterozygous familial hypercholesterolemia;Homozygous familial hypercholesterolaemia;Hypercholesterolaemia;Hyperlipidaemia;Hypertriglyceridaemia;Hypothyroidism;Liver disorder;Myocardial infarction;Nephrotic syndrome;Type II hyperlipidaemia;Type III hyperlipidaemia;Type IIa hyperlipidaemia,Abdominal pain;Accidental injury;Amnesia;Angioedema;Arrhythmia;Arthralgia;Asthenia;Blood creatine phosphokinase increased;Blood disorder;Breast disorder;Bronchitis;Cognitive disorder;Cognitive impairment;Confusional state;Constipation;Cough;Cough increased;Creatine phosphokinase increased;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Dizziness;Drug interaction;Dyspepsia;Feeling abnormal;Flatulence;Forgetfulness;Gastroenteritis;Gastrointestinal pain;Gynaecomastia;Haematuria;Headache;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatobiliary disease;Hypersensitivity;Hypertonia;Immune-mediated necrotising myopathy;Infection;Influenza;Injury;Insomnia;Jaundice;Memory impairment;Memory loss;Mental disorder;Microscopic hematuria;Muscle swelling;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Myoglobin urine present;Myoglobinuria;Myopathy;Myositis;Nausea;Nephropathy;Nervous system disorder;Neuropathy peripheral;Nightmare;Pain;Pancreatitis;Paraesthesia;Pharyngitis;Protein urine present;Proteinuria;Pruritus;Rash;Renal failure acute;Rhabdomyolysis;Rhinitis;Sinusitis;Sleep disorder;Thrombocytopenia;Urinary tract infection;Urine analysis abnormal;Urticaria,small molecule,approved,"(3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; Rosuvastatin; Rosuvastatina; 1.1.1.34; HMG-CoA reductase; CD11 antigen-like family member A; CD11A; Leukocyte adhesion glycoprotein LFA-1 alpha chain; Leukocyte function-associated molecule 1 alpha chain; LFA-1A; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; Amino acid transport system xc-; Calcium channel blocker resistance protein CCBR1; Solute carrier family 7 member 11; xCT; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1",3-hydroxy-3-methylglutaryl-coenzyme A reductase; Integrin alpha-L, A10BH52; C10AA07; C10BA06; C10BA09; C10BX05; C10BX07; C10BX09; C10BX13; C10BX14; C10BX16; C10BX17; C10BX20; C10BX21; G01AE10;C10AA07;C10BX10
esomeprazole,Gastrooesophageal reflux disease,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal vision;Ageusia;Aggression;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Anaemia;Anal pruritus;Anaphylactic shock;Angioedema;Anorectal discomfort;Anorectal disorder;Anorexia;Apathy;Arthralgia;Arthritis;Arthritis aggravated;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Asthma aggravated;Back pain;Barrett's oesophagus;Bladder pain;Blood alkaline phosphatase increased;Blood creatinine increased;Blood gastrin increased;Blood uric acid increased;Body temperature increased;Bronchospasm;Candida infection;Chest pain;Chills;Confusional state;Conjunctivitis;Constipation;Constipation aggravated;Cough;Cramp muscle;Creatinine increased;Cystitis;Cystitis noninfective;Decreased appetite;Depression;Depression aggravated;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Duodenitis;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysplasia;Dyspnoea;Dysuria;Ear pain;Enlargement abdomen;Epigastric pain;Epistaxis;Erectile dysfunction;Erosive oesophagitis;Eructation;Erythema multiforme;Face oedema;Fatigue;Feeling abnormal;Fibromyalgia;Flat affect;Flatulence;Fluid retention;Flushing;Fungal infection;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal candidiasis;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Genital candidiasis;Glycosuria;Goitre;Gynaecomastia;Haematuria;Hallucination;Headache;Hepatic encephalopathy;Hepatic failure;Hepatic function abnormal;Hepatitis;Hernia;Hiccups;Hot flush;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypochromic anaemia;Hyponatraemia;Ill-defined disorder;Increased appetite;Infection;Infestation;Infestation NOS;Insomnia;Jaundice;Laryngeal oedema;Leg edema;Leukocytosis;Leukopenia;Lymphadenopathy;Lymphadenopathy cervical;Malaise;Melaena;Menopausal symptoms;Menstrual disorder;Migraine;Migraine aggravated;Mouth ulceration;Mucosal discolouration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nausea;Nephritis interstitial;Nervousness;Nodule;Oedema peripheral;Oesophageal disorder;Oesophageal stenosis;Oesophageal ulcer;Oesophagitis;Oral disorder;Osteoarthritis;Otitis media;Pain;Pancreatitis;Pancytopenia;Paraesthesia;Parosmia;Pharyngeal disorder;Pharyngitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polymyalgia rheumatica;Polyp;Polyuria;Pruritus;Pruritus genital;Rash;Rash erythematous;Rash maculo-papular;Rectal disorder;Retrosternal pain;Rhinitis;Rigors;Scotoma;Serum gastrin increased;Shock;Sinusitis;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating increased;Tachycardia;Tension;Thirst;Thrombocytopenia;Tinnitus;Tongue disorder;Tongue oedema;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Ulcerative stomatitis;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Varices oesophageal;Vertigo;Vision blurred;Visual impairment;Vitamin B12 deficiency;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"(−)-omeprazole; (S)-(−)-omeprazole; (S)-omeprazole; Esomeprazol; Ésoméprazole; Esomeprazole; Esomeprazolum; Omeprazole S-form; Perprazole; 7.2.2.19; Gastric H(+)/K(+) ATPase subunit alpha; Proton pump; Gastric H(+)/K(+) ATPase subunit beta; Proton pump beta chain; 3.5.3.18; DDAH; DDAH-1; DDAHI; Dimethylargininase-1; Dimethylarginine dimethylaminohydrolase 1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8","Potassium-transporting ATPase alpha chain 1; Potassium-transporting ATPase subunit beta; N(G),N(G)-dimethylarginine dimethylaminohydrolase 1", A02BC05; M01AE52;A02BD06
olmesartan,Hypertension;Hypertensive;Hypotension,Abdominal pain;Alopecia;Angioedema;Arthralgia;Arthritis;Asthenia;Back pain;Bilirubin value increased;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood triglycerides increased;Blood uric acid increased;Bone pain;Bronchitis;Chest pain;Cough;Creatine phosphokinase increased;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Face oedema;Fatigue;Gastroenteritis;Gastrointestinal pain;Haematuria;Headache;Hypercholesterolaemia;Hyperglycaemia;Hyperlipidaemia;Hypertriglyceridaemia;Hyperuricaemia;Inflicted injury;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Malnutrition;Mental disorder;Musculoskeletal discomfort;Myalgia;Nausea;Oedema peripheral;Pain;Pharyngitis;Pruritus;Rash;Renal failure acute;Rhabdomyolysis;Rhinitis;Sinusitis;Tachycardia;Transaminases increased;Upper respiratory tract infection;Urinary tract infection;Urticaria;Vertigo;Vomiting,small molecule,approved; investigational,"4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; Olmesartan; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Type-1 angiotensin II receptor, C09CA08; C09DB02; C09DX03;C09CA08;C09DA08
fosamprenavir,Factor XI deficiency;HIV infection;Human immunodeficiency virus type;Immunodeficiency;Infection,Abdominal pain;Acute coronary syndrome;Alanine aminotransferase increased;Angioedema;Anorexia;Aspartate aminotransferase increased;Asthenia;Autoimmune disorder;Basedow's disease;Blood cholesterol increased;Blood triglycerides increased;Body temperature increased;Breast enlargement;Buffalo hump;Calculus of kidney;Cardiac disorder;Connective tissue disorder;Decreased appetite;Dermatitis;Diabetes mellitus;Diarrhoea;Dizziness;Drug hypersensitivity;Erythema multiforme;Fat redistribution;Fatigue;Flatulence;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Headache;Hypercholesterolaemia;Hyperglycaemia;Hyperlactacidaemia;Hyperlipidaemia;Hypersensitivity;Hypertriglyceridaemia;Hypertrophy of breast;Immune system disorder;Inflammation;Insulin resistance;Lipase increased;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Loose stools;Malnutrition;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myositis;Nausea;Nephrolithiasis;Nervous system disorder;Neutropenia;Opportunistic infection;Osteonecrosis;Paraesthesia oral;Pruritus;Rash;Reaction gastrointestinal;Rhabdomyolysis;Skin disorder;Stevens-Johnson syndrome;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vomiting,small molecule,approved,"FOS-APV; Fosamprenavir; Pr160Gag-Pol; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Pol polyprotein; Gag-Pol polyprotein,J05AE07
pitavastatin,Dyslipidaemia;Hyperlipidaemia,Abdominal discomfort;Abdominal pain;Amnesia;Arthralgia;Asthenia;Back pain;Cognitive disorder;Cognitive impairment;Confusional state;Constipation;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Feeling abnormal;Forgetfulness;Gastrointestinal pain;Headache;Hepatic failure;Hepatitis;Hypersensitivity;Hypoaesthesia;Ill-defined disorder;Immune-mediated necrotising myopathy;Influenza;Insomnia;Interstitial lung disease;Jaundice;Malaise;Memory impairment;Memory loss;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myoglobin urine present;Myoglobinuria;Myopathy;Myositis;Nasopharyngitis;Nausea;Pain in extremity;Pruritus;Rash;Renal failure acute;Rhabdomyolysis;Urticaria,small molecule,approved,"Pitavastatia; Pitavastatin; Pitavastatina; Pitavastatine; Pitavastatinum; 1.1.1.34; HMG-CoA reductase; CD11 antigen-like family member A; CD11A; Leukocyte adhesion glycoprotein LFA-1 alpha chain; Leukocyte function-associated molecule 1 alpha chain; LFA-1A; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",3-hydroxy-3-methylglutaryl-coenzyme A reductase; Integrin alpha-L,C10AA08
abiraterone,Hepatic cancer metastatic;Metastases to liver;Prostate cancer,Acute coronary syndrome;Alanine aminotransferase increased;Anaemia;Angiopathy;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Blood alkaline phosphatase increased;Blood potassium decreased;Blood triglycerides increased;Body temperature increased;Cardiac disorder;Cardiac failure;Cardio-respiratory arrest;Chest discomfort;Chest pain;Connective tissue disorder;Constipation;Contusion;Cough;Dermatitis;Diarrhoea;Discomfort;Dyspepsia;Dyspnoea;Fatigue;Fluid retention;Fracture;Gastrointestinal disorder;Groin pain;Haematuria;Hepatotoxicity;Hot flush;Hypercholesterolaemia;Hyperglycaemia;Hypernatraemia;Hypertension;Hypertriglyceridaemia;Hypokalaemia;Hypophosphataemia;Infection;Infectious pneumonitis;Infestation;Infestation NOS;Insomnia;Joint swelling;Lymphopenia;Mediastinal disorder;Menopausal symptoms;Mental disorder;Multiple fractures;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Nasopharyngitis;Nocturia;Oedema;Phosphatase alkaline increased;Pneumonia;Pollakiuria;Potassium low;Rash;Skin disorder;Sudden death;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Vomiting,small molecule,approved,"(3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol; 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol; Abiraterona; Abiraterone; 1.14.14.19; 17-alpha-hydroxyprogesterone aldolase; CYP17; CYPXVII; Cytochrome P450 17A1; Cytochrome P450-C17; Cytochrome P450c17; S17AH; Steroid 17-alpha-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 2.8.2.2; Bile salt sulfotransferase; Dehydroepiandrosterone sulfotransferase; DHEA-ST; DHEA-ST8; HST; Hydroxysteroid Sulfotransferase; ST2; ST2A1; STD; SULT2A3; AGP 1; AGP1; OMD 1; Orosomucoid-1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6","Steroid 17-alpha-hydroxylase/17,20 lyase", L02BX03; L02BX53;L01XK52
ivabradine,Angina pectoris;Cardiac failure chronic;Coronary artery disease;Sinus rhythm;Stable angina pectoris;Systolic dysfunction,Angioedema;Angiopathy;Asthenia;Atrial fibrillation;Blood and lymphatic system disorders;Blood creatinine increased;Blood uric acid increased;Bradycardia;Cardiac disorder;Connective tissue disorder;Constipation;Cramp muscle;Creatinine increased;Dermatitis;Diarrhoea;Diplopia;Discomfort;Dizziness;Dyspnoea;Ear and labyrinth disorders;Electrocardiogram QT prolonged;Eosinophilia;Erythema;Eye disorder;Fatigue;Feeling abnormal;Gastrointestinal disorder;Headache;Hyperuricaemia;Hypotension;Ill-defined disorder;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Muscle spasms;Nausea;Nervous system disorder;Palpitations;Pruritus;Rash;Shock;Sick sinus syndrome;Skin disorder;Supraventricular extrasystoles;Syncope;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Ventricular extrasystoles;Vertigo;Vision blurred;Visual impairment,small molecule,approved,"3-[3-({[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one; Ivabradin; Ivabradina; Ivabradine; Ivabradinum; BCNG-2; BCNG2; Brain cyclic nucleotide-gated channel 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2, C07FX05; C07FX06;C01EB17
febuxostat,Blood uric acid increased;Gout;Gouty arthritis;Gouty tophus;Hyperuricaemia;Renal failure;Renal impairment,Abdominal discomfort;Abdominal distension;Abdominal pain;Activated partial thromboplastin time prolonged;Acute coronary syndrome;Agitation;Alopecia;Amylase increased;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Arthralgia;Arthritis;Asthenia;Atrial fibrillation;Balance disorder;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine increased;Blood creatinine increased;Blood glucose increased;Blood lactate dehydrogenase increased;Blood potassium increased;Blood sodium increased;Blood thyroid stimulating hormone increased;Blood triglycerides increased;Blood urea increased;Body temperature increased;Breast disorder;Breast pain;Bronchitis;Bursitis;Cardiac disorder;Cardiac flutter;Cardiac murmur;Cerebrovascular accident;Chest discomfort;Chest pain;Cholecystitis;Cholelithiasis;Coagulation test abnormal;Connective tissue disorder;Constipation;Contusion;Cough;Creatine increased;Creatinine increased;Deafness;Decreased appetite;Dehydration;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Drug hypersensitivity;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Ecchymosis;Eczema;Electrocardiogram abnormal;Electroencephalogram abnormal;Endocrine disorder;Eosinophilia;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Exfoliative rash;Eye disorder;Eye irritation;Fatigue;Feeling abnormal;Flatulence;Flushing;Foetor hepaticus;Gait disturbance;Gastric pH decreased;Gastritis;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival pain;Glucose increased;Gout;Gout flare;Guillain-Barre syndrome;Gynaecomastia;Haematemesis;Haematochezia;Haematocrit decreased;Haematuria;Haemoglobin decreased;Hair colour changes;Hair growth abnormal;Headache;Hemiparesis;Hepatic failure;Hepatic steatosis;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Herpes zoster;Hot flush;Hyperchlorhydria;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypoaesthesia;Hypokalaemia;Hyposmia;Hypotension;Hypouricaemia;Idiopathic thrombocytopenic purpura;Immune system disorder;Incontinence;Increased appetite;Infection;Infestation;Infestation NOS;Influenza like illness;Influenza-like symptoms;Insomnia;Irritability;Jaundice;Joint stiffness;Joint swelling;Lactic dehydrogenase activity increased;Lacunar infarction;Lethargy;Leukocytosis;Leukopenia;Libido decreased;Liver disorder;Liver function test abnormal;Liver injury;Lymphocyte count decreased;Malnutrition;Mechanical urticaria;Mediastinal disorder;Menopausal symptoms;Mental disability;Mental disorder;Mental retardation;Micturition urgency;Migraine;Mouth ulceration;Muscle spasms;Muscle tightness;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nasal dryness;Nausea;Nephrolithiasis;Nervous system disorder;Nervousness;Neutropenia;Neutrophil count decreased;Oedema;Pain;Palpitations;Pancreatitis;Pancytopenia;Panic attack;Paraesthesia;Paranasal sinus hypersecretion;Peptic ulcer;Personality change;Petechiae;Pharyngeal oedema;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Platelet count decreased;Pollakiuria;Potassium increased;Prostatic specific antigen increased;Protein urine present;Proteinuria;Prothrombin level increased;Prurigo;Pruritus;Psychotic behaviour;Purpura;Rash;Rash erythematous;Rash follicular;Rash generalised;Rash macular;Rash maculo-papular;Rash papular;Rash pustular;Rash vesicular;Red blood cell count decreased;Renal failure;Respiratory tract congestion;Rhabdomyolysis;Shock;Sinus bradycardia;Skin discolouration;Skin disorder;Skin exfoliation;Skin lesion;Skin odour abnormal;Sneezing;Sodium high;Somnolence;Splenomegaly;Stevens-Johnson syndrome;Stiffness;Stomatitis;Tachycardia;Taste altered;Tension;Thirst;Throat irritation;Thrombocytopenia;Thyrotropin high;Tinnitus;Toxic epidermal necrolysis;Transient ischaemic attack;Traumatic liver injury;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;Urticaria physical;Vascular purpura;Vertigo;Vision blurred;Vomiting;Weight decreased;Weight increased;White blood cell count increased,small molecule,approved,"2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid; Fébuxostat; Febuxostat; Febuxostatum; XDHA; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Xanthine dehydrogenase/oxidase,M04AA03
pixantrone,B-cell lymphoma,Abdominal pain;Alanine aminotransferase increased;Alopecia;Anaemia;Angiopathy;Anorexia;Anxiety;Arrhythmia;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood disorder;Blood phosphorus increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone pain;Bradycardia;Breast disorder;Bronchitis;Bundle branch block;Candida infection;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiotoxicity;Cellulitis;Chest pain;Chills;Chromaturia;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cyst;Decreased appetite;Diarrhoea;Dizziness;Dry eye;Dry mouth;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Ejection fraction decreased;Eosinophilia;Erythema;Eye disorder;Fatigue;Febrile neutropenia;Gamma-glutamyltransferase increased;Gastroenteritis salmonella;Gastrointestinal disorder;Gastrointestinal pain;Haematuria;Headache;Hepatobiliary disease;Herpes zoster;Hyperbilirubinaemia;Hypersensitivity;Hyperuricaemia;Hypocalcaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Immune system disorder;Infection;Infestation;Infestation NOS;Injection site coldness;Insomnia;Keratitis;Left ventricular dysfunction;Lethargy;Leukopenia;Local reaction;Lymphopenia;Malnutrition;Mediastinal disorder;Meningitis;Mental disorder;Mucosal inflammation;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal stiffness;Nail disorder;Nail infection;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Neoplasm progression;Nervous system disorder;Neutropenia;Neutropenic infection;Neutrophil count increased;Night sweats;Oedema;Oesophagitis;Oliguria;Opportunistic infection;Oral fungal infection;Oral herpes;Pain in extremity;Pallor;Pancytopenia;Paraesthesia;Paraesthesia oral;Petechiae;Pleural effusion;Pneumonia;Polyp;Protein urine present;Proteinuria;Pruritus;Rash macular;Rectal haemorrhage;Respiratory tract infection;Rhinorrhoea;Septic shock;Sinus tachycardia;Skin discolouration;Skin disorder;Skin ulcer;Sleep disorder;Somnolence;Spontaneous penile erection;Stomatitis;Tachycardia;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vein discolouration;Vein disorder;Vertigo;Vomiting;Weight decreased,small molecule,approved; investigational,"6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione; Pixantrona; Pixantrone; 5.6.2.2; DNA topoisomerase II, alpha isozyme; TOP2; 5.6.2.2; DNA topoisomerase II, beta isozyme",DNA topoisomerase 2-alpha; DNA topoisomerase 2-beta,L01DB11
pomalidomide,Disease progression;Neuropathy peripheral;Plasma cell myeloma;Plasmacytoma,Alanine aminotransferase increased;Altered state of consciousness;Anaemia;Angiopathy;Anxiety;Arthralgia;Asthenia;Atrial fibrillation;Back pain;Blood and lymphatic system disorders;Blood creatinine increased;Body temperature increased;Bone pain;Breast disorder;Bronchitis;Bronchopneumonia;Cardiac disorder;Cardiac failure congestive;Chills;Confusional state;Congenital anomaly;Connective tissue disorder;Constipation;Cough;Decreased appetite;Deep vein thrombosis;Dehydration;Depressed level of consciousness;Dermatitis;Developmental delay;Diarrhoea;Dizziness;Dry skin;Dyspnoea;Ear and labyrinth disorders;Embolism;Embolism venous;Epistaxis;Fatigue;Febrile neutropenia;Feeling abnormal;Gastrointestinal disorder;General physical health deterioration;Headache;Hepatobiliary disease;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypocalcaemia;Hypokalaemia;Hyponatraemia;Infection;Infestation;Infestation NOS;Insomnia;Interstitial lung disease;Leukopenia;Lymphopenia;Malnutrition;Mediastinal disorder;Mental disorder;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Nasopharyngitis;Nausea;Nervous system disorder;Neuropathy;Neuropathy peripheral;Neutropenia;Neutropenic sepsis;Neutrophil count decreased;Night sweats;Oedema peripheral;Pain;Pain in extremity;Pancytopenia;Pelvic pain;Peripheral sensory neuropathy;Platelet count decreased;Pneumocystis jirovecii pneumonia;Pneumonia;Pruritus;Pulmonary embolism;Rash;Renal failure;Respiratory syncytial virus infection;Respiratory tract infection;Sepsis;Skin disorder;Teratogenicity;Thrombocytopenia;Thromboembolic event;Tremor;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Venous thromboembolism;Vertigo;Vomiting;Weight decreased;Weight increased;White blood cell count decreased,small molecule,approved,"Pomalidomida; Pomalidomide; Cachectin; TNF-a; TNF-alpha; TNFA; TNFSF2; Tumor necrosis factor ligand superfamily member 2; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Protein cereblon; Tumor necrosis factor; Prostaglandin G/H synthase 2,L04AX06
posaconazole,Acute leukaemia;Acute myeloid leukaemia;Aspergillosis;Aspergillus infection;Candida infection;Candidemia;Chromoblastomycosis;Coccidioidomycosis;Cryptococcosis;Floppy iris syndrome;Fungal infection;Fusarium infection;Graft versus host disease;Haematological malignancy;Immunocompromised;Immunodeficiency;Infection;Intraoperative floppy iris syndrome;Mycetoma NOS;Mycetoma mycotic;Neutropenia;Oesophageal candidiasis;Oropharyngeal candidiasis;Palpitations;Systemic candida;Systemic mycosis;Zygomycosis,Abdominal distension;Abdominal pain;Abdominal pain aggravated;Abdominal pain upper;Abdominal tenderness;Abnormal platelets;Acquired immunodeficiency syndrome;Acute coronary syndrome;Adrenal insufficiency;Affect lability;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albuminuria;Alopecia;Amnesia;Amylase increased;Anaemia;Anaemia NOS aggravated;Angiopathy;Anorectal discomfort;Anorexia;Anxiety;Anxiety aggravated;Aortic valve sclerosis;Aphasia;Aplastic anaemia;Areflexia;Arrhythmia;Arteriosclerosis;Arthralgia;Arthralgia aggravated;Ascites;Aspartate aminotransferase increased;Asterixis;Asthenia;Ataxia;Atelectasis;Atherosclerosis;Atrial fibrillation;Atrial flutter;Atrioventricular block;Autoimmune disorder;Back pain;Bacteraemia;Balanoposthitis;Biliary sludge;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood disorder;Blood electrolytes abnormal;Blood gases abnormal;Blood gonadotrophin decreased;Blood lactate dehydrogenase increased;Blood neutrophil count decreased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone pain;Bradycardia;Breast disorder;Breast pain;Bundle branch block;Calculus of kidney;Candida infection;Cardiac disorder;Cardiac failure;Cardio-respiratory arrest;Cardiomegaly;Cardiovascular disorder;Catheter related infection;Cellulitis;Cerebration impaired;Cerebrovascular accident;Cheilitis;Chest pain;Chest wall pain;Chills;Cholelithiasis;Cholestasis;Clotting;Coagulation time prolonged;Coagulopathy;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cramp muscle;Creatinine renal clearance decreased;Cytolytic hepatitis;Cytomegalovirus infection;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Delirium;Depressed level of consciousness;Dermatitis;Dermatitis flare-up;Device related infection;Diarrhoea;Diarrhoea haemorrhagic;Diplegia;Diplopia;Discomfort;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Diverticulitis aggravated;Dizziness;Drug interaction;Drug level changed;Dry cough;Dry eye;Dry mouth;Dry skin;Dry throat;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear pain;Ecchymosis;Ejection fraction decreased;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Electroencephalogram abnormal;Electrolyte abnormality;Electrolyte imbalance;Embolism;Encephalopathy;Endocrine disorder;Eosinophilia;Epistaxis;Eructation;Erythema;Erythema multiforme;Extrasystoles;Eye disorder;Eye irritation;Eye pain;Face oedema;Fasciitis;Fatal outcomes;Fatigue;Fatigue aggravated;Febrile neutropenia;Feeling abnormal;Fibrillation atrial aggravated;Fistula;Flank pain;Flatulence;Fluid retention;Flushing;Furuncle;Furunculosis;Gait disturbance;Gamma-glutamyltransferase increased;Gastric disorder;Gastritis;Gastritis haemorrhagic;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Gingivitis;Glossitis;Glucocorticoids decreased;Gonadotropins NOS low;Gravitational oedema;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic uraemic syndrome;Haemorrhage;Headache;Headache aggravated;Hearing impaired;Hemiparesis;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatitis aggravated;Hepatitis cholestatic;Hepatitis toxic;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hepatosplenomegaly;Herpes labialis;Herpes simplex;Hiccups;Hot flush;Hyperbilirubinaemia;Hyperbilirubinemia aggravated;Hypercalcaemia;Hypercholesterolaemia;Hypercholesterolemia aggravated;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hypernatraemia;Hyperphosphataemia;Hyperproteinaemia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypoalbuminaemia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hyporeflexia;Hypotension;Hypotonia;Ileus;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infection pseudomonas aeruginosa;Infestation;Infestation NOS;Inflammation;Influenza like illness;Influenza-like symptoms;Injury;Inner ear disorder;Insomnia;Interstitial lung disease;Interstitial pneumonia;Ischaemia;Jaundice;Kaposi's sarcoma;Kidney function abnormal;Laboratory test abnormal;Labyrinthine disorder;Lactic dehydrogenase activity increased;Leg edema;Leukopenia;Libido decreased;Lipase increased;Lipoma;Liver function test abnormal;Liver injury;Liver tenderness;Long QT syndrome;Loose stools;Loss of consciousness;Lung infiltration;Lymphadenopathy;Major depression;Malaise;Malnutrition;Mediastinal disorder;Melaena;Memory impairment;Meningism;Meningitis;Menopausal symptoms;Menstrual disorder;Mental disability;Mental disorder;Mental state abnormal;Metabolic acidosis;Metabolic disorder;Micturition disorder;Migraine;Mitral valve disease;Mononeuritis;Monoplegia;Mood swings;Mouth ulceration;Mucosal inflammation;Muscle relaxant therapy;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myelodysplastic syndrome;Myocardial infarction;NPN increased;Nasal congestion;Nasal discomfort;Nasal irritation;Nasopharyngitis;Nausea;Nausea aggravated;Neck stiffness;Neoplasm;Neoplasm malignant;Nephritis interstitial;Nephrolithiasis;Nervous system disorder;Neuritis;Neuropathy;Neuropathy peripheral;Neutropenia;Neutropenia aggravated;Neutrophil count decreased;Neutrophilia;Night sweats;Nightmare;Nocturia;Nuchal rigidity;Odynophagia;Oedema;Oedema mouth;Oedema peripheral;Oesophageal candidiasis;Oesophageal ulcer;Oesophagitis;Oral candidiasis;Oral herpes;Orthostatic hypotension;Pain;Pain in extremity;Pallor;Pancreatic enzymes increased;Pancreatitis;Pancytopenia;Paraesthesia;Paraplegia;Periorbital oedema;Petechiae;Pharyngitis;Phosphatase alkaline increased;Photophobia;Platelet count decreased;Platelet disorder;Pleuritic pain;Pneumonia;Pneumothorax;Pollakiuria;Postnasal drip;Proctalgia;Prothrombin level decreased;Prothrombin level increased;Prurigo;Pruritus;Pseudomonas infection;Psychotic depression;Psychotic disorder;Pulmonary embolism;Pulmonary hypertension;Pulmonary vasculitis;Purpura;Raised liver function tests;Rales;Rash;Rash erythematous;Rash follicular;Rash macular;Rash maculo-papular;Rash mouth;Rash vesicular;Rectal tenesmus;Renal failure;Renal failure acute;Renal impairment;Renal insufficiency aggravated;Renal tubular acidosis;Restless legs syndrome;Retching;Rhinitis;Rhinorrhoea;Rigors;Road traffic accident;Saliva altered;Sarcoidosis;Sciatica;Scotoma;Seborrhoeic dermatitis;Sepsis;Severe acute respiratory syndrome;Shock;Sinus tachycardia;Sinusitis;Skin disorder;Skin mass;Skin nodule;Sleep disorder;Solid tumour;Somnolence;Speech disorder;Splenomegaly;Stevens-Johnson syndrome;Stomatitis;Stupor;Sudden death;Supraventricular extrasystoles;Supraventricular tachycardia;Sweating increased;Syncope;Tachycardia;Taste disorders;Thirst;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thrombotic thrombocytopenic purpura;Tinnitus;Tongue discolouration;Tongue disorder;Tongue oedema;Tooth discolouration;Torsade de pointes;Transplant rejection;Trauma;Traumatic liver injury;Tremor;Tubulointerstitial nephritis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upper-airway cough syndrome;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urinary tract obstruction;Urine abnormality;Urine analysis abnormal;Urticaria;Vaginal haemorrhage;Vascular purpura;Vasculitis;Ventricular extrasystoles;Ventricular hypertrophy;Ventricular tachycardia;Vertigo;Vestibular disorder;Vision blurred;Vitamin K deficiency;Vomiting;Vomiting aggravated;Weight decreased;Weight increased;White blood cell count decreased,small molecule,approved; investigational; vet_approved,"Posaconazole; 1.14.13.70; CYP51; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; ERG16; Sterol 14-alpha demethylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Lanosterol 14-alpha demethylase,J02AC04
pralatrexate,Febrile neutropenia;Mucosal inflammation;Peripheral T-cell lymphoma unspecified;Renal failure chronic,Abdominal pain;Anaemia;Anorexia;Asthenia;Back pain;Body temperature increased;Cardio-respiratory arrest;Constipation;Cough;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Dyspnoea;Epistaxis;Fatigue;Gastrointestinal pain;Hypokalaemia;Laryngeal pain;Leukopenia;Liver function test abnormal;Nausea;Neoplasm malignant;Neutropenia;Night sweats;Oedema;Pain in extremity;Pancytopenia;Pharyngolaryngeal pain;Pruritus;Rash;Renal failure chronic;Sepsis;Tachycardia;Thrombocytopenia;Toxic epidermal necrolysis;Tumour lysis syndrome;Upper respiratory tract infection;Vomiting,small molecule,approved; investigational,"(2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid; (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid; 10-Propargyl-10-deazaaminopterin; N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid; PDX; Pralatrexate; Pralatrexato; Pralatrexatum; 1.5.1.3; 3.5.1.88; PDF1A; Polypeptide deformylase; 6.3.2.17; Folylpoly-gamma-glutamate synthetase; FPGS; Tetrahydrofolate synthase; Tetrahydrofolylpolyglutamate synthase; 2.1.1.45; TS; TSase; Cyclic dinucleotide:anion antiporter SLC19A1; FLOT1; Folate:anion antiporter SLC19A1; FOLT; hRFC; hSLC19A1; IFC-1; Intestinal folate carrier 1; Placental folate transporter; Reduced folate carrier protein; Reduced folate transporter 1; RFC; RFC1; RFT-1; Solute carrier family 19 member 1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; G21; HCP1; Heme carrier protein 1; hPCFT; HsPCFT; PCFT; PCFT/HCP1; Solute carrier family 46 member 1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8","Dihydrofolate reductase; Peptide deformylase, mitochondrial; Folylpolyglutamate synthase, mitochondrial; Thymidylate synthase",L01BA05
ospemifene,Atrophy;Dyspareunia;Menopause,Angiopathy;Breast disorder;Cardiovascular disorder;Cerebral haemorrhage;Connective tissue disorder;Deep vein thrombosis;Embolic stroke;Genital discharge;Haemorrhagic stroke;Hot flush;Hyperhidrosis;Menopausal symptoms;Muscle spasms;Neoplasm malignant;Skin disorder;Thromboembolic stroke;Unspecified disorder of skin and subcutaneous tissue;Vaginal discharge,small molecule,approved; investigational,"2-(4-(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol; 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol; Deamino-hydroxytoremifene; Ospemifene; Ospemifeno; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Estrogen receptor,G03XC05
temsirolimus,Mantle cell lymphoma;Mantle cell lymphoma refractory;Renal cell carcinoma,Abdominal distension;Abdominal pain;Abscess;Acne;Ageusia;Alanine aminotransferase increased;Alveolitis;Alveolitis allergic;Anaemia;Anal candidiasis;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anxiety;Aphthous stomatitis;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Bacterial infection;Bilirubin total increased;Bladder pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood glucose increased;Blood phosphorus decreased;Blood potassium decreased;Blood triglycerides increased;Body temperature increased;Bronchitis;Candida infection;Cardiac disorder;Cataract;Cellulitis;Cervicobrachial syndrome;Chest pain;Chills;Complex regional pain syndrome;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Creatinine increased;Cystitis;Cystitis noninfective;Decreased appetite;Deep vein thrombosis;Dehydration;Depression;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Dizziness;Dry skin;Duodenal perforation;Dysgeusia;Dysphagia;Dyspnoea;Dysuria;Ecchymosis;Eczema;Embolism venous;Eosinophilic pneumonia;Epistaxis;Erythema;Erythema multiforme;Exfoliative rash;Extravasation;Eye disorder;Eye haemorrhage;Face oedema;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling hot;Fluid retention;Folliculitis;Fungal infection;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Generalised oedema;Gingival bleeding;Gingivitis;Glossitis;Glucose increased;Glucose tolerance impaired;Haematuria;Haemoglobin decreased;Haemorrhage intracranial;Headache;Herpes simplex;Herpes virus infection;Herpes zoster;Hypercholesterolaemia;Hyperglycaemia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypocalcaemia;Hypokalaemia;Hypophosphataemia;Immune system disorder;Impaired healing;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal perforation;Lacrimal disorder;Lacrimal structural disorder;Laryngitis;Leukopenia;Lung disorder;Lymphocyte count decreased;Lymphopenia;Malnutrition;Mediastinal disorder;Mental disorder;Mouth haemorrhage;Mouth ulceration;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Nail disorder;Nausea;Nervous system disorder;Neutropenia;Oedema;Oedema genital;Oedema peripheral;Ophthalmic herpes zoster;Oral herpes;Oral pain;Pain;Pericardial effusion;Petechiae;Pharyngitis;Phosphatase alkaline increased;Phosphorus low;Platelet count decreased;Pleural effusion;Pneumocystis jirovecii pneumonia;Pneumonia;Pollakiuria;Postoperative wound infection;Potassium low;Prurigo;Pruritus;Pruritus generalised;Pulmonary embolism;Pulmonary fibrosis;Rash;Rash generalised;Rash macular;Rash maculo-papular;Rash papular;Rash pustular;Rectal haemorrhage;Reflex sympathetic dystrophy;Renal failure;Rhabdomyolysis;Rhinitis;Scrotal oedema;Sepsis;Septic shock;Sinusitis;Skin disorder;Skin infection;Somnolence;Stevens-Johnson syndrome;Stomatitis;Swelling;Thrombocytopenia;Thrombophlebitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Venous thromboembolism;Venous thrombosis;Vesiculobullous rash;Viral infection;Vomiting;Warmth;Weight decreased;White blood cell count decreased;Wound complication;Wound infection,small molecule,approved,"Temsirolimus; 2.7.11.1; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; FRAP; FRAP1; FRAP2; Mammalian target of rapamycin; Mechanistic target of rapamycin; mTOR; RAFT1; Rapamycin and FKBP12 target 1; Rapamycin target protein 1; RAPT1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Serine/threonine-protein kinase mTOR,L01EG01;L01XE09
atazanavir,Hepatitis B,Abdominal distension;Abdominal pain;Acholia;Affect lability;Agitation;Alanine aminotransferase increased;Alopecia;Amenorrhoea;Amnesia;Amylase increased;Angioedema;Angiopathy;Anorexia;Anxiety;Aphthous stomatitis;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrioventricular block;Atrioventricular block complete;Atrioventricular block second degree;Atrophy;Autoimmune disorder;Back pain;Basedow's disease;Bilirubin total increased;Block heart;Blood bilirubin increased;Blood triglycerides increased;Body temperature increased;Bone pain;Breast disorder;Breast enlargement;Buffalo hump;Bundle branch block left;Burning sensation;Calculus of kidney;Cardiac arrest;Cardiac disorder;Cellulitis;Chest pain;Cholecystitis;Cholelithiasis;Cholestasis;Chronic hepatitis B;Colitis;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cough;Cough increased;Crystalluria;Decreased appetite;Deficiency of bile secretion;Dehydration;Depression;Dermatitis;Dermatitis bullous;Dermatophytosis;Diabetes mellitus;Diarrhoea;Discomfort;Disorientation;Disturbance in sexual arousal;Dizziness;Drug eruption;Drug interaction;Dry mouth;Dry skin;Dysgeusia;Dyslipidaemia;Dyspepsia;Dysplasia;Dyspnoea;Ear infection;Ecchymosis;Eczema;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Enlargement abdomen;Eosinophilia;Erectile dysfunction;Eruption;Erythema multiforme;Eye disorder;Fasting;Fatigue;Feeling abnormal;Fertility male decreased;Flatulence;Fluid retention;Gait disturbance;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Generalised oedema;Gout;Gynaecomastia;Haematuria;Haemoglobin decreased;Hallucination;Headache;Heat intolerance;Hepatic steatosis;Hepatitis;Hepatitis C;Hepatitis viral;Hepatobiliary disease;Hepatocellular injury;Hepatomegaly;Hepatosplenomegaly;Hiccups;Hostility;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hyperlactacidaemia;Hyperreflexia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypertrophy of breast;Hypoaesthesia;Hypoglycaemia;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infertility male;Inflammation;Insomnia;Insulin resistance;Jaundice;Lactic acidosis;Libido decreased;Lipase increased;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Liver fatty deposition;Liver injury;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Menstrual disorder;Mental disorder;Mood swings;Mouth ulceration;Muscle atrophy;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myocarditis;Myopathy;Nail disorder;Nasal congestion;Nasopharyngitis;Nausea;Nephritis interstitial;Nephrolithiasis;Nervous system disorder;Nervousness;Neurological symptom;Neuropathy peripheral;Neutropenia;Obesity;Ocular icterus;Oedema;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Oliguria;Opportunistic infection;Oropharyngeal pain;Otitis;Pain;Pain in extremity;Pallor;Palpitations;Pancreatitis;Pelvic pain;Peptic ulcer;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polyuria;Protein urine present;Proteinuria;Pruritus;Psychotic disorder;Purpura;Rash;Rash maculo-papular;Rash pustular;Renal failure;Renal pain;Retrosternal pain;Rhinorrhoea;Scleral icterus;Seborrhoeic dermatitis;Shock;Skin disorder;Sleep disorder;Somnolence;Staphylococcal scalded skin syndrome;Stevens-Johnson syndrome;Stomatitis;Suicide attempt;Sweating;Syncope;Temperature intolerance;Tension;Tinnitus;Toothache;Torsade de pointes;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Vascular purpura;Vesiculobullous rash;Vomiting;Weight decreased;Weight increased;Wheezing,small molecule,approved; investigational,"Atazanavir; Atazanavirum; ATZ; Pr160Gag-Pol; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9",Pol polyprotein; Gag-Pol polyprotein, J05AR15; J05AR23;J05AE08
palonosetron,Nausea;Nausea postoperative;Neoplasm malignant;Procedural nausea;Vomiting,Abdominal distension;Abdominal pain;Abdominal pain upper;Alopecia;Amblyopia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Anorexia;Anxiety;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrioventricular block first degree;Atrioventricular block second degree;Body temperature increased;Bradycardia;Cardiac disorder;Chills;Connective tissue disorder;Constipation;Convulsion;Cyanosis;Decreased appetite;Dermatitis;Dermatitis atopic;Diarrhoea;Discomfort;Distention;Dizziness;Dizziness postural;Dry mouth;Dysgeusia;Dyskinesia;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram T wave amplitude decreased;Epistaxis;Erythema;Euphoric mood;Extrasystoles;Eye disorder;Eye irritation;Eye swelling;Fatigue;Feeling hot;Flatulence;Fluid retention;Gasping;Gastritis;Gastrointestinal disorder;Gastrointestinal hypomotility;Gastrointestinal pain;Generalised oedema;Glycosuria;Headache;Hepatic enzyme increased;Hepatobiliary disease;Hiccups;Hot flush;Hyperbilirubinaemia;Hyperglycaemia;Hyperkalaemia;Hypersensitivity;Hypersomnia;Hypertension;Hypocalcaemia;Hypokalaemia;Hypotension;Hypoventilation;Hypoxia;Immune system disorder;Induration;Infection;Influenza like illness;Infusion site pain;Injection site reaction;Insomnia;Intestinal hypomotility;Joint stiffness;Laryngospasm;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Metabolic acidosis;Metabolic disorder;Motion sickness;Musculoskeletal discomfort;Myalgia;Myocardial ischaemia;Nausea;Nervous system disorder;Pain;Pain in extremity;Pallor;Paraesthesia;Peripheral sensory neuropathy;Platelet count decreased;Prurigo;Pruritus;Pruritus generalised;Rash;Respiratory failure;Salivary hypersecretion;Shock;Sinus arrhythmia;Sinus bradycardia;Sinus tachycardia;Sinusitis;Skin disorder;Somnolence;Supraventricular extrasystoles;Tachycardia;Tinnitus;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Vasodilatation;Vein discolouration;Vein distended;Ventricular extrasystoles;Vomiting,small molecule,approved; investigational,"(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one; 2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one; Palonosetron; Palonosétron; Palonosetrón; Palonosetronum; 5-HT-3; 5-HT3-A; 5-HT3A; 5-HT3R; 5-hydroxytryptamine receptor 3; 5HT3R; HTR3; Serotonin receptor 3A; Serotonin-gated ion channel receptor; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",5-hydroxytryptamine receptor 3A, A04AA05;A04AA05;A04AA55
eplerenone,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Cardiac failure;Cardiac failure congestive;Diabetes mellitus;Diabetic nephropathy;Hyperlipidaemia;Hypertension;Hypotension;Left ventricular dysfunction;Left ventricular systolic dysfunction;Microalbuminuria;Myocardial infarction;Systolic dysfunction;Type 2 diabetes mellitus,Abdominal pain;Acute coronary syndrome;Alanine aminotransferase increased;Albuminuria;Anaemia;Angina pectoris;Angina unstable;Angioedema;Angiopathy;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Autonomic neuropathy;Back pain;Blood and lymphatic system disorders;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose increased;Blood potassium increased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Breast pain;Bronchitis;Cardiac disorder;Cardiovascular disorder;Cerebrovascular disorder;Chest pain;Cholecystitis;Cholesterol serum elevated;Connective tissue disorder;Constipation;Coronary artery disease;Cough;Creatine phosphokinase increased;Creatinine increased;Dehydration;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dyspepsia;Dyspnoea;Electrocardiogram abnormal;Endocrine disorder;Eosinophilia;Epidermal growth factor receptor decreased;Fatigue;Feeling abnormal;Flatulence;Flushing;Function kidney decreased;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gynaecomastia;Haematuria;Headache;Hepatobiliary disease;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypokalaemia;Hyponatraemia;Hypotension;Hypothyroidism;Ill-defined disorder;Infection;Infestation;Infestation NOS;Influenza like illness;Influenza-like symptoms;Insomnia;Kidney function abnormal;Left ventricular failure;Libido decreased;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Menstrual disorder;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Nausea;Nervous system disorder;Neuropathy peripheral;Oedema peripheral;Orthostatic hypotension;Pain;Pharyngitis;Pneumonia;Protein urine present;Proteinuria;Prothrombin level decreased;Pruritus;Pulmonary oedema;Rash;Red blood cell disorders;Renal failure;Renal impairment;Serum creatinine increased;Serum potassium increased;Serum triglycerides increased;Shock;Skin disorder;Sudden death;Syncope;Tinnitus;Unspecified disorder of autonomic nervous system;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Vaginal haemorrhage;Ventricular arrhythmia;Ventricular tachycardia;Vomiting,small molecule,approved,"Eplerenona; Eplerenone; Epoxymexrenone; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; ALDOS; Aldosterone synthase; Aldosterone-synthesizing enzyme; Corticosterone 18-monooxygenase, CYP11B2; CYPXIB2; Cytochrome P-450Aldo; Cytochrome P-450C18; Steroid 11-beta-hydroxylase, CYP11B2; Steroid 18-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3",Mineralocorticoid receptor,C03DA04
ezetimibe,Agitation;Arteriosclerosis;Atherosclerosis;Chronic kidney disease;Dyslipidaemia;Hepatic impairment;High density lipoprotein decreased;Homozygous familial hypercholesterolaemia;Hypercholesterolaemia;Hyperlipidaemia;Increased activity;Liver disorder;Low density lipoprotein increased;Mixed hyperlipidemia;Phytosterolaemia;Renal failure chronic;Type IIa hyperlipidaemia;Type V hyperlipidaemia;Weight decreased,Abdominal pain;Alanine aminotransferase increased;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Body temperature increased;Bone disorder;Breast disorder;Chest pain;Cholecystitis;Cholecystitis and cholelithiasis;Cholelithiasis;Cognitive disorder;Cognitive impairment;Confusional state;Connective tissue disorder;Constipation;Cough;Cramp muscle;Creatine phosphokinase increased;Decreased appetite;Dermatitis;Dermatomyositis;Diarrhoea;Discomfort;Dizziness;Drug interaction;Drug reaction with eosinophilia and systemic symptoms;Dry mouth;Dyspepsia;Dyspnoea;Eosinophilia;Erectile dysfunction;Erythema;Erythema multiforme;Fatigue;Feeling abnormal;Flatulence;Flushing;Foetor hepaticus;Forgetfulness;Gallbladder disorder;Gamma-glutamyltransferase increased;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Headache;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Heterozygous familial hypercholesterolemia;Homozygous familial hypercholesterolaemia;Hot flush;Hypersensitive syndrome;Hypersensitivity;Hypertension;Ill-defined disorder;Immune system disorder;Immune-mediated necrotising myopathy;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Insomnia;Interstitial lung disease;Jaundice;Liver disorder;Liver function test abnormal;Lupus-like syndrome;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Memory loss;Menopausal symptoms;Mental disorder;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myopathy;Nasopharyngitis;Nausea;Neck pain;Neoplasm malignant;Nervous system disorder;Neuropathy peripheral;Oedema peripheral;Pain;Pain in arm;Pain in extremity;Palpitations;Pancreatitis;Panniculitis;Paraesthesia;Pharyngitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Polymyalgia rheumatica;Pruritus;Rash;Red blood cell sedimentation rate increased;Rhabdomyolysis;Sinusitis;Skin disorder;Thrombocytopenia;Transaminases increased;Type IIa hyperlipidaemia;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Vasculitis;Viral infection;Vomiting,small molecule,approved,"Ezetimiba; ézétimibe; Ezetimibe; Ezetimibum; Niemann-Pick C1-like protein 1; NPC1L1; 2.3.1.26; ACACT; ACACT1; ACAT; ACAT-1; ACAT1; Acyl-coenzyme A:cholesterol acyltransferase 1; Cholesterol acyltransferase 1; SOAT; STAT; 3.4.11.2; Alanyl aminopeptidase; Aminopeptidase M; AP-M; AP-N; APN; CD13; gp150; hAPN; Microsomal aminopeptidase; Myeloid plasma membrane glycoprotein CD13; PEPN; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; HLUG4; UDP-glucuronosyltransferase 2B8; UDPGT 2B15; UDPGT 2B8; UDPGTh-3; UGT2B15; UGT2B8; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",NPC1-like intracellular cholesterol transporter 1; Sterol O-acyltransferase 1; Aminopeptidase N, C10AX09; C10BA05; C10BA06; C10BA10; C10BA11; C10BA12;C10AX09;C10BA02
ertapenem,Abdominal infection;Abortion infected;Bacteraemia;Bacterial infection;Community acquired pneumonia;Diabetes mellitus;Diabetic;Diabetic foot infection;Endometritis;Endomyometritis;Genital infection female;Gynecological infection;Infection;Infection mixed;Ischaemia;Osteomyelitis;Pelvic infection;Pneumonia;Pyelonephritis;Pyelonephritis acute;Renal failure;Renal impairment;Sepsis;Septicemia;Urinary tract infection,Abdominal abscess;Abdominal distension;Abdominal pain;Abdominal pain upper;Abortion;Acute renal insufficiency;Aggression;Agitation;Alanine aminotransferase increased;Altered state of consciousness;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Anastomotic leak;Angiopathy;Anorexia;Anuria;Anxiety;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Asthma;Atelectasis;Atrial fibrillation;Bladder dysfunction;Blood albumin decreased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood glucose increased;Blood potassium decreased;Blood potassium increased;Blood pressure increased;Blood urine;Blood urine present;Body temperature decreased;Body temperature increased;Bradycardia;Breast disorder;Bronchoconstriction;Bronchospasm;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac fibrillation;Cardiac murmur;Cellulitis;Cerebrovascular accident;Chest pain;Chills;Cholecystitis;Cholelithiasis;Clostridial infection;Clostridium colitis;Colitis;Confusional state;Connective tissue disorder;Constipation;Contusion;Convulsion;Coordination abnormal;Cough;Cramp muscle;Decreased appetite;Dehydration;Delirium;Depressed level of consciousness;Dermatitis;Dermatitis atopic;Dermatitis diaper;Diabetes mellitus;Diabetic;Diarrhoea;Discomfort;Disorientation;Dizziness;Drug eruption;Dry mouth;Duodenitis;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dysuria;Ear infection;Enteritis;Eosinophil count increased;Eosinophilia;Epistaxis;Epithelial cells urine;Erythema;Extravasation;Eye disorder;Face oedema;Faecal incontinence;Faeces discoloured;Fatigue;Feeling abnormal;Feeling hot;Flank pain;Flatulence;Flushing;Foetor hepaticus;Fungal infection;Fungal rash;Fungal skin infection;Gait disturbance;Gastric ulcer;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal stoma complication;Genital haemorrhage;Genital rash;Glucose increased;Gout;Grand mal convulsion;Haematochezia;Haematocrit decreased;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Haemorrhoids;Hallucination;Headache;Hepatobiliary disease;Hepatocellular injury;Herpes simplex;Hiccups;Hot flush;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoglycaemia;Hypotension;Hypothermia;Hypoxemia;Hypoxia;Ileus;Ill-defined disorder;Immune system disorder;Incision site complication;Incision site haemorrhage;Induration;Infection;Infestation;Infestation NOS;Infusion site burning;Infusion site erythema;Infusion site induration;Infusion site oedema;Infusion site pain;Infusion site phlebitis;Infusion site pruritus;Infusion site reaction;Infusion site swelling;Infusion site warmth;Injection site erythema;Injection site induration;Injection site pain;Injection site stinging;Insomnia;Intestinal stoma complication;Jaundice;Leg pain;Liver disorder;Loose stools;Loss of consciousness;Lung infiltration;Malaise;Malnutrition;Mediastinal disorder;Melaena;Menopausal symptoms;Mental disorder;Mental state abnormal;Mental status changes;Mouth ulceration;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myoclonus;Nasal congestion;Nasopharyngitis;Nausea;Necrosis;Nervous system disorder;Nervousness;Neutropenia;Neutrophil count decreased;Oedema;Oesophagitis;Oliguria;Oral candidiasis;Pain;Pain in elbow;Pain in extremity;Pancreatitis;Paraesthesia;Pelvic abscess;Pelvic peritonitis;Peripheral coldness;Peritonitis;Petechiae;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Platelet count decreased;Pleural effusion;Pleuritic pain;Pneumonia;Pneumothorax;Pollakiuria;Post procedural infection;Postoperative infection;Postoperative wound infection;Pregnancy;Protein urine present;Proteinuria;Prothrombin level increased;Pruritus;Pseudomembranous colitis;Pseudomembranous enterocolitis;Pulmonary congestion;Pulmonary embolism;Pyloric stenosis;Rales;Rash;Rash erythematous;Rash macular;Regurgitation;Renal failure acute;Respiratory distress;Respiratory tract congestion;Restless legs syndrome;Rhinitis;Rhinorrhoea;Rhonchi;Scleral disorder;Sepsis;Septic shock;Septicemia;Seroma;Serum albumin decreased;Serum bilirubin increased;Serum creatinine increased;Serum potassium decreased;Serum potassium increased;Shock;Shoulder pain;Sinus bradycardia;Skin disorder;Skin exfoliation;Skin lesion;Small intestinal obstruction;Somnolence;Stomatitis;Stupor;Subdural haematoma;Sweating;Swelling;Syncope;Tachycardia;Tension;Thirst;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Tongue disorder;Tongue oedema;Tonic-clonic seizures;Tooth discolouration;Toothache;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary retention;Urinary sediment present;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal dryness;Vaginal infection;Vaginal inflammation;Vaginal itching;Vaginal moniliasis;Vasculitis;Ventricular tachycardia;Vertigo;Viral infection;Viral pharyngitis;Voice disturbance;Vomiting;Vulvovaginal candidiasis;Vulvovaginal dryness;Vulvovaginal mycotic infection;Vulvovaginal pruritus;Vulvovaginitis;Warmth;Weight decreased;Wheezing;White blood cell count decreased;White blood cell count increased;Wound complication;Wound dehiscence;Wound infection;Wound secretion,small molecule,approved; investigational,"(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Ertapenem; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; PBP-2; pbp2; PBP-2; pbpA; 2.4.1.129; PBP-3; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; 3.4.16.4; D-alanyl-D-alanine endopeptidase; DD-carboxypeptidase; DD-endopeptidase; PBP-4; Penicillin-binding protein 4; 3.4.16.4; DD-carboxypeptidase; PBP-6; Penicillin-binding protein 6; 3.4.13.19; Beta-lactamase; Dehydropeptidase-I; hRDP; MDP; Microsomal dipeptidase; RDP; Renal dipeptidase",Penicillin-binding protein 1A; Penicillin-binding protein 1B; Penicillin-binding protein 2; Penicillin-binding protein 2; Peptidoglycan synthase FtsI; Peptidoglycan synthase FtsI; D-alanyl-D-alanine carboxypeptidase DacB; D-alanyl-D-alanine carboxypeptidase DacC,J01DH03
nepafenac,Diabetes mellitus;Diabetic;Extravasation;Inflammation;Injury;Macular oedema;Pain;Postoperative pain;Procedural pain;Trauma,Abnormal labour;Angiopathy;Arthritis;Bleeding time prolonged;Blepharitis;Blood pressure increased;Cataract;Choroidal effusion;Conjunctival hyperaemia;Conjunctival oedema;Conjunctivitis allergic;Corneal deposits;Corneal epithelium defect;Corneal oedema;Corneal opacity;Corneal scar;Corneal thinning;Cutis laxa;Dermatitis atopic;Dermatochalasis;Diabetes mellitus;Dizziness;Dry eye;Dry eye syndrome;Dry mouth;Endophthalmitis;Eye discharge;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Eye swelling;Eyelid disorder;Eyelid margin crusting;Foreign body sensation in eyes;Gastrointestinal disorder;Headache;Hypersensitivity;Hypertension;Immune system disorder;Impaired healing;Intraocular pressure increased;Iritis;Keratitis;Lacrimation;Lacrimation decreased;Lacrimation increased;Nausea;Nervous system disorder;Ocular discomfort;Ocular hyperaemia;Photophobia;Polymenorrhoea;Pregnancy;Pruritus;Punctate keratitis;Rheumatoid arthritis;Scab;Sensation of foreign body;Short period;Sinusitis;Skin disorder;Teratogenicity;Ulcerative keratitis;Unspecified disorder of skin and subcutaneous tissue;Vision blurred;Visual acuity reduced;Vitreous detachment;Vomiting,small molecule,approved; investigational,2-amino-3-benzoylbenzeneacetamide; Nepafenac; Népafénac; Nepafenaco; Nepafenacum; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2,Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2,S01BC10
aprepitant,Nausea;Nausea postoperative;Neoplasm malignant;Procedural nausea;Vomiting,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal bowel sounds;Acute coronary syndrome;Alanine aminotransferase increased;Alopecia;Altered state of consciousness;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety disorder;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blood albumin decreased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine increased;Blood creatinine increased;Blood glucose increased;Blood potassium decreased;Blood pressure increased;Blood urea increased;Blood urine;Blood urine present;Body temperature decreased;Body temperature increased;Bradycardia;Breast disorder;Candida infection;Cardiac disorder;Cardiovascular disorder;Chest discomfort;Chest pain;Chills;Cognitive disorder;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cramp muscle;Creatine increased;Cyst;Decreased appetite;Deep vein thrombosis;Dehydration;Depressed level of consciousness;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Disorientation;Dizziness;Dry mouth;Duodenal ulcer;Duodenal ulcer perforation;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Embolism;Enterocolitis;Epigastric discomfort;Eructation;Erythema;Erythema multiforme;Euphoric mood;Eye disorder;Faeces hard;Fasting;Fatigue;Febrile neutropenia;Feeling abnormal;Flatulence;Flushing;Gait disturbance;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal sounds abnormal;Gastrooesophageal reflux disease;Glycosuria;Haematoma;Haematuria;Haemoglobin decreased;Hallucination;Headache;Heartburn;Herpes simplex;Hiccups;Hot flush;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypokalaemia;Hyponatraemia;Hypotension;Hypothermia;Hypovolaemia;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Infection;Infestation;Infestation NOS;Infusion site erythema;Infusion site induration;Infusion site pain;Infusion site pruritus;Infusion site reactions;Infusion site thrombophlebitis;Infusion site thrombosis;Insomnia;Intraoperative hemorrhage;Laryngeal pain;Lethargy;Loss of consciousness;Lower respiratory tract infection;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Microscopic hematuria;Miosis;Mucosal inflammation;Mucous membrane disorder;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Nausea;Neoplasm;Nervous system disorder;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutropenic colitis;Neutropenic sepsis;Neutrophil count decreased;Non-small cell lung cancer;Obstipation;Oedema;Oily skin;Oral candidiasis;Oropharyngeal pain;Osteoarthritis;Pain;Palpitations;Paraesthesia;Pelvic pain;Peripheral sensory neuropathy;Pharyngitis;Pharyngolaryngeal pain;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polydipsia;Polyp;Polyuria;Post procedural infection;Postnasal drip;Postoperative infection;Procedural haemorrhage;Protein urine present;Proteinuria;Prurigo;Pruritus;Pulmonary embolism;Pulmonary function test decreased;Rash;Renal failure;Renal impairment;Respiratory depression;Respiratory failure;Respiratory insufficiency;Respiratory tract infection;Rigors;Salivary hypersecretion;Salivation;Seborrhoeic dermatitis;Sensory disturbance;Septic shock;Serum creatinine increased;Shock;Sinus tachycardia;Skin disorder;Skin lesion;Sneezing;Somnolence;Staphylococcal infection;Stevens-Johnson syndrome;Stomatitis;Subileus;Sweating increased;Syncope;Tachycardia;Thirst;Throat irritation;Thrombocytopenia;Thrombophlebitis;Tinnitus;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upper-airway cough syndrome;Upset stomach;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Visual acuity reduced;Vomiting;Weight decreased;Weight increased;Wheezing;White blood cell count decreased;White blood cell count increased;White blood cells urine positive;Wound dehiscence,small molecule,approved; investigational,"Aprepitant; Aprépitant; Aprepitantum; NK-1 receptor; NK-1R; NK1R; SPR; TAC1R; Tachykinin receptor 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Substance-P receptor,A04AD12
conivaptan,Adrenal insufficiency;Cardiac failure congestive;Hyponatraemia;Hyponatraemic;Hypothyroidism;Inappropriate antidiuretic hormone secretion;Lung disorder,Anaemia;Angiopathy;Arrhythmia supraventricular;Atrial arrhythmia;Atrial fibrillation;Blood and lymphatic system disorders;Body temperature increased;Candida infection;Cannula site reaction;Cardiac disorder;Cardiac failure;Catheter site related reaction;Confusional state;Constipation;Dehydration;Diarrhoea;Dry mouth;Electrocardiogram ST segment depression;Erythema;Feeling abnormal;Gastrointestinal disorder;Haematuria;Headache;Hyperglycaemia;Hypertension;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypotension;Infection;Infestation;Infestation NOS;Infusion site erythema;Infusion site pain;Infusion site phlebitis;Infusion site reaction;Infusion site reactions;Infusion site swelling;Insomnia;Laryngeal pain;Malnutrition;Mediastinal disorder;Mental disorder;Nausea;Nervous system disorder;Oedema peripheral;Oral candidiasis;Orthostatic hypotension;Osmotic demyelination syndrome;Pain;Pharyngolaryngeal pain;Phlebitis;Pneumonia;Pollakiuria;Polyuria;Post procedural diarrhoea;Pruritus;Sepsis;Skin disorder;Thirst;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Vomiting,small molecule,approved; investigational,"4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide; Conivaptan; Antidiuretic hormone receptor 1a; AVPR V1a; AVPR1; V1aR; Vascular/hepatic-type arginine vasopressin receptor; ADHR; Antidiuretic hormone receptor; AVPR V2; DIR; DIR3; Renal-type arginine vasopressin receptor; V2R; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Vasopressin V1a receptor; Vasopressin V2 receptor,C03XA02
dutasteride,Benign prostatic hyperplasia;Diuresis;Polyuria;Prostatomegaly,Angioedema;Anorgasmia;Breast cancer;Breast cancer male;Breast disorder;Breast enlargement;Breast pain;Breast swelling;Breast tenderness;Cardiac failure;Depressed mood;Dermatitis;Disturbance in sexual arousal;Dizziness;Ejaculation delayed;Ejaculation disorder;Ejaculation failure;Erectile dysfunction;Gynaecomastia;Hepatic adenoma;Hepatocellular adenoma;Hyperaesthesia;Hypersensitivity;Immune system disorder;Libido decreased;Libido disorder;Localised oedema;Loss of libido;Male sexual dysfunction;Mental disorder;Neoplasm;Neoplasm malignant;Nipple pain;Nipple swelling;Orgasm abnormal;Orgasmic sensation decreased;Premature ejaculation;Prostate cancer;Pruritus;Rash;Retrograde ejaculation;Semen volume decreased;Sexual dysfunction;Tenderness;Testicular pain;Testicular swelling;Urticaria,small molecule,approved; investigational,"(5α,17β)-N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; Dutasterida; Dutasteride; α,α,α,α',α',α'-hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2',5'-xylidide; 1.3.1.22; S5AR 1; SR type 1; Steroid 5-alpha-reductase 1; 1.3.1.94; 3-oxo-5-alpha-steroid 4-dehydrogenase 3; S5AR 3; SR type 3; SRD5A2L; Steroid 5-alpha-reductase 2-like; Steroid 5-alpha-reductase 3; 1.3.1.22; 5 alpha-SR2; S5AR 2; SR type 2; Steroid 5-alpha-reductase 2; Type II 5-alpha reductase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; AGP 1; AGP1; OMD 1; Orosomucoid-1; DA transporter; Dat; Dat1; Solute carrier family 6 member 3; Monoamine transporter; Solute carrier family 18 member 2; VAT2; Vesicular amine transporter 2; Vmat2",3-oxo-5-alpha-steroid 4-dehydrogenase 1; Polyprenal reductase; 3-oxo-5-alpha-steroid 4-dehydrogenase 2, G04CA52;G04CB02
entecavir,Alanine aminotransferase increased;Chronic hepatitis B;Decompensated cirrhosis;Fibrosis;Foetor hepaticus;HBV coinfection;Hepatic cirrhosis;Hepatitis B;Hepatitis B e antigen positive;Hepatocellular injury;Infection;Inflammation;Liver disorder;Viral infection,Abdominal pain;Abdominal pain upper;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Ascites;Asthenia;Blood and lymphatic system disorders;Blood bicarbonate decreased;Blood creatinine increased;Body temperature increased;Decompensated cirrhosis;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Fatigue;Gastrointestinal disorder;Gastrointestinal pain;Glycosuria;Haematuria;Headache;Hepatic cancer;Hepatic cirrhosis;Hepatic encephalopathy;Hepatic failure;Hepatitis;Hepatitis B;Hepatitis B e antigen positive;Hepatobiliary disease;Hepatocellular carcinoma;Hepatomegaly;Hepatorenal syndrome;Hyperglycaemia;Immune system disorder;Immunodeficiency;Infection;Infection mixed;Insomnia;Laboratory test abnormal;Lactase deficiency;Lactic acidosis;Lactose intolerance;Leukopenia;Malnutrition;Mental disorder;Nausea;Nervous system disorder;Neutropenia;Oedema peripheral;Pancreatitis;Platelet count decreased;Product taste abnormal;Rash;Renal failure;Serum creatinine increased;Skin disorder;Somnolence;Transaminases increased;Unspecified disorder of skin and subcutaneous tissue;Upper gastrointestinal haemorrhage;Upper respiratory tract infection;Viraemia;Vomiting,small molecule,approved; investigational,Anhydrous entecavir; Entecavir; Entecavir (anhydrous); Entecavir anhydrous; Entecavirum,DNA,J05AF10
clevidipine,Essential hypertension;Hypertension;Hypertensive,Acute coronary syndrome;Atrial fibrillation;Blood triglycerides increased;Dyspnoea;Headache;Hypersensitivity;Hypotension;Ileus;Myocardial infarction;Nausea;Oxygen saturation decreased;Reflex tachycardia;Renal failure acute;Tachycardia;Vomiting,small molecule,approved; investigational,"Clevidipine; Clevidipine butyrate; Clevidipino; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase",Voltage-dependent L-type calcium channel subunit alpha-1F; Voltage-dependent L-type calcium channel subunit alpha-1S; Voltage-dependent L-type calcium channel subunit alpha-1D; Voltage-dependent L-type calcium channel subunit alpha-1C,C08CA16
solifenacin,Hypertonic bladder;Micturition urgency;Pollakiuria;Urge incontinence,Abdominal pain;Abdominal pain upper;Airway obstruction NOS;Anaphylactic shock;Angioedema;Angiopathy;Asthenia;Atrial fibrillation;Bladder pain;Cardiac disorder;Colon obstruction;Confusional state;Connective tissue disorder;Constipation;Cough;Cystitis;Cystitis noninfective;Decreased appetite;Delirium;Depression;Dermatitis;Dermatitis exfoliative;Dizziness;Drug - food interaction;Drug interaction;Dry eye;Dry mouth;Dry skin;Dry throat;Dysgeusia;Dyspepsia;Dysphonia;Dysuria;Edema of lower extremities;Erythema multiforme;Eye disorder;Faecalith;Faecaloma;Fatigue;Feeling abnormal;Foetor hepaticus;Food interaction;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Glaucoma;Hallucination;Headache;Hepatobiliary disease;Hepatocellular injury;Hyperkalaemia;Hypersensitivity;Hypertension;Ileus;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Intestinal obstruction;Large intestinal obstruction;Liver disorder;Liver function test abnormal;Malnutrition;Mediastinal disorder;Mental disorder;Muscular weakness;Nasal dryness;Nausea;Nervous system disorder;Obstructive airways disorder;Oedema peripheral;Palpitations;Pharyngitis;Pruritus;Rash;Renal failure;Renal impairment;Skin disorder;Somnolence;Strangury;Tachycardia;Torsade de pointes;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vision blurred;Vomiting,small molecule,approved,"Solifenacin; Solifenacina; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2",Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; Muscarinic acetylcholine receptor M1, G04CA53;G04BD08
bazedoxifene,Fracture;Hip fracture;Menopausal symptoms;Multiple fractures;Osteoporosis;Osteoporosis postmenopausal,Alanine aminotransferase increased;Angiopathy;Aspartate aminotransferase increased;Blepharospasm;Blood triglycerides increased;Bone disorder;Cardiac disorder;Cramps of lower extremities;Deep vein thrombosis;Dermatitis;Dry eye;Dry mouth;Embolism;Eye disorder;Eye pain;Eye swelling;Eyelid oedema;Gastrointestinal disorder;Hot flush;Hypersensitivity;Immune system disorder;Mediastinal disorder;Menopausal symptoms;Muscle spasms;Nervous system disorder;Oedema peripheral;Palpitations;Photopsia;Pruritus;Pulmonary embolism;Rash;Retinal vein thrombosis;Scotoma;Skin disorder;Somnolence;Thromboembolic event;Thrombophlebitis superficial;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vision blurred;Visual acuity reduced;Visual impairment,small molecule,approved; investigational,Bazedoxifene; Bazedoxifeno; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 1-J; UDPGT 1-10; UGT-1J; UGT1; UGT1-10; UGT1.10; UGT1*10; UGT1A10; UGT1J,Estrogen receptor; Estrogen receptor beta, G03CC07;G03XC02
asenapine,Bipolar I disorder;Bipolar disorder;Dementia;Mania;Parkinsonism;Schizoaffective disorder;Schizophrenia,Abdominal discomfort;Accommodation disorder;Agitation;Agranulocytosis;Akathisia;Alanine aminotransferase increased;Amenorrhoea;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anxiety;Arthralgia;Asthenia;Blister;Blood cholesterol increased;Blood disorder;Blood prolactin increased;Blood triglycerides increased;Breast disorder;Bundle branch block;Cardiac disorder;Completed suicide;Connective tissue disorder;Constipation;Convulsion;Depression;Depressive symptom;Dermatitis;Dermatitis bullous;Diabetes mellitus;Dizziness;Drug withdrawal syndrome neonatal;Dry mouth;Dysarthria;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Electrocardiogram QT prolonged;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Fatigue;Galactorrhoea;Gastrointestinal disorder;Glossodynia;Gynaecomastia;Headache;Hepatobiliary disease;High cholesterol;Hyperglycaemia;Hyperprolactinaemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypoaesthesia oral;Hyponatraemia;Hypotension;Idiosyncratic drug reaction;Immune system disorder;Increased appetite;Increased prolactin level;Inflammation;Insomnia;Irritability;Leukopenia;Liver injury;Localized exfoliation;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Mouth ulceration;Movements involuntary;Muscle rigidity;Muscle spasms;Musculoskeletal discomfort;Nausea;Nervous system disorder;Neuroleptic malignant syndrome;Neutropenia;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Pain in extremity;Paraesthesia oral;Parkinsonism;Pharyngeal oedema;Pregnancy;Psychotic disorder;Pulmonary embolism;Rash;Restless legs syndrome;Rhabdomyolysis;Salivary hypersecretion;Schizophrenia;Sexual dysfunction;Shock;Sickness;Sinus bradycardia;Sinus tachycardia;Skin exfoliation;Somnolence;Stomatitis;Suicidal ideation;Suicide;Swelling;Swollen tongue;Syncope;Tachycardia;Tardive dyskinesia;Throat tightness;Thrombocytopenia;Toothache;Traumatic liver injury;Tremor;Ulcer;Upset stomach;Vomiting;Weight increased;Wheezing,small molecule,approved,"Asenapina; Asenapine; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; Dopamine D2 receptor; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 5-HT-1B; 5-HT-1D-beta; 5-HT1B; HTR1DB; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-5; 5-HT-5A; 5-HT5A; Serotonin receptor 5A; 5-HT-6; 5-HT6; Serotonin receptor 6; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; Dopamine D3 receptor; D(2C) dopamine receptor; Dopamine D4 receptor; Dopamine D1 receptor; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; H1-R; H1R; HH1R; Gastric receptor I; H2R; HH2R; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 2.4.1.17; Bilirubin-specific UDPGT isozyme 2; GNT1; hUG-BR2; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-D; UDPGT 1-4; UGT-1D; UGT1; UGT1-04; UGT1.4; UGT1*4; UGT1A4; UGT1D; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2",5-hydroxytryptamine receptor 2A; D(2) dopamine receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 5A; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; D(3) dopamine receptor; D(4) dopamine receptor; D(1A) dopamine receptor; Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Histamine H1 receptor; Histamine H2 receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor,N05AH05
cinacalcet,Carcinoma;Chronic kidney disease;Hypercalcaemia;Hyperparathyroidism primary;Hyperparathyroidism secondary;Neoplasm malignant;Renal failure chronic,Abdominal pain;Anaemia;Angioedema;Anorexia;Arrhythmia;Arthralgia;Asthenia;Body temperature increased;Bone disorder;Carcinoma;Cardiac failure;Chest pain;Chronic kidney disease;Constipation;Convulsion;Cough;Cramp muscle;Decreased appetite;Dehydration;Depression;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Dyspnoea;Fatigue;Fracture;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Headache;Hypercalcaemia;Hyperparathyroidism primary;Hypersensitivity;Hypertension;Hypocalcaemia;Hypotension;Immune system disorder;Infection;Malnutrition;Metastatic carcinoma;Metastatic neoplasm;Multi-organ failure;Multiple fractures;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Neoplasm malignant;Nervous system disorder;Oedema peripheral;Pain in extremity;Paraesthesia;Pruritus;Rash;Renal failure chronic;Skin disorder;Tetany;Thrombosis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Ventricular arrhythmia;Vomiting,small molecule,approved,"(R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine; Cinacalcet; CNC; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; CaR; CaSR; GPRC2A; hCasR; Parathyroid cell calcium-sensing receptor 1; PCAR1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",Extracellular calcium-sensing receptor,H05BX01
vinflunine,Transitional cell carcinoma,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abscess;Acidosis;Acute coronary syndrome;Acute respiratory distress syndrome;Ageusia;Agitation;Alanine aminotransferase increased;Alopecia;Altered state of consciousness;Anaemia;Anal haemorrhage;Angiopathy;Anorexia;Anxiety;Arterial disorder;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Bacteraemia;Bladder pain;Blister;Blood and lymphatic system disorders;Blood disorder;Body temperature increased;Bone pain;Breast disorder;Bronchiolitis obliterans with organizing pneumonia;Bronchitis;Bronchospasm;Cancer pain;Candida infection;Cardiac disorder;Cardio-respiratory arrest;Cardiovascular disorder;Catheter related infection;Chest pain;Chills;Colonic pseudo-obstruction;Condition aggravated;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cough;Cyst;Cystitis;Cystitis noninfective;Death;Decreased appetite;Deep vein thrombosis;Dehydration;Depressed level of consciousness;Dermatitis;Dermatitis bullous;Dermatitis exfoliative;Device related infection;Diarrhoea;Discomfort;Disorientation;Disseminated intravascular coagulation;Dizziness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dyspnoea exertional;Dysuria;Ear and labyrinth disorders;Ear pain;Early satiety;Electrocardiogram ST segment abnormal;Endocrine disorder;Epigastric discomfort;Epistaxis;Eructation;Erythema;Escherichia sepsis;Extravasation;Eye disorder;Facial pain;Faecal incontinence;Faeces discoloured;Fatigue;Febrile neutropenia;Feeling abnormal;Flank pain;Flatulence;Flushing;Gastric disorder;Gastric ulcer haemorrhage;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gingival bleeding;Gingival pain;Glossodynia;Gout;Groin pain;Haematemesis;Haematuria;Haemoptysis;Haemorrhoids;Headache;Hepatic pain;Hepatobiliary disease;Herpes virus infection;Hiccups;Hot flush;Hyperaesthesia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypersomnia;Hypertension;Hypoaesthesia;Hypoalbuminaemia;Hypoglycaemia;Hypomagnesaemia;Hyponatraemia;Hypotension;Hypotrichosis;Hypovolaemia;Hypovolaemic shock;Ileus;Ileus paralytic;Ill-defined disorder;Immune system disorder;Inappropriate antidiuretic hormone secretion;Infection;Infestation;Infestation NOS;Inflammation;Influenza like illness;Infusion related reaction;Infusion site erythema;Infusion site pain;Infusion site phlebitis;Injection site dermatitis;Injection site erythema;Injection site hypersensitivity;Injection site irritation;Injection site pain;Injection site phlebitis;Injection site reaction;Injection site urticaria;Insomnia;Intestinal obstruction;Ischaemia;Joint stiffness;Laryngeal pain;Lethargy;Leukopenia;Lip dry;Loss of consciousness;Lung disorder;Lymphoedema;Malaise;Malnutrition;Mediastinal disorder;Melaena;Menopausal symptoms;Mental disorder;Metastatic pain;Micturition disorder;Mouth ulceration;Mucosal inflammation;Muscle contracture;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Nail disorder;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Neoplasm malignant;Nervous system disorder;Neuralgia;Neuritis;Neuropathy;Neuropathy peripheral;Neutropenia;Neutropenic infection;Neutropenic sepsis;Neutrophil count increased;Night sweats;Nocturia;Non-cardiac chest pain;Odynophagia;Oedema;Oedema peripheral;Oesophagitis;Oral candidiasis;Oral discomfort;Oral disorder;Oral infection;Oral mucosal disorder;Oral pain;Organising pneumonia;Orthostatic hypotension;Pain;Pain in extremity;Pain in jaw;Pain of skin;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Paraesthesia oral;Pelvic pain;Penile discharge;Penile pain;Peripheral coldness;Peripheral motor neuropathy;Peripheral sensory neuropathy;Pharyngolaryngeal pain;Phlebitis;Phlebitis superficial;Pigmentation disorder;Pneumonia;Pollakiuria;Polyp;Posterior reversible encephalopathy syndrome;Presyncope;Proctalgia;Productive cough;Pruritus;Pruritus generalised;Pulmonary embolism;Pulmonary oedema;Purpura;Pyelonephritis;Rash;Renal colic;Renal failure;Retching;Retinal vein thrombosis;Rhinitis seasonal;Saliva altered;Seasonal allergy;Sepsis;Septic shock;Shock;Sinus tachycardia;Skin discolouration;Skin disorder;Skin exfoliation;Skin lesion;Sleep disorder;Small intestinal obstruction;Stomatitis;Subileus;Supraventricular extrasystoles;Swollen tongue;Syncope;Syncope vasovagal;Tachycardia;Thrombocytopenia;Thrombophlebitis;Thrombophlebitis superficial;Tinnitus;Tongue blistering;Toothache;Transaminases increased;Tremor;Trismus;Tumour pain;Unspecified disorder of intestine;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Ureterostomy site discomfort;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular purpura;Vasculitis;Vasospasm;Venous thrombosis;Vertigo;Vertigo positional;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vitreous floaters;Vomiting;Weight decreased;Weight increased;Wound infection,small molecule,approved; investigational,"20',20'-difluoro-3',4'-dihydrovinorelbine; 4'-deoxy-20',20'-difluoro-5'-norvincaleukoblastine; 4'-deoxy-20',20'-difluoro-8'-norvincaleukoblastine; Vinflunina; Vinflunine; Vinfluninum; TUBB5; Tubulin beta-5 chain; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ABCB5 P-gp; P-glycoprotein ABCB5; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Tubulin beta chain,L01CA05
lubiprostone,Cancer pain;Chronic idiopathic constipation;Constipation;Functional gastrointestinal disorder;Irritable bowel syndrome;Opioid induced constipation,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal rigidity;Abdominal tenderness;Alanine aminotransferase increased;Anorexia;Anxiety;Aspartate aminotransferase increased;Asthenia;Blood potassium decreased;Chest discomfort;Chest pain;Chronic idiopathic constipation;Cold sweat;Colitis ischaemic;Connective tissue disorder;Constipation;Cough;Cramp muscle;Decreased appetite;Defaecation urgency;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Electrolyte imbalance;Eructation;Erythema;Faecal incontinence;Faeces hard;Fatigue;Feeling abnormal;Fibromyalgia;Flatulence;Frequent bowel movements;Functional gastrointestinal disorder;Gastritis;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Headache;Hyperhidrosis;Hypersensitivity;Ill-defined disorder;Influenza;Intestinal functional disorder;Joint swelling;Laryngeal pain;Lethargy;Loose stools;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Oedema;Oedema peripheral;Pain;Palpitations;Pharyngolaryngeal pain;Pollakiuria;Rash;Rectal haemorrhage;Shock;Skin disorder;Swelling;Syncope;Tachycardia;Throat tightness;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upset stomach;Urinary tract infection;Vomiting;Weight increased,small molecule,approved; investigational,Lubiprostone; ClC-2; 1.1.1.184; 15-hydroxyprostaglandin dehydrogenase [NADP(+)]; 20-beta-hydroxysteroid dehydrogenase; Alcohol dehydrogenase [NAD(P)+] CBR1; CBR; CRN; NADPH-dependent carbonyl reductase 1; PG-9-KR; Prostaglandin 9-ketoreductase; Prostaglandin-E(2) 9-reductase; SDR21C1; Short chain dehydrogenase/reductase family 21C member 1,Chloride channel protein 2,A06AX03
olmesartan,Acute coronary syndrome;Angina pectoris;Cardiac failure;Diabetes mellitus;Diabetic;Diabetic nephropathy;Hyperlipidaemia;Hypertension;Hypertensive;Hypotension;Myocardial infarction,Abdominal pain;Acute bronchitis;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Angiitis necrotising;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Aplastic anaemia;Appetite absent;Arrhythmia;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthenic conditions;Back pain;Bilirubin value increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose increased;Blood potassium decreased;Blood potassium increased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bone pain;Bronchitis;Chest pain;Connective tissue disorder;Constipation;Cough;Creatine phosphokinase increased;Cutaneous vasculitis;Decreased appetite;Dermatitis;Diabetes mellitus;Diabetic;Diarrhoea;Discomfort;Dizziness;Dyspepsia;Ear and labyrinth disorders;Eczema;Electrolyte imbalance;Eosinophilia;Epigastric discomfort;Erectile dysfunction;Face oedema;Fatigue;Feeling abnormal;Gamma-glutamyltransferase increased;Gastric irritation;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Glycosuria;Gout;Haematuria;Haemolytic anaemia;Headache;Hepatic enzyme increased;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hypertriglyceridaemia;Hyperuricaemia;Hypokalaemia;Hyponatraemia;Hypotension;Hypovolaemia;Ill-defined disorder;Infection;Infestation;Infestation NOS;Inflicted injury;Influenza;Influenza like illness;Influenza-like symptoms;Injury;Insomnia;Jaundice;Jaundice cholestatic;Laryngeal pain;Lethargy;Leukopenia;Lightheadedness;Loss of consciousness;Lupus erythematosus;Malabsorption;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Microalbuminuria;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Nephritis interstitial;Nervous system disorder;Neutropenia;Oedema;Oedema peripheral;Orthostatic hypotension;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancytopenia;Pharyngitis;Pharyngolaryngeal pain;Photosensitivity reaction;Pneumonia;Pruritus;Pseudohyperkalaemia;Rash;Renal failure;Renal failure acute;Respiratory distress;Rhabdomyolysis;Rhinitis;Rhinorrhoea;Shock;Sialoadenitis;Sinusitis;Skin disorder;Sleep disorder;Sleep disturbance;Spinal disorder;Spondyloarthropathy;Sprue;Syncope;Systemic lupus erythematosus;Tachycardia;Thrombocytopenia;Toothache;Toxic epidermal necrolysis;Tracheobronchitis;Transaminases increased;Tubulointerstitial nephritis;Unspecified disorder of intestine;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vasculitis;Vasculitis necrotising;Vertigo;Viral infection;Viral upper respiratory tract infection;Vision blurred;Vomiting;Xanthopsia,small molecule,approved; investigational,"4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; Olmesartan; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP",Type-1 angiotensin II receptor, C09CA08; C09DB02; C09DX03;C09DA08
pegaptanib,Age-related macular degeneration,Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anterior chamber inflammation;Arthritis;Blepharitis;Bone spur;Bronchitis;Carotid artery occlusion;Cataract;Cataract traumatic;Cerebrovascular accident;Chest pain;Conjunctival haemorrhage;Conjunctival oedema;Conjunctivitis;Conjunctivitis allergic;Contusion;Corneal abrasion;Corneal deposits;Corneal disorder;Corneal epithelium disorder;Corneal oedema;Deafness;Dermatitis contact;Diabetes mellitus;Diarrhoea;Dizziness;Dyspepsia;Endophthalmitis;Exostosis;Eye discharge;Eye irritation;Eye pain;Eye swelling;Eyelid irritation;Headache;Hearing impaired;Hypertension;Intraocular pressure increased;Meibomianitis;Mydriasis;Nausea;Ocular discomfort;Panophthalmitis;Periorbital haematoma;Photopsia;Pleural effusion;Punctate keratitis;Retinal detachment;Retinal oedema;Transient ischaemic attack;Urinary retention;Urinary tract infection;Vertigo;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vitreous disorder;Vitreous floaters;Vitreous haemorrhage;Vitreous opacities;Vomiting,biotech,approved; investigational,Pegaptanib Octasodium; Pegaptanib sodium; L-VEGF; Vascular permeability factor; VEGF; VPF,"Vascular endothelial growth factor A, long form",S01LA03
sevelamer,Chronic kidney disease;Constipation;Hyperphosphataemia;Renal failure chronic,Abdominal distension;Abdominal pain;Angiopathy;Anorexia;Arthralgia;Asthenia;Back pain;Body temperature increased;Bone disorder;Bronchitis;Catheter site infection;Chest pain;Constipation;Cough;Cough increased;Decreased appetite;Dermatitis;Diarrhoea;Dyspepsia;Dyspnoea;Faecalith;Faecaloma;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hypercalcaemia;Hypertension;Hypotension;Ileus;Infection;Infestation;Infestation NOS;Intestinal obstruction;Intestinal perforation;Mechanical complication of implant;Mediastinal disorder;Medical device complication;Musculoskeletal discomfort;Nasopharyngitis;Nausea;Nervous system disorder;Pain;Pain in extremity;Peritonitis;Pruritus;Rash;Skin disorder;Thrombosis;Upper respiratory tract infection;Vomiting,small molecule,approved,Sevelamer; Sévélamer; Sevelamero; Sevelamerum,Phosphate,V03AE02
colesevelam,Arteriosclerosis;Atherosclerosis;Blood triglycerides increased;Cardiovascular disorder;Coronary artery disease;Coronary heart disease;Diabetes mellitus;Diabetic ketoacidosis;Dyslipidaemia;Heterozygous familial hypercholesterolemia;High density lipoprotein decreased;Hypercholesterolaemia;Hyperlipidaemia;Hypertension;Hypertriglyceridaemia;Intestinal obstruction;Low density lipoprotein increased;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Type II hyperlipidaemia;Type IIa hyperlipidaemia,Abdominal distension;Abdominal pain;Abnormal faeces;Accidental injury;Acute coronary syndrome;Aortic valve stenosis;Asthenia;Back pain;Blister;Blood triglycerides increased;Bradycardia;Connective tissue disorder;Constipation;Convulsion;Cough;Cough increased;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diabetic;Diarrhoea;Drug interaction;Dyspepsia;Dysphagia;Faecalith;Faecaloma;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Haemorrhoids;Headache;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypoglycaemia;Infection;Influenza;Injury;Intestinal obstruction;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nasopharyngitis;Nausea;Nervous system disorder;Oesophageal obstruction;Pain;Pancreatitis;Pancreatitis acute;Pharyngitis;Rash;Rhinitis;Serum triglycerides increased;Sinusitis;Transaminases increased;Upper respiratory tract infection;Vomiting,small molecule,approved,Colesevelam,Bile acids,C10AC04
tipranavir,Acquired immunodeficiency syndrome;Autoimmune disorder;Drug interaction,"Abdominal distension;Abdominal pain;Abdominal pain upper;Alanine aminotransferase increased;Amylase increased;Anaemia;Anorexia;Aspartate aminotransferase increased;Asthenia;Autoimmune disorder;Basedow's disease;Blood and lymphatic system disorders;Blood bilirubin increased;Blood disorder;Blood triglycerides increased;Body temperature increased;Bone disorder;Breast enlargement;Bronchitis;Buffalo hump;Chills;Connective tissue disorder;Constipation;Cough;Cramp muscle;Cyst;Cytolytic hepatitis;Cytomegalovirus chorioretinitis;Decreased appetite;Dehydration;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Drug eruption;Dyspepsia;Dyspnoea;Epistaxis;Erythema;Erythema multiforme;Facial wasting;Fatal outcomes;Fatigue;Feeling abnormal;Flatulence;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haemarthrosis;Haemoglobin;Haemorrhage;Haemorrhage intracranial;Headache;Hepatic enzyme increased;Hepatic failure;Hepatic impairment;Hepatic steatosis;Hepatitis;Hepatitis B;Hepatitis toxic;Hepatobiliary disease;Hepatotoxicity;Herpes simplex;Herpes zoster;Hyperamylasaemia;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperlipidaemia;Hypersensitivity;Hypertriglyceridaemia;Hypertrophy of breast;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Inflammation;Influenza like illness;Insomnia;Insulin resistance;Jaundice;Lipase increased;Lipoatrophy;Lipodystrophy acquired;Lipohypertrophy;Liver disorder;Liver function test abnormal;Loose stools;Lymphoma;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Mitochondrial toxicity;Muscle haemorrhage;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myositis;Nausea;Neoplasm;Nervous system disorder;Neuropathy peripheral;Neutropenia;Non-Hodgkin's lymphoma;Oesophageal candidiasis;Opportunistic infection;Pain;Pancreatitis;Pneumocystis jirovecii pneumonia;Pneumonia;Pneumonia due to Streptococcus, group b;Pneumonia streptococcal;Polyp;Pregnancy;Progressive multifocal leukoencephalopathy;Prurigo;Pruritus;Rash;Rash macular;Rash maculo-papular;Rash papular;Renal failure;Renal failure acute;Renal impairment;Retching;Rhabdomyolysis;Rigors;Skin disorder;Sleep disorder;Somnolence;Stevens-Johnson syndrome;Thrombocytopenia;Toxic epidermal necrolysis;Transaminases increased;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Varicella zoster;Vomiting;Weight decreased;White blood cell count decreased;White blood cell count low",small molecule,approved; investigational,"Tipranavir; Pr160Gag-Pol; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Gag-Pol polyprotein; Pol polyprotein,J05AE09
Anidulafungin,Abdominal abscess;Abscess;Aspergillosis;Aspergillus infection;Candida infection;Candidemia;Endocarditis;Fungal infection;Infection;Invasive candidiasis;Meningitis;Oesophageal candidiasis;Osteomyelitis;Peritonitis;Systemic candida,Abdominal pain;Abdominal pain upper;Alanine aminotransferase increased;Amylase increased;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Aspartate aminotransferase increased;Atrial fibrillation;Back pain;Bacteraemia;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood potassium decreased;Blood urea increased;Body temperature increased;Bronchospasm;Bundle branch block;Bundle branch block right;Candida infection;Cardiac disorder;Cerebrovascular accident;Chest pain;Chills;Cholestasis;Clostridial infection;Coagulopathy;Confusional state;Connective tissue disorder;Constipation;Convulsion;Cough;Creatine phosphokinase increased;Decubitus ulcer;Deep vein thrombosis;Dehydration;Depression;Dermatitis;Diarrhoea;Dizziness;Drug level decreased;Dyspepsia;Dyspepsia aggravated;Dyspnoea;Electrocardiogram QT prolonged;Erythema;Eye disorder;Eye pain;Faecal incontinence;Feeling abnormal;Flushing;Fungaemia;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hepatic enzyme increased;Hepatic necrosis;Hepatobiliary disease;Hot flush;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypernatraemia;Hypersensitivity;Hypertension;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hypotension;Immune system disorder;Infection;Infestation;Infestation NOS;Infusion related reaction;Infusion site pain;Injection site reaction;Insomnia;Leukocytosis;Leukopenia;Lipase increased;Liver function test abnormal;Loose stools;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Multi-organ failure;Nausea;Nervous system disorder;Neutropenia;Oedema peripheral;Oral candidiasis;Phlebitis;Pleural effusion;Pneumonia;Potassium low;Prothrombin level increased;Pruritus;Pruritus generalised;Rash;Rash maculo-papular;Rash papular;Respiratory distress;Rigors;Sepsis;Sinus arrhythmia;Skin disorder;Sweating increased;Systemic candida;Thrombocytopenia;Thrombocytosis;Thrombophlebitis superficial;Unspecified disorder of skin and subcutaneous tissue;Urea increased;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Ventricular extrasystoles;Vision blurred;Visual disturbance;Visual impairment;Vomiting;White blood cell count decreased;White blood cell count increased,biotech,approved; investigational,"Anidulafungin; Anidulafungina; Anidulafungine; Anidulafunginum; 1,3-beta-D-glucan-UDP glucosyltransferase; 2.4.1.34; fks1; 1,3-beta-D-glucan-UDP glucosyltransferase; 2.4.1.34; FK506 sensitivity protein 2; FKS2; GLS2; Glucan synthase of cerevisiae protein 2","1,3-beta-glucan synthase component FKS1; 1,3-beta-glucan synthase component GSC2",J02AX06
varenicline,Bronchial hyperreactivity;Cardiovascular disorder;Chronic obstructive pulmonary disease;Function kidney decreased;Renal impairment;Schizoaffective disorder;Schizophrenia;Suicidal behaviour,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal behaviour;Abnormal dreams;Abnormal faeces;Accidental injury;Acne;Acquired night blindness;Acute coronary syndrome;Affect lability;Aggression;Agitation;Amnesia;Anaemia;Anger;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Aphthous stomatitis;Arrhythmia;Arthralgia;Arthritis;Asthenia;Asthma;Atrial fibrillation;Back pain;Balance disorder;Blindness transient;Blood and lymphatic system disorders;Blood calcium decreased;Blood pressure increased;Body temperature increased;Bradycardia;Bradyphrenia;Breast disorder;Bronchitis;C-reactive protein increased;Cardiac disorder;Cardiac flutter;Cataract subcapsular;Cerebrovascular accident;Change of bowel habit;Chest discomfort;Chest pain;Chest wall pain;Chills;Circadian rhythm sleep disorder;Completed suicide;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cor pulmonale;Coronary artery disease;Costochondritis;Cough;Cramp muscle;Cyst;Deafness;Decreased appetite;Delusion;Depressed mood;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Disorientation;Dissociation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug hypersensitivity;Drug withdrawal syndrome;Dry eye;Dry mouth;Dry skin;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dysphoria;Dyspnoea;Ear and labyrinth disorders;Eczema;Electrocardiogram ST segment depression;Electrocardiogram T wave amplitude decreased;Electrocardiogram abnormal;Emotional disorder;Endocrine disorder;Enterocolitis;Epidermal and dermal conditions;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Eye irritation;Eye pain;Facial paralysis;Fatigue;Feeling abnormal;Flatulence;Frustration;Fungal infection;Gallbladder disorder;Gastric ulcer;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival pain;Gingivitis;Glycosuria;Haematemesis;Haematochezia;Hallucination;Headache;Hepatobiliary disease;Hoarseness;Homicidal ideation;Hostility;Hot flush;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypertonia;Hypoaesthesia;Hypogeusia;Hypoglycaemia;Hypokalaemia;Hypotension;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza like illness;Initial insomnia;Injury;Insomnia;Intestinal obstruction;Irritability;Joint stiffness;Lacrimation increased;Laryngeal pain;Lethargy;Leukocytosis;Libido decreased;Libido increased;Liver function test abnormal;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mania;Mediastinal disorder;Meniere's disease;Menopausal symptoms;Menorrhagia;Menstrual disorder;Mental disability;Mental disorder;Mental retardation;Middle insomnia;Migraine;Mood swings;Mouth ulceration;Multiple sclerosis;Muscle enzyme increased;Muscle spasms;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Mydriasis;Myocardial infarction;Myopia;Myositis;Nasopharyngitis;Nausea;Nephrolithiasis;Nervous system disorder;Neurological disorders NEC;Night blindness;Night sweats;Nightmare;Nocturia;Nystagmus;Ocular vascular disorder;Oedema;Oedema peripheral;Oesophagitis;Osteoarthritis;Osteoporosis;Pain;Palpitations;Pancreatitis acute;Panic reaction;Paranoia;Parosmia;Peripheral ischaemia;Peripheral vascular disorder;Pharyngolaryngeal pain;Photophobia;Photosensitivity reaction;Platelet count decreased;Pleurisy;Pollakiuria;Polydipsia;Polyuria;Postnasal drip;Pruritus;Psoriasis;Psychomotor skills impaired;Psychotic disorder;Pulmonary embolism;Rash;Rash generalised;Renal failure acute;Respiratory disorders NEC;Respiratory tract congestion;Restless legs syndrome;Rhinitis allergic;Rhinorrhoea;Salivary gland conditions;Salivary hypersecretion;Scleral discolouration;Scotoma;Semen abnormal;Semen analysis abnormal;Sensory disturbance;Sexual dysfunction;Shock;Sinus congestion;Sinusitis;Skin disorder;Sleep disorder;Sleep disturbance;Snoring;Somnambulism;Somnolence;Splenomegaly;Stevens-Johnson syndrome;Stomatitis;Suicidal ideation;Suicide;Suicide attempt;Syncope;Tachycardia;Tenderness;Terminal insomnia;Thinking abnormal;Thirst;Throat irritation;Thrombocytopenia;Thrombosis;Thyroid disorder;Tinnitus;Tongue coated;Toothache;Transient ischaemic attack;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract inflammation;Upper-airway cough syndrome;Upset stomach;Urethral disorder;Urethral syndrome;Urinary retention;Urinary tract disorder;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;VIIth nerve paralysis;Vaginal discharge;Varicose vein;Ventricular extrasystoles;Vertigo;Viral infection;Vision blurred;Visual disturbance;Visual impairment;Vitreous floaters;Vomiting;Weight increased;Withdrawal symptom,small molecule,approved; investigational,Vareniclina; Varenicline; Vareniclinum; NACRA4; NACHRA7; NACHRA3; hOCT2; OCT2; Organic cation transporter 2,Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit alpha-7; Neuronal acetylcholine receptor subunit alpha-3; Neuronal acetylcholine receptor subunit alpha-6; Neuronal acetylcholine receptor subunit beta-2, N07BA03;N07BA03;S01XA28
erlotinib,Malignant neoplasm of pancreas;Metastases to pancreas;Neoplasm;Neoplasm malignant;Non-small cell lung cancer;Pancreatic carcinoma;Pancreatic carcinoma metastatic;Solid tumour,Abdominal pain;Acne;Acute coronary syndrome;Acute respiratory distress syndrome;Alanine aminotransferase increased;Alopecia;Anorexia;Anxiety;Arrhythmia;Arthralgia;Asthenia;Back pain;Blister;Body temperature increased;Bone pain;Cardiovascular disorder;Cellulitis;Cerebral haemorrhage;Cerebrovascular accident;Chest pain;Chills;Colitis;Conjunctivitis;Connective tissue disorder;Constipation;Corneal perforation;Cough;Decreased appetite;Deep vein thrombosis;Dehydration;Depression;Dermatitis;Dermatitis acneiform;Dermatitis bullous;Diarrhoea;Disease progression;Dizziness;Drug interaction;Dry eye;Dry skin;Dyspepsia;Dysphagia;Dyspnoea;Epistaxis;Erythema;Erythema multiforme;Eye disorder;Fatal outcomes;Fatigue;Flatulence;Foetor hepaticus;Folliculitis;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Haematemesis;Haematochezia;Haemoglobin;Haemolytic anaemia;Haemorrhage;Headache;Hepatic cancer metastatic;Hepatic failure;Hepatic impairment;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hepatorenal syndrome;Hepatotoxicity;Hirsutism;Hypokalaemia;Ileus;Infection;Infestation;Infestation NOS;Inflammation;Insomnia;Interstitial lung disease;Interstitial pneumonia;Intestinal perforation;Ischaemia;Keratitis;Keratoconjunctivitis sicca;Liver disorder;Loss of consciousness;Lung disorder;Lung infection;Lung infiltration;Malnutrition;Mediastinal disorder;Melaena;Mental disorder;Metastases to liver;Microangiopathic haemolytic anaemia;Mucosal inflammation;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Myopathy;Nail changes;Nail disorder;Nausea;Nephritis;Nervous system disorder;Neuropathy;Neuropathy peripheral;Neutropenia;Obliterative bronchiolitis;Oedema;Pain;Pancreatic carcinoma;Pancreatitis;Papulopustular rash;Paronychia;Peptic ulcer;Peptic ulcer haemorrhage;Pneumonia;Protein urine present;Proteinuria;Pruritus;Pulmonary fibrosis;Pulmonary toxicity;Pustule;Rash;Rash pustular;Renal failure;Renal failure acute;Renal impairment;Rhabdomyolysis;Rigors;Rosacea;Sepsis;Shock;Skin disorder;Skin exfoliation;Skin fissures;Skin hyperpigmentation;Stevens-Johnson syndrome;Stomatitis;Syncope;Tenderness;Thrombocytopenia;Toxic epidermal necrolysis;Ulcerative keratitis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Uveitis;Vomiting;Weight decreased,small molecule,approved; investigational,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; Erlotinib; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 2.7.10.1; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.7.10.1; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; AGP 1; AGP1; OMD 1; Orosomucoid-1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9",Nuclear receptor subfamily 1 group I member 2; Epidermal growth factor receptor,L01EB02;L01XE03
eslicarbazepine,Convulsion;Corynebacterium infection;Diphtheria;Epilepsy;Hepatitis B;Infection;Pertussis;Poliomyelitis;Tetanus,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Affect lability;Agitation;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Apathy;Aphasia;Appetite absent;Application site pain;Arrhythmia;Asthenia;Ataxia;Atrioventricular block;Attention deficit disorder;Attention deficit/hyperactivity disorder;Balance disorder;Blood and lymphatic system disorders;Blood chloride decreased;Blood pressure increased;Body temperature increased;Bone marrow depression;Bone metabolism disorder;Bradycardia;Brain oedema;Burning sensation;Cardiac disorder;Cerebellar syndrome;Chest pain;Chills;Coagulopathy;Confusional state;Connective tissue disorder;Constipation;Coordination abnormal;Crying;Crying abnormal;Deafness;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Dizziness;Drowsiness;Drug toxicity;Dry mouth;Dry skin;Dysaesthesia;Dysarthria;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Electrocardiogram PR prolongation;Electrolyte imbalance;Encephalitis;Encephalopathy;Endocrine disorder;Endophthalmitis;Epistaxis;Erythema;Erythema multiforme;Eye disorder;Eye movement disorder;Eye rolling;Facial paralysis;Fatigue;Febrile convulsion;Feeling abnormal;Flat affect;Flatulence;Flushing;Foetor hepaticus;Fracture;Gait disturbance;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gingivitis;Guillain-Barre syndrome;Haematocrit decreased;Haemoglobin;Haemoglobin decreased;Haemorrhage;Headache;Hearing impaired;Hepatobiliary disease;Hepatocellular injury;High-pitched crying;Hyperhidrosis;Hypersensitivity;Hypersomnia;Hypertension;Hypertensive crisis;Hypochloraemia;Hyponatraemia;Hypotension;Hypothyroidism;Hypotonia;Hypotonic-hyporesponsive episode;Ill-defined disorder;Immune system disorder;Induration;Injection site pain;Injection site tenderness;Insomnia;Instillation site pain;Irritability;Lethargy;Leukopenia;Liver disorder;Loss of consciousness;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Melaena;Memory impairment;Mental disorder;Migraine;Mood swings;Multiple fractures;Muscle relaxant therapy;Muscular weakness;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Nervousness;Neuritis;Neuropathy peripheral;Nystagmus;Ocular hyperaemia;Oedema;Oedema peripheral;Optic neuritis;Orthostatic hypotension;Oscillopsia;Osteoarthritis;Osteocalcin increased;Osteopenia;Osteoporosis;Pain in extremity;Pallor;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Parosmia;Peripheral coldness;Petechiae;Pruritus;Psychomotor retardation;Psychotic disorder;Purpura;Rash;Redness;Shock;Skin disorder;Sleep disorder;Somnolence;Speech disorder;Stevens-Johnson syndrome;Strabismus;Stridor;Stridor inspiratory;Swelling;Syncope;Systemic lupus erythematosus;Tension;Thermal burn;Thrombocytopenia;Thrombocytopenic purpura;Tinnitus;Toothache;Toxicity to various agents;Transaminases increased;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;VIIth nerve paralysis;Vascular purpura;Vertigo;Vision blurred;Visual impairment;Vomiting;Weight decreased,small molecule,approved,"Eslicarbazepina; Eslicarbazepine; S(+)-Liscarbazepine; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; ATP receptor; P2X4; Purinergic receptor; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Sodium channel protein type 11 subunit alpha; P2X purinoceptor 4,N03AF04
etravirine,Cross resistance;Dermatitis;HIV infection;Human immunodeficiency virus type;Infection;Pathogen resistance;Rash,Abdominal distension;Abdominal pain;Abnormal dreams;Ache;Acute coronary syndrome;Amnesia;Anaemia;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Asthenia;Atrial fibrillation;Autoimmune disorder;Basedow's disease;Blister;Blood and lymphatic system disorders;Blood disorder;Blood triglycerides increased;Body temperature increased;Breast disorder;Breast enlargement;Bronchospasm;Buffalo hump;Cardiac disorder;Cerebral haemorrhage;Chronic hepatitis B;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cytolytic hepatitis;Decreased appetite;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Discomfort;Disorientation;Disturbance in attention;Dizziness;Drug hypersensitivity;Dry mouth;Dry skin;Dyslipidaemia;Dyspnoea exertional;Ear and labyrinth disorders;Eosinophilia;Erythema multiforme;Eye disorder;Fatigue;Feeling abnormal;Flatulence;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gynaecomastia;Haematemesis;Haemoglobin decreased;Haemolytic anaemia;Haemorrhagic stroke;Headache;Hepatic failure;Hepatic steatosis;Hepatitis;Hepatitis B;Hepatitis C;Hepatobiliary disease;Hepatomegaly;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlipidaemia;Hypersensitivity;Hypersomnia;Hypertension;Hypertriglyceridaemia;Hypertrophy of breast;Hypoaesthesia;Ill-defined disorder;Immune system disorder;Infection;Infection mixed;Inflammation;Insomnia;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Neuropathy peripheral;Night sweats;Nightmare;Opportunistic infection;Oral disorder;Oral lesion;Osteonecrosis;Pain;Pancreatitis;Paraesthesia;Prurigo;Rash;Rash vesicular;Renal failure;Renal failure acute;Retching;Rhabdomyolysis;Shock;Skin disorder;Sleep disorder;Sluggishness;Somnolence;Stevens-Johnson syndrome;Stomatitis;Swelling face;Syncope;Tension;Thrombocytopenia;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vertigo;Vision blurred;Vomiting,small molecule,approved,"Etravirina; Etravirine; Pr160Gag-Pol; Pr160Gag-Pol; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.1; ATP-binding cassette sub-family B member 4; MDR3; Multidrug resistance protein 3; P-glycoprotein 3; PGY3",Gag-Pol polyprotein; Gag-Pol polyprotein; Reverse transcriptase/RNaseH,J05AG04
ambrisentan,Connective tissue disorder;Hypertension;Idiopathic pulmonary arterial hypertension;Primary pulmonary hypertension;Pulmonary arterial hypertension,Abdominal pain;Abdominal pain upper;Anaemia;Angina pectoris;Angioedema;Angiopathy;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Autoimmune hepatitis;Blood and lymphatic system disorders;Blood disorder;Body temperature increased;Breast disorder;Bronchitis;Cardiac disorder;Cardiac failure;Chest discomfort;Chest pain;Constipation;Contusion;Cough;Cramp muscle;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dyspnoea;Dyspnoea exacerbated;Epistaxis;Fatigue;Fluid retention;Flushing;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Haematocrit decreased;Haemoglobin;Haemoglobin decreased;Haemorrhage;Headache;Hepatic congestion;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatotoxicity;Hypersensitivity;Hypokalaemia;Hypotension;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Liver injury;Loss of consciousness;Malnutrition;Mediastinal disorder;Mental disorder;Migraine;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nocturia;Non-cardiac chest pain;Oedema;Oedema peripheral;Palpitations;Pharyngitis;Pleural effusion;Pneumonia;Pruritus;Pulmonary hypertension;Pulmonary oedema;Pulmonary veno-occlusive disease;Rales;Rash;Rhinitis;Right ventricular failure;Shock;Sinus headache;Sinusitis;Skin ulcer;Sleep disorder;Sperm concentration decreased;Sperm count decreased;Syncope;Tachycardia;Transaminases increased;Traumatic liver injury;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Vaginal haemorrhage;Vomiting;Wheezing,small molecule,approved; investigational,"(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy- 3,3-diphenylpropanoic acid; Ambrisentan; Endothelin receptor type A; ET-A; ETA; ETA-R; ETRA; hET-AR; Endothelin receptor non-selective type; ET-B; ET-BR; ETRB; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Endothelin-1 receptor; Endothelin receptor type B, C02KX52;C02KX02
dronedarone,Atrial fibrillation;Atrial flutter;Cardiac failure;Left ventricular dysfunction;Left ventricular systolic dysfunction;Persistent atrial fibrillation;Sinus rhythm,Abdominal pain;Acute hepatic failure;Ageusia;Anaphylactic shock;Angioedema;Angiopathy;Asthenia;Asthenic conditions;Atrial flutter;Blood creatinine increased;Bradycardia;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Dermatitis;Dermatitis atopic;Diarrhoea;Dysgeusia;Dyspepsia;Dyspeptic signs and symptoms;Eczema;Erythema;Fatigue;Gastrointestinal disorder;Gastrointestinal pain;Hepatobiliary disease;Hypokalaemia;Hypomagnesaemia;Immune system disorder;Interstitial lung disease;Leukocytoclastic vasculitis;Liver injury;Mediastinal disorder;Nausea;Nervous system disorder;Photosensitivity reaction;Pneumonia;Pruritus;Pulmonary fibrosis;Pulmonary toxicity;Rash;Rash erythematous;Skin disorder;Traumatic liver injury;Unspecified disorder of skin and subcutaneous tissue;Vasculitis;Vomiting,small molecule,approved,"Dronedarona; Dronedarone; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide; N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; HPCN1; Voltage-gated potassium channel HK2; Voltage-gated potassium channel subunit Kv1.5; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; ADRA2L1; ADRA2RL1; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2BAR; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; CACH2; CACN2; CACNL1A1; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; Voltage-gated calcium channel subunit alpha Cav1.2; CACH3; CACN4; CACNL1A2; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CCHL1A2; Voltage-gated calcium channel subunit alpha Cav1.3; CACNAF1; Voltage-gated calcium channel subunit alpha Cav1.4; CACH1; CACN1; CACNL1A3; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; Voltage-gated calcium channel subunit alpha Cav1.1; CAB1; CACNLB1; Calcium channel voltage-dependent subunit beta 1; CAB2; CACNLB2; Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B; MYSB; CAB3; CACNLB3; Calcium channel voltage-dependent subunit beta 3; CAB4; CACNLB4; Calcium channel voltage-dependent subunit beta 4; K2P2.1; Outward rectifying potassium channel protein TREK-1; TREK; TREK-1 K(+) channel subunit; TREK1; Two pore domain potassium channel TREK1; Two pore potassium channel TPKC1; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; GIRK-1; GIRK1; Inward rectifier K(+) channel Kir3.1; Potassium channel, inwardly rectifying subfamily J member 3; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1; KCNA8; KCNA9; KQT-like 1; KVLQT1; Voltage-gated potassium channel subunit Kv7.1; Inward rectifier K(+) channel Kir2.2; Inward rectifier K(+) channel Kir2.2v; IRK-2; IRK2; KCNJN1; Potassium channel, inwardly rectifying subfamily J member 12; Inward rectifier K(+) channel Kir2.4; IRK-4; IRK4; Potassium channel, inwardly rectifying subfamily J member 14; Cardiac inward rectifier potassium channel; hIRK1; Inward rectifier K(+) channel Kir2.1; IRK-1; IRK1; Potassium channel, inwardly rectifying subfamily J member 2; Hippocampal inward rectifier; HIR; HIRK2; HRK1; Inward rectifier K(+) channel Kir2.3; IRK-3; IRK3; Potassium channel, inwardly rectifying subfamily J member 4; CNC; Na(+)/Ca(2+)-exchange protein 1; NCX1; Solute carrier family 8 member 1; Potassium voltage-gated channel subfamily D member 3; Voltage-gated potassium channel subunit Kv4.3; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; c-erbA-1; c-erbA-alpha; EAR-7; EAR7; ERBA1; NR1A1; Nuclear receptor subfamily 1 group A member 1; THRA1; THRA2; V-erbA-related protein 7; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.-; Albendazole monooxygenase (hydroxylating); Albendazole monooxygenase (sulfoxide-forming); Arachidonic acid epoxygenase; CYPIIJ2; Hydroperoxy icosatetraenoate isomerase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT2; OCT2; Organic cation transporter 2; hOCT1; OCT1; Organic cation transporter 1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Alpha-1A adrenergic receptor; Potassium voltage-gated channel subfamily A member 5; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Voltage-gated inwardly rectifying potassium channel KCNH2; Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent L-type calcium channel subunit alpha-1D; Voltage-dependent L-type calcium channel subunit alpha-1F; Voltage-dependent L-type calcium channel subunit alpha-1S; Voltage-dependent L-type calcium channel subunit beta-1; Voltage-dependent L-type calcium channel subunit beta-2; Voltage-dependent L-type calcium channel subunit beta-3; Voltage-dependent L-type calcium channel subunit beta-4; Potassium channel subfamily K member 2; Sodium channel protein type 5 subunit alpha; G protein-activated inward rectifier potassium channel 1; Potassium voltage-gated channel subfamily KQT member 1; Inward rectifier potassium channel; Sodium/calcium exchanger 1; A-type voltage-gated potassium channel KCND3; Beta-1 adrenergic receptor; Thyroid hormone receptor alpha,C01BD07
ramelteon,Insomnia,Anaphylactic shock;Anaphylactoid reaction;Arthralgia;Asthenia;Blood cortisol decreased;Chronic insomnia;Depression;Diarrhoea;Dizziness;Dysgeusia;Fatigue;Headache;Influenza;Insomnia;Insomnia exacerbated;Mental disability;Musculoskeletal discomfort;Myalgia;Nausea;Somnolence;Thinking abnormal;Upper respiratory tract infection,small molecule,approved; investigational,"Ramelteon; Mel-1B-R; Mel1b receptor; Mel-1A-R; Mel1a receptor; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",Melatonin receptor type 1B; Melatonin receptor type 1A,N05CH02
lapatinib,Breast cancer;Breast cancer stage IV;Disease progression;Menopause;Metastatic disease;Metastatic neoplasm;Neoplasm,Abdominal pain;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Angiopathy;Anorexia;Arthralgia;Asthenia;Back pain;Blood and lymphatic system disorders;Blood bilirubin increased;Blood disorder;Cardiac disorder;Cardiac failure;Cardiotoxicity;Connective tissue disorder;Constipation;Cough;Decreased appetite;Dehydration;Dermatitis;Dermatitis acneiform;Diarrhoea;Dry skin;Dyspepsia;Dyspnoea;Ejection fraction decreased;Epistaxis;Fatigue;Gastrointestinal disorder;Gastrointestinal pain;Haemoglobin decreased;Headache;Hepatobiliary disease;Hepatotoxicity;Hot flush;Hyperbilirubinaemia;Hypersensitivity;Immune system disorder;Infection;Infestation;Infestation NOS;Insomnia;Interstitial lung disease;Left ventricular ejection fraction decreased;Leukopenia;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Metastatic disease;Metastatic neoplasm;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Nail disorder;Nausea;Neoplasm malignant;Nervous system disorder;Neuropathy peripheral;Neutropenia;Pain in extremity;Palpitations;Paronychia;Peripheral sensory neuropathy;Pneumonia;Pruritus;Rash;Renal failure acute;Skin disorder;Stomatitis;Unspecified disorder of skin and subcutaneous tissue;Vomiting,small molecule,approved; investigational,"Lapatinib; N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine; 2.7.10.1; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; 2.7.11.20; Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase; eEF-2 kinase; eEF-2K; 2.7.10.1; HER2; Metastatic lymph node gene 19 protein; MLN 19; MLN19; NEU; NGL; p185erbB2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.4.2.14; ABCB2; APT1; ATP-binding cassette sub-family B member 2; Peptide supply factor 1; Peptide transporter involved in antigen processing 1; Peptide transporter PSF1; Peptide transporter TAP1; PSF-1; PSF1; Really interesting new gene 4 protein; RING4; Y3",Epidermal growth factor receptor; Eukaryotic elongation factor 2 kinase; Receptor tyrosine-protein kinase erbB-2,L01EH01;L01XE07
dabigatran,Atrial fibrillation;Cerebrovascular accident;Deep vein thrombosis;Embolism;Pulmonary embolism;Thromboembolic event,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Alanine aminotransferase increased;Allergic oedema;Anaemia;Anaemia postoperative;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blood and lymphatic system disorders;Blood bilirubin increased;Blood urine present;Bloody discharge;Bone disorder;Bronchitis;Bronchospasm;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Catheter site haemorrhage;Cerebral haemorrhage;Chest discomfort;Chest pain;Compartment syndrome;Connective tissue disorder;Constipation;Contusion;Cough;Dermatitis;Diarrhoea;Dizziness;Drug hypersensitivity;Dyspepsia;Dysphagia;Dyspnoea;Dyspnoea exertional;Ecchymosis;Embolic stroke;Epigastric discomfort;Epistaxis;Fatal outcomes;Fatigue;Flatulence;Gastric haemorrhage;Gastritis;Gastritis erosive;Gastritis haemorrhagic;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal ulcer;Gastrooesophageal reflux disease;Gastrooesophagitis;Gout;Haemarthrosis;Haematocrit decreased;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhagic erosive gastritis;Haemorrhagic stroke;Haemorrhoidal haemorrhage;Headache;Hemorrhage symptom;Hepatic enzyme increased;Hepatic function abnormal;Hepatitis viral;Hepatobiliary disease;Hyperbilirubinaemia;Hypersensitivity;Hypertension;Hypotension;Immune system disorder;Incision site haemorrhage;Infection;Infestation;Infestation NOS;Influenza;Injection site haemorrhage;Intraspinal bleeding;Liver function test abnormal;Loss of consciousness;Major bleed;Malnutrition;Mediastinal disorder;Musculoskeletal discomfort;Musculoskeletal pain;Myocardial infarction;Nasopharyngitis;Nausea;Nervous system disorder;Occult blood positive;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Osteoarthritis;Pain in extremity;Palpitations;Pericardial haemorrhage;Pneumonia;Post procedural discharge;Post procedural haematoma;Post procedural haemorrhage;Pruritus;Rash;Rectal haemorrhage;Retroperitoneal haemorrhage;Shock;Sinusitis;Skin disorder;Skin haemorrhage;Spinal cord haemorrhage;Subarachnoid haemorrhage;Surgery;Surgical intervention;Syncope;Thrombocytopenia;Thromboembolic stroke;Thrombosis;Transaminases increased;Traumatic haemorrhage;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urogenital haemorrhage;Urticaria;Vomiting;Wound;Wound haemorrhage;Wound secretion,small molecule,approved; investigational,Dabigatran; 3.4.21.5; Coagulation factor II,Prothrombin,B01AE07
darunavir,Factor XI deficiency;Immunodeficiency;Infection;Infection mixed,Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal dreams;Acute coronary syndrome;Acute generalised exanthematous pustulosis;Acute myocardial infarction;Acute respiratory distress syndrome;Affect lability;Ageusia;Agitation;Alanine aminotransferase increased;Alopecia;Altered state of consciousness;Amylase increased;Anaemia;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Aphthous stomatitis;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Autoimmune disorder;B-cell lymphoma;Basedow's disease;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine decreased;Blood creatinine increased;Blood thyroid stimulating hormone increased;Blood triglycerides increased;Blood uric acid increased;Body temperature increased;Bradycardia;Breast disorder;Breast enlargement;Buffalo hump;Burning mouth syndrome;Cardiac disorder;Cerebrovascular accident;Cheilitis;Chest pain;Chills;Cholestasis;Chronic hepatitis B;Clostridial infection;Completed suicide;Confusional state;Congenital musculoskeletal anomaly;Conjunctival hyperaemia;Connective tissue disorder;Constipation;Convulsion;Cough;Creatinine low;Cryptosporidiosis infection;Cytolytic hepatitis;Decreased appetite;Dermatitis;Dermatitis atopic;Diabetes mellitus;Diarrhoea;Discomfort;Disorientation;Disturbance in attention;Disturbance in sexual arousal;Dizziness;Drug eruption;Drug hypersensitivity;Drug interaction;Dry eye;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Eczema;Electrocardiogram abnormal;Encephalitis cytomegalovirus;Endocrine disorder;Eosinophil count increased;Eosinophilia;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Eye disorder;Eye swelling;Facial paralysis;Fat redistribution;Fatigue;Feeling abnormal;Feeling hot;Flatulence;Flushing;Folliculitis;Gamma-glutamyltransferase increased;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gout;Grand mal convulsion;Gynaecomastia;Haematemesis;Haematuria;Haemoglobin;Haemorrhage;Headache;Hepatic cancer;Hepatic cirrhosis;Hepatic enzyme increased;Hepatic failure;Hepatic steatosis;Hepatitis;Hepatitis B;Hepatitis C;Hepatitis acute;Hepatitis viral;Hepatobiliary disease;Hepatomegaly;Hepatotoxicity;Herpes simplex;Hiccups;High density lipoprotein decreased;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlactacidaemia;Hyperlipidaemia;Hypernatraemia;Hypersensitivity;Hypertension;Hypertriglyceridaemia;Hypertrophy of breast;Hyperuricaemia;Hypoaesthesia;Hypoalbuminaemia;Hypocalcaemia;Hypoglycaemia;Hyponatraemia;Hypothyroidism;Ill-defined disorder;Immune system disorder;Increased appetite;Infestation;Infestation NOS;Inflammation;Insomnia;Insulin resistance;Irritability;Ischaemic cerebral infarction;Jaundice;Joint stiffness;Lethargy;Leukopenia;Libido decreased;Lip dry;Lipase increased;Lipoatrophy;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Liver function test abnormal;Loss of consciousness;Low density lipoprotein increased;Lymphoma;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Mental disorder;Metabolic acidosis;Mood swings;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocarditis;Myositis;Nail pigmentation;Nasopharyngitis;Nausea;Neoplasm;Nephrolithiasis;Nervous system disorder;Neuromyopathy;Neuropathy peripheral;Neutropenia;Night sweats;Nightmare;Nocturia;Non-Hodgkin's lymphoma;Obesity;Oedema peripheral;Oesophageal candidiasis;Opportunistic infection;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancreatitis acute;Pancreatitis chronic;Pancytopenia;Paraesthesia;Petit mal epilepsy;Pharyngeal lesion;Pneumothorax;Pollakiuria;Polydipsia;Polyuria;Progressive multifocal leukoencephalopathy;Protein urine present;Proteinuria;Prurigo;Pruritus;Rash;Rash generalised;Rash maculo-papular;Rectal haemorrhage;Renal failure;Renal failure acute;Renal impairment;Renal tubular necrosis;Respiratory failure;Retching;Rhabdomyolysis;Rhinorrhoea;Rigors;Seborrhoeic dermatitis;Sensation of heaviness;Sepsis;Shock;Sinus bradycardia;Skin disorder;Skin lesion;Sleep disorder;Sleep phase rhythm disturbance;Somnolence;Stevens-Johnson syndrome;Stomatitis;Swelling face;Syncope;Tachycardia;Throat irritation;Thrombocytopenia;Tongue coated;Toxic epidermal necrolysis;Toxic skin eruption;Transient ischaemic attack;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urine output increased;Urticaria;VIIth nerve paralysis;Vertigo;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased;Xeroderma;Xerosis,small molecule,approved,"(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; Darunavir; Darunavirum; N-((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide; Pr160Gag-Pol; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Pol polyprotein; Gag-Pol polyprotein, G01AE10; J05AE10; J05AR22; J05AR26;J05AE10;J05AR14
lurasidone,Bipolar I disorder;Bipolar depression;Bipolar disorder;Dementia;Mania;Schizoaffective disorder;Schizophrenia,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abnormal dreams;Abnormal involuntary movements;Agitation;Agranulocytosis;Akathisia;Alanine aminotransferase increased;Amenorrhoea;Anaemia;Angina pectoris;Angioedema;Angiopathy;Anxiety;Arrhythmia;Asthenia;Atrioventricular block;Atrioventricular block first degree;Back pain;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose increased;Blood pressure increased;Blood prolactin increased;Bradycardia;Bradykinesia;Breast disorder;Breast enlargement;Breast pain;Cardiac disorder;Cardiovascular disorder;Catatonia;Cerebrovascular accident;Cogwheel rigidity;Completed suicide;Connective tissue disorder;Convulsion;Creatine phosphokinase increased;Creatinine increased;Decreased appetite;Deep vein thrombosis;Dementia with Lewy bodies;Dermatitis;Diabetes mellitus;Diarrhoea;Dizziness;Drooling;Drug withdrawal syndrome neonatal;Dry mouth;Dysarthria;Dyskinesia;Dyslipidaemia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Electrocardiogram change;Embolism venous;Eosinophilia;Erectile dysfunction;Extrapyramidal disorder;Extrapyramidal symptoms;Eye disorder;Fatigue;Flatulence;Gait disturbance;Galactorrhoea;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Hepatobiliary disease;Hot flush;Hyperglycaemia;Hyperhidrosis;Hyperprolactinaemia;Hypersomnia;Hypertension;Hypokinesia;Hypomania;Hypotension;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Joint stiffness;Lethargy;Leukopenia;Loss of consciousness;Malaise;Malnutrition;Menopausal symptoms;Mental disorder;Muscle rigidity;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Neuroleptic malignant syndrome;Neutropenia;Nightmare;Oculogyric crisis;Oromandibular dystonia;Orthostatic hypotension;Osteoarthritis;Panic attack;Parkinson's disease;Parkinsonism;Pregnancy;Pruritus;Psychomotor retardation;Psychotic disorder;Pulmonary embolism;Rash;Renal failure;Rhabdomyolysis;Salivary hypersecretion;Serum creatinine increased;Shock;Sickness;Skin disorder;Sleep disorder;Somnolence;Sudden death;Suicidal behaviour;Suicidal ideation;Suicide;Syncope;Tachycardia;Tardive dyskinesia;Throat tightness;Tongue spasm;Torsade de pointes;Torticollis;Tremor;Trismus;Unspecified disorder of skin and subcutaneous tissue;Upset stomach;Urethral disorder;Urinary tract disorder;Urinary tract infection;Venous thromboembolism;Vertigo;Vision blurred;Vomiting;Weight increased,small molecule,approved; investigational,"Lurasidona; Lurasidone; Lurasidonum; Dopamine D2 receptor; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-7; 5-HT-X; 5-HT7; Serotonin receptor 7; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; ADRA2L2; ADRA2RL2; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2CAR; ADRA2R; ADRAR; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",D(2) dopamine receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 7; 5-hydroxytryptamine receptor 1A; Alpha-2C adrenergic receptor; Alpha-2A adrenergic receptor,N05AE05
aliskiren,Acute coronary syndrome;Angina pectoris;Cardiac failure;Diabetes mellitus;Diabetic nephropathy;Essential hypertension;Hyperlipidaemia;Hypertension;Hypertensive;Hypotension;Myocardial infarction;Nephropathy,Abdominal pain;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Arthralgia;Asthenia;Back pain;Blood creatinine increased;Blood potassium increased;Blood urea increased;Blood uric acid increased;Bronchitis;Calculus of kidney;Cardiac disorder;Colon cancer;Connective tissue disorder;Constipation;Convulsion;Cough;Cough increased;Creatinine increased;Dermatitis;Diabetes mellitus;Diabetic;Diarrhoea;Dizziness;Drug effect increased;Dry cough;Dyspepsia;Epistaxis;Erythema;Erythema multiforme;Fatigue;Foetor hepaticus;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gout;Grand mal convulsion;Haematocrit decreased;Haemoglobin decreased;Headache;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hyperkalaemia;Hypersensitivity;Hypertension;Hypotension;Immune system disorder;Increased effect;Influenza;Insomnia;Jaundice;Laryngeal pain;Liver disorder;Loss of consciousness;Mediastinal disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myositis;Nasopharyngitis;Nausea;Neck pain;Nephrolithiasis;Nervous system disorder;Oedema;Oedema peripheral;Pain in extremity;Palpitations;Periorbital oedema;Pharyngolaryngeal pain;Pruritus;Raised serum uric acid;Rash;Renal failure;Renal failure acute;Renal impairment;Rhabdomyolysis;Rhinitis;Serum creatinine increased;Serum potassium increased;Shoulder pain;Skin disorder;Stevens-Johnson syndrome;Swelling;Swelling face;Tonic-clonic seizures;Toxic epidermal necrolysis;Uncontrolled hypertension;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Uric acid level increased;Urinary tract disorder;Urinary tract infection;Urticaria;Vertigo,small molecule,approved; investigational,"Aliskiren; Aliskireno; 3.4.23.15; Angiotensinogenase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Renin, C09DX02; C09XA02; C09XA52; C09XA53;C09XA02;C09XA54
sitaxsentan,Connective tissue disorder;Hypertension;Primary pulmonary hypertension;Pulmonary arterial hypertension;Pulmonary hypertension;Pulmonary hypertension secondary,Abdominal discomfort;Abdominal hernia;Abdominal pain upper;Abdominal strangulated hernia;Abdominal tenderness;Abortion spontaneous;Abscess;Activated partial thromboplastin time prolonged;Acute bronchitis;Acute coronary syndrome;Acute sinusitis;Agitation;Alanine aminotransferase increased;Alopecia;Alveolitis allergic;Amenorrhoea;Anaemia;Anal pruritus;Anal skin tags;Angina pectoris;Angiopathy;Animal bite;Anorectal discomfort;Anorexia;Appendicitis;Application site haematoma;Arteriovenous fistula;Arthritis;Arthritis bacterial;Arthritis infective;Arthropod bite;Arthropod sting;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrial flutter;Atrioventricular block first degree;Basal cell carcinoma;Bladder disorder;Blood and lymphatic system disorders;Blood bicarbonate decreased;Blood bilirubin increased;Blood creatine phosphokinase MB increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose increased;Blood lactate dehydrogenase increased;Blood phosphorus increased;Blood potassium decreased;Blood potassium increased;Blood pressure increased;Blood uric acid increased;Body temperature increased;Bradycardia;Breast calcifications;Breast disorder;Breast microcalcification;Breast pain;Breast tenderness;Bronchitis;Candida infection;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac flutter;Cardiac murmur;Catheter site haemorrhage;Cellulitis;Cerumen impaction;Chest discomfort;Chest pain;Chest wall pain;Cholecystitis chronic;Cholelithiasis;Cholestasis;Coagulation time prolonged;Colitis;Colonic polyp;Confusional state;Conjunctival haemorrhage;Conjunctival hyperaemia;Conjunctivitis;Conjunctivitis allergic;Connective tissue inflammation;Constipation;Contusion;Cramp muscle;Crystalluria;Cyst;Deafness;Decreased appetite;Dehydration;Dermatitis;Dermatitis atopic;Dermatitis contact;Diarrhoea;Dilatation atrial;Discomfort;Disturbance in attention;Diverticulum;Dizziness;Dizziness postural;Drug hypersensitivity;Drug toxicity;Dry eye;Dry mouth;Dry skin;Dry throat;Dysaesthesia;Dyspepsia;Dysphonia;Dyspnoea exertional;Dyspnoea paroxysmal nocturnal;Dysuria;Ear and labyrinth disorders;Ear congestion;Ear discomfort;Ear feels clogged;Ear pain;Electrocardiogram QT prolonged;Endocrine disorder;Endophthalmitis;Enteritis;Eosinophilia;Epistaxis;Eructation;Extrasystoles;Eye disorder;Eye infection;Eye irritation;Eye oedema;Eye pruritus;Facial pain;Facial paralysis;Faecal incontinence;Fatigue;Feeling abnormal;Feeling hot;Fibromyalgia;Flank pain;Fluid retention;Flushing;Food poisoning;Frequent bowel movements;Fungal infection;Furuncle;Gallbladder disorder;Gastritis viral;Gastroenteritis;Gastroenteritis bacterial;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal fungal infection;Gastrointestinal haemorrhage;Gastrointestinal infection;Genital itching female;Gingival bleeding;Gingival pain;Gingivitis;Glossodynia;Goitre;Gout;Gouty tophus;Groin pain;Haematochezia;Haematocrit decreased;Haematocrit increased;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoglobin increased;Haemoptysis;Haemorrhage;Haemorrhoids;Head discomfort;Head injury;Headache;Heart rate irregular;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatobiliary disease;Hepatomegaly;Herpes simplex;Herpes zoster;Hiccups;Hoarseness;Hyperaesthesia;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperkalaemia;Hypernatraemia;Hypersensitivity;Hypocalcaemia;Hypoglycaemia;Hypotension;Hypoxia;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Inflammation;Inflammation localised;Injection site dermatitis;Insomnia;International normalised ratio increased;Intertrigo;Ischaemic stroke;Jaundice;Joint injury;Joint sprain;Joint stiffness;Keratoconjunctivitis sicca;Laceration;Lacrimation increased;Lactic acidosis;Large intestine polyp;Leukopenia;Ligament injury;Ligament sprain;Limb discomfort;Liver function test abnormal;Lobar pneumonia;Localised infection;Localised oedema;Lower respiratory tract infection;Lung infection;Lymphoma;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Menorrhagia;Mental disability;Mental disorder;Metrorrhagia;Migraine;Mouth haemorrhage;Multi-organ failure;Muscle atrophy;Muscle fatigue;Muscle haemorrhage;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal pain;Musculoskeletal stiffness;Myeloproliferative disorder;Myocardial infarction;Nail hypertrophy;Nasal congestion;Nasal discomfort;Nasal sinus drainage;Nausea;Neoplasm;Nephritis interstitial;Nervous system disorder;Nervousness;Night sweats;Nipple pain;Nocturnal dyspnoea;Non-Hodgkin's lymphoma;Oedema;Oedema peripheral;Oesophageal spasm;Onychomycosis;Oral candidiasis;Oral pruritus;Orthopnoea;Orthostatic hypotension;Osteoarthritis;Osteochondrosis;Otitis media;Ovarian cyst;Oxygen saturation decreased;Pain;Pain in jaw;Pallor;Palmar erythema;Pancreatic pseudocyst;Pancreatitis acute;Pancytopenia;Panophthalmitis;Paraesthesia oral;Paranasal sinus hypersecretion;Paronychia;Partial seizures;Peptic ulcer;Pericardial effusion;Peripheral artery aneurysm;Petechiae;Photophobia;Photosensitivity reaction;Pleural effusion;Pleurisy;Pleuritic pain;Pneumonia aspiration;Pneumothorax;Pollakiuria;Polyarthritis;Polydipsia;Polyp;Post procedural haemorrhage;Post thrombotic syndrome;Pregnancy;Pregnancy test positive;Proctalgia;Protein urine present;Proteinuria;Prothrombin level increased;Pruritus generalised;Pruritus genital;Psoriasis;Pulmonary embolism;Puncture site haemorrhage;Raised liver function tests;Rash;Rash macular;Rash papular;Rash pustular;Red blood cell count decreased;Renal failure;Renal impairment;Respiratory failure;Respiratory tract infection;Restless legs syndrome;Retching;Retinal tear;Rhinitis;Rib fracture;Right ventricular failure;Rosacea;Sciatica;Sensation of foreign body;Sinus bradycardia;Sinus congestion;Sinus headache;Sinus operation;Sinus pain;Sinusitis;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin irritation;Skin laceration;Skin lesion;Skin necrosis;Skin papilloma;Skin ulcer;Sleep disorder;Sneezing;Soft tissue injury;Somnolence;Sputum discoloured;Sputum purulent;Stomatitis;Subcutaneous abscess;Sunburn;Supraventricular extrasystoles;Supraventricular tachycardia;Systemic lupus erythematosus;Tachycardia;Tachypnoea;Tendonitis;Tension;Testicular pain;Thermal burn;Thinking abnormal;Throat irritation;Thrombocytopenia;Thrombophlebitis superficial;Tinnitus;Tongue blistering;Tongue discolouration;Tongue disorder;Tongue ulceration;Tooth abscess;Toxicity to various agents;Tracheobronchitis;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urosepsis;Urticaria;Uterine leiomyoma;VIIth nerve paralysis;Vaginal haemorrhage;Vaginal infection;Vaginal mycosis;Vaginal prolapse;Venous insufficiency;Venous pressure jugular increased;Venous thrombosis;Ventricular bigeminy;Ventricular extrasystoles;Ventricular tachycardia;Vertigo;Vessel puncture site inflammation;Viral diarrhoea;Viral infection;Visual disturbance;Visual impairment;Vitreous floaters;Vomiting;Vulvovaginal mycotic infection;Weight decreased;Weight fluctuation;Wheezing;White blood cell count decreased,small molecule,approved; investigational; withdrawn,"Sitaxentan; Sitaxsentan; Endothelin receptor type A; ET-A; ETA; ETA-R; ETRA; hET-AR; Endothelin receptor non-selective type; ET-B; ET-BR; ETRB; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Endothelin-1 receptor; Endothelin receptor type B,C02KX03
tolvaptan,Cardiac failure;Hyponatraemia;Hyponatraemic;Inappropriate antidiuretic hormone secretion;Neurological symptom,Alanine aminotransferase increased;Anaphylactic shock;Angiopathy;Anorexia;Aspartate aminotransferase increased;Asthenia;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood uric acid increased;Blood urine present;Body temperature increased;Breast disorder;Cardiac disorder;Cerebrovascular accident;Colitis ischaemic;Connective tissue disorder;Constipation;Decreased appetite;Deep vein thrombosis;Dehydration;Diabetic ketoacidosis;Diarrhoea;Discomfort;Disseminated intravascular coagulation;Dizziness;Dry mouth;Dysgeusia;Ecchymosis;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal haemorrhage;Headache;Hyperglycaemia;Hyperkalaemia;Hypernatraemia;Hypersensitivity;Hyperuricaemia;Hypoglycaemia;Hyponatraemia;Hyponatraemic;Ill-defined disorder;Immune system disorder;Intracardiac thrombus;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Nausea;Nervous system disorder;Neurological symptom;Orthostatic hypotension;Osmotic demyelination syndrome;Pollakiuria;Polydipsia;Polyuria;Prothrombin level increased;Prurigo;Pruritus;Pulmonary embolism;Rash generalised;Renal failure;Renal impairment;Respiratory failure;Rhabdomyolysis;Shock;Skin disorder;Syncope;Thirst;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urethral haemorrhage;Urinary tract disorder;Urine output increased;Vaginal haemorrhage;Ventricular fibrillation,small molecule,approved,"ADHR; Antidiuretic hormone receptor; AVPR V2; DIR; DIR3; Renal-type arginine vasopressin receptor; V2R; Antidiuretic hormone receptor 1a; AVPR V1a; AVPR1; V1aR; Vascular/hepatic-type arginine vasopressin receptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Vasopressin V2 receptor; Vasopressin V1a receptor,C03XA01
sorafenib,Acute coronary syndrome;Atrial fibrillation;Cerebrovascular accident;Deep vein thrombosis;Embolism;Hepatic cancer;Hepatocellular carcinoma;Hypoparathyroidism;Neoplasm malignant;Non-small cell lung cancer;Pulmonary embolism;Renal cell carcinoma;Thyroid cancer;Thyroid carcinoma,Abdominal discomfort;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal rigidity;Abdominal tenderness;Acute coronary syndrome;Acute interstitial nephritis;Alanine aminotransferase increased;Allergic cutaneous angiitis;Alopecia;Amylase increased;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Aphthous stomatitis;Arrhythmia;Arthralgia;Ascites;Aspartate aminotransferase increased;Asthenia;Blood and lymphatic system disorders;Blood bilirubin increased;Blood potassium decreased;Blood pressure increased;Blood pressure systolic increased;Blood thyroid stimulating hormone increased;Body temperature increased;Bone disorder;Brain cancer metastatic;Breast disorder;Burning mouth syndrome;Carcinoma;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cerebral haemorrhage;Cholangitis;Cholecystitis;Completed suicide;Connective tissue disorder;Constipation;Cough;Decreased appetite;Dehydration;Dermatitis;Dermatitis exfoliative;Diarrhoea;Disease progression;Dizziness;Drug interaction;Drug-induced hepatitis;Drug-induced liver injury;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Ear and labyrinth disorders;Eczema;Embolism;Embolism venous;Endocrine disorder;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Erythema multiforme minor;Fatal outcomes;Fatigue;Flushing;Folliculitis;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal perforation;Gastrointestinal symptom NOS;Gastrooesophageal reflux disease;Glossitis;Glossodynia;Gynaecomastia;Haematoma;Haemoglobin;Haemoglobin decreased;Haemorrhage;Headache;Hepatic cancer;Hepatic failure;Hepatic function abnormal;Hepatic pain;Hepatobiliary disease;Hepatocellular carcinoma;Hoarseness;Hyperkeratosis;Hypersensitivity;Hypertension;Hypertensive crisis;Hyperthyroidism;Hypoalbuminaemia;Hypocalcaemia;Hypokalaemia;Hyponatraemia;Hypophosphataemia;Hypothyroidism;Immune system disorder;Infarction;Infection;Infestation;Infestation NOS;Influenza like illness;International normalised ratio abnormal;Interstitial lung disease;Interstitial pneumonia;Ischaemia;Jaundice;Keratoacanthoma;Leukocytoclastic vasculitis;Leukoencephalopathy;Leukopenia;Lipase increased;Loss of consciousness;Lymphopenia;Malnutrition;Mediastinal disorder;Mental disorder;Metastases to central nervous system;Metastatic renal cell carcinoma;Mood alteration NOS;Mood swings;Mouth ulceration;Mucosal inflammation;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Myocardial ischaemia;Nasopharyngitis;Nausea;Neoplasm;Neoplasm malignant;Nephrotic syndrome;Nervous system disorder;Neuropathy;Neuropathy peripheral;Neutropenia;Oesophageal discomfort;Oesophageal pain;Oral pain;Oropharyngeal discomfort;Osteonecrosis of jaw;Pain;Pain in extremity;Pancreatitis;Peripheral sensory neuropathy;Pleural effusion;Pneumonia;Potassium low;Protein urine present;Proteinuria;Prothrombin level abnormal;Pruritus;Radiation pneumonitis;Radiation recall reaction (dermatologic);Rash;Recall phenomenon;Renal failure;Renal failure acute;Respiratory distress;Rhabdomyolysis;Rhinorrhoea;Shock;Skin cancer;Skin disorder;Skin exfoliation;Squamous cell carcinoma;Squamous cell carcinoma of skin;Stevens-Johnson syndrome;Stomatitis;Suicide;Syncope;Thrombocytopenia;Thromboembolism;Thyrotropin high;Tinnitus;Toxic epidermal necrolysis;Transient ischaemic attack;Tubulointerstitial nephritis;Tumour pain;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urogenital disorder;Urticaria;Varices oesophageal;Vascular headache;Vomiting;Weight decreased,small molecule,approved; investigational,"4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; Sorafénib; Sorafenib; Sorafenibum; 2.7.11.1; BRAF1; p94; Proto-oncogene B-Raf; RAFB1; v-Raf murine sarcoma viral oncogene homolog B1; 2.7.10.1; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; 2.7.11.1; cRaf; Proto-oncogene c-RAF; RAF; Raf-1; 2.7.10.1; FLT-4; Fms-like tyrosine kinase 4; Tyrosine-protein kinase receptor FLT4; VEGFR-3; VEGFR3; 2.7.10.1; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR-2; VEGFR2; 2.7.10.1; FLT; FLT-1; Fms-like tyrosine kinase 1; FRT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; Vascular permeability factor receptor; VEGFR-1; VEGFR1; 2.7.10.1; CD135; Fetal liver kinase-2; FL cytokine receptor; FLK-2; FLK2; FLT-3; Fms-like tyrosine kinase 3; Stem cell tyrosine kinase 1; STK-1; STK1; 2.7.10.1; Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; PDGF-R-beta; PDGFR; PDGFR-1; PDGFR-beta; PDGFR1; Platelet-derived growth factor receptor 1; 2.7.10.1; p145 c-kit; PBT; Piebald trait protein; Proto-oncogene c-Kit; SCFR; Tyrosine-protein kinase Kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; 2.7.10.1; Basic fibroblast growth factor receptor 1; bFGF-R-1; BFGFR; CEK; FGFBR; FGFR-1; FLG; FLT-2; FLT2; Fms-like tyrosine kinase 2; HBGFR; N-sam; Proto-oncogene c-Fgr; 2.7.10.1; Cadherin family member 12; CDHF12; CDHR16; Proto-oncogene c-Ret; PTC; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 76 kDa Ral-interacting protein; Dinitrophenyl S-glutathione ATPase; DNP-SG ATPase; Ral-interacting protein 1; RalBP1; RLIP; RLIP1; RLIP76; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Serine/threonine-protein kinase B-raf; Epidermal growth factor receptor; RAF proto-oncogene serine/threonine-protein kinase; Vascular endothelial growth factor receptor 3; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 1; Receptor-type tyrosine-protein kinase FLT3; Platelet-derived growth factor receptor beta; Mast/stem cell growth factor receptor Kit; Fibroblast growth factor receptor 1; Proto-oncogene tyrosine-protein kinase receptor Ret,L01EX02;L01XE05
Colimycin,Cystic fibrosis;Infection;Lung infection,Abdominal discomfort;Abnormal chest sounds NOS;Anxiety;Apnoea;Arthralgia;Asthenia;Asthma;Balance disorder;Blood creatinine decreased;Blood creatinine increased;Blood urea increased;Body temperature increased;Breath sounds abnormal;Bronchospasm;Candida albicans infection;Candida infection;Chest discomfort;Chest pain;Connective tissue disorder;Convulsion;Cough;Creatinine increased;Creatinine low;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Drug hypersensitivity;Dysarthria;Dysgeusia;Dysphonia;Dyspnoea;Dyspnoea exacerbated;Ear and labyrinth disorders;Ear congestion;Epistaxis;Fatigue;Flatulence;Forced expiratory volume decreased;Gastrointestinal disorder;Gastrointestinal tract irritation;Haemoptysis;Headache;Hypersensitivity;Immune system disorder;Increased upper airway secretion;Laryngeal pain;Lower respiratory tract infection;Malnutrition;Mediastinal disorder;Mental disorder;Musculoskeletal discomfort;Nausea;Nephropathy toxic;Nephrotoxicity;Nervous system disorder;Oliguria;Oropharyngeal discomfort;Oropharyngeal pain;Paraesthesia;Pharyngolaryngeal pain;Productive cough;Protein urine present;Proteinuria;Pruritus generalised;Rales;Rash;Respiratory distress;Salivary hypersecretion;Slurred speech;Somnolence;Sputum purulent;Thirst;Throat irritation;Throat sore;Tingling of extremity;Tinnitus;Toothache;Urethral disorder;Urinary tract disorder;Urticaria;Vertigo;Vomiting;Weight fluctuation;Wheezing,small molecule,approved; vet_approved,"7-CDL; 7(S)-Chloro-7-deoxylincomycin; Clindamicina; Clindamycin; Clindamycine; Clindamycinum; Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",50S ribosomal protein L1, D10AF51; G01AA10; J01FF01;D10AF01
lenalidomide,Anaemia;Dermatitis;Embolism;Embolism venous;Mantle cell lymphoma;Myelodysplastic syndrome;Plasma cell myeloma;Plasmacytoma;Rash;Thromboembolism;Transfusion dependent anaemia,AML progression;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abdominal tenderness;Abnormal dreams;Abrasion NOS;Abscess;Acute coronary syndrome;Acute febrile neutrophilic dermatosis;Acute hepatic failure;Acute leukaemia;Acute myeloid leukaemia;Acute sinusitis;Affect lability;Ageusia;Agitation;Agranulocytosis;Alanine aminotransferase increased;Allergic conditions;Alopecia;Altered state of consciousness;Alveolitis allergic;Amenorrhoea;Anaemia;Aneurysm;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Aortic disorder;Aortic valve stenosis;Aphasia;Aphthous stomatitis;Areflexia;Arrhythmia;Arrhythmia supraventricular;Arterial aneurysm;Arthralgia;Arthritis;Arthritis aggravated;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Atrial fibrillation;Atrial flutter;Autoimmune haemolytic anaemia;Azotaemia;Back pain;Bacteraemia;Basal cell carcinoma;Basedow's disease;Bladder pain;Blindness;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bone pain;Bowel spasm;Bradycardia;Breast disorder;Bronchial hyperreactivity;Bronchioloalveolar carcinoma;Bronchitis;Burning sensation;COPD exacerbation;Caecitis;Calculus ureteric;Candida infection;Carcinoma;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardio-respiratory arrest;Cardiogenic shock;Cardiomyopathy;Cataract;Cataract unilateral;Cellulitis;Central line infection;Cerebellar infarction;Cerebral infarction;Cerebral ischaemia;Cerebrovascular accident;Cervical vertebral fracture;Chest pain;Chills;Cholecystitis;Cholecystitis acute;Cholestasis;Chondrocalcinosis;Chronic obstructive pulmonary disease;Clostridial infection;Clostridium difficile colitis;Coagulopathy;Colitis;Colitis ischaemic;Colonic polyp;Confusional state;Congenital anomaly;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Cough;Cramp muscle;Culture negative;Cyst;Cystitis;Cystitis noninfective;Cytolytic hepatitis;Deafness;Decreased appetite;Decreased interest;Decubitus ulcer;Deep vein thrombosis;Dehydration;Dental discomfort;Depressed level of consciousness;Depression;Dermatitis;Dermatitis atopic;Developmental delay;Device related infection;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disease progression;Diverticulitis;Diverticulum;Dizziness;Drug eruption;Dry eye;Dry mouth;Dry skin;Dry throat;Dysarthria;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dyspnoea exacerbated;Dyspnoea exertional;Dyssomnia;Dysuria;Ear and labyrinth disorders;Ear discomfort;Ear infection;Ear pain;Ecchymosis;Eczema;Embolism;Embolism venous;Endocrine disorder;Enterobacter sepsis;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Excoriation;Eye discharge;Eye disorder;Eye irritation;Eye pruritus;Eyelid oedema;Face oedema;Fanconi syndrome acquired;Fatigue;Febrile neutropenia;Feeling abnormal;Femoral neck fracture;Femur fracture;Fibrillation atrial aggravated;Flatulence;Flushing;Foetor hepaticus;Foot pain;Frequent bowel movements;Functional gastrointestinal disorder;Fungaemia;Fungal infection;Furuncle;Gait disturbance;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;General physical health deterioration;Gingival bleeding;Glioblastoma multiforme;Glossodynia;Gout;Gouty arthritis;Gynaecomastia;Haematoma;Haematuria;Haemochromatosis;Haemoglobin;Haemoglobin decreased;Haemolysis;Haemolytic anaemia;Haemorrhage;Haemorrhage intracranial;Haemorrhagic disorder;Haemorrhoidal haemorrhage;Haemorrhoids;Hallucination;Headache;Hearing impaired;Hepatic failure;Hepatitis;Hepatitis cholestatic;Hepatitis toxic;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Herpes simplex;Herpes virus infection;Hip fracture;Hirsutism;Hoarseness;Hordeolum;Hyperbilirubinaemia;Hypercholesterolaemia;Hypercoagulation;Hyperglycaemia;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Hypothyroidism;Hypotonia;Hypoxia;Ill-defined disorder;Immune system disorder;Impaired healing;Incontinence;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Inguinal hernia;Injection site bruising;Injection site haemorrhage;Insomnia;Intermittent fever;Interstitial lung disease;Interstitial pneumonia;Intestinal perforation;Intracranial venous sinus thrombosis;Iron overload;Irritable bowel syndrome;Ischaemia;Joint stiffness;Joint swelling;Kidney infection;Klebsiella sepsis;Laceration;Large intestine polyp;Lethargy;Leukocytoclastic vasculitis;Leukopenia;Limb injury;Lip dry;Lip haemorrhage;Liver disorder;Liver function test abnormal;Lobar pneumonia;Local swelling;Localised infection;Loose stools;Loss of consciousness;Loss of libido;Lung cancer metastatic;Lung infiltration;Lymphadenopathy;Lymphoma;Lymphoma cutis;Lymphopenia;Macular degeneration;Malaise;Malnutrition;Mediastinal disorder;Melaena;Mental disorder;Mental status changes;Metrorrhagia;Micturition urgency;Migraine;Mood alteration NOS;Mood swings;Mouth ulceration;Mucosal dryness;Mucosal inflammation;Multi-organ failure;Muscle relaxant therapy;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myelodysplastic syndrome;Myelosuppression;Myocardial infarction;Myocardial ischaemia;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Neoplasm malignant;Nervous system disorder;Nervousness;Neuritis;Neuropathy;Neuropathy peripheral;Neutropenia;Neutrophilic dermatosis;Night sweats;Nodule;Non-Hodgkin's lymphoma;Ocular hypertension;Oedema;Oedema peripheral;Opportunistic infection;Oral candidiasis;Oral infection;Orbital oedema;Oropharyngeal pain;Osteoarthritis;Osteopenia;Osteoporosis;Pain;Pain in extremity;Palpitations;Pancreatitis;Pancreatitis due to biliary obstruction;Pancytopenia;Paraesthesia;Pelvic fracture;Pelvic pain;Peptic ulcer haemorrhage;Periarthritis;Peripheral coldness;Peripheral ischaemia;Peripheral motor neuropathy;Peripheral sensory neuropathy;Peripheral swelling;Perirectal abscess;Petechiae;Pharyngitis;Photosensitivity reaction;Pitting edema;Plasma cell myeloma;Plasmacytoma;Pleural effusion;Pneumonia;Pollakiuria;Polycythaemia;Polyneuropathy;Polyp;Post procedural haemorrhage;Presyncope;Primary hypothyroidism;Productive cough;Prostate cancer metastatic;Prurigo;Pruritus;Pruritus generalised;Pseudomonas infection;Psychosomatic disease;Pulmonary embolism;Pulmonary hypertension;Pulmonary oedema;Rales;Rash;Rash erythematous;Rash macular;Rash pustular;Rectal haemorrhage;Refractory anemia;Refractory cytopenia with unilineage dysplasia;Regurgitation;Regurgitation of food;Renal failure;Renal failure acute;Renal mass;Renal tubular necrosis;Respiratory distress;Respiratory failure;Respiratory tract infection;Rhabdomyolysis;Rhinitis;Rhinitis allergic;Rhinorrhoea;Rib fracture;Rigors;Road traffic accident;Sciatica;Sensation of heaviness;Sensory disturbance;Sepsis;Septic shock;Shock;Sinus congestion;Sinusitis;Skin cancer;Skin discolouration;Skin disorder;Skin fissures;Skin hyperpigmentation;Skin irritation;Skin lesion;Sleep disorder;Small intestinal obstruction;Somnolence;Speech disorder;Spinal compression fracture;Spinal cord compression;Splenic infarction;Splenomegaly;Squamous cell carcinoma of skin;Staphylococcal bacteraemia;Staphylococcal infection;Stevens-Johnson syndrome;Stiffness;Stomatitis;Subarachnoid haemorrhage;Sudden death;Supraventricular tachycardia;Sweating;Sweating increased;Swelling face;Syncope;Syncope vasovagal;Tachyarrhythmia;Tachycardia;Tension;Teratogenicity;Thrombocytopenia;Thromboembolic event;Thrombophlebitis;Thrombophlebitis superficial;Thrombosis;Thyroid disorder;Tinnitus;Toothache;Toxic epidermal necrolysis;Transfusion reaction;Transient ischaemic attack;Tremor;Troponin I increased;Tumour flare;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper gastrointestinal haemorrhage;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urosepsis;Urticaria;Varicose vein;Venous thromboembolism;Ventricular dysfunction;Ventricular extrasystoles;Vertigo;Viraemia;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Warm type haemolytic anaemia;Weight decreased;Weight increased;Wheezing,small molecule,approved,"1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; Lenalidomida; Lenalidomide; Cachectin; TNF-a; TNF-alpha; TNFA; TNFSF2; Tumor necrosis factor ligand superfamily member 2; ODF; OPGL; Osteoclast differentiation factor; Osteoprotegerin ligand; RANKL; Receptor activator of nuclear factor kappa-B ligand; TNF-related activation-induced cytokine; TRANCE; 7B4 antigen; Vascular endothelial cadherin; VE-cadherin; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Tumor necrosis factor; Protein cereblon; Tumor necrosis factor ligand superfamily member 11; Cadherin-5; Prostaglandin G/H synthase 2,L04AX04
lasofoxifene,Fracture;Hip fracture;Menopausal symptoms;Multiple fractures;Osteoporosis,5'nucleotidase increased;Abdominal discomfort;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Abnormal dreams;Adenomyosis;Adnexa uteri cyst;Adnexa uteri mass;Affective disorder;Alanine aminotransferase increased;Alopecia;Amnesia;Anaemia;Anaemia megaloblastic;Anal fissure;Anal spasm;Angioedema;Angiopathy;Anorexia;Aortic aneurysm;Aphakia;Arterial occlusive disease;Arthritis;Arthritis infective;Arthropathy;Aspartate aminotransferase increased;Asthenia;Aura;Back pain;Benign breast neoplasm;Blood albumin decreased;Blood and lymphatic system disorders;Blood creatinine abnormal;Blood glucose increased;Blood triglycerides increased;Blood urine present;Body temperature increased;Bone density decreased;Bone disorder;Breast discharge;Breast disorder;Breast disorder female;Breast engorgement;Breast fibroma;Breast fibrosis;Breast induration;Breast pain;Bronchial hyperreactivity;Bronchitis;Burning sensation;Bursitis;Calculus bladder;Cardiac disorder;Cardiac failure;Cardiomegaly;Cellulitis;Cerebral infarction;Cervical dysplasia;Cervical polyp;Cervicitis;Cervix disorder;Cheilitis;Cheilosis;Chest X-ray abnormal;Chest discomfort;Chest pain;Cholecystitis;Cholelithiasis;Chorioretinopathy;Chronic lymphocytic leukaemia;Chronic obstructive pulmonary disease;Clubbing;Coccydynia;Colitis ulcerative;Colpocele;Conjunctival haemorrhage;Conjunctival hyperaemia;Constipation;Cor pulmonale;Costochondritis;Cough;Cyclothymic disorder;Cyst;Cystocele;Dactylitis;Decreased appetite;Deep vein thrombosis;Dementia Alzheimer's type;Diabetes mellitus;Diverticulitis;Dizziness postural;Dry eye;Dry mouth;Dry skin;Duodenal ulcer;Duodenitis;Dysgeusia;Dysphagia;Ear and labyrinth disorders;Ear discomfort;Electrocardiogram T wave abnormal;Embolism;Endocrine disorder;Endometrial disorder;Endometrial hyperplasia;Endometrial hypertrophy;Endometrial neoplasm;Endophthalmitis;Enlarged clitoris;Epilepsy;Erythema;Excoriation;Exostosis;Extremity contracture;Eye disorder;Eye haemorrhage;Eye pruritus;Eyelid oedema;Fallopian tube cyst;Fatigue;Feeling drunk;Feeling hot;Female reproductive neoplasm;Fibroma;Flatulence;Flushing;Foetor hepaticus;Functional gastrointestinal disorder;Fungal infection;Furuncle;Gamma-glutamyltransferase increased;Gastric polyps;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Genital candidiasis;Genital discharge;Genital haemorrhage;Genital injury;Haemangioma;Haemarthrosis;Haematoma;Haemoglobin;Haemorrhage;Hair texture abnormal;Headache;Hepatic cancer;Hepatic steatosis;Hepatitis;Hepatitis B surface antigen positive;Hepatobiliary disease;Hepatocellular injury;High density lipoprotein decreased;Hot flush;Hydrocephalus;Hydrometra;Hypercalciuria;Hyperhidrosis;Hyperparathyroidism;Hypertonic bladder;Hypertriglyceridaemia;Hypoalbuminaemia;Hypochromasia;Hypogeusia;Hypophosphataemia;Immune system disorder;Impetigo;Increased appetite;Infection;Infestation;Infestation NOS;Inflammation;Inguinal hernia;Inner ear disorder;Intermittent claudication;Irritable bowel syndrome;Jaundice;Joint stiffness;Keratoconjunctivitis sicca;Labyrinthitis;Leiomyoma;Limb injury;Liver disorder;Low density lipoprotein increased;Lymphostasis;Macular degeneration;Malformation venous;Malnutrition;Mediastinal disorder;Melanocytic naevus;Memory impairment;Menopausal symptoms;Mental disorder;Metrorrhagia;Microangiopathy;Micturition urgency;Migraine;Motor neurone disease;Mouth ulceration;Muscle contracture;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Nail disorder;Neck pain;Neoplasm;Nephrosclerosis;Nerve compression;Nerve injury;Nervous system disorder;Night sweats;Nipple disorder;Nocturia;Ocular hyperaemia;Oedema;Oedema peripheral;Oesophagitis;Onychoclasis;Ophthalmic herpes simplex;Oral pain;Osteoarthritis;Pain;Pain in extremity;Pain in jaw;Palpitations;Parathyroid tumour benign;Paresis;Pedal pulse decreased;Periarthritis;Perineal injury;Perineal laceration;Phlebitis;Photosensitivity reaction;Plasma cell myeloma;Plasmacytoma;Platelet count decreased;Pollakiuria;Polyp;Post thrombotic syndrome;Presyncope;Proctocolitis;Prurigo;Pruritus;Pruritus generalised;Pruritus genital;Pulmonary embolism;Pulmonary granuloma;Pupils unequal;Pyelonephritis;Pyometra;Rash maculo-papular;Rectal polyp;Rectal ulcer;Rectocele;Restless legs syndrome;Retinal detachment;Retinal disorder;Retinal vascular disorder;Retinal vein thrombosis;Rheumatoid arthritis;Rhinitis allergic;Rhinitis seasonal;Rosacea;Rotator cuff syndrome;Sciatica;Seasonal allergy;Sinus arrest;Skeletal injury;Skin disorder;Skin hyperpigmentation;Skin irritation;Skin lesion;Skin oedema;Smear cervix abnormal;Soft tissue injury;Spinal fracture;Stomatitis;Supraventricular extrasystoles;Tachycardia;Tenosynovitis;Tetany;Therapeutic response unexpected;Thoracic vertebral fracture;Thrombocytopenia;Thromboembolic event;Thrombophlebitis;Thrombophlebitis superficial;Thrombosis;Tooth fracture;Transaminases increased;Tricuspid valve incompetence;Type 2 diabetes mellitus;Ultrasound breast abnormal;Ultrasound ovary abnormal;Unspecified disorder of skin and subcutaneous tissue;Upset stomach;Urethral disorder;Urethral haemorrhage;Urinary bladder polyp;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urticaria;Uterine cervical erosion;Uterine cervical squamous metaplasia;Uterine haemorrhage;Uterine leiomyoma;Uterine mass;Uterine polyp;Uterine prolapse;Vaginal discharge;Vaginal disorder;Vaginal erosion;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vaginal pain;Vaginal prolapse;Vaginal wall congestion;Varicose veins vulval;Vascular headache;Vascular stenosis;Vasomotor rhinitis;Venous insufficiency;Venous thrombosis;Venous thrombosis limb;Vertigo positional;Visual acuity reduced;Visual disturbance;Visual impairment;Vulval disorder;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginal pain;Vulvovaginal pruritus;Vulvovaginitis;Weight increased,small molecule,approved; investigational,"(-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol; Lasofoxifene; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; CB-2; CB2; CB2A; CB2B; CX5; hCB2",Fusion glycoprotein F0; Estrogen receptor; Estrogen receptor beta; Cannabinoid receptor 2,G03XC03
regadenoson,Atrioventricular block;Block heart;Hypovolaemia;Long QT syndrome;Lung disorder,Abdominal discomfort;Abdominal distension;Abdominal pain;Acute coronary syndrome;Altered state of consciousness;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Anxiety;Arthralgia;Asthenia;Asthma;Atrial fibrillation;Atrial flutter;Atrioventricular block;Atrioventricular block complete;Atrioventricular block first degree;Atrioventricular block second degree;Block heart;Blood pressure diastolic decreased;Blood pressure systolic decreased;Bradycardia;Bronchial hyperreactivity;Bronchoconstriction;Bronchospasm;Cardiac arrest;Cardiac disorder;Cardiac flutter;Cerebrovascular accident;Chest discomfort;Chest pain;Chronic obstructive pulmonary disease;Connective tissue disorder;Convulsion;Cough;Depressed level of consciousness;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dropped beats;Dysgeusia;Dyspnoea;Ear and labyrinth disorders;Electrocardiogram PR prolongation;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Electrocardiogram ST segment;Electrocardiogram ST segment depression;Erythema;Extrasystoles;Eye disorder;Eye pain;Faecal incontinence;Feeling abnormal;Feeling hot;Flushing;Gastrointestinal discomfort;Gastrointestinal disorder;Gastrointestinal pain;Generalized aching;Haemorrhage intracranial;Headache;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Hypotension symptomatic;Ill-defined disorder;Immune system disorder;Injection site pain;Insomnia;Ischaemia;Loss of consciousness;Malaise;Mediastinal disorder;Mental disorder;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Nervous system disorder;Nodal block;Oral discomfort;Oxygen saturation decreased;Pain;Pain in extremity;Pain in jaw;Pallor;Palpitations;Paraesthesia;Peripheral coldness;Rash;Renal failure;Renal impairment;Respiratory arrest;Respiratory distress;Shock;Sinus bradycardia;Skin disorder;Somnolence;Supraventricular tachyarrhythmia;Syncope;Tachycardia;Tachypnoea;Throat irritation;Throat tightness;Tinnitus;Transient ischaemic attack;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vasodilation;Vasodilation procedure;Ventricular arrhythmia;Vision blurred;Vomiting;Wandering pacemaker;Wheezing,small molecule,approved; investigational,Regadenoson; Regadenoson anhydrous; ADORA2,Adenosine receptor A2a,C01EB21
lacosamide,Convulsion;Epilepsy,Affect lability;Aggression;Agitation;Agranulocytosis;Anaemia;Angioedema;Asthenia;Ataxia;Atrial fibrillation;Atrial flutter;Atrioventricular block;Atrioventricular block complete;Atrioventricular block first degree;Balance disorder;Blood and lymphatic system disorders;Blood disorder;Body temperature increased;Bradycardia;Cardiac disorder;Cerebellar syndrome;Chest pain;Cognitive disorder;Confusional state;Connective tissue disorder;Constipation;Contusion;Coordination abnormal;Depressed mood;Depression;Dermatitis;Diarrhoea;Diplopia;Discomfort;Disturbance in attention;Dizziness;Drug hypersensitivity;Dry mouth;Dysarthria;Dyspepsia;Ear and labyrinth disorders;Electrocardiogram PR prolongation;Eosinophilia;Erythema;Erythema multiforme;Euphoric mood;Eye disorder;Fatigue;Feeling abnormal;Feeling drunk;Flatulence;Gait disturbance;Gastrointestinal disorder;Hallucination;Headache;Hepatitis;Hepatitis viral;Hepatobiliary disease;Hyperhidrosis;Hypersensitivity;Hypoaesthesia;Hypoaesthesia oral;Immune system disorder;Injection site pain;Inner ear disorder;Insomnia;Irritability;Labyrinthine disorder;Laceration;Liver function test abnormal;Loss of consciousness;Memory impairment;Mental disorder;Mood swings;Muscle spasms;Nausea;Nephritis;Nervous system disorder;Neutropenia;Nystagmus;Osteoarthritis;Palpitations;Paraesthesia;Paraesthesia oral;Protein urine present;Proteinuria;Pruritus;Psychotic disorder;Rash;Shock;Skin disorder;Skin laceration;Somnolence;Stevens-Johnson syndrome;Suicidal ideation;Suicide attempt;Syncope;Tinnitus;Toxic epidermal necrolysis;Tremor;Type IV hypersensitivity reaction;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vertigo;Vision blurred;Vomiting,small molecule,approved,"(+)-(2R)-2-(ACETYLAMINO)-N-BENZYL-3-METHOXYPROPANAMIDE; (2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide; (R)-2-acetamido-N-benzyl-3- methoxypropionamide; (R)-LACOSAMIDE 1; Erlosamide; Harkoseride; Lacosamida; Lacosamide; Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-; Collapsin response mediator protein 2; CRMP-2; CRMP2; DRP-2; N2A3; ULIP-2; ULIP2; Unc-33-like phosphoprotein 2; hNaN; Peripheral nerve sodium channel 5; PN5; SCN12A; Sensory neuron sodium channel 2; SNS2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; hNE-Na; NENA; Neuroendocrine sodium channel; Peripheral sodium channel 1; PN1; Sodium channel protein type IX subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.7; KIAA1356; NAC3; Sodium channel protein brain III subunit alpha; Sodium channel protein type III subunit alpha; Voltage-gated sodium channel subtype III; Voltage-gated sodium channel subunit alpha Nav1.3; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Dihydropyrimidinase-related protein 2; Sodium channel protein type 11 subunit alpha; Sodium channel protein type 9 subunit alpha; Sodium channel protein type 3 subunit alpha; Sodium channel protein type 10 subunit alpha,N03AX18
natamycin,Blepharitis;Conjunctivitis;Keratitis;Keratitis fungal;Mycotic endophthalmitis,Chest pain;Corneal opacity;Dyspnoea;Eye irritation;Eye oedema;Eye pain;Hyperaemia;Hypersensitivity;Lacrimation;Lacrimation increased;Ocular discomfort;Paraesthesia;Sensation of foreign body,small molecule,approved,Natamicina; Natamycin; Natamycine; Natamycinum; Pimaracin; Pimaricin,Ergosterol, A01AB10; A07AA03; D01AA02; S01AA10;A01AB10;G01AA02
cefditoren,Bronchitis chronic;Community acquired pneumonia;Infection;Pharyngitis;Pharyngitis streptococcal;Pneumonia;Renal failure;Renal impairment;Rheumatic disorder;Rheumatic fever;Streptococcus pyogenes pharyngitis;Tonsillitis,Abdominal pain;Abnormal dreams;Agitation;Agranulocytosis;Alanine aminotransferase increased;Albumin low;Anaphylactic shock;Anaphylactoid reaction;Anorexia;Aplastic anaemia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Asthma;Blood albumin decreased;Blood alkaline phosphatase increased;Blood bilirubin increased;Blood calcium decreased;Blood creatinine increased;Blood glucose increased;Blood lactate dehydrogenase increased;Blood potassium increased;Blood urea increased;Body temperature increased;Calcium low;Candida infection;Cholestasis;Coagulation time prolonged;Colitis;Constipation;Convulsion;Creatinine increased;Decreased appetite;Dermatitis;Diarrhoea;Digestion impaired;Disability;Dizziness;Drug fever;Dry mouth;Dysgeusia;Dyspepsia;Eosinophilia;Eosinophilic pneumonia;Eructation;Erythema multiforme;Face oedema;Flatulence;Fungal infection;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Glucose increased;Haematocrit decreased;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic anaemia;Haemorrhage;Headache;Hepatic function abnormal;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypertonia;Hyponatraemia;Hypotension;Increased appetite;Insomnia;Interstitial lung disease;Interstitial pneumonia;Lactic dehydrogenase activity increased;Leukopenia;Leukorrhea;Liver function test abnormal;Loeffler's syndrome;Lymphocyte count increased;Mouth ulceration;Musculoskeletal discomfort;Myalgia;Nausea;Nephropathy toxic;Nervousness;Neutropenia;Oedema peripheral;Oral candidiasis;Pain;Pancytopenia;Phosphatase alkaline increased;Pollakiuria;Potassium increased;Protein urine present;Proteinuria;Prothrombin level increased;Pruritus;Pseudomembranous colitis;Pulmonary eosinophilia;Rash;Renal failure acute;Rhinitis;Serum sickness-like reaction;Sinusitis;Sodium decreased;Somnolence;Stevens-Johnson syndrome;Stomatitis;Superinfection;Sweating;Tension;Thirst;Thrombocytopenia;Thrombocytosis;Toxic epidermal necrolysis;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight decreased;White blood cell count decreased,small molecule,approved; investigational,Cefditoren; Cefditoreno; pbp2b; PBP1,Penicillin-binding protein 2B; Penicillin-binding protein 1A,J01DD16
ciclesonide,Asthma;Glaucoma;Perennial allergic rhinitis;Rhinitis perennial;Rhinitis seasonal;Seasonal allergy,Alanine aminotransferase increased;Angioedema;Arthralgia;Asthenia;Back pain;Bronchitis;Bronchospasm;Bronchospasm paradoxical;Candida albicans infection;Candida infection;Cataract;Cataract subcapsular;Chest discomfort;Chest pain;Conjunctivitis;Contusion;Cough;Dermatitis;Diabetes mellitus;Dizziness;Dry mouth;Dry throat;Dysgeusia;Dyspepsia;Dysphonia;Dyspnoea;Ear infection;Ear pain;Epistaxis;Face oedema;Fatigue;Fracture;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Haemoglobin;Haemorrhage;Headache;Hoarseness;Hyperadrenocorticism;Hypertension;Immune system disorder;Impaired healing;Infection;Infestation;Infestation NOS;Influenza;Intraocular pressure increased;Laboratory test abnormal;Laryngeal pain;Lip swelling;Mediastinal disorder;Multiple fractures;Muscle strain;Musculoskeletal chest pain;Musculoskeletal discomfort;Nasal congestion;Nasal discomfort;Nasal dryness;Nasal passage irritation;Nasal septum disorder;Nasal septum perforation;Nasal ulcer;Nasopharyngitis;Nausea;Obstructive airways disorder;Oral candidiasis;Oral fungal infection;Oropharyngeal pain;Osteopenia;Osteoporosis;Pain in extremity;Palpitations;Pharyngitis;Pharyngitis streptococcal;Pharyngolaryngeal pain;Pneumonia;Rash;Rhinitis;Rhinitis allergic;Rhinorrhoea;Secondary adrenocortical insufficiency;Sinus headache;Sinusitis;Swelling;Throat irritation;Tonsillitis;Type IV hypersensitivity reaction;Ulcer;Upper respiratory tract infection;Urinary tract infection;Urticaria;Viral upper respiratory tract infection;Weight increased;Wheezing;White blood cell count increased,small molecule,approved; investigational,"Ciclesonida; Ciclesonide; CBG; Serpin A6; Transcortin; GR; GRL; Nuclear receptor subfamily 3 group C member 1; ACAT; Acyl-coenzyme A:cholesterol acyltransferase; Brain carboxylesterase hBr1; Carboxylesterase 1; CE-1; CEH; CES2; Cholesteryl ester hydrolase; Cocaine carboxylesterase; Egasyn; hCE-1; HMSE; Methylumbelliferyl-acetate deacetylase 1; Monocyte/macrophage serine esterase; REH; Retinyl ester hydrolase; Serine esterase 1; SES1; TGH; Triacylglycerol hydrolase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; CBG; Serpin A6; Transcortin",Corticosteroid-binding globulin; Glucocorticoid receptor, R01AD13;R03BA08
roflumilast,Bronchial hyperreactivity;Bronchitis chronic;Bronchospasm;Chronic obstructive pulmonary disease,Abdominal pain;Angioedema;Anxiety;Asthenia;Atrial fibrillation;Back pain;Carcinoma of lung;Cardiac disorder;Completed suicide;Connective tissue disorder;Constipation;Decreased appetite;Depression;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dysgeusia;Dyspepsia;Endocrine disorder;Fatigue;Feeling abnormal;Gamma-glutamyltransferase increased;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gynaecomastia;Haematochezia;Headache;Hepatobiliary disease;Hypersensitivity;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Lung neoplasm malignant;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Nervousness;Palpitations;Pancreatitis acute;Pneumonia;Prostate cancer;Rash;Renal failure acute;Respiratory tract infection;Rhinitis;Sinusitis;Skin disorder;Suicidal ideation;Tension;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urinary tract infection;Urticaria;Vertigo;Vomiting;Weight decreased,small molecule,approved,"Roflumilast; Roflumilastum; 3.1.4.53; cAMP-specific phosphodiesterase 4A; DPDE2; PDE46; 3.1.4.53; cAMP-specific phosphodiesterase 4B; DPDE4; PDE32; 3.1.4.53; cAMP-specific phosphodiesterase 4C; DPDE1; PDE21; 3.1.4.53; cAMP-specific phosphodiesterase 4D; DPDE3; PDE43; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase","cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4)", R03DX07;D05AX06;R03DX07
hemin,Hereditary coproporphyria;Hypertension;Pain;Porphyria acute;Tachycardia;Variegate porphyria,Activated partial thromboplastin time prolonged;Body temperature increased;Coagulopathy;Iron overload;Leukocytosis;Phlebitis;Prothrombin level increased;Renal failure acute;Serum ferritin increased;Shutdown renal;Thrombocytopenia,biotech,approved; investigational,chloro(protoporphyrinato)iron(III); Hämin; Hemina; hémine; protohemin; 2.3.1.37; 5-aminolevulinic acid synthase 1; ALAS-H; ALAS3; ALASH; Delta-ALA synthase 1; Delta-aminolevulinate synthase 1,"5-aminolevulinate synthase, non-specific, mitochondrial",B06AB01
nilotinib,Chromosome analysis abnormal;Chronic myeloid leukaemia;Philadelphia chromosome positive,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Alanine aminotransferase increased;Albumin low;Alopecia;Amnesia;Amylase increased;Anaemia;Anal abscess;Angina pectoris;Angiopathy;Anorexia;Anxiety;Appetite disorder;Arrhythmia;Arterial occlusion;Arterial occlusive disease;Arterial stenosis limb;Arteriosclerosis;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Atrioventricular block;Back pain;Blepharitis;Blister;Blood albumin decreased;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood bilirubin unconjugated increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose decreased;Blood glucose increased;Blood insulin decreased;Blood insulin increased;Blood lactate dehydrogenase increased;Blood parathyroid hormone increased;Blood phosphorus decreased;Blood potassium decreased;Blood pressure increased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature altered;Body temperature increased;Bone pain;Bradycardia;Brain oedema;Breast disorder;Breast induration;Breast pain;Bronchitis;Bundle branch block left;Candida infection;Cardiac disorder;Cardiac failure;Cardiac flutter;Cardiac murmur;Cardiomegaly;Chest discomfort;Chest pain;Chills;Cholestasis;Chorioretinopathy;Chromaturia;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Conjunctivitis allergic;Connective tissue disorder;Constipation;Contusion;Coronary artery disease;Cough;Creatinine increased;Cyanosis;Cyst;Deafness;Decreased appetite;Dehydration;Dermal cyst;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Diastolic dysfunction;Diplopia;Discomfort;Disorientation;Disturbance in attention;Dizziness;Drug eruption;Dry eye;Dry mouth;Dry skin;Dysaesthesia;Dysgeusia;Dyslipidaemia;Dyspepsia;Dysphonia;Dysphoria;Dyspnoea;Dyspnoea exertional;Dysuria;Ear and labyrinth disorders;Ear pain;Ecchymosis;Eczema;Electrocardiogram QT prolonged;Electrolyte imbalance;Endocrine disorder;Enterocolitis;Eosinophilia;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Erythema nodosum;Exfoliative rash;Extrasystoles;Eye disorder;Eye haemorrhage;Eye irritation;Eye pain;Eye pruritus;Eye swelling;Eyelid oedema;Face oedema;Fatigue;Febrile neutropenia;Feeling abnormal;Feeling hot;Flank pain;Flatulence;Fluid retention;Flushing;Folliculitis;Furuncle;Gamma-glutamyltransferase increased;Gastric ulcer;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal ulcer perforation;Gastrooesophageal reflux disease;Gingivitis;Globulins decreased;Gout;Gravitational oedema;Gynaecomastia;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemorrhage;Haemorrhage intracranial;Haemorrhoids;Headache;Hearing impaired;Hepatic function abnormal;Hepatitis;Hepatitis toxic;Hepatobiliary disease;Hepatomegaly;Hepatotoxicity;Herpes simplex;Herpes virus infection;Hiatus hernia;Hyperaemia;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkeratosis;Hyperlipidaemia;Hyperparathyroidism secondary;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypertensive crisis;Hyperthyroidism;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Hypothyroidism;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Insomnia;Insulin C-peptide decreased;Intermittent claudication;Interstitial lung disease;Jaundice;Joint swelling;Laryngeal pain;Lethargy;Leukocytosis;Leukopenia;Lipase increased;Localised oedema;Loss of consciousness;Lymphopenia;Malaise;Malnutrition;Mediastinal disorder;Melaena;Menorrhagia;Mental disorder;Micturition urgency;Migraine;Mouth ulceration;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myelosuppression;Myocardial infarction;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Nervous system disorder;Neuropathy peripheral;Neutropenia;Night sweats;Nipple swelling;Nocturia;Non-cardiac chest pain;Ocular surface disease;Oedema;Oedema peripheral;Oesophageal pain;Oesophageal ulcer;Oesophagitis ulcerative;Optic neuritis;Oral candidiasis;Oral papilloma;Oropharyngeal pain;Pain;Pain in extremity;Pain of skin;Palpitations;Pancreatitis;Pancytopenia;Papilloedema;Paraesthesia;Paraproteinaemia;Pericardial effusion;Pericarditis;Periorbital oedema;Peripheral arterial occlusive disease;Peripheral artery stenosis;Petechiae;Pharyngitis;Pharyngolaryngeal pain;Phosphatase alkaline increased;Photophobia;Photopsia;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pleurisy;Pleuritic pain;Pneumonia;Pollakiuria;Polyp;Pruritus;Psoriasis;Pulmonary hypertension;Pulmonary oedema;Rash;Rectal haemorrhage;Renal failure;Restless legs syndrome;Retroperitoneal haemorrhage;Rhinitis;Sebaceous hyperplasia;Sensitivity of teeth;Sepsis;Shock;Shock haemorrhagic;Skin atrophy;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin hypertrophy;Skin papilloma;Skin ulcer;Stomatitis;Subcutaneous abscess;Subileus;Swelling face;Syncope;Tachycardia;Throat irritation;Thrombocytopenia;Thrombocytosis;Thrombosis;Thyroiditis;Tinea pedis;Tinnitus;Torsade de pointes;Transient ischaemic attack;Tremor;Troponin increased;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urinary tract infection;Urticaria;Ventricular dysfunction;Ventricular extrasystoles;Vertigo;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting;Weight decreased;Weight increased;Wheezing;Xerophthalmia,small molecule,approved; investigational,"Nilotinib; Nilotinibum; 2.7.10.2; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; ABL; JTK7; p150; Proto-oncogene c-Abl; 2.7.10.1; p145 c-kit; PBT; Piebald trait protein; Proto-oncogene c-Kit; SCFR; Tyrosine-protein kinase Kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Tyrosine-protein kinase ABL1; Mast/stem cell growth factor receptor Kit,L01EA03;L01XE08
silodosin,Benign prostatic hyperplasia,Abdominal pain;Angiopathy;Asthenia;Breast disorder;Cardiac disorder;Dermatitis;Diarrhoea;Disturbance in sexual arousal;Dizziness;Drug eruption;Dry mouth;Ejaculation failure;Erectile dysfunction;Floppy iris syndrome;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hepatic function abnormal;Hepatobiliary disease;Hypotension;Immune system disorder;Insomnia;Intraoperative floppy iris syndrome;Jaundice;Libido decreased;Liver function test abnormal;Loss of consciousness;Mediastinal disorder;Mental disorder;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Orthostatic hypotension;Palpitations;Pharyngeal oedema;Priapism;Procedural complication;Prostatic specific antigen increased;Pruritus;Purpura;Rash;Retrograde ejaculation;Rhinorrhoea;Shock;Sinusitis;Skin disorder;Swelling face;Swollen tongue;Syncope;Tachycardia;Toxic skin eruption;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vascular purpura,small molecule,approved,"Silodosin; Silodosina; ADRA1C; Alpha-1A adrenoceptor; Alpha-1A adrenoreceptor; Alpha-1C adrenergic receptor; Alpha-adrenergic receptor 1c; ADRA1A; Alpha-1A adrenergic receptor; Alpha-1D adrenoceptor; Alpha-1D adrenoreceptor; Alpha-adrenergic receptor 1a; Alpha-1B adrenoceptor; Alpha-1B adrenoreceptor; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; Eag-related protein 2; ERG-2; ERG2; Ether-a-go-go-related gene potassium channel 2; Ether-a-go-go-related protein 2; hERG-2; hERG2; Potassium voltage-gated channel subfamily H member 6; Voltage-gated potassium channel subunit Kv11.2; Eag-related protein 3; ERG-3; ERG3; Ether-a-go-go-related gene potassium channel 3; Ether-a-go-go-related protein 3; hERG-3; Potassium voltage-gated channel subfamily H member 7; Voltage-gated potassium channel subunit Kv11.3; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.2.1.3; ALDH class 2; ALDH-E2; ALDHI; ALDM; 1.1.1.2; 1.1.1.372; 1.1.1.54; Alcohol dehydrogenase [NADP(+)]; Aldehyde reductase; ALDR1; ALR; Glucuronate reductase; Glucuronolactone reductase; S-nitroso-CoA reductase; ScorR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.1; ATP-binding cassette sub-family B member 4; MDR3; Multidrug resistance protein 3; P-glycoprotein 3; PGY3",Alpha-1A adrenergic receptor; Alpha-1D adrenergic receptor; Alpha-1B adrenergic receptor; HERG human cardiac K+ channel,G04CA04
propylthiouracil,Basedow's disease;Hyperthyroidism;Toxic multinodular goiter;Toxic nodular goitre,Ageusia;Agranulocytosis;Allergic cutaneous angiitis;Alopecia;Antineutrophil cytoplasmic antibody positive;Aplastic anaemia;Arthralgia;Body temperature increased;Dermatitis;Dermatitis exfoliative;Drowsiness;Drug fever;Dysgeusia;Dyspepsia;Epigastric distress;Erythema nodosum;Glomerulonephritis;Glomerulonephritis rapidly progressive;Haemoglobin;Haemorrhage;Headache;Hepatic failure;Hepatitis;Interstitial lung disease;Interstitial pneumonia;Jaundice;Leukocytoclastic vasculitis;Leukopenia;Liver injury;Lung infiltration;Lupus-like syndrome;Lymphadenopathy;Musculoskeletal discomfort;Myalgia;Nausea;Nephritis;Neuritis;Neuropathy peripheral;Oedema;Paraesthesia;Pigmentation disorder;Pigmentation skin;Pruritus;Rash;Renal failure acute;Skin ulcer;Somnolence;Splenomegaly;Thrombocytopenia;Traumatic liver injury;Urticaria;Vasculitis;Vertigo;Vomiting,small molecule,approved; investigational,"2-Mercapto-6-propyl-4-pyrimidone; 2-Mercapto-6-propylpyrimid-4-one; 2-Thio-4-oxo-6-propyl-1,3-pyrimidine; 2-Thio-6-propyl-1,3-pyrimidin-4-one; 4-propyl-2-thiouracil; 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione; 6-propyl-2-thiouracil; 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; 6-Propylthiouracil; 6-Thio-4-propyluracil; Propiltiouracilo; Propylthiouracil; Propylthiouracile; Propylthiouracilum; 1.21.99.4; 5DI; DIOI; ITDI1; TXDI1; Type 1 DI; Type-I 5'-deiodinase; 1.11.1.8; TPO; 1.11.2.2; MPO; 1.14.17.1; Dopamine beta-monooxygenase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase",Type I iodothyronine deiodinase; Thyroid peroxidase,H03BA02
6-mercaptopurine,Acute leukaemia;Acute lymphocytic leukaemia;Acute myeloid leukaemia;Central nervous system leukaemia;Chronic lymphocytic leukaemia;Chronic myeloid leukaemia;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Leukaemia;Leukaemic infiltration brain;Lymphoma;Neoplasm;Neoplasm malignant;Non-Hodgkin's lymphoma;Solid tumour,Alopecia;Anaemia;Anorexia;Arthralgia;Azoospermia;Blood and lymphatic system disorders;Blood uric acid increased;Body temperature increased;Bone marrow depression;Bone marrow toxicity;Breast disorder;Candida infection;Cholestasis;Cyst;Cytopenia;Decreased appetite;Dermatitis;Diarrhoea;Drug fever;Gastrointestinal disorder;Hepatic necrosis;Hepatobiliary disease;Hepatocellular injury;Hepatosplenic T-cell lymphoma;Hepatotoxicity;Hypersensitivity;Hyperuricaemia;Hyperuricosuria;Immune system disorder;Inflammatory bowel disease;Intestinal ulcer;Leukopenia;Liver injury;Malabsorption;Malnutrition;Mouth ulceration;Musculoskeletal discomfort;Myelosuppression;Nausea;Neoplasm;Oedema;Oligospermia;Oral candidiasis;Oral disorder;Oral lesion;Pancreatitis;Pancytopenia;Polyp;Rash;Sepsis;Skin disorder;Skin hyperpigmentation;Sprue;Stomatitis;Thrombocytopenia;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Vomiting,small molecule,approved,"1,9-DIHYDRO-6H-PURINE-6-THIONE; 6 MP; 6-Mercaptopurine; 6-MP; 6-Thiohypoxanthine; 6-Thioxopurine; Mercaptopurina; Mercaptopurine; Mercaptopurine anhydrous; Mercaptopurinum; Mercapurin; 2.4.2.8; HGPRT; HGPRTase; HPRT; 1.1.1.205; IMP dehydrogenase 1; IMPD 1; IMPD1; IMPDH 1; IMPDH-I; 2.4.2.14; ATase; Glutamine phosphoribosylpyrophosphate amidotransferase; GPAT; 1.1.1.205; IMP dehydrogenase 1; IMPD 1; IMPD1; IMPDH 1; IMPDH-I; 1.1.1.205; IMP dehydrogenase 2; IMP dehydrogenase II; IMPD 2; IMPD2; IMPDH 2; IMPDH-II; Inosine-5'-monophosphate dehydrogenase type II; 1.2.3.1; Aldehyde oxidase 1; AO; Azaheterocycle hydroxylase; 2.1.1.67; Thiopurine methyltransferase; XDHA; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; 7.6.2.-; 7.6.2.2; MOAT-C; MRP5; Multi-specific organic anion transporter C; Multidrug resistance-associated protein 5; pABC11; SMRP; CNT 2; CNT2; Concentrative nucleoside transporter 2; hCNT2; Na(+)/nucleoside cotransporter 2; Sodium-coupled nucleoside transporter 2; Sodium/purine nucleoside co-transporter; Solute carrier family 28 member 2; SPNT; CNT 3; CNT3; Concentrative Na(+)-nucleoside cotransporter 3; hCNT3; ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; es nucleoside transporter; hENT1; Nucleoside transporter, es-type; Solute carrier family 29 member 1; 36 kDa nucleolar protein HNP36; Delayed-early response protein 12; DER12; ENT2; Equilibrative NBMPR-insensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter; hENT2; HNP36; Hydrophobic nucleolar protein, 36 kDa; Nucleoside transporter, ei-type; Solute carrier family 29 member 2",Hypoxanthine-guanine phosphoribosyltransferase; Inosine-5'-monophosphate dehydrogenase 1; Amidophosphoribosyltransferase; Inosine-5'-monophosphate dehydrogenase, R03DA20;L01BB02
methimazole,Basedow's disease;Hyperthyroidism;Toxic multinodular goiter;Toxic nodular goitre,Ageusia;Agranulocytosis;Alopecia;Aplastic anaemia;Arthralgia;Body temperature increased;Dermatitis;Drowsiness;Drug fever;Dyspepsia;Epigastric distress;Headache;Hepatitis;Hypoglycaemic coma;Insulin autoimmune syndrome;Jaundice;Leukopenia;Lupus-like syndrome;Lymphadenopathy;Musculoskeletal discomfort;Myalgia;Nausea;Nephritis;Neuritis;Neuropathy peripheral;Oedema;Paraesthesia;Pigmentation disorder;Pigmentation skin;Pruritus;Rash;Somnolence;Thrombocytopenia;Urticaria;Vertigo;Vomiting,small molecule,approved,"1-Methylimidazole-2(3H)-thione; Methimazole; Thiamazol; Thiamazole; Thiamazolum; Tiamazol; 1.11.1.8; TPO; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase",Thyroid peroxidase, H03BB02;H03BB02;H03BB52
6-thioguanine,Acute leukaemia;Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Chronic myeloid leukaemia;Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Neoplasm;Plasma cell myeloma;Plasmacytoma;Solid tumour,Alcohol abuse;Alcoholism;Anorexia;Ascites;Blood uric acid increased;Bone marrow depression;Cytopenia;Decreased appetite;Fibrosis;Fluid retention;Gastrointestinal necrosis;Hepatic necrosis;Hepatomegaly;Hyperbilirubinaemia;Hyperuricaemia;Intestinal necrosis;Jaundice;Myelosuppression;Nausea;Nodular regenerative hyperplasia;Pancytopenia;Peliosis hepatis;Portal hypertension;Splenomegaly;Stomatitis;Thrombocytopenia;Varices oesophageal;Venoocclusive disease;Venoocclusive liver disease;Vomiting;Weight increased,small molecule,approved,"2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-amino-1,9-dihydropurine-6-thione; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-purinethiol; 2-Aminopurin-6-thiol; 2-Aminopurine-6-thiol; 2-Aminopurine-6(1H)-thione; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; TG; ThG; Thioguanine; Thioguanine anhydrous; Thioguanine, anhydrous; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; 2.4.2.8; HGPRT; HGPRTase; HPRT; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4",DNA,L01BB03
ethionamide,Active tuberculosis;Diabetes mellitus;Tuberculosis,Abdominal pain;Agitation;Anorexia;Decreased appetite;Depression;Dermatitis;Diarrhoea;Digestion impaired;Diplopia;Dizziness;Drowsiness;Dysgeusia;Dyspepsia;Erectile dysfunction;Gastrointestinal disorder;Gastrointestinal pain;Gynaecomastia;Headache;Hepatitis;Hypersensitivity;Hypoglycaemia;Hypothyroidism;Jaundice;Nausea;Neuritis;Neuropathy peripheral;Neurotoxicity;Optic neuritis;Orthostatic hypotension;Photosensitivity;Photosensitivity reaction;Psychotic disorder;Purpura;Rash;Salivary hypersecretion;Somnolence;Stomatitis;Taste metallic;Thrombocytopenia;Vascular purpura;Vision blurred;Vomiting;Weight decreased,small molecule,approved,"2-ethyl-4-thiopyridylamide; 2-ethylthioisonicotinamide; ETH; Ethinamide; Ethionamide; Ethionamidum; Ethioniamide; Ethylisothiamide; Ethyonomide; Etionamid; Etionamida; Etionamide; Etioniamid; ETP; 1.3.1.9; ENR; FAS-II enoyl-ACP reductase; NADH-dependent 2-trans-enoyl-ACP reductase; NF-E2-related factor 2; NFE2-related factor 2; Nrf-2; NRF2; Nuclear factor, erythroid derived 2, like 2; 1.11.1.21; CP; Peroxidase/catalase",Enoyl-[acyl-carrier-protein] reductase [NADH]; Nuclear factor erythroid 2-related factor 2; Catalase-peroxidase,J04AD03
rilpivirine,Cross resistance;HIV infection;Human immunodeficiency virus type;Infection;Pathogen resistance,Abdominal discomfort;Abdominal pain;Abnormal dreams;Adrenal insufficiency;Alanine aminotransferase increased;Anxiety;Aspartate aminotransferase increased;Asthenia;Autoimmune disorder;Basedow's disease;Bilirubin total increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood cholesterol increased;Blood creatinine increased;Breast enlargement;Buffalo hump;Cholecystitis;Cholelithiasis;Creatinine increased;Decreased appetite;Depressed mood;Depression;Depressive disorder;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Dysthymic disorder;Fatigue;Gastrointestinal disorder;Gastrointestinal pain;Glomerulonephritis;Glomerulonephritis membranous;Haemoglobin decreased;Headache;Hepatitis B;Hepatitis C;Hepatobiliary disease;Hepatotoxicity;High cholesterol;High density lipoprotein decreased;Hypertrophy of breast;Immune system disorder;Infection;Infection mixed;Inflammation;Insomnia;Lipase increased;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Low density lipoprotein increased;Malnutrition;Mental disorder;Nausea;Nephrolithiasis;Nephrotic syndrome;Nervous system disorder;Opportunistic infection;Platelet count decreased;Rash;Renal failure;Renal impairment;Serum creatinine increased;Skin disorder;Sleep disorder;Somnolence;Transaminases increased;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urogenital disorder;Vomiting;White blood cell count decreased,small molecule,approved,"4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; Rilpivirina; Rilpivirine; hPN3; Peripheral nerve sodium channel 3; PN3; Sodium channel protein type X subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.8; Pr160Gag-Pol; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Reverse transcriptase/RNaseH; Sodium channel protein type 10 subunit alpha; Gag-Pol polyprotein; Nuclear receptor subfamily 1 group I member 2, J05AG05; J05AR08; J05AR21;J05AR19
d-telaprevir,Chronic hepatitis C;Foetor hepaticus;Hepatitis C;Hepatocellular injury;Liver disorder,Acquired immunodeficiency syndrome;Acute prerenal failure;Acute renal insufficiency;Anaemia;Anal fissure;Anal pruritus;Anorectal discomfort;Asthenia;Autoimmune disorder;Azotemia prerenal;Blood and lymphatic system disorders;Blood creatinine increased;Blood uric acid increased;Burning rectal;Candida infection;Dermatitis;Diarrhoea;Dizziness;Drug eruption;Dysgeusia;Eczema;Endocrine disorder;Eosinophilia;Erythema multiforme;Exfoliative rash;Eye disorder;Fatigue;Gastrointestinal disorder;Gout;Gouty arthritis;Haemorrhoids;Hepatobiliary disease;Hyperbilirubinaemia;Hyperuricaemia;Hypokalaemia;Hypothyroidism;Infection;Infestation;Infestation NOS;Loss of consciousness;Lymphopenia;Malnutrition;Nausea;Nervous system disorder;Oedema peripheral;Oral candidiasis;Pregnancy;Proctalgia;Proctitis;Product taste abnormal;Pruritus;Pruritus genital;Raised serum uric acid;Rash;Rectal haemorrhage;Renal failure acute;Retinal disorder;Shock;Skin disorder;Stevens-Johnson syndrome;Swelling face;Syncope;Thrombocytopenia;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urate nephropathy;Urethral disorder;Uric acid level increased;Urinary tract disorder;Urticaria;Vomiting,small molecule,approved; withdrawn,"(1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide; Telaprevir; 3.4.22.-; p23; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Genome polyprotein; Genome polyprotein; Solute carrier organic anion transporter family member 1B1; Solute carrier organic anion transporter family member 2B1,J05AP02
prucalopride,Constipation;Constipation chronic,Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal bowel sounds;Anorexia;Asthenia;Back pain;Body temperature increased;Breast disorder;Cardiac disorder;Connective tissue disorder;Decreased appetite;Diarrhoea;Discomfort;Dizziness;Dyspepsia;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal sounds abnormal;Gastrointestinal symptom NOS;Headache;Ill-defined disorder;Infection;Infestation;Infestation NOS;Influenza;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Nasopharyngitis;Nausea;Nervous system disorder;Palpitations;Pollakiuria;Polyuria;Rectal haemorrhage;Sinusitis;Skin disorder;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Vomiting,small molecule,approved,"Prucaloprida; Prucalopride; 5-HT-4; 5-HT4; Serotonin receptor 4; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",5-hydroxytryptamine receptor 4,A03AE04;A06AX05
pimecrolimus,Dermatitis atopic;Eczema;Immunocompromised;Immunodeficiency,"Abdominal pain;Abdominal pain upper;Acne;Acute bronchitis;Alcohol intolerance;Anaphylactic shock;Angioedema;Application site burn;Application site erythema;Application site irritation;Application site pain;Application site pruritus;Application site reaction;Arthralgia;Arthritis bacterial;Asthma;Asthma aggravated;Back pain;Bacterial infection;Basal cell carcinoma;Body temperature increased;Bone disorder;Breast disorder;Bronchitis;Carcinoma colon;Colon cancer;Condition aggravated;Conjunctivitis;Constipation;Cough;Dermatitis;Dermatitis exfoliative;Diarrhoea;Dysmenorrhoea;Dyspnoea;Ear and labyrinth disorders;Ear infection;Ear pain;Eczema herpeticum;Epistaxis;Erythema;Extranodal NK/T-cell lymphoma, nasal type;Eye disorder;Eye infection;Eye irritation;Face oedema;Flushing;Folliculitis;Furuncle;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Headache;Herpes dermatitis;Herpes simplex;Herpes simplex dermatitis;Hypersensitivity;Immune system disorder;Impetigo;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Laceration;Leukaemia;Leukoderma;Loose stools;Lymphoma;Malignant histiocytosis;Malignant melanoma;Malnutrition;Mediastinal disorder;Molluscum contagiosum;Musculoskeletal discomfort;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm malignant;Neoplasm skin;Nervous system disorder;Non-Hodgkin's lymphoma;Oedema;Oropharyngeal discomfort;Oropharyngeal pain;Other conjunctivitis;Otitis media;Pain;Paraesthesia;Pharyngitis;Pharyngitis streptococcal;Photosensitivity reaction;Phototoxicity;Pneumonia;Pruritus;Rash;Rhinitis;Rhinorrhoea;Sensitisation;Sinus congestion;Sinusitis;Skin atrophy;Skin cancer;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin infection;Skin papilloma;Squamous cell carcinoma;Staphylococcal infection;Superinfection;Swelling;Throat sore;Tonsillitis;Toothache;Tracheobronchitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Varicella;Viral infection;Viral upper respiratory tract infection;Vomiting;Wheezing",small molecule,approved; investigational,"33-Epi-chloro-33-desoxyascomycin; Pimecrolimus; Pimecrolimusum; 3.1.3.16; Calcineurin A alpha; Calmodulin-dependent calcineurin A subunit alpha isoform; CALNA; CAM-PRP catalytic subunit; CNA; CNA alpha; Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform; 2.7.11.1; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; FRAP; FRAP1; FRAP2; Mammalian target of rapamycin; Mechanistic target of rapamycin; mTOR; RAFT1; Rapamycin and FKBP12 target 1; Rapamycin target protein 1; RAPT1; 12 kDa FK506-binding protein; 12 kDa FKBP; 5.2.1.8; Calstabin-1; FK506-binding protein 1A; FKBP-12; FKBP-1A; FKBP1; FKBP12; Immunophilin FKBP12; PPIase FKBP1A; Rotamase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Protein phosphatase 3 catalytic subunit alpha; Serine/threonine-protein kinase mTOR; Peptidyl-prolyl cis-trans isomerase FKBP1A,D11AH02
dasatinib,Acute lymphocytic leukaemia;Blast cell crisis;Cardiac disorder;Chromosome analysis abnormal;Chronic myeloid leukaemia;Chronic phase chronic myeloid leukemia;Leukaemia;Philadelphia chromosome positive;Pleural effusion,Abdominal distension;Abdominal pain;Acute coronary syndrome;Acute febrile neutrophilic dermatosis;Acute respiratory distress syndrome;Affect lability;Alanine aminotransferase increased;Alopecia;Amnesia;Anaemia;Anal fissure;Angina pectoris;Angiopathy;Anorexia;Anxiety;Aplasia pure red cell;Arrhythmia;Arthralgia;Ascites;Aspartate aminotransferase increased;Asthenia;Asthma;Atrial fibrillation;Atrial flutter;Auricular swelling;Blood and lymphatic system disorders;Blood bilirubin increased;Blood calcium decreased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood uric acid increased;Body temperature increased;Breast disorder;Bronchospasm;Bullous conditions;Calcium low;Cardiac disorder;Cardiac failure;Cardiac failure acute;Cardiac failure congestive;Cardiomegaly;Cardiomyopathy;Cardiovascular disorder;Cerebral haematoma;Cerebral haemorrhage;Cerebrovascular accident;Chest pain;Chills;Cholecystitis;Cholestasis;Chronic myeloid leukaemia;Coagulopathy;Colitis;Confusional state;Congestive cardiomyopathy;Conjunctival haemorrhage;Conjunctival oedema;Conjunctivitis;Connective tissue disorder;Constipation;Contusion;Convulsion;Cor pulmonale;Cough;Creatinine increased;Cyst;Cytopenia;Decreased appetite;Deep vein thrombosis;Dermatitis;Diarrhoea;Diastolic dysfunction;Discomfort;Disorder sight;Disturbance in sexual arousal;Dizziness;Drug eruption;Dry eye;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Ear and labyrinth disorders;Ear haemorrhage;Ecchymosis;Eczema;Ejection fraction decreased;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Embolism;Enterocolitis infectious;Epidural haemorrhage;Epistaxis;Erythema;Erythema multiforme;Erythema nodosum;Erythrosis;Exfoliative rash;Eye disorder;Eye haemorrhage;Eye oedema;Eye swelling;Eyelid oedema;Face oedema;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Fluid retention;Flushing;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal ulcer;Generalised erythema;Generalised oedema;Genital rash;Genital swelling;Gingival bleeding;Gravitational oedema;Gynaecomastia;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhagic stroke;Headache;Hepatitis;Hepatobiliary disease;Herpes virus infection;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperuricaemia;Hypoalbuminaemia;Hypocalcaemia;Hypokalaemia;Hypophosphataemia;Hypotension;Ileus;Ill-defined disorder;Immune system disorder;Incision site oedema;Infection;Infestation;Infestation NOS;Inflammation;Insomnia;Interstitial lung disease;Intra-abdominal haematoma;Left ventricular dysfunction;Left ventricular failure;Libido decreased;Lip oedema;Lipoedema;Livedo reticularis;Localised oedema;Loss of consciousness;Lung infiltration;Macular oedema;Malaise;Malnutrition;Mediastinal disorder;Menstruation irregular;Mental disorder;Milia;Miliaria;Miliaria rubra;Mucosal inflammation;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myelosuppression;Myocardial infarction;Myocarditis;Myositis;Nail disorder;Nausea;Neoplasm;Neoplasm malignant;Nervous system disorder;Neuropathy;Neuropathy peripheral;Neutropenia;Neutropenic colitis;Oedema;Oedema genital;Oedema mouth;Oedema peripheral;Oesophagitis;Oligomenorrhoea;Optic neuritis;Oral disorder;Oral soft tissue disorder NOS;Orbital oedema;Pain;Palpitations;Pancreatitis;Pancytopenia;Panniculitis;Penile oedema;Pericardial effusion;Pericarditis;Periorbital oedema;Petechiae;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pitting edema;Platelet aggregation abnormal;Pleural effusion;Pneumonia;Pollakiuria;Polyp;Posterior reversible encephalopathy syndrome;Protein urine present;Protein-losing gastroenteropathy;Proteinuria;Prurigo;Pruritus;Pulmonary embolism;Pulmonary hypertension;Pulmonary oedema;Rash;Rash erythematous;Rash follicular;Rash generalised;Rash macular;Rash maculo-papular;Rash papular;Rash pustular;Rash vesicular;Renal failure;Rhabdomyolysis;Scleral haemorrhage;Scrotal oedema;Sepsis;Shock;Skin discolouration;Skin disorder;Skin exfoliation;Skin irritation;Skin swelling;Skin ulcer;Somnolence;Stomatitis;Subarachnoid haemorrhage;Subdural haematoma;Swelling face;Syncope;Systemic lupus erythematosus rash;Tachycardia;Temperature intolerance;Tendonitis;Thrombocytopenia;Thrombophlebitis;Thrombosis;Tinnitus;Tongue disorder;Tongue oedema;Transient ischaemic attack;Tremor;Troponin increased;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Urticaria vesiculosa;Uterine haemorrhage;VIIth nerve paralysis;Vaginal haemorrhage;Ventricular arrhythmia;Ventricular dysfunction;Ventricular failure;Ventricular tachycardia;Vertigo;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"Anh. dasatinib; Anhydrous dasatinib; BMS dasatinib; Dasatinib; Dasatinib (anh.); dasatinib (anhydrous); Dasatinib anhydrous; Dasatinibum; N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide; 2.7.10.2; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; ABL; JTK7; p150; Proto-oncogene c-Abl; 2.7.10.2; p60-Src; pp60c-src; Proto-oncogene c-Src; SRC1; 2.7.10.1; ECK; Epithelial cell kinase; Tyrosine-protein kinase receptor ECK; 2.7.10.2; Leukocyte C-terminal Src kinase; LSK; Lymphocyte cell-specific protein-tyrosine kinase; p56-LCK; Protein YT16; Proto-oncogene Lck; T cell-specific protein-tyrosine kinase; 2.7.10.2; p61-Yes; Proto-oncogene c-Yes; YES; 2.7.10.1; p145 c-kit; PBT; Piebald trait protein; Proto-oncogene c-Kit; SCFR; Tyrosine-protein kinase Kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; 2.7.10.1; Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; PDGF-R-beta; PDGFR; PDGFR-1; PDGFR-beta; PDGFR1; Platelet-derived growth factor receptor 1; 2.7.10.2; p59-Fyn; Proto-oncogene c-Fyn; Proto-oncogene Syn; SLK; Src-like kinase; 2.7.11.1; BCR1; D22S11; Renal carcinoma antigen NY-REN-26; 2.7.10.2; Abelson murine leukemia viral oncogene homolog 2; Abelson tyrosine-protein kinase 2; Abelson-related gene protein; ABLL; ARG; Tyrosine-protein kinase ARG; 2.7.10.2; Agammaglobulinemia tyrosine kinase; AGMX1; ATK; B-cell progenitor kinase; BPK; Bruton tyrosine kinase; CHN; CSMF; MINOR; Mitogen-induced nuclear orphan receptor; Neuron-derived orphan receptor 1; NOR1; Nuclear hormone receptor NOR-1; TEC; 2.7.10.2; C-Src kinase; Protein-tyrosine kinase CYL; 2.7.10.1; Brain-specific kinase; BSK; EHK-1; EHK1; EK7; EPH homology kinase 1; EPH-like kinase 7; HEK7; TYRO4; 2.7.10.1; Hepatoma transmembrane kinase; HTK; MYK1; TYRO11; Tyrosine-protein kinase TYRO11; 2.7.10.2; Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog; p55-Fgr; p58-Fgr; p58c-Fgr; Proto-oncogene c-Fgr; SRC2; 2.7.10.2; FYN-related kinase; Nuclear tyrosine protein kinase RAK; Protein-tyrosine kinase 5; PTK5; RAK; 3.6.4.10; Heat shock 70 kDa protein 8; Heat shock protein family A member 8; HSC70; HSP73; HSPA10; LAP-1; Lipopolysaccharide-associated protein 1; LPS-associated protein 1; 2.7.10.2; JTK8; Lck/Yes-related novel protein tyrosine kinase; p53Lyn; p56Lyn; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; 2.7.11.25; HCCS-4; Human cervical cancer suppressor gene 4 protein; Leucine zipper- and sterile alpha motif-containing kinase; Mitogen-activated protein kinase kinase kinase MLT; Mixed lineage kinase 7; Mixed lineage kinase-related kinase; MLK-like mitogen-activated protein triple kinase; MLK-related kinase; MLK7; MLTK; MRK; Sterile alpha motif- and leucine zipper-containing kinase AZK; ZAK; 2.7.11.24; CSAID-binding protein; CSBP; CSBP1; CSBP2; CSPB1; Cytokine suppressive anti-inflammatory drug-binding protein; MAP kinase 14; MAP kinase MXI2; MAP kinase p38 alpha; MAPK 14; MAX-interacting protein 2; Mitogen-activated protein kinase p38 alpha; MXI2; SAPK2A; Stress-activated protein kinase 2a; 2.4.2.14; ATase; Glutamine phosphoribosylpyrophosphate amidotransferase; GPAT; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Tyrosine-protein kinase ABL1; Proto-oncogene tyrosine-protein kinase Src; Ephrin type-A receptor 2; Tyrosine-protein kinase Lck; Tyrosine-protein kinase Yes; Mast/stem cell growth factor receptor Kit; Platelet-derived growth factor receptor beta; Tyrosine-protein kinase Fyn; Breakpoint cluster region protein; Signal transducer and activator of transcription 5B; Tyrosine-protein kinase ABL2; Tyrosine-protein kinase BTK; Nuclear receptor subfamily 4 group A member 3; Tyrosine-protein kinase CSK; Ephrin type-A receptor 5; Ephrin type-B receptor 4; Tyrosine-protein kinase Fgr; Tyrosine-protein kinase FRK; Heat shock cognate 71 kDa protein; Tyrosine-protein kinase Lyn; Mitogen-activated protein kinase kinase kinase 20; Mitogen-activated protein kinase 14; Amidophosphoribosyltransferase,L01EA02;L01XE06
Estrofem,Fracture;Multiple fractures;Oestrogen deficiency,Abdominal bloating;Abdominal distension;Abdominal pain;Abnormal vision;Acute coronary syndrome;Alopecia;Anaphylactic shock;Angiopathy;Asthma;Blood pressure increased;Breast cancer;Breast disorder;Breast enlargement;Breast pain;Breast tenderness;Cardiac failure congestive;Cerebral haemorrhage;Cerebrovascular accident;Chloasma;Cholelithiasis;Connective tissue disorder;Cramps of lower extremities;Deep vein thrombosis;Dementia;Depression;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Embolism venous;Endometrial cancer;Endometrial hyperplasia;Epilepsy;Erythema multiforme;Erythema nodosum;Eye disorder;Flatulence;Gallbladder disorder;Gastrointestinal disorder;Gastrointestinal pain;Haemorrhagic stroke;Headache;Hepatobiliary disease;Hypersensitivity;Immune system disorder;Insomnia;Libido disorder;Mental disorder;Migraine;Muscle spasms;Myocardial infarction;Nausea;Neoplasm;Nervous system disorder;Oedema;Ovarian cancer;Pelvic venous thrombosis;Pruritus;Pulmonary embolism;Rash;Shock;Skin disorder;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Uterine leiomyoma;Vaginal haemorrhage;Vaginal moniliasis;Vascular purpura;Venous thromboembolism;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Weight increased,small molecule,approved,"3-Hydroxy-1,3,5(10)-estratrien-17-one; Estrona; Estrone; Estronum; Follicular hormone; Folliculin; Oestrone; ER; ER-alpha; ESR; Estradiol receptor; NR3A1; Nuclear receptor subfamily 3 group A member 1; ER-beta; ESTRB; NR3A2; Nuclear receptor subfamily 3 group A member 2; DHTR; Dihydrotestosterone receptor; NR3C4; Nuclear receptor subfamily 3 group C member 4; 1.14.14.14; ARO1; CYAR; CYP19; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase; ABP; SBP; Sex steroid-binding protein; SHBG; TeBG; Testis-specific androgen-binding protein; Testosterone-estradiol-binding globulin; Testosterone-estrogen-binding globulin; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIB1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Estrogen receptor; Estrogen receptor beta; Androgen receptor; Aromatase; Sex hormone-binding globulin, G03CA07;G03CC04
vandetanib,Medullary thyroid cancer;Metastatic disease;Metastatic neoplasm,Abdominal pain;Abdominal wall abscess;Acne;Alanine aminotransferase increased;Alanine aminotransferase normal;Alopecia;Altered state of consciousness;Amylase increased;Angiopathy;Anuria;Anxiety;Appendicitis;Arrhythmia;Arthralgia;Asthenia;Atrial fibrillation;Balance disorder;Bipolar I disorder;Bipolar disorder;Bladder pain;Blood bilirubin increased;Blood calcium decreased;Blood creatinine increased;Blood glucose decreased;Blood glucose increased;Blood magnesium decreased;Blood magnesium increased;Blood potassium decreased;Blood potassium increased;Body temperature increased;Bone cancer metastatic;Bradycardia;Brain oedema;Bronchitis;Bronchospasm;Ca++ increased;Calcium low;Calculus ureteric;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure acute;Cardio-respiratory arrest;Cataract;Cellulitis;Cerebral ischaemia;Chest pain;Cholecystitis;Cholelithiasis;Chromaturia;Chylothorax;Clonus;Colitis;Conduction disorder;Conjunctivitis;Constipation;Convulsion;Corneal deposits;Corneal opacity;Cough;Creatinine increased;Cyst;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Depressed level of consciousness;Depression;Dermatitis;Dermatitis acneiform;Dermatitis bullous;Device occlusion;Diarrhoea;Diverticulitis;Dizziness;Dry eye;Dry mouth;Dry skin;Dysaesthesia;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Endocrine disorder;Epistaxis;Erythema multiforme;Eye disorder;Faecal incontinence;Fatigue;Folliculitis;Fungal infection;Furuncle;Gastritis;Gastroenteritis;Gastroenteritis bacterial;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;General physical health deterioration;Glaucoma;Glucose decreased;Glucose increased;Glucose low;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoglobin increased;Haemoptysis;Haemorrhage;Halo vision;Headache;Hepatobiliary disease;Hypercalcaemia;Hyperglycaemia;Hypertension;Hypertensive crisis;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypothyroidism;Ileus;Impaired healing;Infected bites;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Interstitial lung disease;Intestinal perforation;Joint injury;Keratopathy;Laryngitis;Lethargy;Loss of consciousness;Malignant hypertension;Malnutrition;Mediastinal disorder;Mental disorder;Mg reduced;Mg++ increased;Micturition urgency;Mucosal inflammation;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal disorder;Nail abnormality NOS;Nail disorder;Nasopharyngitis;Nausea;Neoplasm;Nephrolithiasis;Nephropathy;Nervous system disorder;Neutropenia;Oedema;Pain;Pancreatitis;Paraesthesia;Pelvic venous thrombosis;Pericarditis;Peripheral sensorimotor neuropathy;Peritonitis;Photopsia;Photosensitivity reaction;Platelet count decreased;Pneumatosis intestinalis;Pneumonia;Pneumonia aspiration;Pollakiuria;Polyp;Posterior reversible encephalopathy syndrome;Potassium increased;Potassium low;Protein urine present;Proteinuria;Pruritus;Pyelonephritis;Rash;Renal colic;Renal failure;Respiratory arrest;Respiratory failure;Sepsis;Serum amylase increased;Serum creatinine increased;Sinusitis;Skin disorder;Skin ulcer;Small intestinal perforation;Staphylococcal bacteraemia;Staphylococcal infection;Stent occlusion;Stevens-Johnson syndrome;Stomatitis;Sudden death;Thrombocytopenia;Torsade de pointes;Tracheitis;Transient ischaemic attack;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Vena cava thrombosis;Venomous bite;Ventricular arrhythmia;Viral diarrhoea;Vision blurred;Visual acuity reduced;Visual impairment;Vomiting;Weight decreased;White blood cell count decreased,small molecule,approved,"N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; Vandetanib; 2.7.10.1; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR-2; VEGFR2; 2.7.10.1; Cadherin family member 12; CDHF12; CDHR16; Proto-oncogene c-Ret; PTC; 2.7.10.1; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; L-VEGF; Vascular permeability factor; VEGF; VPF; 2.7.10.2; Breast tumor kinase; BRK; Tyrosine-protein kinase BRK; 2.7.10.1; Endothelial tyrosine kinase; hTIE2; p140 TEK; TIE2; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains-2; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; VMCM; VMCM1; 1.14.13.148; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 1; Dimethylaniline oxidase 1; Fetal hepatic flavin-containing monooxygenase 1; FMO 1; Trimethylamine monooxygenase; 1.14.13.148; 1.14.13.32; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO 3; FMO form 2; FMO II; Hepatic flavin-containing monooxygenase 3; Trimethylamine monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; hOCT2; OCT2; Organic cation transporter 2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1","Vascular endothelial growth factor receptor 2; Proto-oncogene tyrosine-protein kinase receptor Ret; Epidermal growth factor receptor; Vascular endothelial growth factor A, long form; Protein-tyrosine kinase 6; Angiopoietin-1 receptor",L01EX04
telavancin,Infection;Methicillin-resistant Staphylococcus aureus infection;Nosocomial pneumonia;Pneumonia;Pneumonia bacterial;Renal failure;Renal impairment;Staphylococcal infection;Ventilator associated pneumonia,Abdominal pain;Ageusia;Agitation;Alanine aminotransferase increased;Anaemia;Anaphylactic shock;Angina pectoris;Angiopathy;Anxiety;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Back pain;Blood and lymphatic system disorders;Blood creatinine increased;Blood urea increased;Body temperature increased;Bradycardia;Cardiac disorder;Cardiac failure congestive;Chills;Clostridium colitis;Confusional state;Connective tissue disorder;Constipation;Cramp muscle;Deafness;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Eosinophil count increased;Erythema;Eye disorder;Eye irritation;Face oedema;Fatigue;Feeling abnormal;Flatulence;Flushing;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Haematuria;Headache;Hepatitis;Hepatobiliary disease;Hiccups;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypoaesthesia oral;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hypotension;Ill-defined disorder;Immune system disorder;Infestation;Infestation NOS;Infusion site erythema;Infusion site pain;Infusion site reactions;Insomnia;International normalised ratio increased;Laryngeal pain;Leukopenia;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Microalbuminuria;Migraine;Multi-organ failure;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nausea;Nephropathy toxic;Nephrotoxicity;Nervous system disorder;Neutrophil count increased;Non-cardiac chest pain;Oedema peripheral;Oliguria;Pain;Palpitations;Paraesthesia;Parosmia;Pharyngolaryngeal pain;Phlebitis;Pollakiuria;Pruritus;Pruritus generalised;Rash;Red man syndrome;Renal failure;Renal failure acute;Renal impairment;Rigors;Septic shock;Serum creatinine increased;Sinus tachycardia;Skin disorder;Somnolence;Supraventricular extrasystoles;Thrombocytopenia;Thrombocytosis;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine odour abnormal;Urticaria;Ventricular extrasystoles;Vision blurred;Vomiting,small molecule,approved,Telavancin; Telavancina; Télavancine; Telavancinum; NACHRA3; Corticotropin-releasing hormone receptor 1; CRF-R-1; CRF-R1; CRFR; CRFR-1; CRFR1; CRH-R-1; CRH-R1; CRHR,Neuronal acetylcholine receptor subunit alpha-2; Neuronal acetylcholine receptor subunit alpha-3; Corticotropin-releasing factor receptor 1,J01XA03
sevelamer,Chronic kidney disease;Hyperphosphataemia;Renal failure chronic;Renal osteodystrophy,Abdominal distension;Abdominal pain;Anorexia;Arthralgia;Asthenia;Constipation;Decreased appetite;Dermatitis;Diarrhoea;Diverticulitis;Dyspepsia;Faecalith;Faecaloma;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Ileus;Intestinal obstruction;Intestinal perforation;Musculoskeletal discomfort;Nausea;Pain;Peritonitis;Pruritus;Rash;Subileus;Vomiting,small molecule,approved,Sevelamer; Sévélamer; Sevelamero; Sevelamerum,Phosphate,V03AE02
axitinib,Renal cell carcinoma,Abdominal pain;Abdominal pain upper;Acute coronary syndrome;Acute myocardial infarction;Alanine aminotransferase increased;Alopecia;Amylase increased;Anaemia;Anal fistula;Angiopathy;Arthralgia;Aspartate aminotransferase increased;Asthenia;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood thyroid stimulating hormone increased;Brain cancer metastatic;Cardiac failure;Cerebral haemorrhage;Cerebrovascular accident;Connective tissue disorder;Constipation;Cough;Creatinine increased;Decreased appetite;Deep vein thrombosis;Dehydration;Dermatitis;Diarrhoea;Dizziness;Dry skin;Dysfunction thyroid;Dysgeusia;Dyspepsia;Dysphonia;Dyspnoea;Ear and labyrinth disorders;Embolism;Endocrine disorder;Epistaxis;Erythema;Fatigue;Fistula;Flatulence;Gastric haemorrhage;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Gingival bleeding;Glossodynia;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoglobin increased;Haemoptysis;Haemorrhage;Haemorrhoids;Headache;Hepatic impairment;Hepatobiliary disease;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperkalaemia;Hypernatraemia;Hypertension;Hypertensive crisis;Hyperthyroidism;Hypoalbuminaemia;Hypocalcaemia;Hypoglycaemia;Hyponatraemia;Hypophosphataemia;Hypothyroidism;Leukopenia;Lipase increased;Liver disorder;Lower gastrointestinal haemorrhage;Malnutrition;Mediastinal disorder;Metastases to central nervous system;Mucosal inflammation;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nausea;Neoplasm malignant;Nervous system disorder;Neutropenia;Oropharyngeal pain;Pain in extremity;Phosphatase alkaline increased;Platelet count decreased;Polycythaemia;Posterior reversible encephalopathy syndrome;Protein urine present;Proteinuria;Pruritus;Pulmonary embolism;Rash;Rectal haemorrhage;Renal failure;Renal failure acute;Retinal vein occlusion;Skin disorder;Stomatitis;Thrombocytopenia;Thromboembolic event;Thrombosis;Thyroid disorder;Thyrotropin high;Tinnitus;Transient ischaemic attack;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vomiting;Weight decreased;White blood cell count decreased,small molecule,approved; investigational,"Axitinib; Axitinibum; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; 2.7.10.2; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; ABL; JTK7; p150; Proto-oncogene c-Abl; 2.7.10.1; FLT; FLT-1; Fms-like tyrosine kinase 1; FRT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; Vascular permeability factor receptor; VEGFR-1; VEGFR1; 2.7.10.1; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR-2; VEGFR2; 2.7.10.1; FLT-4; Fms-like tyrosine kinase 4; Tyrosine-protein kinase receptor FLT4; VEGFR-3; VEGFR3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Tyrosine-protein kinase ABL1; Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 3,L01EK01
sunitinib,Carcinoma of lung;Convulsion;Disease progression;Gastrointestinal stromal tumour;Hypertension;Hypothyroidism;Lung neoplasm malignant;Metastatic disease;Metastatic neoplasm;Metastatic renal cell carcinoma;Neoplasm;Neoplasm malignant;Neuroendocrine tumour;Protein urine present;Proteinuria;Pulmonary embolism;Renal cell carcinoma;Subclinical hypothyroidism,Abdominal abscess;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abdominal sepsis;Abscess;Abscess limb;Acalculous cholecystitis;Acne;Acute coronary syndrome;Adrenal insufficiency;Ageusia;Alanine aminotransferase increased;Albumin low;Alertness decreased;Alopecia;Amylase increased;Anaemia;Anal abscess;Anal fistula;Angioedema;Angiopathy;Anorexia;Aphthous stomatitis;Apoptosis;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Bacterial infection;Bilirubin total increased;Blindness;Blindness cortical;Blister;Blood albumin decreased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood calcium decreased;Blood creatinine increased;Blood disorder;Blood glucose decreased;Blood glucose increased;Blood magnesium decreased;Blood phosphorus decreased;Blood potassium decreased;Blood potassium increased;Blood pressure increased;Blood sodium increased;Blood thyroid stimulating hormone increased;Blood uric acid increased;Body temperature increased;Bone pain;Bradycardia;Bronchitis;Burkitt's lymphoma;Ca++ increased;Calcium low;Candida infection;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiomyopathy;Cellulitis;Cellulitis gangrenous;Cerebral infarction;Cerebrovascular accident;Cheilitis;Chest pain;Chills;Cholecystitis;Chromaturia;Congenital skin disorder;Connective tissue disorder;Constipation;Convulsion;Cough;Creatinine increased;Decreased appetite;Deep vein thrombosis;Dehydration;Depressed level of consciousness;Depression;Dermatitis;Dermatitis bullous;Dermatitis psoriasiform;Destructive thyroiditis;Diarrhoea;Disseminated intravascular coagulation;Diverticulitis;Dizziness;Dry mouth;Dry skin;Dysfunction thyroid;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dyspnoea exertional;Eczema;Ejection fraction decreased;Electrocardiogram QT prolonged;Embolism;Endocrine disorder;Epistaxis;Eructation;Erythema;Erythema multiforme;Exfoliative rash;Eye disorder;Eyelid oedema;Face oedema;Fatal outcomes;Fatigue;Febrile neutropenia;Fistula;Flank pain;Flatulence;Flushing;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal perforation;Gastrooesophageal reflux disease;Gingival abscess;Gingival bleeding;Gingival pain;Gingivitis;Glossitis;Glossodynia;Glucose decreased;Glucose increased;Haematemesis;Haematochezia;Haematoma;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Haemorrhoids;Hair colour changes;Hair discoloration;Headache;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hepatotoxicity;Hot flush;Hyperaesthesia;Hypercalcaemia;Hyperglycaemia;Hyperkalaemia;Hyperkeratosis;Hypernatraemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hyperuricaemia;Hypoaesthesia;Hypoalbuminaemia;Hypocalcaemia;Hypogeusia;Hypoglycaemia;Hypokalaemia;Hyponatraemia;Hypophosphataemia;Hypothyroidism;Immune system disorder;Impaired healing;Infarction;Infection;Infestation;Infestation NOS;Influenza like illness;Insomnia;Intestinal perforation;Lacrimation increased;Laryngeal pain;Left ventricular dysfunction;Left ventricular failure;Leukoderma;Leukopenia;Limb discomfort;Lipase increased;Liver abscess;Liver function test abnormal;Lower respiratory tract infection;Lymphocyte count decreased;Lymphopenia;Malnutrition;Mediastinal disorder;Melaena;Menopausal symptoms;Mental disorder;Metastasis;Metrorrhagia;Mg reduced;Mouth ulceration;Mucosal dryness;Mucosal inflammation;Multi-organ failure;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myelosuppression;Myocardial disorder;Myocardial ischaemia;Myopathy;Nail disorder;Nasal congestion;Nasal dryness;Nasopharyngitis;Nausea;Necrotising fasciitis;Neoplasm;Neoplasm malignant;Nephrotic syndrome;Nervous system disorder;Neuropathy peripheral;Neutropenia;Oedema;Oedema peripheral;Oesophageal candidiasis;Oesophagitis;Oral candidiasis;Oral discomfort;Oral herpes;Oral pain;Oropharyngeal pain;Osteomyelitis;Osteonecrosis of jaw;Pain;Pain in extremity;Pancreatic abscess;Pancreatitis;Pancytopenia;Paraesthesia;Pericardial effusion;Perineal abscess;Periorbital oedema;Perirectal abscess;Peritoneal haemorrhage;Phosphatase alkaline increased;Phosphorus low;Pigmentation disorder;Platelet count decreased;Pleural effusion;Pneumonia;Pneumothorax;Posterior reversible encephalopathy syndrome;Potassium increased;Potassium low;Primary hypothyroidism;Proctalgia;Protein urine present;Proteinuria;Prurigo;Pruritus;Pulmonary embolism;Pulmonary haemorrhage;Pulmonary oedema;Pyoderma gangrenosum;Raised liver function tests;Rash;Rash erythematous;Rash follicular;Rash generalised;Rash macular;Rash maculo-papular;Rash papular;Rectal abscess;Rectal haemorrhage;Reflux esophagitis;Renal failure;Renal failure acute;Renal impairment;Respiratory failure;Respiratory tract infection;Rhabdomyolysis;Sepsis;Septic shock;Shock;Skin discolouration;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Skin infection;Skin lesion;Sodium decreased;Sodium high;Splinter haemorrhages;Stevens-Johnson syndrome;Stomatitis;Subcutaneous abscess;Sudden death;Taste altered;Thrombocytopenia;Thromboembolic event;Thrombosis;Thrombotic microangiopathy;Thyroid disorder;Thyroiditis;Thyrotoxicosis;Thyrotropin high;Tongue ulceration;Tooth abscess;Torsade de pointes;Toxic epidermal necrolysis;Transient ischaemic attack;Tumour lysis syndrome;Tumour necrosis;Unspecified disorder of skin and subcutaneous tissue;Unspecified visual loss;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine color abnormal;Viral infection;Vomiting;Weight decreased;White blood cell count decreased;Wound haemorrhage;Yellow skin,small molecule,approved; investigational,"Sunitinib; Sunitinibum; 2.7.10.1; Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; PDGF-R-beta; PDGFR; PDGFR-1; PDGFR-beta; PDGFR1; Platelet-derived growth factor receptor 1; 2.7.10.1; FLT; FLT-1; Fms-like tyrosine kinase 1; FRT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; Vascular permeability factor receptor; VEGFR-1; VEGFR1; 2.7.10.1; p145 c-kit; PBT; Piebald trait protein; Proto-oncogene c-Kit; SCFR; Tyrosine-protein kinase Kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; 2.7.10.1; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR-2; VEGFR2; 2.7.10.1; FLT-4; Fms-like tyrosine kinase 4; Tyrosine-protein kinase receptor FLT4; VEGFR-3; VEGFR3; 2.7.10.1; CD135; Fetal liver kinase-2; FL cytokine receptor; FLK-2; FLK2; FLT-3; Fms-like tyrosine kinase 3; Stem cell tyrosine kinase 1; STK-1; STK1; CSF-1 receptor; CSF-1-R; CSF-1R; FMS; M-CSF-R; Proto-oncogene c-Fms; 2.7.10.1; Alpha platelet-derived growth factor receptor; Alpha-type platelet-derived growth factor receptor; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; PDGFR-2; PDGFR-alpha; PDGFR2; Platelet-derived growth factor alpha receptor; Platelet-derived growth factor receptor 2; RHEPDGFRA; 2.7.10.1; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Platelet-derived growth factor receptor beta; Vascular endothelial growth factor receptor 1; Mast/stem cell growth factor receptor Kit; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 3; Receptor-type tyrosine-protein kinase FLT3; Macrophage colony-stimulating factor 1 receptor; Platelet-derived growth factor receptor alpha; Hepatocyte growth factor receptor,L01EX01;L01XE04
sitagliptin,Chronic renal insufficiency;Diabetic ketoacidosis;Hypoglycaemia;Hypoglycemic reaction;Pancreatitis;Renal failure;Renal failure chronic;Renal impairment;Type 1 diabetes mellitus;Type 2 diabetes mellitus,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Acute bronchitis;Anaphylactic responses;Anaphylactic shock;Angioedema;Angiopathy;Anxiety;Arthralgia;Asthenia;Back pain;Blood creatinine increased;Blood glucose decreased;Blood glucose increased;Breast disorder;Bronchitis;Bundle branch block;Cardiac disorder;Cellulitis;Connective tissue disorder;Constipation;Contusion;Cough;Cutaneous vasculitis;Decreased appetite;Depression;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dysmenorrhoea;Dyspepsia;Ear and labyrinth disorders;Eczema;Erectile dysfunction;Erythema multiforme;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Flatulence;Fungal skin infection;Gastric ulcer helicobacter;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Headache;Helicobacter gastritis;Hepatic steatosis;Hepatobiliary disease;Herpes zoster;Hyperglycaemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoglycaemia;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Laryngeal pain;Lung disorder;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Migraine;Muscle spasms;Muscle tightness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasopharyngitis;Nausea;Neck pain;Nephrolithiasis;Nervous system disorder;Nervousness;Neuropathy peripheral;Non-cardiac chest pain;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Pain;Pain in extremity;Pancreatitis;Pancreatitis acute;Pancreatitis necrotising;Parosmia;Pharyngitis;Pharyngolaryngeal pain;Pneumonia;Rash;Reflux esophagitis;Renal failure;Renal failure acute;Renal impairment;Respiratory tract infection;Retching;Sciatica;Serum creatinine increased;Shoulder pain;Sinus congestion;Sinus headache;Sinusitis;Skin disorder;Somnolence;Stevens-Johnson syndrome;Tension;Tooth infection;Toothache;Tracheobronchitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vertigo;Viral diarrhoea;Vision blurred;Vomiting;Weight increased,small molecule,approved; investigational,"Sitagliptin; Sitagliptina; Sitagliptine; Sitagliptinum; 3.4.14.5; ADABP; ADCP-2; ADCP2; Adenosine deaminase complexing protein 2; CD26; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Dipeptidyl peptidase 4, A10BD07; A10BD12; A10BD24; A10BD29; A10BH01;A10BH01;A10BH51
doxercalciferol,Chronic kidney disease;Hyperparathyroidism secondary;Renal failure chronic,Abscess;Albuminuria;Anaemia;Anorexia;Apathy;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Blood urea increased;Body temperature increased;Bone pain;Bradycardia;Calcinosis;Chest pain;Conjunctivitis;Constipation;Cough;Cough increased;Decreased appetite;Dehydration;Depression;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Feeling abnormal;Flat affect;Headache;Hypercalcaemia;Hypercholesterolaemia;Hypertension;Hypertonia;Ill-defined disorder;Infection;Insomnia;Intoxication;Libido decreased;Malaise;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Nocturia;Oedema;Pancreatitis;Paraesthesia;Photophobia;Poisoning;Polydipsia;Polyuria;Pruritus;Psychotic disorder;Rhinitis;Rhinorrhoea;Sleep disorder;Somnolence;Taste metallic;Urinary tract infection;Urine output increased;Vomiting;Weight decreased;Weight increased,small molecule,approved,"(1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol; 1-Hydroxyergocalciferol; 1-Hydroxyvitamin D2; 1α-Hydroxyergocalciferol; 1α-hydroxyvitamin D2; Doxercalciferol; Doxercalciferolum; Doxercalciférolum; 1,25-dihydroxyvitamin D3 receptor; NR1I1; Nuclear receptor subfamily 1 group I member 1; VDR; 1.14.15.15; 5-beta-cholestane-3-alpha,7-alpha,12-alpha-triol 26-hydroxylase; CYP27; Cytochrome P-450C27/25; Cytochrome P450 27; Sterol 27-hydroxylase; Vitamin D(3) 25-hydroxylase",Vitamin D3 receptor,H05BX03
hydroxocobalamin,"Acidemia;Acidosis;Amblyopia tobacco;Anaemia;Apnoea;Breast feeding;Chest discomfort;Chest tightness;Coeliac disease;Coma;Confusional state;Convulsion;Crohn's disease;Diphyllobothriasis;Disorientation;Dyspnoea;Endocrine disorder;Feeling abnormal;Folate deficiency;Gastritis atrophic;Headache;Hereditary optic atrophy;Hyperpnea;Hypertension;Hyperventilation;Hypotension;Ileitis regional;Immobile;Injury;Intestinal parasitism, unspecified;Intoxication;Iron deficiency;Leber's hereditary optic atrophy neuropathy;Malabsorption;Malnutrition;Mental disorder;Mental state abnormal;Multiple sclerosis;Mydriasis;Nausea;Neoplasm;Neoplasm malignant;Neurological symptom;Optic nerve disorder;Panic reaction;Parasitic gastroenteritis;Pernicious anaemia;Poisoning;Respiratory fume inhalation disorder;Respiratory rate decreased;Shock;Smoke inhalation;Stasis syndrome;Tachypnoea;Trauma;Tropical sprue;Vegetarian;Vitamin B12 deficiency;Vomiting",Abdominal discomfort;Agitation;Anaphylactic shock;Angioedema;Angiopathy;Arrhythmia;Blood and lymphatic system disorders;Blood pressure increased;Body temperature increased;Bullous eruption;Cardiac arrest;Cardiac disorder;Cardiac failure congestive;Chest discomfort;Chest pain;Chills;Chromaturia;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Dizziness;Dry throat;Dyspepsia;Dysphagia;Dyspnoea;Eczema;Electrocardiogram repolarisation abnormality;Erythema;Eye disorder;Feeling abnormal;Feeling hot;Folliculitis;Gastrointestinal disorder;General disorders and administration site conditions;Haematochezia;Headache;Hot flush;Hypersensitivity;Hypokalaemia;Ill-defined disorder;Immune system disorder;Infusion site reaction;Infusion site reactions;Injection site reaction;Malaise;Mediastinal disorder;Memory impairment;Menopausal symptoms;Mental disorder;Nausea;Nervous system disorder;Oedema peripheral;Pain;Pleural effusion;Polycythaemia vera;Pruritus;Pulmonary oedema;Rash;Redness;Sensation of heat;Sensitisation;Skin disorder;Swelling;Tachycardia;Throat tightness;Thrombosis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Ventricular extrasystoles,small molecule,approved,Hydroxocobalamin; Hydroxocobalamin anhydrous; Hydroxocobalamine; Hydroxocobalaminum anhydrous; Hydroxycobalamin; OH-Cbl; Vitamin B-12b; 2.1.1.13; 5-methyltetrahydrofolate--homocysteine methyltransferase; Cobalamin-dependent methionine synthase; MS; Vitamin-B12 dependent methionine synthase; 5.4.99.2; MCM; Methylmalonyl-CoA isomerase; MUT; 3.6.-.-; Haptocorrin; HC; Protein R; TC I; TC-1; TC1; TCI; Transcobalamin I; 460 kDa receptor; IFCR; Intestinal intrinsic factor receptor; Intrinsic factor-cobalamin receptor; Intrinsic factor-vitamin B12 receptor; Alkylcobalamin:glutathione S-alkyltransferase; CblC; Cyanocobalamin reductase (cyanide-eliminating); Methylmalonic aciduria and homocystinuria type C protein; MMACHC; TC II; TC-2; TC2; TCII; Transcobalamin II,"Methionine synthase; Methylmalonyl-CoA mutase, mitochondrial; Methylmalonic aciduria type A protein, mitochondrial; Transcobalamin-1; Protein amnionless; Cubilin; Cyanocobalamin reductase / alkylcobalamin dealkylase", B03BA03; V03AB33;B03BA03;B03BA53
alclometasone,Skin disorder,Acneiform eruption;Allergic contact dermatitis;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Erythema;Folliculitis;Infection;Leukoderma;Miliaria;Pruritus;Rash;Secondary infection;Skin atrophy;Skin striae,small molecule,approved,"(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 7α-Chloro-16α-methylprednisolone; Alclometasone; CBG; Serpin A6; Transcortin; GR; GRL; Nuclear receptor subfamily 3 group C member 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; CBG; Serpin A6; Transcortin",Corticosteroid-binding globulin; Glucocorticoid receptor, S01BA10;D07AB10
entacapone,Parkinson's disease;Parkinsonism,Abdominal pain;Abnormal dreams;Acute coronary syndrome;Ageusia;Agitation;Albuminuria;Altered state of consciousness;Angina pectoris;Anorexia;Anxiety;Arthritis;Asthenia;Ataxia;Atrial fibrillation;Back pain;Bacterial infection;Binge eating;Blood alkaline phosphatase increased;Body temperature increased;Bradycardia;Bundle branch block;Bursitis;Cardiac disorder;Cardiac valve disease;Cardiovascular disorder;Carpal tunnel syndrome;Cataract;Cerebration impaired;Change of bowel habit;Chest pain;Cholangitis;Cholecystitis;Cholelithiasis;Chromaturia;Coagulopathy;Cold sweat;Colitis;Confusional state;Congenital eye disorder;Conjunctivitis;Consciousness abnormal;Constipation;Convulsion;Cramps of lower extremities;Decreased appetite;Delusion;Depression;Dermatitis;Diarrhoea;Diplopia;Discomfort;Disorder sight;Disturbance in attention;Disturbance in sexual arousal;Diverticulitis;Dizziness;Dry mouth;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Eczema;Endocrine disorder;Epistaxis;Erectile dysfunction;Erythema multiforme;Excessive daytime sleepiness;Extrasystoles;Eye disorder;Faeces discoloured;Fatigue;Feeling abnormal;Feeling of body temperature change;Fibroadenoma of breast;Fibroadenosis of breast;Flatulence;Fluid retention;Foetor hepaticus;Fungal skin infection;Gamma-glutamyltransferase increased;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Generalised oedema;Haematuria;Haemoglobin;Haemorrhage;Hallucination;Headache;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Herpes simplex;Hot flush;Hyperbilirubinaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypersexuality;Hypertension;Hyperthyroidism;Hypoaesthesia;Hypoglycaemia;Hypokinesia;Hypotension;Hypotonia;Ill-defined disorder;Impulse-control disorder;Inflammation;Inflicted injury;Injury;Insomnia;Intermittent claudication;Leg pain;Leukopenia;Libido increased;Liver disorder;Loose stools;Loss of consciousness;Malaise;Malnutrition;Menopausal symptoms;Menorrhagia;Mental disability;Mental disorder;Movements involuntary;Muscle contractions involuntary;Muscle relaxant therapy;Muscle spasms;Muscle stiffness;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Nausea;Nervous system disorder;Nervousness;Neuroleptic malignant syndrome;Neuropathy peripheral;Nightmare;Nocturia;Oesophagitis;Orthostatic hypotension;Pain;Pain in extremity;Paranoia;Paranoid reaction;Parkinsonism;Parkinsonism aggravated;Pathological gambling;Pharyngitis;Phosphatase alkaline increased;Photopsia;Piloerection;Pneumonia;Prolonged menses;Pruritus;Purpura;Rash;Rash maculo-papular;Renal pain;Rhabdomyolysis;Salivary hypersecretion;Salivation;Sexual dysfunction;Shock;Sinusitis;Skin cold clammy;Skin disorder;Sleep disorder;Sleep disturbance;Somnolence;Stiffness;Sweating;Sweating increased;Syncope;Tendonitis;Tension;Thinking abnormal;Thrombocytopenia;Tooth disorder;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary incontinence;Urinary tract disorder;Urine color abnormal;Urticaria;Vascular purpura;Vertigo;Visual impairment;Vomiting;Weight decreased,small molecule,approved; investigational,"(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; Entacapona; Entacapone; Entacaponum; N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; 2.1.1.6; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 2.1.1.6; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I",Catechol O-methyltransferase,N04BX02
tolcapone,Parkinson's disease;Parkinsonism,Abdominal pain;Abnormal dreams;Abnormal faeces;Abscess;Accidental injury;Acute coronary syndrome;Acute hepatic failure;Affect lability;Agitation;Alanine aminotransferase increased;Alopecia;Amnesia;Anaemia;Angina pectoris;Angiopathy;Anorectal disorder;Anorexia;Antisocial behaviour;Antisocial personality disorder;Anxiety;Aortic valve stenosis;Apathy;Apnoea;Arrhythmia;Arterial spasm;Arteriosclerosis;Arthralgia;Arthritis;Arthropathy;Asocial behaviour;Asthenia;Asthma;Atrial fibrillation;Bacterial infection;Binge eating;Body temperature increased;Bradycardia;Breast neoplasm;Bronchitis;Calculus bladder;Calculus of kidney;Carcinoma;Cardiac arrest;Cardiac failure;Cardiovascular disorder;Cataract;Cellulitis;Cerebral haemorrhage;Cerebral ischaemia;Cerebrovascular accident;Chest discomfort;Chest pain;Chills;Cholecystitis;Cholelithiasis;Choreoathetosis;Chromaturia;Colitis;Confusional state;Constipation;Coronary artery disease;Cough;Cough increased;Cramp muscle;Decreased appetite;Dehydration;Delirium;Delusion;Dermatitis;Diabetes mellitus;Diarrhoea;Diplopia;Discomfort;Disturbance in sexual arousal;Dizziness;Dreaming excessive;Dry mouth;Duodenal ulcer;Dysgeusia;Dyskinesia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ear pain;Eczema;Encephalopathy;Endophthalmitis;Epistaxis;Erectile dysfunction;Erythema multiforme;Euphoric mood;Extrapyramidal disorder;Eye haemorrhage;Eye pain;Face oedema;Fall;Fatigue;Feeling abnormal;Flank pain;Flat affect;Flatulence;Fracture;Fungal infection;Furuncle;Furunculosis;Gait disturbance;Gastric atony;Gastroenteritis;Gastrointestinal carcinoma;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Glaucoma;Haematuria;Haemoglobin;Haemorrhage;Hallucination;Headache;Hemiplegia;Hepatitis viral;Hepatocellular injury;Hernia;Herpes simplex;Herpes zoster;Hiccups;Hostility;Hypercholesterolaemia;Hyperhidrosis;Hyperkinesia;Hypersensitivity;Hypersexuality;Hypertension;Hypertonia;Hyperventilation;Hypoaesthesia;Hypokinesia;Hypotension;Ill-defined disorder;Impaired gastric emptying;Impulse-control disorder;Infection;Infestation;Infestation NOS;Influenza;Injury;Irritability;Lacrimal disorder;Lacrimal structural disorder;Laryngitis;Lethargy;Leukaemia;Libido decreased;Libido increased;Liver injury;Loss of consciousness;Malaise;Mania;Manic psychosis;Mediastinal disorder;Meningitis;Mental deficiency;Mental disability;Mental disorder;Mental retardation;Micturition disorder;Migraine;Mood swings;Mouth ulceration;Multiple fractures;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Myocardial ischaemia;Myoclonus;Nausea;Neck pain;Neoplasm;Neoplasm malignant;Neoplasm skin;Nephrolithiasis;Nervous system disorder;Nervousness;Neuralgia;Neuroleptic malignant syndrome;Neuropathy;Neuropathy peripheral;Nocturia;Ocular hyperaemia;Oedema;Oedema peripheral;Oesophagitis;Oliguria;Osteoarthritis;Otitis media;Ovarian cancer;Ovarian carcinoma;Pain;Palpitations;Panic reaction;Paraesthesia;Paranoia;Paranoid reaction;Paresis;Parosmia;Pathological gambling;Pericardial effusion;Pharyngitis;Pneumonia;Pollakiuria;Polyuria;Prostate cancer;Prostate carcinoma;Prostatic disorder;Pruritus;Psychotic disorder;Pulmonary embolism;Pulmonary oedema;Rash;Rectal disorder;Rhabdomyolysis;Rhinitis;Salivary hypersecretion;Seborrhoeic dermatitis;Shock;Sinus congestion;Sinusitis;Skin discolouration;Skin disorder;Sleep disorder;Somnolence;Speech disorder;Stiffness;Stomatitis;Sweating;Sweating increased;Syncope;Tachycardia;Tenosynovitis;Tension;Thinking abnormal;Thirst;Thrombocytopenia;Thrombosis;Tinnitus;Tongue disorder;Tooth disorder;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine color abnormal;Urine output increased;Urticaria;Uterine atony;Uterine disorder;Uterine haemorrhage;Uterine hypotonus;Uterine neoplasm;Vaginal infection;Vaginal inflammation;Vasodilation;Vasodilation procedure;Vertigo;Viral infection;Vision blurred;Vomiting;Weight decreased,small molecule,approved; withdrawn,"(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone; 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone; 3,4-dihydroxy-5-nitro-4'-methylbenzophenone; 4'-methyl-3,4-dihydroxy-5-nitrobenzophenone; Tolcapon; Tolcapona; Tolcapone; Tolcaponum; 2.1.1.6; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Catechol O-methyltransferase,N04BX01
warfarin,Acute coronary syndrome;Atrial fibrillation;Cardiac failure congestive;Cerebral artery embolism;Cerebrovascular accident;Clotting;Coagulation time prolonged;Coagulopathy;Embolism;Embolism venous;Genetic polymorphism;Haemoglobin;Haemorrhage;Hepatic function abnormal;Hepatic impairment;Increased anticoagulant effect;Liver disorder;Myocardial infarction;Pulmonary embolism;Renal failure;Renal impairment;Thromboembolic event;Thromboembolism;Thrombophlebitis;Thrombosis;Venous thrombosis,Abdominal bloating;Abdominal cramps;Abdominal distension;Abdominal pain;Alopecia;Anaemia;Anaphylactic shock;Angina pectoris;Angiopathy;Asthenia;Blue toe syndrome;Body temperature increased;Bullous eruption;Cerebral haemorrhage;Chest pain;Chills;Cold intolerance;Coma;Cramp muscle;Dermatitis;Dermatitis bullous;Diarrhoea;Discomfort;Dizziness;Dysgeusia;Dyspnoea;Ecchymosis;Epistaxis;Fat embolism;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Haematemesis;Haematuria;Haemoglobin;Haemoglobin decreased;Haemorrhage;Haemothorax;Headache;Hepatic enzyme increased;Hepatic function abnormal;Hepatitis;Hepatitis cholestatic;Hepatobiliary disease;Hypersensitivity;Hypotension;Ill-defined disorder;Immune system disorder;Infarction;Infection;Jaundice;Lethargy;Liver injury;Loss of consciousness;Malaise;Mediastinal disorder;Melaena;Muscle spasms;Nausea;Neoplasm;Nervous system disorder;Oedema;Pain;Pallor;Pancreatitis;Paraesthesia;Paralysis;Priapism;Pruritus;Purple toes syndrome;Rash;Rectal haemorrhage;Shock;Skin disorder;Skin exfoliation;Skin necrosis;Subdural haematoma;Swelling;Syncope;Temperature intolerance;Traumatic liver injury;Ulcer;Urethral disorder;Urinary tract disorder;Urticaria;Vasculitis;Vomiting,small molecule,approved,"4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin; Coumafene; Warfarin; Warfarina; Zoocoumarin; 1.17.4.4; Vitamin K1 2,3-epoxide reductase subunit 1; VKOR; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC18; Cytochrome P450-6b/29c; AGP 1; AGP1; OMD 1; Orosomucoid-1",Vitamin K epoxide reductase complex subunit 1; Nuclear receptor subfamily 1 group I member 2,B01AA03
vildagliptin,Type 2 diabetes mellitus,Angioedema;Angiopathy;Arthralgia;Asthenia;Blister;Blood glucose decreased;Chills;Connective tissue disorder;Constipation;Dermatitis bullous;Diarrhoea;Dizziness;Fatigue;Flatulence;Gastrointestinal disorder;Gastrooesophageal reflux disease;Headache;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hypoglycaemia;Infection;Infestation;Infestation NOS;Liver function test abnormal;Localized exfoliation;Malnutrition;Musculoskeletal discomfort;Nasopharyngitis;Nausea;Nervous system disorder;Oedema;Oedema peripheral;Pancreatitis;Skin disorder;Skin exfoliation;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Weight increased,small molecule,approved; investigational,Vildagliptin; Vildagliptina; 3.4.14.5; ADABP; ADCP-2; ADCP2; Adenosine deaminase complexing protein 2; CD26; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1,Dipeptidyl peptidase 4, A10BD08;A10BH02
elvitegravir,Immunodeficiency;Infection;Mental disorder,Abdominal distension;Abdominal pain;Asthenia;Autoimmune disorder;Basedow's disease;Dermatitis;Diarrhoea;Dizziness;Dysgeusia;Dyspepsia;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Headache;Inflammation;Insomnia;Mental disorder;Nausea;Nervous system disorder;Opportunistic infection;Osteonecrosis;Paraesthesia;Rash;Skin disorder;Somnolence;Suicidal ideation;Suicide attempt;Unspecified disorder of skin and subcutaneous tissue;Vomiting,small molecule,approved,"6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Elvitegravir; elvitégravir; EVG; GS 9137; Pr160Gag-Pol; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1",Integrase; Gag-Pol polyprotein, J05AR09; J05AR18;J05AJ02
dacarbazine,Hodgkin's disease;Hodgkin's disease lymphocyte depletion type stage unspecified;Hodgkin's disease lymphocyte predominance type stage unspecified;Lymphoma;Malignant melanoma;Malignant neoplasm of islets of Langerhans;Medullary thyroid cancer;Metastatic malignant melanoma;Neoplasm malignant;Neuroblastoma;Non-Hodgkin's lymphoma;Sarcoma,Agranulocytosis;Alopecia;Anaphylactic shock;Anorexia;Arrhythmia;Asthenia;Body temperature increased;Bone marrow depression;Budd-Chiari syndrome;Cellulitis;Confusional state;Convulsion;Decreased appetite;Dermatitis;Diarrhoea;Discomfort;Drug eruption;Eosinophilia;Extravasation;Facial paresthesia;Fatigue;Febrile neutropenia;Feeling abnormal;Fixed drug eruption;Flushing;Granulomatous liver disease;Headache;Hepatic enzyme increased;Hepatic necrosis;Hepatic vein occlusion;Hepatic vein thrombosis;Hepatitis acute;Hepatitis granulomatous;Hepatotoxicity;Hypersensitivity;Hypotension;Ill-defined disorder;Influenza;Injection site pain;Lethargy;Leukopenia;Local reaction;Malaise;Musculoskeletal discomfort;Myalgia;Myelosuppression;Nausea;Orthostatic hypotension;Pain;Pancytopenia;Paraesthesia;Photosensitivity reaction;Phototoxicity;Rash;Stomatitis;Thrombocytopenia;Urticaria;Vascular occlusion;Venoocclusive disease;Venoocclusive liver disease;Vision blurred;Vomiting,small molecule,approved; investigational,"4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(dimethyltriazeno)imidazole-5-carboxamide; 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriazeno)imidazole-4-carboxamide; 5-(dimethyltriazeno)imidazole-4-carboxamide; Biocarbazine; Dacarbazin; Dacarbazina; Dacarbazine; Dacarbazinum; DIC; DTIC; ICDMT; DNA polymerase alpha 70 kDa subunit; 1.1.1.44; PGDH; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J","DNA; DNA polymerase alpha subunit B; 6-phosphogluconate dehydrogenase, decarboxylating",L01AX04
halobetasol,Skin disorder,Acneiform eruption;Allergic contact dermatitis;Dermatitis;Dermatitis acneiform;Dermatitis contact;Dermatitis perioral;Dry skin;Erythema;Folliculitis;Hypertrichosis;Infection;Leukoderma;Miliaria;Pain;Paraesthesia;Pruritus;Rash;Secondary infection;Skin atrophy;Skin striae;Stinging;Telangiectasia;Urticaria,small molecule,approved,21-chloro diflorasone; Halobetasol; Ulobetasol; Ulobétasol; Ulobetasolum; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; GR; GRL; Nuclear receptor subfamily 3 group C member 1; CBG; Serpin A6; Transcortin,Steroid hormone receptor ERR1; Steroid hormone receptor ERR2; Estrogen-related receptor gamma; Glucocorticoid receptor, D07AC21;D05AX55
bosutinib,Blast cell crisis;Breast cancer stage IV;Cardiovascular disorder;Chromosome analysis abnormal;Chronic myeloid leukaemia;Chronic phase chronic myeloid leukemia;Diarrhoea;Leukaemia;Philadelphia chromosome positive,Abdominal discomfort;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Acne;Acute lymphocytic leukaemia;Acute pulmonary oedema;Agranulocytosis;Alanine aminotransferase increased;Amylase increased;Anaemia;Anaphylactic shock;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atypical pneumonia;Back pain;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatine phosphokinase increased;Blood creatinine increased;Body temperature increased;Bronchitis;Bronchopneumonia;Cardiac disorder;Chest discomfort;Chest pain;Connective tissue disorder;Cough;Cytolytic hepatitis;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Discomfort;Dizziness;Drug eruption;Drug hypersensitivity;Dysgeusia;Dyspnoea;Ear and labyrinth disorders;Electrocardiogram QT prolonged;Erythema multiforme;Exfoliative rash;Face oedema;Fatigue;Febrile neutropenia;Feeling abnormal;Fluid retention;Gamma-glutamyltransferase increased;Gastric haemorrhage;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal toxicity;Headache;Hepatic function abnormal;Hepatitis;Hepatitis toxic;Hepatobiliary disease;Hepatotoxicity;Hyperkalaemia;Hypophosphataemia;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Leukopenia;Lipase increased;Liver injury;Lobar pneumonia;Long QT syndrome;Lower respiratory tract infection;Malaise;Malnutrition;Mediastinal disorder;Musculoskeletal discomfort;Myalgia;Myelosuppression;Nasopharyngitis;Nausea;Nervous system disorder;Neutropenia;Oedema;Oedema peripheral;Pain;Pancreatitis acute;Pancytopenia;Pericardial effusion;Pericarditis;Pleural effusion;Pneumonia;Prurigo;Pruritus;Pulmonary hypertension;Rash;Rash generalised;Rash macular;Rash maculo-papular;Rash papular;Renal failure;Renal failure acute;Renal impairment;Respiratory failure;Respiratory tract infection;Respiratory tract infection viral;Skin disorder;Thrombocytopenia;Tinnitus;Traumatic liver injury;Unspecified disorder of skin and subcutaneous tissue;Upper gastrointestinal haemorrhage;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Viral upper respiratory tract infection;Vomiting,small molecule,approved,"4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; Bosutinib; 2.7.10.2; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; ABL; JTK7; p150; Proto-oncogene c-Abl; 2.7.10.2; JTK8; Lck/Yes-related novel protein tyrosine kinase; p53Lyn; p56Lyn; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; 2.7.10.2; p60-Src; pp60c-src; Proto-oncogene c-Src; SRC1; 2.7.12.2; ERK activator kinase 1; MAP kinase kinase 1; MAPK/ERK kinase 1; MAPKK 1; MEK 1; MEK1; MKK1; PRKMK1; 2.7.12.2; ERK activator kinase 2; MAP kinase kinase 2; MAPK/ERK kinase 2; MAPKK 2; MEK 2; MEK2; MKK2; PRKMK2; 2.7.11.25; MAPK/ERK kinase kinase 2; MAPKKK2; MEK kinase 2; MEKK 2; MEKK2; 2.7.11.17; CaM kinase II subunit gamma; CAMK; CAMK-II; CaMK-II subunit gamma; CAMKG; 2.7.10.2; Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog; p55-Fgr; p58-Fgr; p58c-Fgr; Proto-oncogene c-Fgr; SRC2; 2.7.10.2; Hematopoietic cell kinase; Hemopoietic cell kinase; p59-HCK/p60-HCK; p59Hck; p61Hck; 2.7.10.2; PSCTK4; 2.7.11.1; CTCL tumor antigen se20-9; hSLK; KIAA0204; Serine/threonine-protein kinase 2; STE20-like kinase; STE20-related kinase; STE20-related serine/threonine-protein kinase; STK2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Tyrosine-protein kinase ABL1; Tyrosine-protein kinase Lyn; Proto-oncogene tyrosine-protein kinase Src; Dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2; Mitogen-activated protein kinase kinase kinase 2; Calcium/calmodulin-dependent protein kinase type II subunit gamma; Tyrosine-protein kinase Fgr; Tyrosine-protein kinase HCK; Tyrosine-protein kinase Tec; STE20-like serine/threonine-protein kinase,L01EA04
pralidoxime,Muscular weakness;Myasthenia gravis;Pulmonary function test decreased;Respiratory depression,Agitation;Diplopia;Dizziness;Drowsiness;Excitement;Haemoglobin;Haemorrhage;Headache;Hyperventilation;Inflammation;Muscle necrosis;Muscular weakness;Nausea;Pain;Somnolence;Tachycardia;Vision blurred,small molecule,approved; vet_approved,2-PAM; Pralidoxim; Pralidoxima; Pralidoxime; Pralidoximum; 3.1.1.7; AChE; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase,Acetylcholinesterase; Cholinesterase, V03AB54;V03AB04
sulfasalazine,Arthritis;Colitis ulcerative;Crohn's disease;Diarrhoea;Haemoglobin;Haemorrhage;Inflammation;Inflammatory bowel disease;Juvenile idiopathic arthritis;Nausea;Oedema mucosal;Proctitis;Proctocolitis;Rheumatic disorder;Rheumatism;Rheumatoid arthritis;Vomiting,Abdominal pain;Acute generalised exanthematous pustulosis;Acute interstitial pneumonitis;Agranulocytosis;Alopecia;Anaemia;Anaemia megaloblastic;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anorexia;Anuria;Aplastic anaemia;Arthralgia;Ataxia;Azoospermia;Blood and lymphatic system disorders;Blood disorder;Body temperature increased;Bone marrow depression;Cardiac disorder;Cauda equina syndrome;Cholestasis;Chromaturia;Connective tissue disorder;Convulsion;Cough;Crystalluria;Cyanosis;Deafness;Decreased appetite;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Diarrhoea haemorrhagic;Distress;Diuresis;Dizziness;Drowsiness;Drug eruption;Drug fever;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Emotional distress;Encephalopathy;Eosinophilia;Eosinophilic myocarditis;Eruption;Erythema;Erythema multiforme;Face oedema;Factor II deficiency;Folate deficiency;Gastrointestinal disorder;Gastrointestinal pain;Goitre;Guillain-Barre syndrome;Haematuria;Haemolytic anaemia;Haemolytic uraemic syndrome;Hallucination;Hamman-Rich syndrome;Headache;Hearing impaired;Hepatic failure;Hepatic necrosis;Hepatitis;Hepatitis cholestatic;Hepatitis fulminant;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hyperaesthesia;Hypersensitivity;Hypoglycaemia;Hypoprothrombinaemia;Idiopathic pulmonary fibrosis;Immune system disorder;Increased skin sensitivity;Infection;Infertility;Infestation;Infestation NOS;Insomnia;Interstitial lung disease;Jaundice;Jaundice cholestatic;Leukopenia;Lichen planus;Liver function test abnormal;Liver injury;Lupus erythematosus;Malnutrition;Mediastinal disorder;Meningitis;Meningitis aseptic;Mental disorder;Methaemoglobinaemia;Musculoskeletal discomfort;Myelitis transverse;Myelodysplastic syndrome;Myocarditis;Nausea;Necrolysis epidermal;Neoplasm malignant;Nephritis;Nephritis interstitial;Nephrolithiasis;Nephrosis;Nephrotic syndrome;Nervous system disorder;Neuritis;Neuropathy peripheral;Neutropenia;Neutropenic colitis;Neutropenic enterocolitis;Oedema;Oligospermia;Oliguria;Oropharyngeal pain;Pallor;Pancreatitis;Pancytopenia;Pericarditis;Periorbital oedema;Petechiae;Photosensitivity;Photosensitivity reaction;Pityriasis lichenoides et varioliformis acuta;Pleurisy;Pneumonia;Polyarteritis nodosa;Polyuria;Protein urine present;Proteinuria;Pruritus;Pseudomembranous colitis;Pseudomononucleosis;Purpura;Raised liver function tests;Rash;Reaction gastrointestinal;Rhabdomyolysis;Scleral hyperaemia;Serum sickness;Sjogren's syndrome;Skin discolouration;Skin disorder;Somnolence;Stevens-Johnson syndrome;Stomatitis;Systemic lupus erythematosus;Taste disorders;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Toxic pustuloderma;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine color abnormal;Urticaria;Vascular purpura;Vasculitis;Vertigo;Vomiting,small molecule,approved,2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid; 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid; 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene; 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid; 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; Azopyrin; Salazosulfapiridina; Salazosulfapyridine; Salazosulfapyridinum; Salicylazosulfapyridine; Sulfasalazin; Sulfasalazina; Sulfasalazine; Sulfasalazinum; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; I-Rel; NFKB3; Nuclear factor NF-kappa-B p65 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; 1.13.11.-; 5-lipoxygenase; 5-LO; Arachidonate 5-lipoxygenase; LOG5; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 2.3.1.9; ACAT; Acetoacetyl-CoA thiolase; MAT; T2; 3.1.1.4; Group IB phospholipase A2; Phosphatidylcholine 2-acylhydrolase 1B; PLA2; PLA2A; PPLA2; 2.7.11.10; I-kappa-B kinase 2; I-kappa-B-kinase beta; IkBKB; IKK-2; IKK-B; IKK-beta; IKK2; IKKB; NFKBIKB; Nuclear factor NF-kappa-B inhibitor kinase beta; Serine/threonine protein kinase IKBKB; Amino acid transport system xc-; Calcium channel blocker resistance protein CCBR1; Solute carrier family 7 member 11; xCT; DNA-binding factor KBF1; EBP-1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; DNA-binding factor KBF2; H2TF1; Lymphocyte translocation chromosome 10 protein; LYT10; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2; Oncogene Lyt-10; 2.7.11.10; Conserved helix-loop-helix ubiquitous kinase; I-kappa-B kinase 1; I-kappa-B kinase alpha; IkappaB kinase; IkBKA; IKK-1; IKK-A; IKK-alpha; IKK1; IKKA; NFKBIKA; Nuclear factor NF-kappa-B inhibitor kinase alpha; TCF-16; TCF16; Transcription factor 16; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; G21; HCP1; Heme carrier protein 1; hPCFT; HsPCFT; PCFT; PCFT/HCP1; Solute carrier family 46 member 1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; Cell growth-inhibiting gene 29 protein; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; NTCP; SLC10A1; Sodium/taurocholate cotransporting polypeptide; Solute carrier family 10 member 1,"Broad substrate specificity ATP-binding cassette transporter ABCG2; Transcription factor RelB; Transcription factor p65; Proto-oncogene c-Rel; Polyunsaturated fatty acid 5-lipoxygenase; Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1; Acetyl-CoA acetyltransferase, mitochondrial; Phospholipase A2; Inhibitor of nuclear factor kappa-B kinase subunit beta; Cystine/glutamate transporter; Nuclear factor NF-kappa-B p105 subunit; Nuclear factor NF-kappa-B p100 subunit; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Peroxisome proliferator-activated receptor gamma", A07EC01;A07EC01;G01AE10
rifabutin,Acquired immunodeficiency syndrome;Autoimmune disorder;Hepatic function abnormal;Immunocompromised;Immunodeficiency;Infection;Mycobacterial infection;Pulmonary tuberculosis;Renal failure;Renal impairment;Tuberculosis,Abdominal pain;Agranulocytosis;Alanine aminotransferase increased;Anaemia;Anorexia;Aphasia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Bacteraemia;Bacterial infection;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Body temperature increased;Bronchospasm;Burkitt's lymphoma;Chest discomfort;Chest pain;Chest pressure;Chromaturia;Clostridium difficile colitis;Confusional state;Congenital anomaly;Connective tissue disorder;Convulsion;Corneal deposits;Cross resistance;Decreased appetite;Dermatitis;Developmental delay;Diarrhoea;Dysgeusia;Dyspepsia;Dyspnoea;Emotional distress;Eosinophilia;Eructation;Eye disorder;Feeling abnormal;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal symptom NOS;Gram-negative bacterial infection NOS;Headache;Hepatic enzyme increased;Hepatitis;Hepatobiliary disease;Hypersensitivity;Immune system disorder;Insomnia;Jaundice;Leukopenia;Lymphopenia;Musculoskeletal discomfort;Myalgia;Myositis;Nausea;Neutropenia;Neutrophil count decreased;Pain;Pancytopenia;Paraesthesia;Pathogen resistance;Phosphatase alkaline increased;Platelet count decreased;Pruritus;Pseudomembranous colitis;Rash;Shock;Skin discolouration;Skin disorder;Testicular atrophy;Thrombocytopenia;Thrombotic thrombocytopenic purpura;Unspecified disorder of skin and subcutaneous tissue;Urine color abnormal;Uveitis;Vomiting;White blood cell count decreased;White blood cell disorder,small molecule,approved; investigational,"1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; 4-N-isobutylspiropiperidylrifamycin S; Ansamicin; Ansamycin; Rifabutin; Rifabutina; Rifabutine; Rifabutinum; 2.7.7.6; pez; phs; RNA polymerase subunit alpha; RNAP subunit alpha; sez; Transcriptase subunit alpha; 2.7.7.6; groN; nitB; rif; RNA polymerase subunit beta; RNAP subunit beta; ron; stl; stv; tabD; Transcriptase subunit beta; 2.7.7.6; RNA polymerase subunit beta'; RNAP subunit beta'; tabB; Transcriptase subunit beta'; 3.6.4.10; Heat shock 86 kDa; Heat shock protein family C member 1; HSP 86; HSP86; HSP90A; HSPC1; HSPCA; LAP-2; Lipopolysaccharide-associated protein 2; LPS-associated protein 2; Renal carcinoma antigen NY-REN-38; 94 kDa glucose-regulated protein; gp96 homolog; GRP-94; GRP94; Heat shock protein 90 kDa beta member 1; Heat shock protein family C member 4; HSPC4; TRA1; Tumor rejection antigen 1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",DNA-directed RNA polymerase subunit alpha; DNA-directed RNA polymerase subunit beta; DNA-directed RNA polymerase subunit beta'; Heat shock protein HSP 90-alpha; Endoplasmin, A02BD16;J04AB04
methylnaltrexone,Constipation;Opioid induced constipation,Abdominal pain;Diarrhoea;Dizziness;Erythema;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal perforation;Hyperhidrosis;Injection site reaction;Nausea;Nervous system disorder;Oedema;Pain;Redness;Skin disorder;Stinging;Unspecified disorder of skin and subcutaneous tissue;Vomiting,small molecule,approved,MNTX; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; MC4-R; K-OR-1; KOR-1; OPRK,Mu-type opioid receptor; Melanocortin receptor 4; Kappa-type opioid receptor,A06AH01
balsalazide,Colitis ulcerative;Proctocolitis,Abdominal pain;Abdominal pain upper;Alopecia;Alveolitis;Anaemia;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blood bilirubin increased;Blood pressure increased;Body temperature increased;Colitis ulcerative;Connective tissue disorder;Constipation;Cough;Cramp muscle;Decreased appetite;Defaecation urgency;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dysmenorrhoea;Dyspepsia;Dyspnoea;Eosinophilia;Erythema nodosum;Face oedema;Faeces hard;Fatigue;Feeling abnormal;Flatulence;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematochezia;Headache;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatic necrosis;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Ill-defined disorder;Infection;Infestation;Infestation NOS;Influenza;Insomnia;Jaundice;Jaundice cholestatic;Laryngeal pain;Lethargy;Liver function test abnormal;Liver injury;Malaise;Mediastinal disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocarditis;Nasopharyngitis;Nausea;Nephritis interstitial;Nervous system disorder;Pain;Pancreatitis;Pericarditis;Pharyngitis;Pharyngolaryngeal pain;Pleural effusion;Pneumonia;Proctocolitis;Pruritus;Raised liver function tests;Rash;Rectal haemorrhage;Renal failure;Respiratory tract infection;Rhinitis;Stomatitis;Swelling;Tachycardia;Tubulointerstitial nephritis;Upper respiratory tract infection;Urinary tract infection;Vasculitis;Vomiting,small molecule,approved; investigational,"(E)-5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid; Balsalazida; Balsalazide; Balsalazidum; NR1C3; Nuclear receptor subfamily 1 group C member 3; PPAR-gamma; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.13.11.-; 5-lipoxygenase; 5-LO; Arachidonate 5-lipoxygenase; LOG5; 1.7.1.6",Peroxisome proliferator-activated receptor gamma; Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1; Polyunsaturated fatty acid 5-lipoxygenase,A07EC04
rifampicin,Borderline leprosy;Brucellosis;Culture positive;Drug hypersensitivity;Infection;Influenza;Lepromatous leprosy;Leprosy;Meningitis bacterial;Meningococcal infection;Pulmonary tuberculosis;Staphylococcal infection;Tuberculoid leprosy;Tuberculosis,Abdominal discomfort;Acute haemolytic anaemia;Acute interstitial nephritis;Adrenal insufficiency;Agranulocytosis;Amenorrhoea;Anaemia;Anaphylactic shock;Anorexia;Asthenia;Ataxia;Bleeding breakthrough;Blood and lymphatic system disorders;Body temperature increased;Bone pain;Cerebral haemorrhage;Cerebration impaired;Chills;Confusional state;Conjunctivitis;Connective tissue disorder;Cramp muscle;Cutaneous hypersensitivity;Decreased appetite;Dermatitis;Dermatitis atopic;Diarrhoea;Digestion impaired;Disseminated intravascular coagulation;Disturbance in attention;Dizziness;Drowsiness;Dyspepsia;Dyspnoea;Endocrine disorder;Eosinophilia;Epigastric distress;Erythema multiforme;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Flatulence;Flushing;Gastrointestinal disorder;Glossodynia;Haematuria;Haemoglobin decreased;Haemoglobinuria;Haemolysis;Haemolytic anaemia;Headache;Heartburn;Hepatitis;Hepatobiliary disease;Hepatocellular injury;Hypersensitivity;Hypoaesthesia;Immune system disorder;Immunosuppression;Infestation;Infestation NOS;Influenza;Jaundice;Leukopenia;Liver function test abnormal;Liver injury;Mental disability;Metrorrhagia;Muscle spasms;Muscular weakness;Myopathy;Nausea;Necrosis;Nephritis interstitial;Nephrosis lower nephron;Nervous system disorder;Numbness;Numbness generalized;Oedema;Oral pain;Pain;Pemphigoid;Pemphigoid reaction;Pemphigus;Porphyrin metabolism disorder;Pruritus;Pseudomembranous colitis;Pseudomembranous enterocolitis;Psychotic disorder;Purpura;Rash;Reaction gastrointestinal;Renal failure;Renal failure acute;Renal impairment;Renal tubular necrosis;Sensory loss;Shock;Skin disorder;Somnolence;Sore mouth;Stevens-Johnson syndrome;Thrombocytopenia;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vascular purpura;Vasculitis;Visual disturbance;Visual impairment;Vomiting;Wheezing,small molecule,approved,"3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate; RFP; Rifampicin; Rifampicina; Rifampicine; Rifampicinum; Rifampin; 2.7.7.6; RNA polymerase subunit beta; RNAP subunit beta; Transcriptase subunit beta; Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; PXR; Steroid and xenobiotic receptor; SXR; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.-; 7.6.2.2; MOAT-C; MRP5; Multi-specific organic anion transporter C; Multidrug resistance-associated protein 5; pABC11; SMRP; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multispecific organic anion transporter 2; CMOAT2; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D; Multidrug resistance-associated protein 3; 7.6.2.-; ATP-binding cassette sub-family B member 11; BSEP; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",DNA-directed RNA polymerase subunit beta; Nuclear receptor subfamily 1 group I member 2, J04AB02; J04AM02; J04AM05; J04AM06; J04AM07; J04BA51;J04AB02;J04BA50
olsalazine,Acute ulcerative colitis;Colitis ulcerative;Proctocolitis,Abdominal bloating;Abdominal distension;Abdominal pain;Abdominal pain upper;Affect lability;Alopecia;Anaemia;Angioedema;Angiopathy;Anorectal discomfort;Anorexia;Aplastic anaemia;Arthralgia;Asthenia;Atrioventricular block second degree;Blood and lymphatic system disorders;Blood bilirubin increased;Blood in stool;Body temperature increased;Breast disorder;Bronchospasm;Cardiac disorder;Chest pain;Chills;Connective tissue disorder;Cramp muscle;Death;Decreased appetite;Dehydration;Depression;Dermatitis;Diarrhoea;Discomfort rectal;Dizziness;Drowsiness;Dry eye;Dry mouth;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Eosinophilia;Epigastric discomfort;Erectile dysfunction;Erythema;Erythema nodosum;Eye disorder;Fatigue;Fever chills;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Granulomatous liver disease;Haematochezia;Haematuria;Haemolytic anaemia;Headache;Heartburn;Hepatic enzyme increased;Hepatic failure;Hepatic necrosis;Hepatitis;Hepatitis cholestatic;Hepatitis granulomatous;Hepatobiliary disease;Hepatocellular injury;Hepatotoxicity;Hot flush;Hypertension;Immune system disorder;Infection;Infestation;Infestation NOS;Insomnia;Interstitial lung disease;Irritability;Jaundice;Jaundice cholestatic;Lacrimation increased;Lethargy;Leukopenia;Lightheadedness;Liver function test abnormal;Liver injury;Loose stools;Lung disorder;Lymphopenia;Malnutrition;Mediastinal disorder;Menopausal symptoms;Menorrhagia;Mental disorder;Mood swings;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocarditis;Nausea;Nephritis interstitial;Nephrotic syndrome;Nervous system disorder;Neuropathy peripheral;Neutropenia;Oedema peripheral;Orthostatic hypotension;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Pericarditis;Photosensitivity reaction;Pollakiuria;Protein urine present;Proteinuria;Pruritus;Raised liver function tests;Rash;Rectal haemorrhage;Reticulocytosis;Rigors;Skin disorder;Somnolence;Stomatitis;Tachycardia;Tearing eyes;Thrombocytopenia;Thyroid disorder;Tinnitus;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Vertigo;Vision blurred;Vomiting,small molecule,approved,Olsalazine; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 2.1.1.67; Thiopurine methyltransferase; XDHA; Glucose transporter type 9; GLUT-9; GLUT9; Urate transporter; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Gibbon ape leukemia virus receptor 1; GLVR-1; GLVR1; Leukemia virus receptor 1 homolog; Phosphate transporter 1; PiT-1; PIT1; Solute carrier family 20 member 1; 7.2.2.13; Na(+)/K(+) ATPase alpha-1 subunit; Sodium pump subunit alpha-1; 7.2.2.13; KIAA0778; Na(+)/K(+) ATPase alpha-2 subunit; Sodium pump subunit alpha-2; 7.2.2.13; Na(+)/K(+) ATPase alpha-3 subunit; Na(+)/K(+) ATPase alpha(III) subunit; Sodium pump subunit alpha-3; 7.2.2.13; ATP1AL2; Na(+)/K(+) ATPase alpha-4 subunit; Sodium pump subunit alpha-4; ATP1B; Sodium/potassium-dependent ATPase subunit beta-1; Adhesion molecule in glia; AMOG; Sodium/potassium-dependent ATPase subunit beta-2; ATPB-3; Sodium/potassium-dependent ATPase subunit beta-3; ATP1C; ATP1G1; FXYD domain-containing ion transport regulator 2; Na(+)/K(+) ATPase subunit gamma; Sodium pump gamma chain,Human Cyclooxygenases; Thiopurine S-methyltransferase; Xanthine dehydrogenase/oxidase,A07EC03
tegaserod,Chronic idiopathic constipation;Constipation;Functional gastrointestinal disorder;Irritable bowel syndrome,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abortion spontaneous;Affect lability;Agitation;Alanine aminotransferase increased;Albuminuria;Alopecia;Angina pectoris;Angiopathy;Anorectal discomfort;Appendicitis;Arrhythmia;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Back pain;Breast cancer;Breast disorder;Bundle branch block;Carcinoma breast;Cardiac disorder;Cerebration impaired;Chest pain;Cholecystitis;Cholelithiasis;Colitis ischaemic;Connective tissue disorder;Cramp muscle;Cyst;Depression;Dermatitis;Diarrhoea;Disturbance in attention;Dizziness;Dysmenorrhoea;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Eosinophil count increased;Eosinophilia;Eructation;Eye disorder;Face oedema;Faecal incontinence;Fatigue;Flatulence;Flushing;Fungal infection;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haemorrhoids;Headache;Headache aggravated;Hepatitis;Hepatobiliary disease;Hyperbilirubinaemia;Hyperhidrosis;Hypersensitivity;Hypokalaemia;Hypotension;Hypovolaemia;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Injury;Insomnia;Intestinal ischaemia;Laryngeal pain;Leg pain;Lightheadedness;Loss of consciousness;Malnutrition;Mediastinal disorder;Menorrhagia;Mental disability;Mental disorder;Mesenteric ischemia;Mesenteric vascular insufficiency;Migraine;Mood swings;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Neoplasm;Oedema peripheral;Osteoarthritis;Ovarian cyst;Pain;Pain in extremity;Pharyngitis;Pharyngolaryngeal pain;Polyp;Polyuria;Proctalgia;Pruritus;Rash;Rectal haemorrhage;Rectal tenesmus;Renal pain;Shock;Sinus congestion;Sinusitis;Skin disorder;Sleep disorder;Spasm of sphincter of Oddi;Sphincter of Oddi dysfunction;Subileus;Suicide attempt;Supraventricular tachycardia;Sweating increased;Syncope;Transaminases increased;Trauma;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vertigo;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational; withdrawn,1-(((5-Methoxyindol-3-yl)methylene)amino)-3-pentylguanidine; Tegaserod; Tégasérod; Tegaserodum; 5-HT-4; 5-HT4; Serotonin receptor 4; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 5-HT-2; 5-HT-2A; HTR2; Serotonin receptor 2A; 5-HT-2B; 5-HT2B; Serotonin receptor 2B; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1,5-hydroxytryptamine receptor 4; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B,A03AE02;A06AX06
ofatumumab,Chronic lymphocytic leukaemia;Chronic lymphocytic leukaemia refractory,Abdominal pain upper;Agranulocytosis;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Aplasia;Arthralgia;Asthenia;Back pain;Bacteraemia;Body temperature increased;Bronchitis;Bronchopneumonia;Bronchospasm;Cardiac arrest;Cardiac disorder;Chest discomfort;Chest pain;Chills;Coagulopathy;Connective tissue disorder;Cough;Cytokine release syndrome;Cytopenia;Death;Dermatitis;Diarrhoea;Dyspnoea;Erythema multiforme;Fatigue;Febrile neutropenia;Flushing;Fungal infection;Gastrointestinal disorder;Genital herpes;Headache;Hepatitis B;Herpes NOS;Herpes simplex;Herpes virus infection;Herpes zoster;Hyperhidrosis;Hypersensitivity;Hypertension;Hypotension;Immune system disorder;Infection;Infestation;Infestation NOS;Insomnia;Laryngeal pain;Leukopenia;Lobar pneumonia;Lower respiratory tract infection;Lung infection;Lymphopenia;Malnutrition;Mediastinal disorder;Muscle spasms;Musculoskeletal discomfort;Nasal congestion;Nasopharyngitis;Nausea;Neutropenia;Neutropenic sepsis;Oedema peripheral;Oral herpes;Pain;Pancytopenia;Pharyngolaryngeal pain;Pneumonia;Porphyria cutanea tarda;Porphyria non-acute;Progressive multifocal leukoencephalopathy;Pruritus;Rash;Rash macular;Rash vesicular;Rigors;Sepsis;Septic shock;Sinusitis;Skin disorder;Small intestinal obstruction;Stevens-Johnson syndrome;Tachycardia;Thrombocytopenia;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urticaria;Viral infection,biotech,approved,"HuMax-CD20; HuMax-CD20, 2F2; Ofatumumab; Ofatumumabum; B-lymphocyte surface antigen B1; Bp35; CD20; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 1",B-lymphocyte antigen CD20, L04AG12;L01FA02;L01XC10
deferasirox,Anaemia;Blood creatinine increased;Chronic iron overload;Cooley's anemia;Haemosiderosis;Hepatic cirrhosis;Iron overload;Myelodysplastic syndrome;Serum creatinine increased;Sickle cell anaemia;Thalassaemia;Thalassaemia beta,Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Acute tonsillitis;Agitation;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Anaemia NOS aggravated;Anaphylactic shock;Angioedema;Anxiety;Arthralgia;Asthenia;Back pain;Blood and lymphatic system disorders;Blood creatinine abnormal;Blood creatinine increased;Blood disorder;Body temperature increased;Bronchitis;Cataract;Cholelithiasis;Constipation;Cough;Creatinine increased;Cytopenia;Deafness;Dermatitis;Diarrhoea;Digestion impaired;Dizziness;Drug fever;Drug-induced hepatitis;Drug-induced liver injury;Duodenal ulcer;Dyspepsia;Ear and labyrinth disorders;Ear infection;Erythema multiforme;Eye disorder;Fanconi syndrome;Fatal outcomes;Fatigue;Gastric ulcer;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal symptom NOS;Glycosuria;Haemoglobin;Haemorrhage;Headache;Hearing impaired;Henoch-Schonlein purpura;Hepatic cirrhosis;Hepatic failure;Hepatitis;Hepatobiliary disease;High frequency deafness;Hyperkinesia;Hypersensitivity;Immune system disorder;Infection;Influenza;Insomnia;Iron overload;Laryngeal pain;Lenticular opacities;Leukocytoclastic vasculitis;Liver function test abnormal;Maculopathy;Mediastinal disorder;Mental disorder;Multi-organ failure;Musculoskeletal discomfort;Nasopharyngitis;Nausea;Nephropathy toxic;Nervous system disorder;Neutropenia;Oedema;Oesophagitis;Optic neuritis;Pancreatitis;Pancreatitis acute;Pancytopenia;Pharyngitis;Pharyngolaryngeal pain;Pigmentation disorder;Protein urine present;Proteinuria;Pruritus;Rash;Renal failure;Renal failure acute;Renal tubular disorder;Respiratory tract infection;Rhinitis;Serum creatinine abnormal;Serum transaminase increased;Skin discolouration;Skin disorder;Sleep disorder;Stevens-Johnson syndrome;Thrombocytopenia;Transaminases increased;Tuberculosis;Tubulointerstitial nephritis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vomiting,small molecule,approved; investigational,"Deferasirox; Deferasiroxum; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase",Iron,V03AC03
rifapentine,Pulmonary tuberculosis,Abdominal pain;Abscess;Acne;Ageusia;Aggression;Aggressive reaction;Agitation;Alanine aminotransferase increased;Alcohol abuse;Alopecia;Anaemia;Angiopathy;Anorectal discomfort;Anorexia;Anxiety;Arthralgia;Arthritis;Arthropathy;Aspartate aminotransferase increased;Asthenia;Asthma;Back pain;Bladder pain;Blood alkaline phosphatase increased;Blood lactate dehydrogenase increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Breath sounds abnormal;Bronchitis;Bronchospasm;Carcinoma;Carcinoma of lung;Cervical smear test positive;Cheilitis;Chest X-ray abnormal;Chest pain;Confusional state;Congenital eye disorder;Constipation;Convulsion;Cough;Cystitis;Cystitis noninfective;Decreased appetite;Depressed level of consciousness;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Dizziness;Drug abuse;Dry mouth;Dry skin;Dyspepsia;Dysphonia;Dyspnoea;Dysuria;Ear disorder;Ear pain;Eczema;Epistaxis;Eye disorder;Eye pain;Face oedema;Fatigue;Feeling abnormal;Fracture;Fungal infection;Fungal skin infection;Furuncle;Furunculosis;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gout;Gravitational oedema;Haematoma;Haematuria;Haemoptysis;Haemorrhoids;Headache;Hepatitis;Hepatomegaly;Hepatotoxicity;Herpes zoster;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypertonia;Hyperuricaemia;Hypoaesthesia;Hypochromic anaemia;Hypoglycaemia;Hypophosphataemia;Hyporeflexia;Hypovolaemia;Ill-defined disorder;Increased bronchial secretion;Infection;Infection parasitic;Influenza;Insomnia;Jaundice;Laboratory test abnormal;Lactic dehydrogenase activity increased;Laryngeal oedema;Laryngitis;Leg edema;Leukocytosis;Leukopenia;Leukorrhea;Lipoma;Liver function test abnormal;Loss of consciousness;Lung neoplasm malignant;Lymphadenopathy;Lymphocytosis;Lymphopenia;Malaise;Mastitis;Mastitis male;Meningitis;Micturition disorder;Migraine;Multiple fractures;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myositis;NPN increased;Nail disorder;Nausea;Neoplasm;Neoplasm malignant;Neutropenia;Neutrophilia;Normochromic normocytic anaemia;Normocytic anemia;Oedema peripheral;Oesophagitis;Orthostatic hypotension;Osteoarthritis;Otitis externa;Otitis media;Pain;Palpitations;Pancreatitis;Penis disorder;Pericarditis;Pharyngitis;Phosphatase alkaline increased;Pleural effusion;Pleurisy;Pneumonia;Pneumothorax;Polycythaemia;Porphyrin metabolism disorder;Pregnancy;Proctalgia;Proctitis;Prostatic disorder;Protein urine present;Proteinuria;Pruritus;Pulmonary fibrosis;Purpura;Pyelonephritis;Pyuria;Raised liver function tests;Rash;Rash erythematous;Rash maculo-papular;Rectal tenesmus;Rhinitis;Salivary gland enlargement;Shock;Sinusitis;Skin discolouration;Skin disorder;Smear cervix abnormal;Somnolence;Sputum increased;Stupor;Sweating increased;Syncope;Tachycardia;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Thrombosis;Tooth disorder;Torticollis;Tremor;Tuberculosis;Tympanic membrane perforation;Upper respiratory tract infection;Urethral disorder;Urinary incontinence;Urinary tract infection;Urticaria;Vaginal discharge;Vaginal haemorrhage;Vaginal infection;Vaginal inflammation;Vascular purpura;Vasodilation;Vasodilation procedure;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Cyclopentylrifampicin; Rifapentin; Rifapentine; 2.7.7.6; RNA polymerase subunit beta'; RNAP subunit beta'; Transcriptase subunit beta'; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",DNA-directed RNA polymerase subunit beta',J04AB05
eribulin,Breast cancer;Breast cancer stage IV;Hepatic impairment;Liver disorder;Neuropathy;Neuropathy peripheral,Abdominal distension;Abdominal pain;Alanine aminotransferase increased;Alopecia;Anaemia;Angioedema;Angiopathy;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blood and lymphatic system disorders;Body temperature increased;Bone pain;Candida infection;Cardiac disorder;Chest pain;Chills;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cytopenia;Decreased appetite;Deep vein thrombosis;Dehydration;Demyelinating polyneuropathy;Depression;Dermatitis;Diarrhoea;Disseminated intravascular coagulation;Dizziness;Drug hypersensitivity;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Epistaxis;Erythema;Eye disorder;Fatigue;Febrile neutropenia;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematuria;Headache;Hepatic cancer metastatic;Hepatobiliary disease;Hepatotoxicity;Herpes zoster;Hot flush;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hypoaesthesia;Hypokalaemia;Hypomagnesaemia;Hypophosphataemia;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza like illness;Insomnia;Interstitial lung disease;Lacrimation increased;Lethargy;Leukopenia;Lymphatic disorder;Lymphopenia;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Metastases to liver;Mouth ulceration;Mucosal inflammation;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nail disorder;Nasopharyngitis;Nausea;Neoplasm;Nervous system disorder;Neuritis;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutropenic sepsis;Night sweats;Oedema peripheral;Oral candidiasis;Oral herpes;Oropharyngeal pain;Pain;Pain in extremity;Pancreatitis;Pancytopenia;Paraesthesia;Peripheral motor neuropathy;Peripheral sensorimotor neuropathy;Peripheral sensory neuropathy;Pneumonia;Polyneuropathy;Protein urine present;Proteinuria;Pruritus;Pulmonary embolism;Rash;Renal failure;Rhinitis;Rhinorrhoea;Sepsis;Skin disorder;Stomatitis;Tachycardia;Thrombocytopenia;Tinnitus;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Vertigo;Vomiting;Weight decreased,small molecule,approved; investigational,Eribulin; Eribulina,Tubulin beta-1 chain; Apoptosis regulator Bcl-2,L01XX41
auranofin,Arthritis;Psoriatic arthropathy;Rheumatoid arthritis;Synovitis,Abdominal pain;Agranulocytosis;Alopecia;Anaemia;Angioedema;Anorexia;Aplasia pure red cell;Aplastic anaemia;Colitis ulcerative;Conjunctivitis;Constipation;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Dysgeusia;Dyspepsia;Dysphagia;Eosinophilia;Eye disorder;Flatulence;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingivitis;Glomerulonephritis membranous;Glossitis;Haematuria;Hepatic enzyme increased;Interstitial lung disease;Interstitial pneumonia;Jaundice;Leukopenia;Loose stools;Melaena;Nausea;Nephrotic syndrome;Neuropathy peripheral;Neutropenia;Pancytopenia;Protein urine present;Proteinuria;Pruritus;Rash;Stomatitis;Thrombocytopenia;Ulcerative enterocolitis;Urticaria;Visual impairment;Vomiting;Weight decreased,small molecule,approved; investigational,"(1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate; 2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold; Auranofin; Auranofina; Auranofine; Auranofinum; Triethylphosphine gold; ERR-alpha; ERR1; ESRL1; Estrogen receptor-like 1; Estrogen-related receptor alpha; NR3B1; Nuclear receptor subfamily 3 group B member 1; ERR beta-2; ERR-beta; ERRB2; ESRL2; Estrogen receptor-like 2; Estrogen-related receptor beta; NR3B2; Nuclear receptor subfamily 3 group B member 2; ERR gamma-2; ERR3; ERRG2; Estrogen receptor-related protein 3; KIAA0832; NR3B3; Nuclear receptor subfamily 3 group B member 3; 1.11.1.24; ACR1; Alu corepressor 1; Antioxidant enzyme B166; AOEB166; Liver tissue 2D-page spot 71B; Peroxiredoxin V; Peroxisomal antioxidant enzyme; PLP; Prx-V; Thioredoxin peroxidase PMP20; Thioredoxin-dependent peroxiredoxin 5; TPx type VI; 2.7.11.10; I-kappa-B kinase 2; I-kappa-B-kinase beta; IkBKB; IKK-2; IKK-B; IKK-beta; IKK2; IKKB; NFKBIKB; Nuclear factor NF-kappa-B inhibitor kinase beta; Serine/threonine protein kinase IKBKB","Steroid hormone receptor ERR1; Steroid hormone receptor ERR2; Estrogen-related receptor gamma; Peroxiredoxin-5, mitochondrial; Inhibitor of nuclear factor kappa-B kinase subunit beta",M01CB03
cefdinir,Acute maxillary sinusitis;Acute sinusitis;Bronchitis chronic;Community acquired pneumonia;Infection;Otitis media bacterial;Pharyngitis;Pneumonia;Renal failure;Renal impairment;Rheumatic disorder;Rheumatic fever;Tonsillitis,Abdominal pain;Abnormal faeces;Acute coronary syndrome;Acute enterocolitis;Acute respiratory failure;Agitation;Agranulocytosis;Allergic cutaneous angiitis;Amylase increased;Anaphylactic shock;Anorexia;Aplastic anaemia;Aspartate aminotransferase increased;Asthenia;Asthma;Asthmatic attack;Bleeding tendency;Blood urine;Blood urine present;Body temperature increased;Candida infection;Cardiac failure;Chest pain;Choking sensation;Cholestasis;Coagulopathy;Conjunctivitis;Constipation;Convulsion;Decreased appetite;Dermatitis;Dermatitis diaper;Dermatitis exfoliative;Diarrhoea;Diarrhoea haemorrhagic;Digestion impaired;Disability;Disseminated intravascular coagulation;Dizziness;Dry mouth;Dyskinesia;Dyspepsia;Enterocolitis;Enterocolitis haemorrhagic;Eosinophilic pneumonia;Erythema multiforme;Erythema nodosum;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Haemorrhagic disorder;Headache;Hemorrhagic colitis;Hepatic failure;Hepatic function abnormal;Hepatitis acute;Hepatitis fulminant;Hyperkinesia;Hypersensitivity;Hypertension;Idiopathic thrombocytopenic purpura;Ileus;Insomnia;Interstitial lung disease;Interstitial pneumonia;Jaundice;Laryngeal oedema;Leukocytoclastic vasculitis;Leukopenia;Leukorrhea;Loss of consciousness;Melaena;Microscopic hematuria;Movements involuntary;Myocardial infarction;Nausea;Nephropathy;Nephropathy toxic;Neutropenia;Pancytopenia;Peptic ulcer;Pneumonia;Pruritus;Pseudomembranous colitis;Purpura;Rash;Rash maculo-papular;Renal failure;Renal failure acute;Renal impairment;Rhabdomyolysis;Serum sickness;Shock;Skin candida;Somnolence;Stevens-Johnson syndrome;Stomatitis;Thrombocytopenia;Toxic epidermal necrolysis;Upper gastrointestinal haemorrhage;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;White blood cells urine positive,small molecule,approved,"(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefdinir; Cefdinirum; CFDN; PBP-2; ftsI; Penicillin-binding protein 3; 1.11.2.2; MPO; High-affinity sodium-dependent carnitine cotransporter; OCTN2; Solute carrier family 22 member 5; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1; Kidney H(+)/peptide cotransporter; Oligopeptide transporter, kidney isoform; PEPT2; Peptide transporter 2; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Penicillin-binding protein 2; PBP3; Myeloperoxidase; Peptidoglycan transpeptidase,J01DD15
tapentadol,Acute pain;Back pain;Chronic pain;Diabetic neuropathy;Diabetic peripheral neuropathy;Low back pain;Neuralgia;Osteoarthritis;Pain;Postoperative pain;Procedural pain,Abdominal discomfort;Abnormal dreams;Agitation;Alanine aminotransferase increased;Altered state of consciousness;Anaphylactic shock;Angioedema;Angiopathy;Anxiety;Arthralgia;Aspartate aminotransferase increased;Asthenia;Ataxia;Balance disorder;Bradycardia;Breast disorder;Bundle branch block left;CNS depression NOS;Cardiac disorder;Chills;Confusional state;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cough;Decreased appetite;Depressed level of consciousness;Depression;Dermatitis;Diarrhoea;Disorientation;Disturbance in attention;Dizziness;Drug abuse;Drug hypersensitivity;Drug interaction;Drug withdrawal syndrome;Dry mouth;Dysarthria;Dyspepsia;Dyspnoea;Erectile dysfunction;Euphoric mood;Eye disorder;Fatigue;Feeling abnormal;Feeling drunk;Feeling hot;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Hallucination;Headache;Hot flush;Hyperhidrosis;Hypersensitivity;Hypoaesthesia;Hypotension;Hypotensive;Illusion;Immune system disorder;Impaired gastric emptying;Infection;Infestation;Infestation NOS;Insomnia;Irritability;Lethargy;Loss of consciousness;Lung disorder;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Mental disability;Mental disorder;Mental retardation;Muscle contractions involuntary;Musculoskeletal discomfort;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Nightmare;Oedema;Osteoarthritis;Oxygen saturation decreased;Palpitations;Panic attack;Paraesthesia;Perceptual disturbance;Pollakiuria;Presyncope;Pruritus;Pruritus generalised;Pulmonary function test decreased;Rash;Respiratory depression;Sensation of heaviness;Serotonin syndrome;Sexual dysfunction;Shock;Skin disorder;Somnolence;Suicidal ideation;Syncope;Tachycardia;Tension;Thinking abnormal;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary hesitation;Urinary tract disorder;Urinary tract infection;Urticaria;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Withdrawal syndrome,small molecule,approved,"3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol; PHENOL, 3-((1R,2R)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL)-; Tapentadol; hMOP; M-OR-1; MOP; MOR-1; MOR1; Mu opiate receptor; Mu opioid receptor; NAT1; NET; NET1; Norepinephrine transporter; SLC6A5; Solute carrier family 6 member 2; K-OR-1; KOR-1; OPRK; D-OR-1; DOR-1; OPRD; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I",Mu-type opioid receptor; Sodium-dependent noradrenaline transporter; Kappa-type opioid receptor; Delta-type opioid receptor; Sodium-dependent serotonin transporter,N02AX06
tafluprost,Ocular hypertension;Open angle glaucoma,Asthma;Blepharal pigmentation;Cataract;Common cold;Conjunctival hyperaemia;Conjunctivitis allergic;Cough;Dry eye;Dyspnoea;Endophthalmitis;Erythema of eyelid;Exacerbation of asthma;Eye discharge;Eye disorder;Eye irritation;Eye pain;Eye pruritus;Eyelash darkening;Eyelash discolouration;Eyelash hyperpigmentation;Eyelash thickening;Eyelid oedema;Foreign body sensation in eyes;Growth of eyelashes;Headache;Iris hyperpigmentation;Iritis;Lacrimation increased;Nasopharyngitis;Nervous system disorder;Ocular hyperaemia;Ocular stinging;Photophobia;Pruritus;Punctate keratitis;Rhinitis;Urinary tract infection;Uveitis;Vision blurred;Visual acuity reduced,small molecule,approved,Tafluprost; PGF receptor; PGF2-alpha receptor; Prostanoid FP receptor; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2,Prostaglandin F2-alpha receptor,S01EE05
indacaterol,Asthma;Bronchial hyperreactivity;Bronchitis chronic;Chronic obstructive pulmonary disease;Emphysema,Anaemia;Angina pectoris;Asthma;Atrial fibrillation;Bronchospasm;Bronchospasm paradoxical;COPD exacerbation;Cardiac disorder;Chest discomfort;Chest pain;Chronic obstructive pulmonary disease;Connective tissue disorder;Cough;Dermatitis;Diabetes mellitus;Dizziness;Dry mouth;Dyspnoea;Exacerbation of asthma;Gastrointestinal disorder;Headache;Hyperglycaemia;Hypersensitivity;Hypokalaemia;Immune system disorder;Infection;Infestation;Infestation NOS;Malnutrition;Mediastinal disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial ischaemia;Nasopharyngitis;Nausea;Nervous system disorder;Oedema peripheral;Oropharyngeal pain;Palpitations;Paraesthesia;Pneumonia;Pruritus;Rash;Rhinorrhoea;Sinusitis;Skin disorder;Tachycardia;Throat irritation;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Vertigo,small molecule,approved,"Indacaterol; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Beta-2 adrenergic receptor, R03AK14; R03AL04; R03AL12;R03AC18
rivaroxaban,Acute coronary syndrome;Atrial fibrillation;Cerebrovascular accident;Deep vein thrombosis;Embolism;Hypertension;Pulmonary embolism,Abdominal pain;Abdominal pain upper;Agranulocytosis;Amylase increased;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Angiopathy;Asthenia;Back pain;Bilirubin conjugated increased;Blister;Blood and lymphatic system disorders;Blood bilirubin increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Bronchiectasis;Cardiac disorder;Cerebral haemorrhage;Chest pain;Cholestasis;Compartment syndrome;Conjunctival haemorrhage;Connective tissue disorder;Constipation;Contusion;Cytolytic hepatitis;Dermatitis;Dermatitis atopic;Dermatitis bullous;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dyspepsia;Dyspnoea;Ecchymosis;Embolism venous;Epidural haemorrhage;Epistaxis;Erythema multiforme;Eye disorder;Eye haemorrhage;Fatal outcomes;Fatigue;Feeling abnormal;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingival bleeding;Haemarthrosis;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Headache;Hemiparesis;Hepatic function abnormal;Hepatitis;Hepatobiliary disease;Hypersensitivity;Hypoperfusion;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Jaundice;Lactic dehydrogenase activity increased;Lipase increased;Loss of consciousness;Malaise;Mediastinal disorder;Menorrhagia;Muscle haemorrhage;Muscle spasms;Myocardial ischaemia;Nausea;Nervous system disorder;Oedema;Oropharyngeal pain;Osteoarthritis;Pain;Pain in extremity;Pallor;Post procedural haemorrhage;Pruritus;Pruritus generalised;Pulmonary haemorrhage;Rash;Rectal haemorrhage;Renal failure;Renal failure acute;Retroperitoneal haemorrhage;Shock;Sinusitis;Skin disorder;Stevens-Johnson syndrome;Subdural haematoma;Swelling;Syncope;Tachycardia;Thrombocytosis;Toothache;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular pseudoaneurysm;Venous thromboembolism;Vomiting;Wound haemorrhage;Wound secretion,small molecule,approved,"Rivaroxaban; 3.4.21.6; Stuart factor; Stuart-Prower factor; 1.14.14.-; Albendazole monooxygenase (hydroxylating); Albendazole monooxygenase (sulfoxide-forming); Arachidonic acid epoxygenase; CYPIIJ2; Hydroperoxy icosatetraenoate isomerase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Coagulation factor X, B01AF01;B01AF51;B01AX06
ivermectin,Acarodermatitis;Filariasis;Filariasis lymphatic;Infection;Nodule;Norwegian scabies;Onchocerciasis;Pruritus;Scabies;Skin mass;Strongyloidiasis;Subcutaneous nodule;Volvulus,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abnormal sensation in eye;Anaemia;Anorexia;Anterior uveitis;Apathy;Arthralgia;Asthenia;Asthma;Back pain;Blindness;Body temperature increased;Chest discomfort;Chest pain;Chills;Chorioretinitis;Choroiditis;Coma;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Constipation;Convulsion;Cough;Dandruff;Decreased appetite;Depressed level of consciousness;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dry skin;Dyspnoea;Dysstasia;Encephalopathy;Endophthalmitis;Eosinophilia;Epigastric pain;Erythema multiforme;Eye irritation;Eye redness;Eyelid oedema;Face oedema;Faecal incontinence;Fatigue;Feeling abnormal;Flat affect;Gastrointestinal pain;Haematuria;Headache;Hepatitis;Hypereosinophilia;Hyperhidrosis;Hypersensitivity;Hypotension;Iridocyclitis;Keratitis;Lethargy;Leukopenia;Loose stools;Lymph node pain;Lymph node tenderness;Lymphadenitis;Lymphadenopathy;Lymphadenopathy axillary;Lymphadenopathy cervical;Lymphadenopathy inguinal;Mental status changes;Musculoskeletal discomfort;Myalgia;Nausea;Ocular hyperaemia;Oedema;Oedema peripheral;Oropharyngeal discomfort;Oropharyngeal pain;Orthostatic hypotension;Pain;Pruritus;Rash;Seborrhoeic dermatitis;Sensitisation;Skin burning sensation;Somnolence;Stevens-Johnson syndrome;Stupor;Sweating increased;Synovitis;Tachycardia;Tenderness;Testicular pain;Throat sore;Toxic epidermal necrolysis;Tremor;Unspecified visual loss;Urticaria;Vertigo;Vomiting;Watery diarrhoea,small molecule,approved; investigational; vet_approved,"Ivermectin; Ivermectina; Ivermectine; Ivermectinum; Avermectin-sensitive glutamate-gated chloride channel subunit; Glu-Cl subunit beta; Avermectin-sensitive glutamate-gated chloride channel GluCl alpha; GluCl alpha; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Glutamate-gated chloride channel subunit beta; Glutamate-gated chloride channel alpha, D11AX22;P02CF01
fidaxomicin,Clostridium difficile infection;Diarrhoea;Infection,Abdominal distension;Abdominal pain;Abdominal tenderness;Alanine aminotransferase increased;Anaemia;Angioedema;Blood and lymphatic system disorders;Constipation;Decreased appetite;Dermatitis;Dizziness;Drug eruption;Dry mouth;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Flatulence;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Headache;Hepatobiliary disease;Hyperglycaemia;Hypersensitivity;Immune system disorder;Intestinal obstruction;Malnutrition;Megacolon;Metabolic acidosis;Nausea;Nervous system disorder;Neutropenia;Platelet count decreased;Pruritus;Rash;Skin disorder;Unspecified disorder of skin and subcutaneous tissue;Vomiting,small molecule,approved,"Difimicin ; Fidaxomicin; Fidaxomicina; Lipiarmicin; Lipiarmycin; Lipiarrmycin; Tiacumicin B; sigA; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",RNA polymerase sigma factor SigA,A07AA12
everolimus,"Advanced breast cancer;Angiomyolipoma;Astrocytoma, low grade;Breast cancer;Cerebrosclerosis;Drug level therapeutic;Hepatic impairment;Insulinoma;Liver disorder;Metastatic disease;Metastatic neoplasm;Metastatic renal cell carcinoma;Neoplasm;Neoplasm malignant;Neuroendocrine tumour;Renal cell carcinoma;Renal failure;Renal impairment;Subependymal giant cell astrocytoma;Tuberous sclerosis",Abdominal distension;Abdominal pain;Abdominal pain upper;Acidosis;Acne;Activated partial thromboplastin time prolonged;Acute coronary syndrome;Acute respiratory distress syndrome;Acute respiratory failure;Ageusia;Aggression;Agitation;Alanine aminotransferase increased;Albumin low;Alopecia;Alveolar proteinosis;Alveolitis;Amenorrhea secondary;Amenorrhoea;Anaemia;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Aphthous stomatitis;Aplasia pure red cell;Arthralgia;Ascites;Aspartate aminotransferase increased;Aspergillosis;Aspergillus infection;Asthenia;Atelectasis;Atrial fibrillation;Azotaemia;BK virus infection;Back pain;Bacteraemia;Basal cell carcinoma;Benign neoplasm;Bladder pain;Bladder spasm;Blood albumin decreased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood calcium decreased;Blood cholesterol increased;Blood creatinine increased;Blood disorder;Blood follicle stimulating hormone increased;Blood glucose increased;Blood lactate dehydrogenase increased;Blood luteinising hormone increased;Blood phosphorus decreased;Blood potassium decreased;Blood potassium increased;Blood testosterone decreased;Blood triglycerides increased;Blood urea increased;Blood uric acid increased;Body temperature increased;Breast cancer;Breast disorder;Bronchitis;Bronchitis viral;Bronchospasm;Calcium low;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cataract;Cellulitis;Cervicobrachial syndrome;Cheilitis;Chest discomfort;Chest pain;Chills;Cholecystitis;Cholelithiasis;Chronic hepatic failure;Chronic hepatitis;Cirrhosis alcoholic;Coagulopathy;Colorectal cancer metastatic;Complex regional pain syndrome;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Creatinine increased;Cytomegalovirus infection;Decreased appetite;Deep vein thrombosis;Dehydration;Dermatitis;Dermatitis acneiform;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Discomfort;Disease progression;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dyslipidaemia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Dyspnoea exertional;Dysuria;Embolism;Embolism venous;End stage liver disease;Endocrine disorder;Epigastric discomfort;Epistaxis;Erectile dysfunction;Erythema;Erythropenia;Eye disorder;Eyelid oedema;Fasting hyperglycaemia;Fatal outcomes;Fatigue;Feeling abnormal;Fibrosis;Flatulence;Fluid retention;Flushing;Foetor hepaticus;Folliculitis;Fungal infection;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Generalised oedema;Gingival hypertrophy;Gingival pain;Gingivitis;Glioblastoma;Glomerulonephritis;Glomerulonephropathy;Glossitis;Glossodynia;Glucose increased;Gonadotropic luteinizing hormone increased;Gout;Graft loss;Graft thrombosis;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemolytic uraemic syndrome;Haemoptysis;Haemorrhage;Haemorrhoids;Hallucination;Headache;Hemiparesis;Hepatic artery thrombosis;Hepatic cancer;Hepatic enzyme abnormal;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hepatitis B;Hepatitis B reactivation;Hepatitis C;Hepatobiliary disease;Hepatocellular carcinoma;Hepatocellular injury;Herpes virus infection;Herpes zoster;Hirsutism;Histiocytosis;Hot flush;Hydronephrosis;Hypercalcaemia;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperlipidaemia;Hyperparathyroidism;Hypersensitivity;Hypertension;Hypertensive crisis;Hypertrichosis;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypoglycaemia;Hypogonadism male;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Ileus;Ill-defined disorder;Immune system disorder;Impaired healing;Incision site pain;Incisional hernia;Infection;Infection reactivation;Infectious pneumonitis;Infertility male;Infestation;Infestation NOS;Inflammation;Influenza;Insomnia;Interstitial lung disease;Iron deficiency;Irritability;Jaundice;Joint swelling;Kaposi's sarcoma;Laryngeal pain;Lethargy;Leukocytoclastic vasculitis;Leukocytosis;Leukopenia;Lip pain;Lip ulceration;Lipids increased;Liver disorder;Liver function test abnormal;Localised intraabdominal fluid collection;Loss of consciousness;Lower respiratory tract infection;Lung infiltration;Lymphadenopathy;Lymphangioleiomyomatosis;Lymphocele;Lymphocyte count decreased;Lymphoma;Lymphopenia;Lymphoproliferative disorder;Lymphorrhoea;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Menorrhagia;Menstruation delayed;Menstruation irregular;Mental disorder;Metastatic malignant melanoma;Metastatic melanoma;Metrorrhagia;Micturition urgency;Migraine;Mouth ulceration;Mucosal inflammation;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Nail disorder;Nasal congestion;Nasopharyngitis;Nausea;Neoplasm;Neoplasm skin;Nephritis interstitial;Nephropathy toxic;Nephrosclerosis;Nephrotoxicity;Nervous system disorder;Neuralgia;Neutropenia;Night sweats;Non-Hodgkin's lymphoma;Non-cardiac chest pain;Oedema;Oedema peripheral;Onychoclasis;Onychomycosis;Opportunistic infection;Oral candidiasis;Oral herpes;Oral pain;Oropharyngeal pain;Osteomyelitis;Osteonecrosis;Osteopenia;Osteoporosis;Otitis media;Ovarian cyst;Pain;Pain in extremity;Pain in jaw;Palpitations;Pancreatitis;Pancreatitis acute;Pancytopenia;Paraesthesia;Pericardial effusion;Perinephric collection;Perirenal haematoma;Peritonitis;Pharyngitis;Pharyngitis streptococcal;Pharyngolaryngeal pain;Phosphatase alkaline increased;Phosphate low;Platelet count decreased;Pleural effusion;Pneumonia;Pneumothorax;Pollakiuria;Polyomavirus infections;Polyuria;Potassium increased;Potassium low;Procedural pain;Productive cough;Protein urine present;Proteinuria;Pruritus;Pruritus generalised;Pulmonary alveolar haemorrhage;Pulmonary embolism;Pulmonary oedema;Pulmonary toxicity;Pyelonephritis;Pyuria;Rash;Rash erythematous;Rash generalised;Rash macular;Rash maculo-papular;Reflex sympathetic dystrophy;Renal artery thrombosis;Renal failure;Renal failure acute;Renal haemorrhage;Renal impairment;Renal tubular necrosis;Renal vein thrombosis;Respiratory distress;Respiratory tract infection;Rhabdomyolysis;Rhinitis;Rhinorrhoea;Scrotal oedema;Seborrhoeic keratosis;Sepsis;Seroma;Serum creatinine increased;Shock;Sinus congestion;Sinusitis;Skin disorder;Skin exfoliation;Skin lesion;Skin papilloma;Sodium decreased;Somnolence;Spondylitis;Spondyloarthropathy;Squamous cell carcinoma;Stomatitis;Sudden death;Syncope;Tachycardia;Testosterone low;Thrombocytopenia;Thrombocytosis;Thromboembolic event;Thrombosis;Thrombotic microangiopathy;Thrombotic thrombocytopenic purpura;Tinea pedis;Tongue ulceration;Transaminases increased;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Uraemic syndrome;Urethral disorder;Urethritis;Urethritis noninfective;Urinary retention;Urinary tract disorder;Urinary tract infection;Urine output increased;Vaginal haemorrhage;Venous thromboembolism;Viral diarrhoea;Viral infection;Vision blurred;Vitamin B12 deficiency;Vomiting;Weight decreased;Wheezing;White blood cell count decreased;Wound;Wound complication;Wound dehiscence;Wound infection;X-linked lymphoproliferative syndrome;Xeroderma,small molecule,approved,"40-O-(2-hydroxyethyl)-rapamycin; 42-O-(2-Hydroxyethyl)rapamycin; Everolimus; évérolimus; 2.7.11.1; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; FRAP; FRAP1; FRAP2; Mammalian target of rapamycin; Mechanistic target of rapamycin; mTOR; RAFT1; Rapamycin and FKBP12 target 1; Rapamycin target protein 1; RAPT1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Serine/threonine-protein kinase mTOR, L04AH02;L01EG02;L01XE10
ixabepilone,Breast cancer;Breast cancer stage IV;Locally advanced breast cancer;Neoplasm;Neoplasm malignant,Abdominal pain;Acute coronary syndrome;Acute hepatic failure;Acute pulmonary oedema;Allodynia;Alopecia;Anaemia;Angina pectoris;Angiopathy;Anorexia;Areflexia;Arrhythmia supraventricular;Arthralgia;Asthenia;Atrial flutter;Bacterial infection;Blood and lymphatic system disorders;Body temperature increased;Bone disorder;Burning sensation;Cardiac disorder;Cardiomyopathy;Cerebral haemorrhage;Chest pain;Chills;Coagulopathy;Cognitive disorder;Colitis;Connective tissue disorder;Constipation;Coordination abnormal;Cough;Decreased appetite;Decreased vibratory sense;Dehydration;Dermatitis;Diarrhoea;Dizziness;Dysaesthesia;Dysphagia;Dysphonia;Dyspnoea;Embolism;Enterocolitis;Erythema multiforme;Eye disorder;Fatigue;Febrile neutropenia;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Headache;Hepatobiliary disease;Hot flush;Hyperaesthesia;Hypersensitivity;Hypoaesthesia;Hypokalaemia;Hyponatraemia;Hyporeflexia;Hypotension;Hypovolaemia;Hypovolaemic shock;Ileus;Immune system disorder;Impaired gastric emptying;Infection;Infestation;Infestation NOS;Insomnia;Jaundice;Lacrimation increased;Laryngeal pain;Laryngitis;Left ventricular dysfunction;Lethargy;Leukopenia;Loss of consciousness;Lower respiratory tract infection;Lymphopenia;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Metabolic acidosis;Mucosal inflammation;Multifocal motor neuropathy;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myelosuppression;Myocardial infarction;Myocardial ischaemia;Nail disorder;Nausea;Nephrolithiasis;Nervous system disorder;Neuralgia;Neuritis;Neuromuscular toxicity;Neuropathy;Neuropathy peripheral;Neurotoxicity;Neutropenia;Neutropenic infection;Oedema;Oesophagitis;Pain;Painful response to normal stimuli;Pallanesthesia;Pancytopenia;Paraesthesia;Peripheral motor neuropathy;Peripheral sensorimotor neuropathy;Peripheral sensory neuropathy;Pharyngolaryngeal pain;Pneumonia;Polyneuropathy;Pruritus;Rash;Renal failure;Respiratory failure;Sensorimotor disorder;Sepsis;Shock;Skin disorder;Skin exfoliation;Skin hyperpigmentation;Stomatitis;Syncope;Taste disorders;Thrombocytopenia;Thrombosis;Toxic neuropathy;Transaminases increased;Trismus;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Vasculitis;Vomiting;Weight decreased,small molecule,approved; investigational,"Aza-epothilone B; Azaepothilone B; Ixabepilone; TUBB4; Tubulin beta-4 chain; Tubulin beta-III; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Tubulin beta-3 chain,L01DC04
iron,Chronic kidney disease;Iron deficiency anaemia;Renal failure chronic,Abdominal pain;Acute coronary syndrome;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Anxiety;Arthralgia;Arthritis;Asthenia;Asthma;Back pain;Blood iron abnormal;Body temperature increased;Bone pain;Bronchospasm;Burning sensation;Cardiac failure congestive;Cardiac murmur;Cardio-respiratory arrest;Catheter site infection;Chest pain;Chills;Conjunctivitis;Constipation;Convulsion;Cough;Cramp muscle;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dysgeusia;Dyspnoea;Dyspnoea exacerbated;Ear and labyrinth disorders;Ear pain;Erythema;Eye disorder;Faecal occult blood positive;Fatigue;Feeling abnormal;Feeling hot;Fluid overload;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Gout;Graft complication;Headache;Hyperglycaemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoglycaemia;Hypotension;Ill-defined disorder;Infection;Infestation;Infestation NOS;Influenza like illness;Infusion site burning;Infusion site pain;Injection site burning;Injection site extravasation;Injection site pain;Injection site reaction;Iron deficiency;Local swelling;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Occult blood positive;Oedema;Oedema peripheral;Pain in extremity;Paraesthesia;Peritoneal infection;Peritonitis;Pharyngitis;Pruritus;Rash;Respiratory failure;Rhinitis allergic;Sepsis;Shock;Sinusitis;Skin discolouration;Skin disorder;Swelling;Tachycardia;Throat tightness;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urticaria;Vomiting;Wheezing,small molecule,approved,"Carbonyl iron; Eisen; Electrolytic iron; Fe; fer; Ferrum; Ferrum metallicum; Hierro; Iron powder; Iron, carbonyl; Iron, electrolytic; Iron, elemental; Iron, reduced; Reduced iron; Alpha-globin; Hemoglobin alpha chain; p90; T9; TfR; TfR1; TR; Trfr; 1.14.11.29; C1orf12; HIF-PH2; HIF-prolyl hydroxylase 2; HPH-2; Hypoxia-inducible factor prolyl hydroxylase 2; PHD2; Prolyl hydroxylase domain-containing protein 2; SM-20; 3.5.1.98; HD8; HDACL1; Protein deacetylase HDAC8; Protein decrotonylase HDAC8; EDRF; ERAF; Erythroid differentiation-related factor; Erythroid-associated factor; 1.16.3.1; FRDA; Friedreich ataxia protein; Fxn; X25; 1.16.3.1; Cell proliferation-inducing gene 15 protein; Ferritin H subunit; FTH; FTHL6; 3.1.-.-; DNase IV; FEN-1; Flap structure-specific endonuclease 1; hFEN-1; Maturation factor 1; MF1; RAD2; 3.2.2.-; 4.2.99.18; DNA glycosylase/AP lyase Neil1; DNA-(apurinic or apyrimidinic site) lyase Neil1; Endonuclease VIII-like 1; FPG1; NEH1; Nei homolog 1; Nei-like protein 1; 3.2.2.-; 4.2.99.18; DNA glycosylase/AP lyase Neil2; DNA-(apurinic or apyrimidinic site) lyase Neil2; Endonuclease VIII-like 2; NEH2; Nei homolog 2; Nei-like protein 2; 2.7.7.7; 5'-deoxyribose-phosphate lyase; 5'-dRP lyase; AP lyase; Cuproxidase ceruloplasmin; Ferroxidase ceruloplasmin; Glutathione peroxidase ceruloplasmin; Glutathione-dependent peroxiredoxin ceruloplasmin; Beta-1 metal-binding globulin; Siderophilin; Transferrin","Hemoglobin subunit alpha; Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin", A11AA01; B03AE01; B03AE03; B03AE04;B03AB02;B03AE02
vilazodone,"Agitation;Asthenia;Bradyphrenia;Bradypsychic response;Cerebration impaired;Decreased interest;Depressed mood;Disturbance in attention;Dysphoria;Fatigue;Feeling guilty;Hypersomnia;Insomnia;Major depression;Major depressive disorder, single episode;Mental disability;Suicidal ideation;Suicide attempt;Weight decreased;Weight increased",Abnormal dreams;Agitation;Angle closure glaucoma;Arthralgia;Asthenia;Breast disorder;Cardiac disorder;Cataract;Completed suicide;Connective tissue disorder;Convulsion;Decreased appetite;Diarrhoea;Disturbance in sexual arousal;Dizziness;Dry eye;Dry mouth;Dysgeusia;Dyspepsia;Ejaculation delayed;Erectile dysfunction;Eye disorder;Fatigue;Feeling abnormal;Feeling jittery;Flatulence;Gastroenteritis;Gastrointestinal disorder;Haemorrhagic disorder;Hallucination;Hemorrhage abnormal;Hyperhidrosis;Hypomania;Hyponatraemia;Increased appetite;Insomnia;Irritability;Libido decreased;Malnutrition;Mania;Mental disorder;Migraine;Musculoskeletal discomfort;Nausea;Nervous system disorder;Nervousness;Night sweats;Orgasm abnormal;Palpitations;Panic attack;Paraesthesia;Pollakiuria;Serotonin syndrome;Sexual dysfunction;Skin disorder;Somnolence;Suicidal ideation;Suicide;Suicide attempt;Tremor;Unspecified disorder of skin and subcutaneous tissue;Ventricular extrasystoles;Vision blurred;Vomiting,small molecule,approved,"Vilazodona; Vilazodone; Vilazodonum; 5HT transporter; 5HTT; HTT; SERT; Solute carrier family 6 member 4; 5-HT-1A; 5-HT1A; ADRB2RL1; ADRBRL1; G-21; Serotonin receptor 1A; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 1A,N06AX24
prasugrel,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Angina unstable;Arteriosclerosis;Atherosclerosis;Cerebrovascular accident;Electrocardiogram ST segment elevation;Haemoglobin;Haemorrhage;Myocardial infarction;ST segment elevation myocardial infarction;Thrombosis,Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Asthenia;Atrial fibrillation;Back pain;Blood and lymphatic system disorders;Body temperature increased;Bradycardia;Cerebrovascular accident;Colorectal cancer;Contusion;Cough;Dermatitis;Diarrhoea;Dizziness;Dyspnoea;Ecchymosis;Epistaxis;Eye disorder;Eye haemorrhage;Fatigue;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gingival bleeding;Haematochezia;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Headache;Hypercholesterolaemia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypotension;Immune system disorder;Leukopenia;Mediastinal disorder;Nausea;Neoplasm;Neoplasm malignant;Non-cardiac chest pain;Oedema peripheral;Pain in extremity;Pericardial effusion;Post procedural haemorrhage;Puncture site haemorrhage;Rash;Rectal haemorrhage;Retinal haemorrhage;Retroperitoneal haemorrhage;Skin disorder;Subcutaneous haematoma;Surgery;Surgical intervention;Thrombocytopenia;Thrombocytopenic purpura;Thrombotic thrombocytopenic purpura;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vessel puncture site haematoma,small molecule,approved,"Prasugrel; ADP-glucose receptor; ADPG-R; HORK3; P2T(AC); P2Y(AC); P2Y(ADP); P2Y(cyc); P2Y12; P2Y12 platelet ADP receptor; SP1999; 3.1.1.84; Carboxylesterase 2; CE-2; hCE-2; ICE; Methylumbelliferyl-acetate deacetylase 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",P2Y purinoceptor 12,B01AC22
retapamulin,Impetigo;Laceration;Skin infection;Wound,Angioedema;Application site burn;Application site irritation;Application site pain;Application site paraesthesia;Application site pruritus;Body temperature increased;Burning sensation;Dermatitis contact;Diarrhoea;Eczema;Erythema;Headache;Hypersensitivity;Immune system disorder;Instillation site pain;Nasopharyngitis;Nausea;Pain;Pruritus;Skin disorder;Unspecified disorder of skin and subcutaneous tissue,small molecule,approved,"Retapamulin; Retapamulina; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",50S ribosomal protein L3,D06AX13
fesoterodine,Hypertonic bladder;Urge incontinence,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Airway obstruction NOS;Alanine aminotransferase increased;Angina pectoris;Angioedema;Asthenia;Back pain;Benign prostatic hyperplasia;Cardiac disorder;Central nervous system disorder;Chest pain;Confusional state;Constipation;Cough;Dermatitis;Diarrhoea;Diverticulitis;Dizziness;Dry cough;Dry eye;Dry mouth;Dry skin;Dry throat;Dysgeusia;Dyspepsia;Dysuria;Ear and labyrinth disorders;Electrocardiogram QT corrected interval;Electrocardiogram QT interval;Eye disorder;Face oedema;Fatigue;Feeling abnormal;Feeling of residual urine;Flatulence;Functional gastrointestinal disorder;Gamma-glutamyltransferase increased;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Headache;Hepatic enzyme increased;Hepatobiliary disease;Hypersensitivity;Infection;Infestation;Infestation NOS;Insomnia;Irritable bowel syndrome;Laryngeal pain;Mediastinal disorder;Mental disorder;Micturition disorder;Musculoskeletal disorder;Nasal dryness;Nausea;Nervous system disorder;Obstructive airways disorder;Oedema peripheral;Palpitations;Pharyngolaryngeal pain;Pruritus;Rash;Skin disorder;Somnolence;Tachycardia;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary hesitation;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vertigo;Vision blurred,small molecule,approved,"FESO; Fesoterodina; Fesoterodine; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M5,G04BD11
belinostat,Blood uric acid increased;Hyperuricaemia;Peripheral T-cell lymphoma unspecified,Abdominal pain;Anaemia;Asthenia;Blood creatinine increased;Body temperature increased;Chills;Constipation;Cough;Creatinine increased;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dyspnoea;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Fatigue;Febrile neutropenia;Gastrointestinal pain;Gastrointestinal toxicity;Headache;Hepatic failure;Hepatotoxicity;Hyperlactacidaemia;Hypokalaemia;Hypotension;Infection;Infusion site pain;Multi-organ failure;Nausea;Neoplasm malignant;Oedema peripheral;Phlebitis;Pneumonia;Pruritus;Rash;Thrombocytopenia;Tumour lysis syndrome;Ventricular fibrillation;Vomiting,small molecule,approved; investigational,"(2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE; 2-PROPENAMIDE, N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)-; 2-PROPENAMIDE, N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)-, (2E)-; Belinostat; N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)-2-PROPENAMIDE; N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; 3.5.1.98; HD1; Protein deacetylase HDAC1; Protein deacylase HDAC1; RPD3L1; 3.5.1.98; HD11; 3.5.1.98; HD2; Protein deacylase HDAC2; 3.5.1.98; HD3; Protein deacetylase HDAC3; Protein deacylase HDAC3; RPD3-2; SMAP45; 3.5.1.98; HD4; KIAA0288; 3.5.1.98; Antigen NY-CO-9; HD5; KIAA0600; 3.5.1.98; HD6; KIAA0901; Protein deacetylase HDAC6; Tubulin-lysine deacetylase HDAC6; 3.5.1.98; HD7; HD7a; HDAC7A; Histone deacetylase 7A; Protein deacetylase HDAC7; 3.5.1.98; HD8; HDACL1; Protein deacetylase HDAC8; Protein decrotonylase HDAC8; 3.5.1.98; HD7; HD7b; HD9; HDAC7; HDAC7B; HDRP; Histone deacetylase 7B; Histone deacetylase-related protein; KIAA0744; MEF2-interacting transcription repressor MITR; MITR; 3.5.1.48; 3.5.1.62; HD10; Histone deacetylase 10; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Histone deacetylase,L01XH04
olodaterol,Asthma;Bronchial hyperreactivity;Bronchitis chronic;Chronic obstructive pulmonary disease;Emphysema,Arthralgia;Atrial fibrillation;Back pain;Body temperature increased;Bronchitis;COPD exacerbation;Chronic obstructive pulmonary disease;Connective tissue disorder;Constipation;Cough;Dermatitis;Diarrhoea;Dizziness;Gastrointestinal disorder;Infection;Infestation;Infestation NOS;Lung neoplasm malignant;Mediastinal disorder;Musculoskeletal discomfort;Nasopharyngitis;Nervous system disorder;Pneumonia;Rash;Skin disorder;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection,small molecule,approved,Olodaterol; ADRB2R; B2AR; Beta-2 adrenoceptor; Beta-2 adrenoreceptor; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase,Beta-2 adrenergic receptor, R03AC19;R03AL06
ceftaroline,Bacteraemia;Community acquired pneumonia;Infection;Pneumonia;Pneumonia bacterial;Soft tissue infection,Abdominal pain;Anaemia;Anaphylactic shock;Angiopathy;Blood and lymphatic system disorders;Body temperature increased;Bradycardia;Clostridium difficile colitis;Constipation;Convulsion;Coombs direct test positive;Dermatitis;Diarrhoea;Dizziness;Eosinophilia;Erythema;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hepatitis;Hepatobiliary disease;Hyperglycaemia;Hyperkalaemia;Hypersensitivity;Hypokalaemia;Immune system disorder;Infestation;Infestation NOS;Infusion site reactions;Malnutrition;Nausea;Nervous system disorder;Neutropenia;Pain;Palpitations;Phlebitis;Pruritus;Rash;Renal failure;Skin disorder;Swelling face;Thrombocytopenia;Transaminases increased;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vomiting,small molecule,approved,"(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefamezin; Cefazolin; Cefazolina; Cefazoline; Cefazolinum; Cephamezine; Cephazolidin; Cephazolin; Cephazoline; CEZ; PBP-1a; ponA; Murein polymerase; PBP-1b; pbpF; ponB; PBP-1c; yfgN; PBP-2; pbpA; 2.4.1.129; PBP-3; pbpB; Penicillin-binding protein 3; Peptidoglycan glycosyltransferase 3; 3.1.1.2; 3.1.1.81; 3.1.8.1; A-esterase 1; Aromatic esterase 1; K-45; PON; PON 1; Serum aryldialkylphosphatase 1; IL-15; IL-2; T-cell growth factor; TCGF; 2.1.1.67; Thiopurine methyltransferase; 7.6.2.-; 7.6.2.2; 7.6.2.3; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B; Multidrug resistance-associated protein 4; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4",Penicillin-binding protein 1A; Penicillin-binding protein 1B; Penicillin-binding protein 1C; Penicillin-binding protein 2; Peptidoglycan synthase FtsI; Serum paraoxonase/arylesterase 1; Interleukin-15; Interleukin-2,J01DB04
cabazitaxel,Prostate cancer;Prostate cancer metastatic,Abdominal distension;Abdominal pain;Abdominal pain upper;Alanine aminotransferase increased;Alopecia;Anaemia;Angiopathy;Anorexia;Anxiety;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Back pain;Bladder pain;Blood and lymphatic system disorders;Blood bilirubin increased;Body temperature increased;Breast disorder;Candida infection;Cardiac arrest;Cardiac disorder;Cardiac failure;Cellulitis;Cerebral haemorrhage;Chest pain;Chills;Colitis;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cystitis;Cystitis noninfective;Decreased appetite;Deep vein thrombosis;Dehydration;Diarrhoea;Discomfort;Disease progression;Dizziness;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Electrolyte imbalance;Enterocolitis;Erythema;Eye disorder;Fatal outcomes;Fatigue;Febrile neutropenia;Feeling abnormal;Flank pain;Flushing;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematuria;Haemorrhoids;Headache;Herpes zoster;Hot flush;Hydronephrosis;Hyperglycaemia;Hypersensitivity;Hypertension;Hypoaesthesia;Hypokalaemia;Hypotension;Ileus;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza;Intestinal obstruction;Lacrimation increased;Lethargy;Leukopenia;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Mucosal inflammation;Muscle spasms;Musculoskeletal chest pain;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Neuropathy peripheral;Neutropenia;Neutropenic colitis;Neutropenic enterocolitis;Neutropenic sepsis;Oedema;Oedema peripheral;Oropharyngeal pain;Orthostatic hypotension;Pain;Pain in extremity;Paraesthesia;Pelvic pain;Peripheral sensory neuropathy;Pneumonia;Pollakiuria;Rectal haemorrhage;Renal colic;Renal failure;Renal failure acute;Sciatica;Sepsis;Septic shock;Skin disorder;Tachycardia;Thrombocytopenia;Tinnitus;Transaminases increased;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Ureteric obstruction;Urethral disorder;Urinary incontinence;Urinary retention;Urinary tract disorder;Urinary tract infection;Ventricular fibrillation;Vertigo;Vomiting;Weight decreased,small molecule,approved,"1-HYDROXY-7.BETA.,10.BETA.-DIMETHOXY-9-OXO-5.BETA.,20-EPOXYTAX-11-ENE-2.ALPHA.,4,13.ALPHA.-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE); Cabazitaxel; Cabazitaxelum; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; LDL receptor; VLDL receptor; VLDL-R; GPI-anchored HDL-binding protein 1; GPI-HBP1; HBP1; High density lipoprotein-binding protein 1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Tubulin beta-1 chain,L01CD04
dalteparin,Acute coronary syndrome;Angina pectoris;Angina unstable;Angiopathy;Atrial fibrillation;Chronic renal insufficiency;Clotting;Coagulopathy;Coronary artery disease;Deep vein thrombosis;Deep vein thrombosis postoperative;Disseminated intravascular coagulation;Electrocardiogram ST segment elevation;Embolism;Embolism arterial;Embolism venous;Flushing;Function kidney decreased;Haematoma;Haemoglobin;Haemorrhage;Injury;Major bleed;Myocardial infarction;Neoplasm;Neoplasm malignant;Pulmonary embolism;Renal failure acute;Renal failure chronic;Renal impairment;Solid tumour;Thromboembolism;Thrombophlebitis;Trauma;Venous thromboembolism;Venous thrombosis,Abdominal pain;Abscess;Adrenal haemorrhage;Adrenocortical insufficiency acute;Agranulocytosis;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angina pectoris;Angioedema;Angiopathy;Aplasia cutis congenita;Application site pain;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Asthma;Back pain;Blood and lymphatic system disorders;Blood calcium abnormal;Blood creatinine increased;Body temperature increased;Bullous eruption;Calcinosis;Calcium abnormal NOS;Cardiac disorder;Cardiac valve replacement complication;Cardiovascular disorder;Cellulitis;Cerebrovascular accident;Chest pain;Chills;Coagulation time prolonged;Coma;Confusional state;Congenital anomaly;Connective tissue disorder;Constipation;Coronary artery thrombosis;Cyanosis;Death;Deep vein thrombosis;Dermatitis;Dermatitis bullous;Developmental delay;Diarrhoea;Diplegia;Dizziness;Dyspepsia;Dyspnoea;Dysuria;Ecchymosis;Emotional distress;Endocrine disorder;Eosinophilia;Epidural haemorrhage;Epistaxis;Eruption;Erythema;Erythema multiforme;Eye haemorrhage;Feeling abnormal;Flatulence;Foetal death;Foetal distress syndrome;Gangrene;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gravitational oedema;Haemarthrosis;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhage urinary tract;Headache;Hemorrhage symptom;Henoch-Schonlein purpura;Heparin-induced thrombocytopenia;Hepatitis cholestatic;Hepatobiliary disease;Hepatocellular injury;Hypereosinophilia;Hyperkalaemia;Hyperlipidaemia;Hypersensitivity;Hypertension;Hypoaldosteronism;Hyponatraemia;Hypotension;Hypotonia neonatal;Immune system disorder;Impaired healing;Increased tendency to bruise;Infection;Injection site haematoma;Injection site haemorrhage;Injection site pain;Injection site reaction;Insomnia;Instillation site pain;Intra-abdominal haemorrhage;Intraoperative hemorrhage;Lacrimation;Lacrimation increased;Liver injury;Local reaction;Malaise;Melaena;Mental disorder;Monoplegia;Myocardial infarction;Nausea;Necrolysis epidermal;Necrosis;Neoplasm;Nervous system disorder;Neurological impairment;Neuropathy peripheral;Nodule;Non-Q wave MI;Osteopenia;Osteoporosis;Pain;Pancytopenia;Paraesthesia;Paralysis;Paraplegia;Pericardial haemorrhage;Peripheral ischaemia;Petechiae;Pneumonia;Priapism;Procedural haemorrhage;Prosthetic cardiac valve thrombosis;Pruritus;Pulmonary embolism;Purpura;Rash;Rash erythematous;Rash maculo-papular;Reaction febrile;Rectal haemorrhage;Red blood cell disorders;Renal failure chronic;Retroperitoneal haemorrhage;Rhinitis;Serum creatinine increased;Shock;Sickness;Skin disorder;Skin exfoliation;Skin necrosis;Spinal epidural haematoma;Spinal haematoma;Stevens-Johnson syndrome;Subarachnoid haemorrhage;Subdural haematoma;Surgery;Surgical intervention;Swelling;Systemic allergic reaction;Tachycardia;Thrombocytopenia;Thrombocytosis;Thrombophlebitis leg deep;Thrombosis;Toxic epidermal necrolysis;Ulcer;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal haemorrhage;Vascular purpura;Vomiting;Wound;Wound haematoma,small molecule,approved,alpha-heparin; AT3; ATIII; Serpin C1; L-VEGF; Vascular permeability factor; VEGF; VPF; CD62 antigen-like family member P; GMP-140; GMRP; Granule membrane protein 140; GRMP; LECAM3; Leukocyte-endothelial cell adhesion molecule 3; PADGEM; Platelet activation dependent granule-external membrane protein; 3.2.1.166; Endo-glucoronidase; HEP; Heparanase-1; HPA; HPA1; HPR1; HPSE1; HSE1,"Antithrombin-III; Vascular endothelial growth factor A, long form; P-selectin",B01AB04
tofacitinib,Arthritis;Rheumatoid arthritis,Abdominal pain;Anaemia;Arthralgia;Asthenia;Blood and lymphatic system disorders;Blood creatinine increased;Body temperature increased;Bone disorder;Breast cancer;Cellulitis;Cough;Cyst;Dehydration;Dermatitis;Diarrhoea;Disseminated tuberculosis;Drug-induced liver injury;Dyspepsia;Dyspnoea;Erythema;Fatigue;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;HDL cholesterol increased;Headache;Hepatic steatosis;Hepatobiliary disease;Herpes zoster;High density lipoprotein decreased;High density lipoprotein increased;Hypertension;Infection;Insomnia;Joint swelling;Low density lipoprotein increased;Lymphoma;Lymphopenia;Malignant melanoma;Malnutrition;Mediastinal disorder;Melanoma skin;Mental disorder;Musculoskeletal discomfort;Musculoskeletal pain;Nasopharyngitis;Nausea;Neoplasm;Neoplasm malignant;Nervous system disorder;Neutropenia;Non-Hodgkin's lymphoma;Oedema peripheral;Opportunistic infection;Paraesthesia;Pneumonia;Polyp;Prostate cancer;Pruritus;Rash;Serum creatinine increased;Sinus congestion;Skin disorder;Tendonitis;Tuberculosis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Vomiting,small molecule,approved; investigational,"Tasocitinib; Tofacitinib; Tofacitinibum; 2.7.10.2; JAK-1; JAK1A; JAK1B; Janus kinase 1; 2.7.10.2; JAK-2; Janus kinase 2; 2.7.10.2; JAK-3; Janus kinase 3; L-JAK; Leukocyte janus kinase; 2.7.10.2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase",Tyrosine-protein kinase JAK1; Tyrosine-protein kinase JAK2; Tyrosine-protein kinase JAK3; Non-receptor tyrosine-protein kinase TYK2,L04AF01
azilsartan,Acute coronary syndrome;Angina pectoris;Cardiac failure;Diabetes mellitus;Diabetic nephropathy;Hyperlipidaemia;Hypertension;Hypotension;Myocardial infarction,Abnormal platelets;Angioedema;Asthenia;Blood creatinine increased;Connective tissue disorder;Cough;Dermatitis;Diarrhoea;Dizziness;Dizziness postural;Fatigue;Gastrointestinal disorder;Haemoglobin decreased;Mediastinal disorder;Muscle spasms;Nausea;Nervous system disorder;Orthostatic hypotension;Platelet disorder;Pruritus;Rash;Renal failure;Renal impairment;Serum creatinine increased,small molecule,approved; investigational,(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; Valsartan; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2,Type-1 angiotensin II receptor, C09CA03; C09DA03; C09DB01; C09DB08; C09DX01; C09DX02; C09DX04; C10BX10;C09DX05
eltrombopag,Aplastic anaemia;Chronic hepatitis C;Chronic liver disease;Haemoglobin;Haemorrhage;Hepatitis C;Infection;Liver disorder;Thrombocytopenia,Abdominal pain;Alanine aminotransferase increased;Alopecia;Anaemia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blood alkaline phosphatase increased;Body temperature increased;Cataract;Chills;Cough;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Dyspnoea;Ecchymosis;Fatigue;Febrile neutropenia;Gastrointestinal pain;Headache;Hepatotoxicity;Hyperbilirubinaemia;Influenza;Influenza like illness;Insomnia;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasopharyngitis;Nausea;Oedema peripheral;Oropharyngeal pain;Pain in extremity;Paraesthesia;Pharyngitis;Pruritus;Rash;Rhinorrhoea;Thrombosis;Transaminases increased;Upper respiratory tract infection;Urinary tract infection;Vomiting,small molecule,approved,Eltrombopag; Eltrombopagum; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; TPO-R; TPOR; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter,Thrombopoietin receptor,B02BX05
lomitapide,High density lipoprotein decreased;Homozygous familial hypercholesterolaemia;Hypercholesterolaemia;Low density lipoprotein increased;Type IIa hyperlipidaemia,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Aerophagia;Alanine aminotransferase increased;Anaemia;Angina pectoris;Anorectal discomfort;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood potassium decreased;Body temperature increased;Cardiac disorder;Carotene decreased;Chest pain;Chills;Connective tissue disorder;Constipation;Decreased appetite;Defaecation urgency;Dehydration;Dermatitis bullous;Diarrhoea;Discomfort;Dizziness;Drug interaction;Dry mouth;Dry skin;Dyspepsia;Ear and labyrinth disorders;Early satiety;Ecchymosis;Epigastric discomfort;Eructation;Eye disorder;Eye swelling;Faeces hard;Fatigue;Feeling abnormal;Flatulence;Frequent bowel movements;Gait disturbance;Gamma-glutamyltransferase increased;Gastric dilatation;Gastric disorder;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal infection;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematemesis;Haematuria;Haemorrhoidal haemorrhage;Headache;Hepatic enzyme increased;Hepatic steatosis;Hepatobiliary disease;Hepatomegaly;Hepatotoxicity;Hyperhidrosis;Ill-defined disorder;Increased appetite;Infection;Infestation;Infestation NOS;Influenza;International normalised ratio abnormal;International normalised ratio increased;Joint swelling;Laryngeal pain;Liver function test abnormal;Lower gastrointestinal haemorrhage;Malaise;Malnutrition;Mediastinal disorder;Migraine;Muscle spasms;Muscle twitching;Musculoskeletal discomfort;Musculoskeletal disorder;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Neutrophil count decreased;Neutrophil percentage increased;Pain in extremity;Palpitations;Papule;Paraesthesia;Pharyngeal lesion;Pharyngolaryngeal pain;Proctalgia;Prothrombin level increased;Pulmonary function test abnormal;Rash erythematous;Reaction gastrointestinal;Rectal tenesmus;Reflux esophagitis;Regurgitation;Sinusitis;Skin disorder;Somnolence;Stomach dilation procedure;Transaminases increased;Unspecified disorder of skin and subcutaneous tissue;Upper-airway cough syndrome;Urethral disorder;Urinary tract disorder;Vertigo;Vitamin E decreased;Vitamin K decreased;Vomiting;Weight decreased;White blood cell count decreased;White blood cell count increased;Xanthoma,small molecule,approved; investigational,"Lomitapida; Lomitapide; Lomitapidum; MTP; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Microsomal triglyceride transfer protein large subunit,C10AX12
fluticasone,Perennial allergic rhinitis;Rhinitis allergic;Rhinitis perennial;Rhinitis seasonal;Seasonal allergy,Agitation;Anaphylactic shock;Angioedema;Atrioventricular block;Back pain;Blood glucose increased;Blood pressure increased;Body temperature increased;Bronchitis;Candida albicans infection;Candida infection;Cataract;Cataract subcapsular;Conjunctivitis;Connective tissue disorder;Cough;Dermatitis;Diarrhoea;Dizziness;Dry throat;Dysphonia;Dyspnoea;Epistaxis;Eye disorder;Glaucoma;Growth retardation;Headache;Herpes simplex;Hyperkinesia;Hypersensitivity;Immune system disorder;Impaired healing;Infection;Intraocular pressure increased;Laryngeal pain;Mediastinal disorder;Menorrhagia;Migraine;Nasal burning;Nasal discomfort;Nasal dryness;Nasal irritation;Nasal septum ulceration;Nasal soreness;Nasopharyngitis;Nausea;Nervous system disorder;Palpitations;Pharyngitis;Pharyngolaryngeal pain;Posterior subcapsular cataract;Prolonged menses;Rash;Rhinalgia;Sinus congestion;Throat irritation;Toothache;Tremor;Ulcer;Urticaria;Vaginal moniliasis;Visual disturbance;Visual impairment;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved; experimental,"Fluticason; Fluticasona; Fluticasone; Fluticasonum; GR; GRL; Nuclear receptor subfamily 3 group C member 1; NR3C3; Nuclear receptor subfamily 3 group C member 3; PR; CPLA2; Phospholipase A2 group IVA; PLA2G4; MCR; MLR; MR; Nuclear receptor subfamily 3 group C member 2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; CBG; Serpin A6; Transcortin; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6",Glucocorticoid receptor; Progesterone receptor; Cytosolic phospholipase A2; Mineralocorticoid receptor, D07AC17; R01AD08; R01AD58; R03AK06; R03AK11;R01AD12;R03BA05
mirabegron,Hypertonic bladder,Abdominal distension;Abdominal pain;Alanine aminotransferase increased;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Back pain;Bladder pain;Blood lactate dehydrogenase increased;Blood pressure increased;Breast cancer;Breast disorder;Cardiac disorder;Cerebrovascular accident;Connective tissue disorder;Constipation;Cystitis;Cystitis noninfective;Dermatitis;Diarrhoea;Dizziness;Dry eye;Dry mouth;Dyspepsia;Erythema multiforme;Eye disorder;Eyelid oedema;Fatigue;Gamma-glutamyltransferase increased;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Glaucoma;Headache;Hypertension;Infection;Infestation;Infestation NOS;Influenza;Joint swelling;Lactic dehydrogenase activity increased;Leukocytoclastic vasculitis;Lip oedema;Lipoedema;Lung neoplasm malignant;Musculoskeletal discomfort;Nasopharyngitis;Nausea;Neoplasm;Nephrolithiasis;Osteoarthritis;Palpitations;Prostate cancer;Pruritus;Purpura;Rash;Rash macular;Rash papular;Rhinitis;Sinusitis;Skin disorder;Stevens-Johnson syndrome;Tachycardia;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vaginal infection;Vascular purpura;Vision blurred;Vulvovaginal pruritus,small molecule,approved,"Mirabegron; ADRB3R; B3AR; Beta-3 adrenoceptor; Beta-3 adrenoreceptor; ADRB1R; B1AR; Beta-1 adrenoceptor; Beta-1 adrenoreceptor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3",Beta-3 adrenergic receptor; Beta-1 adrenergic receptor,G04BD12
avanafil,Erectile dysfunction,AION;Abdominal discomfort;Abdominal pain lower;Agitation;Alanine aminotransferase increased;Angina pectoris;Angina unstable;Angiopathy;Arteritic anterior ischaemic optic neuropathy;Arthralgia;Asthenia;Back pain;Balanitis;Blood bilirubin increased;Blood creatinine increased;Blood glucose increased;Blood pressure increased;Blood urine present;Body temperature increased;Breast disorder;Bronchitis;Cardiac disorder;Cardiac murmur;Chest pain;Connective tissue disorder;Constipation;Cough;Deep vein thrombosis;Dermatitis;Diabetes mellitus;Diarrhoea;Dizziness;Dry mouth;Dyspepsia;Dyspnoea exertional;Electrocardiogram abnormal;Epistaxis;Erection increased;Eye disorder;Fatigue;Flank pain;Flushing;Gastritis;Gastrointestinal disorder;Gastrooesophageal reflux disease;Gout;Haematospermia;Haematuria;Headache;Hepatic enzyme increased;Hot flush;Hypertension;Hypoglycaemia;Hypotension;Immune system disorder;Inappropriate affect;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Insomnia;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Muscle spasms;Muscle tightness;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Nephrolithiasis;Nervous system disorder;Oedema peripheral;Optic ischaemic neuropathy;Oropharyngeal pain;Pain in extremity;Palpitations;Penile haemorrhage;Penis disorder;Pollakiuria;Premature ejaculation;Priapism;Prostate cancer;Prostatic specific antigen increased;Pruritus;Pruritus genital;Rash;Rhinitis seasonal;Rhinorrhoea;Seasonal allergy;Sinus congestion;Sinus headache;Sinusitis;Skin disorder;Somnolence;Spontaneous penile erection;Tachycardia;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract congestion;Upper respiratory tract infection;Upset stomach;Urethral disorder;Urinary tract disorder;Urinary tract infection;Vertigo;Vision blurred;Vomiting;Weight increased;Wheezing,small molecule,approved,"(S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxamide; Avanafil; Avanafilo; 3.1.4.35; CGB-PDE; cGMP-binding cGMP-specific phosphodiesterase; PDE5; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter","cGMP-specific 3',5'-cyclic phosphodiesterase",G04BE10
ticagrelor,Acute coronary syndrome;Angina pectoris;Angina unstable;Asthma;Bronchial hyperreactivity;Cerebrovascular accident;Chronic obstructive pulmonary disease;Electrocardiogram ST segment elevation;Ischaemic stroke;Myocardial infarction;Renal failure;Renal impairment;Thrombosis,Abdominal pain;Angioedema;Angiopathy;Asthenia;Atrial fibrillation;Back pain;Blood creatinine increased;Blood uric acid increased;Blood urine present;Body temperature increased;Bone disorder;Bradycardia;Breast disorder;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiac tamponade;Catheter site haemorrhage;Cerebral haemorrhage;Chest pain;Confusional state;Connective tissue disorder;Constipation;Contusion;Cough;Dermatitis;Diarrhoea;Dizziness;Duodenal ulcer haemorrhage;Dyspepsia;Dyspnoea;Dyspnoea at rest;Dyspnoea exertional;Dyspnoea paroxysmal nocturnal;Ear and labyrinth disorders;Ear haemorrhage;Ecchymosis;Epistaxis;Eye disorder;Eye haemorrhage;Fatigue;Feeling abnormal;Gastric ulcer haemorrhage;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal ulcer haemorrhage;Gingival bleeding;Gout;Gouty arthritis;Gynaecomastia;Haemarthrosis;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhage subcutaneous;Haemorrhage urinary tract;Haemorrhagic stroke;Haemorrhoidal haemorrhage;Headache;Hypersensitivity;Hypertension;Hyperuricaemia;Hypotension;Hypovolaemic shock;Immune system disorder;Increased tendency to bruise;Injection site haemorrhage;Intestinal haemorrhage;Loss of consciousness;Lung disorder;Major bleed;Malnutrition;Mediastinal disorder;Melaena;Mental disorder;Metrorrhagia;Minor bleed;Mouth haemorrhage;Nausea;Neoplasm malignant;Nephropathy toxic;Nervous system disorder;Nocturnal dyspnoea;Non-cardiac chest pain;Oedema peripheral;Oliguria;Paraesthesia;Peptic ulcer haemorrhage;Petechiae;Post procedural haemorrhage;Presyncope;Procedural haemorrhage;Pruritus;Puncture site haemorrhage;Rash;Rectal haemorrhage;Renal failure acute;Renal failure chronic;Retroperitoneal haemorrhage;Serum creatinine increased;Shock;Skin disorder;Skin haemorrhage;Subcutaneous haematoma;Syncope;Transient ischaemic attack;Traumatic haematoma;Traumatic haemorrhage;Ulcer haemorrhage;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vaginal haemorrhage;Vertigo;Vessel puncture site haematoma;Vessel puncture site haemorrhage;Vomiting;Wound haemorrhage,small molecule,approved,"(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; Ticagrelor; ADP-glucose receptor; ADPG-R; HORK3; P2T(AC); P2Y(AC); P2Y(ADP); P2Y(cyc); P2Y12; P2Y12 platelet ADP receptor; SP1999; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",P2Y purinoceptor 12,B01AC24
dapagliflozin,Cardiovascular disorder;Genital infection;Genital infection fungal;Infection;Recurrent urinary tract infection;Renal failure;Renal impairment;Type 2 diabetes mellitus;Urinary tract infection,Acute coronary syndrome;Anaphylactic shock;Angina pectoris;Angina unstable;Angioedema;Autoimmune hepatitis;Back pain;Balanitis;Balanitis candida;Bladder cancer;Blood creatinine increased;Blood pressure fluctuation;Blood urea increased;Carcinogenicity;Cerebrovascular accident;Change in blood pressure;Connective tissue disorder;Constipation;Dehydration;Dermatitis;Diabetes mellitus;Discomfort;Diuresis;Dizziness;Drug-induced hepatitis;Drug-induced liver injury;Dyslipidaemia;Dysuria;Fracture;Fungal infection;Gastrointestinal disorder;Genital candidiasis;Genital infection fungal;Genital infection male;Haematocrit increased;Headache;Hyperhidrosis;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypoglycaemia;Hypoglycemic reaction;Hypotension;Hypovolaemia;Infection;Infestation;Infestation NOS;Influenza;Malnutrition;Multiple fractures;Myocardial infarction;Nasopharyngitis;Nausea;Neoplasm;Neoplasm malignant;Neoplasm prostate;Nocturia;Orthostatic hypotension;Osteopenia;Pain in extremity;Penile infection;Pollakiuria;Polyuria;Rash;Recurrent infection;Renal failure;Serum creatinine increased;Skin disorder;Thirst;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Urticaria;Vaginal infection;Vaginitis bacterial;Vulval abscess;Vulvitis;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginal pruritus;Vulvovaginitis,small molecule,approved,"(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Dapagliflozin; Dapagliflozina; Low affinity sodium-glucose cotransporter; Na(+)/glucose cotransporter 2; SGLT2; Solute carrier family 5 member 2; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Sodium/glucose cotransporter 2, A10BD15; A10BD21; A10BD25; A10BD29;A10BK01
apremilast,Psoriatic arthropathy,Abdominal pain upper;Cough;Decreased appetite;Dermatitis;Diarrhoea;Dyspepsia;Frequent bowel movements;Gastrointestinal disorder;Gastrooesophageal reflux disease;Headache;Hypersensitivity;Immune system disorder;Joint swelling;Malnutrition;Mediastinal disorder;Migraine;Nasopharyngitis;Nausea;Nervous system disorder;Rash;Skin disorder;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Vomiting;Weight decreased,small molecule,approved; investigational,"Apremilast; Aprémilast; Apremilastum; N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide; 2.7.11.22; Cell division protein kinase 4; PSK-J3; 2.7.11.22; CDKN6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Phosphodiesterase isozyme 4; Cyclin-dependent kinase 4; Cyclin-dependent kinase 6,L04AA32
perampanel,Convulsion;Convulsions generalised;Epilepsy,Affect lability;Aggression;Anger;Anxiety;Arthralgia;Asthenia;Ataxia;Back pain;Balance disorder;Confusional state;Connective tissue disorder;Constipation;Contusion;Coordination abnormal;Cough;Decreased appetite;Diplopia;Dizziness;Dysarthria;Ear and labyrinth disorders;Euphoric mood;Eye disorder;Fatigue;Feeling abnormal;Gait disturbance;Gastrointestinal disorder;Head injury;Headache;Hypersomnia;Hypoaesthesia;Hyponatraemia;Increased appetite;Infection;Infestation;Infestation NOS;Irritability;Laceration;Limb injury;Malnutrition;Mediastinal disorder;Memory impairment;Mental disorder;Mood swings;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nausea;Nervous system disorder;Oedema peripheral;Oropharyngeal pain;Osteoarthritis;Pain in extremity;Paraesthesia;Skin laceration;Somnolence;Suicidal behaviour;Upper respiratory tract infection;Vertigo;Vision blurred;Vomiting;Weight increased,small molecule,approved,"3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; Perampanel; Pérampanel; Perampanelum; AMPA-selective glutamate receptor 2; GluA2; GluR-2; GluR-B; GluR-K2; GLUR2; Glutamate receptor ionotropic, AMPA 2; AMPA-selective glutamate receptor 3; GluA3; GluR-3; GluR-C; GluR-K3; GLUR3; GLURC; Glutamate receptor ionotropic, AMPA 3; AMPA-selective glutamate receptor 4; GluA4; GluR-4; GluR-D; GLUR4; Glutamate receptor ionotropic, AMPA 4; AMPA-selective glutamate receptor 1; GLUA1; GLUH1; GluR-1; GluR-A; GluR-K1; GLUR1; Glutamate receptor ionotropic, AMPA 1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1",Glutamate receptor 2; Glutamate receptor 3; Glutamate receptor 4; Glutamate receptor 1,N03AX22
vernakalant,Atrial fibrillation;Sinus rhythm,Angiopathy;Asthenia;Atrial flutter;Atrioventricular block complete;Atrioventricular block first degree;Bradycardia;Bundle branch block left;Bundle branch block right;Burning sensation;Cardiac disorder;Cardiac failure congestive;Cardiogenic shock;Chest discomfort;Chest pain;Choking sensation;Cold sweat;Connective tissue disorder;Cough;Defaecation urgency;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dysgeusia;Dyspnoea;Electrocardiogram QRS complex;Electrocardiogram QT prolonged;Eye disorder;Eye irritation;Fatigue;Feeling abnormal;Feeling hot;Flushing;Gastrointestinal disorder;Headache;Hot flush;Hyperhidrosis;Hypoaesthesia;Hypoaesthesia oral;Hypotension;Ill-defined disorder;Infusion site hypersensitivity;Infusion site irritation;Infusion site pain;Infusion site paraesthesia;Lacrimation increased;Malaise;Mediastinal disorder;Menopausal symptoms;Nasal congestion;Nasal discomfort;Nasopharyngitis;Nausea;Nervous system disorder;Pain in extremity;Pallor;Palpitations;Paraesthesia;Paraesthesia oral;Parosmia;Presyncope;Pruritus;Pruritus generalised;QRS complex;Rhinorrhoea;Sinus arrest;Sinus bradycardia;Skin disorder;Sneezing;Somnolence;Syncope;Syncope vasovagal;Throat irritation;Unspecified disorder of skin and subcutaneous tissue;Ventricular arrhythmia;Ventricular extrasystoles;Ventricular tachycardia;Visual impairment;Vomiting,small molecule,approved; investigational,"(3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol; Vernakalant; hH1; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type V subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.5; HPCN1; Voltage-gated potassium channel HK2; Voltage-gated potassium channel subunit Kv1.5; Potassium voltage-gated channel subfamily D member 3; Voltage-gated potassium channel subunit Kv4.3; Eag homolog; Eag-related protein 1; ERG; ERG-1; ERG1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go-related protein 1; H-ERG; HERG; hERG-1; hERG1; Potassium voltage-gated channel subfamily H member 2; Voltage-gated potassium channel subunit Kv11.1; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Sodium channel protein type 5 subunit alpha; Potassium voltage-gated channel subfamily A member 5; A-type voltage-gated potassium channel KCND3; Voltage-gated inwardly rectifying potassium channel KCNH2,C01BG11
vorapaxar,Acute coronary syndrome;Arteriosclerosis;Atherosclerosis;Cerebrovascular accident;Ischaemic stroke;Myocardial infarction;Peripheral arterial disease;Peripheral arterial occlusive disease;Post MI,Acute coronary syndrome;Anaemia;Depression;Dermatitis;Diplopia;Eruption;Gastrointestinal haemorrhage;Haemoglobin;Haemorrhage;Haemorrhage intracranial;Iron deficiency;Rash;Retinal disorder,small molecule,approved,"[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle; Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester; Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester; Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate; Vorapaxar; CF2R; Coagulation factor II receptor; PAR-1; PAR1; Thrombin receptor; TR; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Albendazole monooxygenase (hydroxylating); Albendazole monooxygenase (sulfoxide-forming); Arachidonic acid epoxygenase; CYPIIJ2; Hydroperoxy icosatetraenoate isomerase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Proteinase-activated receptor 1,B01AC26
linagliptin,Diabetic ketoacidosis;Pancreatitis;Renal failure;Renal impairment;Type 1 diabetes mellitus;Type 2 diabetes mellitus,Anaphylactic shock;Angioedema;Arthralgia;Back pain;Blood triglycerides increased;Bronchial hyperreactivity;Constipation;Cough;Dermatitis;Diabetes mellitus;Diabetic;Diarrhoea;Gastrointestinal disorder;Headache;Hyperlipidaemia;Hypersensitivity;Hypertriglyceridaemia;Hypoglycaemia;Hypoglycemic reaction;Immune system disorder;Infection;Infestation;Infestation NOS;Malnutrition;Mediastinal disorder;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Pain in extremity;Pancreatitis;Pancreatitis acute;Rash;Skin disorder;Skin exfoliation;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urticaria;Weight increased,small molecule,approved,"(R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione; Linagliptin; Linagliptina; 3.4.14.5; ADABP; ADCP-2; ADCP2; Adenosine deaminase complexing protein 2; CD26; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2; EMT; EMTH; Extraneuronal monoamine transporter; OCT3; Organic cation transporter 3",Dipeptidyl peptidase 4, A10BD11; A10BD19; A10BD27;A10BH05
pazopanib,Gastrointestinal stromal tumour;Metastatic disease;Metastatic neoplasm;Metastatic renal cell carcinoma;Neoplasm;Renal cell carcinoma;Sarcoma,Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Acute coronary syndrome;Ageusia;Alanine aminotransferase increased;Albumin high;Albumin low;Alopecia;Amylase increased;Anaemia;Anal haemorrhage;Angiopathy;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Bilirubin total increased;Blood albumin decreased;Blood albumin increased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood calcium decreased;Blood cholesterol abnormal;Blood creatinine increased;Blood glucose decreased;Blood glucose increased;Blood magnesium decreased;Blood phosphorus decreased;Blood potassium increased;Blood pressure increased;Blood pressure systolic increased;Blood thyroid stimulating hormone increased;Blood urea increased;Bradycardia;Breast disorder;Bronchial haemorrhage;Calcium low;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cerebral haemorrhage;Cerebral infarction;Cerebrovascular accident;Chest pain;Chills;Connective tissue disorder;Cough;Creatinine increased;Cyst;Decreased appetite;Deep vein thrombosis;Dehydration;Dermatitis;Diarrhoea;Dizziness;Drug-induced liver injury;Dry mouth;Dry skin;Dysgeusia;Dyspepsia;Dysphonia;Dyspnoea;Electrocardiogram QT prolonged;Embolism;Encephalopathy;Endocrine disorder;Enterocutaneous fistula;Epistaxis;Erythema;Exfoliative rash;Eye disorder;Eye oedema;Eyelash discolouration;Eyelid oedema;Face oedema;Fatigue;Fistula;Flatulence;Flushing;Frequent bowel movements;Gamma-glutamyltransferase increased;Gastric haemorrhage;Gastrointestinal disorder;Gastrointestinal fistula;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Gingival infection;Glucose decreased;Glucose increased;Haematemesis;Haematochezia;Haematuria;Haemoglobin;Haemolytic uraemic syndrome;Haemoptysis;Haemorrhage;Haemorrhage urinary tract;Haemorrhoidal haemorrhage;Hair colour changes;Headache;Hepatic enzyme increased;Hepatic failure;Hepatic function abnormal;Hepatobiliary disease;Hepatotoxicity;Hiccups;Hot flush;Hyperalbuminaemia;Hyperbilirubinaemia;Hyperhidrosis;Hypertension;Hypertensive crisis;Hypoaesthesia;Hypogeusia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypothyroidism;Ileal perforation;Infection;Infectious peritonitis;Infestation;Infestation NOS;Insomnia;Intestinal perforation;Ischaemic stroke;Jaundice;Large intestine perforation;Left ventricular dysfunction;Lethargy;Leukoderma;Leukopenia;Lipase increased;Liver function test abnormal;Localised oedema;Loss of consciousness;Lymphopenia;Malnutrition;Mediastinal disorder;Melaena;Menopausal symptoms;Menorrhagia;Mental disorder;Metabolic disorder;Metrorrhagia;Mg reduced;Mouth haemorrhage;Mouth ulceration;Mucosal inflammation;Mucous membrane disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Myocardial ischaemia;Nail disorder;Nasopharyngitis;Nausea;Neoplasm malignant;Nervous system disorder;Neutropenia;Neutrophil count decreased;Oedema;Oedema peripheral;Oesophageal haemorrhage;Oropharyngeal pain;Pain;Pancreatitis;Paraesthesia;Peripheral sensory neuropathy;Peritonitis;Phosphatase alkaline increased;Phosphorus low;Photosensitivity reaction;Plantar erythema;Platelet count decreased;Pneumothorax;Polyp;Posterior reversible encephalopathy syndrome;Potassium increased;Protein urine present;Proteinuria;Prurigo;Pruritus;Pruritus generalised;Pulmonary embolism;Pulmonary haemorrhage;Rash;Rash erythematous;Rash generalised;Rash macular;Rash papular;Rash vesicular;Rectal haemorrhage;Restrictive cardiomyopathy;Retroperitoneal haemorrhage;Rhinorrhoea;Shock;Sinus bradycardia;Skin depigmentation;Skin discolouration;Skin disorder;Skin exfoliation;Skin ulcer;Sodium decreased;Somnolence;Stomatitis;Syncope;Taste altered;Thrombocytopenia;Thromboembolic event;Thrombosis;Thrombotic microangiopathy;Thrombotic thrombocytopenic purpura;Thyroid function test abnormal;Torsade de pointes;Transient ischaemic attack;Tumour pain;Unspecified disorder of skin and subcutaneous tissue;Upper gastrointestinal haemorrhage;Urethral disorder;Urinary tract disorder;Vaginal haemorrhage;Vision blurred;Vomiting;Weight decreased;White blood cell count decreased,small molecule,approved,"Pazopanib; Pazopanibum; 2.7.10.1; FLT; FLT-1; Fms-like tyrosine kinase 1; FRT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; Vascular permeability factor receptor; VEGFR-1; VEGFR1; 2.7.10.1; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR-2; VEGFR2; 2.7.10.1; FLT-4; Fms-like tyrosine kinase 4; Tyrosine-protein kinase receptor FLT4; VEGFR-3; VEGFR3; 2.7.10.1; Alpha platelet-derived growth factor receptor; Alpha-type platelet-derived growth factor receptor; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; PDGFR-2; PDGFR-alpha; PDGFR2; Platelet-derived growth factor alpha receptor; Platelet-derived growth factor receptor 2; RHEPDGFRA; 2.7.10.1; Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; PDGF-R-beta; PDGFR; PDGFR-1; PDGFR-beta; PDGFR1; Platelet-derived growth factor receptor 1; 2.7.10.1; p145 c-kit; PBT; Piebald trait protein; Proto-oncogene c-Kit; SCFR; Tyrosine-protein kinase Kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; 2.7.10.1; FGFR-3; JTK4; 2.7.10.2; EMT; IL-2-inducible T-cell kinase; Interleukin-2-inducible T-cell kinase; Kinase EMT; LYK; T-cell-specific kinase; Tyrosine-protein kinase Lyk; Acidic fibroblast growth factor; aFGF; ECGF; Endothelial cell growth factor; FGF-1; FGFA; HBGF-1; Heparin-binding growth factor 1; LNK; Lymphocyte adapter protein; Lymphocyte-specific adapter protein Lnk; Signal transduction protein Lnk; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1",Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 3; Platelet-derived growth factor receptor alpha; Platelet-derived growth factor receptor beta; Mast/stem cell growth factor receptor Kit; Fibroblast growth factor receptor 3; Tyrosine-protein kinase ITK/TSK; Fibroblast growth factor 1; SH2B adapter protein 3,L01EX03;L01XE11
afatinib,Neoplasm;Non-small cell lung cancer;Small cell carcinoma;Small cell lung cancer,Acne pustular;Alanine aminotransferase increased;Alopecia;Aphthous stomatitis;Aspartate aminotransferase increased;Asthenia;Back pain;Bladder pain;Blood potassium decreased;Body temperature increased;Chapped skin;Cheilitis;Conjunctival hyperaemia;Conjunctival irritation;Conjunctivitis;Connective tissue disorder;Constipation;Cough;Cystitis;Cystitis noninfective;Decreased appetite;Dehydration;Dermatitis;Dermatitis acneiform;Diarrhoea;Diastolic dysfunction;Disease progression;Dizziness;Dry eye;Dry skin;Dysgeusia;Dyspepsia;Dyspnoea;Epistaxis;Eye disorder;Fatigue;Gastrointestinal disorder;Headache;Hepatobiliary disease;Hypokalaemia;Infection;Infestation;Infestation NOS;Insomnia;Interstitial lung disease;Keratitis;Left ventricular dysfunction;Malnutrition;Mediastinal disorder;Mental disorder;Mouth ulceration;Mucosal erosion;Mucosal inflammation;Mucosal ulceration;Muscle spasms;Nail bed infection;Nail infection;Nasal inflammation;Nasopharyngitis;Nausea;Nervous system disorder;Oral mucosa erosion;Paronychia;Pneumonia;Pruritus;Pruritus generalised;Pulmonary toxicity;Rash;Renal failure;Renal impairment;Rhinorrhoea;Sepsis;Skin disorder;Skin fissures;Stomatitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Ventricular dysfunction;Vomiting;Weight decreased,small molecule,approved,Afatinib; Afatinibum; 2.7.10.1; ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; 2.7.10.1; HER2; Metastatic lymph node gene 19 protein; MLN 19; MLN19; NEU; NGL; p185erbB2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; 2.7.10.1; HER4; p180erbB4; Proto-oncogene-like protein c-ErbB-4; Tyrosine kinase-type cell surface receptor HER4; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter,Epidermal growth factor receptor; Receptor tyrosine-protein kinase erbB-2; Receptor tyrosine-protein kinase erbB-4,L01EB03
besifloxacin,Conjunctivitis bacterial;Conjunctivitis infective;Infection,Conjunctival hyperaemia;Eye irritation;Eye pain;Eye pruritus;Headache;Vision blurred,small molecule,approved,Besifloxacin; 5.99.1.3; Topoisomerase IV subunit A; 5.99.1.3; 5.99.1.3; 5.99.1.3; Topoisomerase IV subunit A; 5.99.1.3; 5.99.1.3; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase,DNA topoisomerase 4 subunit A; DNA gyrase subunit B; DNA gyrase subunit A; DNA topoisomerase 4 subunit A; DNA gyrase subunit A; DNA gyrase subunit A,S01AE08
apixaban,Atrial fibrillation;Cardiac failure;Cerebrovascular accident;Deep vein thrombosis;Diabetes mellitus;Embolism;Hypertension;Pulmonary embolism;Thromboembolic event,Alanine aminotransferase abnormal;Alanine aminotransferase increased;Allergic oedema;Anaemia;Anal haemorrhage;Anaphylactic shock;Angiopathy;Application site haemorrhage;Aspartate aminotransferase increased;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood urine;Blood urine present;Breast disorder;Catheter site haemorrhage;Cerebral haemorrhage;Compartment syndrome;Conjunctival haemorrhage;Connective tissue disorder;Contusion;Dermatitis;Diabetes mellitus;Dizziness;Drug hypersensitivity;Ecchymosis;Epistaxis;Eye disorder;Eye haemorrhage;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal haemorrhage;Genital haemorrhage;Gingival bleeding;Haematemesis;Haematochezia;Haematoma;Haematuria;Haemoglobin;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Haemorrhagic anaemia;Haemorrhagic stroke;Haemorrhoidal haemorrhage;Hepatobiliary disease;Hypersensitivity;Hypotension;Immune system disorder;Incision site haematoma;Incision site haemorrhage;Injection site haematoma;Intra-abdominal haemorrhage;Intraoperative hemorrhage;Intraspinal bleeding;Laryngeal haemorrhage;Liver function test abnormal;Loss of consciousness;Mediastinal disorder;Melaena;Menometrorrhagia;Menorrhagia;Metrorrhagia;Mouth haemorrhage;Muscle haemorrhage;Nausea;Nervous system disorder;Occult blood positive;Periorbital haematoma;Petechiae;Pharyngeal haemorrhage;Post procedural haematoma;Post procedural haemorrhage;Procedural haemorrhage;Procedural hypotension;Pulmonary alveolar haemorrhage;Rash;Rectal haemorrhage;Respiratory tract haemorrhage;Retinal haemorrhage;Retroperitoneal haemorrhage;Shock;Skin disorder;Skin haemorrhage;Spinal cord haemorrhage;Spinal haematoma;Subarachnoid haemorrhage;Subdural haematoma;Syncope;Thrombocytopenia;Transaminases increased;Traumatic haematoma;Traumatic haemorrhage;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urethral haemorrhage;Urinary tract disorder;Urogenital haemorrhage;Vaginal haemorrhage;Vessel puncture site haematoma;Wound haemorrhage;Wound secretion,small molecule,approved,"apixabán; Apixaban; apixabanum; 3.4.21.6; Stuart factor; Stuart-Prower factor; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Albendazole monooxygenase (hydroxylating); Albendazole monooxygenase (sulfoxide-forming); Arachidonic acid epoxygenase; CYPIIJ2; Hydroperoxy icosatetraenoate isomerase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Coagulation factor X,B01AF02
boceprevir,Anaemia;Anemic;Chronic hepatitis C;Foetor hepaticus;Hepatocellular injury;Infection;Infection mixed;Liver disorder;Neutropenia,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abnormal behaviour;Abnormal sensation in eye;Acute myocardial infarction;Affect lability;Aggression;Agitation;Agranulocytosis;Alopecia;Amenorrhoea;Amnesia;Anaemia;Anal pruritus;Anger;Angioedema;Angiopathy;Anorectal discomfort;Anxiety;Apathy;Aphthous stomatitis;Appetite disorder;Arrhythmia;Arthralgia;Arthritis;Aspermia;Asthenia;Atrial fibrillation;Back pain;Bipolar I disorder;Bipolar disorder;Blood and lymphatic system disorders;Blood triglycerides increased;Blood uric acid increased;Body temperature increased;Bone pain;Breast disorder;Bronchitis;Candida infection;Cardiac disorder;Cardiac murmur;Cardiovascular disorder;Cellulitis;Cerebral ischaemia;Cheilitis;Chest discomfort;Chest pain;Chills;Cholecystitis;Cognitive disorder;Colitis;Completed suicide;Confusional state;Conjunctival haemorrhage;Conjunctivitis;Connective tissue disorder;Constipation;Coronary artery disease;Cough;Cyst;Deafness;Decreased appetite;Deep vein thrombosis;Dehydration;Depression;Dermatitis;Dermatitis exfoliative;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in attention;Dizziness;Drug eruption;Dry eye;Dry mouth;Dry skin;Dry throat;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dyspnoea;Dyspnoea exertional;Dysuria;Ear and labyrinth disorders;Ear discomfort;Ear infection;Eczema;Encephalopathy;Endocrine disorder;Endophthalmitis;Eosinophilia;Epiglottitis;Epistaxis;Erectile dysfunction;Erythema;Erythema multiforme;Exfoliative rash;Eye disorder;Eye pain;Eye pruritus;Eye swelling;Eyelid oedema;Faeces discoloured;Fatigue;Feeling abnormal;Feeling of body temperature change;Flat affect;Flatulence;Flushing;Fungal skin infection;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Gingival bleeding;Gingival pain;Gingivitis;Glossitis;Glossodynia;Goitre;Gout;Haemolysis;Haemorrhagic disorder;Haemorrhoids;Hallucination, auditory;Hallucination, visual;Headache;Hearing impaired;Hepatobiliary disease;Herpes simplex;Homicidal ideation;Hyperaesthesia;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypokalaemia;Hypotension;Hypothyroidism;Ill-defined disorder;Immune system disorder;Impaired healing;Increased upper airway secretion;Infection;Infestation;Infestation NOS;Influenza;Influenza like illness;Injection site reaction;Insomnia;Irritability;Joint swelling;Lacrimation increased;Lethargy;Leukopenia;Libido disorder;Lip dry;Loss of consciousness;Lymphadenopathy;Lymphopenia;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Menorrhagia;Mental disability;Mental disorder;Mental retardation;Mental status changes;Metrorrhagia;Migraine;Mood swings;Mouth ulceration;Mucosal dryness;Muscle spasms;Muscular weakness;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Nervous system disorder;Neuralgia;Neuropathy peripheral;Neutropenia;Night sweats;Nocturia;Nodule;Non-cardiac chest pain;Ocular hyperaemia;Odynophagia;Oedema peripheral;Onychomycosis;Optic neuritis;Oral fungal infection;Oral pain;Oropharyngeal blistering;Oropharyngeal pain;Orthopnoea;Otitis media;Pain;Pain in extremity;Pallor;Palpitations;Pancreatic insufficiency;Pancreatitis;Pancytopenia;Panic attack;Papilloedema;Paraesthesia;Paranoia;Parosmia;Pericardial effusion;Pericarditis;Peripheral coldness;Pharyngitis;Photophobia;Photosensitivity reaction;Pleural fibrosis;Pleuritic pain;Pneumonia;Pollakiuria;Polyp;Porphyria non-acute;Presyncope;Proctalgia;Prurigo;Pruritus;Pruritus genital;Psoriasis;Psychiatric decompensation;Psychotic disorder;Pulmonary embolism;Rash;Rash erythematous;Rash macular;Rash maculo-papular;Rash papular;Rectal haemorrhage;Respiratory failure;Respiratory tract congestion;Respiratory tract infection;Retinal disorder;Retinal exudates;Retinal ischaemia;Rhinitis;Salivary hypersecretion;Sarcoidosis;Sensitivity of teeth;Sepsis;Shock;Sinus congestion;Sinusitis;Skin disorder;Skin infection;Skin lesion;Skin ulcer;Sleep disorder;Staphylococcal infection;Stevens-Johnson syndrome;Stomatitis;Substance abuse;Suicidal ideation;Suicide attempt;Syncope;Tachycardia;Thrombocytopenia;Thyroid neoplasm;Tinnitus;Tongue discolouration;Tongue ulceration;Tooth disorder;Toxic skin eruption;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Venous thrombosis;Vertigo;Vision blurred;Visual impairment;Vomiting;Weight decreased;Wheezing",small molecule,approved; withdrawn,"Boceprevir; 3.4.22.-; p23; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Genome polyprotein; Genome polyprotein,J05AP03
lorcaserin,Diabetes mellitus;Diabetic;Obesity;Type 2 diabetes mellitus,Angiopathy;Anxiety;Aortic valve incompetence;Asthenia;Back pain;Cardiac failure congestive;Cardiac valve disease;Cataract conditions;Cerebration impaired;Chills;Cognitive disorder;Cognitive impairment;Confusional state;Connective tissue disorder;Constipation;Cough;Decreased appetite;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Disorder sight;Disorientation;Disturbance in attention;Dizziness;Drug abuse;Dry eye;Dry mouth;Euphoric mood;Eye disorder;Fatigue;Feeling abnormal;Gastroenteritis;Gastrointestinal disorder;Headache;Hyperhidrosis;Hypertension;Hypoglycaemia;Immune system disorder;Infection;Infestation;Infestation NOS;Inflammation;Insomnia;Malnutrition;Mediastinal disorder;Mental disability;Mental disorder;Mitral valve incompetence;Muscle spasms;Musculoskeletal pain;Nasopharyngitis;Nausea;Nervous system disorder;Ocular sensation disorders;Oedema peripheral;Oropharyngeal pain;Rash;Regurgitation;Rhinitis seasonal;Seasonal allergy;Serotonin syndrome;Sinus congestion;Skin disorder;Stress;Suicidal ideation;Toothache;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Vision blurred;Visual impairment;Vomiting;Worsening of diabetes,small molecule,approved; withdrawn,"Lorcaserin; Lorqess; 5-HT-1C; 5-HT-2C; 5-HT1C; 5-HT2C; 5-HTR2C; 5-hydroxytryptamine receptor 1C; HTR1C; Serotonin receptor 2C; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1.14.14.-; Coumarin 7-hydroxylase; CYP2A3; CYPIIA6; Cytochrome P450 IIA3; Cytochrome P450(I); 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.13.148; 1.14.13.8; Dimethylaniline monooxygenase [N-oxide-forming] 1; Dimethylaniline oxidase 1; Fetal hepatic flavin-containing monooxygenase 1; FMO 1; Trimethylamine monooxygenase; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase",5-hydroxytryptamine receptor 2C,A08AA11
tafamidis,Amyloidosis;Polyneuropathy,Abdominal pain upper;Diarrhoea;Gastrointestinal disorder;Infection;Infestation;Infestation NOS;Urinary tract infection;Vaginal infection,small molecule,approved; investigational,Tafamidis; Tafamidisum; ATTR; PALB; Prealbumin; TBPA; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8,Transthyretin,N07XX08
alogliptin,Acute coronary syndrome;Angina pectoris;Angina unstable;Cardiac failure congestive;Dyslipidaemia;Hypertension;Myocardial infarction;Type 2 diabetes mellitus,Acute hepatic failure;Anaphylactic shock;Angioedema;Dermatitis;Diabetes mellitus;Erythema multiforme;Headache;Hypersensitivity;Hypoglycaemia;Nasopharyngitis;Pancreatitis;Pancreatitis acute;Rash;Serum sickness;Stevens-Johnson syndrome;Upper respiratory tract infection;Urticaria,small molecule,approved,"Alogliptin; Alogliptina; Alogliptine; Alogliptinum; 3.4.14.5; ADABP; ADCP-2; ADCP2; Adenosine deaminase complexing protein 2; CD26; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase",Dipeptidyl peptidase 4, A10BD09; A10BH04;A10BD13;A10BH04
regorafenib,Colorectal cancer;Colorectal cancer metastatic;Gastrointestinal stromal tumour;Neoplasm malignant,Abdominal pain;Acute coronary syndrome;Alanine aminotransferase increased;Alopecia;Amylase increased;Anaemia;Angiopathy;Aspartate aminotransferase increased;Asthenia;Blood and lymphatic system disorders;Blood uric acid increased;Body temperature increased;Cardiac disorder;Connective tissue disorder;Cyst;Decreased appetite;Dermatitis;Diarrhoea;Dry mouth;Dry skin;Dysphonia;Endocrine disorder;Erythema multiforme;Exfoliative rash;Fatigue;Fistula;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal fistula;Gastrointestinal pain;Gastrointestinal perforation;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Headache;Hepatobiliary disease;Hepatotoxicity;Hyperbilirubinaemia;Hypertension;Hypertensive crisis;Hyperuricaemia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypothyroidism;Infarction;Infection;Infestation;Infestation NOS;International normalised ratio increased;Keratoacanthoma;Leukopenia;Lipase abnormal;Lipase increased;Liver injury;Lymphopenia;Malnutrition;Mediastinal disorder;Mucosal inflammation;Musculoskeletal stiffness;Myocardial infarction;Myocardial ischaemia;Nail disorder;Nausea;Neoplasm;Nervous system disorder;Neutropenia;Pain;Polyp;Posterior reversible encephalopathy syndrome;Protein urine present;Proteinuria;Rash;Skin disorder;Squamous cell carcinoma;Stevens-Johnson syndrome;Stomatitis;Taste disorders;Thrombocytopenia;Toxic epidermal necrolysis;Traumatic liver injury;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vomiting;Weight decreased,small molecule,approved,"Regorafenib; Régorafénib; Regorafenibum; 2.7.10.1; FLT; FLT-1; Fms-like tyrosine kinase 1; FRT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; Vascular permeability factor receptor; VEGFR-1; VEGFR1; 2.7.10.1; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR-2; VEGFR2; 2.7.10.1; FLT-4; Fms-like tyrosine kinase 4; Tyrosine-protein kinase receptor FLT4; VEGFR-3; VEGFR3; 2.7.10.1; p145 c-kit; PBT; Piebald trait protein; Proto-oncogene c-Kit; SCFR; Tyrosine-protein kinase Kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; 2.7.10.1; Alpha platelet-derived growth factor receptor; Alpha-type platelet-derived growth factor receptor; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; PDGFR-2; PDGFR-alpha; PDGFR2; Platelet-derived growth factor alpha receptor; Platelet-derived growth factor receptor 2; RHEPDGFRA; 2.7.10.1; Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; PDGF-R-beta; PDGFR; PDGFR-1; PDGFR-beta; PDGFR1; Platelet-derived growth factor receptor 1; 2.7.10.1; Basic fibroblast growth factor receptor 1; bFGF-R-1; BFGFR; CEK; FGFBR; FGFR-1; FLG; FLT-2; FLT2; Fms-like tyrosine kinase 2; HBGFR; N-sam; Proto-oncogene c-Fgr; 2.7.10.1; BEK; FGFR-2; K-sam; Keratinocyte growth factor receptor; KGFR; KSAM; 2.7.10.1; Endothelial tyrosine kinase; hTIE2; p140 TEK; TIE2; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains-2; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; VMCM; VMCM1; 2.7.10.1; CD167 antigen-like family member B; Discoidin domain receptor 2; Discoidin domain-containing receptor tyrosine kinase 2; Neurotrophic tyrosine kinase, receptor-related 3; NTRKR3; Receptor protein-tyrosine kinase TKT; TKT; TYRO10; Tyrosine-protein kinase TYRO10; 2.7.10.1; gp140trk; MTC; Neurotrophic tyrosine kinase receptor type 1; p140-TrkA; TRK; Trk-A; TRK1-transforming tyrosine kinase protein; TRKA; Tropomyosin-related kinase A; Tyrosine kinase receptor; Tyrosine kinase receptor A; 2.7.10.1; ECK; Epithelial cell kinase; Tyrosine-protein kinase receptor ECK; 2.7.11.1; cRaf; Proto-oncogene c-RAF; RAF; Raf-1; 2.7.11.1; BRAF1; p94; Proto-oncogene B-Raf; RAFB1; v-Raf murine sarcoma viral oncogene homolog B1; 2.7.11.24; MAP kinase 11; MAP kinase p38 beta; MAPK 11; Mitogen-activated protein kinase p38 beta; p38-2; p38b; PRKM11; SAPK2; SAPK2B; Stress-activated protein kinase 2b; 2.7.10.2; FYN-related kinase; Nuclear tyrosine protein kinase RAK; Protein-tyrosine kinase 5; PTK5; RAK; 2.7.10.2; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; ABL; JTK7; p150; Proto-oncogene c-Abl; 2.7.10.1; Cadherin family member 12; CDHF12; CDHR16; Proto-oncogene c-Ret; PTC; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 3; Mast/stem cell growth factor receptor Kit; Platelet-derived growth factor receptor alpha; Platelet-derived growth factor receptor beta; Fibroblast growth factor receptor 1; Fibroblast growth factor receptor 2; Angiopoietin-1 receptor; Discoidin domain-containing receptor 2; High affinity nerve growth factor receptor; Ephrin type-A receptor 2; RAF proto-oncogene serine/threonine-protein kinase; Serine/threonine-protein kinase B-raf; Mitogen-activated protein kinase 11; Tyrosine-protein kinase FRK; Tyrosine-protein kinase ABL1; Proto-oncogene tyrosine-protein kinase receptor Ret,L01EX05
aclidinium,Angle closure glaucoma;Benign prostatic hyperplasia;Bronchial hyperreactivity;Cardiac disorder;Chronic obstructive pulmonary disease;Prostatic hypertrophy,Atrioventricular block first degree;Bladder neck obstruction;Bronchospasm paradoxical;Cardiac failure;Cardio-respiratory arrest;Cough;Diabetes mellitus;Diarrhoea;Dry mouth;Dysphonia;Eye disorder;Gastrointestinal disorder;Headache;Infection;Infestation;Infestation NOS;Mediastinal disorder;Nasopharyngitis;Nervous system disorder;Osteoarthritis;Rhinitis;Sinusitis;Tachycardia;Toothache;Urethral disorder;Urinary retention;Urinary tract disorder;Vision blurred;Vomiting,small molecule,approved,Aclidinio; 3.1.1.8; Acylcholine acylhydrolase; Butyrylcholine esterase; CHE1; Choline esterase II; Pseudocholinesterase,Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5, R03AL05;R03BB05
Saxagliptin,Diabetic ketoacidosis;Pancreatitis;Renal failure;Renal impairment;Type 1 diabetes mellitus;Type 2 diabetes mellitus,Abdominal pain;Anaphylactic shock;Angioedema;Arthralgia;Asthenia;Blood creatine phosphokinase increased;Blood creatinine increased;Blood triglycerides increased;Dermatitis;Dizziness;Dyslipidaemia;Dyspepsia;Erectile dysfunction;Face oedema;Fatigue;Flatulence;Fracture;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Generalized urticaria;Headache;Hypersensitivity;Hypertriglyceridaemia;Hypoglycaemia;Hypoglycemic reaction;Idiopathic thrombocytopenic purpura;Immune system disorder;Immunodeficiency;Infection;Infestation;Infestation NOS;Lymphopenia;Malnutrition;Multiple fractures;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Oedema peripheral;Opportunistic infection;Pancreatitis;Pancreatitis acute;Pruritus;Purpura;Rash;Renal failure chronic;Salmonella sepsis;Sinusitis;Skin disorder;Thrombocytopenia;Tuberculosis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urticaria;Vomiting,small molecule,approved,"(1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile; Saxagliptin; Saxagliptin anhydrous; Saxagliptina; 3.4.14.5; ADABP; ADCP-2; ADCP2; Adenosine deaminase complexing protein 2; CD26; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; OATP-H; OATP-M1; OATP4C1; OATPX; Organic anion transporter M1; Organic anion transporting polypeptide 4C1; SLC21A20; SLCO4C1; Solute carrier family 21 member 20; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8",Dipeptidyl peptidase 4, A10BD10; A10BD25; A10BH03;A10BD21;A10BH03
azilsartan,Essential hypertension;Hypotension,Angioedema;Angiopathy;Asthenia;Blood creatine phosphokinase increased;Blood creatinine increased;Blood uric acid increased;Connective tissue disorder;Dermatitis;Diarrhoea;Dizziness;Fatigue;Gastrointestinal disorder;Hyperuricaemia;Muscle spasms;Nausea;Nervous system disorder;Oedema peripheral;Pruritus;Rash;Skin disorder;Unspecified disorder of skin and subcutaneous tissue,small molecule,approved; investigational,(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; Valsartan; AGTR1A; AGTR1B; Angiotensin II type-1 receptor; AT1 receptor; AT1AR; AT1BR; AT2R1; AT2R1B; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2,Type-1 angiotensin II receptor, C09CA03; C09DA03; C09DB01; C09DB08; C09DX01; C09DX02; C09DX04; C10BX10;C09DX05
riociguat,Chronic thromboembolic pulmonary hypertension;Connective tissue disorder;Hypertension;Pulmonary hypertension,Abdominal distension;Abdominal pain;Anaemia;Angiopathy;Cardiac disorder;Constipation;Diarrhoea;Dizziness;Dyspepsia;Dysphagia;Epistaxis;Fatal outcomes;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haemoglobin;Haemoptysis;Haemorrhage;Headache;Hypotension;Infection;Infestation;Infestation NOS;Mediastinal disorder;Nasal congestion;Nausea;Nervous system disorder;Oedema peripheral;Palpitations;Pulmonary haemorrhage;Vomiting,small molecule,approved,"Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate; Riociguat; Riociguatum; 4.6.1.2; CG-E; CORD6; Guanylate cyclase 2D, retinal; GUC1A4; GUC2D; RETGC; RETGC-1; RETGC1; Rod outer segment membrane guanylate cyclase; ROS-GC; 4.6.1.2; GCS-alpha-2; GUC1A2; GUCSA2; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Albendazole monooxygenase (hydroxylating); Albendazole monooxygenase (sulfoxide-forming); Arachidonic acid epoxygenase; CYPIIJ2; Hydroperoxy icosatetraenoate isomerase; AGP 1; AGP1; OMD 1; Orosomucoid-1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Retinal guanylyl cyclase 1; Guanylate cyclase soluble subunit alpha-2,C02KX05
umeclidinium,Bronchial hyperreactivity;Chronic obstructive pulmonary disease,Abdominal pain upper;Angle closure glaucoma;Arthralgia;Atrial fibrillation;Back pain;Bronchospasm paradoxical;Cardiac disorder;Connective tissue disorder;Contusion;Cough;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Gastrointestinal disorder;Headache;Infection;Infestation;Infestation NOS;Lower respiratory tract infection;Mediastinal disorder;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Neck pain;Nervous system disorder;Pain in extremity;Pharyngitis;Pneumonia;Rash;Rhinitis;Rhythm idioventricular;Sinus headache;Sinus tachycardia;Sinusitis;Skin disorder;Supraventricular extrasystoles;Supraventricular tachycardia;Tachycardia;Toothache;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary retention;Urinary tract infection;Ventricular arrhythmia;Vertigo;Viral upper respiratory tract infection,small molecule,approved,1-[2-(benzyloxy)ethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane; Umeclidinium; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hOCT1; OCT1; Organic cation transporter 1; hOCT2; OCT2; Organic cation transporter 2,Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5, R03AL03; R03BB07;R03AL08
Carfilzomib,Herpes zoster;Plasma cell myeloma;Plasmacytoma,Acute coronary syndrome;Anaemia;Anorexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Bacterial infection;Blood creatinine increased;Body temperature increased;Cardiac arrest;Cardiac disorder;Cardiac failure congestive;Chest wall pain;Chills;Constipation;Cough;Death;Decreased appetite;Diarrhoea;Disease progression;Dizziness;Dyspnoea;Fatigue;Found dead;Haemorrhage intracranial;Headache;Hepatic failure;Herpes virus infection;Hypercalcaemia;Hyperglycaemia;Hypertension;Hypoaesthesia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Infection;Insomnia;Leukopenia;Lymphopenia;Multi-organ failure;Muscle spasms;Musculoskeletal chest pain;Musculoskeletal discomfort;Myocardial ischaemia;Nausea;Neuritis;Neuropathy peripheral;Neutropenia;Oedema peripheral;Organ failure;Pain;Pain in extremity;Peripheral motor neuropathy;Peripheral sensory neuropathy;Pneumonia;Pulmonary hypertension;Renal failure;Renal failure acute;Sepsis;Thrombocytopenia;Tumour lysis syndrome;Upper respiratory tract infection;Vomiting,small molecule,approved; investigational,Carfilzomib; 3.4.25.1; beta-5; LMPX; Macropain epsilon chain; MB1; Multicatalytic endopeptidase complex epsilon chain; Proteasome chain 6; Proteasome epsilon chain; Proteasome subunit beta-5; Proteasome subunit MB1; Proteasome subunit X; X; 3.4.25.1; LMP7; Low molecular mass protein 7; Macropain subunit C13; Multicatalytic endopeptidase complex subunit C13; Proteasome component C13; Proteasome subunit beta-5i; PSMB5i; Really interesting new gene 10 protein; RING10; Y2; beta-6; Macropain subunit C5; Multicatalytic endopeptidase complex subunit C5; Proteasome component C5; Proteasome gamma chain; Proteasome subunit beta-6; PSC5; 3.4.25.1; LMP2; Low molecular mass protein 2; Macropain chain 7; Multicatalytic endopeptidase complex chain 7; Proteasome chain 7; Proteasome subunit beta-1i; PSMB6i; Really interesting new gene 12 protein; RING12; beta-4; Macropain subunit C7-I; Multicatalytic endopeptidase complex subunit C7-I; Proteasome component C7-I; Proteasome subunit beta-4; 3.4.25.1; LMP10; Low molecular mass protein 10; Macropain subunit MECl-1; MECL1; Multicatalytic endopeptidase complex subunit MECl-1; Proteasome MECl-1; Proteasome subunit beta-2i; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1,Proteasome subunit beta type-5; Proteasome subunit beta type-8; Proteasome subunit beta type-1; Proteasome subunit beta type-9; Proteasome subunit beta type-2; Proteasome subunit beta type-10,L01XG02
sevelamer,Chronic kidney disease;Hyperphosphataemia;Renal failure chronic;Renal osteodystrophy,Abdominal pain;Abdominal pain upper;Constipation;Dermatitis;Diarrhoea;Dyspepsia;Faecalith;Faecaloma;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Ileus;Intestinal obstruction;Intestinal perforation;Nausea;Peritonitis;Pruritus;Rash;Subileus;Vomiting,small molecule,approved,Sevelamer; Sévélamer; Sevelamero; Sevelamerum,Phosphate,V03AE02
crizotinib,Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Hepatic impairment;Liver disorder;Neoplasm;Neutropenia;Non-small cell lung cancer,Abscess;Acute respiratory distress syndrome;Alanine aminotransferase increased;Anaemia;Arrhythmia;Aspartate aminotransferase increased;Asthenia;Balance disorder;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Body temperature increased;Bradycardia;Burning sensation;Cardiac disorder;Congenital renal cyst;Constipation;Decreased appetite;Dermatitis;Diarrhoea;Diplopia;Disease progression;Disorder sight;Dizziness;Dizziness postural;Drug-induced liver injury;Dysaesthesia;Dysgeusia;Dyspepsia;Dyspnoea;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Eye disorder;Face oedema;Fatal outcomes;Fatigue;Febrile neutropenia;Fluid retention;Gait disturbance;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal perforation;Generalised oedema;Haemoglobin decreased;Hepatic failure;Hepatic function abnormal;Hepatobiliary disease;Hepatotoxicity;Hypoaesthesia;Hypokalaemia;Hypophosphataemia;Infection;Infestation;Infestation NOS;Interstitial lung disease;Leukopenia;Local swelling;Localised oedema;Loss of consciousness;Lymphopenia;Malnutrition;Mediastinal disorder;Muscular weakness;Nausea;Nervous system disorder;Neuralgia;Neuropathy;Neuropathy peripheral;Neutropenia;Neutrophil count decreased;Oedema;Oedema peripheral;Paraesthesia;Periorbital oedema;Peripheral sensory neuropathy;Phosphatase alkaline increased;Photophobia;Photopsia;Pneumonia;Polyneuropathy;Pulmonary embolism;Rash;Renal cyst;Respiratory failure;Sepsis;Shock;Sinus bradycardia;Skin burning sensation;Skin disorder;Syncope;Transaminases increased;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vitreous floaters;Vomiting;Weight decreased,small molecule,approved; investigational,"(R)-crizotinib; Crizotinib; Crizotinibum; 2.7.10.1; Anaplastic lymphoma kinase; 2.7.10.1; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met; 2.7.10.1; c-Ros receptor tyrosine kinase; MCF3; Proto-oncogene c-Ros; Proto-oncogene c-Ros-1; Receptor tyrosine kinase c-ros oncogene 1; ROS; 2.7.10.1; CDw136; MSP receptor; p185-Ron; Protein-tyrosine kinase 8; PTK8; RON; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",ALK tyrosine kinase receptor; Hepatocyte growth factor receptor; Proto-oncogene tyrosine-protein kinase ROS; Macrophage-stimulating protein receptor,L01ED01
lisdexamfetamine,Agitation;Attention deficit disorder;Attention deficit/hyperactivity disorder;Forgetfulness;Hyperkinesia;Memory impairment;Mental disorder;Psychotic disorder,Abdominal pain upper;Acute coronary syndrome;Affect lability;Aggression;Agitation;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Asthenia;Blood pressure increased;Body temperature increased;Bruxism;Cardiac disorder;Cardiomyopathy;Cerebrovascular accident;Constipation;Convulsion;Decreased appetite;Depression;Dermatillomania;Dermatitis;Diarrhoea;Digestion impaired;Diplopia;Disturbance in sexual arousal;Dizziness;Dry mouth;Dyskinesia;Dyspepsia;Dysphoria;Dyspnoea;Erectile dysfunction;Erythema multiforme;Euphoric mood;Eye disorder;Fatigue;Feeling jittery;Gastrointestinal disorder;Hallucination;Headache;Hepatitis;Hepatobiliary disease;Hyperhidrosis;Hypersensitivity;Hypertension;Immune system disorder;Initial insomnia;Insomnia;Irritability;Libido decreased;Logorrhoea;Malnutrition;Mania;Mediastinal disorder;Mental disorder;Middle insomnia;Mydriasis;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Palpitations;Psychotic disorder;Psychotic episode;Rash;Skin disorder;Somnolence;Stevens-Johnson syndrome;Sudden death;Tachycardia;Tourette's disorder;Toxic epidermal necrolysis;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Ventricular hypertrophy;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved; investigational,"Lisdexamfetamine; TA1; TaR-1; TAR1; Trace amine receptor 1; TRAR1; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter, small intestine isoform; PEPT1; Peptide transporter 1",Trace amine-associated receptor 1,N06BA12
trametinib,Acute coronary syndrome;Glucose-6-phosphate dehydrogenase deficiency;Interstitial lung disease;Metastatic malignant melanoma;Metastatic melanoma;Pneumonia,Abdominal discomfort;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Abdominal tenderness;Actinic keratosis;Alanine aminotransferase increased;Anaemia;Angiopathy;Aphthous stomatitis;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Blindness transient;Blood alkaline phosphatase increased;Blood creatinine increased;Body temperature increased;Bone disorder;Bradycardia;Brain stem haemorrhage;Cardiac disorder;Cardiac failure congestive;Cardiomyopathy;Cellulitis;Cerebral haemorrhage;Chills;Conjunctival haemorrhage;Connective tissue disorder;Constipation;Cough;Creatinine increased;Cyst;Decreased appetite;Dehydration;Dermatitis;Dermatitis acneiform;Diarrhoea;Disease progression;Dizziness;Dry eye;Dry mouth;Dry skin;Dysgeusia;Ejection fraction decreased;Embolism venous;Epistaxis;Erythema;Eye disorder;Eye haemorrhage;Fatigue;Folliculitis;Gamma-glutamyltransferase increased;Gastric haemorrhage;Gastrointestinal disorder;Gastrointestinal pain;Gingival bleeding;Haematochezia;Haematuria;Haemoglobin;Haemorrhage;Haemorrhage intracranial;Haemorrhoidal haemorrhage;Headache;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkeratosis;Hypertension;Hypoalbuminaemia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Infection;Infestation;Infestation NOS;Insomnia;Left ventricular ejection fraction decreased;Leukopenia;Lymphoedema;Lymphopenia;Malignant melanoma;Malnutrition;Mediastinal disorder;Melaena;Mental disorder;Mouth ulceration;Mucosal inflammation;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nausea;Neoplasm;Neoplasm malignant;Nervous system disorder;Neutropenia;Night sweats;Ocular toxicity;Oedema;Oedema peripheral;Oropharyngeal pain;Pain in extremity;Pancreatitis;Paronychia;Phosphatase alkaline increased;Polyp;Prurigo;Pruritus;Rash;Rash erythematous;Rash generalised;Rash macular;Rash maculo-papular;Rash papular;Rash pustular;Rash vesicular;Reaction febrile;Rectal haemorrhage;Refractory hypertension;Renal failure;Renal failure acute;Rhabdomyolysis;Seborrhoeic keratosis;Skin disorder;Skin papilloma;Skin toxicity;Stomatitis;Thrombocytopenia;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Vaginal haemorrhage;Venous thromboembolism;Vision blurred;Vitreous haemorrhage;Vomiting,small molecule,approved,"Tramétinib; Trametinib; Trametinibum; 2.7.12.2; ERK activator kinase 1; MAP kinase kinase 1; MAPK/ERK kinase 1; MAPKK 1; MEK 1; MEK1; MKK1; PRKMK1; 2.7.12.2; ERK activator kinase 2; MAP kinase kinase 2; MAPK/ERK kinase 2; MAPKK 2; MEK 2; MEK2; MKK2; PRKMK2; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase",Dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2,L01EE01
nitroprusside,Cardiac failure congestive;Haemoglobin;Haemorrhage;Hypertensive crisis;Methaemoglobinaemia,Abdominal pain;Agitation;Anxiety;Apprehension;Bradycardia;Chest discomfort;Dermatitis;Dizziness;Electrocardiogram change;Flushing;Gastrointestinal pain;Headache;Hyperhidrosis;Hyperreflexia;Hypotension;Hypothyroidism;Ileus;Intracranial pressure increased;Miosis;Muscle twitching;Nausea;Palpitations;Platelet count decreased;Rash;Retching;Retrosternal discomfort;Sweating increased;Tachycardia;Tinnitus,small molecule,approved; investigational,Nitroferricyanide; 4.6.1.2; GCS-alpha-1; GCS-alpha-3; Guanylate cyclase soluble subunit alpha-3; GUC1A3; GUCSA3; GUCY1A3; Soluble guanylate cyclase large subunit; 4.6.1.2; GCS-beta-1; GCS-beta-3; Guanylate cyclase soluble subunit beta-3; GUC1B3; GUCSB3; GUCY1B3; Soluble guanylate cyclase small subunit; 4.6.1.2; ANP-A; ANPR-A; ANPRA; Atrial natriuretic peptide receptor type A; GC-A; Guanylate cyclase A; NPR-A; 1.14.14.1; CYPIA1; Cytochrome P450 form 6; Cytochrome P450-C; Cytochrome P450-P1; Hydroperoxy icosatetraenoate dehydratase,Guanylate cyclase soluble subunit alpha-1; Guanylate cyclase soluble subunit beta-1; Atrial natriuretic peptide receptor 1,C02DD01
empagliflozin,Hypoglycaemia;Recurrent urinary tract infection;Renal failure;Renal impairment;Type 2 diabetes mellitus;Urinary tract infection,Angiopathy;Arthralgia;Asymptomatic bacteriuria;Balanitis;Bladder pain;Blood creatinine increased;Blood pressure systolic decreased;Cystitis;Cystitis noninfective;Dehydration;Diabetes mellitus;Diabetic nephropathy;Diuresis;Dizziness;Dyslipidaemia;Dysuria;Fungal infection;Genital infection;Genital infection fungal;Haematocrit decreased;Haematocrit increased;Hypotension;Hypovolaemia;Infection;Infestation;Infestation NOS;Loss of consciousness;Malnutrition;Musculoskeletal discomfort;Nausea;Neuropathy;Neuropathy peripheral;Nocturia;Orthostatic hypotension;Phimosis;Pollakiuria;Polydipsia;Polyuria;Pruritus;Retinal disorder;Serum creatinine increased;Shock;Syncope;Thirst;Tight foreskin;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Vaginal infection;Vaginal moniliasis;Vulvitis;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginitis,small molecule,approved,"(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; Empagliflozin; Empagliflozina; Empagliflozine; Empagliflozinum; Low affinity sodium-glucose cotransporter; Na(+)/glucose cotransporter 2; SGLT2; Solute carrier family 5 member 2; 2.4.1.17; 3,4-catechol estrogen-specific UDPGT; UDP-glucuronosyltransferase 2B9; UDPGT 2B7; UDPGT 2B9; UDPGTh-2; UGT2B7; UGTB2B9; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-H; UDPGT 1-8; UGT-1H; UGT1; UGT1-08; UGT1.8; UGT1*8; UGT1A8; UGT1H; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Sodium/glucose cotransporter 2, A10BD20; A10BD27; A10BK03;A10BD19
vasopressin,Abdominal distension;Diabetes insipidus,Abdominal cramps;Abdominal pain;Anaphylactic shock;Angina pectoris;Arrhythmia;Bronchoconstriction;Bronchospasm;Cardiac arrest;Cardiac output decreased;Diuresis;Gangrene;Hyperhidrosis;Hypersensitivity;Myocardial ischaemia;Nausea;Pallor;Polyuria;Shock;Sweating;Tremor;Urine output increased;Urticaria;Vasoconstriction;Vasoconstriction peripheral;Vertigo;Vomiting;Water intoxication,biotech,approved,"Vasopressin, unspecified; Vasopressina; ADHR; Antidiuretic hormone receptor; AVPR V2; DIR; DIR3; Renal-type arginine vasopressin receptor; V2R; Antidiuretic hormone receptor 1a; AVPR V1a; AVPR1; V1aR; Vascular/hepatic-type arginine vasopressin receptor; Antidiuretic hormone receptor 1b; AVPR V1b; AVPR V3; AVPR3; V1bR; Vasopressin V3 receptor; VPR3; OT-R; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2",Vasopressin V2 receptor; Vasopressin V1a receptor; Vasopressin V1b receptor; Oxytocin receptor,H01BA01
macitentan,Connective tissue disorder;Disease progression;Heart disease congenital;Hypertension,Anaemia;Angiopathy;Blood and lymphatic system disorders;Bronchitis;Cardiac failure right;Fluid retention;Headache;Hepatotoxicity;Hypotension;Infection;Infestation;Infestation NOS;Influenza;Nasopharyngitis;Nervous system disorder;Oedema;Pharyngitis;Right ventricular failure;Urinary tract infection,small molecule,approved,"Macitentán; Macitentan; Macitentanum; Endothelin receptor type A; ET-A; ETA; ETA-R; ETRA; hET-AR; Endothelin receptor non-selective type; ET-B; ET-BR; ETRB; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2",Endothelin-1 receptor; Endothelin receptor type B, C02KX54;C02KX04
Insulin,Abdominal pain;Abdominal pain upper;Appetite absent;Cardiovascular disorder;Collapse;Coma;Confusional state;Decreased appetite;Dehydration;Depressed level of consciousness;Diabetes mellitus;Diabetic;Diabetic coma;Diabetic hyperglycaemic coma;Diabetic ketoacidosis;Drowsiness;Feeling abnormal;Hepatic impairment;Hyperglycaemia;Hypoglycaemia;Increased thirst;Ketoacidosis;Liver disorder;Loss of consciousness;Nausea;Pollakiuria;Precoma;Shock;Somnolence;Stomach ache;Thirst;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Vomiting,Abdominal discomfort;Abnormal behaviour;Acute coronary syndrome;Affect lability;Agitation;Anaphylactic shock;Angina pectoris;Angioedema;Anxiety;Appetite absent;Arthralgia;Asthenia;Asthma;Back pain;Blood potassium decreased;Breath odour ketones;Bronchitis;Bronchospasm;Carcinoma of lung;Cardiac failure;Cellulitis;Cerebration impaired;Chest discomfort;Chest pain;Chest tightness;Cold sweat;Confusional state;Convulsion;Coronary artery disease;Cough;Cough decreased;Cough increased;Decreased appetite;Depressed mood;Dermatitis;Dermatitis atopic;Diabetes mellitus;Diabetic autonomic neuropathy;Diabetic ketoacidosis;Diabetic retinopathy;Diarrhoea;Disorientation;Disturbance in attention;Dizziness;Drowsiness;Dry mouth;Dry skin;Dry throat;Dysarthria;Dysphonia;Dyspnoea;Ear disorder;Ear pain;Epistaxis;Erythema;Eye disorder;Fatigue;Feeling abnormal;Feeling hot;Gastrointestinal disorder;Gastrointestinal tract irritation;Glycosuria;Haemoglobin;Haemorrhage;Headache;Heart failure signs and symptoms;Hunger;Hyperhidrosis;Hypernatraemia;Hypersensitivity;Hypertension;Hypoglycaemia;Hypoglycaemic coma;Hypoglycaemic episode;Hypoglycaemic seizure;Hypokalaemia;Hypotension;Immune system disorder;Increased bronchial secretion;Infection;Infestation;Infestation NOS;Influenza;Infusion site reactions;Injection site erythema;Injection site haematoma;Injection site hypertrophy;Injection site inflammation;Injection site mass;Injection site pain;Injection site pruritus;Injection site reaction;Injection site stinging;Injection site swelling;Injection site urticaria;Irritability;Ketoacidosis;Laryngeal pain;Laryngitis;Lightheadedness;Lipoatrophy;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Local reaction;Local swelling;Loss of consciousness;Lung disorder;Lung neoplasm malignant;Malnutrition;Mediastinal disorder;Mental disability;Mood swings;Musculoskeletal discomfort;Myalgia;Myocardial infarction;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuroglycopenia;Neuropathy;Neuropathy peripheral;Nodule;Obstruction;Oedema;Oedema peripheral;Oropharyngeal discomfort;Oropharyngeal pain;Otitis media;Pain;Pallor;Pallor of skin;Palpitations;Paraesthesia;Personality change;Pharyngitis;Pharyngolaryngeal pain;Pleural effusion;Pneumonia;Pollakiuria;Potassium low;Productive cough;Pruritus;Pulmonary function test decreased;Rash;Rash generalised;Redness;Refraction disorder;Respiratory tract infection;Retinal disorder;Retinopathy proliferative;Rhinitis;Serum sickness;Shock;Sinusitis;Skin disorder;Sleep disorder;Sleep disturbance;Slurred speech;Somnolence;Sputum increased;Sweating;Sweating increased;Swelling;Swollen tongue;Syncope;Systemic allergic reaction;Tachycardia;Tension;Thirst;Throat irritation;Throat sore;Tingling sensation;Tonsillar disorder;Tremor;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Urticaria;Vision blurred;Visual impairment;Vomiting;Warmth;Weight decreased;Weight increased;Wheezing;Worsening of diabetes,biotech,approved; investigational; nutraceutical,Inulin,Insulin; Cycloinulo-oligosaccharide fructanotransferase,A10AB01;V04CH01
ziconotide,Chronic pain;Pain,"Abdominal pain;Abdominal pain upper;Abnormal dreams;Affect lability;Affective disorder;Ageusia;Aggression;Agitation;Altered state of consciousness;Amnesia;Angioedema;Angiopathy;Anorexia;Anxiety;Anxiety aggravated;Aphasia;Areflexia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Ataxia;Atrial fibrillation;Back pain;Blood creatine phosphokinase MM increased;Blood creatine phosphokinase increased;Body temperature increased;Burning sensation;Cardiac disorder;Cerebrovascular accident;Chest pain;Chills;Clonic convulsion;Cognitive disorder;Cognitive impairment;Coma;Confusion aggravated;Confusional state;Connective tissue disorder;Constipation;Convulsion;Coordination abnormal;Cramp muscle;Decreased appetite;Delirium;Depressed level of consciousness;Depression;Depression aggravated;Dermatitis;Dermatitis bullous;Diarrhoea;Diplopia;Disorientation;Disturbance in attention;Dizziness;Dizziness postural;Dry mouth;Dysaesthesia;Dysarthria;Dysgeusia;Dyspepsia;Dyspnoea;Dysuria;Ear and labyrinth disorders;Electrocardiogram abnormal;Encephalopathy;Eye disorder;Fatigue;Feeling abnormal;Feeling jittery;Gait disturbance;Gastrointestinal disorder;Gastrointestinal pain;Grand mal convulsion;Hallucination;Hallucination, auditory;Hallucination, visual;Headache;Hostility;Hyperaesthesia;Hyperhidrosis;Hypersensitivity;Hypoaesthesia;Hyporeflexia;Hypotension;Infection;Infestation;Infestation NOS;Insomnia;Irritability;Lethargy;Local swelling;Loss of consciousness;Malnutrition;Mediastinal disorder;Memory impairment;Meningitis;Mental disability;Mental disorder;Mental retardation;Mental status changes;Muscle spasms;Muscle twitching;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myopathy;Myositis;Nausea;Nausea aggravated;Neck pain;Nervous system disorder;Nervousness;Nystagmus;Oedema peripheral;Orthostatic hypotension;Osteoarthritis;Pain;Pain in extremity;Pain worsened;Paraesthesia;Paranoia;Parosmia;Peripheral swelling;Photophobia;Pneumonia aspiration;Poor quality sleep;Pruritus;Psychotic disorder;Rash;Renal failure acute;Respiratory distress;Rhabdomyolysis;Rigors;Sepsis;Sinusitis;Skin burning sensation;Skin disorder;Skin exfoliation;Skin ulcer;Somnolence;Speech disorder;Stupor;Suicidal ideation;Suicide attempt;Sweating increased;Tension;Thought blocking;Tinnitus;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary hesitation;Urinary incontinence;Urinary retention;Urinary tract disorder;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Wakefulness;Walking disability;Weight decreased",biotech,approved,"Ziconotida; Ziconotide; BIII; Brain calcium channel III; CACH5; CACNL1A5; Calcium channel, L type, alpha-1 polypeptide isoform 5; Voltage-gated calcium channel subunit alpha Cav2.2; BI; Brain calcium channel I; CACH4; CACN3; CACNL1A4; Calcium channel, L type, alpha-1 polypeptide isoform 4; Voltage-gated calcium channel subunit alpha Cav2.1",Voltage-dependent N-type calcium channel subunit alpha-1B; Voltage-dependent P/Q-type calcium channel subunit alpha-1A,N02BG08
Bivalirudin,Acute coronary syndrome;Acute myocardial infarction;Angina pectoris;Angina unstable;Haemoglobin;Haemorrhage;Heparin-induced thrombocytopenia;Major bleed;Myocardial infarction;ST segment elevation myocardial infarction;Thrombosis,Abdominal pain;Acute coronary syndrome;Anaemia;Anal haemorrhage;Anaphylactic shock;Angina pectoris;Angiopathy;Anxiety;Arteriovenous fistula;Atelectasis;Atrial fibrillation;Back pain;Blood and lymphatic system disorders;Body temperature increased;Bradycardia;Cardiac disorder;Cardiac tamponade;Catheter thrombosis;Cerebral ischaemia;Chest pain;Clotting;Coagulopathy;Compartment syndrome;Confusional state;Connective tissue disorder;Contusion;Coronary artery thrombosis;Coronary stent thrombosis;Dermatitis;Dizziness;Drug interaction;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Ear haemorrhage;Ecchymosis;Electrocardiogram ST segment elevation;Epistaxis;Eye disorder;Eye haemorrhage;Facial paralysis;Fatal outcomes;Feeling abnormal;Frank hematuria;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gingival bleeding;Groin pain;Haematemesis;Haematoma;Haematuria;Haemoglobin;Haemoglobin decreased;Haemoptysis;Haemorrhage;Haemorrhage intracranial;Headache;Hemorrhage symptom;Hypersensitivity;Hypertension;Hypotension;Immune system disorder;Increased tendency to bruise;Infection;Injection site discomfort;Injection site haemorrhage;Injection site pain;Injection site reaction;Insomnia;International normalised ratio increased;Loss of consciousness;Major bleed;Mediastinal disorder;Melaena;Myocardial infarction;Nausea;Nervous system disorder;Nervousness;Oesophageal haemorrhage;Oliguria;Pain;Pelvic pain;Pericardial haemorrhage;Peritoneal haemorrhage;Petechiae;Pharyngeal haemorrhage;Pleural effusion;Pneumothorax;Post procedural haemorrhage;Postoperative hemorrhage;Pulmonary haemorrhage;Pulmonary oedema;Puncture site reaction;Rash;Renal failure;Reperfusion injury;Retroperitoneal haematoma;Retroperitoneal haemorrhage;Sepsis;Shock;Skin disorder;Surgery;Surgical intervention;Syncope;Tension;Thrombocytopenia;Thrombosis;Thrombosis in device;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary retention;Urinary tract disorder;Urticaria;VIIth nerve paralysis;Vascular anomaly;Vascular pseudoaneurysm;Ventricular fibrillation;Ventricular tachycardia;Vessel puncture site haematoma;Vomiting,small molecule,approved; investigational,Bivalirudin; Bivalirudina; Bivalirudinum; 3.4.21.5; Coagulation factor II; 1.11.2.2; MPO,Prothrombin,B01AE06
Enfuvirtide,Lung disorder;Pneumonia;Pneumonia recurrent,Abdominal pain;Abdominal pain upper;Abscess;Acne;Acquired immunodeficiency syndrome;Administration site infection;Amylase increased;Anaphylactic shock;Angina pectoris;Angina unstable;Anorexia;Anxiety;Application site pain;Arthralgia;Aspartate aminotransferase increased;Asthenia;Autoimmune disorder;Back pain;Blood and lymphatic system disorders;Blood disorder;Blood triglycerides increased;Body temperature increased;Bone disorder;Bronchopneumonia;Calculus of kidney;Candida infection;Cardiac disorder;Cellulitis;Chills;Conjunctivitis;Constipation;Contusion;Cough;Cramp muscle;Cyst;Decreased appetite;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Disability;Discomfort;Disturbance in attention;Dizziness;Dry mouth;Dry skin;Dysgeusia;Ear and labyrinth disorders;Ear infection;Ecchymosis;Eosinophilia;Erythema;Eye disorder;Fatigue;Folliculitis;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Glomerulonephritis;Guillain-Barre syndrome;Haematoma;Haematuria;Headache;Hepatic steatosis;Hepatitis toxic;Hepatobiliary disease;Herpes simplex;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertriglyceridaemia;Hypoaesthesia;Hypotension;Immune complex reaction;Immune system disorder;Induration;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Injection site infection;Injection site pain;Injection site reaction;Insomnia;Instillation site pain;Irritability;Lipase increased;Lymphadenopathy;Malaise;Malnutrition;Mediastinal disorder;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nausea;Nephrolithiasis;Nervous system disorder;Neuralgia;Neuropathy peripheral;Neutropenia;Night sweats;Nightmare;Nodule;Opportunistic infection;Oral candidiasis;Oropharyngeal discomfort;Oropharyngeal pain;Pain;Pain in extremity;Pain nerve;Pancreatitis;Paraesthesia;Pneumonia;Pneumonia bacterial;Pruritus;Rash;Renal failure;Renal impairment;Renal tubular necrosis;Respiratory distress;Rigors;Seborrhoeic dermatitis;Sepsis;Sickness;Sinusitis;Skin disorder;Skin papilloma;Suicide attempt;Sweating increased;Tenderness;Throat sore;Thrombocytopenia;Tremor;Type III immune complex mediated reaction;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;VIth nerve paralysis;Vertigo;Vomiting;Weight decreased,biotech,approved; investigational,Enfuvirtida; Enfuvirtide; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; 4-nitrophenol 2-hydroxylase; CYP2E; CYPIIE1; Cytochrome P450-J,Envelope glycoprotein,J05AX07
Abarelix,Prostate cancer,Asthenia;Back pain;Blood triglycerides increased;Breast enlargement;Breast pain;Constipation;Diarrhoea;Dizziness;Dysuria;Fatigue;Headache;Hot flush;Hypersensitivity;Menopausal symptoms;Nausea;Nipple pain;Nipple tenderness;Oedema peripheral;Pain;Pollakiuria;Serum triglycerides increased;Sleep disorder;Sleep disturbance;Upper respiratory tract infection;Urinary retention;Urinary tract infection,small molecule,approved; investigational; withdrawn,Abarelix; GnRH receptor; GnRH-R; GRHR,Gonadotropin-releasing hormone receptor,L02BX01
glucagon,Coronary artery disease;Hyperglycaemia;Hypoglycaemia;Type 1 diabetes mellitus,Anaphylactic shock;Blood pressure increased;Drug interaction;Hypersensitivity;Hypertension;Hypoglycaemic coma;Hypotension;Nausea;Tachycardia;Vomiting,biotech,approved,"Glucagon; Glucagon (recombinant dna origin); Glucagon recombinant; Glucagon, human; Glucagon, porcine; Glucagone; Glucagonum; GL-R; GLP-2 receptor; GLP-2-R; GLP-2R; GLP-1 receptor; GLP-1-R; GLP-1R",Glucagon receptor; Glucagon-like peptide 2 receptor; Glucagon-like peptide 1 receptor,H04AA01
liraglutide,Antibody NOS negative;Antibody test negative;Antibody test positive;Diabetic ketoacidosis;Neoplasm;Pancreatitis;Pancreatitis acute;Pancreatitis necrotising;Renal failure;Renal impairment;Type 1 diabetes mellitus;Type 2 diabetes mellitus,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Anaphylactic shock;Angioedema;Anorexia;Asthenia;Blood creatinine increased;Bronchitis;Carcinoma;Cardiac disorder;Constipation;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Discomfort;Dizziness;Dyspepsia;Dyspnoea;Erythema;Fatigue;Feeling abnormal;Flatulence;Gastritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Headache;Hypersensitivity;Hypoglycaemia;Hypotension;Ill-defined disorder;Immune system disorder;Infection;Infestation;Infestation NOS;Injection site dermatitis;Injection site reaction;Intestinal obstruction;Malaise;Malnutrition;Nasopharyngitis;Nausea;Neoplasm malignant;Nervous system disorder;Oedema;Palpitations;Pancreatitis;Pancreatitis acute;Pancreatitis necrotising;Papillary thyroid cancer;Pruritus;Rash;Renal failure;Renal failure acute;Renal failure chronic;Renal impairment;Serum creatinine increased;Tachycardia;Toothache;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Vomiting,biotech,approved,Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]; Liraglutida; Liraglutide; Liraglutide (genetical recombination); Liraglutide (rDNA origin); Liraglutide recombinant; Liraglutidum; N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide; N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide; GLP-1 receptor; GLP-1-R; GLP-1R; 3.4.14.5; ADABP; ADCP-2; ADCP2; Adenosine deaminase complexing protein 2; CD26; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103; 3.4.24.11; Atriopeptidase; CALLA; Common acute lymphocytic leukemia antigen; Enkephalinase; EPN; NEP; Neutral endopeptidase; Neutral endopeptidase 24.11; SFE; Skin fibroblast elastase,Glucagon-like peptide 1 receptor, A10BJ02;A10AE56;A10BX07
degarelix,Hormone-dependent prostate cancer;Prostate cancer,Abdominal discomfort;Abdominal pain;Abscess;Acute coronary syndrome;Administration site infection;Alopecia;Anaemia;Anaphylactic shock;Angiopathy;Arrhythmia;Arthralgia;Asthenia;Atrial fibrillation;Back pain;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Body temperature increased;Bone density decreased;Bone disorder;Breast disorder;Breast pain;Cardiac disorder;Cardiac failure;Chills;Constipation;Decreased appetite;Depression;Dermatitis;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in sexual arousal;Dizziness;Dry mouth;Dyspnoea;Dysuria;Ejaculation failure;Electrocardiogram U wave present;Electrocardiogram U-wave abnormality;Electrocardiogram change;Erectile dysfunction;Erythema;Eye disorder;Fatigue;Febrile neutropenia;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Genital discomfort;Genital irritation;Gynaecomastia;Headache;Hepatobiliary disease;Hot flush;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoaesthesia;Hypotension;Ill-defined disorder;Immune system disorder;Incontinence;Induration;Inflammation;Influenza like illness;Injection site reaction;Insomnia;Joint swelling;Libido decreased;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disability;Mental disorder;Mental retardation;Micturition urgency;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myocardial infarction;Nausea;Nervous system disorder;Night sweats;Nocturia;Nodule;Oedema peripheral;Osteopenia;Osteoporosis;Pain;Palpitations;Pelvic pain;Phosphatase alkaline increased;Pollakiuria;Pruritus;Rash;Renal failure;Renal impairment;Skin disorder;Skin mass;Skin nodule;Stiffness;Swelling;Testicular atrophy;Testicular pain;Transaminases increased;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Vision blurred;Vomiting;Weight decreased;Weight increased,small molecule,approved,Degarelix; GnRH receptor; GnRH-R; GRHR,Gonadotropin-releasing hormone receptor,L02BX02
insulin,Diabetes mellitus;Diabetic;Hepatic impairment;Hyperglycaemia;Liver disorder;Type 1 diabetes mellitus;Type 2 diabetes mellitus,Abdominal discomfort;Abdominal distension;Abdominal pain;Abnormal vision;Abscess;Accidental injury;Acute coronary syndrome;Affect lability;Agitation;Albuminuria;Alopecia;Amenorrhoea;Anaphylactic shock;Aneurysm;Angina pectoris;Angioedema;Angiopathy;Anorexia;Anxiety;Application site pain;Arthralgia;Arthritis;Arthropathy;Asthenia;Asthma;Atrioventricular block;Back pain;Biliary colic;Bladder pain;Block heart;Blood glucose increased;Body temperature increased;Bone pain;Bradycardia;Breast disorder;Bronchitis;Bronchospasm;Bullous eruption;Cardiac disorder;Cardiac failure;Cardiac murmur;Cardiomyopathy;Cardiovascular disorder;Carpal tunnel syndrome;Cellulitis;Cerebration impaired;Cerebrovascular disorder;Chest pain;Cholelithiasis;Coagulopathy;Cold sweat;Colitis;Collagen disorder;Coma;Common wart;Confusional state;Congenital eye disorder;Conjunctivitis;Constipation;Contusion;Convulsion;Coronary artery disease;Cough;Cystitis;Cystitis noninfective;Decreased appetite;Dental caries;Dermatitis;Dermatitis bullous;Dermatitis contact;Diabetes mellitus;Diabetes mellitus exacerbated;Diabetic coma;Diabetic hyperglycaemic coma;Diabetic retinopathy;Diarrhoea;Disorder sight;Disturbance in attention;Dizziness;Drowsiness;Dry mouth;Dry skin;Dysgeusia;Dysmenorrhoea;Dyspepsia;Dysphagia;Dysphonia;Ear disorder;Ear pain;Eczema;Endocrine disorder;Enlargement abdomen;Epistaxis;Eruption;Eruption lichenoid;Erythema;Eye disorder;Eye haemorrhage;Eye infection;Eye pain;Face oedema;Fatigue;Feeling abnormal;Flushing;Food poisoning;Fracture;Functional gastrointestinal disorder;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal tract irritation;Gastrooesophageal reflux disease;Gingivitis;Glycosuria;Goitre;Gout;Gravitational oedema;Haematoma;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoids;Headache;Hot flush;Hunger;Hyperaesthesia;Hyperhidrosis;Hyperkalaemia;Hyperkinesia;Hyperlipidaemia;Hypernatraemia;Hypersensitivity;Hypertension;Hyperthyroidism;Hypertonia;Hypochromic anaemia;Hypoglycaemia;Hypoglycaemic coma;Hypoglycaemic episode;Hyporeflexia;Hypotension;Hypothyroidism;Immune system disorder;Infection;Infection parasitic;Inflammation;Influenza like illness;Influenza-like symptoms;Injection site haematoma;Injection site inflammation;Injection site pain;Injection site reaction;Injury;Injury associated with device;Instillation site pain;Irritable bowel syndrome;Keratitis;Ketosis;Laryngitis;Left ventricular failure;Lichenoid keratosis;Lipoatrophy;Lipodystrophy;Lipodystrophy acquired;Lipohypertrophy;Lipoma;Localized erythema;Loss of consciousness;Lymphadenopathy;Lymphoma;Malnutrition;Mastitis;Menopausal symptoms;Menorrhagia;Mental disability;Mental disorder;Migraine;Mood swings;Motion sickness;Mucosal inflammation;Multiple fractures;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nausea;Neck stiffness;Needle injury;Neoplasm;Nervous system disorder;Nervousness;Neuralgia;Neuropathy;Neuropathy peripheral;Non-Hodgkin's lymphoma;Nuchal rigidity;Oedema;Oedema mouth;Oedema peripheral;Onychomycosis;Osteoarthritis;Osteoporosis;Otitis externa;Otitis media;Ovarian cyst;Pain;Pallor;Pallor of skin;Palpitations;Paralysis;Pharyngitis;Phlebitis;Photosensitivity reaction;Pilonidal cyst;Pneumonia;Polyuria;Pregnancy;Premenstrual syndrome;Premenstrual tension;Pruritus;Pulmonary oedema;Pulse abnormal;Pulse pressure decreased;Purpura;Rash;Red blood cell disorders;Redness;Refraction disorder;Renal pain;Retinal disorder;Retinal haemorrhage;Retrosternal pain;Rheumatoid arthritis;Rhinitis;Sciatica;Shock;Sinusitis;Skin cold clammy;Skin discolouration;Skin disorder;Skin hypertrophy;Skin papilloma;Skin ulcer;Somnolence;Sudden death;Sweating;Sweating increased;Swelling;Syncope;Tendon disorder;Tenosynovitis;Tension;Thirst;Thready pulse;Thrombophlebitis;Thrombosis;Thrombosis leg;Tooth caries aggravated NOS;Tooth disorder;Toothache;Torticollis;Tracheitis;Tremor;Ulcerative keratitis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine abnormality;Urine analysis abnormal;Urine output increased;Urticaria;Vaginal infection;Vaginal inflammation;Varicella;Vascular purpura;Vein disorder;Vestibular disorder;Viral infection;Visual impairment;Vomiting;Weight decreased;Weight increased;Worsening of diabetes;Xerophthalmia,biotech,approved; investigational; nutraceutical,Inulin,Insulin; Cycloinulo-oligosaccharide fructanotransferase,A10AE05;V04CH01
teduglutide,Short-bowel syndrome,Abdominal pain;Angiopathy;Anxiety;Arthralgia;C-reactive protein increased;Cardiac disorder;Cardiac failure congestive;Chest pain;Cholecystitis;Cholestasis;Connective tissue disorder;Costovertebral angle tenderness;Cough;Decreased appetite;Dermatitis atopic;Dizziness;Dyspnoea;Flushing;Gastrointestinal disorder;Gastrointestinal pain;Gastrointestinal stoma complication;Headache;Hepatobiliary disease;Infection;Infestation;Infestation NOS;Influenza;Injection site erythema;Injection site haematoma;Injection site pain;Injection site reaction;Intestinal obstruction;Loss of consciousness;Malnutrition;Mediastinal disorder;Mental disorder;Musculoskeletal discomfort;Nausea;Nervous system disorder;Night sweats;Oedema peripheral;Pancreatitis;Paraesthesia;Renal colic;Respiratory tract infection;Shock;Skin disorder;Sleep disorder;Swelling;Syncope;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vomiting,biotech,approved,(Gly2)GLP-2; Glucagon-like peptide II (2-glycine) (human); Gly(2)-GLP-2; Teduglutida; Teduglutide; Teduglutide [rDNA origin]; Teduglutide Recombinant; GLP-2 receptor; GLP-2-R; GLP-2R,Glucagon-like peptide 2 receptor,A16AX08
exenatide,Antibody NOS negative;Antibody test negative;Antibody test positive;Diabetic ketoacidosis;Hypoglycaemia;Hypoglycaemic episode;Neoplasm;Pancreatitis;Pancreatitis acute;Pancreatitis necrotising;Type 1 diabetes mellitus;Type 2 diabetes mellitus,Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Alopecia;Alveolitis allergic;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anxiety;Arthralgia;Asthenia;Back pain;Blood creatinine increased;Blood glucose decreased;Breast disorder;Chest pain;Chills;Colitis ischaemic;Coma;Connective tissue disorder;Constipation;Convulsion;Cough;Decreased appetite;Dehydration;Depression;Diabetes mellitus;Diabetic;Diabetic neuropathy;Diarrhoea;Dizziness;Drug interaction;Dysgeusia;Dyspepsia;Erectile dysfunction;Eructation;Erythema;Fatigue;Feeling jittery;Flatulence;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haemoglobin;Haemorrhage;Headache;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoglycaemia;Hypokalaemia;Ileus;Immune system disorder;Induration;Infection;Infestation;Infestation NOS;Influenza;Injection site dermatitis;Injection site erythema;Injection site haematoma;Injection site induration;Injection site mass;Injection site nodule;Injection site pain;Injection site pruritus;Injection site reaction;Insomnia;International normalised ratio increased;Ischaemia;Loss of consciousness;Malnutrition;Mediastinal disorder;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Musculoskeletal pain;Nasopharyngitis;Nausea;Nervous system disorder;Nervousness;Neuroglycopenia;Nodule;Oropharyngeal pain;Pain in extremity;Pancreatitis acute;Pancreatitis necrotising;Procedural pain;Pruritus;Pruritus generalised;Rash papular;Renal failure;Renal failure acute;Renal failure chronic;Renal impairment;Serum creatinine increased;Sinusitis;Skin disorder;Somnolence;Tachycardia;Toothache;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urticaria;Viral diarrhoea;Vomiting;Weight decreased,biotech,approved; investigational,Exenatida; Exenatide; Exenatide synthetic; Exendin 4; Exendin-4; Synthetic exendin-4; GLP-1 receptor; GLP-1-R; GLP-1R; 3.4.14.5; ADABP; ADCP-2; ADCP2; Adenosine deaminase complexing protein 2; CD26; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103,Glucagon-like peptide 1 receptor,A10BJ01;A10BX04
linaclotide,Chronic idiopathic constipation;Constipation;Diabetes mellitus;Diabetic;Diarrhoea;Functional gastrointestinal disorder;Hypertension;Hypertensive;Irritable bowel syndrome,Abdominal distension;Abdominal pain;Angiopathy;Asthenia;Blood bicarbonate decreased;Decreased appetite;Defaecation urgency;Dehydration;Dermatitis;Diarrhoea;Dizziness;Dyspepsia;Faecal incontinence;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Haematochezia;Headache;Hypersensitivity;Hypokalaemia;Infection;Infestation;Infestation NOS;Malnutrition;Melaena;Nervous system disorder;Orthostatic hypotension;Rash;Rectal haemorrhage;Sinusitis;Skin disorder;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urticaria;Viral diarrhoea;Vomiting,small molecule,approved,"(9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE; L-TYROSINE, L-CYSTEINYL-L-CYSTEINYL-L-.ALPHA.-GLUTAMYL-L-TYROSYL-L-CYSTEINYL-L-CYSTEINYL-L-ASPARAGINYL-L-PROLYL-L-ALANYL-L-CYSTEINYL-L-THREONYLGLYCYL-L-CYSTEINYL-, CYCLIC (1->6),(2->10),(5->13)-TRIS(DISULFIDE); Linaclotida; Linaclotide; 4.6.1.2; GC-C; GUC2C; Heat-stable enterotoxin receptor; hSTAR; Intestinal guanylate cyclase; STA receptor; STAR",Guanylyl cyclase C,A06AX04
ivacaftor,Cystic fibrosis,Abdominal pain;Arthralgia;Aspartate aminotransferase increased;Bilirubin total increased;Blood bilirubin increased;Blood glucose increased;Breast disorder;Breast mass;Connective tissue disorder;Dermatitis;Diarrhoea;Dizziness;Ear and labyrinth disorders;Ear congestion;Ear discomfort;Ear pain;Gastrointestinal disorder;Gastrointestinal pain;Gynaecomastia;Headache;Hepatic enzyme increased;Hyperaesthesia;Hypoglycaemia;Infection;Infestation;Infestation NOS;Mastitis;Mediastinal disorder;Musculoskeletal chest pain;Musculoskeletal discomfort;Myalgia;Nasal congestion;Nasopharyngitis;Nausea;Nervous system disorder;Nipple disorder;Nipple pain;Oropharyngeal pain;Pharyngeal erythema;Pleuritic pain;Rash;Rhinitis;Sinus congestion;Sinus headache;Skin disorder;Tinnitus;Transaminases increased;Tympanic membrane hyperaemia;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Vestibular disorder;Wheezing,small molecule,approved,"Ivacaftor; Ivacaftorum; N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; ABCC7; ATP-binding cassette sub-family C member 7; cAMP-dependent chloride channel; CFTR; Channel conductance-controlling ATPase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Cystic fibrosis transmembrane conductance regulator, R07AX02; R07AX30; R07AX31;R07AX32
ruxolitinib,Essential thrombocythaemia;Myelofibrosis;Myeloid metaplasia;Polycythaemia vera;Splenomegaly,Alanine aminotransferase increased;Anaemia;Asthenia;Blood and lymphatic system disorders;Blood pressure systolic increased;Body temperature increased;Bone pain;Contusion;Dizziness;Epistaxis;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal haemorrhage;Haematuria;Haemoglobin;Haemorrhage;Haemorrhage intracranial;Headache;Hepatobiliary disease;Herpes zoster;Hypercholesterolaemia;Infection;Infestation;Infestation NOS;Kidney infection;Malnutrition;Myelosuppression;Nervous system disorder;Neutropenia;Night sweats;Pancytopenia;Plasma cell myeloma;Plasmacytoma;Post procedural haemorrhage;Prostate cancer;Pruritus;Skin disorder;Thrombocytopenia;Tuberculosis;Unspecified disorder of skin and subcutaneous tissue;Urinary tract infection;Urosepsis;Weight decreased;Weight increased,small molecule,approved,"Ruxolitinib; MO3; Monocyte activation antigen Mo3; U-PAR; UPAR; 2.7.10.2; JAK-2; Janus kinase 2; 2.7.10.2; JAK-1; JAK1A; JAK1B; Janus kinase 1; 2.7.10.2; JAK-3; Janus kinase 3; L-JAK; Leukocyte janus kinase; 2.7.10.2; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase",Urokinase plasminogen activator surface receptor; Tyrosine-protein kinase JAK2; Tyrosine-protein kinase JAK1; Tyrosine-protein kinase JAK3; Non-receptor tyrosine-protein kinase TYK2, L01EJ01;D11AH09
nesiritide,ADHF;Cardiac failure;Cardiac failure acute;Dyspnoea,Angiopathy;Arrhythmia;Back pain;Blood creatinine increased;Bradycardia;Cardiac failure;Coronary artery disease;Creatinine increased;Dermatitis;Diabetes mellitus;Dizziness;Drug interaction;Dyspnoea;Headache;Hyperhidrosis;Hypersensitivity;Hypertension;Hypoglycaemia;Hypotension;Hypotension asymptomatic;Hypotension symptomatic;Immune system disorder;Infusion site extravasation;Musculoskeletal disorder;Nausea;Nervous system disorder;Pruritus;Rash;Renal failure;Renal impairment;Sweating;Ventricular arrhythmia;Ventricular extrasystoles;Vomiting,biotech,approved; investigational,BNP; BNP-32; Brain natriuretic peptide 32; Human brain natriuretic factor-32; Nesiritide; Nesiritide recombinant; 4.6.1.2; ANP-A; ANPR-A; ANPRA; Atrial natriuretic peptide receptor type A; GC-A; Guanylate cyclase A; NPR-A; 4.6.1.2; ANP-B; ANPR-B; ANPRB; Atrial natriuretic peptide receptor type B; GC-B; Guanylate cyclase B; NPR-B; ANP-C; ANPR-C; ANPRC; Atrial natriuretic peptide clearance receptor; Atrial natriuretic peptide receptor type C; C5orf23; NPR-C; NPRC,Atrial natriuretic peptide receptor 1; Atrial natriuretic peptide receptor 2; Atrial natriuretic peptide receptor 3,C01DX19
raltegravir,Immunodeficiency;Infection;Infection mixed;Mental disorder,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abdominal tenderness;Abnormal behaviour;Abnormal dreams;Absolute neutrophil count decreased;Acquired immunodeficiency syndrome;Acute coronary syndrome;Acute psychosis;Affect lability;Agitation;Alanine aminotransferase increased;Allergic rash;Alopecia;Altered state of consciousness;Amnesia;Amylase increased;Anaemia;Anal cancer;Angiopathy;Anorectal discomfort;Anxiety;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Autoimmune disorder;Back pain;Basedow's disease;Blood albumin decreased;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood cholesterol increased;Blood creatine phosphokinase increased;Blood creatinine increased;Blood glucose increased;Blood pancreatic amylase increased;Blood triglycerides increased;Blood urea increased;Blood urine;Blood urine present;Body fat disorder;Body temperature increased;Breast cancer;Breast disorder;Bronchitis;Cachexia;Cardiac disorder;Carpal tunnel syndrome;Cerebellar ataxia;Cerebration impaired;Chest discomfort;Chest pain;Chills;Cognitive disorder;Completed suicide;Confusional state;Connective tissue disorder;Constipation;Cough;Creatine phosphokinase increased;Cyst;Decreased appetite;Delirium;Depressed level of consciousness;Depressed mood;Depression;Dermatitis;Dermatitis acneiform;Dermatitis atopic;Diabetes mellitus;Diarrhoea;Discomfort;Disturbance in attention;Dizziness;Dizziness postural;Drug eruption;Drug hypersensitivity;Dry mouth;Dry skin;Duodenitis haemorrhagic;Dysgeusia;Dyslipidaemia;Dyspepsia;Dysphonia;Ear and labyrinth disorders;Eosinophilia;Epigastric discomfort;Epistaxis;Erectile dysfunction;Eructation;Erythema;Erythema multiforme;Eye disorder;Face oedema;Facial wasting;Fasting;Fasting blood glucose increased;Fat tissue increased;Fatigue;Feeling abnormal;Feeling jittery;Flank pain;Flatulence;Foetor hepaticus;Folliculitis;Gastritis;Gastroenteritis;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Genital herpes;Gingivitis;Glossitis;Glycosuria;Gynaecomastia;Haematuria;Hallucination;Hallucination, auditory;Headache;Hepatic cancer;Hepatic failure;Hepatic steatosis;Hepatitis;Hepatitis B;Hepatitis C;Hepatitis alcoholic;Hepatobiliary disease;Hepatocellular carcinoma;Hepatocellular injury;Herpes simplex;Herpes virus infection;Herpes zoster;High cholesterol;High density lipoprotein decreased;High density lipoprotein increased;Hot flush;Hypercholesterolaemia;Hyperglycaemia;Hyperhidrosis;Hyperlipidaemia;Hyperphagia;Hypersensitivity;Hypersomnia;Hypertension;Hypoaesthesia;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Insomnia;International normalised ratio increased;Iron deficiency anaemia;Kaposi's sarcoma;Lethargy;Lipase increased;Lipoatrophy;Lipodystrophy acquired;Lipohypertrophy;Liver disorder;Low density lipoprotein increased;Lymph node abscess;Lymph node pain;Lymphadenopathy;Lymphoma;Major depression;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Mental disability;Mental disorder;Middle insomnia;Migraine;Molluscum contagiosum;Mood swings;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myocardial infarction;Myopathy;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Neoplasm;Neoplasm malignant;Nephritis;Nephrolithiasis;Nephropathy toxic;Nervous system disorder;Nervousness;Neuropathy peripheral;Neutropenia;Neutrophil count decreased;Night sweats;Nightmare;Nocturia;Non-Hodgkin's lymphoma;Odynophagia;Oedema peripheral;Opportunistic infection;Osteopenia;Osteoporosis;Pain;Pain in extremity;Palpitations;Pancreatitis acute;Panic attack;Paraesthesia;Paranoia;Peptic ulcer;Phosphatase alkaline increased;Platelet count decreased;Polyarthritis;Polydipsia;Polyp;Poor quality sleep;Prurigo;Pruritus;Pruritus generalised;Psychotic disorder;Rash;Rash macular;Rash maculo-papular;Renal cyst;Renal failure;Renal failure chronic;Renal impairment;Renal tubular necrosis;Rhabdomyolysis;Sinus bradycardia;Skin disorder;Skin lesion;Skin papilloma;Sleep disorder;Somnolence;Squamous cell carcinoma;Stevens-Johnson syndrome;Submandibular mass;Suicidal behaviour;Suicidal ideation;Suicide attempt;Tendonitis;Tension headache;Thrombocytopenia;Tinnitus;Tremor;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urethral disorder;Urinary tract disorder;Urticaria;Ventricular extrasystoles;Vertigo;Visual impairment;Vomiting;Waist circumference increased;Weight decreased;Weight increased;White blood cell count decreased;Xeroderma",small molecule,approved,Raltegravir; Pr160Gag-Pol; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1,Gag-Pol polyprotein; Integrase, J05AJ01;J05AR16;J05AX08
piroxicam,Ankylosing spondylitis;Arthritis;Ligament sprain;Osteoarthritis;Rheumatoid arthritis;Soft tissue injury;Sprain;Tendonitis,Abdominal colic;Abdominal discomfort;Abdominal pain;Acute coronary syndrome;Agranulocytosis;Akathisia;Alopecia;Amnesia;Anaemia;Anaphylactic shock;Angina pectoris;Angioedema;Anorexia;Antinuclear antibody positive;Anxiety;Aplastic anaemia;Arrhythmia;Asthenia;Asthma;Bladder pain;Bleeding time prolonged;Body temperature increased;Bronchospasm;Cardiac failure congestive;Chest pain;Chills;Coma;Confusional state;Conjunctivitis;Constipation;Contusion;Convulsion;Cystitis;Cystitis noninfective;Deafness;Decreased appetite;Dermatitis;Dermatitis contact;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Drowsiness;Dry mouth;Dyspepsia;Dyspnoea;Dysuria;Ecchymosis;Eczema;Eosinophilia;Epidermal necrosis;Epigastric distress;Epistaxis;Eructation;Erythema;Erythema multiforme;Eye irritation;Eye swelling;Feeling abnormal;Flatulence;Fluid retention;Flushing;Gastritis;Gastrointestinal haemorrhage;Gastrointestinal pain;Glomerulonephritis;Glossitis;Haematemesis;Haematuria;Haemoglobin;Haemolytic anaemia;Haemorrhage;Hallucination;Headache;Hearing impaired;Heartburn;Henoch-Schonlein purpura;Hepatic enzyme increased;Hepatic failure;Hepatitis;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hypersensitivity;Hypertension;Hypoglycaemia;Hypotension;Ill-defined disorder;Increased appetite;Infection;Insomnia;Jaundice;Kidney function abnormal;Leukopenia;Local reaction;Loss of consciousness;Lymphadenopathy;Malaise;Melaena;Meningitis;Meningitis aseptic;Menorrhagia;Myocardial infarction;Nausea;Nephritis interstitial;Nephrotic syndrome;Nervousness;Oedema;Oesophagitis;Oliguria;Onycholysis;Pain;Palpitations;Pancreatitis;Pancytopenia;Paraesthesia;Peptic ulcer;Personality change;Petechiae;Photosensitivity;Photosensitivity reaction;Pneumonia;Pollakiuria;Polyuria;Protein urine present;Proteinuria;Pruritus;Pulmonary function test decreased;Purpura;Purpura non-thrombocytopenic;Rash;Rectal haemorrhage;Renal failure;Renal impairment;Respiratory depression;Sepsis;Serum sickness;Shock;Skin discolouration;Skin exfoliation;Somnolence;Stevens-Johnson syndrome;Stomatitis;Sweating;Swelling;Syncope;Tachycardia;Tension;Thirst;Thrombocytopenia;Tinnitus;Toxic epidermal necrolysis;Tremor;Tubulointerstitial nephritis;Ulcer;Urine output increased;Urticaria;Vascular purpura;Vasculitis;Vertigo;Vision blurred;Vomiting;Weight increased,small molecule,approved; investigational,"4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; Piroxicam; Piroxicam betadex; Piroxicamum; Pyroxycam; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9",Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1, M02AA07; S01BC06;M01AC01
vismodegib,Basal cell carcinoma,Abdominal pain;Abdominal pain upper;Ageusia;Alopecia;Amenorrhoea;Arthralgia;Aspartate aminotransferase increased;Asthenia;Azotaemia;Back pain;Blood alkaline phosphatase increased;Blood potassium decreased;Blood urea increased;Breast disorder;Connective tissue disorder;Constipation;Decreased appetite;Dehydration;Dermatitis;Diarrhoea;Dysgeusia;Dyspepsia;Fatigue;Flank pain;Gastrointestinal disorder;Gastrointestinal pain;Hair growth abnormal;Hepatic enzyme increased;Hypogeusia;Hypokalaemia;Hyponatraemia;Madarosis;Malnutrition;Menopause;Muscle spasms;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Myalgia;Nausea;Neoplasm malignant;Nervous system disorder;Pain;Pain in extremity;Phosphatase alkaline increased;Potassium low;Pruritus;Rash;Skin disorder;Sodium decreased;Unspecified disorder of skin and subcutaneous tissue;Vomiting;Weight decreased,small molecule,approved; investigational,"2-chloro-N-(4-chloro-3-pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-; Vismodegib; Vismodégib; Vismodegibum; Protein Gx; SMOH; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; AGP 1; AGP1; OMD 1; Orosomucoid-1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Protein smoothened,L01XJ01
canagliflozin,Balanitis;Balanoposthitis;Genital infection fungal;Renal failure;Renal impairment;Type 2 diabetes mellitus;Uncircumcised;Urticaria,Abdominal pain;Angioedema;Angiopathy;Asthenia;Balanitis candida;Bladder pain;Blood creatinine increased;Blood glucose decreased;Blood phosphate increased;Blood phosphorus increased;Blood potassium increased;Blood urea increased;Breast disorder;Constipation;Convulsion;Cystitis;Cystitis noninfective;Dehydration;Dermatitis;Diabetes mellitus;Diabetic complication;Diuresis;Dizziness;Dizziness postural;Dry mouth;Dyslipidaemia;Erythema;Fatigue;Fracture;Gastrointestinal disorder;Gastrointestinal pain;Genital infection fungal;Glomerular filtration rate decreased;Glucose low;Haematocrit increased;High density lipoprotein decreased;Hyperkalaemia;Hypersensitivity;Hypoglycaemia;Hypotension;Hypovolaemia;Infection;Kidney infection;Loss of consciousness;Low density lipoprotein increased;Malnutrition;Micturition urgency;Multiple fractures;Nausea;Nervous system disorder;Nocturia;Orthostatic hypotension;Pancreatitis;Phimosis;Photosensitivity;Photosensitivity reaction;Pollakiuria;Polydipsia;Polymorphic light eruption;Polyuria;Prurigo;Pruritus;Rash;Rash erythematous;Rash generalised;Rash macular;Rash maculo-papular;Rash papular;Rash pustular;Rash vesicular;Recurrent infection;Renal failure acute;Serum creatinine increased;Serum potassium increased;Shock;Skin disorder;Sunburn;Syncope;Thirst;Tight foreskin;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Urine output increased;Urosepsis;Urticaria;Vaginal infection;Vulvitis;Vulvovaginal candidiasis;Vulvovaginal mycotic infection;Vulvovaginal pruritus;Vulvovaginitis,small molecule,approved,"Canagliflozin; Canagliflozin anhydrous; Canagliflozina; Low affinity sodium-glucose cotransporter; Na(+)/glucose cotransporter 2; SGLT2; Solute carrier family 5 member 2; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; 2.4.1.17; HLUG25; Hyodeoxycholic acid-specific UDPGT; UDPGT 2B4; UDPGTh-1; UGT2B11; UGT2B4; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.-; 7.6.2.2; 7.6.2.3; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; CMRP; MRP2; Multidrug resistance-associated protein 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Sodium/glucose cotransporter 2, A10BK02;A10BD16
florbetapir,Cognitive disorder;Cognitive impairment,Angiopathy;Anxiety;Asthenia;Back pain;Blood pressure increased;Claustrophobia;Dizziness;Dysgeusia;Fatigue;Flushing;Gastrointestinal disorder;Headache;Infusion site rash;Injection site haemorrhage;Injection site irritation;Injection site pain;Injection site reaction;Insomnia;Musculoskeletal pain;Nausea;Neck pain;Neoplasm malignant;Nervous system disorder;Pruritus;Skin disorder;Unspecified disorder of skin and subcutaneous tissue;Urticaria,small molecule,approved; investigational,[18F]Florbetapir; 4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline; Florbetapir (18F); Florbetapir F-18; Florbetapir F18; florbetapir-fluorine-18; A4; ABPP; AD1; Alzheimer disease amyloid A4 protein homolog; Alzheimer disease amyloid protein; Amyloid precursor protein; Amyloid-beta (A4) precursor protein; Amyloid-beta A4 protein; APP; APPI; Cerebral vascular amyloid peptide; CVAP; PN-II; PreA4; Protease nexin-II,Amyloid-beta precursor protein; Beta amyloid plaque,V09AX05
ponatinib,Acute lymphocytic leukaemia;Blast cell crisis;Chromosome analysis abnormal;Chronic myeloid leukaemia;Diabetes mellitus;Hyperlipidaemia;Hypertension;Ischaemia;Philadelphia chromosome positive,Abdominal discomfort;Abdominal distension;Abdominal pain;Acute coronary syndrome;Alanine aminotransferase increased;Albumin low;Alopecia;Amylase decreased;Amylase increased;Anaemia;Angina pectoris;Angiopathy;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Atrial flutter;Back pain;Blood albumin decreased;Blood alkaline phosphatase increased;Blood amylase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Blood calcium decreased;Blood creatinine increased;Blood glucose decreased;Blood glucose increased;Blood phosphorus decreased;Blood potassium decreased;Blood potassium increased;Blood sodium increased;Blood triglycerides increased;Blood uric acid increased;Body temperature increased;Bone pain;Breast disorder;Ca++ increased;Calcium low;Cardiac discomfort;Cardiac disorder;Cardiac failure;Cardiac failure congestive;Cardiovascular disorder;Cellulitis;Cerebral artery stenosis;Cerebral infarction;Cerebrovascular accident;Chills;Connective tissue disorder;Constipation;Coronary artery disease;Cough;Creatinine increased;Decreased appetite;Deep vein thrombosis;Dehydration;Dermatitis;Dermatitis exfoliative;Diarrhoea;Dizziness;Dry eye;Dry mouth;Dry skin;Dyspepsia;Dysphonia;Dyspnoea;Ecchymosis;Effusion;Ejection fraction decreased;Embolism venous;Epistaxis;Erectile dysfunction;Erythema;Exfoliative rash;Eye disorder;Eyelid oedema;Face oedema;Fatigue;Febrile neutropenia;Fluid retention;Flushing;Folliculitis;Gamma-glutamyltransferase increased;Gastric haemorrhage;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrooesophageal reflux disease;Glucose decreased;Glucose increased;Haemoglobin;Haemorrhage;Headache;Hepatobiliary disease;Hepatotoxicity;Hot flush;Hyperaesthesia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hypertension;Hypertriglyceridaemia;Hyperuricaemia;Hypoaesthesia;Hypocalcaemia;Hypokalaemia;Hyponatraemia;Hypophosphataemia;Infection;Infestation;Infestation NOS;Influenza like illness;Insomnia;Intermittent claudication;Ischaemia;Ischaemic cardiomyopathy;Jaundice;Left ventricular dysfunction;Lethargy;Leukopenia;Lipase increased;Lymphopenia;Malnutrition;Mediastinal disorder;Menopausal symptoms;Mental disorder;Migraine;Mucosal inflammation;Muscle spasms;Musculoskeletal chest pain;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Myelosuppression;Myocardial infarction;Myocardial ischaemia;Nasopharyngitis;Nausea;Neck pain;Neoplasm malignant;Nervous system disorder;Neuropathy;Neuropathy peripheral;Neutropenia;Neutrophil count decreased;Night sweats;Non-cardiac chest pain;Ocular toxicity;Oedema;Oedema peripheral;Pain;Pain in extremity;Pain of skin;Pancreatitis;Pancytopenia;Paraesthesia;Pericardial effusion;Periorbital oedema;Peripheral arterial occlusive disease;Peripheral artery stenosis;Peripheral ischaemia;Petechiae;Phosphatase alkaline increased;Phosphorus low;Platelet count decreased;Pleural effusion;Pneumonia;Poor peripheral circulation;Potassium increased;Potassium low;Prinzmetal angina;Prurigo;Pruritus;Pulmonary embolism;Rash;Retinal vein occlusion;Retinal vein thrombosis;Sepsis;Skin disorder;Skin exfoliation;Sodium decreased;Sodium high;Splenic infarction;Stomatitis;Thrombocytopenia;Tumour lysis syndrome;Unspecified disorder of skin and subcutaneous tissue;Upper respiratory tract infection;Urinary tract infection;Vascular occlusion;Venous thromboembolism;Venous thrombosis;Vision blurred;Visual impairment;Vomiting;Weight decreased;White blood cell count decreased,small molecule,approved; investigational,"Ponatinib; Ponatinibum; 2.7.10.2; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; ABL; JTK7; p150; Proto-oncogene c-Abl; 2.7.11.1; BCR1; D22S11; Renal carcinoma antigen NY-REN-26; 2.7.10.1; p145 c-kit; PBT; Piebald trait protein; Proto-oncogene c-Kit; SCFR; Tyrosine-protein kinase Kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; 2.7.10.1; Cadherin family member 12; CDHF12; CDHR16; Proto-oncogene c-Ret; PTC; 2.7.10.1; Endothelial tyrosine kinase; hTIE2; p140 TEK; TIE2; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains-2; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; VMCM; VMCM1; 2.7.10.1; CD135; Fetal liver kinase-2; FL cytokine receptor; FLK-2; FLK2; FLT-3; Fms-like tyrosine kinase 3; Stem cell tyrosine kinase 1; STK-1; STK1; 2.7.10.1; Basic fibroblast growth factor receptor 1; bFGF-R-1; BFGFR; CEK; FGFBR; FGFR-1; FLG; FLT-2; FLT2; Fms-like tyrosine kinase 2; HBGFR; N-sam; Proto-oncogene c-Fgr; 2.7.10.1; BEK; FGFR-2; K-sam; Keratinocyte growth factor receptor; KGFR; KSAM; 2.7.10.1; FGFR-3; JTK4; 2.7.10.1; FGFR-4; JTK2; TKF; 2.7.10.2; Leukocyte C-terminal Src kinase; LSK; Lymphocyte cell-specific protein-tyrosine kinase; p56-LCK; Protein YT16; Proto-oncogene Lck; T cell-specific protein-tyrosine kinase; 2.7.10.2; p60-Src; pp60c-src; Proto-oncogene c-Src; SRC1; 2.7.10.2; JTK8; Lck/Yes-related novel protein tyrosine kinase; p53Lyn; p56Lyn; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; 2.7.10.1; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR-2; VEGFR2; 2.7.10.1; Alpha platelet-derived growth factor receptor; Alpha-type platelet-derived growth factor receptor; CD140 antigen-like family member A; CD140a antigen; PDGF-R-alpha; PDGFR-2; PDGFR-alpha; PDGFR2; Platelet-derived growth factor alpha receptor; Platelet-derived growth factor receptor 2; RHEPDGFRA; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Tyrosine-protein kinase ABL1; Breakpoint cluster region protein; Mast/stem cell growth factor receptor Kit; Proto-oncogene tyrosine-protein kinase receptor Ret; Angiopoietin-1 receptor; Receptor-type tyrosine-protein kinase FLT3; Fibroblast growth factor receptor 1; Fibroblast growth factor receptor 2; Fibroblast growth factor receptor 3; Fibroblast growth factor receptor 4; Tyrosine-protein kinase Lck; Proto-oncogene tyrosine-protein kinase Src; Tyrosine-protein kinase Lyn; Vascular endothelial growth factor receptor 2; Platelet-derived growth factor receptor alpha,L01EA05
glucagon,Coronary artery disease;Hypoglycaemia,Blood pressure increased;Hypersensitivity;Hypertension;Hypotension;Nausea;Tachycardia;Vomiting,biotech,approved,"Glucagon; Glucagon (recombinant dna origin); Glucagon recombinant; Glucagon, human; Glucagon, porcine; Glucagone; Glucagonum; GL-R; GLP-2 receptor; GLP-2-R; GLP-2R; GLP-1 receptor; GLP-1-R; GLP-1R",Glucagon receptor; Glucagon-like peptide 2 receptor; Glucagon-like peptide 1 receptor,H04AA01
cobicistat,Immunodeficiency,Abdominal distension;Abdominal pain;Abnormal dreams;Asthenia;Blood bilirubin increased;Body temperature increased;Connective tissue disorder;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Eye disorder;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Haematuria;Headache;Hepatobiliary disease;Hyperbilirubinaemia;Hyperglycaemia;Increased appetite;Insomnia;Jaundice;Malnutrition;Mental disorder;Musculoskeletal discomfort;Myalgia;Nausea;Nephrolithiasis;Nervous system disorder;Ocular icterus;Protein urine present;Proteinuria;Pruritus;Rash;Renal failure;Renal impairment;Skin disorder;Sleep disorder;Somnolence;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vomiting,small molecule,approved,"1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate; Cobicistat; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8",Cytochrome P450 3A4; Cytochrome P450 3A5; Cytochrome P450 3A7, J05AR14; J05AR15; J05AR18; J05AR22; V03AX03;J05AR09
Triptorelin,Haematuria;Prostate cancer;Prostate cancer metastatic;Prostate carcinoma;Urinary tract obstruction,Abdominal distension;Abdominal pain;Abnormal sensation in eye;Acne;Acute coronary syndrome;Affect lability;Alanine aminotransferase increased;Alopecia;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Anxiety;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Bladder neck obstruction;Blister;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatinine increased;Blood glucose increased;Blood pressure increased;Blood testosterone decreased;Blood testosterone increased;Blood urea increased;Body temperature increased;Bone cancer metastatic;Bone pain;Breast disorder;Breast pain;Breast pain male;Bronchitis;Cardiovascular disorder;Cerebrovascular accident;Chest pain;Chills;Condition aggravated;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Convulsion;Cough;Cramp muscle;Cramps of lower extremities;Decreased appetite;Deep vein thrombosis;Depression;Dermatitis;Dermatitis bullous;Diabetes mellitus;Diarrhoea;Discomfort;Disorder sight;Disturbance in sexual arousal;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Dysstasia;Dysuria;Ear and labyrinth disorders;Ejaculation failure;Embolism;Endocrine disorder;Epistaxis;Erectile dysfunction;Euphoric mood;Eye disorder;Eye pain;Fatigue;Feeling abnormal;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Glucose increased;Gout;Gravitational oedema;Gynaecomastia;Haemoglobin decreased;Headache;Hepatic function abnormal;Hormone-dependent prostate cancer;Hot flush;Hyperglycaemia;Hyperhidrosis;Hypersensitivity;Hypertension;Hypokinesia;Hypotension;IIIrd nerve paralysis;Ill-defined disorder;Immune system disorder;Increased appetite;Infection;Infestation;Infestation NOS;Inflammation;Influenza;Influenza like illness;Injection site erythema;Injection site pain;Injection site reaction;Insomnia;Irritability;Joint stiffness;Joint swelling;Leg edema;Leg pain;Lethargy;Libido decreased;Local reaction;Loss of libido;Lymphocyte count increased;Lymphocytosis;Malaise;Malnutrition;Mediastinal disorder;Memory impairment;Menopausal symptoms;Mental disorder;Mental state abnormal;Metastases to spine;Metastasis;Metastatic pain;Mood swings;Muscle spasms;Muscular weakness;Musculoskeletal discomfort;Musculoskeletal disorder;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Myocardial infarction;Nasopharyngitis;Nausea;Nervous system disorder;Neuropathy;Neuropathy peripheral;Oedema;Oedema peripheral;Ophthalmoplegia;Orthopnoea;Osteoarthritis;Pain;Pain in extremity;Palpitations;Paraesthesia;Paralysis;Paresthesia lower limb;Pharyngitis;Phosphatase alkaline increased;Pituitary adenoma;Pituitary apoplexy;Pituitary haemorrhage;Pituitary infarction;Pituitary tumour benign;Prostate cancer;Pruritus;Purpura;Rash;Red blood cell disorders;Rhinitis;Rigors;Serum testosterone increased;Shock;Skin disorder;Somnolence;Spinal cord compression;Testicular atrophy;Testicular pain;Testosterone low;Thromboembolic event;Thrombophlebitis;Tinnitus;Transient ischaemic attack;Tumour flare;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urethral obstruction;Urinary retention;Urinary tract disorder;Urinary tract infection;Urticaria;Vascular purpura;Vertigo;Vision blurred;Visual disturbance;Visual impairment;Vomiting;Weight decreased;Weight increased,small molecule,approved; vet_approved,"(6-D-Tryptophan)luteinizing hormone-releasing hormone; (D-Trp6)-GnRH; Luteinizing hormone-releasing factor (pig), 6-D-tryptophan; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2	; Triptorelin; Triptorelina; Triptoreline; Triptorelinum; GnRH receptor; GnRH-R; GRHR",Gonadotropin-releasing hormone receptor,L02AE04
cetrorelix,Menopause;Ovarian cancer,Anaphylactic shock;Anaphylactoid reaction;Anencephaly;Assisted fertilisation;Congenital anomaly;Contusion;Cough;Dermatitis;Developmental delay;Developmental glaucoma;Diaphragmatic hernia;Erythema;Fertilization;Glaucoma;Headache;Hot flush;Hypersensitivity;Hypotension;Immune system disorder;Imperforate hymen;Injection site reaction;Klinefelter's syndrome;Local reaction;Melanocytic naevus;Menopausal symptoms;Nausea;Nevus;Ovarian disorder;Ovarian hyperstimulation syndrome;Pruritus;Rash;Redness;Stillbirth;Supernumerary nipple;Swelling;Trisomy 18;Trisomy 21;Ventricular septal defect,small molecule,approved; investigational,Cetrorelix; Cetrorelixum; GnRH receptor; GnRH-R; GRHR; LCGR; LGR2; LH/CG-R; LHR; LHRHR; LSH-R; Luteinizing hormone receptor,Gonadotropin-releasing hormone receptor; Lutropin-choriogonadotropic hormone receptor,H01CC02
Nafarelin,Adrenogenital syndrome;Amenorrhoea;Central precocious puberty;Congenital adrenal hyperplasia;Dysmenorrhoea;Dyspareunia;Endometriosis;Haemoglobin;Haemorrhage;Infertility;Intracranial pressure increased;Osteoporosis;Pelvic pain;Pituitary tumour;Precocious puberty;Rhinitis;Uterine enlargement,Abdominal distension;Acne;Acute coronary syndrome;Affect lability;Alopecia;Anorexia;Arterial thromboembolism;Arthralgia;Ascites;Asthenia;Bladder pain;Body odor;Breast atrophy;Breast engorgement;Breast enlargement;Breast pain;Cerebrovascular accident;Chest pain;Chloasma;Conjunctivitis;Constipation;Convulsion;Coordination abnormal;Cystitis;Cystitis noninfective;Decreased appetite;Deep vein thrombosis;Depression;Dermatitis;Diarrhoea;Disturbance in sexual arousal;Dizziness;Dry skin;Dysgeusia;Dyspnoea;Dysuria;Ear pain;Embolism arterial;Epistaxis;Eye pain;Gastritis;Gastrointestinal fullness;Gynaecomastia;Headache;Hepatic function abnormal;Herpes simplex;High density lipoprotein decreased;Hirsutism;Hot flush;Hyperhidrosis;Hypovolaemia;IIIrd nerve paralysis;Increased appetite;Insomnia;Interstitial lung disease;Interstitial pneumonia;Libido decreased;Libido increased;Liver injury;Loss of libido;Malnutrition;Menopausal symptoms;Menopause;Menorrhagia;Menstrual disorder;Mental disorder;Mental state abnormal;Mood swings;Mucous membrane disorder;Multiple pregnancy;Muscular weakness;Musculoskeletal discomfort;Myalgia;Myasthenia;Myocardial infarction;Nasal discomfort;Nasal dryness;Nasal irritation;Nausea;Neoplasm;Nervousness;Neurosis;Oedema;Oestrogen deficiency;Oliguria;Ophthalmoplegia;Osteopenia;Ovarian hyperstimulation;Ovarian hyperstimulation syndrome;Palpitations;Paraesthesia;Pituitary adenoma;Pituitary apoplexy;Pituitary haemorrhage;Pituitary infarction;Pituitary microadenoma;Pituitary tumour benign;Pleural effusion;Prolonged menses;Pruritus;Puberty;Pulmonary embolism;Pulmonary fibrosis;Rash;Rash maculo-papular;Rhinitis;Seborrhoeic dermatitis;Shock;Sinusitis;Skin odour abnormal;Sweating increased;Tension;Transient ischaemic attack;Traumatic liver injury;Urinary incontinence;Urticaria;Uterine haemorrhage;Vaginal discharge;Vaginal dryness;Vaginal haemorrhage;Vertigo;Vomiting;Vulvovaginal dryness;Weight decreased;Weight increased,small molecule,approved,Nafarelin; Nafarelina; Nafaréline; Nafarelinum; GnRH receptor; GnRH-R; GRHR; GnRH II receptor; GnRH-II-R; Type II GnRH receptor,Gonadotropin-releasing hormone receptor; Putative gonadotropin-releasing hormone II receptor,H01CA02
Histrelin,Adrenogenital syndrome;Central precocious puberty;Congenital adrenal hyperplasia;Haematuria;Neoplasm;Precocious puberty;Prostate cancer;Urinary tract obstruction,Abdominal discomfort;Affect lability;Amblyopia;Anaemia;Angiopathy;Application site pain;Arthralgia;Aspartate aminotransferase increased;Asthenia;Back pain;Back pain aggravated;Blood and lymphatic system disorders;Blood glucose increased;Blood lactate dehydrogenase increased;Blood testosterone increased;Bone density decreased;Bone pain;Breast disorder;Breast pain;Breast tenderness;Calculus of kidney;Cardiac disorder;Connective tissue disorder;Constipation;Contusion;Convulsion;Creatinine renal clearance decreased;Depression;Device breakage;Device occlusion;Discomfort;Disease progression;Disturbance in sexual arousal;Dizziness;Drug-induced liver injury;Dysmenorrhoea;Dyspnoea exertional;Dysuria;Epistaxis;Erectile dysfunction;Erythema;Fatigue;Feeling abnormal;Fluid retention;Flushing;Foetor hepaticus;Gastrointestinal disorder;Genital itching male;Gynaecomastia;Gynecomastia aggravated;Haematoma;Haematuria;Headache;Hematuria aggravated;Hepatobiliary disease;Hepatocellular injury;Hot flush;Hypercalcaemia;Hypercholesterolaemia;Hyperhidrosis;Hypotrichosis;Ill-defined disorder;Implant breakage;Implant site reaction;Increased appetite;Infection;Inflammation;Influenza like illness;Insomnia;Instillation site pain;Irritability;Keloid scar;Lethargy;Libido decreased;Liver disorder;Liver injury;Local reaction;Malaise;Malnutrition;Mediastinal disorder;Menopausal symptoms;Menorrhagia;Mental disorder;Mental state abnormal;Metastases to spine;Metrorrhagia;Migraine;Mood swings;Muscle twitching;Musculoskeletal discomfort;Myalgia;Nausea;Neck pain;Nephrolithiasis;Nervous system disorder;Night sweats;Oedema peripheral;Pain;Pain in extremity;Pain worsened;Palpitations;Paraesthesia;Paresthesia lower limb;Pituitary adenoma;Pituitary apoplexy;Pituitary haemorrhage;Pituitary infarction;Pituitary tumour benign;Pollakiuria;Post procedural pain;Procedural pain;Prostatic acid phosphatase increased;Pruritus;Pruritus genital;Renal failure;Renal failure aggravated;Renal impairment;Scar;Serum testosterone increased;Sexual dysfunction;Shock;Skin disorder;Stargardt's disease;Stent occlusion;Suture related complication;Sweating increased;Swelling;Tenderness;Testicular atrophy;Tingling sensation;Traumatic liver injury;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary frequency aggravated;Urinary retention;Urinary tract disorder;Ventricular extrasystoles;Vomiting;Weight decreased;Weight increased;Wound infection,small molecule,approved; withdrawn,"[(im-Bzl)-D-His6,Pro9-NEt]-gonadotropin releasing hormone; 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide; 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-Nτ-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide	; Histrelin; histrelina; histreline; histrelinum; L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-Nim-benzyl-histidyl-L-leucyl-L-arginyl-L-proline ethylamide; GnRH receptor; GnRH-R; GRHR",Gonadotropin-releasing hormone receptor,H01CA03;L02AE05
sofosbuvir,Chronic hepatitis C;Hepatitis C;Mental disorder,Abdominal discomfort;Agitation;Alopecia;Anaemia;Anxiety;Arthralgia;Asthenia;Back pain;Blood and lymphatic system disorders;Blood bilirubin increased;Body temperature increased;Chest pain;Chills;Completed suicide;Connective tissue disorder;Constipation;Cough;Decreased appetite;Dermatitis;Diarrhoea;Disturbance in attention;Dizziness;Dry mouth;Dry skin;Dyspepsia;Dyspnoea;Dyspnoea exertional;Eye disorder;Fatigue;Gastrointestinal disorder;Gastrooesophageal reflux disease;HCV coinfection;Haemoglobin decreased;Headache;Hepatitis C;Hepatobiliary disease;Infection;Infestation;Infestation NOS;Influenza like illness;Insomnia;Irritability;Lymphocyte count decreased;Malnutrition;Mediastinal disorder;Memory impairment;Migraine;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Nervous system disorder;Neutropenia;Pain;Pancytopenia;Platelet count decreased;Pruritus;Rash;Skin disorder;Suicidal ideation;Suicide;Unspecified disorder of skin and subcutaneous tissue;Vision blurred;Vomiting;Weight decreased,small molecule,approved,"S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate; Sofosbuvir; 3.4.22.-; p23; 3.4.16.5; Carboxypeptidase C; Carboxypeptidase L; Cathepsin A; PPCA; PPGB; Protective protein cathepsin A; Protective protein for beta-galactosidase; Carboxylesterase 1A1; CES1A1; 3.9.1.-; Desumoylating isopeptidase HINT1; HINT; Histidine triad nucleotide-binding protein 1; PKCI-1; PKCI1; PRKCNH1; Protein kinase C inhibitor 1; Protein kinase C-interacting protein 1; 2.7.4.14; CK; CMK; CMPK; dCMP kinase; Deoxycytidylate kinase; Nucleoside-diphosphate kinase; UCK; UMK; UMP/CMP kinase; UMP/CMPK; UMPK; Uridine monophosphate/cytidine monophosphate kinase; 2.7.4.6; GAAD; Granzyme A-activated DNase; Metastasis inhibition factor nm23; NDK A; NDP kinase A; NDPKA; NM23; NM23-H1; Tumor metastatic process-associated protein; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter",Genome polyprotein; RNA-dependent RNA-polymerase, J05AP51; J05AP55; J05AP56;J05AP08
cabozantinib,Medullary thyroid cancer;Neoplasm malignant,Abdominal pain;Abnormal dreams;Abscess;Activated partial thromboplastin time shortened;Ageusia;Alanine aminotransferase increased;Alopecia;Amenorrhoea;Anal fissure;Anal inflammation;Angina pectoris;Angiopathy;Anxiety;Arterial thrombosis;Arthralgia;Aspartate aminotransferase increased;Aspergilloma;Asthenia;Ataxia;Atelectasis;Atrial fibrillation;Blister;Blood alkaline phosphatase increased;Blood lactate dehydrogenase increased;Blood pressure increased;Blood thyroid stimulating hormone increased;Breast disorder;Cardiac arrest;Cardiac disorder;Cataract;Cheilitis;Chills;Cholelithiasis;Confusional state;Conjunctivitis;Connective tissue disorder;Constipation;Deafness;Decreased appetite;Dehydration;Delirium;Dermatitis;Dermatitis bullous;Diarrhoea;Disease progression;Disturbance in attention;Dizziness;Dry skin;Dysgeusia;Dyspepsia;Dysphagia;Dysphonia;Dysuria;Ear and labyrinth disorders;Ear pain;Embolism;Endocrine disorder;Eosinophil count increased;Erythema;Eye disorder;Face oedema;Facial pain;Fatigue;Feeling abnormal;Fistula;Folliculitis;Fungal infection;Gastrointestinal disorder;Gastrointestinal fistula;Gastrointestinal haemorrhage;Gastrointestinal pain;Gastrointestinal perforation;Glossodynia;Haematuria;Haemoglobin;Haemorrhage;Haemorrhoids;Hair colour changes;Hair growth abnormal;Headache;Hearing impaired;Hepatic encephalopathy;Hepatobiliary disease;Hyperbilirubinaemia;Hyperkeratosis;Hypertension;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Hypothyroidism;Impaired healing;Infection;Infestation;Infestation NOS;Lactic dehydrogenase activity increased;Leukoderma;Lipase increased;Localised oedema;Loss of consciousness;Lymphopenia;Malignant hypertension;Malnutrition;Mediastinal disorder;Mental disorder;Mucosal inflammation;Muscle spasms;Musculoskeletal chest pain;Musculoskeletal discomfort;Nausea;Nervous system disorder;Neuropathy peripheral;Neutropenia;Neutrophil count decreased;Oesophagitis;Oral pain;Oropharyngeal pain;Osteonecrosis of jaw;Pallor;Pancreatitis;Paraesthesia;Peripheral coldness;Peripheral sensory neuropathy;Pharyngeal oedema;Phosphatase alkaline increased;Pneumomediastinum;Pneumonia;Pneumonia aspiration;Pneumothorax;Posterior reversible encephalopathy syndrome;Prehypertension;Protein urine present;Proteinuria;Pulmonary embolism;Rash;Renal failure acute;Respiratory failure;Respiratory tract haemorrhage;Rhabdomyolysis;Sepsis;Septicemia;Skin disorder;Skin ulcer;Speech disorder;Stomatitis;Supraventricular tachycardia;Telangiectasia;Thrombocytopenia;Thrombocytosis;Thromboembolic event;Thyrotropin high;Tinnitus;Tracheal fistula;Transient ischaemic attack;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vaginal haemorrhage;Venous thrombosis;Vision blurred;Vomiting;Weight decreased;Wound,small molecule,approved; investigational,"Cabozantinib; 2.7.10.1; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met; 2.7.10.1; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR-2; VEGFR2; 2.7.10.1; Cadherin family member 12; CDHF12; CDHR16; Proto-oncogene c-Ret; PTC; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase",Hepatocyte growth factor receptor; Vascular endothelial growth factor receptor 2; Proto-oncogene tyrosine-protein kinase receptor Ret,L01EX07
doxycycline,Abscess;Acne;Actinomycosis;Amoebic colitis;Anthrax;Atypical pneumonia;Bacterial infection;Bartonellosis;Bladder pain;Body temperature increased;Bronchitis;Bronchopneumonia;Brucellosis;Cat scratch disease;Cellulitis;Cervicitis;Chancroid;Cholera;Chronic periodontitis;Cystitis;Cystitis noninfective;Epidemic typhus;Erythema;Furuncle;Furunculosis;Gastrointestinal infection;Generalised erythema;Gingivitis ulcerative;Gonorrhoea;Granuloma inguinale;Haemoglobin;Haemorrhage;Impetigo;Inclusion conjunctivitis;Infection;Listeriosis;Lymphogranuloma venereum;Malaria;Meningitis;Murine typhus;Necrotising ulcerative gingivostomatitis;Otitis media;Papule;Paronychia;Periodontal disease;Periodontitis;Pharyngitis;Plague;Plasmodium falciparum infection;Plasmodium vivax infection;Pneumonia;Pneumonia anthrax;Pneumonia chlamydial;Psittacosis;Pustule;Pyelonephritis;Q fever;Queensland tick typhus;Rash pustular;Redness;Relapsing fever;Respiratory tract infection;Rheumatic disorder;Rheumatic fever;Rickettsialpox;Rocky mountain spotted fever;Rosacea;Scrub typhus;Sexually transmitted disease;Sinusitis;Soft tissue infection;Staphylococcal infection;Syphilis;Tonsillitis;Trachoma;Trench mouth;Tularaemia;Typhus;Unspecified non-gonococcal urethritis (NGU);Upper respiratory tract infection;Urethritis;Urethritis gonococcal;Urethritis noninfective;Urinary tract infection;Vaginal infection;Vaginal inflammation;Wound sepsis;Yaws,"Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal pain upper;Abscess;Abscess periodontal;Ache;Acid indigestion;Ageusia;Anaemia;Anaphylactic shock;Angioedema;Anorexia;Anxiety;Aphthous stomatitis;Arthralgia;Aspartate aminotransferase increased;Back pain;Benign intracranial hypertension;Black hairy tongue;Blood pressure increased;Blood urea increased;Body temperature increased;Bronchitis;Bronchospasm;Clostridium difficile colitis;Common cold;Confusional state;Conjunctivitis;Cough;Decreased appetite;Dentoalveolar abscess;Depressed level of consciousness;Depression;Dermatitis;Dermatitis exfoliative;Diarrhoea;Diarrhoea, Clostridium difficile;Digestion impaired;Discomfort;Drug eruption;Dry mouth;Dysmenorrhoea;Dyspepsia;Dysphagia;Dyspnoea;Ear infection;Enterocolitis;Eosinophilia;Erythema;Erythema multiforme;Essential hypertension;Feeling abnormal;Fistula;Flu symptoms;Flushing;Fontanelle bulging;Fungal infection;Gastrointestinal disorder;Gastrointestinal pain;Gingival bleeding;Gingival pain;Gingivitis;Glossitis;Haemolytic anaemia;Hallucination;Headache;Henoch-Schonlein purpura;Hepatic steatosis;Hepatitis;Hepatitis cholestatic;Hepatotoxicity;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoplasia enamel;Hypotension;Ill-defined disorder;Infection;Inflammation;Influenza;Insomnia;Intracranial pressure increased;Laryngeal pain;Leukopenia;Liver fatty;Low back pain;Malaise;Mass;Menorrhagia;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nail discolouration;Nasal congestion;Nasopharyngitis;Nausea;Neck pain;Nephropathy toxic;Neutropenia;Oedema peripheral;Oesophageal ulcer;Oesophagitis;Oral pain;Oropharyngeal discomfort;Oropharyngeal pain;Osteopenia;Pain;Pain in jaw;Paraesthesia;Pericarditis;Periorbital oedema;Pharyngolaryngeal pain;Phlebitis;Photoonycholysis;Photosensitivity;Photosensitivity reaction;Postnasal drip;Pre-menstrual tension syndrome;Premenstrual syndrome;Premenstrual tension;Proctitis;Prolonged menses;Pseudomembranous colitis;Pseudotumor;Pulpitis dental;Purpura;Rash;Rash erythematous;Rash maculo-papular;Rash morbilliform;Rash pustular;Renal failure acute;Rhinitis;Sensitivity of teeth;Serum sickness;Serum urea increased;Shoulder pain;Sinus congestion;Sinus headache;Sinusitis;Skin infection;Somnolence;Sore mouth;Stevens-Johnson syndrome;Stomach ache;Stomatitis;Stupor;Swelling;Systemic lupus erythematosus;Tachycardia;Tenderness;Tension headache;Throat sore;Thrombocytopenia;Thrombocytopenic purpura;Tinnitus;Tongue discolouration;Tooth abscess;Tooth discolouration;Tooth disorder;Tooth fracture;Tooth hypoplasia;Tooth loss;Toothache;Toxic epidermal necrolysis;Ulcer;Upper-airway cough syndrome;Upset stomach;Urticaria;Vaginal infection;Vaginal moniliasis;Vaginitis bacterial;Vascular purpura;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection",small molecule,approved; investigational; vet_approved,"5-hydroxy-α-6-deoxytetracycline; 6-alpha-deoxy-5-oxytetracycline; 6alpha-deoxy-5-oxytetracycline; 6α-deoxy-5-oxytetracycline; Anhydrous doxycycline; Doxiciclina; Doxycyclin; Doxycycline; Doxycycline (anhydrous); Doxycycline anhydrous; Doxycyclinum; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; ABCB5 P-gp; P-glycoprotein ABCB5",30S ribosomal protein, A01AB22; J01AA20;A01AB22;J01AA02
tetracycline,Actinomycosis;Amoebic colitis;Anthrax;Bartonellosis;Brucellosis;Campylobacter gastroenteritis;Cat scratch disease;Chancroid;Cholera;Gingivitis ulcerative;Granuloma;Inclusion conjunctivitis;Infection;Lower respiratory tract infection;Lymphogranuloma venereum;Necrotising ulcerative gingivostomatitis;Pneumonia chlamydial;Psittacosis;Q fever;Relapsing fever;Renal failure;Renal impairment;Rickettsialpox;Rocky mountain spotted fever;Soft tissue infection;Staphylococcal infection;Syphilis;Trachoma;Trench mouth;Tularaemia;Typhus;Upper respiratory tract infection;Urinary tract infection;Yaws,Anaphylactic shock;Angioedema;Anorexia;Arthralgia;Black hairy tongue;Body temperature increased;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Dyspepsia;Dysphagia;Enterocolitis;Eosinophilia;Epigastric distress;Fontanelle bulging;Glossitis;Haemolytic anaemia;Henoch-Schonlein purpura;Hepatic failure;Hepatotoxicity;Hypersensitivity;Hypoplasia enamel;Menorrhagia;Musculoskeletal discomfort;Nail discolouration;Nausea;Nephropathy toxic;Neutropenia;Oesophageal ulcer;Oesophagitis;Onycholysis;Pericarditis;Photosensitivity;Photosensitivity reaction;Prolonged menses;Rash;Serum sickness;Systemic lupus erythematosus;Thrombocytopenia;Thrombocytopenic purpura;Tongue discolouration;Tooth hypoplasia;Urticaria;Vomiting,small molecule,approved; vet_approved; withdrawn,"(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; Abramycin; Anhydrotetracycline; Deschlorobiomycin; Tetracyclin; Tétracycline; Tetracycline; Tetracyclinum; Tetrazyklin; Tsiklomitsin; ALTPRP; ASCR; PRIP; PRP; PrP27-30; PrP33-35C; 3.5.3.15; HL-60 PAD; PAD4; PADI5; PDI5; Peptidylarginine deiminase IV; Protein-arginine deiminase type IV; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2; KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; Organic anion transporting polypeptide 2B1; SLC21A9; Solute carrier family 21 member 9",30S ribosomal protein S7; 30S ribosomal protein S14; 30S ribosomal protein S3; 30S ribosomal protein S8; 30S ribosomal protein S19; 16S ribosomal RNA; Major prion protein; Multidrug translocase MdfA; Protein-arginine deiminase type-4, A01AB13; A02BD02; A02BD08; D06AA04; J01AA07; J01AA20; J01RA08; S01AA09; S03AA02;A01AB13;S02AA08
minocycline,Abscess;Actinomycosis;Amoebic colitis;Anthrax;Bacterial rhinitis;Bartonellosis;Bladder pain;Body temperature increased;Bronchiectasis;Bronchiolitis;Bronchitis;Bronchopneumonia;Brucellosis;Cat scratch disease;Cellulitis;Chancroid;Cholecystitis infective;Cholera;Chronic periodontitis;Cystitis;Cystitis noninfective;Dacryocystitis;Dermatitis;Dermatitis infected;Folliculitis;Furuncle;Furunculosis;Gallbladder infection;Gingivitis ulcerative;Gonorrhoea;Granuloma inguinale;Hidradenitis;Hordeolum;Impetigo;Inclusion conjunctivitis;Infection;Internal hordeolum;Laryngotracheitis;Listeriosis;Lung abscess;Lymphadenitis;Lymphogranuloma venereum;Meningitis;Necrotising ulcerative gingivostomatitis;Otitis media;Paronychia;Periodontal disease;Periodontitis;Pharyngitis;Plague;Pneumonia;Pneumonia chlamydial;Prostatitis;Psittacosis;Pyelonephritis;Pyoderma;Q fever;Relapsing fever;Respiratory tract infection;Rickettsialpox;Rocky mountain spotted fever;Sinusitis;Soft tissue infection;Staphylococcal infection;Streptococcal infection;Syphilis;Tonsillitis;Tracheitis;Tracheobronchitis;Trachoma;Trench mouth;Tularaemia;Typhus;Unspecified non-gonococcal urethritis (NGU);Upper respiratory tract infection;Urethritis;Urethritis gonococcal;Urethritis noninfective;Urethritis nonspecific;Urinary tract infection;Wound infection;Yaws,Abdominal pain;Abscess periodontal;Accidental injury;Acute fatty liver;Acute hepatic failure;Agranulocytosis;Alopecia;Anal pruritus;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Anorectal discomfort;Anorexia;Antinuclear antibody positive;Arthralgia;Arthritis;Aspartate aminotransferase increased;Asthenia;Asthma;Ataxia;Autoimmune hepatitis;Back pain;Balanitis;Benign intracranial hypertension;Bronchitis;Bronchospasm;Cholestasis;Cold intolerance;Constipation;Convulsion;Cough;Decreased appetite;Dental caries;Dermatitis;Dermatitis exfoliative;Diarrhoea;Discomfort;Dizziness;Drug eruption;Drug reaction with eosinophilia and systemic symptoms;Dry mouth;Dyspepsia;Dysphagia;Dyspnoea;Enterocolitis;Eosinophilia;Erythema multiforme;Erythema nodosum;Exacerbation of asthma;Fatigue;Feeling abnormal;Fixed drug eruption;Fontanelle bulging;Gastrointestinal pain;Gingivitis;Glossitis;Haemolytic anaemia;Headache;Hearing impaired;Henoch-Schonlein purpura;Hepatic failure;Hepatic steatosis;Hepatitis;Hyperbilirubinaemia;Hypersensitive syndrome;Hypersensitivity;Hypertension;Hypoaesthesia;Hypoplasia enamel;Ill-defined disorder;Infection;Influenza;Injection site erythema;Injection site pain;Injury;Intracranial pressure increased;Jaundice;Joint stiffness;Joint swelling;Leukopenia;Leukoplakia oral;Lightheadedness;Local reaction;Loss of consciousness;Lung infiltration;Lupus erythematosus;Lupus-like syndrome;Lymphadenopathy;Malaise;Menorrhagia;Mood alteration NOS;Mood swings;Mouth ulceration;Mucous membrane disorder;Musculoskeletal discomfort;Myalgia;Myocarditis;Nail discolouration;Nausea;Neoplasm malignant;Nephritis;Nephritis interstitial;Nephropathy toxic;Nephrotoxicity;Neutropenia;Oesophageal ulcer;Oesophagitis;Onycholysis;Pain;Pancreatitis;Pancytopenia;Paraesthesia;Partial hearing loss;Pericarditis;Periodontitis;Pharyngitis;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pigmentation skin;Pneumonia;Polyarthralgia;Prolonged menses;Pruritus;Pruritus genital;Pseudomembranous colitis;Rash;Renal failure;Renal failure acute;Rhinitis;Serum sickness;Shock;Sinusitis;Skin hyperpigmentation;Somnolence;Stevens-Johnson syndrome;Stomatitis;Syncope;Systemic lupus erythematosus;Temperature intolerance;Thrombocytopenia;Thyroid function abnormal;Thyroid function test abnormal;Tinnitus;Tongue discolouration;Tooth abscess;Tooth discolouration;Tooth disorder;Tooth fracture;Tooth hypoplasia;Tooth infection;Toothache;Toxic epidermal necrolysis;Tubulointerstitial nephritis;Urticaria;Vasculitis;Vertigo;Vision blurred;Vomiting;Vulvovaginitis,small molecule,approved; investigational,"(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 7-Dimethylamino-6-demethyl-6-deoxytetracycline; Minociclina; Minociclinum; Minocyclin; Minocycline; Minocyclinum; Minomycin; ramA; Catabolin; IL-1 beta; IL1F2; 1.13.11.-; 5-lipoxygenase; 5-LO; Arachidonate 5-lipoxygenase; LOG5; 3.4.24.35; 92 kDa gelatinase; 92 kDa type IV collagenase; CLG4B; Gelatinase B; GELB; MMP-9; L-VEGF; Vascular permeability factor; VEGF; VPF; 3.4.22.36; CASP-1; ICE; IL-1 beta-converting enzyme; IL-1BC; IL1BC; IL1BCE; Interleukin-1 beta convertase; Interleukin-1 beta-converting enzyme; p45; 3.4.22.56; Apopain; CASP-3; CPP-32; CPP32; Cysteine protease CPP32; Protein Yama; SCA-1; SREBP cleavage activity 1; CYC; 2.7.11.24; ERK-2; ERK2; ERT1; Extracellular signal-regulated kinase 2; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42; MAPK 1; MAPK 2; Mitogen-activated protein kinase 2; p42-MAPK; PRKM1; PRKM2; 2.7.11.24; c-Jun N-terminal kinase 3; JNK3; JNK3A; MAP kinase 10; MAP kinase p49 3F12; MAPK 10; PRKM10; SAPK1B; Stress-activated protein kinase 1b; Stress-activated protein kinase JNK3; 2.7.11.24; MAP kinase 11; MAP kinase p38 beta; MAPK 11; Mitogen-activated protein kinase p38 beta; p38-2; p38b; PRKM11; SAPK2; SAPK2B; Stress-activated protein kinase 2b; 2.7.11.24; ERK-6; ERK6; Extracellular signal-regulated kinase 6; MAP kinase 12; MAP kinase p38 gamma; MAPK 12; Mitogen-activated protein kinase p38 gamma; SAPK3; Stress-activated protein kinase 3; 2.7.11.24; MAP kinase 13; MAP kinase p38 delta; MAPK 13; Mitogen-activated protein kinase p38 delta; PRKM13; SAPK4; Stress-activated protein kinase 4; 2.7.11.24; CSAID-binding protein; CSBP; CSBP1; CSBP2; CSPB1; Cytokine suppressive anti-inflammatory drug-binding protein; MAP kinase 14; MAP kinase MXI2; MAP kinase p38 alpha; MAPK 14; MAX-interacting protein 2; Mitogen-activated protein kinase p38 alpha; MXI2; SAPK2A; Stress-activated protein kinase 2a; 2.7.11.24; ERK-7; ERK-8; ERK7; ERK8; Extracellular signal-regulated kinase 7; Extracellular signal-regulated kinase 8; MAP kinase 15; MAPK 15; 2.7.11.24; ERK-1; ERK1; ERT2; Extracellular signal-regulated kinase 1; Insulin-stimulated MAP2 kinase; MAP kinase 3; MAP kinase isoform p44; MAPK 3; Microtubule-associated protein 2 kinase; p44-ERK1; p44-MAPK; PRKM3; 2.7.11.24; ERK-4; ERK4; Extracellular signal-regulated kinase 4; MAP kinase 4; MAP kinase isoform p63; MAPK 4; p63-MAPK; PRKM4; 2.7.11.24; ERK-3; ERK3; Extracellular signal-regulated kinase 3; MAP kinase 6; MAP kinase isoform p97; MAPK 6; p97-MAPK; PRKM6; 2.7.11.24; Big MAP kinase 1; BMK-1; BMK1; ERK-5; ERK5; Extracellular signal-regulated kinase 5; MAP kinase 7; MAPK 7; PRKM7; 2.7.11.24; c-Jun N-terminal kinase 1; JNK-46; JNK1; MAP kinase 8; MAPK 8; PRKM8; SAPK1; SAPK1C; Stress-activated protein kinase 1c; Stress-activated protein kinase JNK1; 2.7.11.24; c-Jun N-terminal kinase 2; JNK-55; JNK2; MAP kinase 9; MAPK 9; PRKM9; SAPK1A; Stress-activated protein kinase 1a; Stress-activated protein kinase JNK2; 1.14.13.39; HEP-NOS; Hepatocyte NOS; Inducible NO synthase; Inducible NOS; iNOS; NOS type II; NOS2A; Peptidyl-cysteine S-nitrosylase NOS2; cmlB; coa; cry; Outer membrane protein 1A; Outer membrane protein B; Outer membrane protein IA; Porin OmpF; tolF; meoA; Outer membrane protein 1B; Outer membrane protein C; par; Porin OmpC; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2","30S ribosomal protein S9; 30S ribosomal protein S4; 16S ribosomal RNA; Interleukin-1 beta; Polyunsaturated fatty acid 5-lipoxygenase; Matrix metalloproteinase-9; Vascular endothelial growth factor A, long form; Caspase-1; Caspase-3; Cytochrome c; Mitogen-activated Protein Kinases; Nitric oxide synthase, inducible", A01AB23; J01AA08; J01AA20;A01AB23;D10AF07
acenocoumarol,Atrial fibrillation;Clotting;Coagulopathy;Coronary artery occlusion;Pulmonary embolism;Venous thrombosis,Abdominal symptom;Alopecia;Appetite absent;Body temperature increased;Coagulopathy;Decreased appetite;Dermatitis;Diarrhoea;Gastrointestinal disorder;Haematuria;Haemobilia;Haemoglobin;Haemorrhage;Hepatocellular injury;Hypersensitivity;Liver injury;Melaena;Menorrhagia;Metrorrhagia;Microscopic hematuria;Nausea;Neoplasm;Protein C deficiency;Skin exfoliation;Skin necrosis;Ulcer;Urticaria;Vomiting,small molecule,approved; investigational,"3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one; Acenocoumarin; Acénocoumarol; Acenocoumarol; Acenocoumarolum; Acenocumarol; Acenocumarolo; Acenokumarin; Nicoumalone; Nicumalon; Nitrophenylacetylethyl-4-hydroxycoumarine; Nitrovarfarian; Nitrowarfarin; 1.17.4.4; Vitamin K1 2,3-epoxide reductase subunit 1; VKOR; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; AGP 1; AGP1; OMD 1; Orosomucoid-1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Vitamin K epoxide reductase complex subunit 1,B01AA07
vemurafenib,Malignant melanoma;Metastatic malignant melanoma;Metastatic melanoma;Obesity,Actinic keratosis;Alopecia;Anaphylactic shock;Angiopathy;Arthralgia;Arthritis;Asthenia;Atrial fibrillation;Back pain;Basal cell carcinoma;Body temperature increased;Cardiac disorder;Chills;Chronic myelomonocytic leukaemia;Common wart;Connective tissue disorder;Constipation;Cough;Cyst;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dry skin;Dysgeusia;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Eosinophilia;Erythema;Erythema multiforme;Erythema nodosum;Eye disorder;Fatigue;Folliculitis;Gamma-glutamyltransferase increased;Gastrointestinal disorder;Headache;Hepatotoxicity;Hyperkeratosis;Hypersensitivity;Hypotension;Infection;Infestation;Infestation NOS;Keratoacanthoma;Keratosis;Keratosis pilaris;Malignant melanoma;Malnutrition;Mediastinal disorder;Metastatic malignant melanoma;Metastatic melanoma;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nausea;Neoplasm;Neoplasm malignant;Nerve paralysis;Nervous system disorder;Neuropathy peripheral;Oedema peripheral;Oropharyngeal squamous cell carcinoma;Pain in extremity;Palmar erythema;Paralysis;Photosensitivity;Photosensitivity reaction;Polyp;Pruritus;Rash;Rash generalised;Rash maculo-papular;Rash papular;Retinal vein occlusion;Rigors;Seborrhoeic keratosis;Skin disorder;Skin papilloma;Squamous cell carcinoma;Squamous cell carcinoma of skin;Stevens-Johnson syndrome;Sunburn;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Uveitis;VIIth nerve paralysis;Vasculitis;Vomiting;Weight decreased,small molecule,approved,"Vémurafénib; Vemurafenib; Vemurafenibum; 2.7.11.1; BRAF1; p94; Proto-oncogene B-Raf; RAFB1; v-Raf murine sarcoma viral oncogene homolog B1; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 1.14.14.-; Cholesterol 25-hydroxylase; CYP2DL1; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; AGP 1; AGP1; OMD 1; Orosomucoid-1; 7.6.2.2; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter; MRP; MRP1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1",Serine/threonine-protein kinase B-raf, L01EC01;G01AE10
oxytetracycline,Amoebic colitis;Body temperature increased;Chancroid;Gingivitis ulcerative;Granuloma inguinale;Inclusion conjunctivitis;Infection;Lymphogranuloma venereum;Necrotising ulcerative gingivostomatitis;Pneumonia chlamydial;Psittacosis;Q fever;Relapsing fever;Respiratory tract infection;Rheumatic disorder;Rheumatic fever;Rickettsialpox;Rocky mountain spotted fever;Soft tissue infection;Staphylococcal infection;Syphilis;Trachoma;Trench mouth;Typhus;Upper respiratory tract infection;Yaws,Anaphylactic shock;Angioedema;Anorexia;Benign intracranial hypertension;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Dysphagia;Enterocolitis;Eosinophilia;Fontanelle bulging;Glossitis;Haemolytic anaemia;Henoch-Schonlein purpura;Hypersensitivity;Menorrhagia;Nausea;Nephropathy toxic;Neutropenia;Oesophageal ulcer;Oesophagitis;Pericarditis;Photosensitivity;Photosensitivity reaction;Prolonged menses;Rash;Systemic lupus erythematosus;Thrombocytopenia;Urticaria;Vomiting,small molecule,approved; investigational; vet_approved,5-Hydroxytetracycline; Embryostat; Hydroxytetracyclinum; Mepatar; Ossitetraciclina; Oxitetraciclina; Oxyterracin; Oxyterracine; Oxytetracyclin; Oxytétracycline; Oxytetracycline; Oxytetracycline (anhydrous); Oxytetracycline amphoteric; Oxytetracyclinum; ramA; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; OAT4; Organic anion transporter 4; Organic anion:dicarboxylate exchanger OAT4; hOAT2; NLT; Novel liver transporter; OAT2; Organic anion transporter 2,30S ribosomal protein S9; 30S ribosomal protein S4; 16S ribosomal RNA, A01AB25; D06AA03; G01AA07; J01AA20; J01AA56; S01AA04;D06AA03;J01AA06
tesamorelin,Hypersensitivity;Lipodystrophy;Lipodystrophy acquired,Abdominal pain upper;Angiopathy;Antibody test positive;Arthralgia;Blood creatine phosphokinase increased;Cardiac disorder;Carpal tunnel syndrome;Chest pain;Connective tissue disorder;Depression;Dermatitis;Dyspepsia;Gastrointestinal disorder;Haemoglobin;Haemorrhage;Hot flush;Hyperglycaemia;Hypertension;Hypoaesthesia;Injection site dermatitis;Injection site erythema;Injection site haemorrhage;Injection site irritation;Injection site pain;Injection site pruritus;Injection site reaction;Injection site swelling;Injection site urticaria;Insomnia;Joint stiffness;Joint swelling;Menopausal symptoms;Mental disorder;Muscle spasms;Muscle strain;Musculoskeletal discomfort;Musculoskeletal pain;Musculoskeletal stiffness;Myalgia;Nausea;Nervous system disorder;Neuropathy peripheral;Night sweats;Oedema peripheral;Pain;Pain in extremity;Palpitations;Paraesthesia;Pruritus;Rash;Skin disorder;Swelling;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vomiting,biotech,approved; investigational,GHRH(1-44); N-[(3E)-1-oxo-3-hexenyl]Somatoliberin (human pancreatic islet); Tesamorelin; GHRH receptor; GRF receptor; GRFR; Growth hormone-releasing factor receptor,Growth hormone-releasing hormone receptor,H01AC06
ecallantide,Hereditary angioedema,Abdominal pain upper;Anaphylactic shock;Asthenia;Body temperature increased;Contusion;Diarrhoea;Erythema;Fatigue;Headache;Hypersensitivity;Injection site reaction;Nasopharyngitis;Nausea;Pain;Pruritus;Upper respiratory tract infection;Urticaria;Vomiting,biotech,approved; investigational,Ecallantide; 3.4.21.34; Fletcher factor; Kininogenin; KLK3; PKK; Plasma prekallikrein,Plasma kallikrein,B06AC03
dabrafenib,Acute coronary syndrome;Glucose-6-phosphate dehydrogenase deficiency;Interstitial lung disease;Malignant melanoma;Metastatic malignant melanoma;Metastatic melanoma;Pneumonia;Renal failure;Renal impairment,Abdominal discomfort;Abdominal pain;Abdominal pain lower;Abdominal pain upper;Acrochordon;Actinic keratosis;Acute renal insufficiency;Alanine aminotransferase increased;Alopecia;Anaemia;Angiopathy;Arrhythmia;Arthralgia;Aspartate aminotransferase increased;Asthenia;Azotaemia;Back pain;Basal cell carcinoma;Blindness transient;Blood alkaline phosphatase increased;Blood creatinine increased;Body temperature increased;Bone disorder;Bowen's disease;Brain stem haemorrhage;Cardiac failure congestive;Cardiomyopathy;Cellulitis;Cerebral haemorrhage;Chills;Connective tissue disorder;Constipation;Cough;Creatinine increased;Cyst;Decreased appetite;Dehydration;Dermatitis;Dermatitis acneiform;Dermatitis bullous;Diarrhoea;Disease progression;Dizziness;Dry mouth;Dry skin;Ejection fraction decreased;Electrocardiogram QT corrected interval prolonged;Electrocardiogram QT prolonged;Embolism venous;Epistaxis;Erythema;Eye disorder;Eye haemorrhage;Fatigue;Folliculitis;Gamma-glutamyltransferase increased;Gastric haemorrhage;Gastrointestinal disorder;Gastrointestinal pain;Gingival bleeding;Haematuria;Haemoglobin;Haemorrhage;Haemorrhage intracranial;Headache;Hyperbilirubinaemia;Hypercalcaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperkeratosis;Hypersensitivity;Hypertension;Hypoalbuminaemia;Hypocalcaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypotension;Immune system disorder;Infection;Infestation;Infestation NOS;Influenza like illness;Insomnia;Keratoacanthoma;Leukopenia;Lymphoedema;Lymphopenia;Malignant melanoma;Malnutrition;Mediastinal disorder;Mental disorder;Muscle spasms;Musculoskeletal discomfort;Myalgia;Nasopharyngitis;Nausea;Neoplasm;Neoplasm malignant;Nephritis;Nephritis interstitial;Nephropathy;Nervous system disorder;Neutropenia;Night sweats;Ocular toxicity;Oedema;Oedema peripheral;Oropharyngeal pain;Pain in extremity;Pancreatitis;Panniculitis;Papilloma;Paronychia;Phosphatase alkaline increased;Polyp;Prurigo;Pruritus;Rash;Rash bullous;Rash erythematous;Rash generalised;Rash macular;Rash maculo-papular;Rash papular;Rash pustular;Rash vesicular;Reaction febrile;Refractory hypertension;Renal failure;Renal failure acute;Rigors;Seborrhoeic keratosis;Skin disorder;Skin lesion;Skin papilloma;Skin toxicity;Squamous cell carcinoma;Squamous cell carcinoma of skin;Stomatitis;Thrombocytopenia;Tubulointerstitial nephritis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urinary tract infection;Uveitis;Vaginal haemorrhage;Venous thromboembolism;Vision blurred;Vitreous haemorrhage;Vomiting,small molecule,approved; investigational,"Dabrafenib; 2.7.11.1; BRAF1; p94; Proto-oncogene B-Raf; RAFB1; v-Raf murine sarcoma viral oncogene homolog B1; 2.7.11.1; cRaf; Proto-oncogene c-RAF; RAF; Raf-1; 2.7.11.1; Salt-inducible kinase 1; Serine/threonine-protein kinase SNF1-like kinase 1; Serine/threonine-protein kinase SNF1LK; SIK; SIK-1; SNF1LK; 2.7.11.1; Never in mitosis A-related kinase 11; NimA-related protein kinase 11; 2.7.11.1; LIMK; LIMK-1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; CYPIIC8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; S-mephenytoin 4-hydroxylase; 1,4-cineole 2-exo-monooxygenase; 1.14.13.-; CYPIIB6; Cytochrome P450 IIB1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Fenbendazole monooxygenase (4'-hydroxylating); Mephenytoin 4-hydroxylase; 1.14.14.1; Cholesterol 25-hydroxylase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; Organic anion transporter SLC21A6; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Liver-specific organic anion transporter 2; LST-2; LST2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; Solute carrier family 21 member 8; OATP; OATP-1; OATP-A; OATP1; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; hOCT2; OCT2; Organic cation transporter 2",Serine/threonine-protein kinase B-raf; RAF proto-oncogene serine/threonine-protein kinase; Serine/threonine-protein kinase SIK1; Serine/threonine-protein kinase Nek11; LIM domain kinase 1,L01EC02
mipomersen,Antibody test positive;Coronary artery disease;Heterozygous familial hypercholesterolemia;Homozygous familial hypercholesterolaemia;Hypercholesterolaemia;Type IIa hyperlipidaemia,Abdominal pain;Alanine aminotransferase increased;Angina pectoris;Angioedema;Angiopathy;Antibody NOS negative;Antibody test negative;Arthralgia;Aspartate aminotransferase increased;Asthenia;Body temperature increased;Cardiac disorder;Chills;Connective tissue disorder;Discomfort;Erythema;Fatigue;Feeling abnormal;Gastrointestinal disorder;Gastrointestinal pain;Haematoma;Headache;Hepatic enzyme increased;Hepatic steatosis;Hepatobiliary disease;Hypersensitivity;Hypertension;Ill-defined disorder;Influenza like illness;Influenza-like symptoms;Injection site reaction;Insomnia;Liver function test abnormal;Malaise;Mental disorder;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nausea;Neoplasm;Nephritis;Nervous system disorder;Oedema peripheral;Pain;Pain in extremity;Palpitations;Protein urine present;Proteinuria;Pruritus;Swelling;Tenderness;Vomiting,biotech,approved; investigational,Mipomersen; Apo B-100,Apolipoprotein B-100; mRNA of ApoB-100,C10AX11
dalbavancin,Alcohol abuse,Abdominal pain;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Bronchospasm;Candida infection;Clostridium difficile colitis;Dermatitis;Diarrhoea;Dizziness;Eosinophilia;Flushing;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal pain;Haematochezia;Haemorrhagic anaemia;Headache;Hepatitis viral;Hepatobiliary disease;Hepatotoxicity;Hypoglycaemia;Immune system disorder;Infection;Infestation;Infestation NOS;International normalised ratio increased;Leukopenia;Malnutrition;Mediastinal disorder;Melaena;Nausea;Nervous system disorder;Neutropenia;Oral candidiasis;Petechiae;Phlebitis;Pruritus;Rash;Skin disorder;Spontaneous haematoma;Thrombocytopenia;Thrombocytosis;Transaminases increased;Unspecified disorder of skin and subcutaneous tissue;Urticaria;Vomiting;Vulvovaginal mycotic infection;Wound haemorrhage,small molecule,approved; investigational,Dalbavancin; Dalbavancina; 3.1.1.3; Pancreatic lipase; PL; PTL,D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan; Pancreatic triacylglycerol lipase,J01XA04
dolutegravir,Hepatitis B;Immunodeficiency;Infection;Infection mixed,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abnormal dreams;Alanine aminotransferase increased;Asthenia;Autoimmune disorder;Basedow's disease;Bilirubin total increased;Blood bilirubin increased;Blood creatinine increased;Dermatitis;Diarrhoea;Dizziness;Drug eruption;Fat redistribution;Fatigue;Flatulence;Gastrointestinal disorder;Gastrointestinal pain;Headache;Hepatitis;Hepatitis C;Hepatobiliary disease;Hyperglycaemia;Hypersensitivity;Immune system disorder;Inflammation;Insomnia;Mental disorder;Musculoskeletal disorder;Myositis;Nausea;Nervous system disorder;Neutropenia;Opportunistic infection;Prurigo;Pruritus;Rash;Rash generalised;Rash macular;Rash maculo-papular;Renal failure;Renal impairment;Serum creatinine increased;Skin disorder;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Vertigo;Vomiting,small molecule,approved,"Dolutegravir; Pr160Gag-Pol; 2.4.1.17; Bilirubin-specific UDPGT isozyme 1; GNT1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1A isoform 1; UDPGT 1-1; UGT1; UGT1-01; UGT1.1; UGT1*1; UGT1A1; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; 1.14.14.1; 1.14.14.1; CYPIIIA5; Cytochrome P450-PCN3; 1.14.14.1; CYPIIIA7; Cytochrome P450-HFLA; P450HLp2; 2.4.1.17; GNT1; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1A isoform 3; UDPGT 1-3; UGT-1C; UGT1; UGT1-03; UGT1.3; UGT1*3; UGT1A3; UGT1C; 2.4.1.17; GNT1; lugP4; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-I; UDPGT 1-9; UGT-1I; UGT1; UGT1-09; UGT1.9; UGT1*9; UGT1A9; UGT1I; AGP 1; AGP1; OMD 1; Orosomucoid-1; AGP 2; AGP2; OMD 2; Orosomucoid-2; hOCT2; OCT2; Organic cation transporter 2; 7.6.2.2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; Breast cancer resistance protein; CDw338; Mitoxantrone resistance-associated protein; MXR; Placenta-specific ATP-binding cassette transporter; Urate exporter; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8; ATP-binding cassette sub-family B member 1; MDR1; Multidrug resistance protein 1; P-glycoprotein 1; PGY1; Phospholipid transporter ABCB1; hMATE-1; MATE-1; MATE1; Solute carrier family 47 member 1",Gag-Pol polyprotein; Integrase, J05AJ03; J05AR13; J05AR21; J05AR25;J05AR27
tenoxicam,Ankylosing spondylitis;Arthritis;Arthropathy;Bursitis;Cervicobrachial syndrome;Complex regional pain syndrome;Dysmenorrhoea;Gout;Gout acute;Ligament sprain;Osteoarthritis;Periarthritis;Postoperative pain;Primary dysmenorrhea;Procedural pain;Reflex sympathetic dystrophy;Rheumatoid arthritis;Sprain;Tendonitis;Vasculitis,Abdominal discomfort;Acute coronary syndrome;Agranulocytosis;Anaemia;Anaphylactic shock;Angioedema;Angiopathy;Anorexia;Asthenia;Asthma;Blood and lymphatic system disorders;Breast disorder;Cardiac disorder;Cardiac failure;Colitis;Constipation;Crohn's disease;Decreased appetite;Dermatitis;Diarrhoea;Dizziness;Dry mouth;Dyspepsia;Dyspnoea;Ear and labyrinth disorders;Erythema;Erythema multiforme;Eye disorder;Fatigue;Gastritis;Gastrointestinal disorder;Gastrointestinal haemorrhage;Gastrointestinal perforation;Gastrointestinal ulcer;Haematemesis;Headache;Hepatitis;Hepatobiliary disease;Hypersensitivity;Immune system disorder;Infertility female;Leukopenia;Malnutrition;Melaena;Mental disorder;Myocardial infarction;Nausea;Nervous system disorder;Oedema;Palpitations;Peptic ulcer;Photosensitivity reaction;Pruritus;Rash;Skin disorder;Sleep disorder;Sleep disturbance;Stevens-Johnson syndrome;Stomatitis;Thrombocytopenia;Toxic epidermal necrolysis;Unspecified disorder of skin and subcutaneous tissue;Urethral disorder;Urinary tract disorder;Urticaria;Vertigo;Visual disturbance;Visual impairment;Vomiting,small molecule,approved,Tenoxicam; Ténoxicam; Tenoxicamum; 1.14.99.1; COX-2; COX2; Cyclooxygenase-2; PGH synthase 2; PGHS-2; PHS II; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2; 1.14.99.1; COX-1; COX1; Cyclooxygenase-1; PGH synthase 1; PGHS-1; PHS 1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; 1.14.14.1; Cholesterol 25-hydroxylase; CYP2C10; CYPIIC9; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; S-mephenytoin 4-hydroxylase; hOAT3; OAT3; Organic anion/dicarboxylate exchanger; Solute carrier family 22 member 8,Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1,M01AC02
demeclocycline,Actinomycosis;Amoebic colitis;Anthrax;Bartonellosis;Body temperature increased;Brucellosis;Cat scratch disease;Chancroid;Cholera;Gingivitis ulcerative;Gonorrhoea;Granuloma inguinale;Inclusion conjunctivitis;Infection;Listeriosis;Lymphogranuloma venereum;Necrotising ulcerative gingivostomatitis;Plague;Pneumonia chlamydial;Psittacosis;Q fever;Relapsing fever;Respiratory tract infection;Rickettsialpox;Rocky mountain spotted fever;Staphylococcal infection;Syphilis;Trachoma;Trench mouth;Tularaemia;Typhus;Unspecified non-gonococcal urethritis (NGU);Upper respiratory tract infection;Urethritis;Urethritis noninfective;Urinary tract infection;Yaws,Anaphylactic shock;Angioedema;Anorexia;Arthralgia;Balanitis;Benign intracranial hypertension;Decreased appetite;Dermatitis;Dermatitis exfoliative;Diarrhoea;Dizziness;Drug eruption;Dysphagia;Enterocolitis;Eosinophilia;Erythema multiforme;Fixed drug eruption;Fontanelle bulging;Glossitis;Haemolytic anaemia;Headache;Henoch-Schonlein purpura;Hepatic failure;Hepatitis;Hypersensitivity;Lung infiltration;Lupus-like syndrome;Menorrhagia;Myasthenic syndrome;Nausea;Nephrogenic diabetes insipidus;Nephropathy toxic;Neutropenia;Oesophageal ulcer;Pancreatitis;Pericarditis;Photosensitivity;Photosensitivity reaction;Polyarthralgia;Prolonged menses;Rash;Renal failure acute;Stevens-Johnson syndrome;Systemic lupus erythematosus;Thrombocytopenia;Thyroid function abnormal;Thyroid function test abnormal;Tinnitus;Tooth discolouration;Urticaria;Visual disturbance;Visual impairment;Vomiting,small molecule,approved,"[4S-(4α,4aα,5aα,6β,12aα)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 6-demethyl-7-chlorotetracycline; 7-chloro-6-demethyltetracycline; Demeclociclina; Demeclocycline; Demeclocyclinum; Demethylchlortetracyclin; Demethylchlortetracycline; DMCT; DMCTC; ADHR; Antidiuretic hormone receptor; AVPR V2; DIR; DIR3; Renal-type arginine vasopressin receptor; V2R",30S ribosomal protein; Vasopressin V2 receptor, D06AA01; J01AA20;D06AA01;J01AA01
heparin,Arterial thrombosis;Atrial fibrillation;Clotting;Coagulopathy;Deep vein thrombosis;Deep vein thrombosis postoperative;Disseminated intravascular coagulation;Embolism arterial;Pulmonary embolism;Venous thrombosis,Acute coronary syndrome;Adrenal haemorrhage;Adrenocortical insufficiency acute;Alopecia;Anaphylactic shock;Anaphylactoid reaction;Asthma;Body temperature increased;Cardiac failure congestive;Cerebrovascular accident;Chills;Coagulation time prolonged;Cyanosis;Erythema;Extravasation;Fluid overload;Fluid retention;Gangrene;Haematoma;Haemoglobin;Haemorrhage;Haemorrhage urinary tract;Headache;Heparin-induced thrombocytopenia;Hyperlipidaemia;Hypernatraemia;Hypersensitivity;Infection;Injection site irritation;Lacrimation;Lacrimation increased;Myocardial infarction;Nausea;Necrosis;Oedema;Osteoporosis;Pain;Phlebitis;Priapism;Pruritus;Retroperitoneal haemorrhage;Rhinitis;Shock;Skin exfoliation;Skin necrosis;Thrombocytopenia;Thrombosis;Ulcer;Urticaria;Vomiting;Water retention,small molecule,approved; investigational,Eparina; Heparina; Heparine; Heparinic acid; Heparinum; Unfractionated heparin; AT3; ATIII; Serpin C1; 3.4.21.6; Stuart factor; Stuart-Prower factor; CD62 antigen-like family member P; GMP-140; GMRP; Granule membrane protein 140; GRMP; LECAM3; Leukocyte-endothelial cell adhesion molecule 3; PADGEM; Platelet activation dependent granule-external membrane protein; 2.7.10.1; FGFR-4; JTK2; TKF; FGF-4; HBGF-4; Heparin secretory-transforming protein 1; Heparin-binding growth factor 4; HST; HST-1; HSTF-1; HSTF1; KS3; Transforming protein KS3; FGF-19; 2.7.10.1; Basic fibroblast growth factor receptor 1; bFGF-R-1; BFGFR; CEK; FGFBR; FGFR-1; FLG; FLT-2; FLT2; Fms-like tyrosine kinase 2; HBGFR; N-sam; Proto-oncogene c-Fgr; Acidic fibroblast growth factor; aFGF; ECGF; Endothelial cell growth factor; FGF-1; FGFA; HBGF-1; Heparin-binding growth factor 1; 2.7.10.1; BEK; FGFR-2; K-sam; Keratinocyte growth factor receptor; KGFR; KSAM; Basic fibroblast growth factor; bFGF; FGF-2; FGFB; HBGF-2; Heparin-binding growth factor 2; C-X-C motif chemokine 4; CXCL4; Iroplact; Oncostatin-A; PF-4; SCYB4; Hepatopoietin-A; HPTA; Scatter factor; SF; 3.2.1.166; Endo-glucoronidase; HEP; Heparanase-1; HPA; HPA1; HPR1; HPSE1; HSE1,Antithrombin-III; Coagulation factor X; P-selectin; Fibroblast growth factor receptor 4; Fibroblast growth factor 4; Fibroblast growth factor 19; Fibroblast growth factor receptor 1; Fibroblast growth factor 1; Fibroblast growth factor receptor 2; Fibroblast growth factor 2; Platelet factor 4; Hepatocyte growth factor, B01AB01; C05BA03; C05BA53; S01XA14;B01AB01;B01AB51
tigecycline,Abdominal infection;Bacteraemia;Cellulitis gangrenous;Community acquired pneumonia;Decubitus ulcer;Diabetes mellitus;Diabetic foot infection;Immunocompromised;Immunodeficiency;Infection;Necrotising fasciitis;Pneumonia;Pneumonia bacterial;Soft tissue infection,Abdominal distension;Abdominal pain;Abnormal faeces;Abnormal vision;Abscess;Acidosis;Activated partial thromboplastin time prolonged;Alanine aminotransferase increased;Amylase increased;Anaemia;Anaphylactic shock;Anaphylactoid reaction;Angiopathy;Anorexia;Aspartate aminotransferase increased;Asthenia;Atrial fibrillation;Atrioventricular block first degree;Azotaemia;Back pain;Benign intracranial hypertension;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood creatine phosphokinase increased;Blood creatinine increased;Blood lactate dehydrogenase increased;Blood urea increased;Body temperature increased;Bradycardia;Candida infection;Cardiac failure congestive;Cardiovascular disorder;Chest pain;Chills;Cholestasis;Coagulopathy;Confusional state;Constipation;Cough;Cough increased;Creatine phosphokinase increased;Creatinine increased;Creatinine renal clearance decreased;Decreased appetite;Dermatitis;Device malfunction;Diabetes mellitus;Diabetic foot infection;Diarrhoea;Discomfort;Dizziness;Dry mouth;Dysgeusia;Dyspepsia;Dyspnoea;Ecchymosis;Electrocardiogram QT prolonged;Electrocardiogram abnormal;Eosinophilia;Erythema multiforme;Faecal incontinence;Feeling abnormal;Flatulence;Fungal skin infection;Gastrointestinal disorder;Gastrointestinal pain;Gastrooesophageal reflux disease;Glossitis;Headache;Hepatic failure;Hepatobiliary disease;Hepatocellular injury;Herpes simplex;Hiccups;Hyperbilirubinaemia;Hyperglycaemia;Hyperhidrosis;Hyperkalaemia;Hyperphosphataemia;Hypersensitivity;Hypertension;Hypocalcaemia;Hypoglycaemia;Hypokalaemia;Hypomagnesaemia;Hyponatraemia;Hypophosphataemia;Hypoproteinaemia;Hypotension;Ill-defined disorder;Immune system disorder;Impaired healing;Increased bronchial secretion;Infection;Infestation;Infestation NOS;Injection site inflammation;Injection site pain;Injection site phlebitis;Injection site reaction;Injection site swelling;Insomnia;International normalised ratio increased;Jaundice;Kidney function abnormal;Lactic dehydrogenase activity increased;Leukocytosis;Leukopenia;Leukorrhea;Liver function test abnormal;Liver injury;Local reaction;Loss of consciousness;Malaise;Malnutrition;Mediastinal disorder;Mucosal inflammation;Muscle twitching;Musculoskeletal discomfort;Myalgia;Nausea;Nervous system disorder;Nervousness;Neutropenia;Nosocomial pneumonia;Oedema peripheral;Oral candidiasis;Osteomyelitis;Pain;Palpitations;Pancreatitis;Pancreatitis acute;Peritonitis;Pharyngitis;Phlebitis;Phosphatase alkaline increased;Photosensitivity;Photosensitivity reaction;Pleural effusion;Pneumonia;Polyuria;Prothrombin level decreased;Prothrombin level increased;Prothrombin time shortened;Prurigo;Pruritus;Pseudomembranous colitis;Rash;Rash maculo-papular;Renal impairment;Scrotal oedema;Sepsis;Septic shock;Serum urea increased;Shock;Sinus bradycardia;Sinus tachycardia;Skin discolouration;Skin disorder;Somnolence;Sputum increased;Stevens-Johnson syndrome;Sweating;Syncope;Tachycardia;Tension;Thrombocytopenia;Thrombocytosis;Thrombophlebitis;Tooth discolouration;Traumatic liver injury;Tremor;Unspecified disorder of skin and subcutaneous tissue;Urinary tract infection;Urine output increased;Urticaria;Vaginal discharge;Vaginal infection;Vaginal inflammation;Vaginal moniliasis;Ventilator associated pneumonia;Ventricular arrhythmia;Ventricular extrasystoles;Vertigo;Visual impairment;Vomiting;Vulvovaginal candidiasis;Vulvovaginal disorder;Vulvovaginal mycotic infection;Vulvovaginitis;Wound infection,small molecule,approved,"(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; Tigeciclina; Tigecycline; Tigecyclinum; strA",16S ribosomal RNA; 30S ribosomal protein S9; 30S ribosomal protein S12; 30S ribosomal protein S13; 30S ribosomal protein S14; 30S ribosomal protein S19, J01AA12;J01AA12;J01AA20
doxycycline,Acne;Actinomycosis;Amoebic colitis;Anthrax;Bacterial infection;Bartonellosis;Body temperature increased;Brucellosis;Cat scratch disease;Chancroid;Cholera;Chronic periodontitis;Gingivitis ulcerative;Gonorrhoea;Granuloma inguinale;Haemoglobin;Haemorrhage;Inclusion conjunctivitis;Infection;Listeriosis;Lymphogranuloma venereum;Malaria;Necrotising ulcerative gingivostomatitis;Periodontal disease;Periodontitis;Plague;Pneumonia;Pneumonia anthrax;Pneumonia chlamydial;Psittacosis;Q fever;Relapsing fever;Respiratory tract infection;Rickettsialpox;Rocky mountain spotted fever;Sexually transmitted disease;Syphilis;Trachoma;Trench mouth;Tularaemia;Typhus;Unspecified non-gonococcal urethritis (NGU);Upper respiratory tract infection;Urethritis;Urinary tract infection;Yaws,Abdominal discomfort;Abdominal pain;Abdominal pain upper;Abscess;Abscess periodontal;Ache;Acid indigestion;Anaphylactic shock;Angioedema;Anorexia;Aphthous stomatitis;Arthralgia;Back pain;Benign intracranial hypertension;Body temperature increased;Bronchitis;Common cold;Cough;Cutaneous hypersensitivity;Decreased appetite;Dentoalveolar abscess;Dermatitis;Dermatitis atopic;Dermatitis exfoliative;Diarrhoea;Discomfort;Dysmenorrhoea;Dyspepsia;Dysphagia;Ear infection;Enterocolitis;Eosinophilia;Erythema;Essential hypertension;Fistula;Flu symptoms;Fontanelle bulging;Gingival bleeding;Gingival pain;Gingivitis;Glossitis;Haemolytic anaemia;Headache;Henoch-Schonlein purpura;Hepatotoxicity;Hypersensitivity;Hypertension;Infection;Inflammation;Influenza;Insomnia;Low back pain;Menorrhagia;Musculoskeletal discomfort;Musculoskeletal pain;Myalgia;Nasopharyngitis;Nausea;Nephropathy toxic;Neutropenia;Oesophageal ulcer;Oesophagitis;Oral pain;Oropharyngeal discomfort;Oropharyngeal pain;Osteopenia;Pain;Pain in jaw;Pain neck/shoulder;Pericarditis;Photosensitivity;Photosensitivity reaction;Postnasal drip;Pre-menstrual tension syndrome;Premenstrual syndrome;Premenstrual tension;Prolonged menses;Pulpitis dental;Rash;Rhinitis;Sensitivity of teeth;Serum sickness;Sinus congestion;Sinus headache;Sinusitis;Skin infection;Sore mouth;Stomach ache;Swelling;Systemic lupus erythematosus;Tenderness;Tension;Throat sore;Thrombocytopenia;Tooth abscess;Tooth disorder;Tooth fracture;Tooth loss;Toothache;Upper-airway cough syndrome;Upset stomach;Urticaria;Vaginal moniliasis;Vomiting;Vulvovaginal candidiasis;Vulvovaginal mycotic infection,small molecule,approved; investigational; vet_approved,"5-hydroxy-α-6-deoxytetracycline; 6-alpha-deoxy-5-oxytetracycline; 6alpha-deoxy-5-oxytetracycline; 6α-deoxy-5-oxytetracycline; Anhydrous doxycycline; Doxiciclina; Doxycyclin; Doxycycline; Doxycycline (anhydrous); Doxycycline anhydrous; Doxycyclinum; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; 1.14.14.1; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; Cholesterol 25-hydroxylase; CYP3A3; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; hOAT1; hPAHT; hROAT1; OAT1; Organic anion transporter 1; PAH transporter; PAHT; Renal organic anion transporter 1; ABCB5 P-gp; P-glycoprotein ABCB5",30S ribosomal protein, A01AB22; J01AA20;J01AA02
lymecycline,Body temperature increased;Bronchitis chronic;Chlamydial infection;Infection;Soft tissue infection;Staphylococcal infection;Trachoma;Unspecified non-gonococcal urethritis (NGU);Urethritis,Abdominal pain;Abdominal pain upper;Anaphylactic shock;Angioedema;Benign intracranial hypertension;Blindness;Blood alkaline phosphatase increased;Blood and lymphatic system disorders;Blood bilirubin increased;Candida infection;Diarrhoea;Diplopia;Dizziness;Dysphagia;Enterocolitis;Epigastric pain;Erythema multiforme;Eye disorder;Fontanelle bulging;Gastrointestinal disorder;Gastrointestinal pain;Glossitis;Headache;Hepatic failure;Hepatitis;Hepatobiliary disease;Hypersensitivity;Hypoplasia enamel;Immune system disorder;Intracranial pressure increased;Jaundice;Nausea;Nervous system disorder;Neutropenia;Oesophageal ulcer;Oesophagitis;Pancreatitis;Photosensitivity;Photosensitivity reaction;Pigmentation disorder;Pruritus;Pseudomembranous colitis;Rash erythematous;Scotoma;Skin discolouration;Stevens-Johnson syndrome;Stomatitis;Thrombocytopenia;Tooth hypoplasia;Transaminases increased;Unspecified visual loss;Urticaria;Vaginal infection;Vaginal inflammation;Vision blurred;Visual disturbance;Visual impairment;Vomiting,small molecule,approved; investigational,"(+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide; Limeciclina; Lymecycline; Lymecyclinum; N-Lysinomethyltetracycline; N2-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline; N6-((4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamido)methyl)lysine; Tetracycline-L-methylene lysine; Tetracycline-L-methylenelysine; ramA",30S ribosomal protein S4, J01AA20;J01AA04
pegaptanib,Age-related macular degeneration;Glaucoma,Abnormal sensation in eye;Abrasion NOS;Anaphylactic shock;Anaphylactoid reaction;Angioedema;Angiopathy;Anterior chamber inflammation;Anterior uveitis;Aortic aneurysm;Arthritis;Asthenia;Asthenopia;Back pain;Blepharitis;Bone spur;Bronchitis;Cardiac disorder;Carotid artery occlusion;Cataract;Cataract traumatic;Cerebrovascular accident;Chalazion;Chest pain;Chills;Conjunctival haemorrhage;Conjunctival hyperaemia;Conjunctival oedema;Conjunctivitis;Conjunctivitis allergic;Connective tissue disorder;Contusion;Corneal abrasion;Corneal deposits;Corneal disorder;Corneal dystrophy;Corneal epithelium defect;Corneal epithelium disorder;Corneal erosion;Corneal oedema;Deafness;Deposit eye;Dermatitis;Dermatitis contact;Diabetes mellitus;Diarrhoea;Dizziness;Dry eye;Dyspepsia;Ear and labyrinth disorders;Ectropion;Eczema;Endophthalmitis;Excoriation;Exostosis;Eye discharge;Eye disorder;Eye haemorrhage;Eye irritation;Eye movement disorder;Eye pain;Eye pruritus;Eye redness;Eye swelling;Eyelid irritation;Eyelid oedema;Eyelid ptosis;Eyelids pruritus;Fatigue;Gastrointestinal disorder;Hair colour changes;Headache;Hearing impaired;Hypertension;Hyphaema;Hypotony of eye;Immune system disorder;Influenza like illness;Injection site reaction;Injection site vesicles;Intraocular pressure increased;Iridocyclitis;Iris disorder;Iritis;Keratitis;Lacrimation increased;Macular degeneration;Mediastinal disorder;Meibomianitis;Meniere's disease;Meniere's disease aggravated;Mental disorder;Mydriasis;Nasopharyngitis;Nausea;Nervous system disorder;Night sweats;Nightmare;Ocular discomfort;Ocular hyperaemia;Ocular hypertension;Ocular icterus;Optic nerve cupping;Palpitations;Panophthalmitis;Periorbital haematoma;Photophobia;Photopsia;Pleural effusion;Pruritus;Punctate keratitis;Pupillary deformity;Pupillary disorder;Pupillary reflex impaired;Rash;Retinal artery occlusion;Retinal detachment;Retinal exudates;Retinal haemorrhage;Retinal oedema;Retinal scar;Retinal tear;Retinal vein occlusion;Rhinorrhoea;Rigors;Skin disorder;Tenderness;Transient ischaemic attack;Unspecified disorder of skin and subcutaneous tissue;Urinary retention;Urinary tract infection;Vertigo;Vision blurred;Visual acuity reduced;Visual disturbance;Visual impairment;Vitreous detachment;Vitreous disorder;Vitreous floaters;Vitreous haemorrhage;Vitreous opacities;Vitreous prolapse;Vomiting,biotech,approved; investigational,Pegaptanib Octasodium; Pegaptanib sodium; L-VEGF; Vascular permeability factor; VEGF; VPF,"Vascular endothelial growth factor A, long form",S01LA03
colestyramine,Acute coronary syndrome;Biliary cirrhosis;Biliary cirrhosis primary;Blood cholesterol increased;Cholesterol serum elevated;Coronary artery disease;Coronary heart disease;Diarrhoea;Gastrointestinal disorder;Hypercholesterolaemia;Myocardial infarction;Pruritus;Short-bowel syndrome;Unspecified disorder of intestine,Abdominal bloating;Abdominal discomfort;Abdominal distension;Abdominal pain;Abdominal symptom;Acidosis;Acidosis hyperchloraemic;Acute coronary syndrome;Anaemia;Angina pectoris;Anorexia;Anxiety;Arcus juvenilis;Arcus lipoides;Arteritis;Arthralgia;Arthritis;Asthenia;Asthma;Back pain;Biliary colic;Bleeding tendency;Chest pain;Claudication;Constipation;Decreased appetite;Dental caries;Dermatitis;Diarrhoea;Distention;Disturbance in sexual arousal;Diuresis;Diverticulitis;Dizziness;Drowsiness;Duodenal ulcer;Dysgeusia;Dyspepsia;Dysphagia;Dyspnoea;Dysuria;Ecchymosis;Eructation;Factor II deficiency;Faecalith;Faecaloma;Fatigue;Flatulence;Foetor hepaticus;Gastrointestinal pain;Haematuria;Haemoglobin;Haemorrhage;Haemorrhagic disorder;Haemorrhoidal haemorrhage;Haemorrhoids;Headache;Heartburn;Hepatocellular injury;Hiccups;Hypersensitivity;Hypoprothrombinaemia;Intermittent claudication;Intestinal obstruction;Libido increased;Liver disorder;Loss of consciousness;Lymphadenopathy;Musculoskeletal discomfort;Myocardial infarction;Myocardial ischaemia;Nausea;Neuralgia;Night blindness;Oedema;Osteoporosis;Pain;Pain nerve;Pancreatitis;Paraesthesia;Polyuria;Proctalgia;Prothrombin level increased;Prothrombin time shortened;Rash;Rectal haemorrhage;Shock;Skin irritation;Somnolence;Steatorrhoea;Syncope;Taste sour;Thrombophlebitis;Tinnitus;Ulcer;Urticaria;Uveitis;Vertigo;Vitamin K deficiency;Vomiting;Weight decreased;Weight increased;Wheezing;Xanthoma,small molecule,approved; investigational,Cholestyramine resin; Colestiramina; Colestyramine,Bile acids,C10AC01
